<SEC-DOCUMENT>0001193125-21-135440.txt : 20210428
<SEC-HEADER>0001193125-21-135440.hdr.sgml : 20210428
<ACCEPTANCE-DATETIME>20210428074705
ACCESSION NUMBER:		0001193125-21-135440
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		176
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210428
DATE AS OF CHANGE:		20210428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39173
		FILM NUMBER:		21861369

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>d10811d20f.htm
<DESCRIPTION>FORM 20-F
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:imab="http://IMab.com/20201231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>Form 20-F</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style=""><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2020To12_31_2020">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P01_01_2020To12_31_2020">FY</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2020To12_31_2020">0001778016</ix:nonNumeric><ix:nonFraction name="imab:AmericanDepositorySharesCommonShareEquivalent" id="hidden20395666" contextRef="P02_10_2020To02_10_2020" unitRef="Unit_pure" decimals="0">23</ix:nonFraction><ix:nonFraction name="imab:DeferredLiabilityFromCollaborativeArrangementExcludingTax" id="hidden20395917" contextRef="PAsOn12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study1MemberIMABTypeOfLicensesAxis" unitRef="Unit_USD" decimals="-6">0</ix:nonFraction><ix:nonFraction name="imab:DeferredLiabilityFromCollaborativeArrangementExcludingTax" id="hidden20395919" contextRef="PAsOn12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study2MemberIMABTypeOfLicensesAxis" unitRef="Unit_USD" decimals="-6">0</ix:nonFraction><ix:nonNumeric name="dei:NoTradingSymbolFlag" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">true</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="imab-20201231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="imab-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="imab-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="imab-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="imab-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P01_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_25_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_25_2019To12_25_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-25</xbrli:startDate> <xbrli:endDate>2019-12-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2010To12_31_2010" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2010-01-01</xbrli:startDate> <xbrli:endDate>2010-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_31_2016" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-10-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_25_2017" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-09-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To04_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_10_2020To02_10_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-02-10</xbrli:startDate> <xbrli:endDate>2020-02-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesBConvertiblePreferredSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesCConvertiblePreferredSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesAConvertiblePreferredSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesC1ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >imab:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >imab:IprAndDTj103Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_IprAndDTj102MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >imab:IprAndDTj102Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_IprAndDTj101MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >imab:IprAndDTj101Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_PeoplesBankOfChinaMemberIMABBankBranchAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imab:BankBranchAxis" >imab:PeoplesBankOfChinaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesC1ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >imab:SeriescOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:EverestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_IMabBiopharmaHongKongLimitedMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:IMabBiopharmaHongKongLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_IMabtianjinMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:IMabtianjinMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_IMabShanghaiMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:IMabShanghaiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ImabbiopharmaUsLtdMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:ImabbiopharmaUsLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >imab:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >imab:IprAndDTj103Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_IprAndDTj101MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >imab:IprAndDTj101Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PeoplesBankOfChinaMemberIMABBankBranchAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imab:BankBranchAxis" >imab:PeoplesBankOfChinaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FederalReserveBankOfNewYorkMemberIMABBankBranchAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="imab:BankBranchAxis" >imab:FederalReserveBankOfNewYorkMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesAConvertiblePreferredSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesBConvertiblePreferredSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesCConvertiblePreferredSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesC1ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyNineteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:ShareIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >imab:OutLicensingAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:EverestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TwentyNineteenShareIncentivePlanMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >imab:TwentyNineteenShareIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiariesMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >srt:SubsidiariesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PRCMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >imab:PRCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AmericanDepositarySharesMemberusgaapStatementEquityComponentsAxis_InvestorWarrantsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >imab:InvestorWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >imab:AmericanDepositarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:ImabHangzhouMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis_ManagementHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:ImabHangzhouMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >imab:ManagementHoldcoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_DomesticInvestorsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImabHangzhouMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:ImabHangzhouMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >imab:DomesticInvestorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EsopHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImabHangzhouMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:ImabHangzhouMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >imab:EsopHoldcoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_DomesticInvestorsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >imab:DomesticInvestorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EsopHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >imab:EsopHoldcoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_HoldcoMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imab:HoldcoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ImabHongKongMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:ImabHongKongMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ManagementHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >imab:ManagementHoldcoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_InvestorWarrantsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >dei:AdrMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >imab:InvestorWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >dei:AdrMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FirstClosingPeriodMemberIMABPeriodTypeAxis_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:HillhouseEntitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:PeriodTypeAxis" >imab:FirstClosingPeriodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis_SecondClosingPeriodMemberIMABPeriodTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:HillhouseEntitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:PeriodTypeAxis" >imab:SecondClosingPeriodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study1MemberIMABTypeOfLicensesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:GenexineIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:TypeOfLicensesAxis" >imab:Study1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study2MemberIMABTypeOfLicensesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:GenexineIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:TypeOfLicensesAxis" >imab:Study2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_RevenueMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >imab:RevenueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >imab:LongTermInvestmentUnderEquityMethodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_GrossProfitMemberusgaapIncomeStatementLocationAxis_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >imab:GrossProfitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >imab:LongTermInvestmentUnderEquityMethodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_LossFromOperationMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >imab:LossFromOperationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >imab:LongTermInvestmentUnderEquityMethodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NetIncomeLossMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >imab:NetIncomeLossMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >imab:LongTermInvestmentUnderEquityMethodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >imab:LongTermInvestmentUnderEquityMethodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:ShareIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:AbbVieMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_JiangsuTaslydiyiPharmaceuticalCoLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:JiangsuTaslydiyiPharmaceuticalCoLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AdrMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >dei:AdrMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_HKsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:HK</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_LicensingAgreementWithMorphosysMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithMorphosysMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithGenexineIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithMorphosysAgMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:MorphosysMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_LicensingAgreementsWithMorphosysMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementsWithMorphosysMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:MorphosysMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:OtherinlicensingarrangementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_OtherInLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >imab:OtherInLicensingAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:CspcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:HealSunMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:OperatingExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:HealSunMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >imab:OutLicensingAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:EverestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:CollaborationAgreementWithABLBioMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:CollaborationAgreementWithABLBioMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:OperatingExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_HealSunMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis_MilestoneIiiMemberIMABMilestoneTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:HealSunMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:MilestoneTypeAxis" >imab:MilestoneIiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_HealSunMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis_MilestoneIvMemberIMABMilestoneTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:HealSunMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:MilestoneTypeAxis" >imab:MilestoneIvMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_CmabBiopharmaSuzhouIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:CmabBiopharmaSuzhouIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >imab:ReceiptOfContractResearchOrganizationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:EverestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >imab:IprAndDTj103Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AdrMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >dei:AdrMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_HKsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:HK</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_OtherFinancialAssetsMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >imab:OtherFinancialAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_WarrantLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >imab:WarrantLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_LicensingAgreementWithMacrogenicsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithMacrogenicsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithMorphosysAgMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_LicensingAgreementsWithMorphosysMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementsWithMorphosysMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:MorphosysMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_LicensingAgreementWithMacrogenicsMemberusgaapTypeOfArrangementAxis_MacroGenicsMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithMacrogenicsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:MacroGenicsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MacroGenicsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:LicensingAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:MacroGenicsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithMorphosysAgMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:MorphosysMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:OtherinlicensingarrangementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CollaborationAgreementWithEverestMemberusgaapTypeOfArrangementAxis_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:CollaborationAgreementWithEverestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:EverestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ABLBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:ABLBioMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:OperatingExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:ABLBioMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:CollaborationAgreementWithABLBioMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ABLBioMembersrtCounterpartyNameAxis_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:CollaborationAgreementWithABLBioMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:ABLBioMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:CollaborationAgreementWithABLBioMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:OperatingExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CollaborationAgreementsWithTraconPharmaceuticalsIncMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:OperatingExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_DirectorMembersrtTitleOfIndividualAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:DirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:CspcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis_TaslyPharmaceuticalGroupCoLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:TaslyPharmaceuticalGroupCoLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >imab:ReceiptOfContractResearchOrganizationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:EverestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >imab:SeriescOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesC1ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >imab:IprAndDTj103Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyNineteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >dei:AdrMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis" >dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_IMabBiopharmaHongKongLimitedMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:IMabBiopharmaHongKongLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_IMabShanghaiMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:IMabShanghaiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_IMabtianjinMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:IMabtianjinMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ImabbiopharmaUsLtdMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:ImabbiopharmaUsLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_HKsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:HK</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AUsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:AU</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CNMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >imab:CNMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_IMobOtherSubsidiariesMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:IMobOtherSubsidiariesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PutRightLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >imab:PutRightLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >imab:LaboratoryEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >imab:LaboratoryEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_SoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >imab:SoftwareMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_SoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >imab:SoftwareMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OfficeFurnitureAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >imab:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AmericanDepositarySharesMemberusgaapStatementEquityComponentsAxis_InvestorWarrantsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >imab:InvestorWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >imab:AmericanDepositarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SeriesB2PreferredSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >imab:SeriesB2PreferredSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_TrancheIOfSeriesBWarrantsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >imab:TrancheIOfSeriesBWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_TrancheIiOfSeriesBWarrantsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >imab:TrancheIiOfSeriesBWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyNineteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >imab:EquityInLossOfAnAffiliateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithMorphosysAgMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithGenexineIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LicensingAgreementWithMorphosysMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithMorphosysMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LicensingAgreementWithMacrogenicsMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithMacrogenicsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LicensingAgreementWithMorphosysMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithMorphosysMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:ShareIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphoSysAGMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:MorphoSysAGMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithMorphosysAgMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GenexineIncMembersrtCounterpartyNameAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithGenexineIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:GenexineIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LemzoparlimabLicenseMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:AbbVieMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >imab:LemzoparlimabLicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_FirstMilestoneMemberIMABMilestoneTypeAxis_LemzoparlimabLicenseMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:AbbVieMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >imab:LemzoparlimabLicenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:MilestoneTypeAxis" >imab:FirstMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LemzoparlimabLicenseMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SecondMilestoneMemberIMABMilestoneTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:AbbVieMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >imab:LemzoparlimabLicenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:MilestoneTypeAxis" >imab:SecondMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithGenexineIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:GenexineIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:GenexineIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithGenexineIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Gxi7MembersrtProductOrServiceAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithGenexineIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:GenexineIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >imab:Gxi7Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DevelopmentMilestoneMemberIMABMilestoneTypeAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_MacroGenicsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithGenexineIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:MacroGenicsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:MilestoneTypeAxis" >imab:DevelopmentMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MacroGenicsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MinimumMembersrtRangeAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:LicensingAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:MacroGenicsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:OtherinlicensingarrangementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LicensingAgreementWithMacrogenicsMemberusgaapTypeOfArrangementAxis_MacroGenicsMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithMacrogenicsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:MacroGenicsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Study1MemberIMABTypeOfLicensesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:AbbVieMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:TypeOfLicensesAxis" >imab:Study1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Study2MemberIMABTypeOfLicensesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:AbbVieMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:TypeOfLicensesAxis" >imab:Study2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:EverestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >imab:OutLicensingAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ABLBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:ABLBioMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:OperatingExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:ABLBioMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CollaborationAgreementsWithTraconPharmaceuticalsIncMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:OperatingExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GenexineIncMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:GenexineIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GenexineIncMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:GenexineIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study1MemberIMABTypeOfLicensesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:GenexineIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:TypeOfLicensesAxis" >imab:Study1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:OperatingExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:AbbVieMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study2MemberIMABTypeOfLicensesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:GenexineIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:TypeOfLicensesAxis" >imab:Study2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:CollaborationAgreementWithABLBioMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_TwentyNineteenShareIncentivePlanMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >imab:TwentyNineteenShareIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >imab:EquityInLossOfAnAffiliateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >imab:EquityInLossOfAnAffiliateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >imab:EquityInLossOfAnAffiliateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >imab:EquityInLossOfAnAffiliateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >imab:EquityInLossOfAnAffiliateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis" >imab:ThirdOneThirdPortionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis" >imab:ThirdOneThirdPortionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis" >imab:ThirdOneThirdPortionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationTrancheFourMemberusgaapVestingAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >imab:ShareBasedCompensationTrancheFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis" >imab:ThirdOneThirdPortionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OnePerformanceConditionMemberusgaapVestingAxis_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis" >imab:ThirdOneThirdPortionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >imab:OnePerformanceConditionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_TwoPerformanceConditionsMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis" >imab:ThirdOneThirdPortionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >imab:TwoPerformanceConditionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_ThreePerformanceConditionsMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis" >imab:ThirdOneThirdPortionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >imab:ThreePerformanceConditionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FourPerformanceConditionsMemberusgaapVestingAxis_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis" >imab:ThirdOneThirdPortionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >imab:FourPerformanceConditionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CmabBiopharmaSuzhouIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:CmabBiopharmaSuzhouIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >imab:ReceiptOfContractResearchOrganizationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_JiangsuTaslydiyiPharmaceuticalCoLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:JiangsuTaslydiyiPharmaceuticalCoLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >imab:ReceiptOfContractResearchOrganizationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:HealSunMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SeriesBWarrantsSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >imab:SeriesBWarrantsSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesC1ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CollaborationAgreementWithInvestorsMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:CollaborationAgreementWithInvestorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:HillhouseEntitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >imab:IprAndDTj103Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:ImabHangzhouMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DomesticInvestorsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImabHangzhouMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:ImabHangzhouMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >imab:DomesticInvestorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis_ManagementHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:ImabHangzhouMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >imab:ManagementHoldcoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EsopHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImabHangzhouMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:ImabHangzhouMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >imab:EsopHoldcoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >dei:AdrMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_InvestorWarrantsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >imab:InvestorWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >dei:AdrMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis_SecondClosingPeriodMemberIMABPeriodTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:HillhouseEntitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:PeriodTypeAxis" >imab:SecondClosingPeriodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FirstClosingPeriodMemberIMABPeriodTypeAxis_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:HillhouseEntitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:PeriodTypeAxis" >imab:FirstClosingPeriodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:GenexineIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GrantMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:GrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis" >imab:ThirdOneThirdPortionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_SecondOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis" >imab:SecondOneThirdPortionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlan2020MemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:ShareIncentivePlan2020Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:ShareIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:CspcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >imab:LoanOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis" >imab:ChinaMerchantBankCoLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >imab:LoanTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis" >imab:ChinaMerchantBankCoLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_29_2019_DirectorMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:DirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-10-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_18_2016To10_18_2016_SeriesA1AndA2PreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesA1AndA2PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-10-18</xbrli:startDate> <xbrli:endDate>2016-10-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_18_2016_ConvertiblePreferredStockSeriesA3MemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:ConvertiblePreferredStockSeriesA3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-10-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_18_2016_SeriesA1AndA2PreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesA1AndA2PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-10-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_06_2017To09_06_2017_SeriesA3PreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesA3PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-09-06</xbrli:startDate> <xbrli:endDate>2017-09-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_06_2017_SeriesA3PreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesA3PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-09-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_22_2017_ConvertiblePreferredStockSeriesB2MemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:ConvertiblePreferredStockSeriesB2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-09-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_22_2017_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:ConvertiblePreferredStockSeriesBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-09-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_29_2018_SeriesB2PreferredSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >imab:SeriesB2PreferredSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_29_2018_ConvertiblePreferredStockSeriesAThreeUponExerciseMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:ConvertiblePreferredStockSeriesAThreeUponExerciseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_29_2018_ConvertiblePreferredStockSeriesBOneUponConversionMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:ConvertiblePreferredStockSeriesBOneUponConversionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_29_2018_ConvertiblePreferredStockSeriesBTwoUponExerciseMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:ConvertiblePreferredStockSeriesBTwoUponExerciseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_29_2018_ConvertiblePreferredStockSeriesBUponExerciseMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:ConvertiblePreferredStockSeriesBUponExerciseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_29_2018_ConvertiblePreferredStockSeriesBOneUponExerciseMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:ConvertiblePreferredStockSeriesBOneUponExerciseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_29_2018_ConvertiblePromissoryNotes2017MemberusgaapDebtInstrumentAxis_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesB1PreferredSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >imab:ConvertiblePromissoryNotes2017Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_06_2018_TrancheIOfSeriesBWarrantsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >imab:TrancheIOfSeriesBWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-07-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_06_2018_SeriesBWarrantsSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >imab:SeriesBWarrantsSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-07-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_06_2018_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-07-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_06_2018_ConvertiblePreferredStockSeriesBUponExerciseMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:ConvertiblePreferredStockSeriesBUponExerciseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-07-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_06_2018_ConvertiblePreferredStockSeriesBOneUponExerciseMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:ConvertiblePreferredStockSeriesBOneUponExerciseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-07-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_06_2018_ConvertiblePreferredStockSeriesBTwoUponExerciseMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:ConvertiblePreferredStockSeriesBTwoUponExerciseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-07-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_06_2018To07_06_2018_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-06</xbrli:startDate> <xbrli:endDate>2018-07-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_25_2019_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesCOnePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-07-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_17_2019To10_17_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-10-17</xbrli:startDate> <xbrli:endDate>2019-10-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_17_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-10-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P11_06_2019To11_06_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-11-06</xbrli:startDate> <xbrli:endDate>2019-11-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_06_2019To11_06_2019_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesCOnePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-11-06</xbrli:startDate> <xbrli:endDate>2019-11-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_06_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-11-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_25_2019_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_25_2019_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_25_2019To12_25_2019_PreferredStockMemberusgaapStatementEquityComponentsAxis_TemporaryEquityMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:PreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:TemporaryEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-25</xbrli:startDate> <xbrli:endDate>2019-12-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_25_2019To12_25_2019_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesCOnePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-25</xbrli:startDate> <xbrli:endDate>2019-12-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_25_2017To09_25_2017_SeriesBOnshoreInvestorsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >imab:SeriesBOnshoreInvestorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-09-25</xbrli:startDate> <xbrli:endDate>2017-09-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_25_2017To09_25_2017_OnshoreConvertibleLoanMemberusgaapDebtInstrumentAxis_SeriesBOnshoreInvestorsMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesBOnshoreInvestorsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >imab:OnshoreConvertibleLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-09-25</xbrli:startDate> <xbrli:endDate>2017-09-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_25_2017To09_25_2017_OnshoreConvertibleLoanMemberusgaapDebtInstrumentAxis_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >imab:OnshoreConvertibleLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesB1PreferredSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-09-25</xbrli:startDate> <xbrli:endDate>2017-09-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_25_2017To09_25_2017_ConvertiblePromissoryNotes2017MemberusgaapDebtInstrumentAxis_SeriesBPreferredStockHolderMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesBPreferredStockHolderMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >imab:ConvertiblePromissoryNotes2017Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-09-25</xbrli:startDate> <xbrli:endDate>2017-09-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_25_2017_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesB1PreferredSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-09-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_25_2017_OnshoreConvertibleLoanMemberusgaapDebtInstrumentAxis_SeriesBOnshoreInvestorsMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >imab:OnshoreConvertibleLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesBOnshoreInvestorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-09-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_25_2017_ConvertiblePromissoryNotes2017MemberusgaapDebtInstrumentAxis_SeriesBPreferredStockHolderMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesBPreferredStockHolderMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >imab:ConvertiblePromissoryNotes2017Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-09-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_29_2018To06_29_2018_ConvertiblePromissoryNotes2017MemberusgaapDebtInstrumentAxis_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesB1PreferredSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >imab:ConvertiblePromissoryNotes2017Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-06-29</xbrli:startDate> <xbrli:endDate>2018-06-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_03_2018To02_03_2018_SeriesA3PreferredSharesMemberusgaapStatementClassOfStockAxis_TwoZeroOneEightNotesMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >imab:TwoZeroOneEightNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesA3PreferredSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-02-03</xbrli:startDate> <xbrli:endDate>2018-02-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_03_2018To02_03_2018_ConvertiblePromissoryNotes2018MemberusgaapDebtInstrumentAxis_SeriesA3PreferredSharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >imab:ConvertiblePromissoryNotes2018Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesA3PreferredSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-02-03</xbrli:startDate> <xbrli:endDate>2018-02-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_03_2018_ConvertiblePromissoryNotes2018MemberusgaapDebtInstrumentAxis_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesB1PreferredSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >imab:ConvertiblePromissoryNotes2018Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-02-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_03_2018_ConvertiblePromissoryNotes2018MemberusgaapDebtInstrumentAxis_SeriesA3PreferredSharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesA3PreferredSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >imab:ConvertiblePromissoryNotes2018Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-02-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_22_2017To09_22_2017_SeriesBPreferredShareholdersMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >imab:SeriesBPreferredShareholdersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-09-22</xbrli:startDate> <xbrli:endDate>2017-09-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_22_2017To09_22_2017_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:ConvertiblePreferredStockSeriesBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-09-22</xbrli:startDate> <xbrli:endDate>2017-09-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_29_2018To07_06_2018_SeriesB2PreferredSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >imab:SeriesB2PreferredSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-06-29</xbrli:startDate> <xbrli:endDate>2018-07-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2016To12_31_2016_FoundersMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >imab:FoundersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-01-01</xbrli:startDate> <xbrli:endDate>2016-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2016To12_31_2016_ThirdVentureMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis" >imab:ThirdVentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-01-01</xbrli:startDate> <xbrli:endDate>2016-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_01_2016To06_30_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >imab:FoundersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-06-01</xbrli:startDate> <xbrli:endDate>2016-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2016To10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >imab:FoundersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-10-01</xbrli:startDate> <xbrli:endDate>2016-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2016To10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >imab:FoundersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-10-01</xbrli:startDate> <xbrli:endDate>2016-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2016To10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >imab:FoundersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-10-01</xbrli:startDate> <xbrli:endDate>2016-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2016To10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >imab:FoundersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-10-01</xbrli:startDate> <xbrli:endDate>2016-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >imab:FoundersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-10-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_31_2019To10_31_2019_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >imab:FoundersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-10-31</xbrli:startDate> <xbrli:endDate>2019-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2017To10_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-10-01</xbrli:startDate> <xbrli:endDate>2017-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2017To10_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-10-01</xbrli:startDate> <xbrli:endDate>2017-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2017To10_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-10-01</xbrli:startDate> <xbrli:endDate>2017-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_31_2017_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-10-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:MorphosysMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithMorphosysAgMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:HealSunMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:HealSunMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:OperatingExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_DeferredRevenueMemberusgaapBalanceSheetLocationAxis_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >imab:DeferredRevenueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:HealSunMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_LeiFangMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >imab:LeiFangMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:HealSunMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_22_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-02-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_22_2019_DirectorMembersrtTitleOfIndividualAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:DirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-02-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_22_2019_AmendedTwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis_DirectorMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:AmendedTwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:DirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-02-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_22_2019To02_22_2019_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-22</xbrli:startDate> <xbrli:endDate>2019-02-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_22_2019To02_22_2019_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-22</xbrli:startDate> <xbrli:endDate>2019-02-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_22_2019To02_22_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-22</xbrli:startDate> <xbrli:endDate>2019-02-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_22_2019To02_22_2019_DrzangMembersrtTitleOfIndividualAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >imab:DrzangMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-22</xbrli:startDate> <xbrli:endDate>2019-02-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_22_2019To02_22_2019_AmendedTwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis_DirectorMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:AmendedTwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:DirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-22</xbrli:startDate> <xbrli:endDate>2019-02-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_22_2019To02_22_2019_DirectorMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:DirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-22</xbrli:startDate> <xbrli:endDate>2019-02-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_17_2017To11_17_2017_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:MorphosysMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithMorphosysAgMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-11-17</xbrli:startDate> <xbrli:endDate>2017-11-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To01_01_2018_GenexineIncMembersrtCounterpartyNameAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithGenexineIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:GenexineIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-01-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To01_31_2018_GenexineIncMembersrtCounterpartyNameAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithGenexineIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:GenexineIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_04_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:EverestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >imab:OutLicensingAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-11-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_28_2019To02_28_2019_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:CspcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-28</xbrli:startDate> <xbrli:endDate>2019-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_30_2019To09_30_2019_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:CspcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-09-30</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_31_2018To07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >imab:LoanOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis" >imab:ChinaMerchantBankCoLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-31</xbrli:startDate> <xbrli:endDate>2018-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:CollaborationAgreementWithABLBioMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:ABLBioMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-31</xbrli:startDate> <xbrli:endDate>2018-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:ABLBioMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-31</xbrli:startDate> <xbrli:endDate>2018-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_ClinicalMilestonesMemberIMABMilestoneTypeAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:ABLBioMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:MilestoneTypeAxis" >imab:ClinicalMilestonesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-31</xbrli:startDate> <xbrli:endDate>2018-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_SalesMilestonesMemberIMABMilestoneTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:ABLBioMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:MilestoneTypeAxis" >imab:SalesMilestonesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-31</xbrli:startDate> <xbrli:endDate>2018-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_30_2019To06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis" >imab:ChinaMerchantBankCoLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >imab:LoanTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-06-30</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_15_2017_TasgenGroupMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >imab:TasgenGroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-07-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_11_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_11_2020_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_11_2020_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_11_2020_MeasurementInputMaturityMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_11_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >imab:WarrantsToPurchaseOrdinarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_17_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_17_2020_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_17_2020_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_17_2020_MeasurementInputMaturityMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_17_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TwoZeroOneEightNotesMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:GenexineIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >imab:TwoZeroOneEightNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_17_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >imab:WarrantsToPurchaseOrdinarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2020To12_31_2020_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:OtherinlicensingarrangementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-31</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_10_2020To02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >dei:AdrMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-02-10</xbrli:startDate> <xbrli:endDate>2020-02-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_31_2020To01_31_2020_AdrMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >dei:AdrMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-31</xbrli:startDate> <xbrli:endDate>2020-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >dei:AdrMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-02-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_17_2020To01_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-17</xbrli:startDate> <xbrli:endDate>2020-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2020_AdrMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >dei:AdrMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2020_CollaborationAgreementWithEverestMemberusgaapTypeOfArrangementAxis_EverestsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:CollaborationAgreementWithEverestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:EverestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2020_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2020_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:ConvertiblePreferredStockSeriesBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2020_ConvertiblePreferredStockSeriesBOneUponConversionMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:ConvertiblePreferredStockSeriesBOneUponConversionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2020_ConvertiblePreferredStockSeriesB2MemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:ConvertiblePreferredStockSeriesB2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2020_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_16_2019_ImabHangzhouMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:ImabHangzhouMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_17_2020To01_17_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-17</xbrli:startDate> <xbrli:endDate>2020-01-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_17_2020To01_17_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-17</xbrli:startDate> <xbrli:endDate>2020-01-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_17_2020To01_17_2020_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-17</xbrli:startDate> <xbrli:endDate>2020-01-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_17_2020To01_17_2020_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:ConvertiblePreferredStockSeriesBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-17</xbrli:startDate> <xbrli:endDate>2020-01-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_17_2020To01_17_2020_ConvertiblePreferredStockSeriesBOneUponConversionMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:ConvertiblePreferredStockSeriesBOneUponConversionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-17</xbrli:startDate> <xbrli:endDate>2020-01-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_17_2020To01_17_2020_ConvertiblePreferredStockSeriesB2MemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:ConvertiblePreferredStockSeriesB2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-17</xbrli:startDate> <xbrli:endDate>2020-01-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_17_2020To01_17_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-17</xbrli:startDate> <xbrli:endDate>2020-01-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_17_2020To01_17_2020_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-17</xbrli:startDate> <xbrli:endDate>2020-01-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_17_2020To01_17_2020_SeniorManagementEmployeesMembersrtTitleOfIndividualAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >imab:SeniorManagementEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-17</xbrli:startDate> <xbrli:endDate>2020-01-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_17_2020To01_17_2020_SeniorManagementEmployeesMembersrtTitleOfIndividualAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >imab:SeniorManagementEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-17</xbrli:startDate> <xbrli:endDate>2020-01-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_15_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_15_2020_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_15_2020_AdrMemberusgaapStatementClassOfStockAxis_BoardOfDirectorsMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >imab:BoardOfDirectorsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >dei:AdrMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2020To08_31_2020_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphoSysAGMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:MorphoSysAGMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithMorphosysAgMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-08-01</xbrli:startDate> <xbrli:endDate>2020-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_03_2020To09_03_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:AbbVieMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-09-03</xbrli:startDate> <xbrli:endDate>2020-09-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_03_2020To09_03_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ClinicalMilestonesMemberIMABMilestoneTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:AbbVieMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="imab:MilestoneTypeAxis" >imab:ClinicalMilestonesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-09-03</xbrli:startDate> <xbrli:endDate>2020-09-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:ImabHangzhouMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2019_ImabHangzhouMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:ImabHangzhouMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2018To07_31_2018_ABLBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:ABLBioMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-07-01</xbrli:startDate> <xbrli:endDate>2018-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_11_2020To09_11_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >imab:WarrantsToPurchaseOrdinarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-09-11</xbrli:startDate> <xbrli:endDate>2020-09-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_17_2020To12_17_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >imab:WarrantsToPurchaseOrdinarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-17</xbrli:startDate> <xbrli:endDate>2020-12-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2010To12_31_2010_ABLBioMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >imab:ABLBioMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2010-01-01</xbrli:startDate> <xbrli:endDate>2010-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_31_2020_CollaborationAgreementWithEverestMemberusgaapTypeOfArrangementAxis_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:EverestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:CollaborationAgreementWithEverestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_15_2020To12_31_2020_HoldcoMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >imab:HoldcoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-09-15</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_15_2020To12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >imab:ImabHangzhouMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-09-15</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >imab:AbbVieMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2021_CollaborationAgreementsWithTraconPharmaceuticalsIncMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >imab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_OtherFinancialAssetsMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >imab:OtherFinancialAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_WarrantLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >imab:WarrantLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_OtherFinancialAssetsMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >imab:OtherFinancialAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_WarrantLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >imab:WarrantLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PutRightLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >imab:PutRightLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >imab:SeriescOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >imab:SeriesC1ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2016_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001778016</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_CNY" > <xbrli:measure>iso4217:CNY</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month" > <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day" > <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_CNY_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:CNY</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit></ix:resources></ix:header></div><div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 1.67em; line-height: 12pt;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div></div> </div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2020To12_31_2020">20-F</ix:nonNumeric></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Mark One) </div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 12pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentRegistrationStatement" contextRef="P01_01_2020To12_31_2020" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OR </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 12pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentAnnualReport" contextRef="P01_01_2020To12_31_2020" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P01_01_2020To12_31_2020" format="ixt:datemonthdayyearen"><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P01_01_2020To12_31_2020" format="ixt:datemonthdayen">December 31</ix:nonNumeric>, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P01_01_2020To12_31_2020">2020</ix:nonNumeric></ix:nonNumeric>. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OR </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 12pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P01_01_2020To12_31_2020" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OR </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 12pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentShellCompanyReport" contextRef="P01_01_2020To12_31_2020" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Date of event requiring this shell company report&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div></div></div></div> </div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Commission file number: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P01_01_2020To12_31_2020">001-39173</ix:nonNumeric></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 24pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2020To12_31_2020">I-MAB</ix:nonNumeric></div> </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact Name of Registrant as Specified in Its Charter) </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">N/A </div></div></div></div> </div> </div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Translation of Registrant&#8217;s Name Into English) </div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:edgarprovcountryen">Cayman Islands</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Jurisdiction of Incorporation or Organization) </div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2020To12_31_2020">Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2020To12_31_2020">Shanghai</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2020To12_31_2020">201210</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCountry" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:countrynameen">People&#8217;s Republic of China</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Address of Principal Executive Offices) </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P01_01_2020To12_31_2020_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Jielun Zhu</ix:nonNumeric>, Chief Financial Officer </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2020To12_31_2020_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2020To12_31_2020_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Shanghai</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2020To12_31_2020_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">201210</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCountry" contextRef="P01_01_2020To12_31_2020_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" format="ixt-sec:countrynameen">People&#8217;s Republic of China</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Phone: +<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2020To12_31_2020_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">86</ix:nonNumeric> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">21-<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2020To12_31_2020_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">6057-8000</ix:nonNumeric></div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Email: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelEmailAddress" contextRef="P01_01_2020To12_31_2020_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">jielun.zhu@i-mabbiopharma.com</ix:nonNumeric></div> </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person) </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered or to be registered pursuant to Section&#160;12(b) of the Act: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 33%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 31%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title of Each Class</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Trading Symbol</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name of Each Exchange On Which Registered</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis">American depositary shares, each ten (10) American depositary shares representing twenty-three (23) ordinary shares</ix:nonNumeric></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">Ordinary shares, par value US$0.0001 per share</ix:nonNumeric>*</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis">IMAB</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(The Nasdaq Global Market)</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(The Nasdaq Global Market)</div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 0pt; margin-bottom: 0pt; page-break-before: always;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Not for trading, but only in connection with the listing on the Nasdaq Global Market of American depositary shares. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered or to be registered pursuant to Section&#160;12(g) of the Act: </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Title of Class) </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities for which there is a reporting obligation pursuant to Section&#160;15(d) of the Act: </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Title of Class) </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report:&#160;</div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">164,888,519</ix:nonFraction> </div></div></div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ordinary shares outstanding, par value of US$0.0001 per share, including 4,036,868 ordinary shares issued upon the exercising or vesting of awards granted under our share incentive plans, as of December&#160;31, 2020. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div>&#160;&#160;<ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="P01_01_2020To12_31_2020">Yes</ix:nonNumeric>&#160;&#160;&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div>&#160;&#160;No </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934.&#160;&#160;&#160;&#160;&#9744;&#160;&#160;Yes&#160;&#160;&#160;&#160;&#9746;&#160;&#160;<ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="P01_01_2020To12_31_2020">No</ix:nonNumeric> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note &#8211; Checking the box above will not relieve any registrant required to file reports pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160; &#160;</div>&#9746;&#160;&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P01_01_2020To12_31_2020">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;&#9744;&#160;&#160;No </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-T</div> (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;&#9746;&#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P01_01_2020To12_31_2020">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;&#9744;&#160;&#160;No </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act.</div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 25%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 25%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 23%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 24%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 25%;;text-align:center;">Large&#160;accelerated&#160;filer&#160;&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 25%;;text-align:center;">Accelerated filer&#160;&#160;&#9744;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 23%;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric>&#160;&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 24%;;text-align:center;">Emerging&#160;growth&#160;company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2020To12_31_2020" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange Act. &#160;</div><ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2020To12_31_2020" format="ixt:booleantrue">&#9746;</ix:nonNumeric>&#160;&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8224;The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April&#160;5, 2012. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accountant firm that prepared or issued its audit report. &#160;</div><ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" contextRef="P01_01_2020To12_31_2020" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 72%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 12%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 79%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"><ix:nonNumeric name="dei:DocumentAccountingStandard" contextRef="P01_01_2020To12_31_2020">U.S. GAAP</ix:nonNumeric>&#160;&#160;&#9746;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Financial Reporting Standards as issued</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by the International Accounting Standards Board&#160;&#160;&#9744;</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Other&#160;&#160;&#9744;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.&#160;&#160;&#160;&#160;&#9744;&#160;&#160;Item 17&#160;&#160;&#160;&#160;&#9744;&#160;&#160;Item 18 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act).&#160;&#160;&#160;&#160;&#9744;&#160;&#160;Yes&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="P01_01_2020To12_31_2020" format="ixt:booleanfalse">&#9746;</ix:nonNumeric>&#160;&#160;No </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS) </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.&#160;&#160;&#160;&#160;&#9744;&#160;&#160;Yes&#160;&#160;&#160;&#160;&#9744;&#160;&#160;No </div></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TABLE OF CONTENTS </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 6%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 89%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_1">INTRODUCTION </a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_2">FORWARD-LOOKING&#160;STATEMENTS </a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_3">PART&#160;I </a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_4">ITEM&#160;1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_5">ITEM&#160;2. OFFER&#160;STATISTICS&#160;AND&#160;EXPECTED&#160;TIMETABLE</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_6">ITEM&#160;3. KEY&#160;INFORMATION</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_7">ITEM&#160;4. INFORMATION ON THE COMPANY</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">65</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_8">ITEM 4A. UNRESOLVED STAFF COMMENTS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">177</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_9">ITEM&#160;5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">177</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_10">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">205</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_11">ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">223</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_12">ITEM&#160;8. FINANCIAL&#160;INFORMATION</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">228</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_13">ITEM&#160;9. THE&#160;OFFER&#160;AND&#160;LISTING</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">229</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_14">ITEM&#160;10. ADDITIONAL&#160;INFORMATION</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">229</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_15">ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">240</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_16">ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">241</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_17">PART&#160;II. </a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">244</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_18">ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">244</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_19">ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</a></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">244</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_20">ITEM&#160;15. CONTROLS&#160;AND&#160;PROCEDURES</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">244</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_21">ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">246</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_22">ITEM 16B. CODE&#160;OF&#160;ETHICS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">246</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_23">ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">246</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_24">ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">246</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_25">ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">246</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_26">ITEM 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">247</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_27">ITEM 16G. CORPORATE&#160;GOVERNANCE</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">247</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_28">ITEM 16H. MINE&#160;SAFETY&#160;DISCLOSURE</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">247</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_29">PART&#160;III </a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">248</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_30">ITEM&#160;17. FINANCIAL&#160;STATEMENTS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">248</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_31">ITEM&#160;18. FINANCIAL&#160;STATEMENTS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">248</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom10811_32">ITEM&#160;19. EXHIBITS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">248</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">i </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom10811_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INTRODUCTION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Unless otherwise indicated and except where the context otherwise requires, references in this annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> to: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;ADRs&#8221; refer to the American depositary receipts that evidence our ADSs; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;ADSs&#8221; refer to our American depositary shares, each ten (10)&#160;ADSs represent twenty-three (23)&#160;ordinary shares; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;China&#8221; or &#8220;the PRC&#8221; refers to the People&#8217;s Republic of China, excluding, for the purposes of this annual report only, Hong Kong, Macau and Taiwan, and &#8220;Greater China&#8221; does not exclude Hong Kong, Macau and Taiwan; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#8220;China Portfolio&#8221; refers to our investigational drugs of which we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> Greater China rights from reputable global biopharmaceutical companies and rely on our own research and development capabilities to advance into pivotal clinical trials and commercialize in Greater China with an aim for near-term product launch; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Global Portfolio&#8221; refers to our own proprietary novel or differentiated drug candidates that we are advancing towards clinical validation in the United States; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;I-Mab,&#8221;</div> &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our company&#8221; and &#8220;our&#8221; refer to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab,</div> a Cayman Islands exempted company, and its subsidiaries; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;RMB&#8221; refers to the legal currency of China; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;shares&#8221; or &#8220;ordinary shares&#8221; refer to our ordinary shares, par value US$0.0001 per share; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;US$,&#8221; &#8220;U.S. dollars,&#8221; &#8220;$,&#8221; and &#8220;dollars&#8221; refer to the legal currency of the United States. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom10811_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FORWARD-LOOKING STATEMENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">This annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> contains forward-looking statements that relate to our current expectations and views of future events. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements are made under the &#8220;safe harbor&#8221; provisions of the U.S. Private Securities Litigations Reform Act of 1995. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You can identify some of these forward-looking statements by words or phrases such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;aim,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;is/are likely to,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements include statements relating to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the timing of initiation and completion, and the progress of our drug discovery and research programs; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the timing and likelihood of regulatory filings and approvals; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to advance our drug candidates into drugs, and the successful completion of clinical trials; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the approval, pricing and reimbursement of our drug candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the commercialization of our drug candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the market opportunities and competitive landscape of our drug candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the payment, receipt and timing of any milestone payments in relation to the licensing agreements; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">estimates of our costs, expenses, future revenues, capital expenditures and our needs for additional financing; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to attract and retain senior management and key employees; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our future business development, financial condition and results of operations; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">future developments, trends, conditions and competitive landscape in the industry and markets in which we operate; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our strategies, plans, objectives and goals and our ability to successfully implement these strategies, plans, objectives and goals; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to continue to maintain our market position in China&#8217;s biopharmaceutical and biotechnology industries; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to identify and integrate suitable acquisition targets; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes to regulatory and operating conditions in our industry and markets; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">potential impact of COVID-19 pandemic on our current and future business development, financial condition and results of operations. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You should read this annual report and the documents that we refer to in this annual report and have filed as exhibits to this annual report completely and with the understanding that our actual future results may be materially different from what we expect. Other sections of this annual report discuss factors which could adversely impact our business and financial performance. Moreover, we operate in an evolving environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this annual report relate only to events or information as of the date on which the statements are made in this annual report. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our reporting currency is Renminbi, or RMB. Unless otherwise noted, all translations from RMB to U.S. dollars and from U.S. dollars to RMB in this annual report are made at a rate of RMB6.5250 to US$1.00, the exchange rate in effect as of December&#160;31, 2020 as set forth in the H.10 statistical release of The Board of Governors of the Federal Reserve System. We make no representation that any RMB or U.S. dollar amounts could have been, or could be, converted into U.S. dollars or RMB, as the case may be, at any particular rate, or at all. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom10811_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART I </div></div></div> <div id="rom10811_4" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div id="rom10811_5" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;2. OFFER STATISTICS AND EXPECTED TIMETABLE </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div id="rom10811_6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;3. KEY INFORMATION </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Selected Financial Data</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following selected consolidated statements of comprehensive income (loss) data for the years ended December&#160;31, 2018, 2019 and 2020, selected consolidated balance sheet data as of December&#160;31, 2019 and 2020 and selected consolidated statements of cash flow data for the years ended December&#160;31, 2018, 2019 and 2020 have been derived from our audited consolidated financial statements included elsewhere in this annual report. The selected consolidated statements of comprehensive loss data for the year ended December&#160;31, 2017, selected consolidated balance sheet data as of December&#160;31, 2017 and 2018 and selected consolidated statements of cash flow data for the year ended December&#160;31, 2017 have been derived from our audited consolidated financial statements that are not included in this annual report. Our consolidated financial statements are prepared and presented in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our historical results do not necessarily indicate results expected for any future periods. The selected consolidated financial data should be read in conjunction with, and are qualified in their entirety by reference to, our audited consolidated financial statements and related notes and &#8220;Item 5. Operating and Financial Review and Prospects&#8221; below. Our consolidated financial statements are prepared and presented in accordance with U.S. GAAP. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;">(in thousands, except for share and per share data)</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selected&#160;Consolidated&#160;Statements&#160;of&#160;Comprehensive&#160;Income (Loss)&#160;Data:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing and collaboration revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,556</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">53,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">30,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,542,668</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">236,424</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenses</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(267,075</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(426,028</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(840,415</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(984,689</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(150,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative expenses<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(25,436</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(66,391</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(654,553</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(402,409</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(61,672</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) from operations</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(280,955</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(438,638</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,464,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">155,570</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">23,842</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">858</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">30,570</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">24,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,713</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5,643</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(11,695</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2,991</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(957</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(147</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income (expenses), net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,527</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(16,780</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(20,205</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">412,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">63,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in loss of an affiliate<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(108,587</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(16,642</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value change of warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(14,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">61,405</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,644</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before income tax expense</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(298,240</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(401,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,451,950</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">483,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">74,044</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(12,231</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,874</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Net income (loss) attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(298,240</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(402,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,451,950</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">470,915</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">72,170</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Deemed dividend to Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> preferred shareholders at extinguishment of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5,283</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Deemed dividend to Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> and C preferred shareholders at modification of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> and C Preferred Shares</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(27,768</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to ordinary shareholders</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(298,240</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(402,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,485,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">470,915</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">72,170</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustments, net of nil tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,918</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">53,689</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,747</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(120,920</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(18,531</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Total comprehensive income (loss) attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(292,322</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(349,144</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,441,203</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">349,995</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">53,639</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to ordinary share-holders</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(298,240</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(402,833</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,485,001</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">470,915</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">72,170</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 53%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average number of ordinary shares used in calculating net income (loss) per share</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,742,669</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,529,092</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,381,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">134,158,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">134,158,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,742,669</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,529,092</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,381,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">157,231,652</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">157,231,652</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per share attributable to ordinary shareholders</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(51.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(61.70</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(201.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(51.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(61.70</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(201.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per ADS attributable to ordinary shareholders</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(119.44</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(141.91</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(462.74</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(119.44</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(141.91</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(462.74</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses were allocated as follows: </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">(in&#160;thousands)</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,112</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">470</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">284,431</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">43,591</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,927</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">514,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">209,033</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,036</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in loss of an affiliate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,707</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,013</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,039</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,520</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">515,203</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">526,171</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">80,640</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents our selected consolidated statements of balance sheet data as of December&#160;31, 2017, 2018, 2019 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;">(in&#160;thousands)</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selected&#160;Consolidated&#160;Statements&#160;of&#160;Balance&#160;Sheet&#160;Data:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current&#160;assets:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">307,930</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,588,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,137,473</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,758,778</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">729,315</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">104,783</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">92,653</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">55,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">130,498</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">227,391</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">34,849</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31,530</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,832</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepayments and other receivables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">88,972</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">136,036</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">195,467</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">29,957</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other financial assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">266,245</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">255,958</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">691,591</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,036,861</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,361,319</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,343,664</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">818,953</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, equipment and software</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">22,336</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">27,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">30,069</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25,272</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,873</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,435</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,997</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,298</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">148,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">148,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">148,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">120,444</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,459</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">162,574</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">162,574</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">162,574</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">162,574</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">24,916</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment accounted for using the equity method</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">664,832</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">101,890</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,331</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">308</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,025,345</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,375,938</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,737,572</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,333,793</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">970,697</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">309,151</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">415,684</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">668,090</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">706,648</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">108,298</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total mezzanine equity</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,015,989</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,915,358</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,104,177</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; deficit</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares (US$0.0001 par value, 500,000,000 shares authorized as of December&#160;31, 2019 and 800,000,000 shares authorized as of December&#160;31, 2020, respectively; 8,363,719 shares issued and outstanding as of December&#160;31, 2019 and 164,888,519 shares issued and outstanding as of December&#160;31, 2020, respectively)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Treasury stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">52,369</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">389,379</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,701,116</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,180,249</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,691</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">59,380</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">70,127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(50,793</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(7,784</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(357,860</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,014,489</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2,494,207</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2,023,292</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(310,083</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shareholders&#8217; equity/(deficit)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(299,795</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(955,104</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,034,695</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,627,145</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">862,399</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities, mezzanine equity and shareholders&#8217; equity/(deficit)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,025,345</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,375,938</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,737,572</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,333,793</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">970,697</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents our selected consolidated statements of cash flow data for the years ended December&#160;31, 2017, 2018, 2019 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selected&#160;Consolidated&#160;Statements&#160;of&#160;Cash&#160;Flow&#160;Data:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash (used in) generated from operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(252,157</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(280,705</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(867,982</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">433,558</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">66,446</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash (used in) generated from investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(157,665</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">212,462</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(201,901</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(30,943</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash generated from financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">758,585</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,479,669</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">152,709</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,440,481</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">527,277</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of exchange rate changes on cash and cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(132</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">59,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,163</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(106,643</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(16,344</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net increase (decrease) in cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">348,631</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,268,218</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(487,648</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,565,495</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">546,436</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash, beginning of the year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">64,082</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">412,713</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,680,931</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,193,283</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">182,879</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash, end of the year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">412,713</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,680,931</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,193,283</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,758,778</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">729,315</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">B.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capitalization and Indebtedness </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> </div> </div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">C.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reasons for the Offer and Use of Proceeds </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">D.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk Factors </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Financial Position and Need for Additional Capital </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are a clinical stage biopharmaceutical company with a limited operating history. Our operations to date have focused on organizing and staffing our operations, business planning, raising capital, establishing our intellectual property portfolio and conducting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical trials of our drug candidates. We have not yet demonstrated an ability to successfully manufacture, obtain marketing approvals for or commercialize our drug candidates. We have no products approved for commercial sale and have not generated any revenue from product sales. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are focused on the discovery and development of innovative drugs for the treatment of various immuno-oncological and immuno-inflammatory diseases. Our limited operating history, particularly in light of the rapidly evolving drug research and development industry in which we operate and the changing regulatory and market environments we encounter, may make it difficult to evaluate our prospects for future performance. As a result, any assessment of our future performance or viability is subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields as we seek to transition to a company capable of supporting commercial activities. If we do not address these risks and difficulties successfully, our business will suffer. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have incurred net losses in the past and we may not be able to maintain profitability in the future. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in the development of biopharmaceutical products is highly speculative as it entails substantial upfront capital expenditures and significant risks that a drug candidate may fail to demonstrate efficacy and/or safety to gain regulatory or marketing approvals or become commercially viable. To date, we have financed our activities primarily through private placements. While we have generated revenue from licensing and collaboration deals, we have not generated any revenue from commercial product sales to date, and we continue to incur significant research and development expenses and other expenses related to our ongoing operations. As a result, we had incurred net losses of RMB402.8&#160;million and RMB1,452.0&#160;million in 2018 and 2019, respectively, and had net income of RMB470.9&#160;million (US$72.2 million) in 2020. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We cannot assure you that we will be able to continue to generate net profits in the future. Our ability to achieve and maintain profitability depends in large part on our ability to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-license</div> some of our commercialization rights and execute our product commercialization strategies as our business further grows in scale. Accordingly, we intend to continue to invest for the foreseeable future in certain activities relating to our development, including, but not limited to, the following: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">conducting clinical trials of our drug candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">manufacturing clinical trial materials through contract manufacturing organizations, or CMOs, in and out of China; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">seeking regulatory approvals for our drug candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">commercializing our drug candidates for which we have obtained marketing approval; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">completing the construction of and maintaining our manufacturing facilities; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">hiring additional clinical, operational, financial, quality control and scientific personnel; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishing a sales, marketing and commercialization team for any future products that have obtained regulatory approval; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">seeking to identify additional drug candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtaining, maintaining, expanding and protecting our intellectual property portfolio; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">enforcing and defending any intellectual property-related claims; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">acquiring or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> other drug candidates, intellectual property and technologies. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Typically, it takes many years to develop one new drug from the time it is discovered to when it becomes available for treating patients. During the process, we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend partially on the rate of the future growth of our expenses, our ability to generate revenues and the timing and amount of milestone payments and other payments that we receive from or pay to third parties. If any of our drug candidates fails during clinical trials or does not gain regulatory approval, or, even if approved, fails to achieve market acceptance, our business may not become profitable. Even if we continue to achieve profitability in the future, we may not be able to sustain profitability in subsequent periods thereafter. Our prior losses and expected future losses have had, and will continue to have, an adverse effect on our working capital and shareholders&#8217; equity. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We recorded net cash outflow from operating activities in the past. We may need to obtain additional financing to fund our operations. If we are unable to obtain such financing, we may be unable to complete the development and commercialization of our major drug candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Since our inception, our operations have consumed substantial amounts of cash. We had raised over US$400&#160;million in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-IPO</div> financing in the past three years and received total net proceeds of approximately US$105.3&#160;million from our initial public offering. We spent RMB280.7&#160;million and RMB868.0&#160;million in net cash to finance our operations in 2018 and 2019, respectively, and generated RMB433.6&#160;million (US$66.4 million) in net cash from our operations in 2020. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We expect our expenses to increase significantly in connection with our ongoing activities, particularly as we advance the clinical development of our clinical-stage drug candidates, continue the research and development of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> stage drug candidates and initiate additional clinical trials of, and seek regulatory approval for, these and other future drug candidates. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if we obtain regulatory approvals for any of our drug candidates, we expect to incur significant commercialization expenses relating to product manufacturing, marketing, sales and distribution and post-approval commitments to continue monitoring the efficacy and safety data of our future products on the market. In particular, costs that may be required for the manufacture of any drug candidate that has received regulatory approval may be substantial as we may need to modify or increase our production capacity in the future at manufacturing facilities. We may also incur expenses as we create additional infrastructure to support our operations as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations through public or private equity offerings, debt financing, collaborations or licensing arrangements or other sources. If we are unable to raise capital when needed or on acceptable terms, we could be forced to delay, limit, reduce or terminate our research and development programs or any future commercialization efforts. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> has spread globally and the World Health Organization (WHO) has declared it a pandemic. While still evolving, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has brought uncertainties and interruptions to global economy and caused significant volatility across the financial markets, which had a cooling effect on the financing and investing activities in general. We believe that our current cash and cash equivalents, together with our cash generated from operating activities, financing activities, our initial public offering and private placement, will be sufficient to meet our present anticipated working capital requirements and capital expenditures. However, if the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and volatility in the financial markets continue, our financing activities in future to raise additional capital may be materially and adversely affected, which may in turn have an adverse effect on our ability to meet our working capital requirement and our liquidity. For other risks related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> see &#8220;&#8212;Our business and results of operations could be adversely affected by public health crisis (including the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> global pandemic) and natural catastrophes or other disasters outside of our control in the locations in which we, our suppliers, CROs, CMOs and other contractors operate.&#8221; </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Raising additional capital may cause dilution to the interests to the holders of our ADSs and our shareholders, restrict our operations or require us to relinquish rights to our technologies or drug candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may seek additional funding through a combination of equity offerings, debt financings, collaborations, licensing arrangements, strategic alliances or partnerships and government grants or subsidies. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a holder of our ADSs. The incurrence of additional indebtedness or the issuance of certain equity securities could give rise to increased fixed payment obligations and also result in certain additional restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. In addition, the issuance of additional equity securities, or the possibility of such issuance, may cause the market price of our ADSs to decline. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event we enter into collaborations or licensing arrangements in order to raise capital, we may be required to accept unfavorable terms, including relinquishing or licensing to a third party our rights to technologies or drug candidates on unfavorable terms, which we would have otherwise sought to develop or commercialize on our own or reserve for future potential arrangements when we are more likely to achieve more favorable terms. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Clinical Development of Our Drug Candidates </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. While our exclusive focus is to develop drug candidates with potential to become novel or highly differentiated drugs in China and globally, we cannot guarantee that we are able to achieve this for any of our drug candidates. Failure can occur at any time during the clinical development process. The results of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and early clinical trials of our drug candidates may not be predictive of the results of later-stage clinical trials. Drug candidates during later stages of clinical trials may fail to show the desired results in safety and efficacy despite having progressed through <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and initial clinical trials and despite the level of scientific rigor in the study, design and adequacy of execution. In some instances, there can be significant variability in safety and/or efficacy results among different trials of the same drug candidate due to numerous factors, including, but not limited to, differences in individual patient conditions, including genetic differences, and other compounding factors, such as other medications or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-existing</div> medical conditions. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In the case of any trials we conduct, results may differ from earlier trials due to the larger number of clinical trial sites and additional countries and languages involved in such trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to a lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. We cannot guarantee that our future clinical trial results will be favorable based on currently available clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> data. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We depend substantially on the success of our drug candidates, all of which are in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> or clinical development, and our ability to identify additional drug candidates. If we are unable to successfully identify new drug candidates, complete clinical development, obtain regulatory approval and commercialize our drug candidates, or experience significant delays in doing so, our business will be materially harmed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our business will depend on the successful development, regulatory approval and commercialization of our drug candidates for the treatment of patients with our targeted indications, all of which are still in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> or clinical development, and other new drug candidates that we may identify and develop. As of the date of annual report, we have obtained IND approvals from the NMPA for eight of our drug candidates, felzartamab, olamkicept, efineptakin alfa, lemzoparlimab, uliledlimab, plonmarlimab, eftansomatropin alfa and TJ210. In addition, we have obtained IND approvals from the FDA for six of our drug candidates, lemzoparlimab, uliledlimab, plonmarlimab, TJ210, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B;</div> from the Taiwan Food and Drug Administration (the &#8220;TFDA&#8221;) for two of our drug candidates, felzartamab and olamkicept; and from the Korea Ministry of Food and Drug Safety (the &#8220;MFDS&#8221;) for olamkicept. However, we cannot guarantee that we are able to obtain regulatory approvals for our other existing drug candidates in a timely manner, or at all. In addition, none of our drug candidates has been approved for marketing in China or any other jurisdiction. Each of our drug candidates will require additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and/ or clinical development, regulatory approvals in multiple jurisdictions, development of manufacturing supply and capacity, substantial investment and significant marketing efforts before we generate any revenue from product sales. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The success of our drug candidates will depend on several factors, including but not limited to the successful completion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and/or clinical trials or studies, receipt of regulatory approvals from applicable regulatory authorities for planned clinical trials, future clinical trials or drug registrations, establishing adequate manufacturing capabilities and capacities, commercialization of our existing drug candidates, hiring sufficient technical experts to oversee all development and regulatory activities and license renewal and meeting of the safety requirements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we do not achieve one or more of these in a timely manner or at all, we could experience significant delays in our ability to obtain approval for our drug candidates, which would materially harm our business and we may not be able to generate sufficient revenues and cash flows to continue our operations. As a result, our financial condition, results of operations and prospects will be materially and adversely harmed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be able to identify, discover or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> new drug candidates, and may allocate our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may later prove to be more profitable, or for which there is a greater likelihood of success. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Although a substantial amount of our effort will focus on the continued clinical testing, potential approval, and commercialization of our existing drug candidates, the success of our business depends in part upon our ability to identify, license, discover, develop, or commercialize additional drug candidates. Research programs to identify new drug candidates require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs or drug candidates that ultimately prove to be unsuccessful. Our research programs or licensing efforts may fail to identify, discover or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> new drug candidates for clinical development and commercialization for a number of reasons, including, without limitation, the following: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our research or business development methodology or search criteria and process may be unsuccessful in identifying potential drug candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our potential drug candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">it may take greater human and financial resources to identify additional therapeutic opportunities for our drug candidates or to develop suitable potential drug candidates through internal research programs than we possess, thereby limiting our ability to diversify and expand our drug portfolio. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because we have limited financial and managerial resources, we focus on research programs and drug candidates for specific indications. As a result, we may forgo or delay pursuit of opportunities with other drug candidates or for other indications that later may prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our drug candidates or to develop suitable potential drug candidates through internal research programs, which could materially adversely affect our future growth and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we encounter delays or difficulties enrolling patients in our clinical trials, our clinical development progress could be delayed or otherwise adversely affected. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to initiate or continue clinical trials for our drug candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the NMPA, the FDA, or similar regulatory authorities, or if there are delays in the enrollment of eligible patients as a result of the competitive clinical enrollment environment. The inability to enroll a sufficient number of patients who meet the applicable criteria for our clinical trials would result in significant delays. As of the date of this annual report, we have initiated clinical trials for olamkicept in South Korea and Greater China, for efineptakin alfa and eftansomatropin alfa in China, for felzartamab in Greater China, for TJ210 in the United States, for lemzoparlimab, plonmarlimab and uliledlimab in China and the United States. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, some of our competitors have ongoing clinical trials for drug candidates that treat the same indications as our drug candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in the clinical trials of our competitors&#8217; drug candidates, which may further delay our clinical trial enrollments. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patient enrollment for our clinical trials may be affected by other factors, including but not limited to the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">severity of the disease under investigation; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">total size and nature of the relevant patient population; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">design and eligibility criteria for the clinical trial in question; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">perceived risks and benefits of the drug candidate under study; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our resources to facilitate timely enrollment in clinical trials; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">patient referral practices of physicians; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">availability of competing therapies also undergoing clinical trials; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our investigators&#8217; or clinical trial sites&#8217; efforts to screen and recruit eligible patients; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">proximity and availability of clinical trial sites for prospective patients. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we are able to enroll a sufficient number of patients in our clinical trials, delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our drug candidates. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If clinical trials of our drug candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Before obtaining regulatory approval for the sale of our drug candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our drug candidates in humans. We may experience numerous unexpected events during, or as a result of, clinical trials that could delay or prevent our ability to receive regulatory approval or commercialize our drug candidates, including, without limitation: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulators, institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our inability to reach agreements on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">manufacturing issues, including problems with manufacturing, supply quality, compliance with good manufacturing practice, or GMP, or obtaining sufficient quantities of a drug candidate from third parties for use in a clinical trial; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">clinical trials of our drug candidates may produce negative or inconclusive results, and we may decide to conduct additional clinical trials or abandon drug development programs, or regulators may require us to do so; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the number of patients required for clinical trials of our drug candidates may be larger than we anticipate, enrollment may be insufficient or slower than we anticipate or patients may drop out at a higher rate than we anticipate; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our third-party contractors, including clinical investigators, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we might have to suspend or terminate clinical trials of our drug candidates for various reasons, including a finding of a lack of clinical response or other unexpected characteristics or a finding that participants are being exposed to unacceptable health risks; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">regulators, IRBs or ethics committees may require that we or our investigators suspend or terminate clinical research or not rely on the results of clinical research for various reasons, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with regulatory requirements; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the cost of clinical trials of our drug candidates may be greater than we anticipate; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the supply or quality of our drug candidates, companion diagnostics or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are required to conduct additional clinical trials or other testing of our drug candidates beyond those that we currently plan, if we are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if they raise safety concerns, we may (i)&#160;be delayed in obtaining regulatory approval for our drug candidates; (ii)&#160;obtain approval for indications that are not as broad as intended; (iii)&#160;not obtain regulatory approval at all; (iv)&#160;have the drug removed from the market after obtaining regulatory approval; (v)&#160;be subject to additional post-marketing testing requirements; (vi)&#160;be subject to restrictions on how the drug is distributed or used; or (vii)&#160;be unable to obtain reimbursement for use of the drug. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant clinical trial delays may also increase our development costs and could shorten any periods during which we have the exclusive right to commercialize our drug candidates or allow our competitors to bring drugs to market before we do. This could impair our ability to commercialize our drug candidates and may harm our business and results of operations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Obtaining Regulatory Approval for Our Drug Candidates </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">All material aspects of the research, development and commercialization of pharmaceutical products are heavily regulated. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All jurisdictions in which we intend to conduct our pharmaceutical-industry activities regulate these activities in great depth and detail. We intend to focus our activities in the major markets of China and the United States. These jurisdictions strictly regulate the pharmaceutical industry, and in doing so they employ broadly similar regulatory strategies, including regulation of product development and approval, manufacturing, and marketing, sales and distribution of products. However, there are differences in the regulatory regimes that make for a more complex and costly regulatory compliance burden for a company like us that plans to operate in these regions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The process of obtaining regulatory approvals and compliance with appropriate laws and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable requirements at any time during the product development process and approval process, or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include: refusal to approve pending applications; withdrawal of an approval; license revocation; clinical hold; voluntary or mandatory product recalls; product seizures; total or partial suspension of production or distribution; injunctions; fines; refusals of government contracts; providing restitution; undergoing disgorgement; or other civil or criminal penalties. Failure to comply with these regulations could have a material adverse effect on our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The regulatory approval processes of the NMPA, the FDA and other comparable regulatory authorities are time-consuming and may evolve over time, and if we are ultimately unable to obtain regulatory approval for our drug candidates, our business will be substantially harmed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The time required to obtain the approval of the NMPA, the FDA and other comparable regulatory authorities is inherently uncertain and depends on numerous factors, including the substantial discretion of the regulatory authorities. Generally, such approvals take many years to obtain following the commencement of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials, although they are typically provided within 12 to 18 months after clinical trials are completed. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a drug candidate&#8217;s clinical development and may vary among jurisdictions. As of the date of this annual report, we have obtained IND approvals from the NMPA for eight of our drug candidates, felzartamab, olamkicept, efineptakin alfa, lemzoparlimab, uliledlimab, plonmarlimab, eftansomatropin alfa and TJ210.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div>In addition, we have obtained IND approvals from the FDA for six of our drug candidates, lemzoparlimab, uliledlimab, plonmarlimab, TJ210, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B;</div> from the TFDA for two of our drug candidates, felzartamab and olamkicept; and from the MFDS for olamkicept. However, we cannot guarantee that we are able to obtain regulatory approvals for our other existing drug candidates or any drug candidates we may discover, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or acquire and seek to develop in the future. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our drug candidates could fail to receive the regulatory approval of the NMPA, the FDA or a comparable regulatory authority for many reasons, including, without limitation: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">disagreement with the design or implementation of our clinical trials; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to demonstrate that a drug candidate is safe and effective and potent for its proposed indication; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure of our clinical trial results to meet the level of statistical significance required for approval; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure of our clinical trial process to pass relevant good clinical practice (&#8220;GCP&#8221;) inspections; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to demonstrate that a drug candidate&#8217;s clinical and other benefits outweigh its safety risks; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">disagreement with our interpretation of data from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies or clinical trials; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">insufficient data collected from the clinical trials of our drug candidates to support the submission and filing of a new drug application, or NDA, or other submissions or to obtain regulatory approval; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure of our drug candidates to pass current Good Manufacturing Practice (&#8220;cGMP&#8221;), inspections during the regulatory review process or across the production cycle of our drug; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure of our clinical sites to pass audits carried out by the NMPA, the FDA or comparable regulatory authorities, resulting in a potential invalidation of our research data; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">findings by the NMPA, the FDA or comparable regulatory authorities of deficiencies related to our manufacturing processes or the facilities of third-party manufacturers with whom we contract for clinical and commercial supplies; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">changes in approval policies or regulations that render our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical data insufficient for approval; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure of our clinical trial process to keep up with any scientific or technological advancements required by approval policies or regulations. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The NMPA, the FDA or a comparable regulatory authority may require more information, including additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> or clinical data, to support approval, which may delay or prevent approval and our commercialization plans. Even if we were to obtain approval, regulatory authorities may approve any of our drug candidates for fewer or more limited indications than we request, grant approval contingent on the performance of costly post-marketing clinical trials, or approve a drug candidate with an indication that is not desirable for the successful commercialization of that drug candidate. Any of the foregoing scenarios could materially harm the commercial prospects of our drug candidates. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The absence of patent linkage, patent term extension and data and market exclusivity for NMPA-approved pharmaceutical products could increase the risk of early generic competition with our products in China. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the United States, the Federal Food, Drug and Cosmetic Act, as amended by the law generally referred to as &#8220;Hatch-Waxman,&#8221; provides the opportunity for patent-term restoration, meaning a patent term extension of up to five years to reflect patent term lost during certain portions of product development and the FDA regulatory review process. Hatch-Waxman also has a process for patent linkage, pursuant to which the FDA will stay approval of certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> applications during the pendency of litigation between the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> applicant and the patent holder or licensee, generally for a period of 30 months. Finally, Hatch-Waxman provides for statutory exclusivities that can prevent submission or approval of certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> marketing applications. For example, federal law provides a five-year period of exclusivity within the United States to the first applicant to obtain approval of a new chemical entity and three years of exclusivity protecting certain innovations to previously approved active ingredients where the applicant was required to conduct new clinical investigations to obtain approval for the modification. Similarly, the United States Orphan Drug Act provides seven years of market exclusivity for certain drugs to treat rare diseases, where the FDA designates the drug candidate as an orphan drug and the drug is approved for the designated orphan indication. These provisions, designed to promote innovation, can prevent competing products from entering the market for a certain period of time after the FDA grants marketing approval for the innovative product. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depending upon the timing, duration and specifics of any FDA marketing approval process for any drug candidates we may develop, one or more of our U.S. patents, if issued, may be eligible for limited patent term extension under Hatch-Waxman. Hatch-Waxman permits a patent extension term of up to five years as compensation for patent term lost during clinical trials and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of drug approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Furthermore, the applicable time period or the scope of patent protection afforded could be less than we request. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In China, however, there is no currently effective law or regulation providing for patent term extension, patent linkage, or data exclusivity (referred to as regulatory data protection). Therefore, a lower-cost generic drug can emerge onto the market much more quickly. Chinese regulators have set forth a framework for integrating patent linkage and data exclusivity into the Chinese regulatory regime, as well as for establishing a pilot program for patent term extension. To be implemented, this framework will require adoption of regulations. To date, no regulations have been issued. These factors result in weaker protection for us against generic competition in China than could be available to us in the United States. For instance, the patents we have in China are not yet eligible to be extended for patent term lost during clinical trials and the regulatory review process. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our drug candidates may cause undesirable adverse events or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Undesirable adverse events caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and may result in a more restrictive label, a delay or denial of regulatory approval by the NMPA, the FDA or other comparable regulatory authorities, or a significant change in our clinical protocol or even our development plan. In particular, as is the case with drugs treating cancers and auto-immune diseases, it is likely that there may be side effects, such as nausea, fatigue and infusion-related reactions, associated with the use of certain of our drug candidates. Results of our trials could reveal a high and unacceptable severity or prevalence of certain adverse events. In such an event, our trials could be suspended or terminated and the NMPA, the FDA or other comparable regulatory authorities could order us to cease further development of, or deny approval of, our drug candidates for any or all targeted indications. Adverse events related to our drug candidates may affect patient recruitment or the ability of enrolled subjects to complete the trial, and could result in potential liability claims. Any of these occurrences may significantly harm our reputation, business, financial condition and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, if we or others identify undesirable side effects caused by those of our existing drug candidates that have received regulatory approval, or our other drug candidates after having received regulatory approval, this may lead to potentially significant negative consequences which include, but are not limited to, the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may suspend marketing of the drug candidate; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory authorities may withdraw their approvals of or revoke the licenses for the drug candidate; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory authorities may require additional warnings on the label; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA may require the establishment of a Risk Evaluation and Mitigation Strategy, or REMS, or the NMPA or a comparable regulatory authority may require the establishment of a similar strategy that may, for instance, restrict distribution of our drugs and impose burdensome implementation requirements on us; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be required to conduct specific post-marketing studies; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we could be subjected to litigation proceedings and held liable for harm caused to subjects or patients; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our reputation may suffer. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of these events could prevent us from achieving or maintaining market acceptance of any particular drug candidate that is approved and could significantly harm our business, results of operations and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, combination therapy, such as using our wholly-owned drug candidates as well as third-party agents, may involve unique adverse events that could be exacerbated compared with adverse events from monotherapies. Results of our trials could reveal a high and unacceptable severity or prevalence of adverse events. These types of adverse events could be caused by our drug candidates and could cause us or regulatory authorities to interrupt, delay or halt clinical trials and may result in a more restrictive indication or the delay or denial of regulatory approval by the NMPA, the FDA or other comparable regulatory authority. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are unable to obtain the NMPA approval for our drug candidates to be eligible for an expedited registration pathway as innovative drug candidates, the time and cost we incur to obtain regulatory approvals may increase. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The NMPA has mechanisms in place for expedited review and approval for drug candidates that are innovative drug applications, provided such drug or drug candidate has a new and clearly defined structure, pharmacological property and apparent clinical value and has not been marketed anywhere in the world. However, there is no assurance that an innovative drug designation will be granted by the NMPA for any of our drug candidates. Moreover, an innovative drug designation, which is typically granted only towards the end of a drug&#8217;s developmental stage, does not increase the likelihood that our drug candidates will receive regulatory approval on a fast-track basis, or at all. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, there have been recent regulatory initiatives in China in relation to clinical trial approvals, the evaluation and approval of certain drugs and medical devices and the simplification and acceleration of the clinical trial process. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result, the regulatory process in China is evolving and subject to change. Any future policies, or changes to current polices might require us to change our planned clinical study design or otherwise spend additional resources and effort to obtain approval of our drug candidates. In addition, policy changes may contain significant limitations related to use restrictions for certain age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for our drug candidates in the PRC, or any approval contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of our drug candidates or any other drug candidate that we may <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license,</div> acquire or develop in the future. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Even if we receive regulatory approval for our drug candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expenses and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our drug candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the NMPA, the FDA or a comparable regulatory authority approves any of our drug candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the drug will be subject to extensive and ongoing regulatory requirements on pharmacovigilance. These requirements include submissions of safety and other post-marketing information and reports, registration, random quality control testing, adherence to any chemistry, manufacturing, and controls (&#8220;CMC&#8221;), variations, continued compliance with current cGMPs, and GCPs and potential post-approval studies for the purposes of license renewal. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any regulatory approvals that we receive for our drug candidates may also be subject to limitations on the approved indicated uses for which the drug may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing studies, including Phase 4 studies for the surveillance and monitoring of the safety and efficacy of the drug. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, once a drug is approved by the NMPA, the FDA or a comparable regulatory authority for marketing, it is possible that there could be a subsequent discovery of previously unknown problems with the drug, including problems with third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements. If any of the foregoing occurs with respect to our drug products, it may result in, among other things: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on the marketing or manufacturing of the drug, withdrawal of the drug from the market, or voluntary or mandatory drug recalls; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fines, warning letters or holds on our clinical trials; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal by the NMPA, the FDA or comparable regulatory authorities to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of drug license approvals; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal by the NMPA, the FDA or comparable regulatory authorities to accept any of our other IND approvals, NDAs or BLAs; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">drug seizure or detention, or refusal to permit the import or export of drugs; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">injunctions or the imposition of civil, administrative or criminal penalties. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any government investigation of alleged violations of law could require us to expend significant time and resources and could generate negative publicity. Moreover, regulatory policies may change or additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our drug candidates. If we are not able to maintain regulatory compliance, we may lose the regulatory approvals that we have already obtained and may not achieve or sustain profitability, which in turn could significantly harm our business, financial condition and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Illegal and/or parallel imports and counterfeit pharmaceutical products may reduce demand for our future approved drug candidates and could have a negative impact on our reputation and business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The illegal importation of competing products from countries where government price controls or other market dynamics result in lower prices may adversely affect the demand for our future approved drug candidates and, in turn, may adversely affect our sales and profitability in China and other countries where we commercialize our products. Unapproved foreign imports of prescription drugs are illegal under the current laws of China. However, illegal imports may continue to occur or even increase as the ability of patients and other customers to obtain these lower priced imports continues to grow. Furthermore, cross-border imports from lower-priced markets (which are known as parallel imports) into higher-priced markets could harm sales of our future drug products and exert commercial pressure on pricing within one or more markets. In addition, competent government authorities may expand consumers&#8217; ability to import lower priced versions of our future approved products or competing products from outside China or other countries where we operate. Any future legislation or regulations that increase consumer access to lower priced medicines from outside China or other countries where we operate could have a material adverse effect on our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain products distributed or sold in the pharmaceutical market may be manufactured without proper licenses or approvals, or be fraudulently mislabeled with respect to their content or manufacturers. These products are generally referred to as counterfeit pharmaceutical products. The counterfeit pharmaceutical product control and enforcement system, particularly in developing markets such as China, may be inadequate to discourage or eliminate the manufacturing and sale of counterfeit pharmaceutical products imitating our products. Since counterfeit pharmaceutical products in many cases have very similar appearances compared with the authentic pharmaceutical products but are generally sold at lower prices, counterfeits of our products could quickly erode the demand for our future approved drug candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, counterfeit pharmaceutical products are not expected to meet our or our collaborators&#8217; rigorous manufacturing and testing standards. A patient who receives a counterfeit pharmaceutical product may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit pharmaceutical products sold under our or our collaborators&#8217; brand name(s). In addition, thefts of inventory at warehouses, plants or while <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-transit,</div> which are not properly stored and which are sold through unauthorized channels, could adversely impact patient safety, our reputation and our business. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Commercialization of Our Drug Candidates </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our drug candidates may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if our drug candidates receive regulatory approval, they may nonetheless fail to gain sufficient market acceptance by physicians and patients and others in the medical community. Physicians and patients may prefer other drugs or drug candidates to ours. If our drug candidates do not achieve an adequate level of acceptance, we may not generate significant revenue from sales of our drugs or drug candidates and may not become profitable. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The degree of market acceptance of our drug candidates, if and only when they are approved for commercial sale, will depend on a number of factors, including, but not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the clinical indications for which our drug candidates are approved; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">physicians, hospitals and patients considering our drug candidates as a safe and effective treatment; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">whether our drug candidates have achieved the perceived advantages of our drug candidates over alternative treatments; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the prevalence and severity of any side effects; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product labeling or package insert requirements of the NMPA, the FDA or other comparable regulatory authorities; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">limitations or warnings contained in the labeling approved by the NMPA, the FDA or other comparable regulatory authorities; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">timing of market introduction of our drug candidates as well as competitive drugs; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cost of treatment in relation to alternative treatments; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">availability of adequate coverage and reimbursement under the national and provincial reimbursement drug lists in the PRC, or from third-party payors and government authorities in the United States or any other jurisdictions; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">willingness of patients to pay any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> expenses in the absence of coverage and reimbursement by third-party payors and government authorities; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">relative convenience and ease of administration, including as compared with alternative treatments and competitive therapies; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the effectiveness of our sales and marketing efforts. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If our drug candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals or others in the medical community, we will not be able to generate significant revenue or become profitable. Even if our drugs achieve market acceptance, we may not be able to maintain such market acceptance over time if new products or technologies are introduced which are more favorably received than our drugs, are more cost effective or render our drugs obsolete. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our drug candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. While our exclusive focus is to develop drug candidates with potential to become novel or highly differentiated drugs, we continue to face competition with respect to our current drug candidates, and will face competition with respect to any drug candidates that we may seek to develop or commercialize in the future. Our competitors include major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. We are developing our drug candidates for the treatment of cancer in competition with a number of large biopharmaceutical companies that currently market and sell drugs or are pursuing the development of drugs also for the treatment of cancer. Some of these competitive drugs and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. For details, see &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Our Drug Pipeline.&#8221; Potential competitors further include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of our competitors have substantially greater financial, technical, and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval from the NMPA, the FDA or other comparable regulatory authorities more rapidly than we are able to and may be more effective in selling and marketing their products as well. For example, the NMPA has recently accelerated market approval of drugs for diseases with high unmet medical need. In particular, the NMPA may review and approve drugs that have gained regulatory market approval in the United States, the European Union or Japan in the recent ten years without requiring further clinical trials in China. This may lead to potential increased competition from drugs which have already obtained approval in other jurisdictions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring, or licensing on an exclusive basis, products that are more effective or less costly than any drug candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization, and market penetration than we do. Additionally, technologies developed by our competitors may render our potential drug candidates uneconomical or obsolete, and we may not be successful in marketing our drug candidates against competitors. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The manufacture of biopharmaceutical products is a complex process which requires significant expertise and capital investment, and if we encounter problems in establishing our manufacturing capabilities or manufacturing our future products, our business could suffer. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have limited experience in managing the manufacturing process. The manufacture of biopharmaceutical products is a complex process, in part due to strict regulatory requirements. As of the date of this annual report, we have no existing manufacturing infrastructure or capabilities. We intend to build a comprehensive biologics manufacturing facility in Hangzhou, China (the &#8220;Hangzhou Facility&#8221;) as part of our strategic plan to become a fully integrated biopharma company. We have taken concrete steps to execute this plan. These steps include detailed operational planning for the facility, actions taken to secure an appropriate site, and negotiations with external financing providers. The Hangzhou Facility targets to have a pilot capacity of 2 production lines (1 line configured with 2 x 2,000L and another line with 1 x 2,000L) by 2022 and commercially progressive capacity up to 8 x 4,000L to begin operation by the end of 2023. Construction is expected to commence in April 2021 and ready for use by the end of 2023. However, the investment for building this new biologics manufacturing facility that is compliant with cGMP regulations will be a significant upfront cost for us. In turn, this could materially harm our commercialization plans. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, problems may arise during the manufacturing process for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials, delays related to the construction of new facilities or expansion of any future manufacturing facilities, including changes in manufacturing production sites and limits to manufacturing capacity due to regulatory requirements, changes in the types of products produced, increases in the prices of raw materials, physical limitations that could inhibit continuous supply, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">man-made</div> or natural disasters and environmental factors. If problems arise during the production of a batch of future products, that batch of future products may have to be discarded and we may experience product shortages or incur added expenses. This could, among other things, lead to increased costs, lost revenue, damage to customer relationships, time and expense spent investigating the cause and, depending on the cause, similar losses with respect to other batches or products. If problems are not discovered before such product is released to the market, recall and product liability costs may also be incurred. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have no experience in launching and marketing drug candidates. We may not be able to effectively build and manage our sales network, or benefit from third-party collaborators&#8217; sales network. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We currently have no sales, marketing or commercial product distribution capabilities and have no experience in marketing drugs. We intend to develop an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other biopharmaceutical companies to recruit, hire, train and retain marketing and sales personnel. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable or decide not to establish internal sales, marketing and commercial distribution capabilities for any or all of the drugs we develop, we will likely pursue collaborative arrangements regarding the sales and marketing of our drugs. However, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or, if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend on the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties, and our revenue from product sales may be lower than if we had commercialized our drug candidates ourselves. We will also face competition in our search for third parties to assist us with the sales and marketing efforts of our drug candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There can be no assurance that we will be able to develop <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> sales and commercial distribution capabilities or establish or maintain relationships with third-party collaborators to successfully commercialize any product, and as a result, we may not be able to generate product sales revenue. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Even if we are able to commercialize any approved drug candidates, reimbursement may be limited or unavailable in certain market segments for our drug candidates, and we may be subject to unfavorable pricing regulations, which could harm our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The regulations that govern regulatory approvals, pricing and reimbursement for new therapeutic products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or licensing approval is granted. In some <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a drug in a particular country, but then be subject to price regulations that delay our commercial launch of the drug and negatively impact the revenues we are able to generate from the sale of the drug in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more drug candidates, even if our drug candidates obtain regulatory approval. For example, according to a statement, Opinions on Reforming the Review and Approval Process for Pharmaceutical Products and Medical Devices, issued by the PRC State Council in August 2015, the enterprises applying for new drug approval will be required to undertake that the selling price of new drug on PRC mainland market shall not be higher than the comparable market prices of the product in its country of origin or PRC&#8217;s neighboring markets, as applicable. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to commercialize any drugs successfully also will depend in part on the extent to which reimbursement for these drugs and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the global healthcare industry is cost containment. Government authorities and these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Reimbursement may impact the demand for, or the price of, any drug for which we obtain regulatory approval. Obtaining reimbursement for our drugs may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any drug candidate that we successfully develop. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There may be significant delays in obtaining reimbursement for approved drug candidates, and coverage may be more limited than the purposes for which the drug candidates are approved by the NMPA, the FDA or other comparable regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on payments allowed for lower cost drugs that are already reimbursed, and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future weakening of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any future approved drug candidates and any new drugs that we develop could have a material adverse effect on our business, our operating results, and our overall financial condition. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our drug candidates and affect the prices we may obtain. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States and certain other jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our drug candidates, restrict post-approval activities and affect our ability to sell profitably any drug candidates for which we obtain marketing approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, became law. The ACA is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Among the provisions of the ACA of importance to our drug candidates are the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-sale</div></div> discounts off negotiated prices; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">extension of manufacturers&#8217; Medicaid rebate liability; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expansion of eligibility criteria for Medicaid programs; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expansion of the entities eligible for discounts under the Public Health Service Act&#8217;s pharmaceutical pricing program; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">new requirements to report to CMS financial arrangements with physicians and teaching hospitals; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a new requirement to annually report to the FDA drug samples that manufacturers and distributors provide to physicians; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals, if any, of our drug candidates may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing conditions and other requirements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">As we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-license</div> some of our commercialization rights and engage in other forms of collaboration worldwide, including conducting clinical trials abroad, we may be exposed to specific risks of conducting our business and operations in international markets. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Markets outside of China form an important component of our growth strategy, as we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-license</div> some of our commercialization rights to third parties outside the PRC and conduct certain of our clinical trials abroad. If we fail to obtain applicable licenses or fail to enter into strategic collaboration arrangements with third parties in these markets, or if these collaboration arrangements turn out unsuccessful, our revenue-generating growth potential will be adversely affected. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, international business relationships subject us to additional risks that may materially adversely affect our ability to attain or sustain profitable operations, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">efforts to enter into collaboration or licensing arrangements with third parties in connection with our international sales, marketing and distribution efforts may increase our expenses or divert our management&#8217;s attention from the acquisition or development of drug candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in a specific country&#8217;s or region&#8217;s political and cultural climate or economic condition; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">differing regulatory requirements for drug approvals and marketing internationally; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">difficulty of effective enforcement of contractual provisions in local jurisdictions; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">potentially reduced protection for intellectual property rights; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">potential third-party patent rights; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unexpected changes in tariffs, trade barriers and regulatory requirements; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">economic weakness, including inflation or political instability; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">compliance with tax, employment, immigration and labor laws for employees traveling abroad; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the effects of applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PRC</div> tax structures and potentially adverse tax consequences; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incidental to doing business in another country; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">workforce uncertainty and labor unrest; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the potential for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from an international market with low or lower prices rather than buying them locally; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure of our employees and contracted third parties to comply with Office of Foreign Assets Control rules and regulations and the Foreign Corrupt Practices Act of the United States, and other applicable rules and regulations; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">business interruptions resulting from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">geo-political</div> actions, including war and terrorism, or natural disasters, including earthquakes, volcanoes, typhoons, floods, hurricanes and fires. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These and other risks may materially adversely affect our ability to attain or sustain revenue from international markets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If safety, efficacy, or other issues arise with any medical product that is used in combination with our drug candidates, we may be unable to market such drug candidate or may experience significant regulatory delays or supply shortages, and our business could be materially harmed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We plan to develop certain of our drug candidates for use as a combination therapy. If the NMPA, the FDA or another comparable regulatory agency revokes its approval of another therapeutic we use in combination with our drug candidates, we will not be able to market our drug candidates in combination with such revoked therapeutic. If safety or efficacy issues arise with these or other therapeutics that we seek to combine with our drug candidates in the future, we may experience significant regulatory delays, and we may be required to redesign or terminate the applicable clinical trials. In addition, if manufacturing or other issues result in a supply shortage of any component of our combination drug candidates or if we cannot secure supply of any component of our drug candidates at commercially reasonable or acceptable prices, we may not be able to complete clinical development of our drug candidates on our current timeline or within our current budget, or at all. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lack of third-party combination drugs may materially and adversely affect demand for our drugs. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our drug candidates may be administered in combination with drugs of other pharmaceutical companies as one regimen. In addition, we often use such third-party drugs in our development and clinical trials as controls for our studies. As a result, both the results of our clinical trials and the sales of our drugs may be affected by the availability of these third-party drugs. If other pharmaceutical companies discontinue these combination drugs, regimens that use these combination drugs may no longer be prescribed, and we may not be able to introduce or find an alternative drug to be used in combination with our drugs at all or in a timely manner and on a cost-effective basis. As a result, demand for our drugs may be lowered, which would in turn materially and adversely affect our business and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Reliance on Third Parties </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">As we rely on third parties to conduct our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials, if we lose our relationships with these third parties or if they do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have relied on and plan to continue to rely on third-party contract research organization (&#8220;CROs&#8221;) to monitor and manage data for some of our ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical programs. We rely on these parties for the execution of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We also rely on third parties to assist in conducting our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies in accordance with Good Laboratory Practices (&#8220;GLP&#8221;). We and our CROs are required to comply with GCP, GLP and other regulatory regulations and guidelines enforced by the NMPA, the FDA and comparable foreign regulatory authorities for all of our drug candidates in clinical development. Regulatory authorities enforce these GCP, GLP or other regulatory requirements through periodic inspections of trial sponsors, investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP, GLP or other regulatory requirements, the relevant data generated in our clinical trials may be deemed unreliable and the NMPA, the FDA or other comparable regulatory authorities may require us to perform additional clinical studies before approving our marketing applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP requirements. In addition, our clinical trials must be conducted with drug candidates or products produced under cGMP requirements. Failure to comply with these regulations may require us to repeat <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical trials, which would delay the regulatory approval process. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our CROs have the right to terminate their agreements with us in the event of an unrectified material breach. If any of our relationships with our third-party CROs is terminated, we may not be able to (i)&#160;enter into arrangements with alternative CROs or do so on commercially reasonable terms or (ii)&#160;meet our desired clinical development timelines. In addition, there is a natural transition period when a new CRO commences work, and the new CRO may not provide the same type or level of services as the original provider and data from our clinical trials may be compromised as a result. There is also a need for relevant technology to be transferred to the new CRO, which may take time and further delay our development timelines. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Except for remedies available to us under our agreements with our CROs, we cannot control whether or not our CROs devote sufficient time and resources to our ongoing clinical, nonclinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> programs. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. As a result, our results of operations and the commercial prospects for our drug candidates would be harmed and our costs could increase. In turn, our ability to generate revenues could be delayed or compromised. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because we rely on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves certain risks that third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires us to disclose our proprietary information to these third parties, which could increase the risk that such information will be misappropriated. We currently have a small number of employees, which limits the internal resources we have available to identify and monitor our third-party service providers. To the extent we are unable to identify and successfully manage the performance of third-party service providers in the future, our business may be adversely affected. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We expect to rely on third parties to manufacture at least a portion of our drug candidate supplies, and we intend to rely on third parties for at least a portion of the manufacturing process of our drug candidates, if approved. Our business could be harmed if those third parties fail to provide us with sufficient quantities of product or fail to do so at acceptable quality levels or prices. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we plan to either construct or acquire a facility that will be used as our clinical-scale manufacturing and processing facility, we intend to also partially rely on third-party vendors to manufacture supplies and process our drug candidates. We have not yet manufactured or processed our drug candidates on a commercial scale and may not be able to do so for any of our drug candidates. We have limited experience in managing the manufacturing process, and our process may be more difficult or expensive than the approaches currently in use. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our anticipated reliance on third-party manufacturers exposes us to certain risks, including, but not limited to, the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the NMPA, the FDA or other comparable regulatory authorities must approve any manufacturers as part of their regulatory oversight of our drug candidates. This approval would require new testing and cGMP-compliance inspections by the NMPA, the FDA or other comparable regulatory authorities. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our drugs; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our contract manufacturers may have little or no experience with manufacturing our drug candidates, and therefore may require a significant amount of support from us in order to implement and maintain the infrastructure and processes required to manufacture our drug candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our contract manufacturers may have limited capacity or limited manufacturing slots, which may affect the timeline for the production of our drugs; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our contract manufacturers might be unable to timely manufacture our drug candidates or produce the quantity and quality required to meet our clinical and commercial needs, if any; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">contract manufacturers may not be able to execute our manufacturing procedures and other logistical support requirements appropriately; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our future contract manufacturers may not perform as agreed, may not devote sufficient resources to our drugs, or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our drugs; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our contract manufacturers are subject to ongoing periodic unannounced inspections by the NMPA and the FDA to ensure strict compliance with cGMP and other government regulations in the PRC and the United States, respectively, and by other comparable regulatory authorities for corresponding regulatory requirements. We do not have control over third-party manufacturers&#8217; compliance with these regulations and requirements; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our drugs; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our contract manufacturers could breach or terminate their agreements with us; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our contract manufacturers may be unable to sustain their business and become bankrupt as a result; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">raw materials and components used in the manufacturing process, particularly those for which we have no other source or supplier, may not be available or may not be suitable or acceptable for use due to material or component defects; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">products and components from our third-party manufacturers may be subject to additional customs and import charges, which may cause us to incur delays or additional costs as a result; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">our contract manufacturers and critical reagent suppliers may be subject to inclement weather, as well as natural or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">man-made</div> disasters; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our contract manufacturers may have unacceptable or inconsistent product quality success rates and yields. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of these risks could delay or prevent the completion of our clinical trials or the approval of any of our drug candidates by the NMPA, the FDA or other comparable regulatory authorities, result in higher costs or adversely impact the commercialization of our drug candidates. In addition, we will rely on third parties to perform certain specification tests on our drug candidates prior to delivery to patients. If these tests are not appropriately done and test data is not reliable, patients could be put at risk of serious harm and the NMPA, the FDA or other comparable regulatory authorities could place significant restrictions on our company until deficiencies are remedied. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The manufacture of biopharmaceutical products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Currently, our drug raw materials for our manufacturing activities are supplied by multiple source suppliers. We have agreements for the supply of drug materials with manufacturers or suppliers that we believe have sufficient capacity to meet our demands. In addition, we believe that adequate alternative sources for such supplies exist. However, there is a risk that, if supplies are interrupted, our business would be materially harmed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturers of biopharmaceutical products often encounter difficulties in production, particularly in scaling up or out, validating the production process, and assuring high reliability of the manufacturing process, including the absence of contamination. These problems include logistics and shipping, difficulties with production costs and yields, quality control, including stability of the product, product testing, operator error and availability of qualified personnel, as well as compliance with strictly enforced regulations in the PRC, the United States and other applicable jurisdictions. Further, if contaminants are discovered in the supply of our drug candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time for us to investigate and remedy the contamination. There can be no assurance that any stability failures or other issues relating to the manufacture of our drug candidates will not occur in the future. Additionally, our contract manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environment. If our contract manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide our drug candidate to patients in clinical trials would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of our clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to begin new clinical trials at additional expense or terminate clinical trials completely. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have entered into collaborations and may form or seek collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We may form or seek strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our drug candidates and any future drug candidates that we may develop. Any of these relationships may require us to incur recurring or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> expenses and other charges, increase our near and long-term expenditures, issue securities that dilute the value of our ADSs, or disrupt our management and business. For example, we have entered into a license and collaboration agreement with MorphoSys AG (&#8220;MorphoSys&#8221;), pursuant to which we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> from MorphoSys the development and commercialization rights of felzartamab in Greater China. Another example is our collaboration with AbbVie. In September 2020, we granted AbbVie a global license, excluding Mainland China, Hong Kong and Macau, to develop and commercialize lemzoparlimab (as well as certain other compounds directed against CD47), and we will retain all rights to develop and commercialize lemzoparlimab in Mainland China, Hong Kong and Macau. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The effectiveness of the contract with AbbVie is subject to our performance of certain contractual obligations and regulatory approval; such approval may not be obtained or may be delayed, which could result in a detrimental effect on our collaboration. For a more detailed discussion, please see &#8220;Item 4. Information on the Company&#8212;B. Business&#8212;Our Global Strategic Collaborations&#8212;Global Strategic Partnership with AbbVie.&#8221; In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our drug candidates because they may be deemed to be at too early a stage of development for collaborative effort and third parties may not view our drug candidates as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third party for the development and commercialization of a drug candidate, we can expect to relinquish some or all of the control over the future success of that drug candidate to the third party. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, collaborations involving our drug candidates are subject to specific risks, which include, but are not limited to, the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborators may not pursue the development and commercialization of our drug candidates or may elect not to continue or renew the development or commercialization programs based on clinical trial results, change in their strategic focus due to the acquisition of competitive drugs, availability of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, discontinue a clinical trial, repeat or conduct new clinical trials, or require a new formulation of a drug candidate for clinical testing; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborators could independently develop, or develop with third parties, drugs that compete directly or indirectly with our drug candidates or future drugs; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborators with marketing and distribution rights to one or more of our drug candidates or future drugs may not commit sufficient resources to their marketing and distribution; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborators may not always be cooperative or responsive in providing their services in a clinical trial; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">disputes may arise between us and a collaborator that cause a delay or termination of the research, development or commercialization of our drug candidates, or that result in costly litigation or arbitration that diverts management attention and resources; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable drug candidates; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">collaborators may own or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-own</div> intellectual property covering our drug candidates or future drugs that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result, if we enter into collaboration agreements and strategic partnerships or license our drugs, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate these agreements or partnerships with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neither can we be certain that, following a strategic transaction or license, we will be able to achieve the revenue or specific net income that justifies such transaction. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a drug candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our drug candidates or bring them to market and generate product sales revenue, which would harm our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Intellectual Property </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are unable to obtain and maintain patent and other intellectual property protection for our drug candidates, or if the scope of such intellectual property rights obtained is not sufficiently broad, third parties could develop and commercialize products and technologies similar or identical to ours and compete directly against us, and our ability to successfully commercialize any product or technology may be adversely affected. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our success depends in large part on our ability to protect our proprietary technology and drug candidates from competition by obtaining, maintaining, defending and enforcing our intellectual property rights, including patent rights. As of December&#160;31, 2020, our owned patent portfolio consists of 22 issued patents and 241 patent applications primarily in connection with the drug candidates in our Global Portfolio, including 18 Patent Cooperation Treaty (&#8220;PCT&#8221;) patent applications, 18 U.S. patent applications, 16 PRC patent applications and 211 patent applications in other jurisdictions. In addition, as of December&#160;31, 2020, we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> the Greater China and Korea rights relating to 24 issued patents and 31 pending patent applications primarily in connection with felzartamab, eftansomatropin alfa, olamkicept, enoblituzumab and efineptakin alfa. We seek to protect the drug candidates and technology that we consider commercially important by filing patent applications in China, the United States and other countries or regions, relying on trade secrets or pharmaceutical regulatory protection or employing a combination of these methods. This process is expensive and time-consuming, and we or our licensors may not be able to file and prosecute all necessary or desirable patent applications in all jurisdictions at a reasonable cost or in a timely manner. It is also possible that we or our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or drug candidates or which effectively prevent others from commercializing competitive technologies and drug candidates. The patent examination process may require us or our licensors to narrow the scope of the claims of our or our licensors&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. We cannot assure that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent application from being issued as a patent. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if patents do issue on any of these applications, there can be no assurance that a third party will not challenge their validity, enforceability, or scope, which may result in the patent claims being narrowed or invalidated, or that we will obtain sufficient claim scope in those patents to prevent a third party from competing successfully with our drug candidates. We may become involved in interference, inter partes review, post grant review, ex parte reexamination, derivation, opposition or similar other proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or drug candidates and compete directly with us, or result in our inability to manufacture or commercialize drug candidates without infringing third-party patent rights. Thus, even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our competitors may be able to circumvent our patents by developing similar or alternative technologies or drug candidates in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringing</div> manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and other countries. Such challenges may result in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and drug candidates, or limit the duration of the patent protection of our technology and drug candidates. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such assets might expire before or shortly after such assets are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drug candidates similar or identical to ours. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. Under the America Invents Act (&#8220;AIA&#8221;) enacted in 2011, the United States moved to this <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-to-file</div></div> system in early 2013 from the previous system under which the first to make the claimed invention was entitled to the patent. Assuming the other requirements for patentability are met, the first to file a patent application is entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We enjoy only limited geographical protection with respect to certain patents and may not be able to protect our intellectual property rights throughout the world, including in the PRC. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Filing and prosecuting patent applications and defending patents covering our drug candidates in all countries throughout the world could be prohibitively expensive. Competitors may use our and our licensors&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own drug candidates and, further, may export otherwise infringing drug candidates to territories, including the PRC, where we and our licensors have patent protection, but enforcement rights are not as strong as that in the United States or Europe. These drug candidates may compete with our drug candidates, and our and our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The laws of some jurisdictions, including the PRC, do not protect intellectual property rights to the same extent as the laws or rules and regulations in the United States and Europe, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing drug candidates in violation of our proprietary rights generally. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing as patents, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our drug candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our drug candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some countries also have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In those countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with these requirements. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Periodic maintenance and annuity fees on any issued patent are due to be paid to the United States Patent and Trademark Office (&#8220;USPTO&#8221;) and foreign patent agencies over the lifetime of a patent. In addition, the USPTO and other foreign patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent failure to make payment of such fees or to comply with such provisions can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss of patent rights in the relevant jurisdiction. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-compliance</div> events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-payment</div> of fees and failure to properly legalize and submit formal documents within prescribed time limits. If we or our licensors fail to maintain the patents and patent applications covering our drug candidates or if we or our licensors otherwise allow our patents or patent applications to be abandoned or lapse, our competitors might be able to enter the market, which would hurt our competitive position and could impair our ability to successfully commercialize our drug candidates in any indication for which they are approved. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our owned and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents and other intellectual property may be subject to further priority disputes or to inventorship disputes and similar proceedings. If we or our licensors are unsuccessful in any of these proceedings, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, or to modify or cease the development, manufacture and commercialization of one or more of the drug candidates we may develop, which could have a material adverse impact on our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents or other intellectual property as an inventor or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-inventor.</div> If we or our licensors are unsuccessful in any interference proceedings or other priority or validity disputes (including any patent oppositions) to which we or they are subject, we may lose valuable intellectual property rights through the loss of one or more patents owned or licensed or our owned or licensed patent claims may be narrowed, invalidated, or held unenforceable. In addition, if we or our licensors are unsuccessful in any inventorship disputes to which we or they are subject, we may lose valuable intellectual property rights, such as exclusive ownership of, or the exclusive right to use, our owned or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents. If we or our licensors are unsuccessful in any interference proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive.</div> If we are unable to obtain and maintain such licenses, we may need to modify or cease the development, manufacture, and commercialization of one or more of our drug candidates. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical drug products. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations, or prospects. Even if we are successful in an interference proceeding or other similar priority or inventorship disputes, it could result in substantial costs and be a distraction to our management and other employees. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">28 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Claims that our drug candidates or the sale or use of our future products infringe, misappropriate or otherwise violate the patents or other intellectual property rights of third parties could result in costly litigation or could require substantial time and money to resolve, even if litigation is avoided. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We cannot guarantee that our drug candidates or the sale or use of our future products do not and will not in the future infringe, misappropriate or otherwise violate third-party patents or other intellectual property rights. Third parties might allege that we are infringing their patent rights or that we have misappropriated their trade secrets, or that we are otherwise violating their intellectual property rights, whether with respect to the manner in which we have conducted our research, or with respect to the use or manufacture of the compounds we have developed or are developing. Litigation relating to patents and other intellectual property rights in the biopharmaceutical and pharmaceutical industries is common, including patent infringement lawsuits. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. Some claimants may have substantially greater resources than we have and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. Third parties might resort to litigation against us or other parties we have agreed to indemnify, which litigation could be based on either existing intellectual property or intellectual property that arises in the future. For example, we are aware of a third-party U.S. patent and its counterpart European patents that relate to the use of antibodies having specificity to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> to treat cancer. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">It is also possible that we failed to identify, or may in the future fail to identify, relevant patents or patent applications held by third parties that cover our drug candidates. Publication of discoveries in the scientific or patent literature often lags behind actual discoveries. Therefore, we cannot be certain that we were the first to invent, or the first to file patent applications on, our drug candidates or for their uses, or that our drug candidates will not infringe patents that are currently issued or that are issued in the future. In the event that a third party has also filed a patent application covering one of our drug candidates or a similar invention, our patent application may be regarded as a competing application and may not be approved in the end. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our products or their use. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a third party were to assert claims of patent infringement against us, even if we believe such third-party claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize the applicable product unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our compositions, formulations, or methods of treatment, prevention, or use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product unless we obtained a license or until such patent expires or is finally determined to be invalid or unenforceable. In addition, defending such claims would cause us to incur substantial expenses and could cause us to pay substantial damages, if we are found to be infringing a third party&#8217;s patent rights. These damages potentially include increased damages and attorneys&#8217; fees if we are found to have infringed such rights willfully. In order to avoid or settle potential claims with respect to any patent or other intellectual property rights of third parties, we may choose or be required to seek a license from a third party and be required to pay license fees or royalties or both, which could be substantial. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a drug candidate, or be forced, by court order or otherwise, to modify or cease some or all aspects of our business operations, if, as a result of actual or threatened patent or other intellectual property claims, we are unable to enter into licenses on acceptable terms. Further, we could be found liable for significant monetary damages as a result of claims of intellectual property infringement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Defending against claims of patent infringement, misappropriation of trade secrets or other violations of intellectual property rights could be costly and time-consuming, regardless of the outcome. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Thus, even if we were to ultimately prevail, or to settle at an early stage, such litigation could burden us with substantial unanticipated costs. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Issued patents covering one or more of our drug candidates could be found invalid or unenforceable if challenged in court. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Despite measures we take to obtain and maintain patent and other intellectual property rights with respect to our drug candidates, our intellectual property rights could be challenged or invalidated. For example, if we were to initiate legal proceedings against a third party to enforce a patent covering one of our drug candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-enablement.</div> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, SIPO, or the applicable foreign counterpart, or made a misleading statement, during prosecution. Although we believe that we have conducted our patent prosecution in accordance with a duty of candor and in good faith, the outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on a drug candidate. Even if a defendant does not prevail on a legal assertion of invalidity and/or unenforceability, our patent claims may be construed in a manner that would limit our ability to enforce such claims against the defendant and others. Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may not be an adequate remedy. In addition, if the breadth or strength of protection provided by our patents is threatened, it could dissuade companies from collaborating with us to license, develop, or commercialize our current or future drug candidates. Any loss of patent protection could have a material adverse impact on one or more of our drug candidates and our business. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Enforcing our intellectual property rights against third parties may also cause such third parties to file other counterclaims against us, which could be costly to defend and could require us to pay substantial damages, cease the sale of certain drugs or enter into a license agreement and pay royalties (which may not be possible on commercially reasonable terms or at all). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intellectual property litigation may lead to unfavorable publicity which may harm our reputation and cause the market price of our ADSs to decline, and any unfavorable outcome from such litigation could limit our research and development activities and/or our ability to commercialize our drug candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the course of any intellectual property litigation, there could be public announcements of the results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our drug candidates, future drugs, programs or intellectual property could be diminished. Accordingly, the market price of our ADSs may decline. Such announcements could also harm our reputation or the market for our drug candidates, which could have a material adverse effect on our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event of intellectual property litigation, there can be no assurance that we would prevail, even if the case against us is weak or flawed. If third parties successfully assert their intellectual property rights against us, prohibitions against using certain technologies, or prohibitions against commercializing our drug candidates, could be imposed by a court or by a settlement agreement between us and a plaintiff. In addition, if we are unsuccessful in defending against allegations that we have infringed, misappropriated or otherwise violated the patent or other intellectual property rights of others, we may be forced to pay substantial damage awards to the plaintiff. Additionally, we may be required to obtain a license from the intellectual property owner in order to continue our research and development programs or to commercialize any resulting product. It is possible that the necessary license will not be available to us on commercially acceptable terms, or at all. This may not be technically or commercially feasible, may render our products less competitive, or may delay or prevent the launch of our products to the market. Any of the foregoing could limit our research and development activities, our ability to commercialize one or more drug candidates, or both. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex intellectual property litigation longer than we could. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to conduct our clinical trials, continue our internal research programs, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> needed technology, or enter into strategic partnerships that would help us bring our drug candidates to market. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, any future intellectual property litigation, interference or other administrative proceedings will result in additional expense and distraction of our personnel. An adverse outcome in such litigation or proceedings may expose us or any future strategic partners to loss of our proprietary position, expose us to significant liabilities, or require us to seek licenses that may not be available on commercially acceptable terms, if at all, each of which could have a material adverse effect on our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our drug candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patent rights. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity, and is therefore costly, time-consuming, and inherently uncertain. In addition, the United States has recently enacted and is implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained, if any. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in a recent case, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Assoc. for Molecular Pathology v. Myriad Genetics, Inc.</div></div>, the U.S. Supreme Court held that certain claims to naturally-occurring substances are not patentable. Although we do not believe that our currently issued patents and any patents that may issue from our pending patent applications directed to our drug candidates if issued in their currently pending forms, as well as patent rights licensed by us, will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patent rights. There could be similar changes in the laws of foreign jurisdictions that may impact the value of our patent rights or our other intellectual property rights. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. We also may be subject to claims that our employees, consultants, or advisers have wrongfully used or disclosed alleged trade secrets of their former employers or claims asserting ownership of what we regard as our own intellectual property. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition to our issued patents and pending patent applications, we rely on trade secret and confidential information, including unpatented <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> technology and other proprietary information, to maintain our competitive position and to protect our drug candidates. We seek to protect this trade secret and confidential information, in part, by entering into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure</div> and confidentiality agreements with parties that have access to them, such as our employees, corporate collaborators, outside scientific collaborators, sponsored researchers, contract manufacturers, consultants, advisers and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. However, any of these parties may breach such agreements and disclose our proprietary information, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us and our competitive position would be harmed. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Furthermore, many of our employees, consultants, and advisers, including our senior management, were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants, and advisers, including members of our senior management, executed proprietary rights, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competition</div> agreements in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s former employer. We are not aware of any threatened or pending claims related to these matters or concerning the agreements with our senior management, but in the future litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, and furthermore, the assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, each of which may result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs, be a distraction to our management and scientific personnel and have a material adverse effect on our business, financial condition, results of operations and prospects. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be successful in obtaining or maintaining necessary rights for our development pipeline through acquisitions and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licenses.</div> </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Because our programs may involve additional drug candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire and maintain licenses or other rights to use these proprietary rights. We may be unable to acquire or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> any compositions, methods of use, or other intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or drug candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects for growth. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our rights to develop and commercialize our drug candidates are subject, in part, to the terms and conditions of licenses granted to us by others. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We rely on licenses to certain patent rights and other intellectual property from third parties that are important or necessary to the development of our drug candidates. These and other licenses may not provide exclusive rights to use such intellectual property in all relevant fields of use and in all territories in which we may wish to develop or commercialize our drug products. As a result, we may not be able to prevent competitors from developing and commercializing competitive drug products in territories included in all of our licenses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering the drug candidates that we license from third parties. Moreover, we have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights that we jointly own with certain of our licensors and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-licensors.</div> Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our licensors fail to prosecute, maintain, enforce and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our drugs that are subject of such licensed rights could be adversely affected. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity or unenforceability of these patents. Even if we are permitted to pursue the enforcement or defense of our licensed patents, we will require the cooperation of our licensors and any applicable patent owners and such cooperation may not be provided to us. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. If we lose any of our licensed intellectual property, our right to develop and commercialize any of our drug candidates that are subject of such licensed rights could be adversely affected. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In addition, our licensors may have relied on third party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license.</div> This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize drug products covered by these license agreements. If such licenses are terminated, we may be required seek alternative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> arrangements, which may not be available on commercially reasonable terms or at all, or may be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive.</div> If these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licenses</div> are terminated, or if the underlying patents fail to provide the intended exclusivity, we may need to modify or cease the development, manufacture, and commercialization of one or more of our drug candidates and competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties (potentially including our competitors) to receive licenses to a portion of the intellectual property that is subject to our existing licenses. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could be required to pay monetary damages or could lose license rights that are important to our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business relies, in large part, on our ability to develop and commercialize drug candidates we have licensed from third parties, and we have entered into license agreements with third parties providing us with rights to various third-party intellectual property, including rights in patents and patent applications. Our licenses may not encumber all intellectual property rights owned or controlled by the affiliates of our licensors and relevant to our drug candidates, and we may need to obtain additional licenses from our existing licensors and others to advance our research or allow commercialization of drug candidates we may develop. In such case, we may need to obtain additional licenses which may not be available on an exclusive basis, on commercially reasonable terms or at a reasonable cost, if at all. In that event, we may be required to expend significant time and resources to redesign our drug candidates or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected drug candidates, which could harm our business, financial condition, results of operations, and prospects significantly. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if our licensors breach the license agreements, we may not be able to enforce such agreements against our licensors&#8217; parent entity or affiliates. Under each of our license and intellectual property-related agreements, in exchange for licensing or sublicensing us the right to develop and commercialize the applicable drug candidates, our licensors will be eligible to receive from us milestone payments, tiered royalties from commercial sales of such drug candidates, assuming relevant approvals from government authorities are obtained, or other payments. Our license and intellectual property-related agreements also require us to comply with other obligations including development and diligence obligations, providing certain information regarding our activities with respect to such drug candidates and/or maintaining the confidentiality of information we receive from our licensors. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If we fail to comply with our obligations under our current or future license agreements, our counterparties may have the right to terminate these agreements and, upon the effective date of such termination, have the right to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-obtain</div> the licensed and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-licensed</div> technology and intellectual property. If any of our licensors terminate any of our licenses, we might not be able to develop, manufacture or market any drug or drug candidate that is covered by the licenses provided for under these agreements and other third parties may be able to market drug candidates similar or identical to ours. In such case, we may have to negotiate new or reinstated agreements with less favorable terms, and may be required to provide a grant back license to the licensors under our own intellectual property with respect to the terminated products. We may also face claims for monetary damages or other penalties under these agreements. While we would expect to exercise all rights and remedies available to us, including seeking to cure any breach by us, and otherwise seek to preserve our rights under the intellectual property rights licensed and sublicensed to us, we may not be able to do so in a timely manner, at an acceptable cost or at all. In particular, some of the milestone payments are payable upon our drug candidates reaching development milestones before we have commercialized, or received any revenue from, sales of such drug candidate, and we cannot guarantee that we will have sufficient resources to make such milestone payments. Any uncured, material breach under the license agreements could result in our loss of exclusive rights and may lead to a complete termination of our rights to the applicable drug candidate. Any of the foregoing could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">33 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">It is possible that we may be unable to obtain any additional licenses at a reasonable cost or on reasonable terms, if at all. Certain of our license agreements also require us to meet development thresholds to maintain the license, including establishing a set timeline for developing and commercializing products. Disputes may arise regarding intellectual property subject to a license agreement, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the scope of rights granted under the license agreement and other interpretation-related issues; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the extent to which our technology and processes infringe, misappropriate or violate intellectual property of the licensor that is not subject to the license agreement; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the sublicensing of patent and other rights under our collaborative development relationships; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the inventorship and ownership of inventions and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the priority of invention of patented technology. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the agreements under which we license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected drug candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intellectual property rights do not necessarily protect us from all potential threats to our competitive advantage. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may be able to make compounds that are similar to our drug candidates but that are not covered by the claims of the patents that we own or have exclusively licensed; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or may in the future exclusively license, which could result in the patents applied for not being issued or being invalidated after issuing; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we might not have been the first to file patent applications covering certain of our inventions, which could result in the patents applied for not being issued or being invalidated after issuing; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">it is possible that our pending patent applications will not lead to issued patents; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors or other third parties; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may obtain patents for certain compounds many years before we receive regulatory approval for drugs containing such compounds, and because patents have a limited life, which may begin to run prior to the commercial sale of the related drugs, the commercial value of our patents may be limited; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive drugs for commercialization in our major markets; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may fail to develop additional proprietary technologies that are patentable; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may fail to apply for or obtain adequate intellectual property protection in all the jurisdictions in which we operate; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">third parties may gain unauthorized access to our intellectual property due to potential lapses in our information systems; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the patents of others may have an adverse effect on our business, for example by preventing us from commercializing one or more of our drug candidates for one or more indications. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of the aforementioned threats to our competitive advantage could have a material adverse effect on our business and future prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our competitive position may be adversely affected. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We own registered trademarks. We may not be able to obtain trademark protection in territories that we consider of significant importance to us. In addition, any of our trademarks or trade names, whether registered or unregistered, may be challenged, opposed, infringed, cancelled, circumvented or declared generic, or determined to be infringing on other marks, as applicable. We may not be able to protect our rights to these trademarks and trade names, which we will need to build name recognition by potential collaborators or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Terms of our future patents may not be sufficient to effectively protect our drug candidates and business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In many countries where we file applications for patents, the term of an issued patent is generally 20 years from the earliest claimed filing date of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-provisional</div> patent application in the applicable country. Although various extensions may be available, the life of a patent and the protection it affords are limited. Even if we obtain patents covering our drug candidates, we may still be open to competition from other companies, as well as generic medications once the patent life has expired for a drug. While there are patent regulations in the PRC in respect of regulatory data protection of new drugs containing new chemical components, there are currently no other clear mechanisms providing patent term extension or patent linkages for other drugs in the PRC. Therefore, it is possible that a lower-cost generic drug can emerge onto the market much more quickly. PRC regulators have set out a framework for integrating patent linkage and data exclusivity into the PRC regulatory regime, as well as for establishing a pilot program for patent term extension. This framework will require adoption of regulations to be implemented, although no such regulations have been issued to date. These factors may result in weaker protection for us against generic competition in the PRC than could be available to us in other jurisdictions, such as the United States. In addition, patents which we expect to obtain in the PRC may not be eligible to be extended for patent terms lost during clinical trials and the regulatory review process. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">35 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to obtain patent term extensions or if such extensions are less than requested for, our competitors may obtain approval of competing products following our patent expirations and our business, financial condition, results of operations and prospects could be materially harmed as a result. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we do not obtain additional protection under the Hatch-Waxman Amendments and similar legislation in other countries extending the terms of our patents, if issued, relating to our drug candidates, our business may be materially harmed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depending upon the timing, duration and specifics of FDA regulatory approval for our drug candidates, one or more of our U.S. patents, if issued, may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984 (the &#8220;Hatch-Waxman Amendments&#8221;). The Hatch-Waxman Amendments permit a patent term extension of up to five years as compensation for patent term lost during drug development and the FDA regulatory review process. Patent term extensions, however, cannot extend the remaining term of a patent beyond a total of 14 years from the date of drug approval by the FDA, and only one patent can be extended for a particular drug. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The application for patent term extension is subject to approval by the USPTO, in conjunction with the FDA. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain a patent term extension for a given patent or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our drug will be shortened and our competitors may obtain earlier approval of competing drugs, and our ability to generate revenues could be materially adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Industry, Business and Operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our future success depends on our ability to attract, retain and motivate senior management and qualified scientific employees. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are highly dependent on the expertise of the members of our research and development team, as well as the principal members of our management. We have entered into employment agreements with our executive officers, but each of them may terminate their employment with us at any time with prior written notice. In addition, we currently do not have <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;key-man&#8221;</div> insurance for any of our executive officers or other key personnel. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recruiting, retaining and motivating qualified management, scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Further, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize drugs. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous biopharmaceutical companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, our management will be required to devote significant time to new compliance initiatives from our status as a public company, which may require us to recruit more management personnel. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We will need to increase the size and capabilities of our organization, and we may experience difficulties in managing our growth. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect to experience significant growth in the number of our employees and consultants and the scope of our operations, particularly in the areas of clinical development, regulatory affairs and business development. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations, and have a material adverse effect on our business. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">36 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The data and information that we gather in our research and development process could be inaccurate or incomplete, which could harm our business, reputation, financial condition and results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We collect, aggregate, process, and analyze data and information from our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies, manufacturing technology development programs and clinical programs. We also engage in substantial information gathering following the identification of a promising drug candidate. Because data in the healthcare industry is fragmented in origin, inconsistent in format, and often incomplete, the overall quality of data collected or accessed in the healthcare industry is often subject to challenge, the degree or amount of data which is knowingly or unknowingly absent or omitted can be material, and we often discover data issues and errors when monitoring and auditing the quality of our data. If we make mistakes in the capture, input, or analysis of these data, our ability to advance the development of our drug candidates may be materially harmed and our business, prospects and reputation may suffer. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We also engage in the procurement of regulatory approvals necessary for the development and commercialization of our products under development, for which we manage and submit data to governmental entities. These processes and submissions are governed by complex data processing and validation policies and regulations. Notwithstanding such policies and regulations, interim, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data, in which case we may be exposed to liability to a customer, court or government agency that concludes that our storage, handling, submission, delivery, or display of health information or other data was wrongful or erroneous. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we maintain insurance coverage for clinical trials, this coverage may prove to be inadequate or could cease to be available to us on acceptable terms, if at all. Even unsuccessful claims could result in substantial costs and diversion of management time, attention, and resources. A claim brought against us that is uninsured or under-insured could harm our business, financial condition and results of operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, we rely on CROs, our partners and other third parties to monitor and manage data for some of our ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical programs and control only certain aspects of their activities. If any of our CROs, our partners or other third parties do not perform to our standards in terms of data accuracy or completeness, data from those <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical trials may be compromised as a result, and our reliance on these parties does not relieve us of our regulatory responsibilities. For a detailed discussion, see &#8220;&#8212;Risks Related to Our Reliance on Third Parties&#8212;As we rely on third parties to conduct our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials, if we lose our relationships with these third parties or if they do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed&#8221; above. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be subject to liability lawsuits arising from our clinical trials. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We currently carry liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or which is in excess of the limits of our insurance coverage. Our insurance policies also contain various exclusions, and we may be subject to particular liability claims for which we have no coverage. We will have to pay any amount awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. In addition, if we cannot successfully defend ourselves against such claims, we may incur substantial liabilities and be required to suspend or delay our ongoing clinical trials. Even a successful defense would require significant financial and management resources. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regardless of the merits or eventual outcome, liability claims may result in significant negative consequences to our business and prospects, including, but not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">decreased demand for our drug candidates or any resulting products; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">37 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">injury to our reputation; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">withdrawal of other clinical trial participants; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">costs to defend the related litigation; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a diversion of our management&#8217;s time and resources; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">substantial monetary awards to trial participants or patients; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to commercialize our drug candidates; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a decline in the market price of our ADSs. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have limited insurance coverage, and any claims beyond our insurance coverage may result in our incurring substantial costs and a diversion of resources. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We maintain insurance policies that are required under PRC laws and regulations as well as insurance based on our assessment of our operational needs and industry practice. We also maintain liability insurance covering our clinical trials. In line with industry practice in the PRC, we have elected not to maintain certain types of insurances, such as business interruption insurance or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">key-man</div> insurance. Our insurance coverage may be insufficient to cover any claim for product liability, damage to our fixed assets or employee injuries. Any liability or damage to, or caused by, our facilities or our personnel beyond our insurance coverage may result in our incurring substantial costs and a diversion of resources. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Disruptions in the financial markets and economic conditions could affect our ability to raise capital. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Global economies could suffer dramatic downturns as the result of a deterioration in the credit markets and related financial crisis as well as a variety of other factors including, extreme volatility in security prices, severely diminished liquidity and credit availability, ratings downgrades of certain investments and declining valuations of others. In the past, governments have taken unprecedented actions in an attempt to address and rectify these extreme market and economic conditions by providing liquidity and stability to the financial markets. If these actions are not successful, the return of adverse economic conditions may cause a significant impact on our ability to raise capital, if needed, on a timely basis and on acceptable terms or at all. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, there is considerable uncertainty over the long-term effects of the expansionary monetary and fiscal policies adopted by the central banks and financial authorities of some of the world&#8217;s leading economies, including the United States and China. There have been concerns over unrest and terrorist threats in the Middle East, Europe and Africa and over the conflicts involving Ukraine, Syria and North Korea. There have also been concerns on the relationship among China and other Asian countries, which may result in or intensify potential conflicts in relation to territorial disputes or the trade related disputes between the United States and China. In addition, the impact of the decision by the United Kingdom to withdraw from the European Union, commonly referred to as &#8220;Brexit&#8221;, and the resulting effect on the political and economic future of the U.K. and the European Union is uncertain. Brexit could adversely affect European and worldwide economic and market conditions and could contribute to instability in global financial and foreign exchange markets. It is unclear whether these challenges and uncertainties will be contained or resolved, and what effects they may have on the global political and economic conditions in the long term. It is unclear whether these challenges and uncertainties will be contained or resolved, and what effects they may have on the global political and economic conditions in the long term. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with regulatory standards and requirements. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are exposed to the risk of fraud, misconduct or other illegal activities by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">comply with the laws of the NMPA, the FDA and other comparable regulatory authorities; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">38 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">provide true, complete and accurate information to the NMPA, the FDA and other comparable regulatory authorities; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">comply with manufacturing standards we have established; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">comply with healthcare fraud and abuse laws in the PRC, the United States and similar fraudulent misconduct laws in other applicable jurisdictions; or </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">report financial information or data accurately or to disclose unauthorized activities to us. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we obtain approval of any of our drug candidates and begin commercializing those drugs in the PRC, the United States or other applicable jurisdictions, our potential exposure under the laws of such jurisdictions will increase significantly and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">It is not always possible to identify and deter misconduct by employees and other parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute the value of your investment in our ADSs, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including, but not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">increased operating expenses and cash requirements; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the assumption of additional indebtedness or contingent liabilities; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the issuance of our equity securities; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">risks and uncertainties associated with the assimilation of operations, corporate culture and personnel of the acquired business; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and its existing drugs or drug candidates and regulatory approvals; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in accounting principles relating to recognition and measurement of our investments that may have a significant impact on our financial results. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we fail to comply with applicable anti-bribery laws, our reputation may be harmed and we could be subject to penalties and significant expenses that have a material adverse effect on our business, financial condition and results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are subject to anti-bribery laws in China that generally prohibit companies and their intermediaries from making payments to government officials for the purpose of obtaining or retaining business or securing any other improper advantage. In addition, although currently our primary operating business is in China, we are subject to the Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;). The FCPA generally prohibits us from making improper payments to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> officials for the purpose of obtaining or retaining business. Although we have policies and procedures designed to ensure that we, our employees and our agents comply with anti-bribery laws, there is no assurance that such policies or procedures will prevent our agents, employees and intermediaries from engaging in bribery activities. Failure to comply with anti-bribery laws could disrupt our business and lead to severe criminal and civil penalties, including imprisonment, criminal and civil fines, loss of our export licenses, suspension of our ability to do business with the government, denial of government reimbursement for our products and/or exclusion from participation in government healthcare programs. Other remedial measures could include further changes or enhancements to our procedures, policies, and controls and potential personnel changes and/or disciplinary actions, any of which could have a material adverse effect on our business, financial condition, results of operations and liquidity. We could also be adversely affected by any allegation that we violated such laws. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Any failure to comply with applicable regulations and industry standards or obtain various licenses and permits could harm our reputation and our business, results of operations and prospects. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A number of governmental agencies or industry regulatory bodies in the PRC, the United States and other applicable jurisdictions impose strict rules, regulations and industry standards governing biopharmaceutical research and development activities, which apply to us. Our or our CROs&#8217; failure to comply with such regulations could result in the termination of ongoing research, administrative penalties imposed by regulatory bodies or the disqualification of data for submission to regulatory authorities. This could harm our business, reputation, prospects for future work and results of operations. For example, if we or our CROs were to treat research animals inhumanely or in violation of international standards set out by the Association for Assessment and Accreditation of Laboratory Animal Care, it could revoke any such accreditation and the accuracy of our animal research data could be questioned. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we or our CROs or other contractors or consultants fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We and third parties, such as our CROs or other contractors or consultants, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and radioactive and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">40 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of or exposure to hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage, use or disposal of biological, hazardous or radioactive materials. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we may be required to incur substantial costs to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we face allegations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with laws and encounter sanctions, our reputation, revenues and liquidity may suffer, and our drug candidates and future drugs could be subject to restrictions or withdrawal from the market. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any government investigation of alleged violations of laws could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenues from our drugs. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. Additionally, if we are unable to generate revenues from our product sales, our potential for achieving profitability will be diminished and the capital necessary to fund our operations will be increased. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our internal computer systems, or those used by our CROs or other contractors or consultants, may fail or suffer security breaches. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although to our knowledge we have not experienced any material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we partially rely on our third-party research institution collaborators for research and development of our drug candidates and other third parties for the manufacture of our drug candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our drug candidates could be delayed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions, which could include civil or criminal fines or penalties, private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with such laws could increase the costs of our products and services, could limit their use or adoption, and could otherwise negatively affect our operating results and business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of personal information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Regulatory authorities in virtually every jurisdiction in which we operate have implemented and are considering a number of legislative and regulatory proposals concerning personal data protection. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">41 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory authorities in China have implemented and are considering a number of legislative and regulatory proposals concerning data protection. For example, China&#8217;s Cyber Security Law, which became effective in June 2017, created China&#8217;s first national-level data protection for &#8220;network operators,&#8221; which may include all organizations in China that provide services over the internet or another information network. Numerous regulations, guidelines and other measures are expected to be adopted under the umbrella of the Cyber Security Law. Drafts of some of these measures have now been published, including the draft rules on cross-border transfers published by the China Cyberspace Administration in 2017, which may, upon enactment, require security review before transferring human health-related data out of China. In addition, certain industry-specific laws and regulations affect the collection and transfer of personal data in China. For example, the PRC State Council promulgated Regulations on the Administration of Human Genetic Resources (effective in July 2019), which require approval from the Science and Technology Administration Department of the State Council where human genetic resources, or HGR, are involved in any international collaborative project and additional approval for any export or cross-border transfer of the HGR samples or associated data. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices, potentially resulting in confiscation of HGR samples and associated data, administrative fines and criminal liabilities. In addition, the interpretation and application of data protection laws in China and elsewhere are often uncertain and in flux. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, we are subject to laws and regulations that address privacy, personal information protection and data security at both the federal and state levels. Numerous laws and regulations, including security breach notification laws, health information privacy laws, and consumer protection laws, govern the collection, use, disclosure and protection of health-related and other personal information. Given the variability and evolving state of these laws, we face uncertainty as to the exact interpretation of the new requirements, and we may be unsuccessful in implementing all measures required by regulators or courts in their interpretation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Regulatory authorities in Europe have implemented and are considering a number of legislative and regulatory proposals concerning data protection. For example, the General Data Protection Regulation (EU) 2016/679, or GDPR, which became effective in May 2018, imposes a broad range of strict requirements on companies subject to the GDPR, such as us, including, but not limited to, requirements relating to having legal bases for processing personal information relating to identifiable individuals and transferring such information outside the European Economic Area (including to the United States), providing details to those individuals regarding the processing of their personal information, keeping personal information secure, having data processing agreements with third parties who process personal information, responding to individuals&#8217; requests to exercise their rights in respect of their personal information, reporting security breaches involving personal data to the competent national data protection authority and affected individuals, and recordkeeping. The GDPR substantially increases the penalties to which we could be subject in the event of any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance,</div> including fines of up to 10,000,000 Euros or up to 2% of our total worldwide annual turnover for certain comparatively minor offenses, or up to 20,000,000 Euros or up to 4% of our total worldwide annual turnover for more serious offenses. Given the new law, we face uncertainty as to the exact interpretation of the new requirements, and we may be unsuccessful in implementing all measures required by data protection authorities or courts in interpretation of the new law. National laws of member states of the European Union are in the process of being adapted to the requirements under the GDPR. Because the GDPR specifically gives member states flexibility with respect to certain matters, national laws may partially deviate from the GDPR and impose different obligations from country to country, leading to additional complexity and uncertainty. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect that we will continue to face uncertainty as to whether our efforts to comply with evolving obligations under global data protection, privacy and security laws will be sufficient. Any failure or perceived failure by us to comply with applicable laws and regulations could result in reputational damage or proceedings or actions against us by governmental entities, individuals or others. These proceedings or actions could subject us to significant civil or criminal penalties and negative publicity, result in the delayed or halted transfer or confiscation of certain personal information, require us to change our business practices, increase our costs and materially harm our business, prospects, financial condition and results of operations. In addition, our current and future relationships with customers, vendors, pharmaceutical partners and other third parties could be negatively affected by any proceedings or actions against us or current or future data protection obligations imposed on them under applicable law, including the GDPR. In addition, a data breach affecting personal information, including health information, could result in significant legal and financial exposure and reputational damage that could potentially have an adverse effect on our business. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">42 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our operating results for fiscal year 2020, our China operations and our worldwide operations could be adversely affected by the outbreak of and response to the coronavirus or other health crises. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our business, financial condition and results of operations could be adversely affected by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. The global pandemic of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> the disease caused by a novel strain of coronavirus, has created significant business disruption which could materially and adversely affect our business and operations. The pandemic has resulted in governments implementing numerous measures to contain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> such as travel bans and restrictions, quarantines, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">shelter-in-place,</div></div> temporary shutdown of factories, business limitations, or total lock-down orders. These containment measures are subject to change and may be further tightened. This pandemic has led to temporary closure of our offices in the first quarter of 2020, causing cancellation of physical participation in meetings, restrictions on employee travels, and a significant portion of our employees working from home, which resulted in lower work efficiency and productivity, and the disruption to our business operations and clinical trials. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The pandemic of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and the resulting government measures may materially and adversely impact our planned and ongoing clinical trials and development. Clinical site initiation, including recruiting clinical site investigators and clinical site staff, and patient enrollment may be delayed due to prioritization of hospital resources toward the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. The diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, including the attention of physicians serving as our clinical trial investigators and hospitals serving as our clinical trial sites, or other staff supporting the conduct of our clinical trials may significantly disrupt our research activities. Hospitals have also had reduced patient flow in general during the pandemic period. As a result, the expected timeline for data readouts of our clinical trials and potential submission and filings will likely be negatively impacted, which would adversely affect and delay our ability to obtain certain regulatory approvals, increase our operating expenses and have a material adverse effect on our financial condition. Furthermore, we could face the interruption of key clinical activities such as trial site data monitoring, which may impact the integrity of clinical data. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> may be impeded, which would also materially and adversely impact our clinical trial operations. As a result of disruptions caused by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, we may require additional capital to continue our research activities, which we may be unable to secure on favorable terms, if at all. In addition, we believe that our business partners, such as our licensing partners, CROs, CMOs or suppliers, have also experienced and may continue to experience similar or more severe disruptions to their business operations. Any disruption to the business operations of us and our business partners could materially and adversely affect the development of our drug candidates, our business, financial condition and results of operations. To the extent the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section. See also &#8220;Item 5. Operating and Financial Review and Prospects&#8212;A. Operating Results&#8212;Impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Pandemic&#8221; for a detailed description of the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on our business. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Natural disasters, acts of war or terrorism, health epidemics, or other factors beyond our control may adversely affect the economy, infrastructure and livelihood of the people in the regions where we conduct our business. Our operations may be under the threat of floods, earthquakes, sandstorms, snowstorms, fire or drought, power, water or fuel shortages, failures, malfunction and breakdown of information management systems, unexpected maintenance or technical problems, or may be susceptible to potential wars or terrorist attacks. Serious natural disasters may result in loss of lives, injury, destruction of assets and disruption of our business and operations. Acts of war or terrorism may also injure our employees, cause loss of lives, disrupt our business network and destroy our markets. Any of these factors and other factors beyond our control could have an adverse effect on the overall business sentiment and environment, cause uncertainties in the regions where we conduct business, cause our business to suffer in ways that we cannot predict and materially and adversely impact our business, financial conditions and results of operations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">43 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our business and results of operations could be adversely affected by public health crisis (including the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> global pandemic) and natural catastrophes or other disasters outside of our control in the locations in which we, our suppliers, CROs, CMOs and other contractors operate. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our business could be adversely affected by the effects of epidemics, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> avian influenza, severe acute respiratory syndrome, (SARS), influenza A (H1N1), Ebola or another epidemic. Any such occurrences could cause severe disruption to our daily operations and may even require a temporary closure of our offices and laboratories. For example, in early 2020, in response to intensifying efforts to contain the spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> the Chinese government took a number of actions, which included extending the Chinese New Year holiday, quarantining individuals infected with or suspected of having <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> prohibiting residents from free travel, encouraging employees of enterprises to work remotely from home and cancelling public activities, among others. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has also resulted in temporary closure of many corporate offices, retail stores, manufacturing facilities and factories. As research hospitals and government agencies focus clinical resources on the pandemic, we believe that there could be some delay in regulatory interactions and inspections and patient recruitment and participation, particularly in the first quarter of 2020. Meanwhile, the pandemic of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> continues in the United States and other countries, and related government and private sector responsive actions may cause some delay in our ongoing clinical trials in the United States. We have taken a series of measures in response to the pandemic, including, among others, remote working arrangement for our employees. These measures could reduce the capacity and efficiency of our operations, which in turn could negatively affect our results of operations. The extent to which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> impacts our results of operations will depend on the future developments of the pandemic, including new information concerning the global severity of and actions taken to contain the pandemic, which are highly uncertain and unpredictable. These uncertain and unpredictable factors include, but are not limited to, potential adverse effects of the pandemic on the economy, our suppliers, CROs, CMOs and other contractors. In addition, our results of operations could be adversely affected to the extent that the pandemic harms the Chinese economy in general. To the extent the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this annual report, including those relating to our ability to initiate or continue clinical trials for our drug candidates. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we fail to implement and maintain an effective system of internal controls over financial reporting, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud. </div></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are a public company in the United States subject to the Sarbanes-Oxley Act of 2002. Section&#160;404 of the Sarbanes-Oxley Act of 2002, or Section&#160;404, requires that we include a report of management on our internal control over financial reporting in our annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F.</div> In addition, once we cease to be an &#8220;emerging growth company&#8221; as defined in the JOBS Act, our independent registered public accounting firm must attest to and report on the effectiveness of our internal control over financial reporting. Our management may conclude that our internal control over financial reporting is not effective. Moreover, even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm, after conducting its own independent testing, may issue an adverse report if it is not satisfied with our internal controls or the level at which our controls are documented, designed, operated or reviewed, or if it interprets the relevant requirements differently from us. In addition, as a public company, our reporting obligations may place a significant strain on our management, operational and financial resources and systems for the foreseeable future. We may be unable to timely complete our evaluation testing and any required remediation. Our management, with the participation of our chief executive officer and principal financial officer, evaluated the effectiveness of our internal control over financial reporting and concluded that our internal control over financial reporting was effective as of December 31, 2020. See also &#8220;Item 15. Controls and Procedures&#8221; for a detailed description of management&#8217;s report on internal control over financial reporting and remediation of the material weaknesses in internal control over financial reporting reported in 2019. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we fail to maintain the adequacy of our internal control over financial reporting, as these standards are modified, supplemented or amended from time to time, we may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section&#160;404. If we fail to establish and maintain adequate internal controls, we could suffer material misstatements in our financial statements and fail to meet our reporting obligations, which would likely cause investors to lose confidence in our reported financial information. This could limit our access to capital markets, adversely affect our results of operations and lead to a decline in the trading price of the ADSs. Additionally, ineffective internal controls could expose us to an increased risk of fraud or misuse of corporate assets and subject us to potential delisting from the stock exchange on which we list or to other regulatory investigations and civil or criminal sanctions. We could also be required to restate our historical financial statements. </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our ADSs may be delisted under the Holding Foreign Companies Accountable Act if the PCAOB is unable to inspect auditors who are located in China. The delisting of our ADSs, or the threat of their being delisted, may materially and adversely affect the value of your investment. Additionally, the inability of the PCAOB to conduct inspections deprives our investors with the benefits of such inspections. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Holding Foreign Companies Accountable Act, or the HFCA Act, was enacted on December 18, 2020. The HFCA Act states if the SEC determines that we have filed audit reports issued by a registered public accounting firm that has not been subject to inspection by the PCAOB for three consecutive years beginning in 2021, the SEC shall prohibit our shares or ADSs from being traded on a national securities exchange or in the over the counter trading market in the U.S. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our auditor, the independent registered public accounting firm that issues the audit report included elsewhere in this annual report as an auditor of companies that are traded publicly in the United States and a firm registered with the PCAOB, is subject to laws in the United States pursuant to which the PCAOB conducts regular inspections to assess its compliance with the applicable professional standards. Since our auditor is located in China, a jurisdiction where the PCAOB has been unable to conduct inspections without the approval of the Chinese authorities, our auditor is currently not inspected by the PCAOB. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March 24, 2021, the SEC adopted interim final rules relating to the implementation of certain disclosure and documentation requirements of the HFCA Act. We will be required to comply with these rules if the SEC identifies us as having a &#8220;non-inspection&#8221; year under a process to be subsequently established by the SEC. The SEC is assessing how to implement other requirements of the HFCA Act, including the listing and trading prohibition requirements described above. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The SEC may propose additional rules or guidance that could impact us if our auditor is not subject to PCAOB inspection. For example, on August 6, 2020, the President&#8217;s Working Group on Financial Markets, or the PWG, issued the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">R</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">p</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ort on Prote</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">c</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">t</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">i</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ng United States </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">I</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">n</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ve</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">sto</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">r</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">s f</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">r</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">om Sign</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">i</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">f</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">i</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">c</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ant Ris</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">k</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">s f</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">r</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">om </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">C</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">hinese</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compani</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">s</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>to the then President of the United States. This report recommended the SEC implement five recommendations to address companies from jurisdictions that do not provide the PCAOB with sufficient access to fulfil its statutory mandate. Some of the concepts of these recommendations were implemented with the enactment of the HFCA Act. However, some of the recommendations were more stringent than the HFCA Act. For example, if a company was not subject to PCAOB inspection, the report recommended that the transition period before a company would be delisted would end on January 1, 2022. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The SEC has announced that the SEC staff is preparing a consolidated proposal for the rules regarding the implementation of the HFCA Act and to address the recommendations in the PWG report. It is unclear when the SEC will complete its rulemaking and when such rules will become effective and what, if any, of the PWG recommendations will be adopted. The implications of this possible regulation in addition the requirements of the HFCA Act are uncertain. Such uncertainty could cause the market price of our ADSs to be materially and adversely affected, and our securities could be delisted or prohibited from being traded &#8220;over-the-counter&#8221; earlier than would be required by the HFCA Act. If our securities are unable to be listed on another securities exchange by then, such a delisting would substantially impair your ability to sell or purchase our ADSs when you wish to do so, and the risk and uncertainty associated with a potential delisting would have a negative impact on the price of our ADSs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The PCAOB&#8217;s inability to conduct inspections in China prevents it from fully evaluating the audits and quality control procedures of our independent registered public accounting firm. As a result, we and investors in our ordinary shares are deprived of the benefits of such PCAOB inspections. The inability of the PCAOB to conduct inspections of auditors in China makes it more difficult to evaluate the effectiveness of our independent registered public accounting firm&#8217;s audit procedures or quality control procedures as compared to auditors outside of China that are subject to the PCAOB inspections, which could cause investors and potential investors in our stock to lose confidence in our audit procedures and reported financial information and the quality of our financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2013, the PCAOB announced that it had entered into a Memorandum of Understanding on Enforcement Cooperation with the CSRC and the PRC Ministry of Finance, which establishes a cooperative framework between the parties for the production and exchange of audit documents relevant to investigations undertaken by the PCAOB in the PRC or by the CSRC or the PRC Ministry of Finance in the United States. The PCAOB continues to be in discussions with the CSRC and the PRC Ministry of Finance to permit joint inspections in the PRC of audit firms that are registered with the PCAOB and audit Chinese companies that trade on U.S. exchanges. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proceedings instituted by the SEC against &#8220;big four&#8221; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PRC-based</div> accounting firms, including our independent registered public accounting firm, could result in financial statements being determined to not be in compliance with the requirements of the Exchange Act. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Starting in 2011 &#8220;big four&#8221; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PRC-based</div> accounting firms, including our independent registered public accounting firm, were affected by a conflict between U.S. and Chinese law. Specifically, for certain U.S.-listed companies operating and audited in mainland China, the SEC and the PCAOB sought to obtain from the Chinese firms access to their audit work papers and related documents. The firms were, however, advised and directed that under Chinese law, they could not respond directly to the U.S. regulators on those requests, and that requests by foreign regulators for access to such papers in China had to be channeled through the CSRC. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In late 2012, this impasse led the SEC to commence administrative proceedings under Rule 102(e) of its Rules of Practice and also under the Sarbanes-Oxley Act of 2002 against the Chinese accounting firms, including our independent registered public accounting firm. A first instance trial of the proceedings in July 2013 in the SEC&#8217;s internal administrative court resulted in an adverse judgment against the firms. The administrative law judge proposed penalties on the firms including a temporary suspension of their right to practice before the SEC, although that proposed penalty did not take effect pending review by the Commissioners of the SEC. On February&#160;6, 2015, before a review by the Commissioner had taken place, the firms reached a settlement with the SEC. Under the settlement, the SEC accepted that future requests by the SEC for the production of documents will normally be made to the CSRC. The firms were to receive matching Section&#160;106 requests, and were required to abide by a detailed set of procedures with respect to such requests, which in substance require them to facilitate production via the CSRC. If they failed to meet specified criteria, the SEC retained authority to impose a variety of additional remedial measures on the firms depending on the nature of the failure. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the terms of the settlement, the underlying proceeding against the four China-based accounting firms was deemed dismissed with prejudice four years after entry of the settlement. The four-year mark occurred on February&#160;6, 2019. While we cannot predict if the SEC will further challenge the four China-based accounting firms&#8217; compliance with U.S. law in connection with U.S. regulatory requests for audit work papers or if the results of such a challenge would result in the SEC imposing penalties such as suspensions. If additional remedial measures are imposed on the &#8220;big four&#8221; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PRC-based</div> accounting firms, including our independent registered public accounting firm, we could be unable to timely file future financial statements in compliance with the requirements of the Exchange Act. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the event the &#8220;big four&#8221; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PRC-based</div> accounting firms become subject to additional legal challenges by the SEC or PCAOB, depending upon the final outcome, listed companies in the United States with major PRC operations may find it difficult or impossible to retain auditors in respect of their operations in China, which could result in financial statements being determined to not be in compliance with the requirements of the Exchange Act, including possible delisting. Moreover, any negative news about any such future proceedings against these audit firms may cause investor uncertainty regarding China-based, U.S.-listed companies and the market price of our common stock may be adversely affected. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If our independent registered public accounting firm was denied, even temporarily, the ability to practice before the SEC and we were unable to timely find another registered public accounting firm to audit and issue an opinion on our financial statements, our financial statements could be determined not to be in compliance with the requirements of the Exchange Act. Such a determination could ultimately lead to the delisting of the ADSs from the Nasdaq Global Market or deregistration from the SEC, or both, which would substantially reduce or effectively terminate the trading of the ADSs in the United States. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our reputation is important to our business success. Negative publicity may adversely affect our reputation and business prospects. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Any negative publicity concerning us, our affiliates or any entity that shares the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;I-Mab&#8221;</div> name, even if untrue, could adversely affect our reputation and business prospects. There can be no assurance that negative publicity about us or any of our affiliates or any entity that shares the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;I-Mab&#8221;</div> name would not damage our brand image or have a material adverse effect on our business, results of operations and financial condition. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be subject to material litigation and regulatory proceedings. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may be subject to litigation in China and outside China relating to securities law class actions, third-party and principal intellectual property infringement claims, claims relating to data and privacy protection, employment related cases and other matters in the ordinary course of our business. Laws, rules and regulations may vary in their scope and overseas laws and regulations may impose requirements that are more stringent than, or which conflict with, those in China. We have acquired and may acquire companies that may become subject to litigation, as well as regulatory proceedings. In addition, in connection with litigation or regulatory proceedings we may be subject to in various jurisdictions, we may be prohibited by laws, regulations or government authorities in one jurisdiction from complying with subpoenas, orders or other requests from courts or regulators of other jurisdictions, including those relating to data held in or with respect to persons in these jurisdictions. Our failure or inability to comply with the subpoenas, orders or requests could subject us to fines, penalties or other legal liability, which could have a material adverse effect on our reputation, business, results of operations and the trading price of our ADSs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a publicly-listed company, we and certain of our subsidiaries face additional exposure to claims and lawsuits inside and outside China. We will need to defend against these lawsuits, including any appeals should our initial defense be successful. The litigation process may utilize a material portion of our cash resources and divert management&#8217;s attention away from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> operations of our company, all of which could harm our business. There can be no assurance that we will prevail in any of these cases, and any adverse outcome of these cases could have a material adverse effect on our reputation, business and results of operations. In addition, although we have obtained directors&#8217; and officers&#8217; liability insurance, the insurance coverage may not be adequate to cover our obligations to indemnify our directors and officers, fund a settlement of litigation in excess of insurance coverage or pay an adverse judgment in litigation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The existence of litigation, claims, investigations and proceedings may harm our reputation, limit our ability to conduct our business in the affected areas and adversely affect the trading price of our ADSs. The outcome of any claims, investigations and proceedings is inherently uncertain, and in any event defending against these claims could be both costly and time-consuming, and could significantly divert the efforts and resources of our management and other personnel. An adverse determination in any litigation, investigation or proceeding could cause us to pay damages, incur legal and other costs, limit our ability to conduct business or require us to change the manner in which we operate. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Negative publicity with respect to us, our management, employees, business partners, affiliates, or our industry, may materially and adversely affect our reputation, business, results of operations and prospect. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our reputation is vulnerable to many threats that can be difficult or impossible to control, and costly or impossible to remediate. Negative publicity about us, such as alleged misconduct or improper activities, or negative rumors relating to us, our management, employees, business partners or affiliates, can harm our business and results of operations, even if they are unsubstantiated or are satisfactorily addressed. Any regulatory inquiries or investigations or other actions against our management, any perceived unethical, fraudulent, or inappropriate business conduct by us or perceived wrong doing by any key member of our management team or other employees, our business partners or our affiliates, could harm our reputation and materially adversely affect our business. Regardless of the merits or final outcome of any such regulatory inquiries or investigations or other actions, our reputation may be substantially damaged, which may impede our ability to attract and retain talents and business partners and grow our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, any negative media publicity about the biopharmaceutical industry in general or product or service quality problems of other companies in the industry, including our peers, may also negatively impact our reputation. If we are unable to maintain a good reputation, our ability to attract and retain key employees and business partners could be harmed which in turn may materially and adversely affect our business, results of operations and prospect. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Change in business prospects of acquisitions may result in impairment to our goodwill, which could negatively affect our reported results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We acquired a controlling interest in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin in July 2017 and the remaining interest in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin in May 2018. In connection with our acquisition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin, we identified RMB148.8&#160;million of intangible assets and RMB162.6&#160;million of goodwill of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin attributable to core technology and synergy effects expected from combining the operations of the discovery and development of innovative biologics and the development of clinical stage biologics. We are required to test our goodwill annually, or more frequently if events or changes in circumstances indicate that it might be impaired. Goodwill is allocated to cash-generating units or groups of cash-generating units for the purpose of impairment testing. An impairment loss of goodwill is recognized for the amount by which the relevant cash-generating unit&#8217;s or group of cash-generating unit&#8217;s carrying amount exceeds its recoverable amount, and we would be required to write down the carrying value of our goodwill during the period in which it is determined to be impaired, which would materially and adversely affect our results of operations. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are subject to changing law and regulations regarding regulatory matters, corporate governance and public disclosure that have increased both our costs and the risk of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance.</div> </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are or will be subject to rules and regulations by various governing bodies, including, for example, the SEC, which is charged with the protection of investors and the oversight of companies whose securities are publicly traded, and the various regulatory authorities in China and the Cayman Islands, and to new and evolving regulatory measures under applicable law. Our efforts to comply with new and changing laws and regulations have resulted in and are likely to continue to result in, increased general and administrative expenses and a diversion of management time and attention from revenue-generating activities to compliance activities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, because these laws, regulations and standards are subject to varying interpretations, their application in practice may evolve over time as new guidance becomes available. This evolution may result in continuing uncertainty regarding compliance matters and additional costs necessitated by ongoing revisions to our disclosure and governance practices. If we fail to address and comply with these regulations and any subsequent changes, we may be subject to penalty and our business may be harmed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Doing Business in China </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The pharmaceutical industry in China is highly regulated and such regulations are subject to change which may affect approval and commercialization of our drugs. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our research and development operations and manufacturing facilities are in China, which we believe confers clinical, commercial and regulatory advantages. The pharmaceutical industry in China is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new drugs. See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Regulation&#8221; for a discussion of the regulatory requirements that are applicable to our current and planned business activities in China. In recent years, the regulatory framework in China regarding the pharmaceutical industry has undergone significant changes, and we expect that it will continue to undergo significant changes. Any such changes or amendments may result in increased compliance costs on our business or cause delays in or prevent the successful development or commercialization of our drug candidates in China and reduce the current benefits we believe are available to us from developing and manufacturing drugs in China. PRC authorities have become increasingly vigilant in enforcing laws in the pharmaceutical industry and any failure by us or our partners to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our business activities in China. We believe our strategy and approach are aligned with the PRC government&#8217;s regulatory policies, but we cannot ensure that our strategy and approach will continue to be aligned. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in the political and economic policies of the PRC government may materially and adversely affect our business, financial condition and results of operations and may result in our inability to sustain our growth and expansion strategies. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A significant portion of our operations are in China. Our financial condition and results of operations are affected to a large extent by economic, political and legal developments in China. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The PRC economy differs from the economies of most developed countries in many respects, including the extent of government involvement, level of development, growth rate, control of foreign exchange and allocation of resources. Although the PRC government has implemented measures emphasizing the utilization of market forces for economic reform, the reduction of state ownership of productive assets, and the establishment of improved corporate governance in business enterprises, a substantial portion of productive assets in China is still owned by the government. In addition, the PRC government continues to play a significant role in regulating industrial development by imposing industrial policies. The PRC government also exercises significant control over China&#8217;s economic growth by allocating resources, controlling payment of foreign currency-denominated obligations, setting monetary policy, regulating financial services and institutions and providing preferential treatment to particular industries or companies. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">48 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While the PRC economy has experienced significant growth in the past four decades, growth has been uneven, both geographically and among various sectors of the economy. The PRC government has implemented various measures to encourage economic growth and guide the allocation of resources. Some of these measures may benefit the overall PRC economy, but may also have a negative effect on us. Our business, financial condition and results of operations could be materially and adversely affected by government control over capital investments or changes in tax regulations that are applicable to us. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the PRC government had, in the past, implemented certain measures, including interest rate increases, to control the pace of economic growth. These measures may cause decreased economic activity in China, which may adversely affect our business and results of operations. More generally, if the business environment in China deteriorates from the perspective of domestic or international investment, our business in China may also be adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">There are uncertainties regarding the interpretation and enforcement of PRC laws, rules and regulations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our primary business is governed by PRC laws and regulations. Our primary business operation is supervised by relevant regulatory authorities in China. The PRC legal system is a civil law system based on written statutes and, unlike the common law system, prior court decisions can only be cited as reference and have limited precedential value. Additionally, written statutes in the PRC are often principle-oriented and require detailed interpretations by the enforcement bodies to further apply and enforce such laws. Since 1979, the PRC government has developed a comprehensive system of laws, rules and regulations in relation to economic matters, such as foreign investment, corporate organization and governance, commerce, taxation and trade. However, the interpretation and enforcement of these laws, rules and regulations involve uncertainties and may not be as consistent or predictable as in other more developed jurisdictions. As these laws and regulations are continually evolving in response to changing economic and other conditions, and because of the limited volume of published cases and their <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding</div> nature, any particular interpretation of PRC laws and regulations may not be definitive. Moreover, we cannot predict the effect of future developments in the PRC legal system and regulatory structure. Such unpredictability towards our contractual, property and procedural rights as well as our rights licensed, approved or granted by the competent regulatory authority could adversely affect our business and impede our ability to continue our operations. In addition, the PRC legal system is based in part on government policies and internal rules, some of which are not published on a timely basis, if at all, and which may have a retroactive effect. Hence, we may not be aware of violation of these policies and rules until after such violation has occurred. Further, the legal protections available to us and our investors under these laws, rules and regulations may be limited. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, any administrative or court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. Since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. These uncertainties may impede our ability to enforce various contracts we have entered into and could materially and adversely affect our business, financial condition and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">You may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions in China against us or our management named in this annual report based on foreign laws. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a company incorporated under the laws of the Cayman Islands, we conduct substantially all of our operations in China and substantially all of our assets are located in China. In addition, all our senior executive officers reside within China for a significant portion of the time and some of them are PRC nationals. As a result, it may be difficult for you to effect service of process upon us or those persons inside China. It may also be difficult for you to enforce in U.S. courts judgments obtained in U.S. courts based on the civil liability provisions of the U.S. federal securities laws against us and our officers and directors as none of them currently resides in the United States or has substantial assets located in the United States. In addition, there is uncertainty as to whether the courts of the Cayman Islands or the PRC would recognize or enforce judgments of U.S. courts against us or such persons predicated upon the civil liability provisions of the securities laws of the United States or any state. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">49 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedures Law. PRC courts may recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based either on treaties between China and the country where the judgment is made or on principles of reciprocity between jurisdictions. China does not have any treaties or other forms of written arrangement with the United States that provide for the reciprocal recognition and enforcement of foreign judgments. In addition, according to the PRC Civil Procedures Law, the PRC courts will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment violates the basic principles of PRC laws or national sovereignty, security or the public interest. As a result, it is uncertain whether and on what basis a PRC court would enforce a judgment rendered by a court in the United States. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">It may be difficult for overseas regulators to conduct investigation or collect evidence within China. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholder claims or regulatory investigation that are common in the United States generally are difficult to pursue as a matter of law or practicality in China. For example, in China, there are significant legal and other obstacles to providing information needed for regulatory investigations or litigations initiated outside China. Although the authorities in China may establish a regulatory cooperation mechanism with the securities regulatory authorities of another country or region to implement cross-border supervision and administration, such cooperation with the securities regulatory authorities in the Unities States may not be efficient in the absence of mutual and practical cooperation mechanism. Furthermore, according to Article 177 of the PRC Securities Law, which became effective in March 2020, no overseas securities regulator is allowed to directly conduct investigation or evidence collection activities within the PRC territory. While detailed interpretation of or implementation rules under Article 177 have yet to be promulgated, the inability for an overseas securities regulator to directly conduct investigation or evidence collection activities within China may further increase the difficulties you face in protecting your interests. See also &#8220;&#8212;Risks Related to Our ADSs&#8212; You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because we are incorporated under Cayman Islands law.&#8221; for risks associated with investing in us as a Cayman Islands company. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be restricted from transferring our scientific data abroad. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;17, 2018, the General Office of the PRC State Council promulgated the Measures for the Management of Scientific Data, or the Scientific Data Measures, which provide a broad definition of scientific data and relevant rules for the management of scientific data. According to the Scientific Data Measures, enterprises in China must seek governmental approval before any scientific data involving a state secret may be transferred abroad or to foreign parties. Further, any researcher conducting research funded, at least in part, by the PRC government is required to submit relevant scientific data for management by the entity to which such researcher is affiliated before such data may be published in any foreign academic journal. Currently, as the term &#8220;state secret&#8221; is not clearly defined, there is no assurance that we can always obtain relevant approvals for sending scientific data (such as the results of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies or clinical trials conducted within China) abroad, or to our foreign partners in China. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to obtain the necessary approvals in a timely manner, or at all, our research and development of drug candidates may be hindered, which may materially and adversely affect our business, results of operations, financial conditions and prospects. If relevant government authorities consider the transmission of our scientific data to be in violation of the requirements under the Scientific Data Measures, we may be subject to specific administrative penalties imposed by those government authorities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in international trade policies and rising political tensions, particularly between the U.S. and China, may adversely impact our business and operating results. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The U.S. government has made statements and taken certain actions that may lead to potential changes to U.S. and international trade policies towards China. While the &#8220;Phase One&#8221; agreement was signed between the United States and China on trade matters, it remains unclear what additional actions, if any, will be taken by the U.S. or other governments with respect to international trade, tax policy related to international commerce, or other trade matters. The situation is further complicated by the political tensions between the United States and China that escalated during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and in the wake of the PRC National People&#8217;s Congress&#8217; decision on Hong Kong national security legislation, sanctions imposed by the U.S. Department of Treasury on certain officials of the Hong Kong Special Administrative Region and the central government of the PRC and the executive orders issued by the then U.S. President in August 2020 that prohibit certain transactions with certain China-based companies and their respective subsidiaries. Rising trade and political tensions could reduce levels of trades, investments, technological exchanges and other economic activities between China and other countries, which would have an adverse effect on global economic conditions, the stability of global financial markets, and international trade policies. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">50 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While we have not started commercialization of drug candidates, any rising trade and political tensions or unfavorable government policies on international trade, such as capital controls or tariffs, may affect the demand for our drug products, the competitive position of our drug products, the hiring of scientists and other research and development personnel, and import or export of raw materials in relation to drug development, or prevent us from selling our drug products in certain countries. In particular, if any new tariffs, legislation and/or regulations are implemented, or if existing trade agreements are renegotiated or, especially, if the U.S. government takes retaliatory trade actions due to the recent U.S.-China trade and political tension, such changes could have an adverse effect on our business, financial condition and results of operations. In addition, our results of operations could be adversely affected if any such tensions or unfavorable government trade policies harm the Chinese economy or the global economy in general. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PRC</div> shareholders or ADS holders. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Under the PRC Enterprise Income Tax Law and its implementation rules, an enterprise established outside of the PRC with &#8220;de facto management body&#8221; within China is considered a &#8220;resident enterprise&#8221; and will be subject to the enterprise income tax on its global income at the rate of 25%. The implementation rules define the term &#8220;de facto management body&#8221; as the body that exercises full and substantial control and overall management over the business, productions, personnel, accounts and properties of an enterprise. In 2009, the SAT issued the Circular of the State Administration of Taxation on Issues Relating to Identification of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PRC-Controlled</div> Overseas Registered Enterprises as Resident Enterprises in Accordance With the De Facto Standards of Organizational Management, or Circular 82, which provides certain specific criteria for determining whether the &#8220;de facto management body&#8221; of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PRC-controlled</div> enterprise that is incorporated offshore is located in China. Although this Circular only applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those controlled by PRC individuals or foreigners, the criteria set forth in the circular may reflect the SAT&#8217;s general position on how the &#8220;de facto management body&#8221; text should be applied in determining the tax resident status of all offshore enterprises. According to Circular 82, an offshore incorporated enterprise controlled by a PRC enterprise or a PRC enterprise group will be regarded as a PRC tax resident by virtue of having its &#8220;de facto management body&#8221; in China and will be subject to PRC enterprise income tax on its global income if all of the following conditions are met: (i)&#160;the primary location of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> operational management is in China; (ii)&#160;decisions relating to the enterprise&#8217;s financial and human resource matters are made or are subject to approval by organizations or personnel in China; (iii)&#160;the enterprise&#8217;s primary assets, accounting books and records, company seals, and board and shareholder resolutions, are located or maintained in China; and (iv)&#160;at least 50% of voting board members or senior executives habitually reside in China. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our PRC counsel, JunHe LLP, has advised us that, based on its understanding of the current PRC Laws and Regulations, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> should not be considered as a PRC resident enterprise for PRC tax income purposes. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term &#8220;de facto management body.&#8221; If the PRC tax authorities determine that we are a PRC resident enterprise for enterprise income tax purposes, we could be subject to PRC tax at a rate of 25% on our worldwide income, which could materially reduce our net income, and we may be required to withhold a 10% withholding tax from dividends we pay to our shareholders that are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> enterprises (including the holders of our ADSs). In addition, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> enterprise shareholders (including our ADS holders) may be subject to PRC tax at a rate of 10% on gains realized on the sale or other disposition of ADSs or ordinary shares, if such income is treated as sourced from within China. Furthermore, if we are deemed a PRC resident enterprise, dividends payable to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PRC</div> individual shareholders (including our ADS holders) and any gain realized on the transfer of ADSs or ordinary shares by such shareholders may be subject to PRC tax at a rate of 20% in the case of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PRC</div> individuals (which in the case of dividends may be withheld at source) unless a reduced rate is available under an applicable tax treaty. It is unclear whether <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PRC</div> shareholders of our company would be able to claim the benefits of any tax treaties between their country of tax residence and the PRC in the event that we are treated as a PRC resident enterprise. Any such tax may reduce the returns on your investment in the ADSs or ordinary shares. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">51 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Failure to renew our current leases or locate desirable alternatives for our leased properties could materially and adversely affect our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We lease properties for our offices and laboratories. We may not be able to successfully extend or renew such leases upon expiration of the current term on commercially reasonable terms or at all, and may therefore be forced to relocate our affected operations. This could disrupt our operations and result in significant relocation expenses, which could adversely affect our business, financial condition and results of operations. In addition, we compete with other businesses for premises at certain locations or of desirable sizes. As a result, even though we could extend or renew our leases, rental payments may significantly increase as a result of the high demand for the leased properties. In addition, we may not be able to locate desirable alternative sites for our current leased properties as our business continues to grow and failure in relocating our affected operations could adversely affect our business and operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Certain of our leasehold interests in leased properties have not been registered with the relevant PRC governmental authorities as required by relevant PRC laws. The failure to register leasehold interests may expose us to potential fines. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have not registered certain of our lease agreements with the relevant government authorities. Under the relevant PRC laws and regulations, we may be required to register and file with the relevant government authority executed leases. The failure to register the lease agreements for our leased properties will not affect the validity of these lease agreements, but the competent housing authorities may order us to register the lease agreements in a prescribed period of time and impose a fine ranging from RMB1,000 to RMB10,000 for each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-registered</div> lease if we fail to complete the registration within the prescribed timeframe. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have granted, and may continue to grant, options and other types of awards under our share incentive plans, which may result in increased share-based compensation expenses. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have adopted the Second Amended and Restated 2017 Employee Stock Option Plan (the &#8220;2017 Plan&#8221;), the Second Amended and Restated 2018 Employee Stock Option Plan (the &#8220;2018 Plan&#8221;), the 2019 Share Incentive Plan (the &#8220;2019 Plan&#8221;) and the 2020 Share Incentive Plan (the &#8220;2020 Plan&#8221;), for the purpose of granting share-based compensation awards to employees, directors and consultants to incentivize their performance and align their interests with ours. We recognize expenses in our consolidated financial statements in accordance with U.S. GAAP. As of February&#160;28, 2021, the awards that had been granted to our directors, officers, employees and consultants and remained outstanding included (i)&#160;options to purchase an aggregate of 7,115,955 ordinary shares, 9,948,512 ordinary shares, 72,000 ordinary shares and 1,052,025 ordinary shares under the 2017 Plan, the 2018 Plan, the 2019 Plan and the 2020 Plan, respectively, excluding options that were forfeited, cancelled, or exercised after the relevant grant date; and (ii)&#160;restricted share units to receive an aggregate of 5,106,141 ordinary shares under the 2020 Plan, excluding restricted share units that were forfeited, cancelled, or vested after the relevant grant date. See &#8220;Item 6. Directors, Senior Management and Employees&#8212;B. Compensation of Directors and Executive Officers&#8212;Share Incentive Plans.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We believe the granting of share-based compensation is of significant importance to our ability to attract and retain key personnel and employees, and we will continue to grant share-based compensation to employees in the future. As a result, our expenses associated with share-based compensation may increase, which may have an adverse effect on our results of operations. We may <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the vesting schedules, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period, exercise price or other key terms applicable to the grants under our currently effective share incentive plans from time to time. If we choose to do so, we may experience substantial change in our share-based compensation charges. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fluctuations in exchange rates could have a material and adverse effect on our results of operations and the value of your investment. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The conversion of RMB into foreign currencies, including U.S. dollars, is based on rates set by the People&#8217;s Bank of China. The RMB has fluctuated against the U.S. dollar, at times significantly and unpredictably. The value of RMB against the U.S. dollar and other currencies is affected by changes in China&#8217;s political and economic conditions and by China&#8217;s foreign exchange policies, among other things. We cannot assure you that RMB will not appreciate or depreciate significantly in value against the U.S. dollar in the future. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between RMB and the U.S. dollar in the future. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">52 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any significant appreciation or depreciation of RMB may materially and adversely affect our revenues, earnings and financial position, and the value of, and any dividends payable on, our ADSs in U.S. dollars. For example, to the extent that we need to convert U.S. dollars we receive into RMB to pay our operating expenses, appreciation of RMB against the U.S. dollar would have an adverse effect on the RMB amount we would receive from the conversion. Conversely, a significant depreciation of RMB against the U.S. dollar may significantly reduce the U.S. dollar equivalent of our earnings, which in turn could adversely affect the price of our ADSs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Very limited hedging options are available in China to reduce our exposure to exchange rate fluctuations. To date, we have not entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. While we may decide to enter into hedging transactions in the future, the availability and effectiveness of these hedges may be limited and we may not be able to adequately hedge our exposure or at all. In addition, our currency exchange losses may be magnified by PRC exchange control regulations that restrict our ability to convert RMB into foreign currency. As a result, fluctuations in exchange rates may have a material adverse effect on your investment. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Certain PRC regulations may make it more difficult for us to pursue growth through acquisitions. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the M&amp;A Rules, adopted by six PRC regulatory agencies in 2006 and amended in 2009, established additional procedures and requirements that could make merger and acquisition activities by foreign investors more time-consuming and complex. Such regulation requires, among other things, that the Ministry of Commerce, or MOFCOM, be notified in advance of any change of control transaction in which a foreign investor acquires control of a PRC domestic enterprise and involves any of the following circumstances: (i)&#160;any important industry is concerned; (ii)&#160;such transaction involves factors that impact or may impact national economic security; or (iii)&#160;such transaction will lead to a change in control of a domestic enterprise which holds a famous trademark or PRC time-honored brand. Moreover, the Anti-Monopoly Law promulgated by the Standing Committee of National People&#8217;s Congress which became effective in 2008 requires that transactions which are deemed concentrations and involve parties with specified turnover thresholds must be cleared by State Administration for Market Regulation (the &#8220;SAMR&#8221;), the successive authority of MOFCOM, before they can be completed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may rely on dividends and other distributions on equity paid by our PRC subsidiaries to fund any cash and financing requirements we may have, and any limitation on the ability of our PRC subsidiaries to make payments to us could have a material and adverse effect on our ability to conduct our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are a Cayman Islands holding company and we may rely on dividends and other distributions on equity paid by our PRC subsidiaries for our cash and financing requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders and service any debt we may incur. If any of our PRC subsidiaries incur debt on its own behalf in the future, the instruments governing the debt may restrict their ability to pay dividends or make other distributions to us. Under PRC laws and regulations, our PRC subsidiaries, each of which is a wholly foreign-owned enterprise may pay dividends only out of its respective accumulated profits as determined in accordance with PRC accounting standards and regulations. In addition, a wholly foreign-owned enterprise is required to set aside at least 10% of its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits each year, if any, to fund a certain statutory reserve fund, until the aggregate amount of such fund reaches 50% of its registered capital. At its discretion, a wholly foreign-owned enterprise may allocate a portion of its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits based on PRC accounting standards to a staff welfare and bonus fund. The reserve fund and staff welfare and bonus fund cannot be distributed to us as dividends. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our PRC subsidiaries generate primarily all of their revenue in RMB, which is not freely convertible into other currencies. As result, any restriction on currency exchange may limit the ability of our PRC subsidiaries to use their RMB revenues to pay dividends to us. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The PRC government may continue to strengthen its capital controls, and more restrictions and a substantial vetting process may be put forward by SAFE for cross-border transactions falling under both the current account and the capital account. Any limitation on the ability of our PRC subsidiaries to pay dividends or make other kinds of payments to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends, or otherwise fund and conduct our business. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">53 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In addition, the PRC Enterprise Income Tax Law and its implementation rules provide that a withholding tax rate of up to 10% will be applicable to dividends payable by PRC companies to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PRC-resident</div></div> enterprises unless otherwise exempted or reduced according to treaties or arrangements between the PRC central government and governments of other countries or regions where the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PRC-resident</div></div> enterprises are incorporated. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PRC regulations relating to offshore investment activities by PRC residents may limit our PRC subsidiaries&#8217; ability to change their registered capital or distribute profits to us or otherwise expose us or our PRC resident beneficial owners to liability and penalties under PRC laws. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2014, SAFE promulgated the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#8217; Offshore Investment and Financing and Roundtrip Investment Through Special Purpose Vehicles, or SAFE Circular 37. SAFE Circular 37 requires PRC residents (including PRC individuals and PRC corporate entities as well as foreign individuals that are deemed as PRC residents for foreign exchange administration purpose) to register with SAFE or its local branches in connection with their direct or indirect offshore investment activities. SAFE Circular 37 further requires amendment to the SAFE registrations in the event of any changes with respect to the basic information of the offshore special purpose vehicle, such as changes of a PRC individual shareholder, name and operation term, or any significant changes with respect to the offshore special purpose vehicle, such as increase or decrease of capital contribution, share transfer or exchange, or mergers or divisions. SAFE Circular 37 is applicable to our shareholders who are PRC residents. If our shareholders who are PRC residents fail to make the required registration or to update the previously filed registration, our PRC subsidiaries may be prohibited from distributing their profits or the proceeds from any capital reduction, share transfer or liquidation to us, and we may also be prohibited from making additional capital contributions into our PRC subsidiaries. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2015, SAFE promulgated a Notice on Further Simplifying and Improving Foreign Exchange Administration Policy on Direct Investment, or SAFE Notice 13, effective June 2015. Under SAFE Notice 13, applications for foreign exchange registration of inbound foreign direct investments and outbound overseas direct investments, including those required under SAFE Circular 37, will be filed with qualified banks instead of SAFE. The qualified banks will directly examine the applications and accept registrations under the supervision of SAFE. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of our shareholders who we are aware of being subject to the SAFE regulations have completed the initial registrations with the local SAFE branch or qualified banks as required by SAFE Circular 37. However, we may not be informed of the identities of all the PRC residents holding direct or indirect interests in our company, and we cannot provide any assurance that these PRC residents will comply with our request to make or obtain any applicable registrations or continuously comply with all requirements under SAFE Circular 37 or other related rules. The failure or inability of the relevant shareholders to comply with the registration procedures set forth in these regulations may subject us to fines and legal sanctions, such as restrictions on our cross-border investment activities, on the ability of our wholly foreign-owned subsidiaries in China to distribute dividends and the proceeds from any reduction in capital, share transfer or liquidation to us. Moreover, failure to comply with the various foreign exchange registration requirements described above could result in liability under PRC law for circumventing applicable foreign exchange restrictions. As a result, our business operations and our ability to distribute profits could be materially and adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Any failure to comply with PRC regulations regarding our employee equity incentive plans may subject the PRC plan participants or us to fines and other legal or administrative sanctions. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We and our directors, executive officers and other employees who are PRC citizens or who have resided in China for a continuous period of not less than one year and who will be granted restricted shares or options are subject to the Notice on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plan of Overseas Publicly Listed Company, issued by SAFE in February 2012, according to which, employees, directors, supervisors and other management members participating in any share incentive plan of an overseas publicly listed company who are PRC citizens or who are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PRC</div> citizens residing in China for a continuous period of not less than one year, subject to limited exceptions, are required to register with SAFE through a domestic qualified agent, which could be a PRC subsidiary of such overseas listed company, and complete certain other procedures. In addition, an overseas entrusted institution must be retained to handle matters in connection with the exercise or sale of stock options and the purchase or sale of shares and interests. Failure to complete the SAFE registrations may subject them to fines and legal sanctions and may also limit our ability to make payments under our equity incentive plans or receive dividends or sales proceeds related thereto, or our ability to contribute additional capital into our wholly foreign-owned enterprises in China and limit our wholly foreign-owned enterprises&#8217; ability to distribute dividends to us. We also face regulatory uncertainties that could restrict our ability to adopt additional equity incentive plans for our directors and employees under PRC law. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">54 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the SAT has issued circulars concerning employee share options or restricted shares. Under these circulars, employees working in China who exercise share options, or whose restricted shares vest, will be subject to PRC individual income tax. The PRC subsidiaries of an overseas listed company have obligations to file documents related to employee share options or restricted shares with relevant tax authorities and to withhold individual income taxes of those employees related to their share options or restricted shares. If the employees fail to pay, or the PRC subsidiaries fail to withhold applicable income taxes, the PRC subsidiaries may face sanctions imposed by the tax authorities or other PRC government authorities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from making loans to our PRC subsidiaries or making additional capital contributions to our wholly foreign-owned subsidiaries in China, which could materially and adversely affect our liquidity and our ability to fund and expand our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an offshore holding company conducting our operations in China through our PRC subsidiaries. We may make loans to our PRC subsidiaries subject to the approval from governmental authorities and limitation on the available loan amount, or we may make additional capital contributions to our wholly foreign-owned subsidiaries in China. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Any loans to our wholly foreign-owned subsidiaries in China, which are treated as foreign-invested enterprises under PRC law, are subject to PRC regulations and foreign exchange loan registrations. For example, loans by us to our wholly foreign-owned subsidiaries in China to finance their activities cannot exceed statutory limits and must be registered with the local counterpart of SAFE. In addition, a foreign-invested enterprise shall use its capital pursuant to the principle of authenticity and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">self-use</div> within its business scope. The capital of a foreign-invested enterprise shall not be used for the following purposes: (i)&#160;directly or indirectly used for payment beyond the business scope of the enterprises or the payment prohibited by relevant laws and regulations; (ii)&#160;directly or indirectly used for investment in securities or investments other than banks&#8217; principal-secured products unless otherwise provided by relevant laws and regulations; (iii)&#160;the granting of loans to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliated</div> enterprises, except where it is expressly permitted in the business license; and (iv)&#160;paying the expenses related to the purchase of real estate that is not for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">self-use</div> (except for the foreign-invested real estate enterprises). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">SAFE promulgated the Notice of the State Administration of Foreign Exchange on Reforming the Administration of Foreign Exchange Settlement of Capital of Foreign-invested Enterprises, or SAFE Circular 19, effective June 2015, in replacement of the Circular on the Relevant Operating Issues Concerning the Improvement of the Administration of the Payment and Settlement of Foreign Currency Capital of Foreign-Invested Enterprises, the Notice from the State Administration of Foreign Exchange on Relevant Issues Concerning Strengthening the Administration of Foreign Exchange Businesses, and the Circular on Further Clarification and Regulation of the Issues Concerning the Administration of Certain Capital Account Foreign Exchange Businesses. According to SAFE Circular 19, the flow and use of RMB capital converted from foreign currency-denominated registered capital of a foreign-invested company is regulated such that RMB capital may not be used for the issuance of RMB entrusted loans, the repayment of inter-enterprise loans or the repayment of banks loans that have been transferred to a third party. Although SAFE Circular 19 allows RMB capital converted from foreign currency-denominated registered capital of a foreign-invested enterprise to be used for equity investments within China, it also reiterates the principle that RMB converted from the foreign currency-denominated capital of a foreign-invested company may not be directly or indirectly used for purposes beyond its business scope. Thus, it is unclear whether SAFE will permit such capital to be used for equity investments in China in actual practice. SAFE promulgated the Notice of the State Administration of Foreign Exchange on Reforming and Standardizing the Foreign Exchange Settlement Management Policy of Capital Account, or SAFE Circular 16, effective on June&#160;9, 2016, which reiterates some of the rules set forth in SAFE Circular 19, but changes the prohibition against using RMB capital converted from foreign currency-denominated registered capital of a foreign-invested company to issue RMB entrusted loans to a prohibition against using such capital to issue loans to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-associated</div> enterprises. Violations of SAFE Circular 19 and SAFE Circular 16 could result in administrative penalties. SAFE Circular 19 and SAFE Circular 16&#160;may significantly limit our ability to transfer any foreign currency we hold, including the net proceeds from our initial public offering, to our PRC subsidiaries, which may adversely affect our liquidity and our ability to fund and expand our business in China. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">55 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In light of the various requirements imposed by PRC regulations on loans to and direct investment in PRC entities by offshore holding companies, we cannot assure you that we will be able to complete the necessary government registrations or obtain the necessary government approvals on a timely basis, if at all, with respect to future loans to our PRC subsidiaries or future capital contributions by us to our wholly foreign-owned subsidiaries in China. As a result, uncertainties exist as to our ability to provide prompt financial support to our PRC subsidiaries when needed. If we fail to complete such registrations or obtain such approvals, our ability to use foreign currency, including the proceeds we received from our initial public offering, to capitalize or otherwise fund our PRC operations may be negatively affected, which could materially and adversely affect our liquidity and our ability to fund and expand our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We and our shareholders face uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises or other assets attributable to a PRC establishment of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PRC</div> company. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On February&#160;3, 2015, the SAT issued the Bulletin on Issues of Enterprise Income Tax and Indirect Transfers of Assets by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-PRC</div> Resident Enterprises, or Bulletin 7. Pursuant to this Bulletin, an &#8220;indirect transfer&#8221; of &#8220;PRC taxable assets,&#8221; including equity interests in a PRC resident enterprise, by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PRC</div> resident enterprises may be recharacterized and treated as a direct transfer of PRC taxable assets, if such arrangement does not have a reasonable commercial purpose and was established for the purpose of avoiding payment of PRC enterprise income tax. As a result, gains derived from such indirect transfer may be subject to PRC enterprise income tax. When determining whether there is a &#8220;reasonable commercial purpose&#8221; of the transaction arrangement, factors to be taken into consideration include: whether the main value of the equity interest of the relevant offshore enterprise derives from PRC taxable assets; whether the assets of the relevant offshore enterprise mainly consist of direct or indirect investment in China or if its income mainly derives from China; whether the offshore enterprise and its subsidiaries directly or indirectly holding PRC taxable assets have real commercial nature which is evidenced by their actual function and risk exposure; the duration of existence of the business model and organizational structure; the replicability of the transaction by direct transfer of PRC taxable assets; and the tax situation of such indirect transfer and applicable tax treaties or similar arrangements. On October&#160;17, 2017, the SAT issued the Announcement of the State Administration of Taxation on Issues Concerning the Withholding of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-resident</div> Enterprise Income Tax at Source, or Bulletin 37, which came into effect on December&#160;1, 2017. Bulletin 37 further clarifies the practice and procedure of the withholding of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> enterprise income tax. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Late payment of applicable tax will subject the transferor to default interest. Gains derived from the sale of shares by investors are not subject to the PRC enterprise income tax pursuant to Bulletin 7 where such shares were acquired in a transaction through a public stock exchange. However, the sale of ADSs or ordinary shares by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PRC</div> resident enterprise outside a public stock exchange may be subject to PRC enterprise income tax under Bulletin 7. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There are uncertainties as to the application of Bulletin 7. Bulletin 7&#160;may be determined by the tax authorities to be applicable to the sale of the shares of our offshore subsidiaries or investments where PRC taxable assets are involved. The transferors and transferees may be subject to the tax filing and withholding or tax payment obligation, while our PRC subsidiaries may be requested to assist in the filing. Furthermore, we, our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> enterprises and PRC subsidiaries may be required to spend valuable resources to comply with Bulletin 7 or to establish that we and our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> enterprises should not be taxed under Bulletin 7, for our previous and future restructuring or disposal of shares of our offshore subsidiaries, which may have a material adverse effect on our financial condition and results of operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The PRC tax authorities have the discretion under Bulletin 7 to make adjustments to the taxable capital gains based on the difference between the fair value of the taxable assets transferred and the cost of investment. If the PRC tax authorities make adjustments to the taxable income of the transactions under Bulletin 7 / Bulletin 37, our income tax costs associated with such potential acquisitions or disposals will increase, which may have an adverse effect on our financial condition and results of operations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">56 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent litigation and negative publicity surrounding China-based companies listed in the U.S. may result in increased regulatory scrutiny of us and negatively impact the trading price of the ADSs and could have a material adverse effect upon our business, including our results of operations, financial condition, cash flows and prospects. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that litigation and negative publicity surrounding companies with operations in China that are listed in the U.S. have negatively impacted stock prices for such companies. Various equity-based research organizations have published reports on China-based companies after examining, among other things, their corporate governance practices, related party transactions, sales practices and financial statements that have led to special investigations and stock suspensions on national exchanges. Any similar scrutiny of us, regardless of its lack of merit, could result in a diversion of management resources and energy, potential costs to defend ourselves against rumors, decreases and volatility in the ADS trading price, and increased directors and officers insurance premiums and could have a material adverse effect upon our business, including our results of operations, financial condition, cash flows and prospects. </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General Risks Related to Our ADSs </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The trading price of our ADSs may be volatile, which could result in substantial losses to you. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The trading price of our ADSs ranged from US$9.30 to US$65.94 per ADS since the listing of ADSs on Nasdaq. The trading price of our ADSs can be volatile and fluctuate widely in response to a variety of factors, many of which are beyond our control. In addition, the performance and fluctuation of the market prices of other companies with business operations located mainly in the PRC that have listed their securities in the United States may affect the volatility in the price of and trading volumes for our ADSs. Some of these companies have experienced significant volatility. The trading performances of these PRC companies&#8217; securities may affect the overall investor sentiment towards other PRC companies listed in the United States and consequently may impact the trading performance of our ADSs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to market and industry factors, the price and trading volume for our ADSs may be highly volatile for specific business reasons, including: </div></div> </div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">announcements of regulatory approval or a complete response letter, or specific label indications or patient populations for a drug&#8217;s use, or changes or delays in the regulatory review process; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">announcements of therapeutic innovations, new products, acquisitions, strategic relationships, joint ventures or capital commitments by us or our competitors; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any adverse changes to our relationship with manufacturers or suppliers; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the results of our testing and clinical trials; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the results of our efforts to acquire or license additional drug candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">variations in the level of expenses related to our existing drugs and drug candidates or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical,</div> clinical development and commercialization programs; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any intellectual property infringement actions in which we may become involved; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">announcements concerning our competitors or the pharmaceutical industry in general; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fluctuations in product revenue, sales and marketing expenses and profitability; manufacture, supply or distribution shortages; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">variations in our results of operations; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">57 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">announcements about our results of operations that are not in line with analyst expectations, the risk of which is enhanced because it is our policy not to give guidance on results of operations; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">publication of operating or industry metrics by third parties, including government statistical agencies, that differ from expectations of industry or financial analysts; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in financial estimates by securities research analysts; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">media reports, whether or not true, about our business, our competitors or our industry; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">additions to or departures of our management; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fluctuations of exchange rates between the RMB and the U.S. dollar; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">release or expiry of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> or other transfer restrictions on our outstanding ordinary shares or ADSs; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">sales or perceived potential sales of additional ordinary shares or ADSs by us, our executive officers and directors or our shareholders; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any share repurchase program; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">general economic and market conditions and overall fluctuations in the U.S. equity markets; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in accounting principles; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes or developments in the PRC or global regulatory environment. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the stock market, in general, and pharmaceutical and biotechnology companies have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our ADSs, regardless of our actual operating performance. Further, the current volatility in the financial markets and related factors beyond our control may cause the market price of our ADSs to decline rapidly and unexpectedly. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may face an increased risk of securities class action litigation. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Historically, securities class action litigation has often been brought against a company following a significant decline in the market price of its securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies have experienced significant share price volatilities in recent years. If we were to face lawsuits, it could lead to substantial costs and a distraction of management&#8217;s attention and resources, which could harm our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We cannot guarantee that any share repurchase program will be fully consummated or that any share repurchase program will enhance long-term shareholder value, and share repurchases could increase the volatility of the price of our ADSs and could diminish our cash reserves. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;15, 2020, we announced that our board of directors has authorized a share repurchase program, pursuant to which we were authorized to repurchase our own ordinary shares, in the form of ADSs, with an aggregate value of up to US$20.0&#160;million during a twelve-month period effective upon and from the date on which a formal stock repurchase plan engagement agreement is signed with a qualified broker-dealer(s). From July&#160;15, 2020 to the date of this annual report, we did not repurchase any ADSs. Our share repurchase program could affect the price of our ADSs and increase volatility and may be suspended or terminated at any time. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">58 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, or if they adversely change their recommendations regarding our ADSs, the market price for our ADSs and trading volume could decline. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The trading market for our ADSs will depend in part on the research and reports that securities or industry analysts publish about us or our business. If research analysts do not establish and maintain adequate research coverage or if one or more of the analysts who covers us downgrades our ADSs or publishes inaccurate or unfavorable research about our business, the market price for our ADSs would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume for our ADSs to decline. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Because we do not expect to pay dividends in the foreseeable future, you must rely on price appreciation of our ADSs for return on your investment. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We currently intend to retain most, if not all, of our available funds and any future earnings to fund the development and growth of our business. As a result, we do not expect to pay any cash dividends in the foreseeable future. Therefore, you should not rely on an investment in our ADSs as a source for any future dividend income. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors has complete discretion as to whether to distribute dividends, subject to our memorandum and articles of association and certain requirements of Cayman Islands law. In addition, our shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. Under Cayman Islands law, a Cayman Islands company may pay a dividend out of either profit or share premium account of the company, provided that in no circumstances may a dividend be paid out of share premium if this would result in the company being unable to pay its debts as they fall due in the ordinary course of business. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board of directors. Accordingly, the return on your investment in our ADSs will likely depend entirely upon any future price appreciation of our ADSs. There is no guarantee that our ADSs will appreciate in value or even maintain the price at which you purchased the ADSs. You may not realize a return on your investment in our ADSs and you may even lose your entire investment in our ADSs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Substantial future sales or perceived potential sales of our ADSs in the public market could cause the price of our ADSs to decline. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Sales of substantial amounts of our ADSs in the public market, or the perception that these sales could occur, could adversely affect the market price of our ADSs and could materially impair our ability to raise capital through equity offerings in the future. As of March&#160;31, 2021, we had 166,532,087 ordinary shares issued and outstanding (excluding 2,982,401 ordinary shares issued to our depositary bank for bulk issuance of ADSs reserved for future issuances upon the exercising or vesting of awards granted under our share incentive plans). Among these shares, 73,412,688 ordinary shares are in the form of ADSs (including 2,982,401 ordinary shares issued to our depositary bank for bulk issuance of ADSs reserved for future issuances upon the exercising or vesting of awards granted under our share incentive plans), which are freely transferable without restriction or additional registration under the Securities Act. On December&#160;14, 2020, the SEC declared effective a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1,</div> under which the selling shareholders identified therein may offer, from time to time, up to 25,123,751 ordinary shares, including ordinary shares represented by ADSs of our company. On March&#160;23, 2021, the SEC declared effective a post-effective amendment to this registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</div> that terminates the effectiveness of this registration statement and removes from registration all securities registered but not sold under this registration statement. On March&#160;19, 2021, we filed a prospectus supplement as part of a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div> (Registration <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-252793),</div> under which the selling shareholders identified therein may offer, from time to time, up to 19,050,555 ordinary shares, including ordinary shares represented by ADSs of our company. Remaining ordinary shares issued and outstanding will be available for sale in the public market subject to volume and other restrictions as applicable under Rules 144 and 701 under the Securities Act. Certain holders of our ordinary shares may cause us to register under the Securities Act the sale of their shares. Registration of these shares under the Securities Act would result in ADSs representing these shares becoming freely tradable without restriction under the Securities Act immediately upon the effectiveness of the registration. Sales of these registered shares in the form of ADSs in the public market, or sales of securities held by our significant shareholders or any other shareholder or the availability of these securities for future sale could cause the price of our ADSs to decline. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">59 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The voting rights of holders of ADSs are limited by the terms of the deposit agreement, and you may not be able to exercise the same rights as our shareholders. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of ADSs do not have the same rights as our shareholders. As a holder of our ADSs, you will not have any direct right to attend general meetings of our shareholders or to cast any votes at such meetings. As an ADS holder, you will only be able to exercise the voting rights carried by the underlying ordinary shares indirectly by giving voting instructions to the depositary in accordance with the provisions of the deposit agreement. Under the deposit agreement, you may vote only by giving voting instructions to the depositary. Upon receipt of your voting instructions, the depositary will try, as far as is practicable, to vote the ordinary shares underlying your ADSs in accordance with your instructions. If we ask for your instructions, then upon receipt of your voting instructions, the depositary will try to vote the underlying ordinary shares in accordance with these instructions. If we do not instruct the depositary to ask for your instructions, the depositary may still vote in accordance with instructions you give, but it is not required to do so. You will not be able to directly exercise your right to vote with respect to the underlying ordinary shares unless you withdraw the shares, and become the registered holder of such shares prior to the record date for the general meeting. When a general meeting is convened, you may not receive sufficient advance notice of the meeting to withdraw the shares underlying your ADSs and become the registered holder of such shares to allow you to attend the general meeting and to vote directly with respect to any specific matter or resolution to be considered and voted upon at the general meeting. In addition, under our memorandum and articles of association, for the purposes of determining those shareholders who are entitled to attend and vote at any general meeting, our directors may close our register of members and/or fix in advance a record date for such meeting, and such closure of our register of members or the setting of such a record date may prevent you from withdrawing the ordinary shares underlying your ADSs and becoming the registered holder of such shares prior to the record date, so that you would not be able to attend the general meeting or to vote directly. If we ask for your instructions, the depositary will notify you of the upcoming vote and will arrange to deliver our voting materials to you. We have agreed to give the depositary notice of shareholder meetings sufficiently in advance of such meetings. Nevertheless, we cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote the underlying ordinary shares represented by your ADSs. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for their manner of carrying out your voting instructions. This means that you may not be able to exercise your right to direct how the shares underlying your ADSs are voted and you may have no legal remedy if the shares underlying your ADSs are not voted as you requested. In addition, in your capacity as an ADS holder, you will not be able to call a shareholders&#8217; meeting. Except in limited circumstances, the depositary for our ADSs will give us a discretionary proxy to vote the ordinary shares underlying your ADSs if you do not vote at shareholders&#8217; meetings, which could adversely affect your interests. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the deposit agreement for the ADSs, if you do not vote, the depositary will give us a discretionary proxy to vote the ordinary shares underlying your ADSs at shareholders&#8217; meetings unless: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we have instructed the depositary that we do not wish a discretionary proxy to be given; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we have informed the depositary that there is substantial opposition as to a matter to be voted on at the meeting; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a matter to be voted on at the meeting would have an adverse impact on shareholders; or </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the voting at the meeting is to be made on a show of hands. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The effect of this discretionary proxy is that you cannot prevent our ordinary shares underlying your ADSs from being voted, except under the circumstances described above. This may make it more difficult for shareholders to influence the management of our company. Holders of our ordinary shares are not subject to this discretionary proxy. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Your right to participate in any future rights offerings may be limited, which may cause dilution to your holdings. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may from time to time distribute rights to our shareholders, including rights to acquire our securities. However, we cannot make rights available to you in the United States unless we register both the rights and the securities to which the rights relate under the Securities Act or an exemption from the registration requirements is available. Under the deposit agreement, the depositary will not make rights available to you unless both the rights and the underlying securities to be distributed to ADS holders are either registered under the Securities Act or exempt from registration under the Securities Act. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective and we may not be able to establish a necessary exemption from registration under the Securities Act. Accordingly, you may be unable to participate in our rights offerings and may experience dilution in your holdings. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">You may not receive cash dividends if the depositary decides it is impractical to make them available to you. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The depositary will pay cash dividends on the ADSs only to the extent that we decide to distribute dividends on our ordinary shares or other deposited securities, and we do not have any present plan to pay any cash dividends on our ordinary shares in the foreseeable future. To the extent that there is a distribution, the depositary of our ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited securities after deducting its fees and expenses pursuant to the deposit agreement. You will receive these distributions in proportion to the number of ordinary shares your ADSs represent. However, the depositary may, at its discretion, decide that it is inequitable or impractical to make a distribution available to any holders of ADSs. For example, the depositary may determine that it is not practicable to distribute certain property through the mail, or that the value of certain distributions may be less than the cost of mailing them. In these cases, the depositary may decide not to distribute such property to you. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">You may be subject to limitations on transfer of your ADSs. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Your ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may close its books from time to time for a number of reasons, including in connection with corporate events such as a rights offering, during which time the depositary needs to maintain an exact number of ADS holders on its books for a specified period. The depositary may also close its books in emergencies, and on weekends and public holidays. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Certain judgments obtained against us by our shareholders may not be enforceable. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an exempted company incorporated under the laws of the Cayman Islands. We conduct our operations in China and substantially all of our assets are located in China. In addition, our directors and executive officers, and some of the experts named in this annual report, reside within China, and most of the assets of these persons are located within China. As a result, it may be difficult or impossible for you to bring an action against us or against these individuals in the United States in the event that you believe that your rights have been infringed under the U.S. federal securities laws or otherwise. Even if you are successful in bringing an action of this kind, the laws of the Cayman Islands and of the PRC may render you unable to enforce a judgment against our assets or the assets of our directors and officers. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The deposit agreement governing the ADSs representing our ordinary shares provides that, subject to the depositary&#8217;s right to require a claim to be submitted to the federal or state courts in the City of New York have jurisdiction to hear and determine claims arising under the deposit agreement and in that regard, to the fullest extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws. Also, we may amend or terminate the deposit agreement without your consent. If you continue to hold your ADSs after an amendment to the deposit agreement, you agree to be bound by the deposit agreement as amended. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">61 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we or the depositary were to oppose a jury trial demand based on such waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable state and federal law, including whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. The waiver to right to a jury trial of the deposit agreement is not intended to be deemed a waiver by any holder or beneficial owner of ADSs of our or the depositary&#8217;s compliance with the U.S. federal securities laws and the rules and regulations promulgated thereunder. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you or any other holders or beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under U.S. federal securities laws, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and/or the depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, in which the trial would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nevertheless, if this jury trial waiver provision is not enforced, to the extent a court action proceeds, it would proceed under the terms of the deposit agreement with a jury trial. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any substantive provision of the U.S. federal securities laws and the rules and regulations promulgated thereunder. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because we are incorporated under Cayman Islands law. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an exempted company incorporated under the laws of the Cayman Islands with limited liability. Our corporate affairs are governed by our memorandum and articles of association, the Companies Act, Cap. 22 (Act 3 of 1961, as consolidated and revised) of the Cayman Islands (the &#8220;Companies Act&#8221;), which we refer to as the Companies Act, and the common law of the Cayman Islands. The rights of shareholders to take action against our directors, actions by our minority shareholders and the fiduciary duties of our directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands as well as from the common law of England, the decisions of whose courts are of persuasive authority, but are not binding, on a court in the Cayman Islands. The rights of our shareholders and the fiduciary duties of our directors under Cayman Islands law are not as clearly established as they would be under statutes or judicial precedent in some jurisdictions in the United States. In particular, the Cayman Islands has a less developed body of securities laws than the United States. Some U.S. states, such as Delaware, have more fully developed and judicially interpreted bodies of corporate law than the Cayman Islands. In addition, Cayman Islands companies may not have standing to initiate a shareholder derivative action in a federal court of the United States. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders of Cayman Islands exempted companies like us have no general rights under Cayman Islands law to inspect corporate records or to obtain copies of lists of shareholders of these companies. Our directors have discretion under our articles of association to determine whether or not, and under what conditions, our corporate records may be inspected by our shareholders, but are not obliged to make them available to our shareholders. This may make it more difficult for you to obtain the information needed to establish any facts necessary for a shareholder motion or to solicit proxies from other shareholders in connection with a proxy contest. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result of all of the above, our public shareholders may have more difficulty in protecting their interests in the face of actions taken by management, members of the board of directors or controlling shareholders than they would as public shareholders of a company incorporated in the United States. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">62 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We retain broad discretion in the use of the net proceeds from our initial public offering. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We retain broad discretion in the application of the net proceeds from our initial public offering and could spend the proceeds in ways that do not produce income or increase our ADS price. We have not determined a specific use for a portion of the net proceeds of our initial public offering, and our management will have considerable discretion in deciding how to apply these proceeds. You will not have the opportunity to assess whether the net proceeds from our initial public offering are being used appropriately. You must rely on the judgment of our management regarding the application of the net proceeds of our initial public offering. We cannot assure you that the net proceeds from our initial public offering will be used in a manner that would improve our results of operations or increase our ADS price, nor that these net proceeds will be placed only in investments that generate income or appreciate in value. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our memorandum and articles of association contains anti-takeover provisions that could discourage a third party from acquiring us and adversely affect the rights of holders of our ordinary shares and the ADSs. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our memorandum and articles of association contains provisions to limit the ability of others to acquire control of our company or cause us to engage in change of control transactions. These provisions could have the effect of depriving our shareholders of an opportunity to sell their shares at a premium over prevailing market prices by discouraging third parties from seeking to obtain control of our company in a tender offer or similar transaction. Our board of directors has the authority to issue preferred shares in one or more series and to fix their designations, powers, preferences, privileges, and relative participating, optional or special rights and the qualifications, limitations or restrictions, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights associated with our ordinary shares, in the form of ADS or otherwise. Preferred shares could be issued with terms calculated to delay or prevent a change in control of our company or make removal of management more difficult. If our board of directors decides to issue preferred shares, the price of our ADSs may fall and the voting and other rights of the holders of our ordinary shares and ADSs may be materially and adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are an emerging growth company within the meaning of the Securities Act and may take advantage of certain reduced reporting requirements. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an &#8220;emerging growth company,&#8221; as defined in the U.S. Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may take advantage of certain exemptions from various requirements applicable to other public companies that are not emerging growth companies including, most significantly, not being required to comply with the auditor attestation requirements of Section&#160;404 of Sarbanes-Oxley Act of 2002 for so long as we are an emerging growth company. As a result, if we elect not to comply with such auditor attestation requirements, our investors may not have access to certain information they may deem important. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The JOBS Act also provides that an emerging growth company does not need to comply with any new or revised financial accounting standards until such date that a private company is otherwise required to comply with such new or revised accounting standards. However, we have elected to &#8220;opt out&#8221; of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted for public companies. This decision to opt out of the extended transition period under the JOBS Act is irrevocable. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are a foreign private issuer within the meaning of the rules under the Exchange Act, and as such we are exempt from certain provisions applicable to U.S. domestic public companies. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because we qualify as a foreign private issuer under the Exchange Act, we are exempt from certain provisions of the securities rules and regulations in the United States that are applicable to U.S. domestic issuers, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> or current reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K;</div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the sections of the Exchange Act regulating the solicitation of proxies, consents, or authorizations in respect of a security registered under the Exchange Act; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">63 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the selective disclosure rules by issuers of material nonpublic information under Regulation FD promulgated by SEC. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are required to file an annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> within four months of the end of each fiscal year. In addition, we intend to publish our results on a quarterly basis as press releases, distributed pursuant to the rules and regulations of the Nasdaq Stock Market. Press releases relating to financial results and material events will also be furnished to the SEC on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K.</div> However, the information we are required to file with or furnish to the SEC will be less extensive and less timely compared to that required to be filed with the SEC by U.S. domestic issuers. As a result, you may not be afforded the same protections or information that would be made available to you were you investing in a U.S. domestic issuer. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">As an exempted company incorporated in the Cayman Islands, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from the Nasdaq Stock Market&#8217;s corporate governance requirements; these practices may afford less protection to shareholders than they would enjoy if we complied fully with the Nasdaq Stock Market&#8217;s corporate governance requirements. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As a Cayman Islands company listed on the Nasdaq Stock Market, we are subject to the Nasdaq Stock Market&#8217;s corporate governance requirements. However, the Nasdaq Stock Market rules permit a foreign private issuer like us to follow the corporate governance practices of its home country. Certain corporate governance practices in the Cayman Islands, which is our home country, may differ significantly from the Nasdaq Stock Market&#8217;s corporate governance requirements. For example, neither the Companies Act nor our memorandum and articles of association requires a majority of our directors to be independent and we could include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-independent</div> directors as members of our compensation committee and nominating committee, and our independent directors would not necessarily hold regularly scheduled meetings at which only independent directors are present. We follow home country practice with respect to adoption of the 2020 Plan. However, if we choose to follow home country practice in the future, our shareholders may be afforded less protection than they otherwise would under the Nasdaq Stock Market&#8217;s corporate governance requirements applicable to U.S. domestic issuers. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">There can be no assurance that we will not be classified as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes for any taxable year, which could subject U.S. investors in our ADSs or ordinary shares to significant adverse U.S. income tax consequences. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We will be classified as a passive foreign investment company, or PFIC, for any taxable year if either (i) 75% or more of our gross income for such year consists of certain types of &#8220;passive&#8221; income or (ii) 50% or more of the value of our assets (generally determined on the basis of quarterly average) during such year produce or are held for the production of passive income. We do not believe that we were a PFIC for the taxable year ended December&#160;31, 2020. Although we do not believe we were a PFIC for the taxable year ended December&#160;31, 2020, no assurance can be given with respect to our PFIC status for the current taxable year or any future taxable year. The determination of whether we are or will become a PFIC is uncertain, because it is a fact-intensive inquiry made on an annual basis that depends, in part, on the composition of our income and assets. Fluctuations in the market price of our ADSs may cause us to become a PFIC for the current or subsequent taxable years because the value of our assets for the purpose of the asset test may be determined by reference to the market price of our ADSs from time to time (which may be volatile for biopharmaceutical companies, such as ours, that have not yet achieved commercialization with respect to any of their products). The composition of our income and assets may also be affected by how, and how quickly, we use our liquid assets. Under circumstances where our revenue from activities that produce passive income increases relative to our revenue from activities that produce <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-passive</div> income, or where we determine not to deploy cash for active purposes, our risk of becoming classified as a PFIC will substantially increase. Furthermore, prior to the commercialization of any of our drug candidates, interest and other passive income could constitute more than 75% of gross income for any taxable year. In addition, because there are uncertainties in the application of the relevant rules, it is possible that the IRS may challenge our classification of certain income and assets as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-passive</div> or our valuation of our tangible and intangible assets, each of which may result in our being or becoming a PFIC for the current or subsequent taxable years. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">64 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are a PFIC in any taxable year, a U.S. Holder (as defined in &#8220;Item 10. Additional Information&#8212;E. Taxation&#8212;United States Federal Income Tax Considerations&#8221;) may incur significantly increased U.S. income tax on gain recognized on the sale or other disposition of the ADSs or ordinary shares and on the receipt of distributions on the ADSs or ordinary shares to the extent such gain or distribution is treated as an &#8220;excess distribution&#8221; under the U.S. federal income tax rules and such holder may be subject to burdensome reporting requirements. Further, if we are a PFIC for any year during which a U.S. Holder holds our ADSs or ordinary shares, we generally will continue to be treated as a PFIC for all succeeding years during which such U.S. Holder holds our ADSs or ordinary shares. For more information see &#8220;Item 10. Additional Information&#8211;&#8211;E. Taxation&#8212;United States Federal Income Tax Considerations&#8212;Passive Foreign Investment Company Considerations.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We expect to incur increased costs and become subject to additional rules and regulations as a result of being a public company, particularly after we ceased to qualify as an &#8220;emerging growth company.&#8221; </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a public company, we expect to incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, as well as rules subsequently implemented by the SEC and the Nasdaq Global Market, impose various requirements on the corporate governance practices of public companies. As a company with less than US$1.07&#160;billion in net revenues for our last fiscal year, we qualify as an &#8220;emerging growth company&#8221; pursuant to the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies. These provisions include exemption from the auditor attestation requirement under Section&#160;404 of the Sarbanes-Oxley Act of 2002 in the assessment of the emerging growth company&#8217;s internal control over financial reporting and permission to delay adopting new or revised accounting standards until such time as those standards apply to private companies. However, we have elected to &#8220;opt out&#8221; of the provision that allows us to delay adopting new or revised accounting standards and, as a result, we will comply with new or revised accounting standards as required when they are adopted for public companies. This decision to opt out of the extended transition period under the JOBS Act is irrevocable. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect these rules and regulations to increase our legal and financial compliance costs and to make some corporate activities more time-consuming and costly. After we are no longer an &#8220;emerging growth company&#8221;, we expect to incur significant expenses and devote substantial management effort toward ensuring compliance with the requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 and the other rules and regulations of the SEC. We also expect that operating as a public company will make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. In addition, we will incur additional costs associated with our public company reporting requirements. It may also be more difficult for us to find qualified persons to serve on our board of directors or as executive officers. We are currently evaluating and monitoring developments with respect to these rules and regulations, and we cannot predict or estimate with any degree of certainty the amount of additional costs we may incur or the timing of such costs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the past, shareholders of a public company often brought securities class action suits against the company following periods of instability in the market price of that company&#8217;s securities. If we were involved in a class action suit, it could divert a significant amount of our management&#8217;s attention and other resources from our business and operations, which could harm our results of operations and require us to incur significant expenses to defend the suit. Any such class action suit, whether or not successful, could harm our reputation and restrict our ability to raise capital in the future. In addition, if a claim is successfully made against us, we may be required to pay significant damages, which could have a material adverse effect on our financial condition and results of operations. </div></div> <div id="rom10811_7" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;4. INFORMATION ON THE COMPANY </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">History and Development of the Company</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We commenced our operations in November 2014, when our predecessor Third Venture Biopharma (Nanjing) Co., Ltd (&#8220;Third Venture&#8221;) was established. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> was established in June 2016 under the laws of the Cayman Islands as our offshore holding company. In July 2016, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> established <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma Hong Kong Limited <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;I-Mab</div> Hong Kong&#8221;), as its intermediary holding company. In August 2016, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong established a wholly-owned PRC subsidiary, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma Co., Ltd. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;I-Mab</div> Shanghai&#8221;). In September 2016, the assets and operations of Third Venture were consolidated into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">65 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In July 2017, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong acquired a controlling interest in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-tech</div> (Tianjin) Co., Ltd. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;I-Mab</div> Tianjin&#8221;), formerly known as Tasgen <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-tech</div> (Tianjin) Co., Ltd., a company focused on CMC management of biologics in China. Through an internal corporate restructuring, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin became the 100% owner of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai in September 2017 and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong acquired the remaining interest in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin in May 2018, becoming the 100% owner of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In February 2018, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong established in Maryland, United States, a wholly-owned subsidiary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma US Limited <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;I-Mab</div> US&#8221;), as the hub for the discovery and development of the drug candidates in our Global Portfolio. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;17, 2020, our ADSs commenced trading on the Nasdaq Global Market under the symbol &#8220;IMAB.&#8221; We raised from our initial public offering approximately US$103.7&#160;million in net proceeds, after the underwriters exercise in part their over-allotment option to purchase additional ADSs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In 2020, we have taken concrete steps to execute our plan to build a comprehensive biologics manufacturing facility in Hangzhou, China (the &#8220;Hangzhou Facility&#8221;) as part of our strategic plan to become a fully integrated biopharma company. The Hangzhou Facility targets to have a pilot capacity of 2 production lines (1 line configured with 2 x 2,000L and another line with 1 x 2,000L) by 2022 and commercially progressive capacity up to 8 x 4,000L to begin operation by the end of 2023. Construction is expected to commence in April 2021 and ready for use by the end of 2023. The project will be financed by a combination of internal and external sources. A group of domestic investors in China have agreed to invest a total of US$120&#160;million (in RMB equivalent) in cash. Upon closing, we, through our wholly owned subsidiary and parties acting in concert, will remain the majority shareholder <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of&#160;I-Mab&#160;Biopharma</div> (Hangzhou) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Limited&#160;(&#8220;I-Mab&#160;Hangzhou&#8221;),</div> the entity holding the Hangzhou Facility, and retain a managing role and take full control to build and operate the manufacturing facility.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In September 2020, we, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">through&#160;I-Mab&#160;Biopharma</div> Co., Ltd. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;I-Mab&#160;Biopharma</div> US Limited, each a wholly-owned subsidiary of our company, entered into a broad global collaboration with AbbVie Ireland Unlimited Company (&#8220;AbbVie&#8221;), a leading global, research-based biopharmaceutical company. Pursuant to this collaboration, we grant AbbVie a global license, excluding Mainland China, Hong Kong and Macau, to develop and commercialize lemzoparlimab. We retain the rights to develop and commercialize lemzoparlimab (as well as certain other compounds directed against CD47) in Mainland China, Hong Kong and Macau. AbbVie will conduct further global clinical trials (which we may elect <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">to&#160;co-fund)&#160;to</div> evaluate lemzoparlimab in multiple cancers. This deal also allows for potential collaboration on future CD47-related therapeutic agents, including CD47-based bispecific antibodies and combination therapies with lemzoparlimab and AbbVie&#8217;s venetoclax (Venclexta<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>). Each party will have the opportunity, subject to rights of first negotiation to further licenses, to explore certain of each other&#8217;s related CD47-antibody programs in their respective territories. In addition, we and AbbVie will share manufacturing responsibilities, with AbbVie being the primary manufacturer for supply outside of Mainland China, Hong Kong and Macau and us being the primary manufacturer for supply in Mainland China, Hong Kong and Macau. We believe that this collaboration will accelerate the establishment of our commercial production operations in China. Pursuant to this collaboration, AbbVie has paid us an upfront payment of US$180&#160;million and milestone payment of US$20&#160;million. We will also be eligible to receive up to US$1.74&#160;billion in further success-based development, regulatory and sales milestone payments for lemzoparlimab, of which US$840&#160;million are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestones. Upon commercialization of lemzoparlimab, AbbVie will also pay tiered royalties from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-to-mid</div></div> teen percentages on global net sales outside of Mainland China, Hong Kong and Macau. In addition, AbbVie has a license and right of first negotiation to further develop and commercialize two additional lemzoparlimab-based bispecific antibodies discovered and currently being developed by us and we cannot commercialize products containing these two additional lemzoparlimab-based bispecific antibodies outside of Mainland China, Hong Kong and Macau even if AbbVie does not exercise its right of first negotiation or we are unable to come to financial terms on such products. The potential value of each such license is minimum US$500&#160;million in upfront and milestone payments, for a combined total of no less than US$1&#160;billion. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">66 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2020, we entered into definitive subscription agreements (collectively, the &#8220;Subscription Agreements,&#8221; and each, a &#8220;Subscription Agreement&#8221;) with a consortium of institutional investors, pursuant to which we agree to issue and sell to these investors (i)&#160;a total of 29,133,502 ordinary shares of our company for an aggregate purchase price of approximately US$418&#160;million (equivalent to a price of US$33 per ADS); and (ii)&#160;warrants (the &#8220;Investor Warrants&#8221;) to subscribe for up to 5,341,267 ordinary shares of our company at an exercise price of US$45 per ADS, subject to the closing conditions set forth in the Subscription Agreements. On September&#160;11, 2020, we issued 20,421,378 ordinary shares to these investors pursuant to the Subscription Agreements. The Subscription Agreement with the Hillhouse Entities contemplates two closings. The first closing occurred in September 2020 and the second closing occurred in December 2020. The closings of the Subscription Agreements with investors other than the Hillhouse Entities have occurred in September 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On December&#160;14, 2020, the SEC declared effective a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1,</div> under which the selling shareholders identified therein may offer, from time to time, up to 25,123,751 ordinary shares, including ordinary shares represented by ADSs of our company. On March&#160;23, 2021, the SEC declared effective a post-effective amendment to this registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</div> that terminates the effectiveness of this registration statement and removes from registration all securities registered but not sold under this registration statement. On March&#160;19, 2021, we filed a prospectus supplement as part of a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div> (Registration <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-252793),</div> under which the selling shareholders identified therein may offer, from time to time, up to 19,050,555 ordinary shares, including ordinary shares represented by ADSs of our company. We will not receive any of the proceeds from the sale of the ordinary shares or ADSs by the selling shareholders under this registration statement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our principal executive offices are located at Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, People&#8217;s Republic of China. Our telephone number at this address is +86 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">21-6057-8000.</div> Our registered office in the Cayman Islands is located at Vistra (Cayman) Limited, P.O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KY1-1205,</div> Cayman Islands. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">B.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Business Overview</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Summary </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our company has made tremendous progress on multiple fronts since our initial public offering in January 2020. The major progress is highlighted in the three areas of significant business value as summarized below. </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Firstly</div></div>, we have made remarkable progress in rapidly advancing our innovative pipeline and achieved a series of critical clinical milestones. Since IPO in January 2020, we have achieved nineteen significant clinical milestones. As a result, our pipeline today has progressed to include three registrational trials with the first NDA planned in 2021 and more than ten Phase 1 and 2 clinical programs in both the U.S. and China. In particular, critical advancements have been made with the core assets of near-term value realization, which include two late-stage assets, i.e. felzartamab and eftansomatropin alfa, that are progressing towards NDA and two representative homegrown clinical assets, i.e. lemzoparlimab and uliledlimab, that are now among the global front-runners. Our internally developed assets of the global portfolio have begun to demonstrate their innovative potential and value through the U.S.-initiated clinical trials. We have set our goals to deliver a new series of key clinical milestones in 2021 to transform the pipeline in its readiness for near-term product launches in China as well as its validated clinical differentiation as exemplified by lemzoparlimab. </div> </div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Late-stage assets advancing towards NDA</div></div>. Both felzartamab and eftansomatropin alfa are in registrational clinical trials with NDA planned for felzartamab in 2021 and for eftansomatropin alfa in 2023. Both plonmarlimab and efineptakin alfa are now in Phase 2/3 clinical trials in the U.S. or China, respectively. Additional Phase 2 studies are expected in 2021. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Clinical validation and global partnership of internally developed innovative assets</div></div>. Since our IPO in 2020, we have made critical progress on the two core clinical assets developed internally, i.e. lemzoparlimab and uliledlimab, and demonstrated drug safety, clinical activity or clinical differentiation in clinical trials in the U.S. In particular, we will accelerate our clinical development plan for lemzoparlimab to achieve an early product registration in China and globally in collaboration with AbbVie. Our new monoclonal antibody TJ210 in collaboration with MorphoSys is now being evaluated in a Phase 1 clinical trial in the U.S. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">67 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bi-specific</div> antibody panel moving to clinical trial</div></div>. Our novel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> antibodies are now progressing towards clinical trials in the U.S. Our two lead assets, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B,</div> have been granted IND approval by the U.S. FDA to start clinical development. Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> antibodies, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-C4GM</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L1C4,</div> are being developed to enable IND. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Secondly</div></div>, revolving around our globally competitive and rapidly progressing pipeline, we forged a string of collaborations in 2020. Our global partnership with AbbVie on lemzoparlimab represents the largest biotech <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> deal from China. These global and regional deals have started to not only generate a significant revenue stream for the Company but also provide timely validation for our innovative assets that are being evaluated in clinical trials. Moving forward, we will continue to explore global partnership opportunities through an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> approach as part of the strategy for our global portfolio and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> approach as part of the strategy to selectively enrich our China portfolio. Our ongoing business development activities are focused on creating value in the following three specific areas: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Landmark global partnerships with industry leaders. </div></div>Our strategy for the global portfolio is to partner with global pharmaceutical companies for the global rights (excluding China) upon clinical validation. This approach is best demonstrated by our global partnership with AbbVie on lemzoparlimab (also known as TJC4). In September 2020, we entered into a broad global strategic collaboration with AbbVie for the development and commercialization of lemzoparlimab. This deal is valued at US$1.94&#160;billion and was the largest cross-border <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> deal from China. We will continue to seek similar partnership opportunities with global pharma companies for other innovative assets of the global portfolio that are either novel or highly differentiated. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Selective <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> opportunities to enrich our emerging product portfolio</div></div>. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-licensing</div> of innovative late-stage assets or globally marketed products remains a part of our pipeline strategy going forward and will become more selective as our pipeline grows and advances. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> approach aims to fill specific gaps in our rapidly growing pipeline towards commercialization. In addition, we set forth to seek <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> of specific clinical assets as combination partners for our selected clinical assets in development for better treatment efficacy. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">68 </div></div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">New wave of novel drug molecules to sustain our pipeline through partnerships</div></div>. We have been engaging in active negotiations with global and regional biotech companies with transformational technology platforms, such as mRNA technology, cell-penetrating antibody technology and tumor-focused delivery technology. We strive to build a new wave of novel drug molecules created through a combination of our proprietary antibody sequences with our partners&#8217; transformational technologies. In March 2021, we entered into two new collaborations with Complix, an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EU-based</div> biotech company, and Affinity, a Shanghai-based biotech company, respectively, allowing&#160;us to access cutting edge technology platforms&#160;to create next generation novel and highly differentiated drug candidates, including Cell Penetrating&#160;Alphabodies&#160;(CPAB) for otherwise intractable intra-cellular drug targets&#160;and masked antibodies&#160;for targeted tumor-site activation, respectively. These new/third-wave of novel drug molecules will complement our existing clinical programs and sustain our leading position in immuno-oncology with a globally competitive pipeline that has evolved in the past, through the first-wave comprised of highly differentiated monoclonal antibodies such as TJC4, TJD5, TJM2 and TJ210 and the second-wave of innovative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> antibodies such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B.</div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Thirdly</div></div>, we have embarked on a transforming journey and moving from currently a clinical stage biotech to a fully integrated biopharma within the next 3 to 4 years, following our successful listing and subsequent capital market performance. This progress is being accelerated by our strong progress in our pipeline development towards NDA. To this goal, we have been expanding our global R&amp;D and corporate footprint, connecting five hubs in China (Shanghai, Beijing and Hong Kong) and the U.S. (Maryland and San Diego). More importantly, we have begun to construct our manufacturing facility in Hangzhou, China and build our commercialization capability under the leadership of Mr.&#160;Ivan Yifei Zhu, our Chief Commercial Officer, who will drive upcoming product launches, starting in 2022. </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expanded global R&amp;D and corporate footprint</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">. </div></div>Since our IPO in 2020, we have taken steps to expand our geographic reach and R&amp;D footprint to accelerate our transformation to a fully integrated global biopharma company. We opened our Hong Kong office as a regional hub for capital markets and investor relations activities, further benefiting from the Greater Bay Area economic development initiative in the region. We are in the process of establishing a new R&amp;D facility in San Diego, CA, in the U.S. for translational medicine and biomarker research, CMC formulation and global alliance management. These new sites are designed to complement our existing facilities in Shanghai, Beijing and Gaithersburg, MD, by leveraging geographic advantages to enhance our development capability and efficiency. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Manufacturing facility</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">. </div></div>Since our IPO in 2020, we have taken concrete steps to execute our plan to build a comprehensive biologics manufacturing facility in Hangzhou, China (the &#8220;Hangzhou Facility&#8221;). The Hangzhou Facility aims to have a pilot capacity of 2 production lines (1 line configured with 2 x 2,000L and another line with 1 x 2,000L) by 2022 and commercially progressive capacity up to 8 x 4,000L to become operational by the end of 2023. The project has been financed by a combination of internal and external sources. A group of domestic investors in China committed to investing a total of US$120&#160;million (in RMB equivalent) in cash. Upon closing, we, through our wholly owned subsidiary and parties acting in concert, will remain the majority shareholder <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of&#160;I-Mab&#160;Biopharma</div> (Hangzhou) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Limited&#160;(&#8220;I-Mab&#160;Hangzhou&#8221;),</div> the entity holding the Hangzhou Facility. We will retain a managing role and take full control of building and operating the manufacturing facility. This manufacturing facility, when operational, will secure our CMC and manufacturing needs for all clinical trials in the U.S. and China as well as the sustained production of our commercial products in a well-controlled and highly cost-effective manner. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commercialization strategy and capability</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">. </div></div>In August 2020, we appointed Mr.&#160;Ivan Yifei Zhu as our Chief Commercial Officer, to prepare for market launch of our initial series of products in China. Our commercialization strategy is aimed at securing a leading position in the hematologic oncology therapeutic area in China, as we begin the launch of felzartamab (TJ202) for multiple myeloma, lemzoparlimab (TJC4) for various leukemia indications and a late-stage asset/product to be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> for lymphoma indications. With this product portfolio focused on hematologic oncology, we will be uniquely positioned to offer a near-complete therapeutic coverage of the major hematologic oncology indications, i.e. myeloma, leukemia and lymphoma, while working towards achieving a near-cure therapeutic goal through combination with other internal or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> products with proven advantages in treatment efficacy. Our commercialization strategy and plans take consideration of the accessibility of our products by building alliances with the stakeholders on the value chain, the affordability by cooperating with government authorities, charity organizations, insurance companies and the availability by educating doctors, pharmacists and patients. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">69 </div></div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Drug Pipeline </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We were founded to capture the opportunities presented by the confluence of two major developments&#8212;the emergence of an attractive and growing biologics market in China, and the revolutionary scientific breakthroughs in cancer and autoimmune disease medicines. We believe we are well-positioned to become a biopharmaceutical leader in China because of our innovative discovery expertise, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fit-for-purpose</div></div> technology platforms, biomarker-enabled translational medicine capabilities, and clinical development capabilities. These integrated capabilities are further enhanced by our deep understanding of China&#8217;s biologics regulatory framework and our direct access to extensive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical trial resources in China. To date, we have developed an innovative pipeline of more than 15 clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> stage assets through our internal research and development efforts as well as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> arrangements with global pharmaceutical and biotech companies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The chart below summarizes the development status of our drug pipeline: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g10811g22m32.jpg" style="width: 622px; height: 408px;"/><br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Felzartamab (TJ202) has two ongoing registrational trials, a monotherapy trial (3L) and a combination therapy trial (2L) in relapsed or refractory multiple myeloma in Greater China. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Plonmarlimab (TJM2, excluding cytokine release syndrome indications) and Olamkicept (TJ301) are managed by I-Mab Biopharma (Hangzhou) Limited.<br/> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">70 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 99%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-NDA</div> Assets</div></div></div></div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Felzartamab (TJ202): A Potential Highly Differentiated CD38 Antibody for Multiple Myeloma and Autoimmune Diseases </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary </div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Felzartamab is a fully human, highly differentiated monoclonal antibody directed against CD38. In November 2017, we obtained an exclusive license from MorphoSys to develop felzartamab in Greater China. The development of felzartamab is driven by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fast-to-market</div></div> strategy. Felzartamab, if approved, is positioned as a potential highly differentiated CD38 antibody therapy for multiple myeloma (&#8220;MM&#8221;), either as a monotherapy or as a combination therapy with other anti-cancer agents. It also has great potentials for other indications than MM, such as autoimmune diseases. </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We aim to demonstrate the advantages of felzartamab, including its short infusion time, low infusion related reaction (&#8220;IRR&#8221;), in addition to its comparable treatment efficacy, in our ongoing clinical trials in China for an NDA approval. We are conducting two parallel registrational trials with felzartamab as a third-line (3L) monotherapy and as a second-line (2L) combination therapy with lenalidomide, both in patients with multiple myeloma in Greater China. Completion of patient enrollment of the 2L registrational study for MM is anticipated in Q3 2021. We expect to submit an NDA for felzartamab as a 3L monotherapy for MM to the NMPA in Q4 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, a new IND application with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> data and trial design for combination therapy of felzartamab with lemzoparlimab as a potential first-line (1L) treatment for MM will be submitted in Q2 2021 and the study is expected to be initiated in the second half of 2021. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> studies conducted by us and reported by others suggest that felzartamab may work with lemzoparlimab to achieve potentially better efficacy. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Furthermore, as pathogenic CD38-positive B cells and plasma cells are strongly implicated in the pathogenesis and disease progression of antibody-mediated autoimmune diseases, such as systemic lupus erythematosus (&#8220;SLE&#8221;), we and MorphoSys have been working together to explore the potential therapeutic role of felzartamab in selected antibody-mediated autoimmune indications, e.g. SLE by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> and autoimmune kidney disease by MorphoSys. We previously submitted an IND application to the NMPA and expect to initiate a Phase 1b trial in patients with SLE in the second half of 2021. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Multiple Myeloma Drug Market and Competitive Landscape </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Multiple myeloma (&#8220;MM&#8221;) is a type of blood cancer that starts in the bone marrow and is characterized by the excessive proliferation of malignant plasma cells that accumulate in the bone marrow, where they displace and suppress healthy blood progenitor cell populations. The prognosis factors for MM include host factors, tumor characteristics and response to treatment. There is a consensus that disease prognosis in MM is significantly impacted by treatment response and micro-residual disease (&#8220;MRD&#8221;) level. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In China, MM is the second most common hematologic malignancy, accounting for approximately 10% of the malignant tumors in the blood system. MM is primarily a disease of the elderly. The incidence rate of MM in China is about 1.5 per 100,000 in 2020 and is increasing year by year due to the rapidly growing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">65-year</div> or older population. According to a report by Frost&#160;&amp; Sullivan, new cases of MM reached approximately 21,770 in 2020 and are expected to increase to approximately 28,290 in 2030, representing a compound annual growth rate (&#8220;CAGR&#8221;) of 2.7%. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The following diagram illustrates the market size of all MM therapeutics in terms of sales revenue in China market. (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Source: Frost</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;&amp; Sullivan Report</div></div>) </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">71 </div></div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">China Market for MM Therapeutics (2014-2030E) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811sp19.jpg" style="width: 566px; height: 263px;"/></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The treatment options currently approved in China are listed as follows: (1)&#160;Small molecule drugs. Two or three approved drugs known as doublets or triplets are currently being used. Proteasome inhibitors, immunomodulators or CD38 antibody combination therapy is recommended as the first-line treatment for relapsed or refractory MM according to 2020 version of the treatment guideline. In 2019, Velcade (bortezomib), Revlimid (lenalidomide) and dexamethasone (VRD triplet) were included in the National Reimbursement Drug List in China; and (2)&#160;CD38 antibody therapy. Daratumumab (from Johnson&#160;&amp; Johnson) received conditional NDA approval for a third-line treatment in July 2019 and is currently on the market in China. The current intravenous infusion of daratumumab can take up to six hours to be administered and cause a high infusion reaction rate (&#8220;IRR&#8221;). In clinical trials, approximately half of all patients experience an infusion reaction. Symptoms include fever, chills, nausea, bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema. Subcutaneous injection of daratumumab, which requires an injection device, is not yet approved in China. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 28%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 24%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 24%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 21%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="7" style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CD38 Antibody Products Approved or to be Approved in China</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Product<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">&#160;(1)</div></div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Company</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Global&#160;Status</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Greater&#160;China&#160;Status</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Daratumumab</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Johnson&#160;&amp; Johnson</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Approved</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">3L approved</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Felzartamab <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">N/A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3L NDA submission expected in Q4 2021. 2L registrational trial on-going</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Isatuximab<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Sanofi</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Approved</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Phase 3</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TAK-079</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Takeda</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Phase 1/2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">N/A</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product candidates that are prior to clinical Phase 2 are not included in this table. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2017, we and MorphoSys entered into an exclusive regional licensing agreement to develop and commercialize MOR202, which we refer to as felzartamab (TJ202), in Greater China (including Taiwan, Hong Kong and Macao). Felzartamab is currently undergoing two registrational clinical trials in relapsed/refractory multiple myeloma in Greater China. We aim to submit an NDA to the NMPA for felzartamab as a monotherapy in 2021. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As aforementioned, CD38 antibody therapy represents a novel mechanism of action among the current therapeutic classes for MM. We believe that there is rapidly increasing clinical adoption of CD38 antibody therapy in China. The natural evolution of epidemiology driven by the aging population in China will lay a solid foundation for the growth of the overall MM market, while the adoption of multiple combination therapies and new drug classes will further expand the progression-free survival (&#8220;PFS&#8221;) and overall survival (&#8220;OS&#8221;) of MM patients. Currently, clinical outcome for r/r MM patients who had received multiple lines of interventions remain unsatisfactory. MM is still an incurable disease and the extension of PFS and OS remains a major unmet medical need. CD38 antibody therapy has demonstrated synergetic cellular and molecular effects in eliminating CD38+ tumor cells with proven clinical efficacy in terms of significantly prolonged PFS and OS compared to the baseline survival status of other treatment options. </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">72 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Systemic Lupus Erythematosus (SLE) Drug Market and Competitive Landscape </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Systemic lupus erythematosus (&#8220;SLE&#8221;) is a chronic, multi-system and incurable autoimmune disease that can potentially lead to serious organ failure and even death. Patients with SLE have aberrant auto-antibodies in a form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> immune-complexes in their blood, which deposit in the kidneys and cause tissue damage. Common symptoms of SLE include painful and swollen joints, unexplained fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, extreme fatigue, and red rashes appearing most commonly on the face. These symptoms vary widely among different patients and fluctuate unpredictably over time with disease development. More importantly, at the advanced disease stages, patients can develop renal damage and renal failure. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In China, the estimated prevalence of SLE was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">50-100</div> cases per 100,000 persons, which was much higher than that of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-35</div> per 100,000 people in European and North American countries, according to researchers at Peking University First Hospital (L Mu et al., Lupus, 2018). SLE prevalence in China is projected to reach 1.11&#160;million in 2030. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Patients with mild SLE are often given <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-steroidal</div> anti-inflammatory drugs, while more severe patients require treatments with corticosteroids and/or immunosuppressants. Approved by the FDA in 2011 and by the China NMPA in July 2019, Benlysta (belimumab), a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-lymphocyte</div> stimulator (BLyS)-specific inhibitor developed by GSK, is the world&#8217;s first biologic approved to treat SLE. In March 2021, RemeGen announced that its telitacicept, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TACI-Fc</div> fusion protein targeting both BLyS and A PRoliferation-Inducing Ligand (APRIL), has been granted conditional marketing approval by the China NMPA for the treatment of patients with SLE. However, there remains a significant unmet medical need beyond the currently approved treatment options in China and the rest of the world. As dysregulated CD38-positive B cells and plasma cells and the resulting autoimmune complexes are at the core of the pathogenesis of SLE, direct inhibition and selective depletion of pathogenic B cells and plasma cells are believed to provide a more efficacious treatment option, which is supported by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studied reported so far. Felzartamab has the potential to offer such a disease-modifying treatment option. In addition, as described below, the advantages of felzartamab include convenience of use and a lower IRR, making it a more favorable treatment agent in long-term clinical management of SLE if approved. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Advantages of Felzartamab </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Felzartamab, if approved, is a potentially highly differentiated CD38 monoclonal antibody drug and will be the second CD38 antibody therapy for MM to launch in China. A Phase 2a trial of felzartamab in MM revealed treatment effects comparable to those observed in trials of the currently marketed CD38 antibody. However, available trial data from MorphoSys and Johnson&#160;&amp; Johnson indicate that with similar <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-medications</div> of dexamethasone, anti-pyretics and anti-histamines, felzartamab required only a short infusion time of 30 minutes (as subsequent infusions) to 2 hours (as initial infusion), compared to 3.5 to 6.5 hours for the currently marketed CD38 antibody at the first infusion. Moreover, the IRR was as low as 7% for felzartamab, compared to 48% for the currently marketed CD38 antibody. The advantages of felzartamab associated with infusion may be attributed to its lack of antibody CDC activity and show potential for clinical benefits in terms of tolerability and convenience of use as well as economic benefits due to the cost and length of hospital stay. In addition, unlike the currently marketed CD38 antibody, felzartamab treatment does not down-regulate CD38 expression on the surface of bone marrow myeloma cells in vitro, maintaining sensitivity of malignant myeloma cells to repeated felzartamab treatments. As felzartamab is being considered for long-term treatment management of autoimmune diseases, we believe such clinical differentiation is advantageous. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For autoimmune diseases, felzartamab has an advantage over other B cell-targeting therapies such as CD20 antibodies, as it specifically targets pathogenic CD38<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">high</div> B cells and plasma cells involved in autoimmune diseases while CD20 antibodies target a wide range of B lineage cells, including those involved in normal immune functions and regulatory functions, but not CD38+ plasma cells producing pathogenic antibodies. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mechanism of Action </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Felzartamab binds to CD38 overexpressed on the surface of target cells and kills them by inducing antibody-dependent cellular cytotoxicity (&#8220;ADCC&#8221;) and antibody-dependent cellular phagocytosis (&#8220;ADCP&#8221;). The target cells are the malignant plasma cells in MM and a group of dysregulated CD38<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">high</div> B cells and plasma cells that produce pathogenic antibodies in autoimmune conditions such as SLE. </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">73 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; text-indent: 3%; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421180830740.jpg" style="width: 302px; height: 233px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Felzartamab kills CD38-bearing tumor cells by inducing ADCC and ADCP. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of Clinical Results </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MorphoSys has conducted a Phase 1/2a study in adult patients with relapsed or refractory MM in Austria and Germany. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Study Design</div></div>. The open-label, multicenter, dose-escalation study was designed to characterize the safety profile and preliminary efficacy of felzartamab in adults with relapsed or refractory MM. A 3+3 dose escalation design was used to establish the maximum tolerated dose (&#8220;MTD&#8221;), recommended dose and dosing regimen of felzartamab as monotherapy, weekly or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-weekly,</div> with or without dexamethasone (&#8220;DEX&#8221;), and in combination with pomalidomide (&#8220;POM&#8221;) and DEX or lenalidomide (&#8220;LEN&#8221;) and DEX standard regimens. The MTD and recommended dose and dosing regimens were to be confirmed in three confirmation cohorts of at least six evaluable subjects each. Felzartamab dose levels in this study ranged from 0.01 mg/kg to 16.0 mg/kg, administered by intravenous (&#8220;IV&#8221;) infusion. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The clinical study results as of the data cutoff date, December&#160;31, 2017, are summarized as follows. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Safety</div></div>. Felzartamab was well tolerated in patients with relapsed or refractory multiple myeloma (r/r MM), as a single agent and in combination with DEX, or with POM/DEX, or with LEN/DEX. The MTD of felzartamab was not reached. In the 56 patients from three groups receiving combination regimens, grade 3 adverse events (&#8220;AEs&#8221;) were mainly in the hematological system reflected by a decrease of various blood cells. This was as expected, because of decreased bone marrow function due to the presence of myeloma as well as the expression of CD38 on various cell lineages of the myeloid and lymphoid compartments. Most of the hematological adverse events were transient and generally manageable. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Felzartamab was administered as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-hour</div> IV infusion at first dose and infusion time could be reduced to as short as 30 minutes at subsequent doses without obvious safety concerns. Among all cohorts, infusion-related reactions, including tachycardia, pyrexia and hypersensitivity, occurred in 18 of 91 patients (19.8%) and were mostly mild to moderate. In the combination cohorts containing DEX, a very low IRR (4 out of 56 patients (7%)) was observed. These results compared favorably with the historical data of the currently marketed CD38 antibody. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">74 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Efficacy</div></div>. Preliminary efficacy results were based on 56 patients from three groups treated with felzartamab combination therapies. No responses were observed for the monotherapy groups which were primarily serving for dose escalation. Felzartamab in combination with low dose DEX, POM/DEX or LEN/DEX demonstrated an overall response rate (&#8220;ORR&#8221;) of 28%, 48% and 65%, respectively. Durable responses were observed as median progression-free survival (&#8220;PFS&#8221;) was of 8.4 months and 17.5 months for the DEX and the POM/DEX combination groups, respectively, and PFS levels were not reached for the LEN/DEX combination group, as there were not sufficient events of progression recorded. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421180831083.jpg" style="width: 302px; height: 247px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: italic;;display:inline;">Best overall response and ORR. Patients were treated with felzartamab in combination with low dose of DEX (40 mg for 75 years old and younger, or 20 mg for older than 75 years old), POM (4 mg) /Dex or LEN (25 mg)/Dex. Dex: dexamethasone; POM: pomalidomide; LEN: lenalidomide; ITT: intent to treat; NE: not evaluable; PD: progressive disease; SD: stable disease; MR: minimal response; PR: partial response; VGPR: very good partial response; CR: complete response; sCR: stringent complete response; ORR: overall response rate. (Source: MorphoSys) </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The definitions of PD, SD, MR, PR, VGPR, CR and sCR and how these responses were measured for multiple myeloma are set forth in the table below. (Source: International Myeloma Working Group Uniform Response Criteria (2006)&#160;and European Group for Blood and Marrow Transplantation Criteria) </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 22%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">RESPONSE&#160;SUBCATEGORY</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">CRITERIA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">&#160;A</div></div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">sCR</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;CR as defined below plus</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Normal free light chain ratio (FLC) and</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Absence of clonal cells in bone marrow<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">b</div> by immunohistochemistry or immunofluorescence<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">c</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">CR</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Negative immunofixation on the serum and urine and</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Disappearance of any soft tissue plasmacytomas and</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;&lt;5% plasma cells in bone marrow<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">b</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">VGPR</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;Serum and urine <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">M-protein</div> detectable by immunofixation but not electrophoresis or</div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div>90% reduction in serum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">M-protein</div> plus urine <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">M-protein</div> level &lt;100 mg/24 hours</div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">PR</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div>50% reduction of serum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">M-protein</div> and reduction in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">24-hour</div> urinary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">M-protein</div> by &#179;90% or to &lt;200 mg/24 hours</div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;If the serum and urine <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">M-protein</div> were unmeasurable, a <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div>50% decrease in the difference between levels of involved and uninvolved free-light-chains instead of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">M-protein</div> criteria</div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;In addition to the above-listed criteria, if present at baseline, a <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div>50% reduction in the size of soft tissue plasmacytomas was also required</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">MR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#160;d,e</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;25&#8211;49% reduction in level of serum M-protein</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;50&#8211;89% reduction in 24-hour urinary M-protein, which still exceeds 200 mg/24 hours. If present at baseline, 25&#8211;49% reduction in the size of soft tissue plasmacytomas (by radiography or clinical examination)</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;No increase in the size or number of lytic bone lesions (development&#160;of a compression fracture did not exclude response)</div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">75 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 22%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">RESPONSE&#160;SUBCATEGORY</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">CRITERIA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">&#160;A</div></div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">SD <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">f</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Not meeting criteria for CR, VGPR, PR, MR, or PD</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">PD</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE: Required any 1 or more of the following:</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Increase of <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div>25% from nadir in</div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;Serum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">M-component</div> and/or (absolute increase <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div>0.5 g/dL)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">g</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;Urine <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">M-component</div> and/or (absolute increase <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div>200 mg/24 hours)</div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;Only in subjects without measurable serum and urine <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">M-protein</div> levels: the difference between involved and uninvolved FLC levels. Absolute increase &gt;10 mg/dL.</div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;Bone marrow plasma cell percentage: absolute % <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div>10%<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">h</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL or 2.65 mmol/L) that could be attributed solely to the plasma cell proliferative disorder</div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">a</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All response categories required 2 consecutive assessments made at any time before the institution of any new therapy; all categories also required no known evidence of progressive or new bone lesions if radiographic studies were performed. Radiographic studies were not required to satisfy these response requirements. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">b</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Confirmation with repeat bone marrow biopsy not needed. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">c</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Presence/absence of clonal cells was based upon the <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">k</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> / </div></div><div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">l</div> ratio. An abnormal <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">k</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">/ </div></div><div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">l</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>ratio by immunohistochemistry and/or immunofluorescence required a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting presence of an abnormal clone is <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">k</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> / </div></div><div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">l</div> of &gt;4:1 or &lt;1:2. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">d</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MR also included subjects in whom some, but not all, the criteria for PR were fulfilled, provided the remaining criteria satisfied the requirements for MR. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">e</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The response criterion MR did not apply to subjects who presented with serum FLCs only. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">f</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Per the International Myeloma Working Group Uniform Response Criteria, stable disease was not recommended for use as an indicator of response; stability of disease is best described by providing the time to progression estimates. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">g</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">For progressive disease, serum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">M-component</div> increases of <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div>1 g/dL were sufficient to define relapse if starting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">M-component</div> was <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div>5 g/dL. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">h</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Relapse from CR has the 5% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cut-off</div> versus 10% for other categories of relapse. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmacodynamics. </div></div>As a pharmacodynamic marker, serum myeloma (M)&#160;protein levels were used to evaluate severity and clinical response. The median relative change in M protein levels from baseline to post-baseline nadir for felzartamab in combination with low doses of DEX, POM/DEX or LEN/DEX was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-13%,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-58%</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-81%,</div> respectively. The data below show strong effects of felzartamab in reducing M protein levels. </div> <div style="font-size: 24pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421180831411.jpg" style="width: 622px; height: 181px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure: The relative change in M protein levels from baseline to post-baseline nadir. Patients were treated with felzartamab in combination with low doses of DEX, POM/DEX or LEN/DEX. S: serum sample; U: urine sample. (Source: MorphoSys) </div></div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">76 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmacokinetics (&#8220;PK&#8221;)</div></div>. The PK of felzartamab in humans was well characterized by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-compartment</div> model at dose levels greater than 4 mg/kg. At these doses, stable or even increasing trough levels could be observed over time suggesting the potential for full target occupancy, especially at the highest dose level (16 mg/kg). For most subjects, steady state at 16 mg/kg was observed after the fourth infusion. Terminal half-life at high-dose levels (<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div>4 mg/kg) was at approximately two weeks. Pharmacokinetics of felzartamab were generally consistent across different individuals and dosing days and not affected by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-medications.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Immunogenicity</div></div>. No anti-drug antibody (&#8220;ADA&#8221;) against felzartamab was observed as of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cut-off</div> date. Thus, risk of ADA induction for felzartamab in humans is considered low. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Development Plan and Current Development Status </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Immediately after the agreement with MorphoSys, we formulated a robust clinical development strategy with the aim to achieve an NDA submission in 2021. We are currently on track for two <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> registrational clinical trials. One is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-arm</div> registrational trial with felzartamab and DEX as a 3L therapy for MM patients in Greater China using ORR as the primary endpoint (NCT03860038). We have now successfully enrolled all patients (N=113) and moved into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> stage as of January 2021. Data from this study are expected to be the major package supporting NDA filing in 2021 for conditional approval. The other is a parallel registrational trial combining felzartamab with LEN and DEX as a 2L combination therapy in MM patients (NCT03952091). We plan to enroll 291 patients in this study and the patient enrollment is well <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-track.</div> As of February 2021, 155 patients have been randomized and treated in the trial. In addition to our original clinical development plan for felzartamab as 2L and 3L treatment for MM, we will initiate a combination clinical trial of felzartamab with lemzoparlimab in the second half of 2021 to explore the potential as a first-line (1L) treatment for MM based on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> data generated in house and reported by others. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In parallel, the preparation of the initial NDA submission for 3L r/r MM therapy is ongoing, including CMC process characterization and process validation being conducted at our CDMO. Additionally, we expect to receive IND approval and start a Phase 1b clinical trial in patients with SLE in the second half of 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of Expected Milestones </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The major milestones are: (1)&#160;the submission of initial NDA (3L r/r MM) in Q4 2021; (2) completion of patient enrollment of 2L registrational trial by Q3 2021 and follow up of the patients for median PFS as the primary endpoint defined in the study protocol; (3)&#160;the IND submission of a combination trial with lemzoparlimab in Q2 2021 and the study is expected to initiate in the second half of 2021; and (4)&#160;the initiation of Phase 1b SLE trial in the second half of 2021. </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Commercialization Strategy in China </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Through years of research and clinical development, we have established long-term relationships with key opinion leaders and have cultivated an extensive clinical network in the field of hematologic oncology in China. In August 2020, the appointment of Mr. Ivan Yifei Zhu as our Chief Commercial Officer has strengthened our commercial leadership to expand our commercialization team and prepare for launch readiness of felzartamab. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that the CD38 antibody market in China will undergo a significant increase within the next five to ten years. The China market for CD38 antibody is expected to reach US$542 million in 2027, benchmarking the forecast of global CD38 market from DataMonitor. The market experienced an initial period of market build-up and cultivation from 2019 to 2021 with daratumumab launched as the first CD38 antibody in China in 2019. Going forward, we will witness rapidly improved clinical awareness and increased adoption to CD38 antibody therapy from 2021 to 2027, which represents a phase of rapid market expansion for CD38 antibody products. Upon the expected market launch of felzartamab in 2022, we expect to capture the market opportunity provided by this phase of market expansion in the period of 2022-2027, as CD38 antibody therapy will become a mainstream treatment option. </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">77 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Within the next many years, daratumumab and felzartamab will be the two leading CD38 antibody products on the China market. Assuming that daratumumab remains in the China market with the current pricing and market access strategy as a non-NRDL product, we would be able to rapidly build up our position for a significant market share for felzartamab through our unique advantages in the following aspects. (1) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cost of the product</div></div>. We are able to leverage our local manufacturing capability in Hangzhou to reduce the cost of goods to be more competitive and flexible in pricing; (2) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">To be listed in </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">NRDL</div></div>. We are more competitive with flexible pricing to be included in NRDL and are not constrained by global pricing; (3) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product advantages</div></div>. We have been building clinical experience in the convenient use of felzartamab with major clinical sites and network through our on-going clinical trials. The clinical advantages of felzartamab are widely noted and acknowledged by physicians; and (4) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Commercial focus in hematologic </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">oncology</div></div>. Felzartamab is part of our focused commercial strategy for hematologic oncology in China with felzartamab for MM as 2L and 3L therapies and potentially more efficacious combination therapy with lemzoparlimab, and lemzoparlimab for leukemia, e.g. AML and MDS. In addition, we are in the process of potentially in-licensing a global product for lymphoma. With this focused commercialization strategy by leveraging the highly competitive and efficacious hematologic oncology products, we strive to build a leading market position in the hematologic oncology in China. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, we established our core commercialization capability, including market access and medical affairs teams, to prepare for the near-term product launch and have begun to discuss the inclusion of felzartamab in NRDL with national experts as a necessary step to follow the market launch of felzartamab. Plans are being prepared to expand market penetration of felzartamab through the following strategies: (1) increasing accessibility of felzartamab by building alliances with stakeholders on the value chain; (2) ensuring affordability by cooperating with government authorities, charity organizations, insurance companies and research institutions; and (3) improving availability by educating doctors, pharmacists and patients and establishing standardized treatment procedures for patients. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon obtaining NDA approval of felzartamab as 3L treatment for MM, we expect to rapidly build our market position in the period of 2022-2027, starting with the promotion and marketing of felzartamab. Our commercial strategy is to focus on a network of 200-250 top-tier hospitals in the first-tier cities in China to capture approximately 70-80% of national sales while maintaining a premium price based on the product advantages of felzartamab. Following the expected market launch of felzartamab as 2L therapy with Revlimid and the multi-year inclusion of felzartamab (2L and 3L) in NRDL, we aim to reach more than 50% of the national market share for CD38 antibody therapy in China around 2026-2027. We believe that felzartamab will remain as a competitive product even after 2027 when one or two additional global competitors may enter the market because we would have established deep market penetration as the only local product included in NRDL with continued competitiveness through further reduced manufacturing cost. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Eftansomatropin alfa (TJ101): A Potential Highly Differentiated Long-Acting Growth Hormone for Growth Hormone Deficiency </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Eftansomatropin alfa is a potential highly differentiated long-acting recombinant human growth hormone (&#8220;rhGH&#8221;) being developed as a more convenient and effective therapy for growth hormone deficiency (&#8220;GHD&#8221;), for which there is substantial unmet medical need in China. Eftansomatropin alfa is the only rhGH in its proprietary fusion protein format. Eftansomatropin alfa has met the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-set</div> safety endpoints in three multi-regional clinical trials conducted in Europe and Asia and the preliminary efficacy endpoints in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-pubertal</div> patients with growth hormone deficient (&#8220;PGHD&#8221;) in a Phase 2 clinical trial conducted in Europe. In contrast to marketed short-acting rhGH products, such as Genotropin, eftansomatropin alfa showed similar treatment efficacy in a more convenient weekly (vs. daily) regimen. Furthermore, eftansomatropin alfa does not carry the safety concerns typically associated with pegylated hGH drugs, especially for PGHD. We own all rights of eftansomatropin alfa in China and are positioning the investigational drug as a highly differentiated growth hormone replacement therapy, highlighting its advantages over a daily regimen and safety profile (natural protein-based vs. pegylated long-acting hGH) for the rapidly growing GH market in China. With an approved IND by the NMPA in September 2020, we initiated a registrational Phase 3 trial of eftansomatropin alfa in patients with PGHD, and the patient enrollment is on track as of April 2021. This registrational clinical trial involves 165 patients and is expected to complete patient enrollment by early 2022 to support an NDA submission in late 2022. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Growth Hormone Deficiency Drug Market in China </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">GHD is a pituitary disorder that occurs when the production of growth hormone, normally secreted by the pituitary gland, is disrupted. Since growth hormone plays a critical role in stimulating body growth and development and is involved in the production of muscle protein and the breakdown of fats, a decrease in growth hormone affects numerous physiological processes, including short stature in children and other physical ailments in both children (&#8220;PGHD&#8221;) and adults (&#8220;AGHD&#8221;). Both globally and in China, the widely adopted treatment for PGHD is patient-specific growth hormone replacement therapy, which is given in a calculated weight-based dosing regimen. </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">78 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deficiency in growth hormone can be induced by different pathological status, therefore rhGH has an extensive range of clinical application, including ordinary deficiency of growth hormone, idiopathic short stature (&#8220;ISS&#8221;), Turner&#160;&#160;&#160;&#160;Syndrome, etc. We believe that the clinical application of rhGH will cover children and juveniles of different age groups, forming a wide population base to support the substantial market growth in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-to-long</div></div> term. Due to the long duration of treatment usually calculated in years and the dominating route of administration applied by the patients, long-acting rhGH will be more attractive in the available treatment options. As the patients, caregivers and physicians raise their expectations to the quality of life, we believe the long-acting rhGH will witness its booming with the improvement of affordability and drug availability. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">According to the Frost &amp; Sullivan Report, only 5.7% of all PGHD patients projected in China received primarily daily injections of growth hormone replacement therapy in 2020, therefore, the China PGHD patients&#8217; clinical needs are largely untapped. The PGHD market in China is forecasted to grow to RMB19.6 billion (US$3.0 billion) by 2033, representing an estimated CAGR of 11.5% from the year 2018 to 2033. According to a report by Pharmacodia, the overall PGHD market will evolve in three stages: (1) market cultivation for long-acting rhGH from 2018 to 2023, during which short-acting agents still dominate the market; (2) fast growing stage for long-acting rhGH from 2023 to 2028, during which there is an expected progressive migration of short-acting rhGH to long-acting rhGH; and (3) steady status for long-acting rhGH to take the majority of the overall market share of rhGH from 2028 to 2033, due to multiple years of clinical/patient education, affordability and increasing demand. As a result, the long-acting rhGH market is forecasted to grow much faster than the overall rhGH market, representing an estimated CAGR of 20.3% from the year 2023 to 2033. The following figure illustrates the growing rhGH market in China. (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Source: </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmacodia Report</div></div>) </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g10811g16s85.jpg" style="width: 440px; height: 273px;"/><br/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to PGHD, rhGH can be applied to treat other clinical conditions driven by GH deficiency, including AGHD, Idiopathic Short Stature (ISS) and Turner Syndrome. The following figure illustrates the forecasted market opportunities for AGHD, ISS and Turner Syndrome in China, respectively. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(Source: Pharmacodia Report)</div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g10811g17x63.jpg" style="width: 339px; height: 200px;"/><br/></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">79 </div></div> </div> </div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Competitive Landscape in China </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currently, short-acting (daily) recombinant human growth hormone (&#8220;rhGH&#8221;) is commonly used for the long-term treatment of children and adults with inadequate endogenous growth hormone secretion. In China, the daily rhGH market is dominated by domestic companies including GeneScience Pharmaceuticals, Shanghai United Cell Biotechnology and Anhui Anke Biotechnology. Novo Nordisk launched their daily rhGH, Norditropin, in March 2018. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There is only one pegylated long-acting (weekly) rhGH (Jintrolong) for PGHD in China, which has been marketed by GeneScience since 2014. Other companies currently developing long-acting rhGH in China include Novo Nordisk, Anhui Anke Biotechnology, Xiamen Amoytop Biotech, Evive Biotech and Visen Pharmaceuticals. Eftansomatropin alfa is the only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Fc-based</div> long-acting rhGH in China. As there are certain safety concerns related to long-term use of pegylated drugs, such as potential renal toxicity, cellular vacuolation and formation of anti-polyethylene glycol antibodies, eftansomatropin alfa is considered to be clinically advantageous. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The following table illustrates the competitive landscape of long-acting growth hormone products approved and to be approved in China. (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Source: Pharmacodia Report</div></div>) </div> </div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 28%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 24%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 24%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 21%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="7" style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Long-acting&#160;rhGH&#160;Products&#160;Marketed&#160;and&#160;Under&#160;Development&#160;in&#160;China</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Format</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Product<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">&#160;(1)</div></div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Company</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">China&#160;Status</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">PEGylated GH</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Jintrolong<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">GeneScience</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Approved</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fusion Protein</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Eftansomatropin<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Registrational Phase 3</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">TransCon hGH</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Lonapegsomatropin</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Ascendis/Visen</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Phase 3</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">PEGylated GH</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PEG-rhGH</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Anhui Anke</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Phase 3</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-acting growth hormone products prior to clinical Phase 2 are not included in this table. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In December 2017, Genexine, Inc. (KOSDAQ: 095700) granted us exclusive rights to develop and commercialize <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-H9,</div> which we refer to as eftansomatropin alfa (TJ101), in Greater China. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advantages of eftansomatropin alfa </div></div></div> </div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We believe that eftansomatropin alfa has the following advantages: (1)&#160;when compared to the daily regimen of rhGH, eftansomatropin alfa is proven to be a more convenient therapy with better patient compliance due to its weekly dosing frequency (potentially twice-monthly administration), while maintaining similar efficacy; and (2)&#160;eftansomatropin alfa has no safety concerns typically associated with pegylated drugs, such as potential renal toxicity, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-existing</div> or treatment-induced <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PEG</div> antibodies, and cellular vacuolation in macrophages, renal tubule cells and the choroid plexus epithelial cells. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mechanism of Action </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Like endogenous growth hormone, eftansomatropin alfa stimulates the production of insulin-like growth factor 1 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;IGF-1&#8221;)</div> in the liver, which has growth-stimulating effects on a variety of tissues, including osteoblast and chondrocyte activities that stimulate bone growth. Thus, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IGF-1</div> is a reliable pharmacodynamic marker and more importantly, the key mediator of eftansomatropin alfa&#8217;s growth-promoting activity. Eftansomatropin alfa is based on Genexine&#8217;s patented hyFc technology. The hyFc part consists of a portion of human immunoglobulin D (&#8220;IgD&#8221;) and G4 (&#8220;IgG4&#8221;). The former contains a flexible hinge, and the latter is responsible for half-life extension through neonatal Fc receptor (&#8220;FcRn&#8221;)-mediated recycling. Additionally, eftansomatropin alfa&#8217;s increased molecular weight (103 kilodalton) is expected to reduce renal clearance. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; text-indent: 8%; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421180832592.jpg" style="width: 368px; height: 144px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Schematic presentation of the structure of eftansomatropin alfa. CH2 &amp; CH3: Constant regions 2 &amp; 3 of antibody heavy chains, respectively; hGH: human growth hormone. (Source: Genexine) </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">80 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of Clinical Results </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genexine has completed three clinical trials with eftansomatropin alfa, including one Phase 1 trial in healthy adult volunteers, one Phase 1b/2 multi-regional trial in adults with GHD, and one Phase 2 multi-regional trial in PGHD in Europe, altogether involving 32 healthy subjects and 99 patients with GHD and PGHD. Overall, eftansomatropin alfa was shown to be well-tolerated, and clinical efficacy endpoint achieved by weekly or twice-monthly eftansomatropin alfa administration was comparable to that of daily administration of Genotropin. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase 1 Clinical Trial</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-human</div></div> trial of eftansomatropin alfa was a randomized, double-blind, placebo-controlled single dose-ascending study in four groups of healthy subjects. A total of 32 subjects were enrolled, and 31 completed the study. Eftansomatropin alfa was shown to be well-tolerated at all dose levels studied (0.2&#8211;1.6 mg/kg). Eftansomatropin alfa was detectable in the blood until Day 7 for the 0.2 mg/kg dose group, Day 14 for the 0.4 and 0.8 mg/kg dose groups, and Day 21 for the 1.6 mg/kg dose group. A single subcutaneous (&#8220;SC&#8221;) injection of eftansomatropin alfa at dose levels of 0.4 mg/kg and higher increased <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IGF-1</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IGF-binding</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">protein-3</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;IGFBP-3&#8221;)</div> levels for at least one week. No safety concerns were identified. Eftansomatropin alfa showed a half-life ranging from 69.2 to 138 hours. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase 2 Clinical Trial in PGHD</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Study Design. The Phase 2 trial in PGHD was a randomized, open-label, active-controlled study to assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of weekly and twice-monthly doses of eftansomatropin alfa, as compared to a daily injection of Genotropin, which is currently the standard of care for PGHD. Subjects were randomly assigned to receive one of three doses of eftansomatropin alfa (0.8 mg/kg/ weekly, 1.2 mg/kg/weekly or 2.4 mg/kg/twice monthly) or 0.03 mg/kg/daily of Genotropin for up to 24 months. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The primary clinical endpoint was annualized height velocity (aHV) in centimeters (cm)&#160;per year (equivalent to annual growth rate), measured at six months. A total of 56 subjects were randomized at 27 centers in nine European countries and South Korea. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Fifty-two</div> subjects completed the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> treatment (through Visit 7), meeting the primary endpoint. Two subjects withdrew from the study before first drug administration, and two subjects discontinued due to treatment-related adverse events (&#8220;AEs&#8221;). Genexine and its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-developer</div> Handok presented the latest interim results of the Phase 2 clinical trial for PGHD in March 2018 at the Endocrine Society&#8217;s annual meeting. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Safety. No study drug-related serious adverse events (&#8220;SAEs&#8221;) or death were observed. The tolerability of eftansomatropin alfa was consistent with known properties of marketed products. The AE incidence rate was generally similar across the eftansomatropin alfa cohorts treated with three different dose levels (ranging between 69.2% and 84.6%) and the Genotropin cohort (57.1%). A total of two (14.3%), three (23.1%), two (15.4%), and zero subjects experienced treatment-related AEs in the 0.8 mg/kg/week, 1.2 mg/kg/week, and 2.4 mg/kg/twice monthly eftansomatropin alfa groups, and the 0.03 mg/kg/daily Genotropin group, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Two subjects withdrew from the study due to treatment-related AEs. One subject from Cohort 2 (1.2 mg/kg/week of eftansomatropin alfa) discontinued due to retinal vascular disorder. The Data and Safety Monitoring Board (&#8220;DSMB&#8221;) reviewed this case independently, concluding that the retinal finding was more likely to be of completely different etiology than treatment-induced intracranial hypertension. One subject from Cohort 3 (2.4 mg/kg/twice monthly of eftansomatropin alfa) discontinued due to pseudopapilloedema (optic disc drusen), which was assessed by the principal investigator to be mild with continuous frequency and possibly related to the study drug. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Injection site reactions (&#8220;ISRs&#8221;) were reported in 13 out of 40 subjects (32.5%) in the eftansomatropin alfa cohorts. Pain was the most prominent and common symptom that was observed in 10 subjects. Six subjects reported redness, four reported itching, and one reported bruising, swelling and warmness. With respect to the Genotropin cohort, pain was the only ISR reported in 683 cases by 11 out of 14 subjects (78.5%). None of the ISRs led to discontinuation of treatment, and most of the reported ISRs posed no issue for the subjects and were resolved quickly. No safety signal was detected in laboratory parameters or vital signs for either eftansomatropin alfa or Genotropin. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">81 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pharmacokinetics. Half-life of eftansomatropin alfa was 77.75&#8211;141.95 hours after a single dose and 43.92&#8211; 55.66 hours (compared to 5.27 hours for Genotropin) after three months of multiple-dose administration. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immunogenicity. Formation of treatment-emergent ADA with neutralizing property was reported in two subjects (one from Cohort 2 and one from Cohort 3) out of a total of 40 subjects randomized and dosed with eftansomatropin alfa. With respect to the Genotropin cohort, the presence of treatment-emergent ADA with neutralizing property was not observed in any subject. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Clinical Efficacy. Subcutaneous administration of eftansomatropin alfa over the dose range of 0.8 mg/kg/ week&#8211;2.4 mg/kg/twice monthly resulted in an increase in aHV over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> study period. Subjects who received eftansomatropin alfa at 0.8 mg/kg weekly, 1.2 mg/kg weekly, and 2.4 mg/kg twice monthly showed growth rates of 11.50, 11.54, and 11.86 cm/year, respectively, while the growth rate in the control group treated with Genotropin was approximately 11.24 cm/year. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; text-indent: 3%; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">&#160;
<img alt="" src="g10811g0421180832985.jpg" style="width: 278px; height: 221px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The aHV at six months indicated comparable growth rates between all doses of eftansomatropin alfa (both weekly and twice-monthly treatment) and the active comparator, Genotropin. (Source: Genexine) </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In an extension study in which all patients were put on eftansomatropin alfa, greater than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-digit</div> growth velocity remained until 12 months in all eftansomatropin alfa cohorts, while the Genotropin cohort showed 9.14 cm/ year at 12 months. Moreover, no remarkable slow-down of the growth velocity was observed in the second year in either patients who received eftansomatropin alfa throughout, or in subjects who switched from Genotropin cohort. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pharmacodynamics. The growth-promoting effect of eftansomatropin alfa was accompanied by elevated serum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IGF-1</div> levels. This hormone is an important biomarker, which mediates growth hormone&#8217;s biological effects. The Standard Deviation Score (&#8220;SDS&#8221;), which is a calculated score with reference to the normal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">age-</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sex-matched</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IGF-1</div> levels, is a standardized parameter to compare <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IGF-1</div> levels across laboratories and populations. Mean <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IGF-1</div> SDS at the beginning of the study was below the lower limit of the normal range in all treatment arms. Following initiation of treatment, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IGF-1</div> SDS values quickly normalized by five days (Visit 2) and three weeks (Visit 3) after the initial treatment, respectively, for the eftansomatropin alfa treatment arms and the Genotropin treatment arm. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IGF-1</div> responses were maintained throughout the intended dosing interval, supporting both the weekly and twice monthly treatment regimens. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IGF-1</div> mean peak levels were mostly within the upper limit of the physiologic range, which is considered safe in clinical practice. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Development Plan and Expected Milestones </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In September 2020, the NMPA approved our IND application for a registrational Phase 3 trial of eftansomatropin alfa in PGHD in China. This Phase 3 trial (&#8220;TALLER&#8221;) is a multi-center, randomized, open-label, active-controlled clinical study designed to assess the safety, efficacy and pharmacokinetics of eftansomatropin alfa in PGHD. This trial will enroll 165 patients across multiple centers in China. The primary objective is to demonstrate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-inferiority</div> of 1.2 mg/kg/week of eftansomatropin alfa administered SC, compared to the active control Norditropin, a daily rhGH marketed in China. The first patient was dosed in the TALLER study in February 2021. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> clinical data are expected to become available in Q2 2023 to support NDA submission. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Commercialization Strategy in China </div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As described earlier in this section, the growth hormone market in China will continue to grow rapidly, primarily driven by the potential expansion of applicable patient population, the affordability, the improved awareness of short stature, the availability of more convenient weekly administration of rhGH and the improved injection devices. In particular, the market growth of long-acting rhGH such as eftansomatropin alfa will outpace the growth of overall rhGH market, progressively shifting the market dominance from short-acting rhGH to long-acting rhGH within the next 5-8 years. In addition, we have plans to initiate new clinical studies to expand the treatment application of eftansomatropin alfa to other selected indications such as AGHD, Idiopathic Short Stature (ISS) and Turner Syndrome. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While advancing the current registrational clinical trial, we have begun to prepare for market launch of eftansomatropin alfa. Our plan is to co-promote eftansomatropin alfa by partnering with a China domestic big pharma group who has extensive commercial capability and sales network for pediatric drug products. We are currently in negotiation with selected potential commercial partners. Such partnership will leverage the existing well-established commercial capabilities, including medical marketing, patient education and community outreach programs, and commercial channels of our potential partner to rapidly build a market position and penetration for eftansomatropin alfa in the rhGH market in China. In addition, we are in the process of developing a more convenient injection device in an attempt to improve patient adherence and product competitiveness. The expected market launch of eftansomatropin alfa falls nicely within the predicted time window of the fast-growing stage for long-acting rhGH (2023-2028) as described earlier. Together with the commercial strategy mentioned above and the demonstrated product advantages of eftansomatropin alfa, we aim to rapidly build a strong market position for eftansomatropin alfa to become a top three player in the long-acting rhGH market space in China by 2028. It is estimated that annual sales of the top two or three long-acting rhGH players collectively account for US$1.0 billion (RMB6.3 billion) in 2028, which represents approximately 65% of the overall long-acting rhGH market in China. </div></div> </div> </div> </div> </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">83 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Core Assets </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lemzoparlimab (TJC4): A Potential Highly Differentiated CD47 Antibody for Immuno-Oncology </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lemzoparlimab is a fully human CD47 monoclonal antibody discovered and developed internally by us for cancer immunotherapy. CD47 has emerged as one of the most promising immuno-oncology targets. Unlike other immuno-oncology targets being explored, the CD47-SIRP&#945; pathway is involved in tumor progression by delivering a &#8220;don&#8217;t eat me&#8221; signal to tumor-engulfing macrophages, thereby protecting tumors from natural attacks by macrophages. Blockade of this pathway by CD47 antibody represents one of the most effective tumor killing mechanisms. However, due to the inherent epitope sharing between tumor cells and normal red blood cells (&#8220;RBCs&#8221;), the first-generation clinical stage CD47 antibodies were found in clinical trials to bind to RBCs and caused significant hematologic adverse effects, such as severe hemolytic anemia, which has hampered the development of these CD47 antibodies as a potential cancer therapy. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We developed lemzoparlimab by design to embed a unique property or differentiation through a different antibody binding epitope, to minimize binding to RBCs while retaining superb anti-tumor activities. This key differentiation is achieved by incorporating a RBC counter-screen step in the antibody screen champagne in order to select rare antibody clones that bind to CD47 with high affinity but do not to RBCs. Lemzoparlimab was selected as a result and has been validated in a series of in vitro and in vivo <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies, which have consistently shown a unique <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RBC-sparing</div> profile comprised of minimal RBC binding, lack of hemagglutination and no significant adverse hematologic changes in cynomolgus monkeys even when used at a high dose (100 mg/kg). In addition, the topline results of the completed Phase 1a dose escalation monotherapy trial in the United States (NCT03934814) have demonstrated the differentiated profile of lemzoparlimab in drug safety and favorable pharmacokinetics in cancer patients. The key findings include: (1)<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Safety advantage</div></div>. lemzoparlimab was well tolerated up to 30 mg/kg on a weekly basis without priming dosing strategy, with no dose-limiting toxicity and no clinical or laboratory evidence of hemolytic anemia observed throughout; (2)<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;PK and receptor occupancy</div></div>. The PK profile appeared to be linear at mid to high dose levels following a single dose with no significant &#8220;sink effect&#8221;. Maximal receptor occupancy was achieved at 30 mg/kg; and (3)<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Clinical activity</div></div>. One confirmed partial response (PR) was observed in the 30 mg/kg monotherapy cohort (N=3), and this patient had failed prior treatments with checkpoint inhibitors. Three stable disease cases were also reported. The overall <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical data generated so far have provided strong evidence supporting lemzoparlimab as a highly differentiated CD47 antibody with the clinical advantages described above. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2020, to facilitate and accelerate the global development and commercialization of lemzoparlimab, we granted AbbVie a global license valued at US$1.94&#160;billion, including an upfront payment of US$180&#160;million and the first milestone payment of US$20&#160;million based on the phase 1 clinical results. We retain the rights to develop and commercialize lemzoparlimab in Mainland China, Hong Kong and Macau. We believe that this global partnership with AbbVie will greatly facilitate the clinical development, manufacturing and commercialization of lemzoparlimab globally and in China. </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">84 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Therapeutic Indications </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We plan to evaluate the therapeutic role of lemzoparlimab in a variety of solid tumors, such as NSCLC, ovarian cancer and SCCHN, and hematological malignancies such as AML, MDS and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-Hodgkin&#8217;s</div> lymphoma (&#8220;NHL&#8221;). Although <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1</div></div> therapies represent a new paradigm in cancer treatment, less than 40% of cancer patients have a clinically meaningful response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1</div></div> therapies. As a result, targeting other immune components or cells involved in the immune system&#8217;s anti-tumor mechanism has become an area of active pursuit in the field of immuno-oncology. Lemzoparlimab is one such innovative and promising therapeutic antibody, which is capable of mobilizing macrophage functions for effective and direct tumor-killing. Currently, a number of CD47 antibodies are in clinical development by biotech companies including Gilead/Forty-Seven, Inc., Surface Oncology and Arch Oncology. The most advanced asset, magrolimab, originally developed by Forty-Seven, Inc., is in Phase 3 clinical studies for multiple cancer indications. However, almost all clinical trials with CD47 antibodies have shown significant hematologic adverse effects, likely due to inherent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RBC-binding</div> properties of generic CD47 antibodies, and as a result, some clinical studies had to be either terminated or managed with extra precautions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advantages of Lemzoparlimab </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Lemzoparlimab has similar <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-nanomolar</div> binding affinity as other CD47 antibodies and exhibits comparable anti-tumor activity. The key advantage of lemzoparlimab is its minimal binding to RBCs, thus potentially avoiding or minimizing inherent hematologic adverse effects typically seen in other CD47 antibodies in clinical trials. This differentiated property of lemzoparlimab is, at least in part, due to its unique epitope interaction as revealed by crystallography, which is different from those recognized by other CD47 antibodies currently in clinical development based on publicly available information. The differentiation of lemzoparlimab is highlighted in a series of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies summarized as the following: (1)&#160;lemzoparlimab displays only minimal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RBC-binding</div> even at high antibody concentrations by flow cytometry; (2)&#160;lemzoparlimab does not induce RBC agglutination even in a high concentration range; and (3)&#160;most importantly, lemzoparlimab does not cause significant hematologic changes or systemic toxicologic effects even at high doses in multiple cynomolgus monkey studies, including a pivotal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-week</div> GLP toxicity study. Taken together, lemzoparlimab has a potentially better clinical safety profile and may be used in a broader patient population to explore its anti-tumor potential compared to other clinical stage competitor molecules. </div> </div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; text-indent: 3%; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421180834233.jpg" style="width: 314px; height: 267px;"/>&#160;</div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Table:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Differentiated product profile of lemzoparlimab. (Sources for comparator antibodies: American Society of Hematology publication, PLOS One publication, World Intellectual Property Organization and company data) </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mechanism of Action </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lemzoparlimab blocks the interaction between CD47 expressed on cancer cells and SIRP&#945; expressed on macrophages, leading to increased phagocytosis of cancer cells by macrophages. Blockade of CD47 by lemzoparlimab may also promote the development of anti-tumor T cell responses, resulting from increased tumor antigen presentation by professional antigen-presenting cells such as macrophages and dendritic cells. In addition to stimulating the phagocytosis of cancer cells, CD47 blockade was shown to involve other anti-tumor mechanisms, such as the enhancement of ADCC, direct induction of apoptosis (programmed cell death) of cancer cells, induction of differentiation of cancer stem cells, and inhibition of metastasis. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">85 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; text-indent: 3%; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421180834623.jpg" style="width: 302px; height: 233px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Targeting the CD47/SIRP</div></div>&#945;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> myeloid-specific immune checkpoint. CD47 is highly expressed on many different types of cancers. SIRP</div></div>&#945;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> is an inhibitory receptor expressed on macrophages and other myeloid immune cells. When CD47 binds to SIRP</div></div>&#945;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">, it causes the inhibition of phagocytosis. CD47 antibodies disrupt the CD47/SIRP</div></div>&#945;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> axis and enable the phagocytosis of cancer cells. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> Results </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CD47-related In Vitro and In Vivo Anti-tumor Activities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Lemzoparlimab exhibits high-affinity binding to human CD47 protein and CD47-expressing tumor cells at the nanomolar level and effectively blocks interaction of CD47 with its receptor SIRP&#945;. As compared with other CD47 antibodies currently under clinical development, lemzoparlimab (TJC4) demonstrated comparable potency in the enhanced macrophage-mediated phagocytosis of Raji tumor cells (see Figure A below) and comparable anti-tumor activity in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">HL-60</div> leukemia and Raji xenograft models (see Figure B below). Moreover, when combined with rituximab, lemzoparlimab exhibited a markedly enhanced inhibition on tumor growth in a diffuse large B cell lymphoma (DLBCL) animal model, through the synergistic effect of both agents (see Figure C below). </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421180835046.jpg" style="width: 622px; height: 137px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In vitro and in vivo anti-tumor activity of lemzoparlimab (TJC4). (A) In vitro phagocytosis of Raji cells by primary human macrophages in the presence of different doses of lemzoparlimab or comparator CD47 antibodies. (B)&#160;In vivo anti-tumor activity of lemzoparlimab mono-treatment in Raji xenograft model. (C)&#160;In vivo anti-tumor activity of lemzoparlimab (5 mg/kg, BIW) in combination with Rituximab (5 mg/kg, BIW) in the DLBCL model. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Assessment of Potential CD47-related In Vitro and In Vivo Hematologic Effects </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Firstly, in a representative flow cytometric analysis (see Figure A below), lemzoparlimab showed minimal binding to human RBCs compared to comparator CD47 antibodies used at the same concentration (1 <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">m</div>g/ml). The minimal binding of lemzoparlimab to RBCs was confirmed when compared with other CD47 antibodies across multiple concentrations in another flow cytometric experiment (see Figure B below). </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">86 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421180835597.jpg" style="width: 576px; height: 198px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Binding of CD47 monoclonal antibodies to RBCs. (A)&#160;Representative graph of the staining of human RBCs with CD47 monoclonal antibodies or control IgG (1 &#181;g/ml); (B) Dose dependent binding of CD47 monoclonal antibodies with human RBCs from different healthy donors (n = 3). MFI: mean fluorescence intensity. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Secondly, as CD47 is expressed on normal RBCs, binding of CD47 antibodies to the surface of RBCs could cross-link the RBCs into lattices and prevent them from precipitating into compact pellets, which is a phenomenon termed hemagglutination. Our results showed that lemzoparlimab did not induce RBC agglutination across a wide range of antibody concentrations, while a comparator antibody caused significant hemagglutination starting at a concentration of 0.3 <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">m</div>g/ml. Results from a representative experiment are shown below. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421180836199.jpg" style="width: 595px; height: 154px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Hemagglutination by CD47 monoclonal antibodies. Left: representative graph of hemagglutination (haze appearance) or lack thereof (precipitate) by different concentrations of control IgG, lemzoparlimab (TJC4), and comparator antibodies. Right: quantification through an index determined by the area of RBC occupation in the presence of the test antibodies, normalized to that of IgG control. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Thirdly, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vivo </div></div>safety studies were performed in cynomolgus monkeys to assess the effects of lemzoparlimab on the hematology parameters. Whereas a single bolus IV injection of the comparator antibody caused a significant drop in the number of RBCs and hemoglobin (&#8220;HGB&#8221;) levels, treatment with lemzoparlimab at a dose of 10 mg/kg did not significantly affect the number of RBCs, HGB levels or reticulocyte or platelet counts (see figure below). </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">87 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; text-indent: 3%; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">&#160;
<img alt="" src="g10811g0421180836738.jpg" style="width: 499px; height: 307px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Hematological parameters in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-human</div> primates treated with a single dose of CD47 antibodies. On Day 0, naive cynomolgus monkeys were IV injected with PBS control (n=2), lemzoparlimab (TJC4) (n=2, 10 mg/kg) or a comparator antibody (n=2, 10 mg/kg). Blood cells were counted, twice before drug injection (baseline) and at 3, 6, 10, 14 and 21 days post-injection.</div></div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Moreover, in a four-week GLP toxicology study, lemzoparlimab treatment did not induce significant overall toxicologic changes. Only mild decreases in the number of RBCs, HGB and hematocrit were found, which reached nadir at Day 4 post-first administration and then gradually recovered to the normal range following administration. The changes were not dose-dependent. Compared with the placebo control, the average decrease of RBCs in the treated animals was approximately 6% to 9% with only one animal showing an 18% drop at a dose of 30 mg/kg. No <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RBC-associated</div> changes were noted in histopathologic examinations or in bone marrow smears (including erythrocytic series). Therefore, NOAEL was defined at 100 mg/kg. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Four-week GLP Toxicology Study in Monkeys </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; text-indent: 3%; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g19n02.jpg" style="width: 314px; height: 162px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">RBC counts in male cynomolgus monkeys treated with five consecutive weekly dose of lemzoparlimab (TJC4) at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0-100</div> mg/kg in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-week</div> GLP toxicology study.</div></div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key preclinical data described above have been published as a poster presentation (#4063) at American Society of Hematology 2019 Annual Meeting. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">88 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ELUCIDATION OF THE MOLECULAR MECHANISM UNDERLYING MINIMAL BINDING TO RBC </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We set forth to investigate the molecular mechanism underlying the minimal binding of lemzoparlimab to RBC. The crystal structure of the CD47 antibody binding complex revealed that lemzoparlimab binds to a unique epitope of CD47 that is situated in a heavily glycosylated site on RBC. More specifically, the results of crystal structure analysis identified an N-glycosylation site located nearby the epitope residues. We hypothesized that the glycosylation site nearby the epitope may hinder lemzoparlimab from fully binding to its epitope on RBC. A series of experiments were carried out to address this hypothesis. RBCs were treated with PNGase to remove the N-linked oligosaccharides from glycoproteins, followed by testing of CD47 antibody binding to the de-glycosylated RBCs. The results showed that PNGase treatment of RBCs significantly increased the binding of lemzoparlimab as compared to a control antibody, providing the experimental evidence that removal of glycosylation site(s) on RBC effectively restores binding of lemzoparlimab to RBC. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g20j63.jpg" style="width: 576px; height: 174px;"/></div> </div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The left. Crystal structure of the complex of the Fab of lemzoparlimab (TJC4, Cyan) binding with the extracellular domain (ECD) of human CD47 (Green). The right. In a representative experiment, human RBCs were treated with PNGase for 1 hr followed by the addition of lemzoparlimab (TJC4) or a comparator CD47 antibody that binds strongly to RBC at the indicated concentrations. The binding of CD47 antibodies to the treated (de-glycosylated) or untreated RBCs was analyzed by flow cytometry. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Results of Phase 1 Clinical Trial </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ongoing Phase 1 study of lemzoparlimab in the U.S. is an open-label, multi-center, multiple dose study conducted in two parts to determine safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of lemzoparlimab administered alone and in combination (NCT03934814). The first part is comprised of a single agent dose escalation (Part 1a) followed by two separate combination regimens in an escalating dose range with pembrolizumab (Part 1b) and with rituximab (Part 1c), respectively. The second part is a dose expansion study of the combination therapies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The monotherapy dose escalation has been completed and the initial data from the monotherapy were presented at Society for Immunotherapy of Cancer (SITC) in November 2020 (poster #385). The data are described below. </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Single Agent Dose Escalation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Study Design</div></div>. NCT03934814 is an open label, Phase 1 study to evaluate the safety, tolerability, maximal tolerable dose (MTD) or maximum administered dose (MAD), PK, PD, and recommended phase 2 dose (RP2D) of lemzoparlimab in subjects with advanced, relapsed or refractory solid tumors and lymphoma. Part 1 of the study comprises a single agent dose escalation in a standard 3+3 design (1a) and 2 separate dose escalations in combination with pembrolizumab (1b) or rituximab (1c). Part 2 is a dose expansion study. Lemzoparlimab was administered as weekly IV infusions in successive dose cohorts (1, 3, 10, 20 and 30 mg/kg) without any priming dose. Twenty patients were enrolled. Clinical data from the Part 1a study were reported as of November 2020. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">89 </div></div> </div> </div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Safety</div></div>. Lemzoparlimab was well tolerated up to 30 mg/kg on a weekly infusion schedule <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">without priming dosing</div></div>. No dose limited toxicities (DLTs) or drug-related severe adverse event (SAE) were reported throughout the study. Maximal tolerable dose (MTD) was not reached. All treatment-related adverse events (TRAEs) were either Grade 1 or Grade 2, except that one Grade 3 lipase increase was reported. No clinical or laboratory evidence of hemolytic anemia were observed throughout. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g10811g0421055924793.jpg" style="width: 622px; height: 299px;"/><br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Table:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Treatment-related adverse events (TRAE) by cohort. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A transient reduction in the hemoglobin levels during the first cycle was observed across all cohorts. The average drop was ~10% and was not dose-dependent. This finding is consistent with the results of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> GLP toxicity studies. None of the drug-related anemia reported was considered to be severe or hemolytic in nature. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811sp37.jpg" style="width: 364px; height: 363px;"/></div> </div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Time course of hemoglobulin and reticulocyte counts following lemzoparlimab treatment (all groups). Each cycle (C)&#160;is 21 days (D). Mean&#177;SD is shown.</div></div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmacokinetics</div></div>. The PK profile of lemzoparlimab appeared linear at doses higher than 10 mg/kg following a single dose </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">90 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">administration, while its exposure was greater than dose proportional over the dose range of 1 to 10 mg/kg, suggesting that at higher doses, lemzoparlimab could overcome the CD47 &#8220;sink effect&#8221;. Five subjects were confirmed positive for anti-drug antibodies (ADA) following the first treatment: 3 were from 1 mg/kg, 1 from 3 mg/kg and 1 from 10 mg/kg. No impact of ADA was seen on safety or PK profiles. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g01sp38.jpg" style="width: 362px; height: 433px;"/></div> </div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Serum PK of lemzoparlimab Q1W following a single dose (upper) and multiple doses (lower). </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmacodynamics. </div></div>A dose dependent increase of the CD47 receptor occupancy (&#8220;RO&#8221;) on CD3+ T cells in the peripheral blood was observed after the escalation of the lemzoparlimab dosage. Maximal saturation of CD47 RO on peripheral T cells was achieved at 20 and 30 mg/kg following weekly administration of lemzoparlimab. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g10811g01sp38b.jpg" style="width: 313px; height: 163px;"/><br/></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CD3+ T cell receptor occupancy. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preliminary Efficacy</div></div>. One confirmed Partial Response (PR) was observed in the 30 mg/kg monotherapy cohort (1/3) with 11 cycles completed so far. The patient who had metastatic melanoma had failed prior systemic treatment of nivolumab and ipilimumab. In addition, three patients achieved Stable Disease (SD) with SD duration longer than 16 weeks at dose cohorts cross 1 mg/kg, 10 mg/kg and 30 mg/kg. Two patients with head and neck squamous cell carcinoma (HNSCC) and renal cell carcinoma (RCC), respectively, failed nivolumab and the other with ovarian cancer received no prior PD-(L)1 inhibitor treatment. </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">91 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811sp039.jpg" style="width: 428px; height: 187px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Responding hepatic metastases in a melanoma patient.</div></div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of Clinical Data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lemzoparlimab was well tolerated up to 30 mg/kg on a weekly infusion schedule without priming dosing strategy. No dose-limiting toxicity and no clinical or laboratory evidence of hemolytic anemia were observed throughout. Maximal tolerable dose (MTD) was not reached. Lemzoparlimab PK appeared to be linear at mid to high dose levels following a single dose with no significant &#8220;sink effect&#8221;. Lemzoparlimab monotherapy exhibited evidence of anti-tumor activity in both PD-(L)1 refractory and treatment nalve cancer patients. One confirmed Partial Response (PR) was observed in the 30 mg/kg cohort (n=3). This patient had failed prior treatments with checkpoint inhibitors. Three patients achieved Stable Disease (SD) with SD duration longer than 16 weeks starting at 1 mg/kg. Two patients failed nivolumab and the other received no prior PD-(L)1 inhibitor treatment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Development Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The goal of our global and China clinical development plans is three-fold. We will evaluate the therapeutic role of lemzoparlimab in (1)&#160;hematologic malignancies; (2)&#160;solid tumors, in combination with other treatment agents; and (3)&#160;its application to advance the current treatment options of felzartamab as the second-line and the third-line potentially to a first-line treatment. However, our top priority is to launch lemzoparlimab as the first CD47 antibody product in China. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hematologic malignancies</div></div>. Our ambition is to achieve an accelerated marketing authorization of lemzoparlimab in China, potentially as the first CD47 antibody product in China. MDS and possibly NHL are being evaluated as the potential first indication(s), as they hold higher probability of success for accelerated approvals. With the approved IND from the China NMPA, we are initiating an abbreviated phase 2 clinical study of lemzoparlimab in combination with AZA in patients with AML and MDS, potentially bridging the clinical study, pending approval by the NMPA, to a registrational clinical trial in patients with MDS. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, we are continuing to enroll more patients with relapsed or refractory CD20+ diffuse large B cell lymphoma (DLBCL) and follicular lymphoma in a combination clinical trial with rituximab (Rituxan<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>) in the U.S. This clinical trial includes clinical sites in China through an IMCT (international multi-center clinical trial) mechanism in order to potentially bridge, pending approval by the NMPA, to a registrational clinical trial in NHL in China. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, we will participate in a global Phase 3 clinical trial to be led by AbbVie in patients with newly diagnosed AML patients who are unfit for intensive chemotherapy for registrational purposes globally by AbbVie and in China by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab.</div> The objective of this pivotal trial is to confirm the efficacy and safety of lemzoparlimab in combination with AZA and venetoclax (Venclexta<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>) in the aforementioned patient population to support a NDA data package for submission. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Solid tumors</div></div>. We are continuing to advance the current cohort expansion study in the U.S. combining lemzoparlimab with pembrolizumab (Keytruda<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>) to evaluate the safety and efficacy in patients with NSCLC and ovarian cancer. The results of this <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> clinical study are anticipated in Q4 2021.With more clinical data from our ongoing U.S. study, additional clinical data reports from the competing clinical trials and, more importantly, our translational medicine study findings where specimens of various tumor types are analyzed for CD47 expression, we are in preparation of an IND submission to China&#8217;s NMPA to initiate a phase 2 &#8220;basket&#8221; clinical trial in patients with advanced solid tumors that are selected for a higher probability of success in the second half of 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Combination with felzartamab to enhance the treatment efficacy of the current second-line or third-line treatment of MM</div></div>. We believe that lemzoparlimab may work synergistically with other pathways in immuno-oncology to offer significantly better treatment efficacy. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> data generated in house and reported by others support the hypothesis that lemzoparlimab may work synergistically with CD38 antibody for multiple myeloma, to offer significantly better treatment efficacy and potentially move to a first-line treatment option. A clinical trial will be initiated in the second half of 2021 in China to evaluate safety and clinical efficacy of combination therapy of lemzoparlimab with felzartamab in patients with multiple myeloma. </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">92 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Current Development Status and Expected Milestones </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">(1) The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> clinical trial with lemzoparlimab in combination with pembrolizumab in patients with NSCLC and ovarian cancers in the U.S. is on track to deliver preliminary results by Q4 2021; (2) A new clinical trial of lemzoparlimab in combination with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> therapy in patients with selected solid tumors will be initiated in the second half of 2021 in China; (3)&#160;The combination study of lemzoparlimab with AZA in untreated AML and MDS patients is set to commence in Q2 2021 in China. Patient enrollment is expected to complete by Q4 2021; (4) The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> NHL clinical study with rituximab, involving clinical sites in both the U.S. and China, is expected to have topline results by Q4 2021; and (5)&#160;The combination study of lemzoparlimab with felzartamab in patients with MM is planned to start in the second half of 2021 in China. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Uliledlimab (TJD5): A Potential Highly Differentiated CD73 Antibody for Cancer Treatment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Uliledlimab is an internally developed, humanized inhibitory antibody against human CD73. CD73 is a homodimeric enzyme expressed in tumors and plays a critical role in suppressing immune cells in tumor micro-environment. Uliledlimab displays sub-nanomolar binding affinity to CD73 and inhibits its nucleotidase activity. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In vitro</div></div>, uliledlimab completely reversed the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AMP-</div> or tumor cell-mediated suppression of T cells. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In vivo</div></div>, when combined with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> antibody, uliledlimab exhibited a superior or synergistic inhibitory effect on tumor growth. The key differentiation of uliledlimab when compared to some of the other clinical stage antibodies of the same class, is related to its novel epitope, which works through a unique intra-dimer binding mode, resulting in a complete inhibition of the enzymatic activity and avoiding the aberrant pharmacological property known as the &#8220;hook effect&#8221;. With this particular mode of action, uliledlimab, if approved, has the potential to become a highly differentiated CD73 antibody. Since the IPO in January 2020, we have made extensive efforts to understand the structural basis underpinning the mechanism of action that leads to the differentiated properties of uliledlimab from those of other CD73 antibodies. The key findings of our latest mechanistic study were presented at the AACR 2021 annual meeting. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have made significant progress in global clinical development of uliledlimab. In the U.S., we have completed the initial assessment of a Phase 1 clinical study where uliledlimab was evaluated as a monotherapy <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lead-in</div> and followed by combination with atezolizumab (Tecentriq<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>) in patients with solid tumors. Topline results from this clinical study show that uliledlimab is safe and well tolerated at the dose range evaluated and demonstrate clinical activity in patients with advanced solid tumors. The topline results are expected to be presented at ASCO 2021 annual meeting. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In parallel, we are conducting a Phase 1/2 clinical trial in China to evaluate uliledlimab in patients with advanced solid tumors. The first patient was dosed in May 2020 and this study was accelerated by leveraging data from the ongoing Phase 1 clinical study of uliledlimab in the U.S. as described above. Currently, we are advancing the Phase 1/2 dose escalation and cohort expansion study of uliledlimab as a single agent and in combination with toripalimab (TUOYI<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>), a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> antibody, in patients with advanced or metastatic cancers who are refractory to or intolerant of available therapies. In February 2021, the first patient in the combination study was dosed which was significantly ahead of the previous planned clinical development timeline. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Therapeutic Indications </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Despite recent breakthroughs with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1</div></div> therapies, clinical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-response</div> rates to such treatments remains high in cancer patients (exceeding 60%). This <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-responsiveness</div> to these standard treatments is partly due to the fact that T cells within an inhibitory tumor environment are suppressed and fail to respond to stimulation induced by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1</div></div> therapies. CD73, which converts extracellular adenosine monophosphate (&#8220;AMP&#8221;) to adenosine, is implicated in one of the protective mechanisms of tumors that evade immune attack by creating an adenosine-rich microenvironment inhibitory to immune cells. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> studies have indicated that the inhibition of CD73 renders T cells more responsive to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1</div></div> therapies by altering the tumor micro-environment, resulting in a superior anti-tumor effect. As CD73 is widely expressed in various cancers, a combination therapy of uliledlimab with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1</div></div> antibody may increase the likelihood of treatment success in cancer patients who do not respond to standard <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1</div></div> therapies. The potential cancer indications of uliledlimab include thyroid cancer, lung cancer, colorectal cancer, stomach cancer, urothelial cancer, endometrial cancer, head and neck cancer, breast cancer, ovarian cancer, and melanoma, in which CD73 is widely expressed. </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">93 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">A small group of global companies are among the front-runner having active clinical development programs with CD73 antibodies. Oleclumab (MEDI-9447) from Medimmune and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BMS-986179</div> from Bristol-Myers Squibb are the two most advanced CD73 antibodies for cancer therapy, which are in Phase 2 clinical trials. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BMS-986179</div> is being studied as a single agent and in combination with nivolumab for the treatment of advanced colorectal, esophageal, gastric, ovarian, and pancreatic cancers. MedImmune is testing MEDI-9447 for the treatment of solid tumors as a single agent or in combination with durvalumab or chemotherapy. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CPI-006</div> (from Corvus) is being evaluated in a Phase 3 clinical trial for the treatment of hospitalized patients with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and in a multi-center Phase 1 oncology clinical trial. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NZV-930</div> (from Novartis) and AK119 (from AkesoBio) have entered Phase 1 clinical trials for the treatment of solid tumors. Most recently, Arcus Biosciences reported promising results in their Phase 1b/2 trial of AB928, a small molecule CD73 inhibitor, in patients with pancreatic cancer. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advantages of Uliledlimab </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Extracellular AMP can be generated from ATP, cyclic AMP and nicotinamide adenine dinucleotide (&#8220;NAD&#8221;) through separate biochemical pathways, all of which converge to CD73 to generate adenosine. Thus, CD73 antibody is expected to block adenosine generation more completely than other related targets. Further, CD73 antibody works through a substrate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competitive</div> fashion and has advantages over small molecule inhibitors targeting the adenosine pathway through a substrate competing fashion. Immunologically, in addition to the reversal of adenosine mediated T cell suppression, uliledlimab directly increased B cell activation and antigen presentation as evidenced by upregulation of CD69, CD83, CD86 and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">HLA-DR,</div> which was unaffected by the addition of adenosine. Combination of uliledlimab with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-(L)1</div> antibody showed synergistic anti-tumor activities both <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vivo</div></div>. More importantly, uliledlimab, if approved, is potentially highly differentiated among the clinical stage CD73 antibodies as it binds to a novel epitope in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-terminal</div> domain of CD73 without causing a &#8220;hook effect&#8221;. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In summary, uliledlimab has the following key advantages: (1)&#160;uliledlimab exhibits a typical dose-response curve without the &#8220;hook effect&#8221; and with a complete inhibition of both soluble and surface-bound CD73; and (2)&#160;uliledlimab has a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competitive</div> inhibitory effect that is not blunted by high levels of CD73 enzyme substrates, which would be expected for small-molecule competitive blockers. These pharmacological properties may translate into efficient target inhibition in tumors and superior anti-tumor activity, especially in an adenosine-rich micro-environment. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mechanism of Action </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Adenosine is a potent immunosuppressive signaling molecule abundant in the tumor micro-environment. CD73 is the rate-limiting enzyme that generates adenosine from extracellular AMP. Uliledlimab allosterically inhibits the CD73 enzyme by preventing the inactive CD73 dimer from changing into the active conformation in a substrate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competitive</div> manner. This results in a decrease in adenosine production in the tumor micro-environment, increasing T cell anti-tumor activity. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">94 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811sp042.jpg" style="width: 465px; height: 198px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Schematic diagram of CD73-catalyzed adenosine (Ado) generation and immunosuppression by Ado in the tumor micro-environment.</div></div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> Results </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inhibition of CD73 by Uliledlimab. </div></div>As shown in the figure below, uliledlimab displayed complete inhibition of soluble CD73 enzymatic activity (IC50= 0.22 n<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">M</div></div>) without the &#8220;hook effect&#8221; in contrast to the comparator molecule, which at higher concentrations caused a paradoxical rebound of enzymatic activity presumably due to its inter-dimer binding mode. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; text-indent: 3%; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055926650.jpg" style="width: 359px; height: 198px;"/></div></div><br/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure: Inhibition of soluble CD73 enzymatic activity by CD73 antibodies. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restoration of T Cell Activity by Uliledlimab In Vitro</div></div>. We observed that AMP inhibited interferon gamma <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(IFN-g)</div> production by CD4 or CD8 T cells through adenosine generation, mimicking the suppressive tumor micro-environment where AMP is abundantly produced. However, this suppression could be reversed by uliledlimab in a concentration-dependent manner. Moreover, in an experimental system where CD73 high human ovarian cell line <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SK-OV-3</div></div> and human T cells were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-cultured,</div> addition of uliledlimab restored T cell activity as measured by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IFN-g</div> production in a concentration-dependent manner. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stimulation of B Cell Activity Independent of Adenosine</div></div>. In addition to the restoration of AMP mediated T cell suppression, we found that uliledlimab treatment could activate human B cells as evident by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-regulation</div> of activation markers CD69 and CD83 as well as antigen presentation markers CD86 and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">HLA-DR.</div> As compared to T cells, the effects of uliledlimab on B cells were adenosine independent. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">95 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055926915.jpg" style="width: 473px; height: 275px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Up-regulation</div> of activation markers (A)&#160;and antigen presentation markers (B)&#160;on B cells by uliledlimab which was not affected by the addition of adenosine analog (NECA).</div></div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In Vivo Anti-tumor Activity of Uliledlimab. </div></div>Uliledlimab monotherapy inhibited in situ tumor derived CD73 activity, leading to the anti-tumor effect in a mouse xenograft model bearing A375 melanoma cells. To examine whether uliledlimab could enhance the anti-tumor activity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> antibody, we evaluated the therapeutic effects of uliledlimab in combination with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> antibody in MC38 model using CD73 humanized mouse and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> antibody in the A375 xenograft model, respectively. The combination treatments resulted in stronger inhibition of tumor growth than monotherapy of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-(L)1</div> antibody or uliledlimab. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055927227.jpg" style="width: 479px; height: 358px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inhibition of tumor growth and in situ CD73 activity by uliledlimab alone or in combination with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> antibody.</div></div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">96 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmacokinetics of Uliledlimab in Cynomolgus Monkeys</div></div>. Following a single IV injection of uliledlimab at 5, 25 and 50 mg/kg, the mean C<div style="font-size: 85%; vertical-align: bottom;;vertical-align: sub;display:inline;;font-size:9.4px">max</div> ranged dose-proportionally from 136 to 1430 &#181;g/mL, and the systemic exposure indicated by the AUC0-last increased in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-linear</div> manner, ranging from 4020 to 135000 hr*&#181;g/mL. Mean half-life was 44.9 hours, 61.5 hours and 104 hours, respectively, reflecting decreased clearance of uliledlimab with increasing dose. No apparent sex difference was observed in the main PK parameters. Positive ADAs against uliledlimab were detected in the majority of the animals, without an apparent impact on systemic exposure. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; text-indent: 3%; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055927492.jpg" style="width: 380px; height: 213px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration-time profile of uliledlimab in cynomolgus monkeys.</div></div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Repeat-dose Toxicology Study of Uliledlimab in Cynomolgus Monkeys</div></div>. A four-week GLP toxicity study was conducted in cynomolgus monkeys followed by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-week</div> recovery period to evaluate the potential toxicity of uliledlimab. Forty cynomolgus monkeys were randomly assigned into four groups (5/sex/group) and given five weekly doses of uliledlimab at 20, 60 or 200 mg/kg via IV injection. Systemic exposures (C<div style="font-size: 85%; vertical-align: bottom;;vertical-align: sub;display:inline;;font-size:9.4px">max</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AUC0-t)</div> generally increased dose-proportionally, and the Day 22 values were generally higher than those on Day 1, with mean accumulation ratios (AR) ranging between 1.65 and 2.19. No apparent sex difference was observed. Positive ADAs against uliledlimab were detected in the majority of animals following repeat administration at all doses, while no significant impact was observed on the TK profiles. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The only uliledlimab-related effect was decreased monocyte chemoattractant protein 1 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(MCP-1)</div> on Day 1 (24 or 48 hours post-dosing) in treated animals. Due to a lack of corresponding findings or impact on the wellbeing of the animals, this effect was not considered adverse. No abnormality was observed in other study endpoints, including safety pharmacology parameters and immunotoxicity. The no observed adverse effect level (NOAEL) was defined at 200 mg/kg. This dose level corresponded to the mean C<div style="font-size: 85%; vertical-align: bottom;;vertical-align: sub;display:inline;;font-size:9.4px">max</div> and AUC values of 6,890 <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">m</div>g/ mL and 594,000 <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">m</div>g*hr/mL in males, respectively, and 6,450 <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">m</div>g/mL and 501,000 <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">m</div>g*hr/mL in females, respectively, on Day 22 of the dosing phase. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We presented the mechanistic analysis and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> data at 2021 American Association for Cancer Research (AACR) Annual Meeting. The key differentiation of uliledlimab when compared to other clinical stage antibodies of the same class, is related to its novel epitope. The differentiated mechanism of action works through a unique intra-dimer binding mode, resulting in a complete inhibition of the enzymatic activity while avoiding the aberrant pharmacological property known as the &#8220;hook effect&#8221;. With this differentiated mode of action, uliledlimab, has the potential to become a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">best-in-class</div></div> CD73 antibody for its clinical advantages, if fully validated in the clinic. </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">97 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Development Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are rapidly advancing multiple clinical development programs of uliledlimab in the U.S. and China in parallel, leveraging the efficacy, biomarker analysis and safety data from both geographies to accelerate global development towards a pivotal clinical study in patients with selected solid tumor types. We plan to target different cancer indications in the U.S. and China based on unmet medical needs and registration pathways. In the U.S., we recently completed a Phase 1 clinical trial where the safety and efficacy signal of uliledlimab in combination with standard regimen of atezolizumab (TECENTRIQ<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>) were evaluated in patients with advanced or metastatic solid tumors. Topline results from the study showed that uliledlimab is safe and well tolerated at the dose range evaluated. The study also demonstrated clinical activity of uliledlimab in patients with advanced solid tumors. The clinical data set of this Phase 1 study has been selected for presentation at the 2021 ASCO annual meeting in June. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In China, a multi-center, open-label Phase 1/2 dose escalation and cohort expansion clinical trial of uliledlimab in combination with toripalimab (TUOYI<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>) is ongoing in patients with advanced or metastatic solid tumors. The study includes a dose escalation phase and a dose expansion phase. In the dose escalation phase, we will characterize safety, pharmacokinetic and pharmacodynamic profile of uliledlimab and explore preliminary clinical efficacy. In the dose expansion phase, we will continue to explore the clinical activities in different types of solid tumors and potential biomarkers in a &#8220;basket&#8221; trial design by leveraging the data from the uliledlimab trial in the U.S. One of the focused cancer indications is NSCLC, where we will look into the potential subpopulations, based on previous treatment lines, immuno-oncology treatment history and relevant biomarkers. Similarly, we will select a few other cancer types to be included in this basket clinical trial. We will test various relevant biomarkers, including adenosine-A2AR pathway markers, selected cytokines and gene signatures, to potentially correlate with clinical activity of uliledlimab. The overall results will guide us to rapidly advance clinical development towards a registrational study. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Current Development Status and Expected Milestones </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the U.S., we recently completed the Phase 1 clinical trial and plan to move forward with the cohort expansion study in 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In China, we will complete the current dose escalation trial in Q2 2021 and present the preliminary efficacy and safety results at a scientific conference in the second half of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">By leveraging the clinical data from the uliledlimab trial in the U.S., we have been facilitating the cohort expansion study of uliledlimab in combination with toripalimab (TUOYI&#174;). The first patient dosing of this combination therapy was achieved in February 2021 and the study is on track with over 15 clinical sites involved in China. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Efineptakin alfa (TJ107): The First Long-acting Recombinant Human <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7</div> with the Potential for Cancer Treatment-related Lymphopenia and Cancer Immunotherapy </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Efineptakin alfa is the world&#8217;s first and only long-acting recombinant human <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">interleukin-7</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;rhIL-7&#8221;),</div> which is being developed as a T lymphocyte-booster for cancer-related immunotherapy. Due to its advantages in terms of selective immune functions, improved stability, developability, and extended half-life, efineptakin alfa is differentiated from an earlier generation of short-acting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">rhIL-7</div> and other T cell growth factor (e.g., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">interleukin-2).</div> In December 2017, we acquired exclusive rights from Genexine to develop and commercialize efineptakin alfa in Greater China. Efineptakin alfa is positioned to meet unmedical need in two therapeutic areas of oncology. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Firstly</div></div>, it can potentially offer as a monotherapy or an oncology care product to cancer patients with treatment-related lymphopenia (low blood lymphocyte levels) induced by chemotherapy or radiation therapy. This target indication covers a large population of cancer patients who develop treatment-related lymphopenia, a clinical condition that weakens the anti-tumor activity of the immune system and the ability of the patients to continue required chemotherapy or radiation therapy, leading to worsened disease prognosis and poor clinical outcome. Currently, there is no treatment available for this condition. In May 2020, we obtained an IND approval from the NMPA and a Phase 2 clinical trial in GBM patients with lymphopenia is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going.</div> </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">98 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Secondly</div></div>, efineptakin alfa is expected to show a therapeutic effect as a combination therapy with immune checkpoint inhibitors, i.e., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1</div></div> therapies, due to its inherent selective T cell-boosting properties. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> studies have indicated that efineptakin alfa exerted additional anti-tumor effect when combined with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1</div></div> therapies. If proven efficacious in clinical studies, we believe such a combination therapy, can potentially treat a large population of cancer patients who do not respond or respond poorly to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1</div></div> therapies. We plan to initiate a Phase 2 combination clinical trial in the second half of 2021. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Therapeutic Indications </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">One of the target therapeutic indications of efineptakin alfa is cancer treatment-related lymphopenia. Cancer patients who undergo chemotherapy and/or radiation therapy often develop cancer treatment-related lymphopenia, which further damages their already compromised immune systems and their ability to fight against cancers. Advanced solid tumor is another indication for efineptakin alfa as a combination therapy with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> therapy. As more than 60% cancer patients either do not respond or respond poorly to current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1</div></div> therapies, there are intense attempts to identify an effective agent that can work synergistically with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1</div></div> therapies to increase the probability of treatment success. Efineptakin alfa is believed to provide such a treatment option, which is supported by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> reports that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7</div> exhibits a synergistic effect with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1</div></div> therapies in the treatment of cancers and by the recent clinical data reported by Genexine (see elsewhere in this section). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advantages of Efineptakin alfa</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Efineptakin alfa has an advantage over other T lymphocyte cytokines with therapeutic potential in oncology. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> and clinical results generated so far indicate that efineptakin alfa has a favorable immune function profile over recombinant human <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">interleukin-2</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;rhIL-2&#8221;)</div> in that efineptakin alfa activates and expands tumor-fighting CD4, CD8 and natural killer T cells but spares tumor-protecting Treg cells. By contrast, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">rhIL-2</div> is a well-known inducer of Tregs, which suppresses tumor-fighting effector T cells. Furthermore, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">rhIL-2</div> has a narrow therapeutic window and causes serious side effects such as capillary leak syndrome, breathing problems, serious infections, and seizures. A polyethylene glycol (PEG)-conjugated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-2</div> variant developed by Nektar Therapeutics has yielded mixed results, indicating the complexity associated with using <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-2</div> as a cancer treatment. Owing to its preferred immune function and molecular profiles demonstrated in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and Phase 1/2 clinical trials, we believe that efineptakin alfa is a superior T cell cytokine investigational drug for cancer treatment-related lymphopenia and cancer immunotherapy. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Efineptakin alfa, as an engineered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">rhIL-7,</div> has the advantages of improved stability and half-life extension through Genexine&#8217;s proprietary hybrid fragment crystallizable region (&#8220;hyFc&#8221;). Introducing a few hydrophilic amino acid residues to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">N-terminus</div> of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7</div> overcomes stability issues that hampered the development of previous <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">rhIL-7</div> drug candidates. Furthermore, application of the hyFc technology enhances <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7&#8217;s</div> function, increases its half-life (from 48 to 112 hours after a single subcutaneous (&#8220;SC&#8221;) dose in clinical studies), and allows for a robust purification process. By contrast, the half-life of first-generation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">rhIL-7</div> was reported to be about 12 hours after SC dosing in human subjects. The hyFc in efineptakin alfa is also non-cytolytic, so it will not damage the T cells to which it binds. Unlike efineptakin alfa, the previous <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">rhIL-7</div> drug candidates adopt <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-glycosylated</div> (CYT <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">99-007)</div> or glycosylated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(CYT-107)</div> forms of short-acting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">rhIL-7</div> and were developed by Revimmune Inc (formerly known as Cytheris SA). These molecules had low stability, low production yield, and a short half-life because <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7</div> protein is intrinsically unstable and prone to aggregation. However, the preliminary clinical results from Phase 1 and Phase 2 trials in patients with AIDS did show an increase of T lymphocytes following treatment with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CYT-107</div> (Thiebaut R et al., PLoS Comput Biol., 2014). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mechanism of Action </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7</div> is a cytokine essential for the survival and homeostatic proliferation of naive and memory T cells (see figure below). <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7</div> is critically involved in restoring T cells to normal levels in the event of lymphopenia by stimulating T cell proliferation. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7</div> exerts its functions by binding to and activating the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7</div> receptor, which is expressed primarily on lymphocytes, including the lymphoid precursors, developing T and B cells, naive T cells, and memory T cells, but not on tumor-protecting Tregs. Efineptakin alfa as a monotherapy may enhance anti-tumor immunity by augmenting the number and functionality of T cells, whereas efineptakin alfa in combination with an immune checkpoint inhibitor, cancer vaccine or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> may improve the anti-tumor response by restoring T cell numbers, reconstituting T cell pools and reinvigorating exhausted T cells. </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">99 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; text-indent: 3%; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055927757.jpg" style="width: 297px; height: 281px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Role of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7</div> in T cell maintenance and proliferation.</div></div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of Clinical Results </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">First-In-Human</div></div> Phase 1a Trial in South Korea </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-human</div></div> Phase 1 trial has been conducted by Genexine in South Korea. This was a randomized, double-blind, placebo-controlled, single ascending dose study, to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic properties of 20 or 60 &#181;g/kg efineptakin alfa via SC or intramuscular (&#8220;IM&#8221;) administration in healthy volunteers. Each dose group consisted of 10 subjects, eight of whom were administered efineptakin alfa and two were given placebo via the same route of administration. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Safety</div></div>. Efineptakin alfa was well-tolerated in all 30 subjects without serious adverse events. The most common adverse events were transient Grade 1 or 2 injection site skin reactions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmacodynamics (&#8220;PD&#8221;)</div></div>. Because <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7</div> promotes the survival and proliferation of T cells, absolute lymphocyte count (&#8220;ALC&#8221;) in the peripheral blood was used as a reliable and convenient PD marker for efineptakin alfa (see figure below). ALC initially decreased transiently in all efineptakin alfa groups. This effect is often termed margination, which is a physiological phenomenon common to many cytokines as a result of increased adherence of cytokine-stimulated white blood cells to the blood vessels and subsequent trafficking to tissues and lymphoid organs. ALC recovered in approximately seven days, reaching a maximum value at close to 21 days, before gradually declining. This result indicated that a single dose of efineptakin alfa had a long-lasting effect of increasing lymphocyte levels. Overall, a greater increase in ALC was observed in Cohort 2 compared with Cohort 1, demonstrating a dose-dependent response. Additionally, a higher increase in ALC was observed in Cohort 3 compared with Cohort 2, which was consistent with the results of an animal study, where IM injection induced a more effective increase in lymphocytes than SC injection. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">100 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; text-indent: 3%; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055928116.jpg" style="width: 359px; height: 201px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Median fold changes of ALC following a single dose of efineptakin alfa in humans. Cohort 1: 20 ug/kg, SC; Cohort 2: 60 ug/kg, SC; and Cohort 3: 60 ug/kg, IM. (Source: Genexine)</div></div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Efineptakin alfa treatment resulted in a substantial increase in the number of CD4 and CD8 T cells, natural killer T cells, naive T cells, central memory, effector memory, and terminally differentiated effector memory T cells, without affecting the number of B cells, natural killer cells, monocytes or Tregs. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811sp48.jpg" style="width: 574px; height: 290px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Median fold changes of T cells and subsets following a single dose of efineptakin alfa in human subjects. Cohort 1: 20 ug/kg, SC; Cohort 2: 60 ug/kg, SC; Cohort 3: 60 ug/kg, IM. (A)&#160;CD3+T cells, (B)&#160;CD4+T cells, (C)CD8 + T cells, (D)&#160;Natural Killer T cells, and (E)&#160;regulatory T cells (Treg). (Source: Genexine)</div></div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmacokinetics</div></div>. Efineptakin alfa was slowly absorbed, particularly after SC administration, and was slowly removed, resulting in a half-life of 48 to 112 hours, longer than that reported for the first generation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">rhIL-7</div> (about 12 hours). Intramuscular efineptakin alfa showed approximately <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-fold</div> greater exposure than SC administration at the same dose level of 60 &#181;g/kg. The higher plasma exposure of efineptakin alfa after IM administration was well-correlated with a more robust PD effect on ALC in Cohort 3. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Immunogenicity</div></div>. ADAs were detected in 22 of 24 subjects treated with efineptakin alfa. One subject in Cohort 3 was positive for ADAs before treatment. Neutralizing antibodies were observed in 42% and 46% of the subjects within one to two months following administration, respectively, but only one person still harbored neutralizing ADAs five months after administration. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The clinical relevance of ADA was evaluated during long-term <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> monitoring. ALC levels were maintained above the baseline values, endogenous <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7</div> was maintained at normal levels, and no specific adverse events associated with ADAs were observed. These results are consistent with well-documented reports that a normal individual can harbor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-existing</div> auto-antibodies for cytokines such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-2,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-3,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-4,</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7,</div> and that these anti-cytokine antibodies tend to serve as a reservoir and carrier of the cytokines in the blood, extending the half-life of these cytokines and preserving their functions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase 1b Trial in Cancer Patients in China </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">This <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-part</div> study is to evaluate the safety, tolerability, PK/PD profile, and anti-tumor activity of efineptakin alfa in Chinese patients with advanced solid tumors who progressed on or after standard therapy. Patients received efineptakin alfa every 4 weeks (in part A) or every 6 weeks (in part B) by intramuscular (IM) injection. Part A was a 3+3 design dose escalation from 240 &#181;g/kg to up to 1200 &#181;g/kg and was completed. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For part A, as of December&#160;31, 2020, 16 patients (11 colorectal cancer, 3 gastric cancer, 1 nasopharyngeal carcinoma, and 1 laryngeal carcinoma) were enrolled and received efineptakin alfa treatment including 240 &#181;g/kg (n = 3), 480 &#181;g/kg (n = 3), 720 &#181;g/kg (n = 4), 960 &#181;g/kg (n = 3) and 1200 &#181;g/kg (n = 3). No DLTs were reported and MTD was not reached. The most common TEAEs were transient lymphocyte count decrease (100%) which was likely due to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7-induced</div></div> lymphocyte homing. Other common TEAEs were injection site reactions (93.8%) which recovered spontaneously or after topical treatment with antihistamines. Efineptakin alfa exposure (C<div style="font-size: 85%; vertical-align: bottom;;vertical-align: sub;display:inline;;font-size:9.4px">max</div> and AUC<div style="font-size: 85%; vertical-align: bottom;;vertical-align: sub;display:inline;;font-size:9.4px">last</div>) tended to increase dose proportionally in the range of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">240-1200</div> &#181;g/kg. Mean T<div style="font-size: 85%; vertical-align: bottom;;vertical-align: sub;display:inline;;font-size:9.4px">1/2</div> was consistent with results from Phase 1a. Dose-dependent increases in ALC and CD3+ T cells including naive and memory subsets were observed post first dose, while Treg cells were not significantly affected and CD4/Treg ratio was improved. More importantly, IFN-g secreting T cells were significantly amplified, suggesting enhanced anti-tumor potential after treatment. Based on these observations, 960 &#181;g/kg and 1200 &#181;g/kg were chosen for the ongoing part B expansion study, which is fully enrolled (n=12). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase 1b/2 Trial in TNBC Patients in the U.S. by Genexine </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our partner Genexine recently released new data from a Phase 1b/2 study of efineptakin alfa in combination with pembrolizumab (KEYTRUDA&#174;) in patients with relapsed or refractory triple-negative breast cancer (TNBC) at 2020 SITC annual meeting. A total of 60 patients had been enrolled and treated with efineptakin alfa in combination with pembrolizumab with or without cyclophosphamide (&#8220;CPA&#8221;) chemotherapy. The median follow-up period of all treated patients (n=60) was 4.32 months (range 0.9&#8211;15.3 months) including 16 ongoing patients. The combination treatment of efineptakin alfa and pembrolizumab, with or without CPA, was safe and well tolerated. Combination (simultaneous treatment) of efineptakin alfa and pembrolizumab induced higher ORR (7/36, 19.4%) than sequential treatment of efineptakin alfa and pembrolizumab with CPA (2/24, 8.3%). In particular, the cohort (n=18) receiving 1,200&#181;g/kg efineptakin alfa with pembrolizumab without CPA showed the highest ORR (27.8%, 5 PRs) with disease control rate (&#8220;DCR&#8221;) of 44.4% (5 PRs and 3 SDs). Of note, pembrolizumab monotherapy showed 5.3% ORR (KEYNOTE-086) in a Phase 2 study and failed to improve OS as <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div> 2L treatment for mTNBC, compared to the standard chemotherapy. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Development Plan and Current Status </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">By leveraging the clinical results of Genexine&#8217;s ongoing clinical trials in South Korea and the United States, we aim to rapidly advance the clinical development of efineptakin alfa for approval in Greater China. Currently, a Phase 1b trial in China is about to complete. The study is designed to investigate the safety, tolerability and PK/PD response of efineptakin alfa in patients with advanced solid cancers. The clinical trial (NCT04001075) includes: (1)&#160;dose escalation of efineptakin alfa using a conventional &#8220;3 + 3&#8221; study design to identify a safe and active dose range which we have completed; and (2)&#160;dose expansion to confirm the safety and obtain preliminary evidence of efficacy for which we completed enrollment as of January 2021. The safety and tolerability profile as well as the PK/PD response are consistent with other ongoing studies of efineptakin alfa. </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">102 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">More importantly, our current clinical development plan is to focus on evaluating safety and efficacy of efineptakin alfa in cancer patients (1) as a broader oncology care treatment for those who suffer from lymphopenia commonly induced by chemotherapy and radiation therapy and (2) as a combination therapy with PD-1 therapy to achieve better clinical response and efficacy. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cancers with lymphopenia.</div></div> In December 2020, we initiated a phase 2 randomized, single-blind, placebo-controlled clinical trial (NCT04600817) to evaluate the safety and efficacy of efineptakin alfa in glioblastoma multiforme (GBM) patients with lymphopenia who have been treated with standard concurrent chemoradiotherapy. The study involves 160 patients who will receive either efineptakin alfa or a placebo once every eight weeks. The primary outcome of the study is the percentage of patients with an increase in the absolute lymphocyte counts and associated clinical response in relation to the treatment with efineptakin alfa. Our partner, Genexine, will share the clinical trial cost in return for an access to the clinical data. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Combination therapy with PD-1 therapy.</div></div> By leveraging accumulative clinical data and experience with efineptakin alfa in the treatment of cancer patients in the U.S. and South Korea, including relapsed or refractory triple-negative breast cancer (TNBC), glioblastoma and high-risk skin cancer, we plan to submit a new IND in the second half of 2021 in China to initiate a Phase 2 combination therapy of efineptakin alfa with PD-1 therapy following a basket trial design to include selected tumor types, including TNBC. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Clinical Assets</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Plonmarlimab (TJM2): A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> Monoclonal Antibody for Rheumatoid Arthritis and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CRS-related</div> Therapies</div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Plonmarlimab is an internally discovered neutralizing antibody against human granulocyte-macrophage colony-stimulating factor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;GM-CSF&#8221;),</div> an important cytokine that plays a critical role in chronic inflammation and destruction in autoimmune diseases such as rheumatoid arthritis (&#8220;RA&#8221;). Plonmarlimab is a humanized IgG1 that displays high affinity binding to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> and blocks its signaling pathway and downstream effects. Plonmarlimab is being developed for the treatment of autoimmune and inflammatory diseases, including RA and cytokine release syndrome (&#8220;CRS&#8221;). We have completed a single-dose <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-human</div></div> study in healthy volunteers in the United States. In China, plonmarlimab is the first antibody of its class entering clinical development. We dosed the first patient in a Phase 1b study of plonmarlimab in August 2020 in China. We may expand plonmarlimab to other autoimmune and inflammatory indications with high unmet medical need, where <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> is known as a pathogenic cytokine in disease activity and progression. If approved, plonmarlimab is expected to provide an effective treatment option as a disease-modifying anti-rheumatic drug (&#8220;DMARD&#8221;) therapy. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Since the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> outbreak, we have prioritized plonmarlimab in response to the urgent medical needs. In May 2020, we announced preliminary results from part 1 of a clinical study in the United States of plonmarlimab in patients with cytokine release syndrome (CRS) associated with severe <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> in which plonmarlimab was found to be well tolerated. We are currently conducting part 2 of this clinical trial to evaluate the efficacy, safety and effects on cytokine levels following a single dose 6 mg/kg treatment of plonmarlimab or placebo (best supportive care) in patients with severe <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Therapeutic Indications </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our initially focused therapeutic indication is RA, a chronic inflammatory disease that is characterized by polyarticular and causes joint destruction, deformity, and loss of function. Extra-articular manifestations include cardiopulmonary diseases, eye diseases, Sjogren&#8217;s syndrome, rheumatoid vasculitis and neurological diseases. Current therapies for RA in China include traditional Chinese medicine, corticosteroids, and DMARDs, including immunosuppressants and targeted therapies such as TNF inhibitors. Although the market for RA has become more competitive in China, new medicines targeting different pathways with greater clinical efficacy and safety remain a significant unmet need. Plonmarlimab is one of the new biologics that potentially hold such a promise for the treatment of autoimmune diseases such as RA. </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">103 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Clinical evidence supporting the role of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> antibody in RA is highlighted in a few recent global studies. For example, both otilimab (MOR103), a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> antibody from MorphoSys and GSK, and mavrilimumab, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> receptor antibody from Medimmune, have shown an early onset of clinical responses in Phase 2 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">proof-of-concept</div></div> trials with RA patients. In addition to RA, attempts to develop a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> antibody for treating other autoimmune diseases, such as ankylosing spondylitis, are being studied by Amgen and Takeda. These autoimmune conditions involve the same autoimmune cell types, including macrophages, and neutrophils and the same connective tissues such as bones, joints, and tendons. Given the large patient population affected and the burden of these diseases, we are keen to explore the therapeutic role of plonmarlimab in treating these diseases, if initial studies in RA patients meet primary endpoints. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The therapeutic role of plonmarlimab goes beyond autoimmune diseases. A recent study indicates that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> plays a critical role in serious side effects associated with chimeric antigen receptor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(CAR)-T</div> therapy, such as cytokine release syndrome (&#8220;CRS&#8221;) and neurotoxicity. As <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapy has become an effective treatment option for certain cancer types, finding a treatment solution for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T-related</div></div> toxicities that occur frequently and can turn into a serious and potentially fatal condition becomes an urgent need. These severe toxicities add to the morbidity and mortality of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapy. CRS is caused by a massive release of circulating cytokines by expanding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> cells, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> is one of the key driver cytokines of CRS. Currently, there are no effective therapies to prevent CRS or associated neurotoxicity. Tocilizumab, an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> receptor antagonist, is approved for severe CRS with limited therapeutic coverage. Recent studies indicate that neutralizing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> in vivo may ameliorate and potentially prevent CRS and neuroinflammation without affecting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> cell activity. Humanigen has teamed up with Kite to evaluate lenzilumab, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> antibody, as a preventive or treatment agent in association with Yescarta, an approved CD19-directed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapy. In parallel with an RA clinical trial, we are seeking opportunities to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-develop</div> plonmarlimab as a treatment option for CRS associated with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapy. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Furthermore, emerging data indicate that the common features among <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> patients, particularly those who are severely or critically ill, include lymphopenia and significantly elevated serum levels of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-inflammatory</div> cytokines including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IFN-</div><div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">g</div>. Moreover, recently published data indicate that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> can induce a cytokine storm instigated by extensive immune cell infiltration and the release of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6.</div> These inflammatory cytokines drive aberrant activation of monocytes and lymphocytes which in turn provoke increased production of more cytokines and chemokines in a feed forward cycle, resulting in the cytokine storm, or CRS, severe pulmonary complications and mortality. As <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> blocking antibody therapies failed in multiple trials in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> the current hope that targeting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> may impact the upstream of cytokine storm network to prevent or curb the hyperinflammation and immunopathology potentially associated with the complications of severe <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> <br/></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Recently,&#160;Humanigen&#160;announced positive topline results from its Phase 3 clinical trial evaluating the efficacy and safety of lenzilumab in patients hospitalized with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The study achieved its primary endpoint of ventilator-free survival measured through day 28 following treatment (HR: 1.54; 95%CI: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.03-2.33,</div> p=0.0365). The Kaplan-Meier estimate for invasive mechanical ventilation (&#8220;IMV&#8221;) and/or death was 15.6% (95%CI: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">11.5-21.0)</div> in the lenzilumab arm versus 22.1% (95%CI: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">17.4-27.9)</div> in the placebo arm, representing a 54% improvement in the relative likelihood of survival without the need for IMV. Although this study was not powered to demonstrate a statistically significant difference in mortality, a favorable trend in mortality was observed: 9.6% (95%CI: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6.4-14.2)</div> in the lenzilumab arm compared with 13.9% (95%CI: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10.1-19.0)</div> in the placebo arm (HR: 1.39; 95%CI: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.82-2.39;</div> p=0.2287). For our ongoing clinical trial with plonmarlimab in severe <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> we have planned an interim analysis for safety and futility only in Q2 2021. </div> </div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advantages of Plonmarlimab </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Based on reported clinical findings with front-runner <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> antibodies compared to other RA biologics that are clinically used, we have the following expectations: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Fast onset of therapeutic effect. Because <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> acts at a relatively early stage in the inflammatory cascade, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> blockade is expected to take effect after just a few initial doses and provide quick symptomatic relief to patients. This fast onset of clinical responses in RA has been shown in Phase 2 clinical trials on otilimab and mavrilimumab (NCT01023256 and NCT01050998); </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> </div> </div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">104 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convenience and increased patient compliance. Given the favorable development profile (high affinity, excellent PK, clean immunogenicity and concentrated formulation) exhibited by plonmarlimab thus far, the clinically active dose for plonmarlimab is expected to be low, which is advantageous for chronic maintenance of the disease by subcutaneous administration. This provides convenience to the patients and will likely increase patient compliance; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Analgesic effect on inflammatory pain. Because the GM-CSF receptor is also expressed on sensory neurons and is involved in RA-associated inflammatory pain, GM-CSF blockade is expected to provide relief for inflammatory pain, which provides additional clinical benefits to patients. This analgesic effect has been shown in a Phase 2 clinical trial on mavrilimumab (NCT01706926).&#160;</div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mechanism of Action </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> is a central driver cytokine in orchestrating an innate immune response during inflammation. It is responsible for myeloid cell proliferation and functions, such as chemotaxis, adhesion, phagocytosis, and microbial killing. Importantly, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> can polarize macrophages into a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-inflammatory</div> M1 phenotype and is known to induce an inflammatory cascade involving other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-inflammatory</div> cytokines such as TNF, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-12,</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-23.</div> It is evident that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> plays a crucial role in the pathogenesis and disease progression of multiple autoimmune conditions. The action of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> is mediated by binding of its cognate receptor on target cells and subsequent phosphorylation of signal transducer and activator of transcription 5 (&#8220;STAT5&#8221;). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Plonmarlimab specifically binds to human <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> with high affinity and can block <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> from binding to its receptor, thereby preventing downstream signaling and target cell activation. As a result, it can effectively inhibit inflammatory responses mediated by macrophages, neutrophils, and dendritic cells, leading to reduced tissue inflammation and damage. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; text-indent: 3%; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055928818.jpg" style="width: 467px; height: 322px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Role of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> in orchestrating coordinated immune response. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">105 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> Results </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A series of nonclinical studies have been conducted to evaluate the pharmacology, PK, and toxicology profiles of plonmarlimab. Plonmarlimab could potently bind to human and monkey <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> but not rodent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF.</div> Plonmarlimab neutralized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> in a number of pharmacological studies in vitro and in vivo. Plonmarlimab demonstrated linear PK behavior in single dose IV and SC studies in monkeys with a half-life characteristic of IgG and a low ADA potential. Weekly plonmarlimab treatment significantly reduced arthritis score and clinical symptoms in monkeys with established collagen-induced arthritis (a model of RA). Both <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-week</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13-week</div> repeat-dose GLP general toxicology studies in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-human</div> primates have been completed with sufficient safety margin. The nonclinical studies performed to date continue to support plonmarlimab in clinical studies. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of Clinical Results </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Completed single-dose <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-human</div></div> study in healthy volunteers in the U.S. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Based on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> results, we initiated a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-human</div></div> study in healthy volunteers in the United States (NCT03794180). This study has now been completed with a clinical study report (CSR) available. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Study design</div></div>. This randomized, double-blind, placebo-controlled, and single dose-ascending study was designed to assess the safety, tolerability, PK/PD, and immunogenicity of plonmarlimab (referred to as TJ003234) in healthy volunteers. We have enrolled and completed dosing of four planned cohorts at 0.3, 1, 3 and 10 mg/kg dose levels, with each cohort consisting of eight subjects randomized into six receiving plonmarlimab and two receiving placebo IV infusions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Safety</div></div>. Plonmarlimab was well tolerated following a single IV dose up to 10 mg/kg in healthy subjects with no MTD reached. There were no interruptions in dosing or early withdrawals. Fourteen males and 18 females participated in the study. The majority of AEs were mild to moderate in nature. No serious adverse events were reported during the study. Overall, 8 of the 24 subjects who received plonmarlimab and 3 of the 8 subjects on placebo reported treatment-related treatment-emergent adverse events (TEAEs). The most common AEs experienced by subjects dosed with plonmarlimab were headache (25%) and protein urine (25%). These AEs were also the most common AEs reported by subjects receiving placebo (37.5% and 37.5%, respectively). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmacokinetics</div></div>. Serum concentrations of plonmarlimab (TJ003234) were determined by anti-idiotypic antibody capture immunoassay and PK parameters were analyzed by noncompartmental analysis. Results showed that over the dose range of 0.3 mg/kg to 10 mg/kg, both C<div style="font-size: 85%; vertical-align: bottom;;vertical-align: sub;display:inline;;font-size:9.4px">max</div> and exposure increased in an approximately dose-proportional manner, with C<div style="font-size: 85%; vertical-align: bottom;;vertical-align: sub;display:inline;;font-size:9.4px">max</div> increased from 5.75 <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">m</div>g/mL to 260 <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">m</div>g/mL and AUC0-last increased from 90.5 day*<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">m</div>g/mL to 3780 day*<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">m</div>g/mL (see Figure below). In addition, t<div style="font-size: 85%; vertical-align: bottom;;vertical-align: sub;display:inline;;font-size:9.4px">1/2</div> was approximately 3 weeks across the tested dose range. Clearance of plonmarlimab decreased with increasing dose. Volume of distribution decreased slightly with increasing dose. In terms of immunogenicity, two subjects in the 3 mg/kg plonmarlimab cohort and 1 placebo subject were positive for ADA. No subject in the 10 mg/kg dose level was positive for ADA. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; text-indent: 3%; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055929083.jpg" style="width: 488px; height: 233px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mean&#177;SD concentration-time plots of serum plonmarlimab (TJ003234) levels. Linear scale, left; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">semi-log</div> scale, right. LLOQ, lower limit of quantitation. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">106 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmacodynamics</div></div>. Four hours after dosing, the induction of STAT5 phosphorylation by ex vivo <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> in circulating monocytes was inhibited by at least 70% compared to the placebo following a single dose of plonmarlimab for all dose groups. Plonmarlimab inhibited <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF-stimulated</div></div> STAT5 phosphorylation levels by more than 90% in subjects in the 3 mg/kg and 10 mg/kg cohorts at 4 h to up to 2 weeks after dosing, suggesting the saturation of STAT5 inhibition by the treatment at doses of 3 mg/kg and above. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ongoing study of plonmarlimab to treat <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> patients with cytokine release syndrome </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are conducting a Phase 2/3 study of plonmarlimab in the U.S. in patients with CRS associated with severe <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> (NCT04341116). This study adopts a robust clinical trial design and represents one of the first double-blind, placebo-controlled and randomized studies to evaluate the therapeutic role of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-GM-CSF</div></div> antibody in severe <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> patients that could potentially lead to the registration of plonmarlimab in the U.S. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Part 1 of the study evaluated the safety and tolerability of plonmarlimab in a total of 24 patients who were randomized at a ratio of 1:1:1 to receive either a single dose of 3 mg/kg plonmarlimab, a single dose of 6 mg/kg plonmarlimab or placebo (standard care), administered by intravenous (IV)&#160;infusion. Data from part 1 of the study were reviewed by a data monitoring committee (DMC) to assess patient safety and tolerability. After comprehensive review and analysis, the DMC concluded that we could commence part 2 of the study as planned, indicating that plonmarlimab was safe and well-tolerated in severe <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> patients in the study. The DMC also endorsed the recommended protocol changes, including broadening the inclusion criteria and dosing all patients at 6 mg/kg of plonmarlimab or placebo. Part 2 of the study with a design similar to part 1 targets the same patient population (N=360) and is enrolling patients. It will evaluate the efficacy, safety and cytokine levels following a single dose of 6 mg/kg plonmarlimab or placebo in patients with severe <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> To preserve the original clinical trial design with blinding and data integrity, the clinical efficacy data will be revealed upon the planned interim analysis. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">DMC&#8217;s assessment and positive recommendation is a testament to our science-focused clinical development capabilities. The DMC&#8217;s confirmation of plonmarlimab&#8217;s safety profile bolstered the drug&#8217;s potential to address the complications among the severe and critically ill <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> patients and could ultimately save lives. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Development Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Data from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-human</div></div> study support continued development of plonmarlimab. In August 2020, we announced that the first patient had been dosed in a Phase 1b study to evaluate plonmarlimab in patients with RA in China. This trial is a multi-center, double-blind, placebo-controlled study of about 63 patients who will receive a single dose or multiple doses of the treatment for up to eight weeks. The single dose escalation part will be completed by the second half of 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, we are currently developing plonmarlimab for the treatment of cytokine storm in severe and critically ill <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> patients. The part 2 of our clinical study is on track in the U.S. to evaluate the efficacy, safety and cytokine levels following a single dose of 6 mg/kg plonmarlimab or placebo (best supportive care) in patients with severe <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> An interim analysis is planned when at least 100 subjects have finished Day 14 visits for safety and futility only, which is expected in Q2 2021. The results from this <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> study will also be used to further evaluate the potential therapeutic role of plonmarlimab in reducing or preventing cytokine storm and neurotoxicity associated with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapy through collaborations. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Olamkicept (TJ301): A Potential Highly Differentiated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> Blocker for Ulcerative Colitis and other Autoimmune Diseases </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Olamkicept is the only clinical stage selective <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">interleukin-6</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;IL-6&#8221;)</div> inhibitor that works through the trans-signaling mechanism. In November 2016, we acquired an exclusive license from Ferring International Center SA (&#8220;Ferring&#8221;) to develop and commercialize olamkicept in Greater China and South Korea with an option of licensing worldwide rights. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> is an important driver cytokine in the propagation and maintenance of chronic inflammation in autoimmune diseases. Compared to the approved antibody drugs that directly block <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> receptor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;IL-6R&#8221;),</div> olamkicept is expected to provide a novel alternative for the treatment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> mediated inflammation without affecting some of the normal physiological functions of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6,</div> e.g., acute immune response against infection and metabolic regulation. Olamkicept demonstrated therapeutic effects in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> animal models of autoimmune diseases, including inflammatory colitis. Moreover, the safety and tolerability profile of olamkicept was studied in three clinical trials in Germany involving 128 subjects. We believe that olamkicept has the potential to become a highly differentiated therapy to target autoimmune diseases. </div> </div> </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">107 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of our fast-to-market strategy for olamkicept, we selected ulcerative colitis (&#8220;UC&#8221;) as the first indication for the following reasons: (1) olamkicept was shown to be effective in animal models of colitis; (2) an exploratory Phase 2a biomarker trial showed promising interim treatment effects of olamkicept in UC patients; and (3) even though UC incidence is increasing rapidly, innovative biologic treatments for this disease are lacking in China. We have now completed a Phase 2 proof-of-concept study in 91 patients with active UC and announced positive topline results of the study in April 2021. The detailed data presentation has been submitted to professional meetings held at Digestive Disease Week (DDW) 2021 in the U.S. in May and at European Crohn&#8217;s and Colitis Organization (ECCO) meeting in July 2021. In April 2021, we and Ferring signed a memorandum of understanding (MoU) to explore a possible collaboration to advance the development and commercialization of olamkicept in the U.S. and Canada, the European Union and Japan, if so agreed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Therapeutic Indications</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our current therapeutic indication for development is UC. UC and Crohn&#8217;s disease (&#8220;CD&#8221;) are the main types of inflammatory bowel disease (&#8220;IBD&#8221;), which cause chronic and often relapsing inflammation of the large and small intestines, respectively. Anti-inflammatory drugs, such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-aminosalicylic</div> acids <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;5-ASAs&#8221;)</div> and corticosteroids, are often used as initial treatment for UC. Immune system suppressors are also used to control inflammation in patients with UC, including azathioprine, mercaptopurine, and cyclosporine. Biologics that inhibit tumor necrosis factor alpha <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TNF-&#945;),</div> including infliximab (Remicade), adalimumab (Humira), and golimumab (Simponi), are efficacious in some UC patients who fail to respond to conventional therapies. Entyvio, an integrin a4&#223;7 antibody that blocks lymphocytes from accumulating in the intestinal wall, was the first <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-anti-TNF-&#945;</div></div></div> biologics approved for UC STELARA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (ustekinumab), an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-IL-12/IL-23</div></div></div> antibody was approved for the treatment of adult patients with moderately to severely active ulcerative colitis in June 2020. In China, Remicade and Entyvio are currently the only two biologics approved for treatment of UC. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There is a substantial unmet medical need in UC for a treatment agent(s) that is efficacious and safe through pathways beyond the traditional drug targets. The incidence of UC is increasing rapidly, but UC patients, especially those with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">moderate-to-severe</div></div> disease, have few treatment options, which have limited efficacy and considerable side-effects. For example, Jak1/3 kinase inhibitors can carry the risk of serious infections and malignancies. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TNF-&#945;</div> inhibitors also have inherent side effects and do not work in all patients. Thus, as the only clinical stage selective <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">interleukin-6</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;IL-6&#8221;)</div> inhibitor that works through the trans-signaling mechanism, we believe olamkicept has the potential to become a differentiated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> blocker for UC, if approved. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advantages of Olamkicept</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The existing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6R</div> blockers cause total inhibition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> signaling and are associated with significant adverse events in the clinic, such as infection, gastrointestinal perforation, metabolic disturbances, and insulin resistance. Olamkicept is expected to provide a novel alternative as it works through a different mechanism, the trans-signaling pathway. This key advantage has been demonstrated in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and three clinical trials conducted in Germany. The results indicated that olamkicept has no side effects on lipid, glucose or bone metabolism, and it has no agonistic activities that could activate receptors or trigger detrimental immune cascades. We expect that selective inhibition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> trans-signaling is an effective and safer approach to the treatment of chronic inflammation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mechanism of Action</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Olamkicept is a homodimer of a fusion protein consisting of the extracellular domains of human glycoprotein130 (&#8220;gp130&#8221;) and the fragment crystallizable (Fc) domain of human IgG1. Mimicking the function of endogenous soluble gp130, olamkicept works as a decoy by binding to a complex consisting of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> and soluble <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> receptor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;sIL-6R&#8221;),</div> thereby preventing olamkicept from stimulating the trans-signaling pathway in cells that do not express <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6R.</div> The gp130 part selectively binds the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6/sIL-6R</div></div> complex with high affinity (Kd=130 pM), whereas the Fc part initiates dimerization and offers longer half-life for the molecule. Olamkicept is not expected to affect the beneficial effects of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6,</div> such as the acute immune response against infection mediated by the classical pathway. </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">108 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; text-indent: 3%; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055929349.jpg" style="width: 335px; height: 259px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Classical signaling and trans-signaling pathways <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ofIL-6.</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Anti-IL-6R</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-IL-6</div></div> block both pathways, whereas olamkicept blocks only trans-signaling. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6R:</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> receptor; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sIL-6R:</div> Soluble <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> receptor.</div></div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of Clinical Results</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Ferring has completed two Phase 1 trials to evaluate olamkicept&#8217;s preliminary safety and clinical pharmacology. Olamkicept was shown to be well-tolerated based on the clinical results collected from a total of 112 subjects exposed to the drug. In addition, a Phase 2a biomarker study in active IBD (known as the FUTURE study) has been completed in Germany with promising pharmacodynamic and clinical responses observed. We have now completed a Phase 2 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">proof-of-concept</div></div> study in 91 patients with active UC in Greater China and South Korea. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase 1 Clinical Trial: Single Dose Ascending Trial</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Study Design</div></div>. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-human</div></div> trial of olamkicept was a single dose, placebo-controlled, single-blind, randomized within dose, and parallel group dose-escalating trial. The trial recruited both healthy subjects and patients with Crohn&#8217;s Disease (&#8220;CD&#8221;) in clinical remission. The primary objective was to examine the safety, tolerability and pharmacokinetics after a single dose of olamkicept. Several dose levels were tested, ranging from 0.75 mg to 750 mg, with each dose level including six subjects receiving olamkicept and two receiving placebo. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmacokinetics</div></div>. In healthy subjects and CD patients, olamkicept showed similar terminal half-life of 4.3 to 5.1 days. The maximum concentration (C<div style="font-size: 85%; vertical-align: bottom;;vertical-align: sub;display:inline;;font-size:9.4px">max</div>) in plasma and the area under curve (&#8220;AUC&#8221;) of the plasma drug concentration-time curve were dose proportional. For SC administration of olamkicept (60 mg), the C<div style="font-size: 85%; vertical-align: bottom;;vertical-align: sub;display:inline;;font-size:9.4px">max</div> was approximately 1.0 &#181;g/mL at 2.3 days, and the bioavailability was approximately 48%. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; text-indent: 3%; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055929630.jpg" style="width: 435px; height: 203px;"/></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">109 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Single dose pharmacokinetic profile of olamkicept. Left, healthy subjects (colored lines) and IBD patients in remission (gray lines) received a single IV infusion at 75 mg (blue lines), 300 mg (magenta lines) or 600 mg (red lines) fixed doses. Right, healthy subjects received a single SC injection at 60 mg. LLOQ: lower limit of quantitation. (Source: Ferring Pharmaceuticals)</div></div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Safety</div></div>. Olamkicept was well-tolerated when administered as a single IV dose at up to 750 mg and as a single SC dose at 60 mg. No apparent dose-related AE was observed. Infusion was discontinued in two subjects due to mild to moderate infusion-related reactions, with skin symptoms such as urticaria and swelling, which were rapidly resolved. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Only one healthy subject in the 300 mg group showed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-neutralizing</div> treatment-emergent ADAs at the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> visit five to six weeks after administration. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase 1 Clinical Trial: Multiple Dose Ascending Trial</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Study Design</div></div>. This trial was a placebo-controlled, double-blind, and randomized dose-escalating trial in healthy subjects. A total of 24 healthy subjects were randomized into three dose groups and received four weekly infusions of olamkicept at 75 mg, 300 mg or 600 mg. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmacokinetics</div></div>. PK characteristics were similar on the first and last treatment days of the multiple dose-ascending trial and were similar to results in the single dose-ascending study. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; text-indent: 3%; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055929880.jpg" style="width: 282px; height: 263px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Multiple dose pharmacokinetic profile of olamkicept. Healthy subjects received weekly IV infusions at 75 mg (blue lines), 300 mg (magenta lines) or 600 mg (gray lines) fixed doses. LLOQ, lower limit of quantitation. (Source: Ferring Pharmaceuticals)</div></div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Safety</div></div>. There were only a few mild or moderate AEs reported across all treatment groups. One subject from the 600 mg group withdrew due to mild infusion-related reactions with urticaria and pruritus 30 minutes after administrating the first dose. No apparent dose-related trends or treatment-related change in vital signs, electrocardiogram or clinical chemistry parameters were observed. No ADAs were reported by any subject. Overall, olamkicept was well-tolerated when administered by IV at up to 600 mg once weekly for four weeks. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overall Summary of Treatment-Emergent Adverse Events </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">75&#160;mg</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(N&#160;=&#160;6)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">300&#160;mg<br/>(N&#160;=&#160;6)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">600&#160;mg<br/>(N&#160;=&#160;6)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Placebo<br/>(N&#160;=&#160;6)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;Active<br/>(N&#160;=&#160;18)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">n&#160;(%)&#160;E</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">n&#160;(%)&#160;E</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">n&#160;(%)&#160;E</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">n&#160;(%)&#160;E</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">n&#160;(%)&#160;E</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any TEAE <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6&#160;(100)&#160;13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2&#160;(33)&#160;5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4&#160;(67)&#160;6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6&#160;(100)&#160;14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12&#160;(67)&#160;24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Serious TEAEs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adverse Drug Reactions <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6 (100) 11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2 (33) 2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3 (50) 5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4 (67) 6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11 (61) 18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEAEs Leading to Withdrawal</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1 (17) 1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1 (6) 1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deaths</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Source: Ferring Pharmaceuticals</div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reasonably possibly related to treatment; N: number of subjects exposed; n: number of subjects with AE; %: n/N*100; E: number of AEs </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">110 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase 2a Biomarker Study in Active IBD (FUTURE Study) </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Study Design</div></div>. This was an open-label exploratory study to assess the mechanisms of molecular activity (effects on biomarkers), safety and tolerability of olamkicept in adult patients with active IBD. Nine UC patients and seven CD patients were dosed with olamkicept (600 mg, IV, q2w) for up to 12 weeks followed by 42 days of safety <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up.</div> Patients enrolled had moderately to severe active UC or ileocolonic CD with median disease duration of 5.3 (UC) and 6.9 (CD) years and with immunologically active inflammation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(C-reactive</div> protein &gt;5 mg/l), who had failed conventional therapies and had no prior biologics treatment. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The primary endpoint was the proportion of patients with reduced mucosal expression of a predefined set of inflammation-relevant genes (TNFA, IL1A, REG1A, IL8, IL1B and LILRA) as a composite score. Objective assessments included centrally read endoscopies, histology readings, and various explorative molecular parameters and inflammatory biomarkers. The trial was sponsored and conducted by the University Hospital Schleswig Holstein and Paul-Ehrlich Institute <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(EUDRA-CT</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-000205-36),</div> with financial and material support from Ferring Pharmaceuticals. The study has been completed, and the abstract of the results was presented at the United European Gastroenterology Week meeting in October 2019. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Safety</div></div>. Olamkicept was well-tolerated. Reported AEs were unspecific in nature and showed no signs of immune suppression. Five SAEs were observed, none of which were life-threatening or deemed to be related to olamkicept. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmacokinetics</div></div>. After single and repeated IV administration of olamkicept (600 mg, Q2W) to patients with UC and CD, similar serum exposure was observed after the first and last dosing events, with respect to C<div style="font-size: 85%; vertical-align: bottom;;vertical-align: sub;display:inline;;font-size:9.4px">max</div> and total exposure over 14 days. Maximal serum drug concentration after each dosing was reached at the end of infusion. The mean terminal half-life of olamkicept after the last administration was approximately 5.1 days. Circulating biological activity of olamkicept was confirmed by whole-blood STAT3 phosphorylation assays in all patients. A minimal and transient ADA production was observed in three patients. ADAs were only detected at week 12 and week 15, but no longer detectable at week 18. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; text-indent: 3%; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055930161.jpg" style="width: 221px; height: 196px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure: Time course of the mean serum concentration of olamkicept. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmacodynamics</div></div>. In the assessment of the primary endpoint, it was observed that clinical remission was associated with a significant reduction of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-1B,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-8</div> and REG1A gene expression in the intestinal mucosa. Pathway analysis of blood transcriptome signatures showed an early molecular anti-inflammatory signature as early as four hours after treatment in all patients, irrespective of treatment outcome, which indicated a thorough inhibitory effect of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> trans-signaling blockade on inflammatory pathways. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">111 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Efficacy</div></div>. A preliminary clinical response was observed in both UC and CD patients, which appeared to be stronger in patients with UC than those with CD. Overall, 55% of UC patients (5/9) responded to olamkicept, with 22% (2/9) reaching clinical remission, whereas 29% of CD patients (2/7) responded to olamkicept, with 14% (1/7) reaching clinical remission. All three patients in clinical remission showed a fast and thorough induction of clinical, endoscopic, and immunologic remission within the first four weeks. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase 2 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Proof-of-Concept</div></div> Study in Active UC (Multi-regional Clinical Trial) </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Study Design.</div></div> We are positioning olamkicept as a differentiated IL-6 blocker for the treatment of active UC that is not well-controlled by conventional therapies such as mesalazine. We have successfully completed a randomized, double-blind, placebo-controlled, dose-finding, proof-of-concept Phase 2 clinical trial for olamkicept in 91 patients with active UC in Greater China and South Korea (NCT03235752). This was a regional multi-center, randomized, double-blind and placebo-controlled study to evaluate the efficacy and safety of intravenous olamkicept (also known as TJ301) in adult patients with active UC. Overall, 91 patients were randomly assigned to receive biweekly treatment of placebo, 300 mg olamkicept or 600 mg olamkicept for 12 weeks in a 1:1:1 ratio. The primary endpoint was the proportion of patients achieving clinical response and the secondary endpoints included clinical remission and mucosal healing. Patients who were enrolled in the study had moderate to severe active UC (average full Mayo score 8.6) with a median disease duration of 4.6 years and with &gt;95% having been on 5-ASA and &gt;94% having had no prior biologics treatment. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Efficacy and Safety</div></div>. This Phase 2 study is one of the first placebo-controlled, proof-of-concept studies of IL-6 inhibitors in UC and has met both its primary and key secondary endpoints, demonstrating significantly higher clinical response rates after 12 weeks of treatment in patients receiving 600 mg olamkicept compared to those on placebo (p=0.032). Significantly more patients in the 600 mg olamkicept group achieved clinical remission and mucosal healing than in placebo (p&lt;0.001), which are two key secondary endpoints of the study. Olamkicept was well tolerated and showed an excellent safety profile that is considered to be the clinical differentiation of olamkicept because of its underlying mechanism of action. Detailed data analysis has been submitted to professional meetings held at Digestive Disease Week (DDW) 2021 in the U.S. in May and at European Crohn&#8217;s and Colitis Organization (ECCO) meeting in July 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Enoblituzumab: A Potential Highly Differentiated Humanized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3</div> Antibody for Immuno-oncology Treatment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Enoblituzumab is an investigational, humanized, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Fc-optimized</div> monoclonal antibody directed at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3,</div> a member of the B7 family of immune regulators. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3</div> is a promising immuno-oncology target as it is widely expressed across multiple tumor types, minimally expressed on normal tissues and is believed to play a key role in regulating immune response against cancers. Increasing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical evidence suggests that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3</div> antibody and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> antibody may work in concert to elicit an optimal T cell activation for the treatment of a variety of cancers. The expression of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3</div> has been shown to be associated with adverse clinical features and negative outcomes in various solid tumors. Together, these observations suggest that enoblituzumab has a wide potential range of cancer applications as either a monotherapy or in combination with PD-1 therapies or small molecule drugs. </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">112 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">At the molecular level, enoblituzumab is engineered to possess an enhanced anti-tumor ADCC function. Originally developed by MacroGenics, enoblituzumab has been or is currently being evaluated in clinical trials as a monotherapy or in combination with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CTLA-4</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> therapies in patients with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3-expressing</div></div> cancers. Enoblituzumab has also been evaluated in a neoadjuvant Phase 2 study as a single agent in patients with intermediate and high-risk localized prostate cancer. The clinical studies so far have shown that enoblituzumab is well-tolerated, with enoblituzumab monotherapy treatment demonstrating increased CD8 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> infiltration in tumors with more focused <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> repertoires. Clinical studies conducted by MacroGenics indicate that combination therapy with enoblituzumab and pembrolizumab resulted in anti-tumor activity on recurrent or metastatic squamous cell carcinoma of the head and neck (&#8220;SCCHN&#8221;) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-small</div> cell lung cancer (&#8220;NSCLC&#8221;). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We acquired Greater China rights of enoblituzumab from MacroGenics. In the first quarter of 2021, MacroGenics initiated a Phase 2 study of enoblituzumab in a chemotherapy-free regimen in combination with either retifanlimab (an investigational <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> antibody) in front-line patients with SCCHN who are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> positive or with tebotelimab (an investigational <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> x <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">LAG-3</div> bispecific DART<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> molecule) in SCCHN patients who are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> negative. We expect to participate in a subsequent Phase 3 global study if and when initiated. In addition, we will initiate a combination clinical trial of enoblituzumab with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> therapy in selected cancer patients in the second half of 2021 and continue to generate additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> data to position enoblituzumab in other combination therapies. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Therapeutic Indications </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Squamous cell carcinoma of the head and neck (&#8220;SCCHN&#8221;) is among the initial cancer indications which we will be focusing on. Head and neck cancers occur in various parts of the head and neck, including the mouth, nose, throat and salivary glands. More than 90% of head and neck cancers are classified as SCCHN, which begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck. The treatment principles and regimens for head and neck cancer in China are similar to those in the rest of the world. Treatment strategies often depend on the location and stage of the cancer, the patient&#8217;s physical status, and response to prior treatments. Early-stage disease is primarily treated with surgical resection, while patients with locally advanced, recurrent or metastatic disease are typically treated with drug therapy. The combination of surgery and drug therapy, with or without radiation therapy, is the current standard of care for Stage 3 SCCHN patients with locally advanced disease. Platinum-based chemotherapy regimens are widely used as first-line therapies for Stage 4 and distant relapse patients. Erbitux (cetuximab from Eli Lilly and Merck KGaA) was approved in 2006 as a first-line treatment of locally advanced SCCHN in combination with radiation therapy. Regimens containing Erbitux, platinum-based chemotherapy, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-fluorouracil,</div> known as EXTREME, are often considered as the standard of care for first-line treatment of distant relapse SCCHN. However, only about 35% of patients respond to EXTREME, and the resulting overall median survival is only 10.1 months. Furthermore, about half of the patients on first-line therapies need later-line therapies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, even second-line therapy is highly varied, including single-agent docetaxel or paclitaxel, Erbitux monotherapy, and Erbitux and paclitaxel combination therapy. In 2016, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> antibodies were approved globally as second-line therapies. In 2019, Keytruda<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (pembrolizumab from Merck&#160;&amp; Co), used as a single agent or in combination with chemotherapy, was approved by the FDA as a first-line therapy for patients with metastatic or unresectable recurrent SCCHN. The average ORR for second-line therapies has been less than 15%. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the first quarter of 2021, MacroGenics initiated an open-label, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-randomized</div> Phase 2 study of enoblituzumab (NCT04634825) in a chemotherapy-free regimen in combination with either retifanlimab (an investigational <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> antibody) in front-line patients with squamous&#160;cell&#160;carcinoma&#160;of&#160;the&#160;head&#160;and neck&#160;(SCCHN) who are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> positive or with tebotelimab (an investigational <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> x <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">LAG-3</div> bispecific DART<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> molecule) in SCCHN patients who are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> negative. The patients will receive enoblituzumab and retifanlimab or tebotelimab every 3 weeks for up to 35 cycles, and 80 patients in total will be enrolled. Based on the safety and efficacy data from the trial, we and MacroGenics will determine subsequent development options including a potential Phase 3 trial. We expect to participate in this subsequent Phase 3 global study if and when initiated. In addition, we plan to initiate an independent Phase 2 clinical trial of enoblituzumab in selected cancer types by a basket trial design, which is described later in this section. </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">113 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advantages of Enoblituzumab </div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Enoblituzumab is a potential highly differentiated humanized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3</div> antibody for immuno-oncology treatment. The foregoing statement applies only to conventional therapeutic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3</div> antibodies and does not include radio-labeled <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3</div> antibodies in development by Y-mabs Therapeutics. Targeting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3</div> offers several advantages over other target options within the class of T cell checkpoint molecules. First, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3</div> is a tumor-associated antigen that is over-expressed in a variety of solid tumors while its expression in normal tissues is rather limited, enabling the tumor killing mechanism of enoblituzumab. Second, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3</div> is a unique checkpoint whose expression in tumors is associated with disease prognosis. For example, biomarker analysis of more than 400 NSCLC patients revealed that among all the elevated immune checkpoint inhibitors, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1,</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L2,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TIM-3,</div> BTLA and CTLA4, only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3</div> is negatively correlated with clinical efficacies of neoadjuvant treatments (Lou et al., Clinical Cancer Research, 2016). Furthermore, recent studies have shown that when combined with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> therapy, a blockade of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3</div> results in superior treatment effects in relevant cancer animal models while another study indicates that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3</div> expression correlates with a lack of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD-1</div></div> response (Yonesaka et al., Clinical Cancer Research, 2018). The advantages summarized above make <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3</div> a favorable tumor target for immuno-therapeutic intervention. </div> </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mechanism of Action </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Enoblituzumab (MGA271) is an investigational humanized immunoglobulin (IgG1/kappa monoclonal antibody) that binds to B7 homolog 3 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(B7-H3).</div> This antibody consists of an engineered human IgG1 fragment crystallizable (Fc) domain that imparts increased affinity for the human activating Fc gamma receptor FcgRIIIA (CD16A) and decreased affinity for the human inhibitory FcgRIIB (CD32B). The engineered Fc domain confers enoblituzumab with enhanced target-specific antibody-dependent cellular cytotoxicity (&#8220;ADCC&#8221;) in vitro and anti-tumor activity in preclinical studies. Therefore, enhanced cytolysis of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3-expressing</div></div> tumor cells is a mechanism that supports the development of this molecule as an antineoplastic agent. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, data suggest that enoblituzumab impacts <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> homeostasis in vivo. Cancer patients display a more narrowly focused <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> repertoire following enoblituzumab treatment compared to their baseline repertoire distribution. Moreover, enhanced local <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> infiltration has been observed in prostate cancer patients treated with enoblituzumab. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These data are consistent with the notion that enoblituzumab is capable of engaging both innate and adaptive immunity as mediators of its anti-tumor activity. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055930457.jpg" style="width: 479px; height: 241px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Enoblituzumab contributes to the coordination and engagement of innate and adaptive immunity to mediate tumor regression. Enoblituzumab binds to tumor cells, activates innate immune cells such as natural killer cells (NK cells) to kill cancer cells through ADCC. The released tumor antigens may then be presented by antigen-presenting cells, such as macrophages, which, in concert with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> blockade, can promote tumor-specific <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> immunity. (Source: MacroGenics)</div></div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">114 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of Clinical Results </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase 1 Study of Enoblituzumab Monotherapy </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Study Design</div></div>. This was an open-label, multi-dose, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-arm,</div> multi-center, and dose-escalation study to define safety, tolerability, maximum tolerated dose (&#8220;MTD&#8221;), PK, immunogenicity, and potential anti-tumor activity of enoblituzumab in patients with refractory cancers that express <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3</div> conducted by MacroGenics. In the dose escalation segment of the study, six doses (0.15&#8211;15 mg/kg QW) were evaluated in a conventional &#8220;3+3&#8221; design. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No MTD or dose-limiting toxicity (&#8220;DLT&#8221;) was observed in the dose escalation phase, so the highest administered dose, 15 mg/kg, was used in the cohort expansion, in which patients received weekly infusions of enoblituzumab in eight-week cycles for up to 12 cycles. Tumor evaluation was carried out by both Response Evaluation Criteria in Solid Tumors (&#8220;RECIST&#8221;) and immune-related response criteria (&#8220;irRC&#8221;) with an initial response assessment after eight weeks. This entailed seven tumor-specific cohorts, including melanoma (post-checkpoint inhibitor failure, n=31), head and neck cancer (n=19), prostate cancer (n=34), triple-negative breast cancer (n=17), renal cell carcinoma (n=16), NSCLC (n=8), and bladder cancer (n=12). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Safety.</div></div> Interim data analysis as of the data <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cut-off</div> date of April&#160;13, 2017, indicates that enoblituzumab is well-tolerated. Treatment-related AEs (per investigator assessment) were experienced by 134 out of 170 (78.8%) patients, most of which were infusion-related reactions (n=62, 36.5%), fatigue (n=54, 31.8%), nausea (n=32, 18.8%), and chills (n=24, 14.1%). Only three out of 179 patients (1.7%) had a treatment-related discontinuation, and 13 (7.3%) patients experienced treatment-related Grade 3 or higher AEs (fatigue, infusion-related reactions, and nausea), assessed based on Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0. Mild to moderate infusion-related reactions were managed with low dose steroids or a decrease of the infusion rate. No severe immune-mediated toxicity was observed. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmacokinetics</div></div>. Preliminary analysis and population PK modeling based on 18 patients dosed at 15 mg/kg indicate that PK of enoblituzumab was characterized primarily by target-mediated drug disposition and was consistent with a typical human IgG1 with near-linear PK. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Efficacy</div></div>. Evidence of decreased size of target and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-target</div> lesions as well as extended time to progression were observed across a broad range of tumors, including heavily pretreated cancers. Three patients achieved PR (partial responses) by RECIST out of a total of approximately 71 patients being evaluated. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase 1 Study of Enoblituzumab in Combination with Pembrolizumab </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Study Design</div></div>. This is an open-label, dose escalation, cohort expansion, and efficacy <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> study of enoblituzumab in combination with pembrolizumab conducted by MacroGenics. The dose escalation phase is designed to characterize the safety and tolerability of the combination and to define the maximum tolerated or maximum administered dose. Three dose levels of enoblituzumab (3, 10, 15 mg/kg, IV, QW) have been evaluated in combination with pembrolizumab (2 mg/kg, IV, Q3W). No MTD has been identified, and so the maximum administered dose of enoblituzumab (15 mg/kg) in combination with pembrolizumab was given to additional cohorts of patients enrolled during the cohort expansion phase. The efficacy <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> period consists of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> period after administering the final dose of the study drug. All tumor evaluations are carried out by both RECIST and irRC. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A total of 133 patients with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3-expressing</div></div> melanoma, squamous cell carcinoma of the head and neck (SCCHN), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-small</div> cell lung cancer (&#8220;NSCLC&#8221;), and urothelial cancer have been treated in the study. The interim results as of the data <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cut-off</div> date, October&#160;12, 2018, were presented at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which showed an ORR (overall response rate) that compared favorably with historical experience with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> monotherapy in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1</div></div> naive patients. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Safety</div></div>. The combination of enoblituzumab and pembrolizumab demonstrated acceptable tolerability in patients treated to date. Grade 3 or higher AEs, assessed based on Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0, occurred in 27.1% of all patients. Drug-related AEs of all grades included infusion-related reactions (n=73, 54.9%), fatigue (n=37, 27.8%), rash (n=14, 10.5%), and nausea (n=12, 9.0%). The incidence of immune-related AEs in the study was comparable to that observed in patients who received anti <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> monotherapy. Nine patients experienced drug-related AEs leading to treatment discontinuation. Drug-related AEs and immune-related AEs of special interest are summarized in the table below. </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">115 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Drug-Related and Immune-Related Adverse Events </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During Combination Treatment with Enoblituzumab and Pembrolizumab </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="width: 11%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1px;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1px;">&#160;&#160;</td>
<td colspan="5" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NO.&#160;(%)&#160;OF&#160;PATIENTS</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">DRUG-RELATED AES (</div></div><div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5% OF PATIENTS)</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1px;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ALL&#160;GRADES&#160;TOTAL</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(N=133)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1px;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1px;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;GRADE&#160;3<br/>(N=133)</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any adverse event</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">115&#160;(86.5)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">36 (27.1)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Infusion-related reaction</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">73 (54.9)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9 (6.8)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fatigue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">37 (27.8)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2 (1.5)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14 (10.5)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1 (0.8)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nausea</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12 (9.0)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pyrexia</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12 (9.0)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lipase increased</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11 (8.3)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8 (6.0)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Arthralgia</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10 (7.5)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decreased appetite</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9 (6.8)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2 (1.5)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diarrhea</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9 (6.8)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1 (0.8)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hypothyroidism</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8 (6.0)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anemia</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7 (5.3)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1 (0.8)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pneumonitis</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7 (5.3)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2 (1.5)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chills</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7 (5.3)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td style="width: 11%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1px;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1px;">&#160;&#160;</td>
<td colspan="5" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NO.&#160;(%)&#160;OF&#160;PATIENTS</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">IMMUNE-RELATED ADVERSE EVENTS OF SPECIAL INTEREST (AESI)</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1px;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ALL&#160;GRADES&#160;TOTAL</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(N=133)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1px;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1px;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;GRADE&#160;3<br/>(N=133)</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pneumonitis</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5&#160;(3.8)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2 (1.5)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Myocarditis</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2 (1.5)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1 (0.8)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diarrhea</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1 (0.8)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1 (0.8)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adrenal insufficiency</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1 (0.8)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1 (0.8)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Colitis</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1 (0.8)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Drug-related AEs:</div></div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leading to treatment discontinuation: 6.8% (9 patients) </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leading to death: 0.8% (1 patient with pneumonitis) </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nature of events consistent with enoblituzumab or pembrolizumab alone</div></div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Source: MacroGenics. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Efficacy</div></div>. As of October&#160;12, 2018, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cut-off</div> date of the most recent data analysis, preliminary results indicated that among the 18 response-evaluable SCCHN patients who had not previously received <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1</div></div> therapies, six patients (33.3%) had confirmed partial responses (&#8220;PRs&#8221;). Among the subset of patients with 10% or higher <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3</div> tumor expression, six out of 15 (40.0%) had confirmed PRs (see figure below) compared to previously reported SCCHN patients treated with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> monotherapy, which achieved ORRs ranging from 13% to 16%. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">116 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Anti-tumor Activity in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Anti-PD-1/PD-L1-Naive</div></div></div></div> SCCHN Patients </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tumor Volume Change from Baseline (%) </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055930753.jpg" style="width: 484px; height: 245px;"/></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Source: MacroGenics </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Among 14 response-evaluable NSCLC patients who had not previously received <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1</div></div> therapies and were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> negative, i.e., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> less or equal to 1%, five patients (35.7%) had confirmed PRs (see figure below). Objective response rates ranging from 8% to 17% were reported in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> negative NSCLC patients treated with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> monotherapy. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Anti-tumor Activity in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1-Naive</div></div> NSCLC Patients Who are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> Negative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(PD-L1</div> &lt; 1%) </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tumor Volume Change from Baseline (%) </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055931065.jpg" style="width: 513px; height: 234px;"/></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Source: MacroGenics </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the two figures above, CR (complete response) means the disappearance of all target lesions, with the reduction of all pathological lymph nodes to &lt;10 mm; PR (partial response) means at least a 30% decrease in the sum of the target lesions, in comparison to the baseline sum diameter; PD (progressive disease) means a 20% increase in the sum of the diameters in comparison to the smallest sum of diameters with an absolute increase of at least 5 mm, provided that any new lesion is considered progressive disease; and SD (stable disease) means meeting neither the criteria for partial response nor for progressive disease, in comparison to the smallest sum of diameters. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">117 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Development Plan and Expected Timeline </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">By leveraging the clinical data from MacroGenics, we will advance the clinical development of enoblituzumab for approval in Greater China. In addition to planning on an advanced clinical trial in patients with SCCHN, following a potential global registrational study by MacroGenics, we will submit a new IND in Q2 2021 to initiate a Phase 2 clinical trial of enoblituzumab in combination with PD-1 therapy in patients with selected cancer types in China. The study is designed as a basket clinical trial involving NSCLC, SCCHN and two other selected cancer types based on the previous studies conducted by MacroGenics and our own pre-clinical work. Furthermore, we plan to evaluate the therapeutic role of enoblituzumab in combination with small molecule therapies as a potential front-line treatment for selected cancers. Additional pre-clinical work is in progress. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">TJ210: A Potential Highly Differentiated Antibody Targeting Myeloid Derived Suppressor Cells in Cancers and Autoimmune Diseases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">TJ210 is a fully human, high affinity antibody against human C5aR1 for the treatment of cancers and potentially autoimmune diseases. In November 2018, we obtained an exclusive license from MorphoSys to develop and commercialize TJ210 in Greater China and South Korea. Certain tumors produce large amounts of complement factor C5a to attract C5aR1-expressing myeloid derived suppressor cells (&#8220;MDSCs&#8221;), M2 macrophages and neutrophils. These myeloid cells critically contribute to an immunosuppressive microenvironment as part of the evading mechanism of tumors and are associated with poor prognosis and resistance to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1</div></div> therapies in many cancers. TJ210 is designed to block the interaction between C5a and its receptor, thereby potentially neutralizing the immune suppressive function of C5a and enabling immune cells to attack the tumor. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> studies have shown that targeting the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C5aR-C5a</div> axis exerts anti-tumor activity with immune checkpoint inhibitors. Furthermore, in vitro activity was observed for blocking the C5a/C5aR pathway also at very high C5a concentrations, leading to a long duration of action. TJ210 demonstrated a good safety profile with no observed adverse effects up to the highest dose tested in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> safety studies. In September 2020, we received an IND approval from the FDA to initiate a Phase 1 clinical trial to evaluate the safety, tolerability, PK and PD of TJ210 in patients with solid tumors. In January 2021, we dosed the first patient in this trial. A separate IND application with the China NMPA was also approved in February 2021. In addition, TJ210 has therapeutic potential in multiple inflammatory and autoimmune indications, in which the role of the C5a/C5aR axis has been validated. We plan to work jointly with MorphoSys to further explore TJ210&#8217;s potentials in these indications. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Therapeutic Indications </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Traditionally regarded as the critical innate immune response, complement components, especially C5a/C5aR axis, has been demonstrated to be major contributors to immune suppression in the tumor micro-environment (&#8220;TME&#8221;) thereby disabling T cell function and promoting tumor progression. Correspondingly, blockade of C5a/C5aR signaling bears great potentials for cancer immunotherapy in combination with immune check pointers or T cell engagers. High expression of C5aR in TME is correlated with poor diagnostic outcomes in various tumors, including colorectal carcinoma, renal cancer, gastric cancer, and a number of squamous carcinomas. In addition, activation of complement cascade in those tumors either plays a critical role in cancer development or correlates with tumor grade and metastatic status. We will start with all tumor types in the Phase 1 trial, then select those bearing the above properties for further testing. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">IPH5401, an anti-C5aR antibody, initially developed by Novo Nordisk then acquired by Innate Pharma, has been tested in a Phase 1/2 trial in combination with Durvalumab for patients with selected solid tumors. No further development was planned for IPH5401 which is tested to prevent excessive lung inflammation associated with ARDS in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> patients. Another antibody targeting C5a, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IFX-1,</div> developed by InflaRx, will initiate a Phase 2 trial on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1</div></div> resistant cSCC patients by the mid of 2021, alone and in combination with pembrolizumab. </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">118 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advantages of TJ210 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">TJ210 is a human IgG1 subclass monoclonal antibody that specifically binds to the C5aR and thereby blocks interaction with its ligand, the complement component 5a (&#8220;C5a&#8221;). Mutation to the IgG1 silent the Fc effector function. C5aR1 blocking plays an important role in the development and/or progression of various cancers and potentially autoimmune diseases. TJ210 exerts strong anti-tumor activity by blocking the activation and migration of C5aR1-expressing myeloid cells and has a highly differentiated potential, if approved, as it binds to a novel epitope and possesses superior functional properties. Compared to the competitor antibody IPH5401 from Innate Pharma, TJ210 shows a more potent functional response, especially when C5a concentrations are high, indicating a stronger potential for TJ210 at pathologic concentrations. Key results from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies show that TJ210 selectively binds to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">N-terminus</div> of C5aR1 with high affinity and is not cross-reactive to other related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">G-protein-coupled</div> receptors (&#8220;GPCRs&#8221;). TJ210 also demonstrated a good safety profile of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-week</div> repeat dose GLP toxicity study in cynomolgus monkeys, with no observed adverse effects up to the highest dose tested at 200mg/kg and no impact on neutrophils. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mechanism of Action </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">TJ210 is a C5aR-directed antagonist monoclonal antibody. C5aR (also known as C5aR1 or CD88) is a GPCR and is one of the two high-affinity receptors for its ligand, C5a. An extensive investigation of the TME has uncovered molecular mechanism linking imbalanced complement activation and cancer progression. Upon activation, complement components including C5a is released into the TME, inducing recruitment of immunosuppressive cells including&#160;TAMs, TANs, MDSCs, Tregs and DCs thus inhibiting cytotoxic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> attack to the tumor.&#160;Immunosuppressive cytokines, such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Arg-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-10</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TGF-&#223;,</div> are also released.&#160;In addition, C5a can interact with its receptors to promote angiogenesis through an upregulation of growth factor and enhancement of endothelial cell proliferation.&#160;C5a generation through an autocrine manner or intracellular protease from cleavage of C5 produced by tumor cells can act on the surface receptors and induce signaling pathways such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PI3K-AKT,</div> leading to promotion of tumor cell adhesion, proliferation, migration and stemness. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055931346.jpg" style="width: 286px; height: 230px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Role of C5a/C5aR axis in the tumor micro-environment. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> Results </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TJ210 displays specific and high affinity binding to human C5aR1 (Figure A), and in vitro analysis reveals dose-dependent inhibition on neutrophil migration induced by C5a, with a mean IC<div style="font-size: 85%; vertical-align: bottom;;vertical-align: sub;display:inline;;font-size:9.4px">50</div> and IC<div style="font-size: 85%; vertical-align: bottom;;vertical-align: sub;display:inline;;font-size:9.4px">90</div> of 13.4 and 35.8 nM, respectively (Figure B). </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">119 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055931627.jpg" style="width: 622px; height: 198px;"/></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A) Concentration-dependent binding of TJ210 to human neutrophils from three donors. FACS binding data were plotted as signal over background ratio versus TJ210 concentrations. B) Migration of freshly isolated human neutrophils towards C5a (1 nM) in a transwell assay system in the presence or absence of TJ210. Calcein-stained cells were measured at 485/538 nm to detect the fluorescent signal (RFU). </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Inhibition of C5a or its receptor C5aR in mice has an inhibitory effect on tumor growth in various tumor-bearing animal models. The C5aR-blocking antibody has been shown to have significant therapeutic activity when combined with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1</div> therapies in multiple tumor models. The figure below shows that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD1</div> and anti-C5aR combination treatment synergistically reduced tumor volume as calculated by the Q value in a syngeneic MC38 tumor model. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055931987.jpg" style="width: 336px; height: 211px;"/>&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055932314.jpg" style="width: 351px; height: 184px;"/></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Synergistic anti-tumor activity of anti-C5aR mouse surrogate antibody and anti-mouse PD1 in syngeneic MC38 mouse tumor model. Top panel, MC38 tumor growth curve in mice treated with the indicated test articles (arrows indicate the time of i.p. injections twice a week. Asterisks indicate P&lt;0.05 on day 15. Bottom table, group assignment and synergy determination. TGI, tumor growth inhibition. Synergy is determined by Q value, which is calculated by the formula <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TGI(A+B)/[TGI(A)+TGI(B)-TGI(A)*TGI(B)].</div> A synergy is found when Q is </div></div><div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">1.15, an antagonism is found if Q&lt;0.85 and an addition is called if Q value is between 0.85 and 1. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">120 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TJ210 exerts strong anti-tumor activity by blocking the activation and migration of C5aR1-expressing myeloid cells and has a highly differentiated potential, as it binds to a novel epitope and possesses superior functional properties. Compared to the only competitor antibody IPH5401 from Innate Pharma, TJ210 shows a more potent functional response, especially when C5a concentrations are high, indicating a stronger potential for TJ210 at pathologic concentrations. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; text-indent: 3%; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g0421055932611.jpg" style="width: 398px; height: 249px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inhibition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C5a-induced</div> CD11b upregulation by C5aR mAb in human whole blood assay. Briefly, heparinized blood was incubated with serial dilutions of TJ210 or IPH5401, and then human C5a was added (15 or 150 nM) and further incubated. Fluorescence was measured by FACS Array. Median fluorescence intensity (MFI) of the gated granulocytes or monocytes in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CD11b-PE</div> channel was calculated. The inhibition curves were generated using GraphPad Prism via the nonlinear regression function. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">TJ210 is specifically designed to bind to C5a receptors in both humans and monkeys, making <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> safety assessment possible. In the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-week</div> GLP toxicity study, cynomolgus monkeys tolerated TJ210 up to 200 mg/kg which is the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">no-observed-adverse-effect-level</div> (NOAEL) in that study, without impact on neutrophils. TJ210 showed a linear PK profile in monkeys, with a half-life over 100 hours, consistent with a typical IgG1 monoclonal antibody. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811sp68.jpg" style="width: 328px; height: 223px;"/></div></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cynomolgus monkeys were administered a single IV injection of TJ210 at 10, 25 and 75 mg/kg. Blood samples were collected at multiple time slots for concentration-time analysis using a validated MSD method. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">121 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Development Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2020, the U.S. FDA approved our IND for TJ210 to initiate a Phase 1 clinical trial to evaluate the safety, tolerability, PK and PD of TJ210. In January 2021, we announced the dosing of the first patient in this trial to target completion of the patient recruitment by the end of 2021. The development program will evolve into further clinical combination studies of TJ210 with checkpoint inhibitors. A separate IND application with the NMPA in China was also approved in February 2021 and the trial will commence in 2021 as scheduled. In addition, TJ210 has therapeutic potential in multiple inflammatory and autoimmune indications, in which the role of the C5a/C5aR axis has been validated. We plan to work jointly with MorphoSys to develop this asset in the area of autoimmune disease. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B:</div> A Novel, Tumor-Dependent T Cell Engager for Gastric and Other Cancers </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B is a bi-specific antibody targeting both Claudin18.2 (CLDN18.2), a tumor antigen preferentially expressed in gastric and pancreatic cancers, and 4-1BB, a co-stimulatory molecule on T cells. CLDN18.2 is a tight junction molecule whose expression is normally restricted to epithelial cells of the gastric mucosa, but becomes widely expressed in select tumors (such as gastric and pancreatic cancers), making it a highly attractive tumor target. Although a CLDN18.2 monoclonal antibody (zolbetuximab) was active in a Phase 2 trial, only the CLDN18.2 high-expressing tumors seemed to be susceptible. In collaboration with ABL Bio, we developed a bi-specific antibody, TJ-CD4B, which provides two key advantages over current CLDN18.2 antibodies and 4-1BB agonistic antibodies. First, TJ-CD4B (also known as TJ033721) is capable of binding to tumor cells even with low levels of CLDN18.2 expression, making it more suitable for a broader patient population. Second, only upon tumor cell engagement by TJ-CD4B are T cells stimulated by the 4-1BB antibody moiety, making the 4-1BB antibody only active at the tumor site. This localized T cell activation conditional upon tumor engagement is expected to exert strong anti-tumor activity while dramatically reducing systemic side effects such as liver toxicity seen in clinical studies. In a humanized mouse model, a short course of TJ-CD4B treatment not only suppressed tumor growth to a greater extent than anti-CLDN18.2 or anti-4-1BB alone or in combination, but also displayed a memory response that resisted tumor re-challenge. We have completed pre-clinical work and have successfully obtained an IND approval from the U.S. FDA in the first quarter of 2021 to initiate a Phase 1 clinical trial in patients with cancers. A separate IND was submitted to China NMPA in April 2021 to commence a Phase 1 clinical trial in China. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Therapeutic Indications </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide. Treatment for advanced gastric or gastro-esophageal junction (GEJ) adenocarcinoma involves combination of chemotherapy, targeted therapies and now immune therapies. However, the clinical benefit has been modest, with an ORR ranging from 3% to 11%. Therefore, there is a huge unmet medical need for GC treatment. CLDN18.2 has been identified as a new GC tumor marker. Clinical data showed that over 70% GC patients in Asia and Europe are CLDN18.2 positive. The monoclonal antibody zolbetuximab can bind to CLDN18.2 on the tumor surface and stimulate tumor killing through ADCC and CDC. It has demonstrated clinical efficacy (and thus target validation) and was well tolerated when combined with standard chemotherapy in early clinical trials. However, the efficacy was still limited to CLDN18.2 high-expressing tumors. Apart from monoclonal antibodies such as the most advanced asset zolbetuximab which is in Phase 3, there are several CLDN18.2 antibody-based treatment modalities being developed with the hope of increased efficacy. These modalities include antibody-drug conjugates, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CD3-based</div> bispecific T cell engagers, most of which are still at the preclinical stage. However, despite their anticipated high efficacy, these treatment approaches are associated with significant safety concerns stemming from drug toxicity or immunotoxicity. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts</div> also face other challenges, such as limited tissue penetration and lack of persistence. </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">122 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advantages of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We believe that a carefully designed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB-based</div></div> bispecific T cell engager such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> can strike a proper balance between high efficacy and overall safety. First, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> is a more potent CLDN18.2 binder than zolbetuximab and binds to tumor cells with a wider spectrum of CLDN18.2 expression allowing it to target even the low expressors. Second, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> is equipped with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> agonistic antibody moiety that strongly stimulates activated T cells and NK cells. Studies have shown that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> and CD28 are the strongest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-stimulatory</div> molecules for anti-tumor activity but CD28 stimulation can lead to T cell exhaustion while <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> prevents it, making <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> the most desirable T cell <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-stimulator.</div> Moreover, unlike previous generations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> agonist antibodies with hepatotoxicity issues, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> binds to a distinct <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> epitope that only triggers <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> signaling upon CLDN18.2 but not Fc receptor interaction. This unique tumor associated antigen (TAA)-dependent property is expected to drastically reduce peripheral T cell activation and hepatic and systemic immunotoxicity without compromising anti-tumor activity. These properties, if proven in the clinic, enable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> to be highly differentiated from other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CLDN18.2-based</div> compounds. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811sp70a.jpg" style="width: 406px; height: 177px;"/></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Schematic diagram of the overall structure of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> and its components. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> agonistic antibody is a single chain Fv (scFv) connected to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-terminus</div> of a disabled Fc in a full anti-CLDN18.2 antibody via a flexible linker. The design allows the molecule to fit in the immune synapse (left) and trans-activate T cells only upon tumor cell binding. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Key <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> Results </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Broad and potent binding to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CLDN18.2-positive</div> cells by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B.</div> </div></div>As shown in the figure below, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> consistently exhibited stronger binding than the reference antibody zolbetuximab in cells with high, moderate and even low levels of CLDN18.2. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811sp70b.jpg" style="width: 577px; height: 117px;"/></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">More potent binding by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> than zolbetuximab to cells expressing various levels of CLDN18.2. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CLDN18.2-dependent</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> Activation and T Cell Activity by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B.</div> </div></div>The ability of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> to ligate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> and activate downstream signaling was tested in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-culture</div> of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CLDN18.2-positive</div> or negative target cells with T cells as effectors. The results in the figure show that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> elicited by far the strongest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB-mediated</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NF-kB</div> reporter activity, only in the presence of CLDN18.2+ cells but not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CLDN18.2-</div> cells. In contrast, urelumab (first generation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> antibody) induced <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NF-kB</div> reporter activity regardless of target cell CLDN18.2 expression. Importantly, 1A10, the parental <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> antibody from which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> is derived, did not engender <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NF-kB</div> reporter activity even in the presence of CLDN18.2+ cells, confirming a strict <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TAA-dependence</div> on T cell activation. Dose-dependent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CLDN18.2-restricted</div> T cell activation by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> was further demonstrated in a PBMC-target cell coculture system by measurement of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-2</div> production. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">123 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811sp71.jpg" style="width: 542px; height: 275px;"/></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dose-dependent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CLDN18.2-restricted</div> T cell activity by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> but not urelumab in T cell and target cell <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-culture</div> system. Left, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-culture</div> scheme; Middle, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NF-kB</div> reporter activity; Right, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-2</div> production. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In a further experiment where human PBMCs were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-cultured</div> with gastric cancer cells derived from patient biopsies, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> was found to increase <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-2</div> production in a dose-dependent and CLDN18.2 expression-dependent manner. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Superior in vivo Anti-tumor Efficacy of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B.</div> </div></div>In mice grafted with tumor cells expressing human CLDN18.2, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> treatment twice a week for 3 weeks completely suppressed tumor cell growth in 6 out of 7 mice, delivering far better efficacy than equimolar doses of single agents alone or in combination. Remarkably, when these tumor-free mice were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-challenged</div> with a second tumor implant a month after drug cessation, they remained totally protected, indicating that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> produced a durable anti-tumor response. Immune cell analysis revealed a significant increase in CD45+ and CD8+ T cells that infiltrated the tumor tissue after <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> treatment but there were no changes in the periphery, suggesting that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> could turn cold tumor into hot tumor and the effect was localized. The anti-tumor efficacy of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> was dose-dependent with a minimal efficacious dose of 0.4 mg/kg. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g2sp71.jpg" style="width: 396px; height: 170px;"/></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Potent in vivo anti-tumor activity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> in a mouse tumor model. Mice transgenic for humanized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> were grafted with MC38 cells expressing human CLDN18.2. Mice were treated with IgG or zolbetuximab as control, or with parental CLDN18.2 mAb, parental <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> mAb or both, and with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> (4 mg/kg) twice a week for 3 weeks. All mAbs were dosed at the molar equivalent of 3 mg/kg. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">124 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preclinical summary</div></div>. Animal PK and toxicity studies have been completed. Importantly, in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-week</div> GLP monkey toxicity study, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B</div> was well tolerated with no major findings. There was no liver toxicity noted, nor was there evidence of systemic immune activation. There were mild stomach changes that were considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-target</div> but <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-adverse</div> and were reversible. NOAEL was determined to be 100 mg/kg with a sufficient therapeutic window. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Development Plan</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have a comprehensive clinical development plan in execution to develop TJ-CD4B in the United States and China in parallel. In March 2021, we obtained an IND approval with the U.S. FDA for a monotherapy Phase 1 clinical trial in patients with advanced solid tumors including gastric cancer to investigate to assess safety, tolerability, PK, PD and preliminary efficacy. Our goal is to set forth to conduct dose escalation with a Bayesian optimal interval design before going into dose expansion by targeting specific cancers (gastric, gastroesophageal junction or GEJ, esophageal and pancreatic). In conjunction with the clinical study, we will evaluate the expression of CLDN18.2 in tumor biopsies with the aim to develop it as a potential companion diagnostic and clinical monitoring marker. Later in 2021, we will submit a separate IND to China NMPA to initiate a new clinical study focusing on patients with gastric, GEJ, esophageal and pancreatic cancers. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B:</div> A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1-Based</div></div> Tumor-Dependent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-Cell</div> Engager for Solid Cancers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> antibody targeting both <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> and was developed in collaboration with ABL Bio. Also known as ABL503, it was designed to overcome limited efficacy by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD-(L)1</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-4-1BB-related</div></div></div> toxicity. Similar to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB-stimulated</div></div> T cell activity only occurs upon tumor cell binding by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD-L1</div></div> part of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B.</div> This localized T cell activation is expected to exert strong anti-tumor activity while reducing systemic side effects such as liver toxicity. In a humanized mouse tumor model, a short course of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> treatment not only displayed greater anti-tumor efficacy than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD-L1</div></div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-4-1BB</div></div> alone or in combination, but also showed evidence of immunological memory response that resisted tumor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-challenge.</div> GMP material at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1000-L</div> scale was successfully produced. We received IND approval from the U.S. FDA for a Phase 1 study for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> in January 2021 and dosed the first patient in April 2021. We share the global rights with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ABL-Bio</div> except for Greater China and South Korea for which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ABL-Bio</div> has sole rights. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Therapeutic Indications</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As stated before, new therapeutic options are urgently needed for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-(L)1</div> relapsed or refractory cancer patients. One strategy is to maximize T cell activity by simultaneously turning off <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-inhibitory</div> pathways such as PD-1/PD-L1 and turning on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-stimulatory</div> pathways such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB,</div> which is one of the most potent potentiators as discussed earlier. Indeed, several companies have been developing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> x <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> antibodies, and the most advanced are from Genmab, Inhibrx and Merus, all in Phase 1. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advantages of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div></div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We believe that based on publicly available information and preclinical studies <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> has the potential to be a highly differentiated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> bispecific antibody. In terms of format, some of the leading compounds are monovalent heterodimers which may affect the potency of each arm and may encounter cumbersome CMC issues. In addition, as detailed earlier, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-4-1BB</div></div> moiety of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> binds to a novel epitope that only triggers <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> signaling upon tumor binding leading to reduced cytokine release and hepatic and systemic immunotoxicity without compromising anti-tumor activity. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> is also more specific than certain competitor molecules in terms of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> binding relative to other TNFR family of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-stimulatory</div> molecules. These potential advantages, if proven in the clinical trials, could enable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> to be highly differentiated from other competitor compounds. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Key <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> Results</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> level-dependent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> Agonism and T Cell Activity. </div></div>The ability of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> to ligate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> and activate downstream signaling was tested in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-culture</div> of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1+</div> target cells with T cells as effectors. The results in the figure show that the level of NF-<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">k</div>B reporter activity elicited by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> correlated with the level of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> expression on the target cells. In contrast, urelumab induced NF-<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">k</div>B reporter activity regardless of target cell <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> expression. Importantly, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> promoted the proliferation of CD8+ tumor-infiltrating lymphocytes obtained from human tumor samples in a similar extent to urelumab while the parental <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD-L1</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-4-1BB</div></div> antibodies either alone or in combination had no effect, confirming a strict <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1-dependence</div></div> on T cell stimulation by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B.</div> </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">125 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811sp73.jpg" style="width: 194px; height: 402px;"/></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dose-dependent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1-restricted</div></div> T cell activity by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B/ABL503</div> but not urelumab in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-culture</div> system of T cells and target cells expressing different levels of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> (as represented by mean fluorescent intensity (MFI) values). </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Superior in vivo Anti-tumor Efficacy of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B.</div> </div></div>In mice grafted with tumor cells expressing human <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> treatment every 3 days for 4 times suppressed tumor cell growth in a dose-dependent manner, delivering far better efficacy than equimolar doses of single agents alone or in combination. Remarkably, when the treated tumor-free mice were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-challenged</div> with a second tumor graft after drug cessation, they remained totally protected, indicating that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> produced a durable anti-tumor response. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811g2sp73.jpg" style="width: 264px; height: 193px;"/></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">126 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811sp74.jpg" style="width: 282px; height: 198px;"/></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Figure:</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Potent in vivo anti-tumor activity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> in a mouse tumor model. Mice transgenic for humanized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> were grafted with MC38 cells expressing human <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1.</div> Mice were treated with the indicated antibodies every 3 days for 4 times. Tumor-free animals were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-challenged</div> with a second dose of tumor on day 40 with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">treatment-na&#239;ve</div> animals as control. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> is also known as ABL503. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preclinical summary</div></div>. In contrast to certain competitor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> x <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> bispecific antibodies, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> did not induce cytokine release (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TNF-&#945;)</div> up to 0.83 mg/ml, which corresponded to a human equivalent dose of 15 mg/kg. Animal PK and toxicity studies have also been completed. Results of these studies indicate that the NOAEL was 15 mg/kg/dose. This dose was also considered the highest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-severely</div> toxic dose. A starting dose of 0.7 mg is proposed for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-human</div></div> (FIH) study. There is a &gt;3000-fold safety margin between the proposed FIH dose and the nonclinical safety assessment studies including <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro</div></div> cytokine release assays and GLP toxicology studies. </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Development Plan</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> is being developed first for oncology indications in the U.S. An IND approval has been obtained from the U.S. FDA for a FIH, open-label, multicenter, multidose, dose escalation and expansion monotherapy study, which will assess safety, tolerability, PK, PD and preliminary efficacy in adult patients with any progressive locally advanced (unresectable) or metastatic solid tumors. Specific oncology indication(s) will be confirmed further. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B</div> will be administered IV on day 1 and day 15 of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-week</div> treatment cycle. The first patient was dosed in April 2021. </div> <div style="font-size: 24pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: 2em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Clinical</div> Assets</div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">TJX7: A Novel CXCL13 Antibody for Autoimmune Diseases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">TJX7 is an internally discovered novel humanized neutralizing antibody targeting the CXCL13 chemokine. CXCL13, through its receptor CXCR5, plays a key role in forming germinal centers, which are critical for immune response. The role of CXCL13 in forming germinal centers is to guide the migration of germinal center B cells and follicular T cells within the lymphoid organs and facilitate their interaction, maturation and function. One of the key pathogenic features in autoimmune diseases is related to the aberrant formation of ectopic germinal centers formed in affected organs, contributing to chronic inflammation and tissue destruction. Elevated serum CXCL13 levels, CXCR5-expressing T cells and pathogenic germinal center B cells and even ectopic germinal center formation are found in multiple autoimmune diseases, including Sj&#246;gren&#8217;s syndrome, RA, multiple sclerosis, and SLE. TJX7 is being developed for the treatment of autoimmune disorders and has been shown to bind to CXCL13 with sub-nanomolar affinity, effectively blocking the interaction between CXCL13 and CXCR5 and the downstream signaling. TJX7 has been shown to completely inhibit the migration of primary human tonsil B cells. Pharmacodynamic studies in mice and cynomolgus monkeys have confirmed TJX7&#8217;s inhibitory effects on germinal center formation and antibody production. Results generated so far indicate that TJX7 may provide a new therapeutic angle in the treatment of autoimmune diseases as it acts uniquely at the core of tissue pathologies. TJX7 is currently under CMC and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> development. We have completed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IND-enabling</div> studies and are in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-IND</div> consultations with the U.S. FDA on the path forward. </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">127 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bi-Specific</div> Antibodies Under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Clinical</div> Development </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have, over the years, discovered and generated a panel of proprietary monoclonal antibody sequences that can be used to engineer <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-functional</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> antibody molecules that are enabled with unique immunologic properties by dual targeting. The overarching goal behind these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> molecules is to converge enhanced immune responses onto targeted tumor environment to convert immunologically <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-responsive</div> &#8216;cold&#8217; tumors into responsive &#8216;hot&#8217; tumors. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L1C4</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(PD-L1</div> and CD47), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L1T6</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(PD-L1</div> and TIGIT) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L1I7</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(PD-L1</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7)</div> are dual-targeting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-functional</div> antibodies. There are designed to engage tumor cells to concentrate in tumor tissue through a common <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> antibody arm and provide additional stimulation or activation of either T cells or macrophages through a second arm, i.e. CD47, TIGIT or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7.</div> In a series of in vivo and in vitro studies, these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> antibodies exert the unique properties to show an enhanced anti-tumor effect or to overcome the resistance of tumors to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD1/PD-L1</div> treatment, which are otherwise not achievable through either monoclonal antibodies or combination. We are in the process of validating these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> antibodies in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> development. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-C4GM</div> is a &#8220;fortified&#8221; version or a next generation of CD47 antibody, which is specifically designed for the treatment of solid tumors through CD47-mediated macrophage killing mechanism. There is evidence that majority of tumor-associated macrophages residing in tumor belong to a tumor-promoting M2 phenotype rather than a tumor-killing M1 phenotype and are prone to resistance to CD47 antibody therapy. Thus, treatment of solid tumors with CD47 antibody alone may have limited efficacy because of the presence of M2 but not M1 macrophages that are required for anti-tumor activity. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-C4GM</div> is a novel molecule composed of lemzoparlimab with an engineered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> moiety fused at the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-terminus</div> of the antibody heavy chain. As <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> is a potent cytokine known to convert M2 macrophages to M1 macrophages, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-C4GM</div> is shown to exert a markedly increased phagocytic effect on solid tumors through a concert action by lemzoparlimab and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF.</div> This unique functional property of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-C4GM</div> is confirmed in a series of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro </div></div>and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vivo </div></div>studies where <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-C4GM</div> demonstrated a superior anti-tumor activity against solid tumors, which is not achieved by lemzoparlimab or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> used either alone or in combination. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-C4GM</div> is under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> development. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">128 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing and Collaboration Arrangements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Licensing</div> Arrangements </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement with MorphoSys (Felzartamab) </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2017, we entered into a license and collaboration agreement with MorphoSys AG (&#8220;MorphoSys&#8221;) with respect to the development and commercialization of felzartamab (MOR202/TJ202), MorphoSys&#180;s proprietary investigational antibody against CD38 (the &#8220;CD38 product&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under this agreement, MorphoSys granted to us an exclusive, royalty-bearing, sublicensable license to exploit MOR202/TJ202 for any human therapeutic or diagnostic purpose in the licensed territory, namely Greater China. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to this agreement, we granted to MorphoSys an exclusive license to our rights in any inventions that we make while exploiting MOR202/TJ202 under this agreement, solely to exploit MOR202/TJ202 outside of Greater China. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also received the right to sublicense to affiliates and third parties acting as contract manufacturers, contract research organizations, distributors or wholesalers without prior written consent, as well as the right to sublicense to other third parties with the prior written consent of MorphoSys, not to be unreasonably withheld, delayed or conditioned. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">129 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are solely responsible for the development and commercialization of MOR202/TJ202 in Greater China, and must use commercially reasonable efforts as we develop and commercialize MOR202/TJ202. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to this agreement, we paid to MorphoSys an upfront license fee of US$20.0&#160;million. We also agreed to make milestone payments to MorphoSys, conditioned upon the achievement of certain development, regulatory and commercial milestones, in the aggregate amount of US$98.5&#160;million. Such milestones include first patient dosed in human clinical trials, marketing approval, and first annual net sales of CD38 products covered by the agreement in excess of a certain amount. As of the date of this annual report, we have made milestone payments of US$8.0&#160;million to MorphoSys. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, we are required to pay tiered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-teens</div> royalties to MorphoSys on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product</div></div> basis during the term, commencing with the first commercial sale of a relevant licensed product in Greater China. The end of the royalty term is linked to (i)&#160;the expiration, invalidation or abandonment of relevant patent claims, (ii) 10 years from the date of first commercial sale of such CD38 product, and (iii)&#160;marketing exclusivity for such relevant licensed product. To date, we have not paid any royalties to MorphoSys. Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the expiration of our last payment obligation under the agreement. This agreement may be terminated by either party for the other party&#8217;s uncured material breach, bankruptcy or insolvency. In addition, we have the right to terminate the agreement for convenience at any time after a certain specified time period upon a notice period that varies based upon the stage of development. MorphoSys has the right to terminate the agreement if we challenge its patents. To the extent that we terminate for convenience or MorphoSys terminates for our material breach, bankruptcy, insolvency or patent challenge, among other things, all licenses and rights granted by MorphoSys to us will automatically terminate and the licenses and rights granted by us to MorphoSys will survive. In the event of such termination, we must also grant to MorphoSys an exclusive, royalty-bearing, sublicensable license under certain of our intellectual property relating to the licensed product to exploit MOR202/TJ202 for any human therapeutic or diagnostic purpose in Greater China. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Assignment and License Agreement with Genexine </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In October 2015, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-tech</div> Tianjin Co., Ltd., known as Tasgen <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-tech</div> (Tianjin) Co., Ltd. at the time (which subsequently became our subsidiary following the Acquisition) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;I-Mab</div> Tianjin&#8221;), entered into an intellectual property assignment and license agreement with Genexine, Inc. (&#8220;Genexine&#8221;), further amended in December 2017, with respect to four licensed products, namely <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-H9</div> (TJ101), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-G3</div> (TJ102), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-G8</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-P2</div> and one assigned product, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-G6</div> (TJ103). Under this agreement, Genexine (i)&#160;granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin an exclusive, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-transferable,</div> sublicensable license to use and otherwise exploit certain intellectual property to engage in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical development, manufacturing, sale and distribution of the above-mentioned licensed products for (A)&#160;the treatment of any disease with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-H9</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-G3</div> in China (which, for clarity excludes, Hong Kong, Macau and Taiwan), (B) the treatment of chemically induced diarrhea, with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-G8</div> anywhere in the world and (C)&#160;the treatment of rheumatoid arthritis and lupus (not including psoriasis) with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-P2</div> anywhere in the world and further (ii)&#160;assigned to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin a certain Chinese patent and related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> related to the assigned product (TJ103) and granted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin an exclusive license to exploit the assigned intellectual property to engage in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical development, manufacturing, sale and distribution of the assigned product (TJ103) for the treatment of any disease in China (which, for clarity, excludes Hong Kong, Macau and Taiwan). <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin will also receive an exclusive license to any improvements that Genexine develops or acquires related to any of the aforementioned products. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under this agreement, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin paid an aggregate upfront license fee of US$13.0&#160;million in relation to the patents, patent applications, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> data and information in connection with the four licensed products and a purchase fee of US$7.0&#160;million in connection with the assigned product (TJ103). <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin also agreed to make certain milestone payments, including milestone payments in the aggregate amount of US$40.0&#160;million for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-H9,</div> US$25.0&#160;million for TJ103 and US$15.0&#160;million for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-G3,</div> conditioned upon the achievement of certain net sales targets. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">130 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The term of this agreement is 30 years unless terminated earlier in accordance with the terms thereof. This agreement may be terminated by either party for the other party&#8217;s uncured material breach, bankruptcy or insolvency, in the event of force majeure or a PRC regulatory requirement to make material alteration or modification to the contractual rights or obligations of this agreement which has the effect of preventing the parties from achieving their business objectives, or upon the termination of a certain subscription agreement or a certain joint venture agreement entered into by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin and Genexine in October 2015 (provided that the termination of such subscription agreement or joint venture agreement was not due to the material breach of the party electing to terminate this agreement). Genexine has the right to terminate the agreement if we fail to use commercially reasonable efforts to obtain regulatory approvals for commercializing the licensed product in the agreed period due to our own fault or if we cease to pursue clinical development or product registration or to conduct licensed activities on a reasonable scale as approved by our board of directors. During the term of this agreement, if <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin develops or acquires any improvement, modification or alteration to the licensed products, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin will become the sole legal owner of such improvements, modifications and alterations and has full power, right and authority to grant licenses or transfer ownership of the same. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin is required to promptly notify Genexine in writing giving details of any such improvements, modifications or alterations and provide Genexine with such explanations or trainings to enable Genexine to legally and effectively use the same. Additionally, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin shall grant to Genexine a fully paid up, royalty-free, exclusive license to use any such improvements, modifications and alterations anywhere outside of the territory for which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin is licensed under this agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In November 2018, we entered into an intellectual property license agreement with Genexine with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-G3</div> (TJ102). Under this agreement, Genexine granted to us an exclusive, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-transferable,</div> sublicensable license to use and otherwise exploit certain intellectual property to engage in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical development, manufacturing, sale and distribution of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-G3</div> for the treatment of any disease in Taiwan and Hong Kong. We will also receive an exclusive license to use any improvements related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-G3</div> that Genexine develops or acquires free of charge in Taiwan and Hong Kong. Under this agreement, the scope of improvements is limited to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-G3</div> and does not include the hyFc platform. We paid an upfront license fee of US$0.1&#160;million and milestone payments of US$0.9&#160;million to Genexine. No other milestone payments are due under this agreement. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement with Genexine (Efineptakin alfa) </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2017, we entered into an intellectual property license agreement with Genexine with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-I7,</div> a long-acting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7</div> cytokine. Under this agreement, Genexine granted to us an exclusive, sublicensable and transferable license to use and otherwise exploit certain intellectual property (including improvements subsequently developed or acquired by Genexine) in connection with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical development, manufacturing, sale and distribution of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-I7</div> to treat cancers in the field of oncology in China, Hong Kong, Macau and Taiwan. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under this agreement, we paid an upfront license fee of US$12.0&#160;million to Genexine. We also agreed to make milestone payments in the aggregate amount of US$23.0&#160;million, conditioned upon the achievement of certain development milestones, including completion of Phase 2 and Phase 3 clinical studies and NDA or BLA approval in any of China, Hong Kong, Macau or Taiwan. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, we agreed to make milestone payments in the aggregate amount of US$525.0&#160;million, conditioned upon the achievement of certain cumulative net sales of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-I7</div> up to US$2,000&#160;million. We also are required to pay Genexine a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-single-digit</div> percentage royalty in respect of the total annual net sales of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-I7.</div> The aforesaid milestones and royalties (other than the upfront payment) will be reduced by 50% following the entry of a generic version of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-I7</div> in China, Hong Kong, Macau and Taiwan without the consent or authorization of us or any of our sublicensees. As of the date of this annual report, no milestone payments or royalties are due under this agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the later of (i)&#160;the expiry of the last to expire patent of the licensed intellectual property that includes a valid claim for China, Hong Kong, Macau or Taiwan and that covers the composition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-I7;</div> and (ii) 15 years from the date of the first commercial sale of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-I7.</div> This agreement may be terminated by either party for the other party&#8217;s uncured material breach, bankruptcy or insolvency, in the event of force majeure or regulatory requirement to make material alteration or modification to the contractual rights or obligations of this agreement which has the effect of preventing the parties from achieving their business objectives, or by mutual agreement of both parties. Genexine has the right to terminate the agreement if we fail to use commercially reasonable efforts to obtain regulatory approvals or other registrations necessary for commercializing the licensed product in the agreed period due to our fault or if we cease to pursue clinical development or product registration or to conduct licensed activities on a reasonable scale as agreed (&#8220;Development and Commercialization Termination Events&#8221;). Such Development and Commercialization Termination Events expressly include our failure to reach certain development milestones or commercially launch the licensed product in the agreed period. To the extent that we terminate as a result of a regulatory requirement to make material alteration or modification to the contractual rights or obligations of this agreement or Genexine terminates for our material breach, bankruptcy or insolvency, force majeure, or the Development and Commercialization Termination Events, we cannot develop, manufacture, market, promote, sell, offer for sale, distribute or otherwise make available any competing product for a certain period after such termination. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">131 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the term of this agreement, if we develop or acquire any improvement, modification or alteration to the licensed product, we will own such improvements, modifications or alterations and provide Genexine details thereof, whether patentable or not. Additionally, we shall grant to Genexine a fully paid up, royalty-free, exclusive license (with a right to sublicense) to use any such improvements, modifications or alterations anywhere outside of China, Hong Kong, Macau and Taiwan. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2020, we and Genexine entered into an amendment to this agreement, whereby both parties desire to establish a collaboration on TJ107 GBM Study in Greater China. Under the terms of the expanded collaboration, we will be mainly responsible for using commercially reasonable efforts to conduct the Phase 2 GBM clinical trial in Greater China, and Genexine will share the development strategies, data and costs for success of this clinical trial. As of December&#160;31, 2020, the costs incurred for the development of this new indication was RMB4.2&#160;million (US$0.6 million) and thus RMB2.8&#160;million (US$0.4 million) was recorded in our audited consolidated financial statements for the year ended December&#160;31, 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement with Ferring (Olamkicept) </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2016, we entered into a license and sublicense agreement with Ferring International Center SA (&#8220;Ferring&#8221;) with respect to (i)&#160;FE301, an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">interleukin-6</div> inhibitor, and (ii)&#160;all pharmaceutical formulations in finished packaged form containing FE301 covered by certain patents or patent applications. Under this agreement, Ferring granted to us an exclusive, sublicensable license (excluding any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> license that Ferring granted to Conaris Research Institute AG under a licensing agreement entered into in November 2008) under certain Ferring intellectual property to research, develop, make, have made, import, use, sell and offer to sell FE301 (and the licensed products containing FE301) in China, Hong Kong, Macau, Taiwan and South Korea. We also have an option to receive an exclusive, sublicensable license under certain Ferring intellectual property to research, develop, make, have made, import, use, sell and offer to sell FE301 (and the licensed products containing FE301) in the countries in North America, the European Union and Japan that are mutually agreed upon by the parties. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are required to use commercially reasonable efforts to obtain approval of FE301 and to promote, market, distribute and sell it in China, Hong Kong, Macau, Taiwan, and South Korea. Such activities are to be at our own cost and expense. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under this agreement, we paid to Ferring an upfront license fee of US$2.0&#160;million. We also agreed to make milestone payments to Ferring, in the aggregate amount of US$14.5&#160;million, conditioned on the achievement of certain development milestones in the licensed territory, including completion of Phase 1b and Phase 2a clinical studies and the submission and approval of the new drug application. Further, if we exercise our option to receive a license in any of the mutually agreed upon countries in North America, the European Union and Japan, we are required to pay to Ferring an additional US$3.0&#160;million as an upfront license fee (upon the exercise of the option), and milestone fees up to the aggregate amount of US$30.0&#160;million, conditioned upon the licensed product achieving certain development milestones in certain countries in the option territory. As of the date of this annual report, no milestone payments are due under this agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, we agreed to pay Ferring tiered royalties ranging from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single-digit</div> to high-single-digit percentages of annual net sales for countries in China, Hong Kong, Macau, Taiwan, and South Korea, and from the high-single-digits to 10% of annual net sales for the mutually agreed upon countries in North America, the European Union and Japan. To date, we have not paid any royalties to Ferring. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">132 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The royalty term commences with the first commercial sale of the licensed product in the relevant country and ends upon the later of (i) 15 years from the date of launch, and (ii)&#160;the expiry of the last to expire patent of Ferring that includes a valid claim covering the development, making, using or selling of the licensed compound or licensed product in the licensed territory and/or option territory. Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the later of the expiry of the royalty term, and the first date on which we are not conducting any necessary and outstanding clinical study with respect to the licensed product or seeking to obtain any necessary and pending regulatory approval for the licensed product, if applicable. This agreement may be terminated by either party for the other party&#8217;s uncured material breach, bankruptcy or insolvency. In addition, in the event that the original licensor terminates its license to Ferring governing any of the intellectual property sublicensed to us under this agreement, Ferring has the right to terminate this agreement with respect to such sublicenses in which case both parties will discuss in good faith how to resolve and mitigate to mutual satisfaction. To the extent that Ferring terminates for our material breach, bankruptcy or insolvency, among other things, all licenses and rights granted by Ferring to us will automatically terminate and the licenses and rights we granted to Ferring will survive and automatically become irrevocable with the right to sublicense. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the term of the licensing agreement, if we develop or acquire any improvement, modification, enhancement or addition to the licensed product, we will own and retain all rights, title and interest therein, and grant to Ferring a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> fully paid, royalty-free, worldwide license thereto. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License and Collaboration Agreement with MacroGenics (enoblituzumab) </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2019, we entered into a license and collaboration agreement with MacroGenics, Inc. for development and commercialization of an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Fc-optimized</div> antibody known as enoblituzumab that targets <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3,</div> including in combination with other agents, such as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD-1</div></div> antibody known as MGA012, in the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under this agreement, MacroGenics granted to us an exclusive, sublicensable, royalty-bearing license to MacroGenics&#8217; patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> to develop and commercialize the enoblituzumab product, and a combination regimen of enoblituzumab and MGA012, in Greater China during the term of the agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In exchange for these rights, in addition to certain financial consideration, we grant to MacroGenics a royalty-free, sublicensable, license outside of Greater China, to our patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> that are related to the enoblituzumab product or useful or necessary for MacroGenics to develop or commercialize the enoblituzumab product or a product containing MGA012, and combinations thereof. The license is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i)&#160;non-exclusive</div> with respect to the enoblituzumab product, and (ii)&#160;exclusive with regard to MGA012. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Unless prohibited by applicable laws and regulations, which include all international, national, federal, state, regional, provincial, municipal and local government laws, rules, and regulations that apply to either us or MacroGenics or to the conduct of the collaboration under this agreement (including Good Manufacturing Practice, Good Clinical Practices, General Biological Products Standards, and the laws, rules and regulations of the International Conference on Harmonisation, the United States, China, Hong Kong, Macau, and Taiwan, each as may be then in effect, as applicable and amended from time to time), we will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-own</div> all clinical data generated pursuant to this agreement in any clinical trial conducted solely in Greater China, and, to the extent that such joint ownership is not legally permitted, MacroGenics will be the sole and exclusive owner of such clinical data. MacroGenics will solely and exclusively own all other clinical data generated pursuant to this agreement. We are not aware of any applicable laws or regulations that would prohibit us from jointly owning such clinical data and, to our knowledge, we currently qualify for such joint ownership with MacroGenics under this agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to this agreement, we paid MacroGenics an upfront payment of US$15.0&#160;million. We also agreed to pay MacroGenics development and regulatory milestone fees of up to US$135.0&#160;million and tiered double-digit royalties (ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-teens</div> to twenty percent) based on annual net sales in the territories. As of the date of this annual report, no milestone payments or royalties are due under this agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are responsible for, and must use commercially reasonable efforts, to develop and commercialize the enoblituzumab product (which includes the enoblituzumab product in combination with MGA012) in Greater China. This includes conducting all clinical studies required for approval, participating in a planned, global Phase 3 trial (or another mutually agreeable global clinical trial) of the enoblituzumab combination product, the conduct of at least two Phase 2 or Phase 3 trials each targeting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3</div> expressing patient populations, and submissions to regulatory authorities in Greater China. MacroGenics is responsible for, and must use commercially reasonable efforts to, develop and commercialize the enoblituzumab product (which includes the enoblituzumab product in combination with MGA012) in the rest of the world. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">133 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are responsible for all development costs in Greater China. MacroGenics is responsible for all development costs in the rest of the world, except that we are responsible for 20% of the costs incurred in (i)&#160;activities supporting global clinical trials in which we participate, (ii)&#160;certain CMC activities for material intended to be used in clinical trials in Greater China, and (iii)&#160;companion diagnostic development and validation for indications being studied in Greater China. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">region-by-region</div></div> basis, until the later of (i)&#160;the twelfth (12th) anniversary of the first commercial sale of an enoblituzumab product in such country or region, (ii)&#160;the expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">last-to-expire</div></div> MacroGenics patent licensed under this agreement, which will occur in October 2036, and (iii)&#160;the expiration of the latest data exclusivity period for the enoblituzumab product in such country or region. Since there is currently no data exclusivity protection period in China, Hong Kong, Macau or Taiwan, this agreement will remain in effect until the later of clauses (i)&#160;and (ii). This agreement may be terminated by either party for the other party&#8217;s uncured material breach, safety reasons or force majeure. In addition, we have the right to terminate the agreement for convenience at any time after a certain specified time period upon advance notice to MacroGenics. MacroGenics has the right to terminate the agreement if we challenge its patents. To the extent that we terminate for convenience or MacroGenics terminates for our material breach, patent challenge or safety reasons, all licenses and rights granted by MacroGenics to us will automatically terminate and the licenses and rights granted by us to MacroGenics will survive and automatically become exclusive and worldwide. To the extent that we terminate for MacroGenics&#8217; material breach or safety reasons, among other things, all licenses and rights granted by MacroGenics to us will automatically terminate. The licenses and rights granted by us to MacroGenics will also automatically terminate to the extent we terminate for MacroGenics&#8217; material breach. To the extent we terminate for safety reasons, such licenses and rights will terminate only with respect to the licensed territory and will otherwise survive outside the licensed territory. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Licensing</div> Arrangements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2018, we entered into a license and collaboration agreement with MorphoSys for MorphoSys&#8217;s proprietary antibody (MOR210/TJ210) directed against C5aR (the &#8220;C5aR Agreement&#8221;). Under this agreement, MorphoSys granted to us an exclusive, royalty-bearing license to explore, develop and commercialize MOR210/TJ210 in Greater China and South Korea. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> will perform and fund all global development activities related to the development of MOR210/TJ210 in Greater China and South Korea, including all relevant clinical trials (including in the U.S. and China) and all development activities required for IND filing in the U.S. as well as CMC development of manufacturing processes. As of the date of this annual report, we have made an upfront payment of US$3.5&#160;million and milestone payment of US$1&#160;million to MorphoSys. No other milestone payments or royalties are due under this agreement in the reporting period. MorphoSys retains rights in respect of development and commercialization of MOR210/TJ210 in the rest of the world. Additionally, MorphoSys maintains the right to conduct activities in Greater China and South Korea that enable MorphoSys to exploit MOR210/TJ210 outside of those countries. Pursuant to the C5aR Agreement, we are required to use commercially reasonable efforts as we develop and commercialize MOR210/TJ210 in Greater China and South Korea. This agreement may be terminated by either party for the other party&#8217;s uncured material breach, bankruptcy or insolvency. In addition, we have the right to terminate the agreement for convenience at any time after a certain specified time period upon a notice period that varies based upon the stage of development and for safety reasons. MorphoSys has the right to terminate the agreement if we challenge its patents. To the extent that we terminate for convenience or MorphoSys terminates for our material breach, bankruptcy, insolvency or patent challenge, among other things, all licenses and rights granted by MorphoSys to us will automatically terminate and the licenses and rights granted by us to MorphoSys will survive. In the event of such termination, in addition to other obligations, we must grant to MorphoSys an exclusive, royalty-bearing, sublicensable license under certain of our intellectual property relating to the licensed product to exploit MOR210/TJ210 in Greater China and South Korea. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">134 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">B. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Out-Licensing</div> Arrangements </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License and Collaboration Agreement with AbbVie </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In September 2020, we, through our subsidiaries <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma Co., Ltd. and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma US Limited, entered into a license and collaboration agreement with AbbVie Ireland Unlimited Company (&#8220;AbbVie&#8221;) for the development and commercialization of certain compounds and products that target CD47, including lemzoparlimab (which targets a unique epitope of CD47). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under this agreement, we grant AbbVie an exclusive, royalty-bearing, sublicensable license to develop, manufacture and commercialize the licensed compounds and products (but excluding products that are directed to both a CD47 epitope that is not the same or substantially similar to the epitope targeted by lemzoparlimab and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-CD47</div> target) anywhere in the world outside of Mainland China, Hong Kong and Macau, and to conduct development and manufacturing activities in Mainland China, Hong Kong and Macau to further AbbVie&#8217;s commercialization of the licensed products outside of Mainland China, Hong Kong and Macau, except that, with respect to products containing either our preclinical CD47-PDL1 compound or our preclinical CD47-GMCSF compound, AbbVie will not develop, manufacture or commercialize such products until the parties come to financial terms on such products following AbbVie&#8217;s exercise of its rights of first negotiation. We have granted AbbVie a license and cannot commercialize products containing our preclinical CD47-PDL1 compound or our preclinical CD47-GMCSF compound outside of Mainland China, Hong Kong and Macau even if AbbVie does not exercise its right of first negotiation or we are unable to come to financial terms on such products. We also grant AbbVie a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-exclusive,</div> royalty-bearing, sublicensable license to develop, manufacture and commercialize licensed compounds and products that are directed to both a CD47 epitope that is not the same or substantially similar to the epitope targeted by lemzoparlimab and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-CD47</div> target (excluding such compounds and products that have been developed by us) anywhere in the world. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under this agreement, AbbVie grants us an exclusive, royalty-free, sublicensable license under its technology and any joint technology developed under this agreement to clinically develop and commercialize in Mainland China, Hong Kong and Macau certain of the licensed compounds and products that (1)&#160;only target CD47, including lemzoparlimab, and (2)&#160;to the extent AbbVie exercises its rights of first negotiation for such licensed compounds and products, consist of our preclinical CD47-PDL1 compound or our preclinical CD47-GMCSF compound. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are responsible for conducting certain initial development activities, at our cost and expense, following which AbbVie assumes the responsibility and costs for all development, manufacture and commercialization activities of the licensed compounds and products outside of Mainland China, Hong Kong and Macau. Under this agreement, AbbVie is required to use commercially reasonable efforts to develop, seek and obtain approval of, and commercialize at least one licensed product in at least two indications in the United States and at least three of the United Kingdom, France, Germany, Italy and Spain. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are responsible for the development and commercialization of the licensed compounds and products in Mainland China, Hong Kong and Macau. We are required to use commercially reasonable efforts to develop, seek and obtain approval of, and commercialize at least one licensed product in at least two indications in mainland China. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the term of the Agreement, we are not permitted to develop, manufacture or commercialize a compound or product that is directed (1)&#160;solely to CD47 or (2)&#160;to an epitope that is the same or substantially similar to the epitope targeted by lemzoparlimab, and AbbVie is not permitted to market a monoclonal antibody that is solely directed to a CD47 epitope that is the same or substantially similar to the epitope targeted by lemzoparlimab for an indication in any country where the licensed product has received regulatory approval for such indication. Additionally, during the first five (5)&#160;years after the first commercial sale of a licensed product outside of Mainland China, Hong Kong and Macau, AbbVie will not market any monoclonal antibody solely directed to CD47 for an indication in any country where the licensed product has received regulatory approval for such indication in such country. AbbVie&#8217;s exclusivity restrictions will not prevent it from marketing an antibody that demonstrates additive or synergistic effects in combination with a licensed product, or an improvement on a licensed product based on improved efficacy or safety data. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">135 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under this agreement, we and AbbVie formed a joint governance committee that consists of three representatives from each of us. The joint governance committee will oversee and coordinate the development of the licensed compounds and products in both of our territories, including the review and approval of each of our respective development plans, the review and approval of clinical trials and commercialization in Mainland China, Hong Kong and Macau, and discussing commercialization strategies in each of our territories. The joint governance committee may create working groups as it deems appropriate. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under this agreement, AbbVie has paid us an upfront payment of US$180&#160;million and milestone payment of US$20&#160;million. Based on the achievement of certain clinical development and regulatory milestones, including first commercial sales in various markets, we may earn additional milestone payments of up to US$840&#160;million. Further, based on the achievement of certain sales-related milestones, we may earn additional milestone payments. In addition to the upfront and milestone payments that we may earn, we may also earn tiered royalties consisting of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-to-mid</div></div> teen percentages of global net sales. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We will not owe any milestone payments for our development or commercialization in Mainland China, Hong Kong and Macau, but we are required to pay AbbVie tiered royalties in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-to-high</div></div> single-digit percentages of net sales of licensed products in those countries. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under this agreement, we grant AbbVie several rights of first negotiation with respect to our products, including a right of first negotiation to exercise its right to products containing either our preclinical CD47-PDL1 compound or our preclinical CD47-GMCSF compound outside of Mainland China, Hong Kong and Macau. This right of first negotiation is exercisable following completion of preclinical activities sufficient to initiate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IND-enabling,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GLP-conforming</div> animal toxicology studies, and if AbbVie exercises this right, the parties shall negotiate an amendment to allow AbbVie to develop, manufacture and commercialize that product in exchange for additional regulatory and sales milestones that could equal or exceed US$500&#160;million plus royalty payments. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We also grant AbbVie other rights of first negotiation for rights to commercialize: (1)&#160;our preclinical CD47-PDL1 compound or our preclinical CD47-GMCSF compound in Mainland China, Hong Kong and Macau; (2)&#160;our multi-specific or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> licensed compounds that contain a targeting moiety that is directed to both an epitope on CD47 that is not the same or substantially similar to the epitope targeted by lemzoparlimab and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-CD47</div> target, as well as any products containing such compounds anywhere in the world; and (3)&#160;each licensed product that contains a licensed compound as its sole active ingredient that is directed solely to CD47 in Mainland China, Hong Kong and Macau. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">AbbVie grants us a right of first negotiation for rights to: (1)&#160;commercialize its multi-specific or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> compounds that contain a targeting moiety that is directed to both an epitope on CD47 that is not the same or substantially similar to the epitope targeted by lemzoparlimab and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-CD47</div> target, as well as any products containing such compounds in Mainland China, Hong Kong and Macau; and (2)&#160;develop and commercialize licensed compounds as part of combination products (other than products that contain a licensed compound directed against both an epitope on CD47 that is not the same or substantially similar to the epitope targeted by lemzoparlimab and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-CD47</div> target) in Mainland China, Hong Kong and Macau. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This agreement may be terminated by either party in the event of an uncured material breach. If the material breach and failure to cure is by AbbVie with respect to some countries, but not others, we have the right to terminate this agreement solely with respect to the countries to which the breach relates. If the material breach and failure to cure is by us with respect to our obligations in Mainland China, Hong Kong and Macau, AbbVie will have the right to reduce payments to us by a certain percentage. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AbbVie has certain termination rights if it determines not to continue development and commercialization based on documented safety concerns. AbbVie may also terminate this agreement in part or in whole for convenience following prior written notice of a certain period. AbbVie may also terminate this agreement immediately following certain breaches by us of anti-bribery and anti-corruption laws. AbbVie also has termination rights related to the approval process under the Hart-Scott-Rodino Antitrust Improvements Act. If we stop material clinical development and commercialization activities in Mainland China, Hong Kong and Macau without justification, AbbVie may reduce any royalties that would have been due to us by a certain percentage. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">136 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If AbbVie stops material clinical development and commercialization activities without justification, we may terminate this agreement. We also have certain termination rights if AbbVie or its affiliates challenge our valid patents related to the licensed products. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement with ABL Bio </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2018, we entered into a license and collaboration agreement with ABL Bio (the &#8220;ABL Bio License&#8221;), as amended from time to time. Under the ABL Bio License, we granted to ABL Bio exclusive, worldwide (excluding Greater China), royalty-bearing rights to develop and commercialize a bispecific antibody (the &#8220;BsAb&#8221;) using certain of our monoclonal antibody sequences. ABL Bio has developed expertise in the area of bispecific antibodies for cancer treatment and has developed proprietary intellectual property around the BsAb technology, and the license allows ABL Bio to further develop and commercialize the BsAb based on monoclonal antibodies licensed from us under the ABL Bio License. ABL Bio granted to us an exclusive, royalty-free, sublicensable license under its interest in the BsAb and related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> (including improvements thereto) to exploit the licensed BsAb in Greater China. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the ABL Bio License, we and ABL Bio each are responsible for using commercially reasonable efforts to develop the licensed products through the completion of in vivo studies, and ABL Bio is responsible for using commercially reasonable efforts thereafter. We agreed to split costs fifty-fifty (50:50) with ABL Bio through the completion of in vivo studies, with ABL Bio responsible for all costs and activities following that time. ABL Bio is responsible for all development and commercialization activities, subject to our input through a joint committee comprised of an equal number of our and ABL Bio&#8217;s representatives (though ABL Bio has final decision-making authority). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In consideration of the license, ABL Bio paid us an upfront fee of US$2.5&#160;million and agrees to make milestone payments in the aggregate amount of US$97.5&#160;million conditioned upon achieving certain clinical development and sales milestones. Further, ABL Bio agreed to pay us royalties at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single-digit</div> percentages in respect of the total annual net sales of the licensed BsAb product. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, ABL Bio granted to us an exclusive, royalty-free, sublicensable license to use its BsAb technology solely to exploit the licensed BsAb product for all indications in Greater China. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also agreed that, during the term of the ABL Bio License, neither we nor ABL Bio would develop independently from the other a bispecific antibody that uses the same pair of antibodies as the bispecific antibody molecules created under the ABL Bio License. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ABL Bio License will continue to be in effect until expiration of the last payment obligation thereunder, unless earlier terminated according to its terms. The ABL Bio License may be terminated by either party for the other party&#8217;s uncured material breach or in the event that the other party challenges its patents. In addition, after a certain specified time period, ABL Bio may terminate the ABL Bio License upon a notice period that varies based upon the stage of development. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon expiration (but not termination) of the ABL Bio License, we and ABL Bio will each retain our respective licenses granted under the ABL Bio License. If the ABL Bio License is terminated pursuant to ABL Bio&#8217;s right to terminate at will or due to ABL Bio&#8217;s material breach, all rights and obligations (including all licenses granted) shall terminate and upon our request, we and ABL Bio will negotiate in good faith regarding our takeover of the exploitation of the BsAb product outside of Greater China in exchange for reasonable compensation. Such negotiation will include, among other things, ABL Bio&#8217;s assignment of assets related to the licensed BsAb product and the continuation of the licenses granted to us under the ABL Bio License. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement with CSPC Entity </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2018, we entered into a product development agreement (the &#8220;CSPC Agreement&#8221;) with an entity controlled by CSPC Pharmaceutical Group Limited (01093.HK) (&#8220;CSPC entity&#8221;). Under the CSPC Agreement, we granted to CSPC entity exclusive, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-transferable,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-irrevocable</div> and sublicensable rights under our patent rights in China to develop and commercialize TJ103 for treating type 2 diabetes mellitus and any other potential therapeutic applications. CSPC entity&#8217;s right to sublicense is conditioned on our prior written consent, which we cannot unreasonably withhold, other than sublicense to CSPC entity&#8217;s affiliates. CSPC entity is a comprehensive pharmaceutical and drug manufacturing company, with an increasing focus on its research and development of new products focusing the therapeutic area of oncology, among others. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">137 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the CSPC Agreement, CSPC entity is responsible for using commercially reasonable efforts to develop, obtain market approval and commercialize the licensed products, while we are responsible for using commercially reasonable efforts to transfer the manufacturing technology of the licensed products to CSPC entity and assist or guide CSPC entity in the continued optimization of such manufacturing technology thereafter. CSPC entity has final decision-making authority with respect to product development (though the research plan shall be jointly developed by both parties and any changes to the plan shall be discussed and approved by the joint development committee) and commercialization. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We also agreed that, during the term of the CSPC Agreement, we shall not develop, either for ourselves or for third parties, any other hyFc platform technology-based long-acting recombinant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GLP-1</div> Fc fusion proteins that may be in a competitive position with TJ103. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In consideration of the license, CSPC entity paid us an upfront fee of RMB15.0&#160;million and agreed to make milestone payments in an aggregate amount of RMB135.0&#160;million conditioned upon achieving certain clinical development and regulatory approval milestones, including completion of Phase 2 and Phase 3 clinical studies and obtaining NDA approval or market approval. Further, we will also be entitled to tiered royalties ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single-digit</div> percentages to 10&#160;percent in respect of the total annual net sales of the products after their commercialization in China. The royalty term shall terminate at the later of: (i)&#160;the expiry date of the underlying patents of the licensed products with application numbers 201410851771.1 and 201580071643.8 (final grant of rights requested relating to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GLP-1)</div> in China, whichever is later; and (ii)&#160;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-year</div> anniversary of the initial commercialization of the product developed under the CSPC Agreement. We expect any patents that may issue under the aforementioned patent application numbers 201410851771.1 and 201580071643.8 will expire between 2034 and 2035, before taking into account any extension that may be obtained through patent term extensions or adjustments, or term reduction due to filing of terminal disclaimers. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unless terminated earlier in accordance with the terms thereof, the CSPC Agreement will remain in effect until the termination of the royalty term. This agreement may be terminated by either party for the other party&#8217;s uncured material breach, bankruptcy or insolvency or force majeure. We have the right to terminate the agreement if CSPC entity fails to use commercially reasonable efforts to obtain regulatory approvals for commercializing the licensed product in the period stipulated by its board of directors due to its own fault or if CSPC entity ceases to pursue clinical development or product registration as determined by its board of directors. CSPC entity has the right to terminate the agreement if we fail to resolve certain intellectual property disputes relating to TJ103 within six months after signing. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the term of the CSPC Agreement, CSPC entity shall have exclusive, royalty-free rights in China to any work product generated by us, and be responsible for any patent application and maintenance costs of such work product. CSPC entity shall have all rights to any work product generated by itself under the CSPC Agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Out-Licensing</div> Arrangements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In April 2017, our subsidiary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai entered into a technology transfer agreement (the &#8220;HDYM License&#8221;) with Ningbo Hou De Yi Min Information Technology Co., Ltd. (&#8220;HDYM&#8221;) and Hangzhou HealSun Biopharm Co., Ltd. (&#8220;HealSun&#8221;) with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> humanized monoclonal antibodies. HealSun is a portfolio company of Lepu Biotech (&#20048;&#26222;&#29983;&#29289;). Under the HDYM License, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai agreed to grant to HDYM exclusive (even to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai itself), worldwide and sublicensable rights to develop, manufacture, have manufactured, use, sell, have sold, import, or otherwise exploit certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> related patents, patent applications, know-hows, data and information of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai, relevant cell lines as well as any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> monoclonal antibody arising from such cell lines for the treatment of diseases. Further, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai and its cooperative party HealSun agreed to provide subsequent research and development services on such intellectual property to HDYM, including the selection and examination of innovative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> humanized monoclonal antibodies, cultivation and selection of stable cell lines, establishment of cell bank, research and development of manufacturing processes and preparation of samples, toxicological and pharmacological testing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> pharmaceutical experiment report drafting, and application for and registration of clinical trials. If any party breaches the agreement and fails to cure, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-breaching</div> parties may terminate this agreement. In addition, in the event that the development of the licensed product encounters insurmountable technical difficulties, this agreement may be terminated by mutual agreement of all parties. To the extent that the agreement is terminated for HDYM&#8217;s breach, all licenses and rights granted by us to HDYM will automatically terminate and be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-assigned</div> to us. To the extent that the agreement is terminated due to material difficulty, HDYM will have all rights to dispose of any development data and technology held by HealSun and us under this agreement and neither HealSun or us may use such development data and technology without HDYM&#8217;s consent. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">138 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In March 2020, we entered into a strategic partnership with Kalbe Genexine Biologics (&#8220;KG&#8221;), a joint venture of Kalbe Farma Tbk (&#8220;Kalbe&#8221;) and Genexine. Under the terms of the agreement, KG will receive a right of first negotiation for an exclusive license for the commercialization of two <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab-discovered</div></div> product candidates: uliledlimab, a highly differentiated anti-CD73 antibody in Phase 1 development for advanced solid tumors, and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> product candidate to be agreed upon by both parties. With the agreement, KG will have a right of first negotiation for exclusive rights to commercialize these two product candidates in the ASEAN (Brunei Darussalam, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam) and MENA (Algeria, Bahrain, Djibouti, Egypt, Israel, Jordan, Kuwait, Lebanon, Malta, Morocco, Oman, Qatar, Saudi Arabia, Tunisia, United Arab Emirates, and Palestine) regions, as well as Sri Lanka. If and when we and KG enter into the definitive licensing agreement for uliledlimab, we will be eligible to receive from KG an aggregate amount of up to approximately US$340&#160;million, including an upfront payment and subsequent payments conditional upon achieving certain development and commercial milestones. KG will pay us tiered royalties in the low to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-teen</div> percentages on net sales from the ASEAN and MENA regions, as well as Sri Lanka. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">C. Collaboration Arrangements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2018, we entered into a collaboration agreement with ABL Bio whereby both parties agreed to collaborate to develop three <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1-based</div></div> bispecific antibodies by using ABL Bio&#8217;s proprietary BsAb technology and commercialize them in their respective territories, which, collectively, include the PRC, Hong Kong, Macau, Taiwan and South Korea, and other territories throughout the rest of the world if both parties agree to do so in such other territories during the performance of the agreement. This agreement may be terminated by either party for the other party&#8217;s uncured material breach or in the event that the other party challenges its patents. Also, if a party encounters insurmountable technical difficulties and risks, which cannot be resolved by such party within a certain period thereafter despite all reasonable efforts, such party will have the right to terminate this agreement and will no longer have the right to develop the licensed product. As of the date of this annual report, ABL Bio has paid US$2.5&#160;million upfront payment to us. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In September 2018, we entered into a collaboration and platform technology license agreement with WuXi Biologics Ireland Limited (&#8220;WuXi Biologics&#8221;), whereby both parties agreed to collaborate in the research and development of at least three bispecific antibodies for our company to commercialize them worldwide. Such bispecific antibodies shall be created using our proprietary monoclonal antibodies and WuXi Biologics&#8217; proprietary WuXiBody platform technology for generating bispecific antibodies, shall be developed and manufactured through the exclusive service of WuXi Biologics. This agreement may be terminated by either party for the other party&#8217;s uncured material breach, bankruptcy or insolvency. WuXi Biologics has the right to terminate this agreement if we challenge its patents. We have the right to terminate this agreement if we decide to end the development and commercialization of the licensed product in the licensed territory due to scientific, technical, or commercial reasons. As of the date of this annual report, we have made an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment of US$1.0&#160;million to Wuxi Biologics and no milestone payments or royalties are due under this agreement. In April 2019, we extended our existing partnership with WuXi Biologics (Shanghai) Co., Ltd. (&#8220;WuXi Biologics Shanghai&#8221;). We entered into a long-term, strategic collaboration agreement with WuXi Biologics Shanghai to facilitate the CMC development and GMP manufacturing of both clinical and commercial supplies of certain of our monoclonal and bispecific antibodies and fusion products, leveraging WuXi Biologics&#8217; and its affiliates&#8217; expertise in this area and supporting our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-existing</div> collaboration and platform technology license agreement with WuXi Biologics. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">139 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In November 2018, we entered into collaboration agreements with Tracon Pharmaceuticals, Inc. (&#8220;Tracon&#8221;), whereby we and Tracon agreed to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i)&#160;co-develop</div> our proprietary CD73 antibody, TJD5 (the &#8220;TJD5 Agreement&#8221;) and (ii)&#160;collaborate to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-develop</div> up to five bispecific antibodies (the &#8220;BsAbs Agreement&#8221;). Both agreements may be terminated by either party for the other party&#8217;s uncured material breach, bankruptcy or insolvency or for other reasons. In April 2020, Tracon issued a notice of disputes with respect to the TJD5 Agreement and the BsAbs Agreement. As of the date of this annual report, these disputes have not been resolved. In February 2021, we sent Tracon a notice to terminate the TJD5 Agreement, which would result in a prespecified termination fee of US$9.0&#160;million owing to Tracon. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In March 2021, we entered into two collaboration agreements with Complix, an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EU-based</div> biotech company (the &#8220;Complix Agreement&#8221;), and Affinity, a Shanghai-based biotech company (the &#8220;Affinity Agreement&#8221;), respectively, allowing us to access cutting-edge technology platforms to create next generation of novel and highly differentiated drug candidates, including Cell Penetrating Alphabodies (&#8220;CPAB&#8221;) for otherwise intractable intracellular drug targets and masked antibodies for targeted tumor-site activation. Under the Complix Agreement, both parties will collaborate to discover, develop and commercialize novel therapeutics for mutually agreed targets based on the Complix&#8217;s proprietary technology. Under the Affinity Agreement, both parties will collaborate to develop lead compounds for mutually agreed targets based on Affinity&#8217;s Tumor MicroEnvironment Activated body (&#8220;TMEAbody&#8221;) platform technology. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In March 2021, we entered into a license and collaboration agreement with Genbase, a Shanghai-based biotech company to develop bi-specific antibodies or/and multi-specific antibodies using antibody sequences from both companies. Under this agreement, Genbase granted to us a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-transferable,</div> sublicensable, and royalty-bearing license under Genbase parental antibody technology and Genbase parental antibody improvements owned and controlled by Genbase to make, develop and commercialize the licensed compounds and licensed products in all uses and indications worldwide. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competition </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our industry is highly competitive and subject to rapid and significant change. While we believe that our management&#8217;s research, development and commercialization experience provide us with competitive advantages, we face competition from global and China-based biopharmaceutical companies, including specialty pharmaceutical companies, generic drug companies, biologics drug companies, academic institutions, government agencies and research institutions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For our Global Portfolio drug candidates, we expect to face competition from a broad range of global and local pharmaceutical companies. Many of our competitors have significantly greater financial, technical and human resources than we have, and mergers and acquisitions in the biopharmaceutical industry may result in even more resources being concentrated among a smaller number of our competitors. Our commercial opportunity could be reduced or eliminated if our competitors develop or market products or other novel therapies that are more effective, safer or less costly than our current or future drug candidates, or obtain regulatory approval for their products more rapidly than we may obtain approval for our drug candidates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual Property </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for our drug candidates and other commercially important products, technologies, inventions and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> as well as on our ability to defend and enforce our patents including any patent that we have or may issue from our patent applications, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and proprietary rights of other parties. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of December&#160;31, 2020, our owned patent portfolio consists of (i) 22 issued patents, including six issued in the U.S., six issued in the PRC, five issued in Korea and five issued in other jurisdictions; and (ii) 241 pending patent applications, including 18 PCT patent applications, 18 U.S. patent applications, 16 PRC patent applications and 211 patent applications in other jurisdictions. Our owned patents and patent applications primarily relate to the drug candidates in our Global Portfolio. Furthermore, as of December&#160;31, 2020, we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> the Greater China and Korea rights relating to (i) 24 issued patents, including fourteen issued in the PRC, one issued in Korea, seven issued in Hong Kong and two issued in Taiwan; and (ii) 31 pending patent applications, including four PCT patent applications, nine PRC patent applications, nine Hong Kong patent applications, six Taiwan patent applications, two Korean patent applications and one Macau patent application. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents and patent applications primarily relate to felzartamab, eftansomatropin alfa, olamkicept, enoblituzumab and efineptakin alfa. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">140 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 17%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 82%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Felzartamab</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">As of December 31, 2020, we exclusively licensed from MorphoSys ten issued patents (including six issued in the PRC, three issued in Hong Kong and one issued in Taiwan) and ten pending patent applications (including two PCT applications, two in the PRC and three in Hong Kong, two in Taiwan and one in Macau) relating to felzartamab. The licensed patents include composition of matter patents in China, Hong Kong and Taiwan. The patents (including patent applications if issued) in this portfolio are expected to expire between 2025 and 2040, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Eftansomatropin alfa</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">As of December&#160;31, 2020, we (i)&#160;exclusively licensed from Genexine two pending PRC patent applications directly relating to eftansomatropin alfa and (ii)&#160;exclusively licensed from Genexine three issued patents in the PRC relating to a hyFc platform that develops eftansomatropin alfa. The licensed patents include composition of matter patents in China. The patents (including patent applications if issued) in this portfolio are expected to expire between 2028 and 2037, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Olamkicept</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">As of December&#160;31, 2020, we exclusively licensed from Ferring two issued patents in the PRC and Korea relating to olamkicept and six patient applications in the PRC, Hong Kong and Korea relating to olamkicept. The licensed patents include composition of matter patents. These patents are expected to expire between 2027 and 2035, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Enoblituzumab</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">As of December&#160;31, 2020, we exclusively licensed from MacroGenics six issued patents (including two issued in the PRC, three issued in Hong Kong and one issued in Taiwan) and eight pending patent applications (including two in the PRC, four in Hong Kong and two in Taiwan) relating to enoblituzumab. The patents (including patent applications if issued) in this portfolio are expected to expire between 2023 and 2036, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Efineptakin alfa</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">As of December&#160;31, 2020, we (i)&#160;exclusively licensed from Genexine one pending PRC patent application directly relating to efineptakin alfa and (ii)&#160;exclusively license from Genexine three issued patents in the PRC relating to a hyFc platform that develops efineptakin alfa. The patents (including patent applications if issued) in this portfolio are expected to expire between 2028 and 2036, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Plonmarlimab</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">As of December&#160;31, 2020, we owned one PCT patent application that relates to plonmarlimab and it has entered national phases in China, the United States and 24 other jurisdictions. We expect that any patent that may issue under this application will expire in 2037, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lemzoparlimab</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">As of December&#160;31, 2020, we owned two PCT patent application, one of which has entered national phases in the PRC, the United States and 26 other jurisdictions, and the other has entered national phase in the United States and the PRC. We expect that any patents that may issue under these applications will expire between 2037 and 2039, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Uliledlimab</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">As of December&#160;31, 2020, we owned one PCT patent application and it has entered national phases in the PRC, the United States, and 24 other jurisdictions. We expect that any patent that may issue under this application will expire in 2038, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">141 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The term of a patent depends upon the laws of the country in which it is issued. In most jurisdictions, a patent term is 20 years from the earliest filing date of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-provisional</div> patent application. Under the PRC Patent Law, the term of patent protection starts from the date of application. Patents relating to inventions are effective for twenty years, and utility models and designs are effective for ten years from the date of application. There are no patent term adjustments or patent term extensions available in the PRC for issued patents. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to patents, we rely upon unpatented trade secrets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> can be difficult to protect. We seek to protect our proprietary information, in part, by executing confidentiality agreements with our partners, collaborators, scientific advisors, employees, consultants and other third parties, and invention assignment agreements with our consultants and employees. We have also executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. The confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the respective counterparty. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes or that these agreements will afford us adequate protection of our intellectual property and proprietary information rights. If any of the partners, collaborators, scientific advisors, employees and consultants who are parties to these agreements breaches or violates the terms of any of these agreements or otherwise discloses our proprietary information, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, as of December&#160;31, 2020, we had (i)&#160;three registered trademarks in Hong Kong, 16 registered trademarks in the PRC, two registered trademarks in the United States, 43 trademark applications in the PRC, 14 trademark applications in Hong Kong, 17 trademark applications in Macau, 16 trademark applications in Taiwan and four trademark applications in the United States; (ii) 12 domain names in the PRC, including <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">www.i-mabbiopharma.com</div></div>, four domain names in Hong Kong and two domain names in the United States and (iii) 12 software copyrights in the PRC. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For more information on these and other risks related to intellectual property, see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Enterprise Social Responsibility </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As an integral part of our business and as a core value, we strive to make a positive impact around the world through the transformational medicines that we research, develop, manufacture and deliver. We are committed to reflecting ethical, social and environmental responsibilities in our business decisions, ensuring that our products improve people&#8217;s lives and maintaining the sustainability of our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our contribution to improving healthcare and alleviating suffering was evidenced by our work responding to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> outbreak. We joined the global effort by initiating the development of plonmarlimab to treat cytokine storm in severely ill patients with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Cytokine storm is characterized by a surge of inflammatory cytokines and is an overreaction of the immune system in patients infected with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2.</div></div> Recent studies revealed that high levels of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF,</div> along with a few other cytokines, are critically associated with severe complications in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> patients. Research indicates plonmarlimab may be a potential treatment for cytokine storm associated with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> because the antibody effectively neutralizes circulating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> to control acute inflammatory responses, with potential advantages over conventional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> antibodies. We received IND clearance from the FDA in April 2020 and our study commenced initially in the United States. Following a safety assessment of the first part of the study, a Phase 2/3 trial is ongoing in patients with cytokine release syndrome associated with severe <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Initial data indicated that plonmarlimab is safe and well-tolerated in the severe <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> patients in the study. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">142 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In addition, at the peak of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> outbreak, we donated personal protective equipment and funds worth a total of RMB800&#160;thousand to support medical personnel and hospitals in Wuhan. We also donated US$50&#160;thousand to BayHelix, a non-profit organization focused on global life sciences and healthcare community, for the purpose of supporting relief of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> in the United States. Meanwhile, we took the health and safety of our employees as our top priority and implemented employee caring programs to provide health supplies and demonstrated support for the global <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> family. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To help medical communities and health care providers in different parts of the world understand the experiences treating and managing severe <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> patients, we, in collaboration with American Academy of Medical Education and Ding Xiang Yuan, a leading medical media in China, brought together nine distinguished clinical experts from China and the U.S. in April 2020 for a virtual webinar to share insights and important lessons from the frontlines. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have also been on the forefront to promote diversity and inclusiveness in the workplace. In 2020, we launched the Women&#8217;s Leadership Council (&#8220;WLC&#8221;) globally to support the organization&#8217;s future female leaders to accelerate their career and personal development. We organized our global WLC ambassador program and selected eight outstanding female employees to champion our mission of elevating women in scientific leadership. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Recognition and Awards </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The remarkable achievements made by us are well recognized by the international community of pharma industry. We received numerous international awards and citations in 2020 in recognition of our achievements in drug innovation, industry leadership, cross-border collaboration and successful business achievements. We, along with our partner AbbVie, received the Deal of the Year award from BioCentury-Bay Helix for our global strategic partnership to develop and commercialize lemzoparlimab. We were listed among the 50 Smartest Companies in China by MIT Technology Review, a leading global technology business magazine. We also received the China Healthcare New Power Award from People.cn, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-tier</div> Chinese national media and was among the 10 Biotechs to Know in China by FiercePharma, an influential U.S.-based trade journal. Our Founder and Chairman, Dr.&#160;Jingwu Zhang Zang, was named Medical Innovation Pioneer among the 50 leaders in listed companies by 2020 Global Founders Summit. These awards reflect the impact we have made on the innovation development of the healthcare industry as well as the leadership we have demonstrated throughout the year. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to a variety of PRC laws, rules and regulations affecting many aspects of our business. This section summarizes the principal PRC laws, rules and regulations that we believe are relevant to our business and operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PRC Regulation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to a variety of PRC laws, rules and regulations affecting many aspects of our business. This section summarizes the principal PRC laws, rules and regulations that we believe are relevant to our business and operations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Regulations on Company Establishment and Foreign Investment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Company Law </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The establishment, operation and management of companies in China is governed by the PRC Company Law, which was passed by the Standing Committee of the National People&#8217;s Congress (the &#8220;NPC&#8221;), on December&#160;29, 1993 and came into effect on July&#160;1, 1994 and was latest revised or amended on October&#160;26, 2018, respectively. In light of the PRC Company Law, companies established in the PRC are either in the form of a limited liability company or a joint stock company. The PRC Company Law applies to both PRC domestic companies and foreign-invested companies, unless otherwise provided in the relevant foreign investment laws and regulations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">143 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign Investment Law </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;15, 2019, the NPC approved the PRC Foreign Investment Law, which became effective on January&#160;1, 2020 and replaced the three old rules on foreign investment in China, namely, the PRC Equity Joint Venture Law, the PRC Cooperation Joint Venture Law and the Wholly Foreign-Owned Enterprise Law, together with their implementation rules and ancillary regulations. The Foreign Investment Law establishes the basic framework for the access to, and the promotion, protection and administration of foreign investments in view of investment protection and fair competition. According to the Foreign Investment Law, &#8220;foreign investment&#8221; refer to investment activities directly or indirectly conducted by one or more natural persons, business entities, or other organizations of a foreign country (collectively referred to as &#8220;foreign investor&#8221;) within China, and &#8220;investment activities&#8221; include the following activities: (i)&#160;a foreign investor, individually or together with other investors, establishes a foreign-invested enterprise within China; (ii)&#160;a foreign investor acquires stock shares, equity shares, shares in assets, or other similar rights and interests of an enterprise within China; (iii)&#160;a foreign investor, individually or together with other investors, invests in a new construction project within China; and (iv)&#160;investments in other means as provided by the laws, administrative regulations or the State Council. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Regulations Relating to Foreign Investment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;26, 2019, the State Council promulgated the Implementation Rules to the Foreign Investment Law, which became effective on January&#160;1, 2020. The implementation rules further clarified that the state encourages and promotes foreign investment, protects the lawful rights and interests of foreign investors, regulates foreign investment administration, continues to optimize foreign investment environment, and advances a higher-level opening. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Furthermore, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PRC-based</div> investments by foreign investors have historically been regulated by the Catalogue for the Guidance of Foreign Investment Industries (2017 Revision) issued on June&#160;28, 2017 and effective from July&#160;28, 2017, the Special Management Measures (Negative List) for the Access of Foreign Investment (2018)&#160;issued on June&#160;28, 2018 and effective from July&#160;28, 2018, and the Special Management Measures (Negative List) for the Access of Foreign Investment (2019)&#160;issued on June&#160;30, 2019 and effective from July&#160;30, 2019. According to the aforesaid catalogue and management measures, foreign-invested industries fall into four categories, namely, &#8220;encouraged&#8221; &#8220;permitted&#8221; &#8220;restricted&#8221; and &#8220;prohibited&#8221; and certain ownership requirements, requirements for senior executives and other special management measures shall apply to foreign investors with regard to the access of foreign investments in certain categories. Currently, the Catalogue for the Guidance of Foreign Investment Industries (2017 Revision), the Special Management Measures (Negative List) for the Access of Foreign Investment (2018)&#160;and the Special Management Measures (Negative List) for the Access of Foreign Investment (2018)&#160;have all been replaced. The currently effective industry entry clearance requirements governing investment activities in the PRC by foreign investors are set out in two categories, namely the Special Management Measures (Negative List) for the Access of Foreign Investment (2020), and the Catalogue of Industries for Encouraging Foreign Investment (2020 Version), which were promulgated by the National Development and Reform Commission (the &#8220;NDRC&#8221;), and the MOFCOM, and took effect on July&#160;23, 2020 and on January&#160;27, 2021, respectively. The Catalogue of Industries for Encouraging Foreign Investment (2020 Version) and the Special Management Measures (Negative List) for the Access of Foreign Investment (2020)&#160;further reduce restrictions on the foreign investment and expand the scope of industries in which foreign investments are encouraged. Industries not listed in these two catalogues are generally deemed &#8220;permitted&#8221; for foreign investment unless specifically restricted by other PRC laws. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;30, 2019, the MOFCOM and SAMR jointly promulgated Measures for Information Reporting on Foreign Investment, which became effective on January&#160;1, 2020. Pursuant to the Measures for Information Reporting on Foreign Investment, where a foreign investor carries out investment activities in China directly or indirectly, the foreign investor or the foreign-invested enterprise shall submit the investment information to the competent commerce department. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">144 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">M&amp;A Rules </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">According to the Provisions on the Merger or Acquisition of Domestic Enterprises by Foreign Investors jointly issued by the MOFCOM, the State Assets Supervision and Administration Commission of the State Council, the State Administration of Taxation (the &#8220;SAT&#8221;), the State Administration for Industry and Commerce (now known as the State Administration for Market Regulation), the China Securities Regulatory Commission and the State Administration of Foreign Exchange (the &#8220;SAFE&#8221;), on August&#160;8, 2006 and amended by the MOFCOM on June&#160;22, 2009, among other things, (i)&#160;the purchase of an equity interest or subscription to the increase in the registered capital of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-foreign-invested</div> enterprises, (ii)&#160;the establishment of foreign-invested enterprises to purchase and operate the assets of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-foreign-invested</div> enterprises, or (iii)&#160;the purchase of the assets of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-foreign-invested</div> enterprises and the use of such assets to establish foreign-invested enterprises to operate such assets, in each case, by foreign investors shall be subject to the Provisions on the Merger or Acquisition of Domestic Enterprises by Foreign Investors. Particularly, application shall be made for examination and approval of the acquisition of any company in China affiliating to a domestic company, enterprise or natural person, which is made in the name of an oversea company established or controlled by such domestic company, enterprise or natural person. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PRC Drug Regulation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Drug Administration Law of the PRC promulgated by the Standing Committee of the NPC on September&#160;20, 1984 and effective from July&#160;1, 1985 and amended on February&#160;28, 2001, December&#160;28, 2013, April&#160;24, 2015 and August&#160;26, 2019, respectively, and the Implementing Measures of the Drug Administration Law promulgated by the State Council on August&#160;4, 2002 and effective from September&#160;15, 2002 and amended on February&#160;6, 2016 and March&#160;2, 2019, respectively, have jointly established the legal framework for the administration of pharmaceutical products in China, including the research, development and manufacturing of new drugs. The Drug Administration Law applies to entities and individuals engaged in the development, production, trade, application, supervision and administration of pharmaceutical products, which regulates and provides for a framework for the administration of pharmaceutical manufacturers, pharmaceutical trading companies and medicinal preparations of medical institutions, and the development, research, manufacturing, distribution, packaging, pricing and advertisements of pharmaceutical products. The Implementing Measures of the Drug Administration Law, on the other hand, provides detailed implementation regulations for the Drug Administration Law. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The newly amended Drug Administration Law, which became effective on December&#160;1, 2019, brought a series of changes to the drug supervision and administration system, including but not limited to the clarification of the drug marketing authorization holder system, pursuant to which the marketing authorization holder shall assume responsibilities for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies, clinical trials, manufacturing and marketing, post-marketing studies, monitoring, reporting and handling of adverse reactions of the drug. The amendment also stipulates that the State supports the innovation of drugs with clinical value and specific or special effects on human diseases, encourages the development of drugs with new therapeutic mechanisms and have multi-targeted, systematic regulatory and intervention functions on human body and promotes the technological advancement of drugs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are required to follow the above-mentioned regulations in respect of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> research, clinical trials and production of new drugs. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Regulatory Authorities and Recent Government Reorganization </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pharmaceutical products and medical devices and equipment in China are monitored and supervised on a national scale by the NMPA (formerly known as the China Food and Drug Administration, or the &#8220;CFDA&#8221;), while the local provincial medical products administrative authorities are responsible for the supervision and administration of drugs within their respective administrative regions. Pursuant to the Decision of the First Session of the Thirteenth National People&#8217;s Congress on the State Council Institutional Reform Proposal made by the NPC on March&#160;17, 2018, the NMPA is no longer an independent agency and its duties shall be performed by the newly established State Administration for Market Regulation, into which the various agencies responsible for, among other areas, consumer protection, advertising, anticorruption, pricing, fair competition and intellectual property, have been merged. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The NMPA is still the chief drug regulatory agency and implements the same laws, regulations, rules, and guidelines as the CFDA, and the NMPA regulates almost all of the key stages of the life cycle of pharmaceutical products, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies, clinical trials, marketing approvals, manufacturing, advertising and promotion, distribution, and pharmacovigilance (i.e., post-marketing safety reporting obligations). The Center for Drug Evaluation (the &#8220;CDE&#8221;), which remains under the NMPA, conducts the technical evaluation of each drug and biologic application for safety and effectiveness. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">145 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Formed on March 2018, the National Health Commission (the &#8220;NHC&#8221;) (formerly known as the Ministry of Health (&#8220;MOH&#8221;) and the National Health and Family Planning Commission (&#8220;NHFPC&#8221;)) is China&#8217;s chief healthcare regulator. It is primarily responsible for overseeing the operation of medical institutions, which also serve as clinical trial sites, and regulating the licensure of hospitals and medical personnel. The NHC plays a significant role in drug reimbursement. Furthermore, the NHC and its local counterparts at or below provincial-level local governments also oversee and organize public medical institutions&#8217; centralized bidding and procurement process for pharmaceutical products, which is the chief means through which public hospitals and their internal pharmacies acquire drugs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Also, as part of its 2018 reorganization, the PRC government formed a new National Healthcare Security Administration, which focuses on regulating reimbursement under the state-sponsored insurance plans. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Clinical</div> Research </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On August&#160;4, 2003, the NMPA promulgated the Administrative Measures for Good Laboratories Practice of Non-clinical Laboratory, which was revised on July&#160;27, 2017, to improve the quality of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> research, and began to conduct the Good Laboratories Practice. Pursuant to the Circular on Administrative Measures for Certification of Good Laboratory Practice for Non-clinical Laboratory issued by the NMPA on April&#160;16, 2007, the NMPA is responsible for the certification of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> research institutions nationwide and local provincial medical products administrative authorities is in charge of the daily supervision of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> research institution. The NMPA decides whether an institution is qualified for undertaking pharmaceutical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> research by evaluating such institution&#8217;s organizational administration, its research personnel, its equipment and facilities, and its operation and management of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> pharmaceutical projects. A Good Laboratory Practice Certification will be issued by the NMPA if all the relevant requirements are satisfied, which will also be published on the NMPA&#8217;s website. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Regulations for the Administration of Affairs Concerning Experimental Animals promulgated by the State Science and Technology Commission on November&#160;14, 1988 and amended on January&#160;8, 2011, July&#160;18, 2013 and March&#160;1, 2017, respectively, by the State Council, the Administrative Measures on Good Practice of Experimental Animals jointly promulgated by the State Science and Technology Commission and the State Bureau of Quality and Technical Supervision on December&#160;11, 1997, and the Administrative Measures on the Certificate for Experimental Animals (Trial) promulgated by the State Science and Technology Commission and other regulatory authorities on December&#160;5, 2001, a Certificate for Use of Laboratory Animals is required for performing experimentation on animals. Applicants must satisfy the following conditions: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory animals must be qualified and sourced from institutions that have Certificates for Production of Laboratory Animals; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The environment and facilities for the animals&#8217; living and propagating must meet national requirements; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The animals&#8217; feed and water must meet national requirements; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The animals&#8217; feeding and experimentation must be conducted by professionals, specialized and skilled workers, or other trained personnel; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The management systems must be effective and efficient; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The applicable entity must follow other requirements as stipulated by Chinese laws and regulations. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> and Clinical Development </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The NMPA requires supporting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> data for the registration applications for imported and domestic drugs. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> work, including pharmacology and toxicology studies, must satisfy the requirements of the Administrative Measures for Good Laboratories Practice of Non-clinical Laboratory. No approval is required from the NMPA to conduct <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">146 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Trials and Registration of New Drugs </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Categories&#8212; </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to the Administrative Measures for Drug Registration promulgated by the NMPA on July&#160;10, 2007 and effective from October&#160;1, 2007, which provides the standards and requirements for clinical trials and drug registration applications, drug registration applications are divided into three different types, namely, New Drug Application, Generic Drug Application, and Imported Drug Application. Drugs are categorized based on their working mechanism, including chemical medicine, biological product or traditional Chinese or natural medicine. On January&#160;22, 2020, the SAMR promulgated the new Administrative Measures for Drug Registration (the &#8220;New Measures for Registration&#8221;), which became effective from July&#160;1, 2020. According to the New Measures for Registration, drug registration applications are divided into three different types, namely, traditional Chinese medicine, chemical medicine, and biological products, and each type is further divided into several <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-types.</div> The category and corresponding application requirements will be promulgated by the NMPA based on a drug&#8217;s working mechanism, degree of innovation, and the need of review management. As provided in the New Administrative Measures for Registration, the Drug Administration Law and Implementing Measures of the Drug Administration Law, upon completion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> research, clinical trials shall be conducted for the application of new drug registration. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Trial Approval&#8212; </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All clinical trials conducted in China for new drug development must be approved and conducted at pharmaceutical clinical trial institution which shall be under filing administration. For imported drugs, proof of foreign approval is required prior to the trial, unless the drug has never been approved anywhere in the world. In addition to a standalone trial in China, imported drug applicants may establish a site in China as part of an international multi-center trial (the &#8220;IMCT&#8221;) at the outset of the global trial. Domestically manufactured drugs are not subject to foreign approval requirements, and by contrast to prior practice, the NMPA has recently decided to also permit such drugs to be tested and developed through an IMCT. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the NMPA has adopted a notification system for clinical trials of new drugs. Pursuant to the newly amended Drug Administration Law and the New Measures for Registration, effective from July&#160;1, 2020, clinical trials may be commenced as long as the applicant has not received any objections from the CDE within 60 business days of application filing after acceptance of the application, and such application will be deemed as approved. Bioequivalence test may only be conducted after the completion of record-filing on the website of the CDE. All clinical trials that have been approved but not initiated within three years since the execution of the Informed Consent Forms will become invalid. As provided in the New Measures for Registration, a new application of clinical trial must be submitted if an applicant of an approved clinical trial decides to add new indications or drug combinations into the trial. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Drug Clinical Trial Registration </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to the Administrative Measures for Drug Registration, upon obtaining the clinical trial approval and before commencing a clinical trial, the applicant shall file a registration with the NMPA containing various details of the clinical trial, including the clinical study protocol, the name of the principal researcher of the leading institution, names of participating institutions and researchers, an approval letter from the ethics committee, and a sample of the Informed Consent Form, with a copy sent to the competent provincial administration departments where the trial institutions will be located. On September&#160;6, 2013, the NMPA released the Announcement on Drug Clinical Trial Information Platform, providing that for all clinical trials approved by the NMPA and conducted in China, instead of the aforementioned registration filed with the NMPA, clinical trial registration shall be completed and trial information shall be published through the Drug Clinical Trial Information Platform. The applicant shall complete trial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-registration</div> within one month after obtaining the clinical trial approval to obtain the trial&#8217;s unique registration number and shall complete registration of certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> information before the first subject&#8217;s enrollment in the trial. If approval of the foregoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-registration</div> and registration is not obtained within one year after obtaining the clinical trial approval, the applicant shall submit an explanation, and if the procedure is not completed within three years, the clinical trial approval shall automatically expire. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">147 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the New Measures for Registration, during the period of clinical trial, the applicant must continuously update the registration information and the trial results after completion of each clinical trial on the Drug Clinical Trial Information Platform. Applicants are responsible for the authenticity of the registration information. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Human Genetic Resources Approval&#8212; </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;10, 1998, the Ministry of Science and Technology and the MOH jointly established the rules for protecting and utilizing human genetic resources in China. On July&#160;2, 2015, the Ministry of Science and Technology issued the Service Guide for Administrative Licensing Items concerning Examination and Approval of Sampling, Collecting, Trading, Exporting Human Genetic Resources, or Taking Such Resources out of the PRC, which provides that foreign-invested sponsors that sample and collect human genetic resources in clinical trials shall be required to file with the China Human Genetic Resources Management Office through its online system. On October&#160;26, 2017, the Ministry of Science and Technology issued the Circular on Optimizing the Administrative Examination and Approval of Human Genetic Resources, which simplified the approval for sampling and collecting human genetic resources for the purpose of commercializing a drug in the PRC. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;10, 2019, the State Council of the PRC issued the PRC Administrational Rules on the Management of Human Genetic Resources (effective from July&#160;1, 2019) (&#8220;Genetic Rules&#8221;), which formalized the approval requirements pertinent to research collaborations between Chinese and foreign-owned entities. Pursuant to this new rule, a new notification system (as opposed to the advance approval approach originally in place) is put in place for clinical trials using China&#8217;s human genetic resources at clinical institutions without involving the export of human genetic resources outside of China. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;17, 2020, the Standing Committee of the NPC promulgated the Biosecurity Law of the PRC, which became effective from April&#160;15, 2021. The new law restates the approval and notification requirements of human genetic resources sampling, collecting, utilizing and exporting, as provided in the Genetic Rules. Moreover, the promulgation of the new law, which takes the form of national law, further demonstrates the commitments of protecting China&#8217;s human genetic resources and safeguarding state biosecurity by the PRC government. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trial Exemptions and Acceptance of Foreign Data&#8212; </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The NMPA may reduce its requirements for clinical trials and data, depending on the drug and the existing data. The NMPA has granted waivers for all or part of trials and has stated that it will accept data generated abroad (even if not as part of a global study), including early phase data, that meets its requirements. On July&#160;6, 2018, the NMPA issued the Technical Guidance Principles on Accepting Foreign Drug Clinical Trial Data (the &#8220;Guidance Principles&#8221;) as one of the implementing rules for the Innovation Opinion. According to the Guidance Principles, the data of foreign clinical trials must meet the authenticity, completeness, accuracy and traceability requirements, and such data must be obtained in consistency with the relevant requirements under the Good Clinical Trial Practice (GCP) of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (the &#8220;ICH&#8221;). Clinical trial sponsors must be attentive to potentially meaningful ethnic differences in the subject population. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The NMPA now officially permits, and its predecessor agencies have permitted on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">case-by-case</div></div> basis in the past, drugs approved outside of China to be approved in China on a conditional basis without <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> clinical trials being conducted in China. Specifically, in 2018, the NMPA issued the Procedures for Reviewing and Approval of Clinical Urgently Needed Overseas New Drugs, permitting drugs that have been approved within the last ten years in the United States, the European Union or Japan and that prevent or treat orphan diseases or prevent or treat serious life-threatening illnesses for which there is either no effective therapy in China or for which the foreign-approved drug would have clear clinical advantages. Applicants will be required to establish a risk mitigation plan and may be required to complete trials in China after the drug has been marketed. The CDE has developed a list of qualifying drugs that meet the foregoing criteria. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">148 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Trial Process and Good Clinical Practices&#8212; </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Typically, drug clinical trials in China have four phases. Phase 1 refers to the initial clinical pharmacology and human safety evaluation studies. Phase 2 refers to the preliminary evaluation of a drug candidate&#8217;s therapeutic efficacy and safety for target indication(s) in patients. Phase 3 (often the pivotal study) refers to clinical trials that further verify the drug candidate&#8217;s therapeutic efficacy and safety on patients with target indication(s) and ultimately provide sufficient evidence for the review of a drug registration application. Phase 4 refers to a new drug&#8217;s post-marketing study to assess therapeutic effectiveness and adverse reactions when the drug is widely used, to evaluate overall benefit-risk relationships of the drug when used among the general population or specific groups and to adjust the administration dose, etc. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;6, 2003, the NMPA promulgated the Administration of Quality of Drug Clinical Practice (the &#8220;GCP&#8221;) to improve the quality of clinical trials. Pursuant to the newly amended Drug Administrative Law, and the Regulations on the Administration of Drug Clinical Trial Institution jointly promulgated by NMPA and NHC on November&#160;29, 2019 and effective from December&#160;1, 2019, drug clinical trial institutions shall be under filing administration. Clinical trial institutions that only conduct analysis of biological samples related to clinical trials of drugs do not need to be filed. Pursuant to the Circular on Measures for Certification of Good Laboratory Practice for Non-clinical Laboratory, a Good Laboratory Practice Certification will be issued by the NMPA if all the relevant requirements are satisfied, which will also be published on the NMPA&#8217;s website. Pursuant to the Opinions on Deepening the Reform of the Evaluation and Approval System and Inspiring Innovation of Drugs and Medical Devices and Equipment, the accreditation of the institutions for drug clinical trials shall be subject to record-filing administration. The conduct of clinical trials must adhere to the Good Laboratory Practice, and the protocols must be approved by the ethics committees of each study site. On April&#160;23, 2020, the NMPA and NHC jointly issued the amended Administration of Quality of Drug Clinical Practice (the &#8220;new GCP&#8221;), effective from July&#160;1, 2020. The new GCP was highly consistent with ICH E6 (R2) in its structure and content, and highly emphasized the protection of subjects, in particular, the protection of vulnerable subjects was provided through reinforcing the ethics committee&#8217;s responsibilities. Furthermore, the new GCP clarified the investigator&#8217;s responsibilities for medical decisions relevant to the clinical trials and overseeing the clinical trials to ensure the accuracy and completeness of the source data, it also included the sponsor&#8217;s responsibilities for implementing and maintaining the quality management system, requiring that the electronic data management system used by the sponsor should be verifiable, equipped with grant of modification authority and data security measures, to ensure the data modification process is completely recorded and tracked. The new GCP also prohibited the conduct of biological sample testing irrelevant to the study protocol approved by the ethics committee. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reform of Evaluation and Approval System for Drugs </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;9, 2015, the State Council promulgated the Opinions on the Reform of Evaluation and Approval System for Drugs and Medical Devices and Equipment, which establishes the reform framework of the evaluation and approval system for drugs, medical devices and equipment, indicating the enhancement of the standard of approval for drug registration and accelerating the evaluation and approval process for innovative drugs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;11, 2015, the NMPA issued the Circular Concerning Several Policies on Drug Registration Review and Approval, which further clarifies the measures and policies with regard to the simplification and acceleration of the approval process for drugs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">According to the Decision of the NMPA on Adjusting the Approval Procedures under the Administrative Approval Items for Certain Drugs made on March&#160;17, 2017 and effective from May&#160;1, 2017, the approval for a clinical trial application can be directly issued by the CDE under the NMPA on behalf of the NMPA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;8, 2017, the General Office of the State Council promulgated the Innovation Opinions, which further promotes the structural adjustment to and technical innovations of drugs, medical devices and equipment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;17, 2018, the NMPA and the NHC jointly issued the Circular on Issues Concerning Optimizing Drug Registration Review and Approval, which further simplifies and accelerates the clinical trial approval process. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">149 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;22, 2020, the SAMR promulgated the New Measures for Registration, effective from July&#160;1, 2020, which deploys several mechanisms to simplify and accelerate the drug registration process, including the Priority Review Procedure and the Special Review Procedure. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;7, 2020, the NMPA promulgated the Evaluation and Approval Working Process for Revolutionary Therapeutic Drugs (Trial), the Evaluation and Approval Working Process for the Conditional Approval Application of Drugs (Trial) and the Priority Evaluation and Approval Working Process for Drugs (Trial), repealing the Opinions on Encouraging the Prioritized Evaluation and Approval for Drug Innovations, which provide for fast track clinical trial approval, drug registration pathway or conditional approval to innovative drugs or drugs with revolutionary therapeutic effects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;19, 2020, CDE promulgated the Clinical Technical Guidelines for Conditional Approval of Drugs (Tentative), which became effective on the same day, to accelerate the marketing of clinically urgent drugs with outstanding clinical value in China. According to such guidelines, during the period of drug clinical trials, a drug may be applied for conditional approval if it meets the following conditions: (i)&#160;for the treatment of seriously life-threatening diseases with no existing effective treatment available, as well as medicines urgently needed for public health, whose clinical trials have shown efficacy and whose clinical value can be predicted; (ii)&#160;vaccines that are urgently needed in response to major public health emergencies or other vaccines that are identified as being urgently needed by the NHC, and whose benefits are assessed to outweigh the risks. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Special Examination and Fast Track Approval for Innovative Drugs under Current Reform Frame </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Provisions on the Administration of Special Examination and Approval of Registration of New Drugs promulgated by the NMPA on January&#160;7, 2009, the NMPA conducts special examination and approval for new drug registration applications when, among others, (1)&#160;the effective constituent of a drug extracted from plants, animals, minerals, etc., as well as the preparations thereof, have never been marketed in China, or the material medicines and the preparations thereof are newly discovered; (2)&#160;the chemical raw material medicines as well as the preparations thereof and the biological product have not been approved for marketing anywhere in the world; (3)&#160;the new drugs are for treating AIDS, malignant tumors and rare diseases, etc., and have obvious advantages in clinical treatment; or (4)&#160;the new drugs are for treating diseases with no effective methods of treatment. The Provisions on the Administration of Special Examination and Approval of Registration of New Drugs provides that the applicant may file for special examination and approval at the clinical trial application stage if the drug candidate falls within items (1)&#160;or (2). The provisions provide that for drug candidates that fall within items (3)&#160;or (4), the application for special examination and approval cannot be made until filing for production. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Circular Concerning Several Policies on Drug Registration Review and Approval issued on November&#160;11, 2015 further clarifies the above-mentioned policy, potentially simplifying and accelerating the approval process of clinical trials: (x)&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> umbrella approval procedure allowing the overall approval of all phases of a new drug&#8217;s clinical trials, replacing the current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">phase-by-phase</div></div> application and approval procedure, will be adopted for new drugs&#8217; clinical trial applications; and (y)&#160;a fast track drug registration or clinical trial approval pathway for the following applications: (i)&#160;registration of innovative new drugs treating AIDS, malignant tumors, serious infectious diseases and rare diseases; (ii)&#160;registration of pediatric drugs; (iii)&#160;registration of drugs treating specific or prevalent diseases in elders; (iv)&#160;registration of drugs listed in national major science and technology projects or national key research and development plan; (v)&#160;registration of innovative drugs using advanced technology, using innovative treatment methods, or having distinctive clinical benefits; (vi)&#160;registration of foreign innovative drugs to be manufactured locally in China; (vii)&#160;concurrent applications for new drug clinical trials which are already approved in the United States or the European Union or concurrent drug registration applications for drugs which have applied to the competent drug approval authorities for marketing authorization and passed such authorities&#8217; onsite inspections in the United States or European Union and are manufactured using the same production line in China; and (viii)&#160;clinical trial approval for drugs with urgent clinical need and patent expiry within three years, and manufacturing authorization applications for drugs with urgent clinical need and patent expiry within one year. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Opinions on Encouraging the Prioritized Evaluation and Approval for Drug Innovations promulgated on December&#160;21, 2017 provides that a fast track clinical trial approval or drug registration pathway will be available to both innovative drugs with distinctive clinical benefits, which have not been sold within or outside China, and drugs using advanced technology, innovative treatment methods or having distinctive treatment advantages. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">150 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Opinions on the Reform of Evaluation and Approval System for Drugs and Medical Devices and Equipment promulgated on August&#160;9, 2015 provides that the composition of the examiner team of the CDE shall be strengthened by, among other actions, (1)&#160;recruiting professional evaluation talent from the public, (2)&#160;engaging relevant experts to participate in technological examination and evaluation, and (3)&#160;establishing a system of chief professional positions. Additionally, the Opinions on Encouraging the Prioritized Evaluation and Approval for Drug Innovations emphasizes the improvement of the examination and evaluation system, which requires the establishment of a new drug examination and evaluation team comprising professionals specialized in clinical medicine, pharmaceutical sciences, pharmacology, toxicology and statistics. As a result, since 2015, the NMPA and the CDE have started a large-scale expansion of examiners, which could greatly accelerate the new drug approval process in China. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the New Measures for Registration, at the stage of clinical trial application, depending on the characteristics of the drug and the corresponding conditions, applicants may apply for adoption of the Breakthrough Drug Procedure or the Conditioned Approval Procedure. Such procedures may be applied for eligible drugs, including drugs for fatal diseases without any effective treatment and breakthrough drugs, and extra policy support, including communication with the CDE at the critical stage of clinical trials and suggestions from the CDE may be given to applicants in such special procedures. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Manufacturing and Distribution </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">According to the Drug Administration Law, all facilities that manufacture drugs in China must receive a drug manufacturing license from the local drug regulatory authority. Each drug manufacturing license issued to a pharmaceutical manufacturing enterprise is effective for a period of five years. Any enterprise holding a drug manufacturing license is subject to review by the relevant regulatory authorities on an annual basis. A separate certification of compliance with Good Manufacturing Practice (the &#8220;GMP&#8221;) is also required. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Similarly, to conduct sales, importation, shipping and storage (collectively, the &#8220;distribution activities&#8221;), a company must obtain a Drug Distribution License from the local drug regulatory authority, subject to renewal every five years. A separate certification of compliance with the NMPA&#8217;s drug good supply practice (the &#8220;GSP&#8221;), is also required. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">China has implemented a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Two-Invoice</div> System&#8221; to control the distribution of prescription drugs. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Two-Invoice</div> System&#8221; generally requires that no more than two invoices be issued throughout the distribution chain: one from the manufacturer to a distributor and another from the distributor to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-user</div> hospital. This excludes the sale of products invoiced from the manufacturer to its wholly-owned or controlled distributors, or for imported drugs, to its exclusive distributor, or from a distributor to its wholly-owned or controlled subsidiary (or between its wholly-owned or controlled subsidiaries). However, the system still significantly limits the options for companies to use multiple distributors to reach a larger geographic area in China. Compliance with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Two-Invoice</div> System is a prerequisite for pharmaceutical companies to participate in the procurement processes of public hospitals, which currently provide most of China&#8217;s healthcare services. Manufacturers and distributors that fail to implement the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Two-Invoice</div> System may lose their qualifications to participate in the bidding process. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-compliant</div> manufacturers may also be blacklisted from engaging in drug sales to public hospitals in a locality. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Two-Invoice</div> System was first implemented in 11 provinces involved in pilot comprehensive medical reforms, and the program has been expanded to nearly all provinces, each with its own individual rules for the program. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">New Drug Application </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Administrative Measures for Drug Registration, when Phases 1, 2 and 3 clinical trials have been completed, the applicant may apply to the NMPA for approval of a new drug application. The NMPA shall then determine whether to approve the application according to the comprehensive evaluation opinion provided by the CDE of the NMPA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the New Measures for Registration, at the stage of new drug application, depending on the characteristics of the drug and the corresponding conditions, applicants may apply for adoption of special procedures, including the Priority Review Procedure and the Special Review Procedure. Such procedures may be applied for innovative drugs for severe infectious diseases or rare diseases, breakthrough drugs and other eligible drugs stipulated in the New Measures for Registration. Extra policy support, including less review period, may be given to applicants in such special procedures. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">151 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Multi-center Clinical Trials Regulations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;30, 2015, the NMPA promulgated the Notice on Issuing the International Multi-Center Clinical Trial Guidelines (Trial), effective as of March&#160;1, 2015, to provide guidance on the regulation of the application, implementation and administration of international multi-center clinical trials in China. Pursuant to the Notice on Issuing the International Multi-Center Clinical Trial Guidelines (Trial), international multi-center clinical trial applicants may simultaneously perform clinical trials in different centers using the same clinical trial protocol. Where the applicant plans to make use of the data derived from the international multi-center clinical trials for its application to the NMPA for approval of a new drug application, such international multi-center clinical trials shall satisfy, in addition to the requirements set forth in the Drug Administration Law and its implementation measures, the Administrative Measures for Drug Registration and other relevant laws and regulations, the following requirements: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The applicant shall first conduct an overall evaluation on the global clinical trial data and further make trend analysis of the Asian and Chinese clinical trial data. In the analysis of Chinese clinical trial data, the applicant shall consider the representativeness of the research subjects, i.e., the participating patients; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The applicant shall analyze whether the amount of Chinese research subjects is sufficient to assess and adjudicate the safety and effectiveness of the drug under clinical trial, and satisfy the statistical and relevant legal requirements; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The onshore and offshore international multi-center clinical trial research centers shall be subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-site</div> inspections by competent PRC governmental agencies. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International multi-center clinical trials shall follow international prevailing GCP principles and ethics requirements. Applications shall ensure the truthfulness, reliability and trustworthiness of clinical trials results; the researchers shall have the qualification and capability to perform relevant clinical trials; and an ethics committee shall continuously review the trials and protect the subjects&#8217; interests, benefits and safety. Before the performance of the international multi-center clinical trial, applicants shall obtain clinical trial approvals or complete filings pursuant to requirements under the local regulations where clinical trials are conducted, and register and disclose the information of all major researchers and clinical trial organizations on the NMPA Drug Clinical Trial Information Platform. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the Opinions on Deepening the Reform of the Evaluation and Approval System and Inspiring Innovation of Drugs and Medical Devices and Equipment, clinical trial data obtained from foreign centers may be used to apply for registration in China as long as such data meet the relevant requirements for the registration of drugs and medical devices in China. When using international multi-center clinical trial data to support new drug applications in China, applicants shall submit the completed global clinical trial report, statistical analysis report and database, along with relevant supporting data in accordance with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ICH-CTD</div> (International Conference on Harmonization-Common Technical Document) content and format requirements; subgroup research results summary and comparative analysis shall also be conducted concurrently. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketing Authorization Holder System </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Opinions on the Reform of Evaluation and Approval System for Drugs and Medical Devices and Equipment promulgated on August&#160;9, 2015, the State Council published the policy for carrying out a pilot plan for the drug marketing authorization holder mechanism. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the newly amended Drug Administrative Law, under the drug marketing authorization holder mechanism, an enterprise or a research and development institution, which has obtained a drug registration certificate is eligible to be a pharmaceutical marketing authorization holder and the drug marketing authorization holder shall be responsible for nonclinical laboratory studies, clinical trials, production and distribution, post-market studies, and the monitoring, reporting, and handling of adverse reactions in connection with pharmaceuticals in accordance with the provisions of the Drug Administrative Law. The pharmaceutical marketing authorization holder may engage contract manufacturers for manufacturing, provided that the contract manufacturers are licensed and may engage pharmaceutical distribution enterprises with drug distribution license for the distribution activities. Upon the approval of the medical products administrative department under the State Council, a drug marketing authorization holder may transfer the drug marketing license and the transferee shall have the capability of quality management, risk prevention and control, and liability compensation to ensure the safety, effectiveness and quality controllability of drugs, and fulfill the obligations of the drug marketing license holder. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">152 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Administrative Observation Periods for New Drugs </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">According to the Implementing Measures of the Drug Administration Law, the NMPA may, for the purposes of protecting public health, set an administrative observation period of not more than five years for a new drug produced by a drug manufacturer. During the administrative observation period, no approval shall be given to any other manufacturer to produce or import the said drug. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Inferiority</div> Standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In China, a drug may receive regulatory approval without showing superiority in its primary endpoint. Rather, a drug may be approved for use if it shows <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-inferiority</div> in its primary endpoint and superiority in one of its secondary endpoints. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Packaging of Pharmaceutical Products </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Administration of Quality of Drug Clinical Practice, the applicant shall be responsible for proper packaging and labeling of drugs for clinical trials, and in double-blinded clinical trials, the test drug shall be consistent with the control drug or placebo in appearance, odor, packaging, labeling, and certain other features. According to the Measures for the Administration of Pharmaceutical Packaging promulgated on February&#160;12, 1988 and effective from September&#160;1, 1988, pharmaceutical packaging must comply with national and professional standards. If there is no national or professional standard available, an applicant may formulate and implement its own standards after obtaining the approval of the provincial administration or bureau of standards. The applicant must reapply if it needs to change its own packaging standards. Drugs that have not been developed and approved for packaging standards must not be sold or marketed in the PRC (except for drugs for the military). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">National List of Essential Drugs </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;18, 2009, the MOH and eight other ministries and commissions in the PRC issued the Provisional Measures on the Administration of the National List of Essential Drugs which was revised on February&#160;13, 2015 aim to promote essential medicines sold to consumers at fair prices in the PRC and ensure that the general public in the PRC has equal access to the drugs contained in the National List of Essential Drugs. The MOH promulgated the National List of Essential Drugs on March&#160;13, 2013 and on September&#160;30, 2018. According to these regulations, basic healthcare institutions funded by the government shall store up and use drugs listed in the National List of Essential Drugs. The drugs listed in the National List of Essential Drugs shall be purchased by centralized tender process and shall be subject to the price control by the National Development and Reform Commission (the &#8220;NDRC&#8221;). Remedial drugs in the National List of Essential Drugs are all listed in the NRDL and the purchase price of such drugs is entitled to reimbursement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Government Price Controls </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Chinese government has abolished the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15-year-old</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">government-led</div> pricing system for drugs. On May&#160;4, 2015, the NDRC and six other ministries and commissions in the PRC issued the Opinion on Promoting Drug Pricing Reform, which lifted the government-prescribed maximum retail price for most drugs, except for narcotic drugs and Class&#160;I psychotropic drugs. The government regulates drug prices mainly by establishing a consolidated procurement mechanism, restructuring medical insurance reimbursement standards and strengthening the regulation of medical and pricing practices as discussed below. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">153 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Centralized Procurement and Tenders </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the current regulations, public medical institutions owned by the government or owned by State-owned or controlled enterprises are required to purchase pharmaceutical products through centralized online procurement processes. There are exceptions for drugs on the National List of Essential Drugs, which have their own procurement rules, and for certain drugs subject to the central government&#8217;s special control, such as toxic, radioactive and narcotic drugs and traditional Chinese medicines. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The centralized procurement process takes the form of public tenders operated by provincial or municipal-level government agencies. The centralized tender process is typically conducted once every year. The bids are assessed by a committee randomly selected from a database of experts. The committee members assess the bids based on a number of factors, including, but not limited to, bid price, product quality, clinical effectiveness, product safety, level of technology, qualifications and reputation of the manufacturer, after-sale services and innovation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The State Council approved <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">state-run</div> centralized medicine procurement and 11 pilot cities for the program in a circular issued on January&#160;17, 2019. It is an effort to deepen reform of the medical and health sector and optimize the pricing system of drugs. According to the circular, in the 11 pilot cities drugs will be selected from generic brands for centralized medicine procurement. The selected drugs must pass the consistency evaluation on quality and effectiveness. The policy is aimed at lowering drug costs for patients, reducing transaction costs for enterprises, regulating drug use of institutions, and improving the centralized medicine procurement and pricing system. The centralized procurement is open to all approved enterprises that can produce drugs on the procurement list in China. Clinical effects, adverse reactions, and batch stability of the drugs will be considered, and their consistency will be the main criteria for evaluation, while production capacity and stability of the supplier will also be considered. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Commercial Insurance </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;25, 2016, the State Council issued the Plan for Healthy China 2030. According to the Plan, the country will establish a multi-level medical security system built around basic medical insurance, with other forms of insurance supplementing the basic medical insurance, including serious illness insurance for urban and rural residents, commercial health insurance and medical assistance. Furthermore, the Plan encourages enterprises and individuals to participate in commercial health insurance and various forms of supplementary insurance. The evolving medical insurance system makes innovative drugs more affordable and universally available to the Chinese population, which renders greater opportunities to drug manufacturers that focus on the research and development of innovative drugs, such as high-cost cancer therapeutics. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Healthcare System Reform </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The PRC government recently promulgated several healthcare reform policies and regulations to reform the healthcare system. On March&#160;17, 2009, the State Council issued the Guidelines on Strengthening the Reform of Healthcare System. On December&#160;27, 2016, the State Council issued the Notice on the Issuance of the 13th Five-year Plan on Strengthening the Reform of Healthcare System. On May&#160;23, 2019, the General Office of the State Council issued the Notice on the Main Tasks of Strengthening the Reform of Healthcare System in 2019, which specified the key legislative work of the national medical and health system and the key tasks to promote its implementation. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Twenty-one</div> specific tasks have been proposed to address the difficulty and high cost of getting medical services and to strengthen hospital management. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Chronic Diseases Prevention and Treatment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Guiding Opinion of the General Office of the State Council on Promoting the Construction of the Hierarchical Healthcare System issued by the General Office of the State Council on September&#160;8, 2015 and the Notice on Promoting Pilot Work for Hierarchical Healthcare System jointly promulgated by the NHFPC and the State Administration of Traditional Chinese Medicine on August&#160;19, 2016, the hierarchical healthcare system is expected to be gradually improved, and the framework for division and coordination among medical and health institutions shall be substantially established by 2017, and a diagnosis and treatment model featuring objectives, such as initial diagnosis of common diseases and frequent diseases at primary hospitals and separate treatment of acute and chronic diseases, are expected to be gradually established. According to the Guiding Opinion of the General Office of the State Council on Promoting the Construction of the Hierarchical Healthcare System, several chronic diseases, including hypertension, diabetes, cancer and cardiovascular and cerebrovascular diseases, are pilot diseases under the hierarchical healthcare system. Primary healthcare institutions, rehabilitation hospitals and nursing institutions may provide treatment, rehabilitation and nursing services for patients with chronic diseases, patients in stable conditions, elderly patients, and advanced cancer patients who have clear diagnosis and stable disease conditions. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">154 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;22, 2017, the General Office of the State Council issued the Notice on the Medium and Long-Term Plan for Chronic Disease Prevention and Treatment in China (2017-2025), which sets up the objectives of the management of diabetes patients, targeting the involvement of 35&#160;million diabetic patients by 2020 and 40&#160;million by 2025 in chronic disease management. The Notice on the Medium and Long-Term Plan for Chronic Disease Prevention and Treatment in China (2017-2025) reaffirms that the hierarchical healthcare system of chronic diseases such as diabetes shall be promoted and encourages the initial diagnosis of common diseases and frequent diseases at primary hospitals. In addition, social participation in regional medical services, health management and chronic disease prevention services, as well as investments in the field of chronic disease prevention by social capital, are encouraged. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intellectual Property Rights </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">China became a member of the World Trade Organization and a party to the Agreement on Trade-Related Aspects of Intellectual Property Rights on December&#160;11, 2001. China has also entered into several international conventions on intellectual property rights, including, but not limited to, the Paris Convention for the Protection of Industrial Property, the Madrid Agreement Concerning the International Registration of Marks, and the Patent Cooperation Treaty. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patents </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to the PRC Patent Law promulgated by the Standing Committee of the NPC on March&#160;12, 1984 and amended on September&#160;4, 1992, August&#160;25, 2000 and December&#160;27, 2008, respectively, and effective from October&#160;1, 2009, and the Implementation Rules of the Patent Law of the PRC promulgated by the State Council on June&#160;15, 2001 and amended on December&#160;28, 2002 and January&#160;9, 2010, respectively, patents in China fall into three categories: invention, utility model and design. An invention patent is granted to a new technical solution proposed in respect of a product or method or an improvement of a product or method. A utility model is granted to a new technical solution that is practicable for application and proposed in respect of the shape, structure or a combination of both of a product. A design patent is granted to the new design of a certain product in shape, pattern or a combination of both and in color, shape and pattern combinations aesthetically suitable for industrial application. Under the PRC Patent Law, the term of patent protection starts from the date of application. Patents relating to invention are effective for twenty years, and utility models and designs are effective for ten years from the date of application. The PRC Patent Law adopts the principle of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;first-to-file&#8221;</div></div> system, which provides that where more than one person files a patent application for the same invention, a patent will be granted to the person who files the application first. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Existing patents can become narrowed, invalid or unenforceable due to a variety of grounds, including lack of novelty, creativity, and deficiencies in patent application. In China, a patent must have novelty, creativity and practical applicability. Under the PRC Patent Law, novelty means that before a patent application is filed, no identical invention or utility model has been publicly disclosed in any publication in China or overseas or has been publicly used or made known to the public by any other means, whether in or outside of China, nor has any other person filed with the patent authority an application that describes an identical invention or utility model and is recorded in patent application documents or patent documents published after the filing date. Creativity means that, compared with existing technology, an invention has prominent substantial features and represents notable progress, and a utility model has substantial features and represents any progress. Practical applicability means an invention or utility model can be manufactured or used and may produce positive results. Patents in China are filed with the State Intellectual Property Office (the &#8220;SIPO&#8221;). Normally, the SIPO publishes an application for an invention patent within 18 months after the filing date, which may be shortened at the request of applicant. The applicant must apply to the SIPO for a substantive examination within three years from the date of application. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">155 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Article 20 of the PRC Patent Law provides that, for an invention or utility model completed in China, any applicant (not just Chinese companies and individuals), before filing a patent application outside of China, must first submit it to the SIPO for a confidential examination. Failure to comply with this requirement will result in the denial of any Chinese patent for the relevant invention. This added requirement of confidential examination by the SIPO has raised concerns by foreign companies who conduct research and development activities in China or outsource research and development activities to service providers in China. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;17, 2020, the Standing Committee of the NPC promulgated the Amendment to the Patent Law. The Amendment to the Patent Law, which will become effective from June&#160;1, 2021, extends the validity period for design and the time limitation of actions for infringement of patent rights, and increases the maximum amount of infringement compensation. Meanwhile, the Amendment to the Patent Law implements a &#8220;compensation for patent term&#8221; (the &#8220;Term Compensation&#8221;) measure. In the event that an invention patent is granted after the forth (4th) anniversary of the date of application and the third (3rd) anniversary of the date of the request for substantive examination, the Patent Administration Department of the State Council shall, at the request of the patentee, provide the Term Compensation for the unreasonable delay in the process of granting the patent, except for the unreasonable delay caused by the applicant. In particular, in order to compensate the time taken for the review and approval of new drugs, if the new drug-related invention patents are approved for marketing in China, the Patent Administration Department of the State Council shall provide the Term Compensation to the patentee, for the duration of patent rights at the request of the patentee. The Term Compensation shall not exceed five (5)&#160;years, and the total effective patent right period after the new drug is approved for marketing shall not exceed fourteen (14)&#160;years. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patent Enforcement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unauthorized use of patents without consent from owners of patents, forgery of the patents belonging to other persons, or engagement in other patent infringement acts, will subject the infringers to infringement liability. Serious offenses such as forgery of patents may be subject to criminal penalties. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When a dispute arises out of infringement of the patent owner&#8217;s patent right, Chinese law requires that the parties first attempt to settle the dispute through mutual consultation. However, if the dispute cannot be settled through mutual consultation, the patent owner, or an interested party who believes the patent is being infringed, may either file a civil legal suit or file an administrative complaint with the relevant patent administration authority. A Chinese court may issue a preliminary injunction upon the patent owner&#8217;s or an interested party&#8217;s request before instituting any legal proceedings or during the proceedings. Damages for infringement are calculated as the loss suffered by the patent holder arising from the infringement, and if the loss suffered by the patent holder arising from the infringement cannot be determined, the damages for infringement shall be calculated as the benefit gained by the infringer from the infringement. If it is difficult to ascertain damages in this manner, damages may be determined by using a reasonable multiple of the license fee under a contractual license. Statutory damages may be awarded in the circumstances where the damages cannot be determined by the above-mentioned calculation standards. The damage calculation methods shall be applied in the aforementioned order. Generally, the patent owner has the burden of proving that the patent is being infringed. However, if the owner of an invention patent for manufacturing process of a new product alleges infringement of its patent, the alleged infringer has the burden of proof. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Medical Patent Compulsory License </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">According to the PRC Patent Law, for the purpose of public health, the SIPO may grant a compulsory license for manufacturing patented drugs and exporting them to countries or regions covered under relevant international treaties to which the PRC has acceded. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade Secrets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the PRC Anti-Unfair Competition Law promulgated by the Standing Committee of the NPC on September&#160;2, 1993 and amended on November&#160;4, 2017 and April&#160;23, 2019, respectively, the term &#8220;trade secrets&#8221; refers to technical and business information that is unknown to the public, has utility, may create business interests or profits for its legal owners or holders, and is maintained as a secret by its legal owners or holders. Under the PRC Anti-Unfair Competition Law, business persons are prohibited from infringing others&#8217; trade secrets by (1)&#160;obtaining the trade secrets from the legal owners or holders by any unfair methods, such as theft, bribery, fraud, coercion, electronic intrusion, or any other illicit means; (2)&#160;disclosing, using or permitting others to use the trade secrets obtained illegally under item (1)&#160;above; (3) disclosing, using or permitting others to use the trade secrets, in violation of any contractual agreements or any requirements of the legal owners or holders to keep such trade secrets in confidence; or (4)&#160;instigating, inducing or assisting others to disclose, use or permit others to use the trade secrets, in violation of any contractual agreements or any requirement of the legal owners or holders to keep such trade secret in confidence. If a third party knows or should have known of the above-mentioned illegal conduct but nevertheless obtains, uses or discloses trade secrets of others, the third party may be deemed to have committed a misappropriation of the others&#8217; trade secrets. The parties whose trade secrets are being misappropriated may petition for administrative corrections, and regulatory authorities may terminate any illegal activities and impose fines on the infringing parties. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">156 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trademarks </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Trademark Law of the PRC promulgated by the Standing Committee of the NPC on August&#160;23, 1982 and amended on February&#160;22, 1993, October&#160;27, 2001 and August&#160;30, 2013, respectively, and effective from May&#160;1, 2014, which has been amended on April&#160;23, 2019 and became effective from November&#160;1, 2019, the period of validity for a registered trademark is ten years, commencing from the date of registration. The registrant shall go through the formalities for renewal within twelve months prior to the expiry date of the trademark if continued use is intended. Where the registrant fails to do so, a grace period of six months may be granted. The validity period for each renewal of registration is ten years, commencing from the day immediately after the expiry of the preceding period of validity for the trademark. In the absence of a renewal upon expiry, the registered trademark shall be cancelled. Industrial and commercial administrative authorities have the authority to investigate any behavior in infringement of the exclusive right under a registered trademark in accordance with the law. In case of a suspected criminal offense, the case shall be timely referred to a judicial authority and decided according to the law. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Domain Names </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Domain names are protected under the Measures on Administration of Domain Names for the Chinese Internet promulgated by the Ministry of Industry and Information Technology, on November&#160;5, 2004 and effective from December&#160;20, 2004, which was replaced by the Administrative Measures on the Internet Domain Names issued by the Ministry of Industry and Information Technology on August&#160;24, 2017 and effective from November&#160;1, 2017, and the Implementing Rules on Registration of Domain Names issued by China Internet Network Information Center on May&#160;28, 2012, which became effective on May&#160;29, 2012. The Ministry of Industry and Information Technology is the main regulatory body responsible for the administration of PRC internet domain names. Domain name registrations are handled through domain name service agencies established under the relevant regulations, and the applicants become domain name holders upon successful registration. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Liability </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Product Quality Law of the PRC promulgated by the Standing Committee of the NPC on February&#160;22, 1993 and amended on July&#160;8, 2000, August&#160;27, 2009 and December&#160;29, 2018, respectively, is the principal governing law relating to the supervision and administration of product quality. According to the Product Quality Law, manufacturers shall be liable for the quality of products produced by them, and sellers shall take measures to ensure the quality of the products sold by them. A manufacturer shall be liable for compensating for any bodily injuries or property damages, other than the defective product itself, resulting from the defects in the product, unless the manufacturer is able to prove that: (1)&#160;the product has never been distributed; (2)&#160;the defects causing injuries or damages did not exist at the time when the product was distributed; or (3)&#160;the science and technology at the time when the product was distributed was at a level incapable of detecting the defects. A seller shall be liable for compensating for any bodily injuries or property damages of others caused by the defects in the product if such defects are attributable to the seller. A seller shall pay compensation if it fails to indicate either the manufacturer or the supplier of the defective product. A person who is injured or whose property is damaged by the defects in the product may claim for compensation from the manufacturer or the seller. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the General Principles of the Civil Law of the PRC promulgated by the NPC on April&#160;12, 1986 and amended on August&#160;27, 2009, both manufacturers and sellers shall be held liable where the defective products result in property damages or bodily injuries to others. Pursuant to the Tort Liability Law of the PRC promulgated by the Standing Committee of the NPC on December&#160;26, 2009 and effective from July&#160;1, 2010, manufacturers shall assume tort liabilities where the defects in products cause damages to others. Sellers shall assume tort liabilities where the defects in products that have caused damages to others are attributable to the sellers. The aggrieved party may claim for compensation from the manufacturer or the seller of the defected product that has caused damage. On May&#160;28, 2020, the NPC approved the Civil Code of the People&#8217;s Republic of China (the &#8220;Civil Code&#8221;), which took effect on January&#160;1, 2021 and replaced the General Principles of the Civil Law of the PRC and Tort Liability Law of the PRC. According to the Civil Code, patients have the right to claim compensation from the drug marketing authorization holder, medical institution or manufacturer for damage caused by drug defects. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">157 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Regulation of Commercial Bribery </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pharmaceutical companies involved in a criminal investigation or administrative proceedings related to bribery are listed in the Adverse Records of Commercial Briberies by their respective provincial health and family planning administrative department. Pursuant to the Provisions on the Establishment of Adverse Records of Commercial Briberies in the Medicine Purchase and Sales Industry which became effective on March&#160;1, 2014, provincial health and family planning administrative departments formulate the implementing measures for establishment of Adverse Records of Commercial Briberies. Where a pharmaceutical company or its agent is listed in the Adverse Records of Commercial Briberies on one occasion, it will be prohibited from participating in the procurement bidding process or selling its products to public medical institutions located in the local provincial-level region for two years from the publication of the adverse records. The evaluation points of such pharmaceutical company or agent in respect of the procurement bidding process and procurement by public medical institutions must be credited by public medical institutions in the other provincial-level regions for two years from the publication of the adverse records. Where a pharmaceutical company or its agent is listed in the Adverse Records of Commercial Briberies on two or more occasions within five years, it will be prohibited from participating in the procurement bidding process or selling its products to all public medical institutions in the PRC for two years from the publication of these adverse records. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Regulations Relating to Employee Stock Incentive Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2012, the SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plans of Overseas Publicly Listed Companies (the &#8220;Stock Option Rules&#8221;), which replaced the Application Procedures of Foreign Exchange Administration for Domestic Individuals Participating in Employee Stock Ownership Plans or Stock Option Plans of Overseas Publicly Listed Companies issued by the SAFE on March&#160;28, 2007. In accordance with the Stock Option Rules and relevant rules and regulations, PRC citizens or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PRC</div> citizens residing in China for a continuous period of not less than one year, who participate in any stock incentive plan of an overseas publicly listed company, subject to a few exceptions, are required to register with the SAFE through a domestic qualified agent, which could be a PRC subsidiary of such overseas listed company, and complete certain procedures. We and our employees who are PRC citizens or who reside in China for a continuous period of not less than one year and who participate in our stock incentive plan will be subject to such regulation. In addition, the SAT has issued circulars concerning employee share options or restricted shares. Under these circulars, employees working in the PRC who exercise share options, or whose restricted shares vest, will be subject to PRC individual income tax (the &#8220;IIT&#8221;). The PRC subsidiaries of an overseas listed company have obligations to file documents related to employee share options or restricted shares with relevant tax authorities and to withhold IIT of those employees related to their share options or restricted shares. If the employees fail to pay, or the PRC subsidiaries fail to withhold, their IIT according to relevant laws, rules and regulations, the PRC subsidiaries may face sanctions imposed by the tax authorities or other PRC government authorities. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Regulations Relating to Foreign Exchange and the Dividend Distribution </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign Exchange Control </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The State Council promulgated the PRC Regulation for the Foreign Exchange on January&#160;29, 1996, which was amended on January&#160;14, 1997 and August&#160;5, 2008, respectively. On June&#160;20, 1996, the People&#8217;s Bank of China promulgated the Regulation on the Administration of the Foreign Exchange Settlement, Sales and Payment, which came into effect on July&#160;1, 1996. Pursuant to the above-mentioned regulations, foreign exchanges required for distribution of profits and payment of dividends may be purchased from designated foreign exchange banks in the PRC upon presentation of a board resolution authorizing the distribution of profits or payment of dividends. The Regulation on the Administration of the Foreign Exchange Settlement, Sales and Payment removed the previous restrictions on convertibility of foreign exchange in respect of current account items, including the distribution of dividends, interest and royalty payments, trade and service-related foreign exchange transactions, while foreign exchange transactions in respect of capital account items, such as direct investment, loan, securities investment and repatriation of investment, remain subject to the approval of the SAFE. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">158 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;19, 2012, the SAFE issued the Operating Rules for Foreign Exchange Issues with Regard to Direct Investment under Capital Account as an appendix to the Circular of the SAFE on Further Improving and Adjusting the Foreign Exchange Policies on Direct Investment, which was issued on November&#160;19, 2012 and amended on May&#160;4, 2015. According to the Circular of the SAFE on Further Improving and Adjusting the Foreign Exchange Policies on Direct Investment, (i)&#160;the opening of and payment into foreign exchange accounts under direct investment accounts are no longer subject to approval by the SAFE; (ii)&#160;reinvestment with the legal income of foreign investors in China is no longer subject to approval by the SAFE; (iii)&#160;the procedures for capital verification and confirmation that foreign-funded enterprises need to go through are simplified; (iv)&#160;the purchase and external payment of foreign exchange under direct investment accounts are no longer subject to approval by the SAFE; (v)&#160;domestic transfer of foreign exchange under direct investment accounts is no longer subject to approval by the SAFE; and (vi)&#160;the administration over the conversion of foreign exchange capital of foreign-funded enterprises is improved. On February&#160;13, 2015, the SAFE issued the Circular on Further Simplifying and Improving Foreign Exchange Administration Policies in Respect of Direct Investment, which came into effect on June&#160;1, 2015, providing that the banks, instead of the SAFE, can directly handle the foreign exchange registration and approval under foreign direct investment, while the SAFE and its branches indirectly supervise the foreign exchange registration and approval under foreign direct investment through the banks. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;11, 2013, the SAFE promulgated the Provisions on the Administration of Foreign Exchange in Foreign Direct Investments by Foreign Investors, which became effective on May&#160;13, 2013, and relevant supporting documents that regulate and clarify the administration over foreign exchange administration in foreign direct investments. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;30, 2015, the SAFE released the Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises, which came into effect on June&#160;1, 2015 and superseded the Notice on the Relevant Operating Issues Concerning the Improvement of the Administration of Payment and Settlement of Foreign Currency Capital of Foreign-funded Enterprises issued by the SAFE on August&#160;29, 2008. The Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises has made certain adjustments to some regulatory requirements on the settlement of foreign exchange capital of foreign-invested enterprises, and some foreign exchange restrictions provided in the Notice on the Relevant Operating Issues Concerning the Improvement of the Administration of Payment and Settlement of Foreign Currency Capital of Foreign-funded Enterprises. On June&#160;9, 2016, the SAFE issued the Circular on the Reform and Standardization of the Management Policy of the Settlement of Capital Projects. Under the Circular on the Reform and Standardization of the Management Policy of the Settlement of Capital Projects and the Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises, the settlement of foreign exchange by foreign-invested enterprises shall be governed by the policy of foreign exchange settlement on a discretionary basis. However, the aforementioned circulars also reiterate that the settlement of foreign exchange shall only be used for its own operation purposes within the business scope of the foreign-invested enterprises and following the principles of authenticity. Considering that these circulars are relatively new, it is unclear how they will be implemented, and there exist great uncertainties with respect to their interpretation and implementation by the authorities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The SAFE promulgated the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#8217; Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles on July&#160;4, 2014, which requires PRC residents to register with local branches of the SAFE in connection with their direct establishment or indirect control of an offshore entity for the purpose of overseas investment and financing, with such PRC residents&#8217; legally owned assets or equity interests in domestic enterprises or offshore assets or interests as a &#8220;special purpose vehicle&#8221; as defined therein. The aforesaid circular further requires amendment to the registration in the event of any significant changes with respect to the special purpose vehicle. Failure to comply with the SAFE registration requirements under the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#8217; Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles could result in liabilities under PRC law for evasion of foreign exchange controls. The Circular on Further Simplifying and Improving Foreign Exchange Administration Policies in Respect of Direct Investment, provides that local banks, instead of the SAFE, can directly handle the initial foreign exchange registration and amendment registration under the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#8217; Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">159 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">On April&#160;10, 2020, SAFE promulgated the Circular on Optimizing Administration of Foreign Exchange to Support the Development of Foreign-related Business, which allows eligible enterprises to make domestic payments using their capital funds, foreign credits and the income under capital accounts of overseas listing, without providing evidentiary materials concerning authenticity of such capital for banks in advance, provided that their capital use shall be authentic and in line with provisions, and conform to the prevailing administrative regulations on the use of income under capital accounts. The administering bank shall perform <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ex-post</div> sampling in accordance with the relevant requirements. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividend Distribution </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the PRC Company Law and Foreign Investment Law of the PRC, foreign-invested enterprises in the PRC may pay dividends only out of their accumulated profits as determined in accordance with PRC accounting standards and regulations. In addition, a foreign-invested enterprise is required to set aside at least 10% of its accumulated profits each year to fund certain reserve funds, until the accumulative amount of such fund reaches 50% of its registered capital. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;26, 2017, the SAFE issued the Notice on Improving the Check of Authenticity and Compliance to Further Promote Foreign Exchange Control, which stipulates several capital control measures with respect to outbound remittance of profits from domestic entities to offshore entities, including the following: (i)&#160;under the principle of genuine transaction, banks shall check board resolutions regarding profit distribution, the original version of tax filing records and audited financial statements; and (ii)&#160;domestic entities shall hold income to account for previous years&#8217; losses before remitting the profits. Moreover, domestic entities shall provide detailed explanations of the sources of capital and the utilization arrangements and board resolutions, contracts and other proof when completing the registration procedures in connection with an outbound investment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Regulations Relating to Labor </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Labor Law and Labor Contract Law </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the PRC Labor Law promulgated by the Standing Committee of the NPC on July&#160;5, 1994 and effective from January&#160;1, 1995 and amended on August&#160;27, 2009 and December&#160;29, 2018, respectively, the PRC Labor Contract Law promulgated by the Standing Committee of the NPC on June&#160;29, 2007 and effective from January&#160;1, 2008 and amended on December&#160;28, 2012 and effective from July&#160;1, 2013, and the Implementing Regulations of the Employment Contracts Law of the PRC promulgated by the State Council on September&#160;18, 2008, labor contracts in written form shall be executed to establish labor relationships between employers and employees. Wages cannot be lower than the local minimum wage. The employer must establish a system for labor safety and sanitation, strictly abide by the state rules and standards, provide education regarding labor safety and sanitation to its employees, provide employees with labor safety and sanitary conditions and necessary protection materials in compliance with the state rules and standards, and carry out regular health examinations for employees engaged in work involving occupational hazards. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Social Insurance and Housing Provident Funds </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under applicable PRC laws, including the Social Insurance Law of the PRC which became effective on July&#160;1, 2011 and was amended on December&#160;19, 2018, the Interim Regulations on the Collection and Payment of Social Security Funds promulgated by the State Council on January&#160;22, 1999 and amended on March&#160;24, 2019, and the Regulations on the Administration of Housing Provident Funds promulgated by the State Council on April&#160;3, 1999 and amended on March&#160;24, 2002 and March&#160;24, 2019, respectively, employers are required to contribute, on behalf of their employees, to a number of social security funds, including funds for basic pension insurance, unemployment insurance, basic medical insurance, occupational injury insurance, maternity insurance and housing provident funds. These payments are made to local administrative authorities, and any employer who fails to contribute may be fined and ordered to pay the deficit amount within a stipulated time limit. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">160 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Regulations Relating to Enterprise Income Tax </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to the Enterprise Income Tax Law of the PRC effective as of January&#160;1, 2008 and as amended on February&#160;24, 2017 and December&#160;29, 2018, respectively, the income tax rate for both domestic and foreign-invested enterprises is 25% with certain exceptions. To clarify certain provisions in the Enterprise Income Tax Law, the State Council promulgated the Implementation Rules of the Enterprise Income Tax Law on December&#160;6, 2007, which was amended and became effective on April&#160;23, 2019. Under the Enterprise Income Tax Law and the Implementation Rules of the Enterprise Income Tax Law, enterprises are classified as either &#8220;resident enterprises&#8221; or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-resident</div> enterprises.&#8221; Besides enterprises established within the PRC, enterprises established outside of China whose &#8220;de facto management bodies&#8221; are located in China are considered &#8220;resident enterprises&#8221; and subject to the uniform 25% enterprise income tax rate for their global income. In addition, the Enterprise Income Tax Law provides that a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> enterprise refers to an entity established under foreign law whose &#8220;de facto management bodies&#8221; are not within the PRC, but has an establishment or place of business in the PRC, or does not have an establishment or place of business in the PRC but has income sourced within the PRC. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Implementation Rules of the Enterprise Income Tax Law provide that since January&#160;1, 2008, an income tax rate of 10% shall normally be applicable to dividends declared to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PRC</div> resident enterprise investors that do not have an establishment or place of business in the PRC, or have such establishment or place of business but the relevant income is not effectively connected with the establishment or place of business, to the extent such dividends are derived from sources within the PRC. The income tax on the dividends may be reduced pursuant to a tax treaty between China and the jurisdictions in which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PRC</div> shareholders reside. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other PRC National- and Provincial-Level Laws and Regulations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to changing regulations under many other laws and regulations administered by governmental authorities at the national, provincial and municipal levels, some of which are or may become applicable to our business. For example, regulations control the confidentiality of patients&#8217; medical information and the circumstances under which patient medical information may be released for inclusion in our databases, or released by us to third parties. These laws and regulations governing both the disclosure and the use of confidential patient medical information may become more restrictive in the future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also comply with numerous additional national and provincial laws relating to matters such as safe working conditions, manufacturing practices, environmental protection and fire hazard control. We believe that we are currently in compliance with these laws and regulations; however, we may be required to incur significant costs to comply with these laws and regulations in the future. Unanticipated changes in existing regulatory requirements or adoption of new requirements could therefore have a material adverse effect on our business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. Regulation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Government Regulation and Product Approval in the United States </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The FDA and other regulatory authorities in the United States at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, recordkeeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biological products. Along with third-party contractors, we will be required to navigate the various <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical,</div> clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our drug candidates. The processes for obtaining regulatory approvals in the United States and in foreign jurisdictions, along with subsequent compliance with applicable laws and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government policies may change and additional government regulations may be enacted that could prevent or delay further development or regulatory approval of any of our drug candidates, or anticipated manufacturing processes, disease indications, or labeling. We cannot predict the likelihood, nature or extent of government regulation that might arise from future legislative or administrative action. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">161 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Review and Approval for Licensing Biologics in the United States </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, the FDA regulates our current drug candidates as biological products, or biologics, under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;), the Public Health Service Act and associated implementing regulations. Biologics, like other drugs, are used for the treatment, prevention or cure of disease in humans. In contrast to chemically synthesized small molecular weight drugs, which have a well-defined structure and can be thoroughly characterized, biologics are generally derived from living material (human, animal, or microorganism) and are complex in structure, and thus are usually not fully characterized. Biologics include immunomedicines for cancer and other diseases. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Biologics are also subject to other federal, state and local statutes and regulations. The failure to comply with applicable statutory and regulatory requirements at any time during the product development process, approval process or after approval may subject a sponsor or applicant to administrative or judicial enforcement actions. These actions could include the suspension or termination of clinical trials by the FDA, the FDA&#8217;s refusal to approve pending applications or supplemental applications, withdrawal of an approval, &#8220;Warning Letters&#8221; (official messages from the FDA to a manufacturer or other organization that it has violated some rule in a federally regulated activity) or &#8220;Untitled Letters&#8221; (initial correspondences from the FDA with a regulated industry that cite violations that do not meet the threshold of regulatory significance for a Warning Letter and request correction of the violation), product recalls, product seizures, total or partial suspension of production or distribution, import detention, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA, the Department of Justice (the &#8220;DOJ&#8221;), or other governmental entities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An applicant seeking approval to market and distribute a biologic in the United States typically must undertake the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">completion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> laboratory tests and animal studies performed in accordance with the FDA&#8217;s good laboratory practice (the &#8220;GLP&#8221;), regulations; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">submission to the FDA of an application for an Investigational New Drug (&#8220;IND&#8221;), which must become effective before clinical trials may begin and must be updated annually or when significant changes are made; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">manufacture, labeling and distribution of an investigational drug in compliance with current good manufacturing practice (the &#8220;cGMP&#8221;); </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approval by an independent institutional review board (the &#8220;IRB&#8221;), or ethics committee at each clinical site before each clinical trial may be initiated; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">performance of adequate and well-controlled human clinical trials in accordance with the FDA&#8217;s current Good Clinical Practices requirements (the &#8220;cGCP&#8221;), to establish the safety, purity and potency of the proposed biological drug candidate for its intended purpose; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">preparation of and submission to the FDA of a biologics license application (&#8220;BLA&#8221;), after completion of all pivotal clinical trials requesting marketing approval for one or more proposed indications; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">satisfactory completion of an FDA Advisory Committee review, where appropriate or if applicable, as may be requested by the FDA to assist with its review; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the proposed product, or components thereof, are produced to assess compliance with cGMP and data integrity requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#8217;s identity, safety, quality, purity and potency; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">162 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">satisfactory completion of FDA audits of selected clinical investigation sites to assure compliance with cGCP requirements and the integrity of the clinical data; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">payment of user fees under the Prescription Drug User Fee Act (the &#8220;PDUFA&#8221;), for the relevant year; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtaining FDA review and approval of the BLA to permit commercial marketing of the licensed biologic for particular indications for use in the United States; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (the &#8220;REMS&#8221;), and the potential requirement to conduct post-approval studies. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The testing and approval process requires substantial time, effort and financial resources and we cannot be certain that any approvals for our drug candidates will be granted on a timely basis, if at all. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, legislation is drafted, introduced and passed in the Congress of the United States that could significantly change the statutory provisions governing the testing, approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and our drug candidates. It is impossible to predict whether further legislative changes will be enacted or whether FDA regulations, guidance, policies or interpretations will be changed or what the effect of such changes, if any, may be. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> and Clinical Development in the United States </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Before a BLA applicant can begin testing the potential asset in human subjects, the applicant must first conduct <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> studies include laboratory evaluations of product chemistry, toxicity and formulation, as well as in vitro and animal studies to assess the potential safety and activity of the biologic for initial testing in humans and to establish a rationale for therapeutic use. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> studies are subject to federal regulations and requirements, including GLP regulations. The results of an applicant&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies are submitted to the FDA as part of an IND. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. An IND is an exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial. Such authorization must be secured prior to interstate shipment. In support of a request for an IND, applicants must submit a range of information, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> data, manufacturing information and a detailed protocol for each clinical trial. Any subsequent protocol amendments must be submitted to the FDA as part of the IND. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Human clinical trials may not begin until an IND is effective. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises safety concerns or questions about the proposed clinical trial within the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> time period. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA may also place a clinical hold or partial clinical hold on such trial following commencement of a clinical trial under an IND. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30 days after the imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor with a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">163 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with cGCP regulations, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all FDA IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with cGCP regulations in order to use the study as support for an IND or application for marketing approval, including review and approval by an independent ethics committee and informed consent from subjects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some trials also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board (the &#8220;DSMB&#8221;). DSMBs provide authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial and may halt the clinical trial if a DSMB determines that there is an unacceptable safety risk for subjects or based on other grounds, such as no demonstration of efficacy. Other grounds for suspension or termination may be made based on evolving business objectives and/or competitive climate. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Trials </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For purposes of BLA approval, clinical trials are typically conducted in the following sequential phases that may overlap or be combined: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 1: The investigational product is initially introduced into a small number of healthy human subjects or patients with the target disease or condition. These trials are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans and the side effects associated with increasing doses. These trials may also yield early evidence of effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product is suspected or known to be unavoidably toxic, the initial human testing may be conducted in patients. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 2: The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 3: The investigational product is administered to an expanded patient population generally at multiple geographically dispersed clinical trial sites to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety. These clinical trials are intended to generate sufficient data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval by the FDA. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product, referred to as Phase 4 trials. Such post-approval trials, when applicable, are conducted following initial approval, typically to develop additional data and information relating to the biological characteristics of the product and treatment of patients in the intended therapeutic indication. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">164 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: suspected serious and unexpected adverse reactions; findings from epidemiological studies, pooled analysis of multiple studies, animal or in vitro testing, or other clinical studies, whether or not conducted under an IND, and whether or not conducted by the sponsor, that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the rate of a serious suspected adverse reaction over such rate listed in the protocol or investigator brochure, which is a comprehensive document summarizing the body of information about an investigational product obtained during clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> trials. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites to assure compliance with cGCP and the integrity of the clinical data submitted. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During clinical development, the sponsor often refines the indication and endpoints on which the BLA will be based. For endpoints based on patient-reported outcomes (the &#8220;PROs&#8221;), and observer-reported outcomes (the &#8220;OROs&#8221;), the process typically is an iterative one. The FDA has issued guidance on the framework it uses to evaluate PRO instruments. Although the agency may offer advice on optimizing PRO and ORO instruments during the clinical development process, the FDA usually reserves final judgment until it reviews the BLA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrent with clinical trials, companies often complete additional animal studies, and develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, purity and potency of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">BLA Submission and Review </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Assuming successful completion of all required clinical testing in accordance with all applicable regulatory requirements, an applicant may submit a BLA requesting licensing to market the biologic for one or more indications in the United States. The BLA must include the results of product development, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies and clinical trials; detailed information on the product&#8217;s chemistry, manufacture and controls; and proposed labeling. Under the Prescription Drug User Fee Amendments, a BLA submission is subject to an application user fee, unless a waiver or exemption applies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA will initially review the BLA for completeness before accepting it for filing. Under the FDA&#8217;s procedures, the agency has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing and substantive review. If the agency determines that the application does not meet this initial threshold standard, the FDA may refuse to file the application and request additional information, in which case the application must be resubmitted with the requested information and review of the application delayed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With certain exceptions, BLAs must include a pediatric assessment, generally based on clinical trial data, of the safety and effectiveness of the biologic in relevant pediatric populations. Under certain circumstances, the FDA may waive or defer the requirement for a pediatric assessment, either at the sponsor&#8217;s request or by the agency&#8217;s initiative. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After the BLA is accepted for filing, the FDA reviews the BLA to determine, among other things, whether a product is safe, pure and potent and if the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued identity, strength, quality, safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities comply with cGMP and are adequate to assure consistent production of the product within required specifications. In addition, the FDA expects that all data be reliable and accurate, and requires sponsors to implement meaningful and effective strategies to manage data integrity risks. Data integrity is an important component of the sponsor&#8217;s responsibility to ensure the safety, efficacy and quality of its product or products. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">165 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA will typically inspect one or more clinical sites to assure compliance with cGCP regulations before approving a BLA. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA performance goals generally provide for action on a BLA within ten months of filing, which (as discussed above) typically occurs within 60 days of submission, but that deadline is extended in certain circumstances. Furthermore, the review process is often significantly extended by FDA requests for additional information or clarification. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee. Typically, an advisory committee consists of a panel that includes clinicians and other experts who will review, evaluate and provide a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions and usually has followed such recommendations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its components will be produced, the FDA may issue an approval letter or a Complete Response Letter (the &#8220;CRL&#8221;). An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A CRL will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. If and when the deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional data, information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, and may require additional testing or information and/or require post-marketing studies and clinical trials. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the approval process, the FDA will determine whether a REMS is necessary to assure the safe use of the biologic. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes that a REMS is needed, the BLA sponsor must submit a proposed REMS and the FDA will not approve the BLA without a REMS that the agency has determined is acceptable. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, under the Pediatric Research Equity Act of 2003 (the &#8220;PREA&#8221;), as amended and reauthorized, certain applications or supplements must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the FDA approves a product, it may limit the approved indications for use for the product, or require that contraindications, warnings or precautions be included in the product labeling. The FDA may also require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug&#8217;s safety after approval. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">166 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA may also require testing and surveillance programs to monitor the product after commercialization. For biologics, such testing may include official lot release, which requires the manufacturer to perform certain tests on each lot of the product before it is released for distribution. The manufacturer then typically must submit samples of each lot of product to the FDA, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products itself, before releasing the lots for distribution by the manufacturer. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are often subject to further testing requirements and FDA review and approval, depending on the nature of the post-approval change. The FDA may withdraw the product approval if compliance with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-</div> and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Post-Approval Requirements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, reporting of certain deviations and adverse experiences, product sampling and distribution and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their third-party contractors are required to register their establishments with the FDA and certain state agencies. These establishments are subject to routine and periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and data integrity requirements, which impose certain procedural and documentation requirements to assure quality of manufacturing and product. The FDA has increasingly observed cGMP violations involving data integrity during site inspections and investigating compliance with data integrity requirements is a significant focus of its oversight. Requirements with respect to data integrity include, among other things, controls to ensure data are complete and secure; activities documented at the time of performance; audit trail functionality; authorized access and limitations; validated computer systems; and review of records for accuracy, completeness and compliance with established standards. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Post-approval changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP, data integrity, pharmacovigilance (i.e., post-marketing safety reporting obligations) and other aspects of regulatory compliance. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA may withdraw a product approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-approval studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS. Other potential consequences include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fines, Warning Letters, Untitled Letters or holds on post-approval clinical studies; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product seizure or detention, or refusal of the FDA to permit the import or export of products that it believes present safety problems by issuing an Import Alert; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">167 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">permanent injunctions and consent decrees, including the imposition of civil or criminal penalties; or </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">voluntary product recall. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA&#8217;s regulation includes, among other things, standards and regulations for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">direct-to-consumer</div></div> advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional activities involving the Internet and social media. Promotional claims relating to a product&#8217;s safety or effectiveness are prohibited before the drug is approved. After approval, a product generally may not be promoted for uses that are not approved by the FDA, as reflected in the product&#8217;s prescribing information. In the United States, healthcare professionals are generally permitted to prescribe drugs for such uses not described in the drug&#8217;s labeling, known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses, because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#8217; communications, prohibiting the promotion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses. It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-promotional,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-misleading</div> communication regarding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> information, such as distributing scientific or medical journal information. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If a company is found to have promoted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the DOJ or the Office of the Inspector General of the Department of Health and Human Services, as well as other federal and state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion, and has also requested that companies enter into consent decrees and permanent injunctions under which specified promotional conduct is changed or curtailed. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The distribution of prescription drugs and biologics are subject to the Drug Supply Chain Security Act (the &#8220;DSCSA&#8221;), which requires manufacturers and other stakeholders to comply with product identification, tracing, verification, detection and response, notification and licensing requirements. In addition, the Prescription Drug Marketing Act (the &#8220;PDMA&#8221;), and its implementing regulations, and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure accountability in distribution and to identify and remove prescription drug and biological products that may be counterfeit, stolen, contaminated, or otherwise harmful from the market. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patent Term Restoration and Marketing Exclusivity </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">After approval, owners of relevant drug or biological product patents may apply for up to a five-year patent extension to restore a portion of patent term lost during product development and FDA review of a BLA if approval of the application is the first permitted commercial marketing or use of a biologic containing the active ingredient under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. The allowable patent term extension is calculated as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of the product&#8217;s testing phase, which is the time between IND and BLA submission, and all of the review phase, which is the time between BLA submission and approval, up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension may not exceed more than 14 years from the date of FDA approval of the product. Only one patent claiming each approved product is eligible for restoration and the patent holder must apply for restoration within 60 days of approval. The United States Patent and Trademark Office (the &#8220;USPTO&#8221;), in consultation with the FDA, reviews and approves the application for patent term restoration. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the USPTO must determine that approval of the drug candidate covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug candidate for which a BLA has not been submitted. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">168 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expedited Development and Review Programs </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA is required to facilitate the development and expedite the review of pharmaceutical products that are intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrate the potential to address unmet medical need for the condition. Under the fast track program, the sponsor of a new drug candidate may request the FDA to designate the product for a specific indication as a fast track product concurrent with or after the filing of the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for fast track designation within 60 days after receipt of the sponsor&#8217;s request. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to other benefits, such as the ability to have more frequent interactions with the FDA, the agency may initiate review of sections of a fast track product&#8217;s BLA before the application is complete. This rolling review is available if the applicant provides and the FDA approves a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA&#8217;s PDUFA review period for a fast track application does not begin until the last section of the BLA is submitted. In addition, the fast track designation may be withdrawn by the FDA if the agency believes that the designation is no longer supported by data emerging in the clinical trial process. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Healthcare Regulation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmaceutical Coverage and Reimbursement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States, sales of any products for which we may receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payors. Third-party payors include government authorities, managed care providers, private health insurers and other organizations. Third-party payors establish the coverage and reimbursement policies for pharmaceutical products, and the marketability of any products for which we may receive regulatory approval for commercial sale depends on those payors&#8217; coverage policies and reimbursement rates. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include one or more of our drug candidates, if approved. Third-party payors, together with regulators and others, are increasingly challenging the prices charged for pharmaceutical products and health services, in addition to their cost-effectiveness, safety and efficacy. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, no uniform policy for coverage and reimbursement exists in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval process apart from Medicare determinations. Therefore, coverage and reimbursement rates can vary significantly from payor to payor. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, obtaining coverage and adequate reimbursement is a time-consuming and costly process. We may be required to provide scientific and clinical support for the use of any product to each third-party payor separately with no assurance that approval will be obtained, and we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. We cannot be certain that our drug candidates will be considered cost-effective by third-party payors. This process could delay the market acceptance of any drug candidates for which we may receive approval and could have a negative effect on our future revenues and operating results. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other U.S. Healthcare Laws and Compliance Requirements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, our business may be subject to healthcare fraud and abuse regulation and enforcement by both the federal government and the states in which we conduct our business, particularly once third-party reimbursement becomes available for one or more of our products. The healthcare fraud and abuse laws and regulations that may affect our ability to operate include, but are not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under the Medicare and Medicaid programs, or other federal healthcare programs; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">169 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The federal civil and criminal false claims laws and civil monetary penalty laws, including the civil False Claims Act, or FCA, which prohibits, among other things, knowingly presenting, or causing to be presented, claims for payment of government funds that are false or fraudulent, or knowingly making, or using or causing to be made or used, a false record or statement material to a false or fraudulent claim to avoid, decrease, or conceal an obligation to pay money to the federal government; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The federal Health Insurance Portability and Accountability Act of 1996 (the &#8220;HIPAA&#8221;), which, among other things, prohibits executing a scheme to defraud any healthcare benefit program, including private third-party payors, and prohibits (i)&#160;knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation and (ii)&#160;making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (the &#8220;HITECH&#8221;), and their respective implementing regulations, which impose requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities, including health plans, healthcare clearinghouses and certain healthcare providers, and their business associates, individuals or entities that perform certain services on behalf of a covered entity that involve the use or disclosure of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The federal Physician Payments Sunshine Act, being implemented as the Open Payments Program, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare and Medicaid Services (the &#8220;CMS&#8221;), information related to direct or indirect payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held in a company by physicians and their immediate family members. Beginning in 2022, applicable manufacturers will also be required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists and certified nurse-midwives; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">U.S. state and local laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state laws that restrict the ability of manufacturers to offer <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-pay</div> support to patients for certain prescription drugs; state laws that require drug manufacturers to report information related to clinical trials, or information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require drug manufacturers to report information on the pricing of certain drugs; state laws and local ordinances that require identification or licensing of sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">170 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Even then, governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If governmental authorities find that our operations violate any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with these laws, and we may be required to curtail or restructure our operations. Moreover, we expect that there will continue to be federal and state laws and regulations, proposed and implemented, that could impact our operations and business. In addition, the approval and commercialization of any drug candidate we develop outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. The extent to which future legislation or regulations, if any, relating to health care fraud and abuse laws or enforcement, may be enacted or what effect such legislation or regulation would have on our business remains uncertain. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Healthcare Reform </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the United States there have been, and continue to be, several legislative and regulatory changes and proposed reforms of the healthcare system to contain costs, improve quality and expand access to care. In the United States, there have been and continue to be a number of healthcare-related legislative initiatives that have significantly affected the pharmaceutical industry. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;ACA&#8221;), was passed in March 2010, substantially changing the way healthcare is financed by both governmental and private insurers and significantly impacting the U.S. pharmaceutical industry. Among other things, the ACA subjects biologics to potential competition by lower-cost biosimilars; addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations; establishes annual fees and taxes on manufacturers of certain branded prescription drugs; and creates a new Medicare Part D coverage gap discount program in which, as a condition of coverage of its products under Medicare Part D, manufacturers must now agree to offer 70% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-sale</div></div> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Some of the provisions of the ACA have yet to be fully implemented, while certain provisions have been subject to judicial and Congressional challenges. In addition, there have been efforts by the Trump Administration to repeal or replace certain aspects of the ACA and to alter the implementation of the ACA and related laws. For example, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;), includes a provision repealing, effective January&#160;1, 2019, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-based</div> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year commonly referred to as the &#8220;individual mandate.&#8221; On January&#160;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACA-mandated</div> fees, including the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share and the medical device excise tax on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exempt</div> medical devices. The Bipartisan Budget Act of 2018 (the &#8220;BBA&#8221;), among other things, amends the ACA, effective January&#160;1, 2019, to reduce the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; In addition, in July 2018, the CMS issued a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. Additional legislative changes or regulatory changes related to the ACA remain possible. In December 2018, a United States District Court Judge for the Northern District of Texas ruled that the entire ACA is unconstitutional because the tax penalty associated with the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. This ruling is under appeal and stayed pending appeal. While the United States District Court Judge for the Northern District of Texas, as well as the Trump Administration and the CMS, have stated that the ruling will have no effect while this appeal is pending, it is unclear how this decision, subsequent appeals and other efforts to invalidate the ACA, regulations promulgated under the ACA or portions thereof, will impact the ACA and its implementation. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">171 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing; reduce the cost of prescription drugs under Medicare; review the relationship between pricing and manufacturer patient programs; and reform government program reimbursement methodologies for drugs. For example, the Trump Administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> costs of drug products paid by consumers. On January&#160;31, 2019, Office of the Inspector General of the Department of Health and Human Services proposed modifications to the federal Anti-Kickback Statute discount safe harbor for the purpose of reducing the cost of drug products to consumers which, among other things, if finalized, will remove safe harbor protection from rebates paid by manufacturers to Medicare Part D plans, Medicaid managed care organizations and pharmacy benefit managers working with these organizations. Although a number of these, and other proposed measures may require additional authorization to become effective, Congress and the Trump Administration have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement limitations, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, on May&#160;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing and Supply </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our manufacturing strategy for our drug candidates consists of two progressive steps, involving (i)&#160;using contract development and manufacturing organizations (&#8220;CDMOs&#8221;) and (ii)&#160;establishing our own capabilities and infrastructure, including a manufacturing facility. We believe that development of our own manufacturing facility will provide us with enhanced control of material supply for both clinical trials and the commercial market, enable the more rapid implementation of process changes and help us achieve better long-term margins. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We currently outsource the manufacturing of clinical trial material for our internally developed, IND enabling projects to leading CDMOs in China such as WuXi Biologics, and the manufacturing of clinical trial material for clinical stage projects which were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> from our global partners to reputable global CDMOs, which have established track records for both clinical trial material supply and commercial material supply. We have assembled a seasoned internal team with deep experience in this area to drive and monitor this process. For contingency planning purposes, we have also established relationships with other CDMOs. We expect to continue our outsourcing relationships with contract manufacturers to meet the ongoing needs for the development of our drug candidates. We have framework agreements with these external service providers, under which they provide services to us on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">project-by-project</div></div> basis. We also monitor the manufacturing activities of clinical trial material at CDMO to ensure the compliance with local and international cGMP and applicable regulations. Currently, our contract manufacturers obtain raw materials and supplies for the manufacturing activities from multiple suppliers who we believe have sufficient capacity to meet our demands. We typically order materials and services on a purchase order basis. We also enter into long-term capacity or minimum supply arrangements with them. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">172 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We believe it is strategically important and advantageous that we own and control our GMP manufacturing process in order to ensure quality, secure production slots and maximize cost-effectiveness for clinical trial materials and commercial supplies. We intend to build a comprehensive biologics manufacturing facility in Hangzhou, China (the &#8220;Hangzhou Facility&#8221;) as part of our strategic plan to become a fully integrated biopharma company. We have taken concrete steps to execute this plan. These steps include detailed operational planning for the facility, actions taken to secure an appropriate site, and negotiations with external financing providers. The Hangzhou Facility targets to have a pilot capacity of 2 production lines (1 line configured with 2 x 2,000L and another line with 1 x 2,000L) by 2022 and commercially progressive capacity up to 8 x 4,000L to begin operation by the end of 2023. Construction is expected to commence in April 2021 and ready for use by the end of 2023. The project will be financed by a combination of internal and external sources. In September 2020, a group of domestic investors in China invested a total of US$120&#160;million (in RMB equivalent) in cash. Upon closing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou became an affiliate of us. We, through our wholly owned subsidiary, and parties acting in concert, remain the majority shareholder of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma (Hangzhou) Limited <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;I-Mab</div> Hangzhou&#8221;), the entity holding the Hangzhou Facility, and retain a managing role and take full control to build and operate the manufacturing facility. We plan to prioritize our therapeutic focus and resources on immuno-oncology in our global ambition to become a leading immuno-oncology company. This goal has been accelerated by our recent global strategic partnership with AbbVie and its commercialization plan for the initial oncology products. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou is positioned to provide manufacturing capabilities for us, as well as the continued development of selected biologics assets that are unessential to our immuno-oncology focus, i.e. olamkicept, plonmarlimab (excluding cytokine release syndrome indications) and a few <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CMC-stage</div> programs. We believe that this strategic alignment is necessary to maximize the pipeline value and balance the development risk for us. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D Governance </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have established robust governance regime for all stages of our research and development activities, through our internal discovery, CMC, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical development programs, and through product acquisition and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> strategies. The research and development governance regime has enabled our senior management to continuously oversee and monitor our company&#8217;s research and development activities for complying with applicable laws, regulations, rules, guidelines and internal policies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have established various governance and decision-making committees, composed of senior representatives from the respective functional units to review, discuss and determine, for instance, whether a drug candidate molecule is qualified to move forward into the next stage or not, what data package is considered appropriate and compliant to be submitted to regulatory agencies and how clinical safety of our investigational drugs will be monitored and reported. These committees make decisions over the critical &#8220;checkpoints&#8221; of our research and development activities and include our (i)&#160;Science Committee, (ii)&#160;IND Scientific Advisory Committee, (iii)&#160;R&amp;D Project/Program/Portfolio Governance, (iv)&#160;Medical Safety Council, (v)&#160;Safety Management Team, and (vi)&#160;Quality Committees. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Science Committee for Early Stage Research of Drug Candidates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our Science Committee is composed of selected functional heads and members of the leadership, including Dr.&#160;Taylor&#160;B. Guo, Dr.&#160;Zheru Zhang, Dr.&#160;Joan Huaqiong Shen, Dr.&#160;Jane Meng, Yuan Meng, Dr.&#160;Weimin Tang, Dr.&#160;Chao Zhang and Dr.&#160;Zhengyi Wang, chaired by Dr.&#160;Taylor&#160;B. Guo. The Science Committee will collaborate with the management team to enhance our company&#8217;s research practices and assist management in evaluating scientific aspects of potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> opportunities, collaborations and new technologies that may bolster our pipeline and research and development capabilities. The Science Committee&#8217;s responsibilities include: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approving the target review package submitted by our discovery group; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">providing governance on the quality and integrity of drug candidates, before entering into CMC process development; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">examining the experimental data and scientific evidence supporting the drug candidate; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing and making recommendations on our company&#8217;s resource allocation in further development; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">setting the direction for scientific and technical review of potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> opportunities. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, our Corporate Compliance Function led by Mr.&#160;Thomas Song has taken a number of steps to review the integrity and reliability of the experimental data submitted with the selected drug candidate. The design, operation and monitoring of this data integrity program is integral to our quality control and assurance system, and is independent with respect to our research and development unit and Science Committee, to ensure the compliance with the principles of scientific data integrity, including controls over changes to, and deletions of source of data. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">173 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">IND Scientific Advisory Committee for Drug Candidates Entering into Clinical Development Stage </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our IND Scientific Advisory Committee is composed of Dr.&#160;Joan Huaqiong Shen, Dr.&#160;Zheru Zhang and Dr.&#160;Jane Meng. The IND Scientific Advisory Committee is accountable for our IND application strategy and the data quality of our IND registration dossier before submission to the FDA, the NMPA and other comparable authorities. Our IND Scientific Advisory Committee advises the project team on policy matters and provides overall direction of new drug studies, and to that extent serves as a standing modality committee. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">R&amp;D Project/Program/Portfolio Governance (&#8220;IP3 Governance&#8221;) </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our IP3 Governance is composed of Dr.&#160;Joan Huaqiong Shen, Dr.&#160;Zheru Zhang and Dr.&#160;Chao Zhang, with Dr.&#160;Joan Huaqiong Shen serving as the chair. Our IP3 Governance is a decision-making body that assesses and approves research and development portfolio strategy and execution proposals from a multi-discipline perspective, with an integrated approach incorporating scientific, clinical and commercial considerations. Our IP3 Governance aims to ensure that the project, program and/or portfolio-related decisions are logical, robust and repeatable and that our investments in research and development activities is aligned with our vision and strategy. The IP3 Governance responsibilities include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">reviewing and determining the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> strategic plan; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">performing reviews on critical research and development stage gates, including clinical asset selection, GLP pharmacology and toxicology studies, FIH studies, clinical development and regulatory submission; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing product development strategy and monitoring project timeline and costs. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Medical Safety Council (&#8220;MSC&#8221;) </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our MSC is composed of selected research and development functional heads and Subject Matter Experts, including Yuan Meng, Dr.&#160;Joan Huaqiong Shen, Michelle Yang, Dr.&#160;Taylor&#160;B. Guo, Dr.&#160;Jane Meng, Dr.&#160;Claire Xu and Richard Cheng Li, chaired by Yuan Meng, Head of Medical Office. Our MSC is the highest medical safety governance body engaged in setting standards for protecting the medical safety of patients and users of our products, and providing strategic direction in product vigilance and patient or user safety. The MSC&#8217;s responsibilities include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishing standards and policies, and identifying best practices related to medical safety; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">providing oversight of all medical safety relevant activities, and overseeing the implementation of our company&#8217;s medical safety standard, as well as the outcomes of the periodic audits; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">addressing safety information that could result in a significant change in the benefit-risk profile of our products; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing and approving FIH studies and any other issues with respect to the safety of human exposure during early development stage. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Safety Management Teams (&#8220;SMT&#8221;) for Product-Related Safety System </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our SMT is composed of representatives from each research and development function, including Yuan Meng, program lead, clinical physician (on program level), representatives of regulatory affairs (on program level), representatives of project management (on project level), external business partner (if applicable) and representatives of medical affairs (if applicable), chaired by Yuan Meng. The SMT is a product-based, cross-functional collaborative team responsible for the review and evaluation of medical safety data arising from any source throughout the product lifecycle. Our SMT performs assessments to identify changes in safety profiles or potential safety signals. Based on these safety evaluations, the SMT will determine the appropriate safety-related actions to be taken with respect to the product based on its benefit-risk profile for subjects in clinical trials and for patients treated with the marketed product. </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">174 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our SMT works closely with and escalates safety issues, as appropriate, to the MSC to fulfill our medical safety obligations. Our SMT is responsible for reviewing available safety information from multiple sources on a regular basis and make final decisions on safety in a timely manner with appropriate cross-functional input. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Quality Committees </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have formed two Quality Committees, namely, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma Quality Management Review and R&amp;D Quality Council. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma Quality Management Review <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;I-Mab</div> QMR&#8221;) is composed of Dr.&#160;Joan Huaqiong Shen, Dr.&#160;Zheru Zhang, Yuan Meng and Thomas Song, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-chaired</div> by R&amp;D Quality Assurance officer Yuan Meng and CMC Quality Assurance officer Jack Qin. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> QMR is a company-level cross-functional senior leadership meeting to provide management oversight of our company&#8217;s Quality Management System (&#8220;QMS&#8221;) and the compliance status of our company&#8217;s regulated activities with applicable laws, regulations, policies and procedures, focusing on R&amp;D and CMC GXP activities. To ensure our Corporate Quality Plan is set, key QMS elements are established and maintained, quality requirements are met, and trends, changes and risks are identified and addressed proactively. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D Quality Council is composed of representatives from each research and development function, including Dr.&#160;Joan Huaqiong Shen, Yuan Meng, Sophie Song, Michelle Yang, Dr.&#160;Claire Xu, Dr.&#160;Jane Meng and heads of therapeutic areas (in China and the United States), chaired by Dr.&#160;Joan Huaqiong Shen. R&amp;D Quality Council is a governance body that oversees the performance of the QMS and serves as the final decision-making body for critical quality issues that affect subject and patient safety, data integrity and compliance with global and local regulatory authorities. The QMS encompasses the structure, responsibilities and procedures that enable the organization to identify, measure, control and enhance core regulated processes and activities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Code of Conduct </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have adopted a Code of Conduct that is applicable to many aspects of our business operation, such as business ethics, responsible research and development activities, IP and data protection, workplace ethics and other corporate governance topics, as well as implementing high ethical standards that are mandatory for our employees. In addition, we have adopted an employee handbook which describes the compliance management system implemented at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> to ensure compliance with applicable legal and regulatory requirements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quality Control and Assurance </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the research and development governance regime described above, we have established an independent quality control and assurance system and devote significant attention to quality control for the designing, manufacturing and testing of our drug candidates. Our Assurance Board is composed of Dr.&#160;Joan Huaqiong Shen, Dr.&#160;Zheru Zhang and Thomas Song. Our senior management is firmly committed to delivering our quality performance, actively involved in allocating sufficient resources to quality management system and setting quality governance mechanism. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical trials, the overall quality management outlines the implementation of our business policies and procedures in order to consistently comply with the regulatory requirements, including Good Laboratory Practices, or GLP; Good Clinical Practices, or GCP; Good Pharmacovigilance Practice, or GVP and other applicable regulatory requirements in the performance of the trials. This includes: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">predefined policies and procedures to manage <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical studies; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">dedicated resources and personnel with well delineated roles and responsibilities; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">quality risk management across the product lifecycle; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">175 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">continuous quality management system improvement; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-conformance</div> management via quality issue management process; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">development and execution of quality audit program; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory inspection readiness. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For CMC, we have established a quality management system to oversee the process development and API and drug production at the CDMOs. This system takes a holistic approach bringing senior management, quality assurance team and company policies together to create an efficient and agile quality culture. Our CMC quality commitment includes, but not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ensure that the product manufacturing, releasing, packaging, storage, and shipment meets all specifications and the requirements of the FDA and/or NMPA&#8217;s quality system regulations, cGMP or other applicable laws and regulations; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">review of process deviations and changes, root cause analysis, impact assessment, corrective and preventative actions, and validation; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ensure the consistency of key quality practices with our CDMOs; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">proactive quality system review based on audits, process data analysis, equipment condition, and periodic review of internal and external sources of data; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">assessment of regulatory guidance and ensure readiness for regulatory inspections. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">C.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Organizational Structure </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following chart illustrates our company&#8217;s organizational structure, including our principal subsidiaries, as of the date of this annual report: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g10811sp181.jpg" style="width: 547px; height: 311px;"/></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">176 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">D.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Property, Plant and Equipment </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our headquarter is located in Shanghai, China, where we lease and occupy approximately 2,851 square meters as office space and laboratories. We currently lease approximately 435 square meters of office space in Beijing, approximately 54 square meters of office space in Tianjin, approximately 14,495 square meters of office space and manufacturing space in Hangzhou, approximately 187 square meters of office space in Hong Kong, and approximately 441 square meters of office space and laboratories in Maryland. The terms of these leases range from one year to five years. </div></div> <div id="rom10811_8" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;4A. UNRESOLVED STAFF COMMENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div id="rom10811_9" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and the related notes included elsewhere in this annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F.</div> This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8221; or in other parts of this annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F.</div> </div></div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Operating Results </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. To date, we have developed an innovative pipeline of more than 15 clinical and preclinical stage assets through our internal research and development efforts and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> arrangements with global pharmaceutical and biotech companies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our research and development capabilities encompass discovery, translational medicine, biologics CMC development, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> development and clinical development with footprints in Shanghai, Beijing and the United States. We are now at a critical juncture to transition from a clinical stage biotech company into a fully integrated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-to-end</div></div> global biopharmaceutical company in the next few years. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Since the commencement of our operation in 2014, we have devoted most of our efforts and financial resources to organize and staff our operations, business planning, raise capital, establish our intellectual property portfolio and conduct <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical trials of our drug candidates. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not generated any revenue from product sales, and as a result, we have never been profitable and have incurred net losses since the commencement to the end of 2019 of our operations. In 2018 and 2019, our net losses were RMB402.8&#160;million and RMB1,452.0&#160;million, respectively. In 2020, we achieved corporate profitability with net income of RMB470.9&#160;million (US$72.2 million) which was primarily attributable to the revenues recognized in connection with the strategic collaboration with AbbVie of RMB1,542.7&#160;million (US$236.4 million). We do not expect to generate product revenue unless and until we obtain marketing approval for and commercialize a drug candidate, and we cannot assure you that we will ever generate significant revenue or profits. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">177 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key Factors Affecting Our Results of Operations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our results of operations, financial condition, and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-year</div></div> comparability of our financial results have been, and are expected to continue to be, principally affected by the below factors: </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cost and Expenses Structure </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our results of operations are significantly affected by our cost structure, which primarily consists of research and development expenses and administrative expenses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Research and development activities are central to our business model. We believe our ability to successfully develop drug candidates will be the primary factor affecting our long-term competitiveness, as well as our future growth and development. Developing high-quality drug candidates requires a significant investment of resources over a prolonged period of time, and a core part of our strategy is to continue making sustained investments in this area. Since our inception, we have focused our resources on our research and development activities, including conducting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials, and activities related to regulatory filings for our drug candidates. Our research and development expenses primarily include the following: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">costs related to development of our pipeline assets under all stages including discovery, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> testing or clinical trials; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">patent license fees and other fees under the licensing, collaboration and development agreements with respect to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> drug candidates; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">employee salaries and related benefit costs, including share-based compensation expenses, for research and development personnel and key management. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At this time, we are unable to predict when, if ever, we will be able to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods thereafter. This is due to the numerous risks and uncertainties associated with developing such drug candidates, including the uncertainty of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">successful enrollment in and completion of clinical trials; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishing an appropriate safety profile; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">receipt of marketing approvals from applicable regulatory authorities; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">commercializing the drug candidates, if and when approved, whether alone or in collaboration with others; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our drug candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">continued acceptable safety profiles of the products following approval; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">retention of key research and development personnel. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any change in the outcome of any of these variables with respect to the development of any of our drug candidates would significantly change the costs, timing and viability associated with the development of that drug candidate. We expect research and development costs to continue to increase for the foreseeable future as we expand our operations and our development programs progress, including as we continue to support and advance the clinical trials of our drug candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our administrative expenses consist primarily of employee salaries and related benefit costs. Other administrative expenses include professional fees for consulting and auditing as well as other direct and allocated expenses for rental expenses for our facilities, travel costs and other supplies used in administrative activities. We expect our administrative expenses to increase in the future to support our pipeline assets and research and development efforts, and the commercialization of our drug candidates once approval is obtained. We also anticipate that our administrative expenses will increase as we operate as a public company. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">178 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Out-Licensing</div> Agreements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We continue to seek <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> opportunities for our drug assets through our strengthened and expanded network of global partnerships and alliances. In 2018, 2019 and 2020, our revenue consisted primarily of payments from granting licenses to use and otherwise exploit certain of our intellectual properties linked to our drug assets. See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Licensing and Collaboration Arrangements&#8221; for more information on the existing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> arrangements. In addition, after validating clinical safety and preliminary efficacy of a drug candidate in our Global Portfolio in clinical trials in the United States, we may elect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-license</div> the global rights (excluding Greater China) of such drug candidate, while retaining the Greater China rights for further development and commercialization. But we may also choose to retain these rights for the United States or other countries or regions as we may deem fit. Before the commercialization of one or more of our drug candidates, we expect that the majority of our revenue will continue to be generated from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> our intellectual properties. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Funding for Our Operations </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the periods presented, we funded our operations primarily from financing through the issuance and sale of preferred shares and convertible promissory notes in private placement transactions. Going forward, in the event of successful commercialization of one or more of our drug candidates, we expect to fund our operations in part with revenue generated from sales of our commercialized drug products. However, with the continuing expansion of our business and our product pipeline, we may require further funding through public or private offerings, debt financing, collaboration, and licensing arrangements or other sources. Any fluctuation in our ability to fund our operations will impact our cash flow plan and our results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our Ability to Commercialize Our Drug Candidates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our business and results of operations depend on our ability to commercialize our drug candidates, once and if those candidates are approved for marketing by the respective health authority. Currently, our pipeline consists of more than fifteen drug candidates ranging in development status from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> to late-stage clinical programs. Although we currently do not have any product approved for commercial sale and have not generated any revenue from product sales, we expect to generate revenue from sales of a drug candidate after we complete the clinical development, obtain regulatory approval, and successfully commercialize such drug candidate. Our late-stage investigational drugs at or potentially near pivotal trials are felzartamab, eftansomatropin alfa, olamkicept and plonmarlimab. See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Our Drug Pipeline&#8221; for more information on the development status of our various drug candidates. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Effect of Our Acquisition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We acquired a controlling interest in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin on July&#160;15, 2017 and the remaining interest in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin in May 2018. Since our acquisition of the controlling interest in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin on July&#160;15, 2017, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin has been consolidated into our results of operations. Shortly after we acquired the controlling interest in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin, we integrated the operations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin into our operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin did not generate any external revenue from July&#160;15, 2017 to December&#160;31, 2020. In connection with our acquisition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin, we identified RMB148.8&#160;million of intangible assets and RMB162.6&#160;million of goodwill of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin. Goodwill is not amortized, but impairment of goodwill assessment is performed on an least an annual basis on December&#160;31 or whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. No impairment was identified as of December&#160;31, 2018, 2019 and 2020. Impairment charges could substantially affect our results of operations in the periods of such charges. In addition, impairment charges would negatively impact our financial ratios and could limit our ability to obtain financing in the future. See &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks Related to Our Industry, Business and Operations&#8212;Change in business prospects of acquisitions may result in impairment to our goodwill, which could negatively affect our reported results of operations.&#8221; </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">179 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Pandemic </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As of the date of this annual report, the impact of the ongoing global coronavirus- 19 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19)</div> pandemic to our business has been limited. To date, although <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> has caused some delays in the initiation of the ongoing trials of certain clinical-stage drug candidates in early 2020, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has not had a material impact on our ongoing clinical activities, in particular, clinical activities related to our late-stage drug candidates, such as felzartamab, eftansomatropin alfa and olamkicept. See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Our Drug Candidates&#8221; for our clinical development plans for our drug candidates. As of the date of this annual report, the outbreak of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> has not caused any early termination of our clinical trials or necessitated removal of any enrolled patients. We have employed various measures to mitigate impacts of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on our currently ongoing trials in Greater China and the United States. We worked closely with our CROs to monitor the situation and manage the process of our clinical trials. We maintained contact with our patients to ensure that they remain on the trials and that any information they need will be readily available. In addition, we believe the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has not significantly impacted our ability to carry out our obligations under existing contracts or disrupted any supply chains that we rely upon. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of the date of this annual report, we have not had any suspected or confirmed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> cases on our premises or among our employees. To prevent any spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> in our offices and research facilities, we have adopted a thorough disease prevention scheme to protect our employees from contracting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The measures we have implemented include, among others, regularly sterilizing and ventilating our offices, checking the body temperature of our employees, keeping track of the travel history and health conditions of employees and their immediate family members, providing face masks to employees attending the office, minimizing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> meetings to the extent possible and encouraging employees to wear masks when needed. As of the date of this annual report, our ongoing clinical trials and CROs had resumed full and normal operations and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic had not resulted in a major disruption to our operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Taking into account our past and prospective cash burn rate, including but not limited to future clinical development and administrative expenses, lease payment, capital expenditure and current financial position, our ability to control the speed and breadth of our clinical development and business development activities and our expansion in headcount, our current internal resources, we estimate that our financial resources can support our research and development activities and business operations for at least the next 12 months. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Although we believe we have implemented strategies to potentially minimize the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic to our business, we expect that we may experience delays with respect to the initiation and patient enrollment of certain additional trials. The extent to which the COVID- 19 pandemic impacts the timing of these additional trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, any restrictions on the ability of hospitals and trial sites to conduct trials that are not designed to address the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and the perceived effectiveness of actions taken in China and the United States to contain and treat the disease. We will continue to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic to our business. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, there are still uncertainties with regard to the continued development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and its implications, and we will continue to assess the situation and seek to put in place relevant mitigating measures where necessary. The above analyses are made by our management based on currently available information concerning <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> We cannot guarantee that the outbreak of COVID- 19 will not further escalate or have a material adverse effect on our business operations. Please also see &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks Related to Our Industry, Business and Operations&#8212;Our business, financial condition and results of operations could be adversely affected by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic.&#8221; and &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks Related to Our Industry, Business and Operations&#8212; Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.&#8221; </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">180 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key Components of Results of Operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales for the foreseeable future before the successful commercialization of one or more of our drug candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We generated substantially all of our revenues for the years ended December&#160;31, 2018, 2019 and 2020 from granting licenses to use and otherwise exploit certain of our intellectual properties in connection with our drug assets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development expenses primarily consist of: (i)&#160;payroll and other related expenses of research and development personnel, (ii)&#160;fees associated with the exclusive development rights of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> drug candidates, (iii)&#160;fees for services provided by contract research organizations, investigators and clinical trial sites that conduct our clinical studies, and (iv)&#160;expenses relating to the development of our drug candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our current research and development activities primarily relate to the clinical development of the following investigational drugs: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Felzartamab, a potential highly differentiated CD38 antibody for multiple myeloma and autoimmune diseases, if approved; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eftansomatropin alfa, a potential highly differentiated long-acting growth hormone for growth hormone deficiency, if approved; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Efineptakin alfa, the first long-acting recombinant human <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7</div> with the potential for cancer treatment-related lymphopenia and cancer immunotherapy, if approved; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lemzoparlimab, a potential highly differentiated CD47 antibody for immuno-oncology, if approved; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Uliledlimab, a potential highly differentiated CD73 antibody for cancer treatment, if approved; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Plonmarlimab, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> monoclonal antibody for rheumatoid arthritis and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CRS-related</div> therapies, if approved; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Olamkicept, a potential highly differentiated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> blocker for ulcerative colitis and other autoimmune diseases, if approved; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Enoblituzumab, a potential highly differentiated humanized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3</div> antibody for immuno-oncology treatment, if approved; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TJ210, a potential highly differentiated antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases, if approved; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-CD4B,</div> a novel, tumor-dependent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> engager for gastric and other cancers, if approved; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TJ-L14B,</div> a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> based tumor-dependent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> engager for solid cancers, if approved. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We incurred research and development expenses of RMB426.0&#160;million, RMB840.4&#160;million and RMB984.7&#160;million (US$150.9 million) for the years ended December&#160;31, 2018, 2019 and 2020, respectively, representing 86.5%, 56.2% and 71.0% of our total research and development and administrative expenses for the corresponding periods. We expect our research and development expenses to continue to increase for the foreseeable future, as we continue to expand our operations and to advance our pipeline and our drug candidates toward later stages. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">181 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Administrative Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative expenses primarily consist of salaries and related benefit costs, including share-based compensation, for employees engaged in managerial and administrative positions or involved in general corporate functions, professional fees for consulting and auditing as well as other direct and allocated expenses for rental expenses for our facilities, travel costs and other supplies used in administrative activities. For the years ended December&#160;31, 2018, 2019 and 2020, our administrative expenses amounted to RMB66.4&#160;million, RMB654.6&#160;million and RMB402.4&#160;million (US$61.7 million), respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest Expense </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense consist primarily of interest expenses on our (i)&#160;short-term bank borrowings and (ii)&#160;convertible promissory notes issued to certain investors. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest Income </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income consists primarily of interest income derived from our term deposit and restricted cash pledged as collateral for a working capital loan. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Income (Expenses), Net </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Other income consists primarily of income from the equity transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou and other financial assets, fair value change of short-term investments and subsidy income. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expenses consist primarily of the net loss resulting from the conversion of a portion of our convertible promissory notes, loss on the termination agreement with Everest and net foreign exchange losses. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Change of Warrants </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Fair value change of warrants consists primarily of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> items incurred in connection with changes in the fair value of our warrant liabilities that we issued to certain investors. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Taxation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cayman Islands </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab,</div> our holding entity, is incorporated in the Cayman Islands. The Cayman Islands currently has no income, corporation or capital gains tax and no estate duty, inheritance tax or gift tax. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Hong Kong </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab,</div> our holding entity, did its business registration in Hong Kong and had a Hong Kong tax file number. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma Hong Kong Limited is incorporated in Hong Kong. Companies registered in Hong Kong are subject to Hong Kong profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Hong Kong tax laws. Under the current Hong Kong Inland Revenue Ordinance, from the year of assessment 2018/2019 onwards, our subsidiary in Hong Kong is subject to profits tax at the rate of 8.25% on assessable profits up to HK$2,000,000; and 16.5% on any part of assessable profits over HK$2,000,000. For the years ended December&#160;31, 2018, 2019 and 2020, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma Hong&#160;Kong Limited did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earnings in Hong Kong for any of the periods presented. Under the Hong Kong tax law, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma Hong&#160;Kong Limited is exempted from income tax on its foreign-derived income and there are no withholding taxes in Hong Kong on remittance of dividends. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">182 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">United States </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma US Ltd. is incorporated in Maryland and is subject to U.S. federal corporate income tax at a rate of 21%. It is also subject to state income tax in Maryland at a rate of 8.25%. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma US Ltd. has no taxable income for all periods presented and therefore no provision for income taxes is required. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">China </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;16, 2007, the National People&#8217;s Congress of PRC enacted a new Corporate Income Tax Law (&#8220;new CIT law&#8221;) (as amended in 2017 and 2018), under which Foreign Investment Enterprises (&#8220;FIEs&#8221;) and domestic companies would be subject to corporate income tax at a uniform rate of 25%. The new CIT law became effective on January&#160;1, 2008. Under the new CIT law, preferential tax treatments will continue to be granted to entities which conduct businesses in certain encouraged sectors and to entities otherwise classified as &#8220;High and New Technology Enterprises.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai has been qualified as a &#8220;High and New Technology Enterprise&#8221; and enjoys a preferential income tax rate of 15% from 2018 to 2020. Our company&#8217;s other PRC subsidiaries are subject to the statutory income tax rate of 25%. No provision for income taxes has been accrued because all of our PRC subsidiaries are in cumulative loss positions for all the periods presented. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion or all of the deferred tax assets will not be realized in the foreseeable future. In making such determination, we evaluate a variety of positive and negative factors including our operating history, accumulated deficit, the existence of taxable temporary differences and reversal periods. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have incurred net accumulated operating losses for income tax purposes since our inception. We believe that it is more likely than not that these net accumulated operating losses will not be utilized in the future based on the assessment as of December&#160;31, 2020. Therefore, we have provided full valuation allowances for the deferred tax assets as of December&#160;31, 2018, 2019 and 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We evaluate each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of December&#160;31, 2018, 2019 and 2020, we did not have any significant unrecognized uncertain tax positions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Results of Operations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a summary of our consolidated results of operations for the periods indicated. This information should be read together with our consolidated financial statements and related notes included elsewhere in this annual report. The operating results in any period are not necessarily indicative of the results that may be expected for any future period. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands,&#160;except&#160;for&#160;per&#160;share&#160;data)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary Consolidated Statements of Comprehensive Income (Loss) Data:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing and collaboration revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">53,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">30,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,542,668</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">236,424</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenses</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> (1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(426,028</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(840,415</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(984,689</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(150,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative expenses <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(66,391</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(654,553</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(402,409</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(61,672</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) from operations</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(438,638</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,464,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">155,570</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">23,842</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">30,570</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">24,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,713</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(11,695</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2,991</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(957</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(147</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">183 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands,&#160;except&#160;for&#160;per&#160;share&#160;data)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary Consolidated Statements of Comprehensive Income (Loss) Data:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income (expenses), net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(16,780</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(20,205</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">412,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">63,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in loss of an affiliate <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(108,587</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(16,642</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value change of warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">61,405</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,644</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before income tax expense</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(401,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,451,950</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">483,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">74,044</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(12,231</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,874</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Net income (loss) attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(402,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,451,950</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">470,915</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">72,170</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Deemed dividend to Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> preferred shareholders extinguishment of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5,283</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Deemed dividend to Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> and C preferred shareholders at modification of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> and C Preferred Shares</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(27,768</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to ordinary shareholders</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(402,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,485,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">470,915</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">72,170</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustments, net of nil tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">53,689</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,747</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(120,920</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(18,531</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Total comprehensive income (loss) attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(349,144</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,441,203</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">349,995</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">53,639</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to ordinary shareholders</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(402,833</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,485,001</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">470,915</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">72,170</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average number of ordinary shares used in calculating net income (loss) per share</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,529,092</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,381,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">134,158,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">134,158,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,529,092</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,381,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">157,231,652</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">157,231,652</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share attributable to ordinary shareholders</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(61.70</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(201.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(61.70</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(201.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per ADS attributable to ordinary shareholders</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(141.91</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(462.74</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(141.91</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(462.74</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses were allocated as follows: </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> </div> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">470</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">284,431</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">43,591</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">514,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">209,033</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,036</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in loss of an affiliate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,707</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,013</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,520</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">515,203</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">526,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">80,640</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Year Ended December&#160;31, 2020 Compared to Year Ended December&#160;31, 2019 </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues </div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our revenues generated from licensing and collaboration increased from RMB30.0&#160;million for the year ended December&#160;31, 2019 to RMB1,542.7&#160;million (US$236.4 million) for the year ended December&#160;31, 2020. Our revenues generated for the year ended December&#160;31, 2020 solely consisted of the revenue recognized in connection with the strategic collaboration with AbbVie. </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">184 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a breakdown of the major components of our research and development expenses in absolute amounts and as a percentage of our total research and development expenses for the periods indicated: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands,&#160;except&#160;percentages)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CRO service fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">521,920</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">62.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">439,537</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">67,362</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">44.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-licensed</div> patent right fees</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">166,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">28,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,332</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee benefit expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">106,313</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">460,149</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">70,521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">46.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Material costs for drug candidates</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,117</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,610</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,392</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">39,221</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">41,127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,303</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">840,415</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100.0</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">984,689</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">150,910</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100.0</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our research and development expenses increased by 17.2% from RMB840.4&#160;million for the year ended December&#160;31, 2019 to RMB984.7&#160;million (US$150.9&#160;million) for the year ended December&#160;31, 2020, primarily attributable to (i)&#160;an increase in employee benefit expenses of employees involved in research and development from RMB106.3&#160;million for the year ended December&#160;31, 2019 to RMB460.1&#160;million (US$70.5 million) for the year ended December&#160;31, 2020, mainly due to an increase in share-based compensation by RMB284.0&#160;million (US$43.6 million); (ii) partially offset by the decreases in CRO service fees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patent right fees from RMB521.9&#160;million and RMB166.8&#160;million for the year ended December&#160;31, 2019 to RMB439.5&#160;million (US$67.4 million) and RMB28.3&#160;million (US$4.3 million) for the year ended December&#160;31, 2020, respectively. The decrease of CRO service fees was mainly due to the evolution of our outsourcing model in 2020 through hiring more dedicated headcounts on our clinical programs to replace CRO services. The decrease of in-licensed patent right fees was mainly due to that we paid the upfront fee of US$15.0 million to MacroGenics in 2019. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, 77.6% and 22.4% of our total research and development expenses were attributable to clinical programs and preclinical programs, respectively. In 2019, 87.3% and 12.7% of our total research and development expenses were attributable to clinical programs and preclinical programs, respectively. In 2020, felzartamab and lemzoparlimab represented approximately 36.9% and 13.4% of our external research and development expenses, which primarily included payments to CROs and CMOs. In 2019, felzartamab represented approximately 41.4% of our external research and development expenses, which primarily included licensing fees and payments to CROs and CMOs. No other programs represented a significant amount of research and development expenses in 2020 and 2019. Though we manage our external research and development expenses by program, we do not allocate our internal research and development expenses by program because our employees and internal resources may be engaged in projects for multiple programs at any time. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Administrative Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our administrative expenses decreased from RMB654.6&#160;million for the year ended December&#160;31, 2019 to RMB402.4&#160;million (US$61.7 million) for the year ended December&#160;31,2020, primarily attributable to the decrease in employee benefit expenses by RMB305.7&#160;million (US$46.9 million) due to decrease of share-based compensation expenses. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest Income </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded RMB30.6&#160;million of interest income for the year ended December&#160;31, 2019 and RMB24.2&#160;million (US$3.7 million) of interest income for the year ended December&#160;31, 2020. The change was primarily attributable to the interest income derived from bank deposits and an increase in bank balance. </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">185 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest Expense </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded RMB3.0&#160;million of interest expense for the year ended December&#160;31, 2019 and RMB1.0&#160;million (US$0.1 million) of interest expense for the year ended December&#160;31, 2020. The change was primarily attributable to the interest expense related to our short-term borrowings, of which RMB80.0 million was borrowed in July 2018 and repaid in June 2019, RMB50.0 million was borrowed in June 2019 and repaid in June 2020, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Income (Expenses), Net </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We recorded RMB20.2&#160;million of other income for the year ended December&#160;31, 2019 and RMB412.9&#160;million (US$63.3 million) of other income for the year ended December&#160;31, 2020. The change was primarily attributable to RMB407.6&#160;million gain recognized as a result of transfer of equity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong to a group of domestic investors. The equity transfer realized the fair value appreciation in the pipeline assets as well as the employment of a team of designated management and workforce. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity in Loss of An Affiliate </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We recorded equity in loss of an affiliate of nil for the year ended December&#160;31, 2019 and RMB108.6&#160;million (US$16.6 million) for the year ended December&#160;31, 2020. The change was primarily due to that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou became an affiliate of our company since September&#160;15, 2020. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Change of Warrants </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded a gain from change in the fair value of warrant liability of RMB5.6&#160;million for the year ended December&#160;31, 2019 and nil for the year ended December&#160;31, 2020. The change was primarily attributable to the fact that the holders of Series B Warrants have unconditionally and irrevocably waived and cancelled the Tranche II of Series B Warrants in July 2019. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Year Ended December&#160;31, 2019 Compared to Year Ended December&#160;31, 2018 </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our revenues generated from licensing and collaboration decreased by 44.2% from RMB53.8&#160;million for the year ended December&#160;31, 2018 to RMB30.0&#160;million for the year ended December&#160;31, 2019. Our revenues generated for the year ended December&#160;31, 2018 consisted of both HDYM&#8217;s milestone payment and ABL Bio&#8217;s upfront payment to us pursuant to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> arrangements with them, respectively. Our revenues generated for the year ended December&#160;31, 2019 solely consisted of CSPC entity&#8217;s upfront and milestone payments to us pursuant to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> arrangement with CSPC entity. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a breakdown of the major components of our research and development expenses in absolute amounts and as a percentage of our total research and development expenses for the periods indicated: </div></div> </div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands,&#160;except&#160;percentages)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CRO service fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">212,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">49.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">521,920</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">62.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-licensed</div> patent right fees</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">108,794</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">166,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee benefit expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">56,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">106,313</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Material costs for drug candidates</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,652</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,117</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">28,674</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">39,221</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">426,028</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100.0</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">840,415</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100.0</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">186 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Our research and development expenses increased by 97.3% from RMB426.0&#160;million for the year ended December&#160;31, 2018 to RMB840.4&#160;million for the year ended December&#160;31, 2019, primarily attributable to (i)&#160;an increase in the CRO service fees from RMB212.3&#160;million for the year ended December&#160;31, 2018 to RMB521.9&#160;million for the year ended December&#160;31, 2019, as we initiated a few more research and development programs and advanced some of our existing investigational drugs into more advanced clinical development stages; (ii)&#160;an increase in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patent right fees from RMB108.8&#160;million for the year ended December&#160;31, 2018 to RMB166.8&#160;million for the year ended December&#160;31, 2019, mainly due to upfront fees paid to MacroGenics; and (iii)&#160;an increase in employee benefit expenses of employees involved in research and development from RMB56.6&#160;million for the year ended December&#160;31, 2018 to RMB106.3&#160;million for the year ended December&#160;31, 2019, due to an increase in the headcount. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2019, 87.3% and 12.7% of our total research and development expenses were attributable to clinical programs and preclinical programs, respectively. In 2018, 72.3% and 27.7% of our total research and development expenses were attributable to clinical programs and preclinical programs, respectively. In 2019, felzartamab represented approximately 41.4% of our external research and development expenses, which primarily included licensing fees and payments to CROs and CMOs. In 2018, efineptakin alfa and felzartamab represented approximately 25.0% and 9.9% of our external research and development expenses, which primarily included licensing fees and payments to CROs and CMOs. No other programs represented a significant amount of research and development expenses in 2019 and 2018. Though we manage our external research and development expenses by program, we do not allocate our internal research and development expenses by program because our employees and internal resources may be engaged in projects for multiple programs at any time. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Administrative Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our administrative expenses increased from RMB66.4&#160;million for the year ended December&#160;31, 2018 to RMB654.6&#160;million for the year ended December&#160;31, 2019, primarily attributable to (i)&#160;RMB365.3&#160;million in connection with stock options granted to a director of our company under the 2018 Plan which were immediately vested, (ii)&#160;RMB148.3&#160;million in connection with repurchase of share awards held by a director of our company, (iii)&#160;the increase in employee benefit expenses by RMB7.9&#160;million due to headcount increase, and (iv)&#160;the increase in third-party professional expenses by RMB41.4&#160;million. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest Income </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded RMB4.6&#160;million of interest income for the year ended December&#160;31, 2018 and RMB30.6&#160;million of interest income for the year ended December&#160;31, 2019. The change was primarily attributable to the interest income derived from bank deposits. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest Expense </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded RMB11.7&#160;million of interest expense for the year ended December&#160;31, 2018 and RMB3.0&#160;million of interest expense for the year ended December&#160;31, 2019. The change was primarily attributable to the interest expense related to our convertible promissory notes, which were converted in June and July 2018. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Income (Expenses), Net </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded RMB16.8&#160;million of other expenses for the year ended December&#160;31, 2018 and RMB20.2&#160;million of other income for the year ended December&#160;31, 2019. The change was primarily attributable to the conversion of our convertible promissory notes and onshore convertible loans and loss on the termination agreement with Everest in 2019. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Change of Warrants </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded a gain from change in the fair value of warrant liability of RMB61.4&#160;million for the year ended December&#160;31, 2018 and RMB5.6&#160;million for the year ended December&#160;31, 2019. The change was primarily attributable to the change in fair value of warrants due to the increase in the valuation of our company. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">187 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Critical Accounting Policies and Significant Judgments and Estimates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally, estimates are used in determining items such as fair value measurements of wealth management products, warrants and put right liabilities, impairment of accounts receivables, contract assets, other receivables, long-lived assets, intangible assets and goodwill, useful lives of property, equipment and software, recognition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and lease liabilities, variable consideration in collaboration revenue arrangements, determination of the standalone selling price of each performance obligation in our revenue arrangements, valuation of share-based compensation arrangements and deferred tax assets valuation allowances. We base the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We adopted Accounting Standard Codification (&#8220;ASC&#8221;) 606, Revenue from Contracts with Customers (Topic 606) (&#8220;ASC 606&#8221;) for all periods presented. Consistent with the criteria of Topic 606, we recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. The entity performs the following five steps to account for the arrangements that an entity determines are within the scope of ASC 606: (i) identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once a contract is determined to be within the scope of ASC 606 at contract inception, we audit the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration Revenue </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At contract inception, we analyze its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, we first determine if the collaboration is deemed to be within the scope of ASC 808. For any units of account that are reflective of a vendor-customer relationship those units of account are accounted for within the scope of ASC 606. For any units of account that are not accounted for under ASC 606 and therefore accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. In developing the stand-alone selling price for a performance obligation, we consider competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">188 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licenses of Intellectual Property </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Upfront <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> payments for licensing our intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, we recognize revenues from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit from the license. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Services </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The portion of the transaction price allocated to research and development services performance obligations is deferred and recognized as revenue over time as delivery or performance of such services occurs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Milestone Payments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, we evaluate whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the probability of achieving such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect revenues and earnings in the period of adjustment. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties or milestone payments based on the level of sales relate, we recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract Assets and Liabilities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets primarily represent revenue earnings over time that are not yet billable based on the terms of the contracts. We do not have impairment losses associated with contracts with customers for the years ended December&#160;31, 2019 and 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities consist of fees invoiced or paid by our customers for which the associated performance obligations have not been satisfied and revenue has not been recognized based on our revenue recognition criteria described above. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets and contract liabilities are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current in the consolidated balance sheet when we expect to complete the related performance obligations and invoice the customers within one year of the balance sheet date, and as long-term when we expect to complete the related performance obligations and invoice the customers more than one year out from the balance sheet date. Contract liabilities are classified as current in the consolidated balance sheet when the revenue recognition associated with the related customer payments and invoicing is expected to occur within one year of the balance sheet date and as long-term when the revenue recognition associated with the related customer payments and invoicing is expected to occur in more than one year from the balance sheet date. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">189 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Elements of research and development expenses primarily include: (1)&#160;payroll and other related expenses of personnel engaged in research and development activities; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(2)&#160;in-licensed</div> patent rights fee of exclusive development rights of drugs granted to us; (3)&#160;expenses related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> testing of our technologies under development and clinical trials such as payments to contract research organizations (&#8220;CRO&#8221;), investigators and clinical trial sites that conduct our clinical studies; (4)&#160;expenses to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses; and (5)&#160;other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to our research and development services and have no alternative future uses. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-commercial</div> milestone payments, are immediately expensed as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval would be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. The conditions enabling capitalization of development expenses as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when incurred. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Long-term Investments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our long-term investments include equity investments in an affiliate in which we do not have a controlling financial interest, but has the ability to exercise significant influence over the operating and financial policies of the investee. The investment is accounted for using the equity method of accounting in accordance with ASC topic 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Under the equity method, we initially record our investments at fair value. We subsequently adjust the carrying amount of the investment to recognize our proportionate share of the equity investee&#8217;s net income or loss after the date of investment. When the liquidation rights and priorities as defined by an equity investment agreement differ from what is reflected by the underlying percentage ownership interests, applying the percentage ownership interest to U.S. GAAP net income in order to determine earnings or losses does not accurately represent the income allocation and cash flow distributions that will ultimately be received by the investors. As such, for this type of investments, we use the Hypothetical Liquidation at Book Value (&#8220;HLBV&#8221;) method for allocating earnings or losses of the equity method investee. The HLBV method is considered as a balance sheet approach. Specifically, a calculation is prepared at each balance sheet date to determine the amount that we would receive if an equity investment entity were to liquidate all of its assets (as valued in accordance with U.S. GAAP) and distribute that cash to the investors based on the contractually defined liquidation priorities. The difference between the calculated liquidation distribution amounts at the beginning and the end of the reporting period, after adjusting for capital contributions and distributions, is our share of the earnings or losses from the equity investment for the period. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As it relates to the share-based compensation awarded by an equity method investee to its own employees, we recognize our proportionate share of the compensation expense over the vesting period, included in the equity in loss of affiliate in the consolidated statements of comprehensive income (loss). As it relates to the share-based compensation awarded by us to the equity method investee employees that are based on our stock, when the other investors do not provide proportionate value to the investee or we do not receive any consideration, we expense the entire cost associated with the award in the same period the costs are recognized by the investee, to the extent that our claim on the investee&#8217;s book value has not been increased. The expenses recognized by us is included in the equity in loss of affiliate in the consolidated statements of comprehensive income (loss). </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We evaluate the equity method investment for impairment under ASC 323. An impairment loss on the equity method investments is recognized in losses when the decline in value is determined to be other-than-temporary. No impairment charge was recognized for the year ended December&#160;31, 2020. </div></div> </div> </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">190 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Compensation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We grant restricted shares and stock options to eligible employees and account for share-based compensation in accordance with ASC 718, Compensation&#8212;Stock Compensation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employees&#8217; share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses (i)&#160;immediately at the grant date if no vesting conditions are required; (ii)&#160;for share-based awards granted with only service conditions, using the graded vesting method net of estimated forfeitures over the vesting period; or (iii)&#160;for share-based awards granted with service conditions and the occurrence of an initial public offering as performance condition cumulative share-based compensation expenses for the options that have satisfied the service condition should be recorded upon the completion of the initial public offering using the graded vesting method. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. We calculate incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, we recognize incremental compensation cost in the period when the modification occurs. For awards not being fully vested, we recognize the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation in relation to the restricted shares is measured based on the fair market value of our ordinary shares at the grant date of the award. Prior to the listing, estimation of the fair value of our ordinary shares involves significant assumptions that might not be observable in the market, and a number of complex and subjective variables, including discount rate, and subjective judgments regarding our projected financial and operating results, its unique business risks, the liquidity of its ordinary shares and its operating history and prospects at the time the grants are made. Share-based compensation in relation to the share options is estimated using the Binominal Option Pricing Model. The determination of the fair value of share options is affected by the share price of our ordinary shares as well as the assumptions regarding a number of complex and subjective variables, including the expected share price volatility, risk-free interest rate, exercise multiple and expected dividend yield. The fair value of these awards was determined with the assistance from an independent valuation firm. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted ordinary shares </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2016, we issued 4,019,554 ordinary shares to Mr.&#160;Zang Jingwu Zhang, Ms.&#160;Qian Lili, Mr.&#160;Wang Zhengyi and Mr.&#160;Fang Lei (collectively the &#8220;Founders&#8221;), including the 369,301 shares which represented the equity interests of Third Venture held by the Founders, and we recorded share-based compensation expense of RMB18.7&#160;million for issuance and grant of 3,650,253 ordinary shares to the Founders in June 2016. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2016, the Founders entered into an arrangement with our other investors, and the 87,441 ordinary shares issued to the Founders in June 2016 were cancelled, and out of the remaining 3,932,113 ordinary shares held by the Founders, 70% became restricted and subject to service vesting conditions, that shall vest 20%, 20% and 30% over the next three years, respectively. By October 2019, all the restricted shares were vested. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred share-based compensation was measured for the restricted shares using the estimated fair value of our ordinary shares of US$0.77 at the date of imposition of the restriction in October 2016, and was amortized to the consolidated statements of comprehensive loss by using graded vesting method over the vesting term of 3 years. The following table summarizes our Founders&#8217; restricted shares activities for the years ended December&#160;31, 2018, 2019 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Numbers&#160;of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/>Average&#160;Grant</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2018</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,179,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.77</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,179,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">191 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No share-based compensation expense was recognized in the year ended December&#160;31, 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shared-based compensation expenses relating to restricted shares were included in: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB&#8217;000</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB&#8217;000</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB&#8217;000</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#8217;000</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">470</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,520</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,566</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Second Amended and Restated 2017 Employee Stock Option Plan (the &#8220;2017 Plan&#8221;) </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2017, we adopted the 2017 Plan (as last amended and restated on December&#160;25, 2019). Under the 2017 Plan, a maximum aggregate number of 13,376,865 shares that may be issued pursuant to all awards granted were approved. Stock options granted to an employee under the 2017 Plan will be exercisable upon the completion of a listing and the employee renders service to us in accordance with a stipulated service schedule starting from the employee&#8217;s date of employment. Employees are generally subject to a three-year service schedule, under which an employee earns an entitlement to vest in 50% of the option grants on the second anniversary of the grant date, a vesting of the remaining fifty percent 50% on the third anniversary of the applicable grant date. The stock options under the 2017 Plan, to the extent then vested, shall become exercisable only upon the earlier of (i)&#160;a listing, and (ii)&#160;occurrence of a change in control. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On December&#160;25, 2019, the 2017 Plan was approved by our shareholders and board of directors, pursuant to which, in connection with our initial public offering, the maximum aggregate number of shares that may be granted pursuant to all awards under the 2017 Plan shall be adjusted in accordance with a formula <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approved</div> by the shareholders. In connection with above amendments to the 2017 Plan, each of our founders, namely, Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, is willing to irrevocably surrender by him or her, for no consideration, of a portion of the unvested options granted to him or her, which, if vested, would entitle him or her to acquire up to 130,000 ordinary shares of our company, par value US$0.0001 per share, at an exercise price of US$1.0, respectively, under the 2017 Plan (in respect of each individual, the &#8220;Founder&#8217;s Surrendered Options&#8221;). On December&#160;25, 2019, our board of directors approved that our company accepts all Founder&#8217;s Surrendered Options from each of the founders, namely, Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, for no consideration, with effect immediately prior to the completion of the initial public offering and such surrendered options be cancelled with effect immediately prior to the completion of the initial public offering. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to our completion of a listing, all stock options granted to an employee shall be forfeited at the time the employee terminates his employment with us. After we complete a listing, vested options not exercised by an employee shall be exercised until later of: (i) 90 days after the date when the options become exercisable, or (ii) 30 days after the date of cessation of employment or directorship, or such longer period as the board of directors may otherwise determine. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We granted 1,470,000, 640,000 and nil stock options to employees, all with an exercise price of US$1, for the years ended December&#160;31, 2018, 2019 and 2020, respectively. No options were exercisable as of December&#160;31, 2018 and 2019 and 6,790,924 stock options were exercisable as of December&#160;31, 2020. </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the stock options activities for the periods presented: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price&#160;US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value&#160;US$&#8217;000</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2018</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,005,596</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">70,129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">640,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(397,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3,435,215</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,812,881</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7.76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">47,671</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(338,876</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,439,373</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.72</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Surrendered</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(332,566</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,702,066</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.97</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">150,415</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,790,924</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.97</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">132,650</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">192 </div></div> </div> </div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to the employees were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">61.32%-62.13%</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">54.64%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate (per annum)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2.81%-3.06%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2.15%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise multiple</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2.80</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2.80</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;&#160;&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual term (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">10</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">10</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of our options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of our options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As we did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as we have never declared or paid any cash dividends on its shares, and we do not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There were no stock options granted to employees under the 2017 Plan for the year ended December&#160;31, 2020. On January&#160;17, 2020, we completed our initial public offering. After achieving this performance condition, the options continue to vest based only on service period completed according to the graded vesting schedule. We have begun recognizing share-based compensation expense for the options granted using the graded vesting method with a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> for the service period completed to date during the year ended December&#160;31, 2020 and recognized RMB52,802&#160;thousand, RMB69,213&#160;thousand and RMB4,277&#160;thousand share-based compensation expenses in administrative expenses, research and development expenses and equity in loss of an affiliate, respectively, relating to options vested cumulatively. According to the amendments to the 2017 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under the 2017 Plan was changed to 9,609,084. Each of our founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang surrendered 83,142 unvested stock options that were granted to him or her under the 2017 Plan before, totaling 332,566 unvested options, for no consideration, and these stock options were cancelled immediately. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Second Amended and Restated 2018 Employee Stock Option Plan (the &#8220;2018 Plan&#8221;) </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;22, 2019, our company adopted the 2018 Plan, which was subsequently amended and restated on July&#160;22, 2019. Under the amended and restated the 2018 Plan, the maximum aggregate number of ordinary shares which may be issued pursuant to all awards is 14,005,745, and if we successfully list on an internationally recognized securities exchange for a qualified public offering by December&#160;31, 2019, the maximum aggregate number of ordinary shares which may be issued shall be 15,452,620. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">193 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">On December&#160;25, 2019, the 2018 Plan was approved by the shareholders and board of directors of our company, pursuant to which, in connection with offering, the maximum aggregate number of shares that may be granted pursuant to all awards under the 2018 Plan may be adjusted in accordance with a formula <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approved</div> by our shareholders. In connection with above amendments to the 2018 Plan, the director of our company, Dr.&#160;Jingwu Zhang Zang is willing to irrevocably surrender by him, for no consideration, of the right to acquire a certain amount of ordinary shares of our company, par value US$0.0001 per share, at an exercise price of US$1.0 pursuant to the options granted to him under the 2018 Plan (the &#8220;Dr.&#160;Zang&#8217;s Surrendered Options&#8221;). On December&#160;25, 2019, the board of directors of our company approved that our company accepts the irrevocable surrender of Dr.&#160;Zang&#8217;s Surrendered Options for no consideration, with effect immediately prior to the completion of the initial public offering and such surrendered options be cancelled with effect immediately prior to the completion of the initial public offering. See &#8220;Item 6. Directors, Senior Management and Employees&#8212;B. Compensation of Directors and Executive Officers&#8212;Share Incentive Plans&#8212;Second Amended and Restated 2018 Employee Stock Option Plan.&#8221; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Stock options granted to an employee under the 2018 Plan will be generally exercisable when our company completes a listing and the employee renders service to our company in accordance with a stipulated service schedule starting from the employee&#8217;s date of employment. The vesting schedule shall generally be a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> vesting schedule consisting of a cliff vesting of 50% of the stock options on the first anniversary of the applicable vesting commencement date and a vesting of the remaining 50% on the second anniversary of the applicable vesting commencement date. If a listing occurs at any time prior to any stock option granted under the 2018 Plan becoming fully vested, to the extent such stock option has been granted and is outstanding, any such stock option shall vest in full with immediate effect upon the listing. Except as otherwise approved by the Board of Directors, any vested portion of the stock options shall become exercisable upon the earlier of six months after a listing or the occurrence of a change in control; provided, however, that in each case, no stock option of an employee shall become exercisable until the third anniversary of such employee&#8217;s employment commencement date. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the board of director&#8217;s approval of the 2018 Plan on February&#160;22, 2019, the 10,893,028 stock options granted to a director of our company under the 2018 Plan were fully vested and exercisable upon the adoption of 2018 Plan. Out of these 10,893,028 stock options, 454,940 stock options were repurchased by our company (see Note 16(d) to our consolidated financial statements for further details). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount of share-based compensation expense in relation to the aforementioned grant of stock options to a director of our company (except for those repurchased by our company as described in Note 16(d) to our consolidated financial statements) recognized in the year ended December&#160;31, 2019 was RMB365,329&#160;thousand, which were allocated to our administrative expenses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the stock options activities under the 2018 Plan for the periods presented: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;Of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,536,588</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">64,840</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Surrendered</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2,544,917</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(402,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,589,671</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">206,499</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,764,670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">190,411</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to certain directors and employees of our company were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">54.64%-56.31%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate (per annum)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2.15%-2.75%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise multiple</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual term (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">194 </div></div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of our company&#8217;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of our company&#8217;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As our company did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as our company has never declared or paid any cash dividends on its shares, and our company does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except for the aforementioned grant of stock options to a director of our company under the 2018 Plan, since the exercisability is dependent upon the listing, and it is not probable that this performance condition can be achieved until a listing, no share-based compensation expense related to the 2018 Plan was recorded for the year ended December&#160;31, 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;17, 2020, our Company completed its IPO. After achieving this performance condition, the options continue to vest based only on service period completed according to the graded vesting schedule. We have begun recognizing share-based compensation expenses for the options granted using the graded vesting method with a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> for the service period completed to date during the year ended December&#160;31, 2020 and recognized RMB48,055&#160;thousand, RMB65,656&#160;thousand and RMB226&#160;thousand share-based compensation expense in administrative expenses, research and development expenses and equity in loss of an affiliate, respectively, relating to options vested cumulatively. According to the amendments to the 2018 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under the 2018 Plan was changed to 11,005,888. Dr.&#160;Jingwu Zhang Zang, chairman of our Company, surrendered 2,544,917 unvested options that were granted to him under the 2018 Plan, for no consideration, and these stock options were cancelled immediately. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Repurchase of share awards held by a director </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;22, 2019, the amendment and restated 2017 equity incentive plan was approved by the Board of Directors of our company, pursuant to which only the 3,435,215 stock options held by a director of our company under the 2017 equity incentive plan became fully vested and exercisable on February&#160;22, 2019. As a result of the performance condition being waived, the shares held by a director of our company were accounted for as a Type III modification where a condition that our company expects will not be satisfied is changed to a condition that our company expects will be satisfied. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, on the same day, our company repurchased such 3,435,215 stock options under the amendment and restated 2017 equity incentive plan that was held by a director of our company along with 454,940 of his stock options under the 2018 equity incentive plan for which the share awards also became fully vested and exercisable, at a total consideration of US$21,902&#160;thousand (equivalent to approximately RMB148,308 thousand) at an average share price of US$5.63 per share. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2019, our company recorded the total payment of US$21,902&#160;thousand (equivalent to approximately RMB148,308 thousand) as share-based compensation costs (included in administrative expenses) in the condensed consolidated statement of comprehensive loss. There was no impact to the overall stockholder&#8217;s equity balance as the amended shares vested immediately and were repurchased. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2019 Share Incentive Plan (the &#8220;2019 Plan&#8221;) </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;29, 2019, we adopted the 2019 Plan. Under the 2019 Plan, the maximum aggregate number of ordinary shares available for issuance shall initially be 100,000. The options shall vest when our Company completes a listing and the employee renders service to our Company in accordance with a stipulated service schedule starting from the employee&#8217;s date of employment. Stock options granted to 3 independent directors under the 2019 Plan will be generally exercisable under the following terms: (a)&#160;a cliff vesting of 1/3 of the option on the first anniversary of the vesting commencement date (January&#160;17, 2020); (b) a cliff vesting of 1/3 of the option on the second anniversary of the vesting commencement date (January&#160;17, 2020); (c) a vesting of the remaining 1/3 of the option on the third anniversary of the vesting commencement date (January 7, 2020). In the last year of the grantee&#8217;s service, the options shall vest on a prorated basis to reflect the portion of the year during which the grantee provided services to our Company. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">195 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2020, our Company granted 72,000 stock options to 3 independent directors (all with an exercise price of US$6.09) and recognized RMB1,171&#160;thousand share-based compensation expenses relating to the options vested. No options were exercisable as of December&#160;31, 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the stock option activities of the 2019 Plan for the periods presented: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Exercise<br/>Price</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">72,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">72,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9.33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,038</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to certain directors and employees of our company were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 21%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">54.88</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate (per annum)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.79</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise multiple</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual term (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of our company&#8217;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of our options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As our Company did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as our Company has never declared or paid any cash dividends on its shares, and our Company does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2020 Share Incentive Plan (the &#8220;2020 Plan&#8221;) </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2020, we adopted the 2020 Plan. Under the 2020 Plan, the maximum aggregate number of ordinary shares which may be issued pursuant to all awards shall be 10,760,513, provided that the maximum number of shares may be issued pursuant to awards in the form of restricted share units under this plan shall not exceed 7,686,081 ordinary shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to employees under the 2020 Plan are graded vesting in four years with 25% vesting each year. For the year ended December&#160;31, 2020, we granted 1,068,733 stock options to its employees and recognized RMB4,357 RMB10,435 and RMB1,619 share-based compensation expenses in administrative expenses, research and development expenses and equity in loss of an affiliate, respectively, in the consolidated statement of comprehensive income. No option became exercisable as of December&#160;31, 2020. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">196 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the stock options activities of 2020 Plan for the periods presented: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Exercise<br/>Price</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,068,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.91</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(24,365</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.91</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,044,368</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.91</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9.62</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,237</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to the employees were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 18%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">56.51</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate (per annum)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise multiple</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2.20-2.80</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual term (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of our company&#8217;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of our options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As our Company did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as our Company has never declared or paid any cash dividends on its shares, and our Company does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted share units granted to employees under the 2020 Plan will be exercisable under the following items: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) 1/3 of the awarded restricted share units shall vest based on the following time attribution:(i) a vesting of 25% of the time attribution based restricted share units on the first anniversary of the applicable adoption date;(ii) a vesting of 25% of the time attribution based restricted share units on the second anniversary of the applicable adoption date;(iii) a vesting of 25% of the time attribution based restricted share units on the third anniversary of the applicable adoption date;(iv) a vesting of 25% of the time attribution based restricted share units on the fourth anniversary of the applicable adoption date. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) 1/3 of the awarded restricted share units shall vest based on our weighted average market value during the last 30 days prior to the initial vesting date, the terms and conditions of which are set forth in the executed award agreements. In the event that dilution of additional share issuance occurs, the market value targets herein shall be adjusted accordingly with the proportion of additional share issuance. In the event that the average market value of Standard&#160;&amp; Poor&#8217;s 500 index falls by more than 20% from the date of grant, it shall be deemed as a decline of the market, and the board of us or a committee that board delegated its powers or authority to shall adjust the vesting schedule as appropriate. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) 1/3 of the awarded restricted share units shall vest based on certain performance conditions:(i) a vesting of 20% of the performance conditions based restricted share units if one of the performance conditions has been met at the initial vesting date;(ii) a vesting of 40% of the performance conditions based restricted share units if two of the performance conditions have been met at the initial vesting date;(iii) a vesting of 60% of the performance conditions based restricted share units if three of the performance conditions have been met at the initial vesting date;(iv) a vesting of 80% of the performance conditions based restricted share units if four of the performance conditions have been met at the initial vesting date; (v)&#160;a vesting of all of the performance conditions based restricted share units if five of the performance conditions or more have been met at the initial vesting date. As of December&#160;31, 2020, it is probable that the 1/3 of the awarded restricted share units are fully vested because it is probable that at least five of the performance conditions will be met at the initial vesting date. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">197 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the foregoing, if our company&#8217;s weighted average market value during the last 30 days prior to the initial vesting date reaches US$2&#160;billion or above, and to the extent such restricted share units have been granted and outstanding, any such restricted share unit (except for those are based on time attribution) shall vest in full with immediate effect, inure to the benefit of the related grantees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2020, we granted 4,093,079 restricted share units to employees and recognized RMB76,663 RMB71,945 and RMB7,500 share-based compensation expenses in administrative expenses, research and development expenses and equity in loss of an affiliate, respectively, in the consolidated statement of comprehensive income. No restricted share units became exercisable as of December&#160;31, 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the restricted share units activities of 2020 Plan for the periods presented: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Exercise<br/>Price</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,093,079</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(13,461</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,079,618</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9.70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,632</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Apart from the aforementioned restricted share units, up to 1,446,875 shares can be issued in the form of restricted share unit to eligible grantees that the board of our company or a committee that board delegated its powers or authority determined appropriate with immediate effect of being fully vested, which are defined as special awards and are subject to terms and conditions under 2018 Plan. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2020, we granted 1,328,120 such restricted share units to employees and recognized RMB25,985 RMB67,182 and RMB19,085 share-based compensation expenses in administrative expenses, research and development expenses and equity in loss of an affiliate, respectively, in the consolidated statement of comprehensive income (loss). As of December 31, 2020, 565,200 restricted share units were vested, among which 558,200 restricted share units were vested but not issued as ordinary shares as the employees will not be entitled to the rights of ordinary shares from our company until they have the consideration for the transaction settled. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the restricted share units subject to terms and conditions under 2018 Plan for the periods presented: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Exercise<br/>Price</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,328,120</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">vested</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(565,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">762,920</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9.65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,877</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other share-based compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2017, in connection with the adoption of the 2017 Plan, we amended the stock option agreement with the two aforementioned employees, under which the stock options would become exercisable only upon the earlier of (i)&#160;a listing, and (ii)&#160;occurrence of a change in control that defined in the stock option agreements. As the modification of terms and conditions of share-based compensation were not beneficial to its employees, no further accounting impact was resulting from it. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">198 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Establishment of Biomaster Trust </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Biomaster Trust was established under the trust deed, dated October&#160;23, 2019, between us and TMF Trust (HK) Limited, or TMF Trust, as the trustee of the Biomaster Trust. Through the Biomaster Trust, our company&#8217;s ordinary shares and other rights and interests under awards granted pursuant to the 2017 Plan and the 2018 Plan may be provided to certain recipients of equity awards. Upon satisfaction of the vesting conditions, TMF Trust will exercise the equity awards and transfer the relevant ordinary shares and other rights and interests under the equity awards to the relevant grant recipients with the consent of the advisory committee of Biomaster Trust. TMF Trust shall not exercise the voting rights attached to such ordinary shares unless otherwise directed by the advisory committee, whose members shall be appointed by our company. Our company has the power to direct the relevant activities of Biomaster Trust and has the ability to use its power over Biomaster Trust to affect its exposure to returns. Therefore, the assets and liabilities of Biomaster Trust are included in our consolidated balance sheets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Surrender of stock options </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;17, 2020, our Company completed its IPO. According to the amendments to 2017 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2017 Plan was changed to 9,609,084. Each of our founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang surrendered 83,142 unvested stock options that were granted to him or her under 2017 Plan before, totally 332,566 unvested options, for no consideration, and these stock options were cancelled immediately. According to the amendments to 2018 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2018 Plan was changed to 11,005,888. Dr.&#160;Jingwu Zhang Zang, chairman of our Company, surrendered 2,544,917 unvested options that were granted to him under 2018 Plan, for no consideration, and these stock options were cancelled immediately. Upon the completion of our initial public offering in January 2020, we recorded RMB91,051&#160;thousand share-based compensation expense related to these surrendered options. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The stock options surrendered by the founders should be accounted for as capital contribution. As the founders did not get the title of the options to be surrendered and the number of share options would not be determined until listing, the capital contribution was not accounted for during the year ended December&#160;31, 2019. For the year ended December&#160;31, 2020, our Company has reclassified RMB91,051&#160;thousand from additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital&#8212;share-based compensation to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital&#8212;capital contribution relating to the options surrendered in the condensed consolidated statement of comprehensive income. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Ordinary Shares </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are required to estimate the fair value of the ordinary shares on grant dates of share-based compensation awards/share option to our employees and the issuance of financial instruments to investors. Therefore, our board of directors has estimated the fair value of our ordinary shares on various dates, with inputs from management, considering the third-party valuations. The valuations of our ordinary shares were performed using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Audit and Accounting Practice Aid Series: Valuation of Privately-Held-Company Equity Securities Issued as Compensation, or the AICPA Practice Guide. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, our board of directors considered various objective and subjective factors, along with inputs from management and the independent third-party valuation firm, to determine the fair value of our ordinary shares, including: external market conditions affecting the biopharmaceutical industry, trends within the biopharmaceutical industry, the prices at which we sold convertible preferred shares, the superior rights and preference of the convertible preferred shares or other senior securities relative to our ordinary shares at the time of each grant and the likelihood of achieving a liquidity event such as an initial public offering. The option-pricing method was used to allocate the enterprise&#8217;s value to preferred shares or other senior securities and ordinary shares, taking into account the guidance prescribed by the AICPA Practice Guide. This method treats ordinary shares and convertible preferred shares or other senior securities as call options on the enterprise&#8217;s value, with exercise prices based on their respective payoffs upon a liquidity event. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">199 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In determining the enterprise&#8217;s value, we applied the market approach/backsolve method based on pricing from recent transactions in our own securities. The basis for application of this method is our transactions in equity securities with unrelated parties or among unrelated parties themselves. No evidence is observed to indicate these transactions are not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">arm&#8217;s-length</div> transactions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors determined the fair value of our share options, the restricted shares and the restricted share units as of the dates of grant, taking into consideration the various objective and subjective factors described above, including the conclusion of valuation of our ordinary shares as of dates close to the grant dates of our share options and the restricted shares. We computed the per share estimated fair value for share options based on the binomial option pricing model and the per share estimated fair value for restricted shares based on per share estimated fair value of ordinary shares as of the date of grant. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once public trading market of the ADSs has been established in connection with the completion of our initial public offering, it is no longer necessary for our board of directors to estimate the fair value of our ordinary shares in connection with our accounting for granted share options and restricted shares. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our financial assets and liabilities primarily comprise of cash and cash equivalents, restricted cash, short-term investments, other financial assets, accounts receivables, contract assets, other receivables, short-term borrowings, accruals and other payables, warrant liabilities and put right liabilities. As of December&#160;31, 2018, 2019 and 2020, except for short-term investments, other financial assets, warrants liabilities and put right liabilities, the carrying values of these financial assets and liabilities approximated their fair values because of their generally short maturities. We report short-term investments, other financial assets, warrant liabilities and put right liabilities at fair value at each balance sheet date and changes in fair value are reflected in the consolidated statements of comprehensive income (loss). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We measure our financial assets and liabilities using inputs from the following three levels of the fair value hierarchy. The three levels are as follows: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 inputs are unadjusted quoted prices in active markets for identical assets that the management has the ability to access at the measurement date. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 inputs include quoted prices for similar assets in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 includes unobservable inputs that reflect the management&#8217;s assumptions about the assumptions that market participants would use in pricing the asset. The management develops these inputs based on the best information available, including the own data. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We measured our short-term investments, other financial assets, warrant liabilities and put right liabilities at fair value on a recurring basis. As our short-term investments, other financial assets, warrant liabilities and put right liabilities are not traded in an active market with readily observable prices, we use significant unobservable inputs to measure the fair value of short-term investments, other financial assets, warrant liabilities and put right liabilities. These instruments are categorized in the Level&#160;3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A list of recently issued accounting pronouncements that are relevant to us is included in note 2 &#8220;Principal Accounting Policies&#8212;2.27 Recent Accounting Pronouncements&#8221; of our consolidated financial statements included elsewhere in this annual report. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">200 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">B.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Capital Resources</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Flows and Working Capital </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have incurred net losses and negative cash flows from our operations for the years ended December&#160;31, 2018 and 2019. We generated net income and positive cash flow from our operations for the year ended December&#160;31, 2020, which was primarily attributable to the collection of the upfront payment from AbbVie. Substantially all of our losses have resulted from funding our research and development programs and administrative costs associated with our operations. We incurred net losses of RMB402.8&#160;million and RMB1,452.0&#160;million for the years ended December&#160;31, 2018 and 2019, respectively, and net income of RMB470.9&#160;million (US$72.2 million) for the year ended December&#160;31, 2020. Our primary use of cash is to fund our research and development activities. We used RMB280.7&#160;million and RMB868.0&#160;million in cash for our operating activities for the years ended December&#160;31, 2018 and 2019, respectively, and generated RMB433.6&#160;million (US$66.4 million) in cash from our operating activities for the year ended December&#160;31, 2020. Historically, we have financed our operations principally through proceeds from the issuance and sale of preferred shares and convertible promissory notes in private placement transactions, and we also received total net proceeds of approximately US$105.3&#160;million from our initial public offering. As of December&#160;31, 2020, we had cash, cash equivalents and restricted cash of RMB4,790.3&#160;million (US$734.1 million). Our cash, cash equivalents and restricted cash consist primarily of cash in bank and on hand. In September 2020, we entered into definitive subscription agreements with a consortium of institutional investors to raise approximately US$418&#160;million through a private placement. The private placement consists of (i)&#160;the sale to the institutional investors of approximately US$418&#160;million of our 29,133,502 ordinary shares (equivalent to 12,666,740 ADSs) at a purchase price equivalent to US$33 per ADS, representing a 2.9% premium to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> volume weighted average price; and (ii)&#160;warrants to subscribe for an aggregate of 5,341,267 ordinary shares (equivalent to 2,322,290 ADSs) at an exercise price equivalent to US$45 per ADS, representing a 40.3% premium to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> volume weighted average price, which may further increase the proceeds of approximately US$104.5&#160;million if the warrants are fully exercised. The warrants will remain exercisable at the election of the institutional investors within 12 months after the closing of the private placement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a summary of our cash flows for the periods presented: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary&#160;Consolidated&#160;Statements&#160;of&#160;Cash&#160;Flow&#160;Data:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash (used in) generated from operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(280,705</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(867,982</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">433,558</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">66,446</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash generated from (used in) investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">212,462</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(201,901</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(30,943</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash generated from financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,479,669</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">152,709</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,440,481</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">527,277</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of exchange rate changes on cash and cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">59,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,163</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(106,643</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(16,344</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net increase (decrease) in cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,268,218</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(487,648</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,565,495</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">546,436</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash, beginning of the year</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">412,713</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,680,931</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,193,283</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">182,879</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash, end of the year</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,680,931</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,193,283</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,758,778</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">729,315</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval of and commercialize one of our current or future drug candidates. We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our drug candidates and begin to commercialize any approved products. We also expect to incur additional costs associated with operating as a public company. In addition, subject to obtaining regulatory approval of any of our drug candidates, we expect to incur significant commercialization expenses for product sales, marketing and manufacturing. Accordingly, we anticipate that we will need substantial additional funding in connection with our continuing operations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">201 </div></div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on our current operating plan, we believe that our current cash and cash equivalents will be sufficient to meet our current and anticipated working capital requirements and capital expenditures for at least the next 12 months. In that time, we expect that our expenses will increase substantially as we fund new and ongoing research and development activities and working capital needs. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our drug candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development and commercialization of our drug candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may decide to enhance our liquidity position or increase our cash reserve for future operations and investments through additional financing. The issuance and sale of additional equity would result in further dilution to our shareholders and ADS holders, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as an ADS holder. The incurrence of indebtedness would result in increased fixed obligations and could result in operating covenants that would restrict our operations, which could potentially dilute your interest. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or research programs or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or drug candidates that we would otherwise prefer to develop and market ourselves. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of December&#160;31, 2020, 9.5% of our cash and cash equivalents were denominated in RMB and held in China. We may make additional capital contributions to our PRC subsidiaries, establish new PRC subsidiaries and make capital contributions to these new PRC subsidiaries, make loans to our PRC subsidiaries, or acquire offshore entities with business operations in China in offshore transactions. However, most of these uses are subject to PRC regulations and approvals. See &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks Related to Doing Business in China&#8212;PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from making loans to our PRC subsidiaries or making additional capital contributions to our wholly foreign-owned subsidiaries in China, which could materially and adversely affect our liquidity and our ability to fund and expand our business&#8221;. In addition, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic may materially and adversely affect our ability to raise additional capital in future and our liquidity. See &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks Related to Our Business and Our Industry&#8212;Our business and results of operations could be adversely affected by public health crisis (including the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> global pandemic) and natural catastrophes or other disasters outside of our control in the locations in which we, our suppliers, CROs, CMOs and other contractors operate.&#8221; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect that the majority of our future revenues will be denominated in RMB. Under existing PRC foreign exchange regulations, payments of current account items, including profit distributions, interest payments and trade and service-related foreign exchange transactions, can be made in foreign currencies without prior SAFE approval as long as certain routine procedural requirements are fulfilled. Therefore, our PRC subsidiaries are allowed to pay dividends in foreign currencies to us without prior SAFE approval by following certain routine procedural requirements. However, approval from or registration with competent government authorities is required where RMB is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. The PRC government may at its discretion restrict access to foreign currencies for current account transactions in the future. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Activities </div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Net cash generated from operating activities for the year ended December&#160;31, 2020 was RMB433.6&#160;million (US$66.4 million). Our net income was RMB470.9&#160;million (US$72.2 million) for the same period. The difference between our net income and our net cash generated from operating activities was primarily attributable to certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> expenses, including share-based compensation of RMB493.5&#160;million (US$75.6 million), equity in loss of an affiliate of RMB108.6&#160;million (US$16.6 million), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> gains on deconsolidation of a subsidiary of RMB407.6&#160;million (US$62.5 million) and changes in certain working capital items, including an increase in the accounts receivable of RMB130.5&#160;million (US$20.0 million), an increase in the contract assets of RMB227.4&#160;million (US$34.8 million), an increase in the prepayments and other receivables of RMB58.7&#160;million (US$9.0 million), partially offset by an increase in the accruals and other payables of RMB173.7&#160;million (US$26.6 million). The change in share-based compensation was attributable to the grant of stock options to certain directors and employees of our company under the 2017 Plan, 2018 Plan, 2019 Plan and 2020 Plan. </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">202 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net cash used in operating activities for the year ended December&#160;31, 2019 was RMB868.0&#160;million. Our net loss was RMB1,452.0&#160;million for the same period. The difference between our net loss and our net cash used in operating activities was primarily attributable to certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> expenses, including share-based compensation of RMB366.9&#160;million and loss on the termination agreement with Everest of RMB23.0&#160;million, and changes in certain working capital items, including an increase in the research and development funding of RMB53.1&#160;million, an increase in the accruals and other payables of RMB188.4&#160;million, partially offset by an decrease in advance from customers of RMB14.2&#160;million and an decrease in repayments and other receivables of RMB48.8&#160;million. The change in share-based compensation was attributable to the grant of stock options to a director of our company under the 2018 Plan. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Net cash used in operating activities for the year ended December&#160;31, 2018 was RMB280.7&#160;million. Our net loss was RMB402.8&#160;million for the same period. The difference between our net loss and our net cash used in operating activities was primarily attributable to certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> expenses or gains, including fair value gains of warrants of RMB61.4&#160;million, and changes in certain working capital items, including (i)&#160;an increase in the research and development funding of RMB178.7&#160;million and (ii)&#160;an increase in accruals and other payables of RMB55.6&#160;million, partially offset by an increase in prepayments and other receivables of RMB76.3&#160;million. The accruals and other payables principally consist of accrued external research and development activities related expenses and staff salaries and welfare payables. The change in fair value of warrant liabilities was attributable to the exercise of part of the warrants issued in 2017 and the modification in 2018 that added certain forfeiture conditions to the warrants. Prepayments and other receivables primarily consist of our prepayment to CRO partners and value-added tax recoverable. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investing Activities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Net cash used in investing activities for the year ended December&#160;31, 2020 was RMB201.9&#160;million (US$30.9 million). The net cash increase was primarily attributable to RMB2,503.7&#160;million (US$381.9 million) of the cash received from proceeds from disposal of short-term investments, partially offset by RMB2,492.0&#160;million (US$383.7 million) of purchase of short-term investments, and cash disposed of resulting from deconsolidation of a subsidiary, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou of RMB257.7&#160;million (US$39.5 million). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash generated from investing activities for the year ended December&#160;31, 2019 was RMB212.5&#160;million. The net cash increase was primarily attributable to RMB256.0&#160;million of the cash received from disposal of other financial assets and RMB134.0&#160;million of purchase of short-term investments, partially offset by RMB102.0&#160;million of proceeds from disposal of short-term investments. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash generated from investing activities for the year ended December&#160;31, 2018 was RMB9.5&#160;million. The net cash increase was primarily attributable to RMB40.0&#160;million of the cash received from disposal of other financial assets, partially offset by RMB30.0&#160;million of the cash used in other financial assets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financing Activities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash generated from financing activities for the year ended December&#160;31, 2020 was RMB3,440.5&#160;million (US$527.3 million), primarily attributable to the proceeds from the initial public offering of our company, net of payment of offering issuance cost of RMB698.7&#160;million (US$107.1 million), the proceeds from private placement, net of payment of issuance cost of RMB2,782.5&#160;million (US$426.4 million), partially offset by the repayment of bank borrowings of RMB50.0&#160;million (US$7.7 million). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash generated from financing activities for the year ended December&#160;31, 2019 was RMB152.7&#160;million, primarily attributable to the proceeds from issuance of convertible preferred shares, net of issuance cost of RMB183.5&#160;million and the repayment of bank borrowings of RMB80.0&#160;million, partially offset by the proceeds of bank borrowings of RMB50.0&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash generated from financing activities in the year ended December&#160;31, 2018 was RMB1,479.7&#160;million, primarily attributable to (i)&#160;proceeds from issuance of RMB1,306.6&#160;million convertible preferred shares and (ii)&#160;receipt of RMB132.3&#160;million resulting from the exercise of warrants by investors. </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">203 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Capital Expenditures </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our capital expenditures were incurred for purposes of purchasing property, equipment and software. Our capital expenditures were RMB14.4&#160;million, RMB12.2&#160;million and RMB8.0&#160;million (US$1.2 million) in the years ended December&#160;31, 2018, 2019 and 2020, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holding Company Structure </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are a holding company with no material operations of its own. We currently conduct our operations primarily through our PRC subsidiaries. As a result, our ability to pay dividends depends upon dividends paid by our PRC subsidiaries. If our existing PRC subsidiaries or any newly formed ones incur debt on their own behalf in the future, the instruments governing their debt may restrict their ability to pay dividends to us. In addition, our wholly foreign-owned subsidiaries in China are permitted to pay dividends to us only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. Under PRC law, each of our subsidiaries and their subsidiaries in China is required to set aside at least 10% of its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits each year, if any, to fund certain statutory reserve funds until such reserve funds reach 50% of their registered capital. In addition, our wholly foreign-owned subsidiaries in China may allocate a portion of their <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits based on PRC accounting standards to enterprise expansion funds and staff bonus and welfare funds at their discretion, and their subsidiaries may allocate a portion of their <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profits based on PRC accounting standards to a surplus fund at their discretion. The statutory reserve funds and the discretionary funds are not distributable as cash dividends. Remittance of dividends by a wholly foreign-owned company out of China is subject to examination by the banks designated by SAFE. Our PRC subsidiaries have not paid dividends and will not be able to pay dividends until they generate accumulated profits and meet the requirements for statutory reserve funds. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">C.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development, Patents and Licenses, Etc.</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Intellectual Property&#8221; and &#8220;&#8212;R&amp;D Governance.&#8221; </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">D.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Trend Information</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other than as disclosed elsewhere in this annual report, we are not aware of any trends, uncertainties, demands, commitments or events since January&#160;1, 2020 that are reasonably likely to have a material adverse effect on our net revenues, income, profitability, liquidity or capital resources, or that caused the disclosed financial information to be not necessarily indicative of future operating results or financial conditions. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">E.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Off-balance</div> Sheet Arrangements</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties. In addition, we have not entered into any derivative contracts that are indexed to our shares and classified as shareholder&#8217;s equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or product development services with us. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">F.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Tabular Disclosure of Contractual Obligations</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth our contractual obligations as of December&#160;31, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 54%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less&#160;Than</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1&#160;Year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-3&#160;Years</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5&#160;Years</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Than</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5&#160;Years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="38" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease commitments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,901</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,283</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,901</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">919</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">204 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Our operating lease commitments relate to leases for our office premises pursuant to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> operating lease agreements. Other than as shown above, we did not have any significant capital and other commitments, long-term obligations or guarantees as of December&#160;31, 2020. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">G.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Safe Harbor</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See &#8220;Forward-Looking Statements&#8221; on page 1 of this annual report. </div></div> <div id="rom10811_10" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Directors and Senior Management</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth information regarding our directors and executive officers as of the date of this annual report. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 60%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">DIRECTORS&#160;AND&#160;EXECUTIVE&#160;OFFICERS</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGE</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">POSITION/TITLE</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Jingwu Zhang Zang, M.D., Ph.D.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">65</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Founder and Chairman</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Joan Huaqiong Shen, M.D., Ph.D.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">59</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Director and Chief Executive Officer</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Zheru Zhang, Ph.D.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">58</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Director and President</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Jielun Zhu</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">45</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Director and Chief Financial Officer</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Wei Fu</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">39</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Mengjiao Jiang</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">40</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Jie Yu</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">46</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Bing Yuan</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">52</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Chun Kwok Alan Au</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">48</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Independent Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Conor Chia-hung Yang</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">58</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Independent Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Pamela M. Klein</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">59</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Independent Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Weimin Tang, Ph.D.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">55</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Executive Vice President of Global Business Development</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Yunhan Lin, Ph.D.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">43</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Vice President of Corporate Development</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Neil Warma</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">58</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">General Manager of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> US</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Ivan Yifei Zhu</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">52</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Chief Commercial Officer</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Gigi Qi Feng</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">39</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Chief Communications Officer</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Richard Cheng Li</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">37</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Chief Legal Officer</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jingwu Zhang Zang</div></div>, M.D., Ph.D., is our founder and chairman. Our board of directors appointed Dr. Zang as the chairman of the board in March 2021. Prior to this appointment, Dr.&#160;Zang served as our director and honorary chairman from October 2019 to March 2021, and chief executive officer from our inception to October 2019. Prior to founding our company, Dr.&#160;Zang served as the chief scientific officer and president of Simcere Pharmaceutical Group and Bioscikin Co., Ltd. from September 2013 to April 2016. Dr.&#160;Zang held senior management positions at GlaxoSmithKline (GSK), as the global senior vice president and head of GSK&#8217;s Research and Development in China from April 2007 to June 2013. The academic career of Dr.&#160;Zang started in Dr.&#160;Willems Institute and University of Limburg in Belgium. Dr.&#160;Zang became a professor at Baylor College of Medicine in Houston and later joined the Chinese Academy of Sciences as the founding director of the Institute of Health Sciences and as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-director</div> of Institute Pasteur Shanghai, an independent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-profit</div> life science institute to address public health problems in China, where he served as its director from October 2004 to September 2006. Dr.&#160;Zang also served as a director of Shanghai Institute of Immunology from June 2002 to April 2007. Dr.&#160;Zang received his M.D. from Shanghai Second Medical University (now part of Shanghai Jiaotong University) in 1984, and his Ph.D. in neuroimmunology from the University of Brussels in 1990. Dr.&#160;Zang conducted his post-doctoral work at Harvard Medical School in 1992, and obtained his U.S. medical license from the Texas Medical Board through a clinical residency at Baylor College of Medicine in Houston. </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">205 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Joan Huaqiong Shen</div></div>, M.D., Ph.D., has served as our head of discovery and clinical development since September 2017, as our director since July 2019 and as our chief executive officer since October 2019. Prior to joining our company, Dr.&#160;Shen served as the vice president and development head of Janssen Pharmaceutical Companies of Johnson&#160;&amp; Johnson from September 2015 to September 2017. Dr.&#160;Shen was the chief medical officer and vice president in Jiangsu Hengrui Medicine, Co., Ltd. (SHA: 600276) from May 2013 to August 2015. Dr.&#160;Shen served as the head of the China clinical department and a senior director at Pfizer (China) Research and Development Co., Ltd. from August 2011 to May 2013. Prior to that, Dr.&#160;Shen worked as a senior medical director at Pfizer Inc. (NYSE: PFE) from November 2009 to August 2011. From August 2005 to November 2009, Dr.&#160;Shen was the medical director at Wyeth Research, a leading pharmaceutical company. Dr.&#160;Shen worked as a clinical research physician at Eli Lilly and Company (NYSE: LLY) from September 2003 to August 2005. Dr.&#160;Shen served as an adjunctive assistant professor in the department of psychiatry of the Indiana University School of Medicine from October 2003 to October 2005. She has also been a guest professor of Beijing University Clinical Research Institute since March 2018. Dr.&#160;Shen completed three fellowships in the Indiana University School of Medicine, one in endocrinology from August 1996 to July 1998, one in psychopharmacology and one in clinical pharmacology, both from January 2002 to September 2003. Dr.&#160;Shen obtained her U.S. medical license from the Indiana University School of Medicine through a clinical residency. Dr.&#160;Shen received her M.D. from Southeast University Medical College in 1983, master&#8217;s degree in anatomy from West China University of Medical Sciences, currently Sichuan University School of Medicine in 1989, and her Ph.D. in anatomy/neuroscience from the Indiana University School of Medicine in 1996. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zheru Zhang</div></div>, Ph.D., has served as our director and president since September 2017. Prior to joining our company, Dr.&#160;Zhang served as the president at Tasgen <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-tech</div> (Tianjin) Co., Ltd. from November 2015 to April 2017, as the chief executive officer at Shanghai <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">JMT-Bio</div> Co., Ltd. from October 2012 to October 2015, as a vice president, research and development at Celltrion Inc. from March 2008 to October 2012, as a group leader for the development of analytics and drug products at Johnson&#160;&amp; Johnson (NYSE: JNJ) from January 2006 to March 2008, and as a research investigator at Bristol-Myers Squibb Company from May 2000 to January 2006, focusing on bioanalytical development and protein therapeutics development, respectively. Dr.&#160;Zhang received his master&#8217;s degree in chemistry from Suzhou University in 1991, and his Ph.D. in chemistry from University of Alberta in Canada in 2000. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jielun Zhu </div></div>has served as our chief financial officer since August 2018 and as our director since July 2019. Prior to joining our company, Mr.&#160;Zhu held positions as a managing director and the head of healthcare investment banking, Asia, at Jefferies Hong Kong Limited from December 2015 to July 2018, advising biotechnology and healthcare clients globally on initial public offerings, mergers and acquisitions and other strategic transactions. From August 2008 to December 2015, Mr.&#160;Zhu worked at the Deutsche Bank Group in its Hong Kong branch, with his last position being a director in the corporate finance division. He worked as an investment banker at UBS Investment Bank in Hong Kong from July 2007 to July 2008. Mr.&#160;Zhu received his bachelor&#8217;s degree of arts with honors in mathematics-economics from Wesleyan University in May 2000 and master&#8217;s degree in business administration from the Harvard Business School with Distinction in June 2007. Mr.&#160;Zhu was awarded the Chartered Financial Analyst (CFA) charter by the CFA Institute in January 2012. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Wei Fu </div></div>has served as our director since June 2018. Mr.&#160;Fu was appointed by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> entities pursuant to our shareholders agreement dated July&#160;6, 2018. Mr.&#160;Fu has served as the chief executive officer and a managing partner of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> Capital Investment Management, Ltd. since April 2014. Mr.&#160;Fu currently also serves on the board of several private companies. From August 2011 to December 2013, Mr.&#160;Fu served as the general manager of the investment department at Far East Horizon International, a financial services organization. Mr.&#160;Fu served as a partner and the head of the Beijing office of Themes Investment Management Ltd, a private equity firm specializing in healthcare and environmental businesses, from July 2010 to July 2011. From March 2008 to April 2010, Mr.&#160;Fu worked as an associate director of the private equity department at Standard Chartered Business Consulting (Beijing) Co., Ltd, where he was mainly responsible for private equity investment in relation to infrastructure projects. Mr.&#160;Fu received his bachelor&#8217;s degree in electrical engineering and business administration from Nanyang Technological University in Singapore in February 2005. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mengjiao Jiang </div></div>has served as our director since September 2017. Ms.&#160;Jiang was appointed by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> entities pursuant to our shareholders agreement dated July&#160;6, 2018. Ms.&#160;Jiang is a managing director of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> Capital Investment Management, Ltd., a healthcare-dedicated private equity firm, and has served as a partner and a managing director since January 2014. Ms.&#160;Jiang currently also serves on the board of several private companies. Ms.&#160;Jiang served as a director at International Far East Horizon International, a financial services organization, from March 2012 to December 2013. Prior to that, Ms.&#160;Jiang served at ARC China Inc. as a managing director from May 2008 to June 2011. Ms.&#160;Jiang received her bachelor&#8217;s degree in economics with a political science double major from Wellesley College in Massachusetts in May 2003. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jie Yu </div></div>has served as our director since July 2019. Mr.&#160;Yu was appointed by the Tasly entities pursuant to our shareholders agreement dated July&#160;6, 2018. Mr.&#160;Yu has served as the secretary of the board at Tasly Pharmaceutical Group Co., Ltd. since November 2016. Prior to that, Mr.&#160;Yu was a director of brand management office at China Minsheng Investment Co., Ltd., an international private capital investment group, from March 2015 to October 2016. Mr.&#160;Yu worked as the head of the brand management department and the head of Chinese media affairs department at Huawei Technologies Co., Ltd. from April 2001 to March 2015. Mr.&#160;Yu received his bachelor&#8217;s degree in management from Harbin Normal University in 1998 and master&#8217;s degree in management from Northeast Forestry University in 2001. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">206 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bing Yuan</div></div> has served as our director since April 2020. Mr.&#160;Yuan is a managing director of Hony Capital and a member of Hony Capital&#8217;s executive committee, responsible for its equity investment operations. Mr.&#160;Yuan joined Hony Capital in April 2009 and has served as a managing director of the private equity department since January 2010. Prior to joining Hony Capital, Mr.&#160;Yuan served as a managing director of the direct investment department of Morgan Stanley Asia Limited from 2008 to 2009. Before that, Mr.&#160;Yuan served as a managing director of the investment banking division of Morgan Stanley Asia Limited from April 2004 to June 2008. Prior to that, Mr.&#160;Yuan served as a vice president with Credit Suisse First Boston in Hong Kong and New York from August 1998 to March 2004, focusing on corporate finance and merger&#160;&amp; acquisitions transactions in the technology, media and telecom industry. During his investment banking time, Mr.&#160;Yuan assisted numerous prominent Chinese state-owned enterprises and private sector companies in completing their initial public offerings, corporate finance and merger&#160;&amp; acquisition transactions. Mr.&#160;Yuan also worked as a financial analyst in project finance with Fieldstone Private Equity LLP in New York from 1993 to 1995. Mr.&#160;Yuan received his bachelor&#8217;s degree in English from Nanjing University in July 1990 and received his master&#8217;s degree in international relations in June 1993 and his Juris Doctor degree in June 1998 from Yale University. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mr.</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Chun Kwok Alan Au </div></div>has served as our director since January 2020. Mr.&#160;Au is the founder of GT Healthcare Group, a private equity platform focusing on cross border healthcare investments, and has served as the managing partner of GT Healthcare Group since September 2015. Mr.&#160;Au has served as a director of Cellular BioMedicine Group (Nasdaq: CBMG), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, since November 2014. Mr.&#160;Au also has served as a panel member for the Entrepreneur Support Scheme (ESS Program) of the Innovation and Technology Fund of the Hong Kong SAR Government since 2014. Mr.&#160;Au was an advisor to Simcere Pharmaceutical Group, a leading pharmaceutical company in China (previously listed on NYSE: SCR, privatized in December 2013, when Mr.&#160;Au served as chairman of the special committee on the board of directors). Mr.&#160;Au was also a member of the board of China Nepstar Chain Drugstore Ltd. (NYSE: NPD, privatized in September 2016) from March 2013 to August 2016. Mr.&#160;Au served as the head of the Asia Healthcare Investment Banking of Deutsche Bank Group, advising healthcare IPOs and M&amp;A in the region from April 2011 to December 2012. Prior to that, Mr.&#160;Au served as the executive director at JAFCO Asia Investment Group, responsible for healthcare investments in China from 2008 to 2010. Mr.&#160;Au worked at Morningside Group as a director in charge of healthcare investments in Asia from 2000 to 2005. Mr.&#160;Au received his bachelor&#8217;s degree in psychology from Chinese University of Hong Kong in 1995 and his master&#8217;s degree in management from Columbia Business School in New York in 2007. Mr.&#160;Au is a certified public accountant (CPA) in the U.S. and a chartered financial analyst (CFA). He is an associate member of the Hong Kong Institute of Financial Analysts and member of the American Institute of Certified Public Accountants. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mr.</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Conor Chia-hung Yang </div></div>has served as our director since January 2020. Mr.&#160;Yang is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-founder</div> of Black Fish Group Limited and has served as the president of Black Fish Group Limited since November 2017. Prior to that, Mr.&#160;Yang was the chief financial officer of Tuniu Corporation (Nasdaq: TOUR) from January 2013 to November 2017, the chief financial officer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">E-Commerce</div> China Dangdang Inc. from March 2010 to July 2012 and the chief financial officer of AirMedia Group Inc., currently known as AirNet Technology Inc., (Nasdaq: ANTE) from March 2007 to March 2010. Mr.&#160;Yang was the chief executive officer of Rock Mobile Corporation from 2004 to February 2007. From 1999 to 2004, Mr.&#160;Yang served as the chief financial officer of the Asia Pacific region for CellStar Asia Corporation. Mr.&#160;Yang was an executive director of Goldman Sachs (Asia) L.L.C. from 1997 to 1999. Prior to that, Mr.&#160;Yang was a vice president of Lehman Brothers Asia Limited from 1994 to 1996 and an associate at Morgan Stanley Asia Limited from 1992 to 1994. Mr.&#160;Yang currently serves as an independent director and chairman of the audit committee of each of China Online Education Group (NYSE: COE) and Ehang Holdings Limited (Nasdaq: EH). Mr.&#160;Yang received a master&#8217;s degree of business administration from University of California, Los Angeles in 1992. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">207 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dr.</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Pamela</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;M. Klein </div></div>has served as our director since January 2020. Dr.&#160;Klein currently serves a director of Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) since July 2019, a director of argenx SE (Nasdaq: ARGX) since April 2016 and a director of Patrys Limited (ASX: PAB) since October 2019. In addition, Dr.&#160;Klein has served as the president at PMK BioResearch since 2008, offering consultancy in Oncology Drug Development to Biotech, Pharma and the Investment Community. Dr.&#160;Klein has also served as the consulting chief medical officer at Olema Oncology since 2018. Previously, Dr.&#160;Klein served as Chief Medical Officer for successful biotech <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">start-ups</div> and prior to that, Vice President, Genentech, Development. Dr.&#160;Klein received her bachelor&#8217;s degree in cell and molecular biology from California State University in 1985 and an M.D. from Stritch School of Medicine, Loyola University Chicago in 1992 followed by an internal medicine residency at Cedars Sinai, Los Angeles. Dr.&#160;Klein spent seven years at the National Cancer Institute of the NIH in Bethesda, Maryland in medical oncology. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Weimin Tang</div></div>, Ph.D., has served as our executive vice president of global business development since April 2018. Prior to joining our company, Dr.&#160;Tang served as an executive director and a business director at Hengrui Therapeutics, Inc. from July 2015 to April 2018. Dr.&#160;Tang served as the vice president and a business director at Crown Bioscience Inc., a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> contract research organization, from July 2011 to July 2015. Prior to that, Dr.&#160;Tang served as the vice president and a business director at ShanghaiBio Corporation Shanghai Biotechnology Cooperation, a biotech company based in Shanghai, from October 2010 to July 2011. Dr.&#160;Tang received his bachelor&#8217;s degree in plant pathology from Zhejiang University in 1986, master&#8217;s degree in microbiology from Chinese Academy of Sciences in 1989, and Ph.D. in biochemistry from Rutgers University, New Jersey in 1997. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Yunhan Lin</div></div>, Ph.D., has served as our vice president of corporate development since September 2017. Prior to joining our company, Dr.&#160;Lin served as the head of business development at Mycenax Biotech Inc., a Taiwan-based public pharmaceutical company, from January 2016 to September 2017. Prior to that, Dr.&#160;Lin served as the head of business development at SynCore Biotechnology Co., Ltd, a Taiwan-based public biopharmaceutical company, from February 2012 to December 2015. Dr.&#160;Lin worked as a science project deputy manager at Sinphar Pharmaceutical Co, Ltd., a Taiwan-based pharmaceutical company, from September 2001 to January 2012. Dr.&#160;Lin received his bachelor&#8217;s degree in applied chemistry from Providence University, Taiwan in 2000, master&#8217;s degree in chemistry from Fu Jen Catholic University, Taiwan in 2003, and Ph.D. in chemistry from Tamkang University, Taiwan in 2008. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Neil Warma </div></div>has served as the general manager of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> US since September 2019. Mr.&#160;Warma is currently an advisor to several companies and serves on the board of directors of several biotechnology companies and BioHouston, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-profit</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> 501(c)(3) corporation founded by Houston area academic/research institutions. Prior to joining our company, Mr.&#160;Warma served as the president and chief executive officer of Opexa Therapeutics, currently Acer Therapeutics Inc. (Nasdaq: OPXA), from June 2008 to September 2017, and as its director from September 2008 to September 2017. At Opexa Therapeutics, he also served as acting chief financial officer from March 2016 to September 2017, and previously served in such role from March 2009 to August 2012. From July 2004 to September 2007, Mr.&#160;Warma served as president and chief executive officer of Viron Therapeutics Inc., a privately-held clinical stage biopharmaceutical company. Mr.&#160;Warma <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-founded</div> MedExact USA, Inc., an Internet company providing clinical information and services to physicians and pharmaceutical companies in 2000 and served as president until 2003. From 1992 to 2000, Mr.&#160;Warma held senior positions of increasing responsibility at Novartis Pharmaceuticals (previously Ciba-Geigy Ltd.) at its corporate headquarters in Basel, Switzerland. While at Novartis, Mr.&#160;Warma served as the Head of International Pharma Policy&#160;&amp; Advocacy and in senior management within global marketing where he worked on the international launch of a gastrointestinal product. Mr.&#160;Warma obtained an honors degree specializing in neuroscience from the University of Toronto in 1984 and an International M.B.A. from the Schulich School of Management at York University in Toronto in 1992. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ivan Yifei Zhu</div></div> has served as our chief commercial officer since August 2020. Mr.&#160;Zhu has more than 20 years of successful commercialization experience at global and domestic pharma and biotech companies. Prior to joining us, Mr.&#160;Zhu served as vice president and general manager of the sales division of Qilu Pharmaceutical Group where he managed the company&#8217;s sales and marketing team. From April 2018 to March 2019, Mr.&#160;Zhu served as the chief commercial officer of BeiGene (HKEX: 6160) where he played an instrumental role in the expansion of BeiGene&#8217;s commercialization team and the implementation of its commercialization strategies. Mr.&#160;Zhu also worked for Xi&#8217;an Janssen for more than 20 years where he held various senior management positions. During this period, he built and managed numerous business units, covering a wide range of therapeutic areas including oncology, immunotherapy, skin diseases, infectious diseases and the central nervous system. Mr.&#160;Zhu received his bachelor&#8217;s degree in medicine from Zhejiang University in 1992. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">208 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Gigi Qi Feng</div></div> has served as our chief communications officer since October 2020 and served as our vice president and global head of corporate communications from April 2020 to October 2020. Prior to joining us, Ms.&#160;Feng served as Amgen&#8217;s Japan Asia Pacific regional head of corporate affairs from March 2018 to March 2020, where she led communications efforts including executive communications, media relations, employee engagement and philanthropy to build the Amgen brand across 14 markets in the Asia Pacific region. Prior to joining Amgen, Ms.&#160;Feng held progressive China, Asia Pacific and global communications leadership roles at Sanofi from November 2013 to March 2018, positioning the company as a scientific partner of choice. Prior to that, Ms.&#160;Feng led the strategic communications group at an international public affairs consultancy from December 2009 to November 2013 with a focus on the healthcare industry. She also worked at the U.S. Consulate General in Shanghai from 2005 to 2009, where she managed consulate-wide communications and large-scale events. Ms.&#160;Feng received her bachelor&#8217;s degree in Government and Asian studies from Cornell University in 2003 and completed an EMBA program in business strategy from Harvard Business School in 2015. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Richard Cheng Li</div></div> has served as our chief legal officer since March 2021. From December 2013 to May 2018 and from April 2020 to March 2021, Mr.&#160;Li worked at the Shanghai office of Covington&#160;&amp; Burling LLP, a U.S. law firm, with his last position being an of counsel, leading the firm&#8217;s China life sciences transaction practice. From May 2018 to March 2020, Mr.&#160;Li served as the legal director of 6 Dimensions Capital, a life sciences venture capital firm, in charge of all the legal matters relating to 6 Dimensions&#8217; global investments. From August 2008 to June 2012 and from September 2013 to December 2013, Mr.&#160;Li worked in the corporate practice group in the Shanghai office of Hogan Lovells International LLP, an international law firm. Mr.&#160;Li received his bachelor&#8217;s degree in law in 2006 and master&#8217;s degree in international law in 2008 from Sun <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Yat-sen</div> University, and his LL.M. degree from Columbia Law School in 2013. Mr.&#160;Li has been admitted to the New York State bar and passed the PRC bar exam. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Scientific Advisory Board </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The members of our scientific advisory board provide scientific, portfolio and project strategy advice to us, including the evaluation of research and development strategies. The members of our scientific advisory board receive cash compensation for their services. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Howard Weiner</div></div>, M.D., has served on our scientific advisory board since July 2019. Dr.&#160;Weiner is the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director of the Partners Multiple Sclerosis (&#8220;MS&#8221;) Center and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Director</div> of Center for Neurologic Diseases at Brigham&#160;&amp; Women&#8217;s Hospital in Boston. The Partners MS Center is the first integrated MS Center that combines clinical care, MRI imaging and immune monitoring to the MS patient as part of the 2000 patient CLIMB cohort study. Dr.&#160;Weiner has pioneered immunotherapy in MS and has investigated immune mechanisms in nervous system diseases including MS, Alzheimer&#8217;s disease, amyotrophic lateral sclerosis, stroke and brain tumors. Dr.&#160;Weiner has also pioneered the investigation of the mucosal immune system for the treatment of autoimmune and other diseases and the use of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-CD3</div> to induce regulatory T cells for the treatment of these diseases. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Eric K. Rowinsky</div></div>, M.D., has served on our scientific advisory board since June 2019. Dr.&#160;Rowinsky is an independent consultant and/or board member of various public and private companies and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">not-for-profit</div></div> efforts. Since 2017, Dr.&#160;Rowinsky has served as an advisor to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> Capital and the U.S. Chief Medical Officer for Everest Medicines, Inc. Since 2015, Dr.&#160;Rowinsky has served as an Executive Director and President at Rgenix Inc. and as the Chief Scientific Officer of Clearpath Development Co. From 2005 to 2015, Dr.&#160;Rowinsky held various positions with various biotechnology companies. At ImClone Systems (now a wholly-owned subsidiary of Eli Lilly), Dr.&#160;Rowinsky and his team developed and registered cetuximab (Erbitux) and ramucirumab in five indications and two other monoclonal antibodies in North America and elsewhere. Dr.&#160;Rowinsky has been an Adjunct Professor of Medicine at New York University School of Medicine since 2005. From 1987 to 2005, Dr.&#160;Rowinsky held various academic and research positions with various universities and research institutions including the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio, where he held the SBC Endowed Chair for Early Drug Development, and the Johns Hopkins University School of Medicine. Dr.&#160;Rowinsky received his B.A. degree from New York University and his M.D. from the Vanderbilt University School of Medicine and completed fellowship training at the Johns Hopkins University School of Medicine. Dr.&#160;Rowinsky received the career development award of the American Cancer Society and the 6th Annual Emil J. Freireich Award. He has also served on the Board of Scientific Counselors of the NCI. Dr.&#160;Rowinsky is the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Editor-in-Chief</div></div> of Investigational New Drugs, an Editorial Board Member of Cancer Research and several other oncology journals. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">209 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patricia LoRusso</div></div>, D.O., M.A., Ph.D., has served on our scientific advisory board since July 2019. Dr.&#160;LoRusso is currently a professor of medicine and a clinical scholar in medical oncology and Associate Director of Innovative Medicine at Yale Cancer Center in New Haven, Connecticut, USA, where she is also Director of Early Therapeutics Disease-Aligned Team. Dr.&#160;LoRusso&#8217;s expertise is in testing new treatments on patient volunteers with advanced-stage cancer. She heads the early clinical trials program at Yale Cancer Center. She has served as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-leader</div> of the Stand Up To Cancer/Melanoma Research Alliance&#8211;funded Melanoma Dream Team, a Komen Promise grant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-Principal</div> Investigator, and has been a Principal Investigator of the National Cancer Institute Phase 1/early phase clinical trials program grant in excess of 20 years. She is currently primary investigator or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-investigator</div> of numerous clinical trials. Prior to joining Yale in August 2014, Dr.&#160;LoRusso served in numerous leadership roles at Wayne State University&#8217;s Barbara Karmanos Cancer Institute for more than 25 years, most recently as director of the Phase 1 Clinical Trials Program and of the Eisenberg Center for Experimental Therapeutics. Dr.&#160;LoRusso also worked as a director in Karmanos Cancer Institute, a cancer research and provider network, from 1997 to 2014. Dr.&#160;LoRusso received her B.A. degree of science in religion/religious studies and biology, her master&#8217;s degree at Yale University, her D.O. and Ph.D. from Michigan State University, and completed fellowship training at Wayne State University. Dr.&#160;LuRosso served as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-chair</div> of the National Cancer Institute Cancer Therapy Evaluation Program (NCI CTEP) Investigational Drug Steering Committee, a prior parent member of the NCI&#8217;s Quick Trials Clinical Subcommittee, and has served as either an ad hoc or an appointed member on multiple study sections and has reviewed for Komen Promise grants, numerous SPORE and P01 study sections, and translational research grants. She has served on the education and scientific committees of the American Society of Clinical Oncology, the Scientific Committee of the American Association for Cancer Research as well as a Vice-Chair for the 2019 AACR annual meeting. She is a member of the NCI Board of Scientific Council and has served on the Board of Directors for the American Association for Cancer Research. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Yi-Long</div> Wu</div></div>, M.D., FACS, has served on our scientific advisory board since August 2019. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Yi-Long</div> Wu is a tenured professor of Guangdong General Hospital, Guangdong Academy of Medical Sciences and Guangdong Lung Cancer Institute. He is the former President of Chinese Society of Clinical Oncology (CSCO), the Chief of the WUJIEPING Oncology Medical Foundation, the vice-director of the Precision Medicine of the Chinese Medical Doctor Association, the President of Chinese Thoracic Oncology Group <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(C-TONG),</div> the President of International Chinese Society of Thoracic Surgery (ICSTS), a Fellow of the American College of Surgeons, a Member of Board of Directors of the International Association Study of Lung Cancer (IASLC), the Chairman of European Society for Medical Oncology (ESMO) in China, the Chairman of Federation of Asia Clinical Oncology (FACO), a past Member of the International Affairs Committee of American Society of Clinical Oncology (ASCO), and a former Member of staging committee of the IASLC. He graduated from Sun <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Yat-sen</div> University of Medical Sciences in 1982 and completed his thoracic surgery training in Germany in 1989. His main research interests are the multidisciplinary synthetic therapy on lung cancer in translation medicine and evidence-based medicine in oncology. He is leading the Chinese lung cancer research field and has been the Principal Investigator or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-PI</div> of more than 120 international or national multicenter clinical trials. He has contributed 20 books on cancer and has published more than 300 articles in peer-reviewed journals including <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">J Clin Oncol, Lancet Oncol, New Engl J Med, Cancer Cell and J Thorac Oncol</div></div>. He also serves on the editorial boards of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cancer Letters, Annals of Surgical Oncology, Lung Cancer Management, International Journal of Biological Marker and General Thoracic and Cardiovascular Surgery</div></div>. He is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Editor-in-Chief</div></div> of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Journal of Evidence-based Medicine, Journal of Thoracic Oncology (Chinese Edition), and The Oncologist (Chinese Edition) </div></div>etc. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Timothy Yap</div></div>, M.D., Ph.D., has served on our scientific advisory board since August 2019. Dr.&#160;Yap is a medical oncologist and physician-scientist based at the University of Texas MD Anderson Cancer Center. He is an Associate Professor in the Department for Investigational Cancer Therapeutics (Phase I Program), and the Department of Thoracic/Head and Neck Medical Oncology. Dr.&#160;Yap is the Medical Director of the Institute for Applied Cancer Science, a drug discovery biopharmaceutical unit where drug discovery and clinical translation are seamlessly integrated. He is also the Associate Director of Translational Research in the Institute for Personalized Cancer Therapy, which is an integrated research and clinical trials program aimed at implementing personalized cancer therapy and improving patient outcomes. Prior to his current position, Dr.&#160;Yap was a Consultant Medical Oncologist at The Royal Marsden Hospital in London, UK and National Institute for Health Research BRC Clinician Scientist at The Institute of Cancer Research, London, UK. Dr.&#160;Yap gained his BSc degree with First Class&#160;Honors in Immunology and Infectious Diseases at Imperial College London, UK, and was awarded the Huggett Memorial Prize. His BSc laboratory research involved an immunogenetics study under the supervision of Professor Charles Bangham. He subsequently went on to attain his Medical degree from Imperial College London, UK, before completing general medical training in Oxford. Dr.&#160;Yap&#8217;s main research focuses on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-human</div></div> and combinatorial development of molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers. Dr.&#160;Yap leads immuno-oncology clinical and associated translational studies, including novel agents targeting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-1/PD-L1,</div></div> ICOS, IDO, LAG3, TIM3, STING, TGFbeta, adenosine A2A receptor and fucosylation. He was previously the UK Chief Investigator for the CheckMate 331 Phase III trial in relapsed small cell lung cancer and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KEYNOTE-158</div> Phase II biomarker study in advanced solid tumors and multiple novel immunotherapy combination phase I trials. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">210 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Roy S. Herbst, MD, PhD</div></div>, has served on our scientific advisory board since July 2019. Dr.&#160;Roy&#160;S. Herbst is an Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology, the Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital, and an Associate Cancer Center Director for Translational Research, Yale Cancer Center in New Haven, CT. Dr.&#160;Herbst is nationally recognized for his leadership and expertise in lung cancer treatment and research. He is best known for his work in developmental therapeutics and the personalized therapy of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-small</div> cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies. Prior to his appointment at Yale, Dr.&#160;Herbst was the Barnhart Distinguished Professor and Chief of the Section of Thoracic Medical Oncology in the Department of Thoracic/Head and Neck Medical Oncology, at The University of Texas M.D. Anderson Cancer Center <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(UT-MDACC)</div> in Houston, Texas. He also served as Professor in the Department of Cancer Biology and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Director</div> of the Phase I Clinical Trials Program. He has led the Phase I development of several of the new generation of targeted agents for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-small</div> cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and bevacizumab. More recently, he participated in the successful registration of pembrolizumab for the treatment of advanced <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-small</div> cell lung cancer, following the successful <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Yale-led</div> KEYNOTE 10 study of the immune therapy drug commonly used to treat other cancers. He was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-leader</div> for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BATTLE-1</div> clinical trial program, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-leads</div> the subsequent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BATTLE-2</div> clinical trial program, and served as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-program</div> Leader of the Developmental Therapeutics Program for the YCC Support Grant. Dr.&#160;Herbst&#8217;s laboratory work is focused on immunotherapy angiogenesis; dual epidermal growth factor receptor (EGFR)/vascular endothelial growth factor receptor (VEGFR) inhibition in NSCLC, and targeting KRAS-activated pathways. More recently, he has explored predictive biomarkers for the use of immunotherapy agents. This work has been translated from the preclinical to clinical setting in multiple Phase II and III studies which he has led. After earning a B.S. and M.S. degree from Yale University, Dr.&#160;Herbst earned his M.D. at Cornell University Medical College and his Ph.D. in molecular cell biology at The Rockefeller University in New York City, New York. His postgraduate training included an internship and residency in medicine at Brigham and Women&#8217;s Hospital in Boston, Massachusetts. His clinical fellowships in medicine and hematology were completed at the Dana-Farber Cancer Institute and Brigham and Women&#8217;s Hospital, respectively. Subsequently, Dr.&#160;Herbst completed a M.S. degree in clinical translational research at Harvard University in Cambridge, Massachusetts. Dr.&#160;Herbst is an author or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-author</div> of more than 275 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has been published in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, the New England Journal of Medicine, and Nature. Dr.&#160;Herbst was a member of the National Cancer Policy Forum (1998-2014) for which he organized an Institute of Medicine meeting focused on policy issues in personalized medicine. He is a member of ASCO and, as a member of AACR, he chairs the Tobacco Task Force. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. Dr.&#160;Herbst is also a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for ASCO and the International Association for the Study of Lung Cancer. He is currently the Vice Chair for Developmental Therapeutics for the Southwestern Oncology Group (SWOG) Lung Committee, Principal Investigator of the SWOG 0819 trial, and steering committee chair for the Lung Master Protocol (Lung MAP). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Chen Dong, Ph.D.</div></div>, has served on our scientific advisory board since September 2020. Dr.&#160;Dong is a professor and the director of the Institute for Immunology at Tsinghua University. Prior to joining Tsinghua University in 2013, Dr.&#160;Dong served as a professor of immunology and the director of the Center for inflammation and Cancer at the University of Texas MD Anderson Cancer Center from 2004 to 2013. Dr.&#160;Dong&#8217;s research focuses on understanding the molecular mechanisms whereby immune and inflammatory responses are normally regulated, and applying this knowledge to the understanding and treatment of autoimmunity and allergy disorders as well as cancer. The work from Dr.&#160;Dong&#8217;s group has led to the discoveries of Th17 and T follicular helper (Tfh) cell subsets in the immune system and elucidation of their biological and pathological functions. Dr.&#160;Dong has over 200 publications and was rated highly cited researcher for six years from 2014 to 2019. The honors he has received include the 2009 American Association of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Immunologists-BD</div> Bioscience Investigator Award and 2019 International Cytokine and Interferon Society Biolegend-William E. Paul Award. He is a fellow of the American Association for the advancement of Science and a member of the Chinese Academy of Sciences. Dr.&#160;Dong is currently an Editor for Immunity, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Editor-in-chief</div></div> for Frontiers in Immunology- T Cell Biology and Associate Editor for China Sciences- Life Sciences. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">211 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jun Ma</div></div>, has served on our scientific advisory board since December 2020. Dr.&#160;Ma is Chief Physician, Professor, Doctoral Supervisor, Director of Harbin Institute of Hematology&#160;&amp; Oncology, Chief Supervisor of Supervisory Committee, Chinese Society of Clinical Oncology (CSCO), Vice Chairman of ACOS, Chairman of Union for China Leukemia Investigators of CSCO, Past-Vice Chairman of Chinese Society of Hematology, Vice Chairman of CMDA for Hematologist Committee, Vice Chairman of CMDA for Oncology Committee and Past-Chairman of Union for China Lymphoma Investigators of CSCO. Dr.&#160;Ma studied in the University of Tokyo Hospital since 1979. He was devoted to giving the treatment for benign and malignant diseases of hematological system. He earns the fame for treating Leukemia and lymphoma. In 1982, he built the very first multiple hematopoietic progenitor cells culture system in vitro in China. Since 1983, he used the sequential therapy of ATRA and ATO to treat APL for 1200 cases or so. And disease free survival (DFS) were 85% in 10 years, which achieved international advanced level. He has published about 200 articles in Journals from home and abroad, with over 40 monographs and has earned 20 national, provincial and municipal Science&#160;&amp; Technology awards. He has taken 8 programs from National R&amp;D Program (863 Program) and 25 projects from provincial, municipal scientific research project. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">B.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Compensation of Directors and Executive Officers</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the fiscal year ended December&#160;31, 2020, we paid an aggregate of approximately US$7.8&#160;million for salaries and benefits in cash to our executive officers. We did not pay any compensation to our directors who are not our executive officers. We have not set aside or accrued any amount to provide pension, retirement or other similar benefits to our executive officers and directors. Our PRC subsidiaries are required by law to make contributions equal to certain percentages of each employee&#8217;s salary for his or her pension insurance, medical insurance, unemployment insurance and other statutory benefits and a housing provident fund. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employment Agreements and Indemnification Agreements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have entered into employment agreements with all of our executive officers. Under these agreements, each of our executive officers is employed for a specified time period. We may terminate employment for cause, at any time, for certain acts of the executive officer, such as continued failure to satisfactorily perform, willful misconduct or gross negligence in the performance of agreed duties, conviction or nolo contendere plea of guilty to any felony or any misdemeanor involving moral turpitude, or dishonest act that result in material harm to our detriment, or material breach by the executive officer of the employment agreement. We may also terminate an executive officer&#8217;s employment without cause upon a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">60-day</div> prior written notice. In such case of termination by us, we will provide severance payments to the executive officer as may be agreed between the executive officer and us. The executive officer may resign at any time with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">60-day</div> prior written notice. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under these agreements, each executive officer has agreed to hold, both during and after the termination or expiry of his or her employment agreement, in strict confidence and not to use, except as required in the performance of his or her duties in connection with the employment or pursuant to applicable law, any of our confidential information or trade secrets, any confidential information or trade secrets of our clients or prospective clients, or the confidential or proprietary information of any third party received by us and for which we have confidential obligations. The executive officers have also agreed to disclose in confidence to us all inventions, designs and trade secrets which they conceive, develop or reduce to practice during the executive officer&#8217;s employment with us and to assign all right, title and interest in them to us, and assist us in obtaining and enforcing patents, copyrights and other legal rights for these inventions, designs and trade secrets. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, under these agreements, each executive officer has agreed to be bound by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competition</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation</div> restrictions during the term of his or her employment and typically for one year following the last date of employment. Specifically, each executive officer has agreed not to (i)&#160;approach our suppliers, clients, direct or end customers or contacts or other persons or entities introduced to the executive officer in his or her capacity as a representative of us for the purpose of doing business with such persons or entities that will harm our business relationships with these persons or entities; (ii)&#160;assume employment with or provide services to any of our competitors, or engage, whether as principal, partner, licensor or otherwise, any of our competitors, without our express consent; or (iii)&#160;seek directly or indirectly, to solicit the services of any of our employees who is employed by us on or after the date of the executive officer&#8217;s termination, or in the year preceding such termination, without our express consent. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">212 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have also entered into indemnification agreements with each of our directors and executive officers. Under these agreements, we agree to indemnify our directors and executive officers against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being a director or officer of our company. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share Incentive Plans </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Second Amended and Restated 2017 Employee Stock Option Plan </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2017, we adopted an equity incentive plan (as last amended and restated in December 2019), which we refer to as the 2017 Plan, to secure and retain the services of valuable employees, directors or consultants, and provide incentives for such persons to exert their best efforts for the success of our business. The maximum aggregate number of ordinary shares which may be issued pursuant to all awards under the 2017 Plan is 9,609,084, subject to certain adjustments. As of February&#160;28, 2021, options to purchase an aggregate of 7,115,955 ordinary shares under the 2017 Plan had been granted and remained outstanding, excluding options that were forfeited, cancelled or exercised after the relevant grant date. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following paragraphs describe the principal terms of the 2017 Plan. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Types of awards.</div></div> The 2017 Plan permits the awards of options. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Plan administration. </div></div>Our board of directors will administer the 2017 Plan. The board of directors will determine, among other things, the participants to receive options, the number and subscription price of options to be granted to each participant, and the terms and conditions of each option granted. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offer letter.</div></div> Options granted under the 2017 Plan are evidenced by an offer letter that sets forth terms, conditions and limitations for each option, which may include the term of the option, and the provisions applicable in the event that the grantee&#8217;s employment or service terminates. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Eligible participants. </div></div>We may grant awards to employees, officers, directors, contractors, advisors and consultants of our company. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Vesting schedule. </div></div>Unless otherwise approved by the board of directors and set forth in an offer letter, the vesting schedule shall be a three-year vesting schedule consisting of a cliff vesting 50% on the second anniversary of the applicable vesting commencement date, and a vesting of the remaining 50% on the third anniversary of the applicable vesting commencement date. Except as otherwise approved by the board of directors, vested portion of option shall become exercisable upon the earlier of a listing or the occurrence of a change in control. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exercise of options.</div></div> The board of directors determines the subscription price for each option, which is stated in the offer letter. The vested portion of each option will expire if not exercised prior to the time as the board of directors determines at the time of its grant. However, the maximum exercisable term is ten years from the applicable vesting commencement date or such shorter period specified in the award agreement. Further, an option will lapse upon the earliest of, among other circumstances, two years after the date when the option becomes exercisable upon the listing or the occurrence of a change in control, and a violation in transfer restrictions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transfer restrictions. </div></div>Options may not be transferred in any manner by the participant other than in accordance with the exceptions provided in the 2017 Plan or the relevant offer letter or otherwise determined by the board of directors, such as transfers by will or the laws of descent and distribution. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Termination and amendment of the 2017 Plan. </div></div>Unless terminated earlier, the 2017 Plan has a term of ten years. The board of directors has the authority to amend, suspend or terminate the plan, subject to the limitations of applicable laws. No amendment, suspension or termination may adversely affect in any material way any awards previously granted pursuant to the 2017 Plan unless agreed to by the participant. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">213 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes, as of February&#160;28, 2021, the number of ordinary shares underlying outstanding options that we granted under the 2017 Plan, excluding options that were forfeited, cancelled or exercised after the relevant grant date. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 47%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Underlying</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$/Share)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date&#160;of&#160;Grant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date&#160;of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Zheru Zhang</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">October&#160;1,&#160;2017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">October&#160;1,&#160;2027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Joan Huaqiong Shen</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">October&#160;1, 2017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">October&#160;1, 2027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jielun Zhu</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">August&#160;1, 2018</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">October&#160;1, 2027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weimin Tang</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">April&#160;2, 2018</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">October&#160;1, 2027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Yunhan Lin</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">October&#160;1, 2017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">October&#160;1, 2027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other grantees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">3,162,321</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">1.00</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;<br/></td>
<td style="vertical-align: bottom;;text-align:center;">October&#160;1, 2017<br/>to July&#160;25, 2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;<br/>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">October&#160;1, 2027</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,115,955</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less than 1% of our total outstanding shares. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Second Amended and Restated 2018 Employee Stock Option Plan </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2019, we adopted an equity incentive plan (as last amended and restated in December 2019), which we refer to as the 2018 Plan, to secure and retain the services of valuable employees, directors or consultants, and provide incentives for such persons to exert their best efforts for the success of our business. The maximum aggregate number of ordinary shares which may be issued pursuant to all awards under the 2018 Plan is 11,005,888, subject to certain adjustments. As of February&#160;28, 2021, awards to purchase an aggregate of 9,948,512 ordinary shares under the 2018 Plan had been granted and remained outstanding, excluding options that were forfeited, cancelled or exercised after the relevant grant date. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following paragraphs describe the principal terms of the 2018 Plan. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Types of awards. </div></div>The 2018 Plan permits the awards of options. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Plan administration. </div></div>Our board of directors will administer the 2018 Plan. The board of directors will determine, among other things, the participants to receive options, the number and subscription price of options to be granted to each participant, and the terms and conditions of each option granted. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offer letter. </div></div>Options granted under the 2018 Plan are evidenced by an offer letter that sets forth terms, conditions and limitations for each option, which may include the term of the option, and the provisions applicable in the event that the grantee&#8217;s employment or service terminates. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Eligible participants. </div></div>We may grant awards to employees or if approved by the board, designee of any employee. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Vesting schedule. </div></div>Unless otherwise approved by the board of directors and set forth in an offer letter, the vesting schedule shall be a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> vesting schedule consisting of a cliff vesting 50% on the first anniversary of the applicable vesting commencement date, and a vesting of the remaining 50% on the second anniversary of the applicable vesting commencement date. Notwithstanding the foregoing, if a listing occurs at any time prior to any option granted under the 2018 Plan becoming full vested, and to the extent such option has been granted and outstanding, any such option shall vest in full with immediate effect upon the listing. Except as otherwise approved by the board of directors, vested portion of option shall become exercisable upon the earlier of six months after a listing or the occurrence of a change in control; provided, however that in each case, no option of an employee shall become exercisable until the third anniversary of such employee&#8217;s employment commencement date. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exercise of options</div></div>. The board of directors determines the subscription price for each option, which is stated in the offer letter. The vested portion of each option will expire if not exercised prior to the time as the board of directors determines at the time of its grant. However, the maximum exercisable term is ten years from the applicable vesting commencement date or such shorter period specified in the award agreement. Further, an option will lapse upon the earliest of, among other circumstances, two years after the date when the option becomes exercisable upon the listing or the occurrence of a change in control, and a violation in transfer restrictions. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">214 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transfer restrictions.</div></div> Options may not be transferred in any manner by the participant other than in accordance with the exceptions provided in the 2018 Plan or the relevant offer letter or otherwise determined by the board of directors, such as transfers by will or the laws of descent and distribution. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Termination and amendment of the 2018 Plan.</div></div> Unless terminated earlier, the 2018 Plan has a term of ten years. The board of directors has the authority to amend, suspend or terminate the plan, subject to the limitations of applicable laws. No amendment, suspension or termination may adversely affect in any material way any awards previously granted pursuant to the 2018 Plan unless agreed to by the participant. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes, as of February&#160;28, 2021, the number of ordinary shares underlying our outstanding options that we granted under the 2018 Plan, excluding options that were forfeited, cancelled or exercised after the relevant grant date. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 43%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Underlying</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding&#160;Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$/Share)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date&#160;of&#160;Grant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date&#160;of&#160;Expiration</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jingwu Zhang Zang</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,252,023</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1.00</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">February&#160;22,&#160;2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">February&#160;22, 2029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Zheru Zhang</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1.00</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">July&#160;25, 2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">February&#160;22, 2029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Joan Huaqiong Shen</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1.00</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">July&#160;25, 2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">February&#160;22,&#160;2029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jielun Zhu</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1.00</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">July&#160;25, 2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">February&#160;22, 2029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weimin Tang</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1.00</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">July&#160;25, 2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">February&#160;22, 2029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Yunhan Lin</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1.00</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">July&#160;25, 2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">February&#160;22, 2029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other grantees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1.00</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">July&#160;25, 2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">February&#160;22, 2029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,948,512</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less than 1% of our total outstanding shares. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 Share Incentive Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2019, we adopted an equity incentive plan, which we refer to as 2019 Plan, to promote the success and enhance the value of our company. Under the 2019 Plan, the maximum aggregate number of ordinary shares available for issuance is 100,000. As of February&#160;28, 2021, options to purchase an aggregate of 72,000 ordinary shares under the 2019 Plan had been granted and remained outstanding, excluding options that were forfeited, cancelled or exercised after the relevant grant date. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following paragraphs describe the principal terms of the 2019 Plan: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Type of Awards.</div></div> The plan permits the awards of options, restricted shares, restricted share units or other types of awards approved by the board of directors or a committee of one or more members of the board of directors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Plan Administration.</div></div> Our board of directors or a committee of one or more members of the board of directors will administer the plan. The committee or the board of directors, as applicable, will determine the participants to receive awards, the type and number of awards to be granted to each participant, and the terms and conditions of each grant. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Award Agreement. </div></div>Awards granted under the plan are evidenced by an award agreement that sets forth the terms, conditions and limitations for each award, which may include the term of the award, the provisions applicable in the event that the grantee&#8217;s employment or service terminates, and our authority to unilaterally or bilaterally amend, modify, suspend, cancel or rescind the award. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Eligibility.</div></div> We may grant awards to our independent directors, as determined by a committee of one or more members of the board of directors. Vesting Schedule. In general, the plan administrator determines the vesting schedule, which is specified in the relevant award agreement. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">215 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exercise of Options.</div></div> The plan administrator determines the exercise price for each award, which is stated in the relevant award agreement. Options that are vested and exercisable will terminate if they are not exercised prior to the time as the plan administrator determines at the time of grant. However, the maximum exercisable term is ten years from the date of grant. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transfer Restrictions.</div></div> Awards may not be transferred in any manner by the participant other than in accordance with the exceptions provided in the plan or the relevant award agreement or otherwise determined by the plan administrator, such as transfers by will or the laws of descent and distribution. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Termination and Amendment of the Plan.</div></div> Our board of directors has the authority to terminate, amend, suspend or modify the plan in accordance with our articles of association. However, without the prior written consent of the participant, no such action may adversely affect in any material way any award previously granted pursuant to the plan. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes, as of February&#160;28, 2021, the number of ordinary shares underlying outstanding options that we granted under the 2019 Plan, excluding options that were forfeited, cancelled or exercised after the relevant grant date. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Underlying</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/>Price</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$/Share)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date&#160;of&#160;Grant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date&#160;of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chun Kwok Alan Au</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">6.09</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">April&#160;30,&#160;2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">April&#160;30,&#160;2030</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conor Chia-hung Yang</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">6.09</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">April&#160;30, 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">April&#160;30, 2030</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pamela M. Klein</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">6.09</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">April&#160;30, 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">April&#160;30, 2030</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">72,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less than 1% of our total outstanding shares. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2020 Share Incentive Plan </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2020, we adopted 2020 Share Incentive Plan, which we refer to as the 2020 Plan, to promote the success and enhance the value of our company. Under the 2020 Plan, the maximum aggregate number of ordinary shares which may be issued pursuant to all awards shall be 10,760,513 ordinary shares; provided that the maximum number of ordinary shares may be issued pursuant to awards in the form of restricted share units under the 2020 Plan shall not exceed 7,686,081 ordinary shares. As of February&#160;28, 2021, options to purchase an aggregate of 1,052,025 ordinary shares and restricted share units to receive an aggregate of 5,106,141 ordinary shares under the 2020 Plan had been granted and remained outstanding, excluding awards that were forfeited, cancelled, exercised or vested after the relevant grant date. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following paragraphs describe the principal terms of the 2020 Plan: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Type of Awards</div></div>. The plan permits the awards of options, restricted shares, restricted share units or other share-based awards. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Plan Administration</div></div>. Our board of directors or one or more committees or subcommittees of the board of directors, or the Committee, will administer the plan. The Committee or the board of directors, as applicable, will determine the participants to receive awards, the type and number of awards to be granted to each participant, and the terms and conditions of each grant. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Award Agreement</div></div>. Awards granted under the plan are evidenced by an award agreement that sets forth the terms, conditions and restrictions for each award, which may include the term of the award, the provisions applicable in the event that the grantee&#8217;s employment or service terminates, and our authority to unilaterally or bilaterally amend, modify, suspend, cancel or rescind the award. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">216 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Eligibility</div></div>. We may grant awards to our employees, directors and consultants of our company. However, we may grant options that are intended to qualify as incentive share options only to our employees and employees of our subsidiaries. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Vesting Schedule. </div></div>The options and restricted share units shall vest according to the schedules specified in the plan, unless otherwise determined by the plan administrator. The vesting schedule of other share-based awards shall be determined by the plan administrator, which is specified in the relevant award agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exercise of Options</div></div>. The plan administrator determines the exercise price for each award, which is stated in the relevant award agreement. Options that are vested and exercisable will terminate if they are not exercised prior to the time as the plan administrator determines at the time of grant. However, the maximum exercisable term is ten years from the date of grant. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transfer Restrictions</div></div>. Awards may not be transferred in any manner by the participant other than in accordance with the exceptions provided in the plan or the relevant award agreement or otherwise determined by the plan administrator, such as transfers by will or the laws of descent and distribution. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Termination and Amendment of the Plan</div></div>. Our board of directors has the authority to terminate, amend or modify the plan in accordance with our articles of association. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes, as of February&#160;28, 2021, the number of ordinary shares underlying outstanding options and restricted share units that we granted under the 2020 Plan, excluding awards that were forfeited, cancelled, exercised or vested after the relevant grant date. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 46%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares<br/>Underlying</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options&#160;and<br/>Restricted</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share&#160;Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/>Price<br/>(US$/Share)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date&#160;of&#160;Grant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date&#160;of&#160;Expiration</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jingwu Zhang Zang</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">N/A</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;<br/></td>
<td style="vertical-align: bottom;;text-align:center;">September&#160;4,&#160;2020<br/>to&#160;February&#160;8,&#160;2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;<br/>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Zheru Zhang</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">N/A</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;<br/></td>
<td style="vertical-align: bottom;;text-align:center;">September&#160;4, 2020<br/>to February&#160;8, 2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;<br/>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Joan Huaqiong Shen</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">N/A</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;<br/></td>
<td style="vertical-align: bottom;;text-align:center;">September&#160;4, 2020<br/>to February&#160;8, 2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;<br/>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jielun Zhu</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.91</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">August&#160;14, 2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">August&#160;14,&#160;2030</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">N/A</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;<br/></td>
<td style="vertical-align: bottom;;text-align:center;">August&#160;14, 2020 to<br/>February&#160;8, 2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;<br/>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">August&#160;14, 2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weimin Tang</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">N/A</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;<br/></td>
<td style="vertical-align: bottom;;text-align:center;">September&#160;4, 2020<br/>to February&#160;8, 2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;<br/>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">September&#160;4, 2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Yunhan Lin</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.91</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">August&#160;14, 2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">August&#160;14, 2030</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">N/A</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">August&#160;14, 2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gigi Qi Feng</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">N/A</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">September&#160;4, 2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neil Kumar Warma</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">N/A</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December&#160;12, 2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other grantees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.91</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">August&#160;14, 2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">August&#160;14, 2030</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">N/A</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;<br/></td>
<td style="vertical-align: bottom;;text-align:center;">August&#160;14, 2020 to<br/>February&#160;8, 2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;<br/>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;<br/></td>
<td style="vertical-align: bottom;;text-align:center;">August 14, 2020 to<br/>September&#160;4, 2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;<br/>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,158,166</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less than 1% of our total outstanding shares. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents restricted share units. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">217 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Biomaster Trust </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Biomaster Trust was established under the trust deed dated October&#160;23, 2019, between us and TMF Trust (HK) Limited, or TMF Trust, as the trustee of the Biomaster Trust. As of February&#160;28, 2021, all participants in Biomaster Trust are our employees or former employees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Participants in Biomaster Trust transfer their equity awards granted under the 2017 Plan and the 2018 Plan to TMF Trust for their benefit. Upon satisfaction of vesting conditions, TMF Trust will exercise the equity awards and transfer the relevant ordinary shares and other rights and interests under the equity awards to the relevant grant recipients with the consent of the advisory committee. TMF Trust shall not exercise the voting rights attached to such ordinary shares unless otherwise directed by the advisory committee, whose members shall be appointed by our company. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">C.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Board Practices</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors consists of 11 directors. A director is not required to hold any shares in our company by way of qualification. Subject to the Nasdaq Global Market rules and disqualification by the chairman of the relevant board meeting, a director may vote with respect to any contract, proposed contract or arrangement in which he is interested. A director who is interested in a contract, proposed contract or arrangement shall declare the nature of his or her interest at the earliest meeting of the board at which it is practicable for him or her to do so, either specifically or by way of a general notice. The directors may exercise all the powers of our company to borrow money, mortgage its undertaking, property and uncalled capital, and issue debentures or other securities whenever money is borrowed or as security for any obligation of our company or of any third party. None of our directors who are not our executive officers has a service contract with us that provides for benefits upon termination of service. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Committees of the Board of Directors </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have established three committees under the board of directors: an audit committee, a compensation committee and a nominating and corporate governance committee. We have adopted a charter for each of the three committees. Each committee&#8217;s members and functions are described below. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Audit Committee</div></div>. Our audit committee consists of Mr.&#160;Conor Chia-hung Yang, Mr.&#160;Chun Kwok Alan Au and Mr.&#160;Bing Yuan. Mr.&#160;Conor Chia-hung Yang is the chairman of our audit committee. We have determined that each of Mr.&#160;Conor Chia-hung Yang, Mr.&#160;Chun Kwok Alan Au and Mr.&#160;Bing Yuan satisfies the &#8220;independence&#8221; requirements of Rule 5605(c)(2) of the Nasdaq Stock Market Rules and meets the independence standards under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10A-3</div> under the Exchange Act. We have determined that Mr.&#160;Conor Chia-hung Yang qualifies as an &#8220;audit committee financial expert.&#8221; The audit committee will oversee our accounting and financial reporting processes and the audits of the financial statements of our company. The audit committee is responsible for, among other things: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">appointing the independent auditors and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approving</div> all auditing and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-auditing</div> services permitted to be performed by the independent auditors; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing with the independent auditors any audit problems or difficulties and management&#8217;s response; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">discussing the annual audited financial statements with management and the independent auditors; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing the adequacy and effectiveness of our accounting and internal control policies and procedures and any steps taken to monitor and control major financial risk exposures; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing and approving all proposed related party transactions; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">meeting separately and periodically with management and the independent auditors; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">218 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation Committee</div></div>. Our compensation committee consists of Dr.&#160;Jingwu Zhang Zang, Mr.&#160;Chun Kwok Alan Au and Dr.&#160;Pamela&#160;M. Klein. Dr.&#160;Jingwu Zhang Zang is the chairman of our compensation committee. We have determined that each of Mr.&#160;Chun Kwok Alan Au and Dr.&#160;Pamela&#160;M. Klein satisfies the &#8220;independence&#8221; requirements of Rule 5605(a)(2) of the Nasdaq Stock Market Rules. The compensation committee will assist the board in reviewing and approving the compensation structure, including all forms of compensation, relating to our directors and executive officers. Our chief executive officer may not be present at any committee meeting during which his compensation is deliberated. The compensation committee is responsible for, among other things: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing and approving, or recommending to the board for its approval, the compensation for our chief executive officer and other executive officers; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing and recommending to the board for determination with respect to the compensation of our directors who are not our employees; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing periodically and approving any incentive compensation or equity plans, programs or similar arrangements; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">selecting compensation consultant, legal counsel or other adviser only after taking into consideration all factors relevant to that person&#8217;s independence from management. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nominating and Corporate Governance Committee</div></div>. Our nominating and corporate governance committee consists of Mr.&#160;Wei Fu, Mr.&#160;Chun Kwok Alan Au and Mr.&#160;Conor Chia-hung Yang. Mr.&#160;Wei Fu is the chairman of our nominating and corporate governance committee. We have determined that each of Mr.&#160;Chun Kwok Alan Au and Mr.&#160;Conor Chia-hung Yang satisfies the &#8220;independence&#8221; requirements of Rule 5605(a)(2) of the Nasdaq Stock Market Rules. The nominating and corporate governance committee will assist the board of directors in selecting individuals qualified to become our directors and in determining the composition of the board and its committees. The nominating and corporate governance committee is responsible for, among other things: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">selecting and recommending to the board nominees for election by the shareholders or appointment by the board; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing annually with the board the current composition of the board with regards to characteristics such as independence, knowledge, skills, experience and diversity; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">making recommendations on the frequency and structure of board meetings and monitoring the functioning of the committees of the board; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">advising the board periodically with regards to significant developments in the law and practice of corporate governance as well as our compliance with applicable laws and regulations, and making recommendations to the board on all matters of corporate governance and on any corrective action to be taken. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Duties of Directors </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under Cayman Islands law, our directors owe fiduciary duties to our company, including a duty of loyalty, a duty to act honestly, and a duty to act in what they consider in good faith to be in our best interests. Our directors must also exercise their powers only for a proper purpose. A director must exercise the skill and care of a reasonably diligent person having both &#8211; (a) the general knowledge, skill and experience that may reasonably be expected of a person in the same position (an objective test), and (b)&#160;if greater, the general knowledge, skill and experience that that director actually possesses (a subjective test). In fulfilling their duty of care to us, our directors must ensure compliance with our memorandum and articles of association, as amended from time to time, and the class rights vested thereunder in the holders of the shares. Our company has the right to seek damages if a duty owed by our directors is breached. A shareholder may in certain limited circumstances have the right to seek damages in our name if a duty owed by the directors is breached. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">219 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors has all the powers necessary for managing, and for directing and supervising, our business affairs. The functions and powers of our board of directors include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">convening shareholders&#8217; annual general meetings and reporting its work to shareholders at such meetings; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">declaring dividends and other distributions; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">appointing officers and determining the term of office of the officers; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">exercising the borrowing powers of our company and mortgaging the property of our company; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approving the transfer of shares in our company, including the registration of such shares in our share register. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Terms of Directors and Officers </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our directors may be elected by an ordinary resolution of our shareholders. Alternatively, our board of directors may, by the affirmative vote of a simple majority of the directors present and voting at a board meeting appoint any person as a director to fill a casual vacancy on our board or as an addition to the existing board. Our directors (other than independent directors) are not automatically subject to a term of office and hold office until such time as they are removed from office by an ordinary resolution of our shareholders. Our independent directors hold office until the earlier of (i)&#160;the date on which the independent director ceases to be a member of the board for any reason; (ii)&#160;the date of termination of an independent director&#8217;s director agreement, which may be terminated by either the independent director or by us with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> advance written notice or such other shorter period as mutually agreed; or (iii)&#160;three years from the effective date of the director agreement, subject to the terms of our current memorandum and articles of association of our company. In addition, a director will cease to be a director if he or she (i)&#160;becomes bankrupt or makes any arrangement or composition with his or her creditors; (ii)&#160;dies or is found to be or becomes of unsound mind; (iii)&#160;resigns his or her office by notice in writing; (iv)&#160;without special leave of absence from our board, is absent from meetings of our board for three consecutive meetings and our board resolves that his or her office be vacated; or (v)&#160;is removed from office pursuant to any other provision of our articles of association. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our officers are appointed by and serve at the discretion of the board of directors, and may be removed by our board of directors. Under our articles of association, the board of directors may appoint one or more of their number to the office of managing director upon like terms, but any such appointment shall ipso facto terminate if any managing director ceases for any cause to be a director, or if our company by ordinary resolution of shareholders resolves that his tenure of office be terminated. In addition, the board of directors may appoint any natural person or corporation to be a secretary (and if need be an assistant secretary or assistant secretaries) who shall hold office for such term, at such remuneration and upon such conditions and with such powers as they think fit. Any secretary or assistant secretary so appointed by the board of directors may be removed by the board of directors or by ordinary resolution of shareholders. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">D.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Employees</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We had 134, 185 and 228 employees as of December&#160;31, 2018, 2019 and 2020, respectively. As of December&#160;31, 2020, 198 employees were located in China and 30 were located outside China. The table below sets forth our employees by function as of December&#160;31, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 94%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">128</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chemistry, manufacturing and controls</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business and corporate development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">228</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">220 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recruit our employees primarily through recruitment websites, recruiters, internal referrals and job fairs. We recruit our employees based on their qualification and potential. We promote culture diversity, and our employees come from the United States, Taiwan and South Korea, in addition to China. The remuneration package of our employees includes salary, benefits and bonus. Our compensation programs are designed to remunerate our employees based on their performance, measured against specified objective criteria. We are required to make contributions to social insurance and housing provident funds in accordance with PRC laws and regulations from time to time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We provide new hire training to our employees and periodic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-the-job</div></div> training to enhance the skills and knowledge of our employees. We have not established a labor union. We have not experienced any material labor disputes or strikes that may have a material and adverse effect on our business, financial condition or results of operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We enter into standard confidentiality and employment agreements with all of our key management and research staff. The contracts with our key personnel typically include a standard <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreement that prohibits the employee from competing with us, directly or indirectly, during his or her employment and for one year after the termination of his or her employment. The contracts also typically include undertakings regarding assignment of innovations and discoveries made during the course of his or her employment. For further details regarding the terms of confidentiality and employment agreements with our key management, see &#8220;Item 6. Directors, Senior Management and Employees.&#8221; </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">E.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Share Ownership</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth information with respect to the beneficial ownership of our ordinary shares as of March&#160;31, 2021 by: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each of our directors and executive officers; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each person known to us to own beneficially more than 5% of our total outstanding shares. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Percentage of beneficial ownership is based on 166,532,087 total outstanding ordinary shares as of March&#160;31, 2021 (excluding 2,982,401 ordinary shares issued to our depositary bank for bulk issuance of ADSs reserved for future issuances upon the exercising or vesting of awards granted under our share incentive plans). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Beneficial ownership is determined in accordance with the rules and regulations of the SEC. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, we have included shares that the person has the right to acquire within 60 days, including through the exercise of any option, warrant or other right or the conversion of any other security. These shares, however, are not included in the computation of the percentage ownership of any other person.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Beneficially&#160;Owned</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Directors&#160;and&#160;Executive&#160;Officers:**</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jingwu Zhang Zang<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,819,553</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Joan Huaqiong Shen</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,224,235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Zheru Zhang</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,188,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jielun Zhu</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Wei Fu<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31,043,576</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mengjiao Jiang</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jie Yu</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bing Yuan</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chun Kwok Alan Au</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conor Chia-hung Yang</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pamela M. Klein</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weimin Tang</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Yunhan Lin</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neil Warma</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ivan Yifei Zhu</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gigi Qi Feng</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Richard Cheng Li</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All Directors and Executive Officers as a Group</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">49,231,263</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">27.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">221 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Beneficially&#160;Owned</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal Shareholders:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> entities<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31,043,576</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hillhouse entities<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,050,560</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tasly entities<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,442,283</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">GIC Private Limited<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,176,616</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genexine<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> (6)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,799,885</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hony entity<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> (7)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,561,616</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Less than 1% of our total ordinary shares on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis outstanding as of March&#160;31, 2021. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except as otherwise indicated below, the business address of our directors and executive officers is Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, China. The business address of Wei Fu and Mengjiao Jiang is Suite 3306-3307, Two Exchange Square, 8 Connaught Place, Central, Hong Kong. The business address of Jie Yu is Tasly Great Health Town, No.&#160;2, East Puji River Road, Beichen District, Tianjin, China. The business address of Bing Yuan is Flat B, 31/F BLK 2, The Hermitage, Mongkok, Hong Kong. The business address of Chun Kwok Alan Au is 22 Pottinger Street, Central, Hong Kong. The business address of Conor Chia-hung Yang is 7th Floor, Building C, Luneng International Center, No.&#160;209 Guoyao Road, Pudong New Area, Shanghai, China. The business address of Dr.&#160;Pamela&#160;M. Klein is 231 Fort Mason, San Francisco, California 94123, the United States. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents (i) 3,817,113 ordinary shares directly held by Mabcore Limited, a British Virgin Islands company and (ii) 8,002,440 ordinary shares issuable upon exercise of options exercisable and vest of restricted share units within 60 days after March&#160;31, 2021 held by Dr.&#160;Zang through Doctor Zang 2020 Dynasty Trust. Dr.&#160;Zang, through himself and The Jingwu Zhang Zang 2018 Irrevocable Family Trust, owns a 55.6% equity interest in Mabcore Limited. Dr.&#160;Lili Qian and two other individuals own the remaining equity interest in Mabcore Limited. Dr.&#160;Zang is the sole director of Mabcore Limited. The Jingwu Zhang Zang 2018 Irrevocable Family Trust was established under the laws of New York and is managed by Ms.&#160;Ying Qin Zang, as the trustee and Dr.&#160;Zang as the settlor. The Doctor Zang 2020 Dynasty Trust was established under the laws of the State of California and is managed by Dr.&#160;Zang as the settlor and investment trustee and Ms.&#160;Ying Qin Zang as the trustee. Pursuant to the currently effective memorandum and articles of association of Mabcore Limited, Dr.&#160;Zang, as the sole director, has the power to direct the actions of Mabcore Limited, including the voting and disposal of Mabcore Limited&#8217;s shares in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab.</div> Accordingly, Dr.&#160;Zang is deemed to indirectly own all of the 3,817,113 ordinary shares held by Mabcore Limited, while Dr.&#160;Qian and the other two individuals are only entitled to their respective <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rata</div> economic interest in Mabcore Limited. The registered address of Mabcore Limited is Trinity Chambers, P.O. Box 4301, Road Town, Tortola, British Virgin Islands. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents (i) 3,931,802 ordinary shares directly held by IBC Investment Seven Limited, a Hong Kong limited liability company, (ii) 5,574,560 ordinary shares directly held by CBC SPVII LIMITED, a Hong Kong limited liability company, (iii) 12,229,916 ordinary shares directly held by CBC Investment <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Limited, a British Virgin Islands limited liability company, (iv) 2,369,546 ordinary shares directly held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> II Investment Ten Limited, a British Virgin Islands limited liability company, (v) 6,078,571 ordinary shares directly held by Everest, and (vi) 373,557 ADSs (representing 859,181 ordinary shares) held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> II Investment Thirteen Limited, a British Virgin Islands limited liability company. IBC Investment Seven Limited, CBC SPVII LIMITED, CBC Investment <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Limited, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> II Investment Ten Limited, Everest, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> II Investment Thirteen Limited are collectively referred to as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> entities. CBC Investment <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Limited, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> II Investment Ten Limited and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> II Investment Thirteen Limited are controlled by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> Healthcare Fund II, L.P., whose general partner is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> Healthcare Fund GP II, L.P., and its general partner is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> Capital GP, Ltd. CBC SPVII Limited and IBC Investment Seven Limited are controlled by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Bridge</div> Healthcare Fund, L.P., whose general partner is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Bridge</div> Healthcare GP, L.P., and its general partner is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Bridge</div> Capital GP, Ltd., which is indirectly controlled by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> Capital GP, Ltd. Mr.&#160;Wei Fu is the sole director of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> Capital GP, Ltd. Everest is a public company listed on the Hong Kong Stock Exchange and controlled by funds which are under common control of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> group, which, in turn, is controlled by Mr.&#160;Wei Fu. The business address of each of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> entities is Suite 3306-3307, Two Exchange Square, 8 Connaught Place, Central, Hong Kong. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents (i) 6,367,410 ADSs (representing 14,645,043 ordinary shares), 1,229,741 ordinary shares issuable upon exercise of call options and 2,459,482 ordinary shares issuable upon exercise of warrants directly held by Gaoling Fund, L.P., or Gaoling, an exempted limited partnership organized under the laws of the Cayman Islands, (ii) 248,760 ADSs (representing 572,148 ordinary shares), 48,047 ordinary shares issuable upon exercise of call options and 96,094 ordinary shares issuable upon exercise of warrants directly held by YHG Investment, L.P., or YHG, an exempted limited partnership organized under the laws of the Cayman Islands, and (iii) 5 ordinary shares directly held by HH IMB Holdings Limited, or HH IMB, an exempted Cayman Islands company. Hillhouse Capital Advisors, Ltd., or HCA, an exempted Cayman Islands company, acts as sole management company of Gaoling and the sole general partner of YHG, and is deemed to be the beneficial owner of, and to control the voting power of, the ordinary shares held by Gaoling and YHG. HH IMB is wholly owned by Hillhouse Fund IV, L.P., whose sole management company is Hillhouse Capital Management, Ltd., or HCM. HCM is deemed to be the beneficial owner of, and to control the voting power of, the ordinary shares held by HH IMB. HCA and HCM are under common control and share certain policies, personnel and resources. Accordingly, each of HCA and HCM has shared voting and dispositive power of the ordinary shares beneficially owned by each of HCA and HCM. The business address of each of Gaoling, YHG and HH IMB is Suite 2202, 22nd Floor, Two International Finance Centre, 8 Finance Street, Central Hong Kong. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">222 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents (i) 12,942,997 ordinary shares directly held by Tasly Biopharm Limited, a British Virgin Islands limited liability company, and (ii) 499,286 ordinary shares directly held by Tasly International BioInv One Limited. Tasly Biopharm Limited and Tasly International BioInv One Limited are collectively referred to as the Tasly entities. Tasly Biopharm Limited&#8217;s sole shareholder is Tasly Biopharmaceuticals Co., Ltd., which is controlled by Tasly Pharmaceutical Group Co., Ltd., which is in turn controlled by Tasly Holding Group Co., Ltd. Tasly International BioInv One Limited is wholly-owned by Tasly International Capital Limited, whose sole shareholder is Tasly Holding Group Co., Ltd. Tasly Holding Group Co., Ltd. is controlled by Tianjin Tasly Health Industry Investment Group Co., Ltd., which is in turn controlled by Tianjin Fuhuade Science&#160;&amp; Technology Development Co., Ltd. Kaijing Yan is the controlling shareholder of Tianjin Fuhuade Science&#160;&amp; Technology Development Co., Ltd. and the ultimate beneficial owner of Tasly entities. The registered address of Tasly Biopharm Limited is P.O. Box 957, Offshore Incorporation Centre, Road Town, Tortola, British Virgin Islands. The registered address of Tasly International BioInv One Limited is 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KY1-1002,</div> Cayman Islands. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents 8,677,996 ordinary shares, 1,132,249 ADSs (representing 2,604,173 ordinary shares) and 894,447 ordinary shares issuable upon exercise of warrants held by GIC Private Limited, a Singapore fund manager. GIC Private Limited only has two clients: the Government of Singapore, or GoS, and the Monetary Authority of Singapore, or MAS. Under the investment management agreement with GoS, GIC Private Limited has been given the sole discretion to exercise the voting rights attached to, and the disposition of, any shares managed on behalf of GoS. As such, GIC Private Limited has the sole power to vote and dispose of securities beneficially owned by it. GIC Private Limited shares the power to vote and dispose of securities beneficially owned by it with MAS. The business address of GIC Private Limited is 168 Robinson Road, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">#37-01</div> Capital Tower, Singapore 068912. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(6)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents (i) 8,488,885 ordinary shares directly held by Genexine, Inc. (Genexine), and (ii) 570,000 ADSs (representing 1,311,000 ordinary shares) purchased by Genexine. Genexine is a Korean public company. The registered address of Genexine is 4th Fl., Bldg. B, Korea Bio Park, 700 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Daewangpangyo-ro,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Seongnam-si,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Gyeonggi-do</div> 13488, Republic of Korea. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(7)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents 8,561,616 ordinary shares directly held by Fortune Eight Jogging Limited, a British Virgin Islands limited liability company, which we refer to as the Hony entity. Fortune Eight Jogging Limited is wholly-owned by Hony Hongling (Shanghai) Investment Center, a PRC limited partnership, whose general partner is Hony Investment (Shanghai) Limited. The sole shareholder of Hony Investment (Shanghai) Limited is Beijing Hony Hezhong Enterprise Management Limited. Each of Yonggang Cao, Minsheng Xu and Wen Zhao holds 33.3% equity interests in Beijing Hony Hezhong Enterprise Management Limited. The registered address of Fortune Eight Jogging Limited is Kingston Chambers, PO Box 173, Road Town, Tortola, British Virgin Islands. Mr.&#160;Bing Yuan, our director, is a managing director of the sole director of the Hony entity. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To our knowledge, as of March&#160;31, 2021, 73,412,688 of our ordinary shares were held by one record holder in the United States (including 2,982,401 ordinary shares issued to our depositary bank for bulk issuance of ADSs reserved for future issuances upon the exercising or vesting of awards granted under our share incentive plans) , representing approximately 44.1% of our total outstanding shares. The holder is Citibank, N.A., the depositary of our ADS program. The number of beneficial owners of our ADSs in the United States is likely to be much larger than the number of record holders of our ordinary shares in the United States. </div></div> <div id="rom10811_11" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Major Shareholders</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Please refer to &#8220;Item 6. Directors, Senior Management and Employees&#8212;E. Share Ownership.&#8221; </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">B.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Related Party Transactions</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders Agreement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2019, we entered into our fourth amended and restated shareholders agreement with our shareholders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The shareholders agreement provides for certain special rights, including right of first refusal, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-sale</div> rights, preemptive rights and contains provisions governing the board of directors and other corporate governance matters. Those special rights, as well as the corporate governance provisions, automatically terminated upon the completion of our initial public offering. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to our shareholders agreement, we have granted certain registration rights to our shareholders. Set forth below is a description of the registration rights granted under the agreement. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">223 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Demand Registration Rights</div></div>. At any time after the earlier of (i)&#160;December&#160;31, 2020, or (ii)&#160;six months following the effectiveness of a registration statement for a firm underwritten public offering of our ordinary shares on The Stock Exchange of Hong Kong Limited, the New York Stock Exchange, the Nasdaq Stock Market or other internationally recognized securities exchange, with an offering price (exclusive of underwriting commissions and expenses) that reflects a market capitalization (immediately prior to the public offering) of not less than US$1.0&#160;billion, the holders of a majority of the registrable securities then issued and outstanding may request in writing that we file a registration statement covering the registration of at least 20% of the registrable securities (or any lesser percentage if the anticipated gross receipts from the offering are to exceed US$5.0 million). Upon such a request, we shall, within ten business days of the receipt of such written request, give written notice of such request to all holders, and use our best efforts to effect, as soon as practicable, the registration of all registrable securities that the holders request to be registered and included in such registration by written notice given by such holders to us within 20 days after receipt of the request notice. We have the right to defer filing of a registration statement for a period of not more than 90 days after receipt of the request of the initiating holders if our board of directors determines in good faith that filing of such registration statement at such time will be materially detrimental to us or our shareholders, but we cannot exercise the deferral right more than once during any twelve-month period and cannot register any other securities during such twelve-month period. We are not obligated to effect any such registration if we have, within the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> period preceding the date of such request, already effected a registration. We are not obligated to effect more than three demand registrations. This demand registration right is subject to the customary exclusion right of the underwriters. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div></div></div>. If we qualify for registration on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3,</div> any holder or holders of a majority of all registrable securities then issued and outstanding may request in writing that we effect a registration on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div> (or an equivalent registration in a jurisdiction outside of the U.S.). We shall promptly give written notice of the proposed registration and as soon as practicable, effect such registration within 20 days after we provide the aforesaid written notice. The holders are entitled to an unlimited number of registrations on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div> so long as such registration offerings are in excess of US$500,000. We are not obligated to effect any such registration if we have, within the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> period preceding the date of such request, already effected a registration other than a registration from which registrable securities of the holders have been excluded, or if we would be required to qualify to do business or to execute a general consent to service of process in effecting such registration in any particular jurisdiction. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Piggyback Registration Rights</div></div>. If we propose to register for a public offering of our securities (other than registration statements relating to demand registration, Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div> registration, any employee benefit plan or a corporate reorganization), we shall give written notice of such registration to all holders of registrable securities at least 30 days prior to filing any registration statement and afford each such holder an opportunity to be included in such registration. If a holder decides not to include all of its registrable securities in any registration statement thereafter filed by us, such holder shall nevertheless continue to have the right to include any registrable securities in any subsequent registration statement or registration statements as may be filed by us, subject to certain limitations. This piggyback registration right is subject to the customary exclusion right of the underwriters. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expenses of Registration.</div></div> We will bear all registration expenses. Each holder, however, should bear its proportionate share of all of the underwriting discounts and selling commissions applicable to the sale of registrable securities or other amounts payable to underwriter(s) or brokers in connection with such offering by the holders. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Termination of Obligations.</div></div> Our obligations to effect any demand, Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div> or piggyback registration shall terminate upon the earlier of (i)&#160;the tenth anniversary of the initial public offering (ii)&#160;after the initial public offering, the date on which such shareholder is eligible to sell all of the registrable securities held by it under Rule 144 within any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">90-day</div> period without volume limitations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deed of Undertaking </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, a deed of undertaking was made by our company and a few shareholders of our company, each as a warrantor, to the other shareholders of our company (other than the shareholder warrantors), each as a warrantee, pursuant to which each warrantor represents and warrants to each warrantee that it has provided each warrantee with all information and documents in connection with the initial public offering of our company that has the effect of establishing rights or otherwise benefiting any shareholder in a manner more favorable than the corresponding terms applicable to the relevant warrantee in relation to the initial public offering of our company (collectively, the &#8220;More Favorable Arrangements&#8221;). Pursuant to the deed of undertaking, until the fifth anniversary of the completion of our initial public offering, we will not directly or indirectly enter into any agreements or arrangements or modify, amend or waive any existing agreements or arrangements of any kind that would have the effect of establishing the More Favorable Arrangements; provided that it shall be allowed to adopt or modify any employee incentive plans and grant options to the management or any employee of our company after our initial public offering pursuant to such plans and in accordance with the then effective memorandum and articles of association and the applicable listing rules for the purpose of rewarding their bona fide services. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">224 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subscription Agreement with Hillhouse Entities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In September 2020, we entered into a Subscription Agreement with the Hillhouse Entities, as amended by an amendment to Subscription Agreement entered into between Hillhouse Entities and our company in December 2020. The Subscription Agreement, as amended, provides for (i)&#160;certain investors&#8217; rights, such as registration rights, board representation rights and anti-dilution rights and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(ii)&#160;lock-up</div> and other transfer restrictions. Set forth below is a description of certain rights and restrictions thereof. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mandatory Registration after Initial Closing (September 11, 2020)</div></div>. We agree to file with the SEC a registration statement to register the resale of Hillhouse Entities&#8217; registrable securities, which include ordinary shares issued and issuable upon exercise of Investor Warrants under the Subscription Agreement, on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div> or Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1,</div> as applicable. We shall have the relevant registration statement declared effective by the SEC no later than ninety (90)&#160;calendar days after September&#160;11, 2020, which period could be extended to one hundred and twenty (120)&#160;calendar days if the SEC reviews and comments on the registration statement. However, if the SEC prevents inclusion of the registrable securities in the registration statement pursuant to limitations under Rule 415 of the Securities Act, the number of registrable securities to be registered for each selling shareholder named in the registration statement shall be reduced pro rata among all such selling shareholders. We shall maintain the continuous effectiveness of the registration statement for a period of ninety (90)&#160;days after its effectiveness or such shorter period upon which the Hillhouse Entities have notified us that their registrable securities have actually been sold. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mandatory Registration after Subsequent Closing (December 17, 2020)</div></div>. With respect to the registrable securities then held by the Hillhouse Entities which have not been previously registered and sold, we agree to file a prospectus supplement or a registration statement to register the resale of such registrable securities on a Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div> or Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3ASR</div> registration statement (or, if Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div> or Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3ASR</div> is not then available to us, on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</div> or such other form of registration statement as is then available to effect a registration for resale of such registrable securities), and have such registration statement declared effective by the SEC no later than (a)&#160;the ten (10)&#160;business days after the later of (i)&#160;the first date when we become eligible to use registration statement on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3,</div> or (ii)&#160;the expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period with respect to the subsequent closing, or forty-five (45)&#160;calendar days after such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period expiration date if the SEC reviews and comments on the registration statement. We shall maintain the effectiveness of such registration statement for a period ending on the date the registrable securities registered thereon have ceased to be registrable securities. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Demand Registration Rights</div></div>. Upon written request from the Hillhouse Entities at any time after we have effected two registration statements abovementioned, with respect to the registrable securities then held by the Hillhouse Entities, and in no event later than the forty-five (45)&#160;calendar days following the delivery of such request, we shall file a prospectus supplement or a registration statement to register the resale of such registrable securities on a Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div> or Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3ASR</div> registration statement (or, if Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div> or Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3ASR</div> is not then available to us, on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</div> or such other form of registration statement as is then available to effect a registration for resale of such registrable securities), have such registration statement declared effective, and maintain the effectiveness of such registration statement for a period ending on the date the registrable securities registered thereon have ceased to be registrable securities. If the registrable securities are offered by means of an underwritten offering, and we or the underwriters determine that marketing factors require a limitation of the number of securities to be underwritten, the number of registrable securities that may be included in the underwriting shall be r educed and allocated (i)&#160;first, to us and each holder in accordance with the terms of the Shareholders Agreement; (ii)&#160;second, to investors in the private placements entered into in September 2020 (including the Hillhouse Entities) requesting inclusion of their registrable securities in such registration statement on a pro rata basis based on the total number of registrable securities then held by each such investor; and (iii)&#160;third, to other holders of registrable securities, if any. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">225 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Suspension of Registration</div></div>. We may suspend the use of any registration statement for a period not exceeding thirty (30)&#160;consecutive trading days, if we (i)&#160;determine that we would be required to make disclosure of material information in the registration statement that we have a bona fide business purpose for preserving as confidential; (ii)&#160;determine that we must amend or supplement the registration statement so that it shall not include an untrue statement of a material fact or omit to state a material fact; or (iii)&#160;have experienced or are experiencing some other material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> event, the disclosure of which at such time would adversely affect us. However, we cannot exercise the suspension right more than once in any twelve (12)&#160;month period and may not register any other securities during such suspension period. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expenses</div></div>. We will bear all registration expenses, except any (i)&#160;portions of fees and disbursements of counsel for the Hillhouse Entities exceeding US$30,000, (ii) underwriting discounts and selling commissions applicable to sale of registrable securities, and (iii)&#160;fees payable pursuant to the deposit agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ranking of Registration Rights</div></div>. Registration rights granted to the Hillhouse Entities shall not be senior to, or on a parity with, those granted to holders under the Shareholders Agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Board Representation Rights</div></div>. As long as the Hillhouse Entities continue to jointly beneficially own at least five percent (5.0%) of our total issued and outstanding share capital, it is entitled to nominate and maintain one representative to our board of directors. We shall cause an individual jointly designated by the Hillhouse Entities to be appointed as the investor director with immediate effect no later than the fifteenth (15<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">th</div>) business day after receiving written notice from Hillhouse Entities or such later date on which we receive necessary shareholder approval. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-up</div></div></div>. The Hillhouse Entities shall not dispose of any of the ordinary shares purchased by Hillhouse Entities on the applicable initial or subsequent closing date within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">90-day</div> period following September&#160;11, 2020 or a subsequent closing date set forth in the subscription agreement to any person other than affiliates of the Hillhouse Entities, who shall be bound by the Hillhouse Entities&#8217; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> obligations for the balance of each applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period. Each of the Hillhouse Entities and their affiliates may directly or indirectly, place any charge, mortgage, lien, pledge, restrictions, security interest or other encumbrance in respect of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> securities in connection with such Hillhouse Entity&#8217;s (or any of its affiliates&#8217;) margin loans, collars, derivative transactions or other such downside protection transactions to be entered into on or after the date of the subscription agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anti-dilution rights</div></div>. We agree not to issue, offer, sell, or grant any option or right to purchase any new securities, without the prior written consent of the Hillhouse Entities, (i)&#160;during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">90-day</div> period following each closing date; or (ii)&#160;at an effective purchase price per share lower than the purchase price under the Subscription Agreement with Hillhouse Entities during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">90-day</div> period commencing from the expiration of each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employment Agreements and Indemnification Agreements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See &#8220;Item 6. Directors, Senior Management and Employees&#8212;A. Directors and Senior Management &#8212; Employment Agreements and Indemnification Agreements.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share Option Grants </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See &#8220;Item 6. Directors, Senior Management and Employees&#8212;B. Compensation of Directors and Executive Officers&#8212;Share Incentive Plans.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Transactions with Related Parties </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In October 2015, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-tech</div> Tianjin Co., Ltd., known as Tasgen <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-tech</div> (Tianjin) Co., Ltd. at the time (which subsequently became our subsidiary following the Acquisition) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;I-Mab</div> Tianjin&#8221;), entered into an intellectual property assignment and license agreement with Genexine, Inc. (&#8220;Genexine&#8221;), further amended in December 2017, with respect to four licensed products, namely <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-H9</div> (TJ101), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-G3</div> (TJ102), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-G8</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-P2</div> and one assigned product, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-G6</div> (TJ103). For a detailed description of this assignment and license agreement, see &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Licensing and Collaboration Arrangements&#8212;(a) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Licensing</div> Arrangements.&#8221; </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">226 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In September 2016, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin entered into a CRO agreement with Tasly Pharmaceutical Group Co., Ltd. (&#8220;Tasly&#8221;) and three ancillary agreements to this CRO agreement in November 2016, May 2017 and June 2017, respectively. Pursuant to these agreements, Tasly Pharmaceutical Group Co., Ltd. will provide <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin with CRO services in connection with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">G-CSF-HyFc</div></div> fusion protein. All of these agreements were terminated on December&#160;10, 2018. We had paid Tasly nil, RMB5.6&#160;million and nil for the year ended December&#160;31, 2018, 2019 and 2020, respectively. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In August 2017, we entered into a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-way</div> master service agreement with Genexine, further amended in October 2019, whereby both parties agreed that we or Genexine will be engaged by the other party in the business of providing contract research and manufacturing services for biopharmaceutical in this agreement or following work statements. We had paid US$0.7&#160;million, US$0.8&#160;million and US$0.7&#160;million to Genexine for their CMC relevant services for the year ended December&#160;31, 2018, 2019 and 2020, respectively. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On September&#160;25, 2017, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai entered into a loan agreement with each of Qianhai Equity Investment Fund (Limited Partnership) (&#8220;Qianhai Fund&#8221;), Shanghai Tasly Pharmaceutical Co., Ltd. (&#8220;Shanghai Tasly&#8221;), and Tianjin Kangshijing Biopharmaceutical Technology Partnership (Limited Partnership) (&#8220;CBC RMB Fund&#8221;), pursuant to which each of Qianhai Fund, Shanghai Tasly and CBC RMB Fund made a loan to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin to fund its business operations in an aggregate principal amount in RMB equivalent to US$1.3&#160;million, US$5.1&#160;million and US$1.6&#160;million, respectively. Each of these loans bears an annual compound interest rate of 8%. Pursuant to these loan agreements, each of Qianhai Fund, Shanghai Tasly and CBC RMB Fund has the right to contribute its interest in the respective loan to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin in exchange for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin&#8217;s equity interests. We fully repaid the loans made by Qianhai Fund and Shanghai Tasly in 2018, and neither of these lenders exercised such right. The loan agreement with CBC RMB Fund was not performed by CBC RMB Fund and was mutually terminated on September&#160;25, 2017. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2018, we entered into a biologics master services agreement with CMAB Biopharma (Suzhou) Inc. (&#8220;CMAB&#8221;), an affiliate of Bridge Capital Partners LLC. In July 2018, we entered into Service Proposal: CMC Development of A Monoclonal Antibody with CMAB, this agreement was further amended in November 2019, with respect to the change of work scope of the original Service Proposal. Pursuant to these three agreements, CMAB will provide us with CMC services in connection with the preparation of the IND filings to the FDA and the NMPA in a period of 18 to 22 months for US$3.6&#160;million. We had paid CMAB RMB2.8&#160;million for the year ended December&#160;31, 2018 and RMB0.7&#160;million (US$0.1 million) for the year ended December&#160;31, 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In January 2018, we entered into a collaboration agreement with Everest, an affiliate of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-Bridge</div> Capital Investment Management, Ltd., whereby both parties agreed to collaborate on programs to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-develop</div> MorphoSys&#8217; proprietary CD38 antibody for all indications in hematologic oncology and commercialize the CD38 product in China, Hong Kong, Macau and Taiwan. Everest had paid us prepayments of RMB178.7&#160;million, RMB53.1&#160;million (US$7.6 million) and nil for the year ended December&#160;31, 2018, 2019 and 2020, respectively. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On November&#160;4, 2019, we and Everest Medicines Limited, or Everest, terminated the collaboration agreement (including all the supplements and amendments thereto) with respect to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-development</div> and commercialization of felzartamab in Greater China. Upon the termination, Everest will not retain any rights or entitlements to develop or commercialize felzartamab or any economic interest in its commercialization. All intellectual property rights in respect of felzartamab arising from its development under the collaboration agreement are vested and owned by us, and we hold all intellectual property rights and have maximum flexibility to further develop, manufacture and commercialize felzartamab in Greater China. In consideration of the above arrangements, we issued a total value of US$37.0&#160;million of ordinary shares (the &#8220;CPP Shares&#8221;) to Everest, representing Everest&#8217;s historical contribution to our collaboration and the associated time cost. The CPP Shares were issued concurrently with the completion of our initial public offering, at a per share price equal to the initial public offering price adjusted to reflect the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ADS-to-ordinary</div></div> share ratio. The total value of US$37.0&#160;million was calculated based on the sum of (1)&#160;US$33.7&#160;million, which equals cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> contributions historically made by Everest under the collaboration agreement; and (2)&#160;a negotiated US$3.3&#160;million time cost of the foregoing historical contribution in light of our exclusive rights over the commercialization of felzartamab after this termination. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the initial public offering price of US$14.00 per ADS (or US$6.09 per ordinary share), Everest was issued 6,078,571 ordinary shares and became a minority shareholder of our company upon the completion of our initial public offering. Our issuance of ordinary shares to Everest is being made pursuant to an exemption from registration with the U.S. Securities and Exchange Commission under Regulation S of the U.S. Securities Act of 1933, as amended, or the Securities Act. Everest has agreed not to, directly or indirectly, sell, transfer or dispose of any CPP Shares for a period of 180 days after the date of the prospectus of our initial public offering. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">227 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2020, we entered into a product development and supply agreement with Jiangsu Taslydiyi Pharmaceutical Co., Ltd. (&#8220;Jiangsu Taslydidyi&#8221;), an affiliate of Tasly. Both parties agreed that Jiangsu Taslydiyi will supply temozolomide capsules to us free of charge in our efineptakin alfa (TJ107) Phase 2 and future Phase 3 clinical trials in GBM treatment. We agreed that when reaching the commercialization stage, we will grant the Right of First Negotiation (ROFN) to Jiangsu Taslydiyi for the commercialization of efineptakin alfa in mainland China. We incurred RMB2.4&#160;million (US$0.4 million) in research and development expenses for the aforementioned drug supply services for the year ended December&#160;31, 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In July 2019, we entered into a loan agreement with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou, pursuant to which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou borrowed RMB2&#160;million (US$0.3 million) from us for a term of 12 months with a free interest. In July 2020, we entered into another loan agreement with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou, pursuant to which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou borrowed RMB50&#160;million (US$7.7 million) from us for a term of 4 months with a free interest. Under the terms of these two agreements, we provided loans to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou to finance their daily operations. These loans were repaid to us in November 2020. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">C.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Interests of Experts and Counsel</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div id="rom10811_12" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;8. FINANCIAL INFORMATION </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements and Other Financial Information</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have appended consolidated financial statements filed as part of this annual report. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal Proceedings </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition or cash flows. In April 2020, Tracon issued a notice of disputes with respect to the TJD5 Agreement and the BsAbs Agreement. As of the date of this annual report, these disputes have not been resolved. In February 2021, we sent Tracon a notice to terminate the TJD5 Agreement, which would result in a prespecified termination fee of US$9.0&#160;million owing to Tracon. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend Policy </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors has complete discretion on whether to pay dividends, subject to certain requirements of Cayman Islands law. Even if our board of directors decides to pay dividends on our ordinary shares, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that our board of directors may deem relevant. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not have any present plan to pay any cash dividends on our ordinary shares in the foreseeable future. We currently intend to retain most, if not all, of our available funds and any future earnings to operate and expand our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a holding company incorporated in the Cayman Islands. We may rely on dividends from our subsidiaries in China for our cash requirements, including any payment of dividends to our shareholders. PRC regulations may restrict the ability of our PRC subsidiaries to pay dividends to us. See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Regulation&#8212;PRC Regulation&#8212;Regulations Relating to Foreign Exchange and the Dividend Distribution.&#8221; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">228 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we pay any dividends on our ordinary shares, we will pay those dividends which are payable in respect of the ordinary shares underlying our ADSs to the depositary, as the registered holder of such ordinary shares, and the depositary then will pay such amounts to our ADS holders in proportion to the ordinary shares underlying the ADSs held by such ADS holders, subject to the terms of the deposit agreement, including the fees and expenses payable thereunder. Cash dividends on our ordinary shares, if any, will be paid in U.S. dollars. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">B.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Significant Changes</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not experienced any significant changes since the date of our audited consolidated financial statements included in this annual report. </div></div> <div id="rom10811_13" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;9. THE OFFER AND LISTING </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Offering and Listing Details</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ADSs, each ten (10)&#160;ADSs representing twenty-three (23)&#160;ordinary shares of ours, have been listed on the Nasdaq Global Market since January&#160;17, 2020. Our ADSs trade under the symbol &#8220;IMAB.&#8221; </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">B.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Plan of Distribution</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">C.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Markets</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ADSs, each ten (10)&#160;ADSs representing twenty-three (23)&#160;ordinary shares of ours, have been listed on the Nasdaq Global Market since January&#160;17, 2020. Our ADSs trade under the symbol &#8220;IMAB.&#8221; </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">D.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Selling Shareholders</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">E.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Dilution</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">F.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Expenses of the Issue</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div id="rom10811_14" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;10. ADDITIONAL INFORMATION </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Share Capital</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">B.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Memorandum and Articles of Association</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a summary of the material provisions of the sixth memorandum and articles of association of our company and of the Companies Act, insofar as they relate to the material terms of our ordinary shares. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">229 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Objects of Our Company</div></div>. Under our current memorandum and articles of association, the objects of our company are unrestricted and we have the full power and authority to carry out any object not prohibited by the Companies Act or any other law of the Cayman Islands. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares</div></div>. Certificates representing the ordinary shares are issued in registered form and our ordinary shares are issued when registered in our register of members. We may not issue shares to bearers. Our shareholders who are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-residents</div> of the Cayman Islands may freely hold and vote their shares. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends</div></div>. Our directors may from time to time declare dividends (including interim dividends) and other distributions on our shares in issue and authorize payment of the same out of the funds of our company lawfully available therefor. In addition, our company may declare dividends by ordinary resolution, but no dividend shall exceed the amount recommended by our directors. Our current memorandum and articles of association provide that dividends may be declared and paid out of the funds of our company lawfully available therefor. Under the laws of the Cayman Islands, our company may pay a dividend out of either profit or the credit standing in our share premium account; provided that in no circumstances may a dividend be paid out of the share premium account if this would result in our company being unable to pay its debts as they fall due in the ordinary course of business. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights</div></div>. Voting at any meeting of shareholders is by show of hands unless a poll is demanded. A poll may be demanded by the chairman of such meeting or any one shareholder or shareholders collectively holding not less than 5% of the votes attaching to the shares present in person or by proxy. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">An ordinary resolution to be passed at a meeting by the shareholders requires the affirmative vote of a simple majority of the votes attaching to the ordinary shares cast at a meeting, while a special resolution requires the affirmative vote of not less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> of the votes attaching to the ordinary shares cast at a meeting. A special resolution will be required for important matters such as a change of name or making changes to our current memorandum and articles of association. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alternation of Share Capital </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may from time to time by ordinary resolution: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">increase our share capital by such sum, to be divided into shares of such classes and amount, as the resolution shall prescribe; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consolidate and divide all or any of our share capital into shares of a larger amount than its existing shares; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">subdivide our shares, or any of them, into shares of an amount smaller than that fixed by the memorandum of association, provided that in the subdivision the proportion between the amount paid and the amount, if any, unpaid on each reduced share shall be the same as it was in case of the share from which the reduced share is derived; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cancel any shares that, at the date of the passing of the resolution, have not been taken or agreed to be taken by any person and diminish the amount of its share capital by the amount of the shares so cancelled. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may by special resolution, subject to any confirmation or consent required by the Companies Act, reduce our share capital and any capital redemption reserve in any manner authorized by law. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General Meetings of Shareholders</div></div>. As a Cayman Islands exempted company, we are not obliged by the Companies Act to call shareholders&#8217; annual general meetings. Our current memorandum and articles of association provide that we may (but are not obliged to) in each year hold a general meeting as our annual general meeting in which case we shall specify the meeting as such in the notices calling it, and the annual general meeting shall be held at such time and place as may be determined by our directors. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">230 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shareholders&#8217; general meetings may be convened by our directors (acting by a resolution of our board). Advance notice of at least 14 calendar days is required for any general shareholders&#8217; meeting. A quorum required for any general meeting of shareholders consists of, at the time when the meeting proceeds to business, one or more of our shareholders holding shares which carry in aggregate (or representing by proxy) not less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of all votes attaching to all of our shares in issue and entitled to vote at such general meeting. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Companies Act does not provide shareholders with any right to requisition a general meeting, nor any right to put any proposal before a general meeting. However, these rights may be provided in a company&#8217;s articles of association. Our current articles of association allow our shareholders holding in aggregate not less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-tenth</div> of all votes attaching to all issued and outstanding shares of our company that as at the date of the deposit carry the right to vote at general meetings of the company to requisition an extraordinary general meeting of our shareholders, in which case our board is obliged to convene an extraordinary general meeting and to put the resolutions so requisitioned to a vote at such meeting. However, our current memorandum and articles of association do not provide our shareholders with any right to put any proposals before annual general meetings or extraordinary general meetings not called by such shareholders. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transfer of Ordinary Shares</div></div>. Subject to the restrictions set out below, any of our shareholders may transfer all or any of his or her ordinary shares by an instrument of transfer in the usual or common form or any other form approved by our board of directors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors may, in its absolute discretion, decline to register any transfer of any ordinary share which is not fully paid up or on which we have a lien. Our board of directors may also decline to register any transfer of any ordinary share unless: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the instrument of transfer is lodged with us, accompanied by the certificate for the ordinary shares to which it relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the instrument of transfer is in respect of only one class of shares; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the instrument of transfer is properly stamped, if required; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in the case of a transfer to joint holders, the number of joint holders to whom the ordinary share is to be transferred does not exceed four; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a fee of such maximum sum as the Nasdaq Global Market may determine to be payable or such lesser sum as our directors may from time to time require is paid to us in respect thereof. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If our directors refuse to register a transfer, they shall, within three calendar months after the date on which the instrument of transfer was lodged with our company, send to each of the transferor and the transferee notice of such refusal. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration of transfers may, on ten calendar days&#8217; notice being given by advertisement in such one or more newspapers, by electronic means or by any other means in accordance with the rules of the Nasdaq Global Market be suspended and the register closed at such times and for such periods as our board of directors may from time to time determine; provided, however, that the registration of transfers shall not be suspended nor the register closed for more than 30 calendar days in any year. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidation</div></div>. On the winding up of our company, if the assets available for distribution amongst our shareholders shall be more than sufficient to repay the whole of the share capital at the commencement of the winding up, the surplus shall be distributed amongst our shareholders in proportion to the par value of the shares held by them at the commencement of the winding up, subject to a deduction from those shares in respect of which there are monies due, of all monies payable to our company for unpaid calls or otherwise. If our assets available for distribution are insufficient to repay the whole of the share capital, such assets will be distributed so that, as nearly as may be, the losses are borne by our shareholders in proportion to the par value of the shares held by them. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">231 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Calls on Shares and Forfeiture of Shares</div></div>. Our board of directors may from time to time make calls upon shareholders in respect of any moneys unpaid on their shares in a notice served to such shareholders at least 14 calendar days prior to the specified time or times of payment. The shares that have been called upon and remain unpaid are subject to forfeiture. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption, Repurchase and Surrender of Shares</div></div>. We may issue shares on terms that such shares are subject to redemption, at our option or at the option of the holders of these shares, on such terms and in such manner as may be determined, before the issue of such shares, by our board of directors or by our shareholders by a special resolution. Our company may also repurchase any of our shares on such terms and in such manner as have been approved by our board of directors or by an ordinary resolution of our shareholders or are otherwise authorized by the articles of association. Under Cayman Islands law, any redemption or repurchase of shares by our company may be made out of profits of our company, out of our company&#8217;s share premium account or out of the proceeds of a fresh issue of shares made for the purpose of the repurchase or, if so authorized by the articles of association and subject to provisions of the Companies Act, out of capital. Any premium payable on a redemption or repurchase over the par value of the shares to be repurchased or redeemed must be provided for out of profits of our company or from sums standing to the credit of the share premium account of our company or, if authorized by the articles of association and subject to the provisions of the Companies Act, out of capital. At no time may a company redeem or repurchase its shares unless they are fully paid. A company may not redeem or repurchase any of its shares if, as a result of the redemption or repurchase, there would no longer be any issued shares of the company other than shares held as treasury shares. In addition, our company may accept the surrender of any fully paid share for no consideration. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Variations of Rights of Shares</div></div>. Whenever the capital of our company is divided into different classes the rights attached to any such class may, subject to any rights or restrictions for the time being attached to any class, only be varied with the consent in writing of the holders of all of the issued shares of that class or with the sanction of a special resolution passed at a separate meeting of the holders of the shares of that class. The rights conferred upon the holders of the shares of any class issued with preferred or other rights shall not, subject to any rights or restrictions for the time being attached to the shares of that class, be deemed to be varied by the creation, allotment or issue of further shares ranking <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">pari passu </div></div>with or subsequent to them or the redemption or purchase of any shares of any class by our company. The rights of the holders of shares shall not be deemed to be varied by the creation or issue of shares with preferred or other rights including, without limitation, the creation of shares with enhanced or weighted voting rights. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Issuance of Additional Shares</div></div>. Our current memorandum and articles of association authorize our board of directors to issue additional ordinary shares from time to time as our board of directors shall determine. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our current memorandum and articles of association also authorize our board of directors to issue from time to time one or more series of preference shares and to determine, with respect to any series of preference shares, the terms and rights of that series, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the designation of the series; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the number of preferred shares to constitute such series; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the dividend rights, dividend rates, conversion rights, voting rights; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the rights and terms of redemption and liquidation preferences. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of these shares may dilute the voting power of holders of ordinary shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inspection of Books and Records</div></div>. The notice of registered office is a matter of public record. A list of the names of the current directors and alternate directors (if applicable) are made available by the Registrar of Companies of the Cayman Islands for inspection by any person on payment of a fee. The register of mortgages is open to inspection by creditors and shareholders. Shareholders have no general right under Cayman Islands law to inspect or obtain copies of our list of shareholders or our corporate records. However, we intend to provide our shareholders with annual audited financial statements. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">232 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anti-Takeover Provisions</div></div>. Some provisions of our current memorandum and articles of association may discourage, delay or prevent a change of control of our company or management that shareholders may consider favorable, including provisions that authorize our board of directors to issue preference shares in one or more series and to designate the price, rights, preferences, privileges and restrictions of such preference shares. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">However, under Cayman Islands law, our directors may only exercise the rights and powers granted to them under our current memorandum and articles of association for a proper purpose and for what they believe in good faith to be in the best interests of our company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exempted Company</div></div>. We are an exempted company with limited liability incorporated under the Companies Act. The Companies Act distinguishes between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an exempted company are essentially the same as for an ordinary company except that an exempted company: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">does not have to file an annual return of its shareholders with the Registrar of Companies; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">is not required to open its register of members for inspection; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">does not have to hold an annual general meeting; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">may issue shares with no par value; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 20 years in the first instance); </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">may register as a limited duration company; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">may register as a segregated portfolio company. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Limited liability&#8221; means that the liability of each shareholder is limited to the amount unpaid by the shareholder on the shares of the company. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">C.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Material Contracts</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have not entered into any material contracts other than in the ordinary course of business and other than those described under this item, in &#8220;Item 4. Information on the Company&#8221;, &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;B. Related Party Transactions,&#8221; &#8220;Item 10. Additional Information&#8212;C. Material Contracts&#8221; or elsewhere in this annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subscription Agreements with Certain Investors Other Than Hillhouse Entities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2020, we entered into subscription agreements with various investors other than HillHouse Entities. The subscription agreements are of the same form and provide for certain investors&#8217; rights, such as registration rights and anti-dilution right. Set forth below is a description of certain rights and restrictions thereof. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mandatory Registration</div></div>. We agree to file with the SEC a registration statement to register the resale of such investors&#8217; registrable securities, which include ordinary shares issued and issuable upon exercise of Investor Warrants under the Subscription Agreement, on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div> or Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1,</div> as applicable. We shall have the relevant registration statement declared effective by the SEC no later than ninety (90)&#160;calendar days after the initial closing date, which period could be extended to one hundred and twenty (120)&#160;calendar days if the SEC reviews and comments on the registration statement. However, if the SEC prevents inclusion of the registrable securities in the registration statement pursuant to limitations under Rule 415 of the Securities Act, the number of registrable securities to be registered for each selling shareholder named in the registration statement shall be reduced pro rata among all such selling shareholders. We shall maintain the continuous effectiveness of the registration statement for a period of ninety (90)&#160;days after its effectiveness or such shorter period upon which such investors have notified us that their registrable securities have actually been sold. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">233 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Piggyback Registration</div></div>. We agree to notify such investors at least thirty (30)&#160;days prior to filing any registration statement for purposes of effecting a public offering of ADSs (excluding registration statements relating to the mandatory registration described above). The Private Placement Investors has 20 days after receiving notice from us to notify us in writing of their desire to include their registrable securities in the registration statement. However, if the registrable securities in such registration statement are offered by means of an underwritten offering, and we or the underwriters determine that marketing factors require a limitation of the number of securities to be underwritten, the number of registrable securities that may be included in the underwriting shall be reduced and allocated (i)&#160;first, to us and each holder in accordance with the terms of the Shareholders Agreement; (ii)&#160;second, to investors in the private placements entered into in September 2020 requesting inclusion of their registrable securities in such registration statement on a pro rata basis based on the total number of registrable securities then held by each such investor; and (iii)&#160;third, to other holders of registrable securities, if any. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Suspension of Registration</div></div>. We may suspend the use of any registration statement for a period not exceeding thirty (30)&#160;consecutive trading days, if we (i)&#160;determine that we would be required to make disclosure of material information in the registration statement that we have a bona fide business purpose for preserving as confidential; (ii)&#160;determine that we must amend or supplement the registration statement so that it shall not include an untrue statement of a material fact or omit to state a material fact; or (iii)&#160;have experienced or are experiencing some other material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> event, the disclosure of which at such time would adversely affect us. However, we cannot exercise the suspension right more than once in any twelve (12)&#160;month period and may not register any other securities during such suspension period. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expenses</div></div>. We will bear all registration expenses, except any (i)&#160;portions of fees and disbursements of counsel for such investors, and (ii)&#160;underwriting discounts and selling commissions applicable to sale of registrable securities. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ranking of Registration Rights</div></div>. Registration rights granted to such investors shall not be senior to, or on a parity with, those granted to holders under the Shareholders Agreement. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">D.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exchange Controls</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Regulation&#8212;Regulations Relating to Foreign Exchange.&#8221; </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">E.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Taxation</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following summary of the material Cayman Islands, PRC and U.S. federal income tax consequences of an investment in the ADSs or ordinary shares is based upon laws and relevant interpretations thereof in effect as of the date of this annual report, all of which are subject to change. This summary does not deal with all possible tax consequences relating to an investment in the ADSs or ordinary shares, such as the tax consequences under U.S. state and local tax laws or under the tax laws of jurisdictions other than the Cayman Islands, China and the United States. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cayman Islands Taxation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Cayman Islands currently levies no taxes on individuals or corporations based upon profits, income, gains or appreciation and there is no taxation in the nature of inheritance tax or estate duty. There are no other taxes likely to be material to us levied by the government of the Cayman Islands except for stamp duties which may be applicable on instruments executed in, or brought within the jurisdiction of the Cayman Islands. The Cayman Islands are a party to a double tax treaty entered into with the United Kingdom in 2010 but otherwise is not party to any double tax treaties. There are no exchange control regulations or currency restrictions in the Cayman Islands. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">234 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments of dividends and capital in respect of our shares will not be subject to taxation in the Cayman Islands and no withholding will be required on the payment of a dividend or capital to any holder of the shares, nor will gains derived from the disposal of our shares be subject to Cayman Islands income or corporation tax. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No stamp duty is payable in respect of the issue of shares by our company and no stamp duty is payable on transfers of shares of our company provided our company does not hold any interest in land in the Cayman Islands. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PRC Taxation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Under the PRC Enterprise Income Tax Law and its implementation rules, an enterprise established outside China with &#8220;de facto management body&#8221; within China is considered as a Tax Resident Enterprise for PRC enterprise income tax purposes and is generally subject to a uniform 25% enterprise income tax rate on its worldwide income. The implementation rules define the term &#8220;de facto management body&#8221; as the body that exercises full and substantial control and overall management over the business, productions, personnel, accounts and properties of an enterprise. In April 2009, the State Administration of Taxation issued Circular 82, which provides certain specific criteria for determining whether the &#8220;de facto management body&#8221; of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PRC-controlled</div> enterprise that is incorporated offshore is located in China. Although this circular only applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those controlled by PRC individuals or foreigners, the criteria set forth in the circular may reflect the State Administration of Taxation&#8217;s general position on how the &#8220;de facto management body&#8221; text should be applied in determining the tax resident status of all offshore enterprises. According to Circular 82, an offshore incorporated enterprise controlled by a PRC enterprise or a PRC enterprise group will be regarded as a PRC tax resident by virtue of having its &#8220;de facto management body&#8221; in China if all of the following conditions are met: (i)&#160;the primary location of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> operational management is in China; (ii)&#160;decisions relating to the enterprise&#8217;s financial and human resource matters are made or are subject to approval by organizations or personnel located in China; (iii)&#160;the enterprise&#8217;s primary assets, accounting books and records, company seals, and board and shareholder resolutions, are located or maintained in China; and (iv)&#160;at least 50% of voting board members or senior executives habitually reside in China. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our PRC counsel, JunHe LLP, is of the opinion that, based on its understanding of the current PRC Laws and Regulations, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> should not be considered as a PRC resident enterprise for PRC income tax purposes because <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> does not meet all of the above conditions. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> is incorporated outside of China and it is not controlled by a PRC enterprise or PRC enterprise group. We have structured a clear management guideline in place to segregate the policy set up and business operating execution responsibilities in order to differentiate the effective control from our headquarter office and subsidiaries including record keeping and offshore work location plan. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> is a company incorporated outside the PRC. As a holding company, its key assets are its ownership interests in its subsidiaries, and its key assets are located, and its records (including the resolutions of its board of directors and the resolutions of its shareholders) are maintained, outside China. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term &#8220;de facto management body.&#8221; However, we cannot guarantee you that PRC tax authorities will not take a different view. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the PRC tax authorities determine that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> is a PRC resident enterprise for enterprise income tax purposes, our worldwide income could be subject to 25% enterprise income tax; and any dividends payable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> enterprise holders of our common shares or ADSs may be treated as income derived from sources within China and therefore, subject to a 10% withholding tax (or 20% in the case of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> individual holders) unless an applicable income tax treaty provides otherwise. In addition, capital gains realized by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> enterprise shareholders (including our ADS holders) upon the disposition of our common shares or ADSs may be treated as income derived from sources within PRC and therefore, subject to 10% income tax (or 20% in the case of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> individual shareholders or ADS holders) unless an applicable income tax treaty provides otherwise. It is unclear whether <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PRC</div> shareholders of our company would be able to claim the benefits of any tax treaties between their country of tax residence and the PRC in the event that we are treated as a PRC resident enterprise. See &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks Related to Doing Business in China&#8212;If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PRC</div> shareholders or ADS holders.&#8221; </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">235 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States Federal Income Tax Considerations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The following discussion is a summary of U.S. federal income tax considerations relating to the ownership and disposition of our ADSs or ordinary shares by a U.S. Holder (as defined below) that acquires our ADSs or ordinary shares and holds our ADSs or ordinary shares as &#8220;capital assets&#8221; (generally, property held for investment) under the U.S. Internal Revenue Code of 1986, as amended, or the Code. This discussion is based upon existing U.S. federal tax law, which is subject to differing interpretations or change, possibly with retroactive effect. There can be no assurance that the Internal Revenue Service, or the IRS, or a court will not take a contrary position. This discussion does not address the U.S. federal estate, gift, Medicare, and alternative minimum tax considerations, or any state, local, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> tax considerations, relating to the ownership or disposition of our ADSs or ordinary shares. This discussion, moreover, does not discuss all aspects of U.S. federal income taxation that may be important to particular investors in light of their individual investment circumstances or to investors subject to special tax situations such as: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">banks and other financial institutions; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">insurance companies; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pension plans; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cooperatives; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulated investment companies; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">real estate investment trusts; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">broker-dealers; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">traders in securities that elect to use a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> method of accounting; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">certain former U.S. citizens or long-term residents; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> entities (including private foundations); </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">investors who are not U.S. Holders; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">investors who own (directly, indirectly or constructively) 10% or more of our stock (by vote or value); </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">investors who acquire their ADSs or ordinary shares pursuant to any employee share option or otherwise as compensation; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">investors that will hold their ADSs or ordinary shares as part of a straddle, hedge, conversion, constructive sale or other integrated transaction for U.S. federal income tax purposes; or </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">investors that have a functional currency other than the U.S. dollar; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">all of whom may be subject to tax rules that differ significantly from those discussed below. Each U.S. Holder is urged to consult its tax advisor regarding the U.S. federal, state, local and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> income and other tax considerations of an investment in our ADSs or ordinary shares. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">236 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For purposes of this discussion, a &#8220;U.S. Holder&#8221; is a beneficial owner of our ADSs or ordinary shares that is, for U.S. federal income tax purposes, (i)&#160;an individual who is a citizen or resident of the United States, (ii)&#160;a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created in, or organized under the law of, the United States or any state thereof or the District of Columbia, (iii)&#160;an estate the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source, or (iv)&#160;a trust (A)&#160;the administration of which is subject to the primary supervision of a U.S. court and which has one or more U.S. persons who have the authority to control all substantial decisions of the trust or (B)&#160;that has otherwise validly elected to be treated as a U.S. person under the Code. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a partnership (or other entity treated as a partnership for U.S. federal income tax purposes) is a beneficial owner of our ADSs or ordinary shares, the tax treatment of a partner in the partnership will generally depend upon the status of the partner and the activities of the partner and the partnership. Partnerships holding our ADSs or ordinary shares and their partners are urged to consult their tax advisors regarding an investment in our ADSs or ordinary shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For U.S. federal income tax purposes, it is generally expected that a U.S. Holder of ADSs will be treated as the beneficial owner of the underlying shares represented by the ADSs. The remainder of this discussion assumes that a U.S. Holder of our ADSs will be treated as the beneficial owner of the underlying shares represented by the ADSs. Accordingly, deposits or withdrawals of ordinary shares for ADSs will generally not be subject to U.S. federal income tax. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Passive Foreign Investment Company Considerations </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation, such as our company, will be classified as a passive foreign investment company, or, or PFIC, for U.S. federal income tax purposes for any taxable year if either (i) 75% or more of its gross income for such year consists of certain types of &#8220;passive&#8221; income or (ii) 50% or more of the value of its assets (generally determined on the basis of a quarterly average) during such year is attributable to assets that produce or are held for the production of passive income. For this purpose, cash and assets readily convertible into cash are each categorized as a passive asset and the company&#8217;s goodwill and other unbooked intangibles are taken into account. Passive income generally includes, among other things, dividends, interest, rents, royalties, and gains from the disposition of passive assets. We will be treated as owning a proportionate share of the assets and earning a proportionate share of the income of any other corporation in which we own, directly or indirectly, 25% or more (by value) of the stock. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We do not believe that we were a PFIC for the taxable year ended December&#160;31, 2020. Although we do not believe we were a PFIC for the taxable year ended December&#160;31, 2020, no assurance can be given with respect to our PFIC status for the current taxable year or any future taxable year. The determination of whether we are or will become a PFIC is uncertain, because it is a fact-intensive inquiry made on an annual basis that depends, in part, on the composition of our income and assets. Fluctuations in the market price of our ADSs may cause us to become a PFIC for the current or subsequent taxable years because the value of our assets for the purpose of the asset test may be determined by reference to the market price of our ADSs from time to time (which may be volatile for biopharmaceutical companies, such as ours, that have not yet achieved commercialization with respect to any of their products). The composition of our income and assets may also be affected by how, and how quickly, we use our liquid assets. Under circumstances where our revenue from activities that produce passive income increases relative to our revenue from activities that produce <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-passive</div> income, or where we determine not to deploy cash for active purposes, our risk of becoming classified as a PFIC will substantially increase. Furthermore, prior to the commercialization of any of our drug candidates, interest and other passive income could constitute more than 75% of gross income for any taxable year. In addition, because there are uncertainties in the application of the relevant rules, it is possible that the IRS may challenge our classification of certain income and assets as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-passive</div> or our valuation of our tangible and intangible assets, each of which may result in our being or becoming a PFIC for the current or subsequent taxable years. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The discussion below under &#8220;&#8212;Dividends&#8221; and &#8220;&#8212;Sale or Other Disposition of ADSs or Ordinary Shares&#8221; is written on the basis that we will not be classified as a PFIC for U.S. federal income tax purposes. The U.S. federal income tax rules that apply if we are treated as a PFIC are generally discussed below under &#8220;&#8212;Passive Foreign Investment Company Rules.&#8221; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">237 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to the discussion below under &#8220;&#8212;Passive Foreign Investment Company Rules,&#8221; any cash distributions (including the amount of any tax withheld) paid on our ADSs or ordinary shares out of our current or accumulated earnings and profits, as determined under U.S. federal income tax principles, will generally be includible in the gross income of a U.S. Holder as dividend income on the day actually or constructively received by the U.S. Holder. Because we do not intend to determine our earnings and profits on the basis of U.S. federal income tax principles, any distribution we pay will generally be reported as a &#8220;dividend&#8221; for U.S. federal income tax purposes. Dividends received on our ADSs or ordinary shares will not be eligible for the dividends received deduction allowed to corporations in respect of dividends received from U.S. corporations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-corporate</div> U.S. Holder will generally be subject to tax on dividend income from a &#8220;qualified foreign corporation&#8221; at a lower applicable capital gains rate rather than the marginal tax rates generally applicable to ordinary income provided that certain conditions are satisfied, including that (1)&#160;our ADSs or ordinary shares on which the dividends are paid are readily tradable on an established securities market in the United States, or in the event that we are deemed to be a PRC resident enterprise under the PRC tax law, we are eligible for the benefits of the United <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">States-PRC</div> income tax treaty (the &#8220;Treaty&#8221;); (2) we are neither a PFIC nor treated as such with respect to a U.S. Holder for the taxable year in which the dividend is paid and the preceding taxable year, and (3)&#160;certain holding period requirements are met. The ADSs are listed on the Nasdaq Global Market. We believe that the ADSs are readily tradable on an established securities market in the United States, and that we will be a qualified foreign corporation with respect to dividends paid on the ADSs. Since we do not expect that our ordinary shares will be listed on an established securities market, we do not believe that dividends that we pay on our ordinary shares that are not represented by ADSs will meet the conditions required for the reduced tax rate. There can be no assurance, however, that our ADSs will continue to be considered readily tradable on an established securities market in later years. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the event that we are deemed to be a PRC resident enterprise under the PRC Enterprise Income Tax Law, we may be eligible for the benefits of Treaty and in that case we would be treated as a qualified foreign corporation with respect to dividends paid on our ordinary shares or ADSs. Each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-corporate</div> U.S. Holder is advised to consult its tax advisors regarding the availability of the reduced tax rate applicable to qualified dividend income for any dividends we pay with respect to our ADSs or ordinary shares. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends will generally be treated as income from foreign sources for U.S. foreign tax credit purposes and will generally constitute passive category income. In the event that we are deemed to be a PRC resident enterprise under the PRC Enterprise Income Tax Law, a U.S. Holder may be subject to PRC withholding taxes on dividends paid on our ADSs or ordinary shares. See &#8220;&#8212;PRC Taxation&#8221; above. In that case, depending on the U.S. Holder&#8217;s individual facts and circumstances, a U.S. Holder may be eligible, subject to a number of complex limitations, to claim a foreign tax credit not in excess of any applicable treaty rate in respect of any foreign withholding taxes imposed on dividends received on our ADSs or ordinary shares. A U.S. Holder who does not elect to claim a foreign tax credit for foreign tax withheld may instead claim a deduction, for U.S. federal income tax purposes, in respect of such withholding, but only for a year in which such holder elects to do so for all creditable foreign income taxes. The rules governing the foreign tax credit are complex and their outcome depends in large part on the U.S. Holder&#8217;s individual facts and circumstances. Accordingly, U.S. Holders are urged to consult their tax advisors regarding the availability of the foreign tax credit under their particular circumstances. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sale or Other Disposition of ADSs or Ordinary Shares </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Subject to the discussion below under &#8220;&#8211;&#8211;Passive Foreign Investment Company Rules,&#8221; a U.S. Holder will generally recognize capital gain or loss upon the sale or other disposition of ADSs or ordinary shares in an amount equal to the difference between the amount realized upon the disposition and the holder&#8217;s adjusted tax basis in such ADSs or ordinary shares. Any capital gain or loss will be long-term if the ADSs or ordinary shares have been held for more than one year and will generally be U.S. source gain or loss for U.S. foreign tax credit purposes. Long-term capital gain of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-corporate</div> U.S. Holders is generally eligible for a reduced rate of taxation. The deductibility of a capital loss may be subject to limitations. In the event that we are treated as a PRC resident enterprise under the Enterprise Income Tax Law and gain from the disposition of the ADSs or ordinary shares is subject to tax in China, a U.S. Holder that is eligible for the benefits of the Treaty may elect to treat the gain as PRC source income. If a U.S. Holder is not eligible for the benefits of the Treaty or fails to make the election to treat any gain as foreign source, then such U.S. Holder may not be able to use the foreign tax credit arising from any PRC tax imposed on the disposition of the ADSs or ordinary shares unless such credit can be applied (subject to applicable limitations) against U.S. federal income tax due on other income derived from foreign sources in the same income category (generally, the passive category). U.S. Holders are urged to consult their tax advisors regarding the tax consequences if a foreign tax is imposed on a disposition of our ADSs or ordinary shares, including the availability of the foreign tax credit under their particular circumstances and the election to treat any gain as PRC source income. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">238 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Passive Foreign Investment Company Rules </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If we are classified as a PFIC for any taxable year during which a U.S. Holder holds our ADSs or ordinary shares, and unless the U.S. Holder makes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election (as described below), the U.S. Holder will generally be subject to special tax rules that have a penalizing effect, regardless of whether we remain a PFIC, on (i)&#160;any excess distribution that we make to the U.S. Holder (which generally means any distribution paid during a taxable year to a U.S. Holder that is greater than 125&#160;percent of the average annual distributions paid in the three preceding taxable years or, if shorter, the U.S. Holder&#8217;s holding period for the ADSs or ordinary shares), and (ii)&#160;any gain realized on the sale or other disposition (including, under certain circumstances, a pledge) of ADSs or ordinary shares. Under the PFIC rules: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the excess distribution or gain will be allocated ratably over the U.S. Holder&#8217;s holding period for the ADSs or ordinary shares; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the amount allocated to the current taxable year and any taxable years in the U.S. Holder&#8217;s holding period prior to the first taxable year in which we are classified as a PFIC (each, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;pre-PFIC</div> year&#8221;), will be taxable as ordinary income; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the amount allocated to each prior taxable year, other than a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-PFIC</div> year, will be subject to tax at the highest tax rate in effect for individuals or corporations, as appropriate, for that year, increased by an additional tax equal to the interest on the resulting tax deemed deferred with respect to each such taxable year. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are a PFIC for any taxable year during which a U.S. Holder holds our ADSs or ordinary shares and any of our subsidiaries is also a PFIC, such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC for purposes of the application of these rules. U.S. Holders are urged to consult their tax advisors regarding the application of the PFIC rules to any of our subsidiaries. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As an alternative to the foregoing rules, a U.S. Holder of &#8220;marketable stock&#8221; (as defined below) in a PFIC may make a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election with respect to such stock. If a U.S. Holder makes this election, the holder will generally (i)&#160;include as ordinary income for each taxable year that we are a PFIC the excess, if any, of the fair market value of ADSs held at the end of the taxable year over the adjusted tax basis of such ADSs and (ii)&#160;deduct as an ordinary loss the excess, if any, of the adjusted tax basis of the ADSs over the fair market value of such ADSs held at the end of the taxable year, but such deduction will only be allowed to the extent of the amount previously included in income as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election. The U.S. Holder&#8217;s adjusted tax basis in the ADSs would be adjusted to reflect any income or loss resulting from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election. If a U.S. Holder makes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election in respect of a corporation classified as a PFIC and such corporation ceases to be classified as a PFIC, the holder will not be required to take into account the gain or loss described above during any period that such corporation is not classified as a PFIC. If a U.S. Holder makes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election, any gain such U.S. Holder recognizes upon the sale or other disposition of our ADSs in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as ordinary loss, but such loss will only be treated as ordinary loss to the extent of the net amount previously included in income as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election. If a U.S. Holder makes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election it will be effective for the taxable year for which the election is made and all subsequent taxable years unless the ADSs are no longer treated as marketable stock or the IRS consents to the revocation of the election. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election is available only for &#8220;marketable stock,&#8221; which is stock that is regularly traded on a qualified exchange or other market, as defined in applicable United States Treasury Regulations. We believe that the ADSs, but not our ordinary shares, will be treated as marketable stock because the ADSs are listed on the Nasdaq Global Market. However, we cannot guarantee that our ADSs will continue to be listed and traded on the Nasdaq Global Market. Furthermore, while we anticipate that our ADSs should qualify as being regularly traded, no assurances may be given in this regard. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">239 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Because a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election cannot technically be made for any lower-tier PFICs that we may own, a U.S. Holder may continue to be subject to the PFIC rules with respect to such U.S. Holder&#8217;s indirect interest in any investments held by us that are treated as an equity interest in a PFIC for U.S. federal income tax purposes. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not intend to provide information necessary for U.S. Holders to make qualified electing fund elections which, if available, would result in tax treatment different from the general tax treatment for PFICs described above. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If a U.S. Holder owns our ADSs or ordinary shares during any taxable year that we are a PFIC, the holder must generally file an annual IRS Form 8621. Each U.S. Holder is urged to consult its tax advisor concerning the U.S. federal income tax consequences of purchasing, holding and disposing ADSs or ordinary shares if we are or become a PFIC, including the possibility of making a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">F.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Dividends and Paying Agents</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">G.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Statement by Experts</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">H.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Documents on Display</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are subject to periodic reporting and other informational requirements of the Exchange Act as applicable to foreign private issuers, and are required to file reports and other information with the SEC. Specifically, we are required to file annually an annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> within four months after the end of each fiscal year, which is December 31. All information filed with the SEC can be obtained over the internet at the SEC&#8217;s website at www.sec.gov. You can request copies of documents, upon payment of a duplicating fee, by writing to the SEC. As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of quarterly reports and proxy statements, and officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&#160;16 of the Exchange Act. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will furnish Citibank, N.A., the depositary of our ADSs, with our annual reports, which will include a review of operations and annual audited consolidated financial statements prepared in conformity with U.S. GAAP, and all notices of shareholders&#8217; meetings and other reports and communications that are made generally available to our shareholders. The depositary will make such notices, reports and communications available to holders of ADSs and, upon our request, will mail to all record holders of ADSs the information contained in any notice of a shareholders&#8217; meeting received by the depositary from us. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">I.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Subsidiary Information</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div id="rom10811_15" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inflation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To date, inflation in China has not materially impacted our results of operations. According to the National Bureau of Statistics of China, the year-over-year percent changes in the consumer price index for December 2018, 2019 and 2020 were increases of 1.9%, 4.5% and 0.2%, respectively. Although we have not been materially affected by inflation in the past, we can provide no assurance that we will not be affected by higher rates of inflation in China in the future. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">240 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market Risks </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest and Credit Risk </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We had cash, cash equivalents and restricted cash of RMB1,680.9&#160;million, RMB1,193.3&#160;million and RMB4,758.8&#160;million (US$729.3 million) as of December&#160;31, 2018, 2019 and 2020, respectively.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div>Our exposure to interest rate risk primarily relates to the interest income generated by excess cash, which is mostly held in interest-bearing bank deposits. Interest-earning instruments carry a degree of interest rate risk. We have not been exposed to material risks due to changes in interest rates, and we have not used any derivative financial instruments to manage our interest risk exposure. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our credit risk is primarily attributable to the carrying amounts of cash and cash equivalents. The carrying amounts of cash and cash equivalents represent the maximum amount of loss due to credit risk. We mainly place or invest cash and cash equivalents with state-owned or reputable financial institutions in the PRC, and reputable financial institutions outside of the PRC. We do not believe that our cash and cash equivalents have significant risk of default or illiquidity, and we will continually monitor the credit worthiness of these financial institutions. While we believe our cash and cash equivalents do not contain excessive risk, future investments may be subject to adverse changes in market value. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign Exchange Risk </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of our revenues and expenses are denominated in RMB. We do not believe that we currently have any significant direct foreign exchange risk and have not used any derivative financial instruments to hedge exposure to such risk. Although our exposure to foreign exchange risks should be limited in general, the value of your investment in our ADSs will be affected by the exchange rate between U.S. dollar and RMB because the value of our business is effectively denominated in RMB, while our ADSs will be traded in U.S. dollars. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The conversion of RMB into foreign currencies, including U.S. dollars, is based on rates set by the People&#8217;s Bank of China. The RMB has fluctuated against the U.S. dollar, at times significantly and unpredictably. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between RMB and the U.S. dollar in the future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent that we need to convert U.S. dollars into RMB for our operations, appreciation of the RMB against the U.S. dollar would have an adverse effect on the RMB amount we receive from the conversion. Conversely, if we decide to convert RMB into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or ADSs or for other business purposes, appreciation of the U.S. dollar against the RMB would have a negative effect on the U.S. dollar amounts available to us. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of December&#160;31, 2020, we had <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMB-denominated</div> cash and cash equivalents, restricted cash and short-term investments of RMB483.1&#160;million (US$74.0 million). A 10% depreciation of RMB against U.S. dollar based on the foreign exchange rate on December&#160;31, 2020 would result in a decrease of US$7.4&#160;million in cash and cash equivalents. A 10% appreciation of RMB against U.S. dollar based on the foreign exchange rate on December&#160;31, 2020 would result in an increase of US$7.4&#160;million in cash and cash equivalents. </div> <div id="rom10811_16" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Debt Securities</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">B.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Warrants and Rights</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Subscription Agreements, we agree to issue and sell to the investors thereunder the Investor Warrants, exercisable at the election of the applicable investors within 12 months after the initial or subsequent closing dates set forth in the applicable Subscription Agreements. On September&#160;11, 2020 and December&#160;17, 2020, we issued and sold a portion of the Investor Warrants, allowing the applicable investors to purchase 3,744,032 ordinary shares and 1,597,235 ordinary shares, respectively. As of the date of this annual report, none of the Investor Warrants has been exercised. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">241 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">C.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Other Securities</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">D.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">American Depositary Shares</div> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Charges Our ADS Holders May Have to Pay </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The depositary of our ADS facility, Citibank, N.A., shall charge the following fees for the services performed under the terms of the deposit agreement: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ADS Fees </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following ADS fees are payable under the terms of the Deposit Agreement: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 35%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 32%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 31%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Service</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Rate</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">By&#160;Whom&#160;Paid</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: top;">(1) Issuance of ADSs (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, an issuance upon a deposit of Shares, upon a change in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ADS(s)-to-Share(s)</div></div> ratio, or for any other reason), excluding issuances as a result of distributions described in paragraph (4)&#160;below.</td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: top;">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) issued.</td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: top;">Person for whom ADSs are issued.</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">(2) Cancellation of ADSs (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, a cancellation of ADSs for Delivery of deposited Shares, upon a change in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ADS(s)-to-Share(s)</div></div> ratio, or for any other reason).</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) cancelled.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Person for whom ADSs are being cancelled.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">(3) Distribution of cash dividends or other cash distributions (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, upon a sale of rights and other entitlements).</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Person to whom the distribution is made.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">(4) Distribution of ADSs pursuant to (i)&#160;stock dividends or other free stock distributions, or (ii)&#160;an exercise of rights to purchase additional ADSs.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Person to whom the distribution is made.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">(5) Distribution of securities other than ADSs or rights to purchase additional ADSs (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">spin-off</div> shares).</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Person to whom the distribution is made.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">6) ADS Services.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held on the applicable record date(s) established by the Depositary.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Person holding ADSs on the applicable record date(s) established by the Depositary.</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">242 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 35%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 32%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 31%;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">7) Registration of ADS Transfers (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">vice versa</div></div>, or for any other reason).</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) transferred.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Person for whom or to whom ADSs are transferred.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">8) Conversion of ADSs of one series for ADSs of another series (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs into freely transferable ADSs, and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">vice versa</div></div>).</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) converted.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Person for whom ADSs are converted or to whom the converted ADSs are delivered.</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Charges </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An ADS holder will also be responsible for the following ADS charges: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(i)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">taxes (including applicable interest and penalties) and other governmental charges; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(ii)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">such registration fees as may from time to time be in effect for the registration of Shares or other Deposited Securities on the share register and applicable to transfers of Shares or other Deposited Securities to or from the name of the Custodian, the Depositary or any nominees upon the making of deposits and withdrawals, respectively; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(iii)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">such cable, telex and facsimile transmission and delivery expenses as are expressly provided in the Deposit Agreement to be at the expense of the person depositing Shares or withdrawing Deposited Property or of the Holders and Beneficial Owners of ADSs; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(iv)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in connection with the conversion of Foreign Currency, the fees, expenses, spreads, taxes and other charges of the Depositary and/or conversion service providers (which may be a division, branch or Affiliate of the Depositary). Such fees, expenses, spreads, taxes, and other charges shall be deducted from the Foreign Currency; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(v)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">any reasonable and customary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> expenses incurred in such conversion and/or on behalf of the Holders and Beneficial Owners in complying with currency exchange control or other governmental requirements; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(vi)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the fees, charges, costs and expenses incurred by the Depositary, the Custodian, or any nominee in connection with the ADR program. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The above fees and charges may at any time and from time to time be changed by agreement between the Depositary and us. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fees and Other Payments Made by the Depositary to Us </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our depositary anticipates to reimburse us for certain expenses we incur in respect of the ADR program established pursuant to the Deposit Agreement, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and conditions as the Depositary agrees with us from time to time. As of the date of this annual report, we have not received such reimbursement from the depositary. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">243 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom10811_17" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II. </div></div></div> <div id="rom10811_18" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div id="rom10811_19" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Material Modifications to the Rights of Security Holders </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See &#8220;Item 10. Additional Information&#8212;B. Memorandum and Articles of Association&#8221; for a description of the rights of securities holders, which remain unchanged. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Proceeds </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The following &#8220;Use of Proceeds&#8221; information relates to the registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1,</div> as amended (File Number <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-234363)</div> (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;F-1</div> Registration Statement&#8221;) in relation to our initial public offering of 7,407,400 ADSs representing 17,037,020 ordinary shares, at an initial offering price of US$14.00 per ADS. Our initial public offering closed in February 2020. Jefferies LLC and China International Capital Corporation Hong Kong Securities Limited were the representatives of the underwriters for our initial public offering. Counting in the ADSs sold upon the exercise of the over-allotment option by our underwriters, we offered and sold 8,175,750 ADSs and received a total amount of US$105.3&#160;million in net proceeds. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</div> Registration Statement was declared effective by the SEC on January&#160;16, 2020. The total expenses incurred for our company&#8217;s account in connection with our initial public offering was approximately US$14.1&#160;million, which included US$9.1&#160;million in underwriting discounts and commissions for the initial public offering and approximately US$5.0&#160;million in other costs and expenses for our initial public offering. We received net proceeds of approximately US$96.4&#160;million from our initial public offering. None of the transaction expenses included payments to directors or officers of our company or their associates, persons owning more than 10% or more of our equity securities or our affiliates. None of the net proceeds from the initial public offering were paid, directly or indirectly, to any of our directors or officers or their associates, persons owning 10% or more of our equity securities or our affiliates. For the period from January&#160;16, 2020, the date that the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</div> was declared effective by the SEC, to December&#160;31, 2020, we used approximately US$86.3&#160;million of the net proceeds from our initial public offering as follows: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approximately US$45.2&#160;million for research and development of our existing drug candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approximately US$18.4&#160;million for potential investments in the establishment of our own manufacturing capacities, including the construction of our manufacturing facility in China and for expanding our U.S. presence by building research facilities, including a translational medicine laboratory, in the United States; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approximately US$22.7&#160;million for general corporate purposes (including working capital needs). </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div id="rom10811_20" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;15. CONTROLS AND PROCEDURES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Evaluation of Disclosure Controls and Procedures </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our management, with the participation of our chief executive officer and chief financial officer, has performed an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(e)</div> under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this annual report, as required by Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(b)</div> under the Exchange Act. Based upon that evaluation, our management, with the participation of our chief executive officer and chief financial officer, has concluded that, as of December&#160;31, 2020, our disclosure controls and procedures were effective in ensuring that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms, and that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">244 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management&#8217;s Report on Internal Control over Financial Reporting </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rules&#160;13a-15(f)&#160;and</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(f)&#160;under</div> the Securities Exchange Act of 1934, as amended. Our management, with the participation of our chief executive officer and principal financial officer, evaluated the effectiveness of our internal control over financial reporting based on criteria established in the framework in Internal Control&#8212;Integrated Framework (2013)&#160;issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our management has concluded that our internal control over financial reporting was effective as of December&#160;31, 2020. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remediation of the Material Weaknesses in Internal Control over Financial Reporting Reported in 2019 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, based on an assessment performed by our management on the performance of certain remediation measures specified below, we determined that the material weaknesses in our internal control over financial reporting previously identified by us and our independent registered public accounting firm in connection with the audits of our consolidated financial statements as of and for the years ended December&#160;31, 2018 and 2019 had been remediated. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The material weaknesses identified related to (i)&#160;our lack of sufficient and competent financial reporting and accounting personnel with appropriate knowledge of U.S. GAAP and the reporting and compliance requirements of the SEC, to formalize key controls over financial reporting and to prepare consolidated financial statements and related disclosures; and (ii)&#160;our lack of sufficient documented financial closing policies and procedures, specifically those related to (a)&#160;accounting for licensing and collaboration agreements and (b)&#160;period end expenses <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cut-off</div> and accruals. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have implemented a number of measures to address the material weaknesses that were identified in connection with the audits of our consolidated financial statements as of and for the years ended December&#160;31, 2018 and 2019. We have hired qualified financial and accounting staffs with working experience of U.S. GAAP and SEC reporting requirements, in addition, we have engaged an external consulting firm for accounting advisory service on U.S. GAAP and financial reporting. We have also conducted regular and continuous U.S. GAAP accounting and financial reporting training programs for our financial reporting and accounting personnel. We further established sufficient and formal financial closing policies and procedures, specifically those related to accounting for licensing and collaboration arrangements and period end <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cut-off</div> and accruals. We have already engaged an external consulting firm to assist us to assess Sarbanes-Oxley Act compliance requirements and improve our overall internal controls. Furthermore, we have prepared comprehensive guidance on accounting policies, manuals and closing procedures to improve the quality and accuracy of our period end financial closing process. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attestation Report of the Registered Public Accounting Firm </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">This annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> does not include an attestation report of our independent registered public accounting firm because we qualified as an &#8220;emerging growth company&#8221; as defined under the JOBS Act as of December&#160;31, 2020. </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">245 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in Internal Control Over Financial Reporting </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other than as described above, there were no changes in our internal controls over financial reporting that occurred during the period covered by this annual report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </div></div> <div id="rom10811_21" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;16A. AUDIT COMMITTEE FINANCIAL EXPERT </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our board of directors has determined that Conor Chia-hung Yang, a member of our audit committee and independent director (under the standards under Rule 5605(c)(2) of the Nasdaq Stock Market Rules and Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10A-3</div> under the Securities Exchange Act of 1934), is an audit committee financial expert. </div> <div id="rom10811_22" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;16B. CODE OF ETHICS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our board of directors adopted a code of business conduct and ethics that applies to our directors, officers and employees in November 2019. We have posted a copy of our code of business conduct and ethics on our website at <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">http://ir.i-mabbiopharma.com/</div></div></div>. </div> <div id="rom10811_23" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the aggregate fees by categories specified below in connection with certain professional services rendered by PricewaterhouseCoopers Zhong Tian LLP, our principal external auditors, for the periods indicated. We did not pay any other fees to our auditors during the periods indicated below. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands&#160;of&#160;RMB)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audit fees<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,260</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,631</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax fees<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">580</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All other fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">160</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">Notes:</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Audit fees&#8221; means the aggregate fees billed for professional services rendered by our principal auditors for the audit of our annual financial statements and the review of our comparative interim financial statements, including audit fees relating to our initial public offering in 2020. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Tax fees&#8221; includes fees billed for tax consultations. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The policy of our audit committee is to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approve</div> all audit and other service provided by PricewaterhouseCoopers Zhong Tian LLP as described above, other than those for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">de minimis</div></div> services which are approved by the audit committee prior to the completion of the audit. </div> <div id="rom10811_24" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div id="rom10811_25" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;15, 2020, we announced a share repurchase program,&#160;pursuant to which we were authorized to repurchase our own ordinary shares, in the form of ADSs, with an aggregate value of up to US$20.0&#160;million during a twelve-month period effective upon and from the date on which a formal stock repurchase plan engagement agreement is signed with a qualified broker-dealer(s). As of the date of this annual report, we had not repurchased any ADSs in the open market under this program. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">246 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom10811_26" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div id="rom10811_27" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;16G. CORPORATE GOVERNANCE </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a Cayman Islands company listed on Nasdaq, we are subject to the Nasdaq corporate governance listing standards. However, Nasdaq rules permit a foreign private issuer like us to follow the corporate governance practices of its home country. Certain corporate governance practices in the Cayman Islands, which is our home country, may differ significantly from the Nasdaq corporate governance listing standards. We follow home country practice with respect to adoption of the 2020 Plan. If we choose to follow any other home country practice in the future, our shareholders may be afforded less protection than they otherwise would under the Nasdaq corporate governance listing standards applicable to U.S. domestic issuers. See &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks Related to Our ADSs&#8212;We are a foreign private issuer within the meaning of the rules under the Exchange Act, and as such we are exempt from certain provisions applicable to U.S. domestic public companies.&#8221; </div></div> <div id="rom10811_28" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;16H. MINE SAFETY DISCLOSURE </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">247 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom10811_29" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART III. </div></div></div> <div id="rom10811_30" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;17. FINANCIAL STATEMENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have elected to provide financial statements pursuant to Item 18. </div></div> <div id="rom10811_31" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;18. FINANCIAL STATEMENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The consolidated financial statements of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> are included at the end of this annual report. </div> <div id="rom10811_32" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;19. EXHIBITS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 8%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 89%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description&#160;of&#160;Document</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1.1</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312519277698/d713200dex32.htm">Sixth Amended and Restated Memorandum and Articles of Association of the Registrant (incorporated herein by reference to Exhibit&#160;3.2 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</span> (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-234363),</span> as amended, initially filed with the SEC on October&#160;29, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2.1</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312520193325/d75701dex43.htm">Registrant&#8217;s Specimen American Depositary Receipt (included in Exhibit 2.3) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2.2</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312520000969/d713200dex42.htm">Registrant&#8217;s Specimen Certificate for Ordinary Shares (incorporated herein by reference to Exhibit 4.2 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</span> (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-234363),</span> as amended, initially filed with the SEC on October&#160;29, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2.3</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312520193325/d75701dex43.htm">Deposit Agreement, dated as of January&#160;22, 2020, among the Registrant, the depositary and holder of the American Depositary Receipt (incorporated herein by reference to Exhibit 4.3 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</span> (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-239871),</span> as amended, initially filed with the SEC on July&#160;15, 2020) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2.4</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312519277698/d713200dex44.htm">Fourth Amended and Restated Shareholders Agreement, dated as of July&#160;25, 2019, between the Registrant and other parties thereto (incorporated herein by reference to Exhibit 4.4 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</span> (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-234363),</span> as amended, initially filed with the SEC on October&#160;29, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2.5</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312520124785/d882254dex25.htm">Description of American Depositary Shares of the Registrant (incorporated herein by reference to Exhibit 2.5 to the annual report on Form 20-F (File No. <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39173),</span> as amended, initially filed with the SEC on April 29, 2020) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2.6</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312520124785/d882254dex26.htm">Description of Ordinary Shares of the Registrant (incorporated herein by reference to Exhibit 2.6 to the annual report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</span> (File No. <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39173),</span> as amended, initially filed with the SEC on April 29, 2020) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.1</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312520000969/d713200dex101.htm">Second Amended and Restated 2017 Employee Stock Option Plan (incorporated herein by reference to Exhibit 10.1 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</span> (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-234363),</span> as amended, initially filed with the SEC on October&#160;29, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.2</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312520000969/d713200dex102.htm">Second Amended and Restated 2018 Employee Stock Option Plan (incorporated herein by reference to Exhibit 10.2 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</span> (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-234363),</span> as amended, initially filed with the SEC on October&#160;29, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.3</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312519277698/d713200dex1022.htm">2019 Share Incentive Plan (incorporated herein by reference to Exhibit 10.22 to the registration statement on <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;F-1</span> <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(File&#160;No.&#160;333-234363),</span> as amended, initially filed with the SEC on October&#160;29, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.4</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312520193325/d75701dex104.htm">2020 Share Incentive Plan (incorporated herein by reference to Exhibit 10.4 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</span> (File No. <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-239871),</span> as amended, initially filed with the SEC on July 15, 2020) </a></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">248 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 8%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 89%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.5</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312519277698/d713200dex103.htm">Form of Indemnification Agreement, between the Registrant and its directors and executive officers (incorporated herein by reference to Exhibit 10.3 to the registration statement on Form F-1 (File No. 333-234363), as amended, initially filed with the SEC on October 29, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.6</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312519277698/d713200dex104.htm">Form of Employment Agreement, between the Registrant and its executive officers (incorporated herein by reference to Exhibit 10.4 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</span> (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-234363),</span> as amended, initially filed with the SEC on October&#160;29, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.7</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312519277698/d713200dex108.htm">Framework Agreement, dated as of May&#160;26, 2017, among the Registrant and the other parties thereto (incorporated herein by reference to Exhibit 10.8 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</span> (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-234363),</span> as amended, initially filed with the SEC on October&#160;29, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.8&#8224;</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312519277698/d713200dex1013.htm">License and Collaboration Agreement, dated as of November&#160;30, 2017, between the Registrant and MorphoSys AG (incorporated herein by reference to Exhibit 10.13 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</span> (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-234363),</span> as amended, initially filed with the SEC on October&#160;29, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.9</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312519277698/d713200dex1014.htm">Intellectual Property Assignment and License Agreement, dated as of October&#160;16, 2015, between Tasgen <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-tech</span> (Tianjin) Co., Ltd. and Genexine, Inc. (incorporated herein by reference to Exhibit 10.14 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</span> (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-234363),</span> as amended, initially filed with the SEC on October&#160;29, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.10</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312519277698/d713200dex1015.htm">Intellectual Property License Agreement, dated as of December&#160;22, 2017, between the Registrant and Genexine, Inc. (incorporated herein by reference to Exhibit 10.15 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</span> (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-234363),</span> as amended, initially filed with the SEC on October&#160;29, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.11</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312519277698/d713200dex1016.htm">License and Sublicense Agreement, dated as of November&#160;4, 2016, between the Registrant and Ferring International Center SA (incorporated herein by reference to Exhibit 10.16 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</span> (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-234363),</span> as amended, initially filed with the SEC on October&#160;29, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.12&#8224;</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312519277698/d713200dex1017.htm">Collaboration Agreement, dated as of July&#160;9, 2019, between <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</span> US and MacroGenics, Inc. (incorporated herein by reference to Exhibit 10.17 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</span> (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-234363),</span> as amended, initially filed with the SEC on October&#160;29, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.13&#8224;</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312520124785/d882254dex412.htm">License and Collaboration Agreement, dated as of July&#160;26, 2018, between the Registrant and ABL Bio (incorporated herein by reference to Exhibit 4.12 to the annual report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</span> (File No. <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39173),</span> as amended, initially filed with the SEC on April 29, 2020) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.14</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312519277698/d713200dex1019.htm">English translation of Product Development Agreement, dated as of December&#160;10, 2018, between <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</span> Shanghai and CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (incorporated herein by reference to Exhibit 10.19 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</span> (File&#160;No. <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-234363),</span> as amended, initially filed with the SEC on October&#160;29, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.15</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1762304/000090266420003304/exhibit_2.htm">Subscription Agreement, dated as of September&#160;3, 2020, among the Registrant and certain affiliates of Hillhouse (incorporated herein by reference to Exhibit 2 of the Schedule 13D (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;005-91674)</span> jointly filed by Hillhouse Capital Advisors, Ltd. and Hillhouse Capital Management, Ltd. with the SEC on September&#160;14, 2020) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.16</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1762304/000090266420004318/p20-2069exhibit5.htm">Amendment to Subscription Agreement, dated as of December&#160;17, 2020, among the Registrant and certain affiliates of Hillhouse (incorporated herein by reference to Exhibit 5 of the Schedule 13D/A (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;005-91674)</span> jointly filed by Hillhouse Capital Advisors, Ltd. and Hillhouse Capital Management, Ltd. with the SEC on December&#160;21, 2020) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.17</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1762304/000090266420003304/exhibit_4.htm">Form of Call Option granted to affiliates of Hillhouse (incorporated herein by reference to Exhibit 4 of the Schedule 13D (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;005-91674)</span> jointly filed by Hillhouse Capital Advisors, Ltd. and Hillhouse Capital Management, Ltd. with the SEC on September&#160;14, 2020) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.18</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312520307060/d98473dex1017.htm">Form of Subscription Agreement, dated as of September&#160;3, 2020, between the Registrant and certain investors (other than Hillhouse) (incorporated herein by reference to Exhibit 10.17 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</span> (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-</span> 251050), as amended, initially filed with the SEC on December&#160;1, 2020) </a></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">249 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 8%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 89%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.19</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312520307060/d98473dex1018.htm">Form of Warrants to Purchase Ordinary Shares of the Registrant, between the Registrant and certain investors (incorporated herein by reference to Exhibit 10.18 to the registration statement on Form F-1 (File No. 333- 251050), as amended, initially filed&#160;with the SEC on December 1, 2020) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.20&#8224;</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312520307060/d98473dex1019.htm">License and Collaboration Agreement, dated as of September&#160;3, 2020, among <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</span> Shanghai, <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</span> US and AbbVie Ireland Unlimited Company (incorporated herein by reference to Exhibit 10.19 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</span> (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-</span> 251050), as amended, initially filed with the SEC on December&#160;1, 2020) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.21&#8224;</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312520307060/d98473dex1020.htm">English translation of Equity Transfer and Investment Agreement, dated as of September&#160;15, 2020, among <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</span> Biopharma (Hangzhou) Co., Ltd. and the other parties thereto (incorporated herein by reference to Exhibit 10.20 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</span> (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-</span> 251050), as amended, initially filed with the SEC on December&#160;1, 2020) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.22&#8224;</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312520307060/d98473dex1021.htm">English translation of Shareholders Agreement, dated as of September&#160;15, 2020, among <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</span> Biopharma (Hangzhou) Co., Ltd. and other parties thereto (incorporated herein by reference to Exhibit 10.21 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</span> (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-</span> 251050), as amended, initially filed with the SEC on December&#160;1, 2020) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8.1*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d10811dex81.htm">Principal Subsidiaries of the Registrant </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11.1</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1778016/000119312519277698/d713200dex991.htm">Code of Business Conduct and Ethics of the Registrant (incorporated herein by reference to Exhibit 99.1 to the registration statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</span> (File <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-234363),</span> as amended, initially filed with the SEC on October&#160;29, 2019) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12.1*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d10811dex121.htm">Certification by Principal Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12.2*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d10811dex122.htm">Certification by Principal Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13.1**</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d10811dex131.htm">Certification by Principal Executive Officer Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13.2**</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d10811dex132.htm">Certification by Principal Financial Officer Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15.1*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d10811dex151.htm">Consent of JunHe LLP </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15.2*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d10811dex152.htm">Consent of PricewaterhouseCoopers Zhong Tian LLP </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.INS*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Instance Document&#8212;this instance document does not appear in the Interactive Data File because its XBRL tags are not embedded within the Inline XBRL document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.SCH*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Schema Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.CAL*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.DEF*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Definition Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.LAB*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Label Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.PRE*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">104</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Filed herewith. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furnished herewith. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8224;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K.</div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">250 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The registrant hereby certifies that it meets all of the requirements for filing on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-F</div> and that it has duly caused and authorized the undersigned to sign this annual report&#160;on&#160;its&#160;behalf. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 4%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 3%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 45%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="3" style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Jielun Zhu</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Name: Jielun Zhu</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title: Director and Chief Financial Officer</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Date: April 28, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">251 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> </div></div> <div id="index" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 96%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin10811_1">Report of Independent Registered Public Accounting Firm</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin10811_2">Consolidated Balance Sheets as of December&#160;31, 2019 and 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin10811_3">Consolidated Statements of Comprehensive Income (Loss) for the Years Ended December&#160;31, 2018, 2019 and 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin10811_4">Consolidated Statements of Changes in Shareholders&#8217; Equity (Deficit) for the Years Ended December&#160;31, 2018, 2019 and 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin10811_5">Consolidated Statements of Cash Flows for the Years Ended December&#160;31, 2018, 2019 and 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-8</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin10811_6">Notes to the Consolidated Financial Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-11</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin10811_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Board of Directors and Shareholders of I-Mab </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Opinion on the Financial Statements </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated balance sheets of I-Mab and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2020 and 2019, and the related consolidated statements of comprehensive income (loss), of changes in shareholders&#8217; equity (deficit) and of cash flows for each of the three years in the period ended December 31, 2020, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020 in conformity with accounting principles generally accepted in the United States of America. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis for Opinion </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ PricewaterhouseCoopers Zhong Tian LLP </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shanghai, the People&#8217;s Republic of China </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">April 28, 2021 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2018. </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin10811_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB</div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheets </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2019 and 2020 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width:1%;"></td>
<td style="vertical-align: bottom; width: 1%;"></td>
<td></td>
<td style="width:1%;"></td>
<td></td>
<td style="vertical-align: bottom; width: 1%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 1%;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="1" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="1" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notes</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$<br/> (Note&#160;2.5)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,137,473</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">4,758,778</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">729,315</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">10</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">55,810</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:center;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">3, 18</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">130,498</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,000</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">3, 18</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;width:1%;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">227,391</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">34,849</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">2.4,&#160;2.9</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">32,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">31,530</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,832</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepayments and other receivables</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">136,036</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">195,467</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,957</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 74%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,361,319</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,343,664</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">818,953</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, equipment and software</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">30,069</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">25,272</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,873</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">6</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">16,435</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">14,997</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">7</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">148,844</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">120,444</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">8</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">162,574</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">162,574</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,916</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment accounted for using the equity method</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">9</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;width:1%;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">664,832</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">101,890</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">18,331</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,010</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">308</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 74%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 74%; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;">Total assets</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;;width:1%;"><div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;;text-align:right;;width:1%;"><div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,737,572</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">6,333,793</ix:nonFraction></div></div><div style="line-height: 11pt; margin-top: 0pt; margin-bottom: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;"> </div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">970,697</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 74%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities, mezzanine equity and shareholders&#8217; equity (deficit)</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term borrowings</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">10</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">50,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accruals and other payables</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">11</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">273,553</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">560,558</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">85,909</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, current</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">6</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">6,807</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">8,058</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,235</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares to be issued to Everest</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">23</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;width:1%;"><ix:nonFraction name="imab:CommonStockSharesIssuableForServicesAvailedCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">258,119</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred subsidy income</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">2.15</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:1%;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">7,509</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,151</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">588,479</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">576,125</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">88,295</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible promissory notes</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">68,199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Put right liabilities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">2.4, 9</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;width:1%;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="imab:PutRightLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">116,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="imab:PutRightLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,779</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease liabilities, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">6</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">7,492</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,542</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">849</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred subsidy income</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">2.15</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:DeferredIncomeNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">3,920</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">11</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:1%;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">8,975</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,375</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 74%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">668,090</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">706,648</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">108,298</ix:nonFraction> </div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 74%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">22</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 74%; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Mezzanine equity</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;;width:1%;"></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;;width:1%;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Series A convertible preferred shares (US$<ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2019_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2019_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2019_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2019_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">30,227,056</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding as of December&#160;31, 2019, and <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2020_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2020_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2020_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">nil</ix:nonFraction></ix:nonFraction></ix:nonFraction> authorized, issued and outstanding as of December&#160;31, 2020)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">14</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2019_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">687,482</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Series B convertible preferred shares (US$<ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2019_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2019_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2019_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2019_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">30,305,212</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding as of December&#160;31, 2019, and <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2020_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2020_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2020_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">nil</ix:nonFraction></ix:nonFraction></ix:nonFraction> authorized, issued and outstanding as of December&#160;31, 2020)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); text-align: center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">14</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2019_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">921,243</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Series C convertible preferred shares (US$<ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2019_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2019_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2019_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2019_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">31,046,360</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding as of December&#160;31, 2019, and <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2020_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2020_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2020_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">nil</ix:nonFraction></ix:nonFraction></ix:nonFraction> authorized, issued and outstanding as of December&#160;31, 2020)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center;;width:1%;"><div style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">14</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; text-align: center;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2019_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,306,633</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> convertible preferred shares (US$<ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,857,143</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding as of December&#160;31, 2019, and <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">nil</ix:nonFraction></ix:nonFraction></ix:nonFraction> authorized, issued and outstanding as of December&#160;31, 2020)</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); text-align: center;;width:1%;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;width:1%;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">188,819</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 74%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Total mezzanine equity</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">3,104,177</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 74%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheets (Continued) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2019 and 2020 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notes</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; equity (deficit)</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares (US$<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">500,000,000</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">800,000,000</ix:nonFraction> shares authorized as of December&#160;31, 2019 and December&#160;31, 2020, respectively; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,363,719</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">164,888,519</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2019 and December&#160;31, 2020, respectively)</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; text-align: center;">1<div style="display:inline;">3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">114</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">389,379</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">7,701,116</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,180,249</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive income (loss)</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">70,127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">50,793</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,784</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated defici<div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,494,207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,023,292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">310,083</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shareholders&#8217; equity (deficit)</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,034,695</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,627,145</ix:nonFraction> </div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">862,399</ix:nonFraction> </div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities, mezzanine equity and shareholders&#8217; equity (deficit)</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,737,572</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">6,333,793</ix:nonFraction> </div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">970,697</ix:nonFraction> </div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">4</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin10811_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Comprehensive Income (Loss)</div></div></div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the Years Ended December&#160;31, 2018, 2019 and 2020</div></div></div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted)</div></div></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"></td>
<td style="vertical-align: bottom; width: 1%;"></td>
<td></td>
<td style="vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%;"></td>
<td></td>
<td style="vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%;"></td>
<td></td>
<td style="vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%;"></td>
<td></td>
<td style="vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%;"></td>
<td></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Note 2.5)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing and collaboration revenue</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">53,781</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">30,000</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,542,668</ix:nonFraction> </td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">236,424</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenses</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2.1<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">426,028</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">840,415</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">984,689</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">150,910</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative expenses</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">66,391</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">654,553</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">402,409</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">61,672</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) from operations</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">438,638</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,464,968</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">155,570</ix:nonFraction> </div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23,842</ix:nonFraction> </div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">4,597</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">30,570</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">24,228</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,713</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">11,695</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,991</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">957</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">147</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income (expenses), net</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,780</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">20,205</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">412,892</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">63,278</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in loss of an affiliate</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 1%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 1%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">108,587</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,642</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value change of warrants</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2.4</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">61,405</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,644</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 1%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 1%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before income tax expense</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">401,111</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,451,950</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">483,146</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,044</ix:nonFraction> </div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,722</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 1%;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">12,231</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,874</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net income (loss) attributable to<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">402,833</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,451,950</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">470,915</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">72,170</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deemed dividend to Series<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>preferred shareholders at extinguishment of Series<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Preferred Shares</div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 1%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imab:PreferredStockDividendsAtExtinguishmentOfPreferredShares" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,283</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 1%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 1%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deemed dividend to Series B-1,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>and C preferred shareholders at modification of Series B-1,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>and C Preferred Shares</div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 1%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imab:PreferredStockDividendsAtModificationOfPreferredShares" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">27,768</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 1%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 1%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to ordinary shareholders</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">402,833</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,485,001</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">470,915</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">72,170</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net income (loss) attributable to<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">402,833</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,451,950</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">470,915</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">72,170</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss):</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustments, net of nil ta<div style="letter-spacing: 0px; top: 0px;;display:inline;">x</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">53,689</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">10,747</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">120,920</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,531</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total comprehensive income (loss) attributable to<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">349,144</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,441,203</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">349,995</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">53,639</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to ordinary shareholders</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">402,833</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,485,001</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">470,915</ix:nonFraction> </div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">72,170</ix:nonFraction> </div></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average number of ordinary shares used in calculating net income (loss) per share - basic</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,529,092</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,381,230</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">134,158,824</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">134,158,824</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average number of ordinary shares used in calculating net income (loss) per share - diluted</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,529,092</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,381,230</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">157,231,652</ix:nonFraction> </td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">157,231,652</ix:nonFraction> </td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per share attributable to ordinary shareholders</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;Basic</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">61.70</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">201.19</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">3.51</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.54</ix:nonFraction> </td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;Diluted</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">61.70</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">201.19</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">3.00</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.46</ix:nonFraction> </td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; text-indent: 0in; width: 56%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;">Net income (loss) per ADS attributable to ordinary shareholders</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;;text-align:center;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap; vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap; vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap; vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap; vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr>
<td style="vertical-align: top; font-size: 10pt; width: 56%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;Basic</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:center;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2018To12_31_2018_AdrMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">141.91</ix:nonFraction></div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2019To12_31_2019_AdrMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">462.74</ix:nonFraction></div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">8.07</ix:nonFraction></div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.24</ix:nonFraction></div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr>
<td style="vertical-align: top; font-size: 10pt; width: 56%; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;Diluted</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:center;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2018To12_31_2018_AdrMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">141.91</ix:nonFraction></div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2019To12_31_2019_AdrMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">462.74</ix:nonFraction></div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">6.90</ix:nonFraction></div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.06</ix:nonFraction></div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> </div> <div style="text-align: center;"> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"></div> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin10811_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB</div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-top: 0pt; padding-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Changes in Shareholders&#8217; Equity (Deficit) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-top: 0pt; padding-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the Years Ended December&#160;31, 2018, 2019 and 2020 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-top: 0pt; padding-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; padding-top: 0pt; padding-bottom: 0pt; line-height: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 46%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;share&#160;(Note&#160;1<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treasury<br/> stock</div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><br/> capital</div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="display:inline;">Accumulated<br/> other<br/> comprehensive<br/> income (loss)</div></div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> deficit</div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total<br/> shareholders&#8217;<br/> equity<br/> (deficit)</div></div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$0.001 par value)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 12pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2017</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,363,719</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2017_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">52,369</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,691</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">357,860</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2017" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">299,795</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 12pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustments</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">53,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">53,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 12pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2018To12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">402,833</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">402,833</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 12pt; padding-top: 0pt; padding-bottom: 0pt;">Share-based compensation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">3,520</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">3,520</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 12pt; padding-top: 0pt; padding-bottom: 0pt;">Transaction with redeemable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-</div> controlling interests</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">55,889</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" contextRef="P01_01_2018To12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">253,796</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">309,685</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 12pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2018</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,363,719</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">59,380</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,014,489</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">955,104</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 12pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustments</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">10,747</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">10,747</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 12pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,451,950</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,451,950</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 12pt; padding-top: 0pt; padding-bottom: 0pt;">Share-based compensation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To12_31_2019_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">366,894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">366,895</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 12pt; padding-top: 0pt; padding-bottom: 0pt;">Deemed dividend to Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> preferred shareholders at extinguishment of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="imab:PreferredStockDividendsAtExtinguishmentOfPreferredShares" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="imab:PreferredStockDividendsAtExtinguishmentOfPreferredShares" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 12pt; padding-top: 0pt; padding-bottom: 0pt;">Deemed dividend to Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> and C preferred shareholders at modification of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> and C Preferred Shares</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:PreferredStockDividendsAtModificationOfPreferredShares" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">27,768</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="imab:PreferredStockDividendsAtModificationOfPreferredShares" contextRef="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">27,768</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 12pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,363,719</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">389,379</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">70,127</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,494,207</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,034,695</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt; padding-top: 0pt; padding-bottom: 0pt;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; padding-top: 0pt; padding-bottom: 0pt; line-height: 12pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-top: 0pt; padding-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div> </div> </div> <div style="margin-top: 0pt; margin-bottom: 0pt; break-before: page; padding-top: 0pt; padding-bottom: 0pt; line-height: 12pt;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-top: 0pt; padding-bottom: 0pt; line-height: 12pt;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Changes in Shareholders&#8217; Equity (Deficit) (Continued) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the Years Ended December&#160;31, 2018, 2019 and 2020 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 41%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary share (Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treasury<br/> stock</div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><br/> capital</div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; white-space: nowrap; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accumulated<br/> other<br/> comprehensive<br/> <div style="display:inline;">&#160; </div>income (loss) &#160;</div></div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> deficit</div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total<br/> shareholders&#8217;<br/> equity<br/> (deficit)</div></div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$0.001 par value)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 41%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">8,363,719</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">389,379</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">70,127</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,494,207</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,034,695</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 41%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustments</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">120,920</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">120,920</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 41%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">470,915</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">470,915</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 41%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Share-based compensation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">402,413</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">402,413</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 41%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise of stock options</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,841,373</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">7,771</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">7,774</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; width: 41%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Issuance of ordinary shares for restricted share units<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;(Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>&#160;(f))</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">7,000</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0pt 4pt 0pt 0pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">46</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">46</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 41%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Conversion from convertible promissory notes<br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;">(Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>)</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">900,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">58,825</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">58,826</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 41%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capital contribution from stock option <br/> surrender (Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>&#160;(h))</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="imab:AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">91,051</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="imab:AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">91,051</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 41%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion of preferred shares to ordinary shares upon the completion of initial public offering (&#8220;IPO&#8221;)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">99,760,129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">69</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">3,104,108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">3,104,177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 41%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of ordinary shares to Everest</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,078,571</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">254,844</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">254,848</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 41%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of ordinary shares upon IPO and over-allotment, net of issuance cost</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">18,804,225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">697,865</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">697,878</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 41%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of ordinary shares upon private placement, net of issuance cost</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">29,133,502</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">18</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,543,908</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,543,926</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 41%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proportionate share of share-based compensation expenses recorded in an equity method affiliate (Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>(a))</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="imab:ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">41,163</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="imab:ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">41,163</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 41%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of warrants</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">109,743</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">109,743</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 41%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2020</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">164,888,519</ix:nonFraction> </div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">114</ix:nonFraction> </div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">7,701,116</ix:nonFraction> </div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">50,793</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,023,292</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,627,145</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 41%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin10811_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB</div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Cash Flows </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the Years Ended December&#160;31, 2018, 2019 and 2020 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Note&#160;2.5)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from operating activities</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">402,833</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,451,950</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">470,915</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">72,170</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">Adjustments to reconcile net income (loss) to net cash used in operating activities</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation of property, equipment and software</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">6,740</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">9,831</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">12,743</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,953</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of intangible assets</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,556</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">238</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on disposal of property, equipment and software</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expenses of convertible promissory notes and onshore convertible loans</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">6,963</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value change of warrants</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">61,405</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,644</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value change of put right liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="imab:FairValueAdjustmentsOfPutRightLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,024</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="imab:FairValueAdjustmentsOfPutRightLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">463</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value change of other financial assets</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AssetsFairValueAdjustment" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">42</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from other financial assets</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="imab:IncomeFromOtherFinancialAssets" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">13,622</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in loss of an affiliate</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">108,587</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,642</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">3,520</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">366,895</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">493,464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">75,627</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from conversion of 2017 Notes</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:LossFromConversionOfNotes" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">18,375</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from conversion of onshore convertible loans</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:LossFromConversionOfOnshoreConvertibleLoans" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">8,548</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from issuance of 2018 Notes</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:LossFromIssuanceOfNotes" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,081</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on termination agreement with Everest</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnContractTermination" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">23,039</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Amortization of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of</div> use assets and interest of lease liabilities</div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,803</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">8,837</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,354</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gains on deconsolidation of a subsidiary</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfBusiness" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">407,598</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfBusiness" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">62,467</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value change of short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="imab:FairValueChangeOfShortTermInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">703</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="imab:FairValueChangeOfShortTermInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11,288</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="imab:FairValueChangeOfShortTermInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,730</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div> </td>
<td style="vertical-align: bottom; width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0pt 4pt 0pt 0pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0pt 4pt 0pt 0pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">130,498</ix:nonFraction></div></div> </td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,000</ix:nonFraction></div></div> </td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">11,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">227,391</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">34,849</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepayments and other receivables</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">76,276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">48,831</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">58,692</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); text-align: right; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,995</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accruals and other payables</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">55,641</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">188,375</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">173,713</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,624</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">15,803</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; padding: 0pt 4pt 0pt 0pt;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); text-align: right; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; padding: 0pt 4pt 0pt 0pt;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advance from customers</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="imab:IncreaseDecreaseAdvanceFromCustomers" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">14,151</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="imab:IncreaseDecreaseAdvanceFromCustomers" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14,151</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right; padding: 0pt 4pt 0pt 0pt;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right; padding: 0pt 4pt 0pt 0pt;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development funding received</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">178,715</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">53,148</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Other non-current liabilities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">7,474</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,145</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred subsidy incom<div style="letter-spacing: 0px; top: 0px;;display:inline;">e</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,420</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">3,589</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">550</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="imab:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="imab:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,837</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="imab:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,354</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">Net cash generated from (used in) operating activities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">280,705</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">867,982</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">433,558</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"><div style="font-weight:bold;display:inline;width:100%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">66,446</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from investing activities</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of property, equipment and softwar<div style="letter-spacing: 0px; top: 0px;;display:inline;">e</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">14,409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">12,241</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">8,008</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,227</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from disposal of short-term investments</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">102,703</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,503,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">383,716</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of short-term investments</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">134,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,491,991</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;(<ix:nonFraction name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">381,914</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for investments in other financial assets</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireOtherInvestments" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">30,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash disposed of resulting from deconsolidation of a subsidiary</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">257,651</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,487</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash received from disposal of other financial assets</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">40,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">256,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash received on income from other financial assets</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:CashReceivedOnIncomeFromOtherFinancialAssets" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">13,909</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="imab:CashReceivedOnIncomeFromOtherFinancialAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash received from repayment of loans due from an affiliate</div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">52,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,969</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash <div style="letter-spacing: 0px; top: 0px;;display:inline;">generated from (used in)&#160;</div>investing activities</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">9,500</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">212,462</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">201,901</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">30,943</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Cash Flows (Continued) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the Years ended December&#160;31, 2018, 2019 and 2020 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Note&#160;2.5)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from financing activities</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of convertible preferred shares, net of issuance cost</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,306,633</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">183,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of convertible promissory notes</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">59,704</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from initial public offering and over-allotment, net of underwriting discounts and commissions</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">726,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">111,310</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of issuance cost for initial public offering and over-allotment</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">827</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">27,595</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,229</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from private placement, net of payment of issuance cost</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,782,455</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">426,430</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from exercise of warrants</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">132,332</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from exercise of stock options</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt; text-align: right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">9,275</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,422</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of ordinary shares for restricted share units</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">46</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction>&#160;</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from bank borrowings</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromBankDebt" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">80,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromBankDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">50,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of bank borrowings</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfBankDebt" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">99,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfBankDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">80,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfBankDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">50,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:RepaymentsOfBankDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,663</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepayment for stock repurchase program</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfEquity" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">34,859</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfEquity" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,342</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash received from collection of prepayment for stock repurchase program</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="imab:ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">34,859</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="imab:ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,342</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash generated from financing activities</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,479,669</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">152,709</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;">&#160;<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">3,440,481</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;<div style="font-weight:bold;display:inline;width:100%;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">527,277</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of exchange rate changes on cash and cash equivalents and restricted cash</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">59,754</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">15,163</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">106,643</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,344</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 4pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"> <div style="line-height: 4pt;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: 4pt;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: 4pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="line-height: 4pt;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"> <div style="line-height: 4pt;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: 4pt;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: 4pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="line-height: 4pt;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"> <div style="line-height: 4pt;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: 4pt;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: 4pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="line-height: 4pt;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"> <div style="line-height: 4pt;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: 4pt;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: 4pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="line-height: 4pt;">&#160;</div> </td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net increase (decrease) in cash and cash equivalents and restricted cash</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,268,218</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">487,648</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">3,565,495</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">546,436</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents, and restricted cash, beginning of year</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2017" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">412,713</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,680,931</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,193,283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">182,879</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents, and restricted cash, end of the year</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,680,931</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,193,283</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">4,758,778</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">729,315</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Cash Flows (Continued) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the Years ended December&#160;31, 2018, 2019 and 2020 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Note&#160;2.5)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional ASC 842 supplemental disclosures</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for fixed operating lease costs included in the measurement of lease obligations in operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">6,172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">8,837</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,354</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets obtained in exchange for operating lease obligations</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">8,595</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">7,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,143</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other supplemental cash flow disclosures</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">4,862</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,991</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">957</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise of warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:ExerciseOfWarrants" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,314</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Payables for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patent rights</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:PayablesForInLicensedPatentRights" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,970</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued initial public offering costs payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:AccuredInitialPublicOfferingCostPayable" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">17,504</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Deemed dividend to Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> preferred shareholders at extinguishment of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:PreferredStockDividendsAtExtinguishmentOfPreferredShares" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Deemed dividend to Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> and C preferred shareholders at modification of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> and C Preferred Shares</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:PreferredStockDividendsAtModificationOfPreferredShares" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">27,768</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued private placement offering costs payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:AccruedPrivatePlacementOfferingCostsPayable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">128,786</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:AccruedPrivatePlacementOfferingCostsPayable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,737</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares issued to Everest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">254,848</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,057</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion of preferred shares to ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">3,104,177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">475,736</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion of convertible promissory notes to ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">58,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,015</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">10</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin10811_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. PRINCIPAL ACTIVITIES AND ORGANIZATION </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> (the &#8220;Company&#8221;) was incorporated in the Cayman Islands on June&#160;30, 2016 as an exempted company with limited liability under the Companies <div style="letter-spacing: 0px; top: 0px;;display:inline;">Act</div>&#160;of the Cayman Islands. The Company and its subsidiaries (together the &#8220;Group&#8221;) are principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People&#8217;s Republic of China (the &#8220;PRC&#8221;) and other countries and regions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Prior to the incorporation of the Company, the Group carried out its operation in the PRC since November 2014 mainly through Third Venture Biopharma (Nanjing) Co., Ltd. (&#8220;Third Venture&#8221;), which was incorporated on November&#160;17, 2014 in the PRC. For the purpose of introduction of overseas investors and in preparation for a listing of the Company&#8217;s shares on the overseas capital markets, the Group underwent a reorganization (the &#8220;Reorganization&#8221;) in 2016. The Reorganization was approved by the Board of Directors and a restructuring framework agreement was entered into by Third Venture, the Company, and the shareholders of the Company based on Reorganization framework agreement, pursuant to which on July&#160;7, 2016, Third Venture transferred all of its assets and operations to the Company&#8217;s wholly owned subsidiary, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma Co., Ltd. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;I-Mab</div> Shanghai&#8221;), which was a transaction in which shareholders had identical ownership interests before and after the transaction and was accounted for in a manner similar to a common control transaction. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Reorganization, as described above has been accounted for at historical cost. That Reorganization was reverse merger of Third Venture and Third Venture is the predecessor of the Company. As such, the assets and liabilities of Third Venture are consolidated in the Company&#8217;s financial statements at historical cost. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;17, 2020, the Company consummated its IPO on the Nasdaq Global Market, where <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_31_2020To01_31_2020_AdrMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,407,400</ix:nonFraction> American Depositary Shares (&#8220;ADSs&#8221;) were issued at the price of US$<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn01_17_2020_AdrMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">14.00</ix:nonFraction> per ADS for total gross proceeds of US$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_31_2020To01_31_2020_AdrMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">103.7</ix:nonFraction>&#160;million. On February&#160;10, 2020, the underwriters of the IPO have exercised their over-allotment option to purchase an additional <ix:nonFraction name="imab:CommonStockSharesIssuable" contextRef="PAsOn02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">768,350</ix:nonFraction> ADSs of the Company at the IPO price of US$<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">14.00</ix:nonFraction> per ADS. After giving effect to the exercise of the over-allotment option, the Company has issued and sold a total of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P02_10_2020To02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,175,750</ix:nonFraction> ADSs in the IPO, for total gross proceeds of US$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P02_10_2020To02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">114.5</ix:nonFraction>&#160;million. Each ten ADSs represents twenty-three ordinary shares of the Company. </div></div> <ix:nonNumeric name="imab:ScheduleOfPrincipalSubsidiariesTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>December&#160;31, 2020, the Company&#8217;s principal subsidiaries are as follows: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 46%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subsidiaries</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Place of<br/> incorporation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date of<br/> incorporation or<br/> acquisition</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percentage<br/> of direct<br/> or indirect<br/> ownership<br/> by the<br/> Company</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Principal&#160;activities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma Hong Kong Limited <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;I-Mab</div> Hong Kong&#8221;)</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imab:EntityIncorporationCountryStateName" contextRef="P01_01_2020To12_31_2020_IMabBiopharmaHongKongLimitedMembersrtConsolidatedEntitiesAxis">Hong Kong</ix:nonNumeric></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" contextRef="P01_01_2020To12_31_2020_IMabBiopharmaHongKongLimitedMembersrtConsolidatedEntitiesAxis" format="ixt:datemonthdayyearen">July 8, 2016</ix:nonNumeric></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn12_31_2020_IMabBiopharmaHongKongLimitedMembersrtConsolidatedEntitiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: top; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities" contextRef="P01_01_2020To12_31_2020_IMabBiopharmaHongKongLimitedMembersrtConsolidatedEntitiesAxis">Investment holding</ix:nonNumeric></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><ix:nonNumeric name="imab:EntityIncorporationCountryStateName" contextRef="P01_01_2020To12_31_2020_IMabShanghaiMembersrtConsolidatedEntitiesAxis">PRC</ix:nonNumeric></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" contextRef="P01_01_2020To12_31_2020_IMabShanghaiMembersrtConsolidatedEntitiesAxis" format="ixt:datemonthdayyearen">August 24, 2016</ix:nonNumeric></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn12_31_2020_IMabShanghaiMembersrtConsolidatedEntitiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: top; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: top;">&#160;<br/> &#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities" contextRef="P01_01_2020To12_31_2020_IMabShanghaiMembersrtConsolidatedEntitiesAxis">Research and<br/> development of<br/> innovative medicines</ix:nonNumeric></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;<br/> &#160;<br/> &#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-tech</div> (Tianjin) Co., Ltd.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(&#8220;I-Mab</div> Tianjin&#8221;)</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><ix:nonNumeric name="imab:EntityIncorporationCountryStateName" contextRef="P01_01_2020To12_31_2020_IMabtianjinMembersrtConsolidatedEntitiesAxis">PRC</ix:nonNumeric></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" contextRef="P01_01_2020To12_31_2020_IMabtianjinMembersrtConsolidatedEntitiesAxis" format="ixt:datemonthdayyearen">July 15, 2017</ix:nonNumeric></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn12_31_2020_IMabtianjinMembersrtConsolidatedEntitiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: top; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: top;">&#160;<br/> &#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities" contextRef="P01_01_2020To12_31_2020_IMabtianjinMembersrtConsolidatedEntitiesAxis">Research and<br/> development of<br/> innovative medicines</ix:nonNumeric></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;<br/> &#160;<br/> &#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma US Ltd.</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><ix:nonNumeric name="imab:EntityIncorporationCountryStateName" contextRef="P01_01_2020To12_31_2020_ImabbiopharmaUsLtdMembersrtConsolidatedEntitiesAxis">U.S.</ix:nonNumeric></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" contextRef="P01_01_2020To12_31_2020_ImabbiopharmaUsLtdMembersrtConsolidatedEntitiesAxis" format="ixt:datemonthdayyearen">February 28, 2018</ix:nonNumeric></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn12_31_2020_ImabbiopharmaUsLtdMembersrtConsolidatedEntitiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: top; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: top;">&#160;<br/> &#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities" contextRef="P01_01_2020To12_31_2020_ImabbiopharmaUsLtdMembersrtConsolidatedEntitiesAxis">Research and<br/> development of<br/> innovative medicines</ix:nonNumeric></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;<br/> &#160;<br/> &#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20394948"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. PRINCIPAL ACCOUNTING POLICIES </div></div></div> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.1 Basis of presentation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant accounting policies followed by the Group in the preparation of the accompanying consolidated financial statements are summarized below. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ConsolidationPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.2 Basis of consolidation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All inter-company balances and transactions have been eliminated in consolidation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group consolidates entities in which it has a controlling financial interest based on either the variable interest entity (VIE) or voting interest model. The Group is required to first apply the VIE model to determine whether it holds a variable interest in an entity, and if so, whether the entity is a VIE. If the Group determines it does not hold a variable interest in a VIE, it then applies the voting interest model. Under the voting interest model, the Group consolidates an entity when it holds a majority voting interest in an entity. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for investments in which it has significant influence but not a controlling financial interest using the equity method of accounting (see Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">VIE Model </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An entity is considered to be a VIE if any of the following conditions exist: (a)&#160;the total equity investment at risk is not sufficient to permit the entity to finance its activities without additional subordinated financial support, (b)&#160;the holders of the equity investment at risk, as a group, lack either the direct or indirect ability through voting rights or similar rights to make decisions that have a significant effect on the success of the entity or the obligation to absorb the entity&#8217;s expected losses or right to receive the entity&#8217;s expected residual returns, or (c)&#160;the voting rights of some equity investors are disproportionate to their obligation to absorb losses of the entity, their rights to receive returns from an entity, or both and substantially all of the entity&#8217;s activities either involve or are conducted on behalf of an investor with disproportionately few voting rights. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the VIE model, limited partnerships are considered VIE unless the limited partners hold substantive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">kick-out</div> or participating rights over the general partner. The Group consolidates entities that are VIEs when the Group determines it is the primary beneficiary. Generally, the primary beneficiary of a VIE is a reporting entity that has (a)&#160;the power to direct the activities that most significantly affect the VIE&#8217;s economic performance, and (b)&#160;the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the Group determined that the one entity subject to the consolidation guidance is a VIE for which the Group is not the primary beneficiary. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED) </div></div></div></div></div></div><ix:continuation id="TextSelection_20394948" continuedAt="TextSelectionAppend_20394948_1"><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-align: left;"><div style="margin-block: 0em; line-height: 8pt;">&#160;</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.3 Use of estimates </div></div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally, estimates are used in determining items such as fair value measurements of wealth management products, warrants and put right liabilities, impairment of accounts receivables, contract assets, other receivables, long-lived assets, intangible assets and goodwill, useful lives of property, equipment and software, recognition of right-of-use assets and lease liabilities, variable consideration in collaboration revenue arrangements, determination of the standalone selling price of each performance obligation in the Company&#8217;s revenue arrangements, valuation of share-based compensation arrangements and deferred tax assets valuation allowances. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.</div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20394816"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.4 Fair value measurements </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial assets and liabilities of the Group primarily comprise of cash and cash equivalents, restricted cash, short-term investments, other financial assets, accounts receivable, contract assets, other receivables, short-term borrowings, accruals and other payables, warrant liabilities and put right liabilities. As of December 31, 2019 and 2020, except for short-term investments, other financial assets and put right liabilities, the carrying values of these financial assets and liabilities approximated their fair values because of their generally short maturities. The Group reports short-term investments, other financial assets and put right liabilities at fair value at each balance sheet date and changes in fair value are reflected in the consolidated statements of comprehensive income (loss).&#160;</div> </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1<div style="display:inline;">3</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED) </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.4 Fair value measurements (continued) </div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_20394948_1" continuedAt="TextSelectionAppend_20394948_2"><ix:continuation id="TextSelection_20394816" continuedAt="TextSelectionAppend_20394816_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group measures its financial assets and liabilities using inputs from the following three levels of the fair value hierarchy. The three levels are as follows: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 inputs are unadjusted quoted prices in active markets for identical assets that the management has the ability to access at the measurement date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 inputs include quoted prices for similar assets in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 includes unobservable inputs that reflect the management&#8217;s assumptions about the assumptions that market participants would use in pricing the asset. The management develops these inputs based on the best information available, including the own data.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Assets and liabilities measured at fair value on a recurring basis </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Group measures its short-term investments, other financial assets, warrant liabilities, and put right liabilities at fair value on a recurring basis. As the Group&#8217;s short-term investments, other financial assets, warrant liabilities and put right liabilities are not traded in an active market with readily observable prices, the Group uses significant unobservable inputs to measure the fair value of short-term investments, other financial assets, warrant liabilities and put right liabilities. These instruments are categorized in the Level 3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement.</div></div></div> <ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Group&#8217;s financial assets and liabilities measured and recorded at fair value on a recurring basis as of December&#160;31, 2019 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Active&#160;market</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Observable&#160;input</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">observable&#160;input</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">32,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="PAsOn12_31_2019_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">32,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Active&#160;market<br/> (Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Observable&#160;input<br/> (Level 2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">observable&#160;input<br/> (Level 3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">31,530</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">31,530</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Put right liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:PutRightLiabilities" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">116,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:PutRightLiabilities" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">116,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1<div style="display:inline;">4</div></div></div> </div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED) </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.4 Fair value measurements (continued) </div></div></div></div> <ix:continuation id="TextSelectionAppend_20394948_2" continuedAt="TextSelectionAppend_20394948_3"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_20394816_1"><ix:nonNumeric name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The roll forward of major Level&#160;3 financial assets <div style="letter-spacing: 0px; top: 0px;;display:inline;">a</div>nd financial liabilities are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Short-term<br/> investments</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Other&#160;financial<br/> assets</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Warrant<br/> liabilities</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Put right<br/> liabilities</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair&#160;value&#160;of&#160;Level&#160;3&#160;financial&#160;asset&#160;and&#160;liabilities&#160;as&#160;of&#160;December&#160;31,&#160;2018</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2018_OtherFinancialAssetsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">255,958</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2018_WarrantLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,618</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" contextRef="P01_01_2019To12_31_2019_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">134,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposal of short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="imab:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">102,703</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposal of other financial assets due to Termination Agreement</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" contextRef="P01_01_2019To12_31_2019_OtherFinancialAssetsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">256,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value changes</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">703</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" contextRef="P01_01_2019To12_31_2019_OtherFinancialAssetsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">42</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" contextRef="P01_01_2019To12_31_2019_WarrantLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,644</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="imab:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences" contextRef="P01_01_2019To12_31_2019_WarrantLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair&#160;value&#160;of&#160;Level&#160;3&#160;financial&#160;assets&#160;and&#160;liabilities&#160;as&#160;of&#160;December&#160;31,&#160;2019</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2019_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">32,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2019_OtherFinancialAssetsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2019_WarrantLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" contextRef="P01_01_2020To12_31_2020_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,491,991</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposal of short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imab:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments" contextRef="P01_01_2020To12_31_2020_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,503,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant of put right liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" contextRef="P01_01_2020To12_31_2020_PutRightLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">124,321</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value changes</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" contextRef="P01_01_2020To12_31_2020_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">11,288</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" contextRef="P01_01_2020To12_31_2020_PutRightLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,024</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="imab:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences" contextRef="P01_01_2020To12_31_2020_PutRightLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,291</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Level&#160;3 financial assets and liabilities as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2020_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">31,530</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2020_PutRightLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">116,006</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>&#160;for additional information about Level&#160;3 put right liabilities measured at fair value on a recurring basis for the year ended December&#160;31, 2020. </div></div> </ix:continuation></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED) </div></div></div> <ix:continuation id="TextSelectionAppend_20394948_3" continuedAt="TextSelectionAppend_20394948_4"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.5 Foreign currency translation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group uses Chinese Renminbi (&#8220;RMB&#8221;) as its reporting currency. The United States Dollar (&#8220;US$&#8221;) is the functional currency of the Group&#8217;s entities incorporated in the Cayman Islands, the United States of America (&#8220;U.S.&#8221;) and Hong Kong, the Australia Dollar (&#8220;AUD&#8221;) is the functional currency of the Group&#8217;s entity incorporated in Australia and the RMB is the functional currency of the Company&#8217;s PRC subsidiaries. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transactions denominated in other than the functional currencies are translated into the functional currency of the entity at the exchange rates prevailing on the transaction dates. Assets and liabilities denominated in other than the functional currencies are translated at the balance sheet date exchange rate. The resulting exchange differences are recorded in the consolidated statements of comprehensive income (loss). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements of the Group are translated from the functional currency to the reporting currency, RMB. Assets and liabilities of the subsidiaries are translated into RMB using the exchange rate in effect at each balance sheet date. Income and expenses are translated at the average exchange rates prevailing for the year. Foreign currency translation adjustments arising from these are reflected in the accumulated other comprehensive <div style="letter-spacing: 0px; top: 0px;;display:inline;">income (loss). The exchange rates&#160;</div>used for translation on December&#160;31, 2019 and 2020 were US$1.00 = RMB<ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="PAsOn12_31_2019_PeoplesBankOfChinaMemberIMABBankBranchAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:numdotdecimal">6.9762</ix:nonFraction> and RMB<ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="PAsOn12_31_2020_PeoplesBankOfChinaMemberIMABBankBranchAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:numdotdecimal">6.5249</ix:nonFraction> respectively, representing the index rates stipulated by the People&#8217;s Bank of China. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translations of balances in the consolidated balance sheets, consolidated statements of comprehensive income (loss), consolidated statements of changes in shareholders&#8217; equity (deficit) and consolidated statements of cash flows from RMB into US$ as of and for the year ended December&#160;31, 2020 are solely for the convenience of the readers and were calculated at the rate of US$1.00=RMB<ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="PAsOn12_31_2020_FederalReserveBankOfNewYorkMemberIMABBankBranchAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:numdotdecimal">6.5250</ix:nonFraction>, representing the noon buying rate in The City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New York on December&#160;31, 2020. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on December&#160;31, 2020, or at any other rate. The US$ convenience translation is not required under U.S. GAAP and all US$ convenience translation amounts in the accompanying consolidated financial statements are unaudited. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.6 Cash and cash equivalents </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Group considers all highly liquid investments with an original maturity date of three months or less at the date of purchase to be cash equivalents. </div></div></ix:nonNumeric> <div style="text-align: left;"><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.7 Restricted cash </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash consists of the guarantee deposits held in a designated bank account as security deposits under bank borrowing agreements. Such restricted cash will be released when the Group repays the related bank borrowings. The Group has presented restricted cash separately from cash and cash equivalents in the consolidated balance sheets. </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash as reporte<div style="display:inline;">d</div>&#160;in the consolidated statement of cash flows are presented separately on the consolidated balance sheet as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December 31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,137,473</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">4,758,778</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">55,810</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,193,283</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">4,758,778</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td> </tr> </table> </ix:nonNumeric> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:TradeAndOtherAccountsReceivablePolicy" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.8 Accounts receivable </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable are stated at amortized cost less allowance for credit losses. The allowance for credit losses reflects the best estimate of future losses over the contractual life of outstanding accounts receivable and is determined on the basis of historical experience, specific allowances for known troubled accounts, other currently available information including customer financial condition, and both current and forecasted economic conditions. </div></div></div></ix:nonNumeric><ix:nonNumeric name="imab:ShortTermInvestmentsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.9 Short-term investments </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments represent the investments issued by commercial banks or other financial institutions with a variable interest rate indexed to the performance of underlying assets within one year. These investments are stated at fair value. Changes in the fair value are reflected in the consolidated statements of comprehensive income (loss). </div></div></div></ix:nonNumeric></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)</div></div></div></div> </div> </div> <ix:continuation id="TextSelectionAppend_20394948_4" continuedAt="TextSelectionAppend_20394948_5"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.10 Property, equipment and software&#160;</div> </div></div></div></div> <ix:nonNumeric name="imab:ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the following estimated useful lives, taking into account of any estimated residual value: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 46%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2020To12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">3</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2020To12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_SoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">1</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_SoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">5</ix:nonNumeric> years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Office furniture and equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2020To12_31_2020_OfficeFurnitureAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">5</ix:nonNumeric> years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2020To12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Lesser of useful life or lease term</ix:nonNumeric></td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group recognizes the gain or loss on the disposal of property, equipment and software in the consolidated statements of comprehensive income (loss). </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-align: left;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.11 Intangible assets </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets acquired in a business combination that are used in research and development activities, or in-process research and development (IPR&amp;D) intangible assets, are considered indefinite lived until the completion or abandonment of the associated research and development efforts. During the period that those assets are considered indefinite lived, they are not amortized but are tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. If after assessing the totality of events and circumstances and their potential effect on significant inputs to the fair value determination the Group determines that it is not more likely than not that the indefinite-lived intangible is impaired, then the entity shall calculate the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value of the asset with its carrying amount. If the carrying amount exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. For IPR&amp;D assets, the impairment loss is recognized in research and development expenses in the consolidated statements of comprehensive income (loss).</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets with finite useful lives are amortized over their useful lives. The useful life of an intangible asset is the period over which the asset is expected to contribute directly or indirectly to the future cash flows of the Group. The Group uses the straight-line amortization method when the economic benefits of the intangible assets are consumed or otherwise used up cannot be reliably determined. In particular, the Group amortizes the IPR&amp;D intangible assets with finite useful lives over 10 to 20 years on a straight-line basis. Intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. If circumstances require an intangible asset be tested for possible impairment, the Group first compares undiscounted cash flows expected to be generated by that asset to its carrying amount. If the carrying amount is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. For IPR&amp;D assets, the impairment loss is recognized in research and development expenses in the consolidated statements of comprehensive income (loss).</div></div></div></div> </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-align: left;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.12 Impairment of long-lived assets </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets, such as property, plant, and software, and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. For the years ended December&#160;31, 2019 and 2020, there was no impairment of the value of the Group&#8217;s long-lived assets. </div></div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED) </div></div></div> <ix:continuation id="TextSelectionAppend_20394948_5" continuedAt="TextSelectionAppend_20394948_6"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-align: left;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.13 Goodwill </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The Group allocates the cost of an acquired entity to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price for acquisitions over the fair value of the net assets acquired, including other intangible assets, is recorded as goodwill. Goodwill is not amortized, but impairment of goodwill is tested on at least an annual basis or whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Group&#8217;s reporting unit is less than its carrying amount, including goodwill. The qualitative assessment includes the Group&#8217;s evaluation of relevant events and circumstances affecting the Group&#8217;s single reporting unit, including macroeconomic, industry, market conditions and the Group&#8217;s overall financial performance. If qualitative factors indicate that it is more likely than not that the Group&#8217;s reporting unit&#8217;s fair value is less than its carrying amount, then the Group will perform the quantitative impairment test by comparing the reporting unit&#8217;s carrying amount, including goodwill, to its fair value. If the carrying amount of the reporting unit exceeds its fair value, an impairment loss will be recognized in an amount equal to that excess. For the years ended December&#160;31, 2019 and 2020, the Group determined that there were no indicators of impairment of the goodwill. </div></div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric><ix:nonNumeric name="imab:LongTermInvestmentsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-align: left;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.14 Long-term investments </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s long-term investments include equity investments in an affiliate in which it does not have a controlling financial interest, but has the ability to exercise significant influence over the operating and financial policies of the investee. The investment is accounted for using the equity method of accounting in accordance with ASC topic 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Under the equity method, the Group initially records its investments at fair value. The Group subsequently adjusts the carrying amount of the investment to recognize the Group&#8217;s proportionate share of the equity investee&#8217;s net income or loss after the date of investment. When the liquidation rights and priorities as defined by an equity investment agreement diff<div style="display:inline;">e</div>r from what is reflected by the underlying percentage ownership interests, applying the percentage ownership interest to U.S. GAAP net income in order to determine earnings or losses does not accurately represent the income allocation and cash flow distributions that will ultimately be received by the investors. As such, for this type of investments, the Group uses the Hypothetical Liquidation at Book Value (&#8220;HLBV&#8221;) method for allocating earnings or losses of the equity method investee. The HLBV method is considered as a balance sheet approach. Specifically, a calculation is prepared at each balance sheet date to determine the amount that the Group would receive if an equity investment entity were to liquidate all of its assets (as valued in accordance with U.S. GAAP) and distribute that cash to the investors based on the contractually defined liquidation priorities. The difference between the calculated liquidation distribution amounts at the beginning and the end of the reporting period, after adjusting for capital contributions and distributions, is the Group&#8217;s share of the earnings or losses from the equity investment for the period. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As it relates to the share-based compensation awarded by an equity method investee to its own employees, the Group recognizes its proportionate share of the compensation expense over the vesting period, included in the equity in loss of affiliate in the consolidated statements of comprehensive income (loss). As it relates to the share-based compensation awarded by the Group to the equity method investee employees that are based on the Group&#8217;s stock, when the other investors do not provide proportionate value to the investee or the Group does not receive any consideration, the Group expenses the entire cost associated with the award in the same period the costs are recognized by the investee, to the extent that the Group&#8217;s claim on the investee&#8217;s book value has not been increased. The expenses recognized by the Group is included in the equity in loss of affiliate in the consolidated statements of comprehensive income (loss). </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group evaluates the equity method investment for impairment under ASC 323. An impairment loss on the equity method investments is recognized in losses when the decline in value is determined to be other-than-temporary. No impairment charge was recognized for the year ended December&#160;31, 2020. </div></div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED) </div></div></div><ix:continuation id="TextSelectionAppend_20394948_6" continuedAt="TextSelectionAppend_20394948_7"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="imab:DeferredSubsidyIncomePolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.15 Deferred subsidy income&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred subsidy income consists of deferred income from government grants. Government grants mainly consist of cash subsidies received by the Group&#8217;s subsidiaries in the PRC from local governments as support on expenses relating to certain projects. Grants received with government specified performance obligations are recognized as other income when all the obligations have been satisfied. If such obligations are not satisfied, the Group may be required to refund the subsidy. The Group recorded cash grants</div> of RMB<ix:nonFraction name="us-gaap:GrantsReceivable" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">7,509</ix:nonFraction> and RMB<ix:nonFraction name="us-gaap:GrantsReceivable" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">3,920</ix:nonFraction> and in deferred subsidy income as of December&#160;31, 2020 and 2019 respectively. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20394826"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.16 Revenue recognition&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Group adopted Accounting Standard Codification (&#8220;ASC&#8221;) 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div> (Topic 606) (&#8220;ASC 606&#8221;) for all periods presented. Consistent with the criteria of Topic 606, the Group recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. An the entity performs the following five steps to account for the arrangements that an entity determines are within the scope of ASC 606: (i) identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once a contract is determined to be within the scope of ASC 606 at contract inception, the Group audits the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration revenue </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">At contract inception, we analyze its collaboration arrangements to assess whether they are within the scope of ASC 808,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Collaborative Arrangements</div></div>&#160;(&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, we first determine if the collaboration is deemed to be within the scope of ASC 808. For any units of account that are reflective of a vendor-customer relationship those units of account are accounted for within the scope of ASC 606. For any units of account that are not accounted for under ASC 606 and therefore accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.</div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1<div style="display:inline;">9</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED) </div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.16 Revenue recognition (continued) </div></div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration revenue (continued) </div></div></div></div></div></div></div></div><ix:continuation id="TextSelectionAppend_20394948_7" continuedAt="TextSelectionAppend_20394948_8"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_20394826" continuedAt="TextSelectionAppend_20394826_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s collaborative arrangements may contain more than one unit of account, or performance obligation, such as grant of licenses of intellectual property rights, promises to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. When multiple units of account or performance obligations are identified within the arrangements, the Group must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&#160;In developing the stand-alone selling price for a performance obligation, the Group considers competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">20</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.16 Revenue recognition (continued) </div></div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration revenue (continued) </div></div></div></div> </div> </div> </div> </div> <ix:continuation id="TextSelectionAppend_20394948_8" continuedAt="TextSelectionAppend_20394948_9"> <ix:continuation id="TextSelectionAppend_20394826_1" continuedAt="TextSelectionAppend_20394826_2"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licenses of Intellectual Property:</div></div> Upfront <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> payments for licensing the Group&#8217;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For the license that is determined to be distinct, the Group recognizes revenues in the amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> fees allocated to the license at a point in time, upon which the license is transferred to the licensee and the licensee is able to use and benefit from the license. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Services: </div></div>The portion of the transaction price allocated to research and development services performance obligations is deferred and recognized as revenue over time as delivery or performance of such services provided to the Group&#8217;s customers occurs. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Milestone Payments</div></div>: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any resulting adjustment is recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect the Group&#8217;s reported revenues and earnings in the period of the adjustment. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties</div></div>: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the sales-based royalties or milestone payments relate, the Group recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</div> </ix:continuation> <div style="text-align:left;"><ix:continuation id="TextSelectionAppend_20394826_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract assets and liabilities </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets primarily represent revenue earnings over time that are not yet billable based on the terms of the contracts. The Group does <ix:nonFraction name="us-gaap:CapitalizedContractCostImpairmentLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CapitalizedContractCostImpairmentLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t have impairment losses associated with contracts with customers for the years ended December 31, 2019 and 2020. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities consist of fees invoiced or paid by the Group&#8217;s customers for which the associated performance obligations have not been satisfied and revenue has not been recognized based on the Group&#8217;s revenue recognition criteria described above. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets and contract liabilities are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current in the consolidated balance sheet when the Group expects to complete the related performance obligations and invoice the customers within one year of the balance sheet date, and as long-term when the Group expects to complete the related performance obligations and invoice the customers more than one year out from the balance sheet date. Contract liabilities are classified as current in the consolidated balance sheet when the revenue recognition associated with the related customer payments and invoicing is expected to occur within one year of the balance sheet date and as long-term when the revenue recognition associated with the related customer payments and invoicing is expected to occur in more than one year from the balance sheet date. </div></div></div> </ix:continuation></div> <ix:nonNumeric name="imab:ValueAddedTaxesPolicyPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.17 Value-added-tax (&#8220;VAT&#8221;) recoverable and surcharges&#160;</div></div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Value added tax recoverable represent amounts paid by the Group for purchases. The surcharges (i.e., Urban construction and maintenance tax, educational surtax, local educational surtax), vary from <ix:nonFraction name="imab:VATSurchargesPercent" contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>% to <ix:nonFraction name="imab:VATSurchargesPercent" contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>% of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;value-added-tax&#160;depending</div> on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;tax-payer&#8217;s&#160;location.</div> The deductible input VAT balance is included in the prepayments and other receivables in the consolidated balance sheets, and VAT payable balance is recorded in the accruals and other payables in the consolidated balance sheets. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED) </div></div></div></div> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20394949"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><ix:continuation id="TextSelectionAppend_20394948_9" continuedAt="TextSelectionAppend_20394948_10">2.18 Research and development expenses</ix:continuation> </div></div></div></div></div></ix:nonNumeric></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_20394949" continuedAt="TextSelectionAppend_20394949_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelectionAppend_20394948_10" continuedAt="TextSelectionAppend_20394948_11">Elements of research and development expenses primarily include (1)&#160;payroll and other related expenses of personnel engaged in research and development activities, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(2)&#160;in-licensed</div> patent rights fee of exclusive development rights of drugs granted to the Group, (3)&#160;expenses related to preclinical testing of the Group&#8217;s technologies under development and clinical trials such as payments to contract research organizations (&#8220;CRO&#8221;), investigators and clinical trial sites that conduct the clinical studies, (4)&#160;expenses to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, and (5)&#160;other research and development expenses. Research and development expenses are charged to expenses as incurred when these expenditures are used for the Group&#8217;s research and development activities and have no alternative future uses.</ix:continuation> </div></div> </ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_20394949_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><ix:continuation id="TextSelectionAppend_20394948_11" continuedAt="TextSelectionAppend_20394948_12">The Group has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-commercial</div> milestone payments, are immediately expensed as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development in the period in which they are incurred, provided that the new drug compound does not also include processes or activities that would constitute a &#8220;business&#8221; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. All development expenditures are recognized in profit or loss when incurred, as long as the conditions enabling capitalization of development expenses as an asset have not yet been met.</ix:continuation> </div> </ix:continuation><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><ix:continuation id="TextSelectionAppend_20394948_12" continuedAt="TextSelectionAppend_20394948_13"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.19 Leases&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In accordance with ASC 842 adopted on January&#160;1, 2019, the Group determines if an arrangement is a lease at inception. Operating leases are included in operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets, operating lease liability, and operating lease liability, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> in the Group&#8217;s consolidated balance sheets. The Group does not have any finance leases since the adoption date. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROU assets represent the Group&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Group&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. When determining the lease term, the Group includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Group&#8217;s leases do not provide an implicit rate, the Group uses its incremental borrowing rate, which it calculates based on the credit quality of the Group and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group has elected to adopt the following lease policies in conjunction with the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02:</div> (i) elect for each lease not to separate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components from lease components and instead to account for each separate lease component and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components associated with that lease component as a single lease component; (ii)&#160;for leases that have lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Group elected not to apply ASC 842 recognition requirements; and (iii)&#160;the Group elected to apply the package of practical expedients for existing arrangements entered into prior to January&#160;1, 2019 to not reassess (a)&#160;whether an arrangement is or contains a lease, (b)&#160;the lease classification applied to existing leases, and (c)&#160;initial direct costs. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the adoption of ASC 842, on January&#160;1, 2019, the Group recorded an impact of RMB<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn01_01_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">13,100</ix:nonFraction> on its assets and RMB<ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn01_01_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">11,333</ix:nonFraction> on its liabilities for the recognition of operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use-assets</div></div></div> and operating lease liabilities, respectively, which are primarily related to the lease of the Group&#8217;s offices and warehouses. The adoption of ASC 842 did not have a material impact on the Group&#8217;s results of operations or cash flows. </div> </ix:continuation></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_20394948_13" continuedAt="TextSelectionAppend_20394948_14"><ix:nonNumeric name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.20 Comprehensive income (loss)</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive income (loss) is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220,&#160;Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as components of comprehensive income (loss) be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Group&#8217;s comprehensive income (loss) includes net income (loss) and foreign currency translation adjustments, which are presented in the consolidated statements of comprehensive income (loss). </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.21 Share-based compensation&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group grants restricted shares and stock options to eligible employees and accounts for share-based compensation in accordance with ASC 718, Compensation&#8212;Stock Compensation.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employees&#8217; share-based compensation awards, if equity-classified, are measured at the grant date fair value of the awards and are recognized as expenses over the requisite period of the award, which is generally the vesting term of share-based payment awards.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation in relation to the restricted shares is measured based on the fair market value of the Group&#8217;s ordinary shares at the grant date of the award. Prior to the listing, estimation of the fair value of the Group&#8217;s ordinary shares involves significant assumptions that might not be observable in the market, and a number of complex and subjective variables, including discount rate, and subjective judgments regarding the Group&#8217;s projected financial and operating results, its unique business risks, the liquidity of its ordinary shares and its operating history and prospects at the time the grants are made. Share-based compensation in relation to the share options is estimated using the Binominal Option Pricing Model. The determination of the fair value of share options is affected by the share price of the Group&#8217;s ordinary shares as well as the assumptions regarding a number of complex and subjective variables, including the expected share price volatility, risk-free interest rate, exercise multiple and expected dividend yield. In addition, the forfeiture rate is estimated based on an analysis of the Group&#8217;s actual forfeitures and the appropriateness of the forfeiture rate will continue to be evaluated based on the actual forfeiture experience, analysis of employee turnover and other factors. The fair value of these awards was determined with the assistance from an independent third-party valuation firm. </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="display:inline;">3</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_20394948_14" continuedAt="TextSelectionAppend_20394948_15"><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.22 Income taxes&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Group accounts for income taxes under the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates that expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded if it is more likely than not that some portion or all of the deferred income tax assets will not be utilized in the foreseeable future.&#160;</div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group evaluates its uncertain tax positions using the provisions of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-10,&#160;Income</div> Taxes, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Group recognizes in the financial statements the benefit of a tax position which is &#8216;&#8216;more likely than not&#8217;&#8217; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Group&#8217;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.23 Borrowings&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost. Any difference between the proceeds (net&#160;of transaction costs) and the redemption value is recognized as interest expense in the consolidated statements of comprehensive income (loss) over the period of the borrowings, using the effective interest method. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:BusinessCombinationsPolicy" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.24 Business combination&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group accounts for its business combinations using the acquisition method of accounting in accordance with ASC topic 805,&#160;Business Combinations&#160;(&#8220;ASC 805&#8221;). The acquisition method of accounting requires all of the following steps: (i)&#160;identifying the acquirer, (ii)&#160;determining the acquisition date, (iii)&#160;recognizing and measuring the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree, and (iv)&#160;recognizing and measuring goodwill or a gain from a bargain purchase. The consideration transferred in a business combination is measured as the aggregate of the fair values at the date of exchange of the assets given, liabilities incurred, and equity instruments issued as well as the contingent considerations and all contractual contingencies as of the acquisition date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed and intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets may include, but are not limited to, future expected cash flows from acquired assets, timing and probability of success of clinical events and regulatory approvals, and assumptions on useful lives of the patents and discount rates. Management&#8217;s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Additional information, such as that related to income tax and other contingencies, existing as of the acquisition date but unknown to us may become known during the remainder of the measurement period, not to exceed one year from the acquisition date, which may result in changes to the amounts and allocations recorded. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions that do not meet the accounting definition of a business combination are accounted for as asset acquisitions. For transactions determined to be asset acquisitions, the Group allocates the total cost of the acquisition, including transaction costs, to the net assets acquired based on their relative fair values. </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="display:inline;">4</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_20394948_15" continuedAt="TextSelectionAppend_20394948_16"><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.25 Segment information&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with ASC 280,&#160;Segment Reporting, the Group&#8217;s chief operating decision maker, the Chief Executive Officer, reviews the consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for the purpose of internal reporting. As the Group&#8217;s long-lived assets are substantially located in and derived from the PRC, no geographical segments are presented. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.26 Income (loss) per share&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Basic income (loss) per share is computed by dividing net income (loss) attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period using the two-class method. Under the two-class method, the net income (loss) is allocated between ordinary shares and other participating securities based on their participating rights. Net income (loss) is not allocated to other participating securities if based on their contractual terms they are not obligated to share in the income (loss). Diluted income (loss) per share is calculated by dividing net income (loss) attributable to ordinary shareholders by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of shares issuable upon the conversion of the preferred shares using the if-converted method, shares issuable upon the issuance of ordinary shares to be issued to Everest using the if-converted method, shares issuable upon the conversion of the convertible promissory notes using the if-converted method, shares issuable upon the exercise of share options using the treasury stock method, shares issuable upon the issuance of ordinary shares for restricted shares units using the treasury stock method, and shares issuable upon the exercise of warrants using the treasury stock method. Ordinary equivalent shares are not included in the denominator of the diluted income (loss) per share calculation when inclusion of such shares would be anti-dilutive.</div> </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20394810"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.27 Adopted accounting pronouncements&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13&#8221;).</div> This guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability. In November 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-19,</div> Codification Improvements to Topic 326, Financial Instruments-Credit Losses (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-19&#8221;),</div> which clarifies certain topics included within ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13.</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> and ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-19</div> are effective for the annual reporting period beginning after December&#160;15, 2019, including interim periods within that reporting period. The impact of this ASU to the consolidated financial statements is immaterial. The Group elected to adopt this ASU and applied this guidance retrospectively to all periods presented. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In January 2017, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2017-04,</div> Intangibles&#8212;Goodwill and Other (Topic 350), which simplifies the subsequent measurement of goodwill by removing the second step of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-step</div> impairment test. The amendment requires an entity to perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. A goodwill impairment will be the amount by which a reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The Group adopted this ASU on January&#160;1, 2020 and the adoption of this ASU does not have a material impact to its consolidated financial statements. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In August 2018 the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2018-13,</div> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January&#160;1, 2020. </div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="display:inline;">5</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED) </div></div></div><ix:continuation id="TextSelectionAppend_20394948_16"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.27 Adopted accounting pronouncements (continued)&#160;</div> </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_20394810"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In November 2018 the FASB issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASU&#160;No.&#160;2018-18,&#160;Collaborative</div> Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This standard makes targeted improvements for collaborative arrangements as follows: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, Revenue from Contracts with Customers, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Adds&#160;unit-of-account&#160;guidance</div></div> to ASC 808, Collaborative Arrangements, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and </div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This standard became effective for the Group on January&#160;1, 2020. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings. Since the Group&#8217;s all relevant units of accounts were accounted for under ASC 606, the adoption of this ASU does not have a material impact to the Group&#8217;s consolidated financial statements, with no adjustment to its opening retained earnings. </div></div> </ix:continuation><ix:nonNumeric name="imab:NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.28 &#160; &#160; Recent accounting pronouncements&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, the FASB issued ASU 2019-12-Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for the Company beginning on January 1, 2022. Early adoption of the amendments is permitted. The Company is currently evaluating the impact of ASU 2019-12 on its consolidated financial statements.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In January 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-01,</div> Investments &#8211; Equity Securities (Topic 321), Investments &#8211; Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying Interactions between Topic 321, Topic 323, and Topic 815. ASU 2020-01addresses accounting for the transition into and out of the equity method and provides guidance on whether equity method accounting would be applied to certain purchased options and forward contracts upon settlement. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-01</div> is effective for the Group&#8217;s annual periods beginning after December&#160;15, 2021. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-01</div> will be applied prospectively. Early adoption is permitted. The Group is currently evaluating the effect the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-01</div> will have on its consolidated financial statements. </div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="display:inline;">6</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <ix:nonNumeric name="imab:AccountsReceivableAndContractAssetsTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. ACCOUNTS RECEIVABLE AND CONTRACT ASSETS </div></div></div></div> <ix:nonNumeric name="imab:ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable and contract assets, net of allowance for credit losses, consisted of the following: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December 31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, gross</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">130,498</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for credit losses</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">130,498</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December 31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets, gross</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetGrossCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">227,391</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetGrossCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">34,849</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for credit losses</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLossCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" xsi:nil="true"></ix:nonFraction>&#8212;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets, net</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">227,391</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">34,849</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No allowance for credit losses was recorded as of December&#160;31, 2019 and 2020. </div></div></div></ix:nonNumeric> <ix:nonNumeric name="imab:PrepaidexpensesandotherreceivablestextblockTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20792051"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. PREPAYMENTS AND OTHER RECEIVABLES </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><ix:continuation id="TextSelection_20792051">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;RMB&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepayments:</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Prepayments to CRO vendors</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Supplies" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">78,740</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Supplies" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">83,140</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Supplies" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,742</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Prepayments for other services</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">880</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">391</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receivables due from employees <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DueFromEmployeesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">16,201</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Receivables due from an affiliate (Note 2<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>)</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#8212;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><ix:nonFraction name="us-gaap:DueFromAffiliateCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">21,212</ix:nonFraction></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><ix:nonFraction name="us-gaap:DueFromAffiliateCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,251</ix:nonFraction></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Value-added tax recoverable</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="imab:ValueaddedTaxRecoverable" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">12,517</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="imab:ValueaddedTaxRecoverable" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">63,664</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="imab:ValueaddedTaxRecoverable" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,757</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rental deposits</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">546</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,766</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">271</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest receivables</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:InterestReceivable" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">764</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:InterestReceivable" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">236</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:InterestReceivable" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Others</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">26,388</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">22,899</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,509</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 68%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 68%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">136,036</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">195,467</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,957</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 68%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The balance mainly represents the receivables due from <div style="letter-spacing: 0px; top: 0px;;display:inline;">certain&#160;</div>employees, arose from the Group&#8217;s obligation to pay the withholding individual income tax (&#8220;IIT&#8221;) for those employees&#8217; stock option activities. The balance was collected by the Group in January 2020. </div></div> </td> </tr> </table> </ix:continuation></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-27 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">N<div style="letter-spacing: 0px; top: 0px;;display:inline;">O</div>TES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. PROPERTY, EQUIPMENT AND SOFTWARE </div></div></div></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, equipment and software consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipmen<div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2019_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">24,265</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">30,808</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvement</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2019_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">11,856</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">13,842</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,121</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2019_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">10,220</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">9,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,531</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Office furniture and equipment</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2019_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,526</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,531</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property, equipment and software</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">47,867</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">56,171</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,608</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">18,221</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">30,899</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,735</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net book value</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:PropertyPlantAndequipmentnetExcludingConstructionInProcess" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">29,646</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:PropertyPlantAndequipmentnetExcludingConstructionInProcess" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">25,272</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:PropertyPlantAndequipmentnetExcludingConstructionInProcess" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,873</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in <div style="letter-spacing: 0px; top: 0px;;display:inline;">progress</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ConstructionInProgressGross" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">423</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:ConstructionInProgressGross" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total net book value of property, equipment and software</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">30,069</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">25,272</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,873</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total amounts charged to the consolidated statements of comprehensive income/(loss) for depreciation and amortization expenses amounted to approximately RMB<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">6.7</ix:nonFraction>&#160;million, RMB<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">9.8</ix:nonFraction>&#160;million and RMB<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">12.7</ix:nonFraction>&#160;million, for the years ended December&#160;31, 2018, 2019 and 2020, respectively. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:LeasesOfLesseeDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20786830"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div>. LEASES </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the Company has operating leases recorded on its balance sheet for certain office spaces and facilities that expire on various dates through 2023. The Group does not plan to cancel the existing lease agreements for its existing facilities prior to their respective expiration dates. When determining the lease term, the Group includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. All of the Group&#8217;s leases qualify as operating leases. </div></div> <ix:nonNumeric name="imab:OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information related to operating leases as of December&#160;31, 2019 and 2020 is as follows (in thousands, except for percentages and years). </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">16,435</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">14,997</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, current</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">6,807</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">8,058</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,235</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease liabilities, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">7,492</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,542</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">849</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term (years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2019" format="ixt-sec:durmonth">2.4</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2020" format="ixt-sec:duryear">1.7</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2020" format="ixt-sec:duryear">1.7</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2019" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information related to operating lease activity during the years ended December&#160;31, 2019 and 2020 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="imab:ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Year Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease rental expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Amortization of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:OperatingLeaseRightOfUseAssetAmortization" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:OperatingLeaseRightOfUseAssetAmortization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">8,158</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:OperatingLeaseRightOfUseAssetAmortization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expense for short-term leases within 12 months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">592</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest of lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:OperatingLeaseInterestExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">543</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:OperatingLeaseInterestExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">679</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:OperatingLeaseInterestExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">104</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">6,395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">8,837</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,354</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">6</div>. LEASES (CONTINUED) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20786848"><ix:continuation id="TextSelection_20786830" continuedAt="TextSelectionAppend_20786830_1">Maturities of lease liabilities were as follows:</ix:continuation></ix:nonNumeric> </div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelectionAppend_20786830_1"><ix:continuation id="TextSelection_20786848">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">8,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">837</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">82</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total undiscounted lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">14,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,301</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">13,600</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,084</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation></ix:continuation><div style="clear: both; max-height: 0px; background: none;"></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="display:inline;">9</div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:IntangibleAssetsDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">7</div>. INTANGIBLE ASSETS </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets as of December&#160;31, 2019 and 2020 are summarized as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;carrying&#160;amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net carrying amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D TJ103</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">11,670</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,556</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">10,114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D TJ101</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_IprAndDTj101MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">110,330</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020_IprAndDTj101MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">110,330</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020_IprAndDTj101MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,909</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">122,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,556</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">120,444</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross carrying amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;carrying&#160;amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 51%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 51%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D TJ103</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2019_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">11,670</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">11,670</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,788</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 51%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">IPR&amp;D TJ102</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2019_IprAndDTj102MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">26,844</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019_IprAndDTj102MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">26,844</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019_IprAndDTj102MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 51%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D TJ101</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2019_IprAndDTj101MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">110,330</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019_IprAndDTj101MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">110,330</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019_IprAndDTj101MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,909</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 51%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 51%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">148,844</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">148,844</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,811</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 51%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The three IPR&amp;D assets (TJ103, TJ101, and TJ102) were acquired from the business combination of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin and its subsidiaries including Chengdu Tasgen <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-Tech</div> Co., Ltd. and Shanghai Tianyunjian <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-Tech</div> Co., Ltd. (together the &#8220;Tasgen Group&#8221;) in 2017. The licensor of these IPR&amp;D assets was Genexine, Inc. The gross carrying amounts represent the fair value assigned to the respective research and development assets. At the date of acquisition, all three assets had not reached technological feasibility. They were considered indefinite lived. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">IPR&amp;D related to TJ103 was subsequently determined to have a finite useful life as a result of an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> arrangement. Consequently, the Group uses the straight-line method to amortize the asset. The amortization for the years ended December&#160;31, 2018, 2019 and 2020 was <ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2018To12_31_2018_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>nil, <ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2019To12_31_2019_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>nil, and RMB<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2020To12_31_2020_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,556</ix:nonFraction> respectively, recognized as research and development expenses in the consolidated statements of comprehensive income (loss). The estimated amortization expense for each of the five succeeding fiscal years is RMB<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">778</ix:nonFraction>. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On September 15, 2020, I-Mab Hong Kong and Genexine, Inc. entered into amendments to Intellectual Property License Agreement with I-Mab Hangzhou to assign and transfer all the rights and obligations related to TJ102 to I-Mab Biopharma (Hangzhou) Limited (&#8220;I-Mab Hangzhou&#8221;), pursuant to an equity transfer and investment agreement entered into between I-Mab Hong Kong and various parties (see Note <div style="display:inline;">9</div>).</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2019 and 2020, there was <ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> impairment of the value of the Group&#8217;s intangible assets. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">30</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:GoodwillDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div>. GOODWILL </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;15, 2017, the Group acquired <ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="PAsOn07_15_2017_TasgenGroupMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">66.67</ix:nonFraction>% of the equity interests in the Tasgen Group by issuing convertible preferred shares, and controlled the board of directors and business of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin since then. Tasgen Group is principally engaged in the research and development of innovative medicines and the Group acquired Tasgen Group for its research team, technical experience, and IPR&amp;D pipeline assets (see Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>). As of December&#160;31, 2019 and 2020, the goodwill of RMB<ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">162,574</ix:nonFraction></ix:nonFraction> (US$<ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,916</ix:nonFraction>) represented the goodwill generated from the aforementioned acquisition of Tasgen Group and the business of Tasgen Group was fully integrated into the Company after the acquisition. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2019 and 2020, the Group performed a qualitative assessment by evaluating relevant events and circumstances that would affect the Group&#8217;s single reporting unit and did not note any indicator that it is more likely than not that the fair value of the Group&#8217;s reporting unit is less than its carrying amount and therefore the Group&#8217;s goodwill was <ix:nonFraction name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t impaired. </div></div></ix:nonNumeric><ix:nonNumeric name="imab:InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20395951"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>. INVESTMENT ACCOUNTED FOR USING THE EQUITY METHOD AND PUT RIGHT LIABILITIES</div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Investment accounted for using the equity method </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou, incorporated on June&#160;16, 2019, was a wholly owned subsidiary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong with registered capital of US$<ix:nonFraction name="imab:RegisteredCapitalOfSubsidiary" contextRef="PAsOn06_16_2019_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction>&#160;million, which was paid up by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong on September&#160;14, 2020. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On September&#160;15, 2020 (the &#8220;Closing Date&#8221;), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong entered into an equity transfer and investment agreement (the &#8220;SPA&#8221;) with (i)&#160;a limited partnership jointly established by the management of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou to hold restricted equity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou issued to the management (&#8220;Management Holdco&#8221;), (ii) a limited partnership established to hold the shares of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou for future equity incentive plan (&#8220;ESOP Holdco&#8221;) and (iii)&#160;a group of domestic investors in China (&#8220;Domestic Investors&#8221;). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the terms of the SPA, </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(i)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong agreed to assign all rights and obligations/ownership of certain drug candidates in different stages of development (&#8220;Target Pipelines&#8221;) to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou as of the Closing Date as well as to transfer employment of a team of designated management/workforce to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou. The Target Pipelines were evaluated by an independent valuer, with a total value of US$<ix:nonFraction name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized" contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>&#160;million as of the Closing Date; </div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(ii)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Management Holdco would acquire <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis_ManagementHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>% of the equity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong with no consideration. The <div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div>% equity is represented by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou&#8217;s registered capital of US$<ix:nonFraction name="imab:RegisteredCapitalOfSubsidiary" contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis_ManagementHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction>&#160;million, and that after acquiring such equity, Management Holdco is committed to pay US$<ix:nonFraction name="us-gaap:ProceedsFromContributionsFromAffiliates" contextRef="P01_01_2020To12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis_ManagementHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction>&#160;million in cash to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou to fulfil its capital contribution obligations in a period of four years starting from the Closing Date; </div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(iii)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">ESOP Holdco would acquire <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn12_31_2020_EsopHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>% of the equity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong with no consideration. The <div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>% equity is represented by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou&#8217;s registered capital of US$<ix:nonFraction name="us-gaap:ProceedsFromContributionsFromAffiliates" contextRef="P01_01_2020To12_31_2020_EsopHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction>&#160;million. All of such equity would be used for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou&#8217;s future equity incentive plan. </div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(iv)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Domestic Investors would acquire a total of <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn12_31_2020_DomesticInvestorsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>% of the equity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong with no consideration. The <div style="letter-spacing: 0px; top: 0px;;display:inline;">40</div>% equity is represented by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou&#8217;s registered capital of US$<ix:nonFraction name="imab:RegisteredCapitalOfSubsidiary" contextRef="PAsOn12_31_2020_DomesticInvestorsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction>&#160;million, and after acquiring such equity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou, Domestic Investors would pay US$<ix:nonFraction name="us-gaap:ProceedsFromContributionsFromAffiliates" contextRef="P01_01_2020To12_31_2020_DomesticInvestorsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">120</ix:nonFraction>&#160;million collectively in cash to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou to fulfil its capital contribution obligations. </div></td></tr></table> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>. INVESTMENT ACCOUNTED FOR USING THE EQUITY METHOD AND PUT RIGHT LIABILITIES </div></div></div></div><ix:continuation id="TextSelection_20395951" continuedAt="TextSelectionAppend_20395951_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Investment accounted for using the equity method (continued) </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Upon closing of the SPA, the registered capital of I-Mab Hangzhou remained to be</div>&#160;US$<ix:nonFraction name="us-gaap:ProceedsFromContributionsFromAffiliates" contextRef="P01_01_2020To12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million. As of December 31, 2020, among the total&#160;</div> <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020_ManagementHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">25,500,000</ix:nonFraction> outstanding shares of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou, <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">13,500,000</ix:nonFraction> shares were held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> H<div style="letter-spacing: 0px; top: 0px;;display:inline;">ong Kong</div>&#160;while the remaining <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020_DomesticInvestorsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">12,000,000</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">shares was held by Domestic Investors. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares subscribed by Management Holdco and ESOP Holdco, in the total number of <ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,500,000</ix:nonFraction>, have not yet been purchased by or issued to Management Holdco and ESOP Holdco as of December, 31, 2020. </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">Once all the<div style="letter-spacing: 0px; top: 0px;;display:inline;">se <ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="PAsOn12_31_2020_ManagementHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,500,000</ix:nonFraction></div>&#160;subscribed shares of I-Mab Hangzhou are purchased<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">by<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>or issued to Management Holdco and ESOP Holdco, the equity interest in I-Mab Hangzhou held by I-Mab Hong Kong, Domestic Investors, Management Holdco and ESOP Holdco would be</div>&#160;<ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">45</ix:nonFraction>%, <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn12_31_2020_ImabHongKongMembersrtConsolidatedEntitiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%, <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn12_31_2020_DomesticInvestorsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>% and <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn12_31_2020_EsopHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>% respectively<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On the same day, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong also entered into a shareholders agreement with the aforementioned investors (the &#8220;SHA&#8221;). According to the SHA and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou&#8217;s articles of association, the board of directors of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou shall be composed of seven directors. The directors shall be elected in the following ways: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong is entitled to appoint three directors, including the chairman of the board of directors, as well as nominate one independent director; the Management Holdco is entitled to appoint one director; two <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-related</div> entities of the Domestic Investors are entitled to appoint one director respectively (&#8220;Investors Directors&#8221;). Each director of the board of directors shall have one vote. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong, Management Holdco and ESOP Holdco agree to act in concert, as long as each of Management Holdco and ESOP Holdco respectively holds equity in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou, when exercising the rights as a shareholder. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As a result of the above transactions, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou became an affiliate of the Group on the Closing Date in accordance with ASC 810 since <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou meets the definition of a business under ASC 805. In accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">810-10,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou is a variable interest entity, and no shareholder shall consolidate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou under VIE model as neither party have the power to direct all the activities that most significantly impact the economic performance of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou. Therefore, the Group deconsolidated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou and retained significant influence in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou. The investment was accounted for using the equity method. The retained investment in the common stock of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou was initially measured at fair value in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">810-10-40.</div></div></div></div> </ix:continuation></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_20395951_1" continuedAt="TextSelectionAppend_20395951_2"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group determined the fair value of its retained equity interest with the assistance of an independent third-party valuation firm. The Group used equity allocation model to estimate the fair value of the investment. The fair value as of the Closing Date was US$<ix:nonFraction name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">112,039</ix:nonFraction> (equivalent to approximately RMB<ix:nonFraction name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">764,352</ix:nonFraction>), which reflected the fact that the shares subscribed by Management Holdco and ESOP Holdco were not issued and outstanding as of the Closing Date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A gain of RMB<ix:nonFraction name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">407,598</ix:nonFraction>&#160;million was recognized as a result of the deconsolidation. The gain represented the difference between: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">i)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The fair value of the retained noncontrolling investment in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou at the Closing Date; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">ii)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate of all of the following: </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the carrying amount of transferred intellectual property related to TJ102 at the Closing Date (see Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>); </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the fair value of the put right liabilities written by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong to Domestic Investors; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the carrying amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou&#8217;s net assets at the Closing Date<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> </td> </tr> </table> </ix:continuation> <div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>. INVESTMENT ACCOUNTED FOR USING THE EQUITY METHOD AND PUT RIGHT LIABILITIES (CONTINUED) </div></div></div></div> <ix:continuation id="TextSelectionAppend_20395951_2" continuedAt="TextSelectionAppend_20395951_3"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Investment accounted for using the equity method (continued) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Subsequently, pursuant to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou&#8217;s articles of association, the Group applies the HLBV method to allocate earnings or losses of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou because the liquidation rights and priorities sufficiently differ from what is reflected by the underlying percentage ownership interests. For the period from September&#160;15, 2020 to December&#160;31, 2020, the Group recognized RMB<ix:nonFraction name="us-gaap:OciEquityMethodInvestmentAfterTax" contextRef="P09_15_2020To12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">67,425</ix:nonFraction> in equity in loss of an affiliate in the consolidated statements of comprehensive income. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The purchase price of US$<ix:nonFraction name="us-gaap:BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments" contextRef="PAsOn12_31_2020_HoldcoMembersrtOwnershipAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction> million committed by Management Holdco under SPA, representing <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn12_31_2020_HoldcoMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>% of the equity of I-Mab Hangzhou, is significantly lower than the fair value of the corresponding subscribed shares as of the Closing Date. The excess is considered as share-based compensation to the I-Mab Hangzhou&#8217;s management for the services to be used or consumed in the I-Mab Hangzhou&#8217;s own operations. The share-based compensation is considered granted upon the Closing Date and cliff vests after five years of service since the Closing Date. Consequently, the Group recognizes its proportionate share of the compensation expense recorded by I-Mab Hangzhou. For the period from September 15, 2020 to December 31, 2020, the amount included in the equity in loss of an affiliate in the Group&#8217;s consolidated statements of comprehensive income is RMB<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P09_15_2020To12_31_2020_HoldcoMembersrtOwnershipAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">8,456</ix:nonFraction>.</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Along with the equity transfer transaction, the team of designated management/workforce transferred from the Group to I-Mab Hangzhou consists of several grantees under the Group&#8217;s 2020 Share Incentive Plan (&#8220;2020 Plan&#8221;, see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>(f)). These individuals continued to qualify the definition of the eligible participants under the 2020 Plan after the Closing Date. Meanwhile, there has been no change to any of the award terms. The equity transfer transaction did not trigger the modification accounting to the share-based compensation. Additionally, given that I-Mab Hangzhou became an affiliate to the Group upon deconsolidation, and that the other shareholders of I-Mab Hangzhou are not providing proportionate value to sponsor the 2020 Plan nor is the Group receiving any consideration for the awards granted to employees of I-Mab Hangzhou, the Group is required, under Topic 323, to expense the full costs of share-based compensation as incurred at the same period as the costs are recognized by I-Mab Hangzhou. For the year ended</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">December 31, 2020, such expenses of&#160;</div>RMB<ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="P01_01_2020To12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">32,707</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">and was recorded in the equity in loss of an affiliate in the consolidated statements of comprehensive income.</div></div></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2020, the carrying value of the Group&#8217;s long-term investment measured under equity method was&#160;</div> RMB<ix:nonFraction name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" contextRef="P01_01_2020To12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">664,832</ix:nonFraction>. <ix:nonNumeric name="us-gaap:EquityMethodInvestmentsTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20396187"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Group presented the summarized financial information of the Group&#8217;s long-term investment measured under equity method below in accordance with Rule 4-08 of Regulation S-X (RMB in thousands).</div></div></ix:nonNumeric></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_20396187">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"></td>
<td style="width: 15%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;period&#160;from</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">15</div>,&#160;2020&#160;to</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating data:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_RevenueMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="PAsOn12_31_2020_GrossProfitMemberusgaapIncomeStatementLocationAxis_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_LossFromOperationMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">85,945</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NetIncomeLossMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">85,945</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 80%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance sheet data:</div></div></div> </td>
<td style="vertical-align: bottom; width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 80%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets</div></div></div> </td>
<td style="vertical-align: bottom; width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">923,010</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 80%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div></div> </td>
<td style="vertical-align: bottom; width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">810,623</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 80%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities</div></div></div> </td>
<td style="vertical-align: bottom; width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">31,519</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 80%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">10,933</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 80%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interests</div></div> </td>
<td style="vertical-align: bottom; width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>. INVESTMENT ACCOUNTED FOR USING THE EQUITY METHOD AND PUT RIGHT LIABILITIES (CONTINUED) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_20395951_3"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) Put right liabilities </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the SHA, if <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou fails to close a public offering of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou&#8217;s shares on the China Stock Exchange&#8217;s Science and Technology Innovation Board, Main Board, Small and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Medium-Sized</div> Enterprise Board, Growth Enterprise Board, or Hong Kong Stock Exchange, U.S. Stock Exchange, or other stock exchanges approved by the shareholders of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou in accordance with provisions of the SHA within 4 years after September&#160;15, 2020, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong is obligated to repurchase the equity held by Domestic Investors in cash or in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab&#8217;s</div> stock (subject to the approval procedures of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab)</div> within 3 years from the expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-year</div> period after the Closing Date of September&#160;15, 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The put right written by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong to Domestic Investors is a freestanding equity-linked instrument, which is classified as a put right liability and is initially measured at fair value. Subsequent changes in fair value are recorded in other income (loss) in the <div style="letter-spacing: 0px; top: 0px;;display:inline;">consolidated statements of comprehensive income (loss).</div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group determined the fair value of the put right with the assistance of an independent third-party valuation firm. The Group used the option pricing model (finnerty model) to estimate the fair value of the put right using the following assumptions: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;September</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,&#160;and&#160;September<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected terms (Year)</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2020To09_30_2020" format="ixt-sec:duryear">4</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:duryear">4</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated volatility</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">55.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">55.9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Spot price</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">US$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">143,401</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align: bottom;">US$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">143,804</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Probability of triggering event for redemption option</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">65</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">65</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The model requires the input of highly subjective assumptions including the expected terms, estimated volatility, spot price and probability of triggering event for redemption option. Expected terms is estimated based on the timing of a hypothetical redemption event which is assumed to be the earlier of expected redemption date or expected public offering date. Expected volatility is estimated based on daily stock prices of the comparable company for a period with length commensurate to the expected terms of redemption event. The spot price was determined with assistance from an independent third-party valuation firm. The Group&#8217;s management is ultimately responsible for the determination of the spot price and probability of triggering event for redemption option. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant decreases in interval between valuation date and maturity date, estimated volatility, spot price and probability of triggering event for redemption option would result in a significantly lower fair value measurement. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">NOTES </div>TO THE <div style="letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">FINANCIAL </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">STATEMENTS</div> </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ShortTermDebtTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div>. SHORT-TERM BORROWINGS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2018, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-tech</div> (Tianjin) Co., Ltd. borrowed a loan of RMB<ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="PAsOn07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">80,000</ix:nonFraction> from <ix:nonNumeric name="us-gaap:ShortTermDebtLender" contextRef="P07_31_2018To07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis">China Merchant Bank Co., Ltd</ix:nonNumeric>. for a term of <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P07_31_2018To07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis" format="ixt-sec:durwordsen">one year</ix:nonNumeric> and at the interest rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">4.20</ix:nonFraction>% per annum. To facilitate this borrowing, another subsidiary of the Company in Hong Kong placed cash deposits of US$<ix:nonFraction name="us-gaap:DebtInstrumentCollateralAmount" contextRef="PAsOn07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,500</ix:nonFraction> (equivalent to approximately RMB<ix:nonFraction name="us-gaap:DebtInstrumentCollateralAmount" contextRef="PAsOn07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">92,653</ix:nonFraction>) with the bank. The use of such cash deposits and the interest earned thereon are restricted by the bank during the period of the borrowing. The deposits have a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> term and bear interest at <ix:nonFraction name="us-gaap:PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" contextRef="PAsOn07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">3.26</ix:nonFraction>% per annum. The borrowing was fully repaid during the year ended December&#160;31, 2019. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2019, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-tech</div> (Tianjin) Co., Ltd. borrowed a loan of RMB<ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="PAsOn06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">50,000</ix:nonFraction> from <ix:nonNumeric name="us-gaap:ShortTermDebtLender" contextRef="P06_30_2019To06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis">China Merchant Bank Co., Ltd</ix:nonNumeric>. for a term of <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P06_30_2019To06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis" format="ixt-sec:durwordsen">one year</ix:nonNumeric> and at the interest rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">4.15</ix:nonFraction>% per annum. To facilitate this borrowing, another subsidiary of the Company in Hong Kong placed cash deposits of US$<ix:nonFraction name="us-gaap:DebtInstrumentCollateralAmount" contextRef="PAsOn06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,000</ix:nonFraction> (equivalent to approximately RMB<ix:nonFraction name="us-gaap:DebtInstrumentCollateralAmount" contextRef="PAsOn06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">55,810</ix:nonFraction>) with the bank. The use of such cash deposits and the interest earned thereon are restricted by the bank during the period of the borrowing. The deposits have a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> term and bear interest at <ix:nonFraction name="us-gaap:PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" contextRef="PAsOn06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.63</ix:nonFraction>% per annum. <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateDescription" contextRef="P06_30_2019To06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis">The borrowing was fully repaid in June 2020.</ix:nonNumeric> </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20394926"><div style="text-align: left;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div>. ACCRUALS AND OTHER PAYABLES </div></div></div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20394927">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Staff salaries and welfare payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">30,166</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">94,133</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,427</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued external research and development activities related expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">144,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">218,583</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">33,499</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued initial public offering costs payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:AccruedInitialPublicOfferingCostsPayable" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">17,504</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:AccruedInitialPublicOfferingCostsPayable" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:AccruedInitialPublicOfferingCostsPayable" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued private placement offering costs payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:PrivatePlacementOfferingCostsPayable" contextRef="PAsOn12_25_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:PrivatePlacementOfferingCostsPayable" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">128,786</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:PrivatePlacementOfferingCostsPayable" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,737</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Withholding IIT payable related to stock options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:WithholdingIitPayable" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">16,201</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:WithholdingIitPayable" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:WithholdingIitPayable" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-refundable</div> incentive payment from depositary bank <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:NonRefundableIncentivePaymentFromDepositaryBankCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:NonRefundableIncentivePaymentFromDepositaryBankCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,424</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:NonRefundableIncentivePaymentFromDepositaryBankCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">371</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued traveling expenses, office expenses and others</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:AccruedTravellingExpensesOfficeExpensesAndOthers" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">65,682</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:AccruedTravellingExpensesOfficeExpensesAndOthers" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">116,632</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:AccruedTravellingExpensesOfficeExpensesAndOthers" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">273,553</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">560,558</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">85,909</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-refundable</div> incentive payment from depositary bank <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:NonRefundableIncentivePaymentFromDepositaryBankNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:NonRefundableIncentivePaymentFromDepositaryBankNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">7,474</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:NonRefundableIncentivePaymentFromDepositaryBankNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,145</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advance payment received from an employee for exercise of stock options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:AdvanceReceivedFromEmployeeForExerciseOfStockOptions" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:AdvanceReceivedFromEmployeeForExerciseOfStockOptions" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,501</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:AdvanceReceivedFromEmployeeForExerciseOfStockOptions" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">230</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">8,975</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,375</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> <div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">569,533</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">87,284</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_20394926"><ix:continuation id="TextSelection_20394927">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The Group received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> incentive payment&#160;of US$<ix:nonFraction name="imab:ProceedsFromNonRefundableIncentive" contextRef="P04_01_2020To04_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,857</ix:nonFraction>&#160;(equivalent to approximately RMB<ix:nonFraction name="imab:ProceedsFromNonRefundableIncentive" contextRef="P04_01_2020To04_30_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">12,982</ix:nonFraction>) from depositary bank in April 2020.&#160;The amount was recorded ratably as other gains over a five-year arrangement period. For the year ended December&#160;31, 2020, the Group has recorded RMB<ix:nonFraction name="us-gaap:OtherIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,348</ix:nonFraction> as other income in the consolidated statements of comprehensive income. </div> </td> </tr> </table> </ix:continuation></ix:continuation></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20394928"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>. INCOME TAXES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cayman Islands </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab&#160;is</div> incorporated in the Cayman Islands. Under the current laws of the Cayman <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Islands,&#160;I-Mab&#160;is</div> not subject to tax on income or capital gain. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> did business registration in Hong Kong and has a Hong Kong tax file number. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Hong Kong </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab&#160;Biopharma</div> Hong Kong Limited is incorporated in Hong Kong. Companies registered in Hong Kong are subject to Hong Kong profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Hong Kong tax laws. The applicable tax rate in Hong Kong is <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2018To12_31_2018_HKsrtStatementGeographicalAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2019To12_31_2019_HKsrtStatementGeographicalAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020_HKsrtStatementGeographicalAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">16.5</ix:nonFraction></ix:nonFraction></ix:nonFraction>%. For the years ended December&#160;31, 2018, 2019 and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020,&#160;I-Mab&#160;Biopharma</div> Hong Kong Limited did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earnings in Hong Kong for any of the periods presented. Under the Hong Kong tax <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">law,&#160;I-Mab&#160;Biopharma</div> Hong Kong Limited is exempted from income tax on its foreign-derived income and there are no withholding taxes in Hong Kong on remittance of dividends. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Australia </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">I-Mab&#160;Biopharma Australia Pty Ltd is incorporated in Australia. Companies registered in Australia are subject to Australia profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Australia tax laws. The applicable tax rate in Australia is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020_AUsrtStatementGeographicalAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">30</ix:nonFraction>%.&#160;I-Mab&#160;Biopharma</div> Australia Pty Ltd has no taxable income for all periods presented, therefore, no provision for income taxes is required. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">United States </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab&#160;Biopharma</div> US Ltd. is incorporated in U.S. and is subject to U.S. federal corporate income tax at a rate of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>%.&#160;I-Mab&#160;Biopharma</div> US Ltd. is also subject to state income tax in Maryland of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">8.25</ix:nonFraction>%.&#160;I-Mab&#160;Biopharma</div> US Ltd. has no taxable income for all periods presented, therefore, no provision for income taxes is required. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">China </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;16, 2007, the National People&#8217;s Congress of PRC enacted a new Enterprise Income Tax Law (&#8220;new EIT law&#8221;), under which Foreign Investment Enterprises (&#8220;FIEs&#8221;) and domestic companies would be subject to corporate income tax at a uniform rate of <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020_CNMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>%. The new EIT law became effective on January&#160;1, 2008. Under the new EIT law, preferential tax treatments will continue to be granted to entities which conduct businesses in certain encouraged sectors and to entities otherwise classified as &#8220;High and New Technology Enterprises&#8221;.</div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>. INCOME TAXES (CONTINUED) </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">China (continued) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_20394928" continuedAt="TextSelectionAppend_20394928_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab&#160;Shanghai</div> has been qualified as &#8220;High and New Technology Enterprise&#8221; and enjoys a preferential income tax rate of <ix:nonFraction name="imab:EffectivePreferentialIncomeTaxRate" contextRef="P01_01_2020To12_31_2020_CNMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>% from 2018 to 2020. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s other PRC subsidiaries are subject to the statutory income tax rate of <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020_IMobOtherSubsidiariesMembersrtConsolidatedEntitiesAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>%. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No provision for corporate income taxes for corresponding tax residents has been made because the Group are in cumulative loss positions for all the periods presented. During the year ended December 31, 2020, the Group recorded withholding taxes with the amount of RMB<ix:nonFraction name="imab:WithholdingTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">12,231</ix:nonFraction> </div></div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in relation to research and development service and other supporting service charges made by its non-PRC tax resident subsidiaries to its PRC tax resident subsidiaries. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reconciliations of <div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div>he differences between <div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div>he PRC statutory income tax rate and the Group&#8217;s effective income tax rate for the years ended December&#160;31, 2018, 2019 and 2020 are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Note&#160;2.5)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before income ta<div style="letter-spacing: 0px; top: 0px;;display:inline;">x</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">401,111</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,451,950</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">483,146</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,044</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax computed at respective applicable tax rate</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">56,093</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">148,871</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">66,044</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,122</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-deductible</div> expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,548</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">87,021</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">72,256</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,073</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses plus deduction</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imab:EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">6,762</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imab:EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">9,254</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="imab:EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">60,776</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="imab:EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,314</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in valuation allowance</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">62,029</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">71,104</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">65,293</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,007</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">12,231</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,874</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of tax holidays entitled by the PRC subsidiaries on basic income (loss) per share</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">3.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">9.55</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.34</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.05</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20394930">The principal components of the deferred tax assets and liabilities are as follows:</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_20394930">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">RMB</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Note&#160;2.5)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets:</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Net operating loss carryforwar<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">d</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">92,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">136,443</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">107,344</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,451</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciat<div style="letter-spacing: 0px; top: 0px;;display:inline;">i</div>on and amortization of property, equipment, software and intangible asset, net</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="PAsOn12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">18,405</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">44,398</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">30,417</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,662</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrual expense</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="PAsOn12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">21,132</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">21,867</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">10,568</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,620</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: valuation allowance</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">94,511</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">165,497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">100,204</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,358</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax asset<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">37,211</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">37,211</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">48,125</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,375</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities:</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired intangible assets</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="PAsOn12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">37,211</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">37,211</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">18,067</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,768</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr>
<td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:top;"> <div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets</div></div> </td>
<td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;&#160;&#160;</div></div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;&#160;&#160;</div></div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="imab:DeferredTaxAssetsContractAssets" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">30,058</ix:nonFraction></div></div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="imab:DeferredTaxAssetsContractAssets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,607</ix:nonFraction></div></div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif;">&#160;</div> </td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 65%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">37,211</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">37,211</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">48,125</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,375</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets, net</div></div> </td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction> &#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction> &#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> </ix:continuation></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>. INCOME TAXES (CONTINUED) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_20394928_1"><ix:nonNumeric name="us-gaap:SummaryOfValuationAllowanceTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Movement of the valuation allowance is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Note&#160;2.5)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January&#160;1</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2017" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">49,541</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">94,511</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">165,497</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,364</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Addition<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="imab:DeferredTaxesAdditionsValuationAllowance" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">62,029</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="imab:DeferredTaxesAdditionsValuationAllowance" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">71,104</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="imab:DeferredTaxesAdditionsValuationAllowance" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">36,061</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="imab:DeferredTaxesAdditionsValuationAllowance" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,527</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Utilization and reversal of valuation allowances</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="imab:DeferredTaxAssetsValuationAllowanceUtilizationAndReversal" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">89,154</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="imab:DeferredTaxAssetsValuationAllowanceUtilizationAndReversal" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,663</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease due to the change of tax rate</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="imab:DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">17,059</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="imab:DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="imab:DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">12,200</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="imab:DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,870</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 65%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">94,511</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">165,497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">100,204</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,358</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 65%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the Group had a majority of net operating losses of approximately RMB<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2020_PRCMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">556,649</ix:nonFraction>&#160;which arose from the subsidiaries established in the PRC. The tax losses carried forward various in the PRC will expire during the period beginning from 2021 to 2030 based on entity&#8217;s preferential tax status. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered as more likely than not that some portion or all of the deferred tax assets will not be realized in the foreseeable future.&#160;In making such determination, the Group evaluates a variety of positive and negative factors including the Group&#8217;s operating history, accumulated deficit, the existence of taxable temporary differences and reversal periods. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group has incurred net accumulated operating losses for income tax purposes since its inception. The Group believes that it is more likely than not that these net accumulated operating losses together with other deferred tax assets will not be utilized in the foreseeable future. Therefore, the Group has provided full valuation allowances for the deferred tax assets as of December&#160;31, 2019 and 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of December&#160;31, 2019 and 2020, the Group did not have any significant unrecognized uncertain tax positions.</div></div> </ix:continuation></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20394932"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>. ORDINARY SHARES </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2018 and 2019, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2018" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">500,000,000</ix:nonFraction> ordinary shares had been authorized by the Company. <ix:nonNumeric name="us-gaap:CommonStockVotingRights" contextRef="P01_01_2020To12_31_2020">Each ordinary share is entitled to one vote.</ix:nonNumeric> The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors of the Company. </div></div></ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div></div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>. ORDINARY SHARES (CONTINUED) </div></div></div></div><ix:continuation id="TextSelection_20394932" continuedAt="TextSelectionAppend_20394932_1"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;29, 2019, the Company&#8217;s shareholders and board of directors approved that immediately prior to the completion of initial public offering, the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company&#8217;s authorized share capital will be changed into US$</div><ix:nonFraction name="imab:CommonStockValueAuthorized" contextRef="PAsOn10_29_2019_DirectorMembersrtTitleOfIndividualAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">80,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> divided into </div><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn10_29_2019_DirectorMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">800,000,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> ordinary shares of a par value of US$</div><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn10_29_2019_DirectorMembersrtTitleOfIndividualAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> each.</div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_20394932_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;17, 2020, the Company completed its IPO and became listed on the Nasdaq Global Market by issuing <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_31_2020To01_31_2020_AdrMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">7,407,400</ix:nonFraction> American Depositary Shares (&#8220;ADSs&#8221;) at the price of US$<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn01_17_2020_AdrMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">14.00</ix:nonFraction> per ADS for total gross proceeds of US$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_31_2020To01_31_2020_AdrMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">103.7</ix:nonFraction>&#160;million. On February&#160;10, 2020, the underwriters of the IPO have exercised their over-allotment option to purchase an additional <ix:nonFraction name="imab:CommonStockSharesIssuable" contextRef="PAsOn02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">768,350</ix:nonFraction> ADSs of the Company at the IPO price of US$<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">14.00</ix:nonFraction> per ADS. After giving effect to the exercise of the over-allotment option, the Company has issued and sold a total of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P02_10_2020To02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">8,175,750</ix:nonFraction> ADSs in the IPO, for total net proceeds of US$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="P02_10_2020To02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">101.3</ix:nonFraction>&#160;million (equivalent to RMB<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="P02_10_2020To02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">697,788</ix:nonFraction>), netting of issuance cost from total gross proceeds of US$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P02_10_2020To02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">114.5</ix:nonFraction>&#160;million. Each ten ADSs represent <span style="-sec-ix-hidden:hidden20395666">twenty</span>-three ordinary shares of the Company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;17, 2020, the Company also issued <ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="PAsOn01_17_2020_CollaborationAgreementWithEverestMemberusgaapTypeOfArrangementAxis_EverestsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,078,571</ix:nonFraction> ordinary shares to Everest (see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div>&#160;for details). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon the completion of the IPO, the Company&#8217;s then outstanding <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn01_17_2020_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">30,227,056</ix:nonFraction> Series A Preferred Shares, <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn01_17_2020_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">23,288,783</ix:nonFraction> Series B Preferred Shares, <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn01_17_2020_ConvertiblePreferredStockSeriesBOneUponConversionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,714,580</ix:nonFraction> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares, <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn01_17_2020_ConvertiblePreferredStockSeriesB2MemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,301,849</ix:nonFraction> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares, <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn01_17_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">31,046,360</ix:nonFraction> Series C Preferred Shares and <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn01_17_2020_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,857,143</ix:nonFraction> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares were converted into <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="P01_17_2020To01_17_2020_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">30,227,056</ix:nonFraction>, <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="P01_17_2020To01_17_2020_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">23,288,783</ix:nonFraction>, <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="P01_17_2020To01_17_2020_ConvertiblePreferredStockSeriesBOneUponConversionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,714,580</ix:nonFraction>, <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="P01_17_2020To01_17_2020_ConvertiblePreferredStockSeriesB2MemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,571,427</ix:nonFraction>, <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="P01_17_2020To01_17_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">34,420,469</ix:nonFraction> and <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="P01_17_2020To01_17_2020_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,537,814</ix:nonFraction> ordinary shares, respectively. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;15, 2020, the Company&#8217;s Board of Directors approved a share repurchase program to repurchase in the open market up to US$<ix:nonFraction name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="PAsOn07_15_2020_AdrMemberusgaapStatementClassOfStockAxis_BoardOfDirectorsMembersrtTitleOfIndividualAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction>&#160;million worth of outstanding ADSs of the Group. The Company made a total prepayment of US$<ix:nonFraction name="imab:PrepaidExpenseStockRepurchaseProgram" contextRef="PAsOn07_15_2020_AdrMemberusgaapStatementClassOfStockAxis_BoardOfDirectorsMembersrtTitleOfIndividualAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">5,000</ix:nonFraction> (equivalent to RMB<ix:nonFraction name="imab:PrepaidExpenseStockRepurchaseProgram" contextRef="PAsOn07_15_2020_AdrMemberusgaapStatementClassOfStockAxis_BoardOfDirectorsMembersrtTitleOfIndividualAxis" unitRef="Unit_CNY" decimals="0" scale="0" format="ixt:numdotdecimal">34,051</ix:nonFraction>) for the share repurchase. The prepayment was</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>collected subsequently in October 2020. No repurchase activity was taken place for the year ended December, 31, 2020. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On September&#160;3, 2020, the Company entered into definitive subscription agreements with a consortium of institutional investors (the &#8220;Investors&#8221;) to raise approximately US$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2020To12_31_2020_CollaborationAgreementWithInvestorsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">418</ix:nonFraction>&#160;million through a private placement. The consortium is led by Hillhouse Capital Group (&#8220;Hillhouse&#8221;), with significant participation by GIC Private Limited, and also includes certain other leading Asian and U.S. biotech investment funds, Hillhouse is entitled to nominate one representative to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab&#8217;s</div> Board of Directors. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The private placement comprises (1)&#160;the sale to the Investors of the Group&#8217;s <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">29,133,502</ix:nonFraction> ordinary shares (equivalent to 12,666,740 ADSs) at a purchase price equivalent to US$<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:numdotdecimal">33</ix:nonFraction> per ADS amounting to approximately US$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">418</ix:nonFraction>&#160;million; and (2)&#160;warrants (the &#8220;Investor Warrants&#8221;, see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div>(b)) to subscribe for an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_InvestorWarrantsMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">5,341,267</ix:nonFraction> ordinary shares (equivalent to 2,322,290 ADSs) at an exercise price equivalent to US$<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_InvestorWarrantsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:numdotdecimal">45</ix:nonFraction> per ADS, which may further increase the proceeds of approximately US$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_InvestorWarrantsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">104.5</ix:nonFraction>&#160;million if the Investor Warrants are fully exercised. The Investor Warrants will remain exercisable at the election of the Investors within 12 months after the closing of the private placement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The subscription agreement with the Hillhouse entities contemplates two closings. The first closing occurred on September&#160;11, 2020, and the second closing is conditioned upon an existing director of the Company having resigned to enable the Hillhouse entities to appoint a director to replace such director and the lemzoparlimab <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> agreement with AbbVie (see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div>) being or remaining effective. Upon the first closing, <ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2020_FirstClosingPeriodMemberIMABPeriodTypeAxis_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">20,421,378</ix:nonFraction> ordinary shares and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2020_FirstClosingPeriodMemberIMABPeriodTypeAxis_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,744,032</ix:nonFraction> Investor Warrants were issued to the Investors for total gross proceeds of approximately US$<ix:nonFraction name="imab:GrossProceedsOfSharesAndWarrants" contextRef="P01_01_2020To12_31_2020_FirstClosingPeriodMemberIMABPeriodTypeAxis_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">293.0</ix:nonFraction>&#160;million. On December&#160;17, 2020, the Group entered into a written amendment made to the subscription agreement with the Hillhouse entities, which removed one of the two conditions for the second closing that an existing director of the Company having resigned to enable the Hillhouse entities to appoint a director to replace such director. The second closing occurred as the other condition was satisfied and <ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2020_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis_SecondClosingPeriodMemberIMABPeriodTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">8,712,124</ix:nonFraction> ordinary shares as well as <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2020_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis_SecondClosingPeriodMemberIMABPeriodTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,597,235</ix:nonFraction> Investor Warrants were issued to the Hillhouse entities for total gross proceeds of approximately US$<ix:nonFraction name="imab:GrossProceedsOfSharesAndWarrants" contextRef="P01_01_2020To12_31_2020_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis_SecondClosingPeriodMemberIMABPeriodTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">125.0</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million. The total net proceeds, netting of issuance cost, from the private placement was US$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2020To12_31_2020_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis_SecondClosingPeriodMemberIMABPeriodTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">397.2</ix:nonFraction> million (equivalent to RMB<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2020To12_31_2020_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis_SecondClosingPeriodMemberIMABPeriodTypeAxis" unitRef="Unit_CNY" decimals="-6" scale="6" format="ixt:numdotdecimal">2,653,669</ix:nonFraction>). </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, <ix:nonFraction name="us-gaap:SharesHeldInEmployeeStockOptionPlanAllocated" contextRef="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,841,373</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">stock options were exercised, and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">7,000</ix:nonFraction> restricted share units were issued as ordinary shares.</div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></div></div> </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="imab:TemporaryEquityTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20395384"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div>. CONVERTIBLE PREFERRED SHARES </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On October&#160;18, 2016, the Company issued <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn10_18_2016_SeriesA1AndA2PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,141,587</ix:nonFraction> shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> Preferred Shares with a consideration of US$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P10_18_2016To10_18_2016_SeriesA1AndA2PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,282</ix:nonFraction> (equivalent to approximately RMB<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P10_18_2016To10_18_2016_SeriesA1AndA2PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">74,742</ix:nonFraction>). In connection with the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> Preferred Shares issuance, the Company also issued <ix:nonFraction name="imab:IssueOfWarrants" contextRef="PAsOn10_18_2016_ConvertiblePreferredStockSeriesA3MemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,246,744</ix:nonFraction> warrant to purchase its Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-3</div> Preferred Shares (&#8220;Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-3</div> Warrants&#8221;). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On September&#160;6, 2017, in connection with the Group&#8217;s acquisition of Tasgen Group, the Company issued <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn09_06_2017_SeriesA3PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">16,723,646</ix:nonFraction> shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-3</div> Preferred Shares at a price of US$<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn09_06_2017_SeriesA3PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">2.55</ix:nonFraction> per share with a total consideration of US$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="P09_06_2017To09_06_2017_SeriesA3PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">42,645</ix:nonFraction> (equivalent to approximately RMB<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="P09_06_2017To09_06_2017_SeriesA3PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">289,024</ix:nonFraction>). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> Preferred Shares, Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> Preferred Shares and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-3</div> Preferred Shares are also referred to as Series A Preferred Shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On September&#160;22, 2017, the Company issued <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn09_22_2017_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">15,894,594</ix:nonFraction> shares of Series B Preferred Shares with a consideration of US$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="P09_22_2017To09_22_2017_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">52,546</ix:nonFraction> (equivalent to approximately RMB<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="P09_22_2017To09_22_2017_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">346,515</ix:nonFraction>). In connection with the Series B Preferred Shares issuance, the Company also issued convertible promissory notes that are convertible into Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares (&#8220;2017 Notes&#8221; and see Note 14) and <ix:nonFraction name="imab:IssueOfWarrants" contextRef="PAsOn09_22_2017_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">5,633,780</ix:nonFraction> warrants to purchase its Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares (&#8220;Series B Warrant&#8221; and see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div>). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Concurrently with the Company&#8217;s issuance of Series B Preferred Shares, the Company also completed a round of onshore financing with respect to the Group&#8217;s subsidiary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB</div> Tianjin (&#8220;Series B Onshore Financing&#8221;). Series B Onshore Financing comprised 1) capital injection to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin by a number of investors (&#8220;Series B Onshore Investors&#8221;) (see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>), 2) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin&#8217;s issuance of convertible loans (&#8220;Onshore Convertible Loans&#8221; and see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>), and 3) the Company&#8217;s issuance of <ix:nonFraction name="imab:IssueOfWarrants" contextRef="PAsOn09_22_2017_ConvertiblePreferredStockSeriesB2MemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">2,620,842</ix:nonFraction> warrants to purchase its Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares (&#8220;Series B Warrants&#8221; and see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div>). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On June&#160;29, 2018, the Company issued total <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn06_29_2018_ConvertiblePreferredStockSeriesAThreeUponExerciseMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">8,361,823</ix:nonFraction> shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-3</div> Preferred Shares upon exercise of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-3</div> Option held by its holder. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On June&#160;29, 2018, the Company issued <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn06_29_2018_ConvertiblePreferredStockSeriesBOneUponConversionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">2,535,201</ix:nonFraction> shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares upon conversion of 2017 Notes and issued <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn06_29_2018_ConvertiblePreferredStockSeriesBTwoUponExerciseMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">2,253,512</ix:nonFraction> shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares upon exercise of Series B Warrant by Series B preferred shareholders. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On June&#160;29, 2018, the Company issued <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn06_29_2018_ConvertiblePreferredStockSeriesBUponExerciseMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">5,938,640</ix:nonFraction> shares of Series B Preferred Shares upon exercise of the Series B Option held by a Series B Onshore Investor and issued <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn06_29_2018_ConvertiblePreferredStockSeriesBOneUponExerciseMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">947,218</ix:nonFraction> shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>), respectively. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On July&#160;6, 2018, the Company issued <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn07_06_2018_ConvertiblePreferredStockSeriesBUponExerciseMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,455,549</ix:nonFraction> shares of Series B Preferred Shares upon exercise of the Series B Option held by a Series B Onshore Investor, issued <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn07_06_2018_ConvertiblePreferredStockSeriesBOneUponExerciseMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">232,161</ix:nonFraction> shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>) and issued <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn07_06_2018_ConvertiblePreferredStockSeriesBTwoUponExerciseMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,048,337</ix:nonFraction> shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares upon exercise of Series B Warrant by Series B Onshore Investors, respectively. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">40</div></div></div> </div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div>. CONVERTIBLE PREFERRED SHARES (CONTINUED) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_20395384" continuedAt="TextSelectionAppend_20395384_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series B Preferred Shares, Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares are also referred to as Series B Preferred Shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 6, 2018, the Company issued <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn07_06_2018_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">31,046,360</ix:nonFraction> shares of Series C Preferred Shares at a price of US$<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn07_06_2018_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:numdotdecimal">6.4419</ix:nonFraction> per share with a total consideration of US$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="P07_06_2018To07_06_2018_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">200,000</ix:nonFraction> (equivalent to approximately RMB<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="P07_06_2018To07_06_2018_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,323,363</ix:nonFraction>). In connection with the offering of the Series C Preferred Shares, the Company incurred issuance costs of RMB<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P07_06_2018To07_06_2018_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">16,730</ix:nonFraction>. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On July&#160;25, 2019, the Group entered into a share purchase agreement with certain third party investors, under which these investors will subscribe for an aggregate of <ix:nonFraction name="us-gaap:PreferredStockShareSubscriptions" contextRef="PAsOn07_25_2019_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,857,143</ix:nonFraction> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> convertible preferred shares of the Company for an aggregate purchase price of US$<ix:nonFraction name="us-gaap:PreferredStockSharesSubscribedButUnissuedValue" contextRef="PAsOn07_25_2019_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">27.0</ix:nonFraction>&#160;million. Out of the aforementioned subscription of <ix:nonFraction name="us-gaap:PreferredStockShareSubscriptions" contextRef="PAsOn07_25_2019_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,857,143</ix:nonFraction> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> convertible preferred shares by certain third party investors, <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn10_17_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,428,571</ix:nonFraction> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> convertible preferred shares were issued to an investor on October&#160;17, 2019, and the Group also received the cash consideration of US$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="P10_17_2019To10_17_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,000</ix:nonFraction> (equivalent to approximately RMB<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="P10_17_2019To10_17_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">70,036</ix:nonFraction>). On November&#160;6, 2019, the Group received cash consideration of US$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="P11_06_2019To11_06_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,000</ix:nonFraction> (equivalent to approximately RMB<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="P11_06_2019To11_06_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">119,387</ix:nonFraction>) for the remaining <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn11_06_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,428,572</ix:nonFraction> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> convertible preferred shares from the investors and the issuance of such <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn11_06_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,428,572</ix:nonFraction> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> convertible preferred shares was consummated on that day. In connection with the offering of the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> convertible preferred shares, the Company incurred issuance costs of approximately US$<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P11_06_2019To11_06_2019_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">840</ix:nonFraction> (equivalent to approximately RMB<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P11_06_2019To11_06_2019_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,887</ix:nonFraction>). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Series A Preferred Shares, Series B Preferred Shares, Series C Preferred Shares and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares are collectively referred to as Preferred Shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key terms of the Preferred Shares are summarized as follows: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The holders of Preferred Shares are entitled to receive dividends, out of any assets legally available therefore, prior and in preference to any declaration or payment of any dividend on the ordinary shares or any other class or series of shares of the Group at the rate of eight percent (8%) of the original issue price per share per annum on each Preferred Share, payable in US$ and annually when, as and if declared by the Board of Directors. Such distributions shall not be cumulative. No dividend, whether in cash, in property or in shares of the capital of the Group, shall be paid on or declared and set aside for any ordinary shares or any other class or series of shares of the Group unless and until all dividends have been paid in full on the Preferred Shares (on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each Preferred Share may be converted at any time into ordinary shares at the option of the preferred shares holders at the then applicable conversion price. The initial conversion ratio is 1:1, subject to adjustment in the event of (i)&#160;share splits, share combinations, share dividends or distribution, other dividends, recapitalizations and similar events, or (ii)&#160;issuance of ordinary shares (excluding certain events such as issuance of ordinary shares pursuant to a public offering) at a price per share less than the conversion price in effect on the date of or immediately prior to such issuance. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-4<div style="display:inline;">1</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div>. CONVERTIBLE PREFERRED SHARES (CONTINUED) </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion (continued) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_20395384_1" continuedAt="TextSelectionAppend_20395384_2"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Preferred Shares shall be automatically converted into ordinary shares immediately upon the closing of a public offering of the Company&#8217;s shares with an offering price (exclusive of underwriting commissions and expenses) that reflects a market capitalization (immediately prior to the public offering) of not less than US$<ix:nonFraction name="imab:OfferingPriceOfConvertedShares" contextRef="P12_25_2019To12_25_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,000,000,000</ix:nonFraction> or otherwise approved by all directors and certain preferred shareholders as specified in the Company&#8217;s memorandum and articles of association (the &#8220;Qualified Public Offering&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group determined that there were no beneficial conversion features (&#8220;BCF&#8221;) identified for any of the Preferred Shares during any of the periods. In making this determination, the Company compared the fair value of the ordinary shares into which the Preferred Shares are convertible with the respective effective conversion price at the issuance date. In all instances, the effective conversion price was greater than the fair value of the ordinary shares. To the extent a conversion price adjustment occurs, as described above, the Group will reevaluate whether or not a beneficial conversion feature should be recognized. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the event of any liquidation (unless waived by the preferred shareholders) including deemed liquidation, dissolution or winding up of the Company, holders of the Preferred Shares shall be entitled to receive a per share amount equal to one hundred percent (<ix:nonFraction name="imab:PreferredStockLiquidationPreferencePercentage" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">100</ix:nonFraction>%) of the original issue price on each Preferred Share, plus an amount representing an internal rate of return of twelve percent (<ix:nonFraction name="imab:PreferredStockLiquidationPreferenceRateOfReturn" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">12</ix:nonFraction>%) per annum on the original issue price as adjusted for share dividends, share splits, combinations, recapitalizations or similar events, plus all accrued and declared but unpaid dividends thereon, in the sequence of Series C Preferred Shares, Series B Preferred Shares and Series A Preferred Shares. After such liquidation amounts have been paid in full, any remaining funds or assets of the Company legally available for distribution to shareholders shall be distributed on a pro rata basis among the holders of the Preferred Shares, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, together with the holders of the ordinary shares. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting of preferred shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Preferred Shares are redeemable by the holders upon a liquidation event, including a deemed liquidation event (e.g., change in control), and as such are presented as mezzanine equity on the consolidated balance sheets. In accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> each issuance of the convertible preferred shares should be recognized at the date of issuance after deducting fair value allocated to the detachable warrants and issuance costs. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Modification of preferred shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company assesses whether an amendment to the terms of its convertible preferred shares is an extinguishment or a modification using the fair value model.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When convertible redeemable preferred shares are extinguished, the difference between the fair value of the consideration transferred to the convertible redeemable Preferred Shareholders and the carrying amount of such preferred shares (net of issuance costs) is treated as a deemed dividend to the Preferred Shareholders. When convertible redeemable preferred shares are modified and such modification results in value transfer between Preferred Shareholders and ordinary shareholders, the change in fair value resulted from the amendment is treated as a deemed dividend to or from the Preferred Shareholders. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-4<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">4</div>. CONVERTIBLE PREFERRED SHARES (CONTINUED) </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Modification of preferred shares (continued) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_20395384_2" continuedAt="TextSelectionAppend_20395384_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">On December&#160;25, 2019, the Company&#8217;s shareholders and board of directors approved that, where the final offering price of a Qualified Public Offering is no less than US$<ix:nonFraction name="imab:QualifiedPublicOfferingPrice" contextRef="PAsOn12_25_2019_MinimumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">4.176</ix:nonFraction> per ordinary share, the agreed provisions related to the number of shares to be converted into the Company&#8217;s ordinary shares shall apply with respect to the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares, Series C Preferred Shares, Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares, which will generally give rise to a one to multiple conversion of the such rounds of Preferred Shares, provided that unanimous consent of the directors on the final offering price needs to be obtained in the event that the final offering price per ordinary share of such IPO is fixed at a price equal to or higher than US$<ix:nonFraction name="imab:QualifiedPublicOfferingPrice" contextRef="PAsOn12_25_2019_MinimumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">4.176</ix:nonFraction> per ordinary share but lower than US$<ix:nonFraction name="imab:QualifiedPublicOfferingPrice" contextRef="PAsOn12_25_2019_MaximumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">5.22</ix:nonFraction> per ordinary share. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company evaluated the aforementioned modifications and concluded that they represented modifications, rather than extinguishment, to Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> and C Preferred Shares, which resulted in a transfer of value from ordinary shareholders to preferred shareholders. The combined change in fair value of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> and C Preferred Shares immediately before and after the modification was US$<div style="letter-spacing: 0px; top: 0px;;display:inline;">4.0&#160;</div>million (equivalent to approximately RMB<div style="letter-spacing: 0px; top: 0px;;display:inline;">27.8</div> million) on December&#160;25, 2019. This decrease in fair value of the ordinary shares of US$<ix:nonFraction name="us-gaap:EquityFairValueAdjustment" contextRef="P01_25_2019To12_25_2019_PreferredStockMemberusgaapStatementEquityComponentsAxis_TemporaryEquityMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="us-gaap:EquityFairValueAdjustment" contextRef="P01_25_2019To12_25_2019_PreferredStockMemberusgaapStatementEquityComponentsAxis_TemporaryEquityMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">27.8</ix:nonFraction> million) on December&#160;25, 2019 was, in substance, a transfer of wealth mostly from ordinary shareholders to preferred shareholders, and therefore was recorded as a deemed dividend to the preferred shareholders<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company evaluated the aforementioned modifications and concluded that they represented extinguishment to Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares. The difference between the fair value of the modified Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares and the carrying value of the original Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares was amounting US$<ix:nonFraction name="imab:AdjustmentsAtExtinguishmentOfPreferredShares" contextRef="P01_25_2019To12_25_2019_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction>&#160;million on December&#160;25, 2019 and represented the fair value of the consideration transferred, and therefore was recognized as a deemed dividend to the preferred shareholders and adjustment to the carrying amount of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> </div> </ix:continuation></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-4<div style="display:inline;">3</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">4</div>. CONVERTIBLE PREFERRED SHARES (CONTINUED) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_20395384_3"><ix:nonNumeric name="us-gaap:TemporaryEquityTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s convertible preferred shares activities for the years ended December&#160;31, 2019 and 2020 are summarized below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;A&#160;Preferred&#160;Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;B&#160;Preferred&#160;Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;C&#160;Preferred&#160;Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1&#160;Preferred&#160;Shares</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January&#160;1, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">30,227,056</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">102,852</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">687,482</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2018_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">30,305,212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2018_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">139,407</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2018_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">921,243</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2018_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">31,046,360</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2018_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">197,478</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2018_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,306,633</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Issuance of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares, net of issuance costs</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,857,143</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">183,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Adjustment at extinguishment of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:AdjustmentsAtExtinguishmentOfPreferredShares" contextRef="P01_01_2019To12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">754</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:AdjustmentsAtExtinguishmentOfPreferredShares" contextRef="P01_01_2019To12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2019_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">30,227,056</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2019_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">102,852</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2019_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">687,482</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2019_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">30,305,212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2019_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">139,407</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2019_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">921,243</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2019_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">31,046,360</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2019_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">197,478</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2019_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,306,633</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,857,143</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,914</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">188,819</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion to ordinary shares upon IPO</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2020To12_31_2020_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" sign="-" format="ixt:numdotdecimal">30,227,056</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2020To12_31_2020_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">102,852</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2020To12_31_2020_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">687,482</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2020To12_31_2020_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" sign="-" format="ixt:numdotdecimal">30,305,212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2020To12_31_2020_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">139,407</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2020To12_31_2020_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">921,243</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2020To12_31_2020_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" sign="-" format="ixt:numdotdecimal">31,046,360</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2020To12_31_2020_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">197,478</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2020To12_31_2020_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,306,633</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2020To12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" sign="-" format="ixt:numdotdecimal">3,857,143</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2020To12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">26,914</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2020To12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">188,819</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis" unitRef="Unit_CNY" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-4<div style="display:inline;">4</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="imab:ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">5</div>. CONVERTIBLE PROMISSORY NOTES AND ONSHORE CONVERTIBLE LOANS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 Notes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;25, 2017, the Company issued US$<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn09_25_2017_ConvertiblePromissoryNotes2017MemberusgaapDebtInstrumentAxis_SeriesBPreferredStockHolderMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,520</ix:nonFraction> convertible promissory notes (&#8220;2017 Notes&#8221;) to investors of Series B Preferred Shares (see Note 1<div style="display:inline;">4</div>) at a compound interest rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn09_25_2017_ConvertiblePromissoryNotes2017MemberusgaapDebtInstrumentAxis_SeriesBPreferredStockHolderMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction>% per annum, maturing on <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P09_25_2017To09_25_2017_ConvertiblePromissoryNotes2017MemberusgaapDebtInstrumentAxis_SeriesBPreferredStockHolderMemberusgaapStatementClassOfStockAxis" format="ixt-sec:durmonth">36</ix:nonNumeric> months after the issuance date. Under the agreement, the holder of the 2017 Notes may convert the outstanding principal amount into Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares at the conversion price of US$<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn09_25_2017_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">5.38</ix:nonFraction> per share or a lower price as may be agreed by the investors and the Company at any time from six months prior to the maturity date and prior to the repayment in full of the 2017 Note. No interest shall be accrued if the 2017 Notes have been converted into Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the fair value of the Company&#8217;s ordinary shares on September&#160;25, 2017 was lower than the effective conversion price of US$<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn09_25_2017_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">5.38</ix:nonFraction>, the Company did not record a BCF. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On June&#160;29, 2018, the Company&#8217;s 2017 Notes were converted into the Company&#8217;s <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P06_29_2018To06_29_2018_ConvertiblePromissoryNotes2017MemberusgaapDebtInstrumentAxis_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">2,535,201</ix:nonFraction> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares at the nominal conversion price of US$<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn06_29_2018_ConvertiblePromissoryNotes2017MemberusgaapDebtInstrumentAxis_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">5.38</ix:nonFraction> per share. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 Notes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On February&#160;3, 2018, the Company issued US$<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn02_03_2018_ConvertiblePromissoryNotes2018MemberusgaapDebtInstrumentAxis_SeriesA3PreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,000</ix:nonFraction> (equivalent to approximately RMB<ix:nonFraction name="us-gaap:NotesIssued1" contextRef="P02_03_2018To02_03_2018_SeriesA3PreferredSharesMemberusgaapStatementClassOfStockAxis_TwoZeroOneEightNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">59,704</ix:nonFraction>) convertible promissory notes (&#8220;2018 Notes&#8221;) to Genexine, Inc. of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-3</div> Preferred Shares at an annual interest rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn02_03_2018_ConvertiblePromissoryNotes2018MemberusgaapDebtInstrumentAxis_SeriesA3PreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>%, maturing on <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P02_03_2018To02_03_2018_ConvertiblePromissoryNotes2018MemberusgaapDebtInstrumentAxis_SeriesA3PreferredSharesMemberusgaapStatementClassOfStockAxis" format="ixt-sec:durmonth">36</ix:nonNumeric> months after the issuance date. Under the agreement, the holder of the 2018 Notes may convert the 2018 Notes outstanding principal amount into Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares at the conversion price being lower of US$<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn02_03_2018_ConvertiblePromissoryNotes2018MemberusgaapDebtInstrumentAxis_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:numdotdecimal">10</ix:nonFraction> per share and fair market value at any time prior to the maturity date. Alternatively, the 2018 Notes shall be automatically converted into the Company&#8217;s Series B Preferred Shares upon the maturity. As the fair value of the Company&#8217;s ordinary shares on February&#160;3, 2018 of US$<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn02_03_2018_ConvertiblePromissoryNotes2018MemberusgaapDebtInstrumentAxis_SeriesA3PreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">3.96</ix:nonFraction> was equal to the effective conversion price (being lower of US$<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn02_03_2018_ConvertiblePromissoryNotes2018MemberusgaapDebtInstrumentAxis_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:numdotdecimal">10</ix:nonFraction> per share and fair market value), the Company did not record a BCF. On December&#160;17, 2020, the Group issued <ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_17_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TwoZeroOneEightNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">900,000</ix:nonFraction> ordinary shares to Genexine, Inc. upon the full conversion of the 2018 Notes with the conversion price of US$<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_17_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TwoZeroOneEightNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:numdotdecimal">10</ix:nonFraction> per share. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Onshore Convertible Loans </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;25, 2017, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin issued a US$<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn09_25_2017_OnshoreConvertibleLoanMemberusgaapDebtInstrumentAxis_SeriesBOnshoreInvestorsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,359</ix:nonFraction> convertible loan to Series B Onshore Investors at a compound interest rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn09_25_2017" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction>% per annum, maturing on <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P09_25_2017To09_25_2017_OnshoreConvertibleLoanMemberusgaapDebtInstrumentAxis_SeriesBOnshoreInvestorsMemberusgaapStatementClassOfStockAxis" format="ixt-sec:durmonth">36</ix:nonNumeric> months after the issuance date. Under the agreement, the holder of the Onshore Convertible Loans may convert the outstanding principal amount into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin&#8217;s equity interest a stipulated conversion price at any time from six months prior to the maturity date and prior to the repayment in full of the Onshore Convertible Loans. No interest shall be accrued if the Onshore Convertible Loans have been converted into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin&#8217;s equity interest. As the fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin&#8217;s ordinary shares on September&#160;25, 2017 was lower than the effective conversion price of US$<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn09_25_2017_OnshoreConvertibleLoanMemberusgaapDebtInstrumentAxis_SeriesBOnshoreInvestorsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">4.31</ix:nonFraction>, the Company did not record a BCF. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June and July 2018, the Company reached agreements with holders of Onshore Convertible Loans and the principal amount of Onshore Convertible Loans were then effectively converted into <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P09_25_2017To09_25_2017_OnshoreConvertibleLoanMemberusgaapDebtInstrumentAxis_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,179,379</ix:nonFraction> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares of the Company and the accrued interests were waived, resulting in an extinguishment loss of RMB<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P09_25_2017To09_25_2017_OnshoreConvertibleLoanMemberusgaapDebtInstrumentAxis_SeriesBOnshoreInvestorsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">8,548</ix:nonFraction>. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-4<div style="display:inline;">5</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="imab:WarrantsDisclosure" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20394866"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">6</div>. WARRANTS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Warrants to purchase preferred shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In connection with the issuance of the Series B Preferred Shares on September&#160;22, 2017, <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P09_22_2017To09_22_2017_SeriesBPreferredShareholdersMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">5,633,780</ix:nonFraction> Series B Warrants were issued to Series B preferred shareholders, which provided the holders the right to purchase Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the Company&#8217;s Series B Onshore Financing that took place on September&#160;25, 2017, <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P09_25_2017To09_25_2017_SeriesBOnshoreInvestorsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">2,620,842</ix:nonFraction> Series B Warrants were issued to Series B Onshore Investors, which provided the holders the right to purchase Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the period from June&#160;29, 2018 to July&#160;6, 2018, <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn07_06_2018_TrancheIOfSeriesBWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,301,849</ix:nonFraction> Series B Warrants (representing Tranche I of Series B Warrants) were exercised to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn06_29_2018_SeriesB2PreferredSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,301,849</ix:nonFraction> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares with proceeds of US$<ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="P06_29_2018To07_06_2018_SeriesB2PreferredSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,000</ix:nonFraction> (equivalent to approximately RMB<ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="P06_29_2018To07_06_2018_SeriesB2PreferredSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">132,332</ix:nonFraction>). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On July&#160;6, 2018, the Series B Warrants holders agreed that the Series B Warrants shall be divided into two tranches and exercisable in accordance with different time schedules, such that: (i)&#160;the holders have exercised part of the Series B Warrants in the total consideration of US$<ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="P01_01_2020To12_31_2020_TrancheIOfSeriesBWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,000</ix:nonFraction> (&#8220;Tranche I of Series B Warrants&#8221;) and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2020To12_31_2020_SeriesB2PreferredSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,301,849</ix:nonFraction> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares of the Company in aggregate have been newly issued to such holders on a pro rata basis; (ii)&#160;only when the Company fails to submit a Qualified Public Offering application at an internationally recognized securities exchange by March&#160;31, 2019, the Warrant Holders may exercise the remaining part of Series B Warrants, in the total consideration of US$<ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="P01_01_2020To12_31_2020_TrancheIiOfSeriesBWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,000</ix:nonFraction> (&#8220;Tranche II of Series B Warrants&#8221;) and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn07_06_2018_SeriesBWarrantsSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,952,773</ix:nonFraction> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares of the Company in aggregate will be issued to such holders on a pro rata basis; (iii)&#160;provided that the Company successfully submits a Qualified Public Offering application at an internationally recognized securities exchange by March&#160;31, 2019, the holders shall unconditionally and irrevocably waive and cancel Tranche II of Series B Warrants; and (iv)&#160;the Tranche II of Series B Warrants may only be concurrently exercised by all the Warrant Holders in one lump. This is considered to be a modification to Series B Warrants. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">According to the confirmations issued by the Company&#8217;s Series B Warrants holders in July 2019, the holders of Series B Warrants has unconditionally and irrevocably waived and cancelled the Tranche II of Series B Warrants. The fair value gain of warrants for the years ended December&#160;31, 2019 and 2020 was amounting to RMB<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2020To12_31_2020_SeriesBWarrantsSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,644</ix:nonFraction> and nil, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting of warrants for purchase preferred shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The warrant is a freestanding instrument and is recorded as liability in accordance with ASC 480, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity</div></div>. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the Company&#8217;s issuance of warrants were bundled with other instruments (such as convertible preferred shares, convertible promissory notes, etc.), out of total considerations, the warrants are initially recognized at fair value and the remaining were allocated to other instruments on a relative fair value basis (if applicable). The fair value changes of the warrants (including the fair value changes arising from modification of warrants) up to the time of exercise or termination were recognized in earnings. Upon exercise, the total carrying value of the associated warrant liabilities was reclassified into the carrying value of the Preferred Shares into which it was converted. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company determined the fair value of the warrants with the assistance of an independent third-party valuation firm. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) Warrants to purchase ordinary shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As mentioned in Note 1<div style="display:inline;">3</div>, on September&#160;3, 2020, the Group entered into definitive subscription agreements with the Investors to raise approximately US$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2020To12_31_2020_CollaborationAgreementWithInvestorsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">418</ix:nonFraction>&#160;million through a private placement, which comprises the Investor Warrants to subscribe for an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2020To12_31_2020_AmericanDepositarySharesMemberusgaapStatementEquityComponentsAxis_InvestorWarrantsMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,341,267</ix:nonFraction> ordinary shares (equivalent to 2,322,290 ADSs) at an exercise price equivalent to US$<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2020_AmericanDepositarySharesMemberusgaapStatementEquityComponentsAxis_InvestorWarrantsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">45</ix:nonFraction> per ADS. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-4<div style="display:inline;">6</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">6</div>. WARRANTS (CONTINUED) </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) Warrants to purchase ordinary shares (Continued) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_20394866"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Subscription Agreement with the Hillhouse entities contemplates two closings. In the first closing occurred on September&#160;11, 2020 and second closing occurred on December&#160;17, 2020, the Investor Warrants were issued with fixed exercise prices of US$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P01_01_2020To12_31_2020_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="2" scale="0" format="ixt:numdotdecimal">45.00</ix:nonFraction> per ADS (equivalent to US$19.57 per share) and lives of one year. The number of common share purchasable upon exercise of the Investor Warrants shall be proportionally adjusted to reflect any share dividend, share split, combination of shares or reverse share split, or other similar event affecting the number of outstanding common shares. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for warrants to purchase ordinary shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Investor Warrants are regarded as indexed to the Company&#8217;s own stock and were classified as equity and initially measured at fair value and subsequent changes in fair value are not recognized as long as the Investor Warrants continue to be classified as equity. <ix:nonNumeric name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20395404">The estimated fair value of the Investor Warrants was shown below, which were used to determine the allocation of the total proceeds for the sale of ordinary shares between the Investor Warrants and ordinary shares.</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_20395404">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Terms</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price&#160;per<br/> share</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;value&#160;at</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">the&#160;closing</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">date</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB&#8217;000</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrants to purchase ordinary shares (first closing on September 11, 2020)</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imab:Classofwarrantorrightsexercisableterm" contextRef="P09_11_2020To09_11_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durwordsen">12 months</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_11_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">19.57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn09_11_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,744,032</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="PAsOn09_11_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">71,874</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrants to purchase ordinary shares (second closing on </div></div><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;17, 2020)</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="imab:Classofwarrantorrightsexercisableterm" contextRef="P12_17_2020To12_17_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durwordsen">12 months</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_17_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">19.57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_17_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,597,235</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="PAsOn12_17_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">37,869</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group determined the fair value of the warrants with the assistance of an independent third-party valuation firm. <ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20395400">The Group used the binomial model to estimate the fair value of the warrant on September&#160;11, 2020 and December&#160;17, 2020 when the Investor Warrants were issued using the following assumptions:</ix:nonNumeric> </div></div> <ix:continuation id="TextSelection_20395400"> <div style="text-align:left;"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 92%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of September&#160;11,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;17,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 92%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 92%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate of return</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_11_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:numdotdecimal">0.12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_17_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:numdotdecimal">0.08</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 92%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturity date</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="PAsOn09_11_2020_MeasurementInputMaturityMemberusgaapMeasurementInputTypeAxis" format="ixt:datemonthdayyearen">September 11, 2021</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="PAsOn12_17_2020_MeasurementInputMaturityMemberusgaapMeasurementInputTypeAxis" format="ixt:datemonthdayyearen">December 17, 2021</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 92%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated volatility rate</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_11_2020_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:numdotdecimal">60.72</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_17_2020_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:numdotdecimal">59.56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 92%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom; width: 1%;"></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">US$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_11_2020_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:numdotdecimal">19.57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;"></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">US$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_17_2020_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:numdotdecimal">19.57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div></div> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The model requires the input of assumptions including the risk-free rate of return, maturity date and estimated volatility rate. The risk-free rate for periods within the contractual life is based on the US treasury strip bond with maturity similar to the maturity of the warrants as of valuation dates plus a China country risk premium. For expected volatilities, the Group has made reference to the historical daily stock prices volatilities of ordinary shares of several comparable companies in the same industry as the Group. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-4<div style="display:inline;">7</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20395780"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">7</div>. SHARE-BASED COMPENSATION </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(a) Restricted shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2016, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P01_01_2016To12_31_2016_FoundersMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,019,554</ix:nonFraction> ordinary shares to Mr.&#160;Zang Jingwu Zhang, Ms.&#160;Qian Lili, Mr.&#160;Wang Zhengyi and Mr.&#160;Fang Lei (collectively the &#8220;Founders&#8221;), including the <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P01_01_2016To12_31_2016_ThirdVentureMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">369,301</ix:nonFraction> shares which represented the equity interests of Third Venture held by the Founders, and the Company recorded share-based compensation expense of RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P06_01_2016To06_30_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">18.7</ix:nonFraction>&#160;million for issuance and grant of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P06_01_2016To06_30_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,650,253</ix:nonFraction> ordinary shares to the Founders in June 2016. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2016, the Founders entered into an arrangement with other investors of the Company, and the <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="P10_01_2016To10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">87,441</ix:nonFraction> ordinary shares issued to the Founders in June 2016 were canceled and out of the remaining <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="PAsOn10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,932,113</ix:nonFraction> ordinary shares held by the Founders, <ix:nonFraction name="imab:ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted" contextRef="P10_01_2016To10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">70</ix:nonFraction>% became restricted and subject to service vesting conditions, that should vest <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P10_01_2016To10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>%, <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P10_01_2016To10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>% and <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P10_01_2016To10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">30</ix:nonFraction>% over the next three years, respectively. There shall be no acceleration of the vesting schedule except that, in case of a change of control of the Company or a Qualified Public Offering, or the termination of the Founder&#8217;s employment with the Group without cause. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred share-based compensation was measured for the restricted shares using the estimated fair value of the Company&#8217;s ordinary shares of US$<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn10_31_2016" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.77</ix:nonFraction> at the date of imposition of the restriction in October 2016, and was amortized to the consolidated statements of comprehensive loss by using graded vesting method over the vesting term of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P10_31_2019To10_31_2019_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">3</ix:nonNumeric> years. As of December&#160;31, 2019, all the restricted shares were fully vested. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-4<div style="display:inline;">8</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">7</div>. SHARE-BASED COMPENSATION (CONTINUED) </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(a) Restricted shares (continued) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_20395780" continuedAt="TextSelectionAppend_20395780_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amounts of shared-based compensation expense in relation to the restricted shares recognized in the years ended December&#160;31, 2018, 2019 and 2020 were RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">3,520</ix:nonFraction>, RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,566</ix:nonFraction> and <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">nil</ix:nonFraction>, respectively. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses related to restricted shares were included in: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,056</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">470</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative expenses</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,096</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">3,520</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,566</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(b) 2017 Employee Stock Option Plan (&#8220;2017 Plan&#8221;) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2017, the Company adopted the 2017 Plan. Under the 2017 Plan, a maximum aggregate number of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn10_31_2017_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">13,376,865</ix:nonFraction> shares that may be issued pursuant to all awards granted was approved. Stock options granted to an employee under the 2017 Plan will be exercisable upon the Company completes a listing and the employee renders service to the Company in accordance with a stipulated service schedule starting from the employee&#8217;s date of employment. Employees are generally subject to a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P10_01_2017To10_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">three-year</ix:nonNumeric> service schedule, under which an employee earns an entitlement to vest in <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P10_01_2017To10_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% of the option grants on the second anniversary of the grant date, a vesting of the remaining <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P10_01_2017To10_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% on the third anniversary of the applicable grant date. The stock option under 2017 Plan, to the extent then vested, shall become exercisable only upon the earlier of (i)&#160;a listing, and (ii)&#160;occurrence of a change in control. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-4<div style="display:inline;">9</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">7</div>. SHARE-BASED COMPENSATION (CONTINUED) </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(b) 2017 Employee Stock Option Plan (&#8220;2017 Plan&#8221;) (continued) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_20395780_1" continuedAt="TextSelectionAppend_20395780_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">On December&#160;25, 2019, the Second Amended and Restated 2017 Plan was approved by the shareholders and board of directors of the Company, pursuant to which, in connection with the Company&#8217;s IPO, the maximum aggregate number of shares that may be granted pursuant to all awards under 2017 Plan shall be adjusted in accordance with a formula <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approved</div> by the shareholders. In connection with above amendments to 2017 Plan, each of the Company&#8217;s founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, is willing to irrevocably surrender by him or her, for no consideration, a portion of the unvested options granted to him or her, which, if vested, would entitle him or her to acquire up to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2017To12_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_LeiFangMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">130,000</ix:nonFraction> ordinary shares of the Company, par val<div style="letter-spacing: 0px; top: 0px;;display:inline;">u</div>e US$<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2017" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction> per share, at an exercise price of US$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2017To12_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="1" scale="0" format="ixt:numdotdecimal">1.0</ix:nonFraction>, respectively, under the Second Amended and Restated 2017 Plan (in respect of each individual, the &#8220;Founder&#8217;s Surrendered Options&#8221;). On December&#160;25, 2019, the board of directors of the Company approved that the Company accepts all Founder&#8217;s Surrendered Options from each of the founders, Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, for no consideration, with effect immediately prior to the completion of the IPO and such surrendered options be cancelled with effect immediately prior to the completion of the IPO. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the Company completes a listing, all stock options granted to an employee shall be forfeited at the time the employee terminates his employment with the Group. After the Company completes a listing, vested options not exercised by an employee shall be exercised until later of: (i) 90 days after the date when the options become exercisable, or (ii) 30 days after the date of cessation of employment or directorship, or such longer period as the Board of Directors may otherwise determine. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For the years ended December 31, 2018 and 2019, the Group granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2018To12_31_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,470,000</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2019To12_31_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">640,000</ix:nonFraction> stock options respectively, to its employees (all with an exercise price of US$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2019To12_31_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2018To12_31_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction></ix:nonFraction>).&#160;</div>The Group did not grant any stock options to employees for the year ended December&#160;31,&#160;2020. <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> options were exercisable as of December&#160;31, 2019 and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,790,924</ix:nonFraction> stock options were exercisable as of December&#160;31, 2020. <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2019To12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> options were exercised as of December&#160;31, 2019 and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,439,373</ix:nonFraction> stock options were exercised as of December&#160;31, 2020. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">50</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>. SHARE-BASED COMPENSATION (CONTINUED) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(b) 2017 Employee Stock Option Plan (&#8220;2017 Plan&#8221;) (continued) </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" escape="true"><ix:continuation id="TextSelectionAppend_20395780_2" continuedAt="TextSelectionAppend_20395780_3"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the stock options activities of 2017 Plan for the periods presented: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_20395780_3" continuedAt="TextSelectionAppend_20395780_4">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Number&#160;of<br/> shares</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Weighted<br/> average<br/> exercise<br/> price<br/> US$</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Weighted<br/> average<br/> remaining<br/> contractual<br/> term</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Aggregate<br/> intrinsic<br/> value<br/> US$</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2017</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="PAsOn12_31_2016_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">11,761,596</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2016_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2017To12_31_2017_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">9.50</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2017_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,890</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2018To12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,470,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2018To12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="P01_01_2018To12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">226,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2018To12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2018</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="PAsOn12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">13,005,596</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2018To12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">8.61</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">70,129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2019To12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">640,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2019To12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="P01_01_2019To12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">397,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2019To12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased (Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>(d))</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" contextRef="P01_01_2019To12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,435,215</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="imab:SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2019To12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31 ,2019</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="PAsOn12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">9,812,881</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.93</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2019To12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">7.76</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">47,671</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">338,876</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,439,373</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.72</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Surrendered<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;(Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>(h))</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod" contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">332,566</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="imab:Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice" contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31 ,2020</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">7,702,066</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.97</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">6.75</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">150,415</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,790,924</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.97</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">6.75</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">132,650</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> </ix:continuation></ix:nonNumeric><ix:continuation id="TextSelectionAppend_20395780_7" continuedAt="TextSelectionAppend_20395780_8"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" escape="true"><div style="text-align: left;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to the employees were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="width: 0.75%;"></td>
<td style="width: 0.75%;"></td>
<td style="width: 1.5%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0.75%;;text-align:center;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0.75%; text-align: right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="P01_01_2018To12_31_2018_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">61.32</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="P01_01_2018To12_31_2018_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">62.13</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;;text-align:center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">54.64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate (per annum)</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0.75%;;text-align:center;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0.75%; text-align: right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="P01_01_2018To12_31_2018_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.81</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="P01_01_2018To12_31_2018_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">3.06</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; text-align: right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise multiple</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0.75%; padding: 0pt 0.5pt;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0.75%; padding: 0pt 0.5pt; text-align: right;"><ix:nonFraction name="imab:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple" contextRef="PAsOn12_31_2018_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:numdotdecimal">2.80</ix:nonFraction></td>
<td style="vertical-align: bottom; width: 1.5%; padding: 0pt 0.5pt;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; text-align: right;"><ix:nonFraction name="imab:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple" contextRef="PAsOn12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:numdotdecimal">2.80</ix:nonFraction></td>
<td style="vertical-align: bottom; text-align: right;"> <div style="line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.75%;;text-align:center;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.75%; text-align: right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1.5%;;text-align:center;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2019To12_31_2019_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual term (in years)</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 0.75%;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0.75%; text-align: right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2018To12_31_2018_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">10</ix:nonNumeric></td>
<td style="vertical-align: bottom; text-align: right; width: 1.5%;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; text-align: right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">10</ix:nonNumeric></td>
<td style="vertical-align: bottom; text-align: right;"> <div style="line-height: normal;">&#160;</div> </td> </tr> </table> </div> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of the Group&#8217;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the Group&#8217;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>. SHARE-BASED COMPENSATION (CONTINUED) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(b) 2017 Employee Stock Option Plan (&#8220;2017 Plan&#8221;) (continued) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_20395780_4" continuedAt="TextSelectionAppend_20395780_5"><ix:nonNumeric name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">A summa<div style="letter-spacing: 0px; top: 0px;;display:inline;">r</div>y of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock option activities for the year ended December&#160;31, 2020 is presented below: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Grant&#160;date&#160;fair&#160;value</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2019</div> </td>
<td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="PAsOn12_31_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">9,812,881</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">2.10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,790,924</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.90</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">1,439,373</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="imab:Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="2" scale="0" format="ixt:numdotdecimal">1.37</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">338,876</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">2.29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Surrendered</div></div> </td>
<td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="imab:Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">332,566</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="imab:Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="2" scale="0" format="ixt:numdotdecimal">1.47</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2020</div> </td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">911,142</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">4.96</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 64%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since the exercisability <div style="letter-spacing: 0px; top: 0px;;display:inline;">wa</div>s dependent upon the listing, and it <div style="letter-spacing: 0px; top: 0px;;display:inline;">wa</div>s not probable that this performance condition c<div style="letter-spacing: 0px; top: 0px;;display:inline;">ould</div>&#160;be achieved until a listing, <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> share-based compensation expense relating to the 2017 Plan was recorded for the year ended December&#160;31, 2018 and 2019. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;17, 2020, the Group completed its IPO. After achieving this performance condition, the options continue to vest based only on service period completed according to the graded vesting schedule. The Group has begun recognizing share-based compensation expense for the options granted using the graded vesting method with a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> for the service period completed to date during the year ended December&#160;31, 2020 and recognized RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">52,802</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;">RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">69,213</ix:nonFraction> and&#160;</div>RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">4,277</ix:nonFraction> share-based compensation expenses in administrative expenses<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div>&#160;research and development <div style="letter-spacing: 0px; top: 0px;;display:inline;">expenses and equity in loss of an affiliate, respectively&#160;</div>relating to options vested cumulatively. According to the amendments to 2017 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2017 Plan was changed to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_17_2020To01_17_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">9,609,084</ix:nonFraction>. Each of the Group&#8217;s founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang surrendered <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="P01_17_2020To01_17_2020_SeniorManagementEmployeesMembersrtTitleOfIndividualAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">83,142</ix:nonFraction> unvested stock options that were granted to him or her under 2017 Plan before, totally <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="P01_17_2020To01_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">332,566</ix:nonFraction> unvested options, for no consideration, and these stock options were cancelled immediately. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">7</div>. SHARE-BASED COMPENSATION (CONTINUED) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_20395780_5" continuedAt="TextSelectionAppend_20395780_6"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(c) 2018 Employee Stock Option Plan (&#8220;2018 Plan&#8221;) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;22, 2019, the Group adopted the 2018 Plan, which was subsequently amended on July&#160;22, 2019.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Under the amended and restated 2018 Plan, the maximum aggregate number of ordinary shares which may be issued pursuant to all awards is <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn02_22_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">14,005,745</ix:nonFraction>, and if the Group successfully lists on an internationally recognized securities exchange for a Qualified Public Offering by December&#160;31, 2019, the maximum aggregate number of ordinary shares which may be issued shall be <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">15,452,620</ix:nonFraction>. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On December&#160;25, 2019, the Second Amended and Restated 2018 Plan were approved by the shareholders and board of directors of the Company, pursuant to which, in connection with the Company&#8217;s IPO, the maximum aggregate number of shares that may be granted pursuant to all awards under 2018 Plan shall be adjusted in accordance with a formula <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approved</div> by the shareholders. In connection with above amendments to 2018 Plan, the director of the Company, Dr.&#160;Jingwu Zhang Zang is willing to irrevocably surrender by him, for no consideration, of the right to acquire a certain amount of ordinary shares of the Company, par value US$<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2018" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction> per share, at an exercise price of US$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P02_22_2019To02_22_2019_DrzangMembersrtTitleOfIndividualAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="1" scale="0" format="ixt:numdotdecimal">1.0</ix:nonFraction> pursuant to the options granted to him under the Second Amended and Restated 2018 Plan (the &#8220;Dr.&#160;Zang&#8217;s Surrendered Options&#8221;). On December&#160;25, 2019, the board of directors of the Company approved that the Company accepts the irrevocable surrender of Dr.&#160;Zang&#8217;s Surrendered Options for no consideration, with effect immediately prior to the completion of the IPO and such surrendered options be cancelled with effect immediately prior to the completion of the IPO. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Stock options granted to an employee under the 2018 Plan will be generally exercisable when the Company completes a listing and the employee renders service to the Company in accordance with a stipulated service schedule starting from the employee&#8217;s date of employment. The vesting schedule shall generally be a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P02_22_2019To02_22_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">two-year</ix:nonNumeric></div> vesting schedule consisting of a cliff vesting <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P02_22_2019To02_22_2019_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% on the first anniversary of the applicable vesting commencement date, and a vesting of the remaining <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P02_22_2019To02_22_2019_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% on the second anniversary of the applicable vesting commencement date. If a listing occurs at anytime prior to any option granted under the 2018 Plan becoming full vested, and to the extent such option has been granted and outstanding, any such option shall vest in full with immediate effect upon the listing. Except as otherwise approved by the board of directors, vested portion of option shall become exercisable upon the earlier of six months after a listing or the occurrence of a change in control; provided, however that in each case, no option of an employee shall become exercisable until the third anniversary of such employee&#8217;s employment commencement date. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Board of Director&#8217;s approval of 2018 Plan on February&#160;22, 2019, the 10,893,028 stock options granted to a director of the Group under 2018 Plan were fully vested and exercisable upon the adoption of 2018 Plan. Out of aforementioned total <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="PAsOn02_22_2019_DirectorMembersrtTitleOfIndividualAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">10,893,028</ix:nonFraction> stock options, <ix:nonFraction name="imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">454,940</ix:nonFraction> stock options were repurchased by the Group (see Note 1<div style="display:inline;">7</div>&#160;(d) for further details). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amounts of shared-based compensation expense in relation to the aforementioned grant of stock options to a director of the Group (except for those repurchased by the Group as described in Note 1<div style="display:inline;">7 </div>(d)) recognized in the year ended December&#160;31, 2019 was RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">365,329</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;included in administrative expenses.</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5<div style="display:inline;">3</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">7</div>. SHARE-BASED COMPENSATION (CONTINUED) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(c) 2018 Employee Stock Option Plan (&#8220;2018 Plan&#8221;)</div></div></div><ix:continuation id="TextSelectionAppend_20395780_6" continuedAt="TextSelectionAppend_20395780_7"><ix:nonNumeric name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the stock options activities of 2018 Plan for the years ended December&#160;31, 2019 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Number&#160;of<br/> shares</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Weighted<br/> average<br/> exercise<br/> price<br/> US$</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Weighted<br/> average<br/> remaining<br/> contractual<br/> term</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Aggregate<br/> intrinsic<br/> value<br/> US$</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of January&#160;1, 2019</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">13,991,528</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased (Note 1<div style="display:inline;">7</div>&#160;(d))</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">454,940</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="PAsOn12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">13,536,588</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">8.86</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">64,840</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">402,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#8212; &#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Surrendered (Note 1<div style="display:inline;">7</div>&#160;(h))</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;">(<ix:nonFraction name="imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod" contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">2,544,917</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="imab:Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice" contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#8212; &#160;</div>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="PAsOn12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">10,589,671</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">8.15</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">206,499</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">9,764,670</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">8.15</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">190,411</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr></table> </ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to certain directors and employees of the Group were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 17%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">54.64</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">56.31</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate (per annum)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.15</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.75</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise multiple</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple" contextRef="PAsOn12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:numdotdecimal">2.80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">10</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of the Group&#8217;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the Group&#8217;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A summa<div style="letter-spacing: 0px; top: 0px;;display:inline;">r</div>y of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock option activities for the year ended December&#160;31, 2020 is presented below: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2019</div></td>
<td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="PAsOn12_31_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,098,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">5.57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,871,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">5.57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Exercise<div style="letter-spacing: 0px; top: 0px;;display:inline;">d</div></div></div></td>
<td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">402,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="imab:Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="2" scale="0" format="ixt:numdotdecimal">5.57</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2020</div></td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">825,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">5.57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 64%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5<div style="display:inline;">4</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">7</div>. SHARE-BASED COMPENSATION (CONTINUED) </div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(c) 2018 Employee Stock Option Plan (&#8220;2018 Plan&#8221;)(continued) </div></div></div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_20395780_8" continuedAt="TextSelectionAppend_20395780_9"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except for the aforementioned grant of stock options to a director of the Group under 2018 Plan, since the exercisability is dependent upon the listing, and it is not probable that this performance condition can be achieved until a listing, <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> share-based compensation expense related to the 2018 Plan was recorded for the year ended December&#160;31, 2019. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;17, 2020, the Group completed its IPO. After achieving this performance condition, the options continue to vest based only on service period completed according to the graded vesting schedule. The Group has begun recognizing share-based compensation expense for the options granted using the graded vesting method with a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> for the service period completed to date during the year ended December&#160;31, 2020 and recognized RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">48,055</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">, RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">65,656</ix:nonFraction> and&#160;</div></div>RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">226</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">share-based compensation expense in administrative expenses and research, development expenses and equity in loss of an affiliate, respectively relating to options vested cumulatively. According to the amendments to 2018 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2018 Plan was changed to</div> <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_17_2020To01_17_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">11,005,888</ix:nonFraction>. The director of the Company, Dr.&#160;Jingwu Zhang Zang surrendered <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="P01_17_2020To01_17_2020_SeniorManagementEmployeesMembersrtTitleOfIndividualAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">2,544,917</ix:nonFraction> unvested options that were granted to him under 2018 Plan, for no consideration, and these stock options were cancelled immediately. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5<div style="display:inline;">5</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">7</div>. SHARE-BASED COMPENSATION (CONTINUED) </div></div></div> <ix:continuation id="TextSelectionAppend_20395780_9" continuedAt="TextSelectionAppend_20395780_10"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(d) Repurchase of share awards held by a director </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;22, 2019, the amendment and restated 2017 equity incentive plan was approved by the Board of Directors of the Group, pursuant to which only the <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="PAsOn02_22_2019_AmendedTwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis_DirectorMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,435,215</ix:nonFraction> stock options held by the director (see Note 1<div style="display:inline;">7</div>(c)) under the 2017 equity incentive plan became fully vested and exercisable on February&#160;22, 2019. As a result of the performance condition being waived, the stock options held by the director of the Group were accounted for as a Type III modification where a condition that the Group expects will not be satisfied is changed to a condition that the Group expects will be satisfied. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, on the same day, the Group repurchased such <ix:nonFraction name="imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" contextRef="P02_22_2019To02_22_2019_AmendedTwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis_DirectorMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,435,215</ix:nonFraction> stock options under the amendment and restated 2017 equity incentive plan that was held by the director of the Group along with <ix:nonFraction name="imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">454,940</ix:nonFraction> of his stock options under the 2018 equity incentive plan for which the share awards also became fully vested and exercisable, at a total consideration of US$<ix:nonFraction name="imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration" contextRef="P02_22_2019To02_22_2019_DirectorMembersrtTitleOfIndividualAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,902</ix:nonFraction> (equivalent to approximately RMB<ix:nonFraction name="imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration" contextRef="P02_22_2019To02_22_2019_DirectorMembersrtTitleOfIndividualAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">148,308</ix:nonFraction>) at an average share price of US$<ix:nonFraction name="imab:SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" contextRef="P02_22_2019To02_22_2019_DirectorMembersrtTitleOfIndividualAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">5.63</ix:nonFraction> per share. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2019, the Group recorded the total payment of US$<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_DirectorMembersrtTitleOfIndividualAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,902</ix:nonFraction> (equivalent to approximately RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_DirectorMembersrtTitleOfIndividualAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">148,308</ix:nonFraction>) as share-based compensation costs (included in administrative expenses) in the consolidated statement of comprehensive loss. There was no impact to the overall stockholder&#8217;s equity balance as the amended shares vested immediately and were repurchased. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(e) 2019 Share Incentive Plan (&#8220;2019 Plan&#8221;) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;29, 2019, the Group adopted 2019 Share Incentive Plan (the &#8220;2019 Plan&#8221;), which will become effective immediately prior to the completion of the Company&#8217;s initial public offering. Under the 2019 Plan, the maximum aggregate number of ordinary shares available for issuance shall initially be <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn12_31_2020_TwentyNineteenShareIncentivePlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">100,000</ix:nonFraction>. </div></div> <div style="text-align: left;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The options shall vest when the Group completes a listing and the employee renders service to the Group in accordance with a stipulated service schedule starting from the employee&#8217;s date of employment. Stock options granted to 3 independence directors under the 2019 Plan will be generally exercisable under the following terms:(a) a cliff vesting of 1/3 of the option on the first anniversary of the vesting commencement date (January 17, 2020); (b) a cliff vesting of 1/3 of the option on the second anniversary of the vesting commencement date (January 17, 2020); (c) a vesting of the remaining 1/3 of the option on the third anniversary of the vesting commencement date. In the last year of the grantee&#8217;s service, the options shall vest on a prorated basis to reflect the portion of the year during which the grantee provided services to the Group.</div></div></div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2020, the Group granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2020To12_31_2020_TwentyNineteenShareIncentivePlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2020To12_31_2020_TwentyNineteenShareIncentivePlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">72,000</ix:nonFraction></ix:nonFraction> stock options to 3 independent directors (all with an exercise price of US$<ix:nonFraction name="us-gaap:StockOptionExercisePriceIncrease" contextRef="P01_01_2020To12_31_2020_TwentyNineteenShareIncentivePlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">6.09</ix:nonFraction>) and recognized RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_TwentyNineteenShareIncentivePlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,171</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">share-based compensation expenses in administrative expenses according to the options&#8217; vesting schedule.&#160;</div>No options were exercisable as of December&#160;31, 2020. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the stock options activities of 2019 Plan for the year ended December&#160;31, 2020 presented: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number&#160;of</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">shares</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">exercise</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">price</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">remaining</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">contractual</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">term</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregate</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">intrinsic</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">value</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">72,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">6.09</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="PAsOn12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">72,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">6.09</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">9.33</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,038</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5<div style="display:inline;">6</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>. SHARE-BASED COMPENSATION (CONTINUED) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(e) 2019 Share Incentive Plan (&#8220;2019 Plan&#8221;) (Continued) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_20395780_10" continuedAt="TextSelectionAppend_20395780_11"><ix:nonNumeric name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;">A summary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock options activity for the year ended December&#160;31, 2020 is presented below: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2019</div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">72,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">4.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2020</div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="PAsOn12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">72,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">4.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr> </table> </ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" escape="true"><div style="text-align: left;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to the 3 independent directors were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 22%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom; width: 22%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">54.88</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate (per annum)</div></div> </td>
<td style="vertical-align: bottom; width: 22%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.79</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise multiple</div></div> </td>
<td style="vertical-align: bottom; width: 22%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple" contextRef="PAsOn12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:numdotdecimal">2.80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual term (in years)</div></div> </td>
<td style="vertical-align: bottom; width: 22%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">10</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="clear: both; max-height: 0px; background: none;"></div> </div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> </div> </div> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of the Group&#8217;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the Group&#8217;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(f) 2020&#160;Plan</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;15, 2020, the Group adopted 2020 Share Incentive Plan (&#8220;2020 Plan&#8221;). Under the 2020 Plan, the maximum aggregate number of shares authorized to be issued is <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn07_15_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">10,760,513</ix:nonFraction> ordinary shares, provided that the maximum number of shares to be issued in the form of restricted share units shall not exceed <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn07_15_2020_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">7,686,081</ix:nonFraction> ordinary shares. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to employees under the 2020 Plan are graded vesting in four years with <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2020To12_31_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>% vesting each year. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2020, the Group granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2020To12_31_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,068,733</ix:nonFraction> stock options to its employees and recognized RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">4,357</ix:nonFraction> RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">10,435</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;and RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,619</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>share-based compensation expenses in administrative expenses, research and development expenses and equity in loss of an affiliate, respectively, in the <div style="letter-spacing: 0px; top: 0px;;display:inline;">consolidated<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;statement of</div> comprehensive&#160;income</div>.</div>&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> option became exercisable as of December&#160;31, 2020. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>. SHARE-BASED COMPENSATION (CONTINUED) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(f) 2020&#160;Plan (Continued) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" contextRef="P01_01_2020To12_31_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" escape="true" continuedAt="TextSelection_20395796"><ix:continuation id="TextSelectionAppend_20395780_11" continuedAt="TextSelectionAppend_20395780_12">The following table sets forth the stock options activities of 2020 Plan for the year ended December&#160;31, 2020:</ix:continuation></ix:nonNumeric> </div></div> <ix:continuation id="TextSelectionAppend_20395780_12" continuedAt="TextSelectionAppend_20395780_13"><ix:continuation id="TextSelection_20395796"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">exercise</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">price</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">remaining</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">contractual</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">intrinsic</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">value</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,068,733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">5.91</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">24,365</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">)&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">5.91</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0in;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="PAsOn12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,044,368</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">5.91</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" format="ixt-sec:duryear">9.62</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,237</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0in;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0in;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td> </tr> </table> </ix:continuation><ix:nonNumeric name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" contextRef="P01_01_2020To12_31_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A summary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock option activities for the year ended December&#160;31, 2020 is presented below: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2019</div> </td>
<td style="vertical-align: bottom; width: 11in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 11in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,068,733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">8.71</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 11in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">24,365</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 10in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">8.65</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65in;">&#160;</td>
<td style="vertical-align: bottom; width: 11in;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 10in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2020</div> </td>
<td style="vertical-align: bottom; width: 11in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="PAsOn12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,044,368</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">8.71</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 65in;">&#160;</td>
<td style="vertical-align: bottom; width: 11in;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 10in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr> </table> </ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2020To12_31_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" escape="true"><div style="text-align: left;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to the employees were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 18%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom; width: 18in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">56.51</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate (per annum)</div></div> </td>
<td style="vertical-align: bottom; width: 18in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise multiple</div></div> </td>
<td style="vertical-align: bottom; width: 18in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" contextRef="PAsOn12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:numdotdecimal">2.20</ix:nonFraction>-<ix:nonFraction name="imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" contextRef="PAsOn12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:numdotdecimal">2.80</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom; width: 18in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contractual term (in years)</div> </td>
<td style="vertical-align: bottom; width: 18in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" format="ixt-sec:duryear">10</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr> </table> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> </div> </div> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of the Group&#8217;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the Group&#8217;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>. SHARE-BASED COMPENSATION (CONTINUED) </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(f) 2020&#160;Plan (Continued) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_20395780_13" continuedAt="TextSelectionAppend_20395780_14"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted share units granted to employees under the 2020 Plan will be exercisable under the following items: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) 1/3 of the awarded restricted share units shall vest based on the following time attribution:(i) a vesting of <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>% of the time attribution based restricted share units on the first anniversary of the applicable adoption date;(ii) a vesting of <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>% of the time attribution based restricted share units on the second anniversary of the applicable adoption date;(iii) a vesting of <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>% of the time attribution based restricted share units on the third anniversary of the applicable adoption date;(iv) a vesting of <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationTrancheFourMemberusgaapVestingAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>% of the time attribution based restricted share units on the fourth anniversary of the applicable adoption date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) 1/3 of the awarded restricted share units shall vest based on the Group&#8217;s weighted average market value during the last <ix:nonNumeric name="imab:NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">30 days</ix:nonNumeric> prior to the initial vesting date, the terms and conditions of which are set forth in the executed award agreements. In the event that dilution of additional share issuance occurs, the market value targets herein shall be adjusted accordingly with the proportion of additional share issuance. In the event that the average market value of Standard&#160;&amp; Poor&#8217;s 500 index falls by more than <ix:nonFraction name="imab:MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_SecondOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>% from the date of grant, it shall be deemed as a decline of the market, and the board of the Group or a committee that board delegated its powers or authority to shall adjust the vesting schedule as appropriate. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) 1/3 of the awarded restricted share units shall vest based on certain performance conditions:(i) a vesting of <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2020To12_31_2020_OnePerformanceConditionMemberusgaapVestingAxis_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>% of the performance conditions based restricted share units if one of the performance conditions has been met at the initial vesting date;(ii) a vesting of <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_TwoPerformanceConditionsMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>% of the performance conditions based restricted share units if two of the performance conditions have been met at the initial vesting date;(iii) a vesting of <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_ThreePerformanceConditionsMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>% of the performance conditions based restricted share units if three of the performance conditions have been met at the initial vesting date;(iv) a vesting of <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2020To12_31_2020_FourPerformanceConditionsMemberusgaapVestingAxis_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">80</ix:nonFraction>% of the performance conditions based restricted share units if four of the performance conditions have been met at the initial vesting date; (v)&#160;a vesting of all of the performance conditions based restricted share units if five of the performance conditions or more have been met at the initial vesting date. As of December&#160;31, 2020, it is probable that the 1/3 of the awarded restricted share units are fully vested because it is probable that at least five of the performance conditions will be met at the initial vesting date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the foregoing, if the Group&#8217;s weighted average market value during the last <ix:nonNumeric name="imab:NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_SecondOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">30 days</ix:nonNumeric> prior to the initial vesting date reaches US$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-9" scale="9" format="ixt:numdotdecimal">2</ix:nonFraction>&#160;billion or above, and to the extent such restricted share units have been granted and outstanding, any such restricted share unit (except for those are based on time attribution) shall vest in full with immediate effect, inure to the benefit of the related grantees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2020, the Group granted <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlan2020MemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,093,079</ix:nonFraction> restricted share units to employees and recognized RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">76,663</ix:nonFraction>&#160;RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">71,945</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">and RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">7,500</ix:nonFraction> share-based compensation expenses in administrative expenses, research and development expenses and equity in loss of an affiliate, respectively, in the <div style="letter-spacing: 0px; top: 0px;;display:inline;">consolidated statement of comprehensive income</div>. No restricted share units became exercisable as of December 31, 2020.</div> </div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_20395780_14" continuedAt="TextSelectionAppend_20395780_15"><ix:nonNumeric name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the restricted share units of 2020 Plan for the year ended December&#160;31, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"></td>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"></td>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"></td>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"></td>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"></td>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"></td>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"></td>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"></td>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number&#160;of</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">restricted<br/> share units</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">exercise</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">price</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">remaining</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">contractual</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">term</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregate</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">intrinsic</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">value</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,093,079</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">13,461</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,079,618</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" format="ixt-sec:duryear">9.70</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">83,632</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td></tr></table> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>. SHARE-BASED COMPENSATION (CONTINUED) </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(f) 2020&#160;Plan&#160;(Continued) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_20395780_15" continuedAt="TextSelectionAppend_20395780_16"><ix:nonNumeric name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">A summary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> restricted share units activities for the year ended December&#160;31, 2020 is presented below: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"></td>
<td style="width: 15%; vertical-align: bottom;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 14%; vertical-align: bottom;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>restricted<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>share </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">units</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>fair value</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2019</div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,093,079</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.99</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">13,461</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">11.73</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2020</div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,079,618</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">14.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td></tr></table> </ix:nonNumeric></ix:continuation><ix:continuation id="TextSelectionAppend_20395780_16" continuedAt="TextSelectionAppend_20395780_17"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Apart from the aforementioned restricted share units, up to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="P01_01_2020To12_31_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,446,875</ix:nonFraction> shares can be issued in the form of restricted share unit to eligible grantees that the board of the Group or a committee that board delegated its powers or authority determined appropriate with immediate effect of being fully vested, which are defined as special awards and are subject to terms and conditions under 2018 Plan. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2020, the Group granted <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,328,120</ix:nonFraction> such restricted share units to employees and recognized<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">25,985</ix:nonFraction>&#160;RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">67,182</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">and RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">19,085</ix:nonFraction> share-based compensation expenses in administrative expenses, research and development expenses and equity in loss of an affiliate, respectively, in the consolidated statement of comprehensive incomes of December 31, 2020, <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">565,200</ix:nonFraction> restricted share units were vested,<div style="display:inline;">&#160;</div></div></div>among<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>which<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> &#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">558,200</ix:nonFraction></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;">restricted share units were vested but not issued as ordinary shares as the employees will not be entitled to the rights of ordinary shares from the Group until they have the consideration for the transaction settled.</div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the restricted share units subject to terms and conditions under 2018 Plan for the year ended December&#160;31, 2020: </div></div> <br/>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number&#160;of</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">restricted<br/> share units</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">exercise</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">price</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">remaining</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">contractual</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">term</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregate</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">intrinsic</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">value</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,328,120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; </div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">565,200</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; </div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; </div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">762,920</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">9.65</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,877</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr></table> </ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A summary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> restricted share units activities for the year ended December&#160;31, 2020 is presented below: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"></td>
<td style="width: 15%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 14%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>restricted<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>share </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">units</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>fair value</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2019</div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,328,120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.34</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">565,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2020</div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">762,920</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">12.89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr></table> </ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">60</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">7</div>. SHARE-BASED COMPENSATION (CONTINUED) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_20395780_17"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(g) Establishment of Biomaster Trust </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Biomaster Trust was established under the trust deed dated October&#160;23, 2019, between the Company and TMF Trust (HK) Limited, or TMF Trust, as the trustee of the Biomaster Trust. Through the Biomaster Trust, the Company&#8217;s ordinary shares and other rights and interests under awards granted pursuant to 2017 Plan and 2018 Plan may be provided to certain recipients of equity awards. Upon satisfaction of vesting conditions, TMF Trust will exercise the equity awards and transfer the relevant ordinary shares and other rights and interests under the equity awards to the relevant grant recipients with the consent of the advisory committee of Biomaster Trust. TMF Trust shall not exercise the voting rights attached to such ordinary shares unless otherwise directed by the advisory committee, whose members shall be appointed by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab.</div> The Company has the power to direct the relevant activities of Biomaster Trust and it has the ability to use its power over the Biomaster Trust to affect its exposure to returns. Therefore, the assets and liabilities of the Biomaster Trust are included in the <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Group&#8217;s consolidated balance sheets. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(h) Surrender of stock options </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;17, 2020, the Group completed its IPO. According to the amendments to 2017 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2017 Plan was changed to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn01_17_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">9,609,084</ix:nonFraction>. Each of the Company&#8217;s founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang surrendered <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="P01_17_2020To01_17_2020_SeniorManagementEmployeesMembersrtTitleOfIndividualAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">83,142</ix:nonFraction> unvested stock options that were granted to him or her under 2017 Plan before, totally <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="P01_17_2020To01_17_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">332,566</ix:nonFraction> unvested options, for no consideration, and these stock options were cancelled immediately. According to the amendments to 2018 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2018 Plan was changed to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_17_2020To01_17_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">11,005,888</ix:nonFraction>. The director of the Company, Dr.&#160;Jingwu Zhang Zang surrendered <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="P01_17_2020To01_17_2020_SeniorManagementEmployeesMembersrtTitleOfIndividualAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">2,544,917</ix:nonFraction> unvested options that were granted to him under 2018 Plan, for no consideration, and these stock options were cancelled immediately. Upon the completion of the Company&#8217;s IPO in January 2020, the Group has recorded RMB<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_17_2020To01_17_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">91,051</ix:nonFraction> share-based compensation expense related to these surrendered options. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The stock options surrendered by the founders should be accounted for as capital contribution. As the founders did not get the title of the stock options to be surrendered and the number of stock options would not be determined until listing, the capital contribution was not accounted for during the year ended December&#160;31, 2019. For the year ended December&#160;31, 2020, the Group has reclassified RMB<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">91,051</ix:nonFraction> from additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital &#8211; share-based compensation to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital &#8211; capital contribution relating to the stock options surrendered in the <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consolidated statement of comprehensive income. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-Based Compensation Expense </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-align: left;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The allocation of share-based compensation expense was as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr></table></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">US$</div></div><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,056</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">470</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">284,431</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,591</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative expenses</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">514,733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">209,033</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,036</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 67%; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in loss of an affiliate</div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px; text-align: center; margin-left: 0.1in; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#8212;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px; text-align: center; margin-left: 0.15in; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#8212;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">32,707</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,013</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 67%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">3,520</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">515,203</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">526,171</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">80,640</ix:nonFraction> </div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr></table> </ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="display:inline;">1</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20395375"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">8</div>. LICENSING AND COLLABORATION ARRANGEMENTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a description of the Group&#8217;s significant licensing and collaboration agreements entered into from January&#160;1, 2017 to December&#160;31, 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">A. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Licensing</div> Arrangements </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement with MorphoSys AG (&#8220;MorphoSys&#8221;) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2017, the Group entered into a license and collaboration agreement with MorphoSys, with respect to the development and commercialization of MOR202/TJ202, MorphoSys&#180;s proprietary investigational antibody against CD38 (the &#8220;CD38 product&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under this agreement, MorphoSys granted to the Group an exclusive, royalty-bearing, sublicensable license to exploit MOR202/TJ202 for any human therapeutic or diagnostic purpose in the licensed territory, namely mainland China, Hong Kong, Macau and Taiwan (collectively &#8220;Greater China&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to this agreement, the Group granted to MorphoSys an exclusive license to its rights in any inventions that the Group make while exploiting the CD38 product under this agreement, solely to exploit the CD38 product outside of Greater China. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to this agreement, the Group paid to MorphoSys an upfront license fee of US$<ix:nonFraction name="imab:UpfrontLicenseFee" contextRef="P11_17_2017To11_17_2017_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="imab:UpfrontLicenseFee" contextRef="P11_17_2017To11_17_2017_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">132.7</ix:nonFraction> million). The Group also agreed to make milestone payments to MorphoSys, conditioned upon the achievement of certain development, regulatory and commercial milestones, in the aggregate amount of US$<ix:nonFraction name="imab:MilestonePayments" contextRef="P11_17_2017To11_17_2017_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">98.5</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="imab:MilestonePayments" contextRef="P11_17_2017To11_17_2017_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">653.5</ix:nonFraction> million). Such milestones include first patient dosed in human clinical trials, marketing approval, and first annual net sales of CD38 products covered by the agreement in excess of a certain amount. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, the Group is required to pay tiered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-double-digit</div> royalties to MorphoSys on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product</div></div> basis during the term, commencing with the first commercial sale of a relevant licensed product in Greater China. Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the expiration of the Group&#8217;s last payment obligation under the agreement. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2017, the Group paid US$<ix:nonFraction name="imab:UpfrontLicenseFee" contextRef="P01_01_2017To12_31_2017_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="imab:UpfrontLicenseFee" contextRef="P01_01_2017To12_31_2017_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">132.7</ix:nonFraction> million) upfront fee to MorphoSys, which was recorded as research and development expense. <ix:nonFraction name="imab:UpfrontLicenseFee" contextRef="P01_01_2018To12_31_2018_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">No</ix:nonFraction> additional payments were made in 2018. Due to the uncertainty involved in meeting these developments and commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&#160;31, 2018. In March and April 2019, the project achieved the first and second milestone and the Group paid US$<ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2019To12_31_2019_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">8.0</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2019To12_31_2019_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">55.7</ix:nonFraction> million) of milestone fees to MorphoSys, which was recorded as research and development expense in the consolidated statement of comprehensive loss for the year ended December&#160;31, 2019. <ix:nonFraction name="imab:UpfrontLicenseFee" contextRef="P01_01_2020To12_31_2020_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphoSysAGMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">No</ix:nonFraction> additional payments were made for the year ended December&#160;31, 2020 as no milestone has been achieved. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" contextRef="P01_01_2020To12_31_2020_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summarized financial information related to the above agreement is presented below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 41%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Year ended December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">As&#160;of&#160;December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Research and Development Expense</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Upfront&#160;Fees</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Milestones</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Extension/Termination<br/> of agreements</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Amortization&#160;of&#160;prepaid<br/> research and<br/> development</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Intangible&#160;asset&#160;balance</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 41%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 41%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">US$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2019To12_31_2019_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 41%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 41%; padding-bottom: 0.45pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 41%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="display:inline;">2</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">8</div>. LICENSING AND COLLABORATION ARRANGEMENTS (CONTINUED) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement with Genexine, Inc. (&#8220;Genexine&#8221;) </div></div></div><ix:continuation id="TextSelection_20395375" continuedAt="TextSelectionAppend_20395375_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2017, the Group entered into an intellectual property agreement with Genexine with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-I7/TJ107,</div> a long-acting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7</div> cytokine. Under this agreement, the Group obtained an exclusive, sublicensable and transferable license to use and otherwise exploit certain intellectual property in connection with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical development, manufacturing, sale and distribution of GX-I7 to treat cancer in Greater China. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of the agreement, the Group made an upfront payment of US$<ix:nonFraction name="imab:UpfrontLicenseFee" contextRef="P01_01_2020To12_31_2020_GenexineIncMembersrtCounterpartyNameAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="imab:UpfrontLicenseFee" contextRef="P01_01_2020To12_31_2020_GenexineIncMembersrtCounterpartyNameAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">79.6</ix:nonFraction> million) to Genexine which was recorded as a research and development expense in January 2018. The Group also agreed to make milestone payments in the aggregate amount of US$<ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">23.0</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">152.6</ix:nonFraction> million), conditioned upon the achievement of certain development milestones, including completion of Phase 2 and Phase 3 clinical studies and new drug application (&#8220;NDA&#8221;) or biologic license application (&#8220;BLA&#8221;) approval in Greater China. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, the Group agreed to make milestone payments in the aggregate amount of US$<ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">525.0</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">3,482.7</ix:nonFraction> million), conditioned upon the achievement of certain cumulative net sales of GX<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">-I7 </div></div>up to US$<ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Gxi7MembersrtProductOrServiceAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,000</ix:nonFraction>&#160;million. The Group also is required to pay Genexine a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-single-digit</div> percentage royalty in respect of the total annual net sales of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-I7.</div> The aforesaid milestones and royalties (other than the upfront payment) will be reduced by <ix:nonFraction name="imab:PercentageOfReductionInMilestonePayments" contextRef="P01_01_2018To01_01_2018_GenexineIncMembersrtCounterpartyNameAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% following the entry of a generic version of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-I7</div> in China, Hong Kong, Macau and Taiwan without the consent or authorization of the Group or any of the Group&#8217;s sublicensees. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the later of (i)&#160;the expiry of the last to expire patent of the licensed intellectual property that includes a valid claim for Greater China and that covers the composition of GX-I7; and (ii) <ix:nonNumeric name="us-gaap:LongtermPurchaseCommitmentPeriod" contextRef="P01_01_2018To01_31_2018_GenexineIncMembersrtCounterpartyNameAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis" format="ixt-sec:duryear">15</ix:nonNumeric> years from the date of the first commercial sale of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-I7.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No additional payments to Genexine were made in the year ended December&#160;31, 2019 and 2020. Due to the uncertainty involved in meeting these development and commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&#160;31, 2019 and 2020. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" contextRef="P01_01_2020To12_31_2020_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summarized financial information related to the above agreement is presented below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Year ended December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">As&#160;of&#160;December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Research and Development Expense</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Upfront&#160;Fees</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Milestones</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Extension/Termination<br/> of agreements</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Amortization&#160;of&#160;prepaid<br/> research and<br/> development</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Intangible&#160;asset&#160;balance</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 45%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">US$</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;"><ix:nonFraction name="imab:LicensingAgreementUpfrontFees" contextRef="P01_01_2018To12_31_2018_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 45%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In May 2020, the Group and Genexine entered into an amendment to this agreement whereby both parties desire to establish collaboration on TJ107 GBM Study in Greater China Under the terms of the expanded collaboration, the Group will be mainly responsible for using commercially reasonable efforts to conduct the Phase 2 GBM clinical trial in Greater China, and Genexine will share the development strategies, data and costs for success of this clinical trial. The Group shall undertake to bear <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> (2/3) proportion of the clinical development costs and Genexine shall undertake to bear <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> (1/3) proportion of these costs. As of December&#160;31, 2020, the costs incurred for the development of this new indication was RMB<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020_GenexineIncMembersrtCounterpartyNameAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction>&#160;million and thus RMB<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020_GenexineIncMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction>&#160;million expense was recorded in the consolidated statement of comprehensive income for the year ended December&#160;31, 2020. </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="display:inline;">3</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">8</div>. LICENSING AND COLLABORATION ARRANGEMENTS (CONTINUED) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_20395375_1" continuedAt="TextSelectionAppend_20395375_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement with MorphoSys </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In November 2018, the Group entered into a license and collaboration agreement with MorphoSys for MorphoSys&#8217;s proprietary antibody (MOR210/TJ210) directed against C5aR (the &#8220;C5aR Agreement&#8221;). Under this agreement, the Group obtained an exclusive, royalty-bearing license to explore, develop and commercialize certain anti-C5aR antibodies in Greater China and South Korea.</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group will perform and fund all global development activities related to the development of MOR210/TJ210 in Greater China and South Korea, including all relevant clinical trials (including in the U.S. and China) and all development activities required for IND filing in the US as well as CMC development of manufacturing processes. MorphoSys retains rights in respect of development and commercialization of MOR210/TJ210 in the rest of the world. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the terms of the agreement, the Group also agreed to make milestone payments conditional upon the achievement of certain development milestones and certain annual net sales of anti-C5aR antibodies. The Group is also required to pay to MorphoSys tiered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single-digit</div> royalties on annual net sales of anti-C5aR antibody products within the licensed territory. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2018, the Group paid US$<ix:nonFraction name="imab:UpfrontLicenseFee" contextRef="P01_01_2018To12_31_2018_LicensingAgreementsWithMorphosysMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="imab:UpfrontLicenseFee" contextRef="P01_01_2018To12_31_2018_LicensingAgreementsWithMorphosysMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">23.2</ix:nonFraction> million) upfront fee to MorphoSys, which was recorded as research and development expense in the consolidated statement of comprehensive loss for the year ended December&#160;31, 2018. <ix:nonFraction name="imab:UpfrontLicenseFee" contextRef="P01_01_2019To12_31_2019_LicensingAgreementsWithMorphosysMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">No</ix:nonFraction> additional payments were made in the year ended December&#160;31, 2019. In August 2020, the project achieved the first milestone and the Group paid US$<ix:nonFraction name="imab:MilestonePayments" contextRef="P08_01_2020To08_31_2020_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphoSysAGMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="imab:MilestonePayments" contextRef="P08_01_2020To08_31_2020_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphoSysAGMembersrtCounterpartyNameAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">6.9</ix:nonFraction> million) of milestone fees to Morphosys, which was recorded as research and development expenses in the consolidated statement of comprehensive income for the year ended December&#160;31, 2020. Due to the uncertainty involved in meeting these development and commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&#160;31, 2019 and 2020. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" contextRef="P01_01_2020To12_31_2020_LicensingAgreementWithMorphosysMemberusgaapTypeOfArrangementAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summarized financial information related to the above agreement is presented below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 42%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Years Ended December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">As&#160;of&#160;December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Research and Development Expense</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Upfront&#160;Fees</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Milestones</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Extension/Termination<br/> of agreements</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Amortization&#160;of&#160;prepaid<br/> research and<br/> development</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Intangible&#160;asset&#160;balance</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 42%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: top;">US$</td>
<td style="vertical-align: top;;text-align:right;"><ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2020To12_31_2020_LicensingAgreementWithMorphosysMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 42%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 42%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: top;">US$</td>
<td style="vertical-align: top;;text-align:right;"><ix:nonFraction name="imab:LicensingAgreementUpfrontFees" contextRef="P01_01_2018To12_31_2018_LicensingAgreementWithMorphosysMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,500</ix:nonFraction></td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 42%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="display:inline;">4</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div>. LICENSING AND COLLABORATION ARRANGEMENTS (CONTINUED) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_20395375_2" continuedAt="TextSelectionAppend_20395375_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement with MacroGenics </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2019, the Group entered into a license and collaboration agreement with MacroGenics, Inc. for development and commercialization of an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Fc-optimized</div> antibody known as enoblituzumab that targets <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3,</div> including in combination with other agents, such as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD-1</div></div> antibody known as MGA012, in the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(&#8220;Greater China&#8221;). Under this agreement, the Group obtained an exclusive, sublicenseable, royalty-bearing license to MacroGenics&#8217; patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> to develop and commercialize the enoblituzumab product, and a combination regimen of enoblituzumab and MGA012, in Greater China during the term of the agreement. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In exchange for these rights, in addition to certain financial consideration, the Group will grant to MacroGenics a royalty-free, sublicenseable, license outside of Greater China, to the patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> that are related to the enoblituzumab product or useful or necessary for MacroGenics to develop or commercialize the enoblituzumab product or a product containing MGA012, and combinations thereof. The license is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i)&#160;non-exclusive</div> with respect to the enoblituzumab product, and (ii)&#160;exclusive with regard to MGA012. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the agreement, the Group paid an upfront fee of US$<ix:nonFraction name="imab:UpfrontLicenseFee" contextRef="P01_01_2019To12_31_2019_LicensingAgreementWithMacrogenicsMemberusgaapTypeOfArrangementAxis_MacroGenicsMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="imab:UpfrontLicenseFee" contextRef="P01_01_2019To12_31_2019_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MacroGenicsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">104.4</ix:nonFraction> million) to MacroGenics, which was recorded as research and development expense in the consolidated statement of comprehensive loss for the year ended December&#160;31, 2019. No additional payments were made in the year ended December&#160;31, 2020. Under the terms of the agreement, the Group also agreed to pay MacroGenics development milestone fees of up to US$<ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2020To12_31_2020_DevelopmentMilestoneMemberIMABMilestoneTypeAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_MacroGenicsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction>&#160;million and regulatory milestones fees of up to US$<ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2020To12_31_2020_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MacroGenicsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MinimumMembersrtRangeAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction>&#160;million, respectively, and tiered double-digit royalties (ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-teens</div> to twenty percent) based on annual net sales in the territories. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:CollaborativeArrangementRightsAndObligations" contextRef="P01_01_2020To12_31_2020_LicensingAgreementWithMacrogenicsMemberusgaapTypeOfArrangementAxis_MacroGenicsMembersrtCounterpartyNameAxis">The Group is responsible for all development costs in Greater China. MacroGenics is responsible for all development costs in the rest of the world, except that the Group is responsible for 20% of the costs incurred in (i) activities supporting global clinical trials in which the Group participates, (ii) certain CMC activities for material intended to be used in clinical trials in Greater China, and (iii) companion diagnostic development and validation for indications being studied in Greater China.</ix:nonNumeric></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" contextRef="P01_01_2020To12_31_2020_LicensingAgreementWithMacrogenicsMemberusgaapTypeOfArrangementAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to the uncertainty involved in meeting these development and commercialization based targets, the Group evaluated and concluded that no milestones are probable as of December&#160;31, 2019 and 2020. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 40%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td>
<td style="width: 0%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Year ended December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">As&#160;of&#160;December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Research and Development Expense</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Upfront Fees</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Milestones</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Extension/Termination<br/> of agreements</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Amortization&#160;of&#160;prepaid<br/> research and<br/> development</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Intangible&#160;asset&#160;balance</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 40%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: top; width: 0%;">US$</td>
<td style="vertical-align: top; width: 0%;;text-align:right;"><ix:nonFraction name="imab:LicensingAgreementUpfrontFees" contextRef="P01_01_2019To12_31_2019_LicensingAgreementWithMacrogenicsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,000</ix:nonFraction></td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 40%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td></tr></table> </ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div>. LICENSING AND COLLABORATION ARRANGEMENTS (CONTINUED) </div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelectionAppend_20395375_3" continuedAt="TextSelectionAppend_20395375_4"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other In-Licensing Arrangements</div></div></div></div></div></div> </ix:continuation></div></div><ix:continuation id="TextSelectionAppend_20395375_4" continuedAt="TextSelectionAppend_20395375_5"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;">In addition to the above arrangements, the Group has entered into other <div style="letter-spacing: 0px; top: 0px;;display:inline;">various</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> and collaboration agreements with third party licensors to develop and commercialize drug candidates. Based on the terms of these agreements the Group is contingently obligated to make additional material payments upon the achievement of certain contractually defined milestones. The Group recorded US$<ix:nonFraction name="imab:UpfrontLicenseFee" contextRef="P01_01_2018To12_31_2018_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="imab:UpfrontLicenseFee" contextRef="P01_01_2018To12_31_2018_OtherInLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction> million) upfront fee and US$<ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2018To12_31_2018_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2018To12_31_2018_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction> million) milestone payment under these agreements for the year ended December&#160;31, 2018. The Group recorded US$<ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2019To12_31_2019_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2019To12_31_2019_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">8.4</ix:nonFraction> million) milestone payment during the year ended December&#160;31, 2019. The Group additionally recorded US$<ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2020To12_31_2020_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.1</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2020To12_31_2020_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">21.3</ix:nonFraction> million) milestone payment during the year ended December&#160;31, 2020. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2020, </div></div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">under the terms </div></div> of the agreements, the licensors are eligible to receive from the Group up to an aggregate of approximately US$<ix:nonFraction name="imab:MilestonePayments" contextRef="P12_31_2020To12_31_2020_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">107.4</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="imab:MilestonePaymentsOutstanding" contextRef="P01_01_2020To12_31_2020_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">740.4</ix:nonFraction> million) in milestone payments upon the achievement of contractually specified development milestones and sales milestones, such as regulatory approval for the drug candidates, which may be before the Group has commercialized the drug or received any revenue from sales of such drug candidate, which may never occur. </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">8</div>. LICENSING AND COLLABORATION ARRANGEMENTS (CONTINUED) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_20395375_5" continuedAt="TextSelectionAppend_20395375_6"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">B. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Out-Licensing</div> and collaboration Arrangements </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement among HDYM, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> and Hangzhou HealSun Biopharm Co., Ltd. (&#8220;HealSun&#8221;) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In April 2017, one of the Company&#8217;s subsidiaries, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai, entered into a technology transfer agreement with HDYM and HealSun with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD-L1</div></div> humanized monoclonal antibodies. Under the agreement, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai agreed to grant to HDYM exclusive, worldwide and sublicensable rights to develop, manufacture, have manufactured, use, sell, have sold, import, or otherwise exploit certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> related patents, patent applications, know-hows, data and information of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai, relevant cell lines as well as any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD-L1</div></div> monoclonal antibody arising from such cell lines for the treatment of diseases. Further, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai and its cooperative party, HealSun agreed to provide subsequent research and development services on such intellectual property to HDYM, including the selection and examination of innovative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD-L1</div></div> humanized monoclonal antibodies, cultivation and selection of stable cell lines, establishment of cell bank, research and development of manufacturing processes and preparation of samples, toxicological and pharmacological testing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> pharmaceutical experiment report drafting, and application for and registration of clinical trials. HDYM agreed to make milestone payments conditioned upon achieving certain contractually defined milestones. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group determined that this collaboration is reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, due to the early stage nature of the development, in which the underlying intellectual property is significantly modified by the development activities being performed, the Group determined the license to the intellectual property and research and development services are not distinct and thus were accounted for as a single performance obligation that is satisfied over time. The Group would receive RMB<ix:nonFraction name="imab:MilestonePaymentsIncome" contextRef="P01_01_2020To12_31_2020_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-8" scale="9" format="ixt:numdotdecimal">51.0</ix:nonFraction>&#160;million (inclusive of VAT) milestone payments under this agreement, and considered that the achievements of milestone II, III, IV are constrained such that the transaction price shall initially only include the milestones payment which have been achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone payment shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group used a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> input method to measure progress as that method best depicts its performance under the agreement. For the year ended December&#160;31, 2017, the Group achieved milestones I and II and received milestone payments totaling of RMB<ix:nonFraction name="us-gaap:ProceedsFromLicenseFeesReceived" contextRef="P01_01_2017To12_31_2017_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">29.0</ix:nonFraction>&#160;million (inclusive of VAT). The cumulative percentage complete in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> input method related to this agreement as of December&#160;31, 2017 is estimated to approximate <ix:nonFraction name="imab:ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent" contextRef="P01_01_2017To12_31_2017_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">42</ix:nonFraction>%, the Group recognized RMB<ix:nonFraction name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" contextRef="P01_01_2017To12_31_2017_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">11.6</ix:nonFraction>&#160;million (exclusive of VAT of RMB<ix:nonFraction name="us-gaap:ExciseAndSalesTaxes" contextRef="P01_01_2017To12_31_2017_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction> million) of revenue in the consolidated statement of comprehensive loss, and RMB<ix:nonFraction name="imab:DeferredRevenueFromCollaborativeArrangementExcludingVat" contextRef="PAsOn12_31_2017_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">15.8</ix:nonFraction>&#160;million (exclusive of VAT of RMB<ix:nonFraction name="us-gaap:ExciseAndSalesTaxes" contextRef="P01_01_2017To12_31_2017_DeferredRevenueMemberusgaapBalanceSheetLocationAxis_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction> million) were deferred as contract liability related to this arrangement. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the year ended December&#160;31, 2018, the Group achieved milestones III and IV and received milestone III payment of RMB<ix:nonFraction name="us-gaap:ProceedsFromLicenseFeesReceived" contextRef="P01_01_2018To12_31_2018_HealSunMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis_MilestoneIiiMemberIMABMilestoneTypeAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction>&#160;million (inclusive of VAT), milestone IV payment of RMB <ix:nonFraction name="us-gaap:ProceedsFromLicenseFeesReceived" contextRef="P01_01_2018To12_31_2018_HealSunMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis_MilestoneIvMemberIMABMilestoneTypeAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction>&#160;million (inclusive of VAT) was recognized as contract assets as of December&#160;31, 2018. As of December&#160;31, 2018, the cumulative percentage complete in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to</div> cost input method related to this arrangement is estimated to approximate <ix:nonFraction name="imab:ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent" contextRef="P01_01_2018To12_31_2018_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%. The Group recognized RMB<ix:nonFraction name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" contextRef="P01_01_2018To12_31_2018_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">36.5</ix:nonFraction>&#160;million (exclusive of VAT of RMB<ix:nonFraction name="us-gaap:ExciseAndSalesTaxes" contextRef="P01_01_2018To12_31_2018_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million) of revenue in the consolidated statement of comprehensive loss for the year ended December&#160;31, 2018. All of the milestone payments were received by the Group as of December&#160;31, 2019. </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="display:inline;">7</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">8</div>. LICENSING AND COLLABORATION ARRANGEMENTS (CONTINUED) </div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelectionAppend_20395375_6" continuedAt="TextSelectionAppend_20395375_7"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration Agreement with Everest (&#8220;Everest&#8221;)</div></div></div></div> </ix:continuation></div></div><ix:continuation id="TextSelectionAppend_20395375_7" continuedAt="TextSelectionAppend_20395375_8"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;">In January 2018, the Group entered into a collaboration agreement with Everest, which is controlled by the <div style="letter-spacing: 0px; top: 0px;;display:inline;">ultimate </div>controlling party of a principal shareholder of the Group. Under the agreement, both parties agreed to collaborate on programs to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-develop</div> MorphoSys&#8217; proprietary anti-CD38 antibody for all indications in hematologic oncology and commercialize of MOR202/TJ202 in Greater China. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A joint steering committee with equal representation from each party was established to coordinate and oversee the development and commercialization of the CD38 product. All decisions of the joint steering committee shall be made by unanimous vote. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms" contextRef="P01_01_2020To12_31_2020_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">Under the agreement, the Group is primarily responsible for carrying out the development, manufacture and supply of the CD38 product, as well as seeking regulatory approval of the CD38 product. Everest is primarily responsible for sharing the development costs of the CD38 product, including payments due to MorphoSys under the Licensing Agreement, dated November 30, 2017, in the proportion of 75% by Everest and 25% by the Group.</ix:nonNumeric></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The joint steering committee will decide which party shall be responsible for conducting the commercialization of the CD38 product pursuant to the commercialization plan approved by the committee. If Everest is selected to be responsible for commercialization, the Group shall grant an exclusive royalty-free license to Everest to commercialize the CD38 product for all indications in hematologic oncology in Greater China. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group and Everest will share the profit and loss and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> revenue derived from the CD 38 product in proportion to the costs that each party incur in developing the product. The parties will also split <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-license</div> revenue according to the proportion of development costs incurred, with the Group getting an additional five percent (5%) share and Everest receiving five percent (<ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligationPercentage" contextRef="PAsOn12_31_2020_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_pure" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction>%) less. Everest cannot share in any profit from the commercialization of CD38 product until it has fulfilled its payment obligations under this agreement. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon any termination of this arrangement, the terminating party has the right to continue the development and commercialization of CD38 product. If Everest is the rightful terminating party, the Group shall reasonably cooperate with Everest to facilitate the following: (i)&#160;assign the MorphoSys license to Everest (subject to the terms and conditions of such license); (ii) grant to Everest an exclusive license to all intellectual property rights that the Group owns or controls to further develop, manufacture, and commercialize the CD38 product; (iii)&#160;transfer the development, manufacture and commercialization of the CD38 product to Everest. The terminating party shall be solely responsible for the cost and expense of such development and commercialization after termination. In the event that such continuing party successfully develops and commercializes the CD38 product, it shall pay to the other party a percentage of the product profit and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-license</div> revenue generated therefrom in accordance with the terms of this agreement. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2018, the US$<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2018To12_31_2018_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">26.0</ix:nonFraction>&#160;million in aggregate proceeds from Everest under the agreement represented the funding available under the agreement, and was recorded as a research and development funding received liability (equivalent to approximately RMB<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2018To12_31_2018_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">178.7</ix:nonFraction> million) on the consolidated balance sheet as of December&#160;31, 2018, in accordance with ASC 730, Research and Development. Because there is a significant related party relationship between the Group and Everest, the Group is treating its obligation to make payments under the commercialization stage as an implicit obligation to repay the funds advanced by Everest (see Note 2<div style="display:inline;">3</div>). During the year ended December&#160;31, 2019, an additional US$<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019_CollaborationAgreementWithEverestMemberusgaapTypeOfArrangementAxis_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">7.6</ix:nonFraction>million (equivalent to approximately RMB<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019_CollaborationAgreementWithEverestMemberusgaapTypeOfArrangementAxis_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">53.1</ix:nonFraction> million) of funding was received and recorded as a research and development funding received liability. No additional milestone has been achieved in the year ended December&#160;31, 2019. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="display:inline;">8</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">8</div>. LICENSING AND COLLABORATION ARRANGEMENTS (CONTINUED) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Termination Agreement with Everest </div></div></div></div> </div> </div> <ix:continuation id="TextSelectionAppend_20395375_8" continuedAt="TextSelectionAppend_20395375_9"> <div style="font-family: Times New Roman;font-size: 10pt;margin-top: 6pt;margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;4, 2019, the Group and Everest have terminated the collaboration agreement with respect to the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-development</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and commercialization of TJ202 in Greater China. Upon the termination, Everest will not retain any rights or entitlements to develop or commercialize TJ202 or any economic interest in its commercialization. All intellectual property rights in respect of TJ202 arising from its development under the collaboration agreement are vested and owned by </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab,</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and the Group holds all intellectual property rights and have maximum flexibility to further develop, manufacture and commercialize TJ202 in Greater China. In consideration of the above arrangements, the board of directors of the Group has approved the issuance of a total value of US$</div><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn11_04_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">37.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of ordinary shares (the &#8220;CPP Shares&#8221;) to Everest, representing Everest&#8217;s historical contribution to the collaboration and the associated time cost. The CPP Shares will be issued concurrently with, and subject to, the completion of the Company&#8217;s initial public offering within 180 days from termination of the collaboration agreement. The total value of US$</div><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn11_04_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">37.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was calculated based on the sum of (1)&#160;US$</div><ix:nonFraction name="imab:CumulativePaidInContributions" contextRef="PAsOn11_04_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">33.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which equals cumulative </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> contributions historically made by Everest under the collaboration agreement; and (2)&#160;a negotiated US$</div><ix:nonFraction name="imab:TimeCostOfForegoingHistoricalContribution" contextRef="PAsOn11_04_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million time cost of the foregoing historical contribution in light of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab&#8217;s</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> exclusive rights over the commercialization of TJ202 after this termination. The issuance of the CPP Shares was approved by </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab&#8217;s</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> existing shareholders on December&#160;25, 2019. In the event that the initial public offering has not been completed within 180 days from the termination of the collaboration agreement, the Company will issue </div><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn11_04_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,762,751</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> ordinary shares (the &#8220;Subject Shares&#8221;) to Everest on the 181st day. As a result of the aforementioned termination of the collaboration agreement with Everest, the Group derecognized the research and development funding received from Everest and recognized a liability that represented the ordinary shares to be issued to Everest, which was measured at fair value in accordance with ASC 480, and the difference of US$</div><ix:nonFraction name="imab:TimeCostOfForegoingHistoricalContribution" contextRef="PAsOn11_04_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (equivalent to approximately RMB</div><ix:nonFraction name="imab:TimeCostOfForegoingHistoricalContribution" contextRef="PAsOn11_04_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">23.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> million) between the initial fair value of the liability and the carrying amount of research and development funding received was recognized as other expenses in the consolidated statements of comprehensive loss for the year ended December&#160;31, 2019. Upon the completion of the IPO in January 2020, the Group issued </div><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="PAsOn01_31_2020_CollaborationAgreementWithEverestMemberusgaapTypeOfArrangementAxis_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,078,571</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> ordinary shares to Everest.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement with ABL Bio </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2018, the Group entered into a license and collaboration agreement with ABL Bio, under which the Group granted to ABL Bio exclusive, worldwide (excluding Greater China), royalty-bearing rights to develop and commercialize a bispecific antibody (&#8220;BsAb&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group agreed to share costs fifty-fifty (50:50) with ABL Bio through the completion of in vivo studies, with ABL Bio responsible for all costs and activities following that time. For the year ended December&#160;31, 2019, US$<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019_ABLBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019_ABLBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction> million) expenses were incurred by ABL Bio. Accordingly, the Group recorded US$<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction> million) <div style="letter-spacing: 0px; top: 0px;;display:inline;">(</div><ix:nonFraction name="imab:CostSharingRatio" contextRef="P01_01_2019To12_31_2019_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% cost sharing) of expenses in the Group&#8217;s consolidated statement of comprehensive loss for the year ended December&#160;31, 2019. For the year ended December&#160;31, 2020, US$<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020_ABLBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:numdotdecimal">0.04</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020_ABLBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-4" scale="6" format="ixt:numdotdecimal">0.28</ix:nonFraction> million) expenses were incurred by ABL Bio. Accordingly, the Group recorded US$<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:numdotdecimal">0.02</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-4" scale="6" format="ixt:numdotdecimal">0.14</ix:nonFraction> million) <div style="letter-spacing: 0px; top: 0px;;display:inline;">(</div><ix:nonFraction name="imab:CostSharingRatio" contextRef="P01_01_2020To12_31_2020_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% cost sharing) of expenses in the Group&#8217;s consolidated statement of comprehensive income for the year ended December&#160;31, 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the license and collaboration agreement that signed in July 2018 and memorandum of understanding that subsequently entered into with ABL Bio in January 2020, ABL Bio agreed to pay the Group an upfront fee of US$<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2018To07_31_2018_ABLBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2018To07_31_2018_ABLBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">17.2</ix:nonFraction> million), and milestone payments in the aggregate amount of US$<ix:nonFraction name="imab:MilestonePayments" contextRef="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">97.5</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="imab:MilestonePayments" contextRef="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">690.3</ix:nonFraction> million) conditioned upon achieving certain research, clinical development and sales milestones. These include clinical milestones of up to US$<ix:nonFraction name="imab:MilestonePayments" contextRef="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_ClinicalMilestonesMemberIMABMilestoneTypeAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">32.5</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="imab:MilestonePayments" contextRef="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_ClinicalMilestonesMemberIMABMilestoneTypeAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">230.1</ix:nonFraction> million) and sales milestones of up to US$<ix:nonFraction name="imab:MilestonePayments" contextRef="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_SalesMilestonesMemberIMABMilestoneTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="imab:MilestonePayments" contextRef="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_SalesMilestonesMemberIMABMilestoneTypeAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">460.2</ix:nonFraction> million). Further, ABL Bio agreed to pay the Group royalties at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single-digit</div> percentages in respect of the total annual net sales of the licensed BsAb product. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, ABL Bio granted to the Group an exclusive, royalty-free, sublicensable license to use the BsAb technology solely to exploit the licensed BsAb product for all indications in Greater China. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="display:inline;">9</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">8</div>. LICENSING AND COLLABORATION ARRANGEMENTS (CONTINUED) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement with ABL Bio (continued) </div></div></div> <ix:continuation id="TextSelectionAppend_20395375_9" continuedAt="TextSelectionAppend_20395375_10"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group determined that this collaboration is reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, the only one performance obligation was to grant the BsAb license to ABL Bio. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Achievement of milestones that are not within the control of the Group or the licensee, such as regulatory approvals, are not considered probable until the approvals are achieved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group recognized revenue of US$<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction>&#160;million (equivalent to RMB<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">17.2</ix:nonFraction> million) of revenue in the consolidated statements of comprehensive loss for the year ended December&#160;31, 2018, which was the upfront fee related to the grant of the rights of BsAb to ABL Bio as mentioned above. As of December&#160;31, 2019 and 2020, <ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2020To12_31_2020_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2019To12_31_2019_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> other milestone has been achieved. No revenue was recognized for the year ended December&#160;31, 2019 and 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December 4, 2020, I-Mab Hong Kong, ABL Bio and I-Mab Hangzhou entered into an amendment, which is made effective as of September 15, 2020, that I-Mab Hong Kong, as the subject of the aforementioned licensing agreement, shall be replaced and substituted by I-Mab Hangzhou<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration Agreement with ABL Bio </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2018, the Group and ABL Bio entered into a collaboration agreement (the &#8220;ABL Bio Collaboration&#8221;) whereby both parties agreed to collaborate to develop three <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> based bispecific antibodies by using ABL Bio&#8217;s proprietary BsAb technology and commercialize them in their respective territories, which, collectively, include Greater China and South Korea, and other territories throughout the rest of the world if both parties agree to do so in such other territories during the performance of the agreement. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At contract inception, as both <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> and ABL Bio participate actively in the research and development activity. Also, the parties share the risk of failure of the BsAb products and share the income of licensing, so this contract meet the criteria of the definition of a collaborative arrangement, the Group categorized this agreement within the scope ASC 808. Prior to commercialization, the Group recorded the share of the expenses incurred by the collaboration for the development of three <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> based bispecific antibodies products in research and development expense in the consolidated <div style="letter-spacing: 0px; top: 0px;;display:inline;">statements of comprehensive income (loss).</div> As of December&#160;31, 2018, RMB<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2018To12_31_2018_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction>&#160;million expenses were incurred by the Group and ABL Bio did not incur any expense. According to the terms set out in the agreement, the Group recorded RMB<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2018To12_31_2018_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction>&#160;million <div style="letter-spacing: 0px; top: 0px;;display:inline;">(</div><ix:nonFraction name="imab:CostSharingRatio" contextRef="P01_01_2018To12_31_2018_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% cost sharing) of expense in the Group&#8217;s consolidated statement of comprehensive loss for the year ended December&#160;31, 2018. For the year ended December&#160;31, 2019, RMB<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">11.2</ix:nonFraction>&#160;million expenses were incurred by the Group and RMB<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019_ABLBioMembersrtCounterpartyNameAxis_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">8.0</ix:nonFraction>&#160;million expenses were incurred by ABL Bio. Accordingly, the Group recorded RMB<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction>&#160;million (<ix:nonFraction name="imab:CostSharingRatio" contextRef="P01_01_2019To12_31_2019_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% cost sharing) of expenses in the Group&#8217;s consolidated statement of comprehensive loss for the year ended December&#160;31, 2019. For the year ended December&#160;31, 20<div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div>, RMB<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2010To12_31_2010" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">43.6</ix:nonFraction>&#160;million expenses were incurred by the Group and RMB<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2010To12_31_2010_ABLBioMembersrtCounterpartyNameAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">44.0</ix:nonFraction>&#160;million expenses were incurred by ABL Bio. Accordingly, the Group recorded RMB<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">43.8</ix:nonFraction>&#160;million (<ix:nonFraction name="imab:CostSharingRatio" contextRef="P01_01_2020To12_31_2020_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% cost sharing) of expenses in the Group&#8217;s consolidated statement of comprehensive income for the year ended December&#160;31, 2020. </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">70</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">8</div>. LICENSING AND COLLABORATION ARRANGEMENTS (CONTINUED) </div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelectionAppend_20395375_10" continuedAt="TextSelectionAppend_20395375_11"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration Agreements with Tracon Pharmaceuticals, Inc. (&#8220;Tracon&#8221;)</div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2018, the Group entered into collaboration agreements with Tracon, under which both parties agreed to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-develop</div> the Group&#8217;s proprietary CD73 antibody, TJD5 (the &#8220;TJD5 Agreement&#8221;) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-develop</div> up to five BsAbs (the &#8220;BsAbs Agreement&#8221;). Both agreements may be terminated by either party for the other party&#8217;s uncured material breach, bankruptcy or insolvency or for safety reasons. In addition, the agreement in respect of TJD5 may be terminated by the Group: (i)&#160;for convenience within a certain period upon completing different clinical stages subject to certain payments and royalties, based on the clinical stage, that would be owed to Tracon upon the exercise of such termination for convenience; (ii)&#160;in the event that Tracon causes the Phase 1 study timeline to be delayed beyond the agreed extension periods; or (iii)&#160;if the Group decides to end the development of the collaborative product prior to its first commercial sale. Further, prior to the first commercial sale, Tracon may deem this agreement to be terminated by the Group if it reasonably believes that the Group has discontinued all meaningful development of the collaborative product for at least 12 months and certain other conditions are met. Additionally, in March 2019, the Group agreed with Tracon and F. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Hoffmann-La</div> Roche Ltd (&#8220;Roche&#8221;) on a clinical supply agreement for Roche to supply atezolizumab for use in clinical studies under the collaboration agreement with Tracon. As of December&#160;31, 2019, no payments or royalties are due under this agreement. As of December&#160;31, 2019, the Group has recorded US$<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019_CollaborationAgreementsWithTraconPharmaceuticalsIncMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019_CollaborationAgreementsWithTraconPharmaceuticalsIncMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">27.8</ix:nonFraction> million) of research and development costs in the consolidated statement of comprehensive loss for the year ended December&#160;31, 2019. As of December&#160;31, 2020, the Group has recorded US$<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020_CollaborationAgreementsWithTraconPharmaceuticalsIncMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:numdotdecimal">0.03</ix:nonFraction>&#160;million (equivalent to approximately RMB<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020_CollaborationAgreementsWithTraconPharmaceuticalsIncMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_CNY" decimals="-4" scale="6" format="ixt:numdotdecimal">0.17</ix:nonFraction> million) of research and development costs in the consolidated statement of comprehensive <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">income for the year ended December&#160;31, 2020. </div></div></div> <div style="text-align: left;"><div style="text-align: left;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2020, Tracon issued a notice of disputes with respect to the TJD5 Agreement and the BsAbs Agreement. As of the date of this report, these disputes have not been resolved.&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement with CSPC Pharmaceutical Group Limited (&#8220;CSPC&#8221;) </div></div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2018, the Group entered into a product development agreement with CSPC. The Group granted to CSPC exclusive, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-transferable,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-irrevocable</div> and sublicensable rights in the PRC (excluding Hong Kong, Macau and Taiwan) to develop and commercialize TJ103 for treating type 2 diabetes. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CSPC is responsible for developing, obtaining market approval and commercializing the licensed products. The Group is responsible for transferring the manufacturing technology of the licensed products to CSPC and assisting CSPC in the continued optimization of such manufacturing technology thereafter. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In consideration of the license, CSPC agreed to pay the Group an upfront fee of RMB<ix:nonFraction name="imab:UpfrontLicenseFee" contextRef="P01_01_2018To12_31_2018_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction>&#160;million and milestone payments in an aggregate amount of RMB<ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2018To12_31_2018_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">135.0</ix:nonFraction>&#160;million conditioned upon achieving certain clinical development and regulatory approval milestones. In addition, the Group is also entitled to royalties of up to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-double-digit</div> percentages in respect of the total annual net sales of the products after its commercialization in the PRC. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group determined that this collaboration is more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, the only one performance obligation was to grant TJ103 license to CSPC. Considering that the achievements of milestones are constrained such that the transaction price shall initially only include upfront payment and subsequently, once another milestone was achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone payment shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. As of December&#160;31, 2018, the amount received of RMB<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2018_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">14.2</ix:nonFraction>&#160;million (net of VAT) was recorded as advance from customers in the consolidated balance sheet. In February 2019, an additional amount of RMB<ix:nonFraction name="us-gaap:ProceedsFromLicenseFeesReceived" contextRef="P02_28_2019To02_28_2019_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction>&#160;million (net of VAT) was received, and the license was also approved by China intellectual property office in May 2019. The first milestone was achieved in September 2019 and the amount of RMB<ix:nonFraction name="us-gaap:ProceedsFromLicenseFeesReceived" contextRef="P09_30_2019To09_30_2019_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction>&#160;million (net of VAT) was received according to the terms of the agreement. Accordingly, RMB<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction>&#160;million was recognized as revenue in the consolidated statements of comprehensive loss for the year ended December&#160;31, 2019. No additional revenue was recognized in the <div style="letter-spacing: 0px; top: 0px;;display:inline;">year</div>&#160;ended December&#160;31, 2020 as no further milestone has been achieved. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-7<div style="display:inline;">1</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">8</div>. LICENSING AND COLLABORATION ARRANGEMENTS (CONTINUED) </div></div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Strategic Alliance Agreement with PT Kalbe Genexine Biologics (&#8220;KG Bio&#8221;) </div></div></div></div></div></div><ix:continuation id="TextSelectionAppend_20395375_11" continuedAt="TextSelectionAppend_20395375_12"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 6pt;"><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In </div>March 2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Group entered into a strategic partnership with Kalbe Genexine Biologics (&#8220;KG Bio&#8221;) to grant a right of first negotiation for an exclusive license for the development and commercialization of </div>two<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">I-Mab-discovered</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> product candidates: uliledlimab, a highly differentiated anti-CD</div>73<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> antibody in Phase </div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> development for advanced solid tumors (&#8220;First Program&#8221;), and an </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> product candidate (&#8220;Second Program&#8221;) to be agreed upon by both parties in certain regions. Through this agreement, both parties intend to negotiate the terms that will be reflected in definitive agreements for each prospective program covered under this agreement.</div><br/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">If and when the Group and KG Bio enter into the definitive licensing agreement, the Group will be eligible to receive from KG Bio an aggregate amount of up to approximately US$340&#160;million, including an upfront payment and subsequent payments conditional upon achieving certain development and commercial milestones. KG Bio will pay the Group tiered royalties in the low to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-teen</div> percentages on net sales from certain regions. As the right of first negotiation has not been exercised and the definitive agreement has not been entered into as of December&#160;31, 2020, no revenue was recognized during the year ended December&#160;31, 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Global Strategic Partnership with AbbVie </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;3, 2020, the Group, through <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma (Shanghai) Co., Ltd. and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma US Limited, each a wholly-owned subsidiary of the Group, entered into a broad global strategic partnership with AbbVie Ireland Unlimited Group (&#8220;AbbVie&#8221;). </div> <div style="text-align: left;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to this collaboration, the Group will grant AbbVie a global license, excluding Mainland China, Macau, and Hong Kong, to develop and commercialize lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> for the treatment of multiple cancers. The Group will retain all rights to develop and commercialize lemzoparlimab (as well as certain other compounds directed against CD47) in Mainland China, Macau, and Hong Kong. The Group is also responsible for performing the development activities at its sole cost and expense as outlined in the initial development plan. Such initial development activities consist of two studies, Study I and Study II. Study I is conducted in the United States evaluating lemzoparlimab in combination with pembrolizumab or rituximab in patients with relapsed or refractory solid tumors and lymphoma. Study II is conducted in Mainland China evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of lemzoparlimab in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). AbbVie will conduct further global clinical trials (which the Group may elect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-fund)</div> to evaluate lemzoparlimab in multiple cancers. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Potential collaboration on future CD47-related therapeutic agents is also allowed for under this arrangement, including CD47-based bispecific antibodies and combination therapies with lemzoparlimab and AbbVie&#8217;s venetoclax (Venclexta<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>). Each party will have the opportunity, subject to rights of first negotiation to further licenses, to explore certain of each other&#8217;s related CD47-antibody programs in their respective territories.</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A joint governance committee was established as set forth in the agreement, functioning as an oversight and governance mechanism. Both parties will participate in the joint governance committee to facilitate decision-making during the terms of the collaborative endeavor. Furthermore, the Group and AbbVie will share manufacturing responsibilities, with AbbVie having the opportunity to manufacture supply outside of Mainland China, Hong Kong and Macau and the Group being the primary manufacturer for supply for Mainland China, Hong </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kong and Macau. </div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-7<div style="display:inline;">2</div></div></div></div></div></div> </ix:continuation> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div>. LICENSING AND COLLABORATION ARRANGEMENTS (CONTINUED) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Global Strategic Partnership with AbbVie (continued) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_20395375_12"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Upon the satisfaction of all the pre-effect date covenants, the collaborative agreement took effect on December 10, 2020, on which date the Group was entitled to a non-refundable upfront payment of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>US$<ix:nonFraction name="imab:UpfrontLicenseFee" contextRef="P09_03_2020To09_03_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction>&#160;million. <div style="letter-spacing: 0px; top: 0px;;display:inline;">In addition,</div>&#160;the Group <div style="letter-spacing: 0px; top: 0px;;display:inline;">is</div>&#160;eligible to receive up to US$<ix:nonFraction name="us-gaap:ProceedsFromLicenseFeesReceived" contextRef="P09_03_2020To09_03_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-7" scale="9" format="ixt:numdotdecimal">1.76</ix:nonFraction>&#160;billion in further success-based development, regulatory and sales milestone payments for lemzoparlimab, of which US$<ix:nonFraction name="us-gaap:ProceedsFromLicenseFeesReceived" contextRef="P09_03_2020To09_03_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ClinicalMilestonesMemberIMABMilestoneTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">840</ix:nonFraction>&#160;million are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestones. Upon commercialization of lemzoparlimab, AbbVie will also pay tiered royalties<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">from low-to-mid teen double-digit percentages on global net sales outside of Mainland China, Macau, and Hong Kong.&#160;<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group identified three performance obligations: (1)&#160;grant of lemzoparlimab license upon the effective date, (2)&#160;delivering the Study I initial development services, and (3)&#160;delivering the Study II initial development services. The total transaction price under the agreement for the year ended December&#160;31, 2020 is US$<ix:nonFraction name="imab:UpfrontAndMilestonePayments" contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LemzoparlimabLicenseMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>&#160;million consisting of (i)&#160;the upfront payment of US$<ix:nonFraction name="imab:UpfrontLicenseFee" contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LemzoparlimabLicenseMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction>&#160;million upon the effective date, (ii)&#160;the first milestone payment of US$<ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_FirstMilestoneMemberIMABMilestoneTypeAxis_LemzoparlimabLicenseMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction>&#160;million upon the achievement of the first milestone event in late December 2020, and (iii)&#160;the second milestone payment of US$<ix:nonFraction name="imab:MilestonePayments" contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LemzoparlimabLicenseMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SecondMilestoneMemberIMABMilestoneTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction>&#160;million as of December&#160;31, 2020 as the Group deemed that the achievement of the second milestone event is probable as of December&#160;31, 2020 that a significant reversal of revenue would not occur. The achievements of the remaining development and regulatory based milestone events are constrained as of December&#160;31, 2020, and will be included in the transaction price when uncertainty associated with the variable consideration is subsequently resolved. Sales-based milestones and royalties will be recognized when the subsequent sales occur. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The non-constrained consideration of US$<ix:nonFraction name="imab:UpfrontAndMilestonePayments" contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">million is then allocated to the three performance obligations based on the relative stand-alone selling price. For the grant of lemzoparlimab license, the Group adopted an income approach based on key assumptions and several factors including, but not limited to estimated market demand, stand-alone selling price by making reference to market comparable, development timeline, regulatory risks, future revenue potential and discount rate.</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">The allocated price is US$<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">228.8</ix:nonFraction> million. The entire US$<ix:nonFraction name="imab:RevenueFromContractWithCustomerTimeOfTransferOfLicense" contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">228.8</ix:nonFraction></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">million (equivalent to approximately RMB<ix:nonFraction name="imab:RevenueFromContractWithCustomerTimeOfTransferOfLicense" contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">1,502.9</ix:nonFraction> million) was recognized</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;as revenue at</div> the point of the license transfer at the effective date. For the Study I and Study II initial development services, a cost-plus margin approach is utilized. The allocated price to Study I and Study II is</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;US$</div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study1MemberIMABTypeOfLicensesAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction> <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;and US$<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study2MemberIMABTypeOfLicensesAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">10.2</ix:nonFraction> million respectively. These two performance obligations are determined to be satisfied over time. The Group uses a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> input method to measure progress as that method best depicts the transfer of the two performance obligations under the agreement. As of December&#160;31, 2020, the cumulative percentages complete in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> input method for Study I and Study II<div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">wer</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">e</div></div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;estimated to approximate <ix:nonFraction name="imab:ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent" contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study1MemberIMABTypeOfLicensesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">17</ix:nonFraction> % and <ix:nonFraction name="imab:ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent" contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study2MemberIMABTypeOfLicensesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">41</ix:nonFraction> % respectively. As a result, US$<ix:nonFraction name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Study1MemberIMABTypeOfLicensesAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction>&#160;</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">million (equivalent to approximately RMB<ix:nonFraction name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Study1MemberIMABTypeOfLicensesAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction> million)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">and US$</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Study2MemberIMABTypeOfLicensesAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">million (equivalent to approximately RMB<ix:nonFraction name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Study2MemberIMABTypeOfLicensesAxis" unitRef="Unit_CNY" decimals="-5" scale="6" format="ixt:numdotdecimal">27.8</ix:nonFraction> million)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">were</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> recognized as revenue for the year ended December&#160;</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">31</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">, </div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">2020</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> in the consolidated statement of comprehensive income for Study I and Study II respectively, resulting in a contract asset of </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNet" contextRef="PAsOn12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">34.8</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">million</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">for this agreement as of December&#160;</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">31</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">, </div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">2020</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> in the consolidated balance sheets. As of December&#160;</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">31</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">, </div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">2020</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">, the upfront payment of US$</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="imab:UpfrontPaymentReceived" contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was received by the Group. The </div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">1</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">st milestone payment of US$</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="imab:MilestonePaymentReceivable" contextRef="PAsOn03_31_2021_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was subsequently </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">collected by the Group in March 2021. </div></div></div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-7<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>. OTHER INCOME (EXPENSES), NET </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes other income (expenses), net recognized for the years ended December&#160;31, 2018, 2019 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from conversion of 2017 Notes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainsLossesOnRestructuringOfDebt" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,375</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from conversion of Onshore Convertible Loan<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imab:LossFromConversionOfOnshoreConvertibleLoans" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">8,548</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from issuance of 2018 Notes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imab:LossFromIssuanceOfNotes" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,081</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on termination agreement with Everest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnContractTermination" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">23,039</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income of incentive payment from depository bank</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:IncentiveIncomeFromDepositoryBank" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,348</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:IncentiveIncomeFromDepositoryBank" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">360</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value change of short-term investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:FairValueChangeOfShortTermInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">703</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:FairValueChangeOfShortTermInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11,288</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:FairValueChangeOfShortTermInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,730</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value change of put right liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:FairValueAdjustmentsOfPutRightLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,024</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:FairValueAdjustmentsOfPutRightLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">463</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from other financial assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:IncomeFromOtherFinancialAssets" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">13,622</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net foreign exchange gains (losses)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">742</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">1,619</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">22,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,391</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsidy income<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> (3)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CharityCareReimbursementsReceived" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">750</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CharityCareReimbursementsReceived" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">568</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CharityCareReimbursementsReceived" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">11,633</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CharityCareReimbursementsReceived" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,783</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gains on deconsolidation of a subsidiary</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">407,598</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">62,467</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value change of other financial assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:FairValueAdjustmentsOfOtherFinancialAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">42</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Others</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="imab:OtherIncomeexpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imab:OtherIncomeexpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">98</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imab:OtherIncomeexpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">873</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="imab:OtherIncomeexpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">134</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,780</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">20,205</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">412,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">63,278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2020, subsidy income consists primarily of the government grant of RMB<ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2020To12_31_2020_GrantMembersrtProductOrServiceAxis" unitRef="Unit_CNY" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction>&#160;million. The government grant was granted by the project management office of Shanghai Zhangjiang Science City to support the research and development activities in the local region. </div></div> </td> </tr> </table> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-7<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div>. <div style="letter-spacing: 0px; top: 0px;;display:inline;">NET INCOME (LOSS) PER SHARE&#160;</div> </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-align: left;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per share for eac<div style="display:inline;">h</div>&#160;of the periods presented are calculated as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$ (Note 2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;">(in thousands, except for share and per share data)</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">402,833</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,451,950</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">470,915</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">72,170</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 57%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Deemed dividend to Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> preferred shareholders at extinguishment of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="imab:PreferredStockDividendsAtExtinguishmentOfPreferredShares" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Deemed dividend to Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> and C preferred shareholders at modification of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> and C Preferred Shares</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="imab:PreferredStockDividendsAtModificationOfPreferredShares" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">27,768</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to ordinary shareholders</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">402,833</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,485,001</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">470,915</ix:nonFraction> </div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">72,170</ix:nonFraction> </div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 6.5pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: 6.5pt;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 2%;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 1%;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 1%;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 2%;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Denominator for basic calculation-weighted average number of common shares <br/> outstanding</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,529,092</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">7,381,230</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">134,158,824</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">134,158,824</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive effect of convertible preferred shares</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,373,047</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,373,047</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Dilutive effect of ordinary shares to be issued to Everes<div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">266,458</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">266,458</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Dilutive effect of convertible promissory notes</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">865,479</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">865,479</ix:nonFraction> </div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive effect of restricted shares<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;units</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="imab:IncrementalCommonSharesAttributableToRestrictedShareUnits" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">778,130</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="imab:IncrementalCommonSharesAttributableToRestrictedShareUnits" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">778,130</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive effect of stock options</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(255, 255, 255);">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(255, 255, 255);">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">16,789,714</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">16,789,714</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 57%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for diluted income (loss) per share calculation</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,529,092</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">7,381,230</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;<ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">157,231,652</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;<ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">157,231,652</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per share - basic</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">61.70</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">201.19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">3.51</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.54</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per share - diluted</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">61.70</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">201.19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">3.00</ix:nonFraction> </div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.46</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr> </table> </div> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The effects of all outstanding convertible preferred shares, restricted shares and certain stock options have been excluded from the computation of diluted loss per share for the years ended December&#160;31, 2018 and 2019 as their effects would be anti-dilutive. For the years ended December&#160;31, 2018 and 2019, the Company also has certain dilutive potential stock options. These stock options which cannot be exercised until the Company completed its listing are not included in the computation of diluted earnings per shares as such contingent event had not taken place.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20394784">The potentially dilutive securities that have not been included in the calculation of diluted net loss per share as their inclusion would be anti-dilutive are as follows:</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_20394784">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible preferred shares</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2018To12_31_2018_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">64,389,968</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2019To12_31_2019_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">92,238,119</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted shares</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2018To12_31_2018_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,134,058</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">not&#160;applicable</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2019To12_31_2019_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">11,388,776</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:continuation></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-7<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div>. EMPLOYEE BENEFITS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Full time employees of the Group in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical care, employee housing fund and other welfare benefits are provided to the employees. Chinese labor regulations require that the PRC subsidiaries of the Group make contributions to the government for these benefits based on certain percentage of the employees&#8217; salaries, up to a maximum amount specified by the government. The Group has no legal obligation for the benefits beyond the contribution made. The total amounts charged to the consolidated statements of comprehensive income (loss) for such employee benefits amounted to approximately RMB<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">9,294</ix:nonFraction>, RMB<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">14,152</ix:nonFraction> and RMB<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">10,049</ix:nonFraction> for the years ended December&#160;31, 2018, 2019 and 2020, respectively. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>. COMMITMENTS AND CONTINGENCIES </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingencies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group is a party to or an assignee of license and collaboration agreements that may require it to make future payments relating to milestone fees and royalties on future sales of licensed products (see Note&#160;18). In April 2020, Tracon issued a notice of disputes with respect to the TJD5 Agreement and the BsAbs Agreement. As of the date of this report, these disputes have not been resolved (see Note&#160;18). As of December 31, 2020, the Group did not record any liabilities for these disputes. Information available prior to issuance of the financial statements did not indicate that it is probable that a liability had been incurred at the date of the financial statements and the Company is also unable to reasonably estimate the range of any liability or&#160; possible loss, if any. </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group did not have significant capital and other commitments, long-term obligations, or guarantees as of December&#160;31, 2019 and 2020. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20394935"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>. RELATED PARTY BALANCES AND TRANSACTIONS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below sets forth the major related parties and their relationships with the Group as of December&#160;31, 2019 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 48%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Name of related parties</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Relationship with the Group</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Everest</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Controlled by the ultimate controlling party of a principal shareholder of the Group</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">CMAB Biopharma (Suzhou) Inc.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Controlled by the ultimate controlling party of a principal shareholder of the Group</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Tasly Pharmaceutical Group Co., Ltd.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Controlled by the ultimate controlling party of a principal shareholder of the Group</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Jiangsu Taslydiyi Pharmaceutical Co., Ltd.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Controlled by the ultimate controlling party of a principal shareholder of the Group</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma (Hangzhou) Co., Limited</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Subsidiary of the Group before September&#160;15, 2020; Affiliate of the Group after September&#160;15, 2020</td> </tr> </table> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-7<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="display:inline;">3</div>. RELATED PARTY BALANCES AND TRANSACTIONS (CONTINUED) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_20394935" continuedAt="TextSelectionAppend_20394935_1"> <ix:nonNumeric name="imab:ScheduleOfRelatedPartyBalancesTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-align: left;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Details of related party balances as of December&#160;31, 2019 and 2020 are as follows: </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares to be issued to Everest </div></div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Everest (Note 1<div style="display:inline;">8</div>)</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="imab:CommonStockSharesIssuableForServicesAvailedCurrent" contextRef="PAsOn12_31_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">258,119</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other receivables</div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; padding-bottom: 2.2pt; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 2.2pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 2.2pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 2.2pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">21,212</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 2.2pt; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2.2pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,251</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <div style="text-align: left;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accruals and other payables </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jiangsu Taslydiyi Pharmaceutical Co., Ltd.</div></div></div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2020_JiangsuTaslydiyiPharmaceuticalCoLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,395</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2020_JiangsuTaslydiyiPharmaceuticalCoLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">367</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table></div></ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Details of related party transactions for the years ended December&#160;31, 2018, 2019 and 2020 are as follows: </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20394938"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 10pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Receipt of CRO services<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div>recognized in research and development expenses</div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CMAB Biopharma (Suzhou) Inc.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2018To12_31_2018_CmabBiopharmaSuzhouIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,786</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2020To12_31_2020_CmabBiopharmaSuzhouIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">681</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2020To12_31_2020_CmabBiopharmaSuzhouIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">104</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jiangsu Taslydiyi Pharmaceutical Co., Ltd.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2020To12_31_2020_JiangsuTaslydiyiPharmaceuticalCoLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2020To12_31_2020_JiangsuTaslydiyiPharmaceuticalCoLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">367</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tasly Pharmaceutical Group Co., Ltd.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2019To12_31_2019_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis_TaslyPharmaceuticalGroupCoLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">5,590</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 10pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Receipt of research and development funding </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Everest (Note 1<div style="display:inline;">8</div>)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" contextRef="P01_01_2018To12_31_2018_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">178,715</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" contextRef="P01_01_2019To12_31_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">53,148</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td></tr></table> <br/> </ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-7<div style="display:inline;">7</div></div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="display:inline;">3</div>. RELATED PARTY BALANCES AND TRANSACTIONS (CONTINUED) </div></div></div></div><ix:continuation id="TextSelectionAppend_20394935_1" continuedAt="TextSelectionAppend_20394935_2"><ix:continuation id="TextSelection_20394938" continuedAt="TextSelectionAppend_20394938_1"> <div style="text-indent: -2%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collection of loan to an affiliate</div> </div></div> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 2%; line-height: 12pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou <div style="font-size:85%; vertical-align:top;display:inline;;font-size:9.4px">(4)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DueFromAffiliateCurrent" contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">52,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DueFromAffiliateCurrent" contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,969</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:continuation>
<table style="border-spacing: 0px; margin-bottom: 0pt; margin-top: 12pt; width: 100%; table-layout: fixed;">
<tr style="vertical-align: top;">
<td style="padding: 0pt; width: 0%;"></td>
<td style="width: 4%; padding-left: 0px; padding-right: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(4)</div></div></td>
<td style="padding-left: 0px; padding-right: 0px; width: 96%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: normal;">In July 2019 and July 2020, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai provided an interest free loan to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou of RMB<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn07_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">2,000</ix:nonFraction> and RMB<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn07_31_2019_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">50,000</ix:nonFraction> respectively to finance <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou&#8217;s operation. These loans were repaid in November 2020. </div></td></tr></table> </ix:continuation></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"><ix:continuation id="TextSelectionAppend_20394935_2"><ix:continuation id="TextSelectionAppend_20394938_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expenses paid on behalf of an affiliate </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the year ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou</div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="imab:ExpensesPaidOnBehalfOfAnAffiliate" contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_CNY" decimals="-3" scale="3" format="ixt:numdotdecimal">21,212</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="imab:ExpensesPaidOnBehalfOfAnAffiliate" contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,251</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </ix:continuation></ix:continuation> <ix:nonNumeric name="us-gaap:ConcentrationRiskDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_20394941"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div>. CONCENTRATION OF CREDIT RISK</div></div></div></div></ix:nonNumeric> </div> <ix:continuation id="TextSelection_20394941"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that are potentially subject to significant con<div style="display:inline;">c</div>entration of credit risk consist of cash and cash equivalents, restricted cash, short-term investments, other financial assets, accounts receivable, contract assets, and other receivables. The carrying amounts of cash and cash equivalents, restricted cash, short-term investments, contract assets, and other financial assets represent the maximum amount of loss due to credit risk. As of December&#160;31, 2019 and 2020, all of the Group&#8217;s cash and cash equivalents, restricted cash and short-term investments were held by major financial institutions located in the PRC and international financial institutions outside of the PRC which management believes are of high credit quality and continually monitors the credit worthiness of these financial institutions. With respect to the accounts receivable, contract assets, other receivables and other financial assets, the Group performs <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> credit evaluations of the financial condition of its customers and counterparties.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: center;"><div style="font-size: 10pt; letter-spacing: 0px; text-align: center; top: 0px;;display:inline;">F-7</div><div style="font-size: 10pt; letter-spacing: 0px; text-align: center; top: 0px;;display:inline;">8</div></div> </ix:continuation> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="margin-left: calc(-48.56vw + 48.9%);">Table of Contents</a></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(All amounts in thousands, except for share and per share data, unless otherwise noted) </div></div></div> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>. SUBSEQUENT EVENTS </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2021, the Group sent Tracon a notice to terminate the TJD5 Agreement, which would result in a prespecified termination fee of US$<ix:nonFraction name="imab:TerminationFeePayable" contextRef="PAsOn02_28_2021_CollaborationAgreementsWithTraconPharmaceuticalsIncMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">9.0</ix:nonFraction> million owing to Tracon. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2021, the Group entered into two collaboration agreements with Complix, an EU-based biotech company (the &#8220;Complix Agreement&#8221;), and Affinity, a Shanghai-based biotech company (the &#8220;Affinity Agreement&#8221;), respectively, allowing the Group to access cutting edge technology platforms to create next generation of novel and highly differentiated drug candidates, including Cell Penetrating Alphabodies (&#8220;CPAB&#8221;) for otherwise intractable intracellular drug targets and masked antibodies for targeted tumor-site activation. Under the Complix Agreement, both parties will collaborate to discover, develop and commercialize novel therapeutics for mutually agreed targets based on the Complix&#8217;s proprietary technology. Under the Affinity Agreement, both parties will collaborate to develop lead compounds for mutually agreed targets based on Affinity&#8217;s Tumor MicroEnvironment Activated body (&#8220;TMEAbody&#8221;) platform technology. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2021, the Group entered into a license and collaboration agreement with Genbase, a Shanghai-based biotech company to develop bi-specific antibodies or/and multi-specific antibodies using antibody sequences from both companies. Under this agreement, Genbase granted to the Group a non-transferable, sublicensable, and royalty-bearing license under Genbase parental antibody technology and Genbase parental antibody improvements owned and controlled by Genbase to make, develop and commercialize the licensed compounds and licensed products in all uses and indications worldwide. </div></div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:RestrictedAssetsDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="margin-top: 18pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div>. RESTRICTED NET ASSETS </div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s ability to pay dividends may depend on the Group receiving distributions of funds from its PRC subsidiary. Relevant PRC statutory laws and regulations permit payments of dividends by the Group&#8217;s PRC subsidiary only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with U.S. GAAP differ from those reflected in the statutory financial statements of the Group&#8217;s PRC subsidiary. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In accordance with the Company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least <ix:nonFraction name="imab:StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit" contextRef="PAsOn12_31_2020" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>% of its annual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profit until such reserve has reached <ix:nonFraction name="imab:ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation" contextRef="PAsOn12_31_2020" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% of its respective registered capital based on the enterprise&#8217;s PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise&#8217;s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Group&#8217;s PRC subsidiary was established as domestic invested enterprise and therefore is subject to the above mentioned restrictions on distributable profits. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended December&#160;31, 2018, 2019 and 2020, <ix:nonFraction name="imab:AppropriationtoStatutoryReserve" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="imab:AppropriationtoStatutoryReserve" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="imab:AppropriationtoStatutoryReserve" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> appropriation to statutory reserves was made because the PRC subsidiary had substantial losses during such periods. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result of these PRC laws and regulations subject to the limit discussed above that require annual appropriations of <ix:nonFraction name="imab:StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit" contextRef="PAsOn12_31_2020" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>% of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> income to be set aside, prior to payment of dividends, as general reserve fund, the Group&#8217;s PRC subsidiary is restricted in their ability to transfer a portion of their net assets to the Group. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign exchange and other regulations in the PRC further restrict the Company&#8217;s PRC subsidiaries from transferring funds to the Company in the form of dividends, loans and advances. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the net asset base for purposes of calculating the proportionate share of restricted net assets of consolidated subsidiaries should be <ix:nonFraction name="us-gaap:AssetsNet" contextRef="PAsOn12_31_2020_SubsidiariesMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction>, while the Group has a consolidated shareholders&#8217; equity. Therefore, as the restricted net assets of consolidated subsidiaries do not exceed <ix:nonFraction name="imab:PercentageOfNetAssetToNetAssetsOfGroup" contextRef="PAsOn12_31_2020_SubsidiariesMembersrtConsolidatedEntitiesAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>% of consolidated net assets as of the most recent fiscal year end, the Group is not required to provide parent company financial information. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-7<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></div></div> </div> </div> </div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>2
<FILENAME>d10811dex81.htm
<DESCRIPTION>EX-8.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-8.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT 8.1</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>List of Principal Subsidiaries of <FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Subsidiaries</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Place&nbsp;of&nbsp;Incorporation</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Hong Kong</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">People&#146;s Republic of China</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Co., Ltd.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">People&#146;s Republic of China</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>3
<FILENAME>d10811dex121.htm
<DESCRIPTION>EX-12.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-12.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT 12.1</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification by the Principal Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Joan Huaqiong Shen, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules <FONT
STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the Company and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the Company&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the Company&#146;s internal control over financial reporting that
occurred during the period covered by this annual report that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the Company&#146;s auditors and the audit committee of the Company&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the Company&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Date: April&nbsp;28,&nbsp;2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joan Huaqiong Shen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Joan Huaqiong Shen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>4
<FILENAME>d10811dex122.htm
<DESCRIPTION>EX-12.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-12.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT 12.2</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification by the Principal Financial Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Jielun Zhu, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules <FONT
STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the Company and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the Company&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the Company&#146;s internal control over financial reporting that
occurred during the period covered by this annual report that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the Company&#146;s auditors and the audit committee of the Company&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the Company&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Date: April&nbsp;28,&nbsp;2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jielun Zhu</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jielun Zhu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>5
<FILENAME>d10811dex131.htm
<DESCRIPTION>EX-13.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-13.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT 13.1</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification by the Principal Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Annual Report of <FONT STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;) on Form <FONT
STYLE="white-space:nowrap">20-F</FONT> for the fiscal year ended December&nbsp;31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I, Joan Huaqiong Shen, Chief Executive Officer of the Company,
certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act
of 1934, as amended; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">April&nbsp;28,&nbsp;2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joan Huaqiong Shen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Joan Huaqiong Shen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>6
<FILENAME>d10811dex132.htm
<DESCRIPTION>EX-13.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-13.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT 13.2</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification by the Principal Financial Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Annual Report of <FONT STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;) on Form <FONT
STYLE="white-space:nowrap">20-F</FONT> for the fiscal year ended December&nbsp;31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I, Jielun Zhu, Chief Financial Officer of the Company, certify,
pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act
of 1934, as amended; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">April&nbsp;28,&nbsp;2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jielun Zhu</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jielun Zhu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>7
<FILENAME>d10811dex151.htm
<DESCRIPTION>EX-15.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-15.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT 15.1</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 28, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT>
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 802, West Tower, OmniVision </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">88 Shangke Road </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pudong District, Shanghai </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">People&#146;s Republic of China </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sir/Madam: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the reference of our name
under the headings &#147;Item&nbsp;3.D. Key Information&#151;Risk Factors&#151;Risks Related to Doing Business in China&#148; and &#147;Item 10. Additional Information&#151;E. Taxation&#151;PRC Taxation&#148; in
<FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;20-F</FONT> for the year ended December&nbsp;31, 2020 (the &#147;<B>Annual Report</B>&#148;), which will be filed with the Securities
and Exchange Commission (the &#147;<B>SEC</B>&#148;) on the date hereof, and further consent to the incorporation by reference into the Registration Statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT>
<FONT STYLE="white-space:nowrap">(No.&nbsp;333-239871)</FONT> and Form F-3 (No. 333-252793) <FONT STYLE="white-space:nowrap">of&nbsp;I-Mab</FONT> of the summary of our opinions under the headings &#147;Item&nbsp;3.D. Key Information&#151;Risk
Factors&#151;Risks Related to Doing Business in China&#148; and &#147;Item 10. Additional Information&#151;E. Taxation&#151;PRC Taxation&#148; in the Annual Report. We also consent to the filing of this consent letter with the SEC as an exhibit to
the Annual Report. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In giving such consent, we do not thereby admit that we come within the category of persons whose consent is required under
Section&nbsp;7 of the Securities Act of 1933, or under the Securities Exchange Act of 1934, in each case, as amended, or the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ JunHe LLP </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>8
<FILENAME>d10811dex152.htm
<DESCRIPTION>EX-15.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-15.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 15.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the incorporation by reference in the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> (No. <FONT
STYLE="white-space:nowrap">333-239871)</FONT> and Form <FONT STYLE="white-space:nowrap">F-3</FONT> (No. <FONT STYLE="white-space:nowrap">333-252793)</FONT> of <FONT STYLE="white-space:nowrap">I-Mab</FONT> of our report dated April&nbsp;28, 2021
relating to the financial statements, which appears in this Form <FONT STYLE="white-space:nowrap">20-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/PricewaterhouseCoopers Zhong Tian LLP
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shanghai, the People&#146;s Republic of China </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 28,
2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>imab-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-April-2021 [01:14:57] {PM}-->
<schema targetNamespace="http://IMab.com/20201231" elementFormDefault="qualified" xmlns:imab="http://IMab.com/20201231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://IMab.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" id="ConsolidatedStatementsOfComprehensiveIncomeLoss">
<link:definition>1004 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit" id="ConsolidatedStatementsOfChangesInShareholdersEquityDeficit">
<link:definition>1005 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Deficit)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1006 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PrincipalActivitiesAndOrganization" id="PrincipalActivitiesAndOrganization">
<link:definition>1007 - Disclosure - Principal Activities and Organization</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PrincipalAccountingPolicies" id="PrincipalAccountingPolicies">
<link:definition>1008 - Disclosure - Principal Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/AccountsReceivableAndContractAssets" id="AccountsReceivableAndContractAssets">
<link:definition>1009 - Disclosure - Accounts Receivable And Contract  Assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PrepaymentsAndOtherReceivables" id="PrepaymentsAndOtherReceivables">
<link:definition>1010 - Disclosure - Prepayments And Other Receivables</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PropertyEquipmentAndSoftware" id="PropertyEquipmentAndSoftware">
<link:definition>1011 - Disclosure - Property, Equipment And Software</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/Leases" id="Leases">
<link:definition>1012 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/IntangibleAssests" id="IntangibleAssests">
<link:definition>1013 - Disclosure - Intangible Assests</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/Goodwill" id="Goodwill">
<link:definition>1014 - Disclosure - Goodwill</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilities" id="InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilities">
<link:definition>1015 - Disclosure - Investment Accounted for Using the Equity Method and Put Right Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ShortTermBorrowings" id="ShortTermBorrowings">
<link:definition>1016 - Disclosure - Short-Term Borrowings</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/AccrualsAndOtherPayables" id="AccrualsAndOtherPayables">
<link:definition>1017 - Disclosure - Accruals And Other Payables</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1018 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/OrdinaryShares" id="OrdinaryShares">
<link:definition>1019 - Disclosure - Ordinary Shares</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ConvertiblePreferredShares" id="ConvertiblePreferredShares">
<link:definition>1020 - Disclosure - Convertible Preferred Shares</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoans" id="ConvertiblePromissoryNotesAndOnshoreConvertibleLoans">
<link:definition>1021 - Disclosure - Convertible Promissory Notes And Onshore Convertible Loans</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/Warrants" id="Warrants">
<link:definition>1022 - Disclosure - Warrants</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ShareBasedCompensation" id="ShareBasedCompensation">
<link:definition>1023 - Disclosure - Share-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/LicensingAndCollaborationArrangements" id="LicensingAndCollaborationArrangements">
<link:definition>1024 - Disclosure - Licensing And Collaboration Arrangements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/OtherIncomeExpensesNet" id="OtherIncomeExpensesNet">
<link:definition>1025 - Disclosure - Other Income (Expenses), Net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/NetIncomeLossPerShare" id="NetIncomeLossPerShare">
<link:definition>1026 - Disclosure - Net Income (Loss) per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/EmployeeBenefits" id="EmployeeBenefits">
<link:definition>1027 - Disclosure - Employee Benefits</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1028 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/RelatedPartyBalancesAndTransactions" id="RelatedPartyBalancesAndTransactions">
<link:definition>1029 - Disclosure - Related Party Balances and Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ConcentrationOfCreditRisk" id="ConcentrationOfCreditRisk">
<link:definition>1030 - Disclosure - Concentration of Credit Risk</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1031 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/RestrictedNetAssets" id="RestrictedNetAssets">
<link:definition>1032 - Disclosure - Restricted Net Assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PrincipalAccountingPoliciesPolicies" id="PrincipalAccountingPoliciesPolicies">
<link:definition>1033 - Disclosure - Principal Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PrincipalActivitiesAndOrganizationTables" id="PrincipalActivitiesAndOrganizationTables">
<link:definition>1034 - Disclosure - Principal Activities and Organization (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PrincipalAccountingPoliciesTables" id="PrincipalAccountingPoliciesTables">
<link:definition>1035 - Disclosure - Principal Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/AccountsReceivableAndContractAssetsTables" id="AccountsReceivableAndContractAssetsTables">
<link:definition>1036 - Disclosure - Accounts Receivable And Contract Assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PrepaymentsAndOtherReceivablesTables" id="PrepaymentsAndOtherReceivablesTables">
<link:definition>1037 - Disclosure - Prepayments And Other Receivables (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PropertyEquipmentAndSoftwareTables" id="PropertyEquipmentAndSoftwareTables">
<link:definition>1038 - Disclosure - Property, Equipment And Software (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/LeasesTables" id="LeasesTables">
<link:definition>1039 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
<link:definition>1040 - Disclosure - Intangible Assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTables" id="InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTables">
<link:definition>1041 - Disclosure - Investment Accounted for Using the Equity Method and Put Right Liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/AccrualsAndOtherPayablesTables" id="AccrualsAndOtherPayablesTables">
<link:definition>1042 - Disclosure - Accruals And Other Payables (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1043 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ConvertiblePreferredSharesTables" id="ConvertiblePreferredSharesTables">
<link:definition>1044 - Disclosure - Convertible Preferred Shares (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/WarrantsTables" id="WarrantsTables">
<link:definition>1045 - Disclosure - Warrants (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ShareBasedCompensationTables" id="ShareBasedCompensationTables">
<link:definition>1046 - Disclosure - Share-Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/LicensingAndCollaborationAgreementsTables" id="LicensingAndCollaborationAgreementsTables">
<link:definition>1047 - Disclosure - Licensing and Collaboration Agreements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/OtherIncomeExpensesNetTables" id="OtherIncomeExpensesNetTables">
<link:definition>1048 - Disclosure - Other Income (Expenses), Net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/NetIncomeLossPerShareTables" id="NetIncomeLossPerShareTables">
<link:definition>1049 - Disclosure - Net Income (Loss) per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/RelatedPartyBalancesAndTransactionsTables" id="RelatedPartyBalancesAndTransactionsTables">
<link:definition>1050 - Disclosure - Related Party Balances and Transactions (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail" id="PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail">
<link:definition>1051 - Disclosure - Principal Activities and Organization - Schedule of Principal Subsidiaries (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail" id="PrincipalActivitiesAndOrganizationAdditionalInformationDetail">
<link:definition>1052 - Disclosure - Principal Activities and Organization - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" id="PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail">
<link:definition>1053 - Disclosure - Principal Accounting Policies - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail" id="PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail">
<link:definition>1054 - Disclosure - Principal Accounting Policies - Summary of Roll Forward of Major Level 3 Financial Assets and Financial Liability (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfCashCashEquivalentsAndRestrictedCashAsReportedInTheConsolidatedStatementOfCashFlowsDetail" id="PrincipalAccountingPoliciesSummaryOfCashCashEquivalentsAndRestrictedCashAsReportedInTheConsolidatedStatementOfCashFlowsDetail">
<link:definition>1055 - Disclosure - Principal Accounting Policies - summary of Cash, cash equivalents and restricted cash as reported in the consolidated statement of cash flows (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail" id="PrincipalAccountingPoliciesAdditionalInformationDetail">
<link:definition>1056 - Disclosure - Principal Accounting Policies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail" id="PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail">
<link:definition>1057 - Disclosure - Principal Accounting Policies - Summary of Estimated Useful Lives (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/AccountsReceivableAndContractAssetsSummaryOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesDetail" id="AccountsReceivableAndContractAssetsSummaryOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesDetail">
<link:definition>1058 - Disclosure - Accounts Receivable And Contract Assets - summary of Accounts receivable and contract assets, net of allowance for credit losses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail" id="PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail">
<link:definition>1059 - Disclosure - Prepayments And Other Receivables - Summary of Prepayments And Other Receivables (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PropertyEquipmentAndSoftwareAdditionalInformationDetail" id="PropertyEquipmentAndSoftwareAdditionalInformationDetail">
<link:definition>1060 - Disclosure - Property, Equipment And Software - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail" id="PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail">
<link:definition>1061 - Disclosure - Property, Equipment And Software - Schedule of property, equipment and software, net (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail" id="LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail">
<link:definition>1062 - Disclosure - Leases - Operating Lease Related Assets And Liabilities And Other Related Information (Detail))</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail" id="LeasesComponentsOfOperatingLeaseExpenseDetail">
<link:definition>1063 - Disclosure - Leases - Components of Operating Lease Expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/LeasesOperatingLeaseMaturityDetail" id="LeasesOperatingLeaseMaturityDetail">
<link:definition>1064 - Disclosure - Leases - Operating Lease, Maturity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" id="IntangibleAssetsSummaryOfIntangibleAssetsDetail">
<link:definition>1065 - Disclosure - Intangible Assets - Summary Of Intangible Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/IntangibleAssetsAdditionalInformationDetail" id="IntangibleAssetsAdditionalInformationDetail">
<link:definition>1066 - Disclosure - Intangible Assets - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/GoodwillAdditionalInformationDetail" id="GoodwillAdditionalInformationDetail">
<link:definition>1067 - Disclosure - Goodwill - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail" id="InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail">
<link:definition>1068 - Disclosure - Investment Accounted for Using the Equity Method and Put Right Liabilities - Summary of Group Long term Investment Measured Under Equity method (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetail" id="InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetail">
<link:definition>1069 - Disclosure - Investment Accounted for Using the Equity Method and Put Right Liabilities - Summary of Estimate the Fair Value of the Put Right Using the Following Assumptions (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail" id="InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail">
<link:definition>1070 - Disclosure - Investment Accounted for Using the Equity Method and Put Right Liabilities - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail" id="ShortTermBorrowingsAdditionalInformationDetail">
<link:definition>1071 - Disclosure - Short-Term Borrowings - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail" id="AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail">
<link:definition>1072 - Disclosure - Accruals And Other Payables - Summary of accruals and other payables (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/AccrualsAndOtherPayablesAdditionalInformationDetails" id="AccrualsAndOtherPayablesAdditionalInformationDetails">
<link:definition>1073 - Disclosure - Accruals And Other Payables - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
<link:definition>1074 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail" id="IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail">
<link:definition>1075 - Disclosure - Income Taxes - Reconciliations of the Differences Between the PRC Statutory Income Tax Rate and the Group's Effective Income Tax Rate (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail" id="IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail">
<link:definition>1076 - Disclosure - Income Taxes - Components of the Deferred Tax Assets and Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/IncomeTaxesSummaryOfMovementOfTheValuationAllowanceDetail" id="IncomeTaxesSummaryOfMovementOfTheValuationAllowanceDetail">
<link:definition>1077 - Disclosure - Income Taxes - Summary of Movement of the Valuation Allowance (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/OrdinarySharesAdditionalInformationDetail" id="OrdinarySharesAdditionalInformationDetail">
<link:definition>1078 - Disclosure - Ordinary Shares - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail" id="ConvertiblePreferredSharesAdditionalInformationDetail">
<link:definition>1079 - Disclosure - Convertible Preferred Shares - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail" id="ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail">
<link:definition>1080 - Disclosure - Convertible Preferred Shares - Schedule of Convertible Preferred Shares Activities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail" id="ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail">
<link:definition>1081 - Disclosure - Convertible Promissory Notes And Onshore Convertible Loans- Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/WarrantsAdditionalInformationDetail" id="WarrantsAdditionalInformationDetail">
<link:definition>1082 - Disclosure - Warrants - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail" id="WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail">
<link:definition>1083 - Disclosure - Warrants - Details of accounting for warrants to purchase ordinary shares (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail" id="WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail">
<link:definition>1084 - Disclosure - Warrants - Summary of fair value of warrant liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail" id="ShareBasedCompensationAdditionalInformationDetail">
<link:definition>1085 - Disclosure - Share-Based Compensation - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail" id="ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail">
<link:definition>1086 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Expenses Related to Restricted Shares (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail" id="ShareBasedCompensationScheduleOfStockOptionActivitiesDetail">
<link:definition>1087 - Disclosure - Share-Based Compensation - Schedule of Stock Option Activities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail" id="ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail">
<link:definition>1088 - Disclosure - Share-Based Compensation - Summary of Valuation Assumptions Used (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail" id="ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail">
<link:definition>1089 - Disclosure - Share-Based Compensation - Summary of non-vested stock option activities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail" id="ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail">
<link:definition>1090 - Disclosure - Share-Based Compensation -Schedule of Nonvested Restricted Stock Units Activity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail" id="ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail">
<link:definition>1091 - Disclosure - Share-based Compensation - Schedule of Share-based Payment Arrangement Restricted Stock Unit Activity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail" id="LicensingAndCollaborationAgreementsAdditionalInformationDetail">
<link:definition>1092 - Disclosure - Licensing And Collaboration Agreements - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail" id="LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail">
<link:definition>1093 - Disclosure - Licensing And Collaboration Arrangements - Summary of Financial Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail" id="OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail">
<link:definition>1094 - Disclosure - Other Income (Expenses), Net - Summary of Other Income (Expenses), Net (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetParentheticalDetail" id="OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetParentheticalDetail">
<link:definition>1095 - Disclosure - Other Income (Expenses), Net - Summary of Other Income (Expenses), Net (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail" id="NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail">
<link:definition>1096 - Disclosure - Net Income (Loss) per Share - Summary of Basic and Diluted Net Loss per Share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" id="NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail">
<link:definition>1097 - Disclosure - Net Income (Loss) per Share - Summary of Antidilutive Securities Excluded from Computation of Earnings per Share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/EmployeeBenefitsAdditionalInformationDetail" id="EmployeeBenefitsAdditionalInformationDetail">
<link:definition>1098 - Disclosure - Employee Benefits - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail" id="RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail">
<link:definition>1099 - Disclosure - Related Party Balances and Transactions - Summary of Related Party Balances (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesParentheticalDetail" id="RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesParentheticalDetail">
<link:definition>1100 - Disclosure - Related Party Balances and Transactions - Summary of Related Party Balances (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail" id="RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail">
<link:definition>1101 - Disclosure - Related Party Balances and Transactions - Summary of Related Party Transactions (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/SubsequentEventsAdditionalInformationDetail" id="SubsequentEventsAdditionalInformationDetail">
<link:definition>1102 - Disclosure - Subsequent Events - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://IMab.com/role/RestrictedNetAssetsAdditionalInformationDetail" id="RestrictedNetAssetsAdditionalInformationDetail">
<link:definition>1103 - Disclosure - Restricted Net Assets - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="imab-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="imab-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="imab-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="imab-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
<element name="CommonStockSharesIssuableForServicesAvailedCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_CommonStockSharesIssuableForServicesAvailedCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PutRightLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_PutRightLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SeriesC1ConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriesC1ConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesAConvertiblePreferredSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriesAConvertiblePreferredSharesMember" substitutionGroup="xbrli:item" />
<element name="SeriesBConvertiblePreferredSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriesBConvertiblePreferredSharesMember" substitutionGroup="xbrli:item" />
<element name="SeriesCConvertiblePreferredSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriesCConvertiblePreferredSharesMember" substitutionGroup="xbrli:item" />
<element name="PreferredStockDividendsAtExtinguishmentOfPreferredShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PreferredStockDividendsAtModificationOfPreferredShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_PreferredStockDividendsAtModificationOfPreferredShares" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseAdvanceFromCustomers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_IncreaseDecreaseAdvanceFromCustomers" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomeFromOtherFinancialAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_IncomeFromOtherFinancialAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LossFromConversionOfOnshoreConvertibleLoans" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_LossFromConversionOfOnshoreConvertibleLoans" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LossFromConversionOfNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_LossFromConversionOfNotes" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LossFromIssuanceOfNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_LossFromIssuanceOfNotes" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueChangeOfShortTermInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_FairValueChangeOfShortTermInvestments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueAdjustmentsOfPutRightLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_FairValueAdjustmentsOfPutRightLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashReceivedOnIncomeFromOtherFinancialAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_CashReceivedOnIncomeFromOtherFinancialAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherSupplementalCashFlowDisclosuresAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_OtherSupplementalCashFlowDisclosuresAbstract" substitutionGroup="xbrli:item" />
<element name="PayablesForInLicensedPatentRights" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_PayablesForInLicensedPatentRights" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ExerciseOfWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccuredInitialPublicOfferingCostPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_AccuredInitialPublicOfferingCostPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedPrivatePlacementOfferingCostsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_AccruedPrivatePlacementOfferingCostsPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccountsReceivableAndContractAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_AccountsReceivableAndContractAssetsAbstract" substitutionGroup="xbrli:item" />
<element name="AccountsReceivableAndContractAssetsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_AccountsReceivableAndContractAssetsTextBlock" substitutionGroup="xbrli:item" />
<element name="PrepaidexpensesandotherreceivablestextblockTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_PrepaidexpensesandotherreceivablestextblockTextBlock" substitutionGroup="xbrli:item" />
<element name="InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract" substitutionGroup="xbrli:item" />
<element name="InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock" substitutionGroup="xbrli:item" />
<element name="TemporaryEquityTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_TemporaryEquityTextBlock" substitutionGroup="xbrli:item" />
<element name="ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract" substitutionGroup="xbrli:item" />
<element name="ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans" substitutionGroup="xbrli:item" />
<element name="WarrantsDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_WarrantsDisclosureAbstract" substitutionGroup="xbrli:item" />
<element name="WarrantsDisclosure" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_WarrantsDisclosure" substitutionGroup="xbrli:item" />
<element name="RestrictedNetAssetsDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_RestrictedNetAssetsDisclosureAbstract" substitutionGroup="xbrli:item" />
<element name="ShortTermInvestmentsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ShortTermInvestmentsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="DeferredSubsidyIncomePolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_DeferredSubsidyIncomePolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ValueAddedTaxesPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ValueAddedTaxesPolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="LongTermInvestmentsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_LongTermInvestmentsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfPrincipalSubsidiariesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ScheduleOfPrincipalSubsidiariesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock" substitutionGroup="xbrli:item" />
<element name="TwentySeventeenEmployeeStockOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_TwentySeventeenEmployeeStockOptionPlanMember" substitutionGroup="xbrli:item" />
<element name="TwentyEighteenEmployeeStockOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_TwentyEighteenEmployeeStockOptionPlanMember" substitutionGroup="xbrli:item" />
<element name="TwentyNineteenEmployeeStockOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_TwentyNineteenEmployeeStockOptionPlanMember" substitutionGroup="xbrli:item" />
<element name="TwentyTwentyEmployeeStockOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_TwentyTwentyEmployeeStockOptionPlanMember" substitutionGroup="xbrli:item" />
<element name="LicensingAgreementWithMorphosysAgMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_LicensingAgreementWithMorphosysAgMember" substitutionGroup="xbrli:item" />
<element name="LicensingAgreementWithGenexineIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_LicensingAgreementWithGenexineIncMember" substitutionGroup="xbrli:item" />
<element name="LicensingAgreementWithMorphosysMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_LicensingAgreementWithMorphosysMember" substitutionGroup="xbrli:item" />
<element name="LicensingAgreementWithMacrogenicsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_LicensingAgreementWithMacrogenicsMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfRelatedPartyBalancesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ScheduleOfRelatedPartyBalancesTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfPrincipalSubsidiariesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ScheduleOfPrincipalSubsidiariesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IMabBiopharmaHongKongLimitedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_IMabBiopharmaHongKongLimitedMember" substitutionGroup="xbrli:item" />
<element name="IMabShanghaiMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_IMabShanghaiMember" substitutionGroup="xbrli:item" />
<element name="IMabtianjinMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_IMabtianjinMember" substitutionGroup="xbrli:item" />
<element name="ImabbiopharmaUsLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ImabbiopharmaUsLtdMember" substitutionGroup="xbrli:item" />
<element name="EntityIncorporationCountryStateName" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_EntityIncorporationCountryStateName" substitutionGroup="xbrli:item" />
<element name="CommonStockSharesIssuable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_CommonStockSharesIssuable" substitutionGroup="xbrli:item" />
<element name="OtherFinancialAssetsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_OtherFinancialAssetsMember" substitutionGroup="xbrli:item" />
<element name="WarrantLiabilitiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_WarrantLiabilitiesMember" substitutionGroup="xbrli:item" />
<element name="PutRightLiabilitiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_PutRightLiabilitiesMember" substitutionGroup="xbrli:item" />
<element name="FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="VATSurchargesPercent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_VATSurchargesPercent" substitutionGroup="xbrli:item" />
<element name="BankBranchAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_BankBranchAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="BankBranchDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_BankBranchDomain" substitutionGroup="xbrli:item" />
<element name="PeoplesBankOfChinaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_PeoplesBankOfChinaMember" substitutionGroup="xbrli:item" />
<element name="FederalReserveBankOfNewYorkMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_FederalReserveBankOfNewYorkMember" substitutionGroup="xbrli:item" />
<element name="LaboratoryEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_LaboratoryEquipmentMember" substitutionGroup="xbrli:item" />
<element name="SoftwareMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SoftwareMember" substitutionGroup="xbrli:item" />
<element name="OfficeFurnitureAndEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_OfficeFurnitureAndEquipmentMember" substitutionGroup="xbrli:item" />
<element name="ValueaddedTaxRecoverable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_ValueaddedTaxRecoverable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PropertyPlantAndequipmentnetExcludingConstructionInProcess" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_PropertyPlantAndequipmentnetExcludingConstructionInProcess" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems" substitutionGroup="xbrli:item" />
<element name="ScheduleOfComponentsOfOperatingLeaseExpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ScheduleOfComponentsOfOperatingLeaseExpenseTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleofComponentsofOperatingLeaseExpenseLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseRightOfUseAssetAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_OperatingLeaseRightOfUseAssetAmortization" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OperatingLeaseInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_OperatingLeaseInterestExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ScheduleOfOperatingLeaseMaturityTableTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ScheduleOfOperatingLeaseMaturityTableTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfOperatingLeaseMaturityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ScheduleOfOperatingLeaseMaturityLineItems" substitutionGroup="xbrli:item" />
<element name="IprAndDTj103Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_IprAndDTj103Member" substitutionGroup="xbrli:item" />
<element name="IprAndDTj101Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_IprAndDTj101Member" substitutionGroup="xbrli:item" />
<element name="IprAndDTj102Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_IprAndDTj102Member" substitutionGroup="xbrli:item" />
<element name="TasgenGroupMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_TasgenGroupMember" substitutionGroup="xbrli:item" />
<element name="EquityMethodInvestmentSummarizedFinancialInformationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_EquityMethodInvestmentSummarizedFinancialInformationTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="NetIncomeLossMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_NetIncomeLossMember" substitutionGroup="xbrli:item" />
<element name="LossFromOperationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_LossFromOperationMember" substitutionGroup="xbrli:item" />
<element name="GrossProfitMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_GrossProfitMember" substitutionGroup="xbrli:item" />
<element name="RevenueMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_RevenueMember" substitutionGroup="xbrli:item" />
<element name="EquityMethodInvestmentSummarizedFinancialInformationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_EquityMethodInvestmentSummarizedFinancialInformationLineItems" substitutionGroup="xbrli:item" />
<element name="BalanceSheetDataAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_BalanceSheetDataAbstract" substitutionGroup="xbrli:item" />
<element name="OperatingDataAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_OperatingDataAbstract" substitutionGroup="xbrli:item" />
<element name="LongTermInvestmentUnderEquityMethodMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_LongTermInvestmentUnderEquityMethodMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate" substitutionGroup="xbrli:item" />
<element name="ImabHangzhouMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ImabHangzhouMember" substitutionGroup="xbrli:item" />
<element name="ImabHongKongMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ImabHongKongMember" substitutionGroup="xbrli:item" />
<element name="ManagementHoldcoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ManagementHoldcoMember" substitutionGroup="xbrli:item" />
<element name="EsopHoldcoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_EsopHoldcoMember" substitutionGroup="xbrli:item" />
<element name="DomesticInvestorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_DomesticInvestorsMember" substitutionGroup="xbrli:item" />
<element name="RegisteredCapitalOfSubsidiary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_RegisteredCapitalOfSubsidiary" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="HoldcoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_HoldcoMember" substitutionGroup="xbrli:item" />
<element name="ChinaMerchantBankCoLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ChinaMerchantBankCoLtdMember" substitutionGroup="xbrli:item" />
<element name="LoanOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_LoanOneMember" substitutionGroup="xbrli:item" />
<element name="LoanTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_LoanTwoMember" substitutionGroup="xbrli:item" />
<element name="NonRefundableIncentivePaymentFromDepositaryBankNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_NonRefundableIncentivePaymentFromDepositaryBankNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdvanceReceivedFromEmployeeForExerciseOfStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_AdvanceReceivedFromEmployeeForExerciseOfStockOptions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedTravellingExpensesOfficeExpensesAndOthers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_AccruedTravellingExpensesOfficeExpensesAndOthers" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WithholdingIitPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_WithholdingIitPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedInitialPublicOfferingCostsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_AccruedInitialPublicOfferingCostsPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PrivatePlacementOfferingCostsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_PrivatePlacementOfferingCostsPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NonRefundableIncentivePaymentFromDepositaryBankCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_NonRefundableIncentivePaymentFromDepositaryBankCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromNonRefundableIncentive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ProceedsFromNonRefundableIncentive" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IMobOtherSubsidiariesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_IMobOtherSubsidiariesMember" substitutionGroup="xbrli:item" />
<element name="EffectivePreferentialIncomeTaxRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_EffectivePreferentialIncomeTaxRate" substitutionGroup="xbrli:item" />
<element name="WithholdingTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_WithholdingTax" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CNMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_CNMember" substitutionGroup="xbrli:item" />
<element name="PRCMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_PRCMember" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxAssetsContractAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_DeferredTaxAssetsContractAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxesAdditionsValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_DeferredTaxesAdditionsValuationAllowance" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxAssetsValuationAllowanceUtilizationAndReversal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_DeferredTaxAssetsValuationAllowanceUtilizationAndReversal" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SeriesAConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriesAConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="ConvertiblePreferredStockSeriesBMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ConvertiblePreferredStockSeriesBMember" substitutionGroup="xbrli:item" />
<element name="ConvertiblePreferredStockSeriesBOneUponConversionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ConvertiblePreferredStockSeriesBOneUponConversionMember" substitutionGroup="xbrli:item" />
<element name="ConvertiblePreferredStockSeriesB2Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ConvertiblePreferredStockSeriesB2Member" substitutionGroup="xbrli:item" />
<element name="SeriesCOneConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriesCOneConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="CommonStockValueAuthorized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_CommonStockValueAuthorized" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AmericanDepositorySharesCommonShareEquivalent" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_AmericanDepositorySharesCommonShareEquivalent" substitutionGroup="xbrli:item" />
<element name="PrepaidExpenseStockRepurchaseProgram" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_PrepaidExpenseStockRepurchaseProgram" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GrossProceedsOfSharesAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_GrossProceedsOfSharesAndWarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="BoardOfDirectorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_BoardOfDirectorsMember" substitutionGroup="xbrli:item" />
<element name="CollaborationAgreementWithEverestMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_CollaborationAgreementWithEverestMember" substitutionGroup="xbrli:item" />
<element name="HillhouseEntitiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_HillhouseEntitiesMember" substitutionGroup="xbrli:item" />
<element name="CollaborationAgreementWithInvestorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_CollaborationAgreementWithInvestorsMember" substitutionGroup="xbrli:item" />
<element name="EverestsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_EverestsMember" substitutionGroup="xbrli:item" />
<element name="InvestorWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_InvestorWarrantsMember" substitutionGroup="xbrli:item" />
<element name="PeriodTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_PeriodTypeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="PeriodTypeDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_PeriodTypeDomain" substitutionGroup="xbrli:item" />
<element name="FirstClosingPeriodMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_FirstClosingPeriodMember" substitutionGroup="xbrli:item" />
<element name="SecondClosingPeriodMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SecondClosingPeriodMember" substitutionGroup="xbrli:item" />
<element name="IssueOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_IssueOfWarrants" substitutionGroup="xbrli:item" />
<element name="QualifiedPublicOfferingPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_QualifiedPublicOfferingPrice" substitutionGroup="xbrli:item" />
<element name="OfferingPriceOfConvertedShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_OfferingPriceOfConvertedShares" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PreferredStockLiquidationPreferencePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_PreferredStockLiquidationPreferencePercentage" substitutionGroup="xbrli:item" />
<element name="PreferredStockLiquidationPreferenceRateOfReturn" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_PreferredStockLiquidationPreferenceRateOfReturn" substitutionGroup="xbrli:item" />
<element name="AdjustmentsAtExtinguishmentOfPreferredShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_AdjustmentsAtExtinguishmentOfPreferredShares" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ConvertiblePreferredStockSeriesA3Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ConvertiblePreferredStockSeriesA3Member" substitutionGroup="xbrli:item" />
<element name="SeriesA3PreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriesA3PreferredStockMember" substitutionGroup="xbrli:item" />
<element name="ConvertiblePreferredStockSeriesAThreeUponExerciseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ConvertiblePreferredStockSeriesAThreeUponExerciseMember" substitutionGroup="xbrli:item" />
<element name="ConvertiblePreferredStockSeriesBTwoUponExerciseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ConvertiblePreferredStockSeriesBTwoUponExerciseMember" substitutionGroup="xbrli:item" />
<element name="ConvertiblePreferredStockSeriesBUponExerciseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ConvertiblePreferredStockSeriesBUponExerciseMember" substitutionGroup="xbrli:item" />
<element name="SeriesA1AndA2PreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriesA1AndA2PreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesCOnePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriesCOnePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="ConvertiblePreferredStockSeriesBOneUponExerciseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ConvertiblePreferredStockSeriesBOneUponExerciseMember" substitutionGroup="xbrli:item" />
<element name="TemporaryEquityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_TemporaryEquityMember" substitutionGroup="xbrli:item" />
<element name="SeriescOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriescOneMember" substitutionGroup="xbrli:item" />
<element name="SeriesCConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriesCConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesBConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriesBConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesB1PreferredSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriesB1PreferredSharesMember" substitutionGroup="xbrli:item" />
<element name="SeriesA3PreferredSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriesA3PreferredSharesMember" substitutionGroup="xbrli:item" />
<element name="SeriesBOnshoreInvestorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriesBOnshoreInvestorsMember" substitutionGroup="xbrli:item" />
<element name="SeriesBPreferredStockHolderMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriesBPreferredStockHolderMember" substitutionGroup="xbrli:item" />
<element name="OnshoreConvertibleLoanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_OnshoreConvertibleLoanMember" substitutionGroup="xbrli:item" />
<element name="TwoZeroOneEightNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_TwoZeroOneEightNotesMember" substitutionGroup="xbrli:item" />
<element name="ConvertiblePromissoryNotes2017Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ConvertiblePromissoryNotes2017Member" substitutionGroup="xbrli:item" />
<element name="ConvertiblePromissoryNotes2018Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ConvertiblePromissoryNotes2018Member" substitutionGroup="xbrli:item" />
<element name="GenexineIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_GenexineIncMember" substitutionGroup="xbrli:item" />
<element name="SeriesBPreferredShareholdersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriesBPreferredShareholdersMember" substitutionGroup="xbrli:item" />
<element name="TrancheIOfSeriesBWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_TrancheIOfSeriesBWarrantsMember" substitutionGroup="xbrli:item" />
<element name="SeriesB2PreferredSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriesB2PreferredSharesMember" substitutionGroup="xbrli:item" />
<element name="TrancheIiOfSeriesBWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_TrancheIiOfSeriesBWarrantsMember" substitutionGroup="xbrli:item" />
<element name="SeriesBWarrantsSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeriesBWarrantsSharesMember" substitutionGroup="xbrli:item" />
<element name="AmericanDepositarySharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_AmericanDepositarySharesMember" substitutionGroup="xbrli:item" />
<element name="WarrantsToPurchaseOrdinarySharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_WarrantsToPurchaseOrdinarySharesMember" substitutionGroup="xbrli:item" />
<element name="Classofwarrantorrightsexercisableterm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_Classofwarrantorrightsexercisableterm" substitutionGroup="xbrli:item" />
<element name="DrzangMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_DrzangMember" substitutionGroup="xbrli:item" />
<element name="LeiFangMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_LeiFangMember" substitutionGroup="xbrli:item" />
<element name="FoundersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_FoundersMember" substitutionGroup="xbrli:item" />
<element name="SeniorManagementEmployeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SeniorManagementEmployeesMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationTrancheFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ShareBasedCompensationTrancheFourMember" substitutionGroup="xbrli:item" />
<element name="OnePerformanceConditionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_OnePerformanceConditionMember" substitutionGroup="xbrli:item" />
<element name="TwoPerformanceConditionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_TwoPerformanceConditionsMember" substitutionGroup="xbrli:item" />
<element name="ThreePerformanceConditionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ThreePerformanceConditionsMember" substitutionGroup="xbrli:item" />
<element name="FourPerformanceConditionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_FourPerformanceConditionsMember" substitutionGroup="xbrli:item" />
<element name="EquityInLossOfAnAffiliateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_EquityInLossOfAnAffiliateMember" substitutionGroup="xbrli:item" />
<element name="ThirdVentureMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ThirdVentureMember" substitutionGroup="xbrli:item" />
<element name="AmendedTwentySeventeenEmployeeStockOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_AmendedTwentySeventeenEmployeeStockOptionPlanMember" substitutionGroup="xbrli:item" />
<element name="ShareIncentivePlan2020Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ShareIncentivePlan2020Member" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" substitutionGroup="xbrli:item" />
<element name="SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares" substitutionGroup="xbrli:item" />
<element name="MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares" substitutionGroup="xbrli:item" />
<element name="TwentyNineteenShareIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_TwentyNineteenShareIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="PortionOfRestrictedShareUnitsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_PortionOfRestrictedShareUnitsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="PortionOfRestrictedShareUnitsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_PortionOfRestrictedShareUnitsDomain" substitutionGroup="xbrli:item" />
<element name="ThirdOneThirdPortionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ThirdOneThirdPortionMember" substitutionGroup="xbrli:item" />
<element name="SecondOneThirdPortionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SecondOneThirdPortionMember" substitutionGroup="xbrli:item" />
<element name="ShareIncentivePlanTwoThousandTwentyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ShareIncentivePlanTwoThousandTwentyMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod" substitutionGroup="xbrli:item" />
<element name="Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice" substitutionGroup="xbrli:item" />
<element name="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" substitutionGroup="xbrli:item" />
<element name="Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares" substitutionGroup="xbrli:item" />
<element name="Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue" substitutionGroup="xbrli:item" />
<element name="Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue" substitutionGroup="xbrli:item" />
<element name="ScheduleOfNonvestedRestrictedStockUnitsActivityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ScheduleOfNonvestedRestrictedStockUnitsActivityTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems" substitutionGroup="xbrli:item" />
<element name="ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems" substitutionGroup="xbrli:item" />
<element name="MorphoSysAGMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_MorphoSysAGMember" substitutionGroup="xbrli:item" />
<element name="MacroGenicsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_MacroGenicsMember" substitutionGroup="xbrli:item" />
<element name="HealSunMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_HealSunMember" substitutionGroup="xbrli:item" />
<element name="EverestMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_EverestMember" substitutionGroup="xbrli:item" />
<element name="ABLBioMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ABLBioMember" substitutionGroup="xbrli:item" />
<element name="AbbVieMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_AbbVieMember" substitutionGroup="xbrli:item" />
<element name="OtherInLicensingAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_OtherInLicensingAgreementsMember" substitutionGroup="xbrli:item" />
<element name="OutLicensingAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_OutLicensingAgreementsMember" substitutionGroup="xbrli:item" />
<element name="LemzoparlimabLicenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_LemzoparlimabLicenseMember" substitutionGroup="xbrli:item" />
<element name="CspcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_CspcMember" substitutionGroup="xbrli:item" />
<element name="MorphosysMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_MorphosysMember" substitutionGroup="xbrli:item" />
<element name="MilestoneTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_MilestoneTypeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="MilestoneTypeDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_MilestoneTypeDomain" substitutionGroup="xbrli:item" />
<element name="ClinicalMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ClinicalMilestonesMember" substitutionGroup="xbrli:item" />
<element name="SalesMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SalesMilestonesMember" substitutionGroup="xbrli:item" />
<element name="DevelopmentMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_DevelopmentMilestoneMember" substitutionGroup="xbrli:item" />
<element name="MilestoneIiiMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_MilestoneIiiMember" substitutionGroup="xbrli:item" />
<element name="MilestoneIvMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_MilestoneIvMember" substitutionGroup="xbrli:item" />
<element name="FirstMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_FirstMilestoneMember" substitutionGroup="xbrli:item" />
<element name="SecondMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_SecondMilestoneMember" substitutionGroup="xbrli:item" />
<element name="LicensingAgreementWithABLBioMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_LicensingAgreementWithABLBioMember" substitutionGroup="xbrli:item" />
<element name="LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember" substitutionGroup="xbrli:item" />
<element name="CollaborationAgreementWithABLBioMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_CollaborationAgreementWithABLBioMember" substitutionGroup="xbrli:item" />
<element name="CollaborationAgreementsWithTraconPharmaceuticalsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember" substitutionGroup="xbrli:item" />
<element name="OtherinlicensingarrangementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_OtherinlicensingarrangementsMember" substitutionGroup="xbrli:item" />
<element name="LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember" substitutionGroup="xbrli:item" />
<element name="StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember" substitutionGroup="xbrli:item" />
<element name="LicensingAgreementsWithMorphosysMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_LicensingAgreementsWithMorphosysMember" substitutionGroup="xbrli:item" />
<element name="Gxi7Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_Gxi7Member" substitutionGroup="xbrli:item" />
<element name="UpfrontLicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_UpfrontLicenseFee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_MilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CostSharingRatio" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_CostSharingRatio" substitutionGroup="xbrli:item" />
<element name="MilestonePaymentsOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_MilestonePaymentsOutstanding" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfReductionInMilestonePayments" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_PercentageOfReductionInMilestonePayments" substitutionGroup="xbrli:item" />
<element name="CumulativePaidInContributions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_CumulativePaidInContributions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TimeCostOfForegoingHistoricalContribution" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_TimeCostOfForegoingHistoricalContribution" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MilestonePaymentsIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_MilestonePaymentsIncome" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredRevenueFromCollaborativeArrangementExcludingVat" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_DeferredRevenueFromCollaborativeArrangementExcludingVat" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UpfrontAndMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_UpfrontAndMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RevenueFromContractWithCustomerTimeOfTransferOfLicense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_RevenueFromContractWithCustomerTimeOfTransferOfLicense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent" substitutionGroup="xbrli:item" />
<element name="DeferredLiabilityFromCollaborativeArrangementExcludingTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UpfrontPaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_UpfrontPaymentReceived" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MilestonePaymentReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_MilestonePaymentReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredRevenueMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_DeferredRevenueMember" substitutionGroup="xbrli:item" />
<element name="TypeOfLicensesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_TypeOfLicensesAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TypeOfLicensesDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_TypeOfLicensesDomain" substitutionGroup="xbrli:item" />
<element name="Study1Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_Study1Member" substitutionGroup="xbrli:item" />
<element name="Study2Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_Study2Member" substitutionGroup="xbrli:item" />
<element name="LicensingAgreementUpfrontFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_LicensingAgreementUpfrontFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueAdjustmentsOfOtherFinancialAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_FairValueAdjustmentsOfOtherFinancialAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherIncomeexpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_OtherIncomeexpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncentiveIncomeFromDepositoryBank" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_IncentiveIncomeFromDepositoryBank" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncrementalCommonSharesAttributableToRestrictedShareUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_IncrementalCommonSharesAttributableToRestrictedShareUnits" substitutionGroup="xbrli:item" />
<element name="JiangsuTaslydiyiPharmaceuticalCoLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember" substitutionGroup="xbrli:item" />
<element name="ExpensesPaidOnBehalfOfAnAffiliate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_ExpensesPaidOnBehalfOfAnAffiliate" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CmabBiopharmaSuzhouIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_CmabBiopharmaSuzhouIncMember" substitutionGroup="xbrli:item" />
<element name="TaslyPharmaceuticalGroupCoLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_TaslyPharmaceuticalGroupCoLtdMember" substitutionGroup="xbrli:item" />
<element name="ReceiptOfContractResearchOrganizationsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_ReceiptOfContractResearchOrganizationsMember" substitutionGroup="xbrli:item" />
<element name="TerminationFeePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_TerminationFeePayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UnderwriterAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_UnderwriterAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="UnderwriterDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_UnderwriterDomain" substitutionGroup="xbrli:item" />
<element name="RestrictedNetAssetsDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="imab_RestrictedNetAssetsDisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="PercentageOfNetAssetToNetAssetsOfGroup" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_PercentageOfNetAssetToNetAssetsOfGroup" substitutionGroup="xbrli:item" />
<element name="ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation" substitutionGroup="xbrli:item" />
<element name="StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="imab_StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit" substitutionGroup="xbrli:item" />
<element name="AppropriationtoStatutoryReserve" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="imab_AppropriationtoStatutoryReserve" substitutionGroup="xbrli:item" xbrli:balance="credit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>imab-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-April-2021 [01:14:57] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConsolidatedBalanceSheets" roleURI="http://IMab.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://IMab.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalAccountingPoliciesSummaryOfCashCashEquivalentsAndRestrictedCashAsReportedInTheConsolidatedStatementOfCashFlowsDetail" roleURI="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfCashCashEquivalentsAndRestrictedCashAsReportedInTheConsolidatedStatementOfCashFlowsDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail" roleURI="http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail" roleURI="http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#LeasesComponentsOfOperatingLeaseExpenseDetail" roleURI="http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#LeasesOperatingLeaseMaturityDetail" roleURI="http://IMab.com/role/LeasesOperatingLeaseMaturityDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail" roleURI="http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail" roleURI="http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail" roleURI="http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail" roleURI="http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail" />
<calculationLink xlink:type="extended" xlink:role="http://IMab.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ShortTermBorrowings" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CommonStockSharesIssuableForServicesAvailedCurrent" xlink:label="loc_IMAB_CommonStockSharesIssuableForServicesAvailedCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_IMAB_CommonStockSharesIssuableForServicesAvailedCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaap_DeferredIncomeCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredIncomeCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="loc_us-gaap_DeferredIncomeNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredIncomeNoncurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PutRightLiabilities" xlink:label="loc_IMAB_PutRightLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_IMAB_PutRightLiabilities" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="18" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://IMab.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_EquityMethodInvestments" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_RestrictedCashCurrent" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_ShortTermInvestments" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="31" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://IMab.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_Depreciation" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_InterestExpenseDebt" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="loc_us-gaap_AssetsFairValueAdjustment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AssetsFairValueAdjustment" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IncomeFromOtherFinancialAssets" xlink:label="loc_IMAB_IncomeFromOtherFinancialAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IMAB_IncomeFromOtherFinancialAssets" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LossFromConversionOfNotes" xlink:label="loc_IMAB_LossFromConversionOfNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IMAB_LossFromConversionOfNotes" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LossFromConversionOfOnshoreConvertibleLoans" xlink:label="loc_IMAB_LossFromConversionOfOnshoreConvertibleLoans" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IMAB_LossFromConversionOfOnshoreConvertibleLoans" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LossFromIssuanceOfNotes" xlink:label="loc_IMAB_LossFromIssuanceOfNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IMAB_LossFromIssuanceOfNotes" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities" xlink:label="loc_IMAB_AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IMAB_AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueChangeOfShortTermInvestments" xlink:label="loc_IMAB_FairValueChangeOfShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IMAB_FairValueChangeOfShortTermInvestments" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="loc_us-gaap_GainLossOnContractTermination" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnContractTermination" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueAdjustmentsOfPutRightLiabilities" xlink:label="loc_IMAB_FairValueAdjustmentsOfPutRightLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IMAB_FairValueAdjustmentsOfPutRightLiabilities" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness" use="optional" order="20" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" use="optional" order="21" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="22" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IncreaseDecreaseAdvanceFromCustomers" xlink:label="loc_IMAB_IncreaseDecreaseAdvanceFromCustomers" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IMAB_IncreaseDecreaseAdvanceFromCustomers" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:label="loc_IMAB_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IMAB_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="30" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="32" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments" use="optional" order="34" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments" use="optional" order="35" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" use="optional" order="36" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CashReceivedOnIncomeFromOtherFinancialAssets" xlink:label="loc_IMAB_CashReceivedOnIncomeFromOtherFinancialAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_IMAB_CashReceivedOnIncomeFromOtherFinancialAssets" use="optional" order="37" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" use="optional" order="38" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" use="optional" order="39" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="40" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" use="optional" order="41" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt" use="optional" order="42" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises" use="optional" order="43" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromBankDebt" xlink:label="loc_us-gaap_ProceedsFromBankDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromBankDebt" use="optional" order="44" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="loc_us-gaap_RepaymentsOfBankDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfBankDebt" use="optional" order="45" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" use="optional" order="46" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="47" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" use="optional" order="48" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="49" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity" use="optional" order="50" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" use="optional" order="51" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram" xlink:label="loc_IMAB_ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_IMAB_ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram" use="optional" order="52" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_ConstructionInProgressGross" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingLeaseRightOfUseAssetAmortization" xlink:label="loc_IMAB_OperatingLeaseRightOfUseAssetAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="loc_IMAB_OperatingLeaseRightOfUseAssetAmortization" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="loc_us-gaap_ShortTermLeaseCost" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingLeaseInterestExpense" xlink:label="loc_IMAB_OperatingLeaseInterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="loc_IMAB_OperatingLeaseInterestExpense" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://IMab.com/role/LeasesOperatingLeaseMaturityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount" xlink:label="loc_IMAB_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_IMAB_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent" xlink:label="loc_IMAB_AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_IMAB_AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccruedInitialPublicOfferingCostsPayable" xlink:label="loc_IMAB_AccruedInitialPublicOfferingCostsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_IMAB_AccruedInitialPublicOfferingCostsPayable" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccruedTravellingExpensesOfficeExpensesAndOthers" xlink:label="loc_IMAB_AccruedTravellingExpensesOfficeExpensesAndOthers" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_IMAB_AccruedTravellingExpensesOfficeExpensesAndOthers" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WithholdingIitPayable" xlink:label="loc_IMAB_WithholdingIitPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_IMAB_WithholdingIitPayable" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PrivatePlacementOfferingCostsPayable" xlink:label="loc_IMAB_PrivatePlacementOfferingCostsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_IMAB_PrivatePlacementOfferingCostsPayable" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_NonRefundableIncentivePaymentFromDepositaryBankCurrent" xlink:label="loc_IMAB_NonRefundableIncentivePaymentFromDepositaryBankCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_IMAB_NonRefundableIncentivePaymentFromDepositaryBankCurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_NonRefundableIncentivePaymentFromDepositaryBankNoncurrent" xlink:label="loc_IMAB_NonRefundableIncentivePaymentFromDepositaryBankNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="loc_IMAB_NonRefundableIncentivePaymentFromDepositaryBankNoncurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AdvanceReceivedFromEmployeeForExerciseOfStockOptions" xlink:label="loc_IMAB_AdvanceReceivedFromEmployeeForExerciseOfStockOptions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="loc_IMAB_AdvanceReceivedFromEmployeeForExerciseOfStockOptions" use="optional" order="11" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares" xlink:label="loc_IMAB_PreferredStockDividendsAtExtinguishmentOfPreferredShares" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_IMAB_PreferredStockDividendsAtExtinguishmentOfPreferredShares" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockDividendsAtModificationOfPreferredShares" xlink:label="loc_IMAB_PreferredStockDividendsAtModificationOfPreferredShares" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_IMAB_PreferredStockDividendsAtModificationOfPreferredShares" use="optional" order="14" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="16" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies" xlink:label="loc_us-gaap_Supplies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_Supplies" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ValueaddedTaxRecoverable" xlink:label="loc_IMAB_ValueaddedTaxRecoverable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_IMAB_ValueaddedTaxRecoverable" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_SecurityDeposit" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaap_InterestReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_InterestReceivable" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_OtherAssets" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromEmployeesCurrent" xlink:label="loc_us-gaap_DueFromEmployeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_DueFromEmployeesCurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromAffiliateCurrent" xlink:label="loc_us-gaap_DueFromAffiliateCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_DueFromAffiliateCurrent" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LossFromConversionOfOnshoreConvertibleLoans" xlink:label="loc_IMAB_LossFromConversionOfOnshoreConvertibleLoans" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="loc_IMAB_LossFromConversionOfOnshoreConvertibleLoans" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LossFromIssuanceOfNotes" xlink:label="loc_IMAB_LossFromIssuanceOfNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="loc_IMAB_LossFromIssuanceOfNotes" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueChangeOfShortTermInvestments" xlink:label="loc_IMAB_FairValueChangeOfShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="loc_IMAB_FairValueChangeOfShortTermInvestments" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IncomeFromOtherFinancialAssets" xlink:label="loc_IMAB_IncomeFromOtherFinancialAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="loc_IMAB_IncomeFromOtherFinancialAssets" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CharityCareReimbursementsReceived" xlink:label="loc_us-gaap_CharityCareReimbursementsReceived" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="loc_us-gaap_CharityCareReimbursementsReceived" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueAdjustmentsOfOtherFinancialAssets" xlink:label="loc_IMAB_FairValueAdjustmentsOfOtherFinancialAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="loc_IMAB_FairValueAdjustmentsOfOtherFinancialAssets" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OtherIncomeexpense" xlink:label="loc_IMAB_OtherIncomeexpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="loc_IMAB_OtherIncomeexpense" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="loc_us-gaap_GainLossOnContractTermination" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainLossOnContractTermination" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueAdjustmentsOfPutRightLiabilities" xlink:label="loc_IMAB_FairValueAdjustmentsOfPutRightLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="loc_IMAB_FairValueAdjustmentsOfPutRightLiabilities" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IncentiveIncomeFromDepositoryBank" xlink:label="loc_IMAB_IncentiveIncomeFromDepositoryBank" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="loc_IMAB_IncentiveIncomeFromDepositoryBank" use="optional" order="13" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfCashCashEquivalentsAndRestrictedCashAsReportedInTheConsolidatedStatementOfCashFlowsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_RestrictedCashCurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsNet" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredTaxAssetsContractAssets" xlink:label="loc_IMAB_DeferredTaxAssetsContractAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_IMAB_DeferredTaxAssetsContractAssets" use="optional" order="8" weight="-1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>imab-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-April-2021 [01:14:57] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#CoverPage" roleURI="http://IMab.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConsolidatedBalanceSheets" roleURI="http://IMab.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConsolidatedStatementsOfChangesInShareholdersEquityDeficit" roleURI="http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShareBasedCompensationTables" roleURI="http://IMab.com/role/ShareBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#LicensingAndCollaborationAgreementsTables" roleURI="http://IMab.com/role/LicensingAndCollaborationAgreementsTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail" roleURI="http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalActivitiesAndOrganizationAdditionalInformationDetail" roleURI="http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" roleURI="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail" roleURI="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalAccountingPoliciesAdditionalInformationDetail" roleURI="http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail" roleURI="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail" roleURI="http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail" roleURI="http://IMab.com/role/LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#LeasesComponentsOfOperatingLeaseExpenseDetail" roleURI="http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#LeasesOperatingLeaseMaturityDetail" roleURI="http://IMab.com/role/LeasesOperatingLeaseMaturityDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IntangibleAssetsSummaryOfIntangibleAssetsDetail" roleURI="http://IMab.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IntangibleAssetsAdditionalInformationDetail" roleURI="http://IMab.com/role/IntangibleAssetsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#GoodwillAdditionalInformationDetail" roleURI="http://IMab.com/role/GoodwillAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail" roleURI="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail" roleURI="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShortTermBorrowingsAdditionalInformationDetail" roleURI="http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://IMab.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail" roleURI="http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#OrdinarySharesAdditionalInformationDetail" roleURI="http://IMab.com/role/OrdinarySharesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConvertiblePreferredSharesAdditionalInformationDetail" roleURI="http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail" roleURI="http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail" roleURI="http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#WarrantsAdditionalInformationDetail" roleURI="http://IMab.com/role/WarrantsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail" roleURI="http://IMab.com/role/WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail" roleURI="http://IMab.com/role/WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShareBasedCompensationAdditionalInformationDetail" roleURI="http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail" roleURI="http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShareBasedCompensationScheduleOfStockOptionActivitiesDetail" roleURI="http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail" roleURI="http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail" roleURI="http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail" roleURI="http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail" roleURI="http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#LicensingAndCollaborationAgreementsAdditionalInformationDetail" roleURI="http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail" roleURI="http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetParentheticalDetail" roleURI="http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" roleURI="http://IMab.com/role/NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail" roleURI="http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesParentheticalDetail" roleURI="http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail" roleURI="http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#SubsequentEventsAdditionalInformationDetail" roleURI="http://IMab.com/role/SubsequentEventsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#RestrictedNetAssetsAdditionalInformationDetail" roleURI="http://IMab.com/role/RestrictedNetAssetsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://IMab.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalActivitiesAndOrganization" roleURI="http://IMab.com/role/PrincipalActivitiesAndOrganization" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalActivitiesAndOrganizationTables" roleURI="http://IMab.com/role/PrincipalActivitiesAndOrganizationTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrepaymentsAndOtherReceivables" roleURI="http://IMab.com/role/PrepaymentsAndOtherReceivables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrepaymentsAndOtherReceivablesTables" roleURI="http://IMab.com/role/PrepaymentsAndOtherReceivablesTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail" roleURI="http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#RestrictedNetAssets" roleURI="http://IMab.com/role/RestrictedNetAssets" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#SubsequentEvents" roleURI="http://IMab.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PropertyEquipmentAndSoftware" roleURI="http://IMab.com/role/PropertyEquipmentAndSoftware" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PropertyEquipmentAndSoftwareTables" roleURI="http://IMab.com/role/PropertyEquipmentAndSoftwareTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConcentrationOfCreditRisk" roleURI="http://IMab.com/role/ConcentrationOfCreditRisk" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#RelatedPartyBalancesAndTransactions" roleURI="http://IMab.com/role/RelatedPartyBalancesAndTransactions" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PropertyEquipmentAndSoftwareAdditionalInformationDetail" roleURI="http://IMab.com/role/PropertyEquipmentAndSoftwareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#RelatedPartyBalancesAndTransactionsTables" roleURI="http://IMab.com/role/RelatedPartyBalancesAndTransactionsTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalAccountingPolicies" roleURI="http://IMab.com/role/PrincipalAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalAccountingPoliciesPolicies" roleURI="http://IMab.com/role/PrincipalAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#CommitmentsAndContingencies" roleURI="http://IMab.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalAccountingPoliciesTables" roleURI="http://IMab.com/role/PrincipalAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#EmployeeBenefits" roleURI="http://IMab.com/role/EmployeeBenefits" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#EmployeeBenefitsAdditionalInformationDetail" roleURI="http://IMab.com/role/EmployeeBenefitsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#NetIncomeLossPerShare" roleURI="http://IMab.com/role/NetIncomeLossPerShare" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#NetIncomeLossPerShareTables" roleURI="http://IMab.com/role/NetIncomeLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail" roleURI="http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#OtherIncomeExpensesNet" roleURI="http://IMab.com/role/OtherIncomeExpensesNet" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#OtherIncomeExpensesNetTables" roleURI="http://IMab.com/role/OtherIncomeExpensesNetTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail" roleURI="http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#Leases" roleURI="http://IMab.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#LeasesTables" roleURI="http://IMab.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IntangibleAssests" roleURI="http://IMab.com/role/IntangibleAssests" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IntangibleAssetsTables" roleURI="http://IMab.com/role/IntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#Goodwill" roleURI="http://IMab.com/role/Goodwill" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShortTermBorrowings" roleURI="http://IMab.com/role/ShortTermBorrowings" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#AccrualsAndOtherPayables" roleURI="http://IMab.com/role/AccrualsAndOtherPayables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#AccrualsAndOtherPayablesTables" roleURI="http://IMab.com/role/AccrualsAndOtherPayablesTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail" roleURI="http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IncomeTaxes" roleURI="http://IMab.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IncomeTaxesTables" roleURI="http://IMab.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail" roleURI="http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IncomeTaxesSummaryOfMovementOfTheValuationAllowanceDetail" roleURI="http://IMab.com/role/IncomeTaxesSummaryOfMovementOfTheValuationAllowanceDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#OrdinaryShares" roleURI="http://IMab.com/role/OrdinaryShares" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#Warrants" roleURI="http://IMab.com/role/Warrants" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#WarrantsTables" roleURI="http://IMab.com/role/WarrantsTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConvertiblePreferredSharesTables" roleURI="http://IMab.com/role/ConvertiblePreferredSharesTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConvertiblePreferredShares" roleURI="http://IMab.com/role/ConvertiblePreferredShares" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShareBasedCompensation" roleURI="http://IMab.com/role/ShareBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConvertiblePromissoryNotesAndOnshoreConvertibleLoans" roleURI="http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoans" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#LicensingAndCollaborationArrangements" roleURI="http://IMab.com/role/LicensingAndCollaborationArrangements" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilities" roleURI="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilities" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTables" roleURI="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetail" roleURI="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#AccrualsAndOtherPayablesAdditionalInformationDetails" roleURI="http://IMab.com/role/AccrualsAndOtherPayablesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalAccountingPoliciesSummaryOfCashCashEquivalentsAndRestrictedCashAsReportedInTheConsolidatedStatementOfCashFlowsDetail" roleURI="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfCashCashEquivalentsAndRestrictedCashAsReportedInTheConsolidatedStatementOfCashFlowsDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#AccountsReceivableAndContractAssets" roleURI="http://IMab.com/role/AccountsReceivableAndContractAssets" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#AccountsReceivableAndContractAssetsTables" roleURI="http://IMab.com/role/AccountsReceivableAndContractAssetsTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#AccountsReceivableAndContractAssetsSummaryOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesDetail" roleURI="http://IMab.com/role/AccountsReceivableAndContractAssetsSummaryOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesDetail" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_630144" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_617285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentType_617285" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_617286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_AmendmentFlag_617286" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_617288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentPeriodEndDate_617288" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_617289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentFiscalYearFocus_617289" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_617290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentFiscalPeriodFocus_617290" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_617292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityRegistrantName_617292" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_617293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityCentralIndexKey_617293" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_617294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_CurrentFiscalYearEndDate_617294" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_617301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_617301" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_617302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityVoluntaryFilers_617302" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_617303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityCurrentReportingStatus_617303" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_617304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityFilerCategory_617304" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_617306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityShellCompany_617306" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_617308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityEmergingGrowthCompany_617308" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_617311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_TradingSymbol_617311" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_617312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_617312" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_617314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_SecurityExchangeName_617314" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_617316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityAddressCityOrTown_617316" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_617317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityAddressCountry_617317" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_617318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityAddressAddressLine1_617318" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_617340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityInteractiveDataCurrent_617340" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_617341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityFileNumber_617341" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_617343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityIncorporationStateCountryCode_617343" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_617346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityAddressPostalZipCode_617346" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_617347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_CityAreaCode_617347" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_617348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_LocalPhoneNumber_617348" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_617349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentAnnualReport_617349" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_617350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentTransitionReport_617350" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_623273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_Security12bTitle_623273" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_629596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityExTransitionPeriod_629596" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_629600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentShellCompanyReport_629600" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_630141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentInformationTable_630141" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_830287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_630141" xlink:to="loc_us-gaap_StatementClassOfStockAxis_830287" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_830289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_830287" xlink:to="loc_us-gaap_ClassOfStockDomain_830289" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_830289_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_830287" xlink:to="loc_us-gaap_ClassOfStockDomain_830289_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AdrMember" xlink:label="loc_dei_AdrMember_830291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_830289" xlink:to="loc_dei_AdrMember_830291" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_830292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_630141" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_830292" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_830293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_830292" xlink:to="loc_dei_AddressTypeDomain_830293" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_830293_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_830292" xlink:to="loc_dei_AddressTypeDomain_830293_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_830294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_830293" xlink:to="loc_dei_BusinessContactMember_830294" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_830382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_630141" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_830382" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_830383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_830382" xlink:to="loc_us-gaap_EquityComponentDomain_830383" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_830383_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_830382" xlink:to="loc_us-gaap_EquityComponentDomain_830383_default" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_830384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_830383" xlink:to="loc_us-gaap_CommonStockMember_830384" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_dei_NoTradingSymbolFlag_630158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_NoTradingSymbolFlag_630158" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_830308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentRegistrationStatement_830308" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_830336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_ContactPersonnelName_830336" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_830337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_ContactPersonnelEmailAddress_830337" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_830361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentAccountingStandard_830361" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_830362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_IcfrAuditorAttestationFlag_830362" use="optional" order="50" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_617368" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_617366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_617368" xlink:to="loc_us-gaap_StatementTable_617366" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_617372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_617366" xlink:to="loc_us-gaap_StatementClassOfStockAxis_617372" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_617373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_617372" xlink:to="loc_us-gaap_ClassOfStockDomain_617373" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_617373_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_617372" xlink:to="loc_us-gaap_ClassOfStockDomain_617373_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesC1ConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesC1ConvertiblePreferredStockMember_652355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_617373" xlink:to="loc_imab_SeriesC1ConvertiblePreferredStockMember_652355" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesAConvertiblePreferredSharesMember" xlink:label="loc_imab_SeriesAConvertiblePreferredSharesMember_617532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_617373" xlink:to="loc_imab_SeriesAConvertiblePreferredSharesMember_617532" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBConvertiblePreferredSharesMember" xlink:label="loc_imab_SeriesBConvertiblePreferredSharesMember_617533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_617373" xlink:to="loc_imab_SeriesBConvertiblePreferredSharesMember_617533" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesCConvertiblePreferredSharesMember" xlink:label="loc_imab_SeriesCConvertiblePreferredSharesMember_617534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_617373" xlink:to="loc_imab_SeriesCConvertiblePreferredSharesMember_617534" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_671535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_617366" xlink:to="loc_srt_StatementScenarioAxis_671535" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_671536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_671535" xlink:to="loc_srt_ScenarioUnspecifiedDomain_671536" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_671536_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_671535" xlink:to="loc_srt_ScenarioUnspecifiedDomain_671536_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_617468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_617368" xlink:to="loc_us-gaap_AssetsAbstract_617468" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_617470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_617468" xlink:to="loc_us-gaap_AssetsCurrentAbstract_617470" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_617474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_617470" xlink:to="loc_us-gaap_AssetsCurrent_617474" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_617458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_617470" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_617458" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_617459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_617470" xlink:to="loc_us-gaap_RestrictedCashCurrent_617459" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_617460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_617470" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_617460" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_617462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_617470" xlink:to="loc_us-gaap_ShortTermInvestments_617462" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_617463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_617470" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_617463" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_871447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_617470" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_871447" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_617477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_617468" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_617477" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_617478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_617468" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_617478" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_617479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_617468" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_617479" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_617480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_617468" xlink:to="loc_us-gaap_Goodwill_617480" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_617481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_617468" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_617481" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_617482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_617468" xlink:to="loc_us-gaap_Assets_617482" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_828988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_617468" xlink:to="loc_us-gaap_EquityMethodInvestments_828988" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_617483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_617368" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_617483" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_617505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_617483" xlink:to="loc_us-gaap_Liabilities_617505" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_617508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_617483" xlink:to="loc_us-gaap_CommitmentsAndContingencies_617508" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaap_TemporaryEquityAbstract_617512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_617483" xlink:to="loc_us-gaap_TemporaryEquityAbstract_617512" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_617513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityAbstract_617512" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_617513" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_617517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_617483" xlink:to="loc_us-gaap_StockholdersEquityAbstract_617517" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_617522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_617517" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_617522" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_617523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_617517" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_617523" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_617524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_617517" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_617524" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_617519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_617517" xlink:to="loc_us-gaap_CommonStockValue_617519" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_617528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_617517" xlink:to="loc_us-gaap_StockholdersEquity_617528" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_617486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_617483" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_617486" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_617490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_617490" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_617493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_617493" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_617498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_us-gaap_LiabilitiesCurrent_617498" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_617502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_617502" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_617503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_617503" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="loc_us-gaap_DeferredIncomeNoncurrent_617504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_us-gaap_DeferredIncomeNoncurrent_617504" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CommonStockSharesIssuableForServicesAvailedCurrent" xlink:label="loc_imab_CommonStockSharesIssuableForServicesAvailedCurrent_652304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_imab_CommonStockSharesIssuableForServicesAvailedCurrent_652304" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_617487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_us-gaap_ShortTermBorrowings_617487" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PutRightLiabilities" xlink:label="loc_imab_PutRightLiabilities_828990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_imab_PutRightLiabilities_828990" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaap_DeferredIncomeCurrent_828991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_us-gaap_DeferredIncomeCurrent_828991" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_828999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_828999" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_617529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_617483" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_617529" use="optional" order="51" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_622998" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_622999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622998" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_622999" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_623000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622998" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_623000" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_623001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622998" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_623001" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_623002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622998" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_623002" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_623004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622998" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_623004" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_623005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622998" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_623005" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_623006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622998" xlink:to="loc_us-gaap_CommonStockSharesIssued_623006" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_623007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622998" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_623007" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_622988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_622998" xlink:to="loc_us-gaap_StatementTable_622988" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAxis" xlink:label="loc_us-gaap_CollateralAxis_623014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_622988" xlink:to="loc_us-gaap_CollateralAxis_623014" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaap_CollateralDomain_623017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CollateralAxis_623014" xlink:to="loc_us-gaap_CollateralDomain_623017" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaap_CollateralDomain_623017_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CollateralAxis_623014" xlink:to="loc_us-gaap_CollateralDomain_623017_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_622992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_622988" xlink:to="loc_us-gaap_StatementClassOfStockAxis_622992" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_622993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_622992" xlink:to="loc_us-gaap_ClassOfStockDomain_622993" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_622993_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_622992" xlink:to="loc_us-gaap_ClassOfStockDomain_622993_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesCConvertiblePreferredSharesMember" xlink:label="loc_imab_SeriesCConvertiblePreferredSharesMember_622997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_622993" xlink:to="loc_imab_SeriesCConvertiblePreferredSharesMember_622997" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBConvertiblePreferredSharesMember" xlink:label="loc_imab_SeriesBConvertiblePreferredSharesMember_622996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_622993" xlink:to="loc_imab_SeriesBConvertiblePreferredSharesMember_622996" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesAConvertiblePreferredSharesMember" xlink:label="loc_imab_SeriesAConvertiblePreferredSharesMember_622995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_622993" xlink:to="loc_imab_SeriesAConvertiblePreferredSharesMember_622995" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesC1ConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesC1ConvertiblePreferredStockMember_652395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_622993" xlink:to="loc_imab_SeriesC1ConvertiblePreferredStockMember_652395" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_671544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_622988" xlink:to="loc_srt_StatementScenarioAxis_671544" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_671545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_671544" xlink:to="loc_srt_ScenarioUnspecifiedDomain_671545" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_671545_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_671544" xlink:to="loc_srt_ScenarioUnspecifiedDomain_671545_default" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_628111" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_628114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_628111" xlink:to="loc_us-gaap_RevenuesAbstract_628114" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_619023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_628114" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_619023" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_628123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_628111" xlink:to="loc_us-gaap_OperatingExpensesAbstract_628123" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_619025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_619025" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_619026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_619026" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_619027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_619027" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_619028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_InvestmentIncomeInterest_619028" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_619035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_619035" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_619036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_619036" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_619040" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_NetIncomeLoss_619040" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_619047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_619047" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_619050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_619050" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_829011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_829011" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_619032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_619032" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares" xlink:label="loc_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares_652456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares_652456" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockDividendsAtModificationOfPreferredShares" xlink:label="loc_imab_PreferredStockDividendsAtModificationOfPreferredShares_652459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_imab_PreferredStockDividendsAtModificationOfPreferredShares_652459" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_619030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_619030" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_680142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_680142" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_619045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_680142" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_619045" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_619029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_InterestExpense_619029" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_829010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_829010" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_829013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_829013" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_628126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_628111" xlink:to="loc_us-gaap_EarningsPerShareAbstract_628126" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_619067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_628126" xlink:to="loc_us-gaap_EarningsPerShareBasic_619067" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_619073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_628126" xlink:to="loc_us-gaap_EarningsPerShareDiluted_619073" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_628108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_628111" xlink:to="loc_us-gaap_StatementTable_628108" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_628127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_628108" xlink:to="loc_srt_ProductOrServiceAxis_628127" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_628128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_628127" xlink:to="loc_srt_ProductsAndServicesDomain_628128" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_628128_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_628127" xlink:to="loc_srt_ProductsAndServicesDomain_628128_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_628109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_628108" xlink:to="loc_us-gaap_StatementClassOfStockAxis_628109" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_628110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_628109" xlink:to="loc_us-gaap_ClassOfStockDomain_628110" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_628110_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_628109" xlink:to="loc_us-gaap_ClassOfStockDomain_628110_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AdrMember" xlink:label="loc_dei_AdrMember_894007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_628110" xlink:to="loc_dei_AdrMember_894007" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_619430" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_619427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StatementTable_619427" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_619431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_619427" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_619431" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_619432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_619431" xlink:to="loc_us-gaap_EquityComponentDomain_619432" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_619432_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_619431" xlink:to="loc_us-gaap_EquityComponentDomain_619432_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_619435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_619432" xlink:to="loc_us-gaap_TreasuryStockMember_619435" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_619436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_619432" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_619436" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_619437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_619432" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_619437" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_619438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_619432" xlink:to="loc_us-gaap_RetainedEarningsMember_619438" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_619446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_619432" xlink:to="loc_us-gaap_CommonStockMember_619446" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_619428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_619427" xlink:to="loc_us-gaap_StatementClassOfStockAxis_619428" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_619429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_619428" xlink:to="loc_us-gaap_ClassOfStockDomain_619429" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_619429_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_619428" xlink:to="loc_us-gaap_ClassOfStockDomain_619429_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_619452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockholdersEquity_619452" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockDividendsAtModificationOfPreferredShares" xlink:label="loc_imab_PreferredStockDividendsAtModificationOfPreferredShares_652486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_imab_PreferredStockDividendsAtModificationOfPreferredShares_652486" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_619453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_SharesOutstanding_619453" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_619454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_619454" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_619456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_NetIncomeLoss_619456" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_619458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_619458" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_628267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_628267" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares" xlink:label="loc_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares_652481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares_652481" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_829018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_829018" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_829019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_829019" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate" xlink:label="loc_imab_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate_829020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_imab_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate_829020" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_829023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_829023" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_829024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_829024" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender" xlink:label="loc_imab_AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender_829025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_imab_AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender_829025" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_829026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_829026" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829027" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_829028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_829028" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_829029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_829029" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_829030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_829030" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_829032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_829032" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_829033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_829033" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_829034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_829034" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_829035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_829035" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_871854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_871854" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_871855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_871855" use="optional" order="37" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/ShareBasedCompensationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627361" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_627362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627361" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_627362" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_626309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627361" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_626309" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_626321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627361" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_626321" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627361" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627233" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_627235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627233" xlink:to="loc_us-gaap_PlanNameAxis_627235" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_627236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_627235" xlink:to="loc_us-gaap_PlanNameDomain_627236" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_627236_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_627235" xlink:to="loc_us-gaap_PlanNameDomain_627236_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentySeventeenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_627357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_627236" xlink:to="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_627357" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyEighteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_627242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_627236" xlink:to="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_627242" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyNineteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyNineteenEmployeeStockOptionPlanMember_830080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_627236" xlink:to="loc_imab_TwentyNineteenEmployeeStockOptionPlanMember_830080" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyTwentyEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyTwentyEmployeeStockOptionPlanMember_830093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_627236" xlink:to="loc_imab_TwentyTwentyEmployeeStockOptionPlanMember_830093" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_830137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627233" xlink:to="loc_us-gaap_AwardTypeAxis_830137" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_830137" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830138" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830138_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_830137" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830138_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_830140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830138" xlink:to="loc_us-gaap_RestrictedStockMember_830140" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_832492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830138" xlink:to="loc_us-gaap_EmployeeStockOptionMember_832492" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_830058" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627361" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_830058" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_830142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627361" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_830142" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/LicensingAndCollaborationAgreementsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627277" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627277" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627267" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627267" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627272" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627272" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627273" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627273_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627272" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627273_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_628452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627267" xlink:to="loc_us-gaap_TypeOfArrangementAxis_628452" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_628452" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628454" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628454_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_628452" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628454_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMorphosysAgMember" xlink:label="loc_imab_LicensingAgreementWithMorphosysAgMember_628455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628454" xlink:to="loc_imab_LicensingAgreementWithMorphosysAgMember_628455" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithGenexineIncMember" xlink:label="loc_imab_LicensingAgreementWithGenexineIncMember_628458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628454" xlink:to="loc_imab_LicensingAgreementWithGenexineIncMember_628458" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMorphosysMember" xlink:label="loc_imab_LicensingAgreementWithMorphosysMember_628459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628454" xlink:to="loc_imab_LicensingAgreementWithMorphosysMember_628459" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMacrogenicsMember" xlink:label="loc_imab_LicensingAgreementWithMacrogenicsMember_628469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628454" xlink:to="loc_imab_LicensingAgreementWithMacrogenicsMember_628469" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_627268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627267" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_627268" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_627269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_627268" xlink:to="loc_us-gaap_RelatedPartyDomain_627269" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_627269_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_627268" xlink:to="loc_us-gaap_RelatedPartyDomain_627269_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_627280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627277" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_627280" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_621579" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfPrincipalSubsidiariesTable" xlink:label="loc_imab_ScheduleOfPrincipalSubsidiariesTable_621560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_621579" xlink:to="loc_imab_ScheduleOfPrincipalSubsidiariesTable_621560" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_621562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imab_ScheduleOfPrincipalSubsidiariesTable_621560" xlink:to="loc_srt_ConsolidatedEntitiesAxis_621562" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_621566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_621562" xlink:to="loc_srt_ConsolidatedEntitiesDomain_621566" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_621566_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_621562" xlink:to="loc_srt_ConsolidatedEntitiesDomain_621566_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IMabBiopharmaHongKongLimitedMember" xlink:label="loc_imab_IMabBiopharmaHongKongLimitedMember_621572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_621566" xlink:to="loc_imab_IMabBiopharmaHongKongLimitedMember_621572" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IMabShanghaiMember" xlink:label="loc_imab_IMabShanghaiMember_621573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_621566" xlink:to="loc_imab_IMabShanghaiMember_621573" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IMabtianjinMember" xlink:label="loc_imab_IMabtianjinMember_621575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_621566" xlink:to="loc_imab_IMabtianjinMember_621575" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ImabbiopharmaUsLtdMember" xlink:label="loc_imab_ImabbiopharmaUsLtdMember_621576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_621566" xlink:to="loc_imab_ImabbiopharmaUsLtdMember_621576" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EntityIncorporationCountryStateName" xlink:label="loc_imab_EntityIncorporationCountryStateName_630168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_621579" xlink:to="loc_imab_EntityIncorporationCountryStateName_630168" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_621585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_621579" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_621585" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_621590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_621579" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_621590" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="loc_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_621591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_621579" xlink:to="loc_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_621591" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_621618" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfPrincipalSubsidiariesTable" xlink:label="loc_imab_ScheduleOfPrincipalSubsidiariesTable_621614" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_621618" xlink:to="loc_imab_ScheduleOfPrincipalSubsidiariesTable_621614" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_621615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imab_ScheduleOfPrincipalSubsidiariesTable_621614" xlink:to="loc_srt_ConsolidatedEntitiesAxis_621615" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_621616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_621615" xlink:to="loc_srt_ConsolidatedEntitiesDomain_621616" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_621616_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_621615" xlink:to="loc_srt_ConsolidatedEntitiesDomain_621616_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_829088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imab_ScheduleOfPrincipalSubsidiariesTable_621614" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_829088" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_829088" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829089" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829089_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_829088" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829089_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_829090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829089" xlink:to="loc_us-gaap_IPOMember_829090" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_829091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829089" xlink:to="loc_us-gaap_OverAllotmentOptionMember_829091" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_829092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imab_ScheduleOfPrincipalSubsidiariesTable_621614" xlink:to="loc_us-gaap_StatementClassOfStockAxis_829092" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_829093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_829092" xlink:to="loc_us-gaap_ClassOfStockDomain_829093" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_829093_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_829092" xlink:to="loc_us-gaap_ClassOfStockDomain_829093_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AdrMember" xlink:label="loc_dei_AdrMember_829094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_829093" xlink:to="loc_dei_AdrMember_829094" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_829097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_621618" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_829097" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_829098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_621618" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_829098" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_829099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_621618" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_829099" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CommonStockSharesIssuable" xlink:label="loc_imab_CommonStockSharesIssuable_829100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_621618" xlink:to="loc_imab_CommonStockSharesIssuable_829100" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_829101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_621618" xlink:to="loc_us-gaap_SharePrice_829101" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_622858" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_622859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_622858" xlink:to="loc_us-gaap_AssetsAbstract_622859" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_622865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_622859" xlink:to="loc_us-gaap_ShortTermInvestments_622865" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_622861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_622858" xlink:to="loc_us-gaap_LiabilitiesAbstract_622861" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PutRightLiabilities" xlink:label="loc_imab_PutRightLiabilities_829118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_622861" xlink:to="loc_imab_PutRightLiabilities_829118" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_622843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_622858" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_622843" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_628176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_622843" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_628176" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_628177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_628176" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_628177" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_628177_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_628176" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_628177_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_628179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_628177" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_628179" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_622850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_622843" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_622850" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_622852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_622850" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_622852" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_622852_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_622850" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_622852_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_622855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_622852" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_622855" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_622896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_622896" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_622875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_622875" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_622877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_622875" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_622877" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_622879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_622877" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_622879" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_622879_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_622877" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_622879_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_622886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_622879" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_622886" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OtherFinancialAssetsMember" xlink:label="loc_imab_OtherFinancialAssetsMember_622887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_622879" xlink:to="loc_imab_OtherFinancialAssetsMember_622887" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WarrantLiabilitiesMember" xlink:label="loc_imab_WarrantLiabilitiesMember_622891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_622879" xlink:to="loc_imab_WarrantLiabilitiesMember_622891" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PutRightLiabilitiesMember" xlink:label="loc_imab_PutRightLiabilitiesMember_829124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_622879" xlink:to="loc_imab_PutRightLiabilitiesMember_829124" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences" xlink:label="loc_imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences_622907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" xlink:to="loc_imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences_622907" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_622909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_622909" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_622927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_622927" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_628233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_628233" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments" xlink:label="loc_imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments_629914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" xlink:to="loc_imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments_629914" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_829127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_829127" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_622961" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_622969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622961" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_622969" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable_622972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622961" xlink:to="loc_us-gaap_GrantsReceivable_622972" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_VATSurchargesPercent" xlink:label="loc_imab_VATSurchargesPercent_622973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622961" xlink:to="loc_imab_VATSurchargesPercent_622973" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_622958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_622961" xlink:to="loc_us-gaap_StatementTable_622958" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_BankBranchAxis" xlink:label="loc_imab_BankBranchAxis_622964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_622958" xlink:to="loc_imab_BankBranchAxis_622964" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_BankBranchDomain" xlink:label="loc_imab_BankBranchDomain_622965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imab_BankBranchAxis_622964" xlink:to="loc_imab_BankBranchDomain_622965" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_BankBranchDomain" xlink:label="loc_imab_BankBranchDomain_622965_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imab_BankBranchAxis_622964" xlink:to="loc_imab_BankBranchDomain_622965_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PeoplesBankOfChinaMember" xlink:label="loc_imab_PeoplesBankOfChinaMember_622966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_BankBranchDomain_622965" xlink:to="loc_imab_PeoplesBankOfChinaMember_622966" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FederalReserveBankOfNewYorkMember" xlink:label="loc_imab_FederalReserveBankOfNewYorkMember_622967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_BankBranchDomain_622965" xlink:to="loc_imab_FederalReserveBankOfNewYorkMember_622967" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_622974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_622958" xlink:to="loc_srt_RangeAxis_622974" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_622975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_622974" xlink:to="loc_srt_RangeMember_622975" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_622975_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_622974" xlink:to="loc_srt_RangeMember_622975_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_622976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_622975" xlink:to="loc_srt_MaximumMember_622976" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_622977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_622975" xlink:to="loc_srt_MinimumMember_622977" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_671556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622961" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_671556" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_671557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622961" xlink:to="loc_us-gaap_OperatingLeaseLiability_671557" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostImpairmentLoss" xlink:label="loc_us-gaap_CapitalizedContractCostImpairmentLoss_894163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622961" xlink:to="loc_us-gaap_CapitalizedContractCostImpairmentLoss_894163" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_622949" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_622935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_622949" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_622935" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_622936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_622935" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_622936" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_622937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_622936" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_622937" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_622937_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_622936" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_622937_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LaboratoryEquipmentMember" xlink:label="loc_imab_LaboratoryEquipmentMember_622939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_622937" xlink:to="loc_imab_LaboratoryEquipmentMember_622939" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SoftwareMember" xlink:label="loc_imab_SoftwareMember_622940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_622937" xlink:to="loc_imab_SoftwareMember_622940" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OfficeFurnitureAndEquipmentMember" xlink:label="loc_imab_OfficeFurnitureAndEquipmentMember_622942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_622937" xlink:to="loc_imab_OfficeFurnitureAndEquipmentMember_622942" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_622943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_622937" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_622943" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_622944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_622935" xlink:to="loc_srt_RangeAxis_622944" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_622945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_622944" xlink:to="loc_srt_RangeMember_622945" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_622945_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_622944" xlink:to="loc_srt_RangeMember_622945_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_622946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_622945" xlink:to="loc_srt_MaximumMember_622946" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_622948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_622945" xlink:to="loc_srt_MinimumMember_622948" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_622950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_622949" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_622950" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_628254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_622949" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_628254" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_621923" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_621928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_621923" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_621928" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_621929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_621928" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_621929" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_621930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_621928" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_621930" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_621945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_621928" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_621945" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_652604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_621928" xlink:to="loc_us-gaap_ConstructionInProgressGross_652604" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PropertyPlantAndequipmentnetExcludingConstructionInProcess" xlink:label="loc_imab_PropertyPlantAndequipmentnetExcludingConstructionInProcess_652682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_621928" xlink:to="loc_imab_PropertyPlantAndequipmentnetExcludingConstructionInProcess_652682" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_621909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_621923" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_621909" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_621910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_621909" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_621910" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_621912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_621910" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_621912" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_621912_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_621910" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_621912_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LaboratoryEquipmentMember" xlink:label="loc_imab_LaboratoryEquipmentMember_621916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_621912" xlink:to="loc_imab_LaboratoryEquipmentMember_621916" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_621919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_621912" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_621919" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_621920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_621912" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_621920" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_621922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_621912" xlink:to="loc_us-gaap_OfficeEquipmentMember_621922" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems" xlink:label="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems_622530" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTable" xlink:label="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTable_622527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems_622530" xlink:to="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTable_622527" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_622534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems_622530" xlink:to="loc_us-gaap_AssetsAbstract_622534" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_622510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_622534" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_622510" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_622535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems_622530" xlink:to="loc_us-gaap_LiabilitiesAbstract_622535" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_622514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_622535" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_622514" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_622516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_622535" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_622516" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_622518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_622535" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_622518" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_622519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_622535" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_622519" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems" xlink:label="loc_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems_622549" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_652643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems_622549" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_652643" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfComponentsOfOperatingLeaseExpenseTable" xlink:label="loc_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTable_622548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems_622549" xlink:to="loc_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTable_622548" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingLeaseRightOfUseAssetAmortization" xlink:label="loc_imab_OperatingLeaseRightOfUseAssetAmortization_622553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems_622549" xlink:to="loc_imab_OperatingLeaseRightOfUseAssetAmortization_622553" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_622554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems_622549" xlink:to="loc_us-gaap_ShortTermLeaseCost_622554" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingLeaseInterestExpense" xlink:label="loc_imab_OperatingLeaseInterestExpense_622555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems_622549" xlink:to="loc_imab_OperatingLeaseInterestExpense_622555" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/LeasesOperatingLeaseMaturityDetail">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfOperatingLeaseMaturityLineItems" xlink:label="loc_imab_ScheduleOfOperatingLeaseMaturityLineItems_657735" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_657738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleOfOperatingLeaseMaturityLineItems_657735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_657738" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_657739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleOfOperatingLeaseMaturityLineItems_657735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_657739" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_657742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleOfOperatingLeaseMaturityLineItems_657735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_657742" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_657743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleOfOperatingLeaseMaturityLineItems_657735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_657743" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_657744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleOfOperatingLeaseMaturityLineItems_657735" xlink:to="loc_us-gaap_OperatingLeaseLiability_657744" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfOperatingLeaseMaturityTableTable" xlink:label="loc_imab_ScheduleOfOperatingLeaseMaturityTableTable_657734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imab_ScheduleOfOperatingLeaseMaturityLineItems_657735" xlink:to="loc_imab_ScheduleOfOperatingLeaseMaturityTableTable_657734" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_657737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleOfOperatingLeaseMaturityLineItems_657735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_657737" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_629338" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_622647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_629338" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_622647" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_622648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_629338" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_622648" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_629283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_629338" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_629283" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_629329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_629338" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_629329" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_629330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_629329" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_629330" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_629331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_629330" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_629331" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_629331_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_629330" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_629331_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IprAndDTj103Member" xlink:label="loc_imab_IprAndDTj103Member_829132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_629331" xlink:to="loc_imab_IprAndDTj103Member_829132" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IprAndDTj101Member" xlink:label="loc_imab_IprAndDTj101Member_829133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_629331" xlink:to="loc_imab_IprAndDTj101Member_829133" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IprAndDTj102Member" xlink:label="loc_imab_IprAndDTj102Member_829134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_629331" xlink:to="loc_imab_IprAndDTj102Member_829134" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/IntangibleAssetsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_829139" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_629348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_829139" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_629348" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_829136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_829139" xlink:to="loc_us-gaap_StatementTable_829136" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_829137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_829136" xlink:to="loc_us-gaap_StatementClassOfStockAxis_829137" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_829138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_829137" xlink:to="loc_us-gaap_ClassOfStockDomain_829138" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_829138_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_829137" xlink:to="loc_us-gaap_ClassOfStockDomain_829138_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_829140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_829136" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_829140" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_829141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_829140" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_829141" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_829141_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_829140" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_829141_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IprAndDTj103Member" xlink:label="loc_imab_IprAndDTj103Member_829142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_829141" xlink:to="loc_imab_IprAndDTj103Member_829142" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_829144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_829139" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_829144" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_829145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_829139" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_829145" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/GoodwillAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_671567" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_622669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_671567" xlink:to="loc_us-gaap_Goodwill_622669" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_629353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_671567" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_629353" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_671559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_671567" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_671559" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_671566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_671567" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_671566" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_671569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_671566" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_671569" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_671570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_671569" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_671570" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_671570_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_671569" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_671570_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TasgenGroupMember" xlink:label="loc_imab_TasgenGroupMember_671571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_671570" xlink:to="loc_imab_TasgenGroupMember_671571" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EquityMethodInvestmentSummarizedFinancialInformationLineItems" xlink:label="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationLineItems_830527" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EquityMethodInvestmentSummarizedFinancialInformationTable" xlink:label="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationTable_830515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationLineItems_830527" xlink:to="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationTable_830515" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_830517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationTable_830515" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_830517" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_830518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_830517" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_830518" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_830518_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_830517" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_830518_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_NetIncomeLossMember" xlink:label="loc_imab_NetIncomeLossMember_830522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_830518" xlink:to="loc_imab_NetIncomeLossMember_830522" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LossFromOperationMember" xlink:label="loc_imab_LossFromOperationMember_830521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_830518" xlink:to="loc_imab_LossFromOperationMember_830521" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_GrossProfitMember" xlink:label="loc_imab_GrossProfitMember_830520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_830518" xlink:to="loc_imab_GrossProfitMember_830520" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_RevenueMember" xlink:label="loc_imab_RevenueMember_830519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_830518" xlink:to="loc_imab_RevenueMember_830519" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_830523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationTable_830515" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_830523" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_830524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_830523" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_830524" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_830524_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_830523" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_830524_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LongTermInvestmentUnderEquityMethodMember" xlink:label="loc_imab_LongTermInvestmentUnderEquityMethodMember_830525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_830524" xlink:to="loc_imab_LongTermInvestmentUnderEquityMethodMember_830525" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_BalanceSheetDataAbstract" xlink:label="loc_imab_BalanceSheetDataAbstract_830534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationLineItems_830527" xlink:to="loc_imab_BalanceSheetDataAbstract_830534" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_830535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_BalanceSheetDataAbstract_830534" xlink:to="loc_us-gaap_AssetsCurrent_830535" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_830536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_BalanceSheetDataAbstract_830534" xlink:to="loc_us-gaap_AssetsNoncurrent_830536" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_830537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_BalanceSheetDataAbstract_830534" xlink:to="loc_us-gaap_LiabilitiesCurrent_830537" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_830538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_BalanceSheetDataAbstract_830534" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_830538" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_830540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_BalanceSheetDataAbstract_830534" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_830540" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingDataAbstract" xlink:label="loc_imab_OperatingDataAbstract_830528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationLineItems_830527" xlink:to="loc_imab_OperatingDataAbstract_830528" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_830529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_OperatingDataAbstract_830528" xlink:to="loc_us-gaap_EquityMethodInvestments_830529" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_829264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_829264" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_829267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_829264" xlink:to="loc_srt_ConsolidatedEntitiesAxis_829267" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_829268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_829267" xlink:to="loc_srt_ConsolidatedEntitiesDomain_829268" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_829268_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_829267" xlink:to="loc_srt_ConsolidatedEntitiesDomain_829268_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ImabHangzhouMember" xlink:label="loc_imab_ImabHangzhouMember_829269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_829268" xlink:to="loc_imab_ImabHangzhouMember_829269" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ImabHongKongMember" xlink:label="loc_imab_ImabHongKongMember_829275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_829268" xlink:to="loc_imab_ImabHongKongMember_829275" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_829270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_829264" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_829270" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_829271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_829270" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_829271" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_829271_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_829270" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_829271_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ManagementHoldcoMember" xlink:label="loc_imab_ManagementHoldcoMember_829272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_829271" xlink:to="loc_imab_ManagementHoldcoMember_829272" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EsopHoldcoMember" xlink:label="loc_imab_EsopHoldcoMember_829273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_829271" xlink:to="loc_imab_EsopHoldcoMember_829273" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DomesticInvestorsMember" xlink:label="loc_imab_DomesticInvestorsMember_829274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_829271" xlink:to="loc_imab_DomesticInvestorsMember_829274" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_894208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_829264" xlink:to="loc_srt_OwnershipAxis_894208" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_894209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_894208" xlink:to="loc_srt_OwnershipDomain_894209" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_894209_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_894208" xlink:to="loc_srt_OwnershipDomain_894209_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_HoldcoMember" xlink:label="loc_imab_HoldcoMember_894210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_894209" xlink:to="loc_imab_HoldcoMember_894210" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_829277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_829277" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_829280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_829280" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_829284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_829284" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_RegisteredCapitalOfSubsidiary" xlink:label="loc_imab_RegisteredCapitalOfSubsidiary_829285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_imab_RegisteredCapitalOfSubsidiary_829285" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized_829287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized_829287" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_829291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_829291" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_829296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_829296" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_829312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_829312" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments" xlink:label="loc_us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments_829316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments_829316" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_829317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_829317" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_871601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_871601" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciEquityMethodInvestmentAfterTax" xlink:label="loc_us-gaap_OciEquityMethodInvestmentAfterTax_871602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_OciEquityMethodInvestmentAfterTax_871602" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_907668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_907668" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_622701" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLender" xlink:label="loc_us-gaap_ShortTermDebtLender_622702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622701" xlink:to="loc_us-gaap_ShortTermDebtLender_622702" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_622703" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622701" xlink:to="loc_us-gaap_DebtInstrumentTerm_622703" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_622704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622701" xlink:to="loc_us-gaap_ShortTermBorrowings_622704" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_622705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622701" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_622705" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="loc_us-gaap_DebtInstrumentCollateralAmount_622707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622701" xlink:to="loc_us-gaap_DebtInstrumentCollateralAmount_622707" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" xlink:label="loc_us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits_629364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622701" xlink:to="loc_us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits_629364" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_629377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622701" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_629377" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_622694" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_622701" xlink:to="loc_us-gaap_StatementTable_622694" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_629385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_622694" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_629385" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_629387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_629385" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_629387" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_629387_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_629385" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_629387_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ChinaMerchantBankCoLtdMember" xlink:label="loc_imab_ChinaMerchantBankCoLtdMember_629388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_629387" xlink:to="loc_imab_ChinaMerchantBankCoLtdMember_629388" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_622695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_622694" xlink:to="loc_us-gaap_DebtInstrumentAxis_622695" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_622696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_622695" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_622696" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_622696_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_622695" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_622696_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LoanOneMember" xlink:label="loc_imab_LoanOneMember_622699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_622696" xlink:to="loc_imab_LoanOneMember_622699" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LoanTwoMember" xlink:label="loc_imab_LoanTwoMember_622700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_622696" xlink:to="loc_imab_LoanTwoMember_622700" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_622766" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_622767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622766" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_622767" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_622768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622766" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_622768" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EffectivePreferentialIncomeTaxRate" xlink:label="loc_imab_EffectivePreferentialIncomeTaxRate_622771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622766" xlink:to="loc_imab_EffectivePreferentialIncomeTaxRate_622771" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_652673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622766" xlink:to="loc_us-gaap_OperatingLossCarryforwards_652673" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_622758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_622766" xlink:to="loc_us-gaap_StatementTable_622758" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_629422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_622758" xlink:to="loc_srt_ConsolidatedEntitiesAxis_629422" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_629425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_629422" xlink:to="loc_srt_ConsolidatedEntitiesDomain_629425" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_629425_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_629422" xlink:to="loc_srt_ConsolidatedEntitiesDomain_629425_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IMobOtherSubsidiariesMember" xlink:label="loc_imab_IMobOtherSubsidiariesMember_629429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_629425" xlink:to="loc_imab_IMobOtherSubsidiariesMember_629429" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_622759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_622758" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_622759" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_622760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_622759" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_622760" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_622760_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_622759" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_622760_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CNMember" xlink:label="loc_imab_CNMember_629412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_622760" xlink:to="loc_imab_CNMember_629412" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PRCMember" xlink:label="loc_imab_PRCMember_622761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_622760" xlink:to="loc_imab_PRCMember_622761" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_622763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_622758" xlink:to="loc_srt_StatementGeographicalAxis_622763" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_622764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_622763" xlink:to="loc_srt_SegmentGeographicalDomain_622764" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_622764_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_622763" xlink:to="loc_srt_SegmentGeographicalDomain_622764_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_HK" xlink:label="loc_country_HK_622772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_622764" xlink:to="loc_country_HK_622772" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_AU" xlink:label="loc_country_AU_622773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_622764" xlink:to="loc_country_AU_622773" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WithholdingTax" xlink:label="loc_imab_WithholdingTax_908784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622766" xlink:to="loc_imab_WithholdingTax_908784" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_622784" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_622786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622784" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_622786" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_622787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622784" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_622787" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount" xlink:label="loc_imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount_622788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622784" xlink:to="loc_imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount_622788" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_622789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622784" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_622789" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_622790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622784" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_622790" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:label="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_622791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622784" xlink:to="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_622791" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_622792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622784" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_622792" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_622780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_622784" xlink:to="loc_us-gaap_StatementTable_622780" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_622781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_622780" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_622781" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_622782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_622781" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_622782" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_622782_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_622781" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_622782_default" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/OrdinarySharesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_630020" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_622822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_622822" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_622823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_CommonStockVotingRights_622823" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_622825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_622825" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CommonStockValueAuthorized" xlink:label="loc_imab_CommonStockValueAuthorized_629473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_imab_CommonStockValueAuthorized_629473" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_630017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_StatementTable_630017" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_630018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_630017" xlink:to="loc_us-gaap_StatementClassOfStockAxis_630018" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_630019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_630018" xlink:to="loc_us-gaap_ClassOfStockDomain_630019" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_630019_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_630018" xlink:to="loc_us-gaap_ClassOfStockDomain_630019_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesAConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesAConvertiblePreferredStockMember_829477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_630019" xlink:to="loc_imab_SeriesAConvertiblePreferredStockMember_829477" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBMember_829478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_630019" xlink:to="loc_imab_ConvertiblePreferredStockSeriesBMember_829478" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBOneUponConversionMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBOneUponConversionMember_829479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_630019" xlink:to="loc_imab_ConvertiblePreferredStockSeriesBOneUponConversionMember_829479" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesB2Member" xlink:label="loc_imab_ConvertiblePreferredStockSeriesB2Member_829481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_630019" xlink:to="loc_imab_ConvertiblePreferredStockSeriesB2Member_829481" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_829482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_630019" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_829482" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesCOneConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesCOneConvertiblePreferredStockMember_829483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_630019" xlink:to="loc_imab_SeriesCOneConvertiblePreferredStockMember_829483" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AdrMember" xlink:label="loc_dei_AdrMember_832490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_630019" xlink:to="loc_dei_AdrMember_832490" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_630021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_630017" xlink:to="loc_srt_TitleOfIndividualAxis_630021" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_630022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_630021" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_630022" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_630022_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_630021" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_630022_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_630023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_630022" xlink:to="loc_srt_DirectorMember_630023" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_BoardOfDirectorsMember" xlink:label="loc_imab_BoardOfDirectorsMember_829485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_630022" xlink:to="loc_imab_BoardOfDirectorsMember_829485" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_829428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_630017" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_829428" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_829428" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829429" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829429_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_829428" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829429_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_829430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829429" xlink:to="loc_us-gaap_IPOMember_829430" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_829431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829429" xlink:to="loc_us-gaap_PrivatePlacementMember_829431" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_829432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829429" xlink:to="loc_us-gaap_OverAllotmentOptionMember_829432" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_829464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_630017" xlink:to="loc_us-gaap_TypeOfArrangementAxis_829464" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_829465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_829464" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_829465" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_829465_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_829464" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_829465_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CollaborationAgreementWithEverestMember" xlink:label="loc_imab_CollaborationAgreementWithEverestMember_829467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_829465" xlink:to="loc_imab_CollaborationAgreementWithEverestMember_829467" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_HillhouseEntitiesMember" xlink:label="loc_imab_HillhouseEntitiesMember_829504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_829465" xlink:to="loc_imab_HillhouseEntitiesMember_829504" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CollaborationAgreementWithInvestorsMember" xlink:label="loc_imab_CollaborationAgreementWithInvestorsMember_829505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_829465" xlink:to="loc_imab_CollaborationAgreementWithInvestorsMember_829505" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_829469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_630017" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_829469" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_829471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_829469" xlink:to="loc_us-gaap_RelatedPartyDomain_829471" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_829471_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_829469" xlink:to="loc_us-gaap_RelatedPartyDomain_829471_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EverestsMember" xlink:label="loc_imab_EverestsMember_829472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_829471" xlink:to="loc_imab_EverestsMember_829472" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_829506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_630017" xlink:to="loc_us-gaap_InvestmentTypeAxis_829506" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_829507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_829506" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_829507" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_829507_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_829506" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_829507_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_InvestorWarrantsMember" xlink:label="loc_imab_InvestorWarrantsMember_829512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_829507" xlink:to="loc_imab_InvestorWarrantsMember_829512" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PeriodTypeAxis" xlink:label="loc_imab_PeriodTypeAxis_829515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_630017" xlink:to="loc_imab_PeriodTypeAxis_829515" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PeriodTypeDomain" xlink:label="loc_imab_PeriodTypeDomain_829517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imab_PeriodTypeAxis_829515" xlink:to="loc_imab_PeriodTypeDomain_829517" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PeriodTypeDomain" xlink:label="loc_imab_PeriodTypeDomain_829517_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imab_PeriodTypeAxis_829515" xlink:to="loc_imab_PeriodTypeDomain_829517_default" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FirstClosingPeriodMember" xlink:label="loc_imab_FirstClosingPeriodMember_829521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_PeriodTypeDomain_829517" xlink:to="loc_imab_FirstClosingPeriodMember_829521" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SecondClosingPeriodMember" xlink:label="loc_imab_SecondClosingPeriodMember_829522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_PeriodTypeDomain_829517" xlink:to="loc_imab_SecondClosingPeriodMember_829522" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_829524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_630017" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_829524" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_829526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_829524" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_829526" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_829526_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_829524" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_829526_default" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentySeventeenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_829528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_829526" xlink:to="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_829528" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_829436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_829436" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_829440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_829440" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_829449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_829449" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CommonStockSharesIssuable" xlink:label="loc_imab_CommonStockSharesIssuable_829452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_imab_CommonStockSharesIssuable_829452" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_829455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_SharePrice_829455" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_829457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_829457" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_829462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_829462" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_829476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_829476" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_829530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_829530" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_829531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_829531" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AmericanDepositorySharesCommonShareEquivalent" xlink:label="loc_imab_AmericanDepositorySharesCommonShareEquivalent_829534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_imab_AmericanDepositorySharesCommonShareEquivalent_829534" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_829538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_829538" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PrepaidExpenseStockRepurchaseProgram" xlink:label="loc_imab_PrepaidExpenseStockRepurchaseProgram_829544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_imab_PrepaidExpenseStockRepurchaseProgram_829544" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_829548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_829548" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_829552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_829552" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_829555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_SharesIssued_829555" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_829557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_829557" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_GrossProceedsOfSharesAndWarrants" xlink:label="loc_imab_GrossProceedsOfSharesAndWarrants_829563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_imab_GrossProceedsOfSharesAndWarrants_829563" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" xlink:label="loc_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_829567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_829567" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_871856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_871856" use="optional" order="69" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_625402" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_625404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_625404" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IssueOfWarrants" xlink:label="loc_imab_IssueOfWarrants_625405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_imab_IssueOfWarrants_625405" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_625408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_625408" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_625410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_625410" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_625412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_us-gaap_PreferredStockSharesIssued_625412" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_625417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_625417" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockShareSubscriptions" xlink:label="loc_us-gaap_PreferredStockShareSubscriptions_625418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_us-gaap_PreferredStockShareSubscriptions_625418" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesSubscribedButUnissuedValue" xlink:label="loc_us-gaap_PreferredStockSharesSubscribedButUnissuedValue_625419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_us-gaap_PreferredStockSharesSubscribedButUnissuedValue_625419" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_QualifiedPublicOfferingPrice" xlink:label="loc_imab_QualifiedPublicOfferingPrice_625421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_imab_QualifiedPublicOfferingPrice_625421" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_625401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_625401" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_625425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_625401" xlink:to="loc_us-gaap_StatementClassOfStockAxis_625425" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_625426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_625425" xlink:to="loc_us-gaap_ClassOfStockDomain_625426" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_625426_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_625425" xlink:to="loc_us-gaap_ClassOfStockDomain_625426_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesA3Member" xlink:label="loc_imab_ConvertiblePreferredStockSeriesA3Member_625432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_ConvertiblePreferredStockSeriesA3Member_625432" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesA3PreferredStockMember" xlink:label="loc_imab_SeriesA3PreferredStockMember_625433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_SeriesA3PreferredStockMember_625433" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBMember_625434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_ConvertiblePreferredStockSeriesBMember_625434" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesB2Member" xlink:label="loc_imab_ConvertiblePreferredStockSeriesB2Member_625435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_ConvertiblePreferredStockSeriesB2Member_625435" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesAThreeUponExerciseMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesAThreeUponExerciseMember_625436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_ConvertiblePreferredStockSeriesAThreeUponExerciseMember_625436" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBOneUponConversionMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBOneUponConversionMember_625438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_ConvertiblePreferredStockSeriesBOneUponConversionMember_625438" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBTwoUponExerciseMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBTwoUponExerciseMember_625439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_ConvertiblePreferredStockSeriesBTwoUponExerciseMember_625439" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBUponExerciseMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBUponExerciseMember_625440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_ConvertiblePreferredStockSeriesBUponExerciseMember_625440" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesA1AndA2PreferredStockMember" xlink:label="loc_imab_SeriesA1AndA2PreferredStockMember_625431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_SeriesA1AndA2PreferredStockMember_625431" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesCOnePreferredStockMember" xlink:label="loc_imab_SeriesCOnePreferredStockMember_625446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_SeriesCOnePreferredStockMember_625446" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBOneUponExerciseMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBOneUponExerciseMember_625441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_ConvertiblePreferredStockSeriesBOneUponExerciseMember_625441" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_625444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_625444" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesCOneConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesCOneConvertiblePreferredStockMember_625447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_SeriesCOneConvertiblePreferredStockMember_625447" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TemporaryEquityMember" xlink:label="loc_imab_TemporaryEquityMember_652689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_TemporaryEquityMember_652689" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_625427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_625401" xlink:to="loc_srt_RangeAxis_625427" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_625428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_625427" xlink:to="loc_srt_RangeMember_625428" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_625428_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_625427" xlink:to="loc_srt_RangeMember_625428_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_625430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_625428" xlink:to="loc_srt_MinimumMember_625430" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_625429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_625428" xlink:to="loc_srt_MaximumMember_625429" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_652690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_625401" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_652690" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_652691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_652690" xlink:to="loc_us-gaap_EquityComponentDomain_652691" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_652691_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_652690" xlink:to="loc_us-gaap_EquityComponentDomain_652691_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_652692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_652691" xlink:to="loc_us-gaap_PreferredStockMember_652692" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OfferingPriceOfConvertedShares" xlink:label="loc_imab_OfferingPriceOfConvertedShares_625422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_imab_OfferingPriceOfConvertedShares_625422" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockLiquidationPreferencePercentage" xlink:label="loc_imab_PreferredStockLiquidationPreferencePercentage_625423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_imab_PreferredStockLiquidationPreferencePercentage_625423" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockLiquidationPreferenceRateOfReturn" xlink:label="loc_imab_PreferredStockLiquidationPreferenceRateOfReturn_625424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_imab_PreferredStockLiquidationPreferenceRateOfReturn_625424" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityFairValueAdjustment" xlink:label="loc_us-gaap_EquityFairValueAdjustment_652687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_us-gaap_EquityFairValueAdjustment_652687" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AdjustmentsAtExtinguishmentOfPreferredShares" xlink:label="loc_imab_AdjustmentsAtExtinguishmentOfPreferredShares_671577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_imab_AdjustmentsAtExtinguishmentOfPreferredShares_671577" use="optional" order="41" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_625324" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AdjustmentsAtExtinguishmentOfPreferredShares" xlink:label="loc_imab_AdjustmentsAtExtinguishmentOfPreferredShares_625336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625324" xlink:to="loc_imab_AdjustmentsAtExtinguishmentOfPreferredShares_625336" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_625323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625324" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_625323" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_625337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_625323" xlink:to="loc_us-gaap_FinancialInstrumentAxis_625337" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_625338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_625337" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_625338" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_625338_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_625337" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_625338_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriescOneMember" xlink:label="loc_imab_SeriescOneMember_625345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_625338" xlink:to="loc_imab_SeriescOneMember_625345" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_625365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_625323" xlink:to="loc_us-gaap_StatementClassOfStockAxis_625365" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_625366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_625365" xlink:to="loc_us-gaap_ClassOfStockDomain_625366" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_625366_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_625365" xlink:to="loc_us-gaap_ClassOfStockDomain_625366_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesAConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesAConvertiblePreferredStockMember_625367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_625366" xlink:to="loc_imab_SeriesAConvertiblePreferredStockMember_625367" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesCConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesCConvertiblePreferredStockMember_625369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_625366" xlink:to="loc_imab_SeriesCConvertiblePreferredStockMember_625369" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesBConvertiblePreferredStockMember_625368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_625366" xlink:to="loc_imab_SeriesBConvertiblePreferredStockMember_625368" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesC1ConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesC1ConvertiblePreferredStockMember_652717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_625366" xlink:to="loc_imab_SeriesC1ConvertiblePreferredStockMember_652717" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_625325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625324" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_625325" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_625326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625324" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_625326" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_652700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625324" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_652700" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_652709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625324" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_652709" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_829636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625324" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_829636" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625324" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829637" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionLineItems" xlink:label="loc_us-gaap_DebtConversionLineItems_627077" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_627032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_DebtInstrumentTable_627032" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_627043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_627032" xlink:to="loc_us-gaap_StatementClassOfStockAxis_627043" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_627044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_627043" xlink:to="loc_us-gaap_ClassOfStockDomain_627044" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_627044_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_627043" xlink:to="loc_us-gaap_ClassOfStockDomain_627044_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesB1PreferredSharesMember" xlink:label="loc_imab_SeriesB1PreferredSharesMember_627066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_627044" xlink:to="loc_imab_SeriesB1PreferredSharesMember_627066" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesA3PreferredSharesMember" xlink:label="loc_imab_SeriesA3PreferredSharesMember_627073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_627044" xlink:to="loc_imab_SeriesA3PreferredSharesMember_627073" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBOnshoreInvestorsMember" xlink:label="loc_imab_SeriesBOnshoreInvestorsMember_627158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_627044" xlink:to="loc_imab_SeriesBOnshoreInvestorsMember_627158" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBPreferredStockHolderMember" xlink:label="loc_imab_SeriesBPreferredStockHolderMember_630034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_627044" xlink:to="loc_imab_SeriesBPreferredStockHolderMember_630034" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_627033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_627032" xlink:to="loc_us-gaap_DebtInstrumentAxis_627033" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_627034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_627033" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_627034" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_627034_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_627033" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_627034_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OnshoreConvertibleLoanMember" xlink:label="loc_imab_OnshoreConvertibleLoanMember_627038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_627034" xlink:to="loc_imab_OnshoreConvertibleLoanMember_627038" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwoZeroOneEightNotesMember" xlink:label="loc_imab_TwoZeroOneEightNotesMember_627037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_627034" xlink:to="loc_imab_TwoZeroOneEightNotesMember_627037" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePromissoryNotes2017Member" xlink:label="loc_imab_ConvertiblePromissoryNotes2017Member_630033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_627034" xlink:to="loc_imab_ConvertiblePromissoryNotes2017Member_630033" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePromissoryNotes2018Member" xlink:label="loc_imab_ConvertiblePromissoryNotes2018Member_630036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_627034" xlink:to="loc_imab_ConvertiblePromissoryNotes2018Member_630036" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_831832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_627032" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_831832" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_831833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_831832" xlink:to="loc_us-gaap_RelatedPartyDomain_831833" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_831833_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_831832" xlink:to="loc_us-gaap_RelatedPartyDomain_831833_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_GenexineIncMember" xlink:label="loc_imab_GenexineIncMember_831834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_831833" xlink:to="loc_imab_GenexineIncMember_831834" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaap_NotesIssued1_627078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_NotesIssued1_627078" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_627202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_627202" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_627216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_627216" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_627218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_DebtInstrumentTerm_627218" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_630031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_630031" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_630032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_630032" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_630037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_SharePrice_630037" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_627081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_627081" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_831840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_SharesIssued_831840" use="optional" order="28" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/WarrantsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_625003" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_625114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_625003" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_625114" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_625116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_625003" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_625116" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_625112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_625003" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_625112" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_630029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_625003" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_630029" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_625000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_625003" xlink:to="loc_us-gaap_StatementTable_625000" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_625018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_625000" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_625018" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_625019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_625018" xlink:to="loc_us-gaap_EquityComponentDomain_625019" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_625019_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_625018" xlink:to="loc_us-gaap_EquityComponentDomain_625019_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBPreferredShareholdersMember" xlink:label="loc_imab_SeriesBPreferredShareholdersMember_625028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_625019" xlink:to="loc_imab_SeriesBPreferredShareholdersMember_625028" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBOnshoreInvestorsMember" xlink:label="loc_imab_SeriesBOnshoreInvestorsMember_625031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_625019" xlink:to="loc_imab_SeriesBOnshoreInvestorsMember_625031" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TrancheIOfSeriesBWarrantsMember" xlink:label="loc_imab_TrancheIOfSeriesBWarrantsMember_625033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_625019" xlink:to="loc_imab_TrancheIOfSeriesBWarrantsMember_625033" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesB2PreferredSharesMember" xlink:label="loc_imab_SeriesB2PreferredSharesMember_625034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_625019" xlink:to="loc_imab_SeriesB2PreferredSharesMember_625034" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TrancheIiOfSeriesBWarrantsMember" xlink:label="loc_imab_TrancheIiOfSeriesBWarrantsMember_625036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_625019" xlink:to="loc_imab_TrancheIiOfSeriesBWarrantsMember_625036" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBWarrantsSharesMember" xlink:label="loc_imab_SeriesBWarrantsSharesMember_625038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_625019" xlink:to="loc_imab_SeriesBWarrantsSharesMember_625038" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AmericanDepositarySharesMember" xlink:label="loc_imab_AmericanDepositarySharesMember_825494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_625019" xlink:to="loc_imab_AmericanDepositarySharesMember_825494" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_825491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_625000" xlink:to="loc_us-gaap_TypeOfArrangementAxis_825491" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_825492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_825491" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_825492" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_825492_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_825491" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_825492_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_HillhouseEntitiesMember" xlink:label="loc_imab_HillhouseEntitiesMember_825500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_825492" xlink:to="loc_imab_HillhouseEntitiesMember_825500" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CollaborationAgreementWithInvestorsMember" xlink:label="loc_imab_CollaborationAgreementWithInvestorsMember_825493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_825492" xlink:to="loc_imab_CollaborationAgreementWithInvestorsMember_825493" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_825495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_625000" xlink:to="loc_us-gaap_InvestmentTypeAxis_825495" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_825496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_825495" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_825496" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_825496_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_825495" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_825496_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_InvestorWarrantsMember" xlink:label="loc_imab_InvestorWarrantsMember_825497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_825496" xlink:to="loc_imab_InvestorWarrantsMember_825497" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_825490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_625003" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_825490" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_825498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_625003" xlink:to="loc_us-gaap_SharePrice_825498" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_825499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_625003" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_825499" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_825509" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_825505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_825509" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_825505" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_825506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_825505" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_825506" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_825507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_825506" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_825507" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_825507_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_825506" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_825507_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WarrantsToPurchaseOrdinarySharesMember" xlink:label="loc_imab_WarrantsToPurchaseOrdinarySharesMember_825508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_825507" xlink:to="loc_imab_WarrantsToPurchaseOrdinarySharesMember_825508" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Classofwarrantorrightsexercisableterm" xlink:label="loc_imab_Classofwarrantorrightsexercisableterm_825510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_825509" xlink:to="loc_imab_Classofwarrantorrightsexercisableterm_825510" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_825511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_825509" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_825511" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_825512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_825509" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_825512" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_825513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_825509" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_825513" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_625169" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_629462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_625169" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_629462" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_625158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_625169" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_625158" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_625172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_625158" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_625172" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_625173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_625172" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_625173" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_625173_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_625172" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_625173_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_625178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_625173" xlink:to="loc_us-gaap_MeasurementInputExercisePriceMember_625178" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_625177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_625173" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_625177" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_625175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_625173" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_625175" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputMaturityMember" xlink:label="loc_us-gaap_MeasurementInputMaturityMember_625176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_625173" xlink:to="loc_us-gaap_MeasurementInputMaturityMember_625176" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_625171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_625169" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_625171" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_628071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" xlink:to="loc_srt_TitleOfIndividualAxis_628071" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_628073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_628071" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_628073" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_628073_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_628071" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_628073_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_628075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_628073" xlink:to="loc_srt_DirectorMember_628075" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DrzangMember" xlink:label="loc_imab_DrzangMember_628078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_628073" xlink:to="loc_imab_DrzangMember_628078" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LeiFangMember" xlink:label="loc_imab_LeiFangMember_628193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_628073" xlink:to="loc_imab_LeiFangMember_628193" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FoundersMember" xlink:label="loc_imab_FoundersMember_629910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_628073" xlink:to="loc_imab_FoundersMember_629910" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeniorManagementEmployeesMember" xlink:label="loc_imab_SeniorManagementEmployeesMember_630030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_628073" xlink:to="loc_imab_SeniorManagementEmployeesMember_630030" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_628081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" xlink:to="loc_us-gaap_VestingAxis_628081" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_628082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_628081" xlink:to="loc_us-gaap_VestingDomain_628082" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_628082_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_628081" xlink:to="loc_us-gaap_VestingDomain_628082_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_628083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_628082" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_628083" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_628084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_628082" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_628084" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_629908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_628082" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_629908" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationTrancheFourMember" xlink:label="loc_imab_ShareBasedCompensationTrancheFourMember_830409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_628082" xlink:to="loc_imab_ShareBasedCompensationTrancheFourMember_830409" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OnePerformanceConditionMember" xlink:label="loc_imab_OnePerformanceConditionMember_830430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_628082" xlink:to="loc_imab_OnePerformanceConditionMember_830430" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwoPerformanceConditionsMember" xlink:label="loc_imab_TwoPerformanceConditionsMember_830431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_628082" xlink:to="loc_imab_TwoPerformanceConditionsMember_830431" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ThreePerformanceConditionsMember" xlink:label="loc_imab_ThreePerformanceConditionsMember_830432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_628082" xlink:to="loc_imab_ThreePerformanceConditionsMember_830432" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FourPerformanceConditionsMember" xlink:label="loc_imab_FourPerformanceConditionsMember_830433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_628082" xlink:to="loc_imab_FourPerformanceConditionsMember_830433" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_628085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_628085" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_628086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_628085" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_628086" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_628086_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_628085" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_628086_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_628087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_628086" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_628087" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_830235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_628086" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_830235" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EquityInLossOfAnAffiliateMember" xlink:label="loc_imab_EquityInLossOfAnAffiliateMember_871713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_628086" xlink:to="loc_imab_EquityInLossOfAnAffiliateMember_871713" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_628056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_628056" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_628058" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_628056" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_628058" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_628058_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_628056" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_628058_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ThirdVentureMember" xlink:label="loc_imab_ThirdVentureMember_628061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_628058" xlink:to="loc_imab_ThirdVentureMember_628061" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_628067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" xlink:to="loc_us-gaap_PlanNameAxis_628067" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_628068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_628067" xlink:to="loc_us-gaap_PlanNameDomain_628068" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_628068_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_628067" xlink:to="loc_us-gaap_PlanNameDomain_628068_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentySeventeenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_628070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_628068" xlink:to="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_628070" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AmendedTwentySeventeenEmployeeStockOptionPlanMember" xlink:label="loc_imab_AmendedTwentySeventeenEmployeeStockOptionPlanMember_628076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_628068" xlink:to="loc_imab_AmendedTwentySeventeenEmployeeStockOptionPlanMember_628076" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyEighteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_628069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_628068" xlink:to="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_628069" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyTwentyEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyTwentyEmployeeStockOptionPlanMember_830280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_628068" xlink:to="loc_imab_TwentyTwentyEmployeeStockOptionPlanMember_830280" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareIncentivePlan2020Member" xlink:label="loc_imab_ShareIncentivePlan2020Member_832306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_628068" xlink:to="loc_imab_ShareIncentivePlan2020Member_832306" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_629517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" xlink:to="loc_srt_RangeAxis_629517" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_629518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_629517" xlink:to="loc_srt_RangeMember_629518" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_629518_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_629517" xlink:to="loc_srt_RangeMember_629518_default" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_629520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" xlink:to="loc_us-gaap_AwardTypeAxis_629520" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_629520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629521" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629521_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_629520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629521_default" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_629972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629521" xlink:to="loc_us-gaap_EmployeeStockOptionMember_629972" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyNineteenShareIncentivePlanMember" xlink:label="loc_imab_TwentyNineteenShareIncentivePlanMember_629522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629521" xlink:to="loc_imab_TwentyNineteenShareIncentivePlanMember_629522" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_629890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629521" xlink:to="loc_us-gaap_RestrictedStockMember_629890" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_894204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629521" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_894204" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PortionOfRestrictedShareUnitsAxis" xlink:label="loc_imab_PortionOfRestrictedShareUnitsAxis_830398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" xlink:to="loc_imab_PortionOfRestrictedShareUnitsAxis_830398" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PortionOfRestrictedShareUnitsDomain" xlink:label="loc_imab_PortionOfRestrictedShareUnitsDomain_830405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imab_PortionOfRestrictedShareUnitsAxis_830398" xlink:to="loc_imab_PortionOfRestrictedShareUnitsDomain_830405" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PortionOfRestrictedShareUnitsDomain" xlink:label="loc_imab_PortionOfRestrictedShareUnitsDomain_830405_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imab_PortionOfRestrictedShareUnitsAxis_830398" xlink:to="loc_imab_PortionOfRestrictedShareUnitsDomain_830405_default" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ThirdOneThirdPortionMember" xlink:label="loc_imab_ThirdOneThirdPortionMember_830406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_PortionOfRestrictedShareUnitsDomain_830405" xlink:to="loc_imab_ThirdOneThirdPortionMember_830406" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SecondOneThirdPortionMember" xlink:label="loc_imab_SecondOneThirdPortionMember_830422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_PortionOfRestrictedShareUnitsDomain_830405" xlink:to="loc_imab_SecondOneThirdPortionMember_830422" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_628091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_628091" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_628093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_628093" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_628094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_628094" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_628095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_628095" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_628098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_628098" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_628138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_628138" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_628141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_628141" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_628269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_628269" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted" xlink:label="loc_imab_ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted_629904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_imab_ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted_629904" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_629909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_SharePrice_629909" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_629973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_629973" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_629974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_629974" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_629529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_629529" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_629887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_629887" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_629895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_629895" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_629975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_629975" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased_630025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased_630025" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" xlink:label="loc_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice_630027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice_630027" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration_630028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration_630028" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_830205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_830205" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_830206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_830206" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_830247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_830247" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="loc_us-gaap_StockOptionExercisePriceIncrease_830326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_StockOptionExercisePriceIncrease_830326" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares" xlink:label="loc_imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares_830413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares_830413" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares" xlink:label="loc_imab_MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares_830420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_imab_MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares_830420" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_830439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_830439" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_830443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_830443" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_830446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_830446" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_894188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_894188" use="optional" order="82" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_626512" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_626513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_626512" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_626513" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_626499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_626512" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_626499" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_626500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_626499" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_626500" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_626501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_626500" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_626501" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_626501_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_626500" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_626501_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_626508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_626501" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_626508" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_626509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_626501" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_626509" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EquityInLossOfAnAffiliateMember" xlink:label="loc_imab_EquityInLossOfAnAffiliateMember_871700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_626501" xlink:to="loc_imab_EquityInLossOfAnAffiliateMember_871700" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_629954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_626499" xlink:to="loc_us-gaap_AwardTypeAxis_629954" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_629954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629955" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629955_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_629954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629955_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_629956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629955" xlink:to="loc_us-gaap_RestrictedStockMember_629956" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627996" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627996" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627991" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_627992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627991" xlink:to="loc_us-gaap_PlanNameAxis_627992" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_627993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_627992" xlink:to="loc_us-gaap_PlanNameDomain_627993" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_627993_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_627992" xlink:to="loc_us-gaap_PlanNameDomain_627993_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyEighteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_627994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_627993" xlink:to="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_627994" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentySeventeenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_627995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_627993" xlink:to="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_627995" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareIncentivePlanTwoThousandTwentyMember" xlink:label="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_627993" xlink:to="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830600" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyNineteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyNineteenEmployeeStockOptionPlanMember_830599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_627993" xlink:to="loc_imab_TwentyNineteenEmployeeStockOptionPlanMember_830599" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_628032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_628032" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_628041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627996" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_628041" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_627998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_627998" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_628002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_628002" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_627997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_627997" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_628008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_628008" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased_628006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" xlink:to="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased_628006" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_830554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_830554" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod_830555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" xlink:to="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod_830555" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_629979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_629979" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_629978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_629978" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_629981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_629981" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_629983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_629983" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" xlink:label="loc_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice_630009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" xlink:to="loc_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice_630009" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_830556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_830556" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice" xlink:label="loc_imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice_830557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" xlink:to="loc_imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice_830557" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_629987" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627996" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_629987" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_629991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627996" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_629991" use="optional" order="28" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_627368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_627368" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_627369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_627369" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_627365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_627365" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_627366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_627366" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple" xlink:label="loc_imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple_627367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple_627367" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_627371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_627371" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_627372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_627372" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_627373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_627373" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_627374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_627374" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627960" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_627961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627960" xlink:to="loc_us-gaap_PlanNameAxis_627961" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_627962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_627961" xlink:to="loc_us-gaap_PlanNameDomain_627962" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_627962_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_627961" xlink:to="loc_us-gaap_PlanNameDomain_627962_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyEighteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_627963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_627962" xlink:to="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_627963" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareIncentivePlanTwoThousandTwentyMember" xlink:label="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_627962" xlink:to="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830602" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyNineteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyNineteenEmployeeStockOptionPlanMember_830601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_627962" xlink:to="loc_imab_TwentyNineteenEmployeeStockOptionPlanMember_830601" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum_832269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum_832269" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum_832271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum_832271" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830577" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830577" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830569" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_830570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830569" xlink:to="loc_us-gaap_PlanNameAxis_830570" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_830571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_830570" xlink:to="loc_us-gaap_PlanNameDomain_830571" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_830571_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_830570" xlink:to="loc_us-gaap_PlanNameDomain_830571_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentySeventeenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_830572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_830571" xlink:to="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_830572" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyEighteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_830573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_830571" xlink:to="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_830573" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyNineteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyNineteenEmployeeStockOptionPlanMember_830574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_830571" xlink:to="loc_imab_TwentyNineteenEmployeeStockOptionPlanMember_830574" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareIncentivePlanTwoThousandTwentyMember" xlink:label="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_830571" xlink:to="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830575" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_832461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830569" xlink:to="loc_us-gaap_AwardTypeAxis_832461" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_832462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_832461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_832462" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_832462_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_832461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_832462_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_832463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_832462" xlink:to="loc_us-gaap_EmployeeStockOptionMember_832463" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_830578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830577" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_830578" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_830583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_830578" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_830583" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_830579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_830578" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_830579" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_830580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_830578" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_830580" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_830581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_830578" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_830581" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares" xlink:label="loc_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares_830584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_830578" xlink:to="loc_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares_830584" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares_830582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_830578" xlink:to="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares_830582" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_830586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830577" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_830586" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_830587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_830586" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_830587" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_830588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_830586" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_830588" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue" xlink:label="loc_imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue_830589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_830586" xlink:to="loc_imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue_830589" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_830590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_830586" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_830590" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue" xlink:label="loc_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue_830591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_830586" xlink:to="loc_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue_830591" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_830592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_830586" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_830592" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems" xlink:label="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfNonvestedRestrictedStockUnitsActivityTable" xlink:label="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityTable_830606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" xlink:to="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityTable_830606" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_830607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityTable_830606" xlink:to="loc_us-gaap_AwardTypeAxis_830607" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_830607" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830608" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830608_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_830607" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830608_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_830609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830608" xlink:to="loc_us-gaap_RestrictedStockMember_830609" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_830610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityTable_830606" xlink:to="loc_us-gaap_PlanNameAxis_830610" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_830611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_830610" xlink:to="loc_us-gaap_PlanNameDomain_830611" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_830611_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_830610" xlink:to="loc_us-gaap_PlanNameDomain_830611_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareIncentivePlanTwoThousandTwentyMember" xlink:label="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_830611" xlink:to="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830613" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyTwentyEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyTwentyEmployeeStockOptionPlanMember_832362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_830611" xlink:to="loc_imab_TwentyTwentyEmployeeStockOptionPlanMember_832362" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_830625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_830625" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_830616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_830616" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_830617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_830617" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_830618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_830618" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_830619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_830619" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_830622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_830622" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_830623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_830623" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_830624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_830624" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems" xlink:label="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems_830642" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_830643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems_830642" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_830643" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_830644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_830643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_830644" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_830645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_830643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_830645" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_830646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_830643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_830646" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_871682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_830643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_871682" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable" xlink:label="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable_830633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems_830642" xlink:to="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable_830633" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_830634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable_830633" xlink:to="loc_us-gaap_AwardTypeAxis_830634" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_830634" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830635" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830635_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_830634" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830635_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_830636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830635" xlink:to="loc_us-gaap_RestrictedStockMember_830636" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_830637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable_830633" xlink:to="loc_us-gaap_PlanNameAxis_830637" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_830638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_830637" xlink:to="loc_us-gaap_PlanNameDomain_830638" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_830638_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_830637" xlink:to="loc_us-gaap_PlanNameDomain_830638_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyEighteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_830639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_830638" xlink:to="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_830639" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareIncentivePlanTwoThousandTwentyMember" xlink:label="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_830638" xlink:to="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830640" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_830647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems_830642" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_830647" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_830648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_830647" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_830648" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_830649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_830647" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_830649" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_871686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_830647" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_871686" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_830650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems_830642" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_830650" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_830651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems_830642" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_830651" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_627466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_627466" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExciseAndSalesTaxes" xlink:label="loc_us-gaap_ExciseAndSalesTaxes_627467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_ExciseAndSalesTaxes_627467" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_UpfrontLicenseFee" xlink:label="loc_imab_UpfrontLicenseFee_627409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_UpfrontLicenseFee_627409" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestonePayments" xlink:label="loc_imab_MilestonePayments_627410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_MilestonePayments_627410" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_627933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_627933" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_627934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_627934" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CostSharingRatio" xlink:label="loc_imab_CostSharingRatio_627936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_CostSharingRatio_627936" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_627498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_627498" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_627506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_627506" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestonePaymentsOutstanding" xlink:label="loc_imab_MilestonePaymentsOutstanding_627891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_MilestonePaymentsOutstanding_627891" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PercentageOfReductionInMilestonePayments" xlink:label="loc_imab_PercentageOfReductionInMilestonePayments_627441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_PercentageOfReductionInMilestonePayments_627441" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_629592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_629592" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementRightsAndObligations" xlink:label="loc_us-gaap_CollaborativeArrangementRightsAndObligations_627455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_CollaborativeArrangementRightsAndObligations_627455" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_627513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_CommonStockSharesIssued_627513" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_627512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_CommonStockValue_627512" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_627511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_627511" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_627397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_627397" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_627398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_627397" xlink:to="loc_us-gaap_RelatedPartyDomain_627398" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_627398_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_627397" xlink:to="loc_us-gaap_RelatedPartyDomain_627398_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MorphoSysAGMember" xlink:label="loc_imab_MorphoSysAGMember_627400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_627398" xlink:to="loc_imab_MorphoSysAGMember_627400" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MorphoSysAGMember" xlink:label="loc_imab_MorphoSysAGMember_628698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930" xlink:to="loc_imab_MorphoSysAGMember_628698" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_GenexineIncMember" xlink:label="loc_imab_GenexineIncMember_627426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_627398" xlink:to="loc_imab_GenexineIncMember_627426" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_GenexineIncMember" xlink:label="loc_imab_GenexineIncMember_628700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930" xlink:to="loc_imab_GenexineIncMember_628700" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MacroGenicsMember" xlink:label="loc_imab_MacroGenicsMember_627454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_627398" xlink:to="loc_imab_MacroGenicsMember_627454" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MacroGenicsMember" xlink:label="loc_imab_MacroGenicsMember_629799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930" xlink:to="loc_imab_MacroGenicsMember_629799" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_HealSunMember" xlink:label="loc_imab_HealSunMember_627458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_627398" xlink:to="loc_imab_HealSunMember_627458" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_HealSunMember" xlink:label="loc_imab_HealSunMember_629886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930" xlink:to="loc_imab_HealSunMember_629886" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EverestMember" xlink:label="loc_imab_EverestMember_627500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_627398" xlink:to="loc_imab_EverestMember_627500" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ABLBioMember" xlink:label="loc_imab_ABLBioMember_627937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930" xlink:to="loc_imab_ABLBioMember_627937" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ABLBioMember" xlink:label="loc_imab_ABLBioMember_680139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_627398" xlink:to="loc_imab_ABLBioMember_680139" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AbbVieMember" xlink:label="loc_imab_AbbVieMember_829789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_627398" xlink:to="loc_imab_AbbVieMember_829789" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_627470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_srt_MajorCustomersAxis_627470" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_627471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_627470" xlink:to="loc_srt_NameOfMajorCustomerDomain_627471" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_627471_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_627470" xlink:to="loc_srt_NameOfMajorCustomerDomain_627471_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627401" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627401" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627402" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627402_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627401" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627402_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OtherInLicensingAgreementsMember" xlink:label="loc_imab_OtherInLicensingAgreementsMember_627456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627402" xlink:to="loc_imab_OtherInLicensingAgreementsMember_627456" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OutLicensingAgreementsMember" xlink:label="loc_imab_OutLicensingAgreementsMember_627460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627402" xlink:to="loc_imab_OutLicensingAgreementsMember_627460" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_627404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627402" xlink:to="loc_us-gaap_LicensingAgreementsMember_627404" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LemzoparlimabLicenseMember" xlink:label="loc_imab_LemzoparlimabLicenseMember_871760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627402" xlink:to="loc_imab_LemzoparlimabLicenseMember_871760" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_627415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_627415" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_627416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_627415" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_627416" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_627416_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_627415" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_627416_default" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_627417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_627416" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_627417" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_627954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_627416" xlink:to="loc_us-gaap_OperatingExpenseMember_627954" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_627419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_srt_RangeAxis_627419" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_627420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_627419" xlink:to="loc_srt_RangeMember_627420" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_627420_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_627419" xlink:to="loc_srt_RangeMember_627420_default" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_627421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_627420" xlink:to="loc_srt_MinimumMember_627421" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_627929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_srt_CounterpartyNameAxis_627929" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_627929" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_627929" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930_default" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CspcMember" xlink:label="loc_imab_CspcMember_627931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930" xlink:to="loc_imab_CspcMember_627931" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MorphosysMember" xlink:label="loc_imab_MorphosysMember_628701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930" xlink:to="loc_imab_MorphosysMember_628701" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestoneTypeAxis" xlink:label="loc_imab_MilestoneTypeAxis_627938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_imab_MilestoneTypeAxis_627938" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestoneTypeDomain" xlink:label="loc_imab_MilestoneTypeDomain_627939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imab_MilestoneTypeAxis_627938" xlink:to="loc_imab_MilestoneTypeDomain_627939" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestoneTypeDomain" xlink:label="loc_imab_MilestoneTypeDomain_627939_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imab_MilestoneTypeAxis_627938" xlink:to="loc_imab_MilestoneTypeDomain_627939_default" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ClinicalMilestonesMember" xlink:label="loc_imab_ClinicalMilestonesMember_627945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_MilestoneTypeDomain_627939" xlink:to="loc_imab_ClinicalMilestonesMember_627945" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SalesMilestonesMember" xlink:label="loc_imab_SalesMilestonesMember_627946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_MilestoneTypeDomain_627939" xlink:to="loc_imab_SalesMilestonesMember_627946" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DevelopmentMilestoneMember" xlink:label="loc_imab_DevelopmentMilestoneMember_630087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_MilestoneTypeDomain_627939" xlink:to="loc_imab_DevelopmentMilestoneMember_630087" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestoneIiiMember" xlink:label="loc_imab_MilestoneIiiMember_630102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_MilestoneTypeDomain_627939" xlink:to="loc_imab_MilestoneIiiMember_630102" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestoneIvMember" xlink:label="loc_imab_MilestoneIvMember_630103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_MilestoneTypeDomain_627939" xlink:to="loc_imab_MilestoneIvMember_630103" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FirstMilestoneMember" xlink:label="loc_imab_FirstMilestoneMember_871764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_MilestoneTypeDomain_627939" xlink:to="loc_imab_FirstMilestoneMember_871764" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SecondMilestoneMember" xlink:label="loc_imab_SecondMilestoneMember_871766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_MilestoneTypeDomain_627939" xlink:to="loc_imab_SecondMilestoneMember_871766" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_627926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_us-gaap_TypeOfArrangementAxis_627926" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_627926" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_627926" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927_default" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithABLBioMember" xlink:label="loc_imab_LicensingAgreementWithABLBioMember_627935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_LicensingAgreementWithABLBioMember_627935" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember" xlink:label="loc_imab_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember_627928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember_627928" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMorphosysAgMember" xlink:label="loc_imab_LicensingAgreementWithMorphosysAgMember_629649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_LicensingAgreementWithMorphosysAgMember_629649" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CollaborationAgreementWithABLBioMember" xlink:label="loc_imab_CollaborationAgreementWithABLBioMember_627952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_CollaborationAgreementWithABLBioMember_627952" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember" xlink:label="loc_imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember_627956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember_627956" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithGenexineIncMember" xlink:label="loc_imab_LicensingAgreementWithGenexineIncMember_629678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_LicensingAgreementWithGenexineIncMember_629678" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMacrogenicsMember" xlink:label="loc_imab_LicensingAgreementWithMacrogenicsMember_629797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_LicensingAgreementWithMacrogenicsMember_629797" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OtherinlicensingarrangementsMember" xlink:label="loc_imab_OtherinlicensingarrangementsMember_629833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_OtherinlicensingarrangementsMember_629833" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember" xlink:label="loc_imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember_629889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember_629889" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CollaborationAgreementWithEverestMember" xlink:label="loc_imab_CollaborationAgreementWithEverestMember_630128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_CollaborationAgreementWithEverestMember_630128" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember" xlink:label="loc_imab_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember_829814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember_829814" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementsWithMorphosysMember" xlink:label="loc_imab_LicensingAgreementsWithMorphosysMember_629794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_LicensingAgreementsWithMorphosysMember_629794" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_628872" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_srt_ProductOrServiceAxis_628872" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_628873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_628872" xlink:to="loc_srt_ProductsAndServicesDomain_628873" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_628873_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_628872" xlink:to="loc_srt_ProductsAndServicesDomain_628873_default" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Gxi7Member" xlink:label="loc_imab_Gxi7Member_628875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_628873" xlink:to="loc_imab_Gxi7Member_628875" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_629950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_629950" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_629951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_629950" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_629951" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_629951_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_629950" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_629951_default" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredRevenueMember" xlink:label="loc_imab_DeferredRevenueMember_629952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_629951" xlink:to="loc_imab_DeferredRevenueMember_629952" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TypeOfLicensesAxis" xlink:label="loc_imab_TypeOfLicensesAxis_829815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_imab_TypeOfLicensesAxis_829815" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TypeOfLicensesDomain" xlink:label="loc_imab_TypeOfLicensesDomain_829816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imab_TypeOfLicensesAxis_829815" xlink:to="loc_imab_TypeOfLicensesDomain_829816" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TypeOfLicensesDomain" xlink:label="loc_imab_TypeOfLicensesDomain_829816_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imab_TypeOfLicensesAxis_829815" xlink:to="loc_imab_TypeOfLicensesDomain_829816_default" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Study1Member" xlink:label="loc_imab_Study1Member_829811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_TypeOfLicensesDomain_829816" xlink:to="loc_imab_Study1Member_829811" use="optional" order="93" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Study2Member" xlink:label="loc_imab_Study2Member_829812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_TypeOfLicensesDomain_829816" xlink:to="loc_imab_Study2Member_829812" use="optional" order="94" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_872898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_872898" use="optional" order="95" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_872899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_872898" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_872899" use="optional" order="96" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_872899_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_872898" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_872899_default" use="optional" order="97" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_872900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_872899" xlink:to="loc_us-gaap_SubsequentEventMember_872900" use="optional" order="98" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CumulativePaidInContributions" xlink:label="loc_imab_CumulativePaidInContributions_630084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_CumulativePaidInContributions_630084" use="optional" order="99" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TimeCostOfForegoingHistoricalContribution" xlink:label="loc_imab_TimeCostOfForegoingHistoricalContribution_630085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_TimeCostOfForegoingHistoricalContribution_630085" use="optional" order="100" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_627951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_627951" use="optional" order="101" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestonePaymentsIncome" xlink:label="loc_imab_MilestonePaymentsIncome_629903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_MilestonePaymentsIncome_629903" use="optional" order="102" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredRevenueFromCollaborativeArrangementExcludingVat" xlink:label="loc_imab_DeferredRevenueFromCollaborativeArrangementExcludingVat_629944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_DeferredRevenueFromCollaborativeArrangementExcludingVat_629944" use="optional" order="103" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_UpfrontAndMilestonePayments" xlink:label="loc_imab_UpfrontAndMilestonePayments_829796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_UpfrontAndMilestonePayments_829796" use="optional" order="104" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_RevenueFromContractWithCustomerTimeOfTransferOfLicense" xlink:label="loc_imab_RevenueFromContractWithCustomerTimeOfTransferOfLicense_829824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_RevenueFromContractWithCustomerTimeOfTransferOfLicense_829824" use="optional" order="105" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent" xlink:label="loc_imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent_829828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent_829828" use="optional" order="106" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax" xlink:label="loc_imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax_829830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax_829830" use="optional" order="107" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_832108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_832108" use="optional" order="108" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_871786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_871786" use="optional" order="109" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_UpfrontPaymentReceived" xlink:label="loc_imab_UpfrontPaymentReceived_871791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_UpfrontPaymentReceived_871791" use="optional" order="110" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestonePaymentReceivable" xlink:label="loc_imab_MilestonePaymentReceivable_871792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_MilestonePaymentReceivable_871792" use="optional" order="111" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627332" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestonePayments" xlink:label="loc_imab_MilestonePayments_627343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627332" xlink:to="loc_imab_MilestonePayments_627343" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627332" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627310" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_627323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627310" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_627323" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_627324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_627323" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_627324" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_627324_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_627323" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_627324_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_627330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_627324" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_627330" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627310" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627311" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627311" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627312" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627312_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627311" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627312_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_628520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627310" xlink:to="loc_us-gaap_TypeOfArrangementAxis_628520" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_628520" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628522" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628522_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_628520" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628522_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMorphosysAgMember" xlink:label="loc_imab_LicensingAgreementWithMorphosysAgMember_628524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628522" xlink:to="loc_imab_LicensingAgreementWithMorphosysAgMember_628524" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithGenexineIncMember" xlink:label="loc_imab_LicensingAgreementWithGenexineIncMember_628527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628522" xlink:to="loc_imab_LicensingAgreementWithGenexineIncMember_628527" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMorphosysMember" xlink:label="loc_imab_LicensingAgreementWithMorphosysMember_628528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628522" xlink:to="loc_imab_LicensingAgreementWithMorphosysMember_628528" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMacrogenicsMember" xlink:label="loc_imab_LicensingAgreementWithMacrogenicsMember_628532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628522" xlink:to="loc_imab_LicensingAgreementWithMacrogenicsMember_628532" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementUpfrontFees" xlink:label="loc_imab_LicensingAgreementUpfrontFees_627334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627332" xlink:to="loc_imab_LicensingAgreementUpfrontFees_627334" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetParentheticalDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_829853" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_829849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_829853" xlink:to="loc_us-gaap_StatementTable_829849" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_829850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_829849" xlink:to="loc_srt_ProductOrServiceAxis_829850" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_829851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_829850" xlink:to="loc_srt_ProductsAndServicesDomain_829851" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_829851_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_829850" xlink:to="loc_srt_ProductsAndServicesDomain_829851_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_829852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_829851" xlink:to="loc_us-gaap_GrantMember_829852" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_829854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_829853" xlink:to="loc_us-gaap_Revenues_829854" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_622225" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_622226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_622225" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_622226" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_622214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_622225" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_622214" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_622215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_622214" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_622215" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_622216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_622215" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_622216" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_622216_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_622215" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_622216_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_622218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_622216" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_622218" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_622219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_622216" xlink:to="loc_us-gaap_RestrictedStockMember_622219" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_622221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_622216" xlink:to="loc_us-gaap_EmployeeStockOptionMember_622221" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_629739" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_629739" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629736" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_629737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629736" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_629737" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_629738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_629737" xlink:to="loc_us-gaap_RelatedPartyDomain_629738" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_629738_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_629737" xlink:to="loc_us-gaap_RelatedPartyDomain_629738_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EverestMember" xlink:label="loc_imab_EverestMember_629752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_629738" xlink:to="loc_imab_EverestMember_629752" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember" xlink:label="loc_imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember_894067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_629738" xlink:to="loc_imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember_894067" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_829892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629736" xlink:to="loc_srt_ConsolidatedEntitiesAxis_829892" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_829893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_829892" xlink:to="loc_srt_ConsolidatedEntitiesDomain_829893" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_829893_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_829892" xlink:to="loc_srt_ConsolidatedEntitiesDomain_829893_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ImabHangzhouMember" xlink:label="loc_imab_ImabHangzhouMember_829894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_829893" xlink:to="loc_imab_ImabHangzhouMember_829894" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CommonStockSharesIssuableForServicesAvailedCurrent" xlink:label="loc_imab_CommonStockSharesIssuableForServicesAvailedCurrent_652552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_629739" xlink:to="loc_imab_CommonStockSharesIssuableForServicesAvailedCurrent_652552" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromAffiliateCurrent" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_829890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_629739" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_829890" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaap_OtherReceivables_871859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_629739" xlink:to="loc_us-gaap_OtherReceivables_871859" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ExpensesPaidOnBehalfOfAnAffiliate" xlink:label="loc_imab_ExpensesPaidOnBehalfOfAnAffiliate_872903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_629739" xlink:to="loc_imab_ExpensesPaidOnBehalfOfAnAffiliate_872903" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_894054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_629739" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_894054" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesParentheticalDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_829985" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_829981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_829985" xlink:to="loc_us-gaap_StatementTable_829981" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_829982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_829981" xlink:to="loc_srt_ConsolidatedEntitiesAxis_829982" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_829983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_829982" xlink:to="loc_srt_ConsolidatedEntitiesDomain_829983" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_829983_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_829982" xlink:to="loc_srt_ConsolidatedEntitiesDomain_829983_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ImabHangzhouMember" xlink:label="loc_imab_ImabHangzhouMember_829984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_829983" xlink:to="loc_imab_ImabHangzhouMember_829984" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_829986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_829985" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_829986" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_629768" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_629776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_629768" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_629776" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_629781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_629768" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_629781" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_629768" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629765" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_629766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629765" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_629766" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_629767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_629766" xlink:to="loc_us-gaap_RelatedPartyDomain_629767" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_629767_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_629766" xlink:to="loc_us-gaap_RelatedPartyDomain_629767_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CmabBiopharmaSuzhouIncMember" xlink:label="loc_imab_CmabBiopharmaSuzhouIncMember_629769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_629767" xlink:to="loc_imab_CmabBiopharmaSuzhouIncMember_629769" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TaslyPharmaceuticalGroupCoLtdMember" xlink:label="loc_imab_TaslyPharmaceuticalGroupCoLtdMember_629771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_629767" xlink:to="loc_imab_TaslyPharmaceuticalGroupCoLtdMember_629771" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EverestMember" xlink:label="loc_imab_EverestMember_629773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_629767" xlink:to="loc_imab_EverestMember_629773" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember" xlink:label="loc_imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember_825074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_629767" xlink:to="loc_imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember_825074" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_829961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629765" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_829961" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_829962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_829961" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_829962" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_829962_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_829961" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_829962_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ReceiptOfContractResearchOrganizationsMember" xlink:label="loc_imab_ReceiptOfContractResearchOrganizationsMember_829963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_829962" xlink:to="loc_imab_ReceiptOfContractResearchOrganizationsMember_829963" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_871824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629765" xlink:to="loc_srt_ConsolidatedEntitiesAxis_871824" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_871825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_871824" xlink:to="loc_srt_ConsolidatedEntitiesDomain_871825" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_871825_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_871824" xlink:to="loc_srt_ConsolidatedEntitiesDomain_871825_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ImabHangzhouMember" xlink:label="loc_imab_ImabHangzhouMember_871826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_871824" xlink:to="loc_imab_ImabHangzhouMember_871826" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/SubsequentEventsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_621858" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_621841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_621858" xlink:to="loc_us-gaap_SubsequentEventTable_621841" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_629066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_us-gaap_TypeOfArrangementAxis_629066" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_629066" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629067" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629067_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_629066" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629067_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember" xlink:label="loc_imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember_894037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629067" xlink:to="loc_imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember_894037" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_629073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_srt_CounterpartyNameAxis_629073" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_629074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_629073" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_629074" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_629074_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_629073" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_629074_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_621842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_621842" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_621843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_621842" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_621843" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_621843_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_621842" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_621843_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_629675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_629675" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_629676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_629675" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_629676" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_629676_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_629675" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_629676_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_629677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_629676" xlink:to="loc_us-gaap_SubsequentEventMember_629677" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_652471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_srt_TitleOfIndividualAxis_652471" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_652472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_652471" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_652472" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_652472_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_652471" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_652472_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_652402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_us-gaap_StatementClassOfStockAxis_652402" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_652404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_652402" xlink:to="loc_us-gaap_ClassOfStockDomain_652404" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_652404_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_652402" xlink:to="loc_us-gaap_ClassOfStockDomain_652404_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_UnderwriterAxis" xlink:label="loc_imab_UnderwriterAxis_652535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_imab_UnderwriterAxis_652535" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_UnderwriterDomain" xlink:label="loc_imab_UnderwriterDomain_652538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_imab_UnderwriterAxis_652535" xlink:to="loc_imab_UnderwriterDomain_652538" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_UnderwriterDomain" xlink:label="loc_imab_UnderwriterDomain_652538_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_imab_UnderwriterAxis_652535" xlink:to="loc_imab_UnderwriterDomain_652538_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_671655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_srt_ProductOrServiceAxis_671655" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_671656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_671655" xlink:to="loc_srt_ProductsAndServicesDomain_671656" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_671656_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_671655" xlink:to="loc_srt_ProductsAndServicesDomain_671656_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_652485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_us-gaap_PlanNameAxis_652485" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_652487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_652485" xlink:to="loc_us-gaap_PlanNameDomain_652487" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_652487_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_652485" xlink:to="loc_us-gaap_PlanNameDomain_652487_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TerminationFeePayable" xlink:label="loc_imab_TerminationFeePayable_894024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_621858" xlink:to="loc_imab_TerminationFeePayable_894024" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://IMab.com/role/RestrictedNetAssetsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_RestrictedNetAssetsDisclosureLineItems" xlink:label="loc_imab_RestrictedNetAssetsDisclosureLineItems_621797" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PercentageOfNetAssetToNetAssetsOfGroup" xlink:label="loc_imab_PercentageOfNetAssetToNetAssetsOfGroup_621817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_RestrictedNetAssetsDisclosureLineItems_621797" xlink:to="loc_imab_PercentageOfNetAssetToNetAssetsOfGroup_621817" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation" xlink:label="loc_imab_ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation_629177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_RestrictedNetAssetsDisclosureLineItems_621797" xlink:to="loc_imab_ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation_629177" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit" xlink:label="loc_imab_StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit_629174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_RestrictedNetAssetsDisclosureLineItems_621797" xlink:to="loc_imab_StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit_629174" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNet" xlink:label="loc_us-gaap_AssetsNet_652724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_RestrictedNetAssetsDisclosureLineItems_621797" xlink:to="loc_us-gaap_AssetsNet_652724" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AppropriationtoStatutoryReserve" xlink:label="loc_imab_AppropriationtoStatutoryReserve_621769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_imab_RestrictedNetAssetsDisclosureLineItems_621797" xlink:to="loc_imab_AppropriationtoStatutoryReserve_621769" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_621774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_imab_RestrictedNetAssetsDisclosureLineItems_621797" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_621774" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_621777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_621774" xlink:to="loc_srt_ConsolidatedEntitiesAxis_621777" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_621778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_621777" xlink:to="loc_srt_ConsolidatedEntitiesDomain_621778" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_621778_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_621777" xlink:to="loc_srt_ConsolidatedEntitiesDomain_621778_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_621782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_621778" xlink:to="loc_srt_SubsidiariesMember_621782" use="optional" order="10" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>imab-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-April-2021 [01:14:57] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry" xml:lang="en-US">Entity Address, Country</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCountry" xml:lang="en-US">Entity Address, Country</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentShellCompanyReport" xml:lang="en-US">Document Shell Company Report</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentShellCompanyReport" xml:lang="en-US">Document Shell Company Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport" xlink:to="lab_dei_DocumentShellCompanyReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_dei_NoTradingSymbolFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_NoTradingSymbolFlag" xml:lang="en-US">No Trading Symbol Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_NoTradingSymbolFlag" xml:lang="en-US">No Trading Symbol Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_NoTradingSymbolFlag" xlink:to="lab_dei_NoTradingSymbolFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentRegistrationStatement" xml:lang="en-US">Document Registration Statement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentRegistrationStatement" xml:lang="en-US">Document Registration Statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelEmailAddress" xml:lang="en-US">Contact Personnel Email Address</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_ContactPersonnelEmailAddress" xml:lang="en-US">Contact Personnel Email Address</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelEmailAddress" xlink:to="lab_dei_ContactPersonnelEmailAddress" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAccountingStandard" xml:lang="en-US">Document Accounting Standard</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentAccountingStandard" xml:lang="en-US">Document Accounting Standard</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard" xlink:to="lab_dei_DocumentAccountingStandard" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AdrMember" xlink:label="loc_dei_AdrMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AdrMember" xml:lang="en-US">ADR [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AdrMember" xml:lang="en-US">American Depositary Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_AdrMember" xml:lang="en-US">ADS [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AdrMember" xlink:to="lab_dei_AdrMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Ordinary&#160;Share [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Ordinary&#160;share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted Cash, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xml:lang="en-US">Contract with Customer, Asset, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xml:lang="en-US">Contract assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xml:lang="en-US">Contract assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermInvestments" xml:lang="en-US">Short-term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermInvestments" xml:lang="en-US">Short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepayments and other receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, equipment and software</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Total net book value of property, equipment and software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestments" xml:lang="en-US">Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestments" xml:lang="en-US">Investment accounted for using the equity method</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityMethodInvestments" xml:lang="en-US">Investments in subsidiaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities, mezzanine equity and shareholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaap_TemporaryEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xml:lang="en-US">Temporary Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xml:lang="en-US">Mezzanine equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAbstract" xlink:to="lab_us-gaap_TemporaryEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Total mezzanine equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Issuance of Series C-1 Preferred Shares, net of issuance costs, Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Ordinary shares (US$0.0001 par value, 500,000,000 and 800,000,000 shares authorized as of December 31, 2019 and December 31, 2020, respectively; 8,363,719 and 164,888,519 shares issued and outstanding as of December 31, 2019 and December 31, 2020, respectively)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Issue of shares, Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total shareholders' equity (deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accruals and other payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating lease liabilities, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xml:lang="en-US">Convertible Notes Payable, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xml:lang="en-US">Convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liabilities, non-current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="loc_us-gaap_DeferredIncomeNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeNoncurrent" xml:lang="en-US">Deferred Income, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeNoncurrent" xml:lang="en-US">Deferred subsidy income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeNoncurrent" xlink:to="lab_us-gaap_DeferredIncomeNoncurrent" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CommonStockSharesIssuableForServicesAvailedCurrent" xlink:label="loc_imab_CommonStockSharesIssuableForServicesAvailedCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_CommonStockSharesIssuableForServicesAvailedCurrent" xml:lang="en-US">Common Stock Shares Issuable For Services Availed Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_CommonStockSharesIssuableForServicesAvailedCurrent" xml:lang="en-US">Ordinary shares to be issued to Everest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_CommonStockSharesIssuableForServicesAvailedCurrent" xlink:to="lab_imab_CommonStockSharesIssuableForServicesAvailedCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_CommonStockSharesIssuableForServicesAvailedCurrent" xml:lang="en-US">Common stock shares issuable for services availed current.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermBorrowings" xml:lang="en-US">Short-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermBorrowings" xml:lang="en-US">Short-term borrowings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShortTermBorrowings" xml:lang="en-US">Loan Borrowed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PutRightLiabilities" xlink:label="loc_imab_PutRightLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PutRightLiabilities" xml:lang="en-US">Put Right Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_PutRightLiabilities" xml:lang="en-US">Put right liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PutRightLiabilities" xlink:to="lab_imab_PutRightLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_PutRightLiabilities" xml:lang="en-US">Put right liabilities.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaap_DeferredIncomeCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeCurrent" xml:lang="en-US">Deferred Income, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeCurrent" xml:lang="en-US">Deferred subsidy income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeCurrent" xlink:to="lab_us-gaap_DeferredIncomeCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other&#160;non-current&#160;liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities, mezzanine equity and shareholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesC1ConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesC1ConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriesC1ConvertiblePreferredStockMember" xml:lang="en-US">Series C 1 Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeriesC1ConvertiblePreferredStockMember" xml:lang="en-US">Series C-1 Convertible Preferred Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_SeriesC1ConvertiblePreferredStockMember" xml:lang="en-US">Series C-1 Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriesC1ConvertiblePreferredStockMember" xlink:to="lab_imab_SeriesC1ConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_SeriesC1ConvertiblePreferredStockMember" xml:lang="en-US">Series C 1 convertible preferred stock [Member]</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesAConvertiblePreferredSharesMember" xlink:label="loc_imab_SeriesAConvertiblePreferredSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriesAConvertiblePreferredSharesMember" xml:lang="en-US">Series A Convertible Preferred Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeriesAConvertiblePreferredSharesMember" xml:lang="en-US">Series A Convertible Preferred Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriesAConvertiblePreferredSharesMember" xlink:to="lab_imab_SeriesAConvertiblePreferredSharesMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBConvertiblePreferredSharesMember" xlink:label="loc_imab_SeriesBConvertiblePreferredSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriesBConvertiblePreferredSharesMember" xml:lang="en-US">Series B Convertible Preferred Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeriesBConvertiblePreferredSharesMember" xml:lang="en-US">Series B Convertible Preferred Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriesBConvertiblePreferredSharesMember" xlink:to="lab_imab_SeriesBConvertiblePreferredSharesMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesCConvertiblePreferredSharesMember" xlink:label="loc_imab_SeriesCConvertiblePreferredSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriesCConvertiblePreferredSharesMember" xml:lang="en-US">Series C Convertible Preferred Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeriesCConvertiblePreferredSharesMember" xml:lang="en-US">Series C Convertible Preferred Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriesCConvertiblePreferredSharesMember" xlink:to="lab_imab_SeriesCConvertiblePreferredSharesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAxis" xlink:label="loc_us-gaap_CollateralAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollateralAxis" xml:lang="en-US">Collateral [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAxis" xlink:to="lab_us-gaap_CollateralAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaap_CollateralDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollateralDomain" xml:lang="en-US">Collateral [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralDomain" xlink:to="lab_us-gaap_CollateralDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Temporary Stock Par Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Temporary Shares Authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Temporary Equity, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Temporary Shares Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Issuance of Series C-1 Preferred Shares, net of issuance costs, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Ordinary Shares Par Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Ordinary shares, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common shares, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Ordinary Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Ordinary shares, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Ordinary Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Issue of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Ordinary Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Licensing and collaboration revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Milestone revenue recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">Administrative expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Income (loss) from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (loss) before income tax expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before income tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss) attributable to I-MAB</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss) attributable to I-MAB</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss) attributable to I-Mab</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Total comprehensive income (loss) attributable to I-MAB</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net income (loss) attributable to ordinary shareholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net income (loss) attributable to ordinary shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair value change of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair value change of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair value gain of warrants for the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares" xlink:label="loc_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares" xml:lang="en-US">Preferred Stock Dividends At Extinguishment Of Preferred Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:label="lab_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares" xml:lang="en-US">Deemed dividend to Series C-1 preferred shareholders at extinguishment of Series C-1 Preferred Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares" xml:lang="en-US">Deemed dividend to Series C-1 preferred shareholders at extinguishment of Series C-1 Preferred Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares" xml:lang="en-US">Deemed dividend to Series C-1 preferred shareholders at extinguishment of Series C-1 Preferred Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares" xml:lang="en-US">Deemed dividend to Series&#160;C-1&#160;preferred shareholders at extinguishment of Series&#160;C-1&#160;Preferred Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares" xlink:to="lab_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares" xml:lang="en-US">Preferred stock dividends at extinguishment of preferred shares.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockDividendsAtModificationOfPreferredShares" xlink:label="loc_imab_PreferredStockDividendsAtModificationOfPreferredShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PreferredStockDividendsAtModificationOfPreferredShares" xml:lang="en-US">Preferred Stock Dividends At Modification Of Preferred Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:label="lab_imab_PreferredStockDividendsAtModificationOfPreferredShares" xml:lang="en-US">Deemed dividend to Series B-1, B-2 and C preferred shareholders at modification of Series B-1, B-2 and C Preferred Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_PreferredStockDividendsAtModificationOfPreferredShares" xml:lang="en-US">Deemed dividend to Series B-1, B-2 and C preferred shareholders at modification of Series B-1, B-2 and C Preferred Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_PreferredStockDividendsAtModificationOfPreferredShares" xml:lang="en-US">Deemed dividend to Series&#160;B-1,&#160;B-2&#160;and C preferred shareholders at modification of Series&#160;B-1,&#160;B-2&#160;and C Preferred Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_imab_PreferredStockDividendsAtModificationOfPreferredShares" xml:lang="en-US">Deemed dividend to Series&#160;B-1,&#160;B-2&#160;and C preferred shareholders at modification of Series&#160;B-1,&#160;B-2&#160;and C Preferred Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PreferredStockDividendsAtModificationOfPreferredShares" xlink:to="lab_imab_PreferredStockDividendsAtModificationOfPreferredShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_PreferredStockDividendsAtModificationOfPreferredShares" xml:lang="en-US">Preferred stock dividends at modification of preferred shares.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other income (expenses), net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Income (Expenses), Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xml:lang="en-US">Other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Foreign currency translation adjustments, net of nil tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Foreign currency translation adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted-average number of ordinary shares used in calculating net income (loss) per share - basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Denominator for basic calculation-weighted average number of common shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted-average number of ordinary shares used in calculating net income (loss) per share - diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Denominator for diluted income (loss) per share calculation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Equity in loss of an affiliate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Equity in loss of an affiliate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Equity in loss of affiliate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Net income (loss) per share attributable to ordinary shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">&#8212;Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net income (loss) per share - basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">&#8212;Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net income (loss) per share - diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Beginning balance, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Ending balance, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xml:lang="en-US">Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xml:lang="en-US">Transaction with redeemable non- controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Conversion from convertible promissory notes, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt conversion number of share issue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Conversion from convertible promissory notes (Note 15)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Conversion of convertible promissory notes to ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate" xlink:label="loc_imab_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate" xml:lang="en-US">Proportionate Share Of Share Based Compensation Expenses Recorded In An Equity Method Affiliate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate" xml:lang="en-US">Proportionate share of share-based compensation expenses recorded in an equity method affiliate (Note 9(a))</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate" xlink:to="lab_imab_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate" xml:lang="en-US">Proportionate share of share based compensation expenses recorded in an equity method affiliate.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Exercise of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercise of stock options, share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercise of stock options, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender" xlink:label="loc_imab_AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender" xml:lang="en-US">Adjustments To Additional Paid In Capital Stock Option Surrender</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender" xml:lang="en-US">Capital contribution from stock option surrender (Note 17 (h))</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender" xlink:to="lab_imab_AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender" xml:lang="en-US">Adjustments to additional paid in capital, stock option surrender.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Conversion of preferred shares to ordinary shares upon the completion of initial public offering ("IPO")</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Conversion to ordinary shares upon IPO, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Conversion of preferred shares to ordinary shares upon the completion of initial public offering ("IPO"), shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Conversion to ordinary shares upon IPO, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Issuance of ordinary shares to Everest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Issuance of ordinary shares to Everest, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of ordinary shares upon IPO and over-allotment, net of issuance cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of ordinary shares upon IPO and over-allotment, net of issuance cost, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Number of share issued, ADS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Issuance of ordinary shares upon private placement, net of issuance cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Issuance of ordinary shares upon private placement, net of issuance cost, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Ordinary shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Issuance of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of ordinary shares for restricted share units, Shares (Note 17 (f))</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of ordinary shares for restricted share units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of ordinary shares for restricted share units (Note 17 (f))</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockMember" xml:lang="en-US">Treasury Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockMember" xml:lang="en-US">Treasury stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xml:lang="en-US">Contract assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepayments and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accruals and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Contract liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IncreaseDecreaseAdvanceFromCustomers" xlink:label="loc_imab_IncreaseDecreaseAdvanceFromCustomers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_IncreaseDecreaseAdvanceFromCustomers" xml:lang="en-US">Increase Decrease Advance from customers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_IncreaseDecreaseAdvanceFromCustomers" xml:lang="en-US">Advance from customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_IncreaseDecreaseAdvanceFromCustomers" xlink:to="lab_imab_IncreaseDecreaseAdvanceFromCustomers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_IncreaseDecreaseAdvanceFromCustomers" xml:lang="en-US">Increase decrease advance from customers.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xml:lang="en-US">Research and development funding received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" xml:lang="en-US">Increase (Decrease) in Deferred Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" xml:lang="en-US">Deferred subsidy income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:label="loc_imab_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xml:lang="en-US">Increase Decrease In Operating Lease Liabilities Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xml:lang="en-US">Lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:to="lab_imab_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xml:lang="en-US">Increase decrease in operating lease liabilities current.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xml:lang="en-US">Other non-current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation of property, equipment and software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IncomeFromOtherFinancialAssets" xlink:label="loc_imab_IncomeFromOtherFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_IncomeFromOtherFinancialAssets" xml:lang="en-US">Income From Other Financial Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_imab_IncomeFromOtherFinancialAssets" xml:lang="en-US">Income from other financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_IncomeFromOtherFinancialAssets" xml:lang="en-US">Income from other financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_IncomeFromOtherFinancialAssets" xlink:to="lab_imab_IncomeFromOtherFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_IncomeFromOtherFinancialAssets" xml:lang="en-US">Income from other financial assets.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Loss on disposal of property, equipment and software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest Expense, Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest expenses of convertible promissory notes and onshore convertible loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LossFromConversionOfOnshoreConvertibleLoans" xlink:label="loc_imab_LossFromConversionOfOnshoreConvertibleLoans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LossFromConversionOfOnshoreConvertibleLoans" xml:lang="en-US">Loss From Conversion Of Onshore Convertible Loans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_LossFromConversionOfOnshoreConvertibleLoans" xml:lang="en-US">Loss from conversion of onshore convertible loans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_imab_LossFromConversionOfOnshoreConvertibleLoans" xml:lang="en-US">Loss from conversion of Onshore Convertible Loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LossFromConversionOfOnshoreConvertibleLoans" xlink:to="lab_imab_LossFromConversionOfOnshoreConvertibleLoans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LossFromConversionOfOnshoreConvertibleLoans" xml:lang="en-US">Loss from conversion of onshore convertible loans.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities" xlink:label="loc_imab_AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities" xml:lang="en-US">Amortization Of Right Of Use Assets And Interest Of Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities" xml:lang="en-US">Amortization of right-of use assets and interest of lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities" xlink:to="lab_imab_AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities" xml:lang="en-US">Amortization of right of use assets and interest of lease liabilities.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LossFromConversionOfNotes" xlink:label="loc_imab_LossFromConversionOfNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LossFromConversionOfNotes" xml:lang="en-US">Loss From Conversion of Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_LossFromConversionOfNotes" xml:lang="en-US">Loss from conversion of 2017 Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LossFromConversionOfNotes" xlink:to="lab_imab_LossFromConversionOfNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LossFromConversionOfNotes" xml:lang="en-US">Loss From Conversion of Notes.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LossFromIssuanceOfNotes" xlink:label="loc_imab_LossFromIssuanceOfNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LossFromIssuanceOfNotes" xml:lang="en-US">Loss From Issuance of Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_LossFromIssuanceOfNotes" xml:lang="en-US">Loss from issuance of 2018 Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_imab_LossFromIssuanceOfNotes" xml:lang="en-US">Loss from issuance of 2018 Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LossFromIssuanceOfNotes" xlink:to="lab_imab_LossFromIssuanceOfNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LossFromIssuanceOfNotes" xml:lang="en-US">Loss From Issuance of Notes.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="loc_us-gaap_AssetsFairValueAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueAdjustment" xml:lang="en-US">Assets, Fair Value Adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueAdjustment" xml:lang="en-US">Fair value change of other financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueAdjustment" xlink:to="lab_us-gaap_AssetsFairValueAdjustment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="loc_us-gaap_GainLossOnContractTermination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnContractTermination" xml:lang="en-US">Gain (Loss) on Contract Termination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnContractTermination" xml:lang="en-US">Loss on termination agreement with Everest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainLossOnContractTermination" xml:lang="en-US">Loss on termination agreement with Everest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnContractTermination" xlink:to="lab_us-gaap_GainLossOnContractTermination" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueChangeOfShortTermInvestments" xlink:label="loc_imab_FairValueChangeOfShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_FairValueChangeOfShortTermInvestments" xml:lang="en-US">Fair Value Change Of Short Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_FairValueChangeOfShortTermInvestments" xml:lang="en-US">Fair value change of short-term investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_imab_FairValueChangeOfShortTermInvestments" xml:lang="en-US">Fair value change of short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_FairValueChangeOfShortTermInvestments" xlink:to="lab_imab_FairValueChangeOfShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_FairValueChangeOfShortTermInvestments" xml:lang="en-US">Fair Value Change Of Short Term Investments.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueAdjustmentsOfPutRightLiabilities" xlink:label="loc_imab_FairValueAdjustmentsOfPutRightLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_FairValueAdjustmentsOfPutRightLiabilities" xml:lang="en-US">Fair Value Adjustments Of Put Right Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_FairValueAdjustmentsOfPutRightLiabilities" xml:lang="en-US">Fair value change of put right liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_imab_FairValueAdjustmentsOfPutRightLiabilities" xml:lang="en-US">Fair value change of put right liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_FairValueAdjustmentsOfPutRightLiabilities" xlink:to="lab_imab_FairValueAdjustmentsOfPutRightLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_FairValueAdjustmentsOfPutRightLiabilities" xml:lang="en-US">Fair value adjustments of put right liabilities.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xml:lang="en-US">Gain (Loss) on Disposition of Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xml:lang="en-US">Gains on deconsolidation of a subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash generated from (used in) operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property, equipment and software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xml:lang="en-US">Proceeds from Sale of Short-term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xml:lang="en-US">Proceeds from disposal of short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xml:lang="en-US">Payments to Acquire Short-term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xml:lang="en-US">Purchase of short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CashReceivedOnIncomeFromOtherFinancialAssets" xlink:label="loc_imab_CashReceivedOnIncomeFromOtherFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_CashReceivedOnIncomeFromOtherFinancialAssets" xml:lang="en-US">Cash Received On Income From Other Financial Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_CashReceivedOnIncomeFromOtherFinancialAssets" xml:lang="en-US">Cash received on income from other financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_CashReceivedOnIncomeFromOtherFinancialAssets" xlink:to="lab_imab_CashReceivedOnIncomeFromOtherFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_CashReceivedOnIncomeFromOtherFinancialAssets" xml:lang="en-US">Cash received on income from other financial assets.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash generated from (used in) investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xml:lang="en-US">Payments to Acquire Other Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xml:lang="en-US">Cash paid for investments in other financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xml:lang="en-US">Cash received from disposal of other financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xml:lang="en-US">Cash disposed of resulting from deconsolidation of a subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xml:lang="en-US">Proceeds from Collection of Long-term Loans to Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xml:lang="en-US">Cash received from repayment of loans due from an affiliate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:to="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash generated from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Proceeds from issuance of convertible preferred shares, net of issuance cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Consideration in issuance Preference Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from issuance of convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from Warrant Exercises</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from exercise of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Value of outstanding securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromBankDebt" xlink:label="loc_us-gaap_ProceedsFromBankDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromBankDebt" xml:lang="en-US">Proceeds from Bank Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromBankDebt" xml:lang="en-US">Proceeds from bank borrowings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromBankDebt" xlink:to="lab_us-gaap_ProceedsFromBankDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="loc_us-gaap_RepaymentsOfBankDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfBankDebt" xml:lang="en-US">Repayments of Bank Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfBankDebt" xml:lang="en-US">Repayment of bank borrowings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfBankDebt" xlink:to="lab_us-gaap_RepaymentsOfBankDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from initial public offering and over-allotment, net of underwriting discounts and commissions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from initial public offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payment of issuance cost for initial public offering and over-allotment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Stock Issuance Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from private placement, net of payment of issuance cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Issuance of Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from exercise of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity" xml:lang="en-US">Payments for Repurchase of Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity" xml:lang="en-US">Prepayment for stock repurchase program</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfEquity" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xml:lang="en-US">Proceeds from Issuance of Common Limited Partners Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xml:lang="en-US">Proceeds from issuance of ordinary shares for restricted share units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram" xlink:label="loc_imab_ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram" xml:lang="en-US">Proceeds from Cash Received from Collection of Prepayment for Stock Repurchase Program</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram" xml:lang="en-US">Cash received from collection of prepayment for stock repurchase program</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram" xlink:to="lab_imab_ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram" xml:lang="en-US">Proceeds from cash received from collection of prepayment for stock repurchase program.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Additional ASC 842 supplemental disclosures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OtherSupplementalCashFlowDisclosuresAbstract" xlink:label="loc_imab_OtherSupplementalCashFlowDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_OtherSupplementalCashFlowDisclosuresAbstract" xml:lang="en-US">Other Supplemental Cash Flow Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_OtherSupplementalCashFlowDisclosuresAbstract" xml:lang="en-US">Other supplemental cash flow disclosures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_OtherSupplementalCashFlowDisclosuresAbstract" xlink:to="lab_imab_OtherSupplementalCashFlowDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_OtherSupplementalCashFlowDisclosuresAbstract" xml:lang="en-US">Other supplemental cash flow disclosures [abstract].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Non-cash&#160;activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PayablesForInLicensedPatentRights" xlink:label="loc_imab_PayablesForInLicensedPatentRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PayablesForInLicensedPatentRights" xml:lang="en-US">Payables For In Licensed Patent Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_PayablesForInLicensedPatentRights" xml:lang="en-US">Payables for in-licensed patent rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PayablesForInLicensedPatentRights" xlink:to="lab_imab_PayablesForInLicensedPatentRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_PayablesForInLicensedPatentRights" xml:lang="en-US">Payables for in licensed patent rights.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ExerciseOfWarrants" xlink:label="loc_imab_ExerciseOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ExerciseOfWarrants" xml:lang="en-US">Exercise Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ExerciseOfWarrants" xml:lang="en-US">Exercise of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ExerciseOfWarrants" xlink:to="lab_imab_ExerciseOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ExerciseOfWarrants" xml:lang="en-US">Exercise of warrants.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccuredInitialPublicOfferingCostPayable" xlink:label="loc_imab_AccuredInitialPublicOfferingCostPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_AccuredInitialPublicOfferingCostPayable" xml:lang="en-US">Accured Initial Public Offering Cost Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_AccuredInitialPublicOfferingCostPayable" xml:lang="en-US">Accrued initial public offering costs payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_AccuredInitialPublicOfferingCostPayable" xlink:to="lab_imab_AccuredInitialPublicOfferingCostPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_AccuredInitialPublicOfferingCostPayable" xml:lang="en-US">Accrued initial public offering cost payable.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccruedPrivatePlacementOfferingCostsPayable" xlink:label="loc_imab_AccruedPrivatePlacementOfferingCostsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_AccruedPrivatePlacementOfferingCostsPayable" xml:lang="en-US">Accrued Private Placement Offering Costs Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_AccruedPrivatePlacementOfferingCostsPayable" xml:lang="en-US">Accrued private placement offering costs payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_AccruedPrivatePlacementOfferingCostsPayable" xlink:to="lab_imab_AccruedPrivatePlacementOfferingCostsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_AccruedPrivatePlacementOfferingCostsPayable" xml:lang="en-US">Accrued private placement offering costs payable.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Stock Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Ordinary shares issued to Everest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US">Conversion of preferred shares to ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Cash paid for fixed operating lease costs included in the measurement of lease obligations in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Principal Activities and Organization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Principal Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccountsReceivableAndContractAssetsAbstract" xlink:label="loc_imab_AccountsReceivableAndContractAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_AccountsReceivableAndContractAssetsAbstract" xml:lang="en-US">Accounts Receivable And Contract Assets [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_AccountsReceivableAndContractAssetsAbstract" xlink:to="lab_imab_AccountsReceivableAndContractAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_AccountsReceivableAndContractAssetsAbstract" xml:lang="en-US">Accounts Receivable And Contract Assets.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccountsReceivableAndContractAssetsTextBlock" xlink:label="loc_imab_AccountsReceivableAndContractAssetsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_AccountsReceivableAndContractAssetsTextBlock" xml:lang="en-US">Accounts Receivable And Contract Assets [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_AccountsReceivableAndContractAssetsTextBlock" xml:lang="en-US">Accounts Receivable And Contract Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_AccountsReceivableAndContractAssetsTextBlock" xlink:to="lab_imab_AccountsReceivableAndContractAssetsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_AccountsReceivableAndContractAssetsTextBlock" xml:lang="en-US">Accounts Receivable And Contract Assets.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PrepaidexpensesandotherreceivablestextblockTextBlock" xlink:label="loc_imab_PrepaidexpensesandotherreceivablestextblockTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PrepaidexpensesandotherreceivablestextblockTextBlock" xml:lang="en-US">PrepaidExpensesAndOtherReceivablesTextBlock [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_PrepaidexpensesandotherreceivablestextblockTextBlock" xml:lang="en-US">Prepaid Expenses And Other Receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PrepaidexpensesandotherreceivablestextblockTextBlock" xlink:to="lab_imab_PrepaidexpensesandotherreceivablestextblockTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_PrepaidexpensesandotherreceivablestextblockTextBlock" xml:lang="en-US">Prepaid expenses and other receivables [Text Block].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Equipment and Software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Leases of Lessee Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xml:lang="en-US">Goodwill Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract" xlink:label="loc_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract" xml:lang="en-US">Investment Accounted For Using The Equity Method And Put Right Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract" xlink:to="lab_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock" xlink:label="loc_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock" xml:lang="en-US">Investment Accounted For Using The Equity Method And Put Right Liabilities [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock" xml:lang="en-US">Investment Accounted for Using the Equity Method and Put Right Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock" xlink:to="lab_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock" xml:lang="en-US">Investment Accounted for Using the Equity Method and Put Right Liabilities.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureTextBlockAbstract" xml:lang="en-US">Disclosure Text Block [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureTextBlockAbstract" xml:lang="en-US">Disclosure Text Block [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract" xlink:to="lab_us-gaap_DisclosureTextBlockAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_us-gaap_ShortTermDebtTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTextBlock" xml:lang="en-US">Short-term Debt [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtTextBlock" xml:lang="en-US">Short-Term Borrowings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTextBlock" xlink:to="lab_us-gaap_ShortTermDebtTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accruals and other Payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TemporaryEquityTextBlock" xlink:label="loc_imab_TemporaryEquityTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_TemporaryEquityTextBlock" xml:lang="en-US">Temporary Equity [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_TemporaryEquityTextBlock" xml:lang="en-US">Convertible Preferred Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_TemporaryEquityTextBlock" xlink:to="lab_imab_TemporaryEquityTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_TemporaryEquityTextBlock" xml:lang="en-US">Temporary equity.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract" xlink:label="loc_imab_ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract" xml:lang="en-US">Convertible Promissory Notes And Onshore Convertible Loan [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract" xlink:to="lab_imab_ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract" xml:lang="en-US">Convertible promissory notes and onshore convertible loan abstract.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans" xlink:label="loc_imab_ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans" xml:lang="en-US">Schedule of Convertible promissory notes and onshore convertible loans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans" xml:lang="en-US">Convertible promissory notes and onshore convertible loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans" xlink:to="lab_imab_ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans" xml:lang="en-US">Schedule of Convertible promissory notes and onshore convertible loans.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WarrantsDisclosureAbstract" xlink:label="loc_imab_WarrantsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_WarrantsDisclosureAbstract" xml:lang="en-US">Warrants Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_WarrantsDisclosureAbstract" xlink:to="lab_imab_WarrantsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_WarrantsDisclosureAbstract" xml:lang="en-US">Disclosure of Warrants [Abstract].</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WarrantsDisclosure" xlink:label="loc_imab_WarrantsDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_WarrantsDisclosure" xml:lang="en-US">Warrants Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_WarrantsDisclosure" xml:lang="en-US">Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_WarrantsDisclosure" xlink:to="lab_imab_WarrantsDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_WarrantsDisclosure" xml:lang="en-US">Warrants disclosure.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US">Licensing And Collaboration Arrangements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xml:lang="en-US">Other Income (Expenses), Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Net Income (Loss) per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PostemploymentBenefitsAbstract" xml:lang="en-US">Postemployment Benefits [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:to="lab_us-gaap_PostemploymentBenefitsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Employee Benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Balances and Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xml:lang="en-US">Risks and Uncertainties [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xml:lang="en-US">Concentration of Credit Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_RestrictedNetAssetsDisclosureAbstract" xlink:label="loc_imab_RestrictedNetAssetsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_RestrictedNetAssetsDisclosureAbstract" xml:lang="en-US">Restricted Net Assets Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_RestrictedNetAssetsDisclosureAbstract" xlink:to="lab_imab_RestrictedNetAssetsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_RestrictedNetAssetsDisclosureAbstract" xml:lang="en-US">Restricted Net Assets Disclosure [Abstract].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_RestrictedAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedAssetsDisclosureTextBlock" xml:lang="en-US">Restricted Assets Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedAssetsDisclosureTextBlock" xml:lang="en-US">Restricted Net Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_RestrictedAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign currency translation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShortTermInvestmentsPolicyTextBlock" xlink:label="loc_imab_ShortTermInvestmentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ShortTermInvestmentsPolicyTextBlock" xml:lang="en-US">Short Term Investments [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ShortTermInvestmentsPolicyTextBlock" xml:lang="en-US">Short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ShortTermInvestmentsPolicyTextBlock" xlink:to="lab_imab_ShortTermInvestmentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ShortTermInvestmentsPolicyTextBlock" xml:lang="en-US">Short-term investments.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, equipment and software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of long-lived assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Basis of consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Income (loss) per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Adopted accounting pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_imab_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopted [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xml:lang="en-US">Recent accounting pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="lab_imab_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xml:lang="en-US">Recent accounting pronouncements.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredSubsidyIncomePolicyTextBlock" xlink:label="loc_imab_DeferredSubsidyIncomePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_DeferredSubsidyIncomePolicyTextBlock" xml:lang="en-US">Deferred Subsidy Income [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_DeferredSubsidyIncomePolicyTextBlock" xml:lang="en-US">Deferred subsidy income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_DeferredSubsidyIncomePolicyTextBlock" xlink:to="lab_imab_DeferredSubsidyIncomePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_DeferredSubsidyIncomePolicyTextBlock" xml:lang="en-US">Deferred Subsidy Income.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ValueAddedTaxesPolicyPolicyTextBlock" xlink:label="loc_imab_ValueAddedTaxesPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ValueAddedTaxesPolicyPolicyTextBlock" xml:lang="en-US">Value Added Taxes Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ValueAddedTaxesPolicyPolicyTextBlock" xml:lang="en-US">Value-added-tax&#160;("VAT") recoverable and surcharges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ValueAddedTaxesPolicyPolicyTextBlock" xlink:to="lab_imab_ValueAddedTaxesPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ValueAddedTaxesPolicyPolicyTextBlock" xml:lang="en-US">Value Added Taxes Policy.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and development expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xml:lang="en-US">Share-based Payment Arrangement, Forfeiture [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Borrowings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LongTermInvestmentsPolicyTextBlock" xlink:label="loc_imab_LongTermInvestmentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LongTermInvestmentsPolicyTextBlock" xml:lang="en-US">Long Term Investments [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_LongTermInvestmentsPolicyTextBlock" xml:lang="en-US">Long Term Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LongTermInvestmentsPolicyTextBlock" xlink:to="lab_imab_LongTermInvestmentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LongTermInvestmentsPolicyTextBlock" xml:lang="en-US">Long Term Investments.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfPrincipalSubsidiariesTableTextBlock" xlink:label="loc_imab_ScheduleOfPrincipalSubsidiariesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ScheduleOfPrincipalSubsidiariesTableTextBlock" xml:lang="en-US">Schedule Of Principal Subsidiaries [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ScheduleOfPrincipalSubsidiariesTableTextBlock" xml:lang="en-US">Schedule of Principal Subsidiaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ScheduleOfPrincipalSubsidiariesTableTextBlock" xlink:to="lab_imab_ScheduleOfPrincipalSubsidiariesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ScheduleOfPrincipalSubsidiariesTableTextBlock" xml:lang="en-US">Schedule Of Principal Subsidiaries Table Text Block</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xml:lang="en-US">Summary of Roll Forward of Major Level 3 Financial Assets and Financial Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock" xlink:label="loc_imab_ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock" xml:lang="en-US">Schedule Of Useful Life Of Property Plant Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock" xml:lang="en-US">Summary of Estimated Useful Lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock" xlink:to="lab_imab_ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock" xml:lang="en-US">Schedule of useful life of property plant equipment [Table Text Block].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">summary of Cash, cash equivalents and restricted cash as reported in the consolidated statement of cash flows</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock" xlink:label="loc_imab_ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock" xml:lang="en-US">Schedule Of Accounts Receivable and Contract Assets Net of Allowance for Credit Losses [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock" xml:lang="en-US">summary of Accounts receivable and contract assets, net of allowance for credit losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock" xlink:to="lab_imab_ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock" xml:lang="en-US">Schedule Of Accounts Receivable and Contract Assets Net of Allowance for Credit Losses.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xml:lang="en-US">Summary of Prepayments And Other Receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of property, equipment and software, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" xlink:label="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" xml:lang="en-US">Operating Lease Related Assets And Liabilities And Other Related Information [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" xml:lang="en-US">Operating Lease Related Assets And Liabilities And Other Related Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" xlink:to="lab_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" xml:lang="en-US">Operating Lease Related Assets And Liabilities And Other Related Information.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock" xlink:label="loc_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock" xml:lang="en-US">Schedule Of Components Of Operating Lease Expense [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock" xml:lang="en-US">Schedule of Components of Operating Lease Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock" xlink:to="lab_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock" xml:lang="en-US">Schedule of components of operating lease expense.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Schedule of Operating Lease, Maturity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Summary of Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Summary of Estimate the Fair Value of the Put Right Using the Following Assumptions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Summary of Valuation Assumptions Used</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xml:lang="en-US">Equity Method Investments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xml:lang="en-US">Summary of Group Long term Investment Measured Under Equity method</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Summary of accruals and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Reconciliations of the Differences Between the PRC Statutory Income Tax Rate and the Group's Effective Income Tax Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Components of the Deferred Tax Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xml:lang="en-US">Summary of Movement of the Valuation Allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xml:lang="en-US">Temporary Equity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xml:lang="en-US">Schedule of Convertible Preferred Shares Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:to="lab_us-gaap_TemporaryEquityTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Summary of fair value of warrant liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xml:lang="en-US">Schedule of Stock Options Roll Forward [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xml:lang="en-US">Summary of Stock Options Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Summary of Share-Based Compensation Expenses Related to Restricted Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xml:lang="en-US">Schedule of Non vested Share Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentySeventeenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_TwentySeventeenEmployeeStockOptionPlanMember" xml:lang="en-US">Twenty Seventeen Employee Stock Option Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_TwentySeventeenEmployeeStockOptionPlanMember" xml:lang="en-US">2017 Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_TwentySeventeenEmployeeStockOptionPlanMember" xml:lang="en-US">2017 Employee Stock Option Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember" xlink:to="lab_imab_TwentySeventeenEmployeeStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_TwentySeventeenEmployeeStockOptionPlanMember" xml:lang="en-US">2017 plan</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyEighteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_TwentyEighteenEmployeeStockOptionPlanMember" xml:lang="en-US">Twenty Eighteen Employee Stock Option Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_TwentyEighteenEmployeeStockOptionPlanMember" xml:lang="en-US">2018 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember" xlink:to="lab_imab_TwentyEighteenEmployeeStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_TwentyEighteenEmployeeStockOptionPlanMember" xml:lang="en-US">2018 plan</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyNineteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyNineteenEmployeeStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_TwentyNineteenEmployeeStockOptionPlanMember" xml:lang="en-US">Twenty Nineteen Employee Stock Option Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_TwentyNineteenEmployeeStockOptionPlanMember" xml:lang="en-US">2019 Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_TwentyNineteenEmployeeStockOptionPlanMember" xml:lang="en-US">2019 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_TwentyNineteenEmployeeStockOptionPlanMember" xlink:to="lab_imab_TwentyNineteenEmployeeStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_TwentyNineteenEmployeeStockOptionPlanMember" xml:lang="en-US">Twenty Nineteen Employee Stock Option Plan [Member]</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyTwentyEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyTwentyEmployeeStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_TwentyTwentyEmployeeStockOptionPlanMember" xml:lang="en-US">Twenty Twenty Employee Stock Option Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_TwentyTwentyEmployeeStockOptionPlanMember" xml:lang="en-US">2020 Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_TwentyTwentyEmployeeStockOptionPlanMember" xml:lang="en-US">2020 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_TwentyTwentyEmployeeStockOptionPlanMember" xlink:to="lab_imab_TwentyTwentyEmployeeStockOptionPlanMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xml:lang="en-US">Milestone payments due</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of arrangement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Type of arrangement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMorphosysAgMember" xlink:label="loc_imab_LicensingAgreementWithMorphosysAgMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LicensingAgreementWithMorphosysAgMember" xml:lang="en-US">Licensing Agreement with MorphoSys AG [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_LicensingAgreementWithMorphosysAgMember" xml:lang="en-US">Licensing Agreement with MorphoSys AG [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LicensingAgreementWithMorphosysAgMember" xlink:to="lab_imab_LicensingAgreementWithMorphosysAgMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LicensingAgreementWithMorphosysAgMember" xml:lang="en-US">Licensing Agreement with MorphoSys AG.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithGenexineIncMember" xlink:label="loc_imab_LicensingAgreementWithGenexineIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LicensingAgreementWithGenexineIncMember" xml:lang="en-US">Licensing Agreement with Genexine Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LicensingAgreementWithGenexineIncMember" xlink:to="lab_imab_LicensingAgreementWithGenexineIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LicensingAgreementWithGenexineIncMember" xml:lang="en-US">Licensing Agreement with Genexine, Inc.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMorphosysMember" xlink:label="loc_imab_LicensingAgreementWithMorphosysMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LicensingAgreementWithMorphosysMember" xml:lang="en-US">Licensing Agreement with MorphoSys [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LicensingAgreementWithMorphosysMember" xlink:to="lab_imab_LicensingAgreementWithMorphosysMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LicensingAgreementWithMorphosysMember" xml:lang="en-US">Licensing Agreement with MorphoSys.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMacrogenicsMember" xlink:label="loc_imab_LicensingAgreementWithMacrogenicsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LicensingAgreementWithMacrogenicsMember" xml:lang="en-US">Licensing Agreement with MacroGenics [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_LicensingAgreementWithMacrogenicsMember" xml:lang="en-US">Licensing Agreement with MacroGenics [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LicensingAgreementWithMacrogenicsMember" xlink:to="lab_imab_LicensingAgreementWithMacrogenicsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LicensingAgreementWithMacrogenicsMember" xml:lang="en-US">Licensing Agreement with MacroGenics.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xml:lang="en-US">Licensing And Collaboration Arrangements Summarized Financial Information Disclosure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xml:lang="en-US">Summary of Other Income (Expenses), Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Summary of Basic and Diluted Net Loss per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfRelatedPartyBalancesTextBlock" xlink:label="loc_imab_ScheduleOfRelatedPartyBalancesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ScheduleOfRelatedPartyBalancesTextBlock" xml:lang="en-US">Schedule Of Related Party Balances [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ScheduleOfRelatedPartyBalancesTextBlock" xml:lang="en-US">Summary of Related Party Balances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ScheduleOfRelatedPartyBalancesTextBlock" xlink:to="lab_imab_ScheduleOfRelatedPartyBalancesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ScheduleOfRelatedPartyBalancesTextBlock" xml:lang="en-US">Schedule of related party balances [Table Text Block].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Summary of Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfPrincipalSubsidiariesTable" xlink:label="loc_imab_ScheduleOfPrincipalSubsidiariesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ScheduleOfPrincipalSubsidiariesTable" xml:lang="en-US">Schedule Of Principal Subsidiaries [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ScheduleOfPrincipalSubsidiariesTable" xlink:to="lab_imab_ScheduleOfPrincipalSubsidiariesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ScheduleOfPrincipalSubsidiariesTable" xml:lang="en-US">Schedule Of Principal Subsidiaries Table</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xml:lang="en-US">Consolidated Entities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xml:lang="en-US">Consolidated Entities [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IMabBiopharmaHongKongLimitedMember" xlink:label="loc_imab_IMabBiopharmaHongKongLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_IMabBiopharmaHongKongLimitedMember" xml:lang="en-US">I Mab Biopharma Hong Kong Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_IMabBiopharmaHongKongLimitedMember" xml:lang="en-US">I-Mab Biopharma Hong Kong Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_IMabBiopharmaHongKongLimitedMember" xlink:to="lab_imab_IMabBiopharmaHongKongLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_IMabBiopharmaHongKongLimitedMember" xml:lang="en-US">I-Mab&#160;Biopharma Hong Kong Limited.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IMabShanghaiMember" xlink:label="loc_imab_IMabShanghaiMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_IMabShanghaiMember" xml:lang="en-US">I Mab Shanghai [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_IMabShanghaiMember" xml:lang="en-US">I-Mab Shanghai [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_IMabShanghaiMember" xlink:to="lab_imab_IMabShanghaiMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_IMabShanghaiMember" xml:lang="en-US">I-Mab&#160;Shanghai.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IMabtianjinMember" xlink:label="loc_imab_IMabtianjinMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_IMabtianjinMember" xml:lang="en-US">I MabTianjin [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_IMabtianjinMember" xml:lang="en-US">I-MabTianjin [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_IMabtianjinMember" xlink:to="lab_imab_IMabtianjinMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_IMabtianjinMember" xml:lang="en-US">I-Mab&#160;Tianjin.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ImabbiopharmaUsLtdMember" xlink:label="loc_imab_ImabbiopharmaUsLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ImabbiopharmaUsLtdMember" xml:lang="en-US">IMabBiopharma US Ltd [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ImabbiopharmaUsLtdMember" xml:lang="en-US">I-MabBiopharma US Ltd. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ImabbiopharmaUsLtdMember" xlink:to="lab_imab_ImabbiopharmaUsLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ImabbiopharmaUsLtdMember" xml:lang="en-US">I-Mab&#160;Biopharma US Ltd.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EntityIncorporationCountryStateName" xlink:label="loc_imab_EntityIncorporationCountryStateName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_EntityIncorporationCountryStateName" xml:lang="en-US">Entity Incorporation Country State Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_EntityIncorporationCountryStateName" xml:lang="en-US">Place of incorporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_EntityIncorporationCountryStateName" xlink:to="lab_imab_EntityIncorporationCountryStateName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_EntityIncorporationCountryStateName" xml:lang="en-US">Entity incorporation country state name.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xml:lang="en-US">Date of incorporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationDateOfIncorporation" xlink:to="lab_dei_EntityIncorporationDateOfIncorporation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Percentage of direct or indirect ownership by the company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity method investment, Ownership percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="loc_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xml:lang="en-US">Equity Method Investment, Description of Principal Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xml:lang="en-US">Principal activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:to="lab_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Number of share issued, price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CommonStockSharesIssuable" xlink:label="loc_imab_CommonStockSharesIssuable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_CommonStockSharesIssuable" xml:lang="en-US">Common Stock Shares Issuable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_CommonStockSharesIssuable" xml:lang="en-US">Common stock shares issuable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_CommonStockSharesIssuable" xlink:to="lab_imab_CommonStockSharesIssuable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_CommonStockSharesIssuable" xml:lang="en-US">Common stock shares issuable.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Estimated fair value of Company's ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xml:lang="en-US">Short-term Investments [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OtherFinancialAssetsMember" xlink:label="loc_imab_OtherFinancialAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_OtherFinancialAssetsMember" xml:lang="en-US">Other financial assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_OtherFinancialAssetsMember" xlink:to="lab_imab_OtherFinancialAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_OtherFinancialAssetsMember" xml:lang="en-US">Other&#160;financial assets [Member]</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WarrantLiabilitiesMember" xlink:label="loc_imab_WarrantLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_WarrantLiabilitiesMember" xml:lang="en-US">Warrant liabilities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_WarrantLiabilitiesMember" xlink:to="lab_imab_WarrantLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_WarrantLiabilitiesMember" xml:lang="en-US">Warrant liabilities [Member]</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PutRightLiabilitiesMember" xlink:label="loc_imab_PutRightLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PutRightLiabilitiesMember" xml:lang="en-US">Put Right Liabilities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PutRightLiabilitiesMember" xlink:to="lab_imab_PutRightLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xml:lang="en-US">Fair value of Level 3 financial asset and liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xml:lang="en-US">Fair value of Level 3 financial asset and liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences" xlink:label="loc_imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences" xml:lang="en-US">Fair Value Net Derivative Asset Liability Measured on Recurring Basis Unobservable Inputs Reconciliation Currency Translation Differences</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences" xml:lang="en-US">Currency translation differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences" xlink:to="lab_imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences" xml:lang="en-US">Fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation currency translation differences.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xml:lang="en-US">Disposal of other financial assets due to Termination Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xml:lang="en-US">Purchase of short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xml:lang="en-US">Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xml:lang="en-US">Fair value change</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments" xlink:label="loc_imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Short Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments" xml:lang="en-US">Disposal of short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments" xlink:to="lab_imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis short term investments.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xml:lang="en-US">Grant of put right liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xml:lang="en-US">Translation exchange rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrantsReceivable" xml:lang="en-US">Grants Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GrantsReceivable" xml:lang="en-US">Deferred subsidy income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable" xlink:to="lab_us-gaap_GrantsReceivable" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_VATSurchargesPercent" xlink:label="loc_imab_VATSurchargesPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_VATSurchargesPercent" xml:lang="en-US">V A T Surcharges Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_VATSurchargesPercent" xml:lang="en-US">VAT surcharges percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_VATSurchargesPercent" xlink:to="lab_imab_VATSurchargesPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_VATSurchargesPercent" xml:lang="en-US">VAT surcharges percent.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating lease, liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostImpairmentLoss" xlink:label="loc_us-gaap_CapitalizedContractCostImpairmentLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalizedContractCostImpairmentLoss" xml:lang="en-US">Capitalized Contract Cost, Impairment Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalizedContractCostImpairmentLoss" xml:lang="en-US">Impairment loss, contract assets with customer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostImpairmentLoss" xlink:to="lab_us-gaap_CapitalizedContractCostImpairmentLoss" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_BankBranchAxis" xlink:label="loc_imab_BankBranchAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_BankBranchAxis" xml:lang="en-US">Bank Branch [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_BankBranchAxis" xlink:to="lab_imab_BankBranchAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_BankBranchAxis" xml:lang="en-US">Bank Branch</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_BankBranchDomain" xlink:label="loc_imab_BankBranchDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_BankBranchDomain" xml:lang="en-US">Bank Branch [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_BankBranchDomain" xlink:to="lab_imab_BankBranchDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_BankBranchDomain" xml:lang="en-US">Bank Branch</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PeoplesBankOfChinaMember" xlink:label="loc_imab_PeoplesBankOfChinaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PeoplesBankOfChinaMember" xml:lang="en-US">Peoples Bank of China [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PeoplesBankOfChinaMember" xlink:to="lab_imab_PeoplesBankOfChinaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_PeoplesBankOfChinaMember" xml:lang="en-US">People's Bank of China</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FederalReserveBankOfNewYorkMember" xlink:label="loc_imab_FederalReserveBankOfNewYorkMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_FederalReserveBankOfNewYorkMember" xml:lang="en-US">Federal Reserve Bank of New York [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_FederalReserveBankOfNewYorkMember" xlink:to="lab_imab_FederalReserveBankOfNewYorkMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_FederalReserveBankOfNewYorkMember" xml:lang="en-US">Federal Reserve Bank of New York</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LaboratoryEquipmentMember" xlink:label="loc_imab_LaboratoryEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LaboratoryEquipmentMember" xlink:to="lab_imab_LaboratoryEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory Equipment</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SoftwareMember" xlink:label="loc_imab_SoftwareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SoftwareMember" xml:lang="en-US">Software [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SoftwareMember" xlink:to="lab_imab_SoftwareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_SoftwareMember" xml:lang="en-US">Software [Member]</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OfficeFurnitureAndEquipmentMember" xlink:label="loc_imab_OfficeFurnitureAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_OfficeFurnitureAndEquipmentMember" xml:lang="en-US">Office furniture and equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_OfficeFurnitureAndEquipmentMember" xlink:to="lab_imab_OfficeFurnitureAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_OfficeFurnitureAndEquipmentMember" xml:lang="en-US">Office furniture and equipment</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrentAbstract" xlink:label="loc_us-gaap_AccountsReceivableNetCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrentAbstract" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrentAbstract" xml:lang="en-US">Accounts Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="lab_us-gaap_AccountsReceivableNetCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xml:lang="en-US">Accounts receivable, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for credit losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetGrossCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetGrossCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetGrossCurrent" xml:lang="en-US">Contract with Customer, Asset, before Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetGrossCurrent" xml:lang="en-US">Contract assets, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetGrossCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetGrossCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossCurrent" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossCurrent" xml:lang="en-US">Allowance for credit losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAbstract" xml:lang="en-US">Prepaid Expense, Current [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssets" xml:lang="en-US">Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssets" xml:lang="en-US">Others</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies" xlink:label="loc_us-gaap_Supplies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Supplies" xml:lang="en-US">Prepaid Supplies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Supplies" xml:lang="en-US">-Prepayments to CRO vendors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Supplies" xlink:to="lab_us-gaap_Supplies" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xml:lang="en-US">Other Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xml:lang="en-US">-Prepayments for other services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ValueaddedTaxRecoverable" xlink:label="loc_imab_ValueaddedTaxRecoverable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ValueaddedTaxRecoverable" xml:lang="en-US">Valueadded tax recoverable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_ValueaddedTaxRecoverable" xml:lang="en-US">Value-added tax recoverable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ValueaddedTaxRecoverable" xlink:to="lab_imab_ValueaddedTaxRecoverable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ValueaddedTaxRecoverable" xml:lang="en-US">Value-added tax recoverable</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecurityDeposit" xml:lang="en-US">Security Deposit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SecurityDeposit" xml:lang="en-US">Rental deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaap_InterestReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestReceivable" xml:lang="en-US">Interest Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromEmployeesCurrent" xlink:label="loc_us-gaap_DueFromEmployeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueFromEmployeesCurrent" xml:lang="en-US">Due from Employees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DueFromEmployeesCurrent" xml:lang="en-US">Receivables due from employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromEmployeesCurrent" xlink:to="lab_us-gaap_DueFromEmployeesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromAffiliateCurrent" xlink:label="loc_us-gaap_DueFromAffiliateCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueFromAffiliateCurrent" xml:lang="en-US">Due from Affiliate, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DueFromAffiliateCurrent" xml:lang="en-US">Receivables due from an affiliate (Note 23)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DueFromAffiliateCurrent" xml:lang="en-US">Collection of loan to an affiliate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromAffiliateCurrent" xlink:to="lab_us-gaap_DueFromAffiliateCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xml:lang="en-US">Property, Plant and Equipment, Net, by Type [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Total property, equipment and software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: accumulated depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConstructionInProgressGross" xml:lang="en-US">Construction in Progress, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConstructionInProgressGross" xml:lang="en-US">Construction in progress</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PropertyPlantAndequipmentnetExcludingConstructionInProcess" xlink:label="loc_imab_PropertyPlantAndequipmentnetExcludingConstructionInProcess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PropertyPlantAndequipmentnetExcludingConstructionInProcess" xml:lang="en-US">Property Plant And Equipment Net Excluding Construction In Process</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_PropertyPlantAndequipmentnetExcludingConstructionInProcess" xml:lang="en-US">Net book value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PropertyPlantAndequipmentnetExcludingConstructionInProcess" xlink:to="lab_imab_PropertyPlantAndequipmentnetExcludingConstructionInProcess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_PropertyPlantAndequipmentnetExcludingConstructionInProcess" xml:lang="en-US">Property plant and equipment net excluding construction in process.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Software and Software Development Costs [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Software [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office furniture and equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTable" xlink:label="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTable" xml:lang="en-US">Operating Lease Related Assets And Liabilities And Other Related Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTable" xlink:to="lab_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTable" xml:lang="en-US">Operating Lease Related Assets And Liabilities And Other Related Information.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems" xlink:label="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems" xml:lang="en-US">Operating Lease Related Assets And Liabilities And Other Related Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems" xlink:to="lab_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems" xml:lang="en-US">Operating Lease Related Assets And Liabilities And Other Related Information [line items].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted average remaining lease term (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted average discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfComponentsOfOperatingLeaseExpenseTable" xlink:label="loc_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTable" xml:lang="en-US">Schedule of Components of Operating Lease Expense [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTable" xlink:to="lab_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTable" xml:lang="en-US">Schedule of Components of Operating Lease Expense.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems" xlink:label="loc_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems" xml:lang="en-US">Schedule of Components of Operating Lease Expense [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems" xlink:to="lab_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems" xml:lang="en-US">Schedule of Components of Operating Lease Expense [line items].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating lease rental expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingLeaseRightOfUseAssetAmortization" xlink:label="loc_imab_OperatingLeaseRightOfUseAssetAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_OperatingLeaseRightOfUseAssetAmortization" xml:lang="en-US">Operating Lease Right Of Use Asset Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_OperatingLeaseRightOfUseAssetAmortization" xml:lang="en-US">Amortization of right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_OperatingLeaseRightOfUseAssetAmortization" xlink:to="lab_imab_OperatingLeaseRightOfUseAssetAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_OperatingLeaseRightOfUseAssetAmortization" xml:lang="en-US">Operating Lease Right Of Use Asset Amortization.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermLeaseCost" xml:lang="en-US">Short-term Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermLeaseCost" xml:lang="en-US">Expense for short-term leases within 12 months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingLeaseInterestExpense" xlink:label="loc_imab_OperatingLeaseInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_OperatingLeaseInterestExpense" xml:lang="en-US">Operating Lease Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_OperatingLeaseInterestExpense" xml:lang="en-US">Interest of lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_OperatingLeaseInterestExpense" xlink:to="lab_imab_OperatingLeaseInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_OperatingLeaseInterestExpense" xml:lang="en-US">Operating Lease Interest Expense.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfOperatingLeaseMaturityTableTable" xlink:label="loc_imab_ScheduleOfOperatingLeaseMaturityTableTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ScheduleOfOperatingLeaseMaturityTableTable" xml:lang="en-US">Schedule of Operating Lease Maturity Table [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ScheduleOfOperatingLeaseMaturityTableTable" xlink:to="lab_imab_ScheduleOfOperatingLeaseMaturityTableTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ScheduleOfOperatingLeaseMaturityTableTable" xml:lang="en-US">Schedule of Operating Lease Maturity Table</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfOperatingLeaseMaturityLineItems" xlink:label="loc_imab_ScheduleOfOperatingLeaseMaturityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ScheduleOfOperatingLeaseMaturityLineItems" xml:lang="en-US">Schedule of Operating Lease Maturity [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ScheduleOfOperatingLeaseMaturityLineItems" xlink:to="lab_imab_ScheduleOfOperatingLeaseMaturityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ScheduleOfOperatingLeaseMaturityLineItems" xml:lang="en-US">Schedule of Operating Lease Maturity [line items].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total undiscounted lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Accumulated amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Net carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Gross carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IprAndDTj103Member" xlink:label="loc_imab_IprAndDTj103Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_IprAndDTj103Member" xml:lang="en-US">IPR And D TJ103 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_IprAndDTj103Member" xml:lang="en-US">IPR And D TJ103 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_IprAndDTj103Member" xlink:to="lab_imab_IprAndDTj103Member" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IprAndDTj101Member" xlink:label="loc_imab_IprAndDTj101Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_IprAndDTj101Member" xml:lang="en-US">IPR And D TJ101 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_IprAndDTj101Member" xml:lang="en-US">IPR And D TJ101 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_IprAndDTj101Member" xlink:to="lab_imab_IprAndDTj101Member" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IprAndDTj102Member" xlink:label="loc_imab_IprAndDTj102Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_IprAndDTj102Member" xml:lang="en-US">IPR And D TJ102 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_IprAndDTj102Member" xml:lang="en-US">IPR And D TJ102 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_IprAndDTj102Member" xlink:to="lab_imab_IprAndDTj102Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xml:lang="en-US">Impairment of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xml:lang="en-US">Estimated amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xml:lang="en-US">Goodwill, accumulated impairment loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Voting Interests Acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TasgenGroupMember" xlink:label="loc_imab_TasgenGroupMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_TasgenGroupMember" xml:lang="en-US">Tasgen Group [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_TasgenGroupMember" xml:lang="en-US">Tasgen Group [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_TasgenGroupMember" xlink:to="lab_imab_TasgenGroupMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_TasgenGroupMember" xml:lang="en-US">Tasgen group [Member].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract" xml:lang="en-US">Equity Method Investment, Summarized Financial Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EquityMethodInvestmentSummarizedFinancialInformationTable" xlink:label="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_EquityMethodInvestmentSummarizedFinancialInformationTable" xml:lang="en-US">Equity Method Investment Summarized Financial Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationTable" xlink:to="lab_imab_EquityMethodInvestmentSummarizedFinancialInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_EquityMethodInvestmentSummarizedFinancialInformationTable" xml:lang="en-US">Equity Method Investment Summarized Financial Information</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_NetIncomeLossMember" xlink:label="loc_imab_NetIncomeLossMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_NetIncomeLossMember" xml:lang="en-US">Net Income Loss [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_NetIncomeLossMember" xml:lang="en-US">Net Income Loss [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_NetIncomeLossMember" xlink:to="lab_imab_NetIncomeLossMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_NetIncomeLossMember" xml:lang="en-US">Net Income Loss [Member]</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LossFromOperationMember" xlink:label="loc_imab_LossFromOperationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LossFromOperationMember" xml:lang="en-US">Loss from Operation [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_LossFromOperationMember" xml:lang="en-US">Loss from Operation [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LossFromOperationMember" xlink:to="lab_imab_LossFromOperationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LossFromOperationMember" xml:lang="en-US">Loss from Operation [Member]</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_GrossProfitMember" xlink:label="loc_imab_GrossProfitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_GrossProfitMember" xml:lang="en-US">Gross Profit [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_GrossProfitMember" xml:lang="en-US">Gross Profit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_GrossProfitMember" xlink:to="lab_imab_GrossProfitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_GrossProfitMember" xml:lang="en-US">Gross Profit [member]</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_RevenueMember" xlink:label="loc_imab_RevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_RevenueMember" xml:lang="en-US">Revenue [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_RevenueMember" xml:lang="en-US">Revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_RevenueMember" xlink:to="lab_imab_RevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_RevenueMember" xml:lang="en-US">Revenue [member]</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EquityMethodInvestmentSummarizedFinancialInformationLineItems" xlink:label="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_EquityMethodInvestmentSummarizedFinancialInformationLineItems" xml:lang="en-US">Equity Method Investment Summarized Financial Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationLineItems" xlink:to="lab_imab_EquityMethodInvestmentSummarizedFinancialInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_EquityMethodInvestmentSummarizedFinancialInformationLineItems" xml:lang="en-US">Equity Method Investment Summarized Financial Information</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_BalanceSheetDataAbstract" xlink:label="loc_imab_BalanceSheetDataAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_BalanceSheetDataAbstract" xml:lang="en-US">Balance Sheet Data [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_BalanceSheetDataAbstract" xlink:to="lab_imab_BalanceSheetDataAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_BalanceSheetDataAbstract" xml:lang="en-US">Balance Sheet Data [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent" xml:lang="en-US">Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsNoncurrent" xml:lang="en-US">Non-current&#160;assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Non-current&#160;liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Non-controlling&#160;interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingDataAbstract" xlink:label="loc_imab_OperatingDataAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_OperatingDataAbstract" xml:lang="en-US">Operating Data [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_OperatingDataAbstract" xlink:to="lab_imab_OperatingDataAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LongTermInvestmentUnderEquityMethodMember" xlink:label="loc_imab_LongTermInvestmentUnderEquityMethodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LongTermInvestmentUnderEquityMethodMember" xml:lang="en-US">Long Term Investment under Equity Method [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_LongTermInvestmentUnderEquityMethodMember" xml:lang="en-US">Long Term Investment under Equity Method [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LongTermInvestmentUnderEquityMethodMember" xlink:to="lab_imab_LongTermInvestmentUnderEquityMethodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LongTermInvestmentUnderEquityMethodMember" xml:lang="en-US">Long Term Investment under Equity Method [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected terms (Year)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Contractual term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Estimated volatility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Spot Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice" xml:lang="en-US">Spot price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice" xlink:to="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Spot Price.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Striggering Event For Redemption Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate" xml:lang="en-US">Probability of triggering event for redemption option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate" xlink:to="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Striggering Event For Redemption Rate.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xml:lang="en-US">Schedule of Equity Method Investments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ImabHangzhouMember" xlink:label="loc_imab_ImabHangzhouMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ImabHangzhouMember" xml:lang="en-US">Imab Hangzhou [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ImabHangzhouMember" xml:lang="en-US">I-Mab Hangzhou [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ImabHangzhouMember" xlink:to="lab_imab_ImabHangzhouMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ImabHongKongMember" xlink:label="loc_imab_ImabHongKongMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ImabHongKongMember" xml:lang="en-US">Imab Hong Kong [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ImabHongKongMember" xml:lang="en-US">Imab Hong Kong [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ImabHongKongMember" xlink:to="lab_imab_ImabHongKongMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ManagementHoldcoMember" xlink:label="loc_imab_ManagementHoldcoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ManagementHoldcoMember" xml:lang="en-US">Management Holdco [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ManagementHoldcoMember" xlink:to="lab_imab_ManagementHoldcoMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EsopHoldcoMember" xlink:label="loc_imab_EsopHoldcoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_EsopHoldcoMember" xml:lang="en-US">Esop Holdco [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_EsopHoldcoMember" xlink:to="lab_imab_EsopHoldcoMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DomesticInvestorsMember" xlink:label="loc_imab_DomesticInvestorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_DomesticInvestorsMember" xml:lang="en-US">Domestic Investors [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_DomesticInvestorsMember" xlink:to="lab_imab_DomesticInvestorsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xml:lang="en-US">Equity method investment fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xml:lang="en-US">Disposal of an equity method investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xml:lang="en-US">Gains on deconsolidation of a subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xml:lang="en-US">Equity Method Investment, Amount Sold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xml:lang="en-US">Equity method investment, Amount sold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_RegisteredCapitalOfSubsidiary" xlink:label="loc_imab_RegisteredCapitalOfSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_RegisteredCapitalOfSubsidiary" xml:lang="en-US">Registered Capital Of Subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_RegisteredCapitalOfSubsidiary" xml:lang="en-US">Registered capital of subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_RegisteredCapitalOfSubsidiary" xlink:to="lab_imab_RegisteredCapitalOfSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_RegisteredCapitalOfSubsidiary" xml:lang="en-US">Registered capital of subsidiary.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Assets Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized" xml:lang="en-US">Assets recognized value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xml:lang="en-US">Proceeds from Contributions from Affiliates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xml:lang="en-US">Proceeds from contributions from affiliates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="lab_us-gaap_ProceedsFromContributionsFromAffiliates" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments" xlink:label="loc_us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments" xml:lang="en-US">Business Acquisitions, Purchase Price Allocation, Subsequent Years, Remaining Adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments" xml:lang="en-US">Purchase price committed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments" xlink:to="lab_us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xml:lang="en-US">Employee Benefits and Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xml:lang="en-US">Employee benefit and share based compensation recognized in comprehensive income of entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciEquityMethodInvestmentAfterTax" xlink:label="loc_us-gaap_OciEquityMethodInvestmentAfterTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OciEquityMethodInvestmentAfterTax" xml:lang="en-US">OCI, Equity Method Investment, after Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OciEquityMethodInvestmentAfterTax" xml:lang="en-US">OCI, equity method Investment, after tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciEquityMethodInvestmentAfterTax" xlink:to="lab_us-gaap_OciEquityMethodInvestmentAfterTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesSubscribedButUnissued" xml:lang="en-US">Common Stock, Shares Subscribed but Unissued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesSubscribedButUnissued" xml:lang="en-US">Shares subscribed,not yet been purchased or issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="lab_us-gaap_CommonStockSharesSubscribedButUnissued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipAxis" xml:lang="en-US">Ownership [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipDomain" xml:lang="en-US">Ownership [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_HoldcoMember" xlink:label="loc_imab_HoldcoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_HoldcoMember" xml:lang="en-US">HoldCo [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_HoldcoMember" xlink:to="lab_imab_HoldcoMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLender" xlink:label="loc_us-gaap_ShortTermDebtLender" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtLender" xml:lang="en-US">Short-term Debt, Lender</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtLender" xml:lang="en-US">Lender name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLender" xlink:to="lab_us-gaap_ShortTermDebtLender" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt Instrument, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Loan Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Maturity period of debt instrument</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Interest Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="loc_us-gaap_DebtInstrumentCollateralAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCollateralAmount" xml:lang="en-US">Debt Instrument, Collateral Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentCollateralAmount" xml:lang="en-US">Collateral Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCollateralAmount" xlink:to="lab_us-gaap_DebtInstrumentCollateralAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" xlink:label="loc_us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" xml:lang="en-US">Percentage of Interest-bearing Domestic Deposits to Deposits, Time Deposits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" xml:lang="en-US">Percentage of interest bearing on deposit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" xlink:to="lab_us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Debt Instrument, Maturity Date, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Debt instrument, maturity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateDescription" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xml:lang="en-US">Lender Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ChinaMerchantBankCoLtdMember" xlink:label="loc_imab_ChinaMerchantBankCoLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ChinaMerchantBankCoLtdMember" xml:lang="en-US">China Merchant Bank Co Ltd [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ChinaMerchantBankCoLtdMember" xml:lang="en-US">China Merchant Bank Co., Ltd [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ChinaMerchantBankCoLtdMember" xlink:to="lab_imab_ChinaMerchantBankCoLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ChinaMerchantBankCoLtdMember" xml:lang="en-US">China Merchant Bank Co., Ltd [Member].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LoanOneMember" xlink:label="loc_imab_LoanOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LoanOneMember" xml:lang="en-US">Loan One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_LoanOneMember" xml:lang="en-US">Loan One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LoanOneMember" xlink:to="lab_imab_LoanOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LoanOneMember" xml:lang="en-US">Loan One [Member].</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LoanTwoMember" xlink:label="loc_imab_LoanTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LoanTwoMember" xml:lang="en-US">Loan Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_LoanTwoMember" xml:lang="en-US">Loan Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LoanTwoMember" xlink:to="lab_imab_LoanTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LoanTwoMember" xml:lang="en-US">Loan Two [Member].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Noncurrent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xml:lang="en-US">Non-current:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_NonRefundableIncentivePaymentFromDepositaryBankNoncurrent" xlink:label="loc_imab_NonRefundableIncentivePaymentFromDepositaryBankNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_NonRefundableIncentivePaymentFromDepositaryBankNoncurrent" xml:lang="en-US">Non Refundable Incentive Payment From Depositary Bank Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_NonRefundableIncentivePaymentFromDepositaryBankNoncurrent" xml:lang="en-US">Non-refundable incentive payment from depositary bank</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_NonRefundableIncentivePaymentFromDepositaryBankNoncurrent" xlink:to="lab_imab_NonRefundableIncentivePaymentFromDepositaryBankNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_NonRefundableIncentivePaymentFromDepositaryBankNoncurrent" xml:lang="en-US">Non refundable incentive payment from depositary bank, noncurrent.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AdvanceReceivedFromEmployeeForExerciseOfStockOptions" xlink:label="loc_imab_AdvanceReceivedFromEmployeeForExerciseOfStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_AdvanceReceivedFromEmployeeForExerciseOfStockOptions" xml:lang="en-US">Advance Received From Employee For Exercise Of Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_AdvanceReceivedFromEmployeeForExerciseOfStockOptions" xml:lang="en-US">Advance payment received from an employee for exercise of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_AdvanceReceivedFromEmployeeForExerciseOfStockOptions" xlink:to="lab_imab_AdvanceReceivedFromEmployeeForExerciseOfStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_AdvanceReceivedFromEmployeeForExerciseOfStockOptions" xml:lang="en-US">Advanced received from employee for exercise of stock options.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Non-current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xml:lang="en-US">Current:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccruedTravellingExpensesOfficeExpensesAndOthers" xlink:label="loc_imab_AccruedTravellingExpensesOfficeExpensesAndOthers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_AccruedTravellingExpensesOfficeExpensesAndOthers" xml:lang="en-US">Accrued Travelling Expenses Office Expenses And Others</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_AccruedTravellingExpensesOfficeExpensesAndOthers" xml:lang="en-US">Accrued traveling expenses, office expenses and others</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_AccruedTravellingExpensesOfficeExpensesAndOthers" xlink:to="lab_imab_AccruedTravellingExpensesOfficeExpensesAndOthers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_AccruedTravellingExpensesOfficeExpensesAndOthers" xml:lang="en-US">Accrued Travelling Expenses Office Expenses And Others.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WithholdingIitPayable" xlink:label="loc_imab_WithholdingIitPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_WithholdingIitPayable" xml:lang="en-US">Withholding IIT payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_WithholdingIitPayable" xml:lang="en-US">Withholding IIT payable related to stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_WithholdingIitPayable" xlink:to="lab_imab_WithholdingIitPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_WithholdingIitPayable" xml:lang="en-US">Withholding IIT payable.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccruedInitialPublicOfferingCostsPayable" xlink:label="loc_imab_AccruedInitialPublicOfferingCostsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_AccruedInitialPublicOfferingCostsPayable" xml:lang="en-US">Accrued Initial Public Offering Costs Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_AccruedInitialPublicOfferingCostsPayable" xml:lang="en-US">Accrued initial public offering costs payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_AccruedInitialPublicOfferingCostsPayable" xlink:to="lab_imab_AccruedInitialPublicOfferingCostsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_AccruedInitialPublicOfferingCostsPayable" xml:lang="en-US">Accrued initial public offering costs payable.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent" xlink:label="loc_imab_AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent" xml:lang="en-US">Accrued External Research And Development Activities Related Expenses Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent" xml:lang="en-US">Accrued external research and development activities related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent" xlink:to="lab_imab_AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent" xml:lang="en-US">Accrued external research and development activities related expenses.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Staff salaries and welfare payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PrivatePlacementOfferingCostsPayable" xlink:label="loc_imab_PrivatePlacementOfferingCostsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PrivatePlacementOfferingCostsPayable" xml:lang="en-US">Private Placement Offering Costs Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_PrivatePlacementOfferingCostsPayable" xml:lang="en-US">Accrued private placement offering costs payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PrivatePlacementOfferingCostsPayable" xlink:to="lab_imab_PrivatePlacementOfferingCostsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_PrivatePlacementOfferingCostsPayable" xml:lang="en-US">Private Placement offering costs payable.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_NonRefundableIncentivePaymentFromDepositaryBankCurrent" xlink:label="loc_imab_NonRefundableIncentivePaymentFromDepositaryBankCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_NonRefundableIncentivePaymentFromDepositaryBankCurrent" xml:lang="en-US">Non Refundable Incentive Payment From Depositary Bank Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_NonRefundableIncentivePaymentFromDepositaryBankCurrent" xml:lang="en-US">Non-refundable incentive payment from depositary bank</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_NonRefundableIncentivePaymentFromDepositaryBankCurrent" xlink:to="lab_imab_NonRefundableIncentivePaymentFromDepositaryBankCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_NonRefundableIncentivePaymentFromDepositaryBankCurrent" xml:lang="en-US">Non refundable incentive payment from depositary bank current.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ProceedsFromNonRefundableIncentive" xlink:label="loc_imab_ProceedsFromNonRefundableIncentive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ProceedsFromNonRefundableIncentive" xml:lang="en-US">Proceeds From Non Refundable Incentive</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ProceedsFromNonRefundableIncentive" xml:lang="en-US">Proceeds from non-refundable incentive</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ProceedsFromNonRefundableIncentive" xlink:to="lab_imab_ProceedsFromNonRefundableIncentive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ProceedsFromNonRefundableIncentive" xml:lang="en-US">Proceeds from non-refundable incentive.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncome" xml:lang="en-US">Other Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherIncome" xml:lang="en-US">Other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome" xlink:to="lab_us-gaap_OtherIncome" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IMobOtherSubsidiariesMember" xlink:label="loc_imab_IMobOtherSubsidiariesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_IMobOtherSubsidiariesMember" xml:lang="en-US">I MOB Other Subsidiaries [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_IMobOtherSubsidiariesMember" xml:lang="en-US">I MOB other subsidiaries [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_IMobOtherSubsidiariesMember" xlink:to="lab_imab_IMobOtherSubsidiariesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_IMobOtherSubsidiariesMember" xml:lang="en-US">I MOB Other Subsidiaries.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Applicable tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Applicable state tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EffectivePreferentialIncomeTaxRate" xlink:label="loc_imab_EffectivePreferentialIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_EffectivePreferentialIncomeTaxRate" xml:lang="en-US">Effective Preferential Income Tax Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_EffectivePreferentialIncomeTaxRate" xml:lang="en-US">Preferential income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_EffectivePreferentialIncomeTaxRate" xlink:to="lab_imab_EffectivePreferentialIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_EffectivePreferentialIncomeTaxRate" xml:lang="en-US">Effective preferential income tax rate.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WithholdingTax" xlink:label="loc_imab_WithholdingTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_WithholdingTax" xml:lang="en-US">Withholding Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_WithholdingTax" xml:lang="en-US">Withholding Tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_WithholdingTax" xlink:to="lab_imab_WithholdingTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_WithholdingTax" xml:lang="en-US">Withholding Tax.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CNMember" xlink:label="loc_imab_CNMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_CNMember" xml:lang="en-US">C N [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_CNMember" xml:lang="en-US">CN [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_CNMember" xlink:to="lab_imab_CNMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_CNMember" xml:lang="en-US">CN Member</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PRCMember" xlink:label="loc_imab_PRCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PRCMember" xml:lang="en-US">PRC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_PRCMember" xml:lang="en-US">PRC [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PRCMember" xlink:to="lab_imab_PRCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_PRCMember" xml:lang="en-US">PRC.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_HK" xlink:label="loc_country_HK" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_HK" xml:lang="en-US">HONG KONG</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_HK" xlink:to="lab_country_HK" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_AU" xlink:label="loc_country_AU" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_AU" xml:lang="en-US">AUSTRALIA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AU" xlink:to="lab_country_AU" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Income tax computed at respective applicable tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xml:lang="en-US">Non-deductible expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount" xlink:label="loc_imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount" xml:lang="en-US">Effective Income Tax Rate Reconciliation deductible Expense Research and Development Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount" xml:lang="en-US">Research and development expenses plus deduction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount" xlink:to="lab_imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount" xml:lang="en-US">Effective income tax rate reconciliation, deductible expense, research and development, amount.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Changes in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:label="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xml:lang="en-US">Income Tax Holiday, Income Tax Benefits Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xml:lang="en-US">Effect of tax holidays entitled by the PRC subsidiaries on basic income (loss) per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:to="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US">Depreciation and amortization of property, equipment, software and intangible asset, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xml:lang="en-US">Accrual expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Less: valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Balance as of January&#160;1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Balance as of December&#160;31</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Total deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xml:lang="en-US">Acquired intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Total deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredTaxAssetsContractAssets" xlink:label="loc_imab_DeferredTaxAssetsContractAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_DeferredTaxAssetsContractAssets" xml:lang="en-US">Deferred Tax Assets Contract Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_imab_DeferredTaxAssetsContractAssets" xml:lang="en-US">Contract assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_DeferredTaxAssetsContractAssets" xlink:to="lab_imab_DeferredTaxAssetsContractAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_DeferredTaxAssetsContractAssets" xml:lang="en-US">Deferred tax assets contract assets.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred tax assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredTaxesAdditionsValuationAllowance" xlink:label="loc_imab_DeferredTaxesAdditionsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_DeferredTaxesAdditionsValuationAllowance" xml:lang="en-US">Deferred Taxes Additions Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_DeferredTaxesAdditionsValuationAllowance" xml:lang="en-US">Additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_DeferredTaxesAdditionsValuationAllowance" xlink:to="lab_imab_DeferredTaxesAdditionsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_DeferredTaxesAdditionsValuationAllowance" xml:lang="en-US">Deferred Taxes Additions Valuation Allowance.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance" xlink:label="loc_imab_DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance" xml:lang="en-US">Deferred Taxes Decrease Due to Change of Tax Rate Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance" xml:lang="en-US">Decrease due to the change of tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance" xlink:to="lab_imab_DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance" xml:lang="en-US">Deferred Taxes Decrease Due to Change of Tax Rate Valuation Allowance.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredTaxAssetsValuationAllowanceUtilizationAndReversal" xlink:label="loc_imab_DeferredTaxAssetsValuationAllowanceUtilizationAndReversal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_DeferredTaxAssetsValuationAllowanceUtilizationAndReversal" xml:lang="en-US">Deferred Tax Assets Valuation Allowance Utilization and Reversal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_DeferredTaxAssetsValuationAllowanceUtilizationAndReversal" xml:lang="en-US">Utilization and reversal of valuation allowances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_DeferredTaxAssetsValuationAllowanceUtilizationAndReversal" xlink:to="lab_imab_DeferredTaxAssetsValuationAllowanceUtilizationAndReversal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_DeferredTaxAssetsValuationAllowanceUtilizationAndReversal" xml:lang="en-US">Deferred tax assets valuation allowance utilization and reversal.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesAConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesAConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriesAConvertiblePreferredStockMember" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeriesAConvertiblePreferredStockMember" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriesAConvertiblePreferredStockMember" xlink:to="lab_imab_SeriesAConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ConvertiblePreferredStockSeriesBMember" xml:lang="en-US">Convertible Preferred Stock Series B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ConvertiblePreferredStockSeriesBMember" xml:lang="en-US">Convertible Preferred Stock Series B [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ConvertiblePreferredStockSeriesBMember" xlink:to="lab_imab_ConvertiblePreferredStockSeriesBMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBOneUponConversionMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBOneUponConversionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ConvertiblePreferredStockSeriesBOneUponConversionMember" xml:lang="en-US">Convertible Preferred Stock Series B One Upon Conversion [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ConvertiblePreferredStockSeriesBOneUponConversionMember" xml:lang="en-US">Convertible Preferred Stock Series B-1 Upon Conversion [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ConvertiblePreferredStockSeriesBOneUponConversionMember" xlink:to="lab_imab_ConvertiblePreferredStockSeriesBOneUponConversionMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesB2Member" xlink:label="loc_imab_ConvertiblePreferredStockSeriesB2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ConvertiblePreferredStockSeriesB2Member" xml:lang="en-US">Convertible Preferred Stock Series B2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ConvertiblePreferredStockSeriesB2Member" xml:lang="en-US">Convertible Preferred Stock Series B-2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ConvertiblePreferredStockSeriesB2Member" xlink:to="lab_imab_ConvertiblePreferredStockSeriesB2Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesCOneConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesCOneConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriesCOneConvertiblePreferredStockMember" xml:lang="en-US">Series C One Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeriesCOneConvertiblePreferredStockMember" xml:lang="en-US">Series C-1 Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriesCOneConvertiblePreferredStockMember" xlink:to="lab_imab_SeriesCOneConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common Stock, Voting Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockVotingRights" xml:lang="en-US">Voting rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockVotingRights" xlink:to="lab_us-gaap_CommonStockVotingRights" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CommonStockValueAuthorized" xlink:label="loc_imab_CommonStockValueAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_CommonStockValueAuthorized" xml:lang="en-US">Common Stock Value Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_CommonStockValueAuthorized" xml:lang="en-US">Common stock value authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_CommonStockValueAuthorized" xlink:to="lab_imab_CommonStockValueAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_CommonStockValueAuthorized" xml:lang="en-US">Common stock value authorized.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Proceeds from initial public offering, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Shares Issued Upon Conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Opening Balance, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Closing Balance, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Number of preferred shares converted to common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AmericanDepositorySharesCommonShareEquivalent" xlink:label="loc_imab_AmericanDepositorySharesCommonShareEquivalent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_AmericanDepositorySharesCommonShareEquivalent" xml:lang="en-US">American Depository Shares Common Share Equivalent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_AmericanDepositorySharesCommonShareEquivalent" xml:lang="en-US">American depository shares, common share equivalent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_AmericanDepositorySharesCommonShareEquivalent" xlink:to="lab_imab_AmericanDepositorySharesCommonShareEquivalent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_AmericanDepositorySharesCommonShareEquivalent" xml:lang="en-US">American depository shares common share equivalent.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xml:lang="en-US">Amount of stock repurchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PrepaidExpenseStockRepurchaseProgram" xlink:label="loc_imab_PrepaidExpenseStockRepurchaseProgram" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PrepaidExpenseStockRepurchaseProgram" xml:lang="en-US">Prepaid Expense Stock Repurchase Program</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_PrepaidExpenseStockRepurchaseProgram" xml:lang="en-US">Prepaid Expensestock repurchase program</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PrepaidExpenseStockRepurchaseProgram" xlink:to="lab_imab_PrepaidExpenseStockRepurchaseProgram" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_PrepaidExpenseStockRepurchaseProgram" xml:lang="en-US">Prepaid expense stock repurchase program.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from issuance of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Number of warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Warrants issued and exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_GrossProceedsOfSharesAndWarrants" xlink:label="loc_imab_GrossProceedsOfSharesAndWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_GrossProceedsOfSharesAndWarrants" xml:lang="en-US">Gross Proceeds Of Shares And Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_GrossProceedsOfSharesAndWarrants" xml:lang="en-US">Gross proceeds of shares and warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_GrossProceedsOfSharesAndWarrants" xlink:to="lab_imab_GrossProceedsOfSharesAndWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_GrossProceedsOfSharesAndWarrants" xml:lang="en-US">Gross proceeds of shares and warrants.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" xlink:label="loc_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" xml:lang="en-US">Shares Held in Employee Stock Option Plan, Allocated</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" xml:lang="en-US">Shares Held in Employee Stock Option Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" xlink:to="lab_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_DirectorMember" xml:lang="en-US">Director [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_DirectorMember" xml:lang="en-US">Director[Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_BoardOfDirectorsMember" xlink:label="loc_imab_BoardOfDirectorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_BoardOfDirectorsMember" xml:lang="en-US">Board Of Directors [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_BoardOfDirectorsMember" xlink:to="lab_imab_BoardOfDirectorsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CollaborationAgreementWithEverestMember" xlink:label="loc_imab_CollaborationAgreementWithEverestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_CollaborationAgreementWithEverestMember" xml:lang="en-US">Collaboration Agreement with Everest [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_CollaborationAgreementWithEverestMember" xlink:to="lab_imab_CollaborationAgreementWithEverestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_CollaborationAgreementWithEverestMember" xml:lang="en-US">Collaboration Agreement with Everest.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_HillhouseEntitiesMember" xlink:label="loc_imab_HillhouseEntitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_HillhouseEntitiesMember" xml:lang="en-US">Hillhouse Entities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_HillhouseEntitiesMember" xlink:to="lab_imab_HillhouseEntitiesMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CollaborationAgreementWithInvestorsMember" xlink:label="loc_imab_CollaborationAgreementWithInvestorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_CollaborationAgreementWithInvestorsMember" xml:lang="en-US">Collaboration agreement with investors [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_CollaborationAgreementWithInvestorsMember" xlink:to="lab_imab_CollaborationAgreementWithInvestorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_CollaborationAgreementWithInvestorsMember" xml:lang="en-US">Collaboration agreement with investors.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EverestsMember" xlink:label="loc_imab_EverestsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_EverestsMember" xml:lang="en-US">Everests [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_EverestsMember" xlink:to="lab_imab_EverestsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_InvestorWarrantsMember" xlink:label="loc_imab_InvestorWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_InvestorWarrantsMember" xml:lang="en-US">Investor Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_InvestorWarrantsMember" xml:lang="en-US">Investor Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_InvestorWarrantsMember" xlink:to="lab_imab_InvestorWarrantsMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PeriodTypeAxis" xlink:label="loc_imab_PeriodTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PeriodTypeAxis" xml:lang="en-US">Period Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PeriodTypeAxis" xlink:to="lab_imab_PeriodTypeAxis" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PeriodTypeDomain" xlink:label="loc_imab_PeriodTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PeriodTypeDomain" xml:lang="en-US">Period Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PeriodTypeDomain" xlink:to="lab_imab_PeriodTypeDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FirstClosingPeriodMember" xlink:label="loc_imab_FirstClosingPeriodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_FirstClosingPeriodMember" xml:lang="en-US">First Closing Period [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_FirstClosingPeriodMember" xlink:to="lab_imab_FirstClosingPeriodMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SecondClosingPeriodMember" xlink:label="loc_imab_SecondClosingPeriodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SecondClosingPeriodMember" xml:lang="en-US">Second Closing Period [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SecondClosingPeriodMember" xml:lang="en-US">Second Closing Period [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SecondClosingPeriodMember" xlink:to="lab_imab_SecondClosingPeriodMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xml:lang="en-US">Temporary Equity [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IssueOfWarrants" xlink:label="loc_imab_IssueOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_IssueOfWarrants" xml:lang="en-US">Issue Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_IssueOfWarrants" xml:lang="en-US">Issuance of Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_IssueOfWarrants" xlink:to="lab_imab_IssueOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_IssueOfWarrants" xml:lang="en-US">Issue of warrants.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Consideration in issuance Preference Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Issuance of Preference Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockShareSubscriptions" xlink:label="loc_us-gaap_PreferredStockShareSubscriptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockShareSubscriptions" xml:lang="en-US">Preferred Stock, Shares Subscribed but Unissued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockShareSubscriptions" xml:lang="en-US">Subscription of Preferred shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockShareSubscriptions" xlink:to="lab_us-gaap_PreferredStockShareSubscriptions" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesSubscribedButUnissuedValue" xlink:label="loc_us-gaap_PreferredStockSharesSubscribedButUnissuedValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesSubscribedButUnissuedValue" xml:lang="en-US">Preferred Stock, Value, Subscriptions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesSubscribedButUnissuedValue" xml:lang="en-US">Aggregate Purchase Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesSubscribedButUnissuedValue" xlink:to="lab_us-gaap_PreferredStockSharesSubscribedButUnissuedValue" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_QualifiedPublicOfferingPrice" xlink:label="loc_imab_QualifiedPublicOfferingPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_QualifiedPublicOfferingPrice" xml:lang="en-US">Qualified Public Offering Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_QualifiedPublicOfferingPrice" xml:lang="en-US">Final Offering Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_QualifiedPublicOfferingPrice" xlink:to="lab_imab_QualifiedPublicOfferingPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_QualifiedPublicOfferingPrice" xml:lang="en-US">Qualified public offering price.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OfferingPriceOfConvertedShares" xlink:label="loc_imab_OfferingPriceOfConvertedShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_OfferingPriceOfConvertedShares" xml:lang="en-US">Offering Price Of Converted Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_OfferingPriceOfConvertedShares" xml:lang="en-US">Offering Price of converted shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_OfferingPriceOfConvertedShares" xlink:to="lab_imab_OfferingPriceOfConvertedShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_OfferingPriceOfConvertedShares" xml:lang="en-US">Offering Price of converted shares.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockLiquidationPreferencePercentage" xlink:label="loc_imab_PreferredStockLiquidationPreferencePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PreferredStockLiquidationPreferencePercentage" xml:lang="en-US">Preferred Stock Liquidation Preference Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_PreferredStockLiquidationPreferencePercentage" xml:lang="en-US">Preferred Stock Liquidation Preference Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PreferredStockLiquidationPreferencePercentage" xlink:to="lab_imab_PreferredStockLiquidationPreferencePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_PreferredStockLiquidationPreferencePercentage" xml:lang="en-US">Preferred stock liquidation preference percentage.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockLiquidationPreferenceRateOfReturn" xlink:label="loc_imab_PreferredStockLiquidationPreferenceRateOfReturn" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PreferredStockLiquidationPreferenceRateOfReturn" xml:lang="en-US">Preferred Stock Liquidation Preference Rate Of Return</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_PreferredStockLiquidationPreferenceRateOfReturn" xml:lang="en-US">Internal Rate of Return</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PreferredStockLiquidationPreferenceRateOfReturn" xlink:to="lab_imab_PreferredStockLiquidationPreferenceRateOfReturn" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_PreferredStockLiquidationPreferenceRateOfReturn" xml:lang="en-US">Internal rate of return.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityFairValueAdjustment" xlink:label="loc_us-gaap_EquityFairValueAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xml:lang="en-US">Equity, Fair Value Adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xml:lang="en-US">Increase in the fair value of ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueAdjustment" xlink:to="lab_us-gaap_EquityFairValueAdjustment" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AdjustmentsAtExtinguishmentOfPreferredShares" xlink:label="loc_imab_AdjustmentsAtExtinguishmentOfPreferredShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_AdjustmentsAtExtinguishmentOfPreferredShares" xml:lang="en-US">Adjustments At Extinguishment Of Preferred Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_AdjustmentsAtExtinguishmentOfPreferredShares" xml:lang="en-US">Adjustment at extinguishment of Series&#160;C-1&#160;Preferred Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_AdjustmentsAtExtinguishmentOfPreferredShares" xlink:to="lab_imab_AdjustmentsAtExtinguishmentOfPreferredShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_AdjustmentsAtExtinguishmentOfPreferredShares" xml:lang="en-US">Adjustments at extinguishment of preferred shares.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesA3Member" xlink:label="loc_imab_ConvertiblePreferredStockSeriesA3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ConvertiblePreferredStockSeriesA3Member" xml:lang="en-US">Convertible Preferred Stock Series A3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ConvertiblePreferredStockSeriesA3Member" xml:lang="en-US">Convertible Preferred Stock Series A3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ConvertiblePreferredStockSeriesA3Member" xlink:to="lab_imab_ConvertiblePreferredStockSeriesA3Member" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesA3PreferredStockMember" xlink:label="loc_imab_SeriesA3PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriesA3PreferredStockMember" xml:lang="en-US">Series A3 Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeriesA3PreferredStockMember" xml:lang="en-US">Series A3 Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriesA3PreferredStockMember" xlink:to="lab_imab_SeriesA3PreferredStockMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesAThreeUponExerciseMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesAThreeUponExerciseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ConvertiblePreferredStockSeriesAThreeUponExerciseMember" xml:lang="en-US">Convertible Preferred Stock Series A Three Upon Exercise [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ConvertiblePreferredStockSeriesAThreeUponExerciseMember" xml:lang="en-US">Convertible Preferred Stock Series A Three Upon Exercise [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ConvertiblePreferredStockSeriesAThreeUponExerciseMember" xlink:to="lab_imab_ConvertiblePreferredStockSeriesAThreeUponExerciseMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBTwoUponExerciseMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBTwoUponExerciseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ConvertiblePreferredStockSeriesBTwoUponExerciseMember" xml:lang="en-US">Convertible Preferred Stock Series B Two Upon Exercise [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ConvertiblePreferredStockSeriesBTwoUponExerciseMember" xml:lang="en-US">Convertible Preferred Stock Series B Two Upon Exercise [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ConvertiblePreferredStockSeriesBTwoUponExerciseMember" xlink:to="lab_imab_ConvertiblePreferredStockSeriesBTwoUponExerciseMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBUponExerciseMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBUponExerciseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ConvertiblePreferredStockSeriesBUponExerciseMember" xml:lang="en-US">Convertible Preferred Stock Series B Upon Exercise [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ConvertiblePreferredStockSeriesBUponExerciseMember" xml:lang="en-US">Convertible Preferred Stock Series B Upon Exercise [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ConvertiblePreferredStockSeriesBUponExerciseMember" xlink:to="lab_imab_ConvertiblePreferredStockSeriesBUponExerciseMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesA1AndA2PreferredStockMember" xlink:label="loc_imab_SeriesA1AndA2PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriesA1AndA2PreferredStockMember" xml:lang="en-US">Series A1 And A2 Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeriesA1AndA2PreferredStockMember" xml:lang="en-US">Series A1 And A2 Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriesA1AndA2PreferredStockMember" xlink:to="lab_imab_SeriesA1AndA2PreferredStockMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesCOnePreferredStockMember" xlink:label="loc_imab_SeriesCOnePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriesCOnePreferredStockMember" xml:lang="en-US">Series C One Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeriesCOnePreferredStockMember" xml:lang="en-US">Series C One Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriesCOnePreferredStockMember" xlink:to="lab_imab_SeriesCOnePreferredStockMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBOneUponExerciseMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBOneUponExerciseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ConvertiblePreferredStockSeriesBOneUponExerciseMember" xml:lang="en-US">Convertible Preferred Stock Series B One Upon Exercise [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ConvertiblePreferredStockSeriesBOneUponExerciseMember" xml:lang="en-US">Convertible Preferred Stock Series B One Upon Exercise [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ConvertiblePreferredStockSeriesBOneUponExerciseMember" xlink:to="lab_imab_ConvertiblePreferredStockSeriesBOneUponExerciseMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TemporaryEquityMember" xlink:label="loc_imab_TemporaryEquityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_TemporaryEquityMember" xml:lang="en-US">Temporary Equity [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_TemporaryEquityMember" xlink:to="lab_imab_TemporaryEquityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_TemporaryEquityMember" xml:lang="en-US">Temporary equity [Member].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriescOneMember" xlink:label="loc_imab_SeriescOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriescOneMember" xml:lang="en-US">SeriesC One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeriescOneMember" xml:lang="en-US">Series C -1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriescOneMember" xlink:to="lab_imab_SeriescOneMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesCConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesCConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriesCConvertiblePreferredStockMember" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeriesCConvertiblePreferredStockMember" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriesCConvertiblePreferredStockMember" xlink:to="lab_imab_SeriesCConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesBConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriesBConvertiblePreferredStockMember" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeriesBConvertiblePreferredStockMember" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriesBConvertiblePreferredStockMember" xlink:to="lab_imab_SeriesBConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xml:lang="en-US">Preferred Stock, Value, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xml:lang="en-US">Opening Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xml:lang="en-US">Closing Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionLineItems" xlink:label="loc_us-gaap_DebtConversionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionLineItems" xml:lang="en-US">Debt Conversion [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionLineItems" xml:lang="en-US">Debt Conversion [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionLineItems" xlink:to="lab_us-gaap_DebtConversionLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaap_NotesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesIssued1" xml:lang="en-US">Notes Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesIssued1" xml:lang="en-US">Convertible promissory notes&#160; issued to Investors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesIssued1" xlink:to="lab_us-gaap_NotesIssued1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss on Extinguishment of Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Convertible notes&#160;issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt instrument, face amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Conversion price of debt instrument</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesB1PreferredSharesMember" xlink:label="loc_imab_SeriesB1PreferredSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriesB1PreferredSharesMember" xml:lang="en-US">Series B1 Preferred Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeriesB1PreferredSharesMember" xml:lang="en-US">Series B-1 Preferred Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriesB1PreferredSharesMember" xlink:to="lab_imab_SeriesB1PreferredSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_SeriesB1PreferredSharesMember" xml:lang="en-US">Series B1 preferred shares</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesA3PreferredSharesMember" xlink:label="loc_imab_SeriesA3PreferredSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriesA3PreferredSharesMember" xml:lang="en-US">Series A 3 Preferred Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeriesA3PreferredSharesMember" xml:lang="en-US">Series A-3 Preferred Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriesA3PreferredSharesMember" xlink:to="lab_imab_SeriesA3PreferredSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_SeriesA3PreferredSharesMember" xml:lang="en-US">Series A 3 preferred shares</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBOnshoreInvestorsMember" xlink:label="loc_imab_SeriesBOnshoreInvestorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriesBOnshoreInvestorsMember" xml:lang="en-US">Series B Onshore Investors [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeriesBOnshoreInvestorsMember" xml:lang="en-US">Series B Onshore Investors [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriesBOnshoreInvestorsMember" xlink:to="lab_imab_SeriesBOnshoreInvestorsMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBPreferredStockHolderMember" xlink:label="loc_imab_SeriesBPreferredStockHolderMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriesBPreferredStockHolderMember" xml:lang="en-US">Series B Preferred Stock Holder [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriesBPreferredStockHolderMember" xlink:to="lab_imab_SeriesBPreferredStockHolderMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OnshoreConvertibleLoanMember" xlink:label="loc_imab_OnshoreConvertibleLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_OnshoreConvertibleLoanMember" xml:lang="en-US">Onshore Convertible Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_OnshoreConvertibleLoanMember" xml:lang="en-US">Onshore Convertible Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_OnshoreConvertibleLoanMember" xlink:to="lab_imab_OnshoreConvertibleLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_OnshoreConvertibleLoanMember" xml:lang="en-US">Onshore Convertible Loan.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwoZeroOneEightNotesMember" xlink:label="loc_imab_TwoZeroOneEightNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_TwoZeroOneEightNotesMember" xml:lang="en-US">Two Zero One Eight Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_TwoZeroOneEightNotesMember" xml:lang="en-US">2018 Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_TwoZeroOneEightNotesMember" xlink:to="lab_imab_TwoZeroOneEightNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_TwoZeroOneEightNotesMember" xml:lang="en-US">2018 Notes.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePromissoryNotes2017Member" xlink:label="loc_imab_ConvertiblePromissoryNotes2017Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ConvertiblePromissoryNotes2017Member" xml:lang="en-US">Convertible Promissory Notes 2017 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ConvertiblePromissoryNotes2017Member" xlink:to="lab_imab_ConvertiblePromissoryNotes2017Member" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePromissoryNotes2018Member" xlink:label="loc_imab_ConvertiblePromissoryNotes2018Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ConvertiblePromissoryNotes2018Member" xml:lang="en-US">Convertible Promissory Notes 2018 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ConvertiblePromissoryNotes2018Member" xlink:to="lab_imab_ConvertiblePromissoryNotes2018Member" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_GenexineIncMember" xlink:label="loc_imab_GenexineIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_GenexineIncMember" xml:lang="en-US">Genexine Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_GenexineIncMember" xml:lang="en-US">Genexine Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_GenexineIncMember" xlink:to="lab_imab_GenexineIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_GenexineIncMember" xml:lang="en-US">Genexine,Inc.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBPreferredShareholdersMember" xlink:label="loc_imab_SeriesBPreferredShareholdersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriesBPreferredShareholdersMember" xml:lang="en-US">Series B Preferred Shareholders [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeriesBPreferredShareholdersMember" xml:lang="en-US">Series B Preferred Shareholders [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriesBPreferredShareholdersMember" xlink:to="lab_imab_SeriesBPreferredShareholdersMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TrancheIOfSeriesBWarrantsMember" xlink:label="loc_imab_TrancheIOfSeriesBWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_TrancheIOfSeriesBWarrantsMember" xml:lang="en-US">Tranche I Of Series B Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_TrancheIOfSeriesBWarrantsMember" xml:lang="en-US">Tranche I Of Series B Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_TrancheIOfSeriesBWarrantsMember" xlink:to="lab_imab_TrancheIOfSeriesBWarrantsMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesB2PreferredSharesMember" xlink:label="loc_imab_SeriesB2PreferredSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriesB2PreferredSharesMember" xml:lang="en-US">Series B2 Preferred Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeriesB2PreferredSharesMember" xml:lang="en-US">Series B2 Preferred Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriesB2PreferredSharesMember" xlink:to="lab_imab_SeriesB2PreferredSharesMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TrancheIiOfSeriesBWarrantsMember" xlink:label="loc_imab_TrancheIiOfSeriesBWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_TrancheIiOfSeriesBWarrantsMember" xml:lang="en-US">Tranche II of Series B Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_TrancheIiOfSeriesBWarrantsMember" xml:lang="en-US">Tranche II of Series B Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_TrancheIiOfSeriesBWarrantsMember" xlink:to="lab_imab_TrancheIiOfSeriesBWarrantsMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBWarrantsSharesMember" xlink:label="loc_imab_SeriesBWarrantsSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeriesBWarrantsSharesMember" xml:lang="en-US">Series B Warrants Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeriesBWarrantsSharesMember" xml:lang="en-US">Series B Warrants Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeriesBWarrantsSharesMember" xlink:to="lab_imab_SeriesBWarrantsSharesMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AmericanDepositarySharesMember" xlink:label="loc_imab_AmericanDepositarySharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_AmericanDepositarySharesMember" xml:lang="en-US">American Depositary Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_AmericanDepositarySharesMember" xlink:to="lab_imab_AmericanDepositarySharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_AmericanDepositarySharesMember" xml:lang="en-US">American depositary shares.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US">Class of Warrant or Right [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WarrantsToPurchaseOrdinarySharesMember" xlink:label="loc_imab_WarrantsToPurchaseOrdinarySharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_WarrantsToPurchaseOrdinarySharesMember" xml:lang="en-US">Warrants To Purchase Ordinary Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_WarrantsToPurchaseOrdinarySharesMember" xml:lang="en-US">Warrants to purchase ordinary shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_WarrantsToPurchaseOrdinarySharesMember" xlink:to="lab_imab_WarrantsToPurchaseOrdinarySharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_WarrantsToPurchaseOrdinarySharesMember" xml:lang="en-US">Warrants To Purchase Ordinary Shares.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Classofwarrantorrightsexercisableterm" xlink:label="loc_imab_Classofwarrantorrightsexercisableterm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_Classofwarrantorrightsexercisableterm" xml:lang="en-US">Class Of Warrant or Rights Exercisable Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_Classofwarrantorrightsexercisableterm" xlink:to="lab_imab_Classofwarrantorrightsexercisableterm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_Classofwarrantorrightsexercisableterm" xml:lang="en-US">ClassOfWarrantOrRightsExercisableTerm</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants and Rights Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember" xml:lang="en-US">Measurement Input, Exercise Price [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember" xml:lang="en-US">Exercise price [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExercisePriceMember" xlink:to="lab_us-gaap_MeasurementInputExercisePriceMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xml:lang="en-US">Estimated volatility rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US">Risk-free rate of return [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputMaturityMember" xlink:label="loc_us-gaap_MeasurementInputMaturityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputMaturityMember" xml:lang="en-US">Measurement Input, Maturity [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputMaturityMember" xml:lang="en-US">Maturity date [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputMaturityMember" xlink:to="lab_us-gaap_MeasurementInputMaturityMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DrzangMember" xlink:label="loc_imab_DrzangMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_DrzangMember" xml:lang="en-US">DrZang [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_DrzangMember" xml:lang="en-US">Dr. Zang [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_DrzangMember" xlink:to="lab_imab_DrzangMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LeiFangMember" xlink:label="loc_imab_LeiFangMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LeiFangMember" xml:lang="en-US">Lei Fang [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_LeiFangMember" xml:lang="en-US">Lei Fang [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LeiFangMember" xlink:to="lab_imab_LeiFangMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FoundersMember" xlink:label="loc_imab_FoundersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_FoundersMember" xml:lang="en-US">Founders [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_FoundersMember" xml:lang="en-US">Founders [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_FoundersMember" xlink:to="lab_imab_FoundersMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeniorManagementEmployeesMember" xlink:label="loc_imab_SeniorManagementEmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SeniorManagementEmployeesMember" xml:lang="en-US">Senior Management Employees [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SeniorManagementEmployeesMember" xml:lang="en-US">Senior Management Employees [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SeniorManagementEmployeesMember" xlink:to="lab_imab_SeniorManagementEmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_SeniorManagementEmployeesMember" xml:lang="en-US">Senior Management Employees [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Tranche One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US">Tranche Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xml:lang="en-US">Tranche Three [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationTrancheFourMember" xlink:label="loc_imab_ShareBasedCompensationTrancheFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ShareBasedCompensationTrancheFourMember" xml:lang="en-US">Share Based Compensation Tranche Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_ShareBasedCompensationTrancheFourMember" xml:lang="en-US">Tranche Four [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ShareBasedCompensationTrancheFourMember" xlink:to="lab_imab_ShareBasedCompensationTrancheFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ShareBasedCompensationTrancheFourMember" xml:lang="en-US">Share based compensation tranche four.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OnePerformanceConditionMember" xlink:label="loc_imab_OnePerformanceConditionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_OnePerformanceConditionMember" xml:lang="en-US">One Performance Condition [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_OnePerformanceConditionMember" xlink:to="lab_imab_OnePerformanceConditionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_OnePerformanceConditionMember" xml:lang="en-US">One performance condition.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwoPerformanceConditionsMember" xlink:label="loc_imab_TwoPerformanceConditionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_TwoPerformanceConditionsMember" xml:lang="en-US">Two Performance Conditions [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_TwoPerformanceConditionsMember" xlink:to="lab_imab_TwoPerformanceConditionsMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ThreePerformanceConditionsMember" xlink:label="loc_imab_ThreePerformanceConditionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ThreePerformanceConditionsMember" xml:lang="en-US">Three Performance Conditions [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ThreePerformanceConditionsMember" xlink:to="lab_imab_ThreePerformanceConditionsMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FourPerformanceConditionsMember" xlink:label="loc_imab_FourPerformanceConditionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_FourPerformanceConditionsMember" xml:lang="en-US">Four Performance Conditions [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_FourPerformanceConditionsMember" xlink:to="lab_imab_FourPerformanceConditionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_FourPerformanceConditionsMember" xml:lang="en-US">Four Performance Conditions.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EquityInLossOfAnAffiliateMember" xlink:label="loc_imab_EquityInLossOfAnAffiliateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_EquityInLossOfAnAffiliateMember" xml:lang="en-US">Equity in Loss of an Affiliate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_EquityInLossOfAnAffiliateMember" xml:lang="en-US">Equity in Loss of an Affiliate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_EquityInLossOfAnAffiliateMember" xlink:to="lab_imab_EquityInLossOfAnAffiliateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_EquityInLossOfAnAffiliateMember" xml:lang="en-US">Equity in loss of an affiliate.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xml:lang="en-US">Equity Interest Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xml:lang="en-US">Equity Interest Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ThirdVentureMember" xlink:label="loc_imab_ThirdVentureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ThirdVentureMember" xml:lang="en-US">Third Venture [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ThirdVentureMember" xml:lang="en-US">Third Venture [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ThirdVentureMember" xlink:to="lab_imab_ThirdVentureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ThirdVentureMember" xml:lang="en-US">Third Venture</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AmendedTwentySeventeenEmployeeStockOptionPlanMember" xlink:label="loc_imab_AmendedTwentySeventeenEmployeeStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_AmendedTwentySeventeenEmployeeStockOptionPlanMember" xml:lang="en-US">Amended Twenty Seventeen Employee Stock Option Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_AmendedTwentySeventeenEmployeeStockOptionPlanMember" xml:lang="en-US">Amended 2017 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_AmendedTwentySeventeenEmployeeStockOptionPlanMember" xlink:to="lab_imab_AmendedTwentySeventeenEmployeeStockOptionPlanMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareIncentivePlan2020Member" xlink:label="loc_imab_ShareIncentivePlan2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ShareIncentivePlan2020Member" xml:lang="en-US">Share Incentive Plan 2020 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ShareIncentivePlan2020Member" xml:lang="en-US">2020 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ShareIncentivePlan2020Member" xlink:to="lab_imab_ShareIncentivePlan2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ShareIncentivePlan2020Member" xml:lang="en-US">ShareIncentivePlan2020Member [Member].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based compensation expenses related to restricted shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xml:lang="en-US">Number of shares cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xml:lang="en-US">Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Number of shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Numbers of shares, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Share based payment award, vesting percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share based payment award, vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share based payment award, maximum shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xml:lang="en-US">Share Options, Vested And Exercisable Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted" xlink:label="loc_imab_ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted" xml:lang="en-US">Share Based Compensation by Share based Payments Award Percentage of Shares Restricted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted" xml:lang="en-US">Ordinary shares held, restriction percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted" xlink:to="lab_imab_ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted" xml:lang="en-US">Share based compensation by share based payments award percentage of shares restricted.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share based payment award, stock options surrendered</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share based payment award, stock options surrendered, exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share based payment award, stock options granted exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Number of shares granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share based payment award, stock options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Options Repurchased</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" xml:lang="en-US">Stock options, repurchased during the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" xml:lang="en-US">Repurchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" xlink:to="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" xml:lang="en-US">Share based compensation arrangement by share based payment award options nonvested options repurchased.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" xlink:label="loc_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Sharebased Compensation Arrangements by Sharebased Payment Award Options Repurchased in Period Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Stock options, repurchased during the period, average price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Repurchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" xlink:to="lab_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Repurchased in Period, Weighted Average Exercise Price.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Options Repurchased Total Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration" xml:lang="en-US">Stock options, repurchased during the period, total consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration" xlink:to="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Non vested Options Repurchased Total Consideration.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Stock options exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Exercisable as of December&#160;31, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xml:lang="en-US">Number of shares unvested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xml:lang="en-US">Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="loc_us-gaap_StockOptionExercisePriceIncrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionExercisePriceIncrease" xml:lang="en-US">Stock Option, Exercise Price, Increase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionExercisePriceIncrease" xlink:to="lab_us-gaap_StockOptionExercisePriceIncrease" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares" xlink:label="loc_imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares" xml:lang="en-US">Number Of Days For Calculating The Weighted Average Market Value Of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares" xml:lang="en-US">Number of days for calculating the weighted average market value of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares" xlink:to="lab_imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares" xml:lang="en-US">Number of days for calculating the weighted average market value of shares.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares" xlink:label="loc_imab_MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares" xml:lang="en-US">Maximum Percentage Reduction In The Weighted Average Market Value Of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares" xml:lang="en-US">Maximum Percentage Reduction In The Weighted Average Market Value Of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares" xlink:to="lab_imab_MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares" xml:lang="en-US">Maximum Percentage Reduction In The Weighted Average Market Value Of Shares.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xml:lang="en-US">Share based comensation equity instruments other than options aggregate fair value vested in period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Share based compensation by share based payment arrangement restricted stock units granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Share based compensation arrangement, shares vested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyNineteenShareIncentivePlanMember" xlink:label="loc_imab_TwentyNineteenShareIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_TwentyNineteenShareIncentivePlanMember" xml:lang="en-US">Twenty Nineteen Share Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_TwentyNineteenShareIncentivePlanMember" xml:lang="en-US">2019 Share Incentive Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_TwentyNineteenShareIncentivePlanMember" xlink:to="lab_imab_TwentyNineteenShareIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_TwentyNineteenShareIncentivePlanMember" xml:lang="en-US">2019 Share Incentive Plan [Member].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PortionOfRestrictedShareUnitsAxis" xlink:label="loc_imab_PortionOfRestrictedShareUnitsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PortionOfRestrictedShareUnitsAxis" xml:lang="en-US">Portion Of Restricted Share Units [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PortionOfRestrictedShareUnitsAxis" xlink:to="lab_imab_PortionOfRestrictedShareUnitsAxis" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PortionOfRestrictedShareUnitsDomain" xlink:label="loc_imab_PortionOfRestrictedShareUnitsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PortionOfRestrictedShareUnitsDomain" xml:lang="en-US">Portion Of Restricted Share Units [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PortionOfRestrictedShareUnitsDomain" xlink:to="lab_imab_PortionOfRestrictedShareUnitsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_PortionOfRestrictedShareUnitsDomain" xml:lang="en-US">Portion of restricted share units.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ThirdOneThirdPortionMember" xlink:label="loc_imab_ThirdOneThirdPortionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ThirdOneThirdPortionMember" xml:lang="en-US">Third One Third Portion [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ThirdOneThirdPortionMember" xlink:to="lab_imab_ThirdOneThirdPortionMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SecondOneThirdPortionMember" xlink:label="loc_imab_SecondOneThirdPortionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SecondOneThirdPortionMember" xml:lang="en-US">Second One Third Portion [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SecondOneThirdPortionMember" xlink:to="lab_imab_SecondOneThirdPortionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_SecondOneThirdPortionMember" xml:lang="en-US">Second One Third Portion.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareIncentivePlanTwoThousandTwentyMember" xlink:label="loc_imab_ShareIncentivePlanTwoThousandTwentyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ShareIncentivePlanTwoThousandTwentyMember" xml:lang="en-US">Share Incentive Plan Two Thousand Twenty [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ShareIncentivePlanTwoThousandTwentyMember" xml:lang="en-US">2020 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ShareIncentivePlanTwoThousandTwentyMember" xlink:to="lab_imab_ShareIncentivePlanTwoThousandTwentyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ShareIncentivePlanTwoThousandTwentyMember" xml:lang="en-US">ShareIncentivePlanTwoThousandTwentyMember</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate intrinsic value, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate intrinsic value, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Numbers of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xml:lang="en-US">Number of shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xml:lang="en-US">Number of shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Surrenders In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod" xml:lang="en-US">Surrendered</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod" xlink:to="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Exercisable as of December&#160;31, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice" xlink:label="loc_imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsSurrendersInPeriodWeightedAverageExercisePrice</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice" xml:lang="en-US">Surrendered</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice" xlink:to="lab_imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsSurrendersInPeriodWeightedAverageExercisePrice</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted average remaining contractual term, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted average remaining contractual term, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate (per annum)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple" xlink:label="loc_imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple" xml:lang="en-US">Sharebased Compensation Arrangement by Sharebased Payment Award Fair Value Assumptions Exercise Multiple</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple" xml:lang="en-US">Exercise multiple</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple" xlink:to="lab_imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, fair value assumptions, exercise multiple.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xml:lang="en-US">Expected volatility, Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US">Expected volatility, Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Risk-free interest rate, Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Risk-free interest rate, Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Multiple Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" xml:lang="en-US">Exercise multiple, Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" xlink:to="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" xml:lang="en-US">Share based compensation arrangement by share based payment award fair value assumptions exercise multiple maximum.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Multiple Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" xml:lang="en-US">Exercise multiple, Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" xlink:to="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" xml:lang="en-US">Share based compensation arrangement by share based payment award fair value assumptions exercise multiple minimum.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xml:lang="en-US">Numbers of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares" xlink:label="loc_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares" xml:lang="en-US">Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares" xml:lang="en-US">Surrendered</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares" xlink:to="lab_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsSurrendedNumberOfShares.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Non Vested Options Exercised Number Of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares" xml:lang="en-US">Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares" xlink:to="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares" xml:lang="en-US">Share based payment award options non vested options exercised.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xml:lang="en-US">Weighted average Grant date fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue" xlink:label="loc_imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue" xml:lang="en-US">ShareBasedCompensationByShareBasedPaymentArrangementNonVestedOptionsExercisesInPeriodWeightedAverageGrantDateFairValue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue" xml:lang="en-US">Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue" xlink:to="lab_imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue" xml:lang="en-US">ShareBasedCompensationByShareBasedPaymentArrangementNonVestedOptionsExercisesInPeriodWeightedAverageGrantDateFairValue</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue" xlink:label="loc_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue" xml:lang="en-US">Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue" xml:lang="en-US">Surrendered</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue" xlink:to="lab_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue" xml:lang="en-US">Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfNonvestedRestrictedStockUnitsActivityTable" xlink:label="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityTable" xml:lang="en-US">Schedule Of Nonvested Restricted Stock Units Activity [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityTable" xlink:to="lab_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityTable" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems" xlink:label="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems" xml:lang="en-US">Schedule Of Nonvested Restricted Stock Units Activity [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems" xlink:to="lab_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Numbers of shares, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable" xlink:label="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable" xml:lang="en-US">Schedule Of Share Based Compensation Restricted Stock Units Award Activity [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable" xlink:to="lab_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems" xlink:label="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems" xml:lang="en-US">Schedule Of Share Based Compensation Restricted Stock Units Award Activity [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems" xlink:to="lab_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xml:lang="en-US">Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Weighted average remaining contractual term, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xml:lang="en-US">Aggregate intrinsic value, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MorphoSysAGMember" xlink:label="loc_imab_MorphoSysAGMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_MorphoSysAGMember" xml:lang="en-US">MorphoSysAG [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_MorphoSysAGMember" xlink:to="lab_imab_MorphoSysAGMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_MorphoSysAGMember" xml:lang="en-US">MorphoSysAG.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MacroGenicsMember" xlink:label="loc_imab_MacroGenicsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_MacroGenicsMember" xml:lang="en-US">Macro Genics [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_MacroGenicsMember" xml:lang="en-US">MacroGenics [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_MacroGenicsMember" xlink:to="lab_imab_MacroGenicsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_MacroGenicsMember" xml:lang="en-US">Macro Genics.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_HealSunMember" xlink:label="loc_imab_HealSunMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_HealSunMember" xml:lang="en-US">Heal Sun [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_HealSunMember" xml:lang="en-US">HealSun [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_HealSunMember" xlink:to="lab_imab_HealSunMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_HealSunMember" xml:lang="en-US">Heal Sun.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EverestMember" xlink:label="loc_imab_EverestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_EverestMember" xml:lang="en-US">Everest [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_EverestMember" xlink:to="lab_imab_EverestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_EverestMember" xml:lang="en-US">Everest.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ABLBioMember" xlink:label="loc_imab_ABLBioMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ABLBioMember" xml:lang="en-US">ABL Bio [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ABLBioMember" xml:lang="en-US">ABL Bio [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ABLBioMember" xlink:to="lab_imab_ABLBioMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AbbVieMember" xlink:label="loc_imab_AbbVieMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_AbbVieMember" xml:lang="en-US">Abb Vie [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_AbbVieMember" xml:lang="en-US">AbbVie [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_AbbVieMember" xlink:to="lab_imab_AbbVieMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_NameOfMajorCustomerDomain" xml:lang="en-US">Customer [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_NameOfMajorCustomerDomain" xml:lang="en-US">Customer [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OtherInLicensingAgreementsMember" xlink:label="loc_imab_OtherInLicensingAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_OtherInLicensingAgreementsMember" xml:lang="en-US">Other In Licensing Agreements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_OtherInLicensingAgreementsMember" xlink:to="lab_imab_OtherInLicensingAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_OtherInLicensingAgreementsMember" xml:lang="en-US">Other In Licensing Agreements.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OutLicensingAgreementsMember" xlink:label="loc_imab_OutLicensingAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_OutLicensingAgreementsMember" xml:lang="en-US">Out Licensing Agreements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_OutLicensingAgreementsMember" xlink:to="lab_imab_OutLicensingAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_OutLicensingAgreementsMember" xml:lang="en-US">Out licensing agreements.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicensingAgreementsMember" xml:lang="en-US">Licensing Agreements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LemzoparlimabLicenseMember" xlink:label="loc_imab_LemzoparlimabLicenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LemzoparlimabLicenseMember" xml:lang="en-US">Lemzoparlimab License [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_LemzoparlimabLicenseMember" xml:lang="en-US">Lemzoparlimab License [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LemzoparlimabLicenseMember" xlink:to="lab_imab_LemzoparlimabLicenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LemzoparlimabLicenseMember" xml:lang="en-US">Lemzoparlimab license.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenseMember" xml:lang="en-US">Operating Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpenseMember" xml:lang="en-US">Operating Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CspcMember" xlink:label="loc_imab_CspcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_CspcMember" xml:lang="en-US">CSPC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_CspcMember" xml:lang="en-US">CSPC [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_CspcMember" xlink:to="lab_imab_CspcMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MorphosysMember" xlink:label="loc_imab_MorphosysMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_MorphosysMember" xml:lang="en-US">MorphoSys [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_MorphosysMember" xlink:to="lab_imab_MorphosysMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_MorphosysMember" xml:lang="en-US">MorphoSys Member.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestoneTypeAxis" xlink:label="loc_imab_MilestoneTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_MilestoneTypeAxis" xml:lang="en-US">Milestone Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_MilestoneTypeAxis" xlink:to="lab_imab_MilestoneTypeAxis" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestoneTypeDomain" xlink:label="loc_imab_MilestoneTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_MilestoneTypeDomain" xml:lang="en-US">Milestone Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_MilestoneTypeDomain" xml:lang="en-US">Milestone Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_MilestoneTypeDomain" xlink:to="lab_imab_MilestoneTypeDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ClinicalMilestonesMember" xlink:label="loc_imab_ClinicalMilestonesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ClinicalMilestonesMember" xml:lang="en-US">Clinical Milestones [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ClinicalMilestonesMember" xml:lang="en-US">Clinical Milestones [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ClinicalMilestonesMember" xlink:to="lab_imab_ClinicalMilestonesMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SalesMilestonesMember" xlink:label="loc_imab_SalesMilestonesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SalesMilestonesMember" xml:lang="en-US">Sales Milestones [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SalesMilestonesMember" xml:lang="en-US">Sales Milestones [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SalesMilestonesMember" xlink:to="lab_imab_SalesMilestonesMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DevelopmentMilestoneMember" xlink:label="loc_imab_DevelopmentMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_DevelopmentMilestoneMember" xml:lang="en-US">Development Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_DevelopmentMilestoneMember" xlink:to="lab_imab_DevelopmentMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_DevelopmentMilestoneMember" xml:lang="en-US">Development Milestone [Member]</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestoneIiiMember" xlink:label="loc_imab_MilestoneIiiMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_MilestoneIiiMember" xml:lang="en-US">Milestone III [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_MilestoneIiiMember" xlink:to="lab_imab_MilestoneIiiMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_MilestoneIiiMember" xml:lang="en-US">Milestone III [Member].</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestoneIvMember" xlink:label="loc_imab_MilestoneIvMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_MilestoneIvMember" xml:lang="en-US">Milestone IV [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_MilestoneIvMember" xml:lang="en-US">Milestone Four [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_MilestoneIvMember" xlink:to="lab_imab_MilestoneIvMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_MilestoneIvMember" xml:lang="en-US">Milestone IV [Member].</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FirstMilestoneMember" xlink:label="loc_imab_FirstMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_FirstMilestoneMember" xml:lang="en-US">First Milestone [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_FirstMilestoneMember" xml:lang="en-US">First Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_FirstMilestoneMember" xlink:to="lab_imab_FirstMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_FirstMilestoneMember" xml:lang="en-US">First milestone.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SecondMilestoneMember" xlink:label="loc_imab_SecondMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_SecondMilestoneMember" xml:lang="en-US">Second Milestone [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_SecondMilestoneMember" xml:lang="en-US">Second Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_SecondMilestoneMember" xlink:to="lab_imab_SecondMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_SecondMilestoneMember" xml:lang="en-US">Second milestone.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithABLBioMember" xlink:label="loc_imab_LicensingAgreementWithABLBioMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LicensingAgreementWithABLBioMember" xml:lang="en-US">Licensing Agreement With ABL Bio [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_LicensingAgreementWithABLBioMember" xml:lang="en-US">Licensing Agreement With ABL Bio [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LicensingAgreementWithABLBioMember" xlink:to="lab_imab_LicensingAgreementWithABLBioMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LicensingAgreementWithABLBioMember" xml:lang="en-US">Licensing Agreement With ABL Bio.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember" xlink:label="loc_imab_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember" xml:lang="en-US">Licensing Agreement With CSPC Pharmaceutical Group Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember" xml:lang="en-US">Licensing Agreement With CSPC Pharmaceutical Group Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember" xlink:to="lab_imab_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember" xml:lang="en-US">Licensing Agreement With CSPC Pharmaceutical Group Limited.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CollaborationAgreementWithABLBioMember" xlink:label="loc_imab_CollaborationAgreementWithABLBioMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_CollaborationAgreementWithABLBioMember" xml:lang="en-US">Collaboration Agreement With ABL Bio [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_CollaborationAgreementWithABLBioMember" xml:lang="en-US">Collaboration Agreement With ABL Bio [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_CollaborationAgreementWithABLBioMember" xlink:to="lab_imab_CollaborationAgreementWithABLBioMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_CollaborationAgreementWithABLBioMember" xml:lang="en-US">Collaboration agreement with ABL Bio.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember" xlink:label="loc_imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember" xml:lang="en-US">Collaboration Agreements With Tracon Pharmaceuticals Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember" xml:lang="en-US">Collaboration Agreements with Tracon Pharmaceuticals Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember" xlink:to="lab_imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OtherinlicensingarrangementsMember" xlink:label="loc_imab_OtherinlicensingarrangementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_OtherinlicensingarrangementsMember" xml:lang="en-US">OtherInLicensingArrangements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_OtherinlicensingarrangementsMember" xml:lang="en-US">Other&#160;In-Licensing&#160;Arrangements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_OtherinlicensingarrangementsMember" xlink:to="lab_imab_OtherinlicensingarrangementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_OtherinlicensingarrangementsMember" xml:lang="en-US">Other&#160;In-Licensing&#160;Arrangements[Member].</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember" xlink:label="loc_imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember" xml:lang="en-US">Licensing Agreement among HDYM IMab and Hangzhou HealSun Biopharm Co Ltd [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember" xml:lang="en-US">Licensing Agreement among HDYM, I-Mab and Hangzhou HealSun Biopharm Co., Ltd [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember" xlink:to="lab_imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember" xml:lang="en-US">Licensing Agreement among HDYM, I-Mab and Hangzhou HealSun Biopharm Co., Ltd [Member]</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember" xlink:label="loc_imab_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember" xml:lang="en-US">Strategic Alliance Agreement with PT Kalbe Genexine Biologics [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember" xlink:to="lab_imab_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementsWithMorphosysMember" xlink:label="loc_imab_LicensingAgreementsWithMorphosysMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LicensingAgreementsWithMorphosysMember" xml:lang="en-US">Licensing Agreements With Morphosys [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LicensingAgreementsWithMorphosysMember" xlink:to="lab_imab_LicensingAgreementsWithMorphosysMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LicensingAgreementsWithMorphosysMember" xml:lang="en-US">Licensing Agreements With Morphosys.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Gxi7Member" xlink:label="loc_imab_Gxi7Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_Gxi7Member" xml:lang="en-US">GXI7 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_Gxi7Member" xlink:to="lab_imab_Gxi7Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_Gxi7Member" xml:lang="en-US">GX-I7.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xml:lang="en-US">Revenue from collaborative arrangement, excluding assessed tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExciseAndSalesTaxes" xlink:label="loc_us-gaap_ExciseAndSalesTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ExciseAndSalesTaxes" xml:lang="en-US">Excise and Sales Taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ExciseAndSalesTaxes" xml:lang="en-US">Excise and Sales Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExciseAndSalesTaxes" xlink:to="lab_us-gaap_ExciseAndSalesTaxes" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_UpfrontLicenseFee" xlink:label="loc_imab_UpfrontLicenseFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_UpfrontLicenseFee" xml:lang="en-US">Upfront License Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_imab_UpfrontLicenseFee" xml:lang="en-US">Upfront License Fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_UpfrontLicenseFee" xlink:to="lab_imab_UpfrontLicenseFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_UpfrontLicenseFee" xml:lang="en-US">Upfront license fee.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestonePayments" xlink:label="loc_imab_MilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_MilestonePayments" xml:lang="en-US">Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_MilestonePayments" xml:lang="en-US">Milestone payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_MilestonePayments" xml:lang="en-US">Milestones</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_MilestonePayments" xlink:to="lab_imab_MilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_MilestonePayments" xml:lang="en-US">Milestone payments.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Contract with Customer, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Advance from customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xml:lang="en-US">Proceeds from License Fees Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xml:lang="en-US">Proceeds from milestone achievement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="lab_us-gaap_ProceedsFromLicenseFeesReceived" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CostSharingRatio" xlink:label="loc_imab_CostSharingRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_CostSharingRatio" xml:lang="en-US">Cost Sharing Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_CostSharingRatio" xml:lang="en-US">Cost sharing ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_CostSharingRatio" xlink:to="lab_imab_CostSharingRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_CostSharingRatio" xml:lang="en-US">Cost sharing ratio.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xml:lang="en-US">Revenue, Performance Obligation, Description of Payment Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xml:lang="en-US">Description of Payment Terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xml:lang="en-US">Sharing the profit and loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestonePaymentsOutstanding" xlink:label="loc_imab_MilestonePaymentsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_MilestonePaymentsOutstanding" xml:lang="en-US">Milestone Payments Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_MilestonePaymentsOutstanding" xml:lang="en-US">Milestone payments due</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_MilestonePaymentsOutstanding" xlink:to="lab_imab_MilestonePaymentsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_MilestonePaymentsOutstanding" xml:lang="en-US">Milestone payments outstanding.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PercentageOfReductionInMilestonePayments" xlink:label="loc_imab_PercentageOfReductionInMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PercentageOfReductionInMilestonePayments" xml:lang="en-US">Percentage Of Reduction In Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_PercentageOfReductionInMilestonePayments" xml:lang="en-US">Reduction in milestone payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PercentageOfReductionInMilestonePayments" xlink:to="lab_imab_PercentageOfReductionInMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_PercentageOfReductionInMilestonePayments" xml:lang="en-US">Percentage Of Reduction In Milestone Payments.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xml:lang="en-US">Long-term Purchase Commitment, Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="lab_us-gaap_LongtermPurchaseCommitmentPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementRightsAndObligations" xlink:label="loc_us-gaap_CollaborativeArrangementRightsAndObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementRightsAndObligations" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CollaborativeArrangementRightsAndObligations" xml:lang="en-US">Licensing&#160;Arrangements, Description of terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementRightsAndObligations" xlink:to="lab_us-gaap_CollaborativeArrangementRightsAndObligations" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CumulativePaidInContributions" xlink:label="loc_imab_CumulativePaidInContributions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_CumulativePaidInContributions" xml:lang="en-US">Cumulative Paid In Contributions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_CumulativePaidInContributions" xlink:to="lab_imab_CumulativePaidInContributions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_CumulativePaidInContributions" xml:lang="en-US">Cumulative paid in contributions.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TimeCostOfForegoingHistoricalContribution" xlink:label="loc_imab_TimeCostOfForegoingHistoricalContribution" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_TimeCostOfForegoingHistoricalContribution" xml:lang="en-US">Time cost of foregoing historical contribution</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_TimeCostOfForegoingHistoricalContribution" xml:lang="en-US">Time cost of foregoing historical contribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_TimeCostOfForegoingHistoricalContribution" xlink:to="lab_imab_TimeCostOfForegoingHistoricalContribution" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_TimeCostOfForegoingHistoricalContribution" xml:lang="en-US">Time cost of foregoing historical contribution.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestonePaymentsIncome" xlink:label="loc_imab_MilestonePaymentsIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_MilestonePaymentsIncome" xml:lang="en-US">Milestone Payments Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_MilestonePaymentsIncome" xml:lang="en-US">Milestone payments income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_MilestonePaymentsIncome" xlink:to="lab_imab_MilestonePaymentsIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_MilestonePaymentsIncome" xml:lang="en-US">Milestone payments income.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredRevenueFromCollaborativeArrangementExcludingVat" xlink:label="loc_imab_DeferredRevenueFromCollaborativeArrangementExcludingVat" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_DeferredRevenueFromCollaborativeArrangementExcludingVat" xml:lang="en-US">Deferred revenue from collaborative arrangement excluding VAT</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_DeferredRevenueFromCollaborativeArrangementExcludingVat" xml:lang="en-US">Deferred revenue from collaborative arrangement excluding VAT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_DeferredRevenueFromCollaborativeArrangementExcludingVat" xlink:to="lab_imab_DeferredRevenueFromCollaborativeArrangementExcludingVat" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_DeferredRevenueFromCollaborativeArrangementExcludingVat" xml:lang="en-US">Deferred Revenue From Collaborative Arrangement Excluding VAT.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_UpfrontAndMilestonePayments" xlink:label="loc_imab_UpfrontAndMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_UpfrontAndMilestonePayments" xml:lang="en-US">Upfront And Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_UpfrontAndMilestonePayments" xml:lang="en-US">Potential value of license agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_UpfrontAndMilestonePayments" xlink:to="lab_imab_UpfrontAndMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_UpfrontAndMilestonePayments" xml:lang="en-US">Upfront and milestone payments.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_RevenueFromContractWithCustomerTimeOfTransferOfLicense" xlink:label="loc_imab_RevenueFromContractWithCustomerTimeOfTransferOfLicense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_RevenueFromContractWithCustomerTimeOfTransferOfLicense" xml:lang="en-US">Revenue from Contract with customer Time of Transfer of License</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_RevenueFromContractWithCustomerTimeOfTransferOfLicense" xml:lang="en-US">Revenue from contract with customer at time of transfer of license</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_RevenueFromContractWithCustomerTimeOfTransferOfLicense" xlink:to="lab_imab_RevenueFromContractWithCustomerTimeOfTransferOfLicense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_RevenueFromContractWithCustomerTimeOfTransferOfLicense" xml:lang="en-US">Revenue from contract with customer at time of transfer of license</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent" xlink:label="loc_imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent" xml:lang="en-US">Contract With Customer Liability Cumulative Cost to cost Input Method Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent" xml:lang="en-US">Cost-to-cost&#160;input method percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent" xlink:to="lab_imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent" xml:lang="en-US">Contract with customer liability cumulative cost to cost input method percent.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax" xlink:label="loc_imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax" xml:lang="en-US">Deferred Liability From Collaborative Arrangement Excluding Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax" xml:lang="en-US">Deferred Liability from Collabarative Arrangement excluding Tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax" xlink:to="lab_imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax" xml:lang="en-US">Deferred liability from collaborative arrangement excluding tax.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xml:lang="en-US">Contract asset with customer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_UpfrontPaymentReceived" xlink:label="loc_imab_UpfrontPaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_UpfrontPaymentReceived" xml:lang="en-US">Upfront Payment Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_UpfrontPaymentReceived" xml:lang="en-US">Upfront payment received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_UpfrontPaymentReceived" xlink:to="lab_imab_UpfrontPaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_UpfrontPaymentReceived" xml:lang="en-US">Upfront payment received.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestonePaymentReceivable" xlink:label="loc_imab_MilestonePaymentReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_MilestonePaymentReceivable" xml:lang="en-US">Milestone Payment Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_MilestonePaymentReceivable" xml:lang="en-US">Milestone Payment Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_MilestonePaymentReceivable" xlink:to="lab_imab_MilestonePaymentReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_MilestonePaymentReceivable" xml:lang="en-US">Milestone Payment Receivable.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredRevenueMember" xlink:label="loc_imab_DeferredRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_DeferredRevenueMember" xml:lang="en-US">Deferred Revenue [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_DeferredRevenueMember" xml:lang="en-US">Deferred Revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_DeferredRevenueMember" xlink:to="lab_imab_DeferredRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_DeferredRevenueMember" xml:lang="en-US">Deferred Revenue [Member].</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TypeOfLicensesAxis" xlink:label="loc_imab_TypeOfLicensesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_TypeOfLicensesAxis" xml:lang="en-US">Type of Licenses [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_TypeOfLicensesAxis" xlink:to="lab_imab_TypeOfLicensesAxis" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TypeOfLicensesDomain" xlink:label="loc_imab_TypeOfLicensesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_TypeOfLicensesDomain" xml:lang="en-US">Type of Licenses [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_TypeOfLicensesDomain" xlink:to="lab_imab_TypeOfLicensesDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Study1Member" xlink:label="loc_imab_Study1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_Study1Member" xml:lang="en-US">Study 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_Study1Member" xlink:to="lab_imab_Study1Member" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Study2Member" xlink:label="loc_imab_Study2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_Study2Member" xml:lang="en-US">Study 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_Study2Member" xlink:to="lab_imab_Study2Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementUpfrontFees" xlink:label="loc_imab_LicensingAgreementUpfrontFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_LicensingAgreementUpfrontFees" xml:lang="en-US">Licensing Agreement Upfront Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_LicensingAgreementUpfrontFees" xml:lang="en-US">Upfront&#160;Fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_LicensingAgreementUpfrontFees" xlink:to="lab_imab_LicensingAgreementUpfrontFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_LicensingAgreementUpfrontFees" xml:lang="en-US">Licensing agreement upfront fees.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Net foreign exchange gains (losses)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CharityCareReimbursementsReceived" xlink:label="loc_us-gaap_CharityCareReimbursementsReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CharityCareReimbursementsReceived" xml:lang="en-US">Charity Care, Reimbursements Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CharityCareReimbursementsReceived" xml:lang="en-US">Subsidy income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CharityCareReimbursementsReceived" xlink:to="lab_us-gaap_CharityCareReimbursementsReceived" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueAdjustmentsOfOtherFinancialAssets" xlink:label="loc_imab_FairValueAdjustmentsOfOtherFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_FairValueAdjustmentsOfOtherFinancialAssets" xml:lang="en-US">Fair Value Adjustments Of Other Financial Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_FairValueAdjustmentsOfOtherFinancialAssets" xml:lang="en-US">Fair value change of other financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_FairValueAdjustmentsOfOtherFinancialAssets" xlink:to="lab_imab_FairValueAdjustmentsOfOtherFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_FairValueAdjustmentsOfOtherFinancialAssets" xml:lang="en-US">Fair Value Adjustments Of Other Financial Assets.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xml:lang="en-US">Gains (Losses) on Restructuring of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xml:lang="en-US">Loss from conversion of 2017 Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="lab_us-gaap_GainsLossesOnRestructuringOfDebt" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OtherIncomeexpense" xlink:label="loc_imab_OtherIncomeexpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_OtherIncomeexpense" xml:lang="en-US">Other Income Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_imab_OtherIncomeexpense" xml:lang="en-US">Others</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_OtherIncomeexpense" xlink:to="lab_imab_OtherIncomeexpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_OtherIncomeexpense" xml:lang="en-US">Other Income (Expense).</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IncentiveIncomeFromDepositoryBank" xlink:label="loc_imab_IncentiveIncomeFromDepositoryBank" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_IncentiveIncomeFromDepositoryBank" xml:lang="en-US">Incentive Income From Depository Bank</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_IncentiveIncomeFromDepositoryBank" xml:lang="en-US">Income of incentive payment from depository bank</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_IncentiveIncomeFromDepositoryBank" xlink:to="lab_imab_IncentiveIncomeFromDepositoryBank" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_IncentiveIncomeFromDepositoryBank" xml:lang="en-US">Incentive income from depository bank.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrantMember" xml:lang="en-US">Grant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Numerator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US">Denominator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xml:lang="en-US">Dilutive effect of convertible preferred shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" xml:lang="en-US">Dilutive effect of ordinary shares to be issued to Everest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xml:lang="en-US">Dilutive effect of convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IncrementalCommonSharesAttributableToRestrictedShareUnits" xlink:label="loc_imab_IncrementalCommonSharesAttributableToRestrictedShareUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_IncrementalCommonSharesAttributableToRestrictedShareUnits" xml:lang="en-US">Incremental Common Shares Attributable To Restricted Share Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_IncrementalCommonSharesAttributableToRestrictedShareUnits" xml:lang="en-US">Dilutive effect of restricted shares units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_IncrementalCommonSharesAttributableToRestrictedShareUnits" xlink:to="lab_imab_IncrementalCommonSharesAttributableToRestrictedShareUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_IncrementalCommonSharesAttributableToRestrictedShareUnits" xml:lang="en-US">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted shares units</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xml:lang="en-US">Dilutive effect of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Potentially dilutive securities that have not been included in calculation of diluted net loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xml:lang="en-US">Defined Contribution Plan, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xml:lang="en-US">Employee benefit expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember" xlink:label="loc_imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember" xml:lang="en-US">Jiangsu Taslydiyi Pharmaceutical Co Ltd [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember" xml:lang="en-US">Jiangsu Taslydiyi Pharmaceutical Co Ltd [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember" xlink:to="lab_imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember" xml:lang="en-US">Jiangsu taslydiyi pharmaceutical co ltd.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaap_OtherReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherReceivables" xml:lang="en-US">Other Receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_OtherReceivables" xml:lang="en-US">Other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivables" xlink:to="lab_us-gaap_OtherReceivables" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ExpensesPaidOnBehalfOfAnAffiliate" xlink:label="loc_imab_ExpensesPaidOnBehalfOfAnAffiliate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ExpensesPaidOnBehalfOfAnAffiliate" xml:lang="en-US">Expenses Paid on Behalf of an Affiliate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ExpensesPaidOnBehalfOfAnAffiliate" xml:lang="en-US">Expenses paid on behalf of an affiliate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ExpensesPaidOnBehalfOfAnAffiliate" xlink:to="lab_imab_ExpensesPaidOnBehalfOfAnAffiliate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ExpensesPaidOnBehalfOfAnAffiliate" xml:lang="en-US">Expenses paid on behalf of an affiliate.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Due to Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Accruals and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CmabBiopharmaSuzhouIncMember" xlink:label="loc_imab_CmabBiopharmaSuzhouIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_CmabBiopharmaSuzhouIncMember" xml:lang="en-US">CMAB Biopharma Suzhou Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_CmabBiopharmaSuzhouIncMember" xml:lang="en-US">CMAB Bipharma Suzhou Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_CmabBiopharmaSuzhouIncMember" xlink:to="lab_imab_CmabBiopharmaSuzhouIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_CmabBiopharmaSuzhouIncMember" xml:lang="en-US">CMAB Biopharma (Suzhou) Inc.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TaslyPharmaceuticalGroupCoLtdMember" xlink:label="loc_imab_TaslyPharmaceuticalGroupCoLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_TaslyPharmaceuticalGroupCoLtdMember" xml:lang="en-US">Tasly Pharmaceutical Group Co Ltd [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_TaslyPharmaceuticalGroupCoLtdMember" xml:lang="en-US">Tasly Pharmaceutical Group Co Ltd [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_TaslyPharmaceuticalGroupCoLtdMember" xlink:to="lab_imab_TaslyPharmaceuticalGroupCoLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_TaslyPharmaceuticalGroupCoLtdMember" xml:lang="en-US">Tasly Pharmaceutical Group Co., Ltd.Member.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Research and development expenses recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xml:lang="en-US">Related Party Transaction, Other Revenues from Transactions with Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xml:lang="en-US">Receipt of research and development funding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ReceiptOfContractResearchOrganizationsMember" xlink:label="loc_imab_ReceiptOfContractResearchOrganizationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ReceiptOfContractResearchOrganizationsMember" xml:lang="en-US">Receipt Of Contract Research Organizations [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ReceiptOfContractResearchOrganizationsMember" xml:lang="en-US">Receipt of Contract Research Organizations [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ReceiptOfContractResearchOrganizationsMember" xlink:to="lab_imab_ReceiptOfContractResearchOrganizationsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TerminationFeePayable" xlink:label="loc_imab_TerminationFeePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_TerminationFeePayable" xml:lang="en-US">Termination Fee Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_TerminationFeePayable" xml:lang="en-US">Termination fee payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_TerminationFeePayable" xlink:to="lab_imab_TerminationFeePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_TerminationFeePayable" xml:lang="en-US">Termination Fee Payable .</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_UnderwriterAxis" xlink:label="loc_imab_UnderwriterAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_UnderwriterAxis" xml:lang="en-US">Underwriter [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_UnderwriterAxis" xlink:to="lab_imab_UnderwriterAxis" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_UnderwriterDomain" xlink:label="loc_imab_UnderwriterDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_UnderwriterDomain" xml:lang="en-US">Underwriter [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_UnderwriterDomain" xlink:to="lab_imab_UnderwriterDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xml:lang="en-US">Schedule of Subsidiary or Equity Method Investee [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_RestrictedNetAssetsDisclosureLineItems" xlink:label="loc_imab_RestrictedNetAssetsDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_RestrictedNetAssetsDisclosureLineItems" xml:lang="en-US">Restricted Net Assets Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_RestrictedNetAssetsDisclosureLineItems" xlink:to="lab_imab_RestrictedNetAssetsDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_RestrictedNetAssetsDisclosureLineItems" xml:lang="en-US">Restricted Net Assets Disclosure .</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PercentageOfNetAssetToNetAssetsOfGroup" xlink:label="loc_imab_PercentageOfNetAssetToNetAssetsOfGroup" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_PercentageOfNetAssetToNetAssetsOfGroup" xml:lang="en-US">Percentage Of Net Asset To Net Assets Of Group</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_PercentageOfNetAssetToNetAssetsOfGroup" xml:lang="en-US">Percentage of net asset to consolidated net assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_PercentageOfNetAssetToNetAssetsOfGroup" xlink:to="lab_imab_PercentageOfNetAssetToNetAssetsOfGroup" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_PercentageOfNetAssetToNetAssetsOfGroup" xml:lang="en-US">Percentage of net asset to net assets of group.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation" xlink:label="loc_imab_ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation" xml:lang="en-US">Threshold Percentage Of General Reserve To Registered Capital For Reserve Appropriation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation" xml:lang="en-US">Statutory reserve, threshold limit for annual appropriation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation" xlink:to="lab_imab_ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation" xml:lang="en-US">Threshold Percentage Of General Reserve To Registered Capital For Reserve Appropriation.</label>
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit" xlink:label="loc_imab_StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit" xml:lang="en-US">Statutory Reserve Annual Appropriation Percentage from After Tax Profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit" xml:lang="en-US">Statutory reserve, annual appropriation percentage from after tax profit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit" xlink:to="lab_imab_StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit" xml:lang="en-US">Statutory reserve annual appropriation percentage from after tax profit.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNet" xlink:label="loc_us-gaap_AssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNet" xml:lang="en-US">Net Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsNet" xml:lang="en-US">Net assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNet" xlink:to="lab_us-gaap_AssetsNet" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AppropriationtoStatutoryReserve" xlink:label="loc_imab_AppropriationtoStatutoryReserve" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_imab_AppropriationtoStatutoryReserve" xml:lang="en-US">AppropriationTo Statutory Reserve</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_imab_AppropriationtoStatutoryReserve" xml:lang="en-US">Appropriation to statutory reserve</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imab_AppropriationtoStatutoryReserve" xlink:to="lab_imab_AppropriationtoStatutoryReserve" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_imab_AppropriationtoStatutoryReserve" xml:lang="en-US">Appropriation to statutory reserve.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SubsidiariesMember" xml:lang="en-US">Subsidiaries [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_SubsidiariesMember" xml:lang="en-US">Prc Subsidiaries [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SubsidiariesMember" xlink:to="lab_srt_SubsidiariesMember" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>imab-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-April-2021 [01:14:57] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#CoverPage" roleURI="http://IMab.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConsolidatedBalanceSheets" roleURI="http://IMab.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConsolidatedStatementsOfChangesInShareholdersEquityDeficit" roleURI="http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://IMab.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalActivitiesAndOrganization" roleURI="http://IMab.com/role/PrincipalActivitiesAndOrganization" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalAccountingPolicies" roleURI="http://IMab.com/role/PrincipalAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#AccountsReceivableAndContractAssets" roleURI="http://IMab.com/role/AccountsReceivableAndContractAssets" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrepaymentsAndOtherReceivables" roleURI="http://IMab.com/role/PrepaymentsAndOtherReceivables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PropertyEquipmentAndSoftware" roleURI="http://IMab.com/role/PropertyEquipmentAndSoftware" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#Leases" roleURI="http://IMab.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IntangibleAssests" roleURI="http://IMab.com/role/IntangibleAssests" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#Goodwill" roleURI="http://IMab.com/role/Goodwill" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilities" roleURI="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilities" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShortTermBorrowings" roleURI="http://IMab.com/role/ShortTermBorrowings" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#AccrualsAndOtherPayables" roleURI="http://IMab.com/role/AccrualsAndOtherPayables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IncomeTaxes" roleURI="http://IMab.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#OrdinaryShares" roleURI="http://IMab.com/role/OrdinaryShares" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConvertiblePreferredShares" roleURI="http://IMab.com/role/ConvertiblePreferredShares" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConvertiblePromissoryNotesAndOnshoreConvertibleLoans" roleURI="http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoans" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#Warrants" roleURI="http://IMab.com/role/Warrants" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShareBasedCompensation" roleURI="http://IMab.com/role/ShareBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#LicensingAndCollaborationArrangements" roleURI="http://IMab.com/role/LicensingAndCollaborationArrangements" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#OtherIncomeExpensesNet" roleURI="http://IMab.com/role/OtherIncomeExpensesNet" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#NetIncomeLossPerShare" roleURI="http://IMab.com/role/NetIncomeLossPerShare" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#EmployeeBenefits" roleURI="http://IMab.com/role/EmployeeBenefits" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#CommitmentsAndContingencies" roleURI="http://IMab.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#RelatedPartyBalancesAndTransactions" roleURI="http://IMab.com/role/RelatedPartyBalancesAndTransactions" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConcentrationOfCreditRisk" roleURI="http://IMab.com/role/ConcentrationOfCreditRisk" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#SubsequentEvents" roleURI="http://IMab.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#RestrictedNetAssets" roleURI="http://IMab.com/role/RestrictedNetAssets" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalAccountingPoliciesPolicies" roleURI="http://IMab.com/role/PrincipalAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalActivitiesAndOrganizationTables" roleURI="http://IMab.com/role/PrincipalActivitiesAndOrganizationTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalAccountingPoliciesTables" roleURI="http://IMab.com/role/PrincipalAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#AccountsReceivableAndContractAssetsTables" roleURI="http://IMab.com/role/AccountsReceivableAndContractAssetsTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrepaymentsAndOtherReceivablesTables" roleURI="http://IMab.com/role/PrepaymentsAndOtherReceivablesTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PropertyEquipmentAndSoftwareTables" roleURI="http://IMab.com/role/PropertyEquipmentAndSoftwareTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#LeasesTables" roleURI="http://IMab.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IntangibleAssetsTables" roleURI="http://IMab.com/role/IntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTables" roleURI="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#AccrualsAndOtherPayablesTables" roleURI="http://IMab.com/role/AccrualsAndOtherPayablesTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IncomeTaxesTables" roleURI="http://IMab.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConvertiblePreferredSharesTables" roleURI="http://IMab.com/role/ConvertiblePreferredSharesTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#WarrantsTables" roleURI="http://IMab.com/role/WarrantsTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShareBasedCompensationTables" roleURI="http://IMab.com/role/ShareBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#LicensingAndCollaborationAgreementsTables" roleURI="http://IMab.com/role/LicensingAndCollaborationAgreementsTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#OtherIncomeExpensesNetTables" roleURI="http://IMab.com/role/OtherIncomeExpensesNetTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#NetIncomeLossPerShareTables" roleURI="http://IMab.com/role/NetIncomeLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#RelatedPartyBalancesAndTransactionsTables" roleURI="http://IMab.com/role/RelatedPartyBalancesAndTransactionsTables" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail" roleURI="http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalActivitiesAndOrganizationAdditionalInformationDetail" roleURI="http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" roleURI="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail" roleURI="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalAccountingPoliciesSummaryOfCashCashEquivalentsAndRestrictedCashAsReportedInTheConsolidatedStatementOfCashFlowsDetail" roleURI="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfCashCashEquivalentsAndRestrictedCashAsReportedInTheConsolidatedStatementOfCashFlowsDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalAccountingPoliciesAdditionalInformationDetail" roleURI="http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail" roleURI="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#AccountsReceivableAndContractAssetsSummaryOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesDetail" roleURI="http://IMab.com/role/AccountsReceivableAndContractAssetsSummaryOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail" roleURI="http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PropertyEquipmentAndSoftwareAdditionalInformationDetail" roleURI="http://IMab.com/role/PropertyEquipmentAndSoftwareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail" roleURI="http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail" roleURI="http://IMab.com/role/LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#LeasesComponentsOfOperatingLeaseExpenseDetail" roleURI="http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#LeasesOperatingLeaseMaturityDetail" roleURI="http://IMab.com/role/LeasesOperatingLeaseMaturityDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IntangibleAssetsSummaryOfIntangibleAssetsDetail" roleURI="http://IMab.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IntangibleAssetsAdditionalInformationDetail" roleURI="http://IMab.com/role/IntangibleAssetsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#GoodwillAdditionalInformationDetail" roleURI="http://IMab.com/role/GoodwillAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail" roleURI="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetail" roleURI="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail" roleURI="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShortTermBorrowingsAdditionalInformationDetail" roleURI="http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail" roleURI="http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#AccrualsAndOtherPayablesAdditionalInformationDetails" roleURI="http://IMab.com/role/AccrualsAndOtherPayablesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://IMab.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail" roleURI="http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail" roleURI="http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#IncomeTaxesSummaryOfMovementOfTheValuationAllowanceDetail" roleURI="http://IMab.com/role/IncomeTaxesSummaryOfMovementOfTheValuationAllowanceDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#OrdinarySharesAdditionalInformationDetail" roleURI="http://IMab.com/role/OrdinarySharesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConvertiblePreferredSharesAdditionalInformationDetail" roleURI="http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail" roleURI="http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail" roleURI="http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#WarrantsAdditionalInformationDetail" roleURI="http://IMab.com/role/WarrantsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail" roleURI="http://IMab.com/role/WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail" roleURI="http://IMab.com/role/WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShareBasedCompensationAdditionalInformationDetail" roleURI="http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail" roleURI="http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShareBasedCompensationScheduleOfStockOptionActivitiesDetail" roleURI="http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail" roleURI="http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail" roleURI="http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail" roleURI="http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail" roleURI="http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#LicensingAndCollaborationAgreementsAdditionalInformationDetail" roleURI="http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail" roleURI="http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail" roleURI="http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetParentheticalDetail" roleURI="http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail" roleURI="http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" roleURI="http://IMab.com/role/NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#EmployeeBenefitsAdditionalInformationDetail" roleURI="http://IMab.com/role/EmployeeBenefitsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail" roleURI="http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesParentheticalDetail" roleURI="http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail" roleURI="http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#SubsequentEventsAdditionalInformationDetail" roleURI="http://IMab.com/role/SubsequentEventsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="imab-20201231.xsd#RestrictedNetAssetsAdditionalInformationDetail" roleURI="http://IMab.com/role/RestrictedNetAssetsAdditionalInformationDetail" />
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_617284" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_630141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_617284" xlink:to="loc_dei_DocumentInformationTable_630141" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_830287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_630141" xlink:to="loc_us-gaap_StatementClassOfStockAxis_830287" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_830289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_830287" xlink:to="loc_us-gaap_ClassOfStockDomain_830289" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AdrMember" xlink:label="loc_dei_AdrMember_830291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_830289" xlink:to="loc_dei_AdrMember_830291" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_830292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_630141" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_830292" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_830293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_830292" xlink:to="loc_dei_AddressTypeDomain_830293" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_830294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_830293" xlink:to="loc_dei_BusinessContactMember_830294" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_830382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_630141" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_830382" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_830383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_830382" xlink:to="loc_us-gaap_EquityComponentDomain_830383" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_830384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_830383" xlink:to="loc_us-gaap_CommonStockMember_830384" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_630144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_630141" xlink:to="loc_dei_DocumentInformationLineItems_630144" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_617285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentType_617285" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_617286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_AmendmentFlag_617286" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_617288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentPeriodEndDate_617288" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_617289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentFiscalYearFocus_617289" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_617290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentFiscalPeriodFocus_617290" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_617292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityRegistrantName_617292" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_617293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityCentralIndexKey_617293" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_617294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_CurrentFiscalYearEndDate_617294" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_617301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_617301" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_617302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityVoluntaryFilers_617302" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_617303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityCurrentReportingStatus_617303" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_617304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityFilerCategory_617304" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_617311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_TradingSymbol_617311" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_617306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityShellCompany_617306" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_617308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityEmergingGrowthCompany_617308" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_629596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityExTransitionPeriod_629596" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_617314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_SecurityExchangeName_617314" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_617316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityAddressCityOrTown_617316" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_617317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityAddressCountry_617317" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_617318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityAddressAddressLine1_617318" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_617340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityInteractiveDataCurrent_617340" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_617341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityFileNumber_617341" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_617343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityIncorporationStateCountryCode_617343" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_617346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityAddressPostalZipCode_617346" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_617347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_CityAreaCode_617347" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_617348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_LocalPhoneNumber_617348" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_623273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_Security12bTitle_623273" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_830308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentRegistrationStatement_830308" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_617349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentAnnualReport_617349" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_617350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentTransitionReport_617350" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_629600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentShellCompanyReport_629600" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_617312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_617312" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_dei_NoTradingSymbolFlag_630158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_NoTradingSymbolFlag_630158" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_830336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_ContactPersonnelName_830336" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_830337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_ContactPersonnelEmailAddress_830337" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_830361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_DocumentAccountingStandard_830361" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_830362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_630144" xlink:to="loc_dei_IcfrAuditorAttestationFlag_830362" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_617361" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_617366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_617361" xlink:to="loc_us-gaap_StatementTable_617366" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_671535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_617366" xlink:to="loc_srt_StatementScenarioAxis_671535" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_671536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_671535" xlink:to="loc_srt_ScenarioUnspecifiedDomain_671536" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_617372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_617366" xlink:to="loc_us-gaap_StatementClassOfStockAxis_617372" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_617373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_617372" xlink:to="loc_us-gaap_ClassOfStockDomain_617373" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesAConvertiblePreferredSharesMember" xlink:label="loc_imab_SeriesAConvertiblePreferredSharesMember_617532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_617373" xlink:to="loc_imab_SeriesAConvertiblePreferredSharesMember_617532" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBConvertiblePreferredSharesMember" xlink:label="loc_imab_SeriesBConvertiblePreferredSharesMember_617533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_617373" xlink:to="loc_imab_SeriesBConvertiblePreferredSharesMember_617533" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesCConvertiblePreferredSharesMember" xlink:label="loc_imab_SeriesCConvertiblePreferredSharesMember_617534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_617373" xlink:to="loc_imab_SeriesCConvertiblePreferredSharesMember_617534" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesC1ConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesC1ConvertiblePreferredStockMember_652355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_617373" xlink:to="loc_imab_SeriesC1ConvertiblePreferredStockMember_652355" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_617368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_617366" xlink:to="loc_us-gaap_StatementLineItems_617368" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_617468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_617368" xlink:to="loc_us-gaap_AssetsAbstract_617468" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_617470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_617468" xlink:to="loc_us-gaap_AssetsCurrentAbstract_617470" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_617458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_617470" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_617458" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_617459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_617470" xlink:to="loc_us-gaap_RestrictedCashCurrent_617459" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_871447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_617470" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_871447" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_617460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_617470" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_617460" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_617462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_617470" xlink:to="loc_us-gaap_ShortTermInvestments_617462" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_617463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_617470" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_617463" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_617474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_617470" xlink:to="loc_us-gaap_AssetsCurrent_617474" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_617477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_617468" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_617477" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_617478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_617468" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_617478" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_617479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_617468" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_617479" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_617480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_617468" xlink:to="loc_us-gaap_Goodwill_617480" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_828988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_617468" xlink:to="loc_us-gaap_EquityMethodInvestments_828988" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_617481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_617468" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_617481" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_617482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_617468" xlink:to="loc_us-gaap_Assets_617482" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_617483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_617368" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_617483" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_617486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_617483" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_617486" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_617487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_us-gaap_ShortTermBorrowings_617487" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_617490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_617490" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_617493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_617493" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CommonStockSharesIssuableForServicesAvailedCurrent" xlink:label="loc_imab_CommonStockSharesIssuableForServicesAvailedCurrent_652304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_imab_CommonStockSharesIssuableForServicesAvailedCurrent_652304" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaap_DeferredIncomeCurrent_828991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_us-gaap_DeferredIncomeCurrent_828991" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_617498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_us-gaap_LiabilitiesCurrent_617498" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_617502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_617502" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PutRightLiabilities" xlink:label="loc_imab_PutRightLiabilities_828990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_imab_PutRightLiabilities_828990" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_617503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_617503" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="loc_us-gaap_DeferredIncomeNoncurrent_617504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_us-gaap_DeferredIncomeNoncurrent_617504" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_828999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_617486" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_828999" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_617505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_617483" xlink:to="loc_us-gaap_Liabilities_617505" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_617508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_617483" xlink:to="loc_us-gaap_CommitmentsAndContingencies_617508" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaap_TemporaryEquityAbstract_617512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_617483" xlink:to="loc_us-gaap_TemporaryEquityAbstract_617512" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_617513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_617512" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_617513" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_617517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_617483" xlink:to="loc_us-gaap_StockholdersEquityAbstract_617517" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_617519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_617517" xlink:to="loc_us-gaap_CommonStockValue_617519" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_617522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_617517" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_617522" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_617523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_617517" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_617523" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_617524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_617517" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_617524" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_617528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_617517" xlink:to="loc_us-gaap_StockholdersEquity_617528" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_617529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_617483" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_617529" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_622987" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_622988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_622987" xlink:to="loc_us-gaap_StatementTable_622988" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAxis" xlink:label="loc_us-gaap_CollateralAxis_623014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622988" xlink:to="loc_us-gaap_CollateralAxis_623014" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaap_CollateralDomain_623017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralAxis_623014" xlink:to="loc_us-gaap_CollateralDomain_623017" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_671544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622988" xlink:to="loc_srt_StatementScenarioAxis_671544" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_671545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_671544" xlink:to="loc_srt_ScenarioUnspecifiedDomain_671545" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_622992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622988" xlink:to="loc_us-gaap_StatementClassOfStockAxis_622992" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_622993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_622992" xlink:to="loc_us-gaap_ClassOfStockDomain_622993" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesAConvertiblePreferredSharesMember" xlink:label="loc_imab_SeriesAConvertiblePreferredSharesMember_622995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_622993" xlink:to="loc_imab_SeriesAConvertiblePreferredSharesMember_622995" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBConvertiblePreferredSharesMember" xlink:label="loc_imab_SeriesBConvertiblePreferredSharesMember_622996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_622993" xlink:to="loc_imab_SeriesBConvertiblePreferredSharesMember_622996" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesCConvertiblePreferredSharesMember" xlink:label="loc_imab_SeriesCConvertiblePreferredSharesMember_622997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_622993" xlink:to="loc_imab_SeriesCConvertiblePreferredSharesMember_622997" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesC1ConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesC1ConvertiblePreferredStockMember_652395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_622993" xlink:to="loc_imab_SeriesC1ConvertiblePreferredStockMember_652395" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_622998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622988" xlink:to="loc_us-gaap_StatementLineItems_622998" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_622999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622998" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_622999" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_623000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622998" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_623000" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_623001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622998" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_623001" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_623002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622998" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_623002" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_623004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622998" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_623004" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_623005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622998" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_623005" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_623006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622998" xlink:to="loc_us-gaap_CommonStockSharesIssued_623006" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_623007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622998" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_623007" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_619020" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_628108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_619020" xlink:to="loc_us-gaap_StatementTable_628108" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_628127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_628108" xlink:to="loc_srt_ProductOrServiceAxis_628127" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_628128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_628127" xlink:to="loc_srt_ProductsAndServicesDomain_628128" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_628109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_628108" xlink:to="loc_us-gaap_StatementClassOfStockAxis_628109" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_628110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_628109" xlink:to="loc_us-gaap_ClassOfStockDomain_628110" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AdrMember" xlink:label="loc_dei_AdrMember_894007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_628110" xlink:to="loc_dei_AdrMember_894007" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_628111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_628108" xlink:to="loc_us-gaap_StatementLineItems_628111" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_628114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_628111" xlink:to="loc_us-gaap_RevenuesAbstract_628114" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_619023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_628114" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_619023" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_628123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_628111" xlink:to="loc_us-gaap_OperatingExpensesAbstract_628123" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_619025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_619025" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_619026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_619026" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_619027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_619027" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_619028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_InvestmentIncomeInterest_619028" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_619029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_InterestExpense_619029" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_619030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_619030" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_829013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_829013" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_619032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_619032" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_619035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_619035" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_619036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_619036" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_619040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_NetIncomeLoss_619040" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares" xlink:label="loc_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares_652456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares_652456" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockDividendsAtModificationOfPreferredShares" xlink:label="loc_imab_PreferredStockDividendsAtModificationOfPreferredShares_652459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_imab_PreferredStockDividendsAtModificationOfPreferredShares_652459" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_652461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_652461" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_907835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_NetIncomeLoss_907835" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_680142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_680142" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_619045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_680142" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_619045" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_619047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_619047" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_619050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_619050" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_829010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_829010" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_829011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_628123" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_829011" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_628126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_628111" xlink:to="loc_us-gaap_EarningsPerShareAbstract_628126" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_619067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_628126" xlink:to="loc_us-gaap_EarningsPerShareBasic_619067" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_619073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_628126" xlink:to="loc_us-gaap_EarningsPerShareDiluted_619073" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_619421" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_619427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_619421" xlink:to="loc_us-gaap_StatementTable_619427" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_619431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_619427" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_619431" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_619432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_619431" xlink:to="loc_us-gaap_EquityComponentDomain_619432" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_619446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_619432" xlink:to="loc_us-gaap_CommonStockMember_619446" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_619435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_619432" xlink:to="loc_us-gaap_TreasuryStockMember_619435" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_619436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_619432" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_619436" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_619437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_619432" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_619437" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_619438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_619432" xlink:to="loc_us-gaap_RetainedEarningsMember_619438" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_619428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_619427" xlink:to="loc_us-gaap_StatementClassOfStockAxis_619428" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_619429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_619428" xlink:to="loc_us-gaap_ClassOfStockDomain_619429" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_619430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_619427" xlink:to="loc_us-gaap_StatementLineItems_619430" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_619452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockholdersEquity_619452" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_619453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_SharesOutstanding_619453" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_619454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_619454" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_619456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_NetIncomeLoss_619456" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_619458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_619458" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_829023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_829023" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_829024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_829024" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_871855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_871855" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_871854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_871854" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_829019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_829019" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares" xlink:label="loc_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares_652481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares_652481" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_829018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_829018" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockDividendsAtModificationOfPreferredShares" xlink:label="loc_imab_PreferredStockDividendsAtModificationOfPreferredShares_652486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_imab_PreferredStockDividendsAtModificationOfPreferredShares_652486" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_628267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_628267" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate" xlink:label="loc_imab_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate_829020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_imab_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate_829020" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender" xlink:label="loc_imab_AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender_829025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_imab_AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender_829025" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_829026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_829026" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829027" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_829028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_829028" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_829029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_829029" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_829030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_829030" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_829032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_829032" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_829033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_829033" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_829034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_829034" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_829035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_829035" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_619468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_StockholdersEquity_619468" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_628244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_619430" xlink:to="loc_us-gaap_SharesOutstanding_628244" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_619601" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_619606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_619601" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_619606" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_619640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_619606" xlink:to="loc_us-gaap_NetIncomeLoss_619640" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_619601" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_619648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" xlink:to="loc_us-gaap_Depreciation_619648" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_829038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_829038" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_619650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_619650" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_619653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" xlink:to="loc_us-gaap_InterestExpenseDebt_619653" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_619654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_619654" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueAdjustmentsOfPutRightLiabilities" xlink:label="loc_imab_FairValueAdjustmentsOfPutRightLiabilities_829041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" xlink:to="loc_imab_FairValueAdjustmentsOfPutRightLiabilities_829041" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="loc_us-gaap_AssetsFairValueAdjustment_619692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" xlink:to="loc_us-gaap_AssetsFairValueAdjustment_619692" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IncomeFromOtherFinancialAssets" xlink:label="loc_imab_IncomeFromOtherFinancialAssets_619698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" xlink:to="loc_imab_IncomeFromOtherFinancialAssets_619698" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_829042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_829042" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_619701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" xlink:to="loc_us-gaap_ShareBasedCompensation_619701" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LossFromConversionOfNotes" xlink:label="loc_imab_LossFromConversionOfNotes_619714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" xlink:to="loc_imab_LossFromConversionOfNotes_619714" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LossFromConversionOfOnshoreConvertibleLoans" xlink:label="loc_imab_LossFromConversionOfOnshoreConvertibleLoans_619719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" xlink:to="loc_imab_LossFromConversionOfOnshoreConvertibleLoans_619719" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LossFromIssuanceOfNotes" xlink:label="loc_imab_LossFromIssuanceOfNotes_619721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" xlink:to="loc_imab_LossFromIssuanceOfNotes_619721" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="loc_us-gaap_GainLossOnContractTermination_671551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" xlink:to="loc_us-gaap_GainLossOnContractTermination_671551" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities" xlink:label="loc_imab_AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities_619727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" xlink:to="loc_imab_AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities_619727" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_829045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_829045" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueChangeOfShortTermInvestments" xlink:label="loc_imab_FairValueChangeOfShortTermInvestments_619731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619645" xlink:to="loc_imab_FairValueChangeOfShortTermInvestments_619731" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_619734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_619601" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_619734" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_871477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_619734" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_871477" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_619739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_619734" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_619739" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_619742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_619734" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_619742" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_619744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_619734" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_619744" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_619746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_619734" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_619746" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IncreaseDecreaseAdvanceFromCustomers" xlink:label="loc_imab_IncreaseDecreaseAdvanceFromCustomers_619749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_619734" xlink:to="loc_imab_IncreaseDecreaseAdvanceFromCustomers_619749" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_619751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_619734" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_619751" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_871478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_619734" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_871478" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_619753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_619734" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_619753" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent" xlink:label="loc_imab_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent_652664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_619734" xlink:to="loc_imab_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent_652664" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_619823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_619601" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_619823" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_620013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_619601" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_620013" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_620024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_620013" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_620024" use="optional" order="34" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_620025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_620013" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_620025" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_620028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_620013" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_620028" use="optional" order="36" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_620033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_620013" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_620033" use="optional" order="37" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_829047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_620013" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_829047" use="optional" order="38" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_620037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_620013" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_620037" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CashReceivedOnIncomeFromOtherFinancialAssets" xlink:label="loc_imab_CashReceivedOnIncomeFromOtherFinancialAssets_620041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_620013" xlink:to="loc_imab_CashReceivedOnIncomeFromOtherFinancialAssets_620041" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_871484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_620013" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_871484" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_620042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_620013" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_620042" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_620047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_619601" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_620047" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_620048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_620047" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_620048" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_620050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_620047" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_620050" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_829052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_620047" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_829052" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_829053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_620047" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_829053" use="optional" order="47" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_829055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_620047" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_829055" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_620055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_620047" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_620055" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_829057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_620047" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_829057" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits_871494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_620047" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits_871494" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromBankDebt" xlink:label="loc_us-gaap_ProceedsFromBankDebt_620057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_620047" xlink:to="loc_us-gaap_ProceedsFromBankDebt_620057" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="loc_us-gaap_RepaymentsOfBankDebt_620059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_620047" xlink:to="loc_us-gaap_RepaymentsOfBankDebt_620059" use="optional" order="53" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity_829060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_620047" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity_829060" use="optional" order="54" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram" xlink:label="loc_imab_ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram_873034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_620047" xlink:to="loc_imab_ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram_873034" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_620070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_620047" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_620070" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_620109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_619601" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_620109" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_620113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_619601" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_620113" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_620114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_619601" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_620114" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_620115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_619601" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_620115" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_620119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_619601" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_620119" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_620122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_620119" xlink:to="loc_us-gaap_OperatingLeasePayments_620122" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_620125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_620119" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_620125" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OtherSupplementalCashFlowDisclosuresAbstract" xlink:label="loc_imab_OtherSupplementalCashFlowDisclosuresAbstract_620183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_620119" xlink:to="loc_imab_OtherSupplementalCashFlowDisclosuresAbstract_620183" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_620128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_OtherSupplementalCashFlowDisclosuresAbstract_620183" xlink:to="loc_us-gaap_InterestPaidNet_620128" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_620184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_OtherSupplementalCashFlowDisclosuresAbstract_620183" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_620184" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ExerciseOfWarrants" xlink:label="loc_imab_ExerciseOfWarrants_620135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_620184" xlink:to="loc_imab_ExerciseOfWarrants_620135" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PayablesForInLicensedPatentRights" xlink:label="loc_imab_PayablesForInLicensedPatentRights_620146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_620184" xlink:to="loc_imab_PayablesForInLicensedPatentRights_620146" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccuredInitialPublicOfferingCostPayable" xlink:label="loc_imab_AccuredInitialPublicOfferingCostPayable_620157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_620184" xlink:to="loc_imab_AccuredInitialPublicOfferingCostPayable_620157" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares" xlink:label="loc_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares_671552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_620184" xlink:to="loc_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares_671552" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockDividendsAtModificationOfPreferredShares" xlink:label="loc_imab_PreferredStockDividendsAtModificationOfPreferredShares_671553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_620184" xlink:to="loc_imab_PreferredStockDividendsAtModificationOfPreferredShares_671553" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccruedPrivatePlacementOfferingCostsPayable" xlink:label="loc_imab_AccruedPrivatePlacementOfferingCostsPayable_829065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_620184" xlink:to="loc_imab_AccruedPrivatePlacementOfferingCostsPayable_829065" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_829066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_620184" xlink:to="loc_us-gaap_StockIssued1_829066" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_829067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_620184" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_829067" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_829068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_620184" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_829068" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalActivitiesAndOrganization">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_621529" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_621530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_621529" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_621530" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_621989" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_621997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_621989" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_621997" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/AccountsReceivableAndContractAssets">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccountsReceivableAndContractAssetsAbstract" xlink:label="loc_imab_AccountsReceivableAndContractAssetsAbstract_907622" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccountsReceivableAndContractAssetsTextBlock" xlink:label="loc_imab_AccountsReceivableAndContractAssetsTextBlock_907624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_AccountsReceivableAndContractAssetsAbstract_907622" xlink:to="loc_imab_AccountsReceivableAndContractAssetsTextBlock_907624" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PrepaymentsAndOtherReceivables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_621734" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PrepaidexpensesandotherreceivablestextblockTextBlock" xlink:label="loc_imab_PrepaidexpensesandotherreceivablestextblockTextBlock_621735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_621734" xlink:to="loc_imab_PrepaidexpensesandotherreceivablestextblockTextBlock_621735" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PropertyEquipmentAndSoftware">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_621901" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_621902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_621901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_621902" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/Leases">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_622488" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_622489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_622488" xlink:to="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_622489" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/IntangibleAssests">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_622633" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_622634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_622633" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_622634" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/Goodwill">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_622664" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock_622665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_622664" xlink:to="loc_us-gaap_GoodwillDisclosureTextBlock_622665" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilities">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract" xlink:label="loc_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract_829203" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock" xlink:label="loc_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock_829207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract_829203" xlink:to="loc_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock_829207" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ShortTermBorrowings">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract_622686" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_us-gaap_ShortTermDebtTextBlock_622689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_622686" xlink:to="loc_us-gaap_ShortTermDebtTextBlock_622689" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/AccrualsAndOtherPayables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_622713" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_622714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_622713" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_622714" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract_622746" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_622747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_622746" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_622747" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/OrdinaryShares">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_622818" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_622819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_622818" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_622819" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ConvertiblePreferredShares">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_625311" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TemporaryEquityTextBlock" xlink:label="loc_imab_TemporaryEquityTextBlock_625347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_625311" xlink:to="loc_imab_TemporaryEquityTextBlock_625347" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoans">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract" xlink:label="loc_imab_ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract_627002" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans" xlink:label="loc_imab_ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans_627007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract_627002" xlink:to="loc_imab_ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans_627007" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/Warrants">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WarrantsDisclosureAbstract" xlink:label="loc_imab_WarrantsDisclosureAbstract_624780" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WarrantsDisclosure" xlink:label="loc_imab_WarrantsDisclosure_624781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_WarrantsDisclosureAbstract_624780" xlink:to="loc_imab_WarrantsDisclosure_624781" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ShareBasedCompensation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_626279" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_626280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_626279" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_626280" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/LicensingAndCollaborationArrangements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_627256" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_680137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_627256" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_680137" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/OtherIncomeExpensesNet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_622239" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_622240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_622239" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_622240" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/NetIncomeLossPerShare">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_622111" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_622113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_622111" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_622113" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/EmployeeBenefits">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_622098" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_622100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_622098" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_622100" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_622085" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_622086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_622085" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_622086" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/RelatedPartyBalancesAndTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_621935" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_621937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_621935" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_621937" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ConcentrationOfCreditRisk">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_621918" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_621921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_621918" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_621921" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_621830" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_621831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_621830" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_621831" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/RestrictedNetAssets">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_RestrictedNetAssetsDisclosureAbstract" xlink:label="loc_imab_RestrictedNetAssetsDisclosureAbstract_621757" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_RestrictedAssetsDisclosureTextBlock_621760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_RestrictedNetAssetsDisclosureAbstract_621757" xlink:to="loc_us-gaap_RestrictedAssetsDisclosureTextBlock_621760" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_622018" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_622019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_622019" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_622020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_622020" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_622021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_UseOfEstimates_622021" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_622023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_622023" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_622027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_622027" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_622028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_622028" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_622030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_622030" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_871560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_871560" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShortTermInvestmentsPolicyTextBlock" xlink:label="loc_imab_ShortTermInvestmentsPolicyTextBlock_622032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_imab_ShortTermInvestmentsPolicyTextBlock_622032" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_622034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_622034" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_622036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_622036" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_622037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_622037" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_622038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_622038" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LongTermInvestmentsPolicyTextBlock" xlink:label="loc_imab_LongTermInvestmentsPolicyTextBlock_829107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_imab_LongTermInvestmentsPolicyTextBlock_829107" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredSubsidyIncomePolicyTextBlock" xlink:label="loc_imab_DeferredSubsidyIncomePolicyTextBlock_622039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_imab_DeferredSubsidyIncomePolicyTextBlock_622039" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_622041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_622041" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ValueAddedTaxesPolicyPolicyTextBlock" xlink:label="loc_imab_ValueAddedTaxesPolicyPolicyTextBlock_622044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_imab_ValueAddedTaxesPolicyPolicyTextBlock_622044" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_622045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_622045" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_622046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_622046" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_622048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_622048" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_622050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_622050" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_622052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_622052" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_622053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_DebtPolicyTextBlock_622053" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_622054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_622054" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_622055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_622055" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_622056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_622056" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_622058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_622058" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_imab_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock_622059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622018" xlink:to="loc_imab_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock_622059" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalActivitiesAndOrganizationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_621537" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfPrincipalSubsidiariesTableTextBlock" xlink:label="loc_imab_ScheduleOfPrincipalSubsidiariesTableTextBlock_621538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_621537" xlink:to="loc_imab_ScheduleOfPrincipalSubsidiariesTableTextBlock_621538" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_622093" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_622094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622093" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_622094" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_622096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622093" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_622096" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_907599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622093" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_907599" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock" xlink:label="loc_imab_ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock_622099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622093" xlink:to="loc_imab_ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock_622099" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/AccountsReceivableAndContractAssetsTables">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccountsReceivableAndContractAssetsAbstract" xlink:label="loc_imab_AccountsReceivableAndContractAssetsAbstract_907629" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock" xlink:label="loc_imab_ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock_907630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_AccountsReceivableAndContractAssetsAbstract_907629" xlink:to="loc_imab_ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock_907630" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PrepaymentsAndOtherReceivablesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_621739" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_621740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_621739" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_621740" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PropertyEquipmentAndSoftwareTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_621905" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_621906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_621905" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_621906" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_622492" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock" xlink:label="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock_622494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_622492" xlink:to="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock_622494" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock" xlink:label="loc_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock_622538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_622492" xlink:to="loc_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock_622538" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_622576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_622492" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_622576" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/IntangibleAssetsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_622636" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_622637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_622636" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_622637" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTables">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract" xlink:label="loc_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract_829218" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_830507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract_829218" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_830507" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_829221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract_829218" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_829221" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/AccrualsAndOtherPayablesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_622718" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_622719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_622718" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_622719" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_622749" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_622750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_622749" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_622750" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_622752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_622749" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_622752" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_622753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_622749" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_622753" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ConvertiblePreferredSharesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_625314" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_625315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_625314" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_625315" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/WarrantsTables">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WarrantsDisclosureAbstract" xlink:label="loc_imab_WarrantsDisclosureAbstract_625146" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_625148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_WarrantsDisclosureAbstract_625146" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_625148" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_825487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_WarrantsDisclosureAbstract_625146" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_825487" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ShareBasedCompensationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_626306" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_626306" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627233" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_627235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627233" xlink:to="loc_us-gaap_PlanNameAxis_627235" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_627236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_627235" xlink:to="loc_us-gaap_PlanNameDomain_627236" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyEighteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_627242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_627236" xlink:to="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_627242" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentySeventeenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_627357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_627236" xlink:to="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_627357" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyNineteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyNineteenEmployeeStockOptionPlanMember_830080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_627236" xlink:to="loc_imab_TwentyNineteenEmployeeStockOptionPlanMember_830080" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyTwentyEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyTwentyEmployeeStockOptionPlanMember_830093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_627236" xlink:to="loc_imab_TwentyTwentyEmployeeStockOptionPlanMember_830093" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_830137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627233" xlink:to="loc_us-gaap_AwardTypeAxis_830137" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_830137" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830138" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_830140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830138" xlink:to="loc_us-gaap_RestrictedStockMember_830140" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_832492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830138" xlink:to="loc_us-gaap_EmployeeStockOptionMember_832492" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627233" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627361" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_626321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627361" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_626321" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_830058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627361" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_830058" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_626309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627361" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_626309" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_627362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627361" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_627362" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_830142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627361" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_830142" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/LicensingAndCollaborationAgreementsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_627259" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_627259" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627267" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_627268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627267" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_627268" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_627269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_627268" xlink:to="loc_us-gaap_RelatedPartyDomain_627269" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627267" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627272" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627272" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627273" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_628452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627267" xlink:to="loc_us-gaap_TypeOfArrangementAxis_628452" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_628452" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628454" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMorphosysAgMember" xlink:label="loc_imab_LicensingAgreementWithMorphosysAgMember_628455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628454" xlink:to="loc_imab_LicensingAgreementWithMorphosysAgMember_628455" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithGenexineIncMember" xlink:label="loc_imab_LicensingAgreementWithGenexineIncMember_628458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628454" xlink:to="loc_imab_LicensingAgreementWithGenexineIncMember_628458" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMorphosysMember" xlink:label="loc_imab_LicensingAgreementWithMorphosysMember_628459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628454" xlink:to="loc_imab_LicensingAgreementWithMorphosysMember_628459" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMacrogenicsMember" xlink:label="loc_imab_LicensingAgreementWithMacrogenicsMember_628469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628454" xlink:to="loc_imab_LicensingAgreementWithMacrogenicsMember_628469" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627267" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627277" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_627280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627277" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_627280" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/OtherIncomeExpensesNetTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_622245" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_622247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_622245" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_622247" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/NetIncomeLossPerShareTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_622115" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_622116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_622115" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_622116" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_622118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_622115" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_622118" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/RelatedPartyBalancesAndTransactionsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_621964" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfRelatedPartyBalancesTextBlock" xlink:label="loc_imab_ScheduleOfRelatedPartyBalancesTextBlock_621987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_621964" xlink:to="loc_imab_ScheduleOfRelatedPartyBalancesTextBlock_621987" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_621990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_621964" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_621990" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_621541" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfPrincipalSubsidiariesTable" xlink:label="loc_imab_ScheduleOfPrincipalSubsidiariesTable_621560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_621541" xlink:to="loc_imab_ScheduleOfPrincipalSubsidiariesTable_621560" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_621562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfPrincipalSubsidiariesTable_621560" xlink:to="loc_srt_ConsolidatedEntitiesAxis_621562" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_621566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_621562" xlink:to="loc_srt_ConsolidatedEntitiesDomain_621566" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IMabBiopharmaHongKongLimitedMember" xlink:label="loc_imab_IMabBiopharmaHongKongLimitedMember_621572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_621566" xlink:to="loc_imab_IMabBiopharmaHongKongLimitedMember_621572" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IMabShanghaiMember" xlink:label="loc_imab_IMabShanghaiMember_621573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_621566" xlink:to="loc_imab_IMabShanghaiMember_621573" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IMabtianjinMember" xlink:label="loc_imab_IMabtianjinMember_621575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_621566" xlink:to="loc_imab_IMabtianjinMember_621575" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ImabbiopharmaUsLtdMember" xlink:label="loc_imab_ImabbiopharmaUsLtdMember_621576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_621566" xlink:to="loc_imab_ImabbiopharmaUsLtdMember_621576" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_621579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfPrincipalSubsidiariesTable_621560" xlink:to="loc_us-gaap_StatementLineItems_621579" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EntityIncorporationCountryStateName" xlink:label="loc_imab_EntityIncorporationCountryStateName_630168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_621579" xlink:to="loc_imab_EntityIncorporationCountryStateName_630168" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_621585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_621579" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_621585" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_621590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_621579" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_621590" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="loc_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_621591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_621579" xlink:to="loc_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_621591" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_621610" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfPrincipalSubsidiariesTable" xlink:label="loc_imab_ScheduleOfPrincipalSubsidiariesTable_621614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_621610" xlink:to="loc_imab_ScheduleOfPrincipalSubsidiariesTable_621614" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_621615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfPrincipalSubsidiariesTable_621614" xlink:to="loc_srt_ConsolidatedEntitiesAxis_621615" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_621616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_621615" xlink:to="loc_srt_ConsolidatedEntitiesDomain_621616" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_829088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfPrincipalSubsidiariesTable_621614" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_829088" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_829088" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829089" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_829090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829089" xlink:to="loc_us-gaap_IPOMember_829090" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_829091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829089" xlink:to="loc_us-gaap_OverAllotmentOptionMember_829091" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_829092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfPrincipalSubsidiariesTable_621614" xlink:to="loc_us-gaap_StatementClassOfStockAxis_829092" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_829093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_829092" xlink:to="loc_us-gaap_ClassOfStockDomain_829093" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AdrMember" xlink:label="loc_dei_AdrMember_829094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_829093" xlink:to="loc_dei_AdrMember_829094" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_621618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfPrincipalSubsidiariesTable_621614" xlink:to="loc_us-gaap_StatementLineItems_621618" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_829097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_621618" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_829097" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_829098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_621618" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_829098" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_829099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_621618" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_829099" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CommonStockSharesIssuable" xlink:label="loc_imab_CommonStockSharesIssuable_829100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_621618" xlink:to="loc_imab_CommonStockSharesIssuable_829100" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_829101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_621618" xlink:to="loc_us-gaap_SharePrice_829101" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_622836" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_622843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622836" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_622843" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_628176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_622843" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_628176" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_628177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_628176" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_628177" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_628179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_628177" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_628179" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_622850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_622843" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_622850" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_622852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_622850" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_622852" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_622855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_622852" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_622855" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_622858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_622843" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_622858" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_622859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_622858" xlink:to="loc_us-gaap_AssetsAbstract_622859" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_622865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_622859" xlink:to="loc_us-gaap_ShortTermInvestments_622865" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_622861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_622858" xlink:to="loc_us-gaap_LiabilitiesAbstract_622861" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PutRightLiabilities" xlink:label="loc_imab_PutRightLiabilities_829118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_622861" xlink:to="loc_imab_PutRightLiabilities_829118" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_622872" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_622875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622872" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_622875" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_622877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_622875" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_622877" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_622879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_622877" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_622879" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_622886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_622879" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_622886" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OtherFinancialAssetsMember" xlink:label="loc_imab_OtherFinancialAssetsMember_622887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_622879" xlink:to="loc_imab_OtherFinancialAssetsMember_622887" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WarrantLiabilitiesMember" xlink:label="loc_imab_WarrantLiabilitiesMember_622891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_622879" xlink:to="loc_imab_WarrantLiabilitiesMember_622891" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PutRightLiabilitiesMember" xlink:label="loc_imab_PutRightLiabilitiesMember_829124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_622879" xlink:to="loc_imab_PutRightLiabilitiesMember_829124" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_622875" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_622896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_622896" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_622927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_622927" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments" xlink:label="loc_imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments_629914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" xlink:to="loc_imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments_629914" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_622909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_622909" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_829127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_829127" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_628233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_628233" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences" xlink:label="loc_imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences_622907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" xlink:to="loc_imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences_622907" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_622914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_622894" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_622914" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfCashCashEquivalentsAndRestrictedCashAsReportedInTheConsolidatedStatementOfCashFlowsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_907601" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_907602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_907601" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_907602" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_907603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_907601" xlink:to="loc_us-gaap_RestrictedCashCurrent_907603" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_907604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_907601" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_907604" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_622956" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_622958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622956" xlink:to="loc_us-gaap_StatementTable_622958" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_BankBranchAxis" xlink:label="loc_imab_BankBranchAxis_622964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622958" xlink:to="loc_imab_BankBranchAxis_622964" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_BankBranchDomain" xlink:label="loc_imab_BankBranchDomain_622965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_BankBranchAxis_622964" xlink:to="loc_imab_BankBranchDomain_622965" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PeoplesBankOfChinaMember" xlink:label="loc_imab_PeoplesBankOfChinaMember_622966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_BankBranchDomain_622965" xlink:to="loc_imab_PeoplesBankOfChinaMember_622966" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FederalReserveBankOfNewYorkMember" xlink:label="loc_imab_FederalReserveBankOfNewYorkMember_622967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_BankBranchDomain_622965" xlink:to="loc_imab_FederalReserveBankOfNewYorkMember_622967" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_622974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622958" xlink:to="loc_srt_RangeAxis_622974" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_622975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_622974" xlink:to="loc_srt_RangeMember_622975" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_622977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_622975" xlink:to="loc_srt_MinimumMember_622977" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_622976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_622975" xlink:to="loc_srt_MaximumMember_622976" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_622961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622958" xlink:to="loc_us-gaap_StatementLineItems_622961" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_622969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622961" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_622969" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable_622972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622961" xlink:to="loc_us-gaap_GrantsReceivable_622972" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_VATSurchargesPercent" xlink:label="loc_imab_VATSurchargesPercent_622973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622961" xlink:to="loc_imab_VATSurchargesPercent_622973" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_671556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622961" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_671556" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_671557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622961" xlink:to="loc_us-gaap_OperatingLeaseLiability_671557" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostImpairmentLoss" xlink:label="loc_us-gaap_CapitalizedContractCostImpairmentLoss_894163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622961" xlink:to="loc_us-gaap_CapitalizedContractCostImpairmentLoss_894163" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_622932" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_622935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622932" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_622935" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_622936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_622935" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_622936" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_622937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_622936" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_622937" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LaboratoryEquipmentMember" xlink:label="loc_imab_LaboratoryEquipmentMember_622939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_622937" xlink:to="loc_imab_LaboratoryEquipmentMember_622939" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SoftwareMember" xlink:label="loc_imab_SoftwareMember_622940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_622937" xlink:to="loc_imab_SoftwareMember_622940" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OfficeFurnitureAndEquipmentMember" xlink:label="loc_imab_OfficeFurnitureAndEquipmentMember_622942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_622937" xlink:to="loc_imab_OfficeFurnitureAndEquipmentMember_622942" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_622943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_622937" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_622943" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_622944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_622935" xlink:to="loc_srt_RangeAxis_622944" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_622945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_622944" xlink:to="loc_srt_RangeMember_622945" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_622948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_622945" xlink:to="loc_srt_MinimumMember_622948" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_622946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_622945" xlink:to="loc_srt_MaximumMember_622946" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_622949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_622935" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_622949" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_628254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_622949" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_628254" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_622950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_622949" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_622950" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/AccountsReceivableAndContractAssetsSummaryOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesDetail">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccountsReceivableAndContractAssetsAbstract" xlink:label="loc_imab_AccountsReceivableAndContractAssetsAbstract_907635" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrentAbstract" xlink:label="loc_us-gaap_AccountsReceivableNetCurrentAbstract_907636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_AccountsReceivableAndContractAssetsAbstract_907635" xlink:to="loc_us-gaap_AccountsReceivableNetCurrentAbstract_907636" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_907637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_907636" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_907637" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_907638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_907636" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_907638" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_907641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_907636" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_907641" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_907645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_AccountsReceivableAndContractAssetsAbstract_907635" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_907645" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetGrossCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetGrossCurrent_907646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_907645" xlink:to="loc_us-gaap_ContractWithCustomerAssetGrossCurrent_907646" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossCurrent_907647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_907645" xlink:to="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossCurrent_907647" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_907648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_907645" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_907648" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAbstract_621742" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies" xlink:label="loc_us-gaap_Supplies_621743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_621742" xlink:to="loc_us-gaap_Supplies_621743" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_621744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_621742" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_621744" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromEmployeesCurrent" xlink:label="loc_us-gaap_DueFromEmployeesCurrent_671558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_621742" xlink:to="loc_us-gaap_DueFromEmployeesCurrent_671558" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromAffiliateCurrent" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_871581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_621742" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_871581" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ValueaddedTaxRecoverable" xlink:label="loc_imab_ValueaddedTaxRecoverable_621745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_621742" xlink:to="loc_imab_ValueaddedTaxRecoverable_621745" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_621746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_621742" xlink:to="loc_us-gaap_SecurityDeposit_621746" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaap_InterestReceivable_621747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_621742" xlink:to="loc_us-gaap_InterestReceivable_621747" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_621748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_621742" xlink:to="loc_us-gaap_OtherAssets_621748" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_621758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_621742" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_621758" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PropertyEquipmentAndSoftwareAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_621953" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_621954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_621953" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_621954" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_621908" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_621909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_621908" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_621909" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_621910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_621909" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_621910" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_621912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_621910" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_621912" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LaboratoryEquipmentMember" xlink:label="loc_imab_LaboratoryEquipmentMember_621916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_621912" xlink:to="loc_imab_LaboratoryEquipmentMember_621916" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_621919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_621912" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_621919" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_621920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_621912" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_621920" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_621922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_621912" xlink:to="loc_us-gaap_OfficeEquipmentMember_621922" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_621923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_621909" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_621923" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_621928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_621923" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_621928" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_621929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_621928" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_621929" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_621930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_621928" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_621930" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PropertyPlantAndequipmentnetExcludingConstructionInProcess" xlink:label="loc_imab_PropertyPlantAndequipmentnetExcludingConstructionInProcess_652682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_621928" xlink:to="loc_imab_PropertyPlantAndequipmentnetExcludingConstructionInProcess_652682" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_652604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_621928" xlink:to="loc_us-gaap_ConstructionInProgressGross_652604" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_621945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_621928" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_621945" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_622526" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTable" xlink:label="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTable_622527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_622526" xlink:to="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTable_622527" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems" xlink:label="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems_622530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTable_622527" xlink:to="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems_622530" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_622534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems_622530" xlink:to="loc_us-gaap_AssetsAbstract_622534" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_622510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_622534" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_622510" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_622535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems_622530" xlink:to="loc_us-gaap_LiabilitiesAbstract_622535" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_622514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_622535" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_622514" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_622516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_622535" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_622516" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_622518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_622535" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_622518" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_622519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_622535" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_622519" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_622547" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfComponentsOfOperatingLeaseExpenseTable" xlink:label="loc_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTable_622548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_622547" xlink:to="loc_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTable_622548" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems" xlink:label="loc_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems_622549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTable_622548" xlink:to="loc_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems_622549" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingLeaseRightOfUseAssetAmortization" xlink:label="loc_imab_OperatingLeaseRightOfUseAssetAmortization_622553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems_622549" xlink:to="loc_imab_OperatingLeaseRightOfUseAssetAmortization_622553" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_622554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems_622549" xlink:to="loc_us-gaap_ShortTermLeaseCost_622554" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingLeaseInterestExpense" xlink:label="loc_imab_OperatingLeaseInterestExpense_622555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems_622549" xlink:to="loc_imab_OperatingLeaseInterestExpense_622555" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_652643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems_622549" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_652643" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/LeasesOperatingLeaseMaturityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_657733" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfOperatingLeaseMaturityTableTable" xlink:label="loc_imab_ScheduleOfOperatingLeaseMaturityTableTable_657734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_657733" xlink:to="loc_imab_ScheduleOfOperatingLeaseMaturityTableTable_657734" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfOperatingLeaseMaturityLineItems" xlink:label="loc_imab_ScheduleOfOperatingLeaseMaturityLineItems_657735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfOperatingLeaseMaturityTableTable_657734" xlink:to="loc_imab_ScheduleOfOperatingLeaseMaturityLineItems_657735" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_657737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfOperatingLeaseMaturityLineItems_657735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_657737" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_657738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfOperatingLeaseMaturityLineItems_657735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_657738" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_657739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfOperatingLeaseMaturityLineItems_657735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_657739" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_657742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfOperatingLeaseMaturityLineItems_657735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_657742" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_657743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfOperatingLeaseMaturityLineItems_657735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_657743" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_657744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfOperatingLeaseMaturityLineItems_657735" xlink:to="loc_us-gaap_OperatingLeaseLiability_657744" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_622640" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_629329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_622640" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_629329" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_629330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_629329" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_629330" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_629331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_629330" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_629331" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IprAndDTj103Member" xlink:label="loc_imab_IprAndDTj103Member_829132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_629331" xlink:to="loc_imab_IprAndDTj103Member_829132" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IprAndDTj102Member" xlink:label="loc_imab_IprAndDTj102Member_829134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_629331" xlink:to="loc_imab_IprAndDTj102Member_829134" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IprAndDTj101Member" xlink:label="loc_imab_IprAndDTj101Member_829133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_629331" xlink:to="loc_imab_IprAndDTj101Member_829133" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_629338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_629329" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_629338" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_629283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_629338" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_629283" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_622647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_629338" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_622647" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_622648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_629338" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_622648" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/IntangibleAssetsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_629347" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_829136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_629347" xlink:to="loc_us-gaap_StatementTable_829136" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_829137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_829136" xlink:to="loc_us-gaap_StatementClassOfStockAxis_829137" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_829138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_829137" xlink:to="loc_us-gaap_ClassOfStockDomain_829138" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_829140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_829136" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_829140" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_829141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_829140" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_829141" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IprAndDTj103Member" xlink:label="loc_imab_IprAndDTj103Member_829142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_829141" xlink:to="loc_imab_IprAndDTj103Member_829142" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_829139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_829136" xlink:to="loc_us-gaap_StatementLineItems_829139" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_629348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_829139" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_629348" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_829144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_829139" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_829144" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_829145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_829139" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_829145" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/GoodwillAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_622668" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_671566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_622668" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_671566" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_671569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_671566" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_671569" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_671570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_671569" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_671570" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TasgenGroupMember" xlink:label="loc_imab_TasgenGroupMember_671571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_671570" xlink:to="loc_imab_TasgenGroupMember_671571" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_671567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_671566" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_671567" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_622669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_671567" xlink:to="loc_us-gaap_Goodwill_622669" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_629353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_671567" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_629353" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_671559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_671567" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_671559" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_830514" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EquityMethodInvestmentSummarizedFinancialInformationTable" xlink:label="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationTable_830515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_830514" xlink:to="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationTable_830515" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_830517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationTable_830515" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_830517" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_830518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_830517" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_830518" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_RevenueMember" xlink:label="loc_imab_RevenueMember_830519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_830518" xlink:to="loc_imab_RevenueMember_830519" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_GrossProfitMember" xlink:label="loc_imab_GrossProfitMember_830520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_830518" xlink:to="loc_imab_GrossProfitMember_830520" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LossFromOperationMember" xlink:label="loc_imab_LossFromOperationMember_830521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_830518" xlink:to="loc_imab_LossFromOperationMember_830521" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_NetIncomeLossMember" xlink:label="loc_imab_NetIncomeLossMember_830522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_830518" xlink:to="loc_imab_NetIncomeLossMember_830522" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_830523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationTable_830515" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_830523" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_830524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_830523" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_830524" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LongTermInvestmentUnderEquityMethodMember" xlink:label="loc_imab_LongTermInvestmentUnderEquityMethodMember_830525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_830524" xlink:to="loc_imab_LongTermInvestmentUnderEquityMethodMember_830525" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EquityMethodInvestmentSummarizedFinancialInformationLineItems" xlink:label="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationLineItems_830527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationTable_830515" xlink:to="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationLineItems_830527" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OperatingDataAbstract" xlink:label="loc_imab_OperatingDataAbstract_830528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationLineItems_830527" xlink:to="loc_imab_OperatingDataAbstract_830528" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_830529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_OperatingDataAbstract_830528" xlink:to="loc_us-gaap_EquityMethodInvestments_830529" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_BalanceSheetDataAbstract" xlink:label="loc_imab_BalanceSheetDataAbstract_830534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_EquityMethodInvestmentSummarizedFinancialInformationLineItems_830527" xlink:to="loc_imab_BalanceSheetDataAbstract_830534" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_830535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_BalanceSheetDataAbstract_830534" xlink:to="loc_us-gaap_AssetsCurrent_830535" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_830536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_BalanceSheetDataAbstract_830534" xlink:to="loc_us-gaap_AssetsNoncurrent_830536" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_830537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_BalanceSheetDataAbstract_830534" xlink:to="loc_us-gaap_LiabilitiesCurrent_830537" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_830538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_BalanceSheetDataAbstract_830534" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_830538" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_830540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_BalanceSheetDataAbstract_830534" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_830540" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetail">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract" xlink:label="loc_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract_829245" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_829246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract_829245" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_829246" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_829247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract_829245" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_829247" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice_829248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract_829245" xlink:to="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice_829248" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate_829250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract_829245" xlink:to="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate_829250" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract" xlink:label="loc_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract_829262" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_829264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract_829262" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_829264" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_829270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_829264" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_829270" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_829271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_829270" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_829271" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ManagementHoldcoMember" xlink:label="loc_imab_ManagementHoldcoMember_829272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_829271" xlink:to="loc_imab_ManagementHoldcoMember_829272" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EsopHoldcoMember" xlink:label="loc_imab_EsopHoldcoMember_829273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_829271" xlink:to="loc_imab_EsopHoldcoMember_829273" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DomesticInvestorsMember" xlink:label="loc_imab_DomesticInvestorsMember_829274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_829271" xlink:to="loc_imab_DomesticInvestorsMember_829274" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_829267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_829264" xlink:to="loc_srt_ConsolidatedEntitiesAxis_829267" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_829268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_829267" xlink:to="loc_srt_ConsolidatedEntitiesDomain_829268" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ImabHangzhouMember" xlink:label="loc_imab_ImabHangzhouMember_829269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_829268" xlink:to="loc_imab_ImabHangzhouMember_829269" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ImabHongKongMember" xlink:label="loc_imab_ImabHongKongMember_829275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_829268" xlink:to="loc_imab_ImabHongKongMember_829275" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_894208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_829264" xlink:to="loc_srt_OwnershipAxis_894208" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_894209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_894208" xlink:to="loc_srt_OwnershipDomain_894209" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_HoldcoMember" xlink:label="loc_imab_HoldcoMember_894210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_894209" xlink:to="loc_imab_HoldcoMember_894210" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_829264" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_829277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_829277" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_829280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_829280" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_829284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_829284" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_RegisteredCapitalOfSubsidiary" xlink:label="loc_imab_RegisteredCapitalOfSubsidiary_829285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_imab_RegisteredCapitalOfSubsidiary_829285" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized_829287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized_829287" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_829291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_829291" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_829296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_829296" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_829312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_829312" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments" xlink:label="loc_us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments_829316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments_829316" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_829317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_829317" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciEquityMethodInvestmentAfterTax" xlink:label="loc_us-gaap_OciEquityMethodInvestmentAfterTax_871602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_OciEquityMethodInvestmentAfterTax_871602" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_871601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_871601" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_907668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_829276" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_907668" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract_622692" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_622694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_622692" xlink:to="loc_us-gaap_StatementTable_622694" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_622695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622694" xlink:to="loc_us-gaap_DebtInstrumentAxis_622695" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_622696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_622695" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_622696" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LoanOneMember" xlink:label="loc_imab_LoanOneMember_622699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_622696" xlink:to="loc_imab_LoanOneMember_622699" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LoanTwoMember" xlink:label="loc_imab_LoanTwoMember_622700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_622696" xlink:to="loc_imab_LoanTwoMember_622700" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_629385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622694" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_629385" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_629387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_629385" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_629387" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ChinaMerchantBankCoLtdMember" xlink:label="loc_imab_ChinaMerchantBankCoLtdMember_629388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_629387" xlink:to="loc_imab_ChinaMerchantBankCoLtdMember_629388" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_622701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622694" xlink:to="loc_us-gaap_StatementLineItems_622701" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLender" xlink:label="loc_us-gaap_ShortTermDebtLender_622702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622701" xlink:to="loc_us-gaap_ShortTermDebtLender_622702" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_622703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622701" xlink:to="loc_us-gaap_DebtInstrumentTerm_622703" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_622704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622701" xlink:to="loc_us-gaap_ShortTermBorrowings_622704" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_622705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622701" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_622705" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="loc_us-gaap_DebtInstrumentCollateralAmount_622707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622701" xlink:to="loc_us-gaap_DebtInstrumentCollateralAmount_622707" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" xlink:label="loc_us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits_629364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622701" xlink:to="loc_us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits_629364" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_629377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622701" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_629377" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_832456" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_832465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_832456" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_832465" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_622731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_832465" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_622731" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent" xlink:label="loc_imab_AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent_622736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_832465" xlink:to="loc_imab_AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent_622736" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccruedInitialPublicOfferingCostsPayable" xlink:label="loc_imab_AccruedInitialPublicOfferingCostsPayable_622738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_832465" xlink:to="loc_imab_AccruedInitialPublicOfferingCostsPayable_622738" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PrivatePlacementOfferingCostsPayable" xlink:label="loc_imab_PrivatePlacementOfferingCostsPayable_829340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_832465" xlink:to="loc_imab_PrivatePlacementOfferingCostsPayable_829340" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WithholdingIitPayable" xlink:label="loc_imab_WithholdingIitPayable_671576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_832465" xlink:to="loc_imab_WithholdingIitPayable_671576" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_NonRefundableIncentivePaymentFromDepositaryBankCurrent" xlink:label="loc_imab_NonRefundableIncentivePaymentFromDepositaryBankCurrent_829356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_832465" xlink:to="loc_imab_NonRefundableIncentivePaymentFromDepositaryBankCurrent_829356" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AccruedTravellingExpensesOfficeExpensesAndOthers" xlink:label="loc_imab_AccruedTravellingExpensesOfficeExpensesAndOthers_622739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_832465" xlink:to="loc_imab_AccruedTravellingExpensesOfficeExpensesAndOthers_622739" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_622740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_832465" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_622740" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract_829349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_832456" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract_829349" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_NonRefundableIncentivePaymentFromDepositaryBankNoncurrent" xlink:label="loc_imab_NonRefundableIncentivePaymentFromDepositaryBankNoncurrent_829351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract_829349" xlink:to="loc_imab_NonRefundableIncentivePaymentFromDepositaryBankNoncurrent_829351" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AdvanceReceivedFromEmployeeForExerciseOfStockOptions" xlink:label="loc_imab_AdvanceReceivedFromEmployeeForExerciseOfStockOptions_829355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract_829349" xlink:to="loc_imab_AdvanceReceivedFromEmployeeForExerciseOfStockOptions_829355" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_829358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract_829349" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_829358" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_894213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract_829349" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_894213" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/AccrualsAndOtherPayablesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_829378" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ProceedsFromNonRefundableIncentive" xlink:label="loc_imab_ProceedsFromNonRefundableIncentive_829380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_829378" xlink:to="loc_imab_ProceedsFromNonRefundableIncentive_829380" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome_829386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_829378" xlink:to="loc_us-gaap_OtherIncome_829386" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_622756" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_622758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_622756" xlink:to="loc_us-gaap_StatementTable_622758" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_622759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622758" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_622759" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_622760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_622759" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_622760" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PRCMember" xlink:label="loc_imab_PRCMember_622761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_622760" xlink:to="loc_imab_PRCMember_622761" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CNMember" xlink:label="loc_imab_CNMember_629412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_622760" xlink:to="loc_imab_CNMember_629412" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_622763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622758" xlink:to="loc_srt_StatementGeographicalAxis_622763" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_622764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_622763" xlink:to="loc_srt_SegmentGeographicalDomain_622764" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_HK" xlink:label="loc_country_HK_622772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_622764" xlink:to="loc_country_HK_622772" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_AU" xlink:label="loc_country_AU_622773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_622764" xlink:to="loc_country_AU_622773" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_629422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622758" xlink:to="loc_srt_ConsolidatedEntitiesAxis_629422" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_629425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_629422" xlink:to="loc_srt_ConsolidatedEntitiesDomain_629425" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IMobOtherSubsidiariesMember" xlink:label="loc_imab_IMobOtherSubsidiariesMember_629429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_629425" xlink:to="loc_imab_IMobOtherSubsidiariesMember_629429" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_622766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622758" xlink:to="loc_us-gaap_StatementLineItems_622766" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_622767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622766" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_622767" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_622768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622766" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_622768" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EffectivePreferentialIncomeTaxRate" xlink:label="loc_imab_EffectivePreferentialIncomeTaxRate_622771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622766" xlink:to="loc_imab_EffectivePreferentialIncomeTaxRate_622771" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_652673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622766" xlink:to="loc_us-gaap_OperatingLossCarryforwards_652673" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WithholdingTax" xlink:label="loc_imab_WithholdingTax_908784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622766" xlink:to="loc_imab_WithholdingTax_908784" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_622779" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_622780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_622779" xlink:to="loc_us-gaap_StatementTable_622780" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_622781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622780" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_622781" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_622782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_622781" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_622782" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_622784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622780" xlink:to="loc_us-gaap_StatementLineItems_622784" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_622792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622784" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_622792" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_622786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622784" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_622786" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_622787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622784" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_622787" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount" xlink:label="loc_imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount_622788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622784" xlink:to="loc_imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount_622788" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_622789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622784" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_622789" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_622790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622784" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_622790" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:label="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_622791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622784" xlink:to="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_622791" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_622794" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_622795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_622794" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_622795" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_622796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_622795" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_622796" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_622797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_622795" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_622797" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_622799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_622795" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_622799" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_622800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_622795" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_622800" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_622801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_622795" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_622801" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_622802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_622794" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_622802" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_622803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_622802" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_622803" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredTaxAssetsContractAssets" xlink:label="loc_imab_DeferredTaxAssetsContractAssets_894216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_622802" xlink:to="loc_imab_DeferredTaxAssetsContractAssets_894216" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_622804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_622802" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_622804" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_622805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_622794" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_622805" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/IncomeTaxesSummaryOfMovementOfTheValuationAllowanceDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_622811" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_622812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_622811" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_622812" use="optional" order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredTaxesAdditionsValuationAllowance" xlink:label="loc_imab_DeferredTaxesAdditionsValuationAllowance_622814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_622811" xlink:to="loc_imab_DeferredTaxesAdditionsValuationAllowance_622814" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredTaxAssetsValuationAllowanceUtilizationAndReversal" xlink:label="loc_imab_DeferredTaxAssetsValuationAllowanceUtilizationAndReversal_871842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_622811" xlink:to="loc_imab_DeferredTaxAssetsValuationAllowanceUtilizationAndReversal_871842" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance" xlink:label="loc_imab_DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance_622815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_622811" xlink:to="loc_imab_DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance_622815" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_622816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_622811" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_622816" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/OrdinarySharesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_622821" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_630017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_622821" xlink:to="loc_us-gaap_StatementTable_630017" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_630018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_630017" xlink:to="loc_us-gaap_StatementClassOfStockAxis_630018" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_630019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_630018" xlink:to="loc_us-gaap_ClassOfStockDomain_630019" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesAConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesAConvertiblePreferredStockMember_829477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_630019" xlink:to="loc_imab_SeriesAConvertiblePreferredStockMember_829477" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBMember_829478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_630019" xlink:to="loc_imab_ConvertiblePreferredStockSeriesBMember_829478" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBOneUponConversionMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBOneUponConversionMember_829479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_630019" xlink:to="loc_imab_ConvertiblePreferredStockSeriesBOneUponConversionMember_829479" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesB2Member" xlink:label="loc_imab_ConvertiblePreferredStockSeriesB2Member_829481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_630019" xlink:to="loc_imab_ConvertiblePreferredStockSeriesB2Member_829481" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_829482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_630019" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_829482" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesCOneConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesCOneConvertiblePreferredStockMember_829483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_630019" xlink:to="loc_imab_SeriesCOneConvertiblePreferredStockMember_829483" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AdrMember" xlink:label="loc_dei_AdrMember_832490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_630019" xlink:to="loc_dei_AdrMember_832490" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_630021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_630017" xlink:to="loc_srt_TitleOfIndividualAxis_630021" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_630022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_630021" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_630022" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_630023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_630022" xlink:to="loc_srt_DirectorMember_630023" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_BoardOfDirectorsMember" xlink:label="loc_imab_BoardOfDirectorsMember_829485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_630022" xlink:to="loc_imab_BoardOfDirectorsMember_829485" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_829428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_630017" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_829428" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_829428" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829429" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_829430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829429" xlink:to="loc_us-gaap_IPOMember_829430" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_829431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829429" xlink:to="loc_us-gaap_PrivatePlacementMember_829431" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_829432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_829429" xlink:to="loc_us-gaap_OverAllotmentOptionMember_829432" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_829464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_630017" xlink:to="loc_us-gaap_TypeOfArrangementAxis_829464" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_829465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_829464" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_829465" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CollaborationAgreementWithEverestMember" xlink:label="loc_imab_CollaborationAgreementWithEverestMember_829467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_829465" xlink:to="loc_imab_CollaborationAgreementWithEverestMember_829467" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_HillhouseEntitiesMember" xlink:label="loc_imab_HillhouseEntitiesMember_829504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_829465" xlink:to="loc_imab_HillhouseEntitiesMember_829504" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CollaborationAgreementWithInvestorsMember" xlink:label="loc_imab_CollaborationAgreementWithInvestorsMember_829505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_829465" xlink:to="loc_imab_CollaborationAgreementWithInvestorsMember_829505" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_829469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_630017" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_829469" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_829471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_829469" xlink:to="loc_us-gaap_RelatedPartyDomain_829471" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EverestsMember" xlink:label="loc_imab_EverestsMember_829472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_829471" xlink:to="loc_imab_EverestsMember_829472" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_829506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_630017" xlink:to="loc_us-gaap_InvestmentTypeAxis_829506" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_829507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_829506" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_829507" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_InvestorWarrantsMember" xlink:label="loc_imab_InvestorWarrantsMember_829512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_829507" xlink:to="loc_imab_InvestorWarrantsMember_829512" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PeriodTypeAxis" xlink:label="loc_imab_PeriodTypeAxis_829515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_630017" xlink:to="loc_imab_PeriodTypeAxis_829515" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PeriodTypeDomain" xlink:label="loc_imab_PeriodTypeDomain_829517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_PeriodTypeAxis_829515" xlink:to="loc_imab_PeriodTypeDomain_829517" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FirstClosingPeriodMember" xlink:label="loc_imab_FirstClosingPeriodMember_829521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_PeriodTypeDomain_829517" xlink:to="loc_imab_FirstClosingPeriodMember_829521" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SecondClosingPeriodMember" xlink:label="loc_imab_SecondClosingPeriodMember_829522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_PeriodTypeDomain_829517" xlink:to="loc_imab_SecondClosingPeriodMember_829522" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_829524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_630017" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_829524" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_829526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_829524" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_829526" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentySeventeenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_829528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_829526" xlink:to="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_829528" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_630020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_630017" xlink:to="loc_us-gaap_StatementLineItems_630020" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_622822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_622822" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_622823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_CommonStockVotingRights_622823" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_622825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_622825" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CommonStockValueAuthorized" xlink:label="loc_imab_CommonStockValueAuthorized_629473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_imab_CommonStockValueAuthorized_629473" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_829462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_829462" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_829436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_829436" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_829440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_829440" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_829449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_829449" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CommonStockSharesIssuable" xlink:label="loc_imab_CommonStockSharesIssuable_829452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_imab_CommonStockSharesIssuable_829452" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_829455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_SharePrice_829455" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_829457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_829457" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_829476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_829476" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_829530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_829530" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_829531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_829531" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AmericanDepositorySharesCommonShareEquivalent" xlink:label="loc_imab_AmericanDepositorySharesCommonShareEquivalent_829534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_imab_AmericanDepositorySharesCommonShareEquivalent_829534" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_829538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_829538" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PrepaidExpenseStockRepurchaseProgram" xlink:label="loc_imab_PrepaidExpenseStockRepurchaseProgram_829544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_imab_PrepaidExpenseStockRepurchaseProgram_829544" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_829548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_829548" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_829552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_829552" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_829555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_SharesIssued_829555" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_829557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_829557" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_GrossProceedsOfSharesAndWarrants" xlink:label="loc_imab_GrossProceedsOfSharesAndWarrants_829563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_imab_GrossProceedsOfSharesAndWarrants_829563" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated" xlink:label="loc_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_829567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated_829567" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_871856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_630020" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_871856" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_625400" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_625401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_625400" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_625401" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_625425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_625401" xlink:to="loc_us-gaap_StatementClassOfStockAxis_625425" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_625426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_625425" xlink:to="loc_us-gaap_ClassOfStockDomain_625426" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesA1AndA2PreferredStockMember" xlink:label="loc_imab_SeriesA1AndA2PreferredStockMember_625431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_SeriesA1AndA2PreferredStockMember_625431" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesA3Member" xlink:label="loc_imab_ConvertiblePreferredStockSeriesA3Member_625432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_ConvertiblePreferredStockSeriesA3Member_625432" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesA3PreferredStockMember" xlink:label="loc_imab_SeriesA3PreferredStockMember_625433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_SeriesA3PreferredStockMember_625433" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBMember_625434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_ConvertiblePreferredStockSeriesBMember_625434" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesB2Member" xlink:label="loc_imab_ConvertiblePreferredStockSeriesB2Member_625435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_ConvertiblePreferredStockSeriesB2Member_625435" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesAThreeUponExerciseMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesAThreeUponExerciseMember_625436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_ConvertiblePreferredStockSeriesAThreeUponExerciseMember_625436" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBOneUponConversionMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBOneUponConversionMember_625438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_ConvertiblePreferredStockSeriesBOneUponConversionMember_625438" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBTwoUponExerciseMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBTwoUponExerciseMember_625439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_ConvertiblePreferredStockSeriesBTwoUponExerciseMember_625439" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBUponExerciseMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBUponExerciseMember_625440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_ConvertiblePreferredStockSeriesBUponExerciseMember_625440" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePreferredStockSeriesBOneUponExerciseMember" xlink:label="loc_imab_ConvertiblePreferredStockSeriesBOneUponExerciseMember_625441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_ConvertiblePreferredStockSeriesBOneUponExerciseMember_625441" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_625444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_625444" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesCOnePreferredStockMember" xlink:label="loc_imab_SeriesCOnePreferredStockMember_625446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_SeriesCOnePreferredStockMember_625446" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesCOneConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesCOneConvertiblePreferredStockMember_625447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_SeriesCOneConvertiblePreferredStockMember_625447" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TemporaryEquityMember" xlink:label="loc_imab_TemporaryEquityMember_652689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_625426" xlink:to="loc_imab_TemporaryEquityMember_652689" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_625427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_625401" xlink:to="loc_srt_RangeAxis_625427" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_625428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_625427" xlink:to="loc_srt_RangeMember_625428" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_625429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_625428" xlink:to="loc_srt_MaximumMember_625429" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_625430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_625428" xlink:to="loc_srt_MinimumMember_625430" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_652690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_625401" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_652690" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_652691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_652690" xlink:to="loc_us-gaap_EquityComponentDomain_652691" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_652692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_652691" xlink:to="loc_us-gaap_PreferredStockMember_652692" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_625402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_625401" xlink:to="loc_us-gaap_TemporaryEquityLineItems_625402" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_625404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_625404" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IssueOfWarrants" xlink:label="loc_imab_IssueOfWarrants_625405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_imab_IssueOfWarrants_625405" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_625408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_625408" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_625410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_625410" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_625412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_us-gaap_PreferredStockSharesIssued_625412" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_625417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_625417" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockShareSubscriptions" xlink:label="loc_us-gaap_PreferredStockShareSubscriptions_625418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_us-gaap_PreferredStockShareSubscriptions_625418" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesSubscribedButUnissuedValue" xlink:label="loc_us-gaap_PreferredStockSharesSubscribedButUnissuedValue_625419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_us-gaap_PreferredStockSharesSubscribedButUnissuedValue_625419" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_QualifiedPublicOfferingPrice" xlink:label="loc_imab_QualifiedPublicOfferingPrice_625421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_imab_QualifiedPublicOfferingPrice_625421" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OfferingPriceOfConvertedShares" xlink:label="loc_imab_OfferingPriceOfConvertedShares_625422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_imab_OfferingPriceOfConvertedShares_625422" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockLiquidationPreferencePercentage" xlink:label="loc_imab_PreferredStockLiquidationPreferencePercentage_625423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_imab_PreferredStockLiquidationPreferencePercentage_625423" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockLiquidationPreferenceRateOfReturn" xlink:label="loc_imab_PreferredStockLiquidationPreferenceRateOfReturn_625424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_imab_PreferredStockLiquidationPreferenceRateOfReturn_625424" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityFairValueAdjustment" xlink:label="loc_us-gaap_EquityFairValueAdjustment_652687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_us-gaap_EquityFairValueAdjustment_652687" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AdjustmentsAtExtinguishmentOfPreferredShares" xlink:label="loc_imab_AdjustmentsAtExtinguishmentOfPreferredShares_671577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625402" xlink:to="loc_imab_AdjustmentsAtExtinguishmentOfPreferredShares_671577" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_625322" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_625323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_625322" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_625323" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_625365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_625323" xlink:to="loc_us-gaap_StatementClassOfStockAxis_625365" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_625366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_625365" xlink:to="loc_us-gaap_ClassOfStockDomain_625366" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesAConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesAConvertiblePreferredStockMember_625367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_625366" xlink:to="loc_imab_SeriesAConvertiblePreferredStockMember_625367" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesBConvertiblePreferredStockMember_625368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_625366" xlink:to="loc_imab_SeriesBConvertiblePreferredStockMember_625368" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesCConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesCConvertiblePreferredStockMember_625369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_625366" xlink:to="loc_imab_SeriesCConvertiblePreferredStockMember_625369" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesC1ConvertiblePreferredStockMember" xlink:label="loc_imab_SeriesC1ConvertiblePreferredStockMember_652717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_625366" xlink:to="loc_imab_SeriesC1ConvertiblePreferredStockMember_652717" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_625337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_625323" xlink:to="loc_us-gaap_FinancialInstrumentAxis_625337" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_625338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_625337" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_625338" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriescOneMember" xlink:label="loc_imab_SeriescOneMember_625345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_625338" xlink:to="loc_imab_SeriescOneMember_625345" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_625324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_625323" xlink:to="loc_us-gaap_TemporaryEquityLineItems_625324" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_625325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625324" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_625325" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_625326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625324" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_625326" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_652700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625324" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_652700" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_652709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625324" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_652709" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AdjustmentsAtExtinguishmentOfPreferredShares" xlink:label="loc_imab_AdjustmentsAtExtinguishmentOfPreferredShares_625336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625324" xlink:to="loc_imab_AdjustmentsAtExtinguishmentOfPreferredShares_625336" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_829636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625324" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_829636" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625324" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_829637" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_625333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625324" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_625333" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_625334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_625324" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_625334" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract" xlink:label="loc_imab_ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract_627022" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_627032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract_627022" xlink:to="loc_us-gaap_DebtInstrumentTable_627032" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_627033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_627032" xlink:to="loc_us-gaap_DebtInstrumentAxis_627033" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_627034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_627033" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_627034" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwoZeroOneEightNotesMember" xlink:label="loc_imab_TwoZeroOneEightNotesMember_627037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_627034" xlink:to="loc_imab_TwoZeroOneEightNotesMember_627037" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OnshoreConvertibleLoanMember" xlink:label="loc_imab_OnshoreConvertibleLoanMember_627038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_627034" xlink:to="loc_imab_OnshoreConvertibleLoanMember_627038" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePromissoryNotes2017Member" xlink:label="loc_imab_ConvertiblePromissoryNotes2017Member_630033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_627034" xlink:to="loc_imab_ConvertiblePromissoryNotes2017Member_630033" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ConvertiblePromissoryNotes2018Member" xlink:label="loc_imab_ConvertiblePromissoryNotes2018Member_630036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_627034" xlink:to="loc_imab_ConvertiblePromissoryNotes2018Member_630036" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_627043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_627032" xlink:to="loc_us-gaap_StatementClassOfStockAxis_627043" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_627044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_627043" xlink:to="loc_us-gaap_ClassOfStockDomain_627044" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesB1PreferredSharesMember" xlink:label="loc_imab_SeriesB1PreferredSharesMember_627066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_627044" xlink:to="loc_imab_SeriesB1PreferredSharesMember_627066" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesA3PreferredSharesMember" xlink:label="loc_imab_SeriesA3PreferredSharesMember_627073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_627044" xlink:to="loc_imab_SeriesA3PreferredSharesMember_627073" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBOnshoreInvestorsMember" xlink:label="loc_imab_SeriesBOnshoreInvestorsMember_627158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_627044" xlink:to="loc_imab_SeriesBOnshoreInvestorsMember_627158" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBPreferredStockHolderMember" xlink:label="loc_imab_SeriesBPreferredStockHolderMember_630034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_627044" xlink:to="loc_imab_SeriesBPreferredStockHolderMember_630034" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_831832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_627032" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_831832" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_831833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_831832" xlink:to="loc_us-gaap_RelatedPartyDomain_831833" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_GenexineIncMember" xlink:label="loc_imab_GenexineIncMember_831834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_831833" xlink:to="loc_imab_GenexineIncMember_831834" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionLineItems" xlink:label="loc_us-gaap_DebtConversionLineItems_627077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_627032" xlink:to="loc_us-gaap_DebtConversionLineItems_627077" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaap_NotesIssued1_627078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_NotesIssued1_627078" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_627081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_627081" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_627202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_627202" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_627216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_627216" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_627218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_DebtInstrumentTerm_627218" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_630031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_630031" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_630032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_630032" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_630037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_SharePrice_630037" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_831840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_627077" xlink:to="loc_us-gaap_SharesIssued_831840" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/WarrantsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WarrantsDisclosureAbstract" xlink:label="loc_imab_WarrantsDisclosureAbstract_624997" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_625000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_WarrantsDisclosureAbstract_624997" xlink:to="loc_us-gaap_StatementTable_625000" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_625018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_625000" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_625018" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_625019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_625018" xlink:to="loc_us-gaap_EquityComponentDomain_625019" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBPreferredShareholdersMember" xlink:label="loc_imab_SeriesBPreferredShareholdersMember_625028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_625019" xlink:to="loc_imab_SeriesBPreferredShareholdersMember_625028" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBOnshoreInvestorsMember" xlink:label="loc_imab_SeriesBOnshoreInvestorsMember_625031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_625019" xlink:to="loc_imab_SeriesBOnshoreInvestorsMember_625031" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TrancheIOfSeriesBWarrantsMember" xlink:label="loc_imab_TrancheIOfSeriesBWarrantsMember_625033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_625019" xlink:to="loc_imab_TrancheIOfSeriesBWarrantsMember_625033" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesB2PreferredSharesMember" xlink:label="loc_imab_SeriesB2PreferredSharesMember_625034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_625019" xlink:to="loc_imab_SeriesB2PreferredSharesMember_625034" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TrancheIiOfSeriesBWarrantsMember" xlink:label="loc_imab_TrancheIiOfSeriesBWarrantsMember_625036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_625019" xlink:to="loc_imab_TrancheIiOfSeriesBWarrantsMember_625036" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeriesBWarrantsSharesMember" xlink:label="loc_imab_SeriesBWarrantsSharesMember_625038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_625019" xlink:to="loc_imab_SeriesBWarrantsSharesMember_625038" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AmericanDepositarySharesMember" xlink:label="loc_imab_AmericanDepositarySharesMember_825494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_625019" xlink:to="loc_imab_AmericanDepositarySharesMember_825494" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_825491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_625000" xlink:to="loc_us-gaap_TypeOfArrangementAxis_825491" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_825492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_825491" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_825492" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CollaborationAgreementWithInvestorsMember" xlink:label="loc_imab_CollaborationAgreementWithInvestorsMember_825493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_825492" xlink:to="loc_imab_CollaborationAgreementWithInvestorsMember_825493" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_HillhouseEntitiesMember" xlink:label="loc_imab_HillhouseEntitiesMember_825500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_825492" xlink:to="loc_imab_HillhouseEntitiesMember_825500" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_825495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_625000" xlink:to="loc_us-gaap_InvestmentTypeAxis_825495" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_825496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_825495" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_825496" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_InvestorWarrantsMember" xlink:label="loc_imab_InvestorWarrantsMember_825497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_825496" xlink:to="loc_imab_InvestorWarrantsMember_825497" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_625003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_625000" xlink:to="loc_us-gaap_StatementLineItems_625003" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_625112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_625003" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_625112" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_625116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_625003" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_625116" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_625114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_625003" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_625114" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_630029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_625003" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_630029" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_825490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_625003" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_825490" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_825498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_625003" xlink:to="loc_us-gaap_SharePrice_825498" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_825499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_625003" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_825499" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_825504" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_825505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_825504" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_825505" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_825506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_825505" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_825506" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_825507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_825506" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_825507" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WarrantsToPurchaseOrdinarySharesMember" xlink:label="loc_imab_WarrantsToPurchaseOrdinarySharesMember_825508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_825507" xlink:to="loc_imab_WarrantsToPurchaseOrdinarySharesMember_825508" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_825509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_825505" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_825509" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Classofwarrantorrightsexercisableterm" xlink:label="loc_imab_Classofwarrantorrightsexercisableterm_825510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_825509" xlink:to="loc_imab_Classofwarrantorrightsexercisableterm_825510" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_825511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_825509" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_825511" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_825512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_825509" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_825512" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_825513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_825509" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_825513" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_WarrantsDisclosureAbstract" xlink:label="loc_imab_WarrantsDisclosureAbstract_625140" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_625158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_WarrantsDisclosureAbstract_625140" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_625158" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_625172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_625158" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_625172" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_625173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_625172" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_625173" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_625175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_625173" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_625175" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputMaturityMember" xlink:label="loc_us-gaap_MeasurementInputMaturityMember_625176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_625173" xlink:to="loc_us-gaap_MeasurementInputMaturityMember_625176" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_625177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_625173" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_625177" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_625178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_625173" xlink:to="loc_us-gaap_MeasurementInputExercisePriceMember_625178" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_625169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_625158" xlink:to="loc_us-gaap_StatementLineItems_625169" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_625171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_625169" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_625171" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_629462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_625169" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_629462" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_628053" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_628053" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_628067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" xlink:to="loc_us-gaap_PlanNameAxis_628067" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_628068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_628067" xlink:to="loc_us-gaap_PlanNameDomain_628068" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentySeventeenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_628070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_628068" xlink:to="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_628070" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyEighteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_628069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_628068" xlink:to="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_628069" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AmendedTwentySeventeenEmployeeStockOptionPlanMember" xlink:label="loc_imab_AmendedTwentySeventeenEmployeeStockOptionPlanMember_628076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_628068" xlink:to="loc_imab_AmendedTwentySeventeenEmployeeStockOptionPlanMember_628076" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyTwentyEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyTwentyEmployeeStockOptionPlanMember_830280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_628068" xlink:to="loc_imab_TwentyTwentyEmployeeStockOptionPlanMember_830280" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareIncentivePlan2020Member" xlink:label="loc_imab_ShareIncentivePlan2020Member_832306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_628068" xlink:to="loc_imab_ShareIncentivePlan2020Member_832306" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_629520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" xlink:to="loc_us-gaap_AwardTypeAxis_629520" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_629520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629521" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_629890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629521" xlink:to="loc_us-gaap_RestrictedStockMember_629890" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_629972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629521" xlink:to="loc_us-gaap_EmployeeStockOptionMember_629972" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyNineteenShareIncentivePlanMember" xlink:label="loc_imab_TwentyNineteenShareIncentivePlanMember_629522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629521" xlink:to="loc_imab_TwentyNineteenShareIncentivePlanMember_629522" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_894204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629521" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_894204" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_628071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" xlink:to="loc_srt_TitleOfIndividualAxis_628071" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_628073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_628071" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_628073" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FoundersMember" xlink:label="loc_imab_FoundersMember_629910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_628073" xlink:to="loc_imab_FoundersMember_629910" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DrzangMember" xlink:label="loc_imab_DrzangMember_628078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_628073" xlink:to="loc_imab_DrzangMember_628078" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_628075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_628073" xlink:to="loc_srt_DirectorMember_628075" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LeiFangMember" xlink:label="loc_imab_LeiFangMember_628193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_628073" xlink:to="loc_imab_LeiFangMember_628193" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SeniorManagementEmployeesMember" xlink:label="loc_imab_SeniorManagementEmployeesMember_630030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_628073" xlink:to="loc_imab_SeniorManagementEmployeesMember_630030" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_628081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" xlink:to="loc_us-gaap_VestingAxis_628081" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_628082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_628081" xlink:to="loc_us-gaap_VestingDomain_628082" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_628083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_628082" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_628083" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_628084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_628082" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_628084" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_629908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_628082" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_629908" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationTrancheFourMember" xlink:label="loc_imab_ShareBasedCompensationTrancheFourMember_830409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_628082" xlink:to="loc_imab_ShareBasedCompensationTrancheFourMember_830409" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OnePerformanceConditionMember" xlink:label="loc_imab_OnePerformanceConditionMember_830430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_628082" xlink:to="loc_imab_OnePerformanceConditionMember_830430" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwoPerformanceConditionsMember" xlink:label="loc_imab_TwoPerformanceConditionsMember_830431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_628082" xlink:to="loc_imab_TwoPerformanceConditionsMember_830431" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ThreePerformanceConditionsMember" xlink:label="loc_imab_ThreePerformanceConditionsMember_830432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_628082" xlink:to="loc_imab_ThreePerformanceConditionsMember_830432" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FourPerformanceConditionsMember" xlink:label="loc_imab_FourPerformanceConditionsMember_830433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_628082" xlink:to="loc_imab_FourPerformanceConditionsMember_830433" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_628085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_628085" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_628086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_628085" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_628086" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_628087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_628086" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_628087" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_830235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_628086" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_830235" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EquityInLossOfAnAffiliateMember" xlink:label="loc_imab_EquityInLossOfAnAffiliateMember_871713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_628086" xlink:to="loc_imab_EquityInLossOfAnAffiliateMember_871713" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_629517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" xlink:to="loc_srt_RangeAxis_629517" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_629518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_629517" xlink:to="loc_srt_RangeMember_629518" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_628056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_628056" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_628058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_628056" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_628058" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ThirdVentureMember" xlink:label="loc_imab_ThirdVentureMember_628061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_628058" xlink:to="loc_imab_ThirdVentureMember_628061" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PortionOfRestrictedShareUnitsAxis" xlink:label="loc_imab_PortionOfRestrictedShareUnitsAxis_830398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" xlink:to="loc_imab_PortionOfRestrictedShareUnitsAxis_830398" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PortionOfRestrictedShareUnitsDomain" xlink:label="loc_imab_PortionOfRestrictedShareUnitsDomain_830405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_PortionOfRestrictedShareUnitsAxis_830398" xlink:to="loc_imab_PortionOfRestrictedShareUnitsDomain_830405" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ThirdOneThirdPortionMember" xlink:label="loc_imab_ThirdOneThirdPortionMember_830406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_PortionOfRestrictedShareUnitsDomain_830405" xlink:to="loc_imab_ThirdOneThirdPortionMember_830406" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SecondOneThirdPortionMember" xlink:label="loc_imab_SecondOneThirdPortionMember_830422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_PortionOfRestrictedShareUnitsDomain_830405" xlink:to="loc_imab_SecondOneThirdPortionMember_830422" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_628055" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_629887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_629887" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_628091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_628091" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_629895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_629895" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_628093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_628093" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_628094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_628094" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted" xlink:label="loc_imab_ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted_629904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_imab_ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted_629904" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_628095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_628095" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_629909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_SharePrice_629909" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_628098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_628098" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_628138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_628138" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_629973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_629973" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_629974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_629974" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_629975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_629975" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_629529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_629529" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_628141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_628141" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased_630025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased_630025" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" xlink:label="loc_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice_630027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice_630027" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration_630028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration_630028" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_628269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_628269" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_830205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_830205" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_830206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_830206" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_830247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_830247" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="loc_us-gaap_StockOptionExercisePriceIncrease_830326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_StockOptionExercisePriceIncrease_830326" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares" xlink:label="loc_imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares_830413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares_830413" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares" xlink:label="loc_imab_MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares_830420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_imab_MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares_830420" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_830439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_830439" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_830443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_830443" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_830446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_830446" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_894188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_628088" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_894188" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_626494" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_626499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_626494" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_626499" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_626500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_626499" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_626500" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_626501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_626500" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_626501" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_626509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_626501" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_626509" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_626508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_626501" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_626508" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EquityInLossOfAnAffiliateMember" xlink:label="loc_imab_EquityInLossOfAnAffiliateMember_871700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_626501" xlink:to="loc_imab_EquityInLossOfAnAffiliateMember_871700" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_629954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_626499" xlink:to="loc_us-gaap_AwardTypeAxis_629954" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_629954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629955" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_629956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_629955" xlink:to="loc_us-gaap_RestrictedStockMember_629956" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_626512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_626499" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_626512" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_626513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_626512" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_626513" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_626546" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_626546" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627991" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_627992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627991" xlink:to="loc_us-gaap_PlanNameAxis_627992" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_627993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_627992" xlink:to="loc_us-gaap_PlanNameDomain_627993" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentySeventeenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_627995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_627993" xlink:to="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_627995" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyEighteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_627994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_627993" xlink:to="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_627994" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyNineteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyNineteenEmployeeStockOptionPlanMember_830599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_627993" xlink:to="loc_imab_TwentyNineteenEmployeeStockOptionPlanMember_830599" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareIncentivePlanTwoThousandTwentyMember" xlink:label="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_627993" xlink:to="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830600" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627996" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_627997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_627997" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_627998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_627998" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_628002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_628002" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased_628006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" xlink:to="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased_628006" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_830554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_830554" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod_830555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" xlink:to="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod_830555" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_628007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_628007" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_628008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_629976" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_628008" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_629978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_629978" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_629979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_629979" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_629981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_629981" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" xlink:label="loc_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice_630009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" xlink:to="loc_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice_630009" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_830556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_830556" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice" xlink:label="loc_imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice_830557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" xlink:to="loc_imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice_830557" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_629982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_629982" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_629983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_629977" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_629983" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_629987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627996" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_629987" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_629991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627996" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_629991" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_628032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_628032" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_628041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627996" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_628041" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_627364" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_627364" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627960" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_627961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627960" xlink:to="loc_us-gaap_PlanNameAxis_627961" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_627962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_627961" xlink:to="loc_us-gaap_PlanNameDomain_627962" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyEighteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_627963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_627962" xlink:to="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_627963" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyNineteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyNineteenEmployeeStockOptionPlanMember_830601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_627962" xlink:to="loc_imab_TwentyNineteenEmployeeStockOptionPlanMember_830601" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareIncentivePlanTwoThousandTwentyMember" xlink:label="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_627962" xlink:to="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830602" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_627960" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_627365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_627365" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_627371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_627371" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_627372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_627372" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_627366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_627366" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_627374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_627374" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_627373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_627373" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple" xlink:label="loc_imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple_627367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple_627367" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum_832269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum_832269" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum_832271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum_832271" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_627368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_627368" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_627369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_630014" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_627369" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_830568" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_830568" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830569" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_830570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830569" xlink:to="loc_us-gaap_PlanNameAxis_830570" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_830571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_830570" xlink:to="loc_us-gaap_PlanNameDomain_830571" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentySeventeenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_830572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_830571" xlink:to="loc_imab_TwentySeventeenEmployeeStockOptionPlanMember_830572" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyEighteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_830573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_830571" xlink:to="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_830573" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyNineteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyNineteenEmployeeStockOptionPlanMember_830574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_830571" xlink:to="loc_imab_TwentyNineteenEmployeeStockOptionPlanMember_830574" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareIncentivePlanTwoThousandTwentyMember" xlink:label="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_830571" xlink:to="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830575" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_832461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830569" xlink:to="loc_us-gaap_AwardTypeAxis_832461" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_832462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_832461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_832462" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_832463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_832462" xlink:to="loc_us-gaap_EmployeeStockOptionMember_832463" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830569" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830577" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_830578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830577" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_830578" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_830579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_830578" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_830579" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_830580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_830578" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_830580" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_830581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_830578" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_830581" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares" xlink:label="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares_830582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_830578" xlink:to="loc_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares_830582" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_830583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_830578" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_830583" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares" xlink:label="loc_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares_830584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_830578" xlink:to="loc_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares_830584" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_830585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_830578" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_830585" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_830586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830577" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_830586" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_830587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_830586" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_830587" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_830588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_830586" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_830588" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue" xlink:label="loc_imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue_830589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_830586" xlink:to="loc_imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue_830589" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_830590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_830586" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_830590" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue" xlink:label="loc_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue_830591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_830586" xlink:to="loc_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue_830591" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_830592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_830586" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_830592" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_830593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_830586" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_830593" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_830605" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfNonvestedRestrictedStockUnitsActivityTable" xlink:label="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityTable_830606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_830605" xlink:to="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityTable_830606" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_830607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityTable_830606" xlink:to="loc_us-gaap_AwardTypeAxis_830607" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_830607" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830608" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_830609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830608" xlink:to="loc_us-gaap_RestrictedStockMember_830609" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_830610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityTable_830606" xlink:to="loc_us-gaap_PlanNameAxis_830610" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_830611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_830610" xlink:to="loc_us-gaap_PlanNameDomain_830611" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareIncentivePlanTwoThousandTwentyMember" xlink:label="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_830611" xlink:to="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830613" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyTwentyEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyTwentyEmployeeStockOptionPlanMember_832362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_830611" xlink:to="loc_imab_TwentyTwentyEmployeeStockOptionPlanMember_832362" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems" xlink:label="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityTable_830606" xlink:to="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_830616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_830616" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_830617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_830617" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_830618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_830618" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_830619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_830619" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_830622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_830622" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_830623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_830623" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_830624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_830624" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_830625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems_830615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_830625" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_830632" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable" xlink:label="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable_830633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_830632" xlink:to="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable_830633" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_830634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable_830633" xlink:to="loc_us-gaap_AwardTypeAxis_830634" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_830634" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830635" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_830636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830635" xlink:to="loc_us-gaap_RestrictedStockMember_830636" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_830637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable_830633" xlink:to="loc_us-gaap_PlanNameAxis_830637" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_830638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_830637" xlink:to="loc_us-gaap_PlanNameDomain_830638" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TwentyEighteenEmployeeStockOptionPlanMember" xlink:label="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_830639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_830638" xlink:to="loc_imab_TwentyEighteenEmployeeStockOptionPlanMember_830639" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ShareIncentivePlanTwoThousandTwentyMember" xlink:label="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_830638" xlink:to="loc_imab_ShareIncentivePlanTwoThousandTwentyMember_830640" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems" xlink:label="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems_830642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable_830633" xlink:to="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems_830642" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_830643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems_830642" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_830643" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_830644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_830643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_830644" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_830645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_830643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_830645" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_871682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_830643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_871682" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_830646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_830643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_830646" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_830647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems_830642" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_830647" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_830648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_830647" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_830648" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_871686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_830647" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_871686" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_830649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_830647" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_830649" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_830650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems_830642" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_830650" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_830651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems_830642" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_830651" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_627394" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_627394" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_627397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_627397" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_627398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_627397" xlink:to="loc_us-gaap_RelatedPartyDomain_627398" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MorphoSysAGMember" xlink:label="loc_imab_MorphoSysAGMember_627400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_627398" xlink:to="loc_imab_MorphoSysAGMember_627400" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_GenexineIncMember" xlink:label="loc_imab_GenexineIncMember_627426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_627398" xlink:to="loc_imab_GenexineIncMember_627426" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MacroGenicsMember" xlink:label="loc_imab_MacroGenicsMember_627454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_627398" xlink:to="loc_imab_MacroGenicsMember_627454" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_HealSunMember" xlink:label="loc_imab_HealSunMember_627458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_627398" xlink:to="loc_imab_HealSunMember_627458" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EverestMember" xlink:label="loc_imab_EverestMember_627500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_627398" xlink:to="loc_imab_EverestMember_627500" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ABLBioMember" xlink:label="loc_imab_ABLBioMember_680139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_627398" xlink:to="loc_imab_ABLBioMember_680139" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AbbVieMember" xlink:label="loc_imab_AbbVieMember_829789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_627398" xlink:to="loc_imab_AbbVieMember_829789" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627401" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627401" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627402" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_627404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627402" xlink:to="loc_us-gaap_LicensingAgreementsMember_627404" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OtherInLicensingAgreementsMember" xlink:label="loc_imab_OtherInLicensingAgreementsMember_627456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627402" xlink:to="loc_imab_OtherInLicensingAgreementsMember_627456" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OutLicensingAgreementsMember" xlink:label="loc_imab_OutLicensingAgreementsMember_627460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627402" xlink:to="loc_imab_OutLicensingAgreementsMember_627460" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LemzoparlimabLicenseMember" xlink:label="loc_imab_LemzoparlimabLicenseMember_871760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627402" xlink:to="loc_imab_LemzoparlimabLicenseMember_871760" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_627415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_627415" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_627416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_627415" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_627416" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_627417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_627416" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_627417" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_627954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_627416" xlink:to="loc_us-gaap_OperatingExpenseMember_627954" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_627419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_srt_RangeAxis_627419" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_627420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_627419" xlink:to="loc_srt_RangeMember_627420" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_627421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_627420" xlink:to="loc_srt_MinimumMember_627421" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_627470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_srt_MajorCustomersAxis_627470" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_627471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_627470" xlink:to="loc_srt_NameOfMajorCustomerDomain_627471" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_627926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_us-gaap_TypeOfArrangementAxis_627926" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_627926" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember" xlink:label="loc_imab_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember_627928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember_627928" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithABLBioMember" xlink:label="loc_imab_LicensingAgreementWithABLBioMember_627935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_LicensingAgreementWithABLBioMember_627935" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CollaborationAgreementWithABLBioMember" xlink:label="loc_imab_CollaborationAgreementWithABLBioMember_627952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_CollaborationAgreementWithABLBioMember_627952" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember" xlink:label="loc_imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember_627956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember_627956" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMorphosysAgMember" xlink:label="loc_imab_LicensingAgreementWithMorphosysAgMember_629649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_LicensingAgreementWithMorphosysAgMember_629649" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithGenexineIncMember" xlink:label="loc_imab_LicensingAgreementWithGenexineIncMember_629678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_LicensingAgreementWithGenexineIncMember_629678" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementsWithMorphosysMember" xlink:label="loc_imab_LicensingAgreementsWithMorphosysMember_629794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_LicensingAgreementsWithMorphosysMember_629794" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMacrogenicsMember" xlink:label="loc_imab_LicensingAgreementWithMacrogenicsMember_629797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_LicensingAgreementWithMacrogenicsMember_629797" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OtherinlicensingarrangementsMember" xlink:label="loc_imab_OtherinlicensingarrangementsMember_629833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_OtherinlicensingarrangementsMember_629833" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember" xlink:label="loc_imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember_629889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember_629889" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CollaborationAgreementWithEverestMember" xlink:label="loc_imab_CollaborationAgreementWithEverestMember_630128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_CollaborationAgreementWithEverestMember_630128" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember" xlink:label="loc_imab_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember_829814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_627927" xlink:to="loc_imab_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember_829814" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_627929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_srt_CounterpartyNameAxis_627929" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_627929" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CspcMember" xlink:label="loc_imab_CspcMember_627931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930" xlink:to="loc_imab_CspcMember_627931" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ABLBioMember" xlink:label="loc_imab_ABLBioMember_627937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930" xlink:to="loc_imab_ABLBioMember_627937" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MorphoSysAGMember" xlink:label="loc_imab_MorphoSysAGMember_628698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930" xlink:to="loc_imab_MorphoSysAGMember_628698" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_GenexineIncMember" xlink:label="loc_imab_GenexineIncMember_628700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930" xlink:to="loc_imab_GenexineIncMember_628700" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MorphosysMember" xlink:label="loc_imab_MorphosysMember_628701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930" xlink:to="loc_imab_MorphosysMember_628701" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MacroGenicsMember" xlink:label="loc_imab_MacroGenicsMember_629799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930" xlink:to="loc_imab_MacroGenicsMember_629799" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_HealSunMember" xlink:label="loc_imab_HealSunMember_629886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_627930" xlink:to="loc_imab_HealSunMember_629886" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestoneTypeAxis" xlink:label="loc_imab_MilestoneTypeAxis_627938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_imab_MilestoneTypeAxis_627938" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestoneTypeDomain" xlink:label="loc_imab_MilestoneTypeDomain_627939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_MilestoneTypeAxis_627938" xlink:to="loc_imab_MilestoneTypeDomain_627939" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ClinicalMilestonesMember" xlink:label="loc_imab_ClinicalMilestonesMember_627945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_MilestoneTypeDomain_627939" xlink:to="loc_imab_ClinicalMilestonesMember_627945" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SalesMilestonesMember" xlink:label="loc_imab_SalesMilestonesMember_627946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_MilestoneTypeDomain_627939" xlink:to="loc_imab_SalesMilestonesMember_627946" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DevelopmentMilestoneMember" xlink:label="loc_imab_DevelopmentMilestoneMember_630087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_MilestoneTypeDomain_627939" xlink:to="loc_imab_DevelopmentMilestoneMember_630087" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestoneIiiMember" xlink:label="loc_imab_MilestoneIiiMember_630102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_MilestoneTypeDomain_627939" xlink:to="loc_imab_MilestoneIiiMember_630102" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestoneIvMember" xlink:label="loc_imab_MilestoneIvMember_630103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_MilestoneTypeDomain_627939" xlink:to="loc_imab_MilestoneIvMember_630103" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FirstMilestoneMember" xlink:label="loc_imab_FirstMilestoneMember_871764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_MilestoneTypeDomain_627939" xlink:to="loc_imab_FirstMilestoneMember_871764" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_SecondMilestoneMember" xlink:label="loc_imab_SecondMilestoneMember_871766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_MilestoneTypeDomain_627939" xlink:to="loc_imab_SecondMilestoneMember_871766" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_628872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_srt_ProductOrServiceAxis_628872" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_628873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_628872" xlink:to="loc_srt_ProductsAndServicesDomain_628873" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Gxi7Member" xlink:label="loc_imab_Gxi7Member_628875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_628873" xlink:to="loc_imab_Gxi7Member_628875" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_629950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_629950" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_629951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_629950" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_629951" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredRevenueMember" xlink:label="loc_imab_DeferredRevenueMember_629952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_629951" xlink:to="loc_imab_DeferredRevenueMember_629952" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TypeOfLicensesAxis" xlink:label="loc_imab_TypeOfLicensesAxis_829815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_imab_TypeOfLicensesAxis_829815" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TypeOfLicensesDomain" xlink:label="loc_imab_TypeOfLicensesDomain_829816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_TypeOfLicensesAxis_829815" xlink:to="loc_imab_TypeOfLicensesDomain_829816" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Study1Member" xlink:label="loc_imab_Study1Member_829811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_TypeOfLicensesDomain_829816" xlink:to="loc_imab_Study1Member_829811" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_Study2Member" xlink:label="loc_imab_Study2Member_829812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_TypeOfLicensesDomain_829816" xlink:to="loc_imab_Study2Member_829812" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_872898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_872898" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_872899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_872898" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_872899" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_872900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_872899" xlink:to="loc_us-gaap_SubsequentEventMember_872900" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627396" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_UpfrontLicenseFee" xlink:label="loc_imab_UpfrontLicenseFee_627409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_UpfrontLicenseFee_627409" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestonePayments" xlink:label="loc_imab_MilestonePayments_627410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_MilestonePayments_627410" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PercentageOfReductionInMilestonePayments" xlink:label="loc_imab_PercentageOfReductionInMilestonePayments_627441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_PercentageOfReductionInMilestonePayments_627441" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementRightsAndObligations" xlink:label="loc_us-gaap_CollaborativeArrangementRightsAndObligations_627455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_CollaborativeArrangementRightsAndObligations_627455" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_629592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_629592" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_627466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_627466" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExciseAndSalesTaxes" xlink:label="loc_us-gaap_ExciseAndSalesTaxes_627467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_ExciseAndSalesTaxes_627467" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_627498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_627498" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_627506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_627506" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_627511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_627511" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_627512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_CommonStockValue_627512" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_627513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_CommonStockSharesIssued_627513" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestonePaymentsOutstanding" xlink:label="loc_imab_MilestonePaymentsOutstanding_627891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_MilestonePaymentsOutstanding_627891" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_627933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_627933" use="optional" order="85" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_627934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_627934" use="optional" order="86" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CostSharingRatio" xlink:label="loc_imab_CostSharingRatio_627936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_CostSharingRatio_627936" use="optional" order="87" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_627951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_627951" use="optional" order="88" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestonePaymentsIncome" xlink:label="loc_imab_MilestonePaymentsIncome_629903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_MilestonePaymentsIncome_629903" use="optional" order="89" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredRevenueFromCollaborativeArrangementExcludingVat" xlink:label="loc_imab_DeferredRevenueFromCollaborativeArrangementExcludingVat_629944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_DeferredRevenueFromCollaborativeArrangementExcludingVat_629944" use="optional" order="90" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CumulativePaidInContributions" xlink:label="loc_imab_CumulativePaidInContributions_630084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_CumulativePaidInContributions_630084" use="optional" order="91" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TimeCostOfForegoingHistoricalContribution" xlink:label="loc_imab_TimeCostOfForegoingHistoricalContribution_630085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_TimeCostOfForegoingHistoricalContribution_630085" use="optional" order="92" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_UpfrontAndMilestonePayments" xlink:label="loc_imab_UpfrontAndMilestonePayments_829796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_UpfrontAndMilestonePayments_829796" use="optional" order="93" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_RevenueFromContractWithCustomerTimeOfTransferOfLicense" xlink:label="loc_imab_RevenueFromContractWithCustomerTimeOfTransferOfLicense_829824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_RevenueFromContractWithCustomerTimeOfTransferOfLicense_829824" use="optional" order="94" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent" xlink:label="loc_imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent_829828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent_829828" use="optional" order="95" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax" xlink:label="loc_imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax_829830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax_829830" use="optional" order="96" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_832108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_832108" use="optional" order="97" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_871786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_871786" use="optional" order="98" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_UpfrontPaymentReceived" xlink:label="loc_imab_UpfrontPaymentReceived_871791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_UpfrontPaymentReceived_871791" use="optional" order="99" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestonePaymentReceivable" xlink:label="loc_imab_MilestonePaymentReceivable_871792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627407" xlink:to="loc_imab_MilestonePaymentReceivable_871792" use="optional" order="100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_627293" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_627293" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627310" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_627323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627310" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_627323" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_627324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_627323" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_627324" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_627330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_627324" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_627330" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627310" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627311" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_627311" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_627312" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_628520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627310" xlink:to="loc_us-gaap_TypeOfArrangementAxis_628520" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_628520" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628522" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMorphosysAgMember" xlink:label="loc_imab_LicensingAgreementWithMorphosysAgMember_628524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628522" xlink:to="loc_imab_LicensingAgreementWithMorphosysAgMember_628524" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithGenexineIncMember" xlink:label="loc_imab_LicensingAgreementWithGenexineIncMember_628527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628522" xlink:to="loc_imab_LicensingAgreementWithGenexineIncMember_628527" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMorphosysMember" xlink:label="loc_imab_LicensingAgreementWithMorphosysMember_628528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628522" xlink:to="loc_imab_LicensingAgreementWithMorphosysMember_628528" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementWithMacrogenicsMember" xlink:label="loc_imab_LicensingAgreementWithMacrogenicsMember_628532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_628522" xlink:to="loc_imab_LicensingAgreementWithMacrogenicsMember_628532" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_627310" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627332" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LicensingAgreementUpfrontFees" xlink:label="loc_imab_LicensingAgreementUpfrontFees_627334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627332" xlink:to="loc_imab_LicensingAgreementUpfrontFees_627334" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_MilestonePayments" xlink:label="loc_imab_MilestonePayments_627343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_627332" xlink:to="loc_imab_MilestonePayments_627343" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_622251" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_622253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_622251" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_622253" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LossFromConversionOfOnshoreConvertibleLoans" xlink:label="loc_imab_LossFromConversionOfOnshoreConvertibleLoans_622254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_622251" xlink:to="loc_imab_LossFromConversionOfOnshoreConvertibleLoans_622254" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_LossFromIssuanceOfNotes" xlink:label="loc_imab_LossFromIssuanceOfNotes_622256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_622251" xlink:to="loc_imab_LossFromIssuanceOfNotes_622256" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="loc_us-gaap_GainLossOnContractTermination_671578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_622251" xlink:to="loc_us-gaap_GainLossOnContractTermination_671578" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IncentiveIncomeFromDepositoryBank" xlink:label="loc_imab_IncentiveIncomeFromDepositoryBank_829838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_622251" xlink:to="loc_imab_IncentiveIncomeFromDepositoryBank_829838" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueChangeOfShortTermInvestments" xlink:label="loc_imab_FairValueChangeOfShortTermInvestments_622257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_622251" xlink:to="loc_imab_FairValueChangeOfShortTermInvestments_622257" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueAdjustmentsOfPutRightLiabilities" xlink:label="loc_imab_FairValueAdjustmentsOfPutRightLiabilities_829842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_622251" xlink:to="loc_imab_FairValueAdjustmentsOfPutRightLiabilities_829842" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IncomeFromOtherFinancialAssets" xlink:label="loc_imab_IncomeFromOtherFinancialAssets_622258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_622251" xlink:to="loc_imab_IncomeFromOtherFinancialAssets_622258" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_622260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_622251" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_622260" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CharityCareReimbursementsReceived" xlink:label="loc_us-gaap_CharityCareReimbursementsReceived_622261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_622251" xlink:to="loc_us-gaap_CharityCareReimbursementsReceived_622261" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_829841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_622251" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_829841" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_FairValueAdjustmentsOfOtherFinancialAssets" xlink:label="loc_imab_FairValueAdjustmentsOfOtherFinancialAssets_622262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_622251" xlink:to="loc_imab_FairValueAdjustmentsOfOtherFinancialAssets_622262" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_OtherIncomeexpense" xlink:label="loc_imab_OtherIncomeexpense_630119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_622251" xlink:to="loc_imab_OtherIncomeexpense_630119" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_622287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_622251" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_622287" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetParentheticalDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_829848" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_829849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_829848" xlink:to="loc_us-gaap_StatementTable_829849" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_829850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_829849" xlink:to="loc_srt_ProductOrServiceAxis_829850" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_829851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_829850" xlink:to="loc_srt_ProductsAndServicesDomain_829851" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_829852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_829851" xlink:to="loc_us-gaap_GrantMember_829852" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_829853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_829849" xlink:to="loc_us-gaap_StatementLineItems_829853" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_829854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_829853" xlink:to="loc_us-gaap_Revenues_829854" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_622154" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_629787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_622154" xlink:to="loc_us-gaap_NetIncomeLossAbstract_629787" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_622170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_629787" xlink:to="loc_us-gaap_NetIncomeLoss_622170" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares" xlink:label="loc_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares_671579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_629787" xlink:to="loc_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares_671579" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PreferredStockDividendsAtModificationOfPreferredShares" xlink:label="loc_imab_PreferredStockDividendsAtModificationOfPreferredShares_671580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_629787" xlink:to="loc_imab_PreferredStockDividendsAtModificationOfPreferredShares_671580" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_652558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_629787" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_652558" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_629789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_622154" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_629789" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_829857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_629789" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_829857" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_871807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_629789" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_871807" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_871810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_629789" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_871810" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_871812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_629789" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_871812" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_IncrementalCommonSharesAttributableToRestrictedShareUnits" xlink:label="loc_imab_IncrementalCommonSharesAttributableToRestrictedShareUnits_871813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_629789" xlink:to="loc_imab_IncrementalCommonSharesAttributableToRestrictedShareUnits_871813" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_871814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_629789" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_871814" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_829859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_629789" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_829859" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_829861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_622154" xlink:to="loc_us-gaap_EarningsPerShareBasic_829861" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_829862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_622154" xlink:to="loc_us-gaap_EarningsPerShareDiluted_829862" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_622188" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_622214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_622188" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_622214" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_622215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_622214" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_622215" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_622216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_622215" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_622216" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_622218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_622216" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_622218" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_622219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_622216" xlink:to="loc_us-gaap_RestrictedStockMember_622219" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_622221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_622216" xlink:to="loc_us-gaap_EmployeeStockOptionMember_622221" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_622225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_622214" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_622225" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_622226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_622225" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_622226" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/EmployeeBenefitsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_622103" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_622106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_622103" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_622106" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_629734" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_629734" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629736" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_629737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629736" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_629737" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_629738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_629737" xlink:to="loc_us-gaap_RelatedPartyDomain_629738" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EverestMember" xlink:label="loc_imab_EverestMember_629752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_629738" xlink:to="loc_imab_EverestMember_629752" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember" xlink:label="loc_imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember_894067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_629738" xlink:to="loc_imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember_894067" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_829892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629736" xlink:to="loc_srt_ConsolidatedEntitiesAxis_829892" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_829893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_829892" xlink:to="loc_srt_ConsolidatedEntitiesDomain_829893" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ImabHangzhouMember" xlink:label="loc_imab_ImabHangzhouMember_829894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_829893" xlink:to="loc_imab_ImabHangzhouMember_829894" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_629739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629736" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_629739" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CommonStockSharesIssuableForServicesAvailedCurrent" xlink:label="loc_imab_CommonStockSharesIssuableForServicesAvailedCurrent_652552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_629739" xlink:to="loc_imab_CommonStockSharesIssuableForServicesAvailedCurrent_652552" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaap_OtherReceivables_871859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_629739" xlink:to="loc_us-gaap_OtherReceivables_871859" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromAffiliateCurrent" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_829890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_629739" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_829890" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ExpensesPaidOnBehalfOfAnAffiliate" xlink:label="loc_imab_ExpensesPaidOnBehalfOfAnAffiliate_872903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_629739" xlink:to="loc_imab_ExpensesPaidOnBehalfOfAnAffiliate_872903" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_894054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_629739" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_894054" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesParentheticalDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_829980" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_829981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_829980" xlink:to="loc_us-gaap_StatementTable_829981" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_829982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_829981" xlink:to="loc_srt_ConsolidatedEntitiesAxis_829982" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_829983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_829982" xlink:to="loc_srt_ConsolidatedEntitiesDomain_829983" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ImabHangzhouMember" xlink:label="loc_imab_ImabHangzhouMember_829984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_829983" xlink:to="loc_imab_ImabHangzhouMember_829984" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_829985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_829981" xlink:to="loc_us-gaap_StatementLineItems_829985" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_829986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_829985" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_829986" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_629764" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_629764" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629765" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_629766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629765" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_629766" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_629767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_629766" xlink:to="loc_us-gaap_RelatedPartyDomain_629767" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CmabBiopharmaSuzhouIncMember" xlink:label="loc_imab_CmabBiopharmaSuzhouIncMember_629769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_629767" xlink:to="loc_imab_CmabBiopharmaSuzhouIncMember_629769" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember" xlink:label="loc_imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember_825074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_629767" xlink:to="loc_imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember_825074" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TaslyPharmaceuticalGroupCoLtdMember" xlink:label="loc_imab_TaslyPharmaceuticalGroupCoLtdMember_629771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_629767" xlink:to="loc_imab_TaslyPharmaceuticalGroupCoLtdMember_629771" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_EverestMember" xlink:label="loc_imab_EverestMember_629773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_629767" xlink:to="loc_imab_EverestMember_629773" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_829961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629765" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_829961" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_829962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_829961" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_829962" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ReceiptOfContractResearchOrganizationsMember" xlink:label="loc_imab_ReceiptOfContractResearchOrganizationsMember_829963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_829962" xlink:to="loc_imab_ReceiptOfContractResearchOrganizationsMember_829963" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_871824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629765" xlink:to="loc_srt_ConsolidatedEntitiesAxis_871824" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_871825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_871824" xlink:to="loc_srt_ConsolidatedEntitiesDomain_871825" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ImabHangzhouMember" xlink:label="loc_imab_ImabHangzhouMember_871826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_871824" xlink:to="loc_imab_ImabHangzhouMember_871826" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_629768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_629765" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_629768" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_629776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_629768" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_629776" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_629781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_629768" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_629781" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/SubsequentEventsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_621840" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_621841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_621840" xlink:to="loc_us-gaap_SubsequentEventTable_621841" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_621842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_621842" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_621843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_621842" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_621843" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_629066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_us-gaap_TypeOfArrangementAxis_629066" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_629066" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629067" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember" xlink:label="loc_imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember_894037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629067" xlink:to="loc_imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember_894037" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_629073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_srt_CounterpartyNameAxis_629073" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_629074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_629073" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_629074" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_629675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_629675" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_629676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_629675" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_629676" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_629677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_629676" xlink:to="loc_us-gaap_SubsequentEventMember_629677" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_652402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_us-gaap_StatementClassOfStockAxis_652402" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_652404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_652402" xlink:to="loc_us-gaap_ClassOfStockDomain_652404" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_652471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_srt_TitleOfIndividualAxis_652471" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_652472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_652471" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_652472" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_652485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_us-gaap_PlanNameAxis_652485" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_652487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_652485" xlink:to="loc_us-gaap_PlanNameDomain_652487" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_UnderwriterAxis" xlink:label="loc_imab_UnderwriterAxis_652535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_imab_UnderwriterAxis_652535" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_UnderwriterDomain" xlink:label="loc_imab_UnderwriterDomain_652538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_UnderwriterAxis_652535" xlink:to="loc_imab_UnderwriterDomain_652538" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_671655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_srt_ProductOrServiceAxis_671655" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_671656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_671655" xlink:to="loc_srt_ProductsAndServicesDomain_671656" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_621858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_621841" xlink:to="loc_us-gaap_SubsequentEventLineItems_621858" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_TerminationFeePayable" xlink:label="loc_imab_TerminationFeePayable_894024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_621858" xlink:to="loc_imab_TerminationFeePayable_894024" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://IMab.com/role/RestrictedNetAssetsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_RestrictedNetAssetsDisclosureAbstract" xlink:label="loc_imab_RestrictedNetAssetsDisclosureAbstract_621762" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_621774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_RestrictedNetAssetsDisclosureAbstract_621762" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_621774" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_621777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_621774" xlink:to="loc_srt_ConsolidatedEntitiesAxis_621777" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_621778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_621777" xlink:to="loc_srt_ConsolidatedEntitiesDomain_621778" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_621782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_621778" xlink:to="loc_srt_SubsidiariesMember_621782" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_RestrictedNetAssetsDisclosureLineItems" xlink:label="loc_imab_RestrictedNetAssetsDisclosureLineItems_621797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_621774" xlink:to="loc_imab_RestrictedNetAssetsDisclosureLineItems_621797" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit" xlink:label="loc_imab_StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit_629174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_RestrictedNetAssetsDisclosureLineItems_621797" xlink:to="loc_imab_StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit_629174" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation" xlink:label="loc_imab_ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation_629177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_RestrictedNetAssetsDisclosureLineItems_621797" xlink:to="loc_imab_ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation_629177" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_AppropriationtoStatutoryReserve" xlink:label="loc_imab_AppropriationtoStatutoryReserve_621769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_RestrictedNetAssetsDisclosureLineItems_621797" xlink:to="loc_imab_AppropriationtoStatutoryReserve_621769" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNet" xlink:label="loc_us-gaap_AssetsNet_652724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_RestrictedNetAssetsDisclosureLineItems_621797" xlink:to="loc_us-gaap_AssetsNet_652724" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="imab-20201231.xsd#imab_PercentageOfNetAssetToNetAssetsOfGroup" xlink:label="loc_imab_PercentageOfNetAssetToNetAssetsOfGroup_621817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_imab_RestrictedNetAssetsDisclosureLineItems_621797" xlink:to="loc_imab_PercentageOfNetAssetToNetAssetsOfGroup_621817" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g10811g01sp38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g01sp38.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MP]XAU1=.LIYUGE4O!Y]N\2W"CJT98?,,<_2@#I/M,&UV\^/;&<.=PPI]#Z4
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M;Z-#E4N85D /J P- %BWMH+.WCM[:&."",;4CC4*JCT ' H EH * "@ H *
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M:M_7<\^698["U[T9R7+MK=>MG=6^1L^%_#NIGQ);W4BV*YL0?LET@+;<;0K
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M5:;]I'EE8X:U)JK#EE;^OZ1U8EUNUC_?6UK>X[P.8F/T5LC_ ,>KIO-;J_\
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M"#PW^T.?>O-EF>+FK.>GHOZMY%\D4:,EEKNF[#IM\FH0+]ZWOSA\?[,JC/\
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M)+]8_J()?$D?WK/39QZK<O&?RV-_.B]5=%_7R#EP,MI27R3_ /;D2K?ZFO\
MKM&<_P#7&X1O_0MM/FEUB0Z-!_#5^]-?E<5M5FCYDTB^0>RH_P#Z"QHYVMTQ
M+#1?PU(_BOS2(6\2V$9Q/%?0>\EC,!^>W'ZTO:Q6]_N9HLOK/X7%^DH_E>Y3
MU3QSH>FZ=+=+?0321@$0"3:[<XX!Y_2HGB*<8WN=&&R?%UZJIN#2?6VGWFOI
M&I1:QI-MJ$&!'.FX './:M834XJ2.#%8>6%K2HRW1=JSG"@ H * (+NSM;^W
M-O>6T5Q"2"8Y4#J2.G!H G  & ,"@"O:6-II\)ALK6&VB+%RD,80%CU.!WH
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M[>>%V2,2G3EPIS^( !Z70 4 >>Z]X=.J^)-5-F)5FA@BD*,O$K/O'RDD #"
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M%\LEJ/IDA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M>(3&2KKP\;\.A]".U>I3J1J+3[NJ/(J4I4GKMWZ/T+%:&04 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M+\/\Q_5X?\_8_P#DW_R(?VI*!DZ5?#_@*'_V:CV\OY)?A_F'U:/_ #\C^/\
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M8#(/7W&1^5:-6=CD:L[#Z0@H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@"GJDFG1V#MJDT,5ID!VGD")UXR212='VRY&K^1K2E4A-.GN26#VDEC"U
MA)'):E?W;1.&4CV(ZT*G[)<EK6)J.4I-SW+%,@* "@ H * "@ H * "@ H *
M $9E1"S,%51DDG  H \\^'*-'JVK1#2%L4B &4NVE4[CN7 ,K\8YSA<\'O@
M'HE !0!@:;'*GC37FDW;7@M6CSMQC]X., '&0?O9/7G&  #?H * "@#.O-%M
M;[4K2_F>X$UH<Q!)V50>^5!P<@X.>W%:1J.,7%=2XS<8N*ZFC69 4 % '+^+
MO"UKK>F".'38)+KS PD#")E&#D[L'/ICWSVI5*M6,&H:G=@JRI5+SE9?>7;7
MPOH\=G#&=,AC*HH*J2<8'3/&?K6WMZCU;.>567,[,D/AC2.ULR_[LSK_ "-/
MVT^XO:S[C3X6TH]%NU_W;Z=?Y/1[>?E]R_R#VLOZ2&GPII_\-QJB?[NJ7/\
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MR6.;2[62)PZ&)<,IR#Q4S34FF3)6DTRU4$A0 4 % !0 4 % !0 4 % !0 4
M% !0 4 8EDDZ^,=8,LRNC6MJ8E";2BYE&"<_,=P8YXZ@8XR0#;H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H P?%FMS:%IT$\$MM"9)&0RW()C0"*1^
M0".I0+U_B[]* (6\0W<ESX>-K%:M:W\IANR9"7B?R7?8 .,@I@Y/'3'.0 0)
MKCQ>+-2QH^I/BU@7Y8E/1YN?O=#GCZ4 :'_"0O\ ] +5?^_*_P#Q5 !_PD+_
M /0"U7_ORO\ \50 ?\)"_P#T M5_[\K_ /%4 0R^+8X;J"VDT?5%FGW>6OD+
M\VT9/\7I0!-_PD+_ /0"U7_ORO\ \50 ?\)"_P#T M5_[\K_ /%4 '_"0O\
M] +5?^_*_P#Q5 $%[XOATZT>ZN](U2*!" SF!<#) '\7J10!/_PD+_\ 0"U7
M_ORO_P 50 ?\)"__ $ M5_[\K_\ %4 '_"0O_P! +5?^_*__ !5 !_PD+_\
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M_P"*H CE\4K#)"DFBZHK3/LC'D+\S;2V/O>BD_A0!)_PD+_] +5?^_*__%4
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M>">>^,T &@^.#JOB2WTB/3XXK22T65)EEXW>5')L P.<2?=Z@#/0T =K0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % %:'3K*VO+B\@LX(KFXQYTR1@/)CIN(
MY./>@"S0 4 % &;#X=T6V:\:#2;.-KT,+DI H\X-][=Q\V<G.?6@#01%C141
M0JJ,  8 % #J "@""YL;2\,9NK:*<Q$E/,0-M)4J<9]58CZ$B@!+*PL],M$M
M+"UAM;9,[8H4"*N3DX XZT 6* "@".2&*5XGDC5VB;?&6&2C8*Y'H<,1]":
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M@<>U %V@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MK)?>+KJSFE^S*=RA%)<CNW?/TH VK#Q;XCOKC3]"?4H(+J35KVRDU#[.IW+
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MWV=I#AF)&V7L%4A>0.G'I2;2W+A3E._*KVU^1Z+3("@ H * "@ H * "@ H
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M@!X4*@^8#ZCZFLZ<JDKZ=>ITXNAA:+A>5[Q3M%;^;;VOZ/T+8T75A/\ :_\
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M &&&'XD_2G&FX*T7]X1IR@K0>GF/\/:K>:K:W;WUDEI+;W4EOM27>&"G&X'
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M:'4]MIIJ9U"<_-<.V/FZ<)S]:>)6'3CJ_A71?Y@KC%3Q(/'32?\ $J+_ -G
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M9<WI>ZE6!"Y06LBEO8%E _,TJ>7UZDU#37S7Z,;FDB:#Q[X9FMHIGU6*W\Q
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MSM7>P&36<ZD*=N=VN:4Z52I?D3=B1)8Y$WI(K+Z@Y%4I)JZ9+C*+LT/JB0H
MJSZE86LICN+V"%P,E7D"D#\:RG7I0=I22?J;0P]:HN:$6UY(KOX@TJ,Q@WJ$
M.=JE<L,_4<5D\705O>W-5@L0[^[L6X+VTND+6]S%*HY)1P<?E6T*L)J\6F83
MHU*;M.+7R)ZT,PH B%U UTUJ)D,ZJ&,>>0#WQ4*I%RY+ZENG-0Y[:=R6K("@
M H * "@ H * "@ H * "@ H * //]5L+5_B5;3MX=O9KCS(B+E&D\EE"G,C$
M#8"A"#:2">>.F0#T"@ H XKX@PPR2^'/-CW$ZG'&IV @%O?MT[=<5M23:FE_
M*_R.G"R<9W78ZC1W\S1;!_[UO&?_ !T5Q89WHP?DOR%BERUYKS?YEVMSG"@
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M\LC$M+,VY\>F<=/:BC0C1NTVV^KW%7Q,JUDTDET6W_#EZN@Y@H * "@ H *
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MD8NV2S'J2:JC1C134>NI%>O.O).?16^1;K8P"@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MUVW_ . $()27.RQ8_P#"1C3[;(L"?*7)=I=QX[Y&<_7FE+V7,]_P%+V=WO\
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MHF9,;@",'&01^E5"7))270J,N5IHFAB$$$<08L$4*">IP/:DW=W$W=W,2UT
M3V%S;ZI$F6O);B)H96W1[F)5@V 5;GM^M;2JVDG#LD:NI9IQ[#!'XKANY+6*
M:PEM H,=W<*WF?1D4@,1Z@J*=Z+5W>_8?[IJ[O?L3OHNH7/DO<>(+Q)(GWXM
M4CB0\$8(*L2.>A)%2JD5M%?.Y//%;1([VU\36\$C:;J=G<N%.R.\MB"3_O(P
M'_CM.,J+?OIKT?\ F.+I-^\K>A+;WVO1(HOM&AD8#YFL[H-D^P<+C\Z3C3?P
MR^]?Y7$XTW\+^]$,%YK6L,1%:/H]LCE'>X56G?!_@494#_:.?IWJG&G3W?,_
MP&XPAN[O\!1X-T%Y6GNK!+RY?[UQ=$R2'\3T_#%+ZQ42LG9>0>WJ;)V0V3P;
MI9EAEMY;ZU:%]ZB&\D"YQC[I)'?TIK$3LT[/Y(%7EL[/Y$EYIVNQVLG]EZT'
MGV_(M[ K+GZH%(^O-*,Z;?OQT\O^"*,H7]Z/W$D.F:K+"/MVMR"0CYEM(4C7
MW^\&;\<BDYP3]V/W@Y17PQ^\KV_@O1(E(N+>2^.XM_ILK3#).?NL2/TJGB*C
MV=O30;KSZ:>FAKQ:=90#$-G!&,!?DC X';Z<UBYR>[,W*3W8UM+T][B*=K&W
M,T+;HW\H;D.,9![4^>25KASR2M<MU!(4 % !0 4 % !0 4 % !0 4 % 'D5[
M>:5>_%>SNC!=&X2[%O*([J+"E6*1L5V[^61R5##"KNZ,: /7: "@#D/'41>Y
M\,OMN"JZO#DI(!&,G^-<_-[<'!]* +?B#1(X=&N+G25CL[FWMI JQH%25-I)
MC8#'&>0>QY]0>FE4;FE/5-_TS>G.\DI:HDT#2GDMK+4]4(FO?(3RT_Y9VPV]
M$'][U;J?8<4JM2S<(;?G_7852=FXQV_,T-*M+FT%Z+@1#S;IY8_+8M\AQC.0
M,'KQS]:SJ24K6[$3:=K=BU]DMA>&\%O%]JV>7YVP;]F<[=W7&><5',[<M]";
MNUNA-2$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % $:V\"2M*L*"1CDL%&2<8SGZ<4 2
M4 % '+^-(MW_  C[[W&S5[?@' .6[CO0!O:G')-I5Y%$A>1X755! R2IP.>*
MN#2DFRH.TDV.T]'CTVU25#'(L2AD)!*G R../RI3MS.P2W=BQ4DA0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 (&5EW*P*^H- ',>,XXI%\/RE$9EU>VV/@
M$C+=C0!U% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %74[:6\TJ\M8
M)?)FFA>-)/[C%2 ?P- '(:%X4OK/PEJ&B75M%!%>*Y$=M<%1"1'&@4$ '#%7
M8_7'?@ DU'PWK<V@^&K.TNXXGT][4S+Y88 Q@98$D9QZ=Z -K^SM>_Z#\?\
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M9DGC=H8&VF5 W*D[EP._![=#0!S_ (5TGQ/9^+8)M7^T21I8+'-,908WD\J
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ME0!;@GANK>*XMY4EAE4.DB'*LI&00>XQ0!)0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 8WB+3=0OX["33)K6.ZL[GSA]JC9XV!C=""%(/\ 'GKV
MH XN3X;W]I*MVM^+L6]B\"PPQB-V)C/"DL% $AW*">..>,D TM(\$ZA:ZOH^
ML7-Y#]MAC9KT[2QDD<NSA<G 7=)P0 <* <C  !W= !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
5 !0 4 % !0 4 % !0 4 % !0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g10811g01sp38b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g01sp38b.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /?Z "@ H A%W ;UK,2K]H2,2F/N%)(!_,'\J )J "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!"
MP7&2!G@9I7L.S8M,04 % !0 4 % !0 4 % '/P_\E#O?^P7!_P"C9: .@H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MKV3U[/LG^)Z9_:WBR%@K6HE&.ITXKGZE9F_E6'M:7\DE]S/$^IT6KJI'[_\
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M;4CC4*JCT ' JFVW=AL2T@.?\87EW9:*KV>LV.CLTJH]Y>D!(U.<XW<%O0'
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MDB<,K#V(KXZ<)4Y<LU9G1N3U !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M*-8XT5$48"J, "NM)15D<3;D[O<=3$% !0 4 % !0 4 % !0 4 % !0 4 %
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MZ[_,@OM02SV1HAFN9/\ 5PH?F;W]AZDU%6LJ=DE=O9?UT\S6C0=2[;M%;O\
MK=^1R/A/1);3Q/J1O)5EFM57)^]EG&[=D]\ _G7C9?A94\3/VCNXV_'6Y[N9
MXR-3"4_9JRE?[EI8[JO?/F@H * "@ H * "@ H * "@ H * "@ H * "@ H
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MUO\ MW\CLQ/^YT/^WOS-^O1/,"@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % '/P_P#)0[W_ +!<'_HV6@#H* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H Y^'_DH=[_ -@N#_T;+0!T% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!G0Z?<QZ
M_<W[7\CVTL2HEL<[4(ZD<X_( \\DX&%'W5)/J[^FG]?U<):N+71/YZ[F9=^
M?"U]J$U_<Z/%)=3G,DA9LL<Y]?>F!2M_AAX5@NKN9M.$JSN&6-V;;$ H7"\]
M"03SW)H L_\ "NO"/_0$A_[Z;_&@ _X5UX1_Z D/_?3?XT 5K?X8>%8+J[F;
M3A*L[AEC=FVQ *%PO/0D$\]R: +/_"NO"/\ T!(?^^F_QH /^%=>$?\ H"0_
M]]-_C0!!!\,O"D,UT[:8LHFD#JKLV(AL5=J\],J6^K&@"?\ X5UX1_Z D/\
MWTW^- !_PKKPC_T!(?\ OIO\: ((/AEX4AFNG;3%E$T@=5=FQ$-BKM7GIE2W
MU8T 3_\ "NO"/_0$A_[Z;_&@ _X5UX1_Z D/_?3?XT 5K?X8>%8+J[F;3A*L
M[AEC=FVQ *%PO/0D$\]R: +/_"NO"/\ T!(?^^F_QH /^%=>$?\ H"0_]]-_
MC0!!!\,O"D,UT[:8LHFD#JKLV(AL5=J\],J6^K&@"?\ X5UX1_Z D/\ WTW^
M- !_PKKPC_T!(?\ OIO\: ((/AEX4AFNG;3%E$T@=5=FQ$-BKM7GIE2WU8T
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
=* "@ H * "@ H * "@ H * "@ H * "@ H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g10811g0421055924793.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055924793.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $K FX# 2(  A$! Q$!_\0
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M_,SJO^%D>+/^@O)_WPG^%'_"R/%G_07D_P"^$_PKE:*/J]+^5![>K_,SJO\
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MS/\ R%Y/^^$_PJYJOC[Q19ZC)!%J\NQ0N,HIZ@'TKB>X^M:6O?\ (9F^B_\
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MR?\ ?"?X5ZA\*]=U/7M.U"?4[M[AXY55-P VC'L*\%KVGX*?\@;4_P#KNO\
MZ#6&,HTX4KQ5C;"59RJ6DSRCQ#_R,NJ?]?<O_H9K-K2\0_\ (RZI_P!?<O\
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M@4GVNV_Y^(O^^Q1]KMO^?B+_ +[%&H:"_9;?_GA%_P!\"LFTU?2;S6+S3(X
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MEV9=&M6V7+JN5Z '@5I?\('X5_Z =G_WQ4^AW-NJ7F9XAFZD_C'K6K]KMO\
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MX?E *0Z>V5W\*GW?6N2/A>\DA-N\VGB..">)'\[.XNVX$C''ZU9_X1J22VU
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M1Y:%MQ'OSWK:^TV__/>+_OL5=27O>Z3!:>\8NO:1IJ:'=LEA;*PC."(A4O\
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MFY>ZK;@E[SOL0_V+I?\ T#[7_OTM8T&DZ<=:U-38VQ56CP/+''R"NB^TV_\
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M"1HJ*0%4  9[5,I+E5MRE'5W*?\ 8VE_] ^V_P"_8JOI6CZ:]YJ0:PMR%F
M,8X^6M7(_O#\ZK:0R_;M3Y'^O'?_ &14\SL]2XI<R+']AZ5_T#K;_OT*QM=3
M3],\B*VTBREGF#L!(@ "J,GH.M=/N7^\/SK*UG1TU80LMT;>:+<%D4!N&&&&
M#[5,)>][S-)1TT&:?8:1J&G6]XFFVP69 X'ECC-6O[#TK_H'6W_?H5/9V\-C
M9PVL1_=Q($7)]*GW+_>'YTG)WT8U%6U.9&D:;_PD%XGV"WVB&,@>6,#DU<_L
M;2_^@?;?]^Q0"/\ A(KSD?ZB/O[M5W(_O#\ZMR?<QLKF%K%OIVG6T)BTNSDG
MGF6&)73"[CW..W%.T>WTO5=,CN_[+M8V)*N@0$!@<'G\*O:IIZ:G;QQ^?Y,D
M4BRQ2  [6'MWIVF6,6EZ?':1R;PF278C+$G)/YU7,N7S)Y?>\AO]C:7_ - ^
MV_[]BJ@TC3?^$AMT^P6^TVLA(\L8SN6MC(_O#\ZJ C_A)+;D?\>LG?\ VEJ5
M)]RK*Z+7]AZ5_P! ZV_[]"J&LVNDZ3I,]Z=+M7,8 5/+ RQ( 'YFMW<O]X?G
M5/5+&'5=-FLI9"JR ?,IY4@Y!_,"HC)W5WH:RBK:&3HEOIVI0W*SZ59QW%K.
MT$HC0%21@Y&1T((K4_L/2O\ H'6W_?H4W2=-32X)E-QY\T\K32RD!=S'V[#
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MR"+/_KBG\JN5$IRON;*,;;'//:^&$U%;!K>W%RW1/+.,^F>F?;-7O^$=T?\
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M4G\ZUJ4YRYMS2$8\JT.?O[/PUI8C^V6UO'YA^7]V3]3QT'OTJXOA_1F4,MA
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M?^>6F?\ ?V3_ .)HW>(?^>6F?]_9/_B:UJ*GF\A\OF9.[Q#_ ,\M,_[^R?\
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M:WY=MNCTW_CZAQMDDZ[QC^&M^J.J?ZNU_P"OR#_T,4HRUV&T2[O$/_/+3/\
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MK)N8E&X!/'.#D@XK2,$U=D.33L=>QUEL!XM(.",!I)#@]OX>M.W:[_SRTO\
M[^2__$UQL][,-#U.TFMFCN+8Q72SDDL9-R[0>.., ?0UZ&I)12PP2 34SCRC
MB^8SMVN_\\M+_P"_DO\ \32Z(;LZSJGVQ8!)LA_U#,1C#>H%:-5=._Y#NJ?[
MD'\FJ+^ZS2*]Y%;3GUH68\B'3S%O?:7F<'[QZX6K>_Q!_P ^^F?]_P"3_P"(
MK%\-W.WQ)K$4D^%6.'8C/P"3)G JG/XSU2*WU(?9;87&F1M]HW!MOF&3:F.>
MA7YJIP;E9+^F"FE&[?\ 2.FW^(/^??3/^_\ )_\ $4;_ !!_S[Z9_P!_Y/\
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MDMU;ZK>+&)[;2R(Y%E0_:)1AAT.=M2_:-9)(VZ1E>O\ I,G'U^6L_56)7PW
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M[H]P,\F!\@Z?)75UB0?\AS5/]Z/_ - %$);Z"J+;4C\S7/\ GVTS_P ")/\
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MRZ?O^S28'VE\8W+WV5N53'_(R6W_ %ZR?^A+4IKL5;5:DOFZ]_SYZ;_X%/\
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M/LLOE9Z>?QMQ_M>E=98>;_9]OY_^M\M=_P!<4VDHJ5MP3O)HI^;KW_/GIO\
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M11]IUK_H&VO_ (%G_P"(K4HHYEV"S[F7]IUK_H&VO_@6?_B*/M.M?] VU_\
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M -A1]KUG_H%6_P#X&?\ V%:E%',NP6?<R_M>L_\ 0*M__ S_ .PH^UZS_P!
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M.!OV_)GWST]ZF%I2M8TE>*O<V/M6L_\ 0*M__ S_ .PH^UZS_P! JW_\#/\
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M=%3E:+M8(W:O<YC4[G5CJ.E%M-@!$S[1]JSG]T_^SQ5C[3J__0,M_P#P+_\
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M^QH^V:Q_T"8?_ S_ .QK4ILF?+;;][!Q65UV-[/N9@N=64DKH\ )Y.+L<_\
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MUUAZ&L/1/^05%_O-_P"A&B+7*]"9IW6HW[5JW_0*A_\  O\ ^QH-QJI()TB
MD=";H<?^.UI5Q/B:20:\<L1*B1&S&2,L7^;'J<=:N"4G:QG)\JN=)]JU;_H%
M0_\ @7_]C1]JU;_H%0_^!?\ ]C6B,X&>N.:6HNNQ5GW,71;K50EYLTR%LW+Y
MS=8P<_[M:?VO6/\ H$P_^!G_ -C3="_U=[_U]2?SK6I3:YMC2"?*M3*:YU9L
M;M'MS@Y&;L?_ !%+]KUC_H$P_P#@9_\ 8U@>-G(NH5F8K"+65HCD@>>,;<?[
M7I75V!E.GVYG_P!:8UW_ %Q3DDHJ5MP3;DU<I_:]8_Z!,/\ X&?_ &-9$%SJ
MG]LZD1ID)8M'N'VKI\@_V:ZNL2#_ )#FJ?[T?_H H@UKH*HGIJ1_:M6_Z!4/
M_@7_ /8T&YU8CG28"/>['_Q-:5<MK_V-=>TZ>&13?I<QK+$CGS2A! P.FWN>
M*J-I.UOZ^\RE=*]R_=QZA>K")M)B_<RK+&5O,%6'3^&K GU0;L:/;C)RV+H<
M_7Y:QKV.6_UCQ!&;J:W\BTC6,Q-A@N"QQZ9/&:QI0J:'H=^UW;RS6UBABL)X
M]YG+,H)&3U^F36BA>W_!(<K'57D5_?P"&XT>$Q[U<@7@&XJ<C/R\C-6?M6K?
M] J'_P "_P#[&N3E=O#>JM)*\EY$9Q*R [=DC@[02<Y;&>._%=!X;=A-K%MD
MF*"^<1Y[!@&(_ DTI1LK]/Z\QQE=V+?VK5O^@5#_ .!?_P!C3M%DN)-9U0W-
MNL+[(?E63?V;O@5H55T[_D.ZI_N0?R:L[KE>AK%>\BOIUUJ:62K%ID<D8=\,
M;D+GYSVVU;^V:O\ ] B+_P "Q_\ $U-H_P#R#(_]]_\ T,U>J)-7>AI%.VYE
M_;-7_P"@1%_X%C_XFC[9J_\ T"(O_ L?_$UJ44N9=AV?<R_MFK_] B+_ ,"Q
M_P#$T?;-7_Z!$7_@6/\ XFM2BCF78+/N9?VS5_\ H$1?^!8_^)H^V:O_ - B
M+_P+'_Q-:E%',NP6?<R_MFK_ /0(B_\  L?_ !-'VS5_^@1%_P"!8_\ B:U*
M*.9=@L^YE_;-7_Z!$7_@6/\ XFC[9J__ $"(O_ L?_$UJ44<R[!9]SGK^UN]
M2>%[K1%9X23&R:@R%<C!Y4"H&TDO&D;>&K<JD;1*/MG\+=>W?UZUU%><#Q7J
MT6L-93S[4EU(1V\FQ?FC!^9#Q6U/FG\/3U,Y\L=^OH;L.C>0VY/#L>[S%EW-
MJ#,2R]#DCM4O]GR_]"]#_K_M'_'Z?]9_>Z5 ?'$2S7*-8OB*%Y8V60$2!3@C
M.,#\":6\\;):),W]G2N(C$"V_"C>,Y)QP!3M4;V_'_@BO377^ON''2&**H\/
M1J%+$%-093\QR02!D@GMTIJZ/Y%P+J+P[$DL9+H1?G"L1@D+C _*G+XVM7U%
M;9+9G3<B.Z.&(+#/ '51W.:FLO%4>H:J^G?963=&[1RA]RL%X/;'Y$TOWBW7
MY_YA^[?7^ON.5^'EQ?II6H""P253?2$DW 7!STZ5UWVO5?\ H$Q_^!8_^)KG
M?AK_ ,@?4O\ L(2_SKM*JNU[1Z&5)/D6IFFYU1NNCQ-CGFZ!_P#9:/M>J_\
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M(MP<X&SGJ?3.*?X5>5_#MN92QY81ECDE-QV_I567+S6)O[UBQ]KU7_H$Q_\
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M ,"U_P *L:5_R"+/_KBG\JN5$I*^QLD[;F1]IU3S!)_8D6\# ;[4N<?7%/\
MMNK_ /0'3_P+7_"N8NIIO^$P8AV^U+>1I$FXC,)7YN/2N[JII1MI^?\ F*+Y
MKZF4;W5\?\@=/_ M?\*Q]'N]2&F1A=*5AN;G[4H[GVKK#T-8>B?\@J+_ 'F_
M]"-$6N5Z$S3NM1OVS5/^@0O_ (%K_P#$TAN-29@QT2-F7H3<J2/I\M:=<UXC
MCE76M#G%W,L9NMGD*V$/!Y/J:J-I.UOS,Y72N:?VS5/^@0O_ (%K_P#$TOVS
M5/\ H$+_ .!:_P#Q-:-%3==BK/N8NBWFJ*EYLTI6S<N3_I0&#GZ5I_;=7_Z
MZ?\ @6O^%-T+_5WO_7U)_.M:E.2YMC2"?*M3(>YU23&_1(FP<C==*<'\J?\
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ME1GYSVQ5K[=JW_0&'_@4O^%3Z/\ \@R/_??_ -#-7JB35WH:13MN97V[5O\
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M7$__  F#$2.+E;R..)-Y&82OS<>E=W532C;3\_\ ,47S7U,HWVK8_P"0,/\
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MX69- E0@+E5O\*VT8!9<X) ]:9;:4UA<_:X- E65$94)O]P0-R0 3@"DM/&
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M)G2_M6CNO-9^IW* N.W&![Y-=^IW(K8QD XJ9KE6J'%WV,_[=J7_ $!F_P#
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MR,$]?TKHZ*/:2#V:.$\(:=JV@V%Y!=:5,S2W3S*4D3&">.]=%]JO?^@1<_\
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MJ?\ M*\_Z ]U_P!_(_\ XJM.BDY)]"E%]S)-W.9A,="F,H& ^Z+<!Z9W4_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g10811g0421055926650.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055926650.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #& 6<# 2(  A$! Q$!_\0
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MR*=9:C9:E&\EC>07*(Q1FAD#A6'8X[T 6:*** "BBB@ HHHH **** "BBB@
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M#_BG3?$@F%D9E>(([1S1&-BCC*. >JD#@UP,W@/6[R^N-/>%(K-+N_NX[SS
M1)Y\955V]006.<^E;'A;PMJK2WL^JI-IC2:?:V"?9YE,A\H'<X(R "3QWQ0!
M8^'3JC>*RS!1_;UQU./X4KMU=7^ZP;Z'-?,6NB?2(=5E:^F>VBUN>&.,S,99
M&VKN<J!@\%><_A78_"C^U=4L-0N-%U:&&0R(L\5U$[LH .TC)P,\]/2LW.7/
MRJ.G<[XX2B\/[5UDI7MRV?\ E^EO,]K>6.,J'D52QPH8XS3B0 23@#DFO'?&
M_@[Q=JFJV4SR#4=@Q&\"^6(FSUQG@^]=%I_B#Q-!&VFZE#IQOU4(D$\C1-*
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M*** "H+RTAO[&>SN%WP3QM'(OJI&#^E3U2U>&6YT6^@@G%O-);NB3$X\MBI
M;\.M '.:-X*T[3]=AU&WU6ZN?LZD"!Y0RB38$+G'\6T 5V%>*?#J$IXRBC1K
M"T6)I&*07_G-/F)5*[>_S*7R:]KH \\/PS,VMW5Q<:@K6<TES* L>)F,R;2K
M-W09X'L*TO#O@?[ +IM9GAU%YK:"T"^5A/*B!VY!ZDYR:[&B@#@_AC!%:Q^*
M(((UCACUV=411@*-J<"N\KA_AQ]_Q9_V'KC_ -!2NXH **** "BBB@ HHHH
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M5GO/T.Q?N\+YS?X+_-_D2T445H<84444 %%%% !1110 4444 %%%% !1110
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M#I4C:)IDME!+"-[6D3KO4'N5Z_C4]OKNDW:;[?4[.5/-\G<DRD;_ .[UZ^U
M&5X\DU:'P?J$VCW<=K/'"[O,RDLJA23M]_>O/]9US53;1RKJ5U"]CHT%Y%LE
M*^;*S@$O_>XXP?6O8+JVAO+66VN(UDAE4HZ,.&!ZBLVY\,:)>&S-QIEM)]C
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M#'')..:]E.F6#3M.UE;F9F#&0Q#<2.ASZT0:;8VLWG6]G;Q28V[TC"G'ID4
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-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g10811g0421055926915.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055926915.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $3 =D# 2(  A$! Q$!_\0
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M5;V_L[&\CGN+"0174:YS$QSP?R/3T-6+^2YATZYDLX!/=)$QAB+!=[X^49/
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M''6@#JO&?_(FZM_U[-_*MVO,Y_&4NL^!M8_M&".&8Q1^7]GW2*1+$)%!.."
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MBR2OUQ5[Q'XPO- UOR3:VTMD8'8,)3YGF!<@$8P,_GWH [.N?T__ )'36?\
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MQGTSPEHUI<R-)+'K5IEV?<6!N@0<_0BLCQ[I#7_BJ.2:2SMXBEO!')/:PN9
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MBM5^DG_HL4SX6_\ (R>._K+_ .AM5C2+'5;3XQ7_ (CFT34AILP?8XMSDY0
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MQP "?RKTO3M7DO-3O;">T,$MKM.=X8.&&0?:@#5HHHH **** "BBB@ HHHH
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M);%A%Y0+*!_$,#.3['I6?X3\8^%O$=[-;Z$%$T<>]\0A/ESZUN_;;0ZI/;-
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M;-K'AO4-.MY1%-<P-&DA_A)'6O)J451=.2>Z3]"T[W. C^"'A&*5)%N;G<K
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M('D)@EMR/;)?H1Z5Z37DVA@2?$*6+3=4A-U'-*TZO9X;:2,AGW?-[8SBO6:
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M_P!N-.C/+?'?_)%-,_Z_1_[/6?\ %#_D$>!?^N"_^RUH>._^2*:9_P!?H_\
M9ZS_ (H?\@CP+_UP7_V6OH:'_+K_ *^5/R,GU]$6_B#_ ,EJ\)_[EO\ ^AFO
M4?B'_P BA<?[Z_SKR[X@_P#):O"?^Y;_ /H9KU'XA_\ (H7'^^O\Z\"/\7#_
M "_,UZ,\P^)/_))O#_\ UW_H:A^*7_(>\#_]<HO_ $,5-\2?^23>'_\ KO\
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MJ ,9'&!74=!0!S+>%=*T>PUBXMH6+7,3EA*Y<(,LVU0?NC<S' [FN=OM8O\
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M* ^N-WO6;!X-\#>)B\$8FOUTR3R!F]F986P#M4EL>G2NH_X2GP]_T'M+_P#
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M!2T44 %%%% !1110 4444 %%%% !1110 5&]O#(VYXD9O5E!J2B@"'[);?\
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M\TD5JB-#,\$B,@RK*<'_ !_&M#[);?\ /O%_WP*HZ'HXT>"Y4R>9)<W,EP[
M8&6.0!]!@?A6I0!#]DMO^?>+_O@5(D:1#$:*@ZX48IU% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g10811g0421055927227.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055927227.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %F =\# 2(  A$! Q$!_\0
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MRHLJ1-MC,8RP<8RIZ<$=_2I+?XA>%+N6*.'686:5E5 4<9W?=/(Z$\9Z9XH
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M8U7AV?[Q/KGO5^B@"MI^GVFE6$-C80);VL(VQQ(.%'7 JS110 4444 %%%%
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M4D(N,M[#-0WFHV.G(KWU[;VJL<*T\JH#^9J6"X@NH5FMYHYHF^Z\;!E/T(H
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M?[5EOK.YTM;\;K9@HB5=F\D$"0-T&,]*OQ>*=%G:T82DO/M$;"%F W<#Y@,
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M-QZ*V ?;&,4^+0]'AM# MNAA/WLKG=CU-7&BT^A+JIHYF?4-#,K6KW]S#.0
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MQU/+<T6$-W'$L]S(GF,6*GNJ=@..OO6RD.EY)39\V,C;D']*M$VD@1<IS]T
M#G'I4JBV[L;J*UD8YBG2 (8UCR-H;';WK:L<?9$P,8R/UJA.FF22JDD^''(
M[_ITK3@C2*%5C^YU'XUK"'*R)2NB2BBBM" HHHH **** "BBB@#B/B2JPV%A
MJ,J1-#9RLTGGI'+& R%<F)V7>>>,'/H#6_X4BMH?"FEQV<TTUNMNHCDFC,;,
M,=U/*_3L*K>);]-.GTZYFT)]2A61MTL<:N]L=O# -ZGC@YYK;M+C[7:17'DS
M0^8N?+F7:Z^Q'8T 345POQ(\2:OH5M9+IEO=+&\\;7%W%!Y@5/,4>6/1FSU/
M8'N17)MXRUUKB=)-8F@MY)PM]*8D!TS_ $AD51E<+E OWL^O>@#UO5/^03>?
M]<7_ )&J7A+_ )$W0_\ L'P?^BUK(M]9U*;X;VNH76GW-Y>7%I^]2 (C<@_.
M0Q4 $8.!Z]*U_"?_ ")NA_\ 8/@_]%K0!L4444 %%%% !1110 4444 %%%%
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M#^BFWBMSI%@8(<^7']F3:F>N!C JO:>%]*M4OE>W%U]NF\ZX-T!)N(X4<C&
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M\N5L'!Z&MFUNK>^M8[FTGCG@D7<DD;!E8>H(H FHHHH **** "BBB@ HHHH
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ML?NYR<"@#N:*Y/PQXDU;4]=U32M7L;6VFM KH(9&)VMG@[@-W;YE^7G%=90
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M3S$W!=Q&X9 ]?I2"XA(C(FC(D^YAA\WT]: ,#Q=_S!/^PI%_Z"U='7.>+O\
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M4X2_\7WEOI5G-%-;M<,'-P@ )7# =,\=^M0V_P 0YXV=)M/:X"%F9D8+A<G
M'8GCGI75VUYH-W?W%O;O9271YF55&6QZG'S8_'%7?LEEO1_L]ON3)1M@RN>N
M/2N<9P+>/=1AU*=98[1XD(VQ6\H8'Y2<;R/;TXK2E\<7ENC>?I<"R%VCC5+H
MMN=3S_ ,#%=-;P:5()%MX+0B)RKA(U^5AUSQ5A[.TF3;);0NI.2&C!!H Y7P
M[XRFUC4%BD@A$,Y/E;)@9(\*K89<=.>N?PKL:@BLK6"0R0VT,<A&TLD8!QZ9
M%3T %%%% !1110 4444 <_<ZQJL7C"VTB*QM&LYH&G-PUPP<*I4-\FS&<L,<
M]*C\>?\ (FWG_72#_P!')4>I75O9^/+*XNIXH88]*N&=Y'"A0)(N23VKF?&6
MCZO\5-(6STF5M+TF.42K=7(93>$=-L8P0@Z@MU.,#'- 'IJ?<7Z4M4=&L)-+
MT2RL);J2ZDMH$B:>3[TA QN/UJ]0 4444 %%%% !1110 4444 4M7G^S:-?3
M^7')Y<#OLD!*MA2<'':N1^&\*QVUQ*FF0V2SQQR$1V#09R"<;FE?<!GC&,?C
M78:F4&EW6\KM,3##*K9R.F&X/T/6N,\!6TUK=ZD?L4%K:>5'LD%A;VKELMD%
M8F;( Q@G'4T =]17BO\ PEFH2V\\T'BNY?2C<F-KLK'YRNL<I#;0O[N-Y%15
M4C)Q_M4DGB[Q6'N3)=W,5YY)^V6H@&+*+9"1,HVY!RS]<CKQ\M 'L&J?\@F\
M_P"N+_R-4O"7_(FZ'_V#X/\ T6M<Q8:YK4G@MY$TZYUB-WN8TN_.BB+0JY$;
MG=MW97N!SC/>NG\)_P#(FZ'_ -@^#_T6M &Q1110 4444 %%%% !1110 444
M4 %%%% !110>1B@ HK,MI1:)>W%W>OY,+G+3LH5% !SG K$,^H>,SMLWFT_P
M^>&N1E)KP>B=T0_WNI[>M &9XXO-0\4Z5?:!X5N&2X3_ (^M060I%#CK'N )
M+'T7IWQ71>"M,U'1_"6GV.JWYOKR.,;YB2?H,GDX]35\6-KIFBM9V4"06\49
M"1H, 5;M?^/2'_KFO\J ):*** "BBB@#D/$.@R7VL;TUFVM4NT1'BG0F0!&S
MF([Q@^O!KKE&U0N2<#&3U->:>,[;3[CQE"CO>"<QIYRHML%*9XVM,ZL/?9G\
MZZ/QMJIT;PVL\6K'36W*B,(T=Y"1P@+_ "C)QECD 9H ZFBO&Y_''B:WGD4Z
ME!+<I&4>WAC1E1-JG[0"!DCD\YV\4Z'QOK9NH8EUI9HDE"VLGDQ_\3(&3:1P
M.R\_+B@#O_%W_,$_["D7_H+5O7,)N+=X1+)%O&/,B.&7Z&N6\7WDPU+0K3[!
M<F(ZA$QN@4\M3AOE/S;L_ABNNH X*7X<3R>+8]9_X234=BIC!8>;TZ!NF/PK
MMK6V-M:+ 9YI\#'F3-ES]2 *GHK2=6=1)2>Q<ZDII*70Y23P]JTFG?V:9[#[
M)",1?NVW2C<#A_0<8.,Y_2J*^ ?,4-<BR=]V0HC)6-=K#8N?X06&/I7<T5F0
M<&/ MZ))F\VQRQ+;MC9GY4[)/5?E]^O3UZK0M.DTK28K25HRRDG$0(1,G.U<
M]AT%:5% !1110 4444 %%%% !5>]O;;3;&:]O9T@MH5+R2.<!0*DGGBMH))Y
MY$BAC4N[N<*JCDDGL*Y2RAF\97\.K7L;QZ';N'L+608-PPZ3R#T_N*?]X\XP
M <RGP]F\7^/;?QQJ<LEK:*5:#3)H]SE% "%\G"9/S%<''US7JM%5+_5-/TJ%
M9=0O;>TC9MJO/*$!/IDTTG)V0%NBF0S17,"3P2)+%(H9'0Y5@>A![BGTM@"B
MBB@ HHHH **** "BBB@#.UV**;0KT2V]I<*L+.([M08BP&1NSQC(%<G\.(9@
MMS<+91QV<T,16<V<%NSR<[U7RN&C'&"?4\FNUOY5ATZYE><0*D3,92NX( /O
M8[X]*Q/"OAO2]%6XOK"YDNIM0"RS7!8!9.."J( BCGL/KF@#H@ .@ I:** *
MFJ?\@F\_ZXO_ "-4O"7_ ")NA_\ 8/@_]%K5W5/^03>?]<7_ )&J7A+_ )$W
M0_\ L'P?^BUH V**** "BBB@ HHHH **** "BBB@ HHICS11@F25$P,G<P&!
M0 ^LK6]?L]%A42N7NYLK;6T2EY9F]%4<GW/05ER>(+[7I&MO"\:&$';)JLZY
MA3U$8_Y:M]/E]^U:.C^';/1VDN<R7>H2C]]>W!W2R>V?X5]%&!0!P'@K2?%_
MB#6-1E\=0$:?#/YEM9DH$:3/&X)]X 8ZDC->K    # '0"J&G2,TMT&@FCW2
ME@9$P"..E:% $%ZDLEI)' J-(PP-[%1^8!I;594M8TF5%=5 (1B1Q[X%344
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MT\2R1,!C*D9'%6JC@@BM;>.""-8X8U"HB# 4#H *DKSI6N[;%A1112 ****
M"BBB@ HHHH JZDLKZ7=I#!'<2M"X2&7[DAP<*?8]*XSX=Z?/827I.D+9PM%$
M3(=-2S<R\[T"K]Y%XP?<\FNOUI))=#OXX1F5K>0( VWG:<<Y&/KD5Q_PUL6L
MH9Q):)!+Y48<K;0QEB,YRT<K[OJ0* 'S?$&ZVW,<&A.+J.^>UC@N9Q&65(/.
M9V(!VY7H.>HSCG%0_%560SQ:0S6LP*6;F?#2S!8R58;?E7]X!NR?NGCI747W
M@[1=16X%Q!+NN+C[2[QSNC>9L$9(*D$ H-I X()J%_ 7AN26XD.GX\^+RBBR
MN$084$HN<(V$3YA@_** *C>,M-G\,SRZK=6>F73&XMC#-<J TD9*ML)QN&<=
MNXK7\)_\B;H?_8/@_P#1:TU]&L-*\-7%G:P#RHXI&!D)=BS9+,6;))))))IW
MA+_D3=#_ .P?!_Z+6@#8HHHH **** "BBB@ HHI&944LQ"J!DDG@4 +17FWC
M_P >S6^AS#PE;S:O>1N!+):)(\4([DNG!/MFM+1M'UCQ-H]I=>*;F:WBEC#'
M2;<M$H]I7)+O],@=B#0!JWGBVV^U/8Z-;RZQ?H=KQVQ'EQ'_ *:2'Y5^G)]J
MXC5OA;K7BCQM8^(M<U*Q\B+;YEA"CLH4'.W)^]GN<#Z5ZE9V5KI]JEM9V\5O
M @PL<2!5'X"HIKFY2^C@2VC:-QGS#+@CUXQ_6A*XTKEJ.-(HUCC1411A548
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M\<G7].AGT/1[N\DE7)+$1PQ'T:4\$CT4-6%X]T274_#32>+M:>WM?-4I;Z9
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M_P#0Q^(O_!@?\*Z922H)&"1R/2LSQ'!=7'AZ^CLKJ>VN#"Q22!07SCHN>YH
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M@X->86^C>(DO/#N^UU(RQ6]LL<OF';!M+><).>I&.H.>/2HNR+G<?\(I=_\
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MCZOINOL\FM7E_I;VQ!6\:,NLVX8(V(O&W-=#7B,VB:Z^GW"6^CZTEBTUPUE
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M7$;MJ@>)$4>6;4<LL1CSG=Z'.,?C0!U7_"1Z']G\_P#MC3_)$GE>9]I3;O\
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MRR(LYPZ[/+R1_>V\9JTG@S28KZ&]C%PEQ#,LR.LQ'*QB+!]0549% '0T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g10811g0421055927492.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055927492.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #5 7P# 2(  A$! Q$!_\0
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M%(Z-M\LJ4?E<D<<\AJG\?Z/J5U>7TUG9R7/VG3(H8MB%@LD=TCD''8AL_P#
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M!'!!$D4,:A4C1<*H'0 #H*DH>X+8****0!1110 4444 %%%% !1110 C#<I
M)7(QD=17$BUU=4M@RWC2KO$#,6.V3[0>7/H8\=>,9'M7;T4 <'';:D'A^T07
MS6H ^W(%D+23XD^9<<D9V<KQT].+NC1ZK!J$,E^ER9U#?:GVLR,FQ=@'8G=G
MISU]:Z^BG<#AEMM4\P>=%=M#YG_$P 5SYO[TXV8ZC;C[O;BNFTM;]/#]NLF/
MM@C_ .6V3CGC=WSC%:=%+H'6YFZ+=WM]9?:+Q;==S$((=W8D'.?I6E69X?\
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MC>[1'^$@<=!C&": ._\ ^$'CA_X\?$7B*S Z*M^95'X2AJ3^P_%MOS:^,%F
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MX7N3/HZ VT\.UWP95 W9=NF":VJ /,?B]\/+KQ=ID%SH4$*ZPDR^8^_RS+$
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M/CIN]?QJ95"J%4 *!@ #@4M% &9X?_Y L/\ OR?^AM6G69X?_P"0+#_OR?\
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MTSG/5.B2(R.JLC#!5AD$4D444$:QPQI'&O144 #\!0 ^BBB@ HHHH S/#_\
MR!8?]^3_ -#:M.LSP_\ \@6'_?D_]#:M.@ HHHH **** "BBB@ KB_'_ ,-M
M-^(*6'VZ[N;9[-FV-#@Y5L;@0?\ ='-=I10!#:6T=E906D((B@C6-,G)VJ,#
MG\*FHHH I:II&G:U9M::G907=NW.R9 P!]1Z'W%<#XK\.:QHFA2II.IS7>D\
M^99WZ&X:W7!^:*3!<8Z?,&QGJ.M>EU5U&Q&HV,EHT\T*2J5=HMNX@C!'S T
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M[2V<L5/'M\I_2K']BI_S_P"H_P#@4U &G169_8J?\_\ J/\ X%-1_8J?\_\
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MG(&X/R>.I[UWB;MB[CEL<_6EHIW ****0!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!5U*R74M,NK%W9%N(FB++U (QFLZX\-PW&
MMKJ9N)%D6-4" #'"2+G_ ,BG\A110%S*O_A]9WUI;Q&[E62VBACA<H"%\M&3
M)'?(8_2KE]HUO9VFC6D!98H,V2\#[CQE<_48!HHI[@26OA2"TU.SOENI6:TB
MCB52!A@D;QC/X.3^%6_#L8&D+,/O7,DEPP]"[%L?AG%%% &K1112 **** "B
ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g10811g0421055927757.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055927757.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $9 2D# 2(  A$! Q$!_\0
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MGE-(&MP$+$ 8ST&1GFO0: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4I;K)]XY^\Y]S_*MC3KS2=9A%[8O!<)N*"0+W'..:73==TS5BXL+M)MB+(V
M1A69E4\^I1A^%9QHM2YI.X6-&BBBMQA1110 4444 %%%% !1110 4444 %%%
M% !1110!RNM#^R_&&DZHORI=9LY_?/W?U_E755S'CU2/##W"CY[>:.5?8[L?
MUKI48/&KCHP!K>IK3C+U7W?\.9QTDU\QU%%%8&@4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH RO$O_(LZE_U[O\ RJWIO_(+M/\
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MF_T)4?>;%HHHK,H**0G%,\^+=M\Q,^FZBX$E,EE2%"\C!5'<U'<W(@@,H1I
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M^?%/S-'_  BFB?\ /BGYFBU+N_N_X(7GV-%KBS?;OF@;:=PRP.#ZT[[7;?\
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M0H/[QY/T'>L KXQU'Y6-GID9')'[QQ_,58LO!]C#<"ZOY9=1NO[]R<@?1?\
M'-'LX1^.7W:_\ .>3^%?>9[W&J>,#Y5HLEAHYX>=AB28>B^W^?:NIL+"VTRS
M2UM(A'$@X [^Y]35@    8 Z 4M3.KS+E2LNPXPL[O5A1116184444 %%%%
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M8L5B0*"3U.!WJ:DHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
B6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g10811g0421055928116.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055928116.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #) 6<# 2(  A$! Q$!_\0
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M61Y;BYU%9C/Y\<D5Y(C0G9L(C(/RJ5Z@<')/6L?X@:?::3\']:T^PA6"UM[
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MHHH **** "N(^)RZ+/X>%GJ:*+F?/V.9M.DNQ&RE20=BDJ&P%.,$@G'2NWK
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBO-?B9J,]OJ4-N^J7&FVB:1?7D3PW!A\RYC">
M6"01NQDG;T/<&@#TJN1^*/\ R3#Q%_UYM_2L+7]:EOK?PC:7^J/8P7:N=5DM
M[GR&CF%J9%1G4@IEN<<9P*Q/$7B#Q)>_!,&ZT*6ZBNM&1[C4C=1IM) R3&?F
M)Z'CKF@#V.+_ %2?[HI]<8GB7QAL7'P_GQCC_B;6_P#C3O\ A)O&/_1/Y_\
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MX% '<45Q%IXP\5WUG!=V_@&X>">-98V_M2W&589!P3Z&IO\ A)O&/_1/Y_\
MP;6_^- '8T5QW_"3>,?^B?S_ /@VM_\ &C_A)O&/_1/Y_P#P;6_^- '8T5P)
M\>>)!K8T<^!+C[>;8W0C_M.#'E!@I.<XZD<=:N_\)-XQ_P"B?S_^#:W_ ,:
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M0/ VH:7XALI[FZM7T[2Y+V6S\O=YTAN7W$29&!M&1P3G.>* .]HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g10811g0421055928818.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055928818.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %" =,# 2(  A$! Q$!_\0
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MT<BAD<%6![@U)1Y>GQ+UFST>VGU"QL);C4-,@OK/R"Z(AEDCC"R[B2 #*IW
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M.9$^8K.L0(D+@ <]",^G8&&;XG27*22V.FO':?8(KM;F7:Y5FG,)4H&&1E2
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M6;X;_P"HK_X*;G_XW78T4 <=_P +-\-_]17_ ,%-S_\ &Z/^%F^&_P#J*_\
M@IN?_C==C10!QW_"S?#?_45_\%-S_P#&Z/\ A9OAO_J*_P#@IN?_ (W78T4
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MR4C(C9<,.\IV_A74V7PR2UTO2;:35Y);BSUH:S/.80//EYRNW/R@Y]^E5O\
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M<U)Z&C1116IQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2K(36XQ#(+=-T8SD;3CCDD\>M '*6GQ"NKI-&<:-%MU2.2Y7R[X.8K=$1RS
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M^(]1O/$VK2>$-"N'A1 #K&H1GFVC/_+)#_SU<?\ ?(YZUUNFZ=::1IMOI]A
MD%K;H(XHT'"@?YZU(RPB)%&L<:JB* JJHP !T %.HHH **0D*I9B  ,DGM7+
MZC\1/#.GW)LX[\ZA?9P+33HVN9<^F$SC\2* .IHKC?!/BKQ#XEN=0&J>&7TF
MUMI#''+-*0\C9Z;,>G4YQG@9[=!J>I?8QY:#YRN=Q[4TF]AI-NR,C7]29S)#
M$WRQ\8]6]ZY7^T9;2S:6_G#,AR1$OY 5+JLTZVTGV61!.QX,G3ZUR>M:_!I<
M<23GSIGQN"X!^N*[J%"4E:*N;:11U$WB^:!HA#<W".?NY^9?Q!KL?"OB>/Q#
M;RJR!+F# D Z,/45Y7I.G3Z_<7$-K*BSB(21Q,<&3UQ[@5W/@#PWJ.CW5W<W
MT?EB1-BJ3R3G.?TJ:T::C;JA32L=Y12-G:=N-V.,]*X_S?B1GBS\*_\ @5<?
M_&ZXC$[&BN.\WXD?\^?A7_P*N/\ XW1YOQ(_Y\_"O_@5<?\ QN@#KC#$S,QC
M0LZ[6)4?,/0^W)_.H3IUB2Y-G;GS$$;YB7YD'13QR/:N7\WXD?\ /GX5_P#
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M)PQV*#@G=C .:CG^)$5C)=[K*XOL2R>4EJ(_ECCMXYG)8OAAAS@CKT [E63
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M21VKV_D^3D,X;/F0I+V]-^/PIF9O4444 %%%% !1110 4444 %%%% !1110
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M^3DXZFMR\U2SL&"3S*)6^[$OS.WT YII-NR$VDKLN45SLWBHVSYN-(OHX/\
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MT"86WBKPU;C=YBKL*@],H0:]FKYW,::A5NNJ%ETW*DXWO9V"BBBO/.\****
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M:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !36ZK]:** !/XOK2_Q_A110 M%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g10811g0421055929083.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055929083.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #I >@# 2(  A$! Q$!_\0
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M2OLVM&P(51]X@$ 9S[UZ;#Y@A3S2#)M&['3/>@!]%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444F1Z
MCTH 6BC(K,GUVU@O9;3R[F66(*7$4#.%STY'TH TZ*RO[?M_^?2__P# 5_\
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MI?\ _@*_^%']OV__ #Z7_P#X"O\ X4 :M%97]OV__/I?_P#@*_\ A1_;]O\
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M;_R%% &C5#669-&NW0D,L1(( )!Q[\5?JEJT<<FG3>=*T<:KEB%W<>A'?Z4
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MRN6N[9)FA:+>,A6.3@U,-%8<M=2Q1115DA1110 4444 %%%% !1110 4444
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M#=:NW$V^T:2W$4^.<%N*9IDLD]HLTD,<6\!@J'M1<7)KS#KC3;>YE$K[PX&
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MVP*U-)\3+J$5Q,\#*D<,<Z[!DE'+@#'K\GZU7T^\MKN_\0W#QR& )%O5TP2
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M!@8%(R*V-R@X.1D=*!#LU5CU&SFN/(CN$:4?PCK4,UO>P2M+:3"16.3#+T_
M]JRM+URTN/$U]9-$8;E4C&U@.2,YP1]1^=)NP['2T4P31%BHD4L.",\BGU0@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH H+_ ,AR3_K@/YTS7 S:7(BQ
MM)O(78!][VIZ_P#(<D_ZX#^=2:E;+=6A1Y#&JL'+#L!0!2\.Q?9[)X1"8 CX
M$.T@)],]:V*S-'-H1.;2YEG7<-QD;.#CM6G0 5B6O_(WZA_U[Q_UK;K$M?\
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M#<["/4+65MJ7$98=1NZ58!!&000>E9$-]I-\0!$A++G+Q8X^M/2^TR62%$E
M:,_NP"0!2#ED:F>*P[((NNW$PL%C,H"B4%<Y&<GCGGBE>ZLIKHB+6&CD9L;
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M:2#[/G[H4[L5=HI\P%)UU#[7E)(!;Y^Z5.[%$ZZ@;@&"2!8>,AU);WJ[11S
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M6S\.WD>G36Y>0R/-%M9\C8593(X).<,5)'UKM** $'  I:** "BBB@ HHHH
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:@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g10811g0421055929349.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055929349.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $# 4\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRKKP\;##*?<4-=4%SE_$^H7#7364;E(0H+  ?,3ZU'9>&Y;VUBN%NXPCC/\
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MU*T<MQ+M).6)R1@\UKZ1H+W\,5P+D*BOAP5^;@]C4VC:/<?;V6]LCY&PAO,
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M:HP,U)6#M?0].-[*^X5/;]&^M05/;]&^M"%+8GHHHJC(**** "BBB@ HHHH
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MHH IZC_Q[K_O5F5O,H8;6 (/8U']GA_YY)_WS04I6,6BMK[/#_SR3_OFC[/
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*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g10811g0421055929630.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055929630.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #+ ;,# 2(  A$! Q$!_\0
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M;2WF,JQZBXWE]^<HAZ]Z .DHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?[32/BZ@FMCW+KE?^^AD5;BFBG3?#(DB^JMD4 /HHHH **** "BBB@ HHHH
M:>M%!ZT4 8WB\SKX3U$V]Z]C((O^/B,,609&<;03G&0" <9S7)^!9K9O$TRV
M?BB\U,-;2--!>^:KD"11$RHZJ/E3Y68=2<FNN\5V%_J?AF]L]+F\F]E"B*3=
MMVD,#G/T!J+1]%U:SU%KO5-<34R(C''FPCA9,D$X9><<=.G3TH WJ*AN[N"Q
MM);JY<)#$I=V(Z 51/B#3Q:07+/*$FN!; >4V5D+;=K#'R\\9- %^Y\O[.WF
MPF9.Z!-V?PK%\+;-NK^7$8D_M!\(4VX^1.U;VX#J1^=8OAW_ %NL_P#81?\
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M?NH5DNBS*((2-VU>>5]JZ8G R>U9.AZK9ZG]I:T69<L)3Y@QN#<!A[':>O-
M%2VTO6Y$<R^(KQ")&4#[+",@'@_<IMGINNS6OF3^(;N.3<XV_981P&('\/<
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-* "BBB@!,44M% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g10811g0421055929880.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055929880.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $' 1H# 2(  A$! Q$!_\0
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M^34;".Y3'S## =CW%6Z "L;Q)XBMO#-C;WEVK&"6ZCMV8?P;SC<?85LUR7Q
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M_P!ZBD><%)]LC Z]JZ'P]%J5MHTPC@VAKR5K:*Y8KL@+':,<D<=C0!:\7_\
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M"8KB/NDB\,/Z_C6K+&DT3Q2*&1P593T(->?6C/X0\;M#*Q%AJ&U')Z;NB/\
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MH *:Z+)&T;J&5@0P/<&G44 06=G!86<5I;)L@B7:BYZ#TJ>BBFVV[L HHHI
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MIDUHU6U"PM]3LI+2Z3=$^,X.""#D$'U! - &3!X@GN-!U&]CL=]W822PO )
M%9X^N&/;\*NV6LV\^AV6IW+);)=0I( [<*67.,U%'X=M(K.2VBFND27S/-*R
M\R,_WF;U;WJWIVG0Z9IL%A"TCPP($C\UMQ"C@#/M0!B>*-:TR7PGJR)?0,S6
MD@ #CD[36WI/_('L?^O>/_T$5R/CHHNF:LN]5_T1OE\R4?P^BC;77Z5_R!['
M_KWC_P#010!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M35_2?^0-8_\ 7O'_ .@B@"Y1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 (RAE*L 5(P01P:KII]E&RLEI I4$*5C P#VJS10
M!6.GV31I&UI 4C.44QC"GV]*LT44 %%%% !1110 5P>CZMJ">(-U[<S^6#=F
M]20'9"JR 0D#^'()Z=:[RDP.>!SUH \VBU'59GO5GU"\@=H+PW1''D%9,0[<
MC"DKTQUKK="U&XF\):7=+')>W#V\?FX8!MVT;B=V.<UN;0<Y YZ\4  #  'T
MH YKQ%=:A<^&M4@&D3J7M9%!,L>!\I]ZJ6/B/5[>WLK(^%;PR_9P1BXBP0H
M)Z^XKI-8_P"0+?\ _7O)_P"@FEM[6-C:W1W>8D&P<\8."?Y4 <]_PE^I^29?
M^$5OMHE\D_OXOO9VXZ^M2?\ "4ZN+AH/^$4O?,5/,(^T1=,D>OM6Y_9=OY#0
MY?:T_GGG^+=N_+-3&TC-V]S\V]XQ$>>,9)_K0!S(\7:HT-M*/"M]LN2%C/VB
M+DD9'?CI2GQ;J@2Z<^%+W;;9\W_2(N,+N]>>#70+IL"V]I""^VU8-'SSD @9
M_.JEI MS-K4$F0DLVQL<'!C44 9@\5:LTT4(\*7N^6,R*/M$7W1CW]Q3/^$O
MU/R3+_PBM]L$ODG_ $B+[V[;CKZUTBV42W,,X+;X8C$O/&#C_ 5'_9=O]G,.
M7VF?S^O.[=N_+- &&?%.KBX>#_A%+WS$3S"/M$7W<D>OL:8/%VJ-#;RCPK?;
M+@@1G[1%R2,COQTKI#:1FZDN/FWO$(CSQ@$G^M9]Y;I:II%O'DI%<JHSR<!6
MH RSXMU0)<N?"E]MML^;_I$7&!N]>>#3AXJU9IXH1X4O=\L9D4?:(ONC'O[B
MM\Z="T=XA+8N\^9SZJ%X_ 4Y;*);F&<;M\,1B7GC!Q_\2* .;_X3#4_),O\
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MR,JQ4X]N*MWMA;:C;^1=Q"2/<& /!!'0@CD&I+:V@LK:.VMHEBAC&U$48 %
M$M%%% !VXK"T?4;Z[UO5+64P26UF4C\Z-"I,I&67J>@*_G6[4%K9V]DLBVT2
MQB61I7Q_$[=2?>@">BBB@ KED\2W-O)X@&HPVZ_V=-&EN(R?GWJ"H8GODUU-
M9]MHNGVEW<W4-OB:Y(,S%BV\CID$XXH J>$M9FU[PU:ZA<B 7#EUE6 Y0,KE
M>/RK;JO8V-KIMJMK90)! I)"(, $G)_4U8H *QO$>HWFE:>;RV,#;./)=26F
M<D!47!ZG\:V:HWVD66I36\MW"7DMV+1,'(*$\$C!ZT 4-)U:^N?$6J:;=V\$
M4=M%!+#Y9);#ALANV05[5NU0@T:QMM2EU"*$K=3*%DDWL=P'0'G'&35^@ J.
MX\[[/)]G*+-M^0R E0??%25%<VT5Y:RVTZ[HI5*.N2,@]1Q0!PUYXUU&U@W+
M;6\NUY\3*IQ-''M^8#.53)(+DD#'O7=Q/YD*2<?,H/!R.?>LP^&=':UAMFLE
M:&'(C5F)V@XRO7[O XZ5J@!0    , #M0 M%%% '.ZIJ]_8:W;6@BAEAN]ZQ
M H5PP0L!N)P6)'W?2K/AO59M3T\_;=J:A%M%S;B,H86*@[2"3GV/>K4NBZ?-
M>&[EMP\Q!^9F) R,$@9P#CC(J2QTVTTU'6TA$?F-N=LDLQQCDGD\4 6Z***
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I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g10811g0421055930161.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055930161.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #$ -T# 2(  A$! Q$!_\0
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MB<_\?$G7- '7T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTR>YQWJAXGC\[098?+:0221(57'0R*#U]JMZ3(TNEP;_ +Z+Y;_[RG:?U!H
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M7\/M$M %3PSJEY?V>F)/>M.T<<J3N.DCA!D-ZX)/YBNMTO\ Y!-E_P!<$_\
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MAM_+X\M)'&[=_NE3^E:EA(D7BF>Q+#S(XY9%7OL=D;/YEA^%5/$LZVFH7%X
MQFM[)70(/F;YG!4>Y!/Y"@#K**S=!NDN]%M65G9EB17\S[V[:#S^8/XUI4 %
M%%% !1110 4444 %9/B0XT*< D$LB@?WLN!M/L>A^M:U9FKQ7!6*>$1R)$&$
ML$K!5D4CN3Z8H =H3J^C6^V,1A05*+T4@D$"M&J6E(T>G1AVB))9L1'*J"20
MH^G3\*NT <G/X5N&^2&2)(WFF;(SF(/(KAE_VAMQ^-5T\)7V5+20#*K"P7/R
MA=G[P?[1\O\ 6NTHH Y_7X[FTMFN;>^NE9I -BD$ 'T%4/A>2WP^T\L26,MR
M23W/VB2M[6HS+8A0KL=X.$C+G\@:POAEQX L1C&)KGMC_EXDH L^*7$-Q8W1
MX%JLMP3[+MW?^.YK8TAUDT6Q=#E6MXR#Z_**Q/%ZL_V:,;A')#<1RLHR5C*@
M,0*N>$VF.@6RR,SQI'&L4C#!9=B_UR/PH K>.23X9N(HX3-.REHT!QG:"6Y_
MW0:W+&X2YM0RH8]C&-D)SM*G!'Z53\26T5SX>OA*N=D$CJ0<%3M/(K0M[>*U
M@6&%=J+T'\S0!SOC)W\G3H[=)'N!>0OMC.#Y?F*K<_\  A716MQ'=VT=Q%G8
MXR,CD5F>([.*YLH7?>LB7$(5T;! ,J9'^?2M6&&.WA2&)0L:#"@=A0!RGBV2
M0:QI#HT$?V2<2[IL_/N5Q@?0JOYBNJ@D,UO%*4*%T#%3U7(Z5F:XD;R:7YD8
M<_;4QE<XX:M>@#C]:O\ [)XZTF11,8%CE2Z95^52$W+GZ!B?I785@:OIMO/K
MFF.Y<>;*XD0-A9,1-C(_3Z5OT <9+)<IX_%PKD2O#Y'V?R_O1B1/FS]&8_AB
MNEU:UCN=.FW$JZ(71UZJ0#BHI,_\)/;_ "-@6<F6QP,NF!GUX-7+Q6:QN%12
MS&-@ .YQ0!B>%HAIEE;Z>[,WFPI-#(YR7&U05^J\#Z8KHJR8[*6?0;)0IANX
M(D:/=U1PO0^W4'ZU'I'B"+5=0NK4;%:!4RN[+!CD.I^A% &U1110 4444 %%
M%% !61XGC:7P_<*H);*$<@#A@><\8]?:M>N>\8[GT-H/]'\J4[9/-EV''4;?
M4Y X- %SPXSMH-J9(Q&V&RH7'\1[5JUE>'.?#]FQ,A+)N)E!#$DD\Y[UJT %
M%5;O4(+*6VCFW W,GE(0N1G!/)[=*S5\5Z:P4YE&2"<QGY4.W#G_ &3N7GWH
M T=2, M?](N'@3</G1L'/I7._#/'_"!66TDKY]U@GN/M$E=0T\ )5I8P1U!8
M5S'PV_Y$:TQ_S\7?_I3+0!I:SG^T;/ )/V>YX'^ZM7=(S_8MCD%3]GC!##!'
MRBI9;.*:\M[IBPDMPP3!X.X '/Y58H K:A:F]TVYM%?RS-$T>_&=N1C.*L*"
M$4,<L!R1WI:* (;JUAO(/)G4LFY7P#CE2"/U J:BB@ HHHH BDMH99X9I(PT
MD))C8_PY&#^E2T44 %%%% !7'6FBW-IXDNYK29&^S1Q%82N/,R''S'^]CC/?
MC-=C5>*SBAO+BZ7=YLX4/D\87.,?F: &V=]%>*P4,DJ<21.,,A]Q5JJEY8)<
MLLJ.8;E/N3)U'L?4>U16U^ZS+:7R"*Y/W6'W)?=3_2@#0HI 0>A!I: "BBB@
M J"YLK6]""ZMXYO+.Y-Z@[3ZCTJ>B@!D44<$:QQ($1>BCM3Z** *]W917GD^
M;G]S*)5P>I (Y_.LA/"-BFS][.V $8EA\T8V[4/'0;%_7UK?HH Y_P 3:=;/
MI_F)$B2M*"TBJ-QZ]ZS_ (7#;\/-.'I)<C_R8DKH=63?9 ;HU^<<R2M&/S7F
ML#X9<> ;$9!_?77(.?\ EXD[T ==1110 4444 %%%% !1110 4444 %%%% !
M1110 54U*S%_IT]OQO=#Y;'^%L<$>A!JW10!S7A;2;S3&N1/'+%&TCD"6?S3
M)ELANIQ@<5TM%% !1110 4444 %%%% !117+2^*+N'<'M(@T<TJR 2$Y1'1/
MEXY8^8#CVH Z"]&8,?8Q=?,/W9V_G\W%<W\-/^1#L_EV_O[KY?3_ $B3BM^7
M58HI6C-O>,5.,K;.0?H0.:X/P9XH&C^&8;&XT36WDCGN"6BL)'4AIY&&"!SP
M10!Z517()\0K.2 3)HNO-$1D.--EQC\J/^%@VA@\_P#L77O*V[]_]FRXVXSG
MIZ4 =?17(-\0;-8#.VBZ\(@N\N=-EQMQG/2B7X@6D$1DET37D1>K-ILH _2@
M#KZ*Y&3Q_:Q+NDT37E7(7)TV7J3@#IZD42>/[6)09-$UY06"@G39>23@#IZT
M ==17(O\0+6+9OT37EWMM7.FR\GTZ4-X_M49%;1->#.=J Z;+\QP3@<>@/Y4
M ==17(M\0+1'1&T37@TA(0'39<L0,\<>E!\?VHE6(Z)KPD8%@O\ 9LN2!C)Z
M>X_.@#KJ*Y'_ (6!:B41'1->\PJ6"_V;+D@8!/3W'YT?\+ M?.\G^Q->\P+N
MV_V;+G'3/2@#KJ*Y$>/[4RM$-$UXR* S+_9LN0#G';V/Y4+\0+1I7C71->,B
M %E&FRY&>G;V- '745R*^/[5V=4T37V*-M8#39>#@'!X]"/SH3X@6LA<)HFO
M,4;:V--EX.,X/'N* .NHKD8_B!:RAC'HFO,%8J<:;+P1U'2B/Q_:RIOCT37F
M7)&1ILO4'![>HH ZZBJVG7T6I:=;WL(=8YT#J)%*L,]B#T/M5F@ HHHH ***
M* "H'LK21T=[:%F1_,4E!D-Z_6IZ* "J&C6\MII44,R[9%+Y&<]6)'\ZGOEG
M?3[E+5MMPT3")L]&P<?K5'P_!<064PG2:-&EW11SOO=5VJ#DY/\ $&/7O0!?
MBM(8+,6D:D0A2H&>U*+6(60M O[D1^5MS_#C'\JFHH HZC:M)H=U9VZY9K=H
MHUS_ +) %6+FVBN[9H)EW1OC<,XZ'-96M)=RW^GK;6\Y57WM/')@+@CY2,_Q
M=R0<#/<U'X2M]2M=-ECU,2^89 5,CY/W%#=SQN#=^>N!G% &W/!'<1B.494,
MK]>ZL&'Z@4D]O'<HJRC(5UD'/=2"/U J6B@"CJ5O+<-9>4N?*N5D?GHH!_QJ
MU)!'+)#(XRT+%T.>A*E?Y$US&LV6K/JEZ]@9]DT"JSY(\L!ER(QN )*[^P.>
M];VD+<+I-LMU&(YE3#*"3CTZD\XQW/UH L26\<LT,KKEX6+(<]"00?T)I6@C
M:Y2X(_>(C(ISV8@G_P!!%244 4G@E.N0W('[I;:2,G/\19"/T!JQ]GC%T;G;
M^]*",G/\()/]:X=M.\5-97L<7F*TDZR'?<;6X<DJAY^7&W)^7(XP*[V@")8(
MUN9+@#]Y(JHQSU"YQ_Z$:$MXX[F6X5<22A0YSU"YQ_,U+6?K-M/=:?LMFD69
M98W7RWVDX<$@GTQGB@"2S@DAN=0>086:X#ISU'EHO\U-3PV\<#3-&,&5_,?G
MJ< ?R KFM4L=1!U-8DNY8[FXC,+I,<PCR_F91D=".%Z9(-=2OW1UZ=^M $<%
MO';JXB7 =VD;G^(G)H@@CMHO+B&%W,V,YY8DG]2:EK*U.VOGU"RN+)CF)90R
MM(1&24.W<!U^;'KB@";1K>6TT>VMYUVR(N&&<]S5^N,LM/UZ.ZMA>>>[K.66
M59\J%\YF?<.,AD("C!QCM79T %%%% !1110 4444 %%%% !1110 4444 %%%
M% ",ZIC<P&>F30"",@Y%9^KZ:FHK:!H(9?)N$D/F*#A0><9K CT?Q)&J,E\5
M9!Q&L@"<"/;QMZ9$N?J/P .PZ49&<5S4%AJZ:-<)J-P]U*]Q&[H%&"@9=X7!
MR00&X/KBJ2:5XD0O+YV;F3R?,D,_!9"Y;:,#"'<.#0!V5%<UI":G-?6]Q=&1
MU!F19,%081A4+ _Q,1N_"NEH **** "BBB@ HHHH **** $HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g10811g0421055930457.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055930457.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Q =\# 2(  A$! Q$!_\0
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M+=-H5H]R?-D?,S87DY)_*J4I=Q61I?\ "O?"?_0%M_\ OIO\:Y/Q!\-+:_\
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M''+S-&T=I9$C0$LQ  KV+47;P[\/)6&1(EO^3&N \'P:/::S#/>-.^#\FX#
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MM_&4LBI]X1VUNW;OA>.>:\.\*^%+WQ5J0MX 4MT.9YR.$']3[5[E+!;>"O#
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M/=2>^ S9]XQ7?UG:5HMMI+W4L3S37%W)YD\\[[G<@8 Z   <  5HT@"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH CGN(K:(RS2*B#J6-<A-XA%_
MJ[10:];Q6:\"."/=*Q[Y.>/P%<C\1-7N-1U]M*25EM8 -ZJ<;F/K7*'38U0%
M5VL.01P10G+7E5SH]C345[25FSV:*>#3M:L$MIA]BNE:,YR2TO49-=-7E'@R
M]74S'::D#,;>92"S$9/\+<=Q7J]/2R:.=TW3DXL****0!1110 4444 %%%%
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M<T+Q+<ZU?M;G3?)A2+S&N1*61SO91LRHW#Y2<G'TKHZ "BBB@ HHHH ****
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M$KZM?" Z;-;1M&6221N20L;$$8X_U@P>^#6_10 4444 %%%% !1110 4444
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MS48@-MRH/(ZCMVR* ,_Q'X%T[7V\['D7':1.*Y'_ (5+=&3!U-C'GLHS^?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 GI2T44 %%%%
'!1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g10811g0421055930753.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055930753.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #U >0# 2(  A$! Q$!_\0
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M@!LC,L3,B;V"DA<XR?2L#3KW6Y;FV6\MVCW%A(OEC;C+\Y!.,83'KG\NAHH
M\R^)18W5AN !_>< Y_N5PM=W\3/^/RQ_[:?^R5PE>QA?X2/-K_Q&%>T>"O\
MD3]._P!QO_0C7B]>T>"O^1/T[_<;_P!"-98WX%ZFF%^-F_1117F'<%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 -<$Q,% )(.,FL#3M&U"VNX))9U*(S' D)VJ2WRCC!'(
MYX^[70$A5))P ,DFJT6I64[HD5S&[N"54'DXH \\^)((NK ,VX_O.<?[E<+7
M=_$S_C\L?^VG_LE<)D>M>QA?X2/-K_Q&%>T>"O\ D3]._P!QO_0C7B^17L/A
M;/\ P@UAC^Z?_0S6>-7N+U-,-\3.FHK%RWJ:,MZFO.Y#LYC:HJG8$E9,GN*N
M5+5F4@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% #74O&RABI((R.U9=KH,-K-#+Y\KM'RVX#YV&
M[#' Z_,:UNU9D&MPSS6\8BD4S ')QA2=V ?^^6H X?XCDPW%DD9PI\S(_P"^
M*X?SY,_>[8Z=J[;XE,'NK!E.0?,_]DKA:]?#)>R1YU=OVC)!/(""&Z# X[5Z
MUX8C5O!%BQ&25.?^^S7D->P^%_\ D1K#_=/_ *&:SQB7(O4O#/WGZ%G8ISQU
MH\M?3MBG45Q'66K1$\J5MN2!BF?:3Q^[7@8'6I;3_43?2J?:ILKCN3_:2-O[
MM?EZ=:EMG$LH4HH"C(Q5.K-C_K_PH:5@39.TU@C;6N(%93T,@R#^=-^T:=C_
M (^;?KG_ %H_QKQ?Q#_R,>H\G_CX:LW\377'!)I.YS/%-.UCWOS[!SM%Q 2Q
MZ"0<G\ZL&",YRO7K7A.D?\AJQY/^O3^=>]5A7H^R:5S:E5]HF1^1&<_+U&#0
M88R>5ZC%245SFI'Y,?\ =[8_"CR8^/EZ# J2B@",0QC;\OW>E'D1C'R].E24
M4 1^1'_=[YH,$9_A[YJ2B@",P1G.5ZG)H,$9S\O7K4E% $9AC.<KU&#088S_
M  ]L5)10!'Y,?'R]!BCR8_E^7[O2I** (_(C&/EZ=*/(CX^7H<BI** (_(C_
M +O?-!@C.?EZG-244 1F",Y^7KUH,,9SE>O6I** (S#&225ZC%'DQ_W>V*DH
MH C\F/CY>@P*!!&,?+TZ5)10!'Y$8Q\O3I1Y$?'R]#FI** (_(CQ]WOF@P1G
M.5ZG)YJ2B@",P1G.5Z]:##&Q)*]1@U)10!&88R>5[8H\F/CY>@Q^%244 1^1
M&,?+T&!0((QM^7[O2I** (Q!&,?+T.11Y$>/N]\U)10!&8(SG*]3F@P1G.5Z
MG)J2B@",PQL6ROWNM!AC))*]1@U)10!'Y,9/W>VW\*/(CR#MZ#'X5)10!&((
MP5(7[O H$$8VX7[O2I** "BBB@ JI%IME \3Q6T:M$"J$#[H.?\ $_G5NLP7
M5[_;IM]A^S;?[O&-N<Y]<\8H X;XE_\ 'W8_]M/_ &2N$KU+Q=X;O_$,]N]K
MY2^27#AV]0N/Y5S?_"N=:_OVW_?9_P *]/#UJ<::39PUJ<W-M(Y&O8?"_P#R
M(UA_NG_T,UQG_"N=:_OVW_?9_P *[_1=,N-/\-VNGS;3-$"&*GC[Q/\ 6HQ5
M6$HI1?4JA3E&3NA**L?8IO0?G1]BF]!^=<G,CILR2T_U$WTJGVJ_!#)'%(I'
M+#CFH/L4WH/SI)JX[,KU9L?]?^%)]BF]!^=36UO)#+N8#&,<&AM6!)GB_B'_
M )&/4?\ KX:LVNZU7P%J][J]W=1/;B.:4NH+'.#5/_A7.M?W[;_OL_X5ZD:]
M-16IP2I3N]#GM(_Y#5C_ -=T_G7MMS<R13;5(QCTKSRP^'^L6VHVT[O;[(Y5
M=L,<X!^E>AW%O)++N4#&,<FN3%5(3DK.YT4(2BG=$/VV;^\/RH^V3?WA^5'V
M*;T'YT?8IO0?G7->)OJ1ZSX@M-!MH9KQ9")3M'EKGG&:QO\ A9&B_P#/.Z_[
MX'^-3^,- O=>L;6&T\M6B?<V\X[8KC_^%<ZU_?MO^^S_ (5O2A0<;S>IC4E5
M4O=6AU/_  LC1?\ GG=?]\#_ !KH]+U.#5]/CO;<.(I,X#C!KS/_ (5SK7]^
MV_[[/^%>@>'-.N='T&"RG"M-'G.T\<FE6A14?<>HZ4JC?OHV:*AWS?\ /(?]
M]4;YO^>0_P"^JY3<FHJ-7DP=T>/3!IN^;_GD/^^J )J*AWS?\\A_WU2J\N?F
MC 'L: ):*KM>1HQ4@Y'6D^W1?[7Y4[,+EFBJPO8B0!NR?:LS5/%FEZ-=_9;Q
MY%EVAL*F>*:C)NR0G))79N45RW_"P= _Y[3?]^Z/^%@Z!_SVF_[]U7L:G\K)
M]K#N=3163?\ B*PTRQ@O+EG6&?[A"Y)[UF?\+!T#_GM-_P!^Z2IS:ND-SBMV
M=317+?\ "P= _P">TW_?NMC3=;L]6LC=VA=H0Q4DK@YHE3G%7:!3B]$S1HJM
M]NB_VORH^W1?[7Y5-F5<LT5#'<++G8#QUIGVZ+T;\J5F!9HJM]NB_P!K\J5+
MN.1PJ@Y-.S"Y8HKG;WQKHVGWDMI<22B:)MK 1YYJ#_A8.@?\]IO^_=6J51ZV
M9'M(=SJ:*YB/Q]H4LJ1K+-N=@H_=]R<5>U;Q-IVB2Q1WK2(TJ[EVKGBE[.=[
M6#GC:]S9HKEO^%@Z!_SVF_[]T?\ "PM _P">TW_?NG[&I_*P]K#N=315:.^B
MEM(KE-WE2J&4X['FC[=%_M?E469=RS15;[=%_M?E3Q<HT1D .T=:+,":BJWV
MZ+_:_*C[=%_M?E19A<LT5#'<+*2$!..M,^VQ XPWY4K,"S15;[=%_M?E2I=Q
MNX50<GIQ3LPN6****0!13)1(5 C('/S9'45B66FZC%/8O+( (8E63$A/0-D>
M^<KS[4 ;,/WYO]_^@J6H;?=F;<03O[?05-0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 W8I.2H_*DQ%OV?+NQG'>
MGUA2^'Y)/$L>JB]E$:C'D;C@T ;>Q?[H_*O*/B+_ ,C,/^N*UZS7-:[X,M->
MU#[9/<S1OL"X3&.*WP]2,)WD95H.<;(\=I#]T_2O4/\ A66G?\_MS^E'_"LM
M.Q_Q^W/Z5W_6Z7<Y/J]0H^-/^1/T?_@/_H->?5Z3\0[=;7P[IUNI)6.3:">I
MP*\VIX9WI_>*O\85ZCX"_P"12E_Z[-7EU>H^ O\ D4I?^NS4L7_#^8\/\9MT
M445YYV%RP_Y:?2JC?>/UJW8?\M/I51OO'ZTEN/H)4UI_Q\I4-36G_'RE#V!'
MDWBS_D:M1_ZZFL:MGQ9_R-6H_P#74UC5Z]/X%Z'FS^)EBQ_Y"-K_ -=D_P#0
MA78_$S_D(:?_ -<#_.N.L?\ D(VO_79/_0A78_$S_D(:?_UP/\ZSG_&C\RX_
MPY?(X:D/W3]*6D/W3]*W,CVVP_Y%G3?^N*?^@T46'_(LZ;_UQ3_T&BO&ZL]-
M;!5N+_D'R_6JE6XO^0?+]:3&BI1113$7-/\ OO\ 054;[Q^M6]/^^_T%5&^\
M?K2ZCZ"5+;?\?,?UJ*I;;_CYC^M-[ :U%%%8EB%@JEF(  R2>U5X[^TF=$CN
M$9G!*@'DXJ2XA^T0F/>R$]&7M_C6;:Z#%;3P2^<[&+!.5 WL-W)_[Z- &E%]
M^;_?_H*EJ&W4(9E'0/\ T%34 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 </\3?\ D$6?_78_
MRKS"O3_B;_R"+/\ Z['^5>85ZV$_A(\_$?Q KU'P%_R*4O\ UV:O+J]1\!?\
MBE+_ -=FHQ?\/YAA_C-NBBBO/.PN6'_+3Z54;[Q^M6[#_EI]*J-]X_6DMQ]!
M*FM/^/E*AJ:T_P"/E*'L"/)O%G_(U:C_ -=36-6SXL_Y&K4?^NIK&KUZ?P+T
M/-G\3+%C_P A&U_Z[)_Z$*['XF?\A#3_ /K@?YUQUC_R$;7_ *[)_P"A"NQ^
M)G_(0T__ *X'^=9S_C1^9<?X<OD<-2'[I^E+2'[I^E;F1[;8?\BSIO\ UQ3_
M -!HHL/^19TW_KBG_H-%>-U9Z:V"K<7_ "#Y?K52K<7_ "#Y?K28T5****8B
MYI_WW^@JHWWC]:MZ?]]_H*J-]X_6EU'T$J6V_P"/F/ZU%4MM_P ?,?UIO8#6
MHHHK$L9)(L:;F/T&>I]*S;77K:[EBC1) 9#M)(X5LMP?^^6K2DC25"DBAE/8
MU7BTRR@DCDBMU5X\[2.V<_XG\Z 'PRQ[Y/F'S2<>_ J7SH_[PZXID(&^;@</
M_05+@>@H :9HQG+#@XH,T8SEAP<&G8'H*,#T% #3+&,Y8<=:/.C_ +PX&:=@
M>@HP/04 -\U!_$.F?PH\U./F'(R*=@>@HP/04 -\U/E^8?-TH$T9Q\PYZ4[
M]!1@>@H ;YT?'S#DX%'G1_WAUQ3L#T%&!Z"@!IFC&<L.#@T&:,9RPXZT[ ]!
M1@>@H ;YT8S\PXY-!E0=6' S3L#T%&!Z"@!OFI_>'3-'FIQ\PY&13L#T%&!Z
M"@!OFH<?,.>E'G1\?,.>E.P/048'H* &^='_ 'AUQ1YT?]X=<4[ ]!1@>@H
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M%U>S6R2VJQF0D,N<G^+D=L#:,_6@#=AX>;']_P#H*EJ&W;<9B 1\_<8["IJ
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M #P/_?0J6N=EUC4(]&U"YQ;^?:7+(.#M*#!_/!H W?,E_P">!_[Z%)YDO_/
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MKW/K6I10!%]IA_YZ+^='VF$G_6+^=2T4 %%%% !1110 4444 %%%% !1110
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>* #-&:** #-&:** #-&:** #-&:** #-%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g10811g0421055931065.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055931065.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #J @$# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO3UI1OXR%]^:=10 S]YQPOOS1^\XX7WYI]% #?WF.BYSZ]J/WF.B]?7M3J*
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MUQ_D*R<+Z"G'!1:3N)XEIVL>]_VSIG_/_;_]_!3XM4L)Y5BBNX7=NBJX)->
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M@. >& JY&Y\I?D;H!0!+13-YY^0\&@N1GY"<?K0 ^BF%R,_(3C]:-Y_N'I0
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M^1OLO^!?^@FL+RUR!YR<C.?3VK>\%J$\66)#ASAN!]*FJ_W;]"J?QH]4OO\
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MI786/ ]4_P"0O>?]=F_G52K>J?\ (7O/^NS?SJI7O1V1Y+W"NA\$?\C?9?\
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MM5N;4AXF) ;&,X.*L>4G]T?E5+2-.CTFR^S+</*N]F!D/(R>E7]R_P!X?G0
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M0 4444 5K[_CW_X%6=6C??\ 'O\ \"K.K2.Q$MPHHHJA%N3_ ) D_P#UQ?\
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M,6ZO$NH[N6WE">4YC(^=,@XY''(ZBJ2^%M-2*ZB!<)=(5E 8#<=Q8'CN-Q%
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MVEN7O*C_ +B_E1Y4?]Q?RJO:ZG87SE+2\@G=1DK'(&('X5;H::W&G<9Y4?\
M<7\J/*C_ +B_E3Z*0#/*C_N+^5'E1_W%_*GT4 ,\J/\ N+^5'E1_W%_*GT4
M,\J/^XOY4>5'_<7\J>2 ,GI3/.B_YZ+^= !Y4?\ <7\J/*C_ +B_E3E=7&58
M'Z&EH 9Y4?\ <7\J/*C_ +B_E3Z* &>5'_<7\J/*C_N+^5/HH 9Y4?\ <7\J
M/*C_ +B_E3Z* &>5'_<7\J/*C_N+^5/HH 9Y4?\ <7\J<  , 8%+10 4444
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886_AY!R/0\#FK=%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g10811g0421055931346.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055931346.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #F 1X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBFR2+%&TCG"J,DT ,FGBMUW2,!GH.YJO\ VBA/$4F/7 K-\UKB
M4SR?>;[H_NCTJ0&LW/L=4:"MJ:D=W#*<!L-Z,,&IZQC@C!&:DCN9H>%8,OHW
M^--3[D2H/[)JT5GKJ>/]9"P]U.:M0W4,_$;@M_=/!JDTS)PE'=$U%%%,D***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "LS69<01P _P"M;GZ#DUIU@:K)OU3;VCC _$G_ .M4S=D:T(\TT0M,
ML2;F. *8MTS=$ 'N:JZ@2(HW_A5^:KI<@=ZPN>GR7-870Z.-OOVJ0R5CM<@C
MK2V]UDM$3G ROTHN+DL:ADJ*67 !7/F9PF.N>U5S+[U=T]5B07TR[F;B!/ZT
MUJR*C48G0H2(U+X#8&[ZT"1&. ZD^QK&=Y)SNF8M_LCH*853^Z*UYSC6';W9
MO4UY$C0N[!5'4FL:.^DM2"S%XL\@]1]*EU!S)>+&?N*FX#W-/F5KD^Q:ERLM
MC4;<MC+ ?WBO%6ZPSTP:OZ9*6@:,G)C; ^G:E&5QU*7*KHNT45E:MXBT_1;B
MV@O3<![EMD/EV[R!VY.W*@\X!./:K,#5HJNU]:*F]KJ!5P#N,@ P<X/Z'\J/
MMUIY;R?:H/+0X9_,&%/H3VH L45&L\+3&%94,H&XH&&X#UQ6;IOB32]5M6NK
M>X*VX.%EFC:)7Z_=+ ;AQVH UJ*IWFJ6ME;//))O"MM*Q_,Q.1D >HS4AOK1
M<YNH!A_+.9!][T^OM0!8HJ WMJ&D4W,.Z/[X\P?+SCGTYI%OK1T9TNH&5%WL
M1("%7U/M0!8HJ#[;:Y0?:8<R#<@\P?,.N1ZC@TS3]1L]6LH[RPN8[FVD^[)&
M<@T 6J*** "BBB@ HHHH **** "BBB@ KF+U\ZI='T8#]*Z>N5U0&+5;@'^/
M:X_+']*SJ;'3A?C(WVR1LCC*L,&L6XAEMVYRR=F']:T_,IIDXK&QZ"=C&,V/
MXA^=6+(O)/YF#L52,^M7#'$3GRTS]*5FP % R> *+#<M":"(7$A#DB%,&0CO
MZ*/<UJ@L[^8XQQA5'11V%5K6'9$H_A'(]SW-,U&]>S2 ((]TTHB#R'")P3D_
MECZD5?D<^[YF7MU1L]9UCJ,ES=75O,L:O"<J$Y!0D@'.>^.G%6)), D]J3+B
MD]2Q;PM>W:PC_5KAI#[=A^-6+MPVI2XZ*JK^/6EM)1I^CK*1F>X.X#U)Z?D*
MJQ@@?,<L3ECZFJ>BL8QO.;ET1/GBI=.DV7[(>DB?J*H7UU]CL)[G87\J,OM'
M?%9$NNRV%W&]P;<QHF]7A.0[<DKU.!@>G>DG9W'.-XM'?5E:SI#:I=:1,LPC
M^P7HNB"N=X".N/;[_P"E6M,OX]4TRWOH598YT#J&ZBK3.J*6=@JCJ36YYYYY
M8?#:>"6T%W?P7%O:^0B1F#[T<7G8W9/)/G#_ +YI(OAI-:PVHM[VV+6\4"&*
M2 F*5DADB9F7/)_>!AZ%:[A]2CSB)&?WZ"HOMTYZ(@_,TN9%JG)]#,\+>$H_
M#<EU(9A<S2I#$L[I^\V1Q(F">^2A/XUAV7PYEATJSTZXN+:2*U>5@?+8^87B
MD0$@L0""X/'I78"]G'5$/TXJ=+Z,\2 H??I1S('3DNAPA^&<QDF)U,%&MHUC
M0Q\)/B)99>O\0A'TR?6IKSX<&:R,4-S;+)*]Z9V>#(87#Y#CG_6(, 'ZUWP(
M89!!'J*6F0>?3?#8R"4"]CS+).TC-%DR*\T4BACGG C(_P"!4VY^&9D2<6U\
MEMYGG']U%MSNNA.H.#T &W\:]#HH X*#X="&6VE%U'NA-JPRI8KY<[RN 2<X
M8/M_SBNC\*:&WASP_!I3/%((&8*\:;=REB1D>O/-;5% !1110 4444 %%%%
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M2O/!%A&UU=)/=&6:8RN2^< JZD#VQ(WZ51A\+:9%+&^^=A&X>-6;(4Y#'\R
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MZZE34E% '&*&7*/]Y"5;ZBI4/-6=9M_(U#S /DG&?^!#K6?)($C )QN)!/\
ML@9/]*P4&Y<IZ7M4J?..N-2CMP,L0/51DG_ 58TUH-1MVGMFW  \GJ3G&/K7
M"ZCK(,#R _,_S?AV%=5X=MY+32(8D<"0KYLA)QR>3^5=ZIJ$=#RI5)3E>1=U
M/P[;:F$6Y=B1A5"^IR?Z56M/#MKI4,SVKLH>/!;KSV_6KH:[?8J$_O%++SU
M_P#U_K4#2W($>7V!T+*2>-HZYK+V%/VGM++F[C]K/DY+Z=CD;VY2WM8(Y<B=
MX][J>J\D#\\9_&HM#UQXYY(F8L8QNQG[Z=Q]1V-3>,+9622[EV+=+&'#(>J@
M< _A7(:+<%M9##[JQ,6_&NFR<;,R3<971Z_$\;. QS#,NQC['[I_ XKF;J"]
MLO$TTEN@9Q"&FBSCS #M./?H:U;$DZ5:JWWC N?RX_I3+F62;Q+)*Z'#6,14
M^V>3],UXU>*T7F?182;3<N\=5]Q);7D-TIDA;)'WE(PR^Q%6/,P,D\53DLX9
MG\W:5D'_ "TC.&_^O2-YL:;9'$J$_>QAL?UH4FEJ*?+9N'W%?4-7CMSLVF20
MC(C!Z#U-85[>-J&W[1;PD+]WKQ^-0,SO+)))_K'<EOSK5ATRWGM89%DD#R1R
M.00,#80/ZUY\YRJMKH?-.O5=3G3LR32[^U,:61@$!_A /RL?KZT_Q19?VCI\
M=SN99-.C+1QQC_6#()_'CKZ5D:A;?9+RXM\M^Z=E5B,'@\&NEM;EOLUO<$98
MJK$'OD<_SKKP>(E2E==!PFYNT^I4T#4O$.KZQ!?31B+3&1E8#A6P,9'?.:[+
M=[U#Y<4J1B--A,>_ /'7& *>;-4.!,0<XX'^UBO0JS4Y72LCUZ4>2-I.[)-_
MO2%_>DCBW@!I &P"?3G/3\JA0"2)G#' .!Q[9YK+4V7*2%Z8SGJ#AAR".U6%
MMD#,K/NX[?6JEQ'Y*HP;<&'6DTT-2@W8Z*VE\^W23N1S]>]2UE:%O-K*YSM:
M0[?RQ6K6Z=T>=-*,FD%%%%,@**** "BBB@ HHHH **** ,Y7O;BZNEBFCCCB
ME$:@ID_<4_\ LU/\G4?^?N/_ +]TZRQ]IU#'_/P/_1:5<H Q-4T_4+JR8"YC
M+I\Z?N^XKEI?/6-)II5>)3A@$Q@,,9_E^=>B5R.J6HM;Z2(J##*"R@]"#U%2
MWRR4C>E[\73?4\QU;2+JT$C1_OK=>1C[RCW%=5;ZVKK_ **?-WQ%0%'8BB\L
M9X03 &GAQT'WE'H?6N8T^]G\-W<\Z6[70P%B4';M!8%L_@,?C7:IJ:NCCE!P
M=I'5R^(KY8\[8U7:2AQ]T8QQ^E95]XP=X9HYU3,GRAT_A4D$C'X"L2\\4";3
M;FPCL[D*8#%;LPY3,FXY]L;?Q%<]#8:A=L (RN>[4**ZDMF]K.K2ZT1;V@\Q
MBB+(R\*%4 #\\5<\,>&Y;B\6S3YIIR#/(.D:#K5K0O"MU'!M(,2N=SRR#EOH
M*]4\.Z79:=ID9M$.Z4!I)&^\Q]ZB51+1%JG*W,UH9Z^'KLOM+QI'T&.2!_\
MJK1OM!@NH+?RI&@N+88AF7J!Z'U!]*UJ*Y'"+5F=7MZB::>QP1:6TNIK><J)
M8GVEAPK\ Y'X'I4D<2WCSO\ =2*)I..S=JZ46T/]I26KQK)'(AG;>,_,6Q_+
MBK$FG6[6LD*1JFY2H('3-9JD^IM/$0FFK;GDU_926\SRQH3"Y+8'5">H^E51
M<%0 )2  0!GIGK7:7ME)!*5E79)Z]FJ@;;YLF!"?4 5YU3#-2T/-JX2HI7CJ
MF844%QJ4N7+F,\/*WIZ"NEMX!.WE+\J*/R]!3$A<]<(*?:,(KV\5>@\O_P!!
M-:TJ-MS;"X.7,I35D)]JDC;:20R\$9Z4?;F_O'\ZDN84N/FSM?\ O"J#6<X/
M&T^^:Z-3VTT65O&$T9#'[V,9]:O>81D GGK6;;V;K('E8?+R%%720.M-$R:Z
M$GFMG[Q_.I($FO+A+>(DLW4G^$>M100S73[+>,NWKV'XUU.EZ8NGPG)W3/R[
M?T'M5QC<YZM506FXV/1;>*-42:X"CH!(:?\ V3#_ ,][G_OZ:OT5N><4=-4Q
MM>0[W=8YL+O;) V*?YDU>JG9?\?-_P#]=Q_Z+2KE !1110 4444 %%%% !11
M10!2L?\ CYU#_KY'_HM*NU2L?^/G4/\ KY'_ *+2KM !5#5;#[=:X7 F3YD/
MOZ5?HH:N--IW1P9W*Q5@5=3@@]0:9+#%,/WL2/[LHS77:CI$5]^\4^7,!]X#
MK]:YZXTV\MC\\+,O]Y.16+BX['?"K"HO>,D:58!MWV5,U<B6*'_5Q1I_NJ*0
MY'56'U%.57<X6-V^BFES2?4T48+6R)A(2>M=#H#EM.*_W)&4?Y_&L*'2[^<C
M; 4!_B?BNHT^S%C9I #N(Y9O4GK503O<Y\3.+C9%FBBBM3C*/_,>_P"W7_V:
MKU4?^8]_VZ_^S5>H CF@BN$V2HKKZ$5D7/AV)LM;2F,_W6Y%;=%)I/<J,Y1V
M9Q=U87-F?WT?R_WUY%9T'-_>?2/_ -!->B$!@0P!!Z@USK:'!/JNH&$^2V(^
MG3H>U9NGV.J&)_F,:CDLJJI9V.%4=S6C)H5^APHC<>H;%:FDZ/\ 8W,]P0TY
M&% Z**E0;9K.O!*Z93M_#DKJ&N)]F?X4'3\:T(="LHF!*>9C^^<UIT5JHI'%
M*K.6[&+$D:A8P$4=E&*?115&84444 4[+_CYO_\ KN/_ $6E7*IV7_'S?_\
M7<?^BTJY0 4444 %%%% !1110 4444 4K'_CYU#_ *^!_P"BTJ[7$^!K75(-
M?\8-J%U/-"=4VVRR'A4V!N/P=1_P&NVH **** "BBB@!I1#U53^%*% Z #Z"
MEHH **** "BBB@"AN7^W\;AG[+TSS]ZK]<4VASGXRIK.^7[*-&*;=QV^;YF.
MG3[IKM: "BBB@ JA:_\ (7U#Z1_R-7ZH6O\ R%]0^D?\C0!?HHHH **** "B
MBB@ HHHH IV7_'S?_P#7<?\ HM*N5Q?@O2[ZQ\4>,9[J>>2&;4%^SK(Y(5=@
M?Y?^^\?\!KM* "BBB@ HHHH *X[Q9K&HZ=K&F065L\T-S-LG=6QY2[2<^_\
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MI<@A(\2, 6[] /S%6],U6ZO;G9-:>2A#;<YR"H3K]=_Z4-XDLE:1=LY:-29
M$SM(SP?R/M5VTU"&^>9(BV8B V>^1D$>WO37J(M44450CNJ**1N%)]J\XZQ:
M*YTZA<_\]6_2H[?5KBXMXYED8"10P!QQFL?;1(]HCIJ*YF+5Y)U9H;H2*IP2
MI! -+_:TOD^=]J'E;=V_(VX]<^E'MD'M$6AX?C'CAO$7R^8=.%E[_P"L+YK;
MKG?[1N?^>Q_2F+JLSABMP2%)4GC@CK1[:(>T1TM%<Q!K372LT%XLJJ<,48$
MT3ZR]J@:>[$:G."Q Z#)_0$T>V78/:(Z>BN=_M"Z_P">K?I5W3+J:>X*R.6&
MTG!_"FJJ;L"FF[&K1116I84444 %%%% !1110 4444 %4K8?\32^/J(_Y&KM
M<7X<NM:E^)'BVVO9PVG6PMOLJ[ /OH6Z]\<B@#M**** "BBB@"*X4O;2JHRS
M(0!^%<K/H4]PI26WWH3G!-=?16D*CCL3**D<6/#)5PZV**P.05&.P']!^5(?
M#&0H-A&0N,?+TP !^@ _"NUHJO;OL3[-'%_\(R<L?L2@N"&QQG)SSCW)IT/A
MZ2V+&"S6,L IVCL.@^@KLJ*/;R[![-')_P!D7G_/(T?V1>?\\C7644_;R#V2
M"D;[C?2EI&^XWTK T.4/?Z52LHQ-HD$1) >W"DCJ,KBK5PLCP2K"XCE*$(Y&
M0K8X.._-4M#@OK70[.#4I(Y+U(@)FB&%SZ#Z5P=#F*,FC732Z4AD3R;<>5/Y
M>5$D2@%01Z[E7IVS5?\ X11C9_96N8A&(!$,(> (RF,9QM.=Q'J*Z<8R,]*Y
MX0^(/,CW7+*AC<L1&CD/N; QD<8V8_'-4FQW&77AF>Y291?"$R$D/&"&7)4X
MZ_P[<#V)J[8Z3+9WS7#S1RJP.%(/[ODG"<].<?@*S(YO$<LTJ*KJ\00.&*%<
M% 3M/=L\^@Z58$?B M(?.=5SMB!",0I#\L.[#]WWQUHU&79-*<V0@65"1=M<
MD,IVN"Q;8V.W/Z"L]_"SR1S*;PEI)';>V3PP< 8[8WX^@%6]*&M&\9]1(2'R
MP%C4!AT7^+KG.[MW%;-*[0KA6CH__'RW^X?YBLZM'1_^/EO]P_S%53^)#CN;
M=%%%=AN%%%% !1110 5G7.IF"=HQ&#COFM&N>U'_ (_7K*K)Q6A$VTM"9]?V
M3Q1& 9EW8.[I@9]*D_MEO^>*_P#?7_UJY>^U&SMM<TNTGN8X[BX\WR8F/S/P
M.E&R\AN-4FC\Z7;&IMHY'^1FVDD#\<"L?:3[D<TCJ/[9;_GBO_?7_P!:HTU*
M..>69+5%EEQO8-RV.F>*XNZN=;E66*!'\OR 5D\DH[L<YQ_=(.!@GI3G_M:.
M.QF7SV,2S-+&5SN/F +GU^0M@>U/GGW#FEW.V_MEO^>*_P#?7_UJ/[9;_GBO
M_?7_ -:N'.H>(#')*ED3C(2)HL$C#G=U[83CWHGFUF.ZGD@$]R@V-"KP^6,>
M6^>/]X+P?:CGGW#FEW.X_MEO^>*_]]?_ %J/[9;_ )XK_P!]?_6KC8+O6FO0
M'A)M1(JAFAVM(A8@L>?E(&#C_&MVE[2?<.:1LP:JTTRIY0&X@9W5IUS=E_Q]
MQ_[P_F*Z2MJ4G):EP;:U"BBBM2PHHHH **** "D/(QZT44 4?[)M_P"])^G^
M%']DV_\ >D_3_"BBH]G'L3RH/[)M_P"])^G^%']DV_\ >D_3_"BBCV<>P<J#
M^R;?^])^G^%']DV_]Z3]/\***/9Q[!RH/[)M_P"])^G^%']DV_\ >D_3_"BB
MCV<>P<J#^R;?^])^G^%2V]E%;2;T+$D8YQ1134(K9#Y46J***H84444 %%%%
M !5"?34GF,A?&?;_ .O112E%2W$TGN5)?#=G-=6]U*J//;[O)D*<IN&&QSW%
M3_V/'_ST_P#'?_KT45/LX]A<B#^QX_\ GI_X[_\ 7H_L>/\ YZ?^._\ UZ**
M7LH=@Y(A_8\?_/3_ ,=_^O1_8\?_ #T_\=_^O111[*'8.2(?V/'_ ,]/_'?_
M *]']CQ_\]/_ !W_ .O111[*'8.2(^+3$BE5Q)]T@]/_ *]:%%%5&*CL-)+8
/****H84444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g10811g0421055931627.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055931627.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #& FX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR1_:6NM>>Q%VA9L(44'<!SSP?FKUFO+/B&)#KK"W;5#<FW7RH[?P]%>1LW.
M960D?3/%- >E:>JIIEJJ+$JB% %A;<@&!PI[CT-6:JZ;YHTJS$Z%)1 GF*0!
MM;:,C XZ^G%17&MZ5:Z>;^XU&UCLPQ3SVE 3<#C&?7((I <[\0?^/;0?^PU:
M?^C!78UQGCR6.>Q\/2Q.LD;ZQ9LCJ<A@9!@@^E=G0 4444 &<=:,\XKD_B*T
MJ^%,PA3+]KM]@=BJD^8N,D9P/PKG]0U?6M*US6;Z[CLK:ZBL8,>1*TR!/,.2
M=RKC\J /3**\^O\ Q7J<^JW]GI>H685+^TMHI?+$@029W9P>3TJ.S\1>(;>Y
M@EO=2M9[9=2;3Y$6UVEP!GS"0>&&>@XXH ]%HKR]?&^J[=2>WNUFB-@]U;23
MP1IM(<*/E1R=O^]@UT_AS4=5;6;K3=4NX;LK;17*21P^5MW=5QDY'H>M '49
M'J*6O%+F671M-UJZ+N=/U2^DMY?F)$4X<;#[ CBNJB\2>(+CQ'-;VD<?V6TN
M4MVB=H55D(&6)9P^[TPN* /0:*\Z/B^_NK33[:.^@6\N9[J&944;U" [<+V(
MXJ/0=2UZ?3?#-E%KJR27JRM<7$T*R. O.T<]?<T >DTC,J*69@J@9))P!7G=
MOXKU=[F"Z.HVCK-?/9G3!$/,C S\V[.=PQDY&.:HCQ-JE[I:"YU6QO8]0L[H
M26T$04V^Q3@Y!)]CF@#U)65U#*05(R"#P:19$<L$=6*G# '.#Z&O,&U35=.T
M)K"]N;6]B?38;F)?L^P1_O%7;U^88]:D_M+4--35KBPECAB&HN]RRJC2! @.
M45R V.XZXZ4 >FT5A3>,/#]A#;'4-;LK=YHEE43R"-F4]]I.16Q;W$-W;QW%
MO*DL,B[DD0Y##U!JG"27,UH%R6HKFY@L[66YN95BAB4N[L<!0.I-2U5U'4+3
M2[":]O95BMX5+NS=@/;O2BKNP&=I'C#P]K]TUKI6K6UW.J[S'&W('K6W7G/P
MS\4:/K%_KMO83F262^END!B9?W3'@\C]*]&K?$TO95'"S7K_ $B8NZN%%%%<
MY04444 %%%% !1110 4444 %%%% '+^,_#NI>)8+.TMKV"*Q27S+NVF5L7('
MW4)4@A<\D=^*RM6^'DVNWTCWMU8PP&.0*;2R$<N7B\O:S9^9!U&1G@#M7>T4
M <=:>"$.EZ@FL7;S7%[,L\KV4DEL 4C5% VMNZ+D\]34GPTDEE^'^FM-+)*X
M:9=\KEV($S@9)Y/ %=5+_J7_ -TUR?PP_P"2?:=_OW'_ */DH Z^BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H9[N
MVM=OVBXBAW=/,<+G\ZE(RI&2,CJ.U>5^//AMK>O_ &(V>JR7_E%]PU"11LSC
M[NU/;O0!ZE%+'-&LD4BR(W1D.0?QJOJ.H1:9:&YGCG>,'!$$+2M_WRH)Q7->
M"?">H>'M*L8KS5KEF@C*M9HR& $^GRAOUKK9E+P2*OWF4@?E0!EV?B;3;[1I
M]7C-PEC#&96EFMI(\H%W;E# %ACTHB\3Z5-JBZ<D\GGLQ16:%Q&S ;BH<C:6
M YP#G@^AK$NM.UV+P1:Z';6$,[3:<UG<$SA3"Y0*&]&49;..>F*?;VNL7'B:
M'^T=+E.G61*6;)/'Y?W"IE=<[BQR0!C ![D\ &J?%FB?8I;R.]$\,=R;3,"-
M(7E'.Q0H)8_3/0^E:5C?6VIV,-[9S":WF7<C@$9'T/(/L:Y1M"U*PG>]L[*.
M4P:LUU%:K*L?F0M#Y7!Z C).#CI6[X;L+G3M#AAO%1;AGDFD1&W*C.[/M![X
MW8S[4 :U%%% !7FWC+0;[6_$LPM+"WU5DMHTB\S49+9M.<EOWNU1\V[CD<_)
MBO2:\6^)T-G+XNN)+I]!@DAL4>+^TGN4DN.6^2/RY%#8QT )R130'KT=H7TE
M+.]?[0QA$<SGCS#C!/XUQL6G7&D:1H\PTF>6"PO;DM:6\0+*CF1495[@;AT[
M'-;'@G5+W4-'EAOX8$FLI!;YMU=48;%8<.2P(W8()/(/-=+1L!Y5K>E:I9:3
MX0,]V;>WCU2W\S3O)4X9IMR_/U&T$# XXKU6N.^(/_'MH/\ V&K3_P!&"NQH
M8!1112 CF@AN$V3Q)*F0=KJ&&1T/-->TMI6D:2WB<R)L<L@.Y?0^H]JFHH I
MP:3IMJBI;Z?:0HK!@L<*J 1T/ ZBI?L5IQ_HL/$GF#]V/O\ ][Z^]3T4 4H]
M'TN(RF/3;-#+GS-L"C?GKGCFK*P0QRF5(8UD*A2X4 D#H,^E25S7B5VEUKP]
M8DD0S79>0=FV*6 /XT ;K6%F\#0-:0-"[;VC,8*EO4CUICZ7I\MXEY)8VKW2
M#"3-"I=?HV,BO))-2OM*TR^$]Y<-::G>.()&D.89ED'R YX#+^HKN!XNF/B+
M^RS'8!/-\O=YUQYF/IY&W/\ P/'O0!T:Z5IT=VUVEA:K<L=S3"%0Y/J6QFE@
MTVQM6#6]E;0L&+ QQ*O)ZG@=3WKA([46WC:YL)(+BRMKZREVHUVUPMTPZN<D
M["!74^#KF6[\)Z?+,2S^7L+'OM) /Y"@#0.E:?\ :I+M;*W6[D4JUPL2B0C_
M 'L9JKI/AO3-'LQ!!:PLQ39),T2[Y1D\,0.>M:U% %=K"S<8>T@8! G,8/R@
MY ^F>U1SZ3IMRNV?3[25=_F8DA5OF]>1U]ZN5D^(O$6G^&-)DU#4)-J+PD:\
MO*W95'<FJC&4Y*,5=L#BOB9XFT+1M4T.VO\ (EBN5N& @W?N@&'\^U78OB-_
M;0%OX,T2YU5@.;B1?L]M%[%FY)'H!7#^*?"NK>-+[3-:\0DZ6M[<):VMG$ S
MQ1$%MSD_Q<=*]GT;2XM%T:TTV%MT=M&(PQ4 MCO@5Z==8>E1@G[TM>NGX;_>
M9KF;?8Y7_A'?&NM?/K'BE=,C;_EUT>$*1_VU?+?I4-U\(O#MY9S)<S:A=W<B
M%5NKRZ>9D/8@9 X^E=_4%[;M=V<MNEQ-;-(N!-"0'3W&01G\*Y%BZJ?NOE]-
M/R*Y5U/+_A-X)B\/ZKK5VE]).8KA[+:T87(0_>Z]3Z5ZO7.>'?"*^'+JYGCU
MG5+P7+%Y([J1&4N3DM\J Y-='1C*SK57.]P@K*P4445RE!1110 4444 %%%%
M !1110 4444 5[N_L[!%>\NX+=7;:IFD"!CZ#/>C[?9_:GM?M<'VA$WO%Y@W
MJOJ1U ]ZX_XD075Y8VEE9Z,]W)<EX9+U;83&SB88<JO7<1P/UZ5Q][X.UNXF
MO+.QT^Y23=<31WDNT>9"]JL4<18G.[<,$'IC- 'K\5W;7UDT]I<0W$)! DB<
M.I_$5S/PP_Y)]IW^_<?^CY*S-!TWQ#!I.LW&E6UOI;7=S&\%OJ,!PB+"B.2D
M;#!)4XY[9K2^%N[_ (5UIF\@ONGW%>A/G/G'M0!V%%%% !1110 4444 %%%%
M !112%U!P6 /N: %HHKCM5\=3:7XIAT,>'=0N'F(\J:,KM<=R/8=Z .QHH[4
M4 %%%48];TF:\^QQ:G9/=9V^2MPI?/IMSF@"]1110 R61887E?.U%+-@9X%<
MUX=^(/A_Q5J4VGZ5/<27$ )D$ELZ!<>Y&,UU%<!\/?\ D9_''_87/_H(H [^
MBH+RUBOK*:TFW>5,AC?:Q4X(P<$<BO./@_HMK96VLW<;7#3?;9+8&6=G 1&.
MT8)Z^] 'IU%%% !5#5=:TS0K076JW]O9P%@HDGD"@GTYJ\P#*5.<$8X->7^,
M_@M8>);&)+'5;ZUN(Y"P:ZN9;E"#U&UVX/TH ].AFBN(4FAD22*10R.AR&!Z
M$'N*IZQK%KH=B+R\)6 RQQ,V0 N]@H))Z 9YK!\*_#[3/"L-G]GN]1GFMHO+
MW2WDAC;CD^7NVCZ8XK8U_2GUBPAMD:-=EU!.WF#(*I(KD?B!0 B>)-+EE@$5
MW%);RP23BY213$JQD!LMGC!;]#4$WBW2_*A.G2?VK-/(8XH;%E=B0,G)R H
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M "3[3O\ ?N/_ $?)0!U]%%% !1110 5Y3\9]!GU&VT[4([B"-(&\ID<D,2Y
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M: R)%^[D*_Q9SQG'2N_KS34O 6G>&-6C\66<EU+)!<^=<QR."-C<,1@=LYH
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MDF2,E>(X@6 +.W;KP.YK#U+XE?V9?WQET]&T^WEGMDD68^8\T40E(*XP%(.
M<YR* .\E_P!2_P#NFN3^&'_)/M._W[C_ -'R59T/Q.VI6>HQZI';65U92+%+
MLFW1G?&KJ0S 'HV.G456^&!!^'NG$'(+SX/_ &WDH Z^BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ IDT,=Q!)#*H:.12K*>X/6GT4 <WX5FDM/M6@7+$
MS:>V(B>KPGE#_3\*Z2N=\2V=Q;S6^OZ?&9+NR!$L2]9H3]Y?J.HK!\+_ !4L
M_$_B!=)CTR>W9E8K))(#G'; H ] HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O(OB W_%67LL8M$>TL(Y)'FUV>R=UR^%5$X;H>?>O7#T/./>O
M%_$6KV-\]G=RZY?7I@\XI(OA^WG*K$_SS@NN0@)"Y'7;P*: ]&\&:W/K.D.M
MU;Q0W%FZP.(IFE1OD5@0S -G##((SG-='573A%]@ADA=)5E19#,J!?-) ^<@
M=SUK%\9^)$\/:2-MS#;W5SF."68?(A )+'Z =.YP* *7Q!_X]M!_[#5I_P"C
M!6EX@\3#1+^QLDM!/->!RI>X2%5"@9R6[\]*X[Q#XBM]0TKP7 TD\]U=7EC<
M&=8&\ICN&[YP-H.<\9KK/$7A^[U35M-U"U^P.;,2*8;V$NC;@.1@\$8H F'B
M.:;4I+2STFXN5MRBW<J2(%B9@#M&2-Y .3CU%;U<U#HNL6&IW5S8WUFEO>LL
MMQ'+"S&-PH4^60PX( Z],5ER>*]2AWPN]J)XM[NVT-&V!E44AN2??GVI =7?
M:UI>F2I%?ZC:6LCC*K-,J%OIDU1UWQ$-'>PCBMEN9+URL>;A(EX4MG<W':K-
M[I*ZFT,SWE_;,J_<M[@QC\0.M0:]I5UJ5E';6ZZ=(N"K_;[<R\8QD8(YH GU
M768M'TC[?=1-D[5$2L,EVX"Y.!U[]*+36(WT4ZI?+%9PJI9V\]9$51WW+QBL
M:[\)W4^A6^DB\MY(+1(6MS<0%RTB'/SC."IZ8'3UJ2#PI)'X5U'2FN($FOG>
M1C#%MBC+8X5<].* $U/QYI%EI:ZA:L=0B^T) XMR,H6[D'MCGWJY/XIM(_$.
MGZ1'%),UY&9!,A&R,8R,_7M6?<^#7N;SS7NH_*,]O(R>6>5C4@CKWS3-'\%3
M:9<6<\NH"XDM[AY"S)@F+:51!S_"#UH ["BBB@ K@?',[:_K&G^"[1S_ *2P
MGU K_! O.#_O5UNNZS:Z!HMUJ=VP$4"%L9^\>P'N37/> -'N8;.YU_5%/]JZ
ML_G29.?+C_@3\!7507LXNL^FWK_P-_N)>NAUUO!%:V\=O @2*-0J*HX %244
M5R[E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!G:
MYHUMK^DR:==M(L,C(Q,9 ;*L&'Z@5CW7@'1KW4;NZN&N7CN?,9K;S!Y2O(@C
M=P,9#%1CKCOBNIHH Y^R\):98:9=6TZ-J/VA_-FDOE65G8*%7/ ' 4 <50^%
MX"_#S354  /.  . /.>NLE_U+_[IKD_AA_R3[3O]^X_]'R4 =?1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ,E0R0R(/XE(KQ;PO\./%VB^*VU)!
M90!-YC>9_,5LGH0I!&?7M7ME% ')7VL>)[;3;H7/AV-RL+_O[.^4@<'G:X4U
MY/\ #'Q'JL/BJ9I!JFJ(T#9@CE\PCGKAV KZ#=%DC:-P&5@0P/<&LC2O">@Z
M'=O=:9I<%K.Z[6>,')'I0!CZOXROK71[R>'PUK,,D<3,LDL46Q#CJ<.>*Y[X
M6^.-<\4:I?6VK30R)%$KIY<03!R<]*]*OK.'4;">SN 3#.AC< X.",5@>&/
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MI7)_##_DGVG?[]Q_Z/DH Z^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!'4.C*>C#%8/ASPG8^&XV6"66YD+-LEN I>-6;<44@#Y<]J** )Y/"?
MAZ5P\FB:>[!BX+6ZG!)R3T]>:K:=X.T^QU2]U":26]FN9EF'VH(PA91A=F%&
M,"BB@"Z?#6AE&4Z19%6!5AY"X()W$=.YYJY;6-I9&4VMM%"96WR>6@7<>F3C
KJ:** +%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g10811g0421055931987.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055931987.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #3 5 # 2(  A$! Q$!_\0
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M+2:$&%2&55XP1R,4 8C>-[!H&EMX+B7"9&$P"V#A<^O!J.Z\:0P:&]ZBQ?:
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MXHL_[0\+:I9^6\AFMG0(@&XDCMGC- ')?"^$1_VD[317$K[,RK>"=MI+M@X
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M5)./H*I:'XATWQ%;/<:9,TL2-M+%"HS[9ZT :E07E[;:?:275W,D,$8RSN<
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MZBUTZWM[B2\,,?VZ=5$\RKR^!C\O:@#)7PI:WDHU#5%#:K+;B&XE@8JK#'(
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MIAE%@@@?S,#@'S!A,$':.,G/6MD^%/#CG,_@CQ3.?66ZW?SFH ]2FUK2;?\
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,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g10811g0421055932314.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055932314.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "X 5\# 2(  A$! Q$!_\0
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MMOXQN[B.&/Q7XA5I2RHTDQ525!)&2.O!KHW\;.^H?:#9!HBK'R6<8#E@ZL"
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M'/Y.P@JC@E3DGYNAYXZ&M>JUGIUIIX86D"Q!\ X]!T'T'84 6:*** "BBB@
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MX;&UMYY)X8(TED^^ZCD\Y_G5BLS[3-_?-'VF;^^: -.BLS[3-_?-'VF;^^:
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M10 4$X!)[444 007D%PVV)RQQN^Z1Q^-3T44 %6;/[Y^O]#5:K-G]\_7^AH
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MP4>1%_<%<]-XVTR*/39/+NBNH3^1"?)(YXY/MR*Z6@"/R(O[@H\B+^X*DHH
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MCD@^I."?H!2'PO#<S?:;V9I+DW2W+-'E 2J! ,9Z8 K>\Q/[P_.CS$_O#\Z
M,[3],FM-5U*\DG5UO'5@@7&S:H4<]^!6G3?,3^\/SH\Q/[P_.@!U%-\Q/[P_
M.CS$_O#\Z '5B>)O#5MXGTT6EQ-/"4W-$\38VL49<D=^&-;/F)_>'YT>8G]X
M?G0!QT?@%(M2L[U+W$ME %A?R\LTHA,0D?G#8!]/3FJ]_P##>/4]6O+Z[U.0
MF[A>*4I& QWPB(C.?N\;@,=>]=SYB?WA^='F)_>'YT 8?AOPTF@V4T4LRW,D
MLYGSLPL9VA<(,G PN?J36]3?,3^\/SH\Q/[P_.@!U%-\Q/[P_.CS$_O#\Z '
M5SUYH%_/XI.LP:DD.+%[..,P;MNXAMV<\D,H/Z5O^8G]X?G1YB?WA^= '*S^
M$;J[UN\U"\U"&ZCGM#:)#-;Y$2E?FQS_ !-R?7 %:/ACP[%X;T^>W28S27%P
MUQ*^, L0!@#)X 4#KVK9\Q/[P_.CS$_O#\Z '44WS$_O#\Z4,IZ$&@#(HHHH
M *.#TK$ FA\590R3QSM^]5@P%NHC&"#]T@D?7+>U<W.VI&426WGF;SKDNL9;
MF472X48XSY8P,\8- '?<$9'-+65H))MKU0<Q)J%PL/\ N;ST]L[A6K0 4444
M %%%5=1G>UTZ>=$D=D7@1+ENH' H M45R5CJ/B"9H9)E=$4Q!E,/^L#7#HQ)
M]HPK<?6IO#K:E&UJL\<MPZV865YOD(<2MD$G@X&* .GHKBH+34HK"UNKN6X$
M,ES$LT(=RQ42N6=NZC:5&!V%6$:\BGT9Y9;T1C49@D9!YMBKA#)QZ[<9]J .
MMHHHH **** "BFR;_*D\L R;3L!]<<?K6#X6DO6MG2\C<NL43/,X8%I2#O4A
MO0XY''- '04444 %%%% !116'8B:'Q%<QJ9)X93)(\C!AY!RNU!G@@\XQZ4
M;E%%% !1110 444V0JL3EL[0I)V]<8[>] #J*XR1KB;PU=20-=1SS3/):PMY
MA>$;1M7/]XXS@\ L1VK3U:65KBUNH%FDFAS']C*N!(Q9,_,.,@9Y.1R: .@H
MKFM#%\=34S_:-PAF%YYF=OF>=^[VYX^[GIVQ72T %%%% !110>AP,F@ HJ""
M2Y=L36PB7&<B0-SZ<5/0 59L_OGZ_P!#5:K-G]\_7^AH @\M_P"XWY4>6_\
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MS??^#&#_ !HHH /^$R\8_P#1.;[_ ,&,'^-'_"9>,?\ HG-]_P"#&#_&BB@
M_P"$R\8_]$YOO_!C!_C1_P )EXQ_Z)S??^#&#_&BB@ _X3+QC_T3F^_\&,'^
M-'_"9>,?^B<WW_@Q@_QHHH /^$R\8_\ 1.;[_P &,'^-'_"9>,?^B<WW_@Q@
M_P :** #_A,O&/\ T3F^_P#!C!_C1_PF7C'_ *)S??\ @Q@_QHHH /\ A,O&
M/_1.;[_P8P?XT?\ "9>,?^B<WW_@Q@_QHHH /^$R\8_]$YOO_!C!_C6EH?B3
>Q%J6J);:CX-NM,MF5BUS)>12!2!P,*<\]*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g10811g0421055932611.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421055932611.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Y 8X# 2(  A$! Q$!_\0
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M%?7<UX8XK]7<6VY@8\)NVC&T=2>I/U I&U"]$FG_ +Y@7@C8J4X<G.\MQQ@
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M8R);_9E8ITCVE=O_ 'R2,]<'% %6W\::=/HEYJC6U["EI(D3P2P@2LSA"@4
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MT64O'K TX6\;AY60Q;PPYV[CZ9P!WK2D\::5'I=GJ&+AH+NSFO(]L?(2)0S
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M&WCDFB3<@9[AD:)5V 'N90,''4>];$G@?PQ+;);OHMHT* !4*< #=C_T-_\
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M, KE0" _<'!'0C((SQ6+>Z=X9U&&1KC6&EPWE%S<JQ"D, G0Y'S,0>3U(/%
M'8*RN@92"K#(([BEID,:Q01QIG:BA5SZ 4^@ I#T-+2'H: ([;_CUAZ_<'5]
MW;U[_6I:BML?9(<8QL7&%VCIZ=OI61XJU&YT[1]UD3]JFE6.,(NYSD\[1W.
M: +]K-%;Z<99Y%BC5G+-).' &X_Q?T[=.U9DGC/11,(+>:6\G)(6.VB9RQ]!
MV/YU0\,Z/)J-A'?:[%)+,';RH)@ D8R?FV  ;B<Y)&:U8_#-E#J0NTDF$:S&
MX6VW#RA*1C>!C.?QH S=4\936EGO@T34$E9@BM>1"*,$^K9_PJ;3_$]_?V$-
MRGA^[99%SN21-I['&3G%=))&DT;1RHKHPP589!_"E "J%4  #  [4 <CHD7B
M"37%NKR.ZAA9I3.LTRLC*<^6$4?=([UU]%% !1110 5SGCG_ )%H?]?]E_Z4
MQ5LSZE96UW%:SW44<\Q CC=L%R>@'Y5SWBZ^M;[PNSVL\<RIJ%DK,AR ?M,5
M '375S':6LEQ+G9&NXX'-5[#45OGFC,+PR1;=RO@\$9'2I-0N[2QT^XNK^6.
M*TC0F5Y/NA>^:RO#>M^'-62=/#]W;S"(@RB($$9SC.>>QH ;<:Y?H^JQ0Z?N
MEM9H8X0I,AD#XRQ Z <G&>U23>)K:UL;2=XY;CSHGE9H(\!5CQO)#$$8STY-
M)=7>@R#4_, E>&6)+KRU8MYG&P C^+D=.E"R:)<7$.F-:D.(6B1'B8!0RAFC
M)Z;BN"1UQ0!2M_%DT^H)9_98M[:G):G#GB%0<2?4D 8^M:-QJEY_:%U%;1VH
MALMAG:=RI;<,G:1P,#N>IXXZU#<'PWIMTD[K;+<&X2+*#<RR.YQG'(RS-R>.
M34DPT'5%NK^X2.1+)VAG>0$+F,Y(8=& /KD>E %*/Q<+72I+O5('CF0@M;I'
ML>-2I89#-\QP#T_*NEBE6:%)4.4=0RGV-<O(GAR2T$$FFW&&E"K"T$@=BR'I
MGDKM##'3 Q71V\UJ2;:WEB+0J%:)6!*#L".U %BBBB@ J.'[C?[[?Q9[G_..
MU25'#C8V,??;HN.Y_P Y[T 24CNL:,[L%51DDG  ILTT=O$TLSJD:C+,QX%9
M+2KKLXA@<G3X\&9Q_P M3U"CV]: ,U8=2U75#*KSKITCGY_,*AH_0+GVZ]\U
MTT-O#;PB&&)4C'10.*D    & .@%+0!6L/\ CT7@CYGZR^9_$>_].W3M5FJN
MGX^QKMVXWO\ =B\L?>/;^O?KWJU0 4444 %%%% !117GOCF_FL_$VG9O9!:?
M9\R01WL]N(SY@'FN8D;Y?X?F(&3]: /0JS[JPDNM5MKAG7R+>*38N3GS6P W
MX+N'_ JT** //M>T2[L?#]MYMU+%!!J-@([6*=I(R//B4[BXW8SR #P1U-=5
MXJTF;7?"NJ:5;/&DUW;O$C2$[02.^.<53\<?\B]%_P!A&Q_]*HJZ.@#A/ 7@
M[4?#>J:I>7T&CVRW<,$20Z6KA 8]V6(8#D[A6W?: 9KV^N8HH"+D6[%/,:)G
M:)F.2R\@\K@\]*Z"B@#F=-T#4;;4;>:[N8IECE-PTNXF1G,0BV=.@ SNSD^E
M5;SPA<W2SK]HCQ<2L\VYV.X?:%D7KW5 0/3Z5V%% '/:;H%S#IFJ6][<1F?4
M<M))"#PS(%8\^_3\*KW6C:M>+;[HK&%K:/RXF@GD1@VTKOW*!P,\(01UYKJ:
M* .;L-%U2#Q0VHSW,36YC=&VN<R9V;25QU&UNYZ\ <UTE%% !0>E%!Z4 ,A_
MU$?^Z.K;NWKW^M8>F :QK,^KO\UO;LUO9>G'#R#ZGC/HM2:Y?&VT5;>V=/M=
MULMH0!MPS\9QU&!D_A6I96D5A8P6D(Q'"@1?PH ;8AA:C?OSO?[\@<_>/<?R
M[=*LU4TW;]B&SRMN^3_5(47[Y['OZ^IR:GGGBMK>2>>5(H8U+O(YPJJ.22>P
MH DJCJFLZ9HEK]IU2_M[.'LT\@7)]!GJ?85Y=XWCUGXFVMLOAK3F?2K2<M]K
MN)_)6[)!4^6IZJ.SGOT!K>^'GP]M]!TM9]9TVWDU;S7*22R?:&BCW910Q& 1
MZJ!0!S_@WQUK^M>,M.MI]1EGM;J6Y$]L=-$<<**K&)DEZMD =?7OUKV&BB@
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M^B@ HHHH *9%G:<Y^\W5L]Z?4<.-C8V_?;[HQW- &=K_ .\L5M8\_:)Y%6$
MXPP.<GV&,FK&EZ:FEVIA61Y&9B[NW<FJ]B!?W\NHMS&A,-MZ8'WF_$\?05JT
M %%%% %>QW"U&_?G<WWY Y^\>X_R.E6*JZ=M^Q+L\O;O?_5H57[Q[']?4TD>
MJ:?->O917]K)=IG= LREUQURN<B@"W1110 4444 %>8>-K;6[[Q5%%;Z'!>P
MQ1J4G8%$<%P?*D(F4, 1NP5/;CU]/KQ_QYI\.H^*U?&@VY@($+S:C%'(9MR$
MNZ&,ECM^7:3Z&@#V"BBLJZUV"UUJ/365=[1>:SM(%VKSC ZD_*>!0!1\<?\
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MHKES<>.=Z!=/\/,C9RXO9OE]/^6?-->Z\>*?ETK0'^<+Q?2]#C+<Q]!Z=>*
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M.V@::4L$7KM4L?R'- $E%9#^)M+0X:6<?]NLO_Q-5W\9:*@R9KC_ ,!9>?\
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MS. K23 D%88L$G@]68@?\"- &G_PCR=M3U$?]M@?Z4TZ -V!J^H!L9QO0_\
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MQ;>?()& 1F9LJZKU+?*.>E:WANQO["6S60W8ADMI3-'*V4C<2#8 /X>"WUH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g10811g0421180830740.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421180830740.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #I 2X# 2(  A$! Q$!_\0
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M'<1.[+N55<$D>OTH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME8<:M.?PR3+%%)FEJ#0**** "BBB@ HHHH **** "BBB@ HHHH **** "FL
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MV<OR^9P,_P!X5VM<CXDT>2.;^T;4'KF0+U!]:N:-XEAN8UAO'6.<<!C]U_\
MZ])ZZA!\ONLZ*BD!!&0?QI:DU"N<U(?;O%-A:'_5P*9F'\JZ.N?T]3+XMU*1
MA_JXU05M1TYI=E_P#GQ"YN6/=_\ !-\4M%%8G0%%%% !37=41F=@JJ,DD]!3
MJ\_\=^)<!M'LWRQ_X^&4]!_=IQ5W8SJU53CS,Q/%&N3>(]56TLR3:QMB,#^,
M_P!XU%?S1Z-IRV%NW[^09D<=13K*&/0].:]N%S<2#")Z>U3>$]"D\0:J]]>
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&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g10811g0421180831083.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421180831083.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #W 2X# 2(  A$! Q$!_\0
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MG%BHP,MQRPY.%/."<4V7XA:9#:R7#6=_Y8MTN(OW:YF5O[HW<=^N,[6QG!J
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MW>-;@N N5.WGTR0?P]>< &]156SO5O#<!5QY,FS(;(8%0P(/H0PJU0 4444
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MKXT3F[F*QKN&(R67 [GO]:62]GF=WD*L70(V5XP#D?K5>BNNR.>[)9+F659
MY!,C^8YQR3_AR:[?X;]-2^L?_LU<'7>?#?IJ7UC_ /9JPQ7\)FM#^(CO****
M\@](**** "BBB@ KYI\0_P#(S:M_U^2_^AFOI:OFGQ%_R,^K?]?DO_H9KKPF
M[.?$;(9:Z@MM;0H/,\Q)VD)P"NTIM(QGKBKS:_',T\<]N[VL@"I"K8V * .>
MN3CGFL+(HR*['%,YDVC7L-9CL8X0;8RLL+PM\Y7 8L>#[YP?I6?=SK/)&4W8
M2%(\MU.U0,U!D49%.RO<+NUCUKX-_P#'CJ__ %VC_P#037IU>8?!K_CQU?\
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MWB#4+E/$NJJK18%Y*!F%#_&?:OI&OF7Q'_R-&K?]?LW_ *&:WH;LN"3W*_\
M:5U_>B_[\1__ !-']I77]Z+_ +\1_P#Q-5**Z2^2/8M_VE=?WHO^_$?_ ,31
M_:5U_>B_[\1__$U4HH#DCV/4/AXUQ>^&M>D%W-;26[K*CVP6,Y$;<'"X(]C7
MJ.DW$EUHUC<S$-++;QR.0,9)4$UY?\+O^17\3?[O_M-J]+T#_D7-+_Z](O\
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MYDBN?F)P%4@ >@Y->C?!UUC76"[!<M"!N.,GYZ\Q_M*^_P"?VY_[^M_C7?\
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MY>]TI;R.Z$1N +K?:CB,F+!8A!G[SXQ@K_$3M->H5!(4444 %>%_%G_D=O\
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M@$LN.?3\*N50L]'M+&]ENX1)YTJ[7+.3GG.?J:OT <Q\1/\ D0=6_P"N:_\
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MFCHJ3_9GO'MH4R5)0$;<C)8$_-SC!^HL:'_R+^M?]<F_] -=%H'_ "+FE_\
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MIEO]GT#6!Y@?="W\.,?(:V] _P"1<TO_ *](O_0!7//XC.6YHT445(@HHHH
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A0)&BA54=@*** 'T444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g10811g0421180831411.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421180831411.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "U FX# 2(  A$! Q$!_\0
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M6%50@XZ]>35/1^-0N.1SZ#W_ %I]_$SZK"PV_+@Y)]^U %Z_N)+:VWQ!2Y8
M9J6VE\^W23*G(YV]*KZFI:U ! ^<<DX%2:>"MC$&&"!ZT <OX_BCFMM/1Y(4
M+3D 2R>7N^4\!_X?7WKHM$26/1+-)YDFD6)0TD9RK''45ROCG3]6GO;.]MC
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M(N80TK8^\<"JNO>(]4L_AW<:G!<[;M;A4$F.V:K_ /,A>&_^N _]!%4O$_\
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MB!_R-]S_ -<T_E6;_A2]?\S1?Q(^G^1V6I?\@O2/^O9?_016;XK_ .1"M_\
MKY'\S6EJ7_(+TC_KV7_T$5F^*_\ D0K?_KY'\S7=5^&7I_D<5/XH^IF>%_\
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M^9]0_P"2CR_]A$?^ABOIBOF?4/\ DH\O_81'_H8H.C#[LTOBS_R.TW_7"/\
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M L@\H>7MR^/,/S$_W>,?B:](KSC4;=D\0WCII^HG6)+N,6[1O)Y,D 8')(X
M +Y'K7H5Q;I<HJ.6 #!AM8CD4'.8X\7:0;9;@2R>6SLH/EG^'[S?[H]:N:I]
M^P_Z^D_D:PI/!1DNKFX6]6)KD-%(D46$\I@ 0!GAC@<UKZI;#[7I\PDE&+A%
M";OEZ'M0!KT4W9_M-^=&S_:;\Z '44W9_M-^=&S_ &F_.@!U%-V?[3?G1L_V
MF_.@!U%-V?[3?G1L_P!IOSH =13=G^TWYT;/]IOSH =13=G^TWYT;/\ :;\Z
M '5\^_'7_D:[/_KU_K7T!L_VF_.O-?B'\-+_ ,8ZQ!>VM]! D</EE9022<^U
M=6#J1A5YI.R,JT7*%D8GB3_D@&G?[L7\S3/@/_J-:^J?RKHO$W@[4V^%5OX?
MLU%U>0; =IP&P>2,U6^$OA/6/#<.J#5;4VYFV^7\P.<#VKH=2#P\U?=_J9\K
M]HO0ZC3_ /D*1_[YKQ;XS_\ (_R_]>Z?RKVRQ@E&HQEHW W'G%>)?&88\?3<
MG_4)_*M,,_W_ ,C!*U)^IU?Q-_Y)5H'UC_\ 0:N_!#_D4-4_Z^#_ .@U1^)@
M_P"+5: <GK'_ .@U>^"(SX0U3D_\?!_]!J9?[J_7]3;_ )>?([71_P#D(K]#
M7 >+O^1NN_\ KHO]*[[2!G44Y/0UP/B[_D;KO_KHO]*VP?\ '?H>3C_]V7K^
M@WXY?\@;0?\ >;_T$5T/P4_Y$)?^OB3^=<[\<1C1M!Y/5NO^Z*Z'X*C/@-3D
M_P#'Q)_.N>I_N:]?\SUX?Q?D:7Q&,$VG6EDUS,EQ++F*&%@OF$#/S'(^6NA\
M.P-:^'+"&1B6C@4,6/M61XET^\EU1+I-%@U:W:W\H1OL#1/DG=ENQS^E;6C6
MDUKH5I:7@0RI"$D"#Y<XY KS3I*-WXKM+/4;BR>*1GA52""/WA;& OK]X5;A
MU.+4M$FN55HOED1DDX*LN01^8JKJ'A6UU&>.22:5$A4>1&F (F&/F'OP*G.C
M6MKH4EHP,RJKR%I.K.<DDX]230!=TTC^S+7G_EDO\JM9'K5/347^S+7C_EDO
M\JM;%]* '9'K29'K2;%]*/+3^[0 [(]:S-1M'GF1U2-P,8!0$@^Y/:M'8OI1
MY:^E &=>Z4+VU@A>4(8NZ+@'CTK \66(T_P->PK(7S(K9Q_M"NP\M?[M-DMX
M9D*21*ZGJK#(K*I24D^[1I"HXM=D>5^ O^/77O\ KT_HU4/A_P#\C=:?]<W_
M /037KC:9:&WFAC@CB$J%&,:@'!&*P='\"Z?HNI1WL$\SR1@@!R,<C%<?U2<
M7"VMO\SK^M0DIWTO_D>:M_R.K?\ 80_]GJ[\0/\ D;[G_KFG\JZ$_#Z__M\W
MXN8/+^T^=MYSC=G%4?&?AW5K_P 33W%I82RPLB .HX/'-<TZ-14Y777_ #.B
M%:#J1:?3_(Z#4O\ D%Z1_P!>R_\ H(K,\5?\B%!_U\C^9K5U:)H+#2XW7:ZP
M ,#V( S65XJ _P"$#@..?M(_K735^&7I_D<]/>/J9OA?_D2O$7^X/Y&HOAU_
MR'I_^O9OZ5)X8 /@KQ$2/X!_(U'\.AG7I\_\^S?TKFI_%2_KJ=$_AJ?UT1F^
M&O\ D<[/_KZ/\S1XI_Y'*]_Z[+_(4>&QGQG9@_\ /T?YFCQ3_P CC>C_ *;+
M_(5C_P N?^WOT-?^7WR_4T_B+_R%[/\ Z]5KHXO^1,T?_=_QKF_B( -7L\#_
M )=5KHX@!X-T<XYV_P"-=<?XU3^NQS2_A4R+5O\ D0;_ /WQ_,5E_#C_ %NJ
M?]</ZUJ:L!_P@-^?]L?S%9?PX ,NJ9'_ "P_K0_X\/3_ #!?P)^O^1OZ#_R%
MHOH:[2N*T( ZM%D>M=KT%=V'^$XZ_P 1S/CJ6V7PY)#<7,L)F=400L [G/0<
M]*D\$6DEEX7MX968ON8G<<XY]<FD\365S//9W$6EPZG!$6$MM(%R<C@@MQQ5
MKPQ975CHJPWD4<,A=G$,>,1J3PO''%;F W4?$UIINH+:2JQS$9#("-H [>Y]
MJM:5K$6J022"-X&C;:Z28R.,C]*K:EX:M-3$<4KNELA+&%  "WKGK4VGZ%;6
M-G);NSW'FMND>7JWITH FTDC^SDP1U/\ZO9%9^CQ1IID2*H"J2 /QJ]L7TH
M=D5\SZC_ ,E'E_["(_\ 0Q7TML7TKFY/ 'AN743?OIX-P9/-+[S][.<T&M*:
MA>YX_P#%C_D=IO\ KA'_ "KO]2_Y%[0?^O4?R%<9\4M*O[GQG-);6,\L?DH
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MJ/\ T97TP !TI&6(W0M%%%!SA6=JOW[#_KZ3^M:-9VJ_?L/^OI/ZT :-%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5P7BOX6:;XLUIM3N;ZYAD9
M FV,#'%=[15PJ2IN\784HJ2LSR3XR6::=X!TNSC8LD$RH&/4@"CX(?\ (H:I
M_P!?!_\ 0:L_'3_D4K/_ *^A_*JWP0_Y%#5/^O@_^@UWIWP=_/\ 4YI?Q?D=
MKH__ "$5^AK@/%W_ "-UW_UT7^E=_H__ "$5^AK@/%W_ "-UW_UT7^E=&#_C
MOT/)Q_\ NR]?T&_'+_D#:#_O-_Z"*Z'X*?\ (A+_ -?$G\ZY[XY?\@;0?]YO
M_0170_!3_D0E_P"OB3^=<]3_ '->O^9Z\/XOR/1J***\TZ0J"\_X\;C_ *YM
M_*IZ@O/^/&X_ZYM_*@!FF_\ (,M?^N2_RJU573?^09:_]<E_E5J@ HHHH **
M** "BBB@ HHHH **** .9\4_ZZV^C?TK \5_\B%;_P#7R/YFNWO]*AU%D:5G
M&P$#::Y3Q]:)9>$(H(R2JW"XS^-<6(@U&<O(ZZ$TY0CYF!X7_P"1*\1?[@_D
M:B^'/_(>G_Z]F_I4OA?_ )$KQ%_N#^1J+X<_\AZ?_KV;^E<5/XJ7]=3LG\-3
M^NB,WPU_R.=G_P!?1_F:/%/_ ".5[_UV7^0H\-?\CG9_]?1_F:/%/_(Y7O\
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MMO\ ]_!1_:FG_P#/[;_]_!0!;HJI_:FG_P#/[;_]_!1_:FG_ //[;_\ ?P4
M6Z*J?VII_P#S^V__ '\%']J:?_S^V_\ W\% %NBJG]J:?_S^V_\ W\%']J:?
M_P _MO\ ]_!0!;HJI_:FG_\ /[;_ /?P4?VII_\ S^V__?P4 6Z*J?VII_\
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MU;^=7:P-,\0:0E@@;4;<')XWCUJY_P )%H__ $$;;_OX* -.BLS_ (2+1_\
MH(VW_?P4?\)%H_\ T$;;_OX* -.BLS_A(M'_ .@C;?\ ?P4?\)%H_P#T$;;_
M +^"@#3I" PP0"#V-9O_  D6C_\ 01MO^_@H_P"$BT?_ *"-M_W\% &@L4:_
M=C09XX6J\>E:=%*)8["U20'(=85!!^N*K_\ "1:/_P!!&V_[^"C_ (2+1_\
MH(VW_?P4!<AN?">@7EX]W<:5;27#MO:1EY)]:\M^*^AZI?\ BF&6RT^XGA^S
M*@:.,D9R>*]8_P"$BT?_ *"-M_W\%4KO5=)GD5TU:!3T(,W ]Q@]:"X5'%W.
M8N()K7P3X?@GC:*5(0KHXP5.!P:SO$__ "2:Z_Z^E_\ 0A6YXMU739+2S2"^
MCE\LG)#[CT'6N;\17UM/\,;FTBF5[@W*L(EY8C<.<4&D7>S\S(^&W_(N^+_^
MO+_V5ZI?"/\ Y'R#_KWD_I5GX?7$5IH'BE+EO*>>TVQ*X(+G:_ ]>U4_A=*M
MAXUBGN\P1""12\BE0#QQDTS637O&=H__ "4JS_["H_\ 1E?3%?,VE9C^(5K<
M.CK"NI"0R%3M"[^N?2OI2WN8;N!9K>19(F^ZRG(-(RKN[1+4,]K!<^7YT:OY
M;B1,]F'0U-108&0/"VB!0/[/CP'W_>;\NOW?]GI[4[5X(9);%GAC8FY0990>
M.:U:SM5^_8?]?2?UH M?8;3_ )]8/^_8H^PVG_/K!_W[%-N[^WLFA69F#3R>
M7&JJ6+'KT'L":FFE2"%YI6"QHI9F/8"@"/[#:?\ /K!_W[%'V&T_Y]8/^_8I
M;6YCO+6.YAW>7(-REE*DCZ&F6]_;W5S<6\+,SVY"R':< XSC/3.,4 .^PVG_
M #ZP?]^Q1]AM/^?6#_OV*;/?V]M=6]K(S>=<$B-%4G..IXZ#WI]W=0V-K)<W
M#[(HQEFQG% "?8;3_GU@_P"_8H^PVG_/K!_W[%212":))%#!6&0&4@_B#4-I
M?V]]YIMV9A$YC9MI W#K@GK^% #OL-I_SZP?]^Q1]AM/^?6#_OV*:VH6Z:@E
MB7)N'0N%"DX7U)Z"EO;V#3[?S[ABJ;@HPI8DG@  4 +]AM/^?6#_ +]BC[#:
M?\^L'_?L5+O'E[SD+C/(QBH;*]@U"W\^W+-&20&*D9QZ9ZB@!?L-I_SZP?\
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M;3_GU@_[]BH[;4K2[D\N"4.VW=C!Z9Q_,4Z2_MX[^.R+,;B12X4*3A?4GM0
M[[#:?\^L'_?L4JVELCATMXE8="$ (IM[?6^GVQN+ERL8(7A222>  !U-3JP9
M0PS@C/(P: %IDL23PO%*H:.12K*>X/!%/HH RY?#FD32-))8QLS($)R>@P!W
MZ\#GKQ4[6=O9:1+;VT0CB2)MJCZ&KM07G_'C<?\ 7-OY4 1Z:!_9EKP/]4O;
MVJUM'H/RJG9S1V^BPSRMMCC@#L?0 9-36=U'?6D=S$'$<@RN]2IQ]#0!-M'H
M/RHVCT'Y55L=1@U%))+?>420Q[F4@$C@XSU&:(M0@FU&>QCWF6  R'8=JYY
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M'7&.  !_6D33(4U:34M\AF>,1X. H'X#)_$FBB@ N=-ANM0M;R1Y-]L245<
M9(QR<9[],XI=3TV'58$AG>18UD5\)C)(.1R02/PP:** );RU2]LI;5V94D7:
M2H!./^! C\Q1;VJ6MC':1%Q''&(U).6P!CJ>]%% $6F:=#I5I]G@9V4NSDN1
MDECD\  #Z "DL],ALKR\ND>1I;I@TFXC QTP !^9Y]Z** #^S(3K U,O(9A$
48E7@* 2">@R>@ZDX[5=S110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g10811g0421180832592.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421180832592.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "0 7 # 2(  A$! Q$!_\0
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M%1!A5'0"GT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g10811g0421180832985.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421180832985.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #= 18# 2(  A$! Q$!_\0
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M:6+C^SXGNKDW$CJ'WE F,@<8%)K'_(%O?^N+?RJ6P_Y!]M_UR7^0H L4444
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M(H50 H& !VI: "BBB@ HHHH *\KU+5@_Q#DAOM4@DDMY8(X[&":[4QY<X(5
M%=B""<Y QZ5ZI7G/B.[G@^(5O_ITOV7;;K(BS7,<=N2Y WF)=AW\ !SV[ T
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M\AO^D^D7ZTG^E=A#^M3T5Q'KGE'QGW_8-*W[=WFO]WIT%>0U[!\:O^/+2O\
MKH_\A7C]==+X3S,3_$85ZS\&-^S5MF-V4QNZ5Y-7K7P5Z:K]4HJ_ PP_\1'J
MO^D^D7ZT?Z3Z0_F:FHKD/3*[?:-C;_*VX.<9S7 /_K&_WC7HDO\ JG_W37G;
M_P"L;_>-85^AZV5[R^0E/A_UT?\ O"F4^'_71_[PKG6YZTOA9W_[_P#A\O;C
MC.<TG^E>D/YFIE^Z/I2UWGR9!_I7I#^9K@?B3NWZ=OQNP^<=.U>BUYY\3/\
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M]H@_X]X_]T?RKCQ?0]7*_M?(DHHHKB/7/*OC5_QY:5_UT?\ D*\?KV#XU?\
M'EI7_71_Y"O'ZZZ7PGF8G^(PKUKX*]-5^J5Y+7K7P5Z:K]4HJ_ PP_\ $1ZW
M1117(>F,E_U3_P"Z:\[?_6-_O&O1)?\ 5/\ [IKSM_\ 6-_O&L*_0];*]Y?(
M2GP_ZZ/_ 'A3*?#_ *Z/_>%<Z/6E\+/1%^Z*6D7I2UWGR85YY\3/];IWT?\
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M?XNW6@#U?M11VJIJ>HQ:582WDT<TD<0W,(8R[8[G H Q/$W_ "'?"W_80?\
M]$R5TU<5JVM:;JFM^$39WL,CRW1G6(.!)L:!R&*]0.1U%=K0 4AI:0T >-7G
M_']<?]=&_G4%37A'VZXY_P"6C?SJ'(]:]E;'R<OB8J_?7_>'\Z]H@_X]X_\
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M .AOC_\ !7'_ /%5T]%26<N=$\5$$'Q?'@_]0N/_ .*K+/@36B2?^$LZG/\
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M@G'.W/>H]*\"7&C^+H=3MM05["&$0I#,FZ14"L @/;&X8;K@8YZT =Q1110
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&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g10811g0421180834233.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421180834233.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $+ 3H# 2(  A$! Q$!_\0
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M-'N'++L345#]LMO^?B+_ +[%'VRV_P"?B+_OL4<T>X<LNQ-14/VRV_Y^(O\
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MQ^9!*DJ;BNY&R,@X(_ @BI*/90_E0>UJ?S/[RE_8^F_\^-O_ -^Q1_8^F_\
M/C;_ /?L5=J.XGBM;:6XF;9%$A=V/90,DT>RA_*@]K4_F?WE;^Q]-_Y\;?\
M[]BC^Q]-_P"?&W_[]BLOP_XTTCQ&9%M7EB9!&P6XC,9=9%+(RYZ@A2?PJ?\
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M,DDBI#$7(2, NQQV (H]E#^5![6I_,_O-'^Q]-_Y\;?_ +]BC^Q]-_Y\;?\
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MHY 4=?PJY-XKL/(TZXLG6[AO9X8M\;C]V)1E&(//(Q1[*'\J#VM3^9_>:/\
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MXK@N%CBA='&>Y)8'%9%[X*UKP_X6+0[I)7TR"UNQ%*SEYQ<JQ<CNHCR#[<4
M>Q*RN,HRL/4'-+7+?#V V_A18VM)K9OM,S'S?^6F6SO4=E/0#T%=30 4444
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MC^T+?R=VP/O&-V,XK,\4^$[;Q!:$1QP1732QNT[)DE5(R/RXK2.@Z4;;[/\
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M/,/M1YA]J ,"+P#I4/B0:U').L@F$ZQ*V%#B,1CWVA0/EZ5U55/,/M1YA]J
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MW4HBA4@%CVR<"IZ+.UPNKV"BBBD,5?O#ZU;3[B_2JB_>'UJVGW%^E %5_O\
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M9)_*LQ?%&B/917BZE UO+;R722 Y#11XWM]%R,UC["RLFSTGFBE+FE3BWO\
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M3$AW#.>H]Z[@7,#3^0)HS,!DQAQNQ]*9]NLS"TPNH/*4E2_F#:".HS4>Q?\
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MM+Y#8YR@!''>@#4N/!EY.UTOV^%$,UU<P.L)\SS9D= 7.>0BN0 ,9POI4O\
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/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g10811g0421180834623.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421180834623.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #I 2X# 2(  A$! Q$!_\0
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M%U:,Z32FK-BT4451D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4(?JQ7D?2K6CR7JZC%'82NDDC ';T(]Q6<H7U&>KT4BYVC)R<<FEK 84444
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MT,BQR;GB65<$;6Z55GMH)VC>6)7,3;TS_"?44MV!:TFVU!]3(MY#-([9B38
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; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g10811g0421180835046.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421180835046.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ") FX# 2(  A$! Q$!_\0
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M/FX^3?VQUQGC-=)I']G_ -EP?V7L^Q8_=;,[<9[9[4 7J*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BL74]*
MO;K6;2_MKI+=;>*12<,S$L,#C.TC.#SZ58T"\GU#0;.ZN2IFDCRY5< GUQVH
M TJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,@]"* %HHHH
M*:R*^-RAL<C(Z4ZB@ HHKFY?$MW#XD;31I,MU:;E4W5N?]63V8-C/_ 2<=Z
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M@L+WSH[Y9"%\MD&.2>1GD_AW]<T ;M%,$T19E$B%E&6&X9'UIP((!!!!Y!%
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M*,#./6C^Q;<+,DVHQAI (P4(5@-V>N>23_*H&\'N\[(VHS?93&5QDEP3Z'H
M.OUH 8WA"00ILU%OM1C".&SL;!SG&<\=*Z/3K0V-DD#2;RN<M]36-I6B265^
MUW)J"SQ1DJ#DD]"/F.<9Y_2NCH *1LE2%.#C@^E+10!YZD>E6GC'^R=4LX=1
MU"Z*S"[DBA1H^O0Y#'\!7H708K@=0G ^*MI"(E0F)"7RP+]?]L X_P!TUWU
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M-9U2.R_LYHMZLV\2[NGH,<CL?0\58\&2":#5I KJ&U&7AU*D=.H- '34444
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M&B?\DJU[_KO'7;_"#_D4YO\ KX;^0K;#?Q(>GZGF9W_N>(_Z^+_TE'&^/O\
MDIL7UB_G2:__ ,E<3_KXC_D*7Q]_R4V+ZQ?SI-?_ .2N)_U\1_R%93^*7^)?
MJ?DM3XI?XE^I8N?^2UC_ *^E_E4&G?\ )9/^WPU/<_\ ):Q_U]+_ "J#3O\
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MK\2:'8>&)8KO5[&"0SDA99U4XP.>375ZEJMEI6C6XCTA5N9P1'9RQ[>?XER
M1GK@=^U;&G)9R:3;SFP2T3RP?*DC ,8].:JGAE"2E?96.?&9U/%4JE)Q2YY<
MWX)?H>(^-]8TRZ^(D=S!J-K+!^[_ 'B2@KP>>:36]8TR7XI+=1ZA:M;^>A\T
M2@KC [UZO9ZSIVJ:VR0:;'+;VX;%R$&Z-N<Y7&=IQPPS18ZWI5_?3W'V")+.
MW0A;UE "^H8$ K['H:EX1-MWW=SY>6!C)MWW=SR^XUK2S\7Q>#4K0VWVE6\[
MS5VXQUS4-CK&F)\63=MJ-J+;[46\TRC;CUS7L=C+:WFJRD:9 8C&/(O(BKK(
MAYP<?=.>QZTJO#!?7TE[HRP)"F4ND0.)8Q]!D'/:CZHKWOUN'U&-[WZW/&O"
MNL:9!\39+J;4+6.W\V0^8TH"X)..:]ZL[VUU"V6XL[B*X@;I)$X93^(KG_#N
MI6^M75Y)_9$<*\;+@)E94[<D#GVKI41(UVHJJH[*,"M:-%4DTF;X>@J,6D[W
M=QU%%%;&X4444 %%%% !7)?9[NY\8V]X-#O(4C9Q)<W%T&CQC *()#@G_=KK
M:* ,G4_$FEZ1,8;R=DE$?F;5C9CMSCL*I:QK%E>^&-5>*8*D:%"TGR@G&1C-
M:>HZ)INK'-]:K,0NP$DC SGL:I>)I-.T[PU-]KL([BT ">02%![#D\#ZT 7H
M-5TX6\8-_:_='_+9?3ZT_P#M;3?^@A:_]_E_QJO9Z;I%U90SII=JJR(& :!<
M@$?2IO[&TO\ Z!MG_P!^%_PH =_:VF_]!"U_[_+_ (TO]JZ=_P _]K_W^7_&
MHVTC2E4L=-L\ 9_U"_X5C^&(]#U?2FN+?1K6 ><X>-HU8JV<GG'OVXH V_[6
MTW_H(6O_ '^7_&C^UM-_Z"%K_P!_E_QIO]C:7_T#;/\ [\+_ (4?V-I?_0-L
M_P#OPO\ A0 _^U=._P"?^U_[_+_C2?VMIO\ T$+7_O\ +_C7)6FHZ!+XF%D/
M#T45Q<2O [ND?'EEL';Z'!Z=,C/6NK_L;2_^@;9_]^%_PH =_:VF_P#00M?^
M_P O^-+_ &KIW_/_ &O_ '^7_&F?V-I?_0-L_P#OPO\ A7,>(KW0M'OMMQX?
MAD:UC2X20(BK\[&,^_ R3Q].: .I_M;3?^@A:_\ ?Y?\:/[6TW_H(6O_ '^7
M_&F+I&E,H8:;9D$9'[A?\*7^QM+_ .@;9_\ ?A?\* '_ -JZ=_S_ -K_ -_E
M_P :3^UM._Z"%K_W^7_&N?\ %)T/2+.*.YT2UN([MC$418U<C!)VCJ3C)XZ8
MJ[H<>D:UI,5['I%I$')7;Y2,!@XX(&"..M &G_:VF_\ 00M?^_R_XT?VMIO_
M $$+7_O\O^--_L;2_P#H&V?_ 'X7_"J>K6VD:5I=Q?/I=@5A0N0Z1H/Q8C H
M UXY8YHQ)$ZNAZ,IR#^-/KF?">L6-X;FPL[ V*P8E\HL#]_YB0!P!D^OX5TU
M !1110 4444 %%%% &?!H6DVUV]W%IULMR[F0S&(%]Q[[CS6A110!0?6+)-5
M&F-*?M13>%VG&/KTS[5P.B>)M25=7BTS3K3S#?R-YM]>K$BY]AECT[5Z!)I=
MB=1_M-K96NU0H),G./3'2L#PO'HVJQ7TD6AVT!%RV_<@?<QZGD<'CIVJXR2W
M5RDTEJCC&TCQEJ6N7-S?>,K"U@E0 I:W1\K_ '57((^O>K,G@.UEL+B&3Q)8
M22RH5+-CD^_S5Z1_8VE_] VS_P"_"_X55U/3=*MM+NICI=BP2)B5:$ 'CID#
M(K3ZQ.Z<;+TT+59QV2^Y?J<QX?\ "^F:3H]M97&O6S-"N#Y1CP#[;LG^57M&
M\/\ A_1X)X1K4DZ32F0A[[:,GV4@5KZ3I&G/I-JTFBV4#-&#Y0C5]OMDCFKG
M]C:7_P! VS_[\+_A4.K-MON.5>I)6;T,>YT?PA>(J7"V$H5@X+SY.1[[LUKQ
M:AI,$8CBO+*- ,!5E4 ?K6!XE.C:7Y:7/A^"> QO/OCB7(9,$+@#/.?I6KI=
MII6IZ5:WPTFTC$\8?88%.,]NE2YR:LV9N4GHV7?[6TW_ *"%K_W^7_&E_M73
MO^?^U_[_ "_XTS^QM+_Z!MG_ -^%_P *Y.XOM)3Q#+ OAVQF:VG2V,L;+\GF
M?WEV]>!Z_6I).N_M;3?^@A:_]_E_QH_M;3?^@A:_]_E_QIO]C:7_ - VS_[\
M+_A39-(TM(V?^S;+Y03S"@'YXH E_M73O^?^U_[_ "_XU9CDCFC$D3JZ-R&4
MY!_&O/?#^JZ+J7B+[-'X=LD:\1I6G0JZ-L.T8&T<$#VKT&**."-8XHUCC48"
MHN /PH ?1110 4444 %%%% !1110 4444 9VMG4UTN1M($;78((609R,\@9(
M&<>IK&TGPA;0QW-Y-#]GOKQ"3Y; FV+ [MC8R#ECSGTKJJ* ,31/#XTR-'NY
MQ>WD:F-+AT^94SPH))/?N:M66AZ=IU[<7=K;B.:<Y<Y)'<\#H.23QZUHT4 %
M,\M!(90B^81M+XY(],^E,NI)(;2:2&/S)$0LB?WCC@5PMEXUU&&Q@DF3^TI)
MI,.([22W\EL F$9!WMG@=.G)H O?\(]?:[JQD\06\0CM928)(B,2H3G:1SQP
M.>#U%:+^%EDU=YVNV;39(PK6#+F/CI@9P!]!GWK'B\=WS7"Q2Z(8MTF [.^T
MKS@#Y/OG;TZ>]1)X^U2>TBFC\/.A?=D/(25^8*. O7+<CCH: .MOM"TW46MF
MN;96-L1Y6TE< =N.HX''M6@    , = *\_C\?ZHEA;2S:,K2RR+#B,R8)V@L
MWW> ">A/8T6?CS51'']JTAI)7(#",,JY[JGRY+=\''0\T =])''*NV1%=<YP
MPR*PO$=OJUX\-K;6\-QI\X,=RC'##/?.>@]LUF#Q?J,VD//_ &<+:<7,40#$
MLI5^_('/:J,_Q*DBCC?^RBBLP4F1V'S<94#;RP)Z>U &RW@R&#18[/3KN2TN
M%<2&X489R/[VW&16O;Z+90V$MJ\,<@G'^D-L ,K=R<5QS>.M:A#12:*6()7S
MEW9SQ@[-ON._8UTGA75KO5K"9[P+YL4@0LB[0?E!Z>HS0!IZ=IEII-H+:SC*
M1@YY8L2?<GDU;HHH 9'''$"(T5 3DA1C)]:?110 4444 %%%% !1110 4444
M %<YXZUBXT+P??7]I9->7"*!'"(O,!)/4CT%='4%Y:QWUG+:S;O+E4JVTX.*
M (M)O3J.D6EXT,D+31*YCD4JR$CH0>E7*15"(JCH!@4M ".P1&<YPHR<#-<E
M\/\ Q%<^(M+O9+K3);!H+R6.-'@,89-WRD9ZGL?<&NNJ"TM(K*%HHMVUI'D.
MXYY9BQ_4T 3T5SB^-=,6^NK>YCNK6. R@7$L?[N3RV"OM()/!(Z@58?Q?X?1
M$=M6MMLC!5PV<DG 'Y@T 9-GXDFG^)U]H+:7(EI;VBR179MR 9"?G^;'0C ^
MJ&NQK#N=7T+3M=F-SJ$<-ZUNH='8@!%W,/;/+?7%1W'C;P_;6\DQU!9/*B$S
MI$K,X4MMY7&1SQ@\T =!4<D$,W^MB1^GWE!Z'(_6LB?Q;HMKJ4]A<WGD3P;=
MWF(0O*%^#C'"@D^E17'C;P];V:W1U%)(WB,L8B4L74':<#')!ZCJ* .@HK 7
MQKX;9I0-7MP8@Q?)(QCKU'L?R--N?&_AZWB9_P"T4EVHC[85+DJQ7!&.OWE_
M.@#=EMX9F1I88Y"ARI=0=I]O2G1QI$@2-%1!T51@"G44 %,DBCFC,<L:R(W5
M6&0?PI]% $<4$,&?*B2/.,[% SCI4E%% !1110 4444 %%%% !1110 4@ '0
M8I:* "LB;Q+I$&KG2YKK9= #(:-@@R,@;\;<X[9K7KG-1\'VVI:E/=RZA?(D
MVUFMXW4)O48#_=SD#WQ[4 ;']J:?Y7F"^M?+_O><N/SS3VO[-&B5KN!3-_J@
M9 -_^[Z_A7'0?#+3HGEB:XD>U:W,*JP!;<3DN<C&>PXJY>^!+6^FTY)+N8V=
MG;F H<%Y!G(R^./PP: .@DU;3(XS*]_:A!N^;S5_A^]W[5"/$.CEX4_M*U#3
MQ":+=(!N0G (SVS6"/AQI'F12&>Z+QEOF!4$J1C;D+TQ^?>KD_@K3KE[!I99
MV-G&L2CY<.JG(SQ[]L4 ;$FKZ;%$9)+^V5!NY\U?X1D]^U1VVLZ/=[&MM0LI
M&E *[95W-Z<=:YO_ (5CHGEQQ":[6))6EV*R@,3QS\O/!ZTX?#31" 'DN6(Z
MME03^(6@#I9=:TN"$RRZC:J@0ODS+RHZD<\XP:M03PW5O'/!(LD,BAD=3D,#
MWKDD^&NAI;) #/M5=N1M!_B_V?\ :-=59VRV5E#;*S.L2! S8R0/IQ0!*J(O
MW54?04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH 9+%',FR6-77.<,,BHY[*UNI8I;BVAEDB.Z-G0$H?4$]*GHH *9'%'""(
MHU0$EB%&,D]Z?10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!SMQX(T*ZENI)[:5S<LS.#</A2S!FVC.%R0,XZU#%X"T58KV&6)I(;IHR
M4W%0JQJ%1<CD\9R3U)KJ** .?N_!VE:AJL][>K).)8TC$#.0B[0P#8!Y;#'D
M\CM2-X(T&0Y>U=F,;QEC,Y8[CN9B<Y+$\YKH:* ,>Z\+Z1?7DEU<VQDDEC,<
MF9&VL"A0Y&<9VDC-5&\"Z TB2-:.SI"8%8S/PIS[]>>M='10!SK>!O#\D1C>
MR+*>3NE8\_-SUZ_,WYU))X.T27[UJV<8W"5@>BC/7KA%Y]JWJ* #M1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>g10811g0421180835597.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421180835597.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #& D # 2(  A$! Q$!_\0
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MMG_X$-_\11YFJ_\ /K9_^!#?_$4 7Z*H>9JO_/K9_P#@0W_Q%'F:K_SZV?\
MX$-_\10!?HJAYFJ_\^MG_P"!#?\ Q%'F:K_SZV?_ ($-_P#$4 7Z*H>9JO\
MSZV?_@0W_P 13]/NY;K[0LT21R0R^60C[@> <YP/6@"Y1110 4444 %%%% !
M1110 4444 %%%% !1110 5EZOX;T77S$=6TRVO3%]SSHPVWZ5J44 010VFFV
M2Q0QQ6UK"O"J B(H_0"H8]8TV7R/+U"V?[1GR=LJGS,==O/-0^(M/FU7P]?6
M-OY?G3Q%$\S[N?>O-;;X;:XL,$4@LTWC:TGF9>WPQ.00H!)Z<8H ]6M;VUO4
M9[6XBG56*L8W# $=1QWJ>O/--\-ZWH>@ZK<1W4&F7"H&06Z"57$:'D@@<MUK
MM-#NI;W0K&ZG(:66%7<@8R2.: +]%%% !1110 4444 %%%% !1110 4444 %
M%%% !113)IHK>%I9I%CC099F. * 'T5!:WMK?1>;:7$<\><;HV##/X5/0G<$
MT]4%%%-<L$8HH9@. 3C)H =17FOB3Q#\1+37-+AT[P[";:5\2[)/-#<\AFP-
M@QWKO-+GU&>!FU*RBM)0V%2.;S 1ZYP*Z*N&E3@IMIW[-,2E=EW(]:6N5O;.
M.U\6O?F&\EBCLFG*122$-(&[+G!..U8ZW(N;R:YU2345TB:29K9HS*OS;AC[
MO(X'RCIUKG&>A45Q.GW&LR>,=.^T6VHQ:>+26.,3%<$ 1D/)@_?)R,8X_.NV
MH **** "BBB@ HHHH *Y[PG_ *K6/^PK<?S%=#7.^$C\NM#_ *BL_P#,4 =%
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9VE_\?.I?]?1_] 6M
M&L[2_P#CYU+_ *^C_P"@+0!HT444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!0UO_ ) &I?\ 7K+_ .@FH?#/_(KZ9_U[)_*IM;_Y &I?]>LO
M_H)J'PS_ ,BOIG_7LG\J -6BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MDM(\5W^H^,+[1YM+>&W@W;9CGL>_UKI[J6&.W<SO&J;3G>1C]:RKO4;F\OI-
M/TD)YD?%Q=.,K%[ ?Q-[=JJ:EI=AI.DW6IWD,NISPQER9SO)/LO0?@*Q3DD]
M;^9SQE*,7K?S+WA4*/#.GE H!A!X'6MBN7\ :I_:GA2W;[.\/D?N<-T..X]J
MZBKI-.":-*,E*G%KL%%%(RAU*L,@C!JS0J7.K:?9W$,%S>012SG$2.X!8^U6
MPP;H0?I7)ZG\.M#U*^MKIDFB,)Y1)"0XSG!SDC\*Z.QTZUTV)HK2+RT8[B-Q
M;G\36<7.[YEH==:&%5.+I2;EUNK?J4I=?B6_DMHK.ZG2&18IIHDRD;''![GJ
M,X!QGFI&\1:,BR,VIVH$3[')E'RMSQ^A_(U7DT&87T\MKJ4MM;W,JS3PH@)+
M#&=K?P@X&>#WK/M_!$,-W9SO>M(+(A;=/* VH X /J?GZ^WN:T.0UCXET01F
M0ZK:; VW=YHQG&?Y<U))KNDQ2R12:C;*\4?F.#(!M7@Y/MR/SKF[CP3-'>Z6
MUA=K&EO"()'>)6PJQ,@(7U.ZB3X=V\DX8ZC.8DC:..-DSM4JJXZX/W1V_.@#
M<O/%>B65M--)J$+"&,2.J-EMI(&<?\"'YU8?7](C,X?4;93;@&4&0?)D@<_B
M0/QK!O? JWNI7%X^IRYD$H12F1'OV^^" 5'8>]3?\(7$UQ&\MZSQPS&:&/R@
M-I:996R?XLLO'IGO0!L7>M6MG=Z?;/YCO?2;(BB$J/E+9)Z <5HU3O\ 3UOI
M+)VD*?9;@3@ ?>(5EQ_X]5R@ HHKA-6\?WEAK%SI]OHDLYLYQ]I8L5 @/EA7
M7CYF9I" O^R: .[KF_")^;7!Z:K/_,5TE<CX&F:6?Q*K'/EZS.H^GRG^M4HM
MIOL!UU%%%2 4444 %%%% !1110 4444 %%%% !1110 4444 %9VE_P#'SJ7_
M %]'_P! 6M&L[2_^/G4O^OH_^@+0!HT444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% $-U=065K+=7,BQPQ*6=V/  K%C\;>'Y3:!=00?:L^7N!'3U]
M/QJ_KNE+K>AWFF/(8Q<1E-X'2N(B^&%P(HH9=54Q.NRY0(3\H.0$).1SZT =
M1)KNG:[X<U>33K@3+%!*C\$8.P^O:K?AG_D5],_Z]D_E7+MX,EL?#6KB[U.4
MR- =KVO[OY$0A0<YSQUKI_#'_(KZ9_U[)_*@#6HHHH **** "BBB@ HHHH *
M*** "BBB@ K+UR^EMK:.WM,?;;M_*AS_  GNQ]@.?RK4K#L1_:/B*\OFYBM!
M]E@^O5S^>!^%1-]%U(FW:RZFAIME!IMFEI"0=O+,3EF8]6/N35MMI4AL;2.<
M]*IP0QKJ5RRHH;"\@>U6W570JRAE(Y!JEM8U<(QLEL)$L21A8514'0(  *?5
M738TCT^$(H7*@G JU0M@DE&32"D8D(Q W$#@>M+13).'USQ9XBL-4L+>V\/2
M&.9L-N8,6YZ J<#\:ZVPN;FYA9KFR>U8-@(SJV1Z\&G7%_9VDT,-Q<Q12S'$
M2.X!<^U6:SC"2;;E<RA"49-N5SCKB\_XGEY]MU&[MKF*ZC2TMX>1)&0O\./F
MR2V3V_"J</BW6KJYM[>&.UWW#J&.QC]E)$A*/ZM\@_6NN.JZ>)K@2S1QM;2^
M2[2<88J&P"?8BJSZ_81WK0+'-(%D5))HXBT:.<8!8=^1^=:&IRK^,M8A^QQW
M/V&W:ZB682.K;5!B+[/<Y7'XTVX\=ZL+MXH;) 3 Q\MT8&*0(K8/J,L>W:N\
MELK:>>">6%6D@),3'^'(P?TJ?8N2=HR>IQ0!YSJ_B[6DN;W3[=HE>.*0>>L)
M_=NFS)P>H(+?EU-79/%FKM</!!';-(\IB"[6)M\3)&&?U#!BP^GXUW&Q<D[1
MD]>.M+L4$D*.>O% ')^(KMH]:TVTCU*6&^;RVVA@L2H'&]F'\1;[H'_ZZZVF
MM'&Y!9%8CH2,XIU !7C$EIJ9\4:IIHU7Q)J5J-1C:Y^SQ(L:MB-@I8\@ ;>G
M&/QKV>O%O$-_I]M\0M2\W3L79D3R8UN95DN9080#M'&TJ[8_ZYG- 'M-<5X
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M)9);PR0,P:8X*A4(4#'H*W/#'_(KZ9_U[)_*@#5HHHH **** "BBB@ HHHH
M**** "BBD9@BEF.% R30!RE[H5AXE\52R7T1DCT]$1,' +GYCG\Q5U%&M:X6
MQFPTYMJ#M)-W/T7I]<UB'Q'!H^BF620)J&K2O);@_P"TV%)]@,?E77:78QZ=
MIL%K'R$7EN['N3]37/!1D]/5_H;T*3H4?K#5G/;TZO\ 3[RY111708!1110
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M?+0,S!%W-]XXZU']DMMR-Y$6Y/NG8./I4U%.PE)KJ1F"%E96B0ASE@5ZFG@
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MTYO8:BD0VMI;V4"P6L$<,2]$C7 %3445SMMN[&%%%%( HHHH **** "BBB@
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M^8T>!@\ 8_\ '11R1[!R1[%+3_"?A?4-)MYTT2V2.7$P5D&X'.<9^M2-\/\
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M$D*N>B@DX ]:V*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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? 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>g10811g0421180836199.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421180836199.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ": E,# 2(  A$! Q$!_\0
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M //[%_X#_P#V57*Q+_7X_M']GZ9)!/J1D">6[8"#^)O]K:.2H.?I0!?\B_\
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M2A)9&;"2JUPMN/WK0_Q;/]KOZG! Y-2_\)%HPZZE;#_MH*/^$BT;&?[3M?\
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M'@U*TMBLA+-MVN1SA2:E2=RO9QY;W+UYY<,A4-YBY^3'\7I5=\@#<[#G.%/
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M?2#<QNF^%PLJ[N3GN!7-)IMZNL?:C-F$-G&?TQ0W84(1DG=G1VZ),LB2S[6
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MMQ,MU* 7'0Y]*TFC\J-6/WB.F>GUJ',)C(:,;RW##T[BFTF$9..Q$I\V3Y'
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MK?$,**K^48SMY)(3')SDYKT7%)@4 8=G 8_"JC5[JZN?,A5[EW!#\@%@ @!
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MYK=73[-+U[U+6!;IUVM,(P'8>A/6K.* ."UK0O$4?BMM5TF1IO-:/8S7)40
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ I#2T4 9W]A:9OO'-C 7O6W7+%,F0[=N3^ Q1I^AZ
M;I5L]O96<443G+*!G=P!SGKP /PK1HH A-M"W6&,\YY0=:E P*6B@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>g10811g0421180836738.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g0421180836738.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $S ?,# 2(  A$! Q$!_\0
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M70N)=.93Y06V($("@CS&/?.>02#Z"N[H **** "BBB@ HHHH **** "BBB@
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MS*8RAW9(^[VZ9K9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU2L=(T[2S(;"QM[8RG,AAC"[C[XJ[10 4444 %%%% !1110 4444 1SW$-K
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M_P"X2N#GT/-<]J>SE^!/LG-.5+5=NO\ P?5?.Q#XH\5>*E\.W<_AOPM>FZ0
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M"TB$5O#'%&.BHH _2I:*M12V.>=:I45I/3MT^[8****HR"JLFFV,VH17\MG
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MCGLH/7WKL**J,W%-+J4I22LF5;W3K348?*NX%D4<J3P5/J#U!^E9ODZSI/\
MQ[R?VG:#_EE,VV=1[/T?\<'WK<HK-Q3U-(5Y17*]5V?]:?(S+/5=.U5S#@+<
MI]ZVN$VR+_P$_P Q4&O>%-'\26 L=2M ]N'#[48IDCIRN#5Z_P!*LM3C"W<"
MN5Y1QPZ'U##D?A7->(=3UWPCI9N8 NK6^\(OFJ1+'G^\5^\..O!IJM.C[][6
MZHVIX>&)FH4=)/H_T?\ G;YER'P'H%I;0Q6-O+9/"NV.>VF9)!]6!Y_'->=>
M)M \8CXAZ>+&^U:?3%:/S;Q8S\@SSNQ\K$#OCZUZOH&JC6]$MK\H(Y)%_>1@
MY\MNZFM.N[#9A4IOG?O7777<Y*M%PDZ<M&G^1E:9X>T[2I&GBC:6\?\ UEW.
MQDE?ZL?Y# K5HIK.B8WNJYZ9.*Y)SE)WD[B2Z(=39)$BC:21U1%&2S' %5[S
M4K+3[<3W5S'%&?NDG[WL!W_"L/4KS5=:TNYATK3FCBEC*B>ZPI;(_A0\_BV*
MRE-+U.BCAY5&F](]WHCH8;F"Y!,$\<H7J8W#8_*JMYK6FV!VW-["CYQL#9;\
MAS7&^"/!-S8:7/;ZV)P3+N6%+C$9'OM/)^M=M9Z786 _T2SAA/JB '\^M3"4
MY13:L;XFCA:%64(S<TNUDG\]?R*']O37/_(/TB]N 1P\BB%/S;G]*AO++Q#J
MMC/!)=VNG+*A4>0K2.,C^\< ?@*Z"BJY&]V8K$*#O3@EZZO\=/P.<\&>';OP
MUH[6=Y?F[=I2X(SM0>@SS[UT=%%.,5&/*B*]>=>HZM3=B,JNI5E#*>H(R*
M!@  #H!2T51B(55@0R@@]<BC:N_?M&[&,XYQ2T4 %%%% !1110 4444 %%%%
M ')IYL/B/[ OBN!6ED,ILEMHA,W0D%OICG&<5UE>::;%/-\4KQIK'3-\5P=]
MS$")"/*&T89^N",D+72>+]=N=$_LXVMS CRW*J\$D99ID) (0YZC.<=30!/X
MJ^YH_P#V%;?^9KH*Y;Q9<S"]T.V%E,T+:E;LUR&78IR>",[L_05U- !1110
M4444 %%%% ''>)? [Z_XALM3CU%K98=JRHBX9@#G@@]>U=#9Z'IEBV^"SB$A
MZR,-SG_@1YK0HJ%3@FY):LZJF-Q%2G&E*7NQ5DOZW^844459RA1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *@NK*VO5B6YB6012+*@/\+KT/X5/61K/B.QT*:UBNQ,6
MN#QY:;@B@@%F]%R0/QH K>*P-NC' S_:MOS^)KH*YCQC>VEM_8Z3W4$3?VG
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M'_@2G^-']OZ-_P!!:P_\"4_QH T:*SO[?T;_ *"UA_X$I_C1_;^C?]!:P_\
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MG!&!\HRI^4]*[>L_3=$T[1VN&L+583</ODP2<G\3P/8<4 )_8&C?] FP_P#
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M@# \.KH'B/2%U&#0[2&-I'15DMDW?*Q&3QQGK^-:C:%HJ(S'2;#"C)_T9/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***CGGAMH'GN)4BB09:21@JJ/<GI0!YX? ?B"XC-K/J>G1VULUS)9-# QD+2
MEO\ 6%N, ,>!UK/TSX>W^G:[IUJV&LWF>YOS$#Y+(I5HH\L<E@X)Z=*]+MM6
MTZ\6-K74+6=9&*(8IE8,P&2!@\D"KE !14;3Q)-'"\J++)G8A8!FQUP.^*DH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **K7NH6>FPB
M:]N8K>(L$#RN%!)Z#FJQ\0:.%9CJ=H LPMV/FCB0]%^M &E1110 4444 %%%
M% !7$^/?#%_XFO=#2R=(5MY)G>X>%)5C)CPN4<$$$\5VU% 'D<?AWQC::9H%
MCIJW5A#;QM'/'#,IQ/YN3(3D QE<D#!QG&*;9^&_%^GK-#:I>HJ";S6-WDS
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M@D#OS7H515H^PFZ5[\NE^XJ]6-:K*K&/*F[V[!1114&04444 %%%% !1110
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M< \XK9H **** "BBB@ HHHH **** "BBB@ HHHH :Z+(A1U#*PP589!I0 H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
?%%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>g10811g16s85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g16s85.jpg
M_]C_X1?O17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@ +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,3HP-#HR-B Q
M.#HS,SHS-@!R<C$U,3$X,0       Z !  ,    !__\  * "  0    !   !
MN* #  0    !   !$0         & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M9+;7-(V;'"7-K^CNK][/H/9['H&)Z4.QL6RMX:YKW,%YL+ "WZ+7-W-;[?\
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M\3,_1W;7*PDI22'?D4XU1NO=LK! +CP-Q#&[OW6[G?35,=6-PG#QK,C0;N&
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M"K_JG*5G_(6/_P"&7_DN4<3_ )-ZC\*O^J<HB2<D239.$DG_ *C)9=D?W?\
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M_522^54DE/\ _]G_[1_B4&AO=&]S:&]P(#,N,  X0DE-! 0      #<< 5H
M QLE1QP"   "'! < E  "')R,34Q,3@Q' (% !9-:6-R;W-O9G0@5V]R9" M
M(#$P.#$Q #A"24T$)0      $%<KOX0\$...[J>A'?#;,3@X0DE-!#H
M .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
M    26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I
M=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F
M4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O
M9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O
M;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/
M<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB
M;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
M  !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG
M3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F14
M56YT1B-2;'0               !";&0@56YT1B-2;'0               !2
M<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0
M<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M     %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M        $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O
M;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T
M4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M    $ $L     0 " 2P    !  (X0DE-!"8       X             /X
M #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S       )
M           ! #A"24TG$       "@ !          (X0DE- _4      $@
M+V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@
M  8       $ -0    $ +0    8       $X0DE- _@      '   /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z   .$))300(       0     0   D    )      #A"
M24T$'@      !      X0DE-!!H      T4    &              $1   !
MN     @ ,0 P #@ ,0 Q "T .  S     0                         !
M              &X   !$0                     !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   !$0    !29VAT;&]N9P   ;@    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M 1$     4F=H=&QO;F<   &X     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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MP  1" !C * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M --V[/\ D+'_ /#+_P ERCB?\F]1^%7_ %3EEOZEEL^J6'D$MLL?G6,)>W2
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M ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "
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M#Z,_Y\SU7_Z+_:G_ -:??NO=>_T!]&?\^:ZK_P#1?[4_^M/OW7NO?Z ^C/\
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M8W_O+]L^XX]P/^2C[9?^+)'_ -H-_P!2?[<_\DSW5_\ %8E_[3]NZ,%\7O\
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MDHL-NN9JW>K;?QZXO/5#)2[?@&6S5.U?D9CXJ#&"IJ&#",JT;<O?]/.]RO\
MGAVG_!?=2AS+_P!.J]KO^>_>/\-AT*G<?:^%^/&3ZBPG=.]>V<7F.T.U-N[(
MR\VP_D1N+<NU^M]@[GJ,1M3&]S;PRV;V;MZIPFSU[=W3A=K2BMCID$^3%4LQ
MBAF2.2>HOZ O+?,7 8SKG&]DPY+N):/<T^]LCL[:.<[S[9DW]-L7K7Y&[8^.
M'8>X]X;<V1U/NQ:#=VVMQ;GBJ8]IXFHR6>J*C1C%@>MD98O=>Z/;\=<!!W]T
M;U=W2=^=\[0_TF;0Q>[EVS%WJF[4PL>5C,T5$-P8.&3'UYCCL3Q'/"28JB*&
M=)8D]U[H:/\ 0#3_ //X._?_ $:64_\ J7W[KW7O] -/_P _@[]_]&EE/_J7
MW[KW0)]W]*4^-H^JV_TJ=Y5?F[ZZDCTU79N3D"AMP,A !IOT-K]0%B;#D6]^
MZ]T-G^@&G_Y_!W[_ .C2RG_U+[]U[H-]T_"#J/?&1J<MO'/]J;ER5;1T./KJ
MO+[_ *^KDKJ'&&M.,I*Y6IA'5PXTY.J^W$BL8?NYPA GE#HY["WN9/$E#ZJ
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MFJ:"AI=U-4U>XJ63 UU=E5?%T6,R,$SI5RU*O"E+Y"R2?YMHWY=_Z>=[E_\
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M]^]H938& ZSK\3B,1L[JW>L^[:S=%)7Q5V&[9Z[K=^[>K\3C\9AZBDDQ].]
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MOW7NAI]^Z]U7?N'XP=E5.[OF3O#:\_\ #I_D[@,5L@XO.]H;DKIL8=J;,R^
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M''4.?@@QJ9RLJJO'Q3^Z]TJ?CI\B=J=B=2[([1Q?3?5O5G878>Q\UG^G.O\
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MM1.Z,]5[BD3L0%(J,@4/F5R*'-+G>;B2\@CMXF6S6XDC:2JG44AD<J%(J &
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M[/@Q];99<=4;HVAUQ@BIY FH\'EJ&9XN>5D\G]+>T,D7,EY59(Y=)\M2H/V
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M6)))Z%."G@I8DIZ:"&G@C!$<,$:0Q1@DL0D<:JB@L2>!]3[$"(D:A(U"H.
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MKX_2Z#<64II)$P]+,+!Z:G9JMEN&EA/I]BSE?VKO=Q,5]S26@M.(MU/ZC?\
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M5\Q_\K#O?_/0W^ =!#[ '1-T?[^71_S-?L7_ ,1YC/\ WI/>5/W1/^5ZYO\
M^E3%_P!I'4@^V_\ R5]R_P">9?\ C_7_TM_CW[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1=MA_]E(_(;_PS>A?^M'9
MWN-.7O\ IY_N3_SQ;3_@ONI1YD_Z=3[8?\]V\?X;#HQ/N2^HNZ][]U[ILRV2
M;%49JTQN3RS"2*):/$P0U%8YE;3K"3U%+"L:?5F9U"CVQ<3&WC\00/(:@40
MG/VD"GKGI^V@%Q+X9GCC%"=3DA<?8":^@ Z14NZ-_5#E,7UE/%&W$55N'=F"
MQL8!-A)+3X@[BJE4 W*Z=7%N/90^X[RY(MM@8#R,LT:#[2$\5OY5Z.4VW8T
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M_P"?K7CP_P"_E_:.A'V+L;KO9,F8&Q\;BZ"HS3T$N6EI:Z7(UL]-B:1<9A*
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M&_Z6TO\ QU.HKYC_ .5AWO\ YZ&_P#H(?8 Z)NC_ '\NC_F:_8O_ (CS&?\
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MND&^[Q;V0WR% J.45YU"UTA0 7&FK:33M#, 0&-0^C^>?QY6OFQV0RVZL--
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M!0_]0=-_UI3WR%M/]Q;;_FFO^ =8VQ_V:?8/\'4SVHZOU8[\<?\ F3_QP_\
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M_I:)_P!6Y.CKEO\ Y6'9/^>@?\=;JS[^8'_V3\W_ (?VR?\ W82^\U/O6_\
M3J#_ -+6S_ZN'J4O</\ Y5[_ *B(_P#">J7/?.?J$^H>0_X 5W_4'4_]:7]I
M[O\ W%N?^:;?X#U23^S?[#_@ZV%)_P#LF&;_ ,0-)_[[T^^L<O\ TY63_P 5
M8_\ :!UD2W_*K-_TK_\ K#UKVT/_  "H_P#J%I_^M2>^3MM_N/!_I%_P#K'=
M/@3[!U*]O]6ZNJ^ 7_9/=+_X>^]?_=M[Z.?=6_Z=/#_TLKS_ *N]3;[??\JZ
MO_->7_CW56?R%_YG_P!T_P#B0LK_ .XM![PB]V?^GJ^XW_2VE_XZG45\Q_\
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MCQKJ!CC0UTDC)(SPKT,^1MZW;<MTO(;^_>6);?4 0H .M17"CR-.@\_F+_\
M,U>N?_$?97_WHU]A+[W?_*\\H?\ 2IE_[2!T7>Y'_)6VW_GG;_C_ $0#WBKU
M'O0O_'K_ )G]TO\ ^)"Q/_N/6^Q_[3_]/4]N?^EM%_QU^CCEW_E8-D_YZ5_P
M'JTSY^?]D]5G_AZ[)_\ =POO-_[U'_3IKC_I96?_ %='4K>X/_*NO_S7B_X]
MU2I[YP]0CU%KO^ 59_U"U'_6I_;%S_N//_I&_P !ZJ_P/]AZV$J/_LF&E_\
M$#0?^^^7WUB@_P"G*P_^*N/^T#K(A/\ E5T_YX!_U9ZUZ\?_ , *'_J#IO\
MK2GODY:?[BVW_--?\ ZQVC_LT^P?X.IGM1U?JQWXX_\ ,G_CA_XN'G?_ 'W_
M &;[S0]DO^G=^V7_ (O,_P#VB7O677W=O^5+]UO^E!<_]W';NBD?([_LH/N?
M_P /JJ_]U6)]XY^[_P#T]CW%_P"EFW_5J+K%_F3_ )6'>O\ GH/_ !U>@9]Q
MWT2]'Y_EU_\ ,WM_?^(WI_\ WIZ+WE+]T;_E?^:?^E.O_:2G4@>W'_)8W#_G
MF'_'QUW_ #%?^9N; _\ $<57_O357O?WN?\ E?N5/^E.W_:2W7O<?_DL;?\
M\\Q_X^>B"^\6>H_Z&7XY?]E!=,?^'W1_^ZW*>Y$]H?\ IZ_MW_TM$_ZMR='7
M+?\ RL.R?\] _P".MU9]_,#_ .R?F_\ #^V3_P"["7WFI]ZW_IU!_P"EK9_]
M7#U*7N'_ ,J]_P!1$?\ A/5+GOG/U"?4/(?\ *[_ *@ZG_K2_M/=_P"XMS_S
M3;_ >J2?V;_8?\'6PI/_ -DPS?\ B!I/_?>GWUCE_P"G*R?^*L?^T#K(EO\
ME5F_Z5__ %AZU[:'_@%1_P#4+3_]:D]\G;;_ ''@_P!(O^ =8[I\"?8.I7M_
MJW5U7P"_[)[I?_#WWK_[MO?1S[JW_3IX?^EE>?\ 5WJ;?;[_ )5U?^:\O_'N
MJL_D+_S/_NG_ ,2%E?\ W%H/>$7NS_T]7W&_Z6TO_'4ZBOF/_E8=[_YZ&_P#
MH(?8 Z)NC_?RZ/\ F:_8O_B/,9_[TGO*G[HG_*]<W_\ 2IB_[2.I!]M_^2ON
M7_/,O_'^O__7W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$N^:70(
M[PV[U-5T>VJC/YCKWM_;.7>?"UT.'WI@=I;GCJME;QW-L'/S3TQP6\-E4><@
MW'0U$;K+]SA$C D#M#(/_;_F;^KMUO:278B@NK&1:."T3RQTEBCF0 ZXI2A@
M=2*:9B<4#"+O=+D[^MEERY+%8M-<V6Y1/5&"3QPRU@FEMY"1X<T"R+<QL"#J
M@ &JI5@AVE\.NYMRQ[IS'<G:.(Q&_MW9'O\ V1O/>G5-#583)[RZF[!VEL?:
M>Q<SC&>2(;'WG15W6.&SM;1K]]CH:V:OIX?\GG72>WO/FP6ALX-AV9WVR!+*
M:**Y(=8KF"6:69&_W]$1<2PHW8Y01.W<IJ&]O]LN9KX;A=<R\P1Q[Q<ON$$\
M]HIC>:TN8;>&!US^A,K6L,[H/$C#F9% 1P 8SIGXG=<]1'%Y<^3<^\\7NS=.
M^:+<3T&.VOC<'N/?.TL!LO>$6SMG[5@QFW=K;7SF&VS2%\5''-3+5H:HZJIW
MF8*;_P [;KO@F@Q#8/!'"4U-(SQPRO+$999"SR2(TC4D)#:3HP@"@;<K^W6R
M<MFWN<W&Z1W$LZR:5B6.6>&."80PPA(XHI$B2L0#+K!DS(2Q,;AL!@MNT--B
M]OX7$X+&T231T>.PV.H\90TD=14R5E1'34E%#!3P)/5S/*X50&D8L;L2?85G
MN;FZD>:ZN'DF:E69BQ-!05)))H  /D*=#:UL[2RACM[*UCA@4$*J*J* 26-
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MNMOV@'TZEC8?;7EC8S'.UL;N^7_1)J-0^JQT$:_+M+#^+HUP 4       "P
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M/_I&_P !ZJ_P/]AZV$J/_LF&E_\ $#0?^^^7WUB@_P"G*P_^*N/^T#K(A/\
ME5T_YX!_U9ZUZ\?_ , *'_J#IO\ K2GODY:?[BVW_--?\ ZQVC_LT^P?X.IG
MM1U?JQWXX_\ ,G_CA_XN'G?_ 'W_ &;[S0]DO^G=^V7_ (O,_P#VB7O677W=
MO^5+]UO^E!<_]W';NBD?([_LH/N?_P /JJ_]U6)]XY^[_P#T]CW%_P"EFW_5
MJ+K%_F3_ )6'>O\ GH/_ !U>@9]QWT2]'Y_EU_\ ,WM_?^(WI_\ WIZ+WE+]
MT;_E?^:?^E.O_:2G4@>W'_)8W#_GF'_'QUW_ #%?^9N; _\ $<57_O357O?W
MN?\ E?N5/^E.W_:2W7O<?_DL;?\ \\Q_X^>B"^\6>H_Z&7XY?]E!=,?^'W1_
M^ZW*>Y$]H?\ IZ_MW_TM$_ZMR='7+?\ RL.R?\] _P".MU9]_,#_ .R?F_\
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M(5!45"XI@8'RX=2CR 4;9;AH_P"S-W*1BF"13'E]G5<WR8_[*&[C_P##Q_\
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M]RI_TIV_[26Z][C_ /)8V_\ YYC_ ,?/1!?>+/4?]#+\<O\ LH+IC_P^Z/\
M]UN4]R)[0_\ 3U_;O_I:)_U;DZ.N6_\ E8=D_P">@?\ '6ZL]_F"ZA\>YF10
M[IOG9\B(SB-9'CK)W6-I2&6)9&6Q<@A ;D$"WO-3[UE#[5 $T!W:R'K2LA%:
M>=/3SX=2E[A?\J^*\/J8O\/6OUM#NW:N[,EA<8T3X63)]3TW;%=/4U]+70XJ
MCJ,A1T;;;I4I8TFW%E(*6L6H,](OA8%8E4RM9<%MWY*W3:K>\N0PF6/=6L5
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M?V=-"[5WJYM4=GY;019A1[:VI3/R+'1)-C:QD/\ 0\V]J/K+ &J[0GYR2'_
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MK"V"J6T>&20ZUJM36G"OF //H0_YB_\ S-7KG_Q'V5_]Z-?97][O_E>>4/\
MI4R_]I Z3^Y'_)6VW_GG;_C_ $0#WBKU'O0O_'K_ )G]TO\ ^)"Q/_N/6^Q_
M[3_]/4]N?^EM%_QU^CCEW_E8-D_YZ5_P'JTSY^?]D]5G_AZ[)_\ =POO-_[U
M'_3IKC_I96?_ %='4K>X/_*NO_S7B_X]U1%GM@[9W-'44V8IZZ:@KJVLR>3Q
MU/DZVDH\KE*N.@@3(9%(9@:J7'T^-CCI8V_:@1G"KZS[Y\V._;EMK1R6DD8G
M1%1'**S(BESH2H[0Y<ER.YB%J<#J&X;N> JT1 <  $@$@"IH/2M<GB<=1Z+8
M&S]NPY*IPN%6BDGK$SC@UM?4QID\?BJ_%8V>)*NIGTKC:')5"4X);QF9B#<+
MI3[MOV[[C9R1WMYK5;=X_A4'0Y#N#I ^-D0MPKI ]:TN+RYFC*RRU 0KP P2
M"> \R!7[.MD*C_[)AI?_ ! T'_OOE]]2X/\ IRL/_BKC_M ZG]/^573_ )X!
M_P!6>M;"OZZV]N&LI]S5!K*3<,NTTVJN3HY8XS%@,A3M29RG^W,/CJ:W,X.K
MJ,8:J8R34M#52I3&$NS'EQLO,.X;?L]GML>A]O$B3Z&!-94"M$:UJ%CE5)M"
MT5Y$4R!P .H!M;R:&VB@6AAU!Z'^(4*FOD%8!J#!8 M6G2<7X^]8"":%\;DI
M7EH*S'K5MD*>*LIEKQ2PSY"EDI,=2P09VFQU%'245:(_-CX?(U-XYII97/SS
M_P S:U=;F, .KZ=)*G3J(1@SL3$78O)'73*VD2:D15"P[Q?D@^(O$&E#0TK@
MU)[234K6C&FJH  M]^,5!18KI#XPXK&TL5%C<7\MLEC<=1PZO%24-#UOV32T
ME.A<L[^*")068EG-V8DDGWE%[,SS77(7MS=7,I>YEY\N7=CQ9FM;YF/IDG@,
M#@,=94?=Y=Y.3O=B21JR-L-T2?4G<=N)Z*G\C21\A.YR+7_OU5<V&JW\)Q:D
M:K7TE6((^A!Y]XW>\ K[L>XO_2S;_JW%UB[S)_RL.]?\]!_XZO0+)''&TKI%
M"KSRFHG811ZIIR%4S2MIO)(50"YN; #Z >X\+,P4,Y(44&3@>@]!T3$DTJ3@
M4Z/Y_+K8GMW?POQ_HYA<@6 +MN>AU,0+#4P47/UL!_3WE)]T8#_7 YI_Z4R_
M]I*=#_VX_P"2QN'_ #S#_CXZX?S&(H9NV^OTG@@J(QUU4.(ZF"&IB$D>YZIH
MI1%.DD8FA?U(]M2,+J0>?=_O;LZ<_P#*I1V5OW.XJ"0:&X:HJ"#0\".!&#CK
M?N,2-YV\@D'Z4\/].>J^$P^%BF^XBP6"AG\;QF2'"XR(E))TJY-2QTJHTDE9
M$DS.07,R*Y;4H(Q?:\O63PWOIRE:T,CG@"HXM6@4E0. 4D4H3T 3+*1I,SD?
MZ8^E/7TQ]F.AL^-E%04OR"Z7^TQN+H[=@0S@T>,H*1EJ*G%9..JJ5:FIHF6J
MJXP%FE'[DRBSEAQ['_M)-/+[K^W?BW,K_P"[*,=SNV DA49)[5.5'!3D ='/
M+CNW,.RZG8_KKQ)/ -0<> \AY=6C_P P/_LGYO\ P_MD_P#NPE]YH_>M_P"G
M4'_I:V?_ %</4H>X?_*O?]1$?^$]4N>^<_4)]0\A_P  *[_J#J?^M+^T]W_N
M+<_\TV_P'JDG]F_V'_!UL*3_ /9,,W_B!I/_ 'WI]]8Y?^G*R?\ BK'_ +0.
MLB6_Y59O^E?_ -8>M>VA_P" 5'_U"T__ %J3WR=MO]QX/](O^ =8[I\"?8.I
M7M_JW5U7P"_[)[I?_#WWK_[MO?1S[JW_ $Z>'_I97G_5WJ;?;[_E75_YKR_\
M>ZJS^0O_ #/_ +I_\2%E?_<6@]X1>[/_ $]7W&_Z6TO_ !U.HKYC_P"5AWO_
M )Z&_P  Z"'V .B;H_W\NC_F:_8O_B/,9_[TGO*G[HG_ "O7-_\ TJ8O^TCJ
M0?;?_DK[E_SS+_Q_K__3WW9=L[<GFJ:B; 862HK*V/)5=0^+HFJ*G(PT+XN'
M(3SF#RRUT.,D:G29B9%@8H"%-O?NO=1Z39^TZ""EIJ+;&WZ2GHFP[T<-/AL=
M%'3/MZECHL!) J4X$4F$HXEBI&%FIHU"QE0 /?NO=.]#CZ#&4_VN-H:/'TOF
MJ*C[:AIH:2G\]7/)554_AITCC\U34S/)(UM3R,6)))/OW7NIGOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNB2_*+Y4[CZ!W7M3;V&V=@MR4VX=N9/.5-9ELW78IZ.2@R5/1"%$IL?5Q/"T
M<Q=G9ETV^EN?>-WO7[X;Q[6;]L.S[9RY;7L=Y:23%I)GC96214"JJ1OJ!U5K
M4&N #T!^:>:[KE^[L[:"R2598V8EF(((8"@ 4UX]%I'\Q_?+211+U?LMI:C5
M]K"N\<HTM6$"LYHXAAC)6*B,&8Q!PJD$\$'W#9^][S4%=CR'8Z5^(_4S47TU
M'P*+7@-5*G''H,_ZY.X4)_=$5!Q[WQ]O9C\^EAUI\^]V[][%V)LF7K_9M/2;
MMW/BL'65^-W?6Y&JQ]'DIJBG_B$-*N+5)@)J9T0NR1NZ,NJZD 1\H_>AYFYC
MYNY7Y;N^2;2WM]POH[=I!/,60/DE5:!0S**'22,$$T!'2W;>?K^]W*PL9-KC
M1)IE0G6U17T!4 D>E>E9_-)[+Q74OQ(S^\LSB<IFZ&FWWUOCVH,/-1T]:\N4
MW70T<,JR5[+3B.%Y S@FY4<<^\MN8O8CF'[QVV/[8<L<Q[?M6[3NMP+B\2:2
M +:L)G4K;@R:G52J$"@8]V.C+W+NTLN59YY$+*)XA04KEP//K6X_V>OK[_GW
M._O_ #Y[9_Z_>P'_ ,FCO>;_ ,+=R?\ ]DNZ?] =8]_UAMO^463]J]-^7^>'
M7L.)R<S=<;_98L=6RE5RFV-3".FE<@7FM<@>]-_=#^]%TK6R>^')P>0:03:;
MK0%L FB5H*]-R\PVPBD/TLGPGS7TZV3<3D8LOLSY2Y:&*2"'*?#?IO(PP3,C
M30Q5O5':U3'%*T=XVDC60!BO!(X]B;VMV6?EOWNW[ERZN$ENMO78+9W0$([0
M/=Q,Z!NX*Q4E0V0"*YZSXYJ8/]W_ -M7 P1O)_;'8=:/.W?^/?P7_:FQG_N%
M![[@WG^Y=U_S4;_CQZYN0?V$/^D'^#IY]I^G>MNO^0__ -D/Y/\ \3]VS_UL
MP'O 7[T/_3RX?^E5:_\ /_63'L[_ ,JB_P#SVS?\^] ;\F/^RANX_P#P\?\
MY!X;WP1]YO\ I[7N%_TL/^L,70,YG_Y6+>?^:W_/J] A[C7HBZ/I_+M_YG'O
M?_Q&;?\ O4X;WE']TC_IX7,O_2F_[68NA_[<_P#)9OO^>7_G]>I?\Q?_ )FK
MUS_XC[*_^]&OM_[W?_*\\H?]*F7_ +2!U?W(_P"2MMO_ #SM_P ?Z(![Q5ZC
MWH7_ (]?\S^Z7_\ $A8G_P!QZWV/_:?_ *>I[<_]+:+_ (Z_1QR[_P K!LG_
M #TK_@/5IGS\_P"R>JS_ ,/79/\ [N%]YO\ WJ/^G37'_2RL_P#JZ.I6]P?^
M5=?_ )KQ?\>ZI4]\X>H1ZBUW_ *L_P"H6H_ZU/[8N?\ <>?_ $C?X#U5_@?[
M#UL)4?\ V3#2_P#B!H/_ 'WR^^L4'_3E8?\ Q5Q_V@=9$)_RJZ?\\ _ZL]:]
M>/\ ^ %#_P!0=-_UI3WR<M/]Q;;_ )IK_@'6.T?]FGV#_!U,]J.K]6._''_F
M3_QP_P#%P\[_ .^_[-]YH>R7_3N_;+_Q>9_^T2]ZRZ^[M_RI?NM_TH+G_NX[
M=T4CY'?]E!]S_P#A]57_ +JL3[QS]W_^GL>XO_2S;_JU%UB_S)_RL.]?\]!_
MXZO0,^X[Z)>C\_RZ_P#F;V_O_$;T_P#[T]%[RE^Z-_RO_-/_ $IU_P"TE.I
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MU5G\A?\ F?\ W3_XD+*_^XM![PB]V?\ IZON-_TMI?\ CJ=17S'_ ,K#O?\
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M[<_]+:+_ (Z_1QR[_P K!LG_ #TK_@/5IGS\_P"R>JS_ ,/79/\ [N%]YO\
MWJ/^G37'_2RL_P#JZ.I6]P?^5=?_ )KQ?\>ZI4]\X>H1ZBUW_ *L_P"H6H_Z
MU/[8N?\ <>?_ $C?X#U5_@?[#UL)4?\ V3#2_P#B!H/_ 'WR^^L4'_3E8?\
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MHPR_(38)!"BX/W%5R/\ 'V"/<Z]NW]L_<%'N'*G:)P17C@="'E$#^MO+&/\
MB='_ )>MGW^=]_V0/NK_ ,2AT[_[W6-]X1?=I_Z>I8?\\5W_ -6&ZR"]V_\
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MX3U2Y[YS]0GU#R'_   KO^H.I_ZTO[3W?^XMS_S3;_ >J2?V;_8?\'6PI/\
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MPCIJ;^QE_P!*?\'6[=LO_F5_R*_\4@Z*_P#?.]H^^,'+G_B37N/_ ,]^T?\
M:3?==(.9?_$>_;'_ $F\?]6K#K2/V[_Q[^"_[4V,_P#<*#WV?O/]R[K_ )J-
M_P >/7-^#^PA_P!(/\'3S[3].];=?\A__LA_)_\ B?NV?^MF ]X"_>A_Z>7#
M_P!*JU_Y_P"LF/9W_E47_P">V;_GWJL3YI?,C#;%^77R(V9/UMG<K-MKL/\
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MOO(7VT^ZK["^_>T;GS-[L<G7&Y;W87*VL$D=]=6H2!T\5D*0.JN3)W:F!8<
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M7_S-[?W_ (C>G_\ >GHO>4OW1O\ E?\ FG_I3K_VDIU('MQ_R6-P_P">8?\
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M8>M>VA_X!4?_ %"T_P#UJ3WR=MO]QX/](O\ @'6.Z? GV#J5[?ZMU=5\ O\
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MYS<5C[038;74A<5/S-.L5XN8;@Q1GZ6/X1YMZ=./^SW;X_Y]CL7_ ,_FYO\
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M0\A_P KO^H.I_P"M+^T]W_N+<_\ --O\!ZI)_9O]A_P=;"D__9,,W_B!I/\
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M[DGH)]7J_P @+_LI/Y"?^(.VE_[WM9[QB^]7_P J;RG_ -+.7_JP.I?]E_\
MDO[W_P \:?\ 5P]9?^% '_91GQR_\0IOK_WNL'[K]U/_ )5#F_\ Z64'_5A^
MM^]'_)=V+_GDD_ZN+U1+[R?ZA_HS_P '?^RV_B%_XL'L+_W(JO8*]S/^G;<_
M_P#2IG_P#H0<H_\ *V\L?\]T?^7K9W_G??\ 9 ^ZO_$H=._^]UC?>%?W:?\
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MK[K/_3O/=7_I1W?_ '<=MZI&_F!_]EW?+O\ \33DO_>9VO[Z$>U'_3K^0/\
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MU&_PGK#N'^RB_P!*/\'3M[8Z<ZV<OY3W_9&_QQ_\7W['_P#>)[']\N?OO?\
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M .]UC?>%?W:?^GJ6'_/%=_\ 5ANL@?=O_E3+G_GH@_ZN#K3I]]">L7NFC/\
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MISWH_P"5@V7_ )XW_P"K@ZHP]Y-]1#T:OX'?]ER?$+_Q/&UO_<',^P-[H?\
M3LO<#_I5R_\ 'DZ$7)W_ "MW+'_/8G^!NMES^>5_V0=E?_$P]._^]9%[PT^[
M+_T]&#_I7W?_ %:ZGSW>_P"5.D_YZH/^/]:?'OH)UC#TVYC_ (M&4_[5U=_[
MC2^WK?\ W(@_TZ_X1TW+_9R?Z4_X.M\'%?\ ;N#&_P#BD='_ .^(C]\O)_\
MI\$W_BRG_M-ZS$C_ .5%C_Z5(_[1^M#K _\ %CPW_:JQW_N'#[ZB77^Y-Q_S
M4;_">L.X?[*+_2C_  =.WMCISK9R_E/?]D;_ !Q_\7W['_\ >)[']\N?OO?]
M/?\ ;'_I8V'_ ';MQZSJ^ZS_ -.\]U?^E'=_]W';>J1OY@?_ &7=\N__ !-.
M2_\ >9VO[Z$>U'_3K^0/^E:O_5R3K#OG7_E<.9O^>L_\=3HHWL?=!GJ\+^03
M_P!E5]X_^*^4'_OQ\1[QH^]1_P J-RS_ -+9O^T=NI;]F?\ E8]W_P">(?\
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M&7GJJJHQT5/301CEGD944?4CV#?<>ZLF]N>?E3<;5G.T7- )HB2='  .23Z
M D]'W*D%R.:N6BUI,%%]%4F-P!W>9*T ^9ZV@/YTU3%7_ 3L"#&E\K4#?_4
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M:_+K0;V]C<V,!@P=M;M4C#XP%6VEN56!%%!<,IQ0*D'Z@\CWU0N[NP^JN?\
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MW_W:6GQK_P 2(?4?T^FYK>Z\*7_$I_A/^A2>G^EZWL*RMI/^&Z*JC\\?WO\
MLDTT7V%_]R'F/1+**?[#_@9]R7.D1Z/)JXM?CWS!C>/_ %WHW\5/#_K*.[4-
M-/K>.JNFGSK2F:]9@,K_ -1F70VO]T\*&O\ N/PIQK\N/6BGA\;FQB,6#MK=
M@(QU""#M+<H(/VT5P0<4""/?3VXN[#ZB?_=I:?&W^CP^I_I]8?Q6]UX4?^)3
M_"/]"D]/]+TX_P -S7_/-[K_ /03W)_]:_;/U=A_T<[3_G/#_P!!].?3W7_*
M'/\ \XI/^@>MO3^1_41XWX*8R'*>3$3MW'W"139B";$514[F#J_VN2CI:C0R
M.K*VFS*01<$>\ /O,2PR^Y\QAGCD7]W6F4=7']GZJ2/Y]9->T:2)R>@DB=3]
M5/AE*GXO0@'K6U^>%#E9OG'\NY8,%N2I@D[UW(T-32;:SU72SI_#,&ODIZJF
MQTM/41ZE(U(S+<$7N#[S&]KKJR'MER &W&U5OW7'4&:($=S\07!!^1'4#\XP
M7)YOYG*VDQ'UCY$;D'"\"%H?RZ*K_#<U_P \WNO_ -!/<G_UK]CGZNP_Z.=I
M_P YX?\ H/H._3W7_*'/_P XI/\ H'J\/^0>E3C_ )-=^SY.@RN(@;HC;B)4
M9G$Y/#TTDG^D(#QQ5&3I*2&64:A=58L 0;<^\9_O3SVLG)?*JPWD$C?O23"2
MQN?[#S",2!\SCJ6_9J*=.8-Z:2WD1?HERR,H_M?5@!U__];?X]^Z]U@JJ6FK
M::HHZRG@JZ.K@EI:JEJ8DGIJFFGC:*>GJ()5:*:":)RKHP*LI((M[]U[I+[)
MV'M;KO#-@=HXS^&8V2MGR,R/55E?4U-94)#"T]579"HJJVI:&DIH:>(/(PAI
MH(HDTQQHH]U[IYJ*>GQ=#7U&,PL534K#/4QXZ@BHJ2;)U:1NT-.)IC3TJ35,
MED$DSK&A:[LJ@D4>..2A>-6(]0#UL,R_"Q'1,(OG7UI%CZVNS/77:N!FQ6-P
M4N7Q&2VUAH,SC]P5V[NN]J;GVL]!-GX6FR&PHNV=O9;(3HQHZG#Y%:B@EK"K
M1BGT\'^^$_8/\W5O$D_C/[3T.?3W=>T>\)NU:';^$RM$O5/9^Z>H]R+G*7'1
MI5[BVI.M/E134\%755"TK"1)8Q41Q&6GFBE0-'(I][$$*D$0J"/D.M%W."YI
M]O0Q0XC%4T@EI\9CX)5#*LL-%312!6%F4.D:L P^HOS[NRJXTNH*_//6@2#4
M&AZ+'GOE1M3:G9:=7;HZ_P!_8/,3;QP>WZ3,5F)Q8VQ7[;W)6;5P&([!Q^9&
M4\-?@!O;?6%P=92PA\KCJ[)0O4TL=,3.&_IX/]\)^P?YNK>))_&?VGIGZN^9
M_5':V].L]D87!;QPF7[5Z[7L';<.Y\/C\=64R"ER&2J,%DZ&CR>1E6LH,7C)
M7J*ZE:JP\-2!1/6"M9:<^^G@_P!\)_O(_P W7O$?^,_MZ-B<+AB_D.)QADU^
M3R&@I=?DU:_)J\6K7KYO];\^W:"E*8ZI4UKY]%>W5\LMH;'[ J.N]W=?]A83
M)Q;HQ6)AR\^&QDFW<EM?.3;7PV,[ Q>53)^/)8+^^N^,-@JNEA#Y7'U^2A>I
MI8Z8M.&OIX/]\)_O(_S=7\1_XS^WH-MX?/K86Q8<G!N;JOLW#;@P-=18+<.W
M\IC]N44V%W/599(),5+7OG7H,ICH=K2+N*/*8]JS'5F%=6I99JIA2GWT\'^^
M$_8/\W7O$D_C/[3T<O:U9C-[[8VWNVIVTN.?<."QF73'9BFQE3D:"'(TL=9%
M2U$U+)64S-&DW]B0CGD W <5%0:44!?ECJI).2:GH*NV^\\5TKE=NX:OZTWQ
MGZ#=%%54>V,IL_$XBKP]7OALGA\3MSKNJDJ<ECX]O9C>60SL,.-K*[[;%25)
M,+U*2E5:K0PL2S1*6/F0.MAW H'-/MZ1M)\NMCU3[1J!L+L--O\ 8FX^FMN[
M W:<)B#MW<C=WXS<]3MO(_<',K6XZ# Y7:-50YJFD@.1Q[34E1]L]+51S>Z_
M3P?[X3]@_P W6_$D_C/[3TK?CGWGM;Y1=:T?9>&V7E,#@:NL\%!1[JCP=36F
M44%'4U,<L..K,C%2UV.DK#35*AFC$T;"*69/7[ND4:$E(U!^0 ZJ69OB8GI<
M]E[THNI-IR;L@V%N'=6-I\OA:?.8_8>&I,EFL=BLEDJ3%5>Y!A8Y*>MS5-@E
MJUGJ*>C2HKFID=H89"A7WYXXY""\:L1Z@'KP9E^%B.@8VC\L=N[_ %QS[+ZP
M[!S\63RN?PL=32TNV$HZ*MAZ^INU>OZS,5;[@\.)VYVKU]74U=C,G,1244M7
M3TN1:DJI5B]T^G@_WPG[!_FZMXDG\9_:>I'3?RCVYW?O_<W7%%UCOS:=;MK;
MF$SV;3?F-PN'K:.#<6V]H;FQU)D]O?Q.JR=#)44>\(X=$J>3[BEGO&(?#-+L
M00J0RPJ&'R'6B[D4+FGV]&7J:"AQE+5U^-V_2U5?34E0]+1T--CZ2KK9A$QC
MH8:F?[>G@:KD 37+(D2WN[!02+LJN-+J"OH<]:!(R#0]$^QGS6VGF*/*'']/
M]P2[@PVU:[<-=LV;;>&I-U-E-KP;>RW8FRJ#%5><@ER.ZME;3W=BLNL<=Z?.
M4F2IUQ4U9*_C#?T\'^^$_8/\W5O$D_C/[3UGK/FELF#M3'=246P=XY'<=7V9
MN?JZHGB_NY2TE%GML8KK7<4PDCK,O!7J^2VUVE05U*LL,*21T]4ID#Q*LGOI
MX/\ ?"?[R/\ -U[Q'_C/[>CB'#XDE"<7CB8Y'F0FBIB4F=P[RI^UZ9'=02PY
M)%_;WX0OX?3RZ;H Q<#N-*GS-.'[/+HKVYOE?M/9>_ZWK[=G7G8>&R-)NC#X
M=<S-A<7+MRNVUN*?;&&PF_<=EH\H8\A@Y][;WP^"JJ6$/E,?7Y&)JFFCIKSA
MGZ>#_?"?[R/\W3GB/_&?V]!UOKY]=9=>44%)N;8&_P#&[[BV]FMS[CZ\K*7:
M]/G=H8?!=L;6ZAJLAG9_[PR4DN/R.7W;3Y;&3T)K(\IMR.7(4WD0(DGOIX/]
M\)^P?YNO>))_&?VGHXNUJS%;WVQMS=U1MR.@;<6"Q>8CH<K3XRKKZ.GR-)%6
M04\]12/64SE(YP1HD(L>0IN XJ(@THH"_(4ZJ23DFIZ"GMWO3%=*9/;^(R'6
MF]L]0;FH:BCVOE=HXK$5.%J]\/E,/A]N==UD]3D:"';F7WCD<]3P8VLK_ML3
M+4L87J4ELK4:&%B6:)2Q\R!UL.X% YI]O06Y[YL;*PN/VCFX^K>ULGMGL#=7
M2FW-E[RHMMXX;*KZ/O&++Q8#<N?W5-E(\1L7#X+.X23%9$9J2BJ%R59CX8(Y
MVR-)Y-?3P?[X3]@_S=;\23^,_M/0K_'WNK;GR5Z]B[ QFRLOM["S5_VU%0[L
MAPLU:TJ4-)4U"S4]!5UZ4E?CI*PTU5&252>-Q')*GK-UBC0U2-0?D .M%F;X
MF)Z5W9V]Z#J#:,N[H]A[BW3BZ7*X>'.T&P\-29',XW$Y'(TF+K-R#"I+35N:
MIL&M6L]13T25%<U,CM##(4*^_/%'(07C4D>H!ZT&9?A8CHO;_-_K2GVQ/OFK
MV)V6-D8RJS%)N'<.,VQ2;C.!=]HX7?G6\T^$V[DLIGLA3=S;5W+C&V\:.FJ'
MDR.4H\=4K3UM0D7NGT\'^^$_8/\ -U;Q)/XS^T]/_27RNV5W[OG<FP=N[.R\
M,>!V]C,_69RLK-L9+!5V/S&+V[E*44S8S*5K3A),^V/J8ROGI,MCJRFGBC\(
M=]B"%2&6%0P^0ZT7<X+FGV]&=K*.CQ-%6Y'%[=IJW(4M'4R4E!008ZBJ\A.L
M3-%00U=2::EIVK)55-<LB1)?4[!02+LJN-+J"OH<]:!(R#GHG^(^;6S,Y#EH
M\?U+V\^=P6UY=QY+:$^U\92[L2HV[4;0/9FUZ3!5.8BK:_='7.%W_A,E)3Q*
MT>:I,G#_  F2N<E0W]/!_OA/V#_-U;Q)/XS^T]8J;YGTH[9H.HLUT)VCM;-9
MC?F>V5MW*YO(=7SXG<L6 .S*BISF(?;6^]PU-,KX;?N/KVH<G'CLA2P^5*F*
M&HC$+^^G@_WPG[!_FZ]XDG\9_;T=#^#8<R>8XK&^4R>4R_8TOD\NK7Y-?BU>
M37S>][\^W:"FFG;2E/EU2IK6N>BO9WY7[4VMV/4=8[FZ[["PV=BW3A<+%D*G
M$8IMOUVW=T5VUMN[8WYC\PN5\&0V]DM^[WQ&WZF&'R9'%Y&O1JRGAI@9_;7T
M\'^^$_8/\W5_$D_C/[>@LW7_ # MB[+DR&-W%U#VMA=RX3:&V-Y[AVYF\9MS
M%5>%PFY>T9>HQF&GJ,ZT&;VWC-UQKYLCBOOX9*::*6%91+&&]]/!_OA/V#_-
MU[Q)/XS^T]'7VM6XS>>V=O[LDP"4!W/M_%97[')P8ZIKJ:DR='!7PT57-2/5
MTTWB687"2,E^>#P'458P5C4*OH,=48!R"PJ0:BOD?7H(NW^^<5TGE<#A<CUG
MOC/46YJ&2BVEE=IXO$5.$R6^9,KBL3@>MZFJJ<E0T^V<WNNJS4*8RJR1I,34
M3!X35), C-F&%B6:)2Q\Z#JP=Q@,:?;T$NY?G;U=M2CVYF<OLCL2+;&]J79^
M:V)NL8''#;^\]L;SV[09NBR>$R$F32)LY0UN5IJ&?;\OBSSRS+-!234X>5-?
M3P?[X3]@_P W6_$D_C/[3T-70G<. ^1G7T&_J+962V]BYJX4]+C]SC!5M7Y?
MX=05LX88NLR-+%5X]Z\TM2JNT:U,,BQ231A9&NL4:$E(U!^0 ZJ69OB8GI2=
MH[[QW3NTGW=_<3<6YL+297%1[BIMB8:ER>6PV&KJZFQ]?NAL'%)!D<U1X)*E
M9ZFGH8ZFN-+'(\4,GC*^_/%&Y!>-2?F >O!F7X6(Z+E+\[>IH:#;U;+M?>,<
MN[*O=6*VW0/1X$567SF+P77>Z]D8JDE&:./>7MC:O:V!KL*XG*QQUUJ[[0P5
M/AI]/!_OA/V#_-U;Q)/XS^T]*KHWY8[%^0V]MV[%VQLS<5'!MC'FKK<MGDP2
MT-=&JX5)1#04^0JZMJ3^(Y6:B5W74U3CJBZ+#X)IMB&%2&6)0P^0ZT7<BA8D
M?;T9NOI:3#8^OR>*VW3Y#(TE%4RTF.QT.+H:S(SK&6BQ\-96/24=,:N553R3
M2QPI?4[!02+LJN-+J"OSSUH$C(-#T2N?Y]]54& W%N#,[#[+V_#M3"8G+9_'
M[@V[CL/F,;6+NSKK:._=OU>.KLI#-29;K.J[9V]59"2;Q4%70Y))Z&IJHDD9
M6_IX/]\)^P?YNK>))_&?VGI2Q?,[8U?V/MKK?#[ WS5Y+</9?;O5OW]92[>Q
ME)2[AZ6WKL[9FZYHDES<L];CJT[XH\GCI5""HQD<[2>&HC6G?WT\'^^$_8/\
MW7O$D_C/[>C>_P &P_D\W\*QOE\GE\OV-+Y/+JU^37XM7DU\WO>_/MV@IIIV
MTI3Y=5J:UKGHK^0^5NU<)V@.I]Q=>=@X+<3;LQ&!BR%?AL<=NU.W]T9#;>W-
MI;]H<Q!D98,IMO,;ZWCC,!414@GR.)R54/OJ:"%3-[:^G@_WPG[!_FZMXDG\
M9_;T'F6^>.R,?UIM3MJDZI[+RFQMW8'&9>DW#2T6V_X/A*V?LRDZKS.$W96K
MG97V_7X'<.1AE99(F>MI5J#2)-/2SP)[Z>#_ 'PG[!_FZ]XDG\9_:>CC[;J,
M1O+;FWMUR[?AI#N'!8G,QT>4IL;4U]'#DJ&&MAI*F:F:KIWD@2<*?'(R7^A]
MN*JH-** ORQU4DDU)J>@?[=[[Q?2N8P6!R/6.^\]2[EH6I-H97:>*Q%5@LMO
M5LEC<?BNNIZN?)4=/M?-[@_BBMCJG*?98JJ>*6%:D3((VH886)9HE+'Y#K8=
MP*!C3[>@WB^</457*ZXW#;ER$+[NZ/VK0U24F(HX*]/D/UV.PNL,V#D\G0M0
M8O*1NN/G:J$'AKFT OI;3KZ>#_?"?L'^;K?B2?QG]IZ%CX_]R[=^2?6F+[*Q
MVS<EM_#Y.2FEQV.W1'AZFN"5>'Q>65I$H*FN@IZRC3*"FJ4#$1U4,J(\L861
MKI%&A)2-0?D .JEF;XF)Z__7W^/?NO=>]^Z]U[W[KW3!NO:^!WOM?<>S-TX]
M,MMG=V"RVV=Q8J2>JIH\G@L[05&+RV/DJ**>FK(8ZV@JI(V:*1) &.E@>??N
MO=%_Q7PN^+F%V=3;!QO36UX-J4>SMC[ AQKRYBIF_NAUMN/';LV1AILK5Y2?
M,5,>W]P8:BJ(Y9:AYY/LJ:.1WBIX43W7NACV5U?U]US4;IK-C[1PNV:O>V>J
M=S[KJL92B*ISF;JWDDEJZV=F>5HTDGD,4"E:> ROXT36]_=>Z7GOW7NBZ;;^
M)/QSVGNK.[WP756 IMU[D[9KN\\QFZJHS.6K*GM?)X]<97[QA.7R==%05M52
MQ1%H:=8J3S4\$WB\U/"\?NO=*SK7H+IOI^+!1=:=>;=VBNU]G+U]MQL=3RO-
M@MDC-U6Y)-LXJHK)JJHH,159^L>LJ(HV45-0(WEUF*+1[KW0O^_=>Z+1C/AW
M\:,1F-W[@HNI<!_&M^=CYWMW=63JZS.Y*KR78VYL')MS/;IBER.6JSBZS)8I
ME5XZ3P4XF@@G6,3T\$D?NO=-& ^#GQ2VMM';FQL!TSM[&;;VCB\3AMM4\&1W
M(<EAZ#!;HAWEA5H]PRYN3<256*W%3QS4]2:LU,4<:0+((%6(>Z]T9';.VL+L
M_ XO;.W:,X_"8:E6CQU(:FLK7B@5F<^6LR%155U7-)([,\LTLDLCL69BQ)]^
MZ]T$&^_B]T+V=V$_:F_NN,5NC?LG6F6Z>;/9*NSC$]<9O*KG<AMH8R'*18=8
MWS2+5Q5(IQ6T]2BR0S1NJD>Z]TRXKX=_&G![@W'NG$]3X.ASNZ^P-@=IYJLA
MKL_HE[ ZLP\VW^O=RX^B;+M082LVGAIVIZ1*&*F@1+70E5(]U[H2>K>F^MNE
M<%_=GK';,6UL"L&,I(<9#DLSDJ>DH<+CXL7B,=0_QK(Y*3'XO%X^%8J>E@:.
MGA6^E 68GW7NH?;G1O57>^,VGA^V=I0;PQNQM^[:[/VI2U.3S>-3#[\V?-/4
M;:W'"^$R>,EGJ\3-4R&-)FD@.LAD8'W[KW02;H^"GQ+WC61U^?Z4VW-41[>[
M,VFG\/K]R8&G_N[W%4)4]D8MJ/ YO&4;P;F,4<;$QEZ:GAB@IVAABC1?=>Z7
MW6?QGZ/Z=R--E>MMBP;6K*3'T^,I_MLYN>MI4IJ7 8+:M/(<?E,W74$F0CVW
MMF@H?NVB-4:6E2,R%00?=>Z%?=FUL#OC:^Y-E[JQZ9;;&[L#E]L;CQ4D]531
MY/!9Z@J,7E\?)444]-60QUM!521,T4B2 ,=+ \^_=>Z+'5? SXBUNQ,5UI4=
M);<;9F$P?7VV\;BTR6YX:J#"=5YF//[!H),Y!G8]P54>W<I!"Z--52/,E-3Q
M3-)%3P)'[KW2YF^*_04^3PN;DZ[HAF=OOEVQN7BS6YH,IX<[D<+E,GC\AD(,
MW'5YK#356VZ!4H:UZBCAIZ.&GBB2!%C'NO=&"]^Z]T6C&_#OXT8G+;NSU'U+
M@/XSOOL?/=N[IR=769W(UF1['W/@I-MY[=,4V1RU4V,K<CB)%1XZ3P4ZRPPS
MK&L\$,D?NO=-6(^#WQ.P.R=F]>XCH_9]%MOKVCCQ^RFC_BK[DVY0P[DQ&[XJ
M/&[WER4F]HZ6+<N H*M4.095EHH+#3%&%]U[HR&VMMX79^!Q>V=NT9Q^%PU*
MM'CZ1JFKK7B@5F<^6LR%155U7-)([,\LTLDLCL69B23[]U[H']]_%[H3L[L&
M3M/?W7&*W1OR3K7*=/OGLE7YQC_HYS.4&<K]MKC(<K%AT1LTJU<52M.*VGJ4
M62&9'52/=>ZB[7^*/Q[V5N7>>[=K=:8S"YOL/,8G.[TDH\IN(8[<&1P.W$VG
MA368*7,28%:+%X"&*""ECIDI8V@BE6,30Q2)[KW2ZZNZ=ZWZ7P7]VNL]MIMC
M!"'&TT6.CRF:RD--1X;'PXK$8^B?.9+)S4.-QF/@6*"FA9((EOI0$DGW7NH7
M;G1O57>^-VGA^V=I4^\,;L;?FVNSMJ4E3DLWC8\1OS9\T\^VMQQ-A,GC)*BJ
MQ,M3(8TF,D!UD,C V]^Z]T&]=\+/BUD=RX;=U5TQM8Y[;^.W]BL14029BCHZ
M.B[/R$.5WK&,/1Y.##3RY/(TM/+#+)3O-CVI:?[-H!3P"/W7NEOL7X[=,=9[
MDK-V;#V-1;9SE>TTE7-CLCG!0SU53BL/@ZK(MA9LI-A!EZO$X"D@FK!3BJE2
M'UR,6<M[KW0C;QVCMW?^TMS[%W?C5S&U-Y[?S&UMS8AZBLI(\KM_/X^HQ>8Q
MDM3CZBDK88:_'U4D3F*6-]+FS#W[KW1:,E\#/B+E]CXOKBOZ2VY+L_#8?KO
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M;U;E>Z]_[2Q5%7;;ZNP9R(RN[ZNIS6,QT]#1G$XS,Y#R4U#6RU)\5-,=,!N
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MP,OUI0;*ZNRO8U'O#=,>%W/78UZZ./9V*:JQ4#9JM>DQF0B6 15TKWF:&,"
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..[]U[KWOW7NO>_=>Z_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>g10811g17x63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g17x63.jpg
M_]C_X1)617AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@ +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,3HP-#HR-B Q
M.#HS-3HS-0!R<C$U,3$X,0       Z !  ,    !__\  * "  0    !   !
M4Z #  0    !    R          & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M!:X&00>""DIDL3&^KV310S';U+(%;&UL:&^W;Z>R#7[MK-U;/2=7M?1_P/\
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MXC\H4/Q#^>']P?\ 2DMS?-]'M53ZO_R9D_\ %E7%2ZRYK.E93GN#6BLRYQ
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M[Q_U?<XOPXED.#7@X?'A?__9_^T:A%!H;W1O<VAO<" S+C  .$))300$
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M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! !+     $  @$L     0 ".$))300F       .
M     #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         ".$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$         @  .$))300"
M   "   X0DE-!#        $! #A"24T$+0      !@ !     CA"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  -%    !@              R    5,    ( #$ ,  X #$ ,0 M #@ ,P
M  $                          0             !4P   ,@
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ,@     4F=H
M=&QO;F<   %3    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   #(     %)G:'1L;VYG   !4P    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$$0       0$ .$))3004       $     CA"24T$
M#      1)     $   "@    7@   >   +!    1"  8  '_V/_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 7@"@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M'?R6N]KMBD/VF00?1!VB'#<??#-PV?N;O5]V_P#<3L?O\/ZOW.&_T.+AXO\
M!1+V[]7#?]:FQM/[Q_!!S<.C,Q+<7)#K*+6EMC 2TD>&ZN+/\Q1#NIET%E+6
MP?<'.<08.WV[&?G;?SU'=U:1^CHC\Z7NDF/ZGM]RB%V.&[O2M[7FJUV<(?5C
MH%A:QW3,D-L]KB;;H$^T[OTO^O\ (73,K#&M8TD-:  /(*%!RB'?:&L:9]OI
MN+I'\K<UB,I,GO:>[Q_U?<XOPXED.#7@X?'A?__9.$))300A      !5
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-! 8
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MPAWFC]:!EY]^Z]U-_P!)1_Y]_P!F?^@LG_UQ]^Z]U[_24?\ GW_9G_H+)_\
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M+YF2BI8J9\KE#1[OIJ,Y'(M$9I_%'''Y7;2JK8#W7ND1N+=N\\WV]\=://\
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MB=G8B>JJZ7&OE*R>MK"AJ<AE<]F,AN'.Y&5(U6& Y'-Y6HG$486*$2!$ 15
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MIW]^Z]U[W[KW7O?NO=%2^;/_ &37V#_P;;7_ +U.&]P;]Y#_ *<[S9_U#_\
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M6I18U=H4+$ GB6730@<% +?#FI!Z,M\/MK1;2[TZPHX!101Y?MRNW*V-Q/\
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MVDR]3?R)_P JU9?Z>3_JXW1N?<]]##KWOW7NO>_=>ZU[?DQ_V4+W#_X>+?\
MNGQ'OD[[S?\ 3VO<'_I8?]88NL=^9_\ E8MY_P":W_/J] A[C7HBZ&CXW_\
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M_JXW1N?<]]##KWOW7NO>_=>ZU[?DQ_V4+W#_ .'BW_NGQ'OD[[S?]/:]P?\
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M^;__ &CR]1_[H?\ *D;Q_P V_P#JZG6E;[Z/=8I=>]^Z]UMJ?R%/^R.=\_\
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MGE0$>:AHU1@I -#J_%TBN8HH_!\(@U4US7(9A^50 :?GY];$WQ&_[)NZC_\
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M?NO=:RF_Z7%)O'L62MI<7'2#>6_&KIJNGHXZ9:1MQ9@5;5<TR+&E.T!;R,Y
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M8MI%EN2=(O>PO]!<^_  5H.O=7Y_$;_LF[J/_P -C_Y)9#WU.]@_^G/<@_\
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MH)!IU:2RO(55I;5U4H7X?@4@,QH< $@&M""0".MTS^3%_P!N^NI?_#B[3_\
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M-NC\;7+*VE%K!(HU,>%6( ^9'0)]Q+&]W'E'=;3;[22>[;P]*(*L:2(30?(
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85+!F8W)]U[IR]^Z]U[W[KW7O?NO=?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>g10811g19n02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g19n02.jpg
M_]C_X1##17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@ +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,3HP-#HR-B Q
M.#HS.#HQ-P!R<C$U,3$X,0       Z !  ,    !__\  * "  0    !   !
M.J #  0    !    H@         & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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MY5224_522^54DE/U4DOE5))3_]G_[1BV4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ $L     0 " 2P    !  (X0DE-!"8       X
M        /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          (X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      T4    &
M      "B   !.@    @ ,0 P #@ ,0 Q "T .0 Q     0
M           !              $Z    H@                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    H@    !29VAT;&]N9P   3H    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   *(     4F=H=&QO;F<   $Z     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    ".$))300,      ^1     0
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MY=ZI:_'_ $8Q<QUSK:_4^UX3,?&915^K97Z3U>EZ;5F4X&/5G6-NRZV!MUK
MX-<X#Z8]0O>K*22E))))*4DDJG4^IX?2L0YF:_TZ&N:PN\WG8W_I)*;:2A==
M314ZZ][:JJP7/L>0UK0-7.<]WM:U#=FXC:69'K---NM=K3N8X%IL#FO;+=KF
M-24G255O4^G.<6C*JW- +AO;H#,=_P"2C49%&0S?18VUO!+2#!@.VN_==M<D
MI(DDDDI__]#T>_J+Z>HT89I'IWG:VTV,#B_:^W;7CD^I9MKJ>]__ ']975&=
M99TO+^W656-/4:78Y:#IB&_']*OVMK_66?R_51,1K*_K-D?:V.?E6#]5N;5
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MG_7[;[O^V\JI97UB^KF3F],-=6#=EY!LK,VWLW[=WZ39=E6YSJV[?S:[:_\
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M &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$!@      !P (
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M P,# P,# P/_P  1" "B 3H# 1$  A$! Q$!_]T !  H_\0!H@    8" P$
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M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5!/\ /"WG\F:7=O\
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MZ Q??XV;<^^,Y34V3HY@LT,AA=%F12RLMU/@2""#0]:(!%",=,OP+_EZ]3?
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M)S'+N#"1R+I+))E:!'74H=;JTX8:D8$?U!O[]U[KA_>K;'_/1X'_ ,_&/_\
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MM-O8OM.NIMGU.#Q=+1[DCDJ-FQ9FKI#E=RT#P8I9ZR.5![KW1[O^&I/Y9_\
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MEAL;Y!XSN5=F;)(^,'^FKK1]B4^X,OOZ3X:=Y[T^1'1#;+WS-N"@_P!'@G[
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HO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>g10811g20j63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g20j63.jpg
M_]C_X0P'17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@ +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,3HP-#HR-B Q
M.#HS.3HQ. !R<C$U,3$X,0       Z !  ,    !__\  * "  0    !   "
M0* #  0    !    K@         & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M,3@X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0
M  !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R
M:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ $L     0 " 2P    !  (X0DE-!"8       X
M            /X   #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          (X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      T4    &
M          "N   "0     @ ,0 P #@ ,0 Q "T .0 R     0
M               !              )     K@                     !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG    K@    !29VAT;&]N9P   D
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   *X     4F=H=&QO;F<   )      W5R;%1%6%0    !
M        ;G5L;%1%6%0    !        37-G951%6%0    !       &86QT
M5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q4
M97AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!
M;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R
M=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC
M94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *
M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    ".$))300,      K5
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
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MDD[H<YS6_3=]!6DQ2DDDDE*22224_P#_V0 X0DE-!"$      %4    ! 0
M  \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$!@
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M P,# P,# P,# P,# P/_P  1" "N D # 1$  A$! Q$!_]T ! !(_\0!H@
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M_&8RDIZ#'T%) @2&EHZ.ECBIJ:GA065$554< >\BXXXXHTBBC"Q**    #R
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MBI*9'F=8H(5DE9?+45,S!(HDU22R,%12Q +]O;3W<J06T3/,W  5/_%#B2<
M9/17O.][1R[MUQNV^;C#:[=%35)(P502:*HK\3,2%1%JSL0J@L0.@([8[+Q^
M<ZFW3E>N>Q*3"U&)R&"@W-E,:V/AW?A-O-EJ*IW328/%[D%.N.WKDMI15@Q
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MDEK9R^,A<C6KQT6:% B* @CD$RG :- $J$/2[[L/N'+ND'L_SMSWM>WVN_\
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M ONO=.6W/Y;_ ,.-M4M3!!U579ROR%+VG19O<^].R.T]];VW-3]S]<[=ZA[
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M;/<;=U[NWSLMMF=H;KV#@Z/86>WGV@^3VM09"&OCI-S5W5?4&+V?'E,7L!8
M]#D-Q9^NI\M49/(R4U&85@HD^V0W/[O%G9^-"T$<P9E2/N8 $J))"^6!8,$0
M%:*"U:M4BS9FYMEYCYA_=FY1;I>;<T,$]Q=CP8G<H)7M+..V!6!DB>*2XN7$
MS232)%H"14C)1L/';-RWR2[BA[>R'4CU^Z=\8_N#>7;.<[(I,7+N#JW84#[6
MBV%UGUQ2P?Q2GZ_VGV&TU#)GLODT_B%+#+6^$+)!'"-9KK>;:QVJ+:8[D$V7
MAB!4J$<F@FD?2 6DC(.D@Z20JF@-<7=OV#VSWSFOGZ^]Q+S9B8^9_K)-TFN
MK7%LBJ3MMG")F*6]M=JR>,C*\L2M+,@=E"K+ _(CK?X>=49;NVCZ??LO;.>[
M,E@J>V]G8##[9W)N/JO=LV2W3E\GL^OR4<=#V)A.LLZ(L=%CJ*IQ29FFA;)T
ME.SK.96MPY9W'F#=FM6O56\CMZO'K\30ZE5!9 Q:(2*=9 \3PR=!I55!GR?[
MX<F>T/M[#OT7+$TO+-WO#1V]W].ME]3#*LT\JPW#Q1Q7SVDJ?2QR.+,7JJ;A
M:B.:9K<MB[VVUV3LW;&_]FY2'-;4WC@\=N+;V4A26)*W$Y6ECJZ.9H9TCJ*>
M4Q2 212*LD3@HP# CW&M]97.W7ES8W<>FYB<JPXY'H1@@\01@C(ZS:Y5YGV7
MG3ES9>:^7;OQ]CW"W2:%Z%24<5 96HRNIJKHP#*P*L 01TJ_:7H_Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM4?\
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M?D<;N"GH7VQ2Y+>&!PE=78C%U=;3Y7*4=#4S4M-+'3S,GNO=%<HO^W]^Y?\
MQD)LC_X,WL'W[KW5O?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z*C\U,MU33= 9S:O=&V=R;UV)VUN[K/I.MV;M&NFQN
M?W/D.W>Q-L[#Q6,I*ZGR>'GIZ1*W-+45QCJ$D:@@G50[$1N%^<I=J78;BUWF
MVDFL;J6&W,<9(=S/*D2@$%:"K5;([0W$X,[_ ';;#GV?W8VO?O;7>[+;.:N7
M[#<MZ2\NT$D%M'M.WW-]+(R-%,K.4A,<&J,J)WB+% "ZJ/Y:=D?Z%/BO\A>T
M*&9,?6=>]*]C;BP31?LA,[BMH91]MTU.(P/')/FEIH8@HX9A;VHYKW+]R\K\
MP;FC:7M[*9T_TRQMH ^UJ =$WL#R4/<OWU]H>1;F,RVV\<S;=;SU[JP2W<0N
M6:O$+#XCM7R!KU/^*W6C=-?&?X_]42TZ4M7UYTWUOM')Q(NC5F<'M'$T.:J'
M'%YJO+132R'\R.3[OROMO[GY;V':M&EK>SAC8?TEC4,?M+5)^9Z3>^G.H]Q_
M>KW:Y^CG,EOO',FXW<1/E#/=RO"H_HI$41?Z('0^>SWJ*NBI_+3<N^*3:W7'
M6NS_ (_4_P A\1\@NW]I]%]N8+/01S]>[(Z$WGC\]4=V=@]EQ30U%/6[9H.O
M,178VFH)$:/*9K*4-')^U.Y$B^VUAM,NX[_O^Z<['8[G9-KFW"RDC)%S/N,#
M1BPMK4@@K*UR\<K2 UB@AFE'<@Z1WCN$BBCMO%$CA&!^$(:ZBWRTXIYD@=&<
MQ.*QF!Q>.PF$QU#B,-AZ"CQ>(Q.,I(*#&8O%X^GCI*#&XZAI8XJ6BH*&DA2*
M&&-5CCC4*H  'L 7%S<7EQ<7EW.\MW*[.[NQ9W=B2S,Q)+,Q)+,22222:]*P
MH4!5%%'ETX>V>M]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1/?DQ\C>R_C=62=A9
M#IG";G^*VQNL>P.Q^]>X*7L^:B[(V(=F8#-9O&[>V)T=3[ S-1VKE=TSXZGH
MJ=4SV(*U-:HLP0ZY/Y!Y&V#GJ$;+#S5-;^XMYN%M:[?9&T#6MQX\B1O+<7YN
M4%HD09G;_%IZK&?-A1%=7,ML?$, -HJ$LVKN% 30+0ZJ_:,GJH?^4S_,M^0?
MR0C^3'7&ZLCL'Y(]UP]>4'S"Z=QF#R^[>LMM;6I.XJVK.9^$&Z]T[BZQJ*+!
MYGXQ;S%)B)-P6RLE;B\U22?:N]-4>\EOO(>PG)7(DG(6][?#>[%RF;YMEO7D
MCANI939 "/?H88KL&1-UMP\PMJPA)H)1XBB1.B;:-TN;GZF-BLL^GQ%H2H&K
MC$25P4-!7.",8/6PSE,)0[PVKDMM[OQ%)5XS=& J\)N? R3-5T-509O'24.;
MP\E0BTSU-)/3U,L#.%C+H;@*3Q@[($6218G+1!CI)%"17!(J:5&:5-/7H3=4
M-_#^/XS?R^\?\T>^]V=/;XV5MZ@_F#]G?'BEW[MW8_8F[XNM>D,I'UK-M/)9
M>GJ)\G78#X^X#<T:B7*8^GFQ>.FJ1)9(?/(E.O=$CZKQ716&ZLVU2?S-Z#Y+
MT.+KOB#U1F/A51TD?R/CW:N4W%G.R<WVG4=)IL5CG,=\U,AOS+;>J$2L,6[8
M,3-MR.B6*FCK$3W7NCA[8WG\JLW_ #3/@_6=I=.?+#9G5-)LKY)=9]64V[LQ
ML?/[);K7$=#=5[AC[L^0=?LW>.2G/R![#WRT]!44N3IJ>+!P4D=-1PSU55D:
ME?=>Z6?R@ZXVU\B]A_SH\GVSBLKOG?\ T3M#.;:Z,V(F0SM77=8X#:GPJQ?9
M_6>]^N\9MFIILG1[KWYV3V/N"N6KI%:NGJJ*"F5F>AB5/=>Z##M/?'R?^&NT
M=W[>^$&SZ7 ]<=.?R]>HOD1!TEC>ELQNV/?O>7=_;FZ]@]F[_P!P;XKILMNN
M5^F-A[=_O;/MG%Q/DLI40%JHO%(*>?W7N@![<_F9_-[97Q[&8VCVB.P-^T=%
M\G-[=(;\V#TS@-R;/^2V(Z<P>Q:_;.P]Y[MR_7FUMNY_?(WEF<KBY=L=9[:I
M\MN3"4ZUU%E<?-05VOW7NN79'S"^:?0V4[GQ.SN\,SC,1O7YB_*/>6X.Q^X>
MOJNKPO22#H;H'LKXP?'':\N1Z_WU3576/<=)O7,Y/%20T4V4R5+M^7&XRLIL
MK+*K>Z]T,V-[W^0'R)^<GQRZH^16[Z_;%12=^]J[6WQ\,]J])]BX';&*Z:K_
M ("=QPX_Y"5'R*--B,Q5[0W_ +EW/4-14N7FIH8:RLI,=%3TVX,%43-[KW5M
MO\M7L'L#M+X*_&K>_9U57Y/=^5Z_%)/G\JM1_%-W8';^<S&W-F;ZR,U46FK:
M_?FR\1C\S-4WTU4E<9E]+CW[KW1X_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U_]??
MX]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U%K:
MZBQE'4Y#)5E+CZ"CADJ:RNK:B*DHZ2GB4O+/4U,[QPP0QH"69F"@?4^[QQR3
M2)%%&SRL:  $DGT &2>DUY>V>W6MQ?[A=Q06,*%GDD941%&2SNQ"JH&220!Y
M]:QGSA^=';V$[ [WZ1^/VQX,AUGAJR'?'9?8VX&W+B9L;0[WR6#?.9:'%"JP
M.+S&+R%'%#2[<DGG:/*?=-X89S:19SV+E^&.UV>]NC$=U,8B5"5;*ZNVFDE6
M05,E"""*$C2P/*7W7]W]RO-_]Q>6=@6^7V_6\:_EN5CF@.F8P5G#/)%'<0SL
MJI9JZO')$^M4<R1NJ\Z<[>V'VY!L?JKXX_'/)UK]][^Z\P';%)V'79M'V'\;
M.O*G;KU>)J-X+1*^Y5WW@<9DLC6)32-C%QM:E"R32RQDTWWES=&VG==XWG>/
M$VZRK1TT_J74I(IHK13%6-%7-*:ZK4KTN]JO>;D*/G_V^]N?;3VV-ISES/X0
MEMKGQ"UAL.WHI5TN"@,T=_IN[B:8T5Z^ T<M(I.G;>.WMI[JWKW]\3NP>YL!
ML3IOL?<.9ROQLPNY]M9C&8KL'JS%U5#NCL+8WQB["S&7@ZQQ6\*?>XDVW6O2
M-79>APY@K:"E@6;64T5_<>'L\DNVR-OVF-9E@*JRANV-[I47Q79H_P!18P45
M6_M*D8.]PY4V?ZWW&L++G6UB]HS+>3;?+NRR2QRO'2>\MN7YKB7]WVUO%>TL
MYKQXKJ>6,#Z/PD)+G,Z/_F??!+*=O5?PB^,TV]>S<QT#A,-MW?\ -TIUWNCL
M#I[HW$XFBJ:&HH]]=MX^.?:M.^V9\:*2NT5=96-6N5TRRI4^&-9K*]W6\O+B
MYOHCN+S,-,A*/(U>"]OAJ:T&@LI%5% *=9M;;S1RM[?\L<M;7LO*]\.3+7;H
MF$UHBW-O:0!00TI\7ZN9-&J1KF."9) LC&0RAEZM7I*NEKZ6GK:*H@K**L@A
MJJ2KI9HZBEJJ6HC6:GJ::HA9XIZ>>)PR.I*LI!!M[(I(Y(I'BE0K*I(((H01
M@@@Y!!P0>'4L6EW:;A:6M_874<]C/&LD<D;!TD1P&1T=259&4AE920P(()!Z
MD>Z=*.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>ZHM_F<YWYD=X]T?'KHO^7)\H^D-M=I=%_([X\=F?*/I>J>MK^V-J]6Y;,U
M552=E]B8?$=V]:Y+<WQSBQ-;$,]M2*AEJ]Q^:!8*ZG*%']U[J[G;L.>I]OX.
MGW378S*;G@P^,AW'D\+CZC$8?(YZ.B@3+U^)Q-7D,M58O&5>0$DE/32U53)!
M$RHTLC*7/NO=5-_S@/AUWI\J-@?&?=_QW&X,UV%\7OD;3=T2=>;0[ZR7Q@WO
MV)MC*]6]D=4[@PW7W?F.V]N?_1GOG'0]@I6TM=+2I'+1P5=,M132SQRCW7NJ
MM.J/Y3'\R.C[S^/DW?NY.DNTJ#/_ "-_EZ_.KY/?*+'[@3![KVYVM\&>ELMU
M3D>A=L=6T&T\:F]3V!]M@UI=X038:C-+_&:BLQR557'%)[KW1WOCUU)NOIS^
M>GV]A]W=]]N?(:JW?_+&VYO?$9[N5>NQE^O,-D?F-OZ&+K;9O^C7877F..R,
M=(OEA_B5/D,H'L'K70!%]U[J^KW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO= 1W+5=RIN+HG'=3[?V_E<%D^X\?\ Z:\Q
MN&.BJ$VOU)C-F[SRU;7X6FJ,KCJD[ER.\J/#45)-3QU;TXJ)':'0&DC)-W?>
M!/L<>U6\;P->#ZAGH=$ CD8E06!UF01JI&HBI-*5(D[V[@]MVVGW3O.?]WO(
M-U@Y<D_<L-N74W6[27EG$D<SK%(OTT=F]Y-*DC1"3PU42:B$<N/\RHT^X.@-
MG]-S<O\ (OY)_&GI&WJ;_<5G^X=K;FW@3&GJEB78>T<J90/I$&/X]ASW&TW&
MP6FSGCN.XV=M_M6N$>3\O"C>ORKU,_W+_%VCW9YB]QH^')O)?,>]?\W8-HNK
M:TR< _77=KI/FVD>?5@OL?=8E=>]^Z]T4';&*S&^_F;OGM+;OR4AW'U=U#T[
M!\=]Q?&?:U>M3B-I=^;CW-@^VMR]@]E-2Y":E?>\/6$^V*+"T4T$=3C,=D:Z
M4L5R( DW<+JTV?VKV?ER^Y ,',6Z;H=SBW692))MNBBDLXK:UU*"+<W8NY)Y
M%8K-+%"O&#I$H:2^>5;JL*)H,8X!R0Q9OGIT@#R!/KT;[W&72WKWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I&
MT?7VR\=OO.]G4&W,=1;]W1MS ;2W)N>EC>#(Y[;NU:[-9';6-RYB=8,@F!J]
MQU[4DDJ-+ M7*B,$<K[]U[I9>_=>Z][]U[KWOW7NF+=.V<'O3;.X=G;GH$RN
MVMUX3*[;W#BI9)X8<G@\Y0SXS+8Z:6FE@J8X:Z@J9(F,;HX5CI8'GW[KW4C!
M8/#;8PF'VUMS%T&#V]M[%8_!X+"8JDAH,7A\-B:2&@Q>*QM#3)'3T>/Q]#3I
M##%&JI'&@50 ![]U[IU]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_T-_CW[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1$X>X>J^Z/EEW
M3T=D=X0YV;XF[$ZXW?NOJ=*&04<NZ.Q*3-;CI-S;A%4D<>YO[M[;H<?]A2IY
M*&EJ<D9I==2(/MA):I?V&T+?60"M<3&(R ]ZBE50'\ DH]64ZF"%31:AH4W^
MYY3YK]Q)^5N9W>>VV7;EW!+-UK:SR!Z2SRID7#V0>W*12 QQO<I*%>4(T-"F
M=RF3_FL_*+LS>NT-C;CVK\2.LI<-6]R;AV#D$J=Q;SK,/@\CB-N[K45])14V
MXM]?P:E@B;&TQ9\/MNDDGIC)7U%.*J2;>X3D39XMNBG23?[E^S70+'6@;S.D
M9(!)&ICJ:@';A-N^TWGWK/<;<N;]PVJYL/:78K:EQ]/5[B\9!(\?:RKXS80O
M&JDQ0(\<599?U@MVKV%VIWCWY-!UU14^S^G,3N_#5E/G:')[ECKZ3K?94*-C
M,/M_/3S4,ZU6\WIE7[6J'WN2PU&JF..&-U]S(VU;?.>6N7[B 3;=!(2B.:>,
MVFLMS(BT&IW9F+D$IK!!!(/7->/GSG+;(_>SW=VK<FVWFW=+6-+F>W74-NC\
M<1V&RV=S.'E^GM[6.*$6BM&MS]*ZNKJDB ].([?Z"WCCQ\-?DMTU5T./V?V7
MB\7CM^4.WJ^HS_7FSY<335/6.^J.KRDE4O5M9#D\I*(\G0.(6P%*S/1^.>0
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MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*YO3";:W5\M.CI/\
M3+4X3=W575W<>\FZ(Q]34Q_W^P&^ZW8NQZ;L/<$$&4IX)\5L*OHIZ.D2>EJ5
M:KRY=&B:*[!J\AMKGFK9&_?!2[M;:XD^E!/ZJ2F*(2N*CMB(*K4'N>H(IF;>
M6]QWG8_83W1C/MLMUR]OV^;/:#?9%4_07%BE]>MM]NS1,RRWT;I+*4EC(BM
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MD=I'J+,!\4M%I0.7!6//>&KY=8=<Z/NG-G(?M9]S'V*VRZWGF1.=[J[YANO
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M(4$@5-* ]![F'F;;.6(8;G=1,MJ^K]18V:-"JU ED T1>(:)$9617D*H&U,
M=??9W?FY=S]H]TYGICK5XOG7\S<[C*O?>;Q^6AS>=Z%^/.U]N83&=6]09;=$
M)EVYL;=^S,#*:G>DM,YH-OYVIJD:6JR:P+#-6R[%LECM]IO/,=4Y;M5K'"PI
M+>7%7HSH<E<GP8ZD:6))T%M?,/W.]U?<WFKF_F/VX]F'BN?>S?G,5YN4,H>P
MY:V;PK<O!;W2T N.U/WC>JL;>/%''&@GCM_I3:;2DVE\&,E7+UKL/._)/N+
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MCLJDP$_7&TNS.R]J[.S&3V[MW)96ES&8H<9-+34[AZ?S>Z]T5JB_[?W[E_\
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MBL7797'463SLM53X3'55;34]?F9Z&CER%=#BJ2:5*C(S4>/@>>585=HX49V
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M0,@$@$X)'2+]W+Y7=Q7_ )J-U7-\%/Y(WSQZJW1W?5?+3^9G\@ZG;O:^Y?\
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@>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>g10811g22m32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g22m32.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!F )N P$1  (1 0,1 ?_$ /X  0 !!0$! 0$
M       ' P4&" D$"@(! 0$   <! 0               @,$!08'" D!$
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MDMF353J9;LJD\-S:=C58ML#6)X)O&)HX_(!/SL"(#<74A0)A1!/9@$TT>O\
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M\! 77WV!O_<ZIG_=*XOYKI1S5'3G]F]Y^E@^>8MU?RY?:Q8_H;G]GD7)&?\
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MR6T#22 8V=#W2-);ONXM.+[6.6*,O;/;.873B(Q%CFS$2,>)HB)&%T8:ZKG
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MU[T;HN0O)MGSXQW?W&3WD2X/CF.5NPE[PN*;[41H"ECFKR,XT)!)1(1CS@
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MDFL)@ ]A9$ X APQ:P': <"-BNFC=$G1UN]J<6LZ-ID4&IP$F.0/F):2TM)
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MJN(5Y?QUW!_*E8'[['?G?^Z'U3TO^'6WS+%Y;[]_7C6?XK=_M$B\;/45G/\
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M@L/)2,,13&$H2#&X"\I.HF7#)FOF,?/5.3+0O(J22ZF) &'W!LPJI=I) ]D
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MK4C::4VT4-K9Z:UL=S*[*' D![F$'C.;2F4'8*YME113^X;O^Z SSEI@CYK
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M>X'?]L:HM;TWS^$6).,V(===-0V*7#K#&7&E* VWT9DBFQH/%KNL!+8J'U)
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M-7".UXSP/:4$>6JFZS[=J*N(Q-+'L?5RKD]23*PK IYR836Z2-: ;=("S$9
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MQ=[QW>5M66+#^<D[']EO9>> ; ,3P R=[M[K+=6RSOI)J,@/-15V_P!IW"&
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M3.+68QYS&8BXMVG(XN+<?[3@=K7%I!.;;E[Q.WNW5L-YG0"V-[;MEYL2MF#
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M*X07/-;+BKTJL#:*/6FJ1JQ]]HK-A:%<C4H0&-Z?E,/,WR4>Z,"OQR6< =B
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MCC<W/I#%89KH?*FL<YG:E(I.?#W%4]G-1:J2G>F#7@]V/$J$U]%E1D0?$[V
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MA40QT^%@'X" >[M&"B?>Z@QV4SRUPV2$C$5VAQ'W>P<#BM;;,]PG7"G9C:L
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M<"EC%)&F(5_(J<1N\8KM9%ZUEU.ZGN[:W&6D4C<%6L=<3UW1$]TI(-\5*@+
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MY2*]G"M0!C53?,]-<\Y9#D!(QD8#0.IF!R[* G* 7.P(VKPVOO7[GM7PQQF
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M9;39-"2*TDAB#7RI49D@KA*WMC2E@#V-/$2Q.L)3-;(B3%M1_B( )TA)>"L
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M&9(JZ-V7J5 "3HP^-Y8NA[5:Q1&AIR^K;5"X_OA02%<JSY8J)"B/[I8N\I-
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M>$#VYC,* *'2,H)A[04,T:J(Y+)+<DPCUJHW!<I,-R1'C0X)68 $9HS18RE
MI+[3,$7]4*U"Z.GJE38N9CS23>^VN1C::M3=P\18?&,:'!U;A>, &# ^&H,[
M "QWNZ+O!P11SPB<(G")PB<(G"*L5_:*/S$/^<$<(OE)O+^.NX/Y4K _?8[\
M]1-T/JGI?\.MOF6+QCW[^O&L_P 5N_VB13FT5]1@Z'R[.K/:(+;=*[?)6W*0
M,\AS&D@XY,I @+?4IJ:/J&IRC$A0A2(!'B/"2A.0+A&G%F9("/$+G6M[QOCY
MM;2Z<=VH[Z.%PSQ\Z[G8(W<V09 ]LL;L\@:&YI&R0AK7-SD9Y9[N[ANW!\\N
MX=5&]\NFRW#'<W-S+3#<RL$K2V$QO@F;S<1<7!L3HIR][7<V#F/MI?TNX%_J
M2=?O/>.6OI\^S.\_36_SS%>?Y8OMAT_]!=?L\BV)VYVVV=K'<@^GJ<KN/SBM
MXKK8_;*V. J#L,BFRPEBG,Q95,80R:7[6:^L4)1R-''242%Q(9)FH2.:H)JE
M!E'@P9?&#+B=@CCC:"P0-<<*G9LJ7MI6FVCL>"B]!W6MM(999G%LAN7,&) V
M[:!CB:5Q%6X<-5HI1OOF8;:_2O&T=2V8[SY74T=NMXC=&4S7D8C\%KM52M?7
MJ^2T^02S=BR3)M%3H)9[8O;C? 8'[)19B=2RE+Q@2!ABU6C*SM<7Y<U&M H,
MH=7%YJ*$=@_!53)M%K)2V>T,S%M7.)).8M H(Q0U!!VCX:8K:L7O*TDLD#XS
M1C6S=*7-26[5FOT+L%OI^'QNJ[=L=M5SI ZMM9V38MI0F(N 6I?7ZTE04YJF
MI:6(0!93]P"D1$_UE%4AK)2,V4&@ )QV$D#@X:*E]43!H+I(0<F8C,2YHPV@
M-)X1LJ%$AWOQ4LWQF<6.NUGV6>:O9U]7%P5YK]/4LOG,U9K!UT6[*/T@<ZQ5
MV=&WR+-E:P1I6*7HX@YV2I&\K"T\\@O"DM++];1!I>6/,8I2E"35N;944H-N
MW#%3?4DQ<V,21B0YJUS "C\@%:$&IV;,</NVN"^]7$Y(\SIB>&-V*4UWLY,8
M,\K8I5Z)X;5=/>%?;O5S$:"5;!01_:K3E,4I!:N6OZ)O?8VD.)Z0:(L]5C"/
MXS4VDD$8B0C ?)XU-KAB0W;B."G8^OT=S6M<"*.C!Q=\KBYC@TC*"ZE*@\-<
M,=AI![K%<NFH&S>QL,A4JKF446TP-M:(CL85#HLWN,ROB!5_,]>75\<858TI
M94L!F:6V6!4M$-V1.3>C,485E(S2L]D\W[#;/F:"US ,'4&+@"W83@:CAJ%(
M;I<@NX[=Y#FO)Q94X-)#Z5 -1E/!0\%5H>=[S]_RA@KE!4D+I.Q9E,$M!UV^
MO<+;0RZ)L5S3[<:T-9)I)61"\;&5JRRRM7QI@"%=$6\,K2&&J9$@/7/06OJ5
M::C]9S. $8:YQRC#$9B\M)^,*C##'A%315WJ>!KG&4O:P9B <"6B-KP#Q#0X
MD..7@-&UP6\<5]S5%M+K9M?:FI[#(ZOF^K\1-GAY>TE/^?1:>1C$-DT[C[O#
MF^LKWCXWV)6&SQ8\+6_$O822P# J"D5DB $RK;?">"22W!:Z,5XPP(H3A1VP
MTP-51.TTVUQ%%=$.9*:<1U"#4 UJTT(KB*?!4+7RT?<2W5K&N;4<TC9JY.)E
M /;8J+>\+FH@5L5]&2%]@6/:B!_BPHV7<%D.L@1LD&A")(C(\W:1K'8TY:8L
M(3]QO#)?>7+&./YLN$ DV$#$G"E3P#LC'&O I\5A9R2-!,K6.N'1;6DX!M#7
M**8GL'#"G"LH4>XOL*]WS8< 1O>N%3UHT2/9J'-\LG%96/8<AK<&IE7:_7!.
MK1L!K9;TK9),87-H[9[JC2-R/,?/8AX;5AB]T"8:C'$;R8RE@+&L!<*D$D9
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M).0JCT_?@<RW:XN+6Y_C;*N-#MH!4T-/OT4QDET]H8U[^;^+BXAHS BE20T
M@';0$5X%F<(ULUTK-GG,=KB@J5K^/V<4<193'"*L@T49["(4I7!"H)G+8PL2
M!%+"CT3LJ)&%>!1@12DT&>T)@\9C;!"P%K&- =MH *_=[*@?<7$A:Z21[G-V
M$N)I]RIP^\M>[&@?MX,L]^#-D49KNJF]V%5>0X1)SUUCDF!8!+")XB50$RM0
MF@#JRN)452QA>F9 NAW8TH&\\1/@)B#!!DO99A_-O8S.ZF&4&O *X<%,*[%/
MC??EG/1ODR,KCG(I7%U,>&HK3:3V59;=C?MY:N #\0-9:[BK5:D79:?>WR"Z
M12:?Q!VA*ETBT'C%967+:FI26Q6/Q%>Z*FAM;&>1JTB%1D!):<H02>P'R1MG
M!\=C0'"F#"13  $AI%-@ *BB=?W/^'(XEI+J&0 UQ)(#G D[22,5LS:M 02W
M':DGM^&\,[E0%FI;1@)\9.;$  N1<*EU>.<:=TZYI<TZR&R*'39>B7(RP$&#
M (L19I0RPBQ.DA9(6DU!8ZHI]PBGW""J:*=\0>UM")&Y37[H-?N@@+#"]']+
M"8Y((>3J#JZ5$I:]L\EE46+H"J 1R32./%O!+!() R!B6&QY>V,J0N 4:M24
M8>F"N48+$'!QG>A\UMJ%O-QY2:D91B?AP^%1^>WF8/YV7.!0',ZH!V@&NPT'
M:61*=3M6%C,JCJO6G7]5'US=(&A:Q*::KH]F6-,L?&&3RIK5-AL<$B4-TFDL
M5:W%P(&#)2U<VI3S@C-3E#!%YO!3+D9E_NCAQ/!PD _>4(NKD',)),V&.8\
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M#7ICT>?&2GP^K6U!/-U  P938X&OQC0D8$X]E1^MGT<!SU"2<9*[6EM#Q14
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MV1PRM$CP!4 -XO" &@"IPJ=I&'"5M5R>J9.$3A$X1.$3A$X1.$4T5I^E2_\
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M3)<'Y3NSB?\ *D4@M;^.E&XYP^K7-)#BUP=\:@J21V1\)5<;W3)<P<_BY#&
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M#8JI94;4R!@N%J)E(6P]*H\/"O*@*@0S"S@"R#("+&M=_;&K/6^\(;=T=O\
MVPGF*WIH5&UG4%H6C&I#1E;0]2TP=I=UD#KYHKV.@B\BD(*^;SW!2E5%EJU&
M!"&5W<% +(ND_"+F7/?]NII_O9(_UX6<W_HW[GM/U:+\AJY?W@_?U[^MS?..
M6)\N2M*<(G")PB<(G")PB<(G")PB<(G")PB<(O[C&19P$.,B$+.,!#C&<YSG
M.>S&,8Q]7.<YY\) %3L0 DT&U;DTY3N&;"662I-C+QG #VEJ.#VX:L9[!%K%
M@,_V7//]D ,__A_[.?E/RO5F].]'G>;3=.=_PNQ[Q\OLM;_8[)^5_=^-NG<S
M<SS+)J^K-_XS;'&?_E]ASAW_ &!\C;\;XNRW,"6S4X1.$3A$X1.$3A$X1.$3
MA$X1.$5K>OTJ6_F.?_,'A%!,FB$3FK<!GF47CLM:2U12T#7)F5M?FX"TD!I1
M*L")U3*TP5119XPA,P'OA",6,9[,YY<--U;5-&N#=Z1<W%K=%I:7PR/B?E)!
M+<S"TT) )%:$@=A6O5]#T77[46.O6=K>V0>'B.XBCF8' $!V21KFY@"0#2H!
M(KB5CXJDJD8_$'65>B'AA#%<#%"XV(>(N G"8$;[V6W.?(0)PX+PC_\ P^ 8
M[O<[/J<KQO5O0!E&I7X;S_/_ .HF_P :M>>^/_BUQYSX]<:U5L.Y.YCG9CI&
MF%WFWF]?-8*^;@91!_A_X(;AS7Q*89:+S)Z8I])AJPCJJN$?D2HY>Q"1PB-)
M!LB]0,@T]>S#3MA8VM<<:E*&(XC)9F1E SWNT(<XF2;X;VRF4RZIJ+^?:&R9
MKF9W.-%0&R O.=H#G -=44)%*$J5%N%N- (1!HVE1^;/+X<MI TQ/<02^(MC
M!C>2UI+F975:TUJ OW\'JL,BC'"%\ BK[%8V(PQD9I0SI)8G0J3A'C4+PF28
MMV4GN:LQ4:,]4:,:D\9HQ&#$(0LY^>]N\S=4GUJ"_NH-4N*"22&1T!<!2C:0
ME@#&AK0U@ 8T !K0 %]]QMSG:-;[O7.F6=SHUI4Q17$3;EK'&I<^LXD<9'%S
MB^1Q+WESBYQ))/H45-5:P;B8KK2OU1CNV(61V,40V.'C=&9KPB"V-#B(UM$)
M:V-V&U-@A.9WBB<)R^X''<#V2X]Z=YXA&V+4K]K8I'2, N)1DD?FSO91_%>_
M._,X4<[,ZI.8UFR[E;FSNE=-I.F/=/"R*0NM8"9(H\G-QOJSCQLYMF1CJM;D
M9E RBEU;H)!VAI:V%IAL4:V-C<BWIE96Z/-")I9W@I0:K*=FMN3(RD;>Y%JS
MQFA/*  W!@Q"P+MSG/*6XUO6KNZEOKJ\NI;V:,QR2/ED<^2,@-+'O+BYS"T
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M>&/?@-IW425V2GL_FT? N?49%*+:_"6-K<L<6.01]>L;8^N6L+D@*7N3&ID
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M$$J..4"4)RR1G/L>74FRT:7&,O-22R@%12@I7*6\ H:_AEAVD.AJ\-$@C;0
M25)(.:IK3,'<)JTM[/R;Q$:0]P>>4CMC/;F9;'%L)9M:ZZ5='HB\R[6J'R=7
M"HA(G2;[)PNFY'0SV3%J]CLW'8DC88<IDLF5R'!*-M5N[J09VY3?6Q7CXI'R
M!W/.:T 5:#0&K@,N !J0*FNRI4+YK!DT3(2WF&N>XFCR*D487!V)(H"Z@IM
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M[\AQST/?M[83S>X[Q_)/<5[CT0D$G=DK.UMYXE*D7UQAQ1I*9*2'./%5*CA
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M^-Z%E7B=#U?2=9".HZCS+H?+.]ZQZ7KNE^W>]XG3=-];XO4?(<(JXWMS 8:
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MOZ,1F9%)51NZ;!UB%0F;4B038NP6N4AP0,TBQ=?_ %C%:R6*77#WIVPE.C9
M]DW29C;=JFTU>RV/KI]*W"N)QJ+/]'1F73^O)3G5M1^S5O0^7,XWM.F7)BW
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M3C,3JDBI.8$PLPL0@# + @YSC.,\(O7PB<(G")PB<(G")PB<(G")PBY;[/\
MNST1J9:=@5E9%67^[I:Q98JX2^R(4Q56ZP1$]SVK+CMV"0M.D=K>8;&72*61
MBB)"42>5'Q,J-804%<O2%'!.X1;%1#?[2B902M[$0[5ZZML>MAV(BL)R]7E4
MR-2[S_+?'G!RK!)DF9*D*^RXZ&5MQ3BRI#U*U(<L)",'RI61D5^?=WM+HNSI
M)#)=O-7XZP+T,?=$+X^W]5#2SK&R6$2Y5%G%(YKY8G1*$,E30!^,;S@#R6L
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M#8R:I'%V6.[.K4FM:0MP6A5D6,3+VTO<BLE;-8O,[LC3A3:W6Z&05G87O?\
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M"S;#[>67/;.M)MBM4,I=@2^M;=4"UYBJEN7PAS, ZQ%HCSPZC=5"IV$M5K%
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MV&&%%A2R/ C3VA.#(X=+BB\&/B82M$(TTQC 42024#.%AH\A*;S>PM4(DS.
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M'<3XXVW^WQ]_PQ/V'CW^WQ]H7';'<3UWJWCW_@[B?'&V_P!OC[_AB?L/'O\
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M:'[]*5O]P7_CB^$47<(G")PB<(G")PB]J7\H<O\ (B_UQ0<(OFDN((AW!:8
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M\+E$6@MI,4I.+DB>22ANVHVP(DUDH9=,7FP)(U7/(,7=EXO%E=9E(W%P,0S
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M?IZV)W9\K68 )0Q!O-5HD\W;3!KG%;%#RPMQA%8_5V[?D/4?1[U7]4>A^O\
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M"*^+I/MN6O<RVVD=<U;64^6\G9UB[:6S&]>OC3+&DRJA79S;2-/7-.TOEE3
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MBF31MCD"B'S%,W(Y=%#WEL2N)T:E2-G='MI2R1B,4Y2KBTJU8G+5%#"6>:#
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M![G#JE+1I1#QA2ZJ2@EA$H,!C)%5< UXEF+-#U<+,/?I2W3:3)7%-5L@=(J
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MYABW80+[HV\+-1?YO<!L=S\FFQP[ KPCL</ MDQ1B-#Z'OQYC%Y7Y3Y9WFE
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M5SO7PQD%7US'FZAI14;=.2(B58C_  :YJF;[*;95*<P&T+1B1:9_2.9*IL3
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M\T=R?QO6K_*1.?WSNG/(+??ZYZO_ !2Z^?D7*FL_O>Z_69?RW*-^8PK:MO\
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M7+0$G@<FK+6%EEU44I-->-U_5=LST5,UU-5.7[=;86U[ BA#B3;$D>(@.'2
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MJ@%4XKUV&_P&9J:;KH^5P=],.1J1O4/D1L<$[QIV&H;DYF5*(X@[(R"Q=[M
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M"C3 L1HBB')'G)BPS !B0FXP66!6'/B8(J"Q1)0*!A0-+&I2XZ[PSEDA7H5
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M6-,JST/B$HY"O7)P^(Y*"G+N*3HPWF#Z1G"4>1VE!ZA2,9 O! #"@PB+%$E
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M#X1.$3A$X1.$3A%[4OY0Y?Y$7^N*#A%\T=R?QO6K_*1.?WSNG/(+??ZYZO\
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M@&NA]4V3*[ULLYJJ>[G&P,IY(HC;4BC[&_0=.4N1NA0E:L> $7;?A%Q.D_\
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MUC&MD#6M:T -:     *+F[7==UN'6[R**\NFQ-NI0UHED  $C@  '4  P &
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M]G5FI".S/R28T90>P LAR15P,3(46446S-191)#0E)+ WI %E)H\I$M8$Y0
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M%(78*DP 1-2A&5G EA"P6,8R#'UV!=@@Y",(18O>[NJ:OI&KPW6B%QORX-#
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MA$E*R9%C#<D1XT.3D>1B&:,T6<*AJ2^PO!%[DK>K3A3X-?75;DD\HTP2HED
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MG:H(E3RNQZJ9Z20*5B.3'/*3IF?" 9S@<A$+P D4I(/=[]O!SD!L=17^I-$
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M#XQC,R$A<0'/9@\C.>T*=Q3ASG)1N,?_ '1=H,YQS+MT-[]0W2U#GX*R6,A
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CL< DK\"1*<9,2  #&2AXR,6%R(S(0_4^KGN SG_^6.$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>g10811g2sp71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g2sp71.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( *H!C ,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /?Z "@#S,?$;47L]?EVVL$EA>) GG6Y\N",RE-\C"3DX&2"
M(R,CJ"#67._8PJ+=W_\ 2>:R\V_=O?=VM?0<M*K@NB_5)OT6KVU2NF6K3QYJ
ML^KQ6SV,*[M,%V;8(WG;C%OSG/W-WR8QU[]JNLW3]M;7DO;Y<MK^MV^FB?RS
MIR<G23^U;7UYMO2R[_$OG?T+Q5K>J^$5U2UTRWU6[^T&,+;3""-TQ]Y2Y;H>
M,9/(-:RC:WS_  ;5_1I77DR:<W.]U:UOQ2=GYINWRV-WPQKB^)?#.GZTD!MU
MO(O,$1;<5]L]Z@U-:@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@#C_A7_ ,DO\/?]>H_F: .PH * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * ,.;6M2CU]+%-"F>R,BQF\\SCE2<A0#P,8))'\@5#WGKIO^
M'^?]=;*;<=M=OQ=OPW]/E?<IC"@ H * ./\ A7_R2_P]_P!>H_F: .PH * "
M@ H * "@ H * "@ H * "@ H * "@#+UGQ!I^@)"^H?:@DS!$:&SFG&XL% /
MEJV"2P !QDG S0!<L;R+4+..ZA29(WS@3P/"XP<<HX##IW'O0!8H * "@ H
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MSK"M"K*WLY<OR3.;$4ZT[>RGR_)._P!YR&CZ9XX.I3M=7CV*7'SR3%(9@6
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MGH%*RC)OM*R=_.RZ-VV\_F9EI>^*K33M4$[75]<M;)]D\VU";9FDDCY**.
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M[\VUTKZ1?5I=RG*VECR[PW\3O%VH_$6XTJYT=YK8-(K6,4:++;A<X.YF SG
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M5QQPRMSSP,5:5XW[.W]+=?CWN2F[I]&K_EUZ[KL=#4EA0 4 % !0 4 % !0
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M>_Y_D]UY'/!IR>G;_AGYKJ=A69J% !0!Q_PK_P"27^'O^O4?S- '84 % !0
M4 % !0 4 % !0 4 % !0 4 >*R36_@76=5N1H>@Q7T<JLAM;3$D;/"$"P\<+
MP,KW9S_>KQWBL2JKI65_*_5;_+J> \;C%6="T7+ROU5[^BZGI'@W0I]&T<RW
MYWZK>-YUV^<X8]$SW"YQ[G)[UZ5"BJ,;=>K[L]?#T%0ARK5]7W9D?$ZS:?2;
M"8ZK#811WL"MYKRJ&+3QX;Y)4'RX+<@G )4H?FKV\KYY590C%2]V3UBI:J+M
MNGUMZ[&L]B6+Q+%H=I!H=H[^(M<4$F*T9R "209'D=R@P1RSD^@QP'# U:]Z
M]=JG#NTE]T4E=^B%S):+4\P^)?A#Q3JFO:7J&J?9VDOF2TC2V("1N=Y6,%CD
MG R6( Y]J^IR?,<'0HU*=%.T;RUW:T3>BLM]MS:GAH5K<\[.[OIT2O?\#W71
M8)K;0=.@N(Q'/%;1I(@.=K!0",\]Z^%KN+JR<-KNPZEN=\KNKEZLB H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#(\1RW,.DE[
M.6\CN Z[/LENLSD^A5N,>I)'U%1)R37+_P #;KM^>X]+._\ 7Y_D-\-3Z]/I
MA;Q#:V]O=;L*(3]Y<<%AE@IZ\!F'O6LK65M^O_ V,XMW=]NG?^OZLC$F\<WD
M$&J.^AJ&M;J.V@)NP4E9W*X9PI"D<$@;L;@.N0,/:)4XS?6_W*/,[=]FNUUO
M;4MZ3<>BM^+LOT?>VMAMM\1(KB\C0::RVSV(NO,,OSAC%YNW9MZ;?XL]>U75
ME[+VB?V+_.W+]WQ+OU(A+G=./65OE?F^_P"%]NA;L/&<UWX;_M0Z#=SSK/Y+
MVM@RS,.,[@6V9&",^]:2C;\?P;3_ !1-.HJEVO+\4FOS(OA7_P DO\/?]>H_
MF:DU.PH * "@ H * "@ H * "@ H * /+KB;2K;XCR%]#O6D4DK$CJ[//OWB
M48D^Z1S@X/JHKPZBHT\9\-^NG\U[]SYNJL/2S#X6W:]E_->_?M\CKKR^UUK.
M>ZD%IHUI$A=I)W$C@ 9R>0B_B37H7Q%39**^]_Y'JWQ=79*"\]7_ )?F>0>"
MO$%KXF^(&A2WD<MS<7,TL^),9C=(VPS#/'J/I[5-#*LPP]:56O3DDMVXM+7L
MVN^AYN!H5X8N4YM/N^]^WIU/<=9UW3?#]E]JU.Z2",G:@/+2-_=51RQ]A7KX
M?"UL5/DI1N_R]7T/H')1W/)/B=I6O^,]'MM9ELDTK3[*58X(+ECY\OFNB;W4
M9"8.WY>N,^PKZ?+,;A,H]HG)S?*Y-QV7(G*RO:^E]=MC/V4J\HQ6EVE]^AZ=
MX.\,P^$_#-II2>6TL:YFE1 OF.>23Z]<#/8"OGLPQDL;B)5G>SV79%Q7*K'/
M?$>^E@O?#\*:?/-Y=]'<0NCQ!6F&55"&<'')R< <CGK6>'^LVFL-4IQ;C+F4
M^>_+IJN5/^NAZ&#IQDY2E&3LNENJ:>_X&A81^+&U"6XD6*(R1JS1SME%S_"-
MI/(Y!P<>YX-?+1I9E#$S?-%KOKROTV?WI>9VSGE[H15G\K7^?3^M#J;3[5]E
M3[9Y7VCG=Y.=O7C&>>F*]FE[3D7M;<WEM^)Y%7V?._9WMY[G*0FX_P"$M<70
MUK[7]J/E^3Y@L_L^WC.?W7U_CSTXJZ-^7SUO?U=K7\K6Y?GU,:E[OMI:WRO?
MYWWZ;:V*<6H>*)1JJ+)?"0 A3)9!5@?S<*(OE_>+Y?S$Y;ZCI4PYG3C?JX:]
M=?CT[+H[?-DSE*,I66REZ:?#\WU5_DNL0E\5KHFN+<7=_/)]EF^S,+54D5TE
M=%*[%7<60*V/?(P#BJ;TC?O3;^?Q+Y=?74J=[M+M/\E;7YNWHNJ;:7>J>)TT
M."2"34_];,(IAIP,\V%'E"2/9\BLVX$[5X Y&<T>]S1TUMMT^+2[Z>[KZW[6
M'#6_-M=>J5M;=[2T6CT[[G4:E<72W.@1.YA%Q<XG"9Y(B=@N1VW*/KC'>M++
MVK2V2;7WI?DV_P >A"YG23DM=+^7].R^9FP)JRR7UH\U\_G:NHCF=3\D(1';
M!  "_*RY'<^I-135XP3Z<U_DY6_1V[>0WS<U1KRM\TD[>EV_5%WPYISVMYJM
MT7OQ%+.8XHKJYFE 5>"P$C'&YBW3 P%IPTI)/S]>R_!7UZLJ6M1OM;T=]6_Q
MM\O,Y==0\2:5;>3$NJ3M)-=J"UF7(?[2"ASLX7RRQ!/'IT I0=U"+[4_U4[_
M (>?7NR*W,N>4?[W_I*Y;?/\='V+1G\7+J)G%Y>&#[6?]'-FFWR_M7E@9V;L
M>42V<YX!SC.72^)*79?>XRO]S2^]WW5M*OQ-1VLW\THO\6VORU0MWJ?BA-0U
MM;<7K&*WN6BC-F/*C*@>08GV_O&;G(RW/&!WB'-*GKW6O7XK6MVY=;_CT6D5
M'VT4]KK[K:MOHU+3=:=.IJ:M8:G/8^'K<:EJ19;M&NY8=L;R*$9L/L487<%!
M QUQ5U/=J.4>B=NU[:>OY>1A"\J#YMW;UU:O]R;\]-]S BO_ !M$?#JM+</]
MI1);II[8C#EANC81P-M 7IDISU8]*J*2K.+^%)?/>[[7VZ_)E5=%)Q[RM\G:
M/=V?71^JT+-MJ'B6:_\ $B:I(]I8P13&%@CKY8!_=NC>4JGY1D_O'.>R\BL;
MM8?GWDK:>?;I=7LEI\W<T<4Z\8+X7_P.O1[]5Y;7.XL999K"VEF79*\2LZ^A
M(Y%;U$HS:6QST9.5.,I;M(GJ#4* "@ H * "@ H * "@ H HZS-=6VB7T]B8
M1=1P.T1F.$W 9&XY&!^-1.7(N;T^Z^OX%P2E))E#PGXB/B;2#?\ D01+O*+Y
M%VEPK8ZG<O ^E;2BDD^YA"3;L^GYEE?#.@QQ7<2:)IZQWAS<H+5 )CG.7&/F
MYYYK.R45'HMO(TZ\W4L+I.G)=B[73[87(B\D2B%=XC_N9QG;[=*;UNGUW\_7
MN))))+IMY>A)96%GIEJMK86D-I;KDK%!&$09Y. .*;;>X65V^YR/PON[:+X;
M>&[>2>-)GL]ZHS $J#R0/09'YTEKL-Z*[.Q:X@3;NFC&[.,L.<4;AL/WH'V%
M@&QG&><>M "":(Q"02)Y9Z-N&#^- #(KRVG>9(IT=H&VR -RAZX/I1?3FZ?Y
M:"OK;J1/JEA',D+W<0D<*57<,D,<+CZGBCKR]?\ @-_DG]P-I*[_ *V7YM?>
M3F>$!294 8[0=PY/I0,7S8]S+YB[D&6&>0/>E</(<"& *D$'D$4]@%H * ,*
M]U2YOKM],T4@S(=MQ=$92W]A_>?V_.N.=64Y>SH[]7T7_!."I7G4DZ5#?J^B
M_P WY'E5YXK\-^'?B"]K=6SSSVK!&5+AI99)=^?,X'+D?\L_4UPPPLXXA2]G
MIWOY_%_P#S88*<,4I^RNEUYNM_B_X!VT&@ZEXRG35/%\7V328R)+71"V5XY#
MW!Z,W?9]T=\G->TE?1'T)P7A7QZ=6\8WNG^'/#=A;W6HW!DM+F<8^S*L2J<A
M5[K&3@$<L1S7V>+X>PV$PU.O7>E-6:25W>3=D^FLONU."G&FI^Y!)]--CU;1
MO"%MI][_ &IJ-Q)JVLD8-Y<@?)[1ITC7V'YU\]B<PG5A[&DN2GV7ZO=OU.Q0
MMJ]S*^)4UJVE064^JS6;2N'$<9B DV.K L74G@J,8(Z\Y%>7/%5J%.4:%#VL
MI)K:3LFFG?E:W3:_+8]3 8-XBHI7LHZ]-^FZ9JZ/?:CJ6EPO8W'G6[9Q>W91
MI).3_#& O'3MTKFJU<56F^2E[)=G>Z^3;?WO\!2H4<,^6K)RDNB_S_R1YI\0
M)K>3Q%91KK$TH5]EQ<,G[N)U(SMVCDJ&Y Z<=S7U63X#V="<JT5.4DU=I7<7
MT_PNVESV<%*7LG:%ENE?_/OW-[2OBO;#4(K&[MXX+"/*?:][N2 .#MVY.<#K
MZU57)6J?-3>O;1?K;0X:N62Y7.+O+MI_F>BZ9J5IK&GQ7]A-YMM+G8^TKG!(
M/! /4&O#JTIT9N$U9H\BI3E2DX35FC/'B:T&MWMC(!%;6<!EEO)7"Q@@@,N3
MZ C)Z=NQQA&2:<GHE;YWNOS5O/[KYO248+=I_*UOT=_3U%'B*&76K"RM8A<6
MMY:R7,=Y'*K1L$*C"XSG[W7@?7LY7BIMKX4GZW#3E4EK=V_!O]#F]-^)$U[H
M^HW\VBF VMD;R*/S)1YRCMN>)<]N4WCGK3E=1\[Q7_@3MZ_AKT\B5HU7#HN;
M_P EW\OQTZV.@\+>(I?$%K=/<6)LI[:7RVC/F<@J&!Q)'&PZ]U'3C(YJFDHJ
M2??\/ZN0I7E;T?W_ /#=+KS*-KXUT_4]2@L7TB_4/(NR6:*,Q@G=L;AR1DQM
M@XZCMD$Q3]]*:TOM_P" WMZ\K^ZZ\AS:C=/6S_\ ;K?A*WYK9V6U\=V-YK>O
M:7 B/+I,9DXG4F7 ^88'*X.!SUK-U/W$JRZ7_6WWV?RL^II;][&D^O\ P/T:
M_%=#3T/Q!%K5E+,;6>RE@QYL,^W<N5# _*2"""#Z^H!XK6I:G%R;T5[_ "W,
MJ<G.VFZ3^3_X9[V?D41XHO';2)%T@?9-1"8=KD"0;\D!8]N6PH#-DK@'C=BJ
MY6JGLY;_ '[*[^5]$^KMHKA*:4.>.NMOE>R:]5KZ)ZA=^)-05H&L--M;B&6]
M:S'FWC1.Q5MK%5\L@XVN3R.%]ZF%Y.*EI=7^6NOS5OF[>M2O%2MT_5+]7;R_
M*QKWB4:#>V\<ME++;/;SW$DL97*"/;Q@D9SNHC[TN7T^]NPY^[#G\_T;_0@U
M+QM8Z;!),UE>SK%++&XA1"5$8!=CEAP ?K[5,9<THQ76_P#Z5R_BQ)IW^2^^
M/-^0YO&-NNFQ70TS4&E>:2$VH1!*A3)<G+[< #/#'/&,FB4XQLV]+-W[).SO
MZ/32X)WT6]TEYMJZ^]:ZVMUL6[36;36KV>PCLI9K=8(Y6GD5/*8.,JN"V[..
M?NX]ZJUN:^\7;YJST]+HA3C-*VJDK_)W6OK9F):_$!2EW)J.CW-G!;^?(91+
M&ZK%$Y3<WS#!+ @ ;O4G%0IKD4GO:+_\"^%7\]];)=S1Z3Y5Y_@E=^BOZOL)
M-\3_  ];Z%;:M)(PAGE>(*)H25*<M\WF;&P".%8DYX!J_MQAW_SMZ[]O7;4F
M+YDVNCM\[7]%IW:[/4Z2UU1+G5+BR" &.*.>-PV0Z/D ].#E3QSV]:=G9WZ.
MWX+^OD-2346MFKK]?P:^_P C0I#"@ H * "@ H * "@#.U]=/;P]J*ZMD:<;
M=_M&,_<P=W3GIZ5$[)?-6MO>^GXFE/FYER[F7X,CL%TZYFL8]3!FFWRR:E \
M4LC;0 <,!D;0 "!VK:5U%+U_.[O\SGARWT[+[NB1TM0:!0 4 >:>!_#%GKOP
MU\.33RRQ2+IDEL&CV\*[ D\@\@H,?CUI)6;:_N_^2NZ"5I1Y)+37\4T_P9MW
MGPYTG4+*SMKJ>XE%K$T2NP0L=S;B3\N,Y] *GD2=UIHE]R:7YW]4A)6:?FW]
M\E+]+>C9H?\ "(6/]N1:J9Y_.CMQ %RN" I7.<;NC'C.,\XS3G%251/[=_QM
M?\E_3%&*BH)?9M^%[?FQMWX,TZZ\,V.A!GBM;/9Y914.< CYE*E3D$]NISUK
M64W*JJO5?U_5M0A'DIN"Z_YWO]XC>"]/-QJ\ZS3I)JD30S,NT$!@!QQVQQG/
M6L>1<CAT>OXR?_MWW)#A[E15%NO\HK_VW\60V?@33K*"TB2ZNG6U5%4LRY(2
M1I!G ]6(^E-Q3?RM_P"2N/Y/[R>1<JCYM_?)2_-%6V^&NCVNC6NEBXNI(;:=
MIXVD968,1CKCL *K7FC+JO\ Y)2_-?<*=-3YD_M-O[XN/Z_>#> EN-7\17-U
M?L;75X?*$<481XLXR=_.[D<9X[=*SC!1I\GFG]S<E^+_ *Z:2LZBGY-?>DOR
M7]=>ET;2X=$T>TTRW>1X;6,1JTA!8@>N*WG)SE=DQCRK[W][N0>(;O4+#1Y;
MS3A;%X 9)!<;L% I) Q_%G&*Y,3.I3IN=.VG?L<^+J5:5)SI6TUU[?YF!I&I
MZ[XJLO+8PVELQ_>W5N&!*X'R(&_BSD%N@[5Q4:M?%1MLNZ_)7Z]V>?AZV)QL
M+.T5U:_)7Z]W]Q)J?B.T\.M%X<\.:?\ VCK17*64)PL0_P">DS_P+]>3VZUZ
M5.G&G'E@K(]:E2A2BH05DCPAM.TZP^+2RZG?3ZAJ"WWGSQ6%FJ*]WOW>4C,^
M=I<XW$ \=.<C[.AEF)J9?[27(D[.[C&ZC9W=^6]]G>]]-[F;FE.Q[HOAW5_%
M#"?Q7,+>PZII%K(=A_Z[..7/L,+]:\EXNA@ERX-7E_.UK_VZNGKN:<KE\1Q_
M@[1;3P[XSN[F:UU&U2"3Y))39_,K1 %9!&<GY@<",=QN[UYN/Q]&48PGBU+V
M:7NWG=R<I:ZQM+W6EJ]+->OI0HUYT_=I_&WK9;*UO35>5_,],\[4]2X@0V%L
M?^6DHS*P]EZ+^->-SXC$? N2/=[_ "73YCY:%#XWSR[+;[^OR.4^(MCHVG^$
M+I)!$VI2;3#).0TSX=-Q!//3KCM7T.0X9T,1>G>S^)]]':_Z'5@JU:M77\JZ
M+9:,THYCKZ?V7X<"V.AQ$B:\@38'YY2$#\<M6CC]7?M<1[TWLGK\Y?Y',U['
M]Y7UGT3_ #?^1'XJL+72[+PO9V4*PV\>M6P5%_X%^9]ZK!U)U95IS=VX2_0>
M&G*I*K*3N^5G6QV5M%>37<<*K<3JJR.!RP7.,_3)KS'4DXJ#>B.!SDXJ+>B)
MZ@DS+?P[HMGK$NKVVEVL&H2J5DN(X@KN"<G)'4DCJ>:(^XG&.B?Z?\.$O>:;
MZ%J6PMIKZ"]DCS<0(\<;[CPK8W#'3G:/RI6337?1COI;SO\ /5?JS)MO!FAV
MEC<64=M.;>XA,#))=S2;8S_"A9B4'LN*;U5GY/STVUWT$]9.;WU_'?3;7J:&
MEZ/9:/%)'9K+^];?(\T[S.YP!R[DL> !UIMW5A)).Y%#X=TJ"5)8K7:Z;-I\
MQN-A8KW[%V_/Z5*2245T_P N7\E;_@@TG>_7_/F_/7_@ /#VEB*"(6N%@61$
M_>-D"3[X)SDYZ\YYYZTG!./*]K<ORT_R]?O&M'==^;YZZ_BQVEZ#IVBV<EK8
MP,D4AR^^5Y&;@*,LQ)X   SP  *JI^\CR2VU_'<44H.\?ZM^A1L_"&GVTVGW
M,LES)>6$*V\4RW4L8,:G@,BOM;MG(YQ^%/F?,Y]9;^;M_P /;L)Q37+T3=O*
M[V_)?(TXM*LH?LFR''V0L8<NQVE@03R>2<GKZU*2CMVM\M-/P0W%/[[_ #U_
MS8S4M$T_5]OVZ R[4>,?O&7Y7&&!P1D'CKZ ]1197O\ UO?[TUH]RKZ6^?YK
M\FRHGA+1$L6L_LCM"XD#!YY&9O,&'RQ;)) ZYIK1J2Z;??S?GK_P"%%+\_PY
M?RT);SPUI-];^1/;OL\YI\QSO&P=AACN4@X()!&<$'&*GE6GE?\ %W:?=7Z,
M=DK_ "_!65NSMU1<M=.M+*666VA$32JBMM)QA1A0!T&!Z57?S=_GI_DA**C:
MW1)?)7_S94'AS2529/L8VS))&X+L<J[EV'7NQ)]NU2XIJW^'_P E^'[BMW=^
M?XVO]]D-?PUIKVEO;L;PBV8M%(;Z?S5SU'F;]Y!]"<57VE+JOZU[_,7*K./3
M^MNWR+,&G"+5[K4&DWO-''"JXQL1<G'7DDL3GCMZ4+1-=W?\$OZ]1O6W9+\]
M_P E]WF7J "@ H * "@ H * "@#-\0VT=YX;U*VEDEBCEMI$9X4+NH*GE57D
MGV'6LZJ3CKY>?4TI.TTT<Y\-+;3+/1KVWTV4N([G$H.FFR*-M4X*$#/!!S[U
MTS;<(OIK^9S1BHR:ZV7ZD]YXUFM(M7_XE.)[&\BM(XY+@*)3(%(8L =H^;W/
M\JYG/EIQF^O-\N5-OYV7I?K;4V:M*S[)_?)Q_-?=T*]M\1(KB\C0::RVSV(N
MO,,OSAC%YNW9MZ;?XL]>U55E[+VB?V+_ #MR_=\2[]3.$N=TX]96^5^;[_A?
M;H6[#QH]SX;_ +5ET6[DE6?R'MK ?:6!QG<#A<C!&>.M:2C;\?P;3_%$TZBJ
M7:\OQ2:_,P/!]]<67PE\'I:2^5-=200!L X4N2W!_P!D&N>K)Q2MU:/5R^C"
MK*;J*ZC&3^Y:?C8]*K8\\* "@ H * "@ H BN;J"RMI+BYE6*&,99V. *F4X
MPCS2=D1.<:<7*3LD>:_$'Q',GAU;V[#V6CSSB")6R))V*LP8C!POR\#J>O'%
M<?U7&9G^[P\=]E=1;\]6ONW>YXF,>(Q5*\(^[VV;\WY>74Y;2?'LLFB)HVC7
MILX6D(DN\>?<$D#,=O"%!+$\Y/RKGJ2:]; Y%CZ,71JPY;;MR32]6G9>FYTY
M;&5&ARS5M=KW^ZWF=;HGAW58M-:*W;_A%M)E;?--(XEU&Z)ZO)(>$8_B1[5W
MRJ8# *[_ 'DEU>D%^LOP1Z<85*KM%?YG(V>E6=K\2+:\L_"<]RD$[1K(=1$G
MFN)%V7.2<YP&8KCJ1S6=3B?VV%GAUB(MNUHJ,T[6ES1OR<O\J6MK7O*QWK+:
MD4IRBUO=NVVEM+W[]+[:'LGE:Q>?ZR:*QC_NQ#S'_P"^CP/P%?.\N+J_$U!>
M6K^_;\ YL-2V3F_/1?=N<%X.\0:%>^+Q;VT-\7ES]F:8+P0A+%L'V..M=<.%
MZF7SGB9R32M;5WUT=]$>QCW7^JI.WG;UTM^IV^H>*+&SN396JR:AJ'_/M:C>
MR_[QZ*/J:]"EA)SCSR]V/=_IW/#IX:<ES2]V/=_UJ<7\0-,UG4?"TVJZO);6
MRVC*T-G"N\C<P4[I#WYZ 8XKU,MJTJ>(5*C=WO=OR5]%_F>E@*E*G65.G=WZ
M_P# /0M(T\:5I-M8!PZP+L5@FWCMQ]/SKYY2JR]ZM+FD]W:WX'E5ZBJU'-*U
M_F<OXS\+:MK^I6<UBNG"*W*.3<O*'9E+';\O&WD>A]Z[,*L%#GG64G*47!V_
ME?SW._!8V&'IN,F_E;[]>OX'6:?#+;Z;:PS+&LL<2JXB)* @ ';GG'IGFN3D
MIP]RE\*VOVZ'G59<\Y2[LLT&84 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M7R^ZZ.U5@R*RL&4C(([TQK0Y7Q!X5M[WQ+8>);B_^S1:8F^5-I^<(2P)(8#
MR>H;VQS4TUR5'/O_ )-?D_7SMH*HO:04.S_5/_VU>7E>S6]I>I6FN:/:ZC9M
MYMI=Q+(A(ZJPZ$>OJ*;2:LQIVU1P_B7PU9:)X0E%QJ5E::=%?/<2--8[U"2O
MCRE"NI4?,%)!&1QT--7YJ<GKRK[];[^NMM=4K["DDU)+2]OE:*C^-OE=V[GH
M$MO%<6K6\T:2Q.NUD905(^A[5,X\Z:"*Y58\_N/#EOX;U+P<9?$<ELT!&GQH
ML947).7VX#X .W!W!A]W&#S6BE:I*;ZI*WHFOUOWOUM="J14T[:/F;^]IV_"
MW;NMK=IKVD1:[H5[I<VP+<Q-&'= ^PD8#8]0>:SE&]O+^O\ @&M.?)-2:O8Y
M72]$LW^)=S=0:PLMUI=K%%<6GDD%=T>%.[=CD#/W=W;=CBKB^64Y?S-OTO;_
M "\O.]E;G]G:-./\MOG;F_\ DO/RM=FSXK\/R:['9L+RUMH;63S9O/M3+YB#
MDKN#J5'&3@\X&>,@S%<M13?3_._X=.E]>B-)KFIRAW_R:_%.W>S=AOAJWTZ_
MO9_%>E3H]IJ]M#M18MN"A<EB<\D[\'C^'O3A[L'!=V_O27Z7^827-)2[*P[6
M/#4VJ>(]-U-;NWB@L^6B:U+2.W8B0.,8R< @C)S@G&)4;2D^ZMYK1J_KKVT5
M[;L<O>BH^?ZIV^]+[ET5FSP?X07PA%J,,>IW%['>7/V@&X50RG: <E0-Q)&2
M>/SR3HG:G&':_P"=_P"O\K)*2YJDJCZV%7PQ<+XNNM<%W:!983'%&MF5DB8@
M L7#X<G:O5<X  ([Y)-4YP3U?7M\OQZ7>_2U2]Z46]ET[[_Y^=M>[-71=+CT
M71[;3XW\PQ+\\A&#(YY9S[DDD_6MIR4GHK+HNRZ(B*:7O.[>_J<K+\/9))M9
ME75HT>_DCDBVV:@1E)3*NX C?R2#C;D<G+$L<HIQ@HKH[_AR[>GR36B6Q<GS
M3<GLTU]Z_KSZ-M)6ZC1-)71?#]GI*S&5;:$1>85QNP.N/Z5=9^UOYBC=-R>[
M;?WNYQA^&$IT::P_MF$&6Z\\NNG( HV!,  _*< ="%[;=IVTHNTH-_9_S3\^
MJZW^])I37.YM_:_X*_)]+?>VWW.H6/V_2+FQ,H4S0M%O:-7 R,9*L-I^A&*F
M:<MM/Z_KS\RJ3Y&O+Y'$1?# HVBNVLDR:=,\KA+<JDFZ59<!=_'S+U;?U]0"
M-(/DFI+HDON4DOPEZ^>]\I0YH.+ZO_+_ "OV\K62ZOQ-HC>(-$ET]+A+=G((
M=X1*!@^F01]5((Z@BL9PY[?UT:_7TZ---HVC+E_KY_U_F8=EX!6T\2Z5J[:F
M\GV"U2#RQ%L\QE1D#':0O1CQM)X&"!D'=2M4J3_F_"_+?_TE=O.^EL/9^Y"'
M\OZ7MY]>K?WMMZ'C+PDGB_3(K-]1N++R91*IB564L.FY6!SCJ.F#@]JR2M4C
M4[?YI_?I:_F]UH:27-3E!]5_7R_K073O#4UEXKO-:EN[:9)H_+C1;3RY$^[N
M)</AB=HR=H/ Y &*J'N1DN[_ ,]+?-_-MOR4HWE%]OZOZ_DM%U&^(O"*^(-7
MTC4O[3N;633)A*D:*C(W()R&!PV!C(/ )]:45RU.?RM^#7ZZ][+K9IS7/#D\
MT_N:?Z:?JM!?"?AB?PRE]%)JTM[#/,9(T<,!%DDGJS<DGG&T>BCFG'W:48=M
M/N27Z=6]^UD)Q_>2FNO3SNW^MOEK=ZE;4O! O_%IU]=7N8Y&M)+5H&CC= K*
M -N1D 'D@DY/ISG/V?N5(?S_ -?\,:<VL'_*[_G^=]^R]+7?!_AMO"NA#36O
M!=GS&D\P1E.N./F9B>G=C^ P!O*7-;^NK?Z^O=MZF,*?(W\OP27Z>G9%2R\&
MM;:UK=W/J;7-EJF6-G(A*(QQ\Q!8J2, #"KQUSUKG=.]!T7YV?:[;_-][::)
M:FNU55%\UWT2_3SW>MM#:T+3/[$\/Z?I?G>=]CMT@\S;MW[5 SC)QT]:Z:M3
MVE1SM:YG"')&QH5F6% $-S:PWD(BG3>@97 R1AE((((]"!1U3[ U=-,FH *
M"@ H * "@ H * (;2TALK9+>W39$N<#))R3DDD\DDG.31T2[?H'5OOK]Y-0
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M\'&?49'XT <E\%]-;3?AAI>;IYDN 9U5ACRMQY4>V<G\30!W] !0 4 % !0
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M]NHX=3A,5Q FS824V;P2I8-MP.N/:B*Y=/._Y?G8T4VIQFMX_P";?YME'4O
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M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
+0 4 % !0 4 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>g10811g2sp73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811g2sp73.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MR)-$DL;!D<!E8="#T- #J "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@#F==\!>$O$%^E[J^C6T]T2%\TY1G] <$;OQS32;V%=(Z"TM+>QM(K6
MT@C@MXEVI'&H55'H *0RGK&BQZO'#FZN;.>%B8Y[5PLB@C!&2",$>WH>H% &
M1<> M*N;HRRW%Z\8&4B:;<$?RQ&9,D%BQ0;3N)'4XSS0!8/@[3S>_:?.N/\
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MP)_UI&3SUP,X !BWNJ>,M%MK*35+ORX90OG/B .'"S952<+CY82<\G<P7G@
M#=+T_P 8KK6F:[^\*7=M(]\DL@PK$QJ@5,\?*@8X&0"X&&(H D\+:WJ^L:W:
MM=S22>3=>6&PH!B-INE^Y\I F* =QP#SF@#TF@ H * "@ H * "@ H * "@
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M%M!9SQK)-Y#&;"LCF$3)P"<@IDYSP0!CG@ Z:@ H * "@ H * "@ H * "@
MH * "@ H P_$_B6/POI_VV73KR\A4,TAME7$2*,EF+, ![9R>U &+)\3M&BU
M:YLY+>YC@MH3/)=/L5<"+S2 I;>QVG& IY^E #I/B3816@=])U);W>X:QV)Y
MRHL:R-(?FV[0CJ>N><8S0!O3^*/#]HR+=:W86[NBR*DURB,5(R#@D'D4 :-O
M<P7EO'<6TT<\$@W))&P96'J".#0!+0 4 <]=0>&&NI3<SVPG+'>&N,'/?C-7
M]2G+WE!Z^IVPQF(A%1B]%Y(U=,CL8[,#3F1K<L2"C[AGOS4NDZ7NM6.>K5G5
MES3>H7ZZ='Y=SJ!@0+F)'F8 #?@;>>YX%(R*+^%_#\=DL+Z=;I;P@[0> @\L
M1=>WR*%^@H +H>'-/M[:>[FL;>&"Z>2&2:5559SOWX)/WN7SWZT 588?!]QX
MG%[#+ILNMR;9 5G5I6_=X#!<_P!S&#CI0!H'1]'FUQM2\B)M2A #2!SN7CC(
M!]#WH %TS2[O3K%;79]DMG66W,+ KT(X/((*LP/L30!'%I.@Z+80Z>EO:VEK
M)<(8HB0H>4$,@&>I&P8'^R.PH S]6\"^';_3X+62W2TAB"QH8@@PN&54^8$8
M_>,/^!4 7(]#\.V]E;2+!;+#"BQ0S%AP"^0 V>I<_B3[T 4](\(Z%X8G@,$S
M)(TS21K+(JAY/+"Y"@ 9$:D<#H6)]: -1?$N@M:M=+K>GFW5@AE%TFP,1D#.
M<9P#Q0!=^VVOD13_ &F'R91F.3>-KC!;(/?@$_04 +:W=M?6R7-G<17$#_=D
MB<.K=N".* )J (8;NVN))8X+B*5XCB14<$H?0XZ=#^5 $V<=>* ()[VUM988
MKBYABDG;;$CN%,A]%!ZGZ4 3T 0S7EK;RQ13W,44DQVQH[@%SZ 'K0!))(D2
MAI'5%)"@L<#). /Q) H =0 4 % !0!@^)O"T/B=+-)]1O+1;63S56W9-KMQ@
ML&5@<=1QP>?2@"M>>!K#4[@MJ=_J%];F-E^S3SYBW-&8V<  $$JS=#@;B0!0
M!5D^'&ERVBQOJ&HM=!V)O/.7SF5D6-D)VXVE$4=,\9SGF@"3QAX8T";POJUU
M-HMC+<P:?((YI+=6= L9VX8C/':@!?AC_P DR\._]>:4 =90!!<132;?)N3#
MCKA0<_G5PE&.ZN,Y+7/!\][J,-Q%/N,SA9V* ;1C[V!],?E7K8;,(TZ;BUMM
M_D7&=D='::9-96\5O#>LL,8 "B)>GY5Y\ZT9R<I1U?FR6[F;XP\,S>*K""R6
M]6UB1VD9C$)"6V%5P#P,;B<]00"*YB3%U3P-JFK"26XU1//GW>>JEQ&X,")L
M SP/,3?^/K0!->>!]3OYK%I?$-Q'%;:C)>*D04&-6\W 1R"<XE4<Y&%X H 6
MR\$7&GZE=+:W,,>G375O<H2"TT9BB1 .>#DIDD]B>* -'3]!U*TO+M+R\AU.
MTO5"W$DZA)6 4KC:BA<8P.U $4W@S[3X%M/#37\EM]G6,>;;C;G:<XQZ?_6H
M 9XC\)7FM2:88=26)=,7S(6FC\UWF!7:[$],;>HY^8T 5M0\#3WLDLKW8F9[
MDSE))'VG%RLJ+UXPH=>!_'F@"*^\#:U>Z?9V[^*)&%M/'.L4MLCH&1@1SPQZ
M$_,3R?84 :USX5>ZU&SU"XO!=7=K<2O'-+"@:.)XG3RE*@< L#DY)QR3Q0!@
M6G@#5+:UM@=04S6_V=5Q<2@D1)*IQ)]Y0?-^Z.!@_P!XT ;4'AV]LM+T&Q\R
M*Z-D)(Y&>/\ =_-$X5BN?F R%/<[B?6@"CJ/@O4M0T6"S&IBVE6YN;AS&[XS
M(D@4;L@MM=U;)_NT 9>J^%=;M-1AALQ<WMM/=EXF6<A;)2\1.27!.0LG0'J?
M7D 74? >KVK7FI6>H2W#R6R(]E$2HE< ;V!W+\S'<.3]UVZ&@"_I'A74-4\"
M7&EZI+=Z9+<WDLZ(LN]XHS(2B$Y/&W'&>.* -CQ+X<N=:M]-@M[B*/[+-'*T
MTREY/D=6X['.WG/?:PY44 <Q_P (!K&FZ,IM]6GN+J&%E=4E?=.#;*A0;F &
M9%+]1UZB@")/ 6KZ[HB&:[ET6?[49H5W%Y;9-TO (8XR&3@'@+V/0 IWGA3Q
M/>ZW<VR6T\$.R1#>>>-C%VB\LJN\G]V%<C(!POJ>0#UR@ H * "@ H * "@#
M'\6?\B=KG_7A/_Z+:@#+^&/_ "3+P[_UYI0!UE %>YN9("H2TFGSU,97C\R*
MEMKH:TZ<9[R2];_HF>7>)OB#XAT_Q;#:6^G/!#$V!;R+EK@'C.1G\,5YU7$U
M(U+)?\$^SR_(\%6P;J3G=OJOL_UUN>D6>HW-S'"TNE75N7 +!RGR?7#9KOC)
MO='R56A"#:C43MZZ_@8_CBZU6RL=-DTK46LWFOX+:0K"DF5DD5"?F!QC.:T.
M0H3^++H:_JUG8O+>06%@JNT< S%=;I 2^<8&%4X]"".#0 VR\8RZMH>@W6EZ
MC9W+O-;0ZEL&YU9]N5 '"_Q9STQP.X .=U7Q]KD;7_FS'2DAU86Z;XD0K$;<
MR*"91C);&?KQVH ZB;Q7J4*:"!9---=Z7)>RQI&0TDBK&!&%ZCYI<GN OUH
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MKQ[T 3^+_%_AV'POJEK/K-G!=7&G2-'!+,JR,'C.WY2<\YH F^&/_),O#O\
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M2H4_-G."H"D9Q@ =!0 OBJ*-?!NM 1J MA,!@=!Y9H SOAC_ ,DR\._]>:4
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MH F\8>-]*@\-ZC92Q7PGN=.=EV6<KH-\9QEU4J.O//% &A\,?^29>'?^O-*
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MQGF@";X8_P#),O#O_7FE '64 % %._U!+%$4(9KF4E88$(#2-C/&>@'<G@4
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M1BJGU8\LQ_J:\]R<GJ8D%C(")5V2*3(S#=&R\$^XK2JK6?DALN5B(* "@ H
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MT(TV1JI"@@8.T8'X"LGY$-W(+BS,\T4IEP8FW(-@.#@C^M:0J<J:MN%[%D<
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M&62'YG;A5_UG4U1B7?\ A.=2_P"A$\0_]\0__'* #_A.=2_Z$3Q#_P!\0_\
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M5&U:U:32UM J^9POFN,;MIPJDGG(QCKQ0!W=E=P:CI]O>V[;[>XC66,D=58
M@_D: +% ",BN &4$ Y&10 M !0!SWBS4M'BLXM$U4N_]M-]B6&(_.ROA&;V4
M;AD^X[D4 4O"7B/1))4\,Z7%<Q16$+1VSS+\LZ1-Y;E3G)VM@'('J,T ==0
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M"2VO+6]5VM;F*<1L4<Q.&VL.H..A]J )Z "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H X!?AW?-;O#-X@P+<77
M]G-#:[&MGG+;G8[CO(#$#&WJ>^, %>Q^&LUA>:)*]]]IDM[V6>ZE^8!XV*R!
M,.S,V)8XR"6/0YH Z?PGX=N/#EG=V\^H?:EFN#+&BHR1P*0!L0,S$#@G&<#/
M  H Z"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
H "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>g10811sp039.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811sp039.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M_P! 33?SD_QH /\ AI+Q#_T!--_.3_&@ _X:2\0_] 33?SD_QH /^&DO$/\
MT!--_.3_ !H /^&DO$/_ $!--_.3_&@ _P"&DO$/_0$TW\Y/\: #_AI+Q#_T
M!--_.3_&@ _X:2\0_P#0$TW\Y/\ &@"O)^T?XL,A,6EZ0J=@T4K'\_,% #?^
M&CO&'_0-T;_OS+_\<H /^&CO&'_0-T;_ +\R_P#QR@ _X:.\8?\ 0-T;_OS+
M_P#'* #_ (:.\8?] W1O^_,O_P <H ]!^$GQ5USQ[K]]8:I:V$,4%MYRFVC=
M23N YW.>.: '?%+XLZIX"\06VG66GVES'+;B4M-NR#N(QP?:@#AO^&DO$/\
MT!--_.3_ !H /^&DO$/_ $!--_.3_&@ _P"&DO$/_0$TW\Y/\: #_AI+Q#_T
M!--_.3_&@ _X:2\0_P#0$TW\Y/\ &@ _X:2\0_\ 0$TW\Y/\: #_ (:2\0_]
M 33?SD_QH /^&DO$/_0$TW\Y/\: #_AI+Q#_ - 33?SD_P : #_AI+Q#_P!
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M!-*2]U&=ICCWE&PWR-TX;&.3V- %72-#M+C3KG5-5OWL["&58 88?.D>1@2
M%+*, *223Z=: &R^&[B2X8Z7(E]9_.4N 0@(2,2-N#'Y2%//;((!- $\?@_4
M(WD%\%MU6WFF&UTD(:--Y1@I^1N1P<$9Z4 4=1\/:GI5LMQ=P*L1;82LJ.4;
M&=KA22C8[-@\&@"V^AZ<_AN;4+74Y)KJV6-IXC;%8EWG 59"<EAZ;0.#@G%
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M&['./;VH ]2_9O\ ^1YU/_L'-_Z,2@!/VC?^1WT__KQ'_H;4 >.4 % !0 4
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M-I%%:8^88YZ=J3$SG=;\4ZSX@*C4;^6:)#E(BWR)]!3&8] !0 JJ68*H))Z
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M5TEGXC65O[I'3- 'M7GP^4V!N.  "OW<]J ,[5_#-OJ]F]L(MTH'+#^0]^*
M/!M9TU])U.6T<Y*&@""UMFN7VJ"3Z+R30!Z?X9TG[%ID9).1ELG "$^OK0!+
M=W:1P20KL=\88CJ?\_TH \X\00-!J;;D"E@&X&,^] &50 4 /CFDBE62-V1T
M(*L#@@CI0![E\/\ QG;>,(3X<UZ:,27$1CE$Y&RX[!E_NR#]?K0!XWKFEOHV
MLWE@S!_L\S1;AT.#B@#.H ]D_9O_ .1YU/\ [!S?^C$H 3]HW_D=]/\ ^O$?
M^AM0!XY0 4 % !0 H&2!0![WX0\%:!X'\,V_B;Q9:QW$EQ&)@)@-L /W553]
MYS^E 'E7CSQ+:^*_%$^I65@EE;%52.-0 < =3CC- ',4 % $L)P6YQE3VS28
MF1&F,* -'2=.6]U&SBN7\FVGDVF4]!Z_C0!].^&?AOX=CL[>XTZPCPJC,LHW
M-(?7GI0!VMGH=OI<<AAMU=I!R,?UH N6^GC(>< D'*J#PM !J%U' OE+CS7'
MY#U)[4 >>Z[9>$[JTDLUT.TN9#R9-@^7WSUH Y ?#71M10S1:/M51@^7N"Y_
M.@#D/%OP\U7P?9G6](FNH;9#MD(8JRY]QVH Y-_'?B>>S6SN=9NKBV#!O+E?
M<./K0!1NDMM07SK.,I,!EX_7W% &5C'!H * "@#[QT7_ ) 6G_\ 7M'_ .@B
M@#P[]IK_ )E;_MZ_]I4 ?/\ 0 4  H W='\.7>HZK:6DL,D,4R^9O9"-R>H]
M?2@#U.STNRL;15MX5!!^4J@!X]_6@!FJ2V=N/+N+/YSGY67&.G:@#B+FUA25
M28HUEQG_ %>%QUH H&RBN)!$(F7G!/12: *NI:!<Q1I-&3,2N6 '(Q_/C%(2
MT,*F,* +VE7PT^\6<C./\YH ]0TOQ49;7>-[0 _,^<@$X[4 =%;>++9+$%LQ
M%V)VY!8]J .&\;:%JVMWB7]EIUQ<)]UBD98CV.* .-TNPOY+N6*+$+1#,GFG
M9C!Z>M '86.H7=_9B'<((HR=Q"\+ZG)]: ,^_OTLU_<S;XT/7=W^G^>M ')7
M=T]W,99"2YZDF@"O0 4 % "JS*<J2#[4 2!VE?$CDECG+'/- $9!4X/:@#V/
M]F__ )'G4_\ L'-_Z,2@!/VC?^1WT_\ Z\1_Z&U 'CE !0 4 % %RQMS(7G;
M(BA&YC[]J /2]+\):]XMTZUO/$>KW#VB+_H\#2995[=>E &U#\-]$AC#+:,Y
M'<R9/Y&@"&[^%FE.A8>8A(S\O:@#D==^&]S8@O82&9>3M(Y H XI8I(+AHI%
M=' (*XY'%)B97-,9=TBW6ZUBT@>,R(\J@H.XSTH ^@-,\&Z-X>\'$:_HLM\V
MHW_G6EG;@F2+C@9R#T'- 'L&F2)%:00)9R6RA!M1N=OMF@"^#DG(P.U &=K.
MKII%KYS)O)X50<$F@#S/4]8O=6O4A>0J9#\R1$<^@SV^E '=Z1X6L([)3/ S
MNX^82&@#?B@AM80D2*B*. !C H \R\?Z^M]8WEB0OV4(5;@Y)]J /E5\!SMZ
M9XH DM[F6UD+Q-M)&/PH Z/6?!E_I_A;3/$ZRBYL-07YG5<&)\D%6_+K0!RU
M !0!]XZ+_P @+3_^O:/_ -!% 'AW[37_ #*W_;U_[2H ^?Z "@#O?@]X>L_$
M?Q M;>_026]NK3M&>CE>@^F<4 >S>.+BTE\3&.W 66UMU@^4#'7=@#VXH P(
MKGSHF#K@]#D\J?<?UH HZKIR7L#O-NW(/EXQCIWH X>\LEAE7;;@DDXPY.3[
M4 1PQO&NV-BKY''U]: -)&+RERI7H,]\4GH)Z&)XL\*/8%;RW!99%WLBCA:8
MSCJ "@"_INL7NDNYM)MJN,.A&58>X/!H +69Y]0\R2Z^S*S%F<<8]< 4 >Q>
M'_B=H/A3PN=/CU&_O)]^X>7&$QSTW=30!Q-]K6BZOJ<UY::;Y#-)O>668Y8G
MU_.@"AJ6MP1VYA6=II@<KLP$4>F/ZT <W<73SX!X4=J *] $ZV<[QB01G:>A
MH <UL(HRTK@-V0<DT 5J "@#I/ GA7_A,_%5OHWVK[*)%9C)MW8 &>E %7Q7
MX>N?"WB2\T>Z8/+;MC>!@.",@_B"* /3/V;PO_";:H=WS?V>?EQ_TT2@!G[1
MO_([Z?\ ]>(_]#:@#QR@ H * % +$!023T H ]"\!Z9%?ZK%IDR(T<0\^93_
M !8Z#^5 'M$AA3*^2%C&!QQ0 UMH9N .G)&10 U5PP5FV^@YYH \U\8^)+\W
M#QV:D6B/M<QMAC_A0!SUQ86&MPQSQS,)E0Y ^\#CO28F<=J&G7.FS^5<1E<C
M*MCAAZBF,[;X+6BW?Q.TX,%*QAWPPST6@#Z[V(Q5BH++T..E #L 4 9FM:Y9
MZ):--.X+=$0'EC0!Y;JVM7.J7GFRRL1C]VJKQ0!?\.Z"\UXLS*"(R&)?H,>]
M '=0^(([F]6UM%\X@X=Q]T4 .\0ZB;.S\J/ DD&-Q. !0!XCXYU1+/0+R1#D
MGY V>23Q0!X30 4 ?07P3U'3_$_@S4O!&J1>8J;I%4GK&Q&<>X;G\: /$/$6
ME-H7B+4-*9]YM)WBW>H!QF@#,H ^\=%_Y 6G_P#7M'_Z"* /#OVFO^96_P"W
MK_VE0!\_T % &AHNHZAI>JPW&F74EK=9V+)&<$9XH ]CB,UM##+<2"5^KO*<
MER>ISGK0!;B>.7;LD">I# _SH M*0\GEONY/.1\N>V?:@!NH>'[9M!?4_M\"
MRPO\T2#+$9 X]30!S]SX<%RAEMIL[QPNW'XT )#HD=F!->31HD)PYSD9/3:.
M_-*W436ERS?QVESITSPW# 9^;/4X/\^]"=T"=T>2ZWIYLKH'855QGI@'Z4QF
MMX8\":CXD3ST9(+4''F/U/T% &]J?PGN;>R::RNO,=!DK*-@/7I0!YS)&T4C
M1NI5U."#U!H ;0!(9G,0BSA <X% $= !0 4 7(]1G08)W    ].* *LDC22,
M[=2<T -H * -CPKKLGAKQ1I^KQ@G[-*&90<;E[C\LT :_P 2_%-IXP\:7.K6
M,<B6S1HB"088X7G/XYH [7]F_P#Y'G4_^P<W_HQ* $_:-_Y'?3_^O$?^AM0!
MXY0 4 % '4^!=);5-<B0#EG6-3UPS'% 'TIK/AG2]#CLI-/LXXKA8C$TJCEE
MX//XB@#(?=@Y"GC)R^0* (B9!M_?IMZX7D@4 :5G!#<6SB!FAN%7YE;&Q_8'
ML: .)O?"A>Z=@\0,A).Y^5/N/2@#E[GP-<Z9J*RVZ9;[QV9=34L3-CQ'X974
M_"R1-$1<P1[HFR!D]QS5#1P_PNCOXOB7I<5KN2<2E7 '1<'/6@#[)484 G-
M QPIQ0!\R6^IZ[>>+M>L=1G9WAN&*H5X W'I[=* /7/"?A=+FVAO;Z0,XZ1@
M@C% '2:[8W5U9QV=EB.)CB0@XXH 9'!:>&=(:129' ZG&6/^% 'G>L:M)J$C
M2/,TC_W01P/Z4 >*^/=9-W>K8HPV0DEU7H&]* .-H * -3P_XAU'PQJ\.J:7
M-Y5U%T)&00>H([B@"#5]2N=8U>ZU&\;=<7,AD<XQR>>E %*@#[QT7_D!:?\
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M#DY]J$"V.4ME?P5X[T[Q*H!M)9?*N-R_=#<%OUIC/IF*>.6%)$<%&4,#Z@T
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MG41ZHB&C9.EX "5&T8.T$YSV.15EES3-1A\,:]#<,Y33+X;)5P0$?L3_ %H
MV_%OBI-)T][6PN8Q?W;80KT0=WX_3ZT >:C3%9$ :*224XVYRQ)_^O0!ZO>_
M &XU5]/NK:_ALHG@07,10Y# <D=J /%?$VD-H/B/4-*9MWV29HP3U(!X/Y4
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MJ2".A% &I<VQCT^-V;<Q4$\],T 95 'WCHO_ " M/_Z]H_\ T$4 >'?M-?\
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M'M0!XW0 4 =EX+\6QZ(?LMRN(F;(D')'M]* .[U'Q-I]G:&ZAD,G&<#^'ZT
M>:>(O$\NM2@A=J 8VD9_*@# \U_+V;CM]* &4 /262-'1)&57X8 X#?6@!E
M'LG[-_\ R/.I_P#8.;_T8E "?M&_\COI_P#UXC_T-J /'* "@ H ?'D-N4X*
M\T ?2_PDUB'Q-\-)])?:;W3F;@CL264C]10!Q/Q"O[M+6*WB39;MU;!YQ^E
M&!X U62/4WM-TC!AQDYZ>@H ]BT]D>S>6[0D#[BGALT 0W$4-S$\$JJX<<Y&
M<#Z4!8\JUGX<:LDINK,13PNY"J6 /Y4; M-C8\*> YDU6PN-5\KRU;!BSG'?
M%)+425KGKFK2VUD(A$B(57A%7Y<>IIC/"/BY=/=:KI\>T$[&88&"<D?X4 <C
MI1U6TG>""T\XN"IC<9% %:UM-1U[6+;384,EW*XAC3I@YZ4 >KR?LYZTFE/.
MNK6S7@3(@"G!/INH \:N();6YEMYD*2Q,4=3U!!P10!'0 4 .CD:-MRXSC'(
MS0 WM0 4 ;LGA;4[$Z9)?VY@BOXS-%D\E >N.U $VO3Q-"D<<6&=N/H* .</
M7TH ^\=%_P"0%I__ %[1_P#H(H \._::_P"96_[>O_:5 'S_ $ % !0!JZ3<
M.I\GJLG QU_^M0!MV]B!C;'AP"%W< 9ZGWH OVFGM<3*'.\@[MT9# ^@/I0!
MV.BZ8D3@JH+;\'CN>WO]: .@UG2+:WNY;,XF 0%790W49./3GB@#EIO#<21M
MY)& W+%LEO;VH K-HDDLL<4+^:QSYC-].G'6E;6XK6E<U]/T.UTU%8,K.HW.
MC+A2:8S,\774MW#8^'[$;;O4)1%MSC R.M 'K7AF#1_!L$>CV,:DKQ-<L1NE
M<<8)^M $7BOPKH?CZ"6TNH(XM1,>;6[CQDX[9[@'J* / -"\8ZIX#OGTN6-K
MBTAF=9[21R%+9P2OH>* *OC/QU<^*YRD</V6Q# I#NW'\3WH Y&@ H * %W'
MU- "4 % !0 4 % 'LO[-X_XKC4SV_LYO_1B4 -_:-_Y'?3_^O$?^AM0!XY0
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M6@# ;C"XP10 V@#V;]F]F_X3;4UR=O\ 9[''_;1* &?M&_\ ([Z?_P!>(_\
M0VH \<H * "@":VE\J0G.,J10 R5-C\D'//':@#O_AIK::?>FRF<^1=';P<;
M'[?G0![*#Y42 , B] !WH =-'OV^:%D/\*DXQ]: &!UNQO&0(^"JC]>?2@"L
MBNK!$?.<Y.,<4 7?.5(7A$*[WX5NE '%^/-6GL]-BTJR4-J&H'R(]C?,<G!_
MGB@#TGX8^%+WP]\/8M*U5?(NFE>1PA!*Y/'/?I0!U$']FZF[+!+$YMGQF)P2
M"/7% 'AGQO\ !.N7FL7GB&*"-M-MX5=I/, 8#@$8^M 'AOF.$\O<=F<[<\4
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MP[K=SIMR.8F^1^SH>58>Q&#0!E4 % !0 4 2V]O-=W$=O;QM)-(P5$49+$]
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M&K7C?OA$1YL_J@_NIZT 9^F^*IH;-?%6IWUO;173M'(VW)AC0X6",=?4GZT
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M 2>25;$IV#]?RH :Y7H@PH]>] #* /O'1?\ D!:?_P!>T?\ Z"* /#OVFO\
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MKQUH Y!@#(0%(]CVH <PC50 /G]/2@!FX@\G//([&@!&D+$=!CH ,4 -))H
M/I0 I&W@]: $H ]F_9O;_BMM37 _Y!Y.<<_ZQ* &?M&_\COI_P#UXC_T-J /
M'* -'1M$O=>O&M-/19+@(7$98 L!UQGJ: *4\$MM.\,\;1RH<,CC!!]Q0!'0
M H)4Y!P: '^<6^^ _N>OYT )M5ONG'L: %&^(?*W&<_*: .TTGXL>+M&M4MK
M;5I?*0859,2 #T&[.* -$_&GQ5=1>5=ZA*O^U  F?KB@"M'X@LM3F%]-</\
M;<;6>0$L?QH 'ELIHC=3A9!@[B8^<>E ',ZEJ<7VY)+6W6/RAB-P-I^I'K0!
M/JWB[4-7NEN9I7\Y($@#$[CA>_- #M%U*Q0XNH(T;<&:4C)- &VVO6LNX+?Q
MPQ=P%PQH U;3XL:AI-HMK:ZK<M&H^7"@X'IS0 'X\^+(V(AG5EQQYB*3^@H
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M*AZ'- "-Y"  ;G;OV% #3*<8557C' ZT 1T % 'LG[-__(\ZG_V#F_\ 1B4
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MQG2K,Q9\OR4VYZXVC% %J@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
6 H * "@ H * "@ H * "@ H * /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>g10811sp042.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811sp042.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MY.Z<^6=P7%-T97M$4<3&WO:&DI# $'(]16&QU;BT % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M''3KUQ6-:G[2-D>EEN-6"K<\E=-6*7PW\$7?@VSOA?7,4L]TR$K"254+G')
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M2 ;WP_N-0N="G?49)Y)A. #.26QY49[]LD_K0!U= !0 4 % !0 4 % !0 4
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MF8X"@=230!!8ZC8ZI;_:-/O(+N$';YD$@=<^F0?<4 0Z=K6FZLTBZ?>Q7!C
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M[HTY.$;V/1Y] TJZU2SU.XLHY;RR4I;R/D^4#W4= ??&:]?8^(;N[LTJ!!0
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M:_>;.A:]'J-K"+EXHKQ\XC!QN [@?YZ5M2JJ:5]S@QF"=";Y$W%=3;K<\X*
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MSHIMTW+'RQ* "?I,?^^1@"@".X^&EE+/J<L6HW$)U.1GNE4#;)^]$J\>JD$
M^C'VH 27X9V4D2 7TWF1.LB%E!7(>X;D#&1_I+CJ.@H T;'P+IMGHNL:5DFW
MU5!'+L0(47R4BPN.@PF1Z$T 5KCP))>QV*W^LR7C6<;0IYUNFUHF"9!"XR?D
M'/3KQ0!<T'P;;:#K=UJ<5U+*]PDB%&  &Z>2;^<A'T% '2T % !0 4 % !0
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MUZX\3>$;+5;N.&.YEWB1(22H*N5Z'D' !P>1G!H Z&@ H * "@ H * "@ H
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M$D)ST7;D\ALD#\<;<TP',N(E"] &QS_#V_7%);@+,'\Y=G7C.#WR/Z9_"A;
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M>6_EY^[WSZXI\T.87+.P][6_\V+<K%@!M(_AJ5*%F-J=T/>UOC?,RAM^?O\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 R6,21/&3@,I4XIIV=P6AQ6D_#E-
M+U>WOO[3:40/O5/)VY_'/]*]&KCW4@X<NYTRK\T;6-/Q3X17Q-);/]M-LT (
M_P!7O!!_$>E8X;%>P35KW(IU?9]#0\/:*N@:2EBLYFVL6+E=N<^U95ZWMI\U
MK$5)\[N:M8$!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
D!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>g10811sp181.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811sp181.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M /CE !_PLNX_Z%'4_P#O_;__ !R@ _X67<?]"CJ?_?\ M_\ XY0 ?\++N/\
MH4=3_P"_]O\ _'* #_A9=Q_T*.I_]_[?_P".4 '_  LNX_Z%'4_^_P#;_P#Q
MR@ _X67<?]"CJ?\ W_M__CE !_PLNX_Z%'4_^_\ ;_\ QR@ _P"%EW'_ $*.
MI_\ ?^W_ /CE !_PLNX_Z%'4_P#O_;__ !R@ _X67<?]"CJ?_?\ M_\ XY0
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M8L?WO*\R3R=V<^5O.SKS]W&/:AWTOO9?UZ]_,-+OEV_J_P"-[&K4C"@ H *
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MX%I_C0 ?\)_X/_Z&?2O_  +3_&@ _P"$_P#!_P#T,^E?^!:?XT '_"?^#_\
MH9]*_P# M/\ &@ _X3_P?_T,^E?^!:?XT '_  G_ (/_ .AGTK_P+3_&@#D/
M!%Q#=^.+&YMY4E@FDUEXY$.5=3=1D$'N"* /7Z "@ H * "@ H * "@ H *
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MW(C-25U_7]?\#<N5)04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 8.OW5NESI"-/&
MK+?KD%P"/D>@#4GMK74HHBY$L:.)%*MP2/IU^E2XJ6_G^*:_)ATMZ?@T_P T
M4(?"NCV\OFQ6I63 !;S6R<*57)SSA20,].U4]4T^M_QW^;ZOMIL*RT\ON]+;
M6TVVOJ6M.T73])EN)+&W$)GV[P&./E&  .@'TIWLK>;?S>XN5<W-UT_ OTB@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MF@"]_P )EI?_ #ZZS_X)+S_XU0 ?\)EI?_/KK/\ X)+S_P"-4 '_  F6E_\
M/KK/_@DO/_C5 !_PF6E_\^NL_P#@DO/_ (U0 ?\ "9:7_P ^NL_^"2\_^-4
M'_"9:7_SZZS_ ."2\_\ C5 !_P )EI?_ #ZZS_X)+S_XU0!H:3K5EK<4[V33
M?Z/+Y,J3V\D#H^U6P5D53]UU/3O0!H4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0!S_@W_D!W/\ V%-0_P#2R:@#H* (+RY^
MQV4]R(9)O)0OY<>-S8&<#<0,_4BIE)15V5&/,[(RSXF@CET9)K*[A&JJ3&S!
M"L1V@A7(8X)S@$9&>,\BM'&TW!]/TW,U)."FMG^NQ4'CO1O[.DNRY0J[A8'D
MC65T638TJJ6^X#DYZX'2I[7ZV^5]KEM6;7:_SLKZ?U^ OB#QMI?A^PL;^0&[
ML[UBL4\$\"Q_=+#YI)%'(!Q@G./I1M+E?]?KU!*ZNO0NIXIT7[*MQ<:C;6D;
ML50W$Z(6(4,1C=P0#R#@C'(IM6=O7\';^O\ ,F#YU=>7XJXV/Q9HDM[';QZC
M;,DJ%HIUN(S'(02&12&Y88R1CI^-+O?I^6NOIH/M;^MOSNK"'QCX7 0GQ)I0
M#KN7_38_F'J.>1P?RHZV!:[%N'7M'N+J.U@U:REN)2PCB2X0LY7[V #DX[^E
M-)O83:6YBIX_TDZR^ERJT%S%-+'*)+BW'DJB[C(X$FY4(Z$C/J!Q2BU*/-?2
MU_36UO6Y4EROEZZ+UNK_ )&NOB30FW;=:T\[8O..+E.(\ [^OW<$'/3!%#TO
M?H"5[6Z_U^C^XJ7OBRPMK>QN;16U*VO2ZQ364L3H2H)QDN,DX(&,\\4.Z=K=
M+_E_F)6?7K;^O2Q87Q)I*19O;VWL)U1'EMKJXC62'=T#@,0#^--V742_K\BQ
M!K6E7-]]AM]3M);SRQ+Y"3JTFPX(;:#G'(Y]Z+/7RW"ZLGWV+U(84 <_X>_Y
M#GBS_L*)_P"D=M0!T% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M[6SO;N0["$BGD0(P"J$1F$98*"BG(^;CDGI2J.4T^[_S;O\ *[_4=-1A)/\
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MNTANIY];T:"-ED>60Z2RA ?,W')GP.)#R>RKZ4XR5.S[6_"W^2^92]Y[7?\
M7_!^]]QMKX'T[5=>GO=(\66+;XY'E@LK>)MWFAL,S!BVT[CD9 8*O]W--7C%
MJVGX;WL_ET\V^I+=[?GUT5KKL[K?Y'<^%M#?PYH4>FM-!*$DD=3;V_D1J&<M
MM5-S8 S@<]*)2O;R27W"2LV^YK12QS1K)$ZNC=&4Y!_&I&/H * "@ H * .?
M\/?\ASQ9_P!A1/\ TCMJ .@H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@#G_  ;_ ,@.Y_["FH?^EDU '04 % !0 4 % '#W
M_A[4-2U"2+[.=D<T\KS"^FM&DWJ/+VM$,L!C:02,8S@\5'*W#Y-?-N_W??VZ
M%W7-\T_DE;[[W_IF>?"?C!;&.)+R(.JHI5-7N(D8 8P-L?R8''RCYLY."!6D
MWS-M=6_QO_FM-M/-F=-<B2[)+[K?G9Z[ZVV1)X8M?$W_  D&L_VGYDC+:B*,
M/<W/D^9M )^=!&02,AHP2!G(R:4TITIJ/5NWIK\^OH]/FX7A.',]DK_AK_P^
MM_+98?#'BZ"PAL8[BS2%$0F5+Z5)O,"[>66,;D4X(4]<;3QTMRO/F?=_CW[O
M=>CONB(QY8I??\KZ+LGOY._1F1K6C>-[.W>/[3(\=S<KM,&HWDK*-TA.3''N
M3AD YV@H"V1Q4P:3BFMO\EU^3W[OKJ:-:-I_UZ?Y:[+8]"\/0216MU(\#V\<
MUPTD<+_>5< '/U8,W_ N>:;^%+^MVU^'W;$*]VWY?DE_7?<V*DH* "@ H *
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MC;E2<_\ 'QS]V@"Y]C\8?]!W1O\ P42__)- !]C\8?\ 0=T;_P %$O\ \DT
M'V/QA_T'=&_\%$O_ ,DT 'V/QA_T'=&_\%$O_P DT 'V/QA_T'=&_P#!1+_\
MDT 'V/QA_P!!W1O_  42_P#R30 ?8_&'_0=T;_P42_\ R30 ?8_&'_0=T;_P
M42__ "30!8T'2;S3&U*:_O8;NZO[H7#M!;F%%Q%'& %+N>D8.<]Z -B@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M_P#CM %&^\.V.F:CHUQ!/J+N+Y1BXU.XG3E'_AD<K^E '74 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'SMXR^&5_=_&BSM;.2
M=-*U=FNG=7($*@@S*/3G!'^^HH ]_FLT?2Y+&$+'&83$@QD*,8'%9U8<\''N
M7"7+)2['+W7@1KF9)3J*J45P%\G(8O$L;;N><!<CT]ZUO[S??[_B<M//6R?;
MU,:<73C%+=6_"WX.UVN^O0N:1X1_L358[FROW6U </;L"VX'&T DG&,9/]!Q
M2A[J:Z6^[5O];?>^H.&J:WZ^>EOTZ>7:YTU!84 % !0 4 % !0 4 % !0 4
M% !0 4 8^N_Z_1_^O]?_ $!Z -B@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M]O$D,$6HWZ1QQJ%5%%W,  !P !VH Z2@ H * "@ H * "@ H Q]=_P!?H_\
MU_K_ .@/0!L4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M'/\ N/0!LT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@#B_#6H:UHWA72-+N/!^K-/9
M6<-O(T<UF5+(@4D9G!QD>E &I_PD.J?]"9K/_?VS_P#C] !_PD.J?]"9K/\
MW]L__C] !_PD.J?]"9K/_?VS_P#C] !_PD.J?]"9K/\ W]L__C] !_PD.J?]
M"9K/_?VS_P#C] !_PD.J?]"9K/\ W]L__C] !_PD.J?]"9K/_?VS_P#C] !_
MPD.J?]"9K/\ W]L__C] !_PD.J?]"9K/_?VS_P#C] !_PD.J?]"9K/\ W]L_
M_C] !_PD.J?]"9K/_?VS_P#C] !_PD.J?]"9K/\ W]L__C] !_PD.J?]"9K/
M_?VS_P#C] !_PD.J?]"9K/\ W]L__C] !_PD.J?]"9K/_?VS_P#C] !_PD.J
M?]"9K/\ W]L__C] $GA*VN[70F6]M7M)Y;R[N/)D969%DN))%!*DKG:PZ$T
M;E !0 4 % !0 4 % !0!S_BK_F"?]A2'^M '04 % !0 4 % !0 4 % !0 4
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M!P#QD (=5O)=4-H_A_4(8 S+]L=[<Q$#.&P)2^#CCY<\C('. ".UUF_N//\
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M(+=1N"CU(H CAUF_DL[F9_#.IQ20[=D#R6Q>;)P=I$Q48ZG<5]LT ']LW_\
M9WVG_A&=3\[S?+^R^9;>9MQG?GSMFWM][.>V.: ";6;^.SMID\,ZG+)+NWP)
M);!X<' W$S!3GJ-I;WQ0 76LW]OY'E>&=3NO,B61O*DMAY3'JC;IA\P[XR.>
M": )(=5O)=4-H_A_4(8 S+]L=[<Q$#.&P)2^#CCY<\C('. ".UUF_N//\WPS
MJ=KY<32+YLEL?-8=$7;,?F/;.!QR10 0ZS?R6=S,_AG4XI(=NR!Y+8O-DX.T
MB8J,=3N*^V: #^V;_P#L[[3_ ,(SJ?G>;Y?V7S+;S-N,[\^=LV]OO9SVQS0
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M2&:.>%)H9%DBD4,CH<JP/0@CJ*IIIV9*::NA](84 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0!XE\9?'/BCPEK^FPV]G82Z8[I=6LCQ.7,B<,C$. >H/ '#"@#TVSMM6U?P
MQI;:R+>WU3=#<3I%&P1"&#[ "Q(..,Y/.:EQNT_7\4U^HI*\;>GX-/\ 0QG^
M',4J-%/?^;"RQ*4\LK_J@-A!5@0Q*C<>X '&*;7-J_ZT:^[6Z7>_<J3<I<WK
M]SDI/\K&_P"']#FT);F$W[W-N[*8D=<%,#!R<\Y_ # JW*ZUWN_Q?]:]3*,.
M5Z;66GI_7RV-JI- H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M6J@_-(W:@#H* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MW2TO9PN0EQ<Z=>/E-[8.QG+<_*N&)9<[B2O -UMKI\]]+[+O?;H]=2-%^/\
M[;\][Z=>ED:OB3Q!XRTKR;FVTA)(S&Y-O:P27K'E,$X\O:V"WRY.<'!/9;2M
MOM^O7[NFE[]-6E>*?];?I^.VERCJWBCQ&A@NETV]BN()"PM(M,N95 \IOE=T
M.V3<Q7&  IZ]*J*BIVOIM\KK\;7=_N$KRBKZ/1_.WY>7E?L:?BLSW]KK CGU
M**:VL%EM(;*26.1W8-SMCPS?,%&.V/<U*23N_P"9+Y:=OG]WD73=W%/9J_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M /L?C#_H.Z-_X*)?_DF@ ^Q^,/\ H.Z-_P""B7_Y)H /L?C#_H.Z-_X*)?\
MY)H /L?C#_H.Z-_X*)?_ ))H /L?C#_H.Z-_X*)?_DF@ ^Q^,/\ H.Z-_P""
MB7_Y)H /L?C#_H.Z-_X*)?\ Y)H L:#I-YIC:E-?WL-W=7]T+AV@MS"BXBCC
M "EW/2,'.>] &Q0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M /)- !]C\8?]!W1O_!1+_P#)- !]C\8?]!W1O_!1+_\ )- !]C\8?]!W1O\
MP42__)- !]C\8?\ 0=T;_P %$O\ \DT 'V/QA_T'=&_\%$O_ ,DT 'V/QA_T
M'=&_\%$O_P DT 'V/QA_T'=&_P#!1+_\DT &C7NL?\)#J6DZK<V5S]GM;>XC
MDM;9X/\ 6-,I!#2/G'E#G(ZF@#H* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MH::=F2FFKH?2&% '/V?_ "4/6?\ L%V/_HVZH Z"@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M6?\ L%V/_HVZH Z"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H HZ;HVFZ0)O[/L8;8SR
M&65HT ,C$Y)8]2>>] %Z@ H * "@"K%IMA!?SWT-E;QWDX EG2)1)(!T#-C)
MQ[T+166P/5IOH6B,C!Z4FDU9@0VMI;6%LEM9V\5O G"QQ($5?H!P*J]PZMDU
M( H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
- H * "@ H * "@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>g10811sp19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811sp19.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M_OB'_P"-T ']GW/_ $&+S_OB'_XW0 ?V?<_]!B\_[XA_^-T ']GW/_08O/\
MOB'_ .-T ']GW/\ T&+S_OB'_P"-T ']GW/_ $&+S_OB'_XW0 ?V?<_]!B\_
M[XA_^-T ']GW/_08O/\ OB'_ .-T ']GW/\ T&+S_OB'_P"-T ']GW/_ $&+
MS_OB'_XW0 ?V?<_]!B\_[XA_^-T ']GW/_08O/\ OB'_ .-T ']GW/\ T&+S
M_OB'_P"-T ']GW/_ $&+S_OB'_XW0 ?V?<_]!B\_[XA_^-T ']GW/_08O/\
MOB'_ .-T ']GW/\ T&+S_OB'_P"-T ']GW/_ $&+S_OB'_XW0 ?V?<_]!B\_
M[XA_^-T ']GW/_08O/\ OB'_ .-T ']GW/\ T&+S_OB'_P"-T ']GW/_ $&+
MS_OB'_XW0 ?V?<_]!B\_[XA_^-T ']GW/_08O/\ OB'_ .-T ']GW/\ T&+S
M_OB'_P"-T ']GW/_ $&+S_OB'_XW0 ?V?<_]!B\_[XA_^-T ']GW/_08O/\
MOB'_ .-T ']GW/\ T&+S_OB'_P"-T ']GW/_ $&+S_OB'_XW0 ?V?<_]!B\_
M[XA_^-T ']GW/_08O/\ OB'_ .-T ']GW/\ T&+S_OB'_P"-T ']GW/_ $&+
MS_OB'_XW0 ?V?<_]!B\_[XA_^-T ']GW/_08O/\ OB'_ .-T ']GW/\ T&+S
M_OB'_P"-T ']GW/_ $&+S_OB'_XW0 ?V?<_]!B\_[XA_^-T ']GW/_08O/\
MOB'_ .-T ']GW/\ T&+S_OB'_P"-T ']GW/_ $&+S_OB'_XW0 ?V?<_]!B\_
M[XA_^-T ']GW/_08O/\ OB'_ .-T ']GW/\ T&+S_OB'_P"-T ']GW/_ $&+
MS_OB'_XW0 ?V?<_]!B\_[XA_^-T ']GW/_08O/\ OB'_ .-T ']GW/\ T&+S
M_OB'_P"-T ']GW/_ $&+S_OB'_XW0 ?V?<_]!B\_[XA_^-T ']GW/_08O/\
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MBAWL_EJ%W-C+8&,G  S]*)/F;9$8\L5'L24B@H * "@ H * "@ H * "@ H
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M_0I: #3_ /C]U7_KY7_T3'0!?H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0NY] !DU,I*$7)]!QBY-)'-R>)]5A\/3:W)HD2VHA^T1 WGS&/ /SC9\K8Z
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M4N;C[BB-B/;+ 87.#C)&<'&:%J[('[JN]B_0!0A_Y&"\_P"O:'_T*6@ T_\
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MM4'//.2?PJW-RO?J[_?;_(A0C&UM+*WXM_J;-04% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 8OB33;S5;&.SM J R!FF-R\318.0P"@^
M9S_"Q />B.DXM[+^OQ_ '\+2ZZ%2\\/76H>)(-0DD%O;H$\Y8YMWG^7(6C!4
MIQC.<ANY&#P:<'RMO^KM6?X??Y!/WHJ/]='^GR^>G2T@*$/_ ",%Y_U[0_\
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MG#-UX5<$D^Q]J4=6H]_Z_'2WJ@?NIM]/\K_UZ,UZ "@ H * "@ H * "@ H
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M\@N#Z'^9KGEN;1V&P_\ (P7G_7M#_P"A2U)0:?\ \?NJ_P#7RO\ Z)CH OT
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M6KP !AD _O>N"#CWJY1<6T^A*9>_X0W2_P#GZUG_ ,'=Y_\ ':D8?\(;I?\
MS]:S_P"#N\_^.T '_"&Z7_S]:S_X.[S_ ..T '_"&Z7_ ,_6L_\ @[O/_CM
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MI[[-LMN9O/52-C@B1=I [$'##/.!57NU*7;_ (#^_P#(J;NY6ZMO[];?UO\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MWC37F >1"6L[90&1MK YMACGIZ]1D4EJKC>C:[?\.7/^$>U3_H<]9_[]6?\
M\8H SYH)[?68=)D\:>(/MDT;2HJV-NR%5ZG>+;:,<<$YY'J*%JF^PVK)/N58
M;J.?[/L\<>(@;A69 ^G0(0 <98&U&P9X!;&>V::5W9>7X[">BN_/\-_NZC+>
M_AN+_P"Q#QSXBBF,I@!GTV&%&D'\ =[4*6]@>>U*/O*Z_K_ANH2]V]^AN_\
M"/:I_P!#GK/_ 'ZL_P#XQ0 ?\(]JG_0YZS_WZL__ (Q0!''X7U&)YG7QIKI,
MK;VW+:, =H' ,&%& .!@9R>I)(!)_P (]JG_ $.>L_\ ?JS_ /C% !_PCVJ?
M]#GK/_?JS_\ C% !_P (]JG_ $.>L_\ ?JS_ /C% !_PCVJ?]#GK/_?JS_\
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MZL__ (Q0 ?\ "/:I_P!#GK/_ 'ZL_P#XQ0 ?\(]JG_0YZS_WZL__ (Q0 ?\
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MA3&H!)49.XX].]*E[O*W]F_XW_*_S\ARO[UOM:?*R7Z?([6@ H * "@ H *
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M5<\MS>.PZ^_X\+G_ *Y-_*E'= ]CSC7;^?3;!;F%T4+(H??"\@*DX/*GY/\
M>.0/2NC[27?^OZ[[&'V6^R)+FZGBU>QMU,?D3K)O!4[L@ @@YQCKVH3]YKRO
M^*_S!_"GY_H_\CO=)_Y!<'T/\S6$MS:.PV'_ )&"\_Z]H?\ T*6I*#3_ /C]
MU7_KY7_T3'0!?H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#(T[0Y-/NK
MF<ZO?7+3R;R)A%A>ORC:@..@YR<* #0M(V_K^NH/5W_K^OZWU+&C:4NC:?\
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M ,C!>?\ 7M#_ .A2U)0:?_Q^ZK_U\K_Z)CH OT % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % '&6ZHOASQ':0V%['YMS="..*U>)G)7.4RH'/.&Z$^IJ;?NHI_TN;JO2
MVF]BHOEK-^:_])77U3U[FCX(A-OX8BB^R&U"R2;4^SM N-QP5C8!D4]E/3WZ
MUK+I_7]?Y:&4;)NW]:+^F^KN^IT5069&K:E/93HD03#+D[AGO6D(IHB4FBA_
M;]YZ1?\ ?)_QJ_9HGG99T_5[FZOHX9 FULYP.>A-3*"2N.,FW8W:R-# \1_?
MM_HW]*UIF<S#K4S+.G?\A&W_ -\5,MAQW.RKG-S$\1_ZNW^I_I6M,SF<_6IF
M36G_ !^0?]=%_G2>P+<[6N8Z#)\0_P#'A'_UU'\C6E/<B>QS5;&0Z/\ UB_4
M4 =S7*=!GZW_ ,@N3ZC^=7#<F>QQ%SJ*VM[;V[VTY68[?.4#8K'H#SGG'8'W
MQD5LG=V,7HKC7U%H]4CLC8W&R3.VX^3R\@9QC=N_';CWH6K:!Z),]%@_U$?^
MZ/Y5SO<Z$5M6_P"07/\ 0?S%..Y,MC@M0TQM0E@?[?<VZ1')CBV;7^NY2?R(
MZUNE:7,8WTL-31K8:JNI2DS72)L1W1 4'.<$*#SGN<>F.:(KEO;J#=]#T/3_
M /D'6_\ US'\JPEN;QV'7W_'A<_]<F_E2CN@>QQ==)@% '7:3_R"X/H?YFN>
M6YM'8;#_ ,C!>?\ 7M#_ .A2U)0:?_Q^ZK_U\K_Z)CH OT % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 =N* .;B\07D7A"75)K9+J^262!(8!Y:RR"4QH!N)VY..IXS0[VCR[M)_>K
MO[APUE)/9-_<KFAX=U&75=#@N[C G8LLJB/R]CJQ5EQN;D$$?>(.,U4DE:W9
M?D0KZI[_ -?U?J:E24127-O$VV2>-&]&8 T[-BND-^W6G_/U#_W\%'*^P70Z
M.YMY6VQSQNWHK FBS071+2&<YXB_X^XO]S^M;4]C*>YCUH07]&_Y"T'_  +_
M -!-1/X2H[G65@;&!XC^_;_1OZ5K3,YF'6IF6=._Y"-O_OBIEL..YV5<YN8G
MB/\ U=O]3_2M:9G,Y^M3,FM/^/R#_KHO\Z3V!;G:US'09/B'_CPC_P"NH_D:
MTI[D3V.-?45BU.*R>VG E!V38'EE@,[>N<X!/3'OFMEJVC)Z),=::G%<ZQ/8
MQ1LQMMOF2!T*JQP=N-VX'!SR,>]):IL&K-(]&KF.@S];_P"07)]1_.KAN3/8
MX.]L;VYU"UECO(8[6$[FB: LS'U#;@!QQR#U^F-DFG<Q>UD6$MG^TQW$TBNZ
M1;,*NT9)!8]3Z#CM3V;!GH$'^HC_ -T?RKF>YT(K:M_R"Y_H/YBG'<F6QR-=
M!B% '9:?_P @ZW_ZYC^5<\MS>.PZ^_X\+G_KDW\J4=T#V.+KI, H Z[2?^07
M!]#_ #-<\MS:.PV'_D8+S_KVA_\ 0I:DH-/_ ./W5?\ KY7_ -$QT 7Z "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_D%P?0_S-<\MS:.PV'_D8+S_ *]H?_0I:DH-/_X_=5_Z^5_]$QT 7Z "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * (;NZBL;.:
M[G+"&%"[E$9R !DX502?P%)M15V-)MV1!<ZK9V>G)?S2,+9]F'6-F^\0 < $
M@<CGMWJFFI<CWO;YDJ2<>9;6O\B[2&% #9%+QLH8H2" RXR/?FE)<R:&G9W,
M./PEIK>'[?1+\'4K*"(1HMY%%)@C.&^X!N .,XIU/?U81DT[WW;;\[NYK6%E
M!INGV]E:QB."WC$:*H   &!P.*J4G*3DR(Q459%BI*.;U2_NH=2ECCG94&,
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MN\MK"UDNKRYBMK>,9>65PBJ/<G@4#2OL,N=1L;*&*:ZO8((I65(WDE"AV/0
MD\D]A3L[\O45].;H6:0!0!4U2&>YTF\@MEC:>2%T02,57)! R0"0/P-14BY0
M<5U+A)1DF^ACW^G:Q<>$ETV*"R^UB"%?FN7";E(W#/EDXP.#CG/05M-J5126
MW,G\KW,H1Y:?(^S7X6.B&<#(P>^*@I"T <Y>:O>0WDT:2 *K$ ;16R@FC)R:
M9!_;=]_ST7_OD4^1"YV:FC7UQ>-,)F!V@8P,5$XI;%Q;9K5F6<GK/_(6G_X#
M_P"@BMX?"8RW*%62;'AW_C[E_P!S^M9U-BX;G1UB:G+Z[_R$C_NBMX;&,]S,
MJR33T+_D)#_=-1/8J&YU%8&QSGB+_C[B_P!S^M;4]C*>YST%_;7"W#1N<6[F
M.7<A7:0,GJ!Q@@YZ5=TH\W0BVO+U+OA;4K75+^*:TD9T5F4[D9"#MST8 ]"#
M[@BE->[<J/Q';USFQ@>(_OV_T;^E:TS.9QT,6J?VQ/<S6]H(=HCB*SL6*[AG
M(V#!ZGJ<\#CK6D=$[_UO_7WF;M=6+WABVNK74)/M21+YMXTD?ER%LJ2,9RHP
M?;GZU-K4TO7\V_U*^W=>7Y)?H>A5@;&)XC_U=O\ 4_TK6F9S.?K4S)K3_C\@
M_P"NB_SI/8%N=K7,=!D^(?\ CPC_ .NH_D:TI[D3V.:K8R'1_P"L7ZB@#N:Y
M3H,_6_\ D%R?4?SJX;DSV.4K<Q"@#MX/]1'_ +H_E7,]SH16U;_D%S_0?S%.
M.Y,MCD:Z#$* .RT__D'6_P#US'\JYY;F\=AU]_QX7/\ UR;^5*.Z!['%UTF
M4 ==I/\ R"X/H?YFN>6YM'8;#_R,%Y_U[0_^A2U)0:?_ ,?NJ_\ 7RO_ *)C
MH OT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!D^(+>YEM
M+>6VMFNGMKA)C;HR@R@9X!8@9YSR1TJ6M5\_Q30]XM>GX-/]#G=0\/:K<Z#I
M.FPQE)X86MIG=4DA"/'AN-X;CH" >1TP<U>]2]]/SLT[KS=OZT#FLKI=;I??
MH_*SU_"^J.V1?+C5,D[0!DT-W=R8KE20ZD,R7U^W1V4Q294X[5I[-D<Z&_\
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M*W,0H [>#_41_P"Z/Y5S/<Z$5M6_Y!<_T'\Q3CN3+8Y&N@Q"@#LM/_Y!UO\
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M<O\ N?UK.IL7#<Z.L34Y?7?^0D?]T5O#8QGN9E62:>A?\A(?[IJ)[%0W.HK
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ME%U(4<"4*PP3R#[TI*$Z/.ENK_@/WH5.5O9GU37CG:?'?C%2_C[7T499M2N
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M#]61>,8Z'&2!DU=*5ZLTG=:=;_T^Z):M2BVM=?T^\^L:\8[3YR^/W_(]V/\
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MFT?<A(Y',G4?2FG8'J4O^$9O/^@E#_X#'_XNK]HR.1!_PC-Y_P!!*'_P&/\
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M=&&(&,K&[M&!MP5RJC)R?O#.1D3>T6][)OUVM^;VMM]]6]]+H[+TWU_+?O\
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M\]PE>*E;HY?AM]^S_P""7/!]WJ]S?W3:CJ.H30K-/#$+E+58I=DI4&/RP'R
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MO6Z"3Y?>2^7S23_-OTZ$=OK&I1QV&HRWDUS&8I/.M([=6WJH;;(NT%BS,HP
M<$$X'&:+];;I/T;MI^=]]@L]NS:]4FU_E_3,*/7]>U6]LUM]0U:)9/M0E6WL
MX(1'Y<J!69;E VT*^#CGCIG-5%)>\]M/3=WO;76Q4MG9=?SC?\_ZV/348-&K
M*P8$9##H?>D]&0MCEM=O]2TV_GD@U$O#)"5,1B3;;,64*P.,D[2[$,2/E[=Y
MCK[OFM?5V_R^?J5*R5^R?X)O\UY:7[7([2]U4M8N=6:4QW4EL\;Q1@7"*[+Y
MC$+P?NCY<#/&.0 ]79I;K[NWWOUT?E<4E:Z[-?HW]RO]QD7E_P"(U^Q6XO\
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M2&0W5I;7UK):WEO%<6\@VO%*@=6'H0>#2:3W&FUL5K;0](LC;FUTJS@-LK)
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M_P#7RO\ Z)CH OT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % '@'Q(_X3__ (3[4_[$_P"$B_L[]UY7V/S_ "O]4F=NWCKG
M..^:].A['V:YK7^1R5.?F=KG4^*-.\SQS>W5CI&ZYVVQ64:+,TDLBL2WEW0
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M &G_ /'[JO\ U\K_ .B8Z +] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M^?&S_P# MO\ XW0 >=J__/C9_P#@6W_QN@ \[5_^?&S_ / MO_C= !YVK_\
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M^!;?_&Z #SM7_P"?&S_\"V_^-T 'G:O_ ,^-G_X%M_\ &Z #SM7_ .?&S_\
M MO_ (W0 >=J_P#SXV?_ (%M_P#&Z #SM7_Y\;/_ ,"V_P#C= !YVK_\^-G_
M .!;?_&Z #SM7_Y\;/\ \"V_^-T 'G:O_P ^-G_X%M_\;H /.U?_ )\;/_P+
M;_XW0 >=J_\ SXV?_@6W_P ;H /.U?\ Y\;/_P "V_\ C= !YVK_ //C9_\
M@6W_ ,;H /.U?_GQL_\ P+;_ .-T 'G:O_SXV?\ X%M_\;H /.U?_GQL_P#P
M+;_XW0 >=J__ #XV?_@6W_QN@ \[5_\ GQL__ MO_C= !YVK_P#/C9_^!;?_
M !N@ \[5_P#GQL__  +;_P"-T 'G:O\ \^-G_P"!;?\ QN@ \[5_^?&S_P#
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MW0 >=J__ #XV?_@6W_QN@ LX;O\ M"XNKJ.&/S(HXU6*0O\ =+DDDJ/[WZ4
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>g10811sp37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811sp37.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M$RE8=S(HSD@GF1>@]:V]F_:.GV_X/^3,U-2@IKK=_)?\.6]5\0_V7J]AI_\
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M"BU&US1M(7M[6.&25I608WMU/UK*34G=(I*Q-4C"@ H * "@ H * "@ H *
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M85LG.!CG%>C2I7PL]5JT]U?3FOI>_4AOWCKZ\XLYKP1_R"+_ /["^H?^E4M
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M(MFZ.E D% '->%O^0OXM_P"PN/\ TEMZ .EH * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % '->"/^01?_P#87U#_ -*I: .EH PF@'_"9I-_PCR$BV(_M7<N
MY>?N8Z]J(:<W3]=OZ^02^SU_3?\ KYF[0!A>*/$+>';2UF6W28SSB'YY-@7*
MDYS@^F/QHCK-1[C:M%R[&Z.E D&* .:\+?\ (7\6_P#87'_I+;T =+0 4 %
M!0 4 % !0 4 % !0!E7VKSV6HP6B:5<W GX26-XPN0,G[S \#GI6<IN,DK?D
M=M'"PJTI5'42MT:E?\$T:M:'$% &3XB^U1Z3+<6E]-:20C=F-4;=['>I_3%9
M5;J-T['=@/9NLH5(*2?>_P"C1I6\3PP)&\[SLHP9) H9O<[0!^0%:)65CDG)
M2DVE;R5_U;?XDE,@9-*(8FD*NP7LBEC^0I-V*C'F=D06.H0:C$9;<2; <9>,
MIGMQGKTI1DI*Z-:U"=!\L[7]4RU5& 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 <UX(_Y!%__ -A?4/\ TJEH Z6@# NM9:S\2VMC-JU@JW+;
M([,0.TY."<EPV%& >JXXZT0]YM?U_6J"6BN;] &7KO\ ;!M81HD]E#<><OF&
M[#%3'_%C'?I_];K0OB5]NH/X7WZ&I0!335+*2XO($N%>6R -PJ@DQY&1GWP,
MXH6JNO3^OO!Z.WS_ *^XP/!=W#>WWBJYMV+1/JWRDJ5/_'K;CH<&@#JZ "@
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MU&[MYD@$=N5&4)R<KD=:SC*3DT^AV5J5*%*,XMWE^CL:5:'&% !0 4 % !0
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M_P"<J!V'.>>.M<T.3VCLOP/:Q*Q#P4%*=TKZ<R>]K:7O^&AU%=)XH4 % !0
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MP2,'''?VKGE14JBGH>Q0S.5'"2PR<M?/;?1:;.^NO0Z6N@\<YKP1_P @B_\
M^POJ'_I5+0!TM !0 4 % !0 4 <UX6_Y"_BW_L+C_P!);>@#I: "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@"I?Z5I^J(B7
M]E!=*ARHF0, ?;-3*$9_$KF]'$UL.VZ,G&_9V)[>WAM+=+>WB6*&,;41!@*/
M0"FDHJR,YSE4DYS=VR2F0% !0 4 % !0 4 % !0 4 <UX(_Y!%__ -A?4/\
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MM1MI;S3Y[:&X:WDD7:LJYROY$'\B#[U#5RT[%==-G6UT^+[;(K6K!G(9SYH
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@!I=595+ ,W09Y- $?VNV\CS_M$7DYQOWC;GIUH
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M#^\4KO;LUZ/O^7W#I=%N+C0(M-?5[M)DQFZA<K(V#ZY].*3UL^W^7],:TO\
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M "@ H * "@ H * "@ H * "@ H * .:\+?\ (7\6_P#87'_I+;T =+0 4 %
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MI]*I*HXW5[(+ZER."*$L8HU3<=S;1C)]36;;>XR2D 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!%<B=K:46KQI<%3Y
M;2(64-V) ()'MD54>5-<VP&5X7O-3U#1(KS5)+5Y9OF46T+1JJ],$,S9.<\\
M?2M\3&G"HXTT[+N[_HA1O;4VJYAG->%O^0OXM_["X_\ 26WH Z6@ H * "@
MH * .:^'O_)./#?_ &#H/_0!0!T,\T=O;RS2N(XXT+,Y_A &2:<4VTD!YYX-
M^)V@ZHVH"^\2(ABE(B^W".W#1Y.TJ>,G'4=O2O8Q>65Z7+RT]UTN]3.,T^IV
M%OXJ\.W>[[-KVFS;<;O+NXVQ]<&O.EA:\/B@U\F7S+N3_P!NZ/\ ]!6R_P#
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M2-AS_=,9'3WH4<.UK)I^B?ZK\@U%EUG5[< OX8NYO7[-<0MC_OMUI1HTI?\
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M*LS":T,VYE(*]'7 ZYZY]JZ</5IT[\\6[Z:.WZ,33>QM#( !.3W-<PQ: "@
MH * "@#FO"W_ "%_%O\ V%Q_Z2V] '2T 9EPT_\ ;UK&-(CFMC&6>^:108F'
MW5"D9/4\CIGZT1W?3]0>R-.@##\1?:8TM9[+0(-7N8WRHED2,Q#KN#,..0.G
M-$?C7Y_U\P?PO\C4DN7CNX(1;NRRJQ:0?=0C'!^N?TH[AT3*4>HZC>:,+NRT
MQ%NV; M[R9H!@'&2P1B./]G_ !IM6#9M&?\ #W_DG'AO_L'0?^@"D!TM !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!S7A;_D+^+?\ L+C_ -);>@#I: .<U/1Y+WQE
MI5^;/?#:HW[_ /<'8W.  T9?GH2K+U'!Z@A[LI/R">L4O,Z.@#&UZ708Y-/&
MMP6LK23B.U-Q$KXD/3:3T/ZT1^-);@](MO8V: "@#FOA[_R3CPW_ -@Z#_T
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MQX;_ .P=!_Z * .EH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .:\+?\A?Q;_V%Q_Z
M2V] '2]* .>OH+5?&.FRI9Z>UX4<^;)>&.<+C!*QA3Y@Z Y(QQ1#1RMV_K\M
MPEK%7[_U^;T.AH Y[Q7;"[AL("^KQB2X";],;:RY'5S@X7WX^OJ1_B)_\-\P
M?P/^G_7]>:Z$# Q0"T*-YK.F:=IYO[S4+:"S!VF>24! <XQNZ=>* ,CX>_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@#FO"W_(7\6_]A<?^DMO0!TM
M'.:G>:I%XMTZVLX=0EM9%W3E%C6VC7)&68H6+9QA58<<G&.2&K=]OZV_4)Z1
M36]_ZN='0!SGB:^T^'4-&M;S4;FSEEN0T*V]RD7FD<;7!()4Y' [X'4@%P5Y
MZ=%_7]?\$):0;Z'1T@"@#FOA[_R3CPW_ -@Z#_T 4 =+0 4 % !0 4 % !0
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M=<<!;213GZ^8:ZTJG5K[O^"?/RE@FO=A)?\ ;R?_ +:B4?VVJG)L7/88=?\
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MQ*Y]O6N6CAZ:G+K8][,\WQL\-23]WF5VU=:W:M]RO;]#T&*"&W7;#$D:^B*
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &?JFEMJ?D
M:A<V@A<.! (SE@<@G>K=*SG#FZV.K#8E8>_N*5]-;_HT: X &<^]:'*% !0
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M;V5Q](84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>g10811sp48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811sp48.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M3E<]#_K>0.0%SWH [S2[[^TM,M[S[/-;^:N[RYEVLOU% %N@ H * "@ H *
M"@ H * "@ H * "@ H * "@#*\1:'%XCT>32[B>2*WE=#+Y?!=58,4SV!Q@^
MQH @T/PM9>'=1U&XT]I$AOO+9K<L6574$;@3SDC&?]T4 ;E !0 4 % !0 4
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M H * "@ H * "@ H * "@ H * "@"CJ^K0:+8M>7,<SQ+][RHR^T $DG'0
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MD@9]!GG&<4 <UXLURTU7PQ9.@>WF.K6:&WGPL@*W$>> 3V(/'K0!WM !0 4
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MFU6XOF+&-DV1)Y>#@J"#DD84X^HSQTH H_#5!%X/\L,S!;Z\&6.2<7$G4]Z
M.OH * #M0!SV@Z^NM:;)<:8[7ZK/)%YTA5%&UB,<#/3!Z=Z[*^']C-1J>[HM
M/E_74E.^QHR6%S=V\D5U?2)O4J1;?N\9]#R<^^1]*Q52,'>,?OU'8@T[0VT7
M2X+'3KZ;RH%V(MR?-&.PSP?;K55*_MIN<X[]M 2LK(I^)M4_LWPMJ%QJ<301
MQQ$F:"0D _P\C# YQV_&M<-2]I6C&F[Z[/\ JPF[+4T;/5+>XLX9+&"YF@9
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MN/\ M$]?+7\39EL[H6DRIIMG+*48#SIVDW''0DKTK5Q=MD;PIX927-)V]/\
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M0!2TY59)KD'/VB4MGU4?*N/P /XUI4TM'L)&!KNI:C'XOTJSL-.2Y3&992Q
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M&5@RGH0<T&9!?7D=A92W4W^KC&30 ^VN$NK6*XC^Y(H8?0T 2T % !0 4 %
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MRL3Z=8#3[58O->9QUD<Y9N:0RW0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M''>'+U&\::[;XU,3R$321W7EA(@,(-H!)(.W(/3% '8T <E\18TF\-6\4BAX
MWU*R5E/0@W" BDTFK,32DK,?;BP\,W]Q;I"MO:1D7"B-"<(_RMP.P8+2:C"F
MFNFGW_TS7"4N9RH4UOJE_7S)=<MDUS0;BR=WC;5B((B!AE3KNY] &;GZ5I1M
MS*<E=+6WH+$Q22H]M_7K_E\A-,\*R>'O#)TO2M0F>4,7$MR0Q8ELG/'\JNM4
M52;FHI7Z+8RC%15D=%#$(EY.YS]YCU8UD424 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!QOQ%;=I%M;OI#:A#),"V&D781R#\BD^O;H".I% '2Z//+<Z-9S
M36C6DCQ*6@8Y,9QT_P#UT 7: .+6T:\U_P 81(2)!]F=".S"/(_E34G%J2Z$
M35XZ&S8Z@K:?Y:RJDLI!CY&0&&XG\/F_[YJ)+EDX([N7G4:K6EM?EI^.GWE2
MRT2WO7M-42/&YS(K;RI"8 3C']T X]2:UDE'W5T.3F<VYOJ:4.DPQ:Z^H;)&
MD,03>SY&?I]*@#4H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@#B?&3QQZ[8%Y+%#]CN2/[0C#0G&PX!+##'C\,^E "7>N7/ASP%H,]F-^^
M*.,R749R!Y+,H90>&9E5.O5N] %U/%,LWC'^RX%2>U^R&4")=SF0%@PW%@
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MR16D0M;>23[S*OWG]LD?DH]:T4?905,PQ%9XBM*LU:[N;E29!0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!S'BF..34=*1C 9#YVQ;F)9(ON@DG++\W&!
M[$]LT 4(M:.@?#;2KVS/F1E8D$MTN%C1CC<P!Z#/8XZ<T 3MXQE_M30+7RHX
M_P"T(@T\>-\D<A"G8!N&,!LDX.!@XH D\-S-/XO\4.T$D!W6XV28S_J^O!-
M'.MIDX\<S6'VF;9(AA6($!1"Q+,?R+#ZGTI^R=UB+[>[\^GX:_([%C8+ /!\
MOO<U[^1Z8JA%"J % P .U(XQ: "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * &2PQ3*%EC1P#D!E!P: 'XH , =J .3^'/_(J/_P!A"\_]
M*)* +WAKPE8>%FU V,D[F^F\^3S6!PWMQ[UK4JSJVY^BLM$M/D9PIJ%[&]61
MH% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %.VTG3[.ZDN;:TBBFDSN91
MSR<G'ID\G'4T .;3+!IY)VL;<S2$%W,2[F(Z9..<4 <SXWM+:R\,64%I;Q6\
M*ZI98CB0*H_TE.PH N^./#MUXI\,RZ79WHLI7=6\T@G !Z<5OAJD*5:-2:NE
MK8SJ0YU8T/#NF3:-X=L--N)Q/+;1"-I " Q'?FLI\KDW':XX1Y(J)IU)84 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 17%M;W<?EW,$<T><[9%##/T- $
MFU0NT ;<8QCB@ VC.<#- '-Z)_R.OBGZVW_HN@"FWAO4C\4E\1>8OV$6OD8W
M\XQTV_[W-/VU>WL=.3?;6_J<W+5]MS?9.QI'2% !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!C>)/$"^'K."8VS7#32,@4/MP%C>1C
MG_=0X]\?6@")_$\$?B(Z5)"4C$7F&X9P #M+8(]-H/- &!X"U_1[+PX]O<ZG
M:PS?;;I_+>4!MK7$A4X/8CD&@#I_^$HT'_H,67_?]?\ &@ _X2C0?^@Q9?\
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M,$YGW$>BF@#TN@ H * ,!_"ELUY>S_;+D)=AE>+*[55\>8!\N?F(!//&.,4
M0R^%= M=)=]9C2^CMR]Q)<WJJ2.A+'  & HZ#M0!!H?A?PM>:+;2V]C;W:!=
MAF>(JS,IVMN!Y!R#D'O0!H?\(;X<_P"@-:_]\4 8^OZ#X-M+<V5Q'9Z?<7,;
MF.0)\RA5+,WL %)S0!>T_P />$M4LDN[/2K9X6) +0E""#@@@@$'([B@"U_P
MAOAS_H#6O_?% '/ZI9>![+4H[>>VB@FMF\QXEM7;S@5V[1@?-@R(<#)'&: -
MR#PIX8N8(YX=)M'BD4.C!.&!&0: )/\ A#?#G_0&M?\ OB@#G!:^!#J2R^5
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MMT9R^*/]="_5F@4 % !0 4 % !0 4 % !0 4 '>@ H * "@ H * "@ [T %
M!0 4 <OX-_U_B7_L,S?^@1T =10 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MMW907*8VS1JXPP/!&>HX- $U !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M^9ISQ>Q.NHEQE+&Z8?[@7^9%/V:7VD.XXWES_#IL_P#P)XQ_[-2Y(_S+\?\
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MEZUW;#RI%D9(K79L*NS!8OF_=J=^&'.<>] ':4 % !0 4 % !0 4 % !0 4
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ME2A%*75E_6*SBH<SLMM=BK_86@_\)(;P"-=1\G9Y2R8^7UVC^=9_5U?VEO\
M(Z?[1Q'L/J_-[M[^9I'3+4]I5_W9W'\C3Y$<ZQ%1=ON7^1EQ>&K"+Q'/J27]
MW]HDA$9A^TDA0,<^O_ZZA4+2Y]3KEF526'6'<8V3O>RO_D:GV!A]R]NE_P"!
M@_S!JN7S.7VRZQ7]>C.0A>*U\?ZH+GQ/<(BVT7[J26)5&2?\#V'4^O/0L+4<
M%.,7K?7TM\OP-)8Z+IJE[-::_P!=?O;V-X7NAOPVN(__ &^X_D14_5:O6+_$
MR^L-;)?<OU'K=>'QQ]NMW_W[G?\ S)H^K3_E?XB>)GW_  2'B[\/YXDL2?\
M@.:/J\_Y?P)]O4_F?WDJ:CH\8PD]NO\ N@"G[":^R2ZDGNR0:QIPX%TGZT_8
MU.Q%Q?[6L?\ GN/^^3_A2]E/L%Q?[4M/[[_]^F_PH]E(+F9X>U'3K[4M>2RD
M1I(;M5E 7:0?+3K^(;\<UOB*=2$*;GU6GWL2:UL;]<A04 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '(Z3J]Y-XJET^>TBBV;B<6\
M:.!S@DB9FY_W>?:@#KJ ./\ !]RWVF\M?M*[?MEX_E<9S]H?\:B_OVN9\WOV
MN=A5FAYEKMO<:A\9])MX;G;%';&60!QE=N>@/N5[?RIPH<W-7U]W3RUO^@E0
MI.:K2EJNG1_U<] M])L+2\DO(;6-;J5=LDV,NX]SWK-0BG=+4Z9XFM4@J<I>
MZMET7R+A52P8J,CH<=*LPNUH+0(HWE^EK>V=NTT:&X<KM8<GCMSZX'XT 7J
M*]S/)#) J(K"1]I+-C'&?3VH L4 % !0!')!%*,2Q(X]&4&DTGN5&<H_"[$"
MZ99I_JX!%_UR)3^6*7)%;&KQ%5[N_KK^8-8_\\[JXC^C[O\ T+-'+V8*MWBG
M\K?E8%@NT&%O0_\ UTB!_EBBS74'.F]XV]'_ )W,KQ(VNQZ'<+IUI;WD[84(
M"5.,\G!/]:RJ^T4'RJYVX!81XB+K2<5]_P#7W&W;-*]K"T\8CF* N@.0K8Y&
M?K6RO;4\ZHHJ;4'=="6F0% !0 4 % !0 4 % !0!QEL)[OQC(VH:+=1HCGRY
MTW^4Y5V$;,,X.$P<XZGV% %S5-#O;WQIIFIQPVRVMK&P,XD(FW$,,8VD%1NS
MC(R3SG % &?X"CDCU/Q/%-.UQ)%J+AI64 L2!V  ["I^T;/2BO5_H;6G:3J-
MKXDU"]N+J*2PE4"VA5<-'ZY_7UZ]JSC"2FVWIT.ROB:,\+3I0BU-;OOV+\MY
M)%JBP,(UM_):5G)((P0/IWKK4$X76]['F&5IU]K5QKNJH-)%O8[T:WN9WQYH
MV@'Y1R.1WQ714A1C2@^:[ZI=!)NX\6_B+_A*#-FP&FFV";]K&3>"3]W/3G'6
MES8?V-M>:_RL&MS6V7__ #\6_P#WX;_XNN>\.S^__@#U.0BU2['Q&OK.:\TV
M"%+11Y@7$N[(/()XX/OT'%:NOAE24+OF3VZ6_K\S'VL?:.#9T*_V=(NV;4'O
M#W'F9!_X"F!^E8^W7V;(TYH]S!TR^\.P>/=0MK72_L]Z+= TZV^T%1C(XY[K
MV[5D\=.I+V,I-I:G/&O!UG"QUD=]8R-MCN8"W]T.,_E3YT^ITJ<7LRR IY %
M,H7 ]* "@ H * "@"**UM[>21X8(XWE.79% +GU/K5.4I))O8"6I * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#DK?2W3Q_/?'0=
M@;)^W^>=K#RP =N[[V=R_=''>@#JO-C$PA\Q?-*[@F><>N/2@#RKPG'IB?$&
MZN&F(OOMEVFS?QS+(.F/IW[US^RM5]H9?5DI_6->WE]YZ+!JD3ZA?0FXRMJH
M9U\LC9^/>MV[&C=M3'\/:39ZAJ$OB6YLXVO7D802L/F1.1@'\2/PK:-6<*/L
MT]):M?E^%BYJS2:U7]/_ "^1U=9$D$D[1W,46P%7!.XMC&/:@!#<-*2MLH?_
M *:'[H_Q_"@"-],MYWCDNT%Q+&259QPI/H.@H D%C;+]V/9_NL5_E0!4O=#M
M;Z6VDD:4&WDWK^\)_G^'Y4 6C:R#[MY./^^3_,4 )Y%TOW;S/^_&#_+% "A;
MY3_K8&'_ %S(_K0 [==C_EG$?^!D?TH 0RW*];93_NR?X@4 -^U2K]ZRF^H*
MG^M !]N0?>AG3ZQ$_P LT 4=9U:WM=*EFS,"N,;%96'\J -6)@\*, P!4'#=
M1]: 'T % !0 4 % !0 4 % !0!YYXGN9YO&:Z1:ZO-:7-Q$IB*RRJL9 (QM5
ML-DD'..U 'H0!"@$Y/K0!PO@VX\CQ1XFMF0DW.IRNK9Z!40']31&*LY7-ZCM
M3@O5_C_P#NZ# X!]3>^^+-K;><QL%M&18B/D=\[M_7_9P..V?0UT?6*=*G[#
ME?.];]O(Y_:+VW(=O#>13W,T"!M\)PV1Q7,G=V-T[NQFR^)[&+Q VBX=KL)O
MVHI.>,XJ'5BI<O4R=:*GR=2^5N[C&6^S1]U&"Y_'H/PS]:K5E^\_(H6^DZ1#
MXAFN8[)?MYC&^=GW,PX'<^P[5*IP4N:VI*HP4N=+4V@ . ,5H:E5+F%M0DMP
MF)44,6RO(/XY_2@">2&*9=LL2./1E!I-)[B:3W*ZZ;9H<QP+$?\ IGE/Y4N5
M+8GDBMD*UD /W=S<1GU$F[_T+-'+YAR]F1^3>1_<U!6_ZZQ _P#H)%%I=PM)
M;,<)[I%^8VKGU$A3],&CWA^\,;46C^_;%AZQR(1^I!HNUT%S-=!!K5D.)'>(
M_P"W&?Y]*.9!SHK:+K::K>:C%'*CI;2!5**1QSSG//(/Y41=V$6VV;-46% !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!R'AO4 ;V*
MP;7;F^N5\SS;;R!B'!/#MMW+[;CD^XH T)O#I?Q<^MPSB!I+!K5W0 R9W*58
M9!' !XQWH X+0O#UW:S3ZQ>W4,UFMU/;3;8BL@*NR>;D'^\,GZUO*-&5-J"?
M-Z_\#L53C*7[MO?\SK]:N;:328H+'REU"\*V^V,@8YP00.PYKE5IM1[[_J33
M=WZ:OY?\'0U[2\LM-^RZ0S>5*D>%#D<@#KGO6LI<SN-MMW80ZR)M8N;&)?-\
MI P**>_^UG'^?:I$.ET:*]U"WO[P!IH 0J+]W!]?6@#4Z4 % !0 4 % !0 4
M % !0 4 % ",JLI5@"#U!H 6@ H * "@ H * "@ H * "@#E+"ZOK_7Y;AX+
MY(HKB2W&V.$P[48C.6_>#/?'X4 7=1N]5@\7:3!!\VFSPSF9%BR=Z@%<OVSG
M@<=Z //O#EGJE[XWU'6(%>VBBO'$RS C9(P(V#L>V>?X@:;4Z;C>UGOM?H93
MJ5)2CV2M^?\ F=NOB"2^O[S3981 MLH,Q5B7((Y4#'Z]AZ&MW&%.*FG<MON6
M4T*2>^_M&9PDI0H(.=BC/R]#U ].]<MK[B4;K4JZ?9^(_P"U]0%W<*MDQ'ED
M8![8Y R>/I4J,KZO0E0DGJ]#0A\-64.I_P!HKN6YV;-R?+^/KGW-6HI;%J*6
MR-'[&G>6<_\ ;5A_(TRBLNB6*7SW@23SW0(S&5LD?G_G% %C[!;^C_\ ?QO\
M: (%T33TO)+H0?OI%"LVX]!_G]* )AIUH/\ EB/S- "_V=9_\^T9^JT ']G6
M6<_9(<_[@H <+*U7I;1#_@ H =]F@'2&/_OD4 .$,0Z1H/\ @(H 4(HZ*!^%
M $4%C:VLLTMO;QQ23'=(R* 7/J?7J:226PE%+8GIC"@ H * "@ H * "@ H
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MJG.32BWH@L3U(!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MR7W$N>A(/ ]J .KH YGQEX7G\36UDEM=I;RVLQD!==R\HRYQW(W9P>#C!ZT
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MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
C0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>g10811sp68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811sp68.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M(OSC:"&(]!V':@!3XZU#3KV9@]N(+C5C$RS,TL@4Q0$+&AD7O(<[,XZ[#R:
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!QOC/0%O=<\,ZK!:2SW=MJ4*LZ[F$4.'+''0#)&3]*
M .+N_#&NWIN=-M["XCNX3K#/<,NV.47 /D[9.ASN7Z;><4 26FG:C'XHMO$;
M:-?C2H)K=7M?LI\W*V<L;,(^I 9T7..V1P,T 9UAX3\16.B)I5Q87+WM[:Z4
MD$RIN6V,,[/(KMT3:I!]^V: .\\6Q^+]+TW6=:L?$UK':VEO+<QVCZ8&.$0M
MM+^9WQUQ^% '6:7<27>D65S+CS)8$=L# R5!- %N@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * $+J"06 *C)YZ#_ "*
M$1UD171@RL,@@Y!% #J &O(D2%Y'5%'4L< 4 .H * "@ H * "@ H * .?\
M'?\ R3SQ+_V"[G_T4U &AH7_ "+VF?\ 7K%_Z"* -"@ H * "@ H * "@ H
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MN8F H T- 8-X<TME(*FUB(([_(* -&@ H * "@ H * "@ H * "@ H * "@
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M,&*J,D*I8_@!R: (K*^@OX?-MS(4SC+Q,F?IN S0!8H * "@ H * "@ H *
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MMAX,?^AY_2@"1;J[48ET]R__ $QD5E_-BI_2@"O?Z[#IEE/<W5I>*(8VD*K
M7R ,]5R!^)% '.>$O&MOK>N36JZ;=VQOT-[ \IC*E%CA4@[6)!^930!V] !0
M 4 % !0 4 % !0 4 % !0!4U0.VD7HCNQ9N8'"W#=(3M/SGZ=?PH XCX=V&J
M65[.FI:Q;W'^BHT<$5W-.61W9UE8R $?>(XSGN> * /0J "@ H * .?\=_\
M)//$O_8+N?\ T4U &AH7_(O:9_UZQ?\ H(H T* "@ H * "@ H * "@ H *
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MEECAB:65UCC499F. ![F@#.\/7$%QH\7DS1R;"P;8P.#DG!Q0!J4 % !0 4
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M1A9V,FCRI+)%&?+,GG1D MTS@'CT!H [^@ H * "@ H * "@ H * "@ H *
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M=-OHR]M<)M<!B#[$$="#@@^U &"_P^TEXF)N+[[8\SS/>B;]^Y=!&P)QC!0
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MTH +CP<B6=I8V<Q^R_VQ_:=R9FRQ_>&7:N!_STV\'MGD]P#JJ "@ H * "@
9H * "@ H * "@ H * "@ H * "@ H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>g10811sp70a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811sp70a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MFC^S,3_+^0?VCA^_X,/L-[_SY7'_ '[-']F8G^7\@_M'#]_P8?8;W_GRN/\
MOV:/[,Q/\OY!_:.'[_@P^PWO_/E<?]^S1_9F)_E_(/[1P_?\&'V&^_Y\KC_O
MT:/[,Q/\OY!_:.'[_@P^PWO_ #Y7'_?LT?V9B?Y?Q0?VCA^_X,/L-[_SY7'_
M '[-']F8G^7\@_M'#]_P8?8;W_GRN/\ OV:/[,Q/\OY!_:.'[_@R6WTG4;F0
M(EG*#ZNNT"KAE5=O70F694$O=U.\T32QI5B(2P:1CN<CUKZ+#T(X>FJ<3P*]
M:5>;FS2K<P(I9XXB%8DL2 %49/)QG [>]2Y)%*+>I#Y,MTO^D_)&?^62]^""
M&/<<^U3RN7Q?<5=1?NEI55%"J %48 ':K2MHB&[ZL;)$DH4.N0K!A[$=*'%/
M<$VMC.NM&L)'0;C!(6)4J^"3\Q_FY-<T\/2;71_\/_F=%.O4BG;5%EK.UC0.
MZ_ZO+;B3G.0Q/YJ*V]G!:O\ K^K&?M)MZ$*V5F]G+:J^%DE\QP#ALEMV/;T^
ME9^RI\K@N]_QN6ZM124WVM^%B2/3[%'C9(UR@POS$@]>V>3R>3ZU2I4TU9$N
MK4:=V(NG6 4A0=C)M(\UL%>G///UH5*FE_P1NK4;U_(<8[*WF$V520DG.X\[
MB!T],XI\L(N_7_,GFJ25NG^1&NEZ;&C*(U QSF0\ J5]>!@D5"H44M%_5K?D
M4Z]5O?\ J]_S)8[*S@G$J(%DY(.X^@!XSZ 5:IPB[I$NI.2LR"2QTR6X=67]
MY(0Q =@"<@Y&#C/3FH=*E)M/KYLM5*L8IK9>2'C3].65OE!D=2I#2$YXP>IZ
MXXS35&DGM_6PO:U6MQ9]/L93(9$YD9=^UV&2.!G![42HTY7NM_T%&K4C:SV_
M45;&Q21I ,-G)/F'CG/KQDC\::ITT[K\P=2HU;]!;:RLXH3# I\L.#M+L<$'
MW/'(HA2IQ7+';_()U:C=Y#UL+560B$90 +DDX SC_P!"/YU2I070EU9OJ-BT
MRS@F66.':Z]#N/'&.F?2E&C"+ND.5:<E9LMUJ9!0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % %*35K*.5H1-YLR]8X5,C#ZA<XK54IM7MH
M8NO33LG=^6I'_:-U(?W.DW)']Z1D0?EG/Z4_9Q6\A>UF_A@_R%^U:E_T#4 ]
M[@?X4<E/^;\ YZO\GXB&_OH^7TF5AW\J5&_0D4<D.DA>TJ+>'XH7^V;-,?:3
M):$G'^D1E!_WUT_6E[&3^'7T']8@OCT]=/\ @%]65U#(P92,@@Y!K+8V3OJA
M:!A0 C,$4LQP!R32;L-*^B*WFR72$6Q\M&7B8X/4 @J._7OCI47<E[OWEV4'
M[WW$T<,<9)5?F))R3D\G)Z]O:J44B7)O0DJB0H * (I+:&:6*62,,\1)0G^'
M-1*$9--K8N,Y132>X^1!)$R'&&&.1D?E5-75B4[.Y2&EPLJYD9EZCI_=*]?H
M?TK+V46C;VTDQCZ9$4F59?WTB]3C@D$=!V_PJ71CKKJ/VTM--!5TR-!F5\%A
MM(SQU./Q^:DJ,8K7^OZN-UI-Z%F:UCN'!+?<P"!CL0V/T_6M904F91FXJQ%'
MIL<; EV90  IQ@8Q_P#$U*HI%.LVK VFQF*WCWMM@38N0#VQGZ\?SINDFDNP
MHU7&^FXQM*B/'F,,YSTYSUQZ?A4^PB6L1+L.73H=HV2$X! ;KZ?_ !(IJBDK
M(3K2O=C5TF)>3*Y.<YX_O;OYTE02=[C]N]K#FTN$Q-&C,@;(.W XX_PI^QC:
MR)59WNR:WM%MG9@Y.?4#US^-5"FH$SJ.>A,)$95974AOND'K]*NZ(LT+O7=M
MW#.,XS1=!9AN7^\/SIW"S#>H!.X8'4YZ4KH+,7Z4Q$<SF--PZ=Z:5P(/M9]J
MKE%</M9]J.4+E2#Q!I]S</;V]_;2SQL4:-) 65AG((SP>#^5'*%R"'Q9HMQ$
M9(=6LI$&<LLZD<#)[]AS1RA<G/B#3UNX[0WUL+B1F1(O,&YF7J ,\D4<H7'6
MNN65[O\ LEY;S^7(8F\N0-M<=5.#U]J.4+DTFH1PQ/++(B1H"S,QP !U)HY0
MN1KK%J\/G)<PM%O\O>&&-V[;C/KNX^M'*%R?[6?:CE"XOVL^@HY0N3Q.9$W$
M8]*EZ#'T@"@ H * "@"E<ZE'#-]FA1KBZQGRD[#U8]%'UK2--M<ST1E*JD^6
M.K(ET^XNV+:C<$H>EO"2J#ZGJWZ#VJO:*/P+YD>RE/6H_DMB[!;06L0BMX4B
MC'144 5G*3D[MFT81@K15B6I*"@ H 1E#*58 @]0:$[;":3T9G/I"1 MITAL
MI,YP@S&?JG3\L'WK;VK?QZ_UW,704=:>GY?<*FHO;2+#J48A8X"S+S$Y^O\
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MNZ(J04X\I%IEU)=68,ZA+B,F.91T#CKCV/4>QJJD>5Z;$TIN4==UN7*S-0H
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M^[,@8#D;0,<>_ Q5N2:,HTG%WO\ UH+-IDTET]P+C+,RGRR/EPK*0/7^$_\
M?1I*2M8'3E=NX1Z9)&DZ"2,B=6W';RI)8X'M\W3Z^M-R5[@J32:ON3W%O<3P
MJ Z(X)R%) Z$#GVZ_P"<U*:3+<6U85K1_) 63<ZRF3YB<-R>#^'\A1?43@[%
M=]-EDD+L\8P^]<*>3A>#_L\=/IZ57,D2Z;;-&,,$&\*&[[>E9FRV'4#"@ H
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MI*UF*Q)!<B5C&Z-%,H!9&_H>AZ=J35AD]2!GWQ-OJ%C<@?(6,#GT#8P?^^E
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M_P"1I5B= 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M?<CS=7M_F<TFZL^1;+?_ "_S-2L3I"@ H * "@ H * "@ H * "@ H * "@
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MZO4TN_\ AK)&OI%F^GZ1:6;[=\$80E22#COSZU:5E8ZJ,'3IQ@^A=IFH4 %
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MFV/_ #YP_P#? H /[-L?^?.'_O@4 ']FV/\ SYP_]\"@ _LVQ_Y\X?\ O@4
M']FV/_/G#_WP* #^S;$?\ND/_? H L(BQKM10JCL!B@!U !0 4 % !0 4 (R
MJZE64%3P01P: W&/;PR,6>%&8C:25!)'I18EQB]6A/LT&&'DQX;.X;1SGKG\
MS18.6*Z"^1%M*^4FTDDC:,9/4T#LMA3#$6W&)"W7)49[?X#\A0'*M[#5MH$C
M:-88U1OO*% !^HHL+E5K6$^RV^2?(CR>OR#GJ/ZG\S18.6/84VMN228(R3D'
M*#OG/YY/YT!RK>Q(5!QD X.1GM041O;02,S/!&S, &+*#D Y%%B7"+U:!+:"
M-]\<,:/C&54 X_R*+ HQ3ND1?V=:"59%A5"O(V# [>GT%+E1+I0O>Q*MM;HN
MU8(POH%&*=BN6.U@%M ,XAC&>ORBE9!RQ[$BJJ#"@ >@IE;"T % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
I% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>g10811sp70b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811sp70b.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M(Z@EE5L8)&&_(^AH CMO%VCWES=V]M.\TED7%R(XV;R2KE,-@=25.!U(&>E
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M[YO(F@$ERZLP64(&Q\N 1L&,#UZYH 6/P7I:W*O))=301[S';22_NHV<$.P
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M2\DN+F>1&W(0 JJ(,#ISS;J>@X)'O0!VE !0 4 % !0 4 % !0 4 % !0 4
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M^ZEN+/>TDB[29 I(Z9Y"@\D D9QZ 4 ;M !0 4 % !0 4 % !0 4 % !0 4
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MXB"<=Z -S29=<TX:1::DT4@N'ECD+L6E4_O'3YNAPJJ#[T =/0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &=X@_P"1;U3_ *])
M?_0#0!=@_P"/>/\ W1_*@"2@ H * "@ H * "@ H * "@ H * "@ H * "@
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M+BY6QBFLFC1WDC'[^)CPS =,@@\CKZ5YS5G8LSW\1(_VF.VDA+),D4<Q#&(
MJA)9AQU?&,@GBD!F77C*>RLKB\<V4ZJI$<<+L3NV*VXMW3+=<#MUS0!IZ#KM
MQJM_=PRQ(L2,_E,N/F"NR?WCZ \A>O?K0!OT % !0!AZ[X@ET:XBACT]KDRP
M2R(WFJ@+( 0G/KGKT'O0!SR_$V$B,_V;D.(V^6?)VLS*0 5&6RIPO<<Y'2@#
M1M==CUR?P[<"!XGDN9CM 9D&U)4.'P >1G'7':@#K* "@ H * "@ H * "@
MH * "@ H * (;B[M[./S+F>.%-RKN=@!DD #GU) _&@![28B9T4R%02%0C+>
MPR<?G0!B_P#"6Z:MA]JF\R%L;A VTR%=^P, "003T.>1R* )SXFT<1QN+U&\
MPJ%5>6^9P@X_WCB@"5]=TQ61!=QL[;"%##)#8P?IR/S'J* &1>)-&G0/%J,+
MKN5<@]"V<?@<'GI0!9T[4K75;)+JTD#QL/Q4XS@^AY% %N@ H BN+:&[@,-Q
M&)(R02IZ9!!'Z@4 4)?#>CSRF6:PCDD)9M[Y)R1M/)/IP/3MB@"EJ^AZ79^'
M=6:WL8D)M'!^7/1, \]\ <]>!Z4 ;L'_ ![Q_P"Z/Y4 24 % !0 4 % !0 V
M1UBC:1R%1022>P%-*[L@.0\.^)K?Q^;FXTVXFATFUD\I@,QRS/@'J.549[<D
M]P.#Z.(PTL#:-17D_FE_FR$^;8Z>RTZRTY&6SM8H YRY1 "Q]2>Y]S7#.I.I
M\3N4E8M5F,YY]$U<^.(]8&M2#2E@\LZ?SM+X/S=<?I78J])8;V7)[U]R;.]S
MH:XRC)U?Q-H>@*QU75;6T*KOV22 ,1G&0O4T 7++4;+4[8W&GW<%W$#MWPR!
MUSZ9'U% &/'XKB2V9KNV:&;:SHB$NK+\VUM^  &V-C/7'N* (8_'NCM:12.9
MH[B2'S?LS1,''R!\<CN",>M %RZ\5Z7:P&1I6SL+*"C<D;N.G7]VY^BDT 1S
M>--&MXY9)9)TCB^\[0.%_ D8/?\ (T 7-)UVUU@RK LBM&S8WH0'4.5W*2.1
M\OX9H U* "@#+G\.:1<*%FL(W4!E .< ,VYL>F3U]>AH =%H&E07/VB*QB67
M).<>H(/'T)'L"0.M $/AA530U55"J)YP !@ ><] &Q0 4 % !0 4 % !0 4
M% !0 4 % #&AB=U=HT9U^ZQ4$CZ4TVE9 17EY9V$'G7US#;P@@;YG"+GMR:0
M XLU MG$($^2(SCY_7COU'YT .%O:I,Q$,2RRK\Q"@,X''/J.E "QPV\,KF.
M...27YF*J 6QW/KU_6@![.B%0SJI8[5!.,GK@?D: '4 % #)(HY1B2-7&"/F
M&>#UH :+6W7&((Q@AAA!U P#^ H S=118]3T)$4*HN7  & /W,E &O0 4 %
M!0 4 % !0 4 % !0 4 % !0!CZYX4T'Q(@76-+M[LC&&=<. #D#<.<<],T 6
MXM(T^VTZ2PMK.*VM9 0T<"^4#D8)^7'/OUH KR>&]*E0)+;%U"JH#RN<!3E>
MI[?_ %NE  OAO2%N?M/V3,^ /-:1BQPVX9).3@@4 ">&])1D86I)0 *3*YP
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MGE6WMY)F^[&I8\@< 9[\4 4='U67589)7TZ:S53A3)+$^_UQY;MC'OB@#2H
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MAQC> H'!^7/.">: .CM],T^TNGN;:QMX;B10KRQQ*K,!T!(&2.!^5 %J@ H
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M\A(.Z.5R2OW<Y)YQ[4 =-0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % &=X@_P"1;U3_ *])?_0#0!=@_P"/>/\ W1_*@"2@ H *
M "@ H QYW;4M>CLT/^C6&V:<C^*0_<3\/OG_ (!73%>SI<SWEHO3J_T^\6[+
M]_?1:=8RW4P9E0<*@RSDG 4#N22 !ZFN89SGA&>_UUIM;UO2[G3KV.1X8+6<
M86&/CYE]2PZM[8&!U .LH * "@ H * "@ H * "@ H * "@ H * "@#(\-?\
M@4?]?%Q_Z.>@#7H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M+;9,\#J,YX'!^4 D]J (;+5O%,FJ>5/I:"WW2 ?(5! 5L?-DX^8( <<AB>U
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MGL"&1^NZ7(&6'9<8!YY.".0HZ"@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H R/#7_(%'_7Q<?\ HYZ ->@ H * "@#)\1^(].\*Z0^IZI(R6ZL%^1=S
M$DX&!WKHPV&J8FI[.GN)M15V9&HR:MXR\+.NA2R:1'>(CPWLCE9=N0P*JAR
M1W)!YZ5TTU2PE?\ ?+FMNNGX_P!>9+O):$FF^#[:+0H;;Q)</K4\<>)9;R1G
MC/N%8X'UZ^]35QDO:.5!<B\M/Q&HZ:BQ:OX,T_1#86UWIXTXQ,3;VY#C8P)/
MRKDX()[5RRK5)S]I)WEW'9)6*?A7Q)HLWAV"3POH%\=/8L5C@MUC53D[OO,
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MW*2LK%ZLAA0 R2*.4 21JX!R-PS@TTVM@'T@"@ H * "@ H * "@ H * "@
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M(AU!&P"<]2Q)ZT 7AXY\(*,#Q1HX'M>Q?XT +_PG?A#_ *&G1_\ P.C_ ,:
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MMA?7UEINA1K 9X?,,3!0QD\M"[+C X;'&<E&Z8S0!UCV=K(^][:)GX^9D!/
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M[' !6B\?Z+(L[L9TCCW,',1PZ )\P]B94 !Y.: "'Q[I,LLN?-2%-VURC$R
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M2 ??(H ZK3+Y-3TNUOHU*+<1K(%;JN1T/TH MT % !0 4 % !0 4 % !0 4
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M!]EIMIIWG"T@6$2L&95&!PH4 #L % P* +5 !0 4 % !0 4 % !0 4 % !0
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>R[AG!]1[T .H * "@ H * "@ H * "@ H * /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>g10811sp71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811sp71.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M_P""'L/,/^$2UG_GWC_[^?\ UJ/[(?\ /^'_  0]AYA_PB6L_P#/O'_W\_\
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M&VP'+29!!(ZT :OB1AJOBW19+6W\0PREXF-RMO<+# @<Y7:%QN?HQ?@+@^U
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M\ !@'VGIP>.U %+Q!XOCGU74[K1O%<_VM(X&TJQMV5X[MCG(V;26!(P2",4
M6[?Q'XCB\3Z;I]W*YMK[7+D6\J\KY4?G*T+_ $948>H/^S0!5\1:_P"(-/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M 4 % !0 4 96D_\ (2UW_K]7_P!)X: -6@ H * "@ H * "@ H * "@ H *
M"@ H * &K(CDA'5BO4 YQ3::W JW>J6EC<007#NLDYVQA8F;<>>,@$= 3^%(
M!\VH6EO \\LZK&C^63U^;.-H'<Y["@"M!KVF7-RMO%=!I&(4?*P!;&[;DC&[
M'..M "IKVF27$<"7:L\F-I )4Y) ^;&.2#CGF@#1H * "@#&G\110WNHV:V=
MS/-8P>>RP@.7!Z* #D,>< XZ$ULJ3:3ON*XMCXHTB]N;2S6\C2^NHC-';,<2
M%02"<'G@JP/T-9SBX2Y6,V*D H * "@ H * "@ H * "@ H * "@ H * "@
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M;M<7=Q%;P)C=)*X51VY)XH Y_1?'WA[7;TVEI?(LQ *+(ZKYF20-O/)XZ=:
M-J[U!;.[LK=H9&%U(T8D&-J$(S<Y/?:>E &3#XQT^XTZUOX(Y);:=Y5WH5(C
MV(SY//=5R![\XH U].O?MUL93"T+JQ1XV()4CW'MB@"W0 4 % &8OB'2GO\
M[$MT#-O\OA&V[O[N_&W/MFM/934>:PKBMH&EO-=2M9HSW1S-DDB0[=N2,XSC
MBCVLTDK[!8S=2MH;/7O"MO;QK'#'/,%51P!Y#U#;;NQG24@"@ H * "@ H *
M "@ H * /(?"OQ.>_P#B)X@LKNQC@MH8Y'DE5RQ"P9&<8[CFO7K8*U&#B[MV
M_$S4M3LOAWKVG:[X75].E,BV\KQR90KABQ;O[,*PS&A4H5K36Z7^0X--:'65
MYY84 % 'F7C#X.6?B[Q+<:U+K$UL\ZH#&L08#:H7KGVKW,'G,\+15)0O;S,I
M4^9W.D\#>"H/!&@W&E0WLETDT[3%V781E57 P?\ 9Z^]<6.QLL9551JUE;\R
MXQY58V=(TB#1K>6WMGD:-Y-X$CEBO & 3VXKFJUI56G(:5C0K$84 96C?\?.
MK_\ 7Z?_ $6E7/9>A,>IJU!04 % !0 4 % &7J>I+%+]AL[F ZH8S*EJ95$C
M+R-VT]L]_:IGS*+Y=^@G?H8&I7>F66DC5?&!6UG$ODPLY(VL,LNS;T/!.?;T
MJ*%2K&G^\W(]DIN[5VC<T2YU6X1CJ4'DLO&, 9X&#P?K2H.HXOVJU*5^IKUL
M4% !0 4 % &5XG_Y%/6?^O*;_P! -73^->I,_A9JU!14U,A=+N2998@(S\\,
M7FNON$P=Q]L&@#G?"*QG5M5E0ZC.SQ0!KJ\M/LV_!D^14\M/N]2><[P.U '6
MT % !0!E:3_R$M=_Z_5_])X: -6@ H * "@ H * "@#%L?\ 3/$^I77\%HB6
M:?[V/,<_CN0?\!KMJ?N\/"'\UY?HOR?WDK5FU7$4% !0 4 % !0 C*&&& (]
M#0!E:7X9TG1IWFL;9DD=0F7F>0*H)("AB=HR3TQ0!>O+&VOXUCN8]ZKDCDC&
M5*GI[,1^- $7]D:?N)%J@R^\@="VS9G'3[IQ0!+964&GVJVULA2)<X!8L>3G
MJ22: +% !0 4 <%9S>5\4;BR746"1DD6TEZS,VZ(,2$:7IENR8&*[I*^'4K?
M.WGZ?J3U.DG\0QPW6KVRV-U)+IMNDY"QY,V[=@(.IY0CZUSJDVHNZU'<R;K6
MK'4?$WA1(KF'[2[S3>0'^<)Y4BY*G! W CIU!%9RBXNS&=?4@% !0 4 % !0
M 4 % !0 4 ?+OA3_ )*-XR_Z\M1_K7U,_P"%2]8F"W9UGPF=(_A+XC,DGEC[
M2V&W[>?+3'-:YDF\QI65]/U8H? SW2-D>-6B8,A'RE3D$5\DTT[,Z!U( H \
MJ\:WGQ2B\4W*>&87;2@J>41%">=HW<MSUS7U>6T\FEAHO%OW];ZR[Z;:;&$W
M4O[NQT_@&;Q;/X=N6\6)LU/[0PB#*B_N]BX^YQ][=[UY>:QP4:\5@O@MKOO=
M]_*Q=/FM[PDT7B4^'WCA6Z%WYH(+R1E]OE\\A@,>9D]>A].*Q3P_M;NUK>??
MT[?UU'K8ZV/=Y2;QA\#<,YYKSW:^A8ZD!E:-_P ?.K_]?I_]%I5SV7H3'J:M
M04% !0 4 % #6D1/O.%^IJ)3C#XG8:BWL?.'C+Q%JTGQ"O+Z+4'@EM'>W@>
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M*]#-<//#8CV4^B27HE;\=R8--71T]>66% !0 4 % !0 4 % !0 4 % !0 4
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MO<=/7K0 >6AZHO;MZ=* #8@.=HSG/3O0!F:3_P A+7?^OU?_ $GAH U: "@
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M+FY:6\LK*6<XW-*BECQQUKIIU\1"-H2:7E<A\M]2S8VEC9P-'8000Q%LE85
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MGF+('#>3\O$/E8VY_N^_7VXIO$)RO;\?._YFMA/^$;=9/EO%$+% Z&'.]5Z
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M8FR.G<5I3DX,B2YD71TXKT#G,KQ/_P BGK/_ %Y3?^@&KI_&O4F?PLU:@H*
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MR+_3+*P\2>%A;6R1E)9HPV,MM\F0X+'D\DGD]3FIE)R=V/8ZJI * "@ H *
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MD!<8ZCKVH Z"]TZQU*)8K^S@NHU;<$GC#@'UP1UY- $>H30Z7HES,KP6T-M
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MC/FFY3:3Z9SC]:^5=&U-5+KT*56\^2QIV_B70KR=(+;6M/FF<X6..Y1F8^@
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M/4@].AH Z7 SG'- !0 A (P1D>E  %"C"@ >@H 6@ P...E !0 4 % !0 4
M% !0 4 9,WAK29[BZGDM29+H8E(E< \8/ .!T!X[@'J :U5::22>PK(D'A[1
M_)AB?3+:585V(9HQ(P&2>K9)Y)/U)J)2<G=CV$_X1S0_^@-8?^ R?X5(&#XB
M?PYX?GM8KCP]:RI<Q3,/*MXMV4 8_>P/NECU[>];TJ+JIV>UOQ$W8SO!R>';
MR1=(@T/3DM[>%OLXD3S)RD;^63(2F 20#]XG!'K55:'LXI_UW!.YU_\ PCFA
M_P#0&L/_  &3_"N88?\ ".:'_P! :P_\!D_PH Y_Q VA:'/Y1T'3&9K9YD#P
MHI=E=%VCCG[];TJ/M%?S_P Q-V,RX\1^%HTD\GPJI:)H@S/91A,-*B?>&></
MN _#BM5A)=6OZ0N8BBUSP580ND7AHRQ9>=G^S0MC=YLK#EL\".0X[  >E"PD
M^Z_JWEYAS%B#7_"USK"6D?ANW\@OY3R&VBRKEXE0XSRI\Y>1GKTQ2>%DHW;_
M *U_R#F.P_X1S0_^@-8?^ R?X5R%&=KNDZ=IVBW5[9:#I4LL"&39- JJ0!D\
MA3S6E*,9349"9CW^H^'-.^V))HNE32VEJ'<10J5$V7!0G;\H!0_,:VCAW*UN
MK_ 5[&; -)TF_</HF@R+<S>?=-'*)0I+)%B/*<$#!*\=_6J6'BTVK_=Y!<AL
M_$^C7NK6=M'X7TL6\]P86;RU+(#+L4G"D \@X)[XJY8/EBVWJO\ *X<QZ+#H
M>D6TRS0:59Q2H<JZ0*I!]B!7 47Z "@ H * "@ H RKK6&-T]EIEO]LNTXD.
M[;%#_OMSS_L@$^U6HZ7EH2Y:V0T6&L3?-<:SY!_NVEN@ _%PV?KQ1S16R%:7
M5CO[)O?^AAU'_OW;_P#QJCF7\J_'_,?*^_Y!_9-[_P!##J/_ '[M_P#XU1S+
M^5?C_F'*^_Y!_9-[_P!##J/_ '[M_P#XU1S+^5?C_F'*^_Y!_9-[_P!##J/_
M '[M_P#XU1S+^5?C_F'*^_Y!_9-[_P!##J/_ '[M_P#XU1S+^5?C_F'*^_Y!
M_9-[_P!##J/_ '[M_P#XU1S+^5?C_F'*^_Y!_9-[_P!##J/_ '[M_P#XU1S+
M^5?C_F'*^_Y!_9-[_P!##J/_ '[M_P#XU1S+^5?C_F'*^_Y!_9-[_P!##J/_
M '[M_P#XU1S+^5?C_F'*^_Y!_9-[_P!##J/_ '[M_P#XU1S+^5?C_F'*^_Y"
M'2K\#*>(;XMVWQ0$?I&#^M',OY?S_P Q<K[C'N=9TWY[F&/4+8?>>V0I*H]=
MA)#?@0?8T[1EMH%Y+?4T[2[M[ZV2XM95EB<<,O\ G@^U0TT[,I-/5$U(84 %
M !0 4 % !0 4 % !0 4 % &-=>%M(O+Z6]FMF-Q*VYV65EW?*JE3@_=(C3(Z
M'% %2S\%:?8VNJ6\-Q=%-0MQ;-N<'RHQOP$XXQYC?I0 MSX%\/WL$L5S9M*L
MHD#DRL-V]V=CP>,L['CIGB@"QIOA;3])U1;VR\R)5ADB6'.4&]P[-SSDD#OC
MVH VZ "@ H * "@ H * "@ H * "@ H * "@ H * "@"AJNC6&M6PM]0@\V,
M'H&*G\P0<>WL*N%25-WBQ6N6(+.UMG9X+>*-V #,J %@.!D]\4G)O=C)ZD H
M AFM+:Y:)I[>*5HFW1ET#%#ZC/0TU)K9@,_LZRWA_L<&X +GRQG .0/P//UI
M\\NX#%TK3HTV)I]LJ8QM$*@8P1Z>C-^9]:?/+N%A4TK3HY%DCL+9)$8LK+$H
M()ZD''7BCGD]+A8MU #719$9'4,C#!4C((HV 8MK;H\SK!&K3?ZPA "_&.?7
MCUI\S A32M.C:!DL+93!GRBL*CR\]=O''X57/)WU"PXZ=8M<)<&RMS.A++(8
MEW*3U(.,BESRM:X%FI * "@ H * "@#+UFZG18+"R?9>7C%$?&?*0#+O^ Z>
MY%7!+=[(F3>R+EC8P:=9QVMLFV-!WY)/<D]R>I-2VV[L:22LA[3A6*D=*+!<
M;]H'I3Y0N'V@>E'*%P^T#THY0N'V@>E'*%Q?M"^GZT<H7#[0OI^M'*%P^T+Z
M?K1RA</M"^GZT<H7#[0OI^M'*%P^T+Z4<H7#[0OI1RA<?&^\9 P*35AF+>1C
M0]274H $M+F0)>(.@8D!9?8YP#Z@Y[5:]Y<K^1#]UW1NUF6% !0 4 % !0 4
M % ",P12S$!1R2>U "++&Q4*ZDL-PP>H]: &K/"\IB65#(O50PR/PH <)(V*
MA74[AE<'J/44 )YL8V?O%^?[O/7Z4 *7175"ZAF^Z">30 Z@ Z4 -26.3[CJ
MW /!SP>E #J "@ H * "@ H * "@ H * "@ H * "@ H * "@ H .E #%FB<
M*5D1@WW<,#GZ4 )Y\/G>3YJ>;_<W#/Y4 .$D9*@.OS$@<]2.M "&6-0"TB@$
M[1D]_2@!6=$*AF"EC@9.,F@!U !0 Q98W.$D5CC. <^U #Z "@ H * "@ H
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MQP1F@#UVQ,YL+8W2!+CRU\U0VX!L<C/?GO0!/0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 <[XWTR]U;PO-:V$?G2^9$[V^_9]HC5P7CW=MR@CTYYH
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MQVZT :5 !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M)&)?,5Y K;F89&=^<<XQP:*LU-*W0$K'H%8C"@ H * "@ H * "@ H * "@
MH * "@ H 898P<&10?K3LP$EGAMX6FFE2.)1DN[ */QH47)V2U ([B&5V2*9
M'90"P5@2 >F?K3<6M6@!IX4+!I47:0#E@,$]!^-+E;Z 24@,JT_Y&;5/^N,'
M_M2K?P+YDKXF:M04% !0 4 % ",BN,,H8>A&:-@*[:=9-UM8O^^0*OGDNI/*
MNPW^R[$?\NL?Y4>TEW#ECV)8[.VB.8[>-3ZA12<I/=CLD(;NW%TMJ95$[ L$
M[D"L?:0Y^2^II[.7+SVT%NKN"R@,]Q((XQ@9-.I4C3CS2=D$*<JDN6*U)$D2
M1 \;!E]0<U2:DKHEIQ=F.IB"@ H RO#'_(IZ-_UY0_\ H JZGQOU)A\*-6H*
M"@#E?%;^)EO;0:"KF'R)_-VA,;]G[O[W?/3MGK0!A2R^//*EV"YQ\VS:L6[9
MM'E=?X]V=W;% %RSD\:_VO&+D2_9_M&'^6/9CS>??9Y73ONH Z#0&N&O==-S
M%'%+]N'RQR%QC[/#CD@?RH VZ "@ H * "@ H * "@!&944LQ"J!DDG  H Q
MY?%OAR#(DU[3PV,[1<H3CZ9S0!A>%OB5I>NZ;-<7Q&FS).Z+#-D%D!^1A]5(
MS[YH UO#VMS:SJ6K!;JTN+*VE5(6@B96Y4-\Q+'.,XX Z?A0!T% !0!C2>$]
M DU:/5'TBU-[&NU9=G0<]NG<UTK%UU3]FI.PN57N:DL$,MN;>1 8F&TKT&/2
MN896;2-/E,[26J2&?.\O\WKTSTZGICJ: &'0].<DM$[[@ ^Z9SY@SG#<_,/K
MF@"-?#FCQ ^58QP(22R1$QJV<=5! /0=: -6@ H * "@ H Y7XC_ /(BWW_7
M2#_T>E '54 % !0 4 % !0 4 % !0 4 % !0 4 % !0!XEK'[/S:KK=_J/\
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M]=+:(S.RK\S -RH)^[NZ4 ;]NGEVT2&-(RJ ;$^ZO'0=.* )* "@ H * "@
MH * "@ H * "@ H * .1\77U_9:A8I ]\(9OE LR"=V>25$3D@#'/"^M==",
M91=[?/\ X=$LZN)6CB1'D,C*H!=@ 6/J<<?E7*]RCF/B/_R(M]_UT@_]'I2
MZJ@ H * "@ H * "@ H * "@ H * "@ H * //;_ .,WA/3M0N;&<WGG6TK1
M/M@R-RD@XY]17T-+AS&U:<:D;6:3W[F3K13L=>FMP3:'::K;Q2RQ7:1/"@ #
M-YF-O4X'49YKQI8>4*TJ,G9QNG\MS2]U<CC\16LEYIULL4NZ_C\Q"<?+\I;!
MY_V3TSVH>'DHRE_*%S7KG&% &5:?\C-JG_7&#_VI5OX%\R5\3-6H*"@ H *
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MDVFK[A9%H$, 5((/0BL]ABT 95I_R,VJ?]<8/_:E6_@7S)7Q,U:@H* "@ H
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M8MCDDG&<9)[5C6J>TFY#2LB_60S*M/\ D9M4_P"N,'_M2K?P+YDKXF:M04%
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M * *NI\;]28?"C5J"@H * "@ H RM)_Y"6N_]?J_^D\- &K0 4 % !0 4 %
M$<\R6]O)/(=L<:EV/H ,F@#-\,6TMKX;L5G7;<2)YTP])')=_P#QYC0!K4 %
M !0 4 % !0 4 % !0 4 % !0 4 % '.>(SKL!GO+"_@M[2"VW;9%!!?)W$\$
M\#!&.X((Y!'11]F[1DKNXG<T=2L);B[L;RWVF>S=V57D95;=&RX. >Y'.#@9
MQ[YPDDG%]?\ ,#@/%7AS4-*\&ZI(;](XY+V"1TB0-YZ^<O+$CAB6!./[HYJZ
MU15+6Z E8]1K 84 % !0 4 % !0 4 % !0 4 % !0 4 % '$WGB77H;V>**P
M5HTD95/DN<@'CO7M4\'AI03<M;=T>7/$UXR:4?P9OW5Y=_\ "/V]RN^*>01&
M4QQ;FC#$;B%P>@)['%><H059QW2O;]#T(2;@F]S/;4]3*V)8S1.T"F95M2P#
M%&+'&,@J0F![XY)XU5*FN;UTU\U;[]?S*NQV@ZCJ-W?+'=22[5C?>)(=@)#X
M0J=H))49)X'(P!SA5Z=.,;Q\NOEKU_KN";.EKB*,JT_Y&;5/^N,'_M2K?P+Y
MDKXF:M04% %.XN"<I&<#N:X:]9OW8&].G;5E3;7#RG1<HZMJ5OH]E]JG21\N
ML4<<2Y>1V("J!ZDGN0*<:=W83E8R+OQA#8P++<Z-J<8$<DLZF-,VZ1D!F;Y_
MF'S Y3=D5:HWV9//80>.=$5M5\Z5[>/33B227: _7[H!R?NG (&>HR.:/82T
M\PYT6]7\10Z7!93Q6%SJ,-Y(L4<EHT17<Q 499UZYZC(XYQ4QI7\AN5BW+K&
MGVMU#:7,ZP7,B!Q$W5 <_>(R!T(Y/.#C-+V;>J'S(R[GQOHL"Q/%))<QR([!
MH5&!M:-2#DC_ )[(1ZCGTS2H,GG1TFVHY"[CD+1MN4X-5!R@[Q):35F:,,PE
M7T8=17JTZBFO,Y91<625J0% &5X8_P"13T;_ *\H?_0!5U/C?J3#X4:M04%
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M#Q##?ZJ_VZP19[D2)NM&;</*C7/$O'*D<^A/>@"]Y&O_ /02T[_P!?\ ^.T
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M_P# Q6D=8M$/1W-FLRPH * "@ H * /+_&D6IZ'XJEUJVMEF@N(E7?)%O1"
M 0?0_*#^->%C54HUG5BKIH^SRF5#%8-8:<K.+Z.S?]7*WA=-5\3>*+'4I;:.
M*WLSEI(HA&IZX'N<U&%53$5HU&K)?(VS%X? 82=",KRET;NSUFOH#X8* "@
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MA%;PQPQCHL:A0/P%2VWN4E;8DI#"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
8 H * "@ H * "@ H * "@ H * "@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>g10811sp73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811sp73.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MVOB"VGGM8[F(6\Q@D2XB,3JX4-]T\]&!H U\T &<4 &: "@!,B@!>* "@ H
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MUMY5:0^4"#L4R,5&02#\I'.: "?POH5TUR9]*MI3=.))BT8/F,.A/YG\SZT
M,?PEX>8N3H]I^\E\YL1@9?GG]3^9H =_PBV@^:)O[(M?,\[[1N,8SYAZM]>!
M^5 %7PMQJ7BC_L*_^V\% '24 % !0 4 (>*3 SK_ /?SV]GD_,V]A_LK_P#7
MQ7-6?,U#OJ;TO<3D:(&!72M$8"TP"@ H * &YH#<%.:;$G?4=2&% !0 4 %
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M9WHWG=/]80I7Z-UH Z3P1;26<WB6"6ZENI$U4YFEV[F_T>'KM 'Z4 =90 4
M(>* *EY>QVB\MF1AA$!Y8UC5K1IJ[W[&E.E*;NMB&UM&EWW%[&ID?C8?F"@?
MYS65.'M?WDUOT+G4Y?=AH7D18T"HH51T &!75%)*T48-N^NY7OM1MM-M3<7<
M@CC'&3W/H!W/M5I&E*E.K+DBM3D["RUG7=:FGU821Z+G?!;/@$GMN Y([X-:
M-VT/4K5J&%I*%'6H]Y=O)';(%5 %  '0 5DSR&.I""@ H * "@ H * "@ H
M* ,[5M&MM72(3EU:(DHR8X)&.A!!_$4 2Z=IT>FV_D1R.ZY)RY''T   'L!Z
MT 7* $('I0!G7.LV5IJ<&G32,MQ.,K\AVCKC+8P,[3C)YQ28'-:!K^FP7?BB
M1+VWE9M3+(BS+EQ]GA&1SSR#^515G[.-S2E!U9<J+J>.M,V;IDN8FSC;Y#$?
MGBIIUHSA=NS_ *\CT99563LFG\R&/XA:6&(NUFMQ_!F-CN_2E1JNHVG;[_\
M@#JY54@DTT5&^(U@UP\:9$?\+NK9_(4FZKGR12^__@&BRIJ'.Y&=>^-=+CU2
MQ:19KJ1VYDW",)@]E[_F*E8"+E[6<KM=>QO1PDI49J$XQ7]=;&EJ/CU!8R'3
M+<FY'W?/DC51]</DUVP@K;G'2P%/F_?58V\F_P#)!:^*-4U#2XV:YTBQN2N6
M>6Y#9/L@/'XDT[),SJ0P5&HTY.2\E;]2+PP\7[R^\1ZI93WX;$6^Z1A&N.P!
MP#G/2G*6FA6,Q5%J,<+[L.OF=<-=T; QJME_X$)_C61YFPO]NZ/_ -!6R_\
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M$?#'U&=N1[T </9Z'JLEA#)XG\/WM_"TMV_V2U?_ %<[3;E?[R_+MR >WXT
M=+I-AXCM=3U9X;2.*WN)82_VR9GDV"W0-L89#,&!&3U/- &9I?AGQ"L/E:G=
MW$J'05A0Q)Y+1."#Y18$Y/&">.,T 85IX:\51_#W0+1+.<:M#).-LK$&!VD#
M)*6!X( .,\88_0@'37_A3[7=^*+PZ=/;R2I';))9J@EG0A7FD ;AB2=O/]S
MH EL;&]T[X>6UG=P_9XQJ$:L&1(F-N;D<NJ_*"5ZXQQF@"31;"[T?QCK%^MA
M>S6UVY\QY(H]X=I<*(R,%H]O)R3C [Y% $OA73;JUUS6YDTV[LK*XB3"7,FY
MC,"^X@[FW9!4[OH.V  <'H?A'Q7#:V$5Y:W/DV*RF%"W.9H)-X//4. !_OT
M;^@>!+WP_'X8F1?,G:\CEO-D7EF)1;R A_F.[YF S0!M:W%XIF\07<=NUT+5
MQMA\K:(?),3!B3]X2;\8_#MF@#'F\%7C^ ?"6BPV@\Q+A);Q+E6=5)C<MO"L
MI/S$=#Z4 0:QX1FLFM+.33K_ %B>#3/)LKN'Y1!<>8Q4DE\J!E<9SPO>@#>U
MP^([37]$O[G3S>V5G.QQIX+RD-"RDN&P/O$8P: $U?3[B3Q))K$HO%T^?1+D
M2K,V%MV/ED( . V Y]<YYH ZSPZ]Y)X;TM]0!%ZUK&9\]=^T;OUS0!IT % #
M9)(XD+R.J(HR68X H 9!<P7*;X)XY5Z91@P_2@"K-KFD6UQ+;SZK9Q30KNDC
M>=59!QR03P.1^8H 1]>T>(.9-6LD$84ONN$&T-]W//&>WK0 LFNZ1")#+JMF
M@B8)(6G4;&/(!YX/!X]J +P((R",4 +0 F!0 8 Z"@!<4 )@4 &!0 ,BLNU@
M"/0T &T>E "T ( !T% !Q0 8% "XH ,4 &,4 (5!&",CTH 7% !0 4 8/C.(
MR>$M2PR)LA,F]QD1[>=P&ULD8R.* *?@6!QHK75Q#LNIY#O<H%9@.G1%X_#O
M0!?U#P^;VYN+E;H1SOY'DL8]PB\M]X&,C(+=>G;TH YM_AC'BW\K5F0VI!@W
M0 X)7:V[GYL]NF/>@"9OATHLWMH=59$V-%&6AW%8V$@8'YOF/[TX/; X/.0!
MWA>W.F^/?$>F17-S):PVUHZ)/.\NUF\W=C<3C.!P/2@#MZ "@ H * "@ H *
M "@ H :6Q3#4!0 ZD 4 % !0 4 % !0!7O[R+3[">\GW"*!"[[5R< =AWH P
M9=3M/%&D7]M91W3O&PBEA(\E^3@CYQC'!_(B@";PGIDND:.;9H$@7SF:.-2I
M*H>F2H )_P : .>U'Q5KT'B/6+#[,\%G;B,0W"VK.%0M'ND)[\.V ,_</ P<
M@&9<^-/%<:#-J8BWE^<?L3M]F!4$$?WMQR/]GO0!-<^,/$T=G=2M$T$J'E19
ML_E/B4K&!_%NV)SVW^XH T/"=U=W?Q%\42WMB]G-]DLAY;.K''[WG*DCF@#>
ML?%=G?>(KO18XYA<6V[+,HVG!P<<^]5RZ'=6P-6CAXXF7PLT[^^%E:^>5+#>
MJX!QU8#^M)*YR4X>TE9/S*KZY;Q7LUM+N0QOM#!2V?E#$\= ,]35<IJL/.45
M)>7XMK]!$UZTE:'RW8HY()*E2I^7&01GG<*.4;PM2":?3^OP)+O7+*Q9EGF*
ME?O (QQQGL.F#FERD4\/5J*\41GQ%IXC63SGV[MI_=-\IXZ\<#D<GCFCE&L-
M5YK6U)-/UF*_FFA5722)W7#*<$*VW(.,'MT]:'&P5J$Z24GUM\KFI4F E ',
M^.-0;3?#S3I#)(_F(HV.5(YZDC\OQJXK4]'+*2K5U&3LM?R-NSG,UG#,T9A#
MQJVU^JY&<'Z4FM3AJ1:J2BM;/<<]]:Q#,EW"H[;G HL^PE3F]D9]KXGTV>25
M'N88!$VW=+-& WTPWTH<6=,\'6C:T6[^3-"VO[2]W?9;R&<+U\J0-C\C2M8P
MJ4:E/XXM>I:I&84 % !0!A^+;M+?PY=QE@KW$3Q1EAE=Q1B,\'CCT- &#HMG
M:P?#2\^S66PRV\V](7"LY ('S[5YQ@9QQ0!?^'\/V;PO'""65)"$8R!LK@8^
MZ !@8!&.H- &K<>(](L[NXM9[Z-)K9 \J<_("1C/N<CCKS0!%+XLT"$2&35K
M91&%+?/_ 'AE<>OX4 +-XJT*WCF:35(%6!PCMNX!.2/Y'GV/I0!CZ*RO\3_%
M!4@@V5E_[5H Z6%;$7LK0B 73_ZPIC><>O>LU6A)\J>IHXU%'6]AU[;Q7-J\
M4X_=GD\XQCG-:.7*FV3"4HRNMS+^R:4B+)+*TOGJ[;G;<7! 4YP/3 J'B(*S
MON=2JU]HJUK?@$.A:5#;-Y>0B?,74@$< YX^@-7[:-FT]$-XFNVKK?H,-CI<
MT4S2W,LHD#*[.W)W+MP./0=JR6)@U>Y3JUD^512V_!W"71=(O;A2SDN^' 5N
M#\H _'"CWJU7C)V01Q%>FMC1M=)ALYGEC>0EMV%9LA=S;FP/<_RJW+R.:I6E
M5CRR2_X8T:1B-)P>E '.>);A[I1I%B9&OI,/MC( 10>KD@X&>W4]JN.FIZ&#
MBH/VLM(H)/#5QJ-M*NJ:O<R-*FW9"?+1./0<G\3CVHYK L9"G*U&"5NN[&Z/
MX&T?2;/R7@2]DR29;B-2WTZ=*'-L>)S*OB9<S?+Z%?P]X3@TK4-1N9;)$$[Y
MC!D\P*OH 5&.:;DWH7C,PJXBG&'->Q';^(9HO'Q\/Q6,*6I3<9%0ALA<YSG&
M.U-K2Y<L'!X#ZSS/GOM?S.SK(\@* "@ H RO$B0GP]?/,"%CA9PRJ"R8!Y&>
M,T 8,*!/AC>I+,DJ?9K@EG;>N/FZE&;/'H<T 6_ LT%QX=$]O#'$'D+LL<C.
M,D ]2!ZCCM0!7O/ =K<^(;S6H[V:"[GV,NQ$^1E,9!/&6_U2X!X&3CK0!3D^
M&5H5B$6J741M\&W.U#Y1V[7/3G</7I0!+)\.[<VLD%OJEU$A!2,A4)CC(D#+
MR.2?-;D]./2@"OX0TFQT7XB>*;33[<00_9;-RH).6/FY/- '76^DPV^HRWJN
MYDDSD'IS7)#"QA6=5=3HGB)3I*EV)KV"6>V:&)MF_ACZ+WQ[UM5@YKE77\C*
M$E"2D^AFMI5VLR%'$L:AP-SE&PV#_"/4'\ZXGA&G9:V_4Z5B$T]+;?@3I9W:
M126^V)XI%P68G)^0+TQ[>M;1I3C&4;+7_*QFYPDU+M_G<ACTJYCE$ZB)70@K
M&"=IX(R3Z_-Z=JRCAIQL^IHZ\7=.Y-!87,;VH9D\N(9)!.<X.1CICGK6L:$N
M9-]#-U8V=C4 P.AKKOU.="Y'K3 Y+QA>:_:WFFG1I8!'*_ELCX)D8G@?3&3Q
M6D5H>KE]+"SYW7OHKFSHVF?V= QE;S+R=M]Q+C[[?X#H*3.+$5O:RLOA6R\C
M3QCM4G-ML+CBD%A,>U 60T1('W[!N]<<TQW:TOH24@"@ H * ,OQ#EM$NH\,
M%DB=6=6"^7\IYY(_GWH X^VL#)X U:ZBU.Y$4ZO*IA=LPA"<A,,Q/3U/04 ;
M_@HHN@F-'#K',Z[E(*GZ$<$?3OF@#&U[5O$\>NW\,-I>6VEI;KY5Q!"DS?ZQ
M \@')+!2X"[3TSCF@##N]<\;JC$C4(AB+S_)L0_D@H"#'\AWEC]X<[?:@":\
MUKQBEK>NWV^&=9!E8;$2>6^V3:B?(=R,1'N;G&[J.P!J>#Y]1N/B'XG?5+*.
MTN/LMF-D<OF K^]P<X&"?3M0!Z!0 4 % !0 4 % !0 PY]:8MSG[(#5?$%QJ
M.X/:V7^CV^.[_P ;?KM_ U;=E8[ZC]E0C2^U+5^FR7X7^9T ZCBH."W4?2&%
M !0 4 % !0 4 % ',>.->BT+14,UK#<QW;M R3R;$(\MF()P>H7&/4T &E:A
M93^#WE,ME86VZ2'S(IL0@ABN5;*G!//!!]Z )?"#1'3KI(+U;N*.Y95E1RZ$
M84X4EF..?4T 27?BW0[*[OK6>[(GLD5YD6)V(!(  P#N.67@9/S#UH KS^//
M#=L)3)J)_=!"<0N=V\97;@?-QUQG'?% "W'CCP[:1W$DE\=EO(L<C+"Y&2"<
MC"_,,*V6' VG)&* *6B,K?%#Q.RD$&RL2#Z_ZV@#LJ "@ H * "@ H * ,C7
MKXV.D3-$,SRXAA [NQP/YY_"JC>Z.C"TU5K*^RU?HM69KP2Z!:V5G8S!;>,8
M9>"[DG)..IS7FXRO5C47L[6[=3K4HXESG56OX;&S'>3R,I6U9(CU:5@I_*M8
MUYNS<;+S.*5*,=$[OR+P/&<UU75KF.HX=*8!0 4 % !0 4 % &!XK8'3%M_[
M2AL&G9E$DL1DSA&8A<,,'"DYSVH KZ9::AIO@98[A1<:FMLTI65"<R'+8*@G
M."<<?ACI0!+X.O[C4_#\5Q="V64L586Y!4$#!R 3@Y!X[<4 )?>$(;[5I-1;
M4;M)B%$04IMBVLK# *\C<@.#D#)]: ,Q_AIII$7EWUW&;<@P$%#Y9V[6/*\Y
M'KT[4 2O\.[#[*]O#?742;2D> A*(1(&7D<Y\UN3R.,=* *GA32K+1_B/XIM
M;"W6"'[+9N57NQ\W)H [R@ H * "@ H .E "9H#4XF[O+W4/&R:?&JM#9?O0
M&& '(X)]<9)KE=2O"3BEHSVZ5*G2P3K2WEI\O^"=5:V"0YD8^9.>LC=?_K"J
MIT%%<SW/)G5E+W=D%_IR:A;B&1V4!@V5ZT5Z"K146PHU71ES(L00""!(E)(1
M0H)]JUA!0CRHSE)S;;)1P,58@H * "@ H * "@#E?'=@U_HT$:6-Q=R+-E5@
M4$KE6!)Y&!@D'&>O2@"ND5WI_P -KD3NPN(K>5W,P*>I(.X,<8^N?:@#1\(2
MB713M*%5E8 (FS P#@C8G//]T4 9.J7WB)-?OH[6YNULHQ'@)IQ; +)N,;;2
M&(7>3G/4 +P20#'FU;QXJQDPW: [/M'EVBL8QMX*?*=Q)^]UQ[4 3S:IXV6Q
MN&9+M+@9R(K16V/MEVJGRG<I(BR><9ZCL 6_"<FH2?$;Q.VI6\,%Q]DLLK#(
M7&/WN#D@<^U '>T % !0 4 % "'I0!GZQJL.CZ=+>3<A!PO=CV%1.?+HMS?#
M4)XBIR1.;\/^&;H:PGB*_N&%S,K.;?9C86&.N>PXZ5M)]#T,7C8.E]6I+W5U
M.S4;1BHW/'2LK#J!A0 4 % !0 4 % !0 4 % &/XGD6+PY?.TJQ;8B06D5 Q
M[*6/ !.!^- &?X%DDD\.AIH?)E\UO,7<I.[ SG;P.<^^,>M %^Z\3Z;:3WEN
MS223V:QF2..,DYD.$ ]23_.@#/D^(.@QKGS9WW;?+"0L?-)&2%]2 >?2@!\O
MCS1(XI90UQ)&G.Z.$G<OS98>H&Q\GV^E &?X=O+>]^)?BB>UGCFB-G9#=&P8
M9_>\4 =M0 4 % !0 4 1S2+%$9'8*J\DFIE)15V.,7)V1QT4R^*O$8Y/V&P.
MXIV=^P/\_P JYZ$_:2=27_;O^?Y'LS@\!A_[TSM1Q74>*% !0 4 % !0 4 %
M !0 4 % !0!FZY82:CIYAA_UBNDBY8*,JP/4JP[>AH @\.:?<Z5ID=E+$B0P
MJ%C <.V/?"*/T)]30!+?Z%::BT[S&59)DC0O&Y5EV.74J>Q#'- &/)\/- D
M'EW";=OE[)V'EX&/E],CKZT /E\!:')!+#LN(XY#TCG8;%PP*KZ*=[Y'O]*
M*'ANRM;#XE>*8+.WC@B%I9-MC4*,GS<G [T =KNZ4DTUIJ)Z!O!)"L,CJ,]*
M+KN-IH9]HB$P@,T8F(W!-PW$>N*7,KVN/EER\UM"*ZU&TL3&MU=10&4[4\Q@
M-Q]!0Y1CN[%0ISG\*OZ$-]K-AIMN9KN\BB4#/+#)_"IE4C%7;-:6%K57RPBV
M<Z]_?>+)1#IZO!IP.6N67&<?W1W/Z"LHQ=9\TOA[?U^3/1]E3P$>:HUS]OZT
M+OACPU+X>-TK7OVB.0XC7RPNT9/4]SS6ZI0B^:*U.;'8[ZTHIQM8Z:J//"@
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M8"& V?>Z\YH N;?B%_ST\.?]^Y__ (J@"32;OQ8OB'[%K=MI[636S2K<V2R
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M H * "@ H * "@ H * "@ H * #(H * "@ H 3 Z<4 &!0 87/O0 8 X H
M .10 M !0 4 % !0 9'K0 4 % !0 4 % !0 4 % !0 4 8.N>+=+\/7\-MJ=
MS%:B:WDF226145BA4;1GN=W'TH RM-\>KJZVTNGZ+>W,#1PO</&4/V<RJ&4$
M9RV P)(Z9H ?_P )K<QZGJEI/X>O%33D#R/')'(6#9V84'/.#].] #-)^(5G
MJWA[2]7BTZ\6+4+H6RKM!\HF01[G(X R1]: -#2_&%EJWB6_T6")UELRREV(
M 8J0& '7@D?UQD9 (V\:6?FVZQ6EQ-'/J!L%E1?D#*P5F)[#<<>IP: ':[XP
ML]!U6UL9X)7$VPO(N (P\@C4X/)^9ATZ"@"KKOCZPT#7Y=(N;69I4L3>(R8Q
M(<L!&/\ :.TXH SK+XGVU_=Z=;PZ8RO>P).!)=1(RJQ88"D@L1M/W<T ;=CX
MTTZX\*Z?K\R310WX AA6,R2LQSA0J@DG )X[ T .LO%UKJ6OMIME;3RQ+9+>
M&[V$1%6^Z <<DX/Y$=C@ YW3/BO;:IITEW%I$I/DB6&);F)V?,BQX;!.PY=?
MO8[^E '16/BV*>VU#[;92:?>V!Q+;32(2V5W+M920V10 R_\8VNG^#+?Q*]G
M<RP3PK,L42[F 9=W)Z  =3TH U;/5$NM2N[$Q-');)')R<AD<'!'XJP_#WH
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M;DNP)"J6(Z <_.?TH AC\%Z?#X>T[1H)[J%=-8/:W"./-B;D9!(P>&8<CH:
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MX3$;$,5#88]0C$8R/7&: -6PUG3-4>9-/U"VNV@QY@@E5]F>F<'CH?RH O4
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MWEALEN?-9E.Z0H%PI/4*W)Q@"@#*U2^M-2T"SU746@T])OW.RXLQ.X8DC R
M>V>G3F@#J=+2&+2K-+>0RP+"@C<_Q+M&#^5 $3Z_I$=S]F;4K83^;Y/E^:N[
M?@';C/7#+Q[CUH :OB/16\K;JUF?-)6/]^OS$=0.>3R* 'V^NZ5=O EOJ-M*
MTX)B"2J2X&<XP><8/Y4 <_H__)4?%)_Z<[+_ -JT 7[_ ,.O>^*+'6A?/$+5
M"GDJ.&SGOGCKS]*I/0ZZ6*C3H2I.*=^ILW$;2V\D:G!92OZ4D]3D3LX^J.;7
M3M39+#:KP-;PQP2%9!DC>N\@YZ8!]#5W2/1]I27-?6]VONT'+8ZPS.LTK/\
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M%7*8?<9,*-I!\O:..#T- #O"\E])\2/%+7]M%;S_ &6S 6*4R+M_>X.2J\T
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H H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>66
<FILENAME>g10811sp74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10811sp74.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M;NX&>IP1Q]>*VI;OYDR-&F2% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MLGAC0II?-DTBT:3!&XQ#.#U'T.!^5(+%&]TWPWI4T)?2K57F;"[81DG=O_\
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MP?7(/&,$ ]!H XKQ';^(!>SZB^I:?:Z58RQSQ":)3A0!O9F;[O!?ISTP1SD
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M ,.GXT 3>,]&U;5]2TH:?IUO)'!<13&Z>0 Q['!964CYEVY(Q_%@]J .9L_
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M<8)!!&>H((([$$=J8C%OT/C/7WTQ74Z#IKJ;LH>;BX'(BS_=7@MZD@>M '9
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M#365L_;KKKG&Y<=2?[ON!]%'OF>>/\J^X"A=^$K"^=GNF>:5HO),DD<;,1@
M<E.Q7=]?PJE52^RON[:@6TT=T92-3O0JMG9E,8W$X^[TP=OT [\TO:*UN5?<
M/8IW'A.TNRK7<\UQ,L9C\V5(W<J4VXR4]RWU)['%/VD?Y5]PB]%I*P*B175Q
M'$A!6-=H50&!"@;>!@;?I[\U//'^5?<,K3^&+*\EA?4"U[Y)RHN$1_X2I'W>
MAR"?<"FZJM917W"/,_BIXTOO"NLZ/X:\/Z<D0>/S5>&/YE+[X\1J.,\L>>Y%
M9@>LZ+I5IHVD6UA91>7#"@ !ZD]R?4D\D^M &A0 4 (1F@#'TFV6.^OV\Z9B
MDVQ0\K, -JGH3CO3.JM)\L=.G^9LTCE#% !0 4 % !0 F,4 +0 4 % !0 4
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MS926L<:RAIBRL2<@**S4KL]_,<NAAZ$*B?1'H0Z59\^+0 4 % !0 4 % !0
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M:-I5A:7U_);6<,3I-M4H@!"[%XII)$5Z]2I&*E*YNCI0<@M !0 4 % !0 4
M% !0 4 % !0 4 <_XR@:]\-75@=.NKV"[4PS+:LHDC0@_.H8@-@XXH Q_ <M
MM/=ZG(^M3:CJJ+%#<)/:?97@1=VQ2F.OS,<]Z .XH * "@#B_B?_ ,BU9?\
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M0S/Z%FZGZDT ;5 !0 4 <7\3_P#D6K+_ +"EG_Z.6@#M* "@ H * "@ H *
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M2ZGRAECQ$[JO3)Q[5$979[6(R>E0H*I.=OE_D=M+::W>KA[^*Q0]5MDWN/\
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MYH /AUJ5S>VMY'>ZA_:%P@CE:XCN/-A.\$@+\JE2,<J<XX]: .WH * "@ H
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M+JRM;Z'R;RVBN(LYV2H'7/T- #(],L(?(\JRMT^S@B';$!Y8/7;QQ^% %J@
MQ0!7-A9M%-$UI"8YR6E0QC$A/4L.Y^M $ZJJ*%4  <8% "T 0M:6SW*7+V\3
M7$:E4E* LH/4 ]0* ""UM[0,MO!'"'8NPC4+N8]2<=_>@":@ H * "@ H *
M$H * "@ H * "@ H * "@ H * "@ H * ,#6?!6@^(+];W4[-IIQ%Y)(F= R
M9SM(4@$9)X-  W@[1$U-=3M[-8;V-Q)&ZNP17"; VP''W>/H* (--\$Z=9>'
M%TB?=(IF>>62!F@WNY)8_*V0.<8R> * -^RLK;3;*"RLXEAMH$$<<:]%4# %
F $] !0 4 % !0 4 % !0 4 % !0 9^8"@!: "@ H * "@ H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>d10811d20f_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:imab="http://IMab.com/20201231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="imab-20201231.xsd" xlink:type="simple"/>
    <context id="P01_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_25_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
        </entity>
        <period>
            <instant>2019-12-25</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="P12_25_2019To12_25_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
        </entity>
        <period>
            <startDate>2019-12-25</startDate>
            <endDate>2019-12-25</endDate>
        </period>
    </context>
    <context id="P01_01_2010To12_31_2010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
        </entity>
        <period>
            <startDate>2010-01-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn10_31_2016">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
        </entity>
        <period>
            <instant>2016-10-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_25_2017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
        </entity>
        <period>
            <instant>2017-09-25</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To04_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="P02_10_2020To02_10_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
        </entity>
        <period>
            <startDate>2020-02-10</startDate>
            <endDate>2020-02-10</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesBConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesCConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesAConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesC1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imab:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">imab:IprAndDTj103Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_IprAndDTj102MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">imab:IprAndDTj102Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_IprAndDTj101MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">imab:IprAndDTj101Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_PeoplesBankOfChinaMemberIMABBankBranchAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:BankBranchAxis">imab:PeoplesBankOfChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">imab:SeriescOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesC1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:EverestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_IMabBiopharmaHongKongLimitedMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:IMabBiopharmaHongKongLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_IMabtianjinMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:IMabtianjinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_IMabShanghaiMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:IMabShanghaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ImabbiopharmaUsLtdMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:ImabbiopharmaUsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imab:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">imab:IprAndDTj103Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_IprAndDTj101MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">imab:IprAndDTj101Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PeoplesBankOfChinaMemberIMABBankBranchAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:BankBranchAxis">imab:PeoplesBankOfChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FederalReserveBankOfNewYorkMemberIMABBankBranchAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:BankBranchAxis">imab:FederalReserveBankOfNewYorkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesAConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesBConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesCConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesC1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyNineteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:ShareIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">imab:OutLicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:EverestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TwentyNineteenShareIncentivePlanMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imab:TwentyNineteenShareIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiariesMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PRCMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">imab:PRCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AmericanDepositarySharesMemberusgaapStatementEquityComponentsAxis_InvestorWarrantsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">imab:InvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">imab:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:ImabHangzhouMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis_ManagementHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:ImabHangzhouMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">imab:ManagementHoldcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_DomesticInvestorsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImabHangzhouMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:ImabHangzhouMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">imab:DomesticInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EsopHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImabHangzhouMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:ImabHangzhouMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">imab:EsopHoldcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_DomesticInvestorsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">imab:DomesticInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EsopHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">imab:EsopHoldcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_HoldcoMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imab:HoldcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ImabHongKongMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:ImabHongKongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ManagementHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">imab:ManagementHoldcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_InvestorWarrantsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">imab:InvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FirstClosingPeriodMemberIMABPeriodTypeAxis_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:PeriodTypeAxis">imab:FirstClosingPeriodMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:HillhouseEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis_SecondClosingPeriodMemberIMABPeriodTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:PeriodTypeAxis">imab:SecondClosingPeriodMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:HillhouseEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study1MemberIMABTypeOfLicensesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:TypeOfLicensesAxis">imab:Study1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:GenexineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study2MemberIMABTypeOfLicensesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:TypeOfLicensesAxis">imab:Study2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:GenexineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_RevenueMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">imab:LongTermInvestmentUnderEquityMethodMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">imab:RevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_GrossProfitMemberusgaapIncomeStatementLocationAxis_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">imab:LongTermInvestmentUnderEquityMethodMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">imab:GrossProfitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_LossFromOperationMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">imab:LongTermInvestmentUnderEquityMethodMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">imab:LossFromOperationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NetIncomeLossMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">imab:LongTermInvestmentUnderEquityMethodMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">imab:NetIncomeLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">imab:LongTermInvestmentUnderEquityMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:ShareIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_JiangsuTaslydiyiPharmaceuticalCoLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:JiangsuTaslydiyiPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AdrMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_HKsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_LicensingAgreementWithMorphosysMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithMorphosysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithGenexineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:MorphosysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithMorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_LicensingAgreementsWithMorphosysMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:MorphosysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementsWithMorphosysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:OtherinlicensingarrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_OtherInLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">imab:OtherInLicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:CspcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:HealSunMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:HealSunMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">imab:OutLicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:EverestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:CollaborationAgreementWithABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:CollaborationAgreementWithABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_HealSunMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis_MilestoneIiiMemberIMABMilestoneTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:MilestoneTypeAxis">imab:MilestoneIiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:HealSunMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_HealSunMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis_MilestoneIvMemberIMABMilestoneTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:MilestoneTypeAxis">imab:MilestoneIvMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:HealSunMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_CmabBiopharmaSuzhouIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">imab:ReceiptOfContractResearchOrganizationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:CmabBiopharmaSuzhouIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:EverestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">imab:IprAndDTj103Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AdrMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_HKsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_OtherFinancialAssetsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">imab:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_WarrantLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">imab:WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_LicensingAgreementWithMacrogenicsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithMacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithMorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_LicensingAgreementsWithMorphosysMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:MorphosysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementsWithMorphosysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_LicensingAgreementWithMacrogenicsMemberusgaapTypeOfArrangementAxis_MacroGenicsMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:MacroGenicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithMacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MacroGenicsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:MacroGenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:MorphosysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithMorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:OtherinlicensingarrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CollaborationAgreementWithEverestMemberusgaapTypeOfArrangementAxis_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:EverestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:CollaborationAgreementWithEverestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ABLBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:ABLBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:ABLBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:CollaborationAgreementWithABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ABLBioMembersrtCounterpartyNameAxis_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:ABLBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:CollaborationAgreementWithABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:CollaborationAgreementWithABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CollaborationAgreementsWithTraconPharmaceuticalsIncMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_DirectorMembersrtTitleOfIndividualAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:CspcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis_TaslyPharmaceuticalGroupCoLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">imab:ReceiptOfContractResearchOrganizationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:TaslyPharmaceuticalGroupCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:EverestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">imab:SeriescOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesC1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">imab:IprAndDTj103Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyNineteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_IMabBiopharmaHongKongLimitedMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:IMabBiopharmaHongKongLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_IMabShanghaiMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:IMabShanghaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_IMabtianjinMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:IMabtianjinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ImabbiopharmaUsLtdMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:ImabbiopharmaUsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_HKsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AUsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CNMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">imab:CNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_IMobOtherSubsidiariesMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:IMobOtherSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PutRightLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">imab:PutRightLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imab:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imab:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_SoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imab:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_SoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imab:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OfficeFurnitureAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imab:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AmericanDepositarySharesMemberusgaapStatementEquityComponentsAxis_InvestorWarrantsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">imab:InvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">imab:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SeriesB2PreferredSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">imab:SeriesB2PreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_TrancheIOfSeriesBWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">imab:TrancheIOfSeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_TrancheIiOfSeriesBWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">imab:TrancheIiOfSeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyNineteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">imab:EquityInLossOfAnAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithMorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithGenexineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LicensingAgreementWithMorphosysMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithMorphosysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LicensingAgreementWithMacrogenicsMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithMacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LicensingAgreementWithMorphosysMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithMorphosysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:ShareIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphoSysAGMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:MorphoSysAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithMorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GenexineIncMembersrtCounterpartyNameAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:GenexineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithGenexineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LemzoparlimabLicenseMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">imab:LemzoparlimabLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_FirstMilestoneMemberIMABMilestoneTypeAxis_LemzoparlimabLicenseMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:MilestoneTypeAxis">imab:FirstMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">imab:LemzoparlimabLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LemzoparlimabLicenseMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SecondMilestoneMemberIMABMilestoneTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:MilestoneTypeAxis">imab:SecondMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">imab:LemzoparlimabLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:GenexineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithGenexineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:GenexineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithGenexineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Gxi7MembersrtProductOrServiceAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">imab:Gxi7Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:GenexineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithGenexineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DevelopmentMilestoneMemberIMABMilestoneTypeAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_MacroGenicsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:MilestoneTypeAxis">imab:DevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:MacroGenicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithGenexineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MacroGenicsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MinimumMembersrtRangeAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:MacroGenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:OtherinlicensingarrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LicensingAgreementWithMacrogenicsMemberusgaapTypeOfArrangementAxis_MacroGenicsMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:MacroGenicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithMacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Study1MemberIMABTypeOfLicensesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:TypeOfLicensesAxis">imab:Study1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Study2MemberIMABTypeOfLicensesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:TypeOfLicensesAxis">imab:Study2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">imab:OutLicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:EverestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ABLBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:ABLBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:ABLBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CollaborationAgreementsWithTraconPharmaceuticalsIncMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GenexineIncMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:GenexineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GenexineIncMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:GenexineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study1MemberIMABTypeOfLicensesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:TypeOfLicensesAxis">imab:Study1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:GenexineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OperatingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study2MemberIMABTypeOfLicensesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:TypeOfLicensesAxis">imab:Study2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:GenexineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:CollaborationAgreementWithABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_TwentyNineteenShareIncentivePlanMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imab:TwentyNineteenShareIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">imab:EquityInLossOfAnAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">imab:EquityInLossOfAnAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">imab:EquityInLossOfAnAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">imab:EquityInLossOfAnAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">imab:EquityInLossOfAnAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis">imab:ThirdOneThirdPortionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis">imab:ThirdOneThirdPortionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis">imab:ThirdOneThirdPortionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationTrancheFourMemberusgaapVestingAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis">imab:ThirdOneThirdPortionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">imab:ShareBasedCompensationTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OnePerformanceConditionMemberusgaapVestingAxis_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis">imab:ThirdOneThirdPortionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">imab:OnePerformanceConditionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_TwoPerformanceConditionsMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis">imab:ThirdOneThirdPortionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">imab:TwoPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_ThreePerformanceConditionsMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis">imab:ThirdOneThirdPortionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">imab:ThreePerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FourPerformanceConditionsMemberusgaapVestingAxis_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis">imab:ThirdOneThirdPortionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">imab:FourPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CmabBiopharmaSuzhouIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">imab:ReceiptOfContractResearchOrganizationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:CmabBiopharmaSuzhouIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_JiangsuTaslydiyiPharmaceuticalCoLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">imab:ReceiptOfContractResearchOrganizationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:JiangsuTaslydiyiPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:HealSunMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SeriesBWarrantsSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">imab:SeriesBWarrantsSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesC1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CollaborationAgreementWithInvestorsMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:CollaborationAgreementWithInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:HillhouseEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">imab:IprAndDTj103Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:ImabHangzhouMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DomesticInvestorsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImabHangzhouMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:ImabHangzhouMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">imab:DomesticInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis_ManagementHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:ImabHangzhouMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">imab:ManagementHoldcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EsopHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImabHangzhouMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:ImabHangzhouMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">imab:EsopHoldcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_InvestorWarrantsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">imab:InvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis_SecondClosingPeriodMemberIMABPeriodTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:PeriodTypeAxis">imab:SecondClosingPeriodMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:HillhouseEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FirstClosingPeriodMemberIMABPeriodTypeAxis_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:PeriodTypeAxis">imab:FirstClosingPeriodMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:HillhouseEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:GenexineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GrantMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis">imab:ThirdOneThirdPortionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_SecondOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:PortionOfRestrictedShareUnitsAxis">imab:SecondOneThirdPortionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlan2020MemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:ShareIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:ShareIncentivePlanTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2018_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:CspcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">imab:LoanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">imab:ChinaMerchantBankCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">imab:LoanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">imab:ChinaMerchantBankCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn10_29_2019_DirectorMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-29</instant>
        </period>
    </context>
    <context id="P10_18_2016To10_18_2016_SeriesA1AndA2PreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesA1AndA2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-18</startDate>
            <endDate>2016-10-18</endDate>
        </period>
    </context>
    <context id="PAsOn10_18_2016_ConvertiblePreferredStockSeriesA3MemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:ConvertiblePreferredStockSeriesA3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-18</instant>
        </period>
    </context>
    <context id="PAsOn10_18_2016_SeriesA1AndA2PreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesA1AndA2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-18</instant>
        </period>
    </context>
    <context id="P09_06_2017To09_06_2017_SeriesA3PreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesA3PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-06</startDate>
            <endDate>2017-09-06</endDate>
        </period>
    </context>
    <context id="PAsOn09_06_2017_SeriesA3PreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesA3PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-06</instant>
        </period>
    </context>
    <context id="PAsOn09_22_2017_ConvertiblePreferredStockSeriesB2MemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:ConvertiblePreferredStockSeriesB2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-22</instant>
        </period>
    </context>
    <context id="PAsOn09_22_2017_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:ConvertiblePreferredStockSeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-22</instant>
        </period>
    </context>
    <context id="PAsOn06_29_2018_SeriesB2PreferredSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">imab:SeriesB2PreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="PAsOn06_29_2018_ConvertiblePreferredStockSeriesAThreeUponExerciseMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:ConvertiblePreferredStockSeriesAThreeUponExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="PAsOn06_29_2018_ConvertiblePreferredStockSeriesBOneUponConversionMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:ConvertiblePreferredStockSeriesBOneUponConversionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="PAsOn06_29_2018_ConvertiblePreferredStockSeriesBTwoUponExerciseMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:ConvertiblePreferredStockSeriesBTwoUponExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="PAsOn06_29_2018_ConvertiblePreferredStockSeriesBUponExerciseMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:ConvertiblePreferredStockSeriesBUponExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="PAsOn06_29_2018_ConvertiblePreferredStockSeriesBOneUponExerciseMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:ConvertiblePreferredStockSeriesBOneUponExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="PAsOn06_29_2018_ConvertiblePromissoryNotes2017MemberusgaapDebtInstrumentAxis_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">imab:ConvertiblePromissoryNotes2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesB1PreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="PAsOn07_06_2018_TrancheIOfSeriesBWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">imab:TrancheIOfSeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-06</instant>
        </period>
    </context>
    <context id="PAsOn07_06_2018_SeriesBWarrantsSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">imab:SeriesBWarrantsSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-06</instant>
        </period>
    </context>
    <context id="PAsOn07_06_2018_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-06</instant>
        </period>
    </context>
    <context id="PAsOn07_06_2018_ConvertiblePreferredStockSeriesBUponExerciseMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:ConvertiblePreferredStockSeriesBUponExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-06</instant>
        </period>
    </context>
    <context id="PAsOn07_06_2018_ConvertiblePreferredStockSeriesBOneUponExerciseMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:ConvertiblePreferredStockSeriesBOneUponExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-06</instant>
        </period>
    </context>
    <context id="PAsOn07_06_2018_ConvertiblePreferredStockSeriesBTwoUponExerciseMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:ConvertiblePreferredStockSeriesBTwoUponExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-06</instant>
        </period>
    </context>
    <context id="P07_06_2018To07_06_2018_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-06</startDate>
            <endDate>2018-07-06</endDate>
        </period>
    </context>
    <context id="PAsOn07_25_2019_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesCOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-25</instant>
        </period>
    </context>
    <context id="P10_17_2019To10_17_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-17</startDate>
            <endDate>2019-10-17</endDate>
        </period>
    </context>
    <context id="PAsOn10_17_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-17</instant>
        </period>
    </context>
    <context id="P11_06_2019To11_06_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-06</startDate>
            <endDate>2019-11-06</endDate>
        </period>
    </context>
    <context id="P11_06_2019To11_06_2019_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesCOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-06</startDate>
            <endDate>2019-11-06</endDate>
        </period>
    </context>
    <context id="PAsOn11_06_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-06</instant>
        </period>
    </context>
    <context id="PAsOn12_25_2019_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-25</instant>
        </period>
    </context>
    <context id="PAsOn12_25_2019_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-25</instant>
        </period>
    </context>
    <context id="P01_25_2019To12_25_2019_PreferredStockMemberusgaapStatementEquityComponentsAxis_TemporaryEquityMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:TemporaryEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-25</startDate>
            <endDate>2019-12-25</endDate>
        </period>
    </context>
    <context id="P01_25_2019To12_25_2019_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesCOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-25</startDate>
            <endDate>2019-12-25</endDate>
        </period>
    </context>
    <context id="P09_25_2017To09_25_2017_SeriesBOnshoreInvestorsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">imab:SeriesBOnshoreInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-25</startDate>
            <endDate>2017-09-25</endDate>
        </period>
    </context>
    <context id="P09_25_2017To09_25_2017_OnshoreConvertibleLoanMemberusgaapDebtInstrumentAxis_SeriesBOnshoreInvestorsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">imab:OnshoreConvertibleLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesBOnshoreInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-25</startDate>
            <endDate>2017-09-25</endDate>
        </period>
    </context>
    <context id="P09_25_2017To09_25_2017_OnshoreConvertibleLoanMemberusgaapDebtInstrumentAxis_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">imab:OnshoreConvertibleLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesB1PreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-25</startDate>
            <endDate>2017-09-25</endDate>
        </period>
    </context>
    <context id="P09_25_2017To09_25_2017_ConvertiblePromissoryNotes2017MemberusgaapDebtInstrumentAxis_SeriesBPreferredStockHolderMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">imab:ConvertiblePromissoryNotes2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesBPreferredStockHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-25</startDate>
            <endDate>2017-09-25</endDate>
        </period>
    </context>
    <context id="PAsOn09_25_2017_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesB1PreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-25</instant>
        </period>
    </context>
    <context id="PAsOn09_25_2017_OnshoreConvertibleLoanMemberusgaapDebtInstrumentAxis_SeriesBOnshoreInvestorsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">imab:OnshoreConvertibleLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesBOnshoreInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-25</instant>
        </period>
    </context>
    <context id="PAsOn09_25_2017_ConvertiblePromissoryNotes2017MemberusgaapDebtInstrumentAxis_SeriesBPreferredStockHolderMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">imab:ConvertiblePromissoryNotes2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesBPreferredStockHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-25</instant>
        </period>
    </context>
    <context id="P06_29_2018To06_29_2018_ConvertiblePromissoryNotes2017MemberusgaapDebtInstrumentAxis_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">imab:ConvertiblePromissoryNotes2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesB1PreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-29</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="P02_03_2018To02_03_2018_SeriesA3PreferredSharesMemberusgaapStatementClassOfStockAxis_TwoZeroOneEightNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">imab:TwoZeroOneEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-03</startDate>
            <endDate>2018-02-03</endDate>
        </period>
    </context>
    <context id="P02_03_2018To02_03_2018_ConvertiblePromissoryNotes2018MemberusgaapDebtInstrumentAxis_SeriesA3PreferredSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">imab:ConvertiblePromissoryNotes2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-03</startDate>
            <endDate>2018-02-03</endDate>
        </period>
    </context>
    <context id="PAsOn02_03_2018_ConvertiblePromissoryNotes2018MemberusgaapDebtInstrumentAxis_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">imab:ConvertiblePromissoryNotes2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesB1PreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-03</instant>
        </period>
    </context>
    <context id="PAsOn02_03_2018_ConvertiblePromissoryNotes2018MemberusgaapDebtInstrumentAxis_SeriesA3PreferredSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">imab:ConvertiblePromissoryNotes2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-03</instant>
        </period>
    </context>
    <context id="P09_22_2017To09_22_2017_SeriesBPreferredShareholdersMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">imab:SeriesBPreferredShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-22</startDate>
            <endDate>2017-09-22</endDate>
        </period>
    </context>
    <context id="P09_22_2017To09_22_2017_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:ConvertiblePreferredStockSeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-22</startDate>
            <endDate>2017-09-22</endDate>
        </period>
    </context>
    <context id="P06_29_2018To07_06_2018_SeriesB2PreferredSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">imab:SeriesB2PreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-29</startDate>
            <endDate>2018-07-06</endDate>
        </period>
    </context>
    <context id="P01_01_2016To12_31_2016_FoundersMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imab:FoundersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2016To12_31_2016_ThirdVentureMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">imab:ThirdVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="P06_01_2016To06_30_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imab:FoundersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="P10_01_2016To10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imab:FoundersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-31</endDate>
        </period>
    </context>
    <context id="P10_01_2016To10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imab:FoundersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-31</endDate>
        </period>
    </context>
    <context id="P10_01_2016To10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imab:FoundersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-31</endDate>
        </period>
    </context>
    <context id="P10_01_2016To10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imab:FoundersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-31</endDate>
        </period>
    </context>
    <context id="PAsOn10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imab:FoundersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-31</instant>
        </period>
    </context>
    <context id="P10_31_2019To10_31_2019_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imab:FoundersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-31</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="P10_01_2017To10_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="P10_01_2017To10_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="P10_01_2017To10_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="PAsOn10_31_2017_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:MorphosysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithMorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:HealSunMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:HealSunMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_DeferredRevenueMemberusgaapBalanceSheetLocationAxis_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:HealSunMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">imab:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_LeiFangMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imab:LeiFangMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2017_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:HealSunMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn02_22_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-22</instant>
        </period>
    </context>
    <context id="PAsOn02_22_2019_DirectorMembersrtTitleOfIndividualAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-22</instant>
        </period>
    </context>
    <context id="PAsOn02_22_2019_AmendedTwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis_DirectorMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:AmendedTwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-22</instant>
        </period>
    </context>
    <context id="P02_22_2019To02_22_2019_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-22</startDate>
            <endDate>2019-02-22</endDate>
        </period>
    </context>
    <context id="P02_22_2019To02_22_2019_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-22</startDate>
            <endDate>2019-02-22</endDate>
        </period>
    </context>
    <context id="P02_22_2019To02_22_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-22</startDate>
            <endDate>2019-02-22</endDate>
        </period>
    </context>
    <context id="P02_22_2019To02_22_2019_DrzangMembersrtTitleOfIndividualAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imab:DrzangMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-22</startDate>
            <endDate>2019-02-22</endDate>
        </period>
    </context>
    <context id="P02_22_2019To02_22_2019_AmendedTwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis_DirectorMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:AmendedTwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-22</startDate>
            <endDate>2019-02-22</endDate>
        </period>
    </context>
    <context id="P02_22_2019To02_22_2019_DirectorMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-22</startDate>
            <endDate>2019-02-22</endDate>
        </period>
    </context>
    <context id="P11_17_2017To11_17_2017_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:MorphosysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithMorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-17</startDate>
            <endDate>2017-11-17</endDate>
        </period>
    </context>
    <context id="P01_01_2018To01_01_2018_GenexineIncMembersrtCounterpartyNameAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:GenexineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithGenexineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-01</endDate>
        </period>
    </context>
    <context id="P01_01_2018To01_31_2018_GenexineIncMembersrtCounterpartyNameAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:GenexineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithGenexineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="PAsOn11_04_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">imab:OutLicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:EverestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-04</instant>
        </period>
    </context>
    <context id="P02_28_2019To02_28_2019_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:CspcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-28</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="P09_30_2019To09_30_2019_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:CspcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-30</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P07_31_2018To07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">imab:LoanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">imab:ChinaMerchantBankCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-31</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:ABLBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:CollaborationAgreementWithABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-31</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:ABLBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-31</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_ClinicalMilestonesMemberIMABMilestoneTypeAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:MilestoneTypeAxis">imab:ClinicalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:ABLBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-31</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_SalesMilestonesMemberIMABMilestoneTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:MilestoneTypeAxis">imab:SalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:ABLBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-31</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="P06_30_2019To06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">imab:LoanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">imab:ChinaMerchantBankCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-30</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn07_15_2017_TasgenGroupMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imab:TasgenGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-15</instant>
        </period>
    </context>
    <context id="PAsOn09_11_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-11</instant>
        </period>
    </context>
    <context id="PAsOn09_11_2020_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-11</instant>
        </period>
    </context>
    <context id="PAsOn09_11_2020_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-11</instant>
        </period>
    </context>
    <context id="PAsOn09_11_2020_MeasurementInputMaturityMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-11</instant>
        </period>
    </context>
    <context id="PAsOn09_11_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">imab:WarrantsToPurchaseOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-11</instant>
        </period>
    </context>
    <context id="PAsOn12_17_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-17</instant>
        </period>
    </context>
    <context id="PAsOn12_17_2020_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-17</instant>
        </period>
    </context>
    <context id="PAsOn12_17_2020_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-17</instant>
        </period>
    </context>
    <context id="PAsOn12_17_2020_MeasurementInputMaturityMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-17</instant>
        </period>
    </context>
    <context id="PAsOn12_17_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TwoZeroOneEightNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">imab:TwoZeroOneEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:GenexineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-17</instant>
        </period>
    </context>
    <context id="PAsOn12_17_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">imab:WarrantsToPurchaseOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-17</instant>
        </period>
    </context>
    <context id="P12_31_2020To12_31_2020_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:OtherinlicensingarrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-31</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P02_10_2020To02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-10</startDate>
            <endDate>2020-02-10</endDate>
        </period>
    </context>
    <context id="P01_31_2020To01_31_2020_AdrMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-31</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="PAsOn02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-10</instant>
        </period>
    </context>
    <context id="P01_17_2020To01_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-17</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="PAsOn01_17_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-17</instant>
        </period>
    </context>
    <context id="PAsOn01_17_2020_AdrMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-17</instant>
        </period>
    </context>
    <context id="PAsOn01_17_2020_CollaborationAgreementWithEverestMemberusgaapTypeOfArrangementAxis_EverestsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:EverestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:CollaborationAgreementWithEverestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-17</instant>
        </period>
    </context>
    <context id="PAsOn01_17_2020_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-17</instant>
        </period>
    </context>
    <context id="PAsOn01_17_2020_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:ConvertiblePreferredStockSeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-17</instant>
        </period>
    </context>
    <context id="PAsOn01_17_2020_ConvertiblePreferredStockSeriesBOneUponConversionMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:ConvertiblePreferredStockSeriesBOneUponConversionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-17</instant>
        </period>
    </context>
    <context id="PAsOn01_17_2020_ConvertiblePreferredStockSeriesB2MemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:ConvertiblePreferredStockSeriesB2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-17</instant>
        </period>
    </context>
    <context id="PAsOn01_17_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-17</instant>
        </period>
    </context>
    <context id="PAsOn01_17_2020_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-17</instant>
        </period>
    </context>
    <context id="PAsOn06_16_2019_ImabHangzhouMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:ImabHangzhouMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-16</instant>
        </period>
    </context>
    <context id="P01_17_2020To01_17_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-17</startDate>
            <endDate>2020-01-17</endDate>
        </period>
    </context>
    <context id="P01_17_2020To01_17_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-17</startDate>
            <endDate>2020-01-17</endDate>
        </period>
    </context>
    <context id="P01_17_2020To01_17_2020_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-17</startDate>
            <endDate>2020-01-17</endDate>
        </period>
    </context>
    <context id="P01_17_2020To01_17_2020_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:ConvertiblePreferredStockSeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-17</startDate>
            <endDate>2020-01-17</endDate>
        </period>
    </context>
    <context id="P01_17_2020To01_17_2020_ConvertiblePreferredStockSeriesBOneUponConversionMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:ConvertiblePreferredStockSeriesBOneUponConversionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-17</startDate>
            <endDate>2020-01-17</endDate>
        </period>
    </context>
    <context id="P01_17_2020To01_17_2020_ConvertiblePreferredStockSeriesB2MemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:ConvertiblePreferredStockSeriesB2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-17</startDate>
            <endDate>2020-01-17</endDate>
        </period>
    </context>
    <context id="P01_17_2020To01_17_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-17</startDate>
            <endDate>2020-01-17</endDate>
        </period>
    </context>
    <context id="P01_17_2020To01_17_2020_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesCOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-17</startDate>
            <endDate>2020-01-17</endDate>
        </period>
    </context>
    <context id="P01_17_2020To01_17_2020_SeniorManagementEmployeesMembersrtTitleOfIndividualAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imab:SeniorManagementEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-17</startDate>
            <endDate>2020-01-17</endDate>
        </period>
    </context>
    <context id="P01_17_2020To01_17_2020_SeniorManagementEmployeesMembersrtTitleOfIndividualAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imab:SeniorManagementEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-17</startDate>
            <endDate>2020-01-17</endDate>
        </period>
    </context>
    <context id="PAsOn07_15_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="PAsOn07_15_2020_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="PAsOn07_15_2020_AdrMemberusgaapStatementClassOfStockAxis_BoardOfDirectorsMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imab:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="P08_01_2020To08_31_2020_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphoSysAGMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:MorphoSysAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithMorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="P09_03_2020To09_03_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-03</startDate>
            <endDate>2020-09-03</endDate>
        </period>
    </context>
    <context id="P09_03_2020To09_03_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ClinicalMilestonesMemberIMABMilestoneTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imab:MilestoneTypeAxis">imab:ClinicalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-03</startDate>
            <endDate>2020-09-03</endDate>
        </period>
    </context>
    <context id="PAsOn07_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:ImabHangzhouMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="PAsOn07_31_2019_ImabHangzhouMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:ImabHangzhouMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="P07_01_2018To07_31_2018_ABLBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:ABLBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:LicensingAgreementWithABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="P09_11_2020To09_11_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">imab:WarrantsToPurchaseOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-11</startDate>
            <endDate>2020-09-11</endDate>
        </period>
    </context>
    <context id="P12_17_2020To12_17_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">imab:WarrantsToPurchaseOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-17</startDate>
            <endDate>2020-12-17</endDate>
        </period>
    </context>
    <context id="P01_01_2010To12_31_2010_ABLBioMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imab:ABLBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-01-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn01_31_2020_CollaborationAgreementWithEverestMemberusgaapTypeOfArrangementAxis_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:EverestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:CollaborationAgreementWithEverestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="P09_15_2020To12_31_2020_HoldcoMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">imab:HoldcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-15</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P09_15_2020To12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">imab:ImabHangzhouMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-15</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imab:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2021_CollaborationAgreementsWithTraconPharmaceuticalsIncMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">imab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_OtherFinancialAssetsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">imab:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_WarrantLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">imab:WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_OtherFinancialAssetsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">imab:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_WarrantLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">imab:WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PutRightLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">imab:PutRightLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">imab:SeriescOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imab:SeriesC1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyEighteenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentyTwentyEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2016_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001778016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imab:TwentySeventeenEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <unit id="Unit_CNY">
        <measure>iso4217:CNY</measure>
    </unit>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_CNY_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:CNY</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2020To12_31_2020">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2020To12_31_2020">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="P01_01_2020To12_31_2020">0001778016</dei:EntityCentralIndexKey>
    <imab:AmericanDepositorySharesCommonShareEquivalent
      contextRef="P02_10_2020To02_10_2020"
      decimals="0"
      id="hidden20395666"
      unitRef="Unit_pure">23</imab:AmericanDepositorySharesCommonShareEquivalent>
    <imab:DeferredLiabilityFromCollaborativeArrangementExcludingTax
      contextRef="PAsOn12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study1MemberIMABTypeOfLicensesAxis"
      decimals="-6"
      id="hidden20395917"
      unitRef="Unit_USD">0</imab:DeferredLiabilityFromCollaborativeArrangementExcludingTax>
    <imab:DeferredLiabilityFromCollaborativeArrangementExcludingTax
      contextRef="PAsOn12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study2MemberIMABTypeOfLicensesAxis"
      decimals="-6"
      id="hidden20395919"
      unitRef="Unit_USD">0</imab:DeferredLiabilityFromCollaborativeArrangementExcludingTax>
    <dei:NoTradingSymbolFlag contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">true</dei:NoTradingSymbolFlag>
    <dei:DocumentType contextRef="P01_01_2020To12_31_2020">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="P01_01_2020To12_31_2020">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="P01_01_2020To12_31_2020">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="P01_01_2020To12_31_2020">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="P01_01_2020To12_31_2020">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2020To12_31_2020">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="P01_01_2020To12_31_2020">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="P01_01_2020To12_31_2020">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="P01_01_2020To12_31_2020">001-39173</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P01_01_2020To12_31_2020">I-MAB</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2020To12_31_2020">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2020To12_31_2020">Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2020To12_31_2020">Shanghai</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2020To12_31_2020">201210</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="P01_01_2020To12_31_2020">CN</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="P01_01_2020To12_31_2020_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Jielun Zhu</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2020To12_31_2020_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2020To12_31_2020_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Shanghai</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2020To12_31_2020_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">201210</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="P01_01_2020To12_31_2020_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">CN</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="P01_01_2020To12_31_2020_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">86</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2020To12_31_2020_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">6057-8000</dei:LocalPhoneNumber>
    <dei:ContactPersonnelEmailAddress contextRef="P01_01_2020To12_31_2020_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">jielun.zhu@i-mabbiopharma.com</dei:ContactPersonnelEmailAddress>
    <dei:Security12bTitle contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis">American depositary shares, each ten (10) American depositary shares representing twenty-three (23) ordinary shares</dei:Security12bTitle>
    <dei:Security12bTitle contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">Ordinary shares, par value US$0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis">IMAB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis">NASDAQ</dei:SecurityExchangeName>
    <dei:SecurityExchangeName contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">164888519</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="P01_01_2020To12_31_2020">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="P01_01_2020To12_31_2020">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="P01_01_2020To12_31_2020">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P01_01_2020To12_31_2020">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P01_01_2020To12_31_2020">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2020To12_31_2020">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2020To12_31_2020">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="P01_01_2020To12_31_2020">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard contextRef="P01_01_2020To12_31_2020">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="P01_01_2020To12_31_2020">false</dei:EntityShellCompany>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">1137473000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">4758778000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">729315000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">55810000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">130498000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">20000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">227391000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">34849000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ShortTermInvestments
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">32000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">31530000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4832000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">136036000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">195467000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">29957000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">1361319000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">5343664000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">818953000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">30069000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">25272000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3873000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">16435000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">14997000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2298000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">148844000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">120444000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">18459000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">162574000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">162574000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">24916000</us-gaap:Goodwill>
    <us-gaap:EquityMethodInvestments
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">664832000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">101890000</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">18331000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">2010000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">308000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">1737572000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">6333793000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">970697000</us-gaap:Assets>
    <us-gaap:ShortTermBorrowings
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">50000000</us-gaap:ShortTermBorrowings>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">273553000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">560558000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">85909000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">6807000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">8058000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1235000</us-gaap:OperatingLeaseLiabilityCurrent>
    <imab:CommonStockSharesIssuableForServicesAvailedCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">258119000</imab:CommonStockSharesIssuableForServicesAvailedCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">7509000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1151000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">588479000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">576125000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">88295000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">68199000</us-gaap:ConvertibleLongTermNotesPayable>
    <imab:PutRightLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">116006000</imab:PutRightLiabilities>
    <imab:PutRightLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">17779000</imab:PutRightLiabilities>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">7492000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">5542000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">849000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">3920000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">8975000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1375000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">668090000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">706648000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">108298000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2019"
      unitRef="Unit_CNY"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2020"
      unitRef="Unit_CNY"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2020"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2019_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2019_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">30227056</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2019_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">30227056</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2019_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">30227056</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2020_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2020_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2019_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">687482000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2019_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2019_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">30305212</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2019_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">30305212</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2019_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">30305212</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2020_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2020_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2019_SeriesBConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">921243000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2019_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2019_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">31046360</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2019_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">31046360</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2019_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">31046360</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2020_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2020_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2019_SeriesCConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">1306633000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">3857143</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">3857143</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">3857143</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">188819000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">3104177000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">8363719</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">8363719</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">164888519</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">164888519</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">6000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">114000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">17000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">389379000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">7701116000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1180249000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">70127000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-50793000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-7784000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-2494207000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-2023292000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-310083000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-2034695000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">5627145000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">862399000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">1737572000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">6333793000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">970697000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">53781000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">1542668000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">236424000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">426028000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">840415000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">984689000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">150910000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">66391000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">654553000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">402409000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">61672000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-438638000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-1464968000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">155570000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">23842000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">4597000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">30570000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">24228000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3713000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">11695000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">2991000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">957000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">147000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-16780000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-20205000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">412892000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">63278000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-108587000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-16642000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-61405000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-5644000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-401111000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-1451950000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">483146000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">74044000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">1722000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">12231000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1874000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-402833000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-1451950000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">470915000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">72170000</us-gaap:NetIncomeLoss>
    <imab:PreferredStockDividendsAtExtinguishmentOfPreferredShares
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">5283000</imab:PreferredStockDividendsAtExtinguishmentOfPreferredShares>
    <imab:PreferredStockDividendsAtModificationOfPreferredShares
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">27768000</imab:PreferredStockDividendsAtModificationOfPreferredShares>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-402833000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-1485001000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">470915000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">72170000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-402833000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-1451950000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">470915000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">72170000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">53689000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">10747000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-120920000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-18531000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-349144000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-1441203000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">349995000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">53639000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-402833000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-1485001000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">470915000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">72170000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2018To12_31_2018"
      decimals="INF"
      unitRef="Unit_shares">6529092</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">7381230</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">134158824</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">134158824</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2018To12_31_2018"
      decimals="INF"
      unitRef="Unit_shares">6529092</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2019To12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">7381230</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">157231652</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">157231652</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_CNY_per_Share">-61.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_CNY_per_Share">-201.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_CNY_per_Share">3.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_CNY_per_Share">-61.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_CNY_per_Share">-201.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_CNY_per_Share">3.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2018To12_31_2018_AdrMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_CNY_per_Share">-141.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2019To12_31_2019_AdrMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_CNY_per_Share">-462.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_CNY_per_Share">8.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2018To12_31_2018_AdrMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_CNY_per_Share">-141.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2019To12_31_2019_AdrMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_CNY_per_Share">-462.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_CNY_per_Share">6.90</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">8363719</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2017_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">-1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">52369000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">5691000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">-357860000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2017"
      decimals="-3"
      unitRef="Unit_CNY">-299795000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">53689000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">53689000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2018To12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">-402833000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-402833000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">3520000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">3520000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">-55889000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="P01_01_2018To12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">-253796000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-309685000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">8363719</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">-1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">59380000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">-1014489000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-955104000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">10747000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">10747000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">-1451950000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-1451950000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To12_31_2019_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">1000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">366894000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">366895000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <imab:PreferredStockDividendsAtExtinguishmentOfPreferredShares
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">5283000</imab:PreferredStockDividendsAtExtinguishmentOfPreferredShares>
    <imab:PreferredStockDividendsAtExtinguishmentOfPreferredShares
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">5283000</imab:PreferredStockDividendsAtExtinguishmentOfPreferredShares>
    <imab:PreferredStockDividendsAtModificationOfPreferredShares
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">27768000</imab:PreferredStockDividendsAtModificationOfPreferredShares>
    <imab:PreferredStockDividendsAtModificationOfPreferredShares
      contextRef="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">-27768000</imab:PreferredStockDividendsAtModificationOfPreferredShares>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">8363719</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">389379000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">70127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">-2494207000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-2034695000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">8363719</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">389379000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">70127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">-2494207000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-2034695000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">-120920000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-120920000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">470915000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">470915000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">402413000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">402413000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">1841373</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">7771000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">7774000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">7000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">46000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">46000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">900000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">1000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">58825000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">58826000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <imab:AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">91051000</imab:AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender>
    <imab:AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">91051000</imab:AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">99760129</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">69000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">3104108000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">3104177000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">6078571</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">4000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">254844000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">254848000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">18804225</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">13000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">697865000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">697878000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">29133502</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">18000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">2543908000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">2543926000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <imab:ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">41163000</imab:ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate>
    <imab:ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">41163000</imab:ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">109743000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">109743000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">164888519</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">114000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">7701116000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">-50793000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">-2023292000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">5627145000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-402833000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-1451950000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">470915000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">72170000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">6740000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">9831000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">12743000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1953000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">1556000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">238000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-8000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">6963000</us-gaap:InterestExpenseDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-61405000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-5644000</us-gaap:FairValueAdjustmentOfWarrants>
    <imab:FairValueAdjustmentsOfPutRightLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-3024000</imab:FairValueAdjustmentsOfPutRightLiabilities>
    <imab:FairValueAdjustmentsOfPutRightLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-463000</imab:FairValueAdjustmentsOfPutRightLiabilities>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-42000</us-gaap:AssetsFairValueAdjustment>
    <imab:IncomeFromOtherFinancialAssets
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">13622000</imab:IncomeFromOtherFinancialAssets>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-108587000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-16642000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">3520000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">366895000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">493464000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">75627000</us-gaap:ShareBasedCompensation>
    <imab:LossFromConversionOfNotes
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">18375000</imab:LossFromConversionOfNotes>
    <imab:LossFromConversionOfOnshoreConvertibleLoans
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">8548000</imab:LossFromConversionOfOnshoreConvertibleLoans>
    <imab:LossFromIssuanceOfNotes
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">5081000</imab:LossFromIssuanceOfNotes>
    <us-gaap:GainLossOnContractTermination
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-23039000</us-gaap:GainLossOnContractTermination>
    <imab:AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">5803000</imab:AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities>
    <imab:AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">8837000</imab:AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities>
    <imab:AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1354000</imab:AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">407598000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">62467000</us-gaap:GainLossOnSaleOfBusiness>
    <imab:FairValueChangeOfShortTermInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-703000</imab:FairValueChangeOfShortTermInvestments>
    <imab:FairValueChangeOfShortTermInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-11288000</imab:FairValueChangeOfShortTermInvestments>
    <imab:FairValueChangeOfShortTermInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-1730000</imab:FairValueChangeOfShortTermInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">130498000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">20000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">11000000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-11000000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">227391000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">34849000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">76276000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">48831000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">58692000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8995000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">55641000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">188375000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">173713000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">26624000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-15803000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <imab:IncreaseDecreaseAdvanceFromCustomers
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">14151000</imab:IncreaseDecreaseAdvanceFromCustomers>
    <imab:IncreaseDecreaseAdvanceFromCustomers
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-14151000</imab:IncreaseDecreaseAdvanceFromCustomers>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">178715000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">53148000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">7474000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1145000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">2500000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">1420000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">3589000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">550000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <imab:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-6172000</imab:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent>
    <imab:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-8837000</imab:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent>
    <imab:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-1354000</imab:IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-280705000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-867982000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">433558000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">66446000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">14409000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">12241000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">8008000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1227000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">102703000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">2503749000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">383716000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">134000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">2491991000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">381914000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">30000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">257651000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">39487000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">40000000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">256000000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <imab:CashReceivedOnIncomeFromOtherFinancialAssets
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">13909000</imab:CashReceivedOnIncomeFromOtherFinancialAssets>
    <imab:CashReceivedOnIncomeFromOtherFinancialAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">0</imab:CashReceivedOnIncomeFromOtherFinancialAssets>
    <us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">52000000</us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
    <us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7969000</us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">9500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">212462000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-201901000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-30943000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">1306633000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">183536000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">59704000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">726300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">111310000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">827000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">27595000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4229000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2018To12_31_2018"
      unitRef="Unit_CNY"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2018To12_31_2018"
      unitRef="Unit_CNY"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">2782455000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">426430000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">132332000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">9275000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1422000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">46000</us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits>
    <us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits>
    <us-gaap:ProceedsFromBankDebt
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">80000000</us-gaap:ProceedsFromBankDebt>
    <us-gaap:ProceedsFromBankDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">50000000</us-gaap:ProceedsFromBankDebt>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">99000000</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">80000000</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">50000000</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7663000</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:PaymentsForRepurchaseOfEquity
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">34859000</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:PaymentsForRepurchaseOfEquity
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5342000</us-gaap:PaymentsForRepurchaseOfEquity>
    <imab:ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">34859000</imab:ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram>
    <imab:ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5342000</imab:ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">1479669000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">152709000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">3440481000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">527277000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">59754000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">15163000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-106643000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-16344000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">1268218000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-487648000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">3565495000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">546436000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2017"
      decimals="-3"
      unitRef="Unit_CNY">412713000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">1680931000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">1193283000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">182879000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">1680931000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">1193283000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">4758778000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">729315000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">6172000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">8837000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1354000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">8595000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">7459000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1143000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">4862000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">2991000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">957000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">147000</us-gaap:InterestPaidNet>
    <imab:ExerciseOfWarrants
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">1314000</imab:ExerciseOfWarrants>
    <imab:PayablesForInLicensedPatentRights
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">5970000</imab:PayablesForInLicensedPatentRights>
    <imab:AccuredInitialPublicOfferingCostPayable
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">17504000</imab:AccuredInitialPublicOfferingCostPayable>
    <imab:PreferredStockDividendsAtExtinguishmentOfPreferredShares
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">5283000</imab:PreferredStockDividendsAtExtinguishmentOfPreferredShares>
    <imab:PreferredStockDividendsAtModificationOfPreferredShares
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">27768000</imab:PreferredStockDividendsAtModificationOfPreferredShares>
    <imab:AccruedPrivatePlacementOfferingCostsPayable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">128786000</imab:AccruedPrivatePlacementOfferingCostsPayable>
    <imab:AccruedPrivatePlacementOfferingCostsPayable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">19737000</imab:AccruedPrivatePlacementOfferingCostsPayable>
    <us-gaap:StockIssued1
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">254848000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">39057000</us-gaap:StockIssued1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">3104177000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">475736000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">58826000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">9015000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1. PRINCIPAL ACTIVITIES AND ORGANIZATION &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; (the &#x201c;Company&#x201d;) was incorporated in the Cayman Islands on June&#160;30, 2016 as an exempted company with limited liability under the Companies &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Act&lt;/div&gt;&#160;of the Cayman Islands. The Company and its subsidiaries (together the &#x201c;Group&#x201d;) are principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People&#x2019;s Republic of China (the &#x201c;PRC&#x201d;) and other countries and regions. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Prior to the incorporation of the Company, the Group carried out its operation in the PRC since November 2014 mainly through Third Venture Biopharma (Nanjing) Co., Ltd. (&#x201c;Third Venture&#x201d;), which was incorporated on November&#160;17, 2014 in the PRC. For the purpose of introduction of overseas investors and in preparation for a listing of the Company&#x2019;s shares on the overseas capital markets, the Group underwent a reorganization (the &#x201c;Reorganization&#x201d;) in 2016. The Reorganization was approved by the Board of Directors and a restructuring framework agreement was entered into by Third Venture, the Company, and the shareholders of the Company based on Reorganization framework agreement, pursuant to which on July&#160;7, 2016, Third Venture transferred all of its assets and operations to the Company&#x2019;s wholly owned subsidiary, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Biopharma Co., Ltd. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;I-Mab&lt;/div&gt; Shanghai&#x201d;), which was a transaction in which shareholders had identical ownership interests before and after the transaction and was accounted for in a manner similar to a common control transaction. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Reorganization, as described above has been accounted for at historical cost. That Reorganization was reverse merger of Third Venture and Third Venture is the predecessor of the Company. As such, the assets and liabilities of Third Venture are consolidated in the Company&#x2019;s financial statements at historical cost. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;17, 2020, the Company consummated its IPO on the Nasdaq Global Market, where 7,407,400 American Depositary Shares (&#x201c;ADSs&#x201d;) were issued at the price of US$14.00 per ADS for total gross proceeds of US$103.7&#160;million. On February&#160;10, 2020, the underwriters of the IPO have exercised their over-allotment option to purchase an additional 768,350 ADSs of the Company at the IPO price of US$14.00 per ADS. After giving effect to the exercise of the over-allotment option, the Company has issued and sold a total of 8,175,750 ADSs in the IPO, for total gross proceeds of US$114.5&#160;million. Each ten ADSs represents twenty-three ordinary shares of the Company. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;December&#160;31, 2020, the Company&#x2019;s principal subsidiaries are as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 46%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Subsidiaries&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Place of&lt;br/&gt; incorporation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Date of&lt;br/&gt; incorporation or&lt;br/&gt; acquisition&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Percentage&lt;br/&gt; of direct&lt;br/&gt; or indirect&lt;br/&gt; ownership&lt;br/&gt; by the&lt;br/&gt; Company&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Principal&#160;activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Biopharma Hong Kong Limited &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;I-Mab&lt;/div&gt; Hong Kong&#x201d;)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;;text-align:right;"&gt;Hong Kong&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;July 8, 2016&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;;text-align:right;"&gt;Investment holding&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Shanghai&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;PRC&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;August 24, 2016&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;;text-align:right;"&gt;Research and&lt;br/&gt; development of&lt;br/&gt; innovative medicines&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;br/&gt; &#160;&lt;br/&gt; &#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 46%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bio-tech&lt;/div&gt; (Tianjin) Co., Ltd.&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;(&#x201c;I-Mab&lt;/div&gt; Tianjin&#x201d;)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;PRC&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;July 15, 2017&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;;text-align:right;"&gt;Research and&lt;br/&gt; development of&lt;br/&gt; innovative medicines&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;br/&gt; &#160;&lt;br/&gt; &#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Biopharma US Ltd.&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;U.S.&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;;text-align:right;"&gt;February 28, 2018&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;;text-align:right;"&gt;Research and&lt;br/&gt; development of&lt;br/&gt; innovative medicines&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;br/&gt; &#160;&lt;br/&gt; &#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_31_2020To01_31_2020_AdrMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">7407400</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn01_17_2020_AdrMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">14.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_31_2020To01_31_2020_AdrMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">103700000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <imab:CommonStockSharesIssuable
      contextRef="PAsOn02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">768350</imab:CommonStockSharesIssuable>
    <us-gaap:SharePrice
      contextRef="PAsOn02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">14.00</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P02_10_2020To02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">8175750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P02_10_2020To02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">114500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <imab:ScheduleOfPrincipalSubsidiariesTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;December&#160;31, 2020, the Company&#x2019;s principal subsidiaries are as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 46%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Subsidiaries&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Place of&lt;br/&gt; incorporation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Date of&lt;br/&gt; incorporation or&lt;br/&gt; acquisition&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Percentage&lt;br/&gt; of direct&lt;br/&gt; or indirect&lt;br/&gt; ownership&lt;br/&gt; by the&lt;br/&gt; Company&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Principal&#160;activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Biopharma Hong Kong Limited &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;I-Mab&lt;/div&gt; Hong Kong&#x201d;)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;;text-align:right;"&gt;Hong Kong&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;July 8, 2016&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;;text-align:right;"&gt;Investment holding&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Shanghai&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;PRC&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;August 24, 2016&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;;text-align:right;"&gt;Research and&lt;br/&gt; development of&lt;br/&gt; innovative medicines&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;br/&gt; &#160;&lt;br/&gt; &#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 46%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bio-tech&lt;/div&gt; (Tianjin) Co., Ltd.&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;(&#x201c;I-Mab&lt;/div&gt; Tianjin&#x201d;)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;PRC&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;July 15, 2017&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;;text-align:right;"&gt;Research and&lt;br/&gt; development of&lt;br/&gt; innovative medicines&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;br/&gt; &#160;&lt;br/&gt; &#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Biopharma US Ltd.&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;U.S.&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;;text-align:right;"&gt;February 28, 2018&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;;text-align:right;"&gt;Research and&lt;br/&gt; development of&lt;br/&gt; innovative medicines&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;br/&gt; &#160;&lt;br/&gt; &#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </imab:ScheduleOfPrincipalSubsidiariesTableTextBlock>
    <imab:EntityIncorporationCountryStateName contextRef="P01_01_2020To12_31_2020_IMabBiopharmaHongKongLimitedMembersrtConsolidatedEntitiesAxis">Hong Kong</imab:EntityIncorporationCountryStateName>
    <dei:EntityIncorporationDateOfIncorporation contextRef="P01_01_2020To12_31_2020_IMabBiopharmaHongKongLimitedMembersrtConsolidatedEntitiesAxis">2016-07-08</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2020_IMabBiopharmaHongKongLimitedMembersrtConsolidatedEntitiesAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities contextRef="P01_01_2020To12_31_2020_IMabBiopharmaHongKongLimitedMembersrtConsolidatedEntitiesAxis">Investment holding</us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities>
    <imab:EntityIncorporationCountryStateName contextRef="P01_01_2020To12_31_2020_IMabShanghaiMembersrtConsolidatedEntitiesAxis">PRC</imab:EntityIncorporationCountryStateName>
    <dei:EntityIncorporationDateOfIncorporation contextRef="P01_01_2020To12_31_2020_IMabShanghaiMembersrtConsolidatedEntitiesAxis">2016-08-24</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2020_IMabShanghaiMembersrtConsolidatedEntitiesAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities contextRef="P01_01_2020To12_31_2020_IMabShanghaiMembersrtConsolidatedEntitiesAxis">Research and development of innovative medicines</us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities>
    <imab:EntityIncorporationCountryStateName contextRef="P01_01_2020To12_31_2020_IMabtianjinMembersrtConsolidatedEntitiesAxis">PRC</imab:EntityIncorporationCountryStateName>
    <dei:EntityIncorporationDateOfIncorporation contextRef="P01_01_2020To12_31_2020_IMabtianjinMembersrtConsolidatedEntitiesAxis">2017-07-15</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2020_IMabtianjinMembersrtConsolidatedEntitiesAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities contextRef="P01_01_2020To12_31_2020_IMabtianjinMembersrtConsolidatedEntitiesAxis">Research and development of innovative medicines</us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities>
    <imab:EntityIncorporationCountryStateName contextRef="P01_01_2020To12_31_2020_ImabbiopharmaUsLtdMembersrtConsolidatedEntitiesAxis">U.S.</imab:EntityIncorporationCountryStateName>
    <dei:EntityIncorporationDateOfIncorporation contextRef="P01_01_2020To12_31_2020_ImabbiopharmaUsLtdMembersrtConsolidatedEntitiesAxis">2018-02-28</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2020_ImabbiopharmaUsLtdMembersrtConsolidatedEntitiesAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities contextRef="P01_01_2020To12_31_2020_ImabbiopharmaUsLtdMembersrtConsolidatedEntitiesAxis">Research and development of innovative medicines</us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2. PRINCIPAL ACCOUNTING POLICIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.1 Basis of presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant accounting policies followed by the Group in the preparation of the accompanying consolidated financial statements are summarized below. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.2 Basis of consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All inter-company balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group consolidates entities in which it has a controlling financial interest based on either the variable interest entity (VIE) or voting interest model. The Group is required to first apply the VIE model to determine whether it holds a variable interest in an entity, and if so, whether the entity is a VIE. If the Group determines it does not hold a variable interest in a VIE, it then applies the voting interest model. Under the voting interest model, the Group consolidates an entity when it holds a majority voting interest in an entity. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for investments in which it has significant influence but not a controlling financial interest using the equity method of accounting (see Note &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;VIE Model &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An entity is considered to be a VIE if any of the following conditions exist: (a)&#160;the total equity investment at risk is not sufficient to permit the entity to finance its activities without additional subordinated financial support, (b)&#160;the holders of the equity investment at risk, as a group, lack either the direct or indirect ability through voting rights or similar rights to make decisions that have a significant effect on the success of the entity or the obligation to absorb the entity&#x2019;s expected losses or right to receive the entity&#x2019;s expected residual returns, or (c)&#160;the voting rights of some equity investors are disproportionate to their obligation to absorb losses of the entity, their rights to receive returns from an entity, or both and substantially all of the entity&#x2019;s activities either involve or are conducted on behalf of an investor with disproportionately few voting rights. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Under the VIE model, limited partnerships are considered VIE unless the limited partners hold substantive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;kick-out&lt;/div&gt; or participating rights over the general partner. The Group consolidates entities that are VIEs when the Group determines it is the primary beneficiary. Generally, the primary beneficiary of a VIE is a reporting entity that has (a)&#160;the power to direct the activities that most significantly affect the VIE&#x2019;s economic performance, and (b)&#160;the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020, the Group determined that the one entity subject to the consolidation guidance is a VIE for which the Group is not the primary beneficiary. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;div style="margin-block: 0em; line-height: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.3 Use of estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally, estimates are used in determining items such as fair value measurements of wealth management products, warrants and put right liabilities, impairment of accounts receivables, contract assets, other receivables, long-lived assets, intangible assets and goodwill, useful lives of property, equipment and software, recognition of right-of-use assets and lease liabilities, variable consideration in collaboration revenue arrangements, determination of the standalone selling price of each performance obligation in the Company&#x2019;s revenue arrangements, valuation of share-based compensation arrangements and deferred tax assets valuation allowances. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.4 Fair value measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets and liabilities of the Group primarily comprise of cash and cash equivalents, restricted cash, short-term investments, other financial assets, accounts receivable, contract assets, other receivables, short-term borrowings, accruals and other payables, warrant liabilities and put right liabilities. As of December 31, 2019 and 2020, except for short-term investments, other financial assets and put right liabilities, the carrying values of these financial assets and liabilities approximated their fair values because of their generally short maturities. The Group reports short-term investments, other financial assets and put right liabilities at fair value at each balance sheet date and changes in fair value are reflected in the consolidated statements of comprehensive income (loss).&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group measures its financial assets and liabilities using inputs from the following three levels of the fair value hierarchy. The three levels are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1 inputs are unadjusted quoted prices in active markets for identical assets that the management has the ability to access at the measurement date. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2 inputs include quoted prices for similar assets in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3 includes unobservable inputs that reflect the management&#x2019;s assumptions about the assumptions that market participants would use in pricing the asset. The management develops these inputs based on the best information available, including the own data.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Assets and liabilities measured at fair value on a recurring basis &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group measures its short-term investments, other financial assets, warrant liabilities, and put right liabilities at fair value on a recurring basis. As the Group&#x2019;s short-term investments, other financial assets, warrant liabilities and put right liabilities are not traded in an active market with readily observable prices, the Group uses significant unobservable inputs to measure the fair value of short-term investments, other financial assets, warrant liabilities and put right liabilities. These instruments are categorized in the Level 3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Group&#x2019;s financial assets and liabilities measured and recorded at fair value on a recurring basis as of December&#160;31, 2019 and 2020: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Active&#160;market&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Observable&#160;input&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;observable&#160;input&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level 2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term investments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 56%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Active&#160;market&lt;br/&gt; (Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Observable&#160;input&lt;br/&gt; (Level 2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;observable&#160;input&lt;br/&gt; (Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term investments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;31,530&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;31,530&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 56%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Put right liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;116,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;116,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 56%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The roll forward of major Level&#160;3 financial assets &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;a&lt;/div&gt;nd financial liabilities are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Short-term&lt;br/&gt; investments&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Other&#160;financial&lt;br/&gt; assets&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Warrant&lt;br/&gt; liabilities&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Put right&lt;br/&gt; liabilities&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair&#160;value&#160;of&#160;Level&#160;3&#160;financial&#160;asset&#160;and&#160;liabilities&#160;as&#160;of&#160;December&#160;31,&#160;2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;255,958&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(5,618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Purchase of short-term investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;134,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposal of short-term investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(102,703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposal of other financial assets due to Termination Agreement&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(256,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value changes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;42&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,644&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency translation differences&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair&#160;value&#160;of&#160;Level&#160;3&#160;financial&#160;assets&#160;and&#160;liabilities&#160;as&#160;of&#160;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;32,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Purchase of short-term investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,491,991&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposal of short-term investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,503,749&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant of put right liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;124,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value changes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,288&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(3,024&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency translation differences&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(5,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of Level&#160;3 financial assets and liabilities as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31,530&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;116,006&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;See Note &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&#160;for additional information about Level&#160;3 put right liabilities measured at fair value on a recurring basis for the year ended December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.5 Foreign currency translation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group uses Chinese Renminbi (&#x201c;RMB&#x201d;) as its reporting currency. The United States Dollar (&#x201c;US$&#x201d;) is the functional currency of the Group&#x2019;s entities incorporated in the Cayman Islands, the United States of America (&#x201c;U.S.&#x201d;) and Hong Kong, the Australia Dollar (&#x201c;AUD&#x201d;) is the functional currency of the Group&#x2019;s entity incorporated in Australia and the RMB is the functional currency of the Company&#x2019;s PRC subsidiaries. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transactions denominated in other than the functional currencies are translated into the functional currency of the entity at the exchange rates prevailing on the transaction dates. Assets and liabilities denominated in other than the functional currencies are translated at the balance sheet date exchange rate. The resulting exchange differences are recorded in the consolidated statements of comprehensive income (loss). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements of the Group are translated from the functional currency to the reporting currency, RMB. Assets and liabilities of the subsidiaries are translated into RMB using the exchange rate in effect at each balance sheet date. Income and expenses are translated at the average exchange rates prevailing for the year. Foreign currency translation adjustments arising from these are reflected in the accumulated other comprehensive &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;income (loss). The exchange rates&#160;&lt;/div&gt;used for translation on December&#160;31, 2019 and 2020 were US$1.00 = RMB6.9762 and RMB6.5249 respectively, representing the index rates stipulated by the People&#x2019;s Bank of China. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Translations of balances in the consolidated balance sheets, consolidated statements of comprehensive income (loss), consolidated statements of changes in shareholders&#x2019; equity (deficit) and consolidated statements of cash flows from RMB into US$ as of and for the year ended December&#160;31, 2020 are solely for the convenience of the readers and were calculated at the rate of US$1.00=RMB6.5250, representing the noon buying rate in The City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New York on December&#160;31, 2020. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on December&#160;31, 2020, or at any other rate. The US$ convenience translation is not required under U.S. GAAP and all US$ convenience translation amounts in the accompanying consolidated financial statements are unaudited. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.6 Cash and cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Group considers all highly liquid investments with an original maturity date of three months or less at the date of purchase to be cash equivalents. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.7 Restricted cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash consists of the guarantee deposits held in a designated bank account as security deposits under bank borrowing agreements. Such restricted cash will be released when the Group repays the related bank borrowings. The Group has presented restricted cash separately from cash and cash equivalents in the consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and restricted cash as reporte&lt;div style="display:inline;"&gt;d&lt;/div&gt;&#160;in the consolidated statement of cash flows are presented separately on the consolidated balance sheet as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,137,473&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,758,778&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;55,810&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,193,283&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,758,778&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.8 Accounts receivable &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable are stated at amortized cost less allowance for credit losses. The allowance for credit losses reflects the best estimate of future losses over the contractual life of outstanding accounts receivable and is determined on the basis of historical experience, specific allowances for known troubled accounts, other currently available information including customer financial condition, and both current and forecasted economic conditions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.9 Short-term investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term investments represent the investments issued by commercial banks or other financial institutions with a variable interest rate indexed to the performance of underlying assets within one year. These investments are stated at fair value. Changes in the fair value are reflected in the consolidated statements of comprehensive income (loss). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.10 Property, equipment and software&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the following estimated useful lives, taking into account of any estimated residual value: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 51%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 46%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;3 to 10 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;1 to 5 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Office furniture and equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;5 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;Lesser of useful life or lease term&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group recognizes the gain or loss on the disposal of property, equipment and software in the consolidated statements of comprehensive income (loss). &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.11 Intangible assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets acquired in a business combination that are used in research and development activities, or in-process research and development (IPR&amp;amp;D) intangible assets, are considered indefinite lived until the completion or abandonment of the associated research and development efforts. During the period that those assets are considered indefinite lived, they are not amortized but are tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. If after assessing the totality of events and circumstances and their potential effect on significant inputs to the fair value determination the Group determines that it is not more likely than not that the indefinite-lived intangible is impaired, then the entity shall calculate the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value of the asset with its carrying amount. If the carrying amount exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. For IPR&amp;amp;D assets, the impairment loss is recognized in research and development expenses in the consolidated statements of comprehensive income (loss).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets with finite useful lives are amortized over their useful lives. The useful life of an intangible asset is the period over which the asset is expected to contribute directly or indirectly to the future cash flows of the Group. The Group uses the straight-line amortization method when the economic benefits of the intangible assets are consumed or otherwise used up cannot be reliably determined. In particular, the Group amortizes the IPR&amp;amp;D intangible assets with finite useful lives over 10 to 20 years on a straight-line basis. Intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. If circumstances require an intangible asset be tested for possible impairment, the Group first compares undiscounted cash flows expected to be generated by that asset to its carrying amount. If the carrying amount is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. For IPR&amp;amp;D assets, the impairment loss is recognized in research and development expenses in the consolidated statements of comprehensive income (loss).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;div style="text-align: left;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.12 Impairment of long-lived assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-lived assets, such as property, plant, and software, and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. For the years ended December&#160;31, 2019 and 2020, there was no impairment of the value of the Group&#x2019;s long-lived assets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.13 Goodwill &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The Group allocates the cost of an acquired entity to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price for acquisitions over the fair value of the net assets acquired, including other intangible assets, is recorded as goodwill. Goodwill is not amortized, but impairment of goodwill is tested on at least an annual basis or whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Group&#x2019;s reporting unit is less than its carrying amount, including goodwill. The qualitative assessment includes the Group&#x2019;s evaluation of relevant events and circumstances affecting the Group&#x2019;s single reporting unit, including macroeconomic, industry, market conditions and the Group&#x2019;s overall financial performance. If qualitative factors indicate that it is more likely than not that the Group&#x2019;s reporting unit&#x2019;s fair value is less than its carrying amount, then the Group will perform the quantitative impairment test by comparing the reporting unit&#x2019;s carrying amount, including goodwill, to its fair value. If the carrying amount of the reporting unit exceeds its fair value, an impairment loss will be recognized in an amount equal to that excess. For the years ended December&#160;31, 2019 and 2020, the Group determined that there were no indicators of impairment of the goodwill. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="text-align: left;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.14 Long-term investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group&#x2019;s long-term investments include equity investments in an affiliate in which it does not have a controlling financial interest, but has the ability to exercise significant influence over the operating and financial policies of the investee. The investment is accounted for using the equity method of accounting in accordance with ASC topic 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Under the equity method, the Group initially records its investments at fair value. The Group subsequently adjusts the carrying amount of the investment to recognize the Group&#x2019;s proportionate share of the equity investee&#x2019;s net income or loss after the date of investment. When the liquidation rights and priorities as defined by an equity investment agreement diff&lt;div style="display:inline;"&gt;e&lt;/div&gt;r from what is reflected by the underlying percentage ownership interests, applying the percentage ownership interest to U.S. GAAP net income in order to determine earnings or losses does not accurately represent the income allocation and cash flow distributions that will ultimately be received by the investors. As such, for this type of investments, the Group uses the Hypothetical Liquidation at Book Value (&#x201c;HLBV&#x201d;) method for allocating earnings or losses of the equity method investee. The HLBV method is considered as a balance sheet approach. Specifically, a calculation is prepared at each balance sheet date to determine the amount that the Group would receive if an equity investment entity were to liquidate all of its assets (as valued in accordance with U.S. GAAP) and distribute that cash to the investors based on the contractually defined liquidation priorities. The difference between the calculated liquidation distribution amounts at the beginning and the end of the reporting period, after adjusting for capital contributions and distributions, is the Group&#x2019;s share of the earnings or losses from the equity investment for the period. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As it relates to the share-based compensation awarded by an equity method investee to its own employees, the Group recognizes its proportionate share of the compensation expense over the vesting period, included in the equity in loss of affiliate in the consolidated statements of comprehensive income (loss). As it relates to the share-based compensation awarded by the Group to the equity method investee employees that are based on the Group&#x2019;s stock, when the other investors do not provide proportionate value to the investee or the Group does not receive any consideration, the Group expenses the entire cost associated with the award in the same period the costs are recognized by the investee, to the extent that the Group&#x2019;s claim on the investee&#x2019;s book value has not been increased. The expenses recognized by the Group is included in the equity in loss of affiliate in the consolidated statements of comprehensive income (loss). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group evaluates the equity method investment for impairment under ASC 323. An impairment loss on the equity method investments is recognized in losses when the decline in value is determined to be other-than-temporary. No impairment charge was recognized for the year ended December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.15 Deferred subsidy income&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred subsidy income consists of deferred income from government grants. Government grants mainly consist of cash subsidies received by the Group&#x2019;s subsidiaries in the PRC from local governments as support on expenses relating to certain projects. Grants received with government specified performance obligations are recognized as other income when all the obligations have been satisfied. If such obligations are not satisfied, the Group may be required to refund the subsidy. The Group recorded cash grants&lt;/div&gt; of RMB7,509 and RMB3,920 and in deferred subsidy income as of December&#160;31, 2020 and 2019 respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.16 Revenue recognition&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Group adopted Accounting Standard Codification (&#x201c;ASC&#x201d;) 606, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers&lt;/div&gt;&lt;/div&gt; (Topic 606) (&#x201c;ASC 606&#x201d;) for all periods presented. Consistent with the criteria of Topic 606, the Group recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. An the entity performs the following five steps to account for the arrangements that an entity determines are within the scope of ASC 606: (i) identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Once a contract is determined to be within the scope of ASC 606 at contract inception, the Group audits the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Collaboration revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;At contract inception, we analyze its collaboration arrangements to assess whether they are within the scope of ASC 808,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Collaborative Arrangements&lt;/div&gt;&lt;/div&gt;&#160;(&#x201c;ASC 808&#x201d;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, we first determine if the collaboration is deemed to be within the scope of ASC 808. For any units of account that are reflective of a vendor-customer relationship those units of account are accounted for within the scope of ASC 606. For any units of account that are not accounted for under ASC 606 and therefore accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group&#x2019;s collaborative arrangements may contain more than one unit of account, or performance obligation, such as grant of licenses of intellectual property rights, promises to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. When multiple units of account or performance obligations are identified within the arrangements, the Group must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&#160;In developing the stand-alone selling price for a performance obligation, the Group considers competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;   &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licenses of Intellectual Property:&lt;/div&gt;&lt;/div&gt; Upfront &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; payments for licensing the Group&#x2019;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For the license that is determined to be distinct, the Group recognizes revenues in the amount of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; fees allocated to the license at a point in time, upon which the license is transferred to the licensee and the licensee is able to use and benefit from the license. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Services: &lt;/div&gt;&lt;/div&gt;The portion of the transaction price allocated to research and development services performance obligations is deferred and recognized as revenue over time as delivery or performance of such services provided to the Group&#x2019;s customers occurs. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Milestone Payments&lt;/div&gt;&lt;/div&gt;: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any resulting adjustment is recorded on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis, which would affect the Group&#x2019;s reported revenues and earnings in the period of the adjustment. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Royalties&lt;/div&gt;&lt;/div&gt;: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the sales-based royalties or milestone payments relate, the Group recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/div&gt;  &lt;div style="text-align:left;"&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contract assets and liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets primarily represent revenue earnings over time that are not yet billable based on the terms of the contracts. The Group does not have impairment losses associated with contracts with customers for the years ended December 31, 2019 and 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract liabilities consist of fees invoiced or paid by the Group&#x2019;s customers for which the associated performance obligations have not been satisfied and revenue has not been recognized based on the Group&#x2019;s revenue recognition criteria described above. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets and contract liabilities are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current in the consolidated balance sheet when the Group expects to complete the related performance obligations and invoice the customers within one year of the balance sheet date, and as long-term when the Group expects to complete the related performance obligations and invoice the customers more than one year out from the balance sheet date. Contract liabilities are classified as current in the consolidated balance sheet when the revenue recognition associated with the related customer payments and invoicing is expected to occur within one year of the balance sheet date and as long-term when the revenue recognition associated with the related customer payments and invoicing is expected to occur in more than one year from the balance sheet date. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.17 Value-added-tax (&#x201c;VAT&#x201d;) recoverable and surcharges&#160;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Value added tax recoverable represent amounts paid by the Group for purchases. The surcharges (i.e., Urban construction and maintenance tax, educational surtax, local educational surtax), vary from 6% to 12% of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&#160;value-added-tax&#160;depending&lt;/div&gt; on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&#160;tax-payer&#x2019;s&#160;location.&lt;/div&gt; The deductible input VAT balance is included in the prepayments and other receivables in the consolidated balance sheets, and VAT payable balance is recorded in the accruals and other payables in the consolidated balance sheets. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; 2.18 Research and development expensesElements of research and development expenses primarily include (1)&#160;payroll and other related expenses of personnel engaged in research and development activities, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2)&#160;in-licensed&lt;/div&gt; patent rights fee of exclusive development rights of drugs granted to the Group, (3)&#160;expenses related to preclinical testing of the Group&#x2019;s technologies under development and clinical trials such as payments to contract research organizations (&#x201c;CRO&#x201d;), investigators and clinical trial sites that conduct the clinical studies, (4)&#160;expenses to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, and (5)&#160;other research and development expenses. Research and development expenses are charged to expenses as incurred when these expenditures are used for the Group&#x2019;s research and development activities and have no alternative future uses.The Group has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-commercial&lt;/div&gt; milestone payments, are immediately expensed as acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development in the period in which they are incurred, provided that the new drug compound does not also include processes or activities that would constitute a &#x201c;business&#x201d; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. All development expenditures are recognized in profit or loss when incurred, as long as the conditions enabling capitalization of development expenses as an asset have not yet been met. &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.19 Leases&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In accordance with ASC 842 adopted on January&#160;1, 2019, the Group determines if an arrangement is a lease at inception. Operating leases are included in operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets, operating lease liability, and operating lease liability, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; in the Group&#x2019;s consolidated balance sheets. The Group does not have any finance leases since the adoption date. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ROU assets represent the Group&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Group&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. When determining the lease term, the Group includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Group&#x2019;s leases do not provide an implicit rate, the Group uses its incremental borrowing rate, which it calculates based on the credit quality of the Group and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Group has elected to adopt the following lease policies in conjunction with the adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02:&lt;/div&gt; (i) elect for each lease not to separate &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components from lease components and instead to account for each separate lease component and the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components associated with that lease component as a single lease component; (ii)&#160;for leases that have lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Group elected not to apply ASC 842 recognition requirements; and (iii)&#160;the Group elected to apply the package of practical expedients for existing arrangements entered into prior to January&#160;1, 2019 to not reassess (a)&#160;whether an arrangement is or contains a lease, (b)&#160;the lease classification applied to existing leases, and (c)&#160;initial direct costs. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In connection with the adoption of ASC 842, on January&#160;1, 2019, the Group recorded an impact of RMB13,100 on its assets and RMB11,333 on its liabilities for the recognition of operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use-assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; and operating lease liabilities, respectively, which are primarily related to the lease of the Group&#x2019;s offices and warehouses. The adoption of ASC 842 did not have a material impact on the Group&#x2019;s results of operations or cash flows. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.20 Comprehensive income (loss)&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Comprehensive income (loss) is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220,&#160;Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as components of comprehensive income (loss) be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Group&#x2019;s comprehensive income (loss) includes net income (loss) and foreign currency translation adjustments, which are presented in the consolidated statements of comprehensive income (loss). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.21 Share-based compensation&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group grants restricted shares and stock options to eligible employees and accounts for share-based compensation in accordance with ASC 718, Compensation&#x2014;Stock Compensation.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employees&#x2019; share-based compensation awards, if equity-classified, are measured at the grant date fair value of the awards and are recognized as expenses over the requisite period of the award, which is generally the vesting term of share-based payment awards.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation in relation to the restricted shares is measured based on the fair market value of the Group&#x2019;s ordinary shares at the grant date of the award. Prior to the listing, estimation of the fair value of the Group&#x2019;s ordinary shares involves significant assumptions that might not be observable in the market, and a number of complex and subjective variables, including discount rate, and subjective judgments regarding the Group&#x2019;s projected financial and operating results, its unique business risks, the liquidity of its ordinary shares and its operating history and prospects at the time the grants are made. Share-based compensation in relation to the share options is estimated using the Binominal Option Pricing Model. The determination of the fair value of share options is affected by the share price of the Group&#x2019;s ordinary shares as well as the assumptions regarding a number of complex and subjective variables, including the expected share price volatility, risk-free interest rate, exercise multiple and expected dividend yield. In addition, the forfeiture rate is estimated based on an analysis of the Group&#x2019;s actual forfeitures and the appropriateness of the forfeiture rate will continue to be evaluated based on the actual forfeiture experience, analysis of employee turnover and other factors. The fair value of these awards was determined with the assistance from an independent third-party valuation firm. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.22 Income taxes&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group accounts for income taxes under the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates that expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded if it is more likely than not that some portion or all of the deferred income tax assets will not be utilized in the foreseeable future.&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Group evaluates its uncertain tax positions using the provisions of ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;740-10,&#160;Income&lt;/div&gt; Taxes, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Group recognizes in the financial statements the benefit of a tax position which is &#x2018;&#x2018;more likely than not&#x2019;&#x2019; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Group&#x2019;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.23 Borrowings&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost. Any difference between the proceeds (net&#160;of transaction costs) and the redemption value is recognized as interest expense in the consolidated statements of comprehensive income (loss) over the period of the borrowings, using the effective interest method. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.24 Business combination&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group accounts for its business combinations using the acquisition method of accounting in accordance with ASC topic 805,&#160;Business Combinations&#160;(&#x201c;ASC 805&#x201d;). The acquisition method of accounting requires all of the following steps: (i)&#160;identifying the acquirer, (ii)&#160;determining the acquisition date, (iii)&#160;recognizing and measuring the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree, and (iv)&#160;recognizing and measuring goodwill or a gain from a bargain purchase. The consideration transferred in a business combination is measured as the aggregate of the fair values at the date of exchange of the assets given, liabilities incurred, and equity instruments issued as well as the contingent considerations and all contractual contingencies as of the acquisition date. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed and intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets may include, but are not limited to, future expected cash flows from acquired assets, timing and probability of success of clinical events and regulatory approvals, and assumptions on useful lives of the patents and discount rates. Management&#x2019;s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Additional information, such as that related to income tax and other contingencies, existing as of the acquisition date but unknown to us may become known during the remainder of the measurement period, not to exceed one year from the acquisition date, which may result in changes to the amounts and allocations recorded. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisitions that do not meet the accounting definition of a business combination are accounted for as asset acquisitions. For transactions determined to be asset acquisitions, the Group allocates the total cost of the acquisition, including transaction costs, to the net assets acquired based on their relative fair values. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.25 Segment information&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance with ASC 280,&#160;Segment Reporting, the Group&#x2019;s chief operating decision maker, the Chief Executive Officer, reviews the consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for the purpose of internal reporting. As the Group&#x2019;s long-lived assets are substantially located in and derived from the PRC, no geographical segments are presented. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.26 Income (loss) per share&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic income (loss) per share is computed by dividing net income (loss) attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period using the two-class method. Under the two-class method, the net income (loss) is allocated between ordinary shares and other participating securities based on their participating rights. Net income (loss) is not allocated to other participating securities if based on their contractual terms they are not obligated to share in the income (loss). Diluted income (loss) per share is calculated by dividing net income (loss) attributable to ordinary shareholders by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of shares issuable upon the conversion of the preferred shares using the if-converted method, shares issuable upon the issuance of ordinary shares to be issued to Everest using the if-converted method, shares issuable upon the conversion of the convertible promissory notes using the if-converted method, shares issuable upon the exercise of share options using the treasury stock method, shares issuable upon the issuance of ordinary shares for restricted shares units using the treasury stock method, and shares issuable upon the exercise of warrants using the treasury stock method. Ordinary equivalent shares are not included in the denominator of the diluted income (loss) per share calculation when inclusion of such shares would be anti-dilutive.&lt;/div&gt; &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.27 Adopted accounting pronouncements&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13,&lt;/div&gt; Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&#x201d;).&lt;/div&gt; This guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability. In November 2018, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-19,&lt;/div&gt; Codification Improvements to Topic 326, Financial Instruments-Credit Losses (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-19&#x201d;),&lt;/div&gt; which clarifies certain topics included within ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13.&lt;/div&gt; ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; and ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-19&lt;/div&gt; are effective for the annual reporting period beginning after December&#160;15, 2019, including interim periods within that reporting period. The impact of this ASU to the consolidated financial statements is immaterial. The Group elected to adopt this ASU and applied this guidance retrospectively to all periods presented. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In January 2017, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017-04,&lt;/div&gt; Intangibles&#x2014;Goodwill and Other (Topic 350), which simplifies the subsequent measurement of goodwill by removing the second step of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-step&lt;/div&gt; impairment test. The amendment requires an entity to perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. A goodwill impairment will be the amount by which a reporting unit&#x2019;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The Group adopted this ASU on January&#160;1, 2020 and the adoption of this ASU does not have a material impact to its consolidated financial statements. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In August 2018 the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2018-13,&lt;/div&gt; Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January&#160;1, 2020. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.27 Adopted accounting pronouncements (continued)&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;In November 2018 the FASB issued &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASU&#160;No.&#160;2018-18,&#160;Collaborative&lt;/div&gt; Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This standard makes targeted improvements for collaborative arrangements as follows: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, Revenue from Contracts with Customers, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adds&#160;unit-of-account&#160;guidance&lt;/div&gt;&lt;/div&gt; to ASC 808, Collaborative Arrangements, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;This standard became effective for the Group on January&#160;1, 2020. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings. Since the Group&#x2019;s all relevant units of accounts were accounted for under ASC 606, the adoption of this ASU does not have a material impact to the Group&#x2019;s consolidated financial statements, with no adjustment to its opening retained earnings. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.28 &#160; &#160; Recent accounting pronouncements&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2019, the FASB issued ASU 2019-12-Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for the Company beginning on January 1, 2022. Early adoption of the amendments is permitted. The Company is currently evaluating the impact of ASU 2019-12 on its consolidated financial statements.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In January 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-01,&lt;/div&gt; Investments &#x2013; Equity Securities (Topic 321), Investments &#x2013; Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying Interactions between Topic 321, Topic 323, and Topic 815. ASU 2020-01addresses accounting for the transition into and out of the equity method and provides guidance on whether equity method accounting would be applied to certain purchased options and forward contracts upon settlement. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-01&lt;/div&gt; is effective for the Group&#x2019;s annual periods beginning after December&#160;15, 2021. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-01&lt;/div&gt; will be applied prospectively. Early adoption is permitted. The Group is currently evaluating the effect the adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-01&lt;/div&gt; will have on its consolidated financial statements. &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.1 Basis of presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant accounting policies followed by the Group in the preparation of the accompanying consolidated financial statements are summarized below. &lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.2 Basis of consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All inter-company balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group consolidates entities in which it has a controlling financial interest based on either the variable interest entity (VIE) or voting interest model. The Group is required to first apply the VIE model to determine whether it holds a variable interest in an entity, and if so, whether the entity is a VIE. If the Group determines it does not hold a variable interest in a VIE, it then applies the voting interest model. Under the voting interest model, the Group consolidates an entity when it holds a majority voting interest in an entity. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for investments in which it has significant influence but not a controlling financial interest using the equity method of accounting (see Note &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;VIE Model &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An entity is considered to be a VIE if any of the following conditions exist: (a)&#160;the total equity investment at risk is not sufficient to permit the entity to finance its activities without additional subordinated financial support, (b)&#160;the holders of the equity investment at risk, as a group, lack either the direct or indirect ability through voting rights or similar rights to make decisions that have a significant effect on the success of the entity or the obligation to absorb the entity&#x2019;s expected losses or right to receive the entity&#x2019;s expected residual returns, or (c)&#160;the voting rights of some equity investors are disproportionate to their obligation to absorb losses of the entity, their rights to receive returns from an entity, or both and substantially all of the entity&#x2019;s activities either involve or are conducted on behalf of an investor with disproportionately few voting rights. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Under the VIE model, limited partnerships are considered VIE unless the limited partners hold substantive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;kick-out&lt;/div&gt; or participating rights over the general partner. The Group consolidates entities that are VIEs when the Group determines it is the primary beneficiary. Generally, the primary beneficiary of a VIE is a reporting entity that has (a)&#160;the power to direct the activities that most significantly affect the VIE&#x2019;s economic performance, and (b)&#160;the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020, the Group determined that the one entity subject to the consolidation guidance is a VIE for which the Group is not the primary beneficiary. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2020To12_31_2020">&lt;div style="text-align: left;"&gt;&lt;div style="margin-block: 0em; line-height: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.3 Use of estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally, estimates are used in determining items such as fair value measurements of wealth management products, warrants and put right liabilities, impairment of accounts receivables, contract assets, other receivables, long-lived assets, intangible assets and goodwill, useful lives of property, equipment and software, recognition of right-of-use assets and lease liabilities, variable consideration in collaboration revenue arrangements, determination of the standalone selling price of each performance obligation in the Company&#x2019;s revenue arrangements, valuation of share-based compensation arrangements and deferred tax assets valuation allowances. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.4 Fair value measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets and liabilities of the Group primarily comprise of cash and cash equivalents, restricted cash, short-term investments, other financial assets, accounts receivable, contract assets, other receivables, short-term borrowings, accruals and other payables, warrant liabilities and put right liabilities. As of December 31, 2019 and 2020, except for short-term investments, other financial assets and put right liabilities, the carrying values of these financial assets and liabilities approximated their fair values because of their generally short maturities. The Group reports short-term investments, other financial assets and put right liabilities at fair value at each balance sheet date and changes in fair value are reflected in the consolidated statements of comprehensive income (loss).&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group measures its financial assets and liabilities using inputs from the following three levels of the fair value hierarchy. The three levels are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1 inputs are unadjusted quoted prices in active markets for identical assets that the management has the ability to access at the measurement date. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2 inputs include quoted prices for similar assets in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3 includes unobservable inputs that reflect the management&#x2019;s assumptions about the assumptions that market participants would use in pricing the asset. The management develops these inputs based on the best information available, including the own data.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Assets and liabilities measured at fair value on a recurring basis &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group measures its short-term investments, other financial assets, warrant liabilities, and put right liabilities at fair value on a recurring basis. As the Group&#x2019;s short-term investments, other financial assets, warrant liabilities and put right liabilities are not traded in an active market with readily observable prices, the Group uses significant unobservable inputs to measure the fair value of short-term investments, other financial assets, warrant liabilities and put right liabilities. These instruments are categorized in the Level 3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Group&#x2019;s financial assets and liabilities measured and recorded at fair value on a recurring basis as of December&#160;31, 2019 and 2020: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Active&#160;market&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Observable&#160;input&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;observable&#160;input&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level 2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term investments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 56%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Active&#160;market&lt;br/&gt; (Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Observable&#160;input&lt;br/&gt; (Level 2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;observable&#160;input&lt;br/&gt; (Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term investments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;31,530&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;31,530&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 56%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Put right liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;116,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;116,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 56%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The roll forward of major Level&#160;3 financial assets &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;a&lt;/div&gt;nd financial liabilities are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Short-term&lt;br/&gt; investments&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Other&#160;financial&lt;br/&gt; assets&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Warrant&lt;br/&gt; liabilities&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Put right&lt;br/&gt; liabilities&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair&#160;value&#160;of&#160;Level&#160;3&#160;financial&#160;asset&#160;and&#160;liabilities&#160;as&#160;of&#160;December&#160;31,&#160;2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;255,958&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(5,618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Purchase of short-term investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;134,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposal of short-term investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(102,703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposal of other financial assets due to Termination Agreement&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(256,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value changes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;42&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,644&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency translation differences&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair&#160;value&#160;of&#160;Level&#160;3&#160;financial&#160;assets&#160;and&#160;liabilities&#160;as&#160;of&#160;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;32,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Purchase of short-term investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,491,991&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposal of short-term investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,503,749&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant of put right liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;124,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value changes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,288&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(3,024&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency translation differences&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(5,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of Level&#160;3 financial assets and liabilities as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31,530&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;116,006&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;See Note &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&#160;for additional information about Level&#160;3 put right liabilities measured at fair value on a recurring basis for the year ended December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Group&#x2019;s financial assets and liabilities measured and recorded at fair value on a recurring basis as of December&#160;31, 2019 and 2020: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Active&#160;market&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Observable&#160;input&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;observable&#160;input&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level 2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term investments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 56%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Active&#160;market&lt;br/&gt; (Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Observable&#160;input&lt;br/&gt; (Level 2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;observable&#160;input&lt;br/&gt; (Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term investments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;31,530&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;31,530&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 56%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Put right liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;116,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;116,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 56%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:ShortTermInvestments
      contextRef="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_CNY">32000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="PAsOn12_31_2019_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_CNY">32000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_CNY">31530000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_CNY">31530000</us-gaap:ShortTermInvestments>
    <imab:PutRightLiabilities
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_CNY">116006000</imab:PutRightLiabilities>
    <imab:PutRightLiabilities
      contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_CNY">116006000</imab:PutRightLiabilities>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The roll forward of major Level&#160;3 financial assets &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;a&lt;/div&gt;nd financial liabilities are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Short-term&lt;br/&gt; investments&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Other&#160;financial&lt;br/&gt; assets&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Warrant&lt;br/&gt; liabilities&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Put right&lt;br/&gt; liabilities&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair&#160;value&#160;of&#160;Level&#160;3&#160;financial&#160;asset&#160;and&#160;liabilities&#160;as&#160;of&#160;December&#160;31,&#160;2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;255,958&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(5,618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Purchase of short-term investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;134,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposal of short-term investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(102,703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposal of other financial assets due to Termination Agreement&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(256,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value changes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;42&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,644&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency translation differences&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair&#160;value&#160;of&#160;Level&#160;3&#160;financial&#160;assets&#160;and&#160;liabilities&#160;as&#160;of&#160;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;32,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Purchase of short-term investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,491,991&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposal of short-term investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,503,749&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant of put right liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;124,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value changes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,288&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(3,024&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency translation differences&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(5,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of Level&#160;3 financial assets and liabilities as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31,530&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;116,006&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2018_OtherFinancialAssetsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_CNY">255958000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2018_WarrantLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_CNY">-5618000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements
      contextRef="P01_01_2019To12_31_2019_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_CNY">134000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements>
    <imab:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-102703000</imab:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="P01_01_2019To12_31_2019_OtherFinancialAssetsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_CNY">256000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">703000</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="P01_01_2019To12_31_2019_OtherFinancialAssetsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_CNY">42000</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="P01_01_2019To12_31_2019_WarrantLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_CNY">5644000</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <imab:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences
      contextRef="P01_01_2019To12_31_2019_WarrantLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_CNY">-26000</imab:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2019_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_CNY">32000000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2019_OtherFinancialAssetsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_CNY">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2019_WarrantLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_CNY">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements
      contextRef="P01_01_2020To12_31_2020_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_CNY">2491991000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements>
    <imab:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments
      contextRef="P01_01_2020To12_31_2020_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_CNY">-2503749000</imab:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
      contextRef="P01_01_2020To12_31_2020_PutRightLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_CNY">124321000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="P01_01_2020To12_31_2020_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_CNY">11288000</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="P01_01_2020To12_31_2020_PutRightLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_CNY">-3024000</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <imab:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences
      contextRef="P01_01_2020To12_31_2020_PutRightLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_CNY">-5291000</imab:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2020_ShortTermInvestmentsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_CNY">31530000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2020_PutRightLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_CNY">116006000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.5 Foreign currency translation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group uses Chinese Renminbi (&#x201c;RMB&#x201d;) as its reporting currency. The United States Dollar (&#x201c;US$&#x201d;) is the functional currency of the Group&#x2019;s entities incorporated in the Cayman Islands, the United States of America (&#x201c;U.S.&#x201d;) and Hong Kong, the Australia Dollar (&#x201c;AUD&#x201d;) is the functional currency of the Group&#x2019;s entity incorporated in Australia and the RMB is the functional currency of the Company&#x2019;s PRC subsidiaries. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transactions denominated in other than the functional currencies are translated into the functional currency of the entity at the exchange rates prevailing on the transaction dates. Assets and liabilities denominated in other than the functional currencies are translated at the balance sheet date exchange rate. The resulting exchange differences are recorded in the consolidated statements of comprehensive income (loss). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements of the Group are translated from the functional currency to the reporting currency, RMB. Assets and liabilities of the subsidiaries are translated into RMB using the exchange rate in effect at each balance sheet date. Income and expenses are translated at the average exchange rates prevailing for the year. Foreign currency translation adjustments arising from these are reflected in the accumulated other comprehensive &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;income (loss). The exchange rates&#160;&lt;/div&gt;used for translation on December&#160;31, 2019 and 2020 were US$1.00 = RMB6.9762 and RMB6.5249 respectively, representing the index rates stipulated by the People&#x2019;s Bank of China. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Translations of balances in the consolidated balance sheets, consolidated statements of comprehensive income (loss), consolidated statements of changes in shareholders&#x2019; equity (deficit) and consolidated statements of cash flows from RMB into US$ as of and for the year ended December&#160;31, 2020 are solely for the convenience of the readers and were calculated at the rate of US$1.00=RMB6.5250, representing the noon buying rate in The City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New York on December&#160;31, 2020. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on December&#160;31, 2020, or at any other rate. The US$ convenience translation is not required under U.S. GAAP and all US$ convenience translation amounts in the accompanying consolidated financial statements are unaudited. &lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="PAsOn12_31_2019_PeoplesBankOfChinaMemberIMABBankBranchAxis"
      decimals="4"
      unitRef="Unit_pure">6.9762</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="PAsOn12_31_2020_PeoplesBankOfChinaMemberIMABBankBranchAxis"
      decimals="4"
      unitRef="Unit_pure">6.5249</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="PAsOn12_31_2020_FederalReserveBankOfNewYorkMemberIMABBankBranchAxis"
      decimals="4"
      unitRef="Unit_pure">6.5250</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.6 Cash and cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Group considers all highly liquid investments with an original maturity date of three months or less at the date of purchase to be cash equivalents. &lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.7 Restricted cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash consists of the guarantee deposits held in a designated bank account as security deposits under bank borrowing agreements. Such restricted cash will be released when the Group repays the related bank borrowings. The Group has presented restricted cash separately from cash and cash equivalents in the consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and restricted cash as reporte&lt;div style="display:inline;"&gt;d&lt;/div&gt;&#160;in the consolidated statement of cash flows are presented separately on the consolidated balance sheet as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,137,473&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,758,778&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;55,810&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,193,283&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,758,778&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and restricted cash as reporte&lt;div style="display:inline;"&gt;d&lt;/div&gt;&#160;in the consolidated statement of cash flows are presented separately on the consolidated balance sheet as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,137,473&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,758,778&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;55,810&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,193,283&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,758,778&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">1137473000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">4758778000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">55810000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">1193283000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">4758778000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.8 Accounts receivable &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable are stated at amortized cost less allowance for credit losses. The allowance for credit losses reflects the best estimate of future losses over the contractual life of outstanding accounts receivable and is determined on the basis of historical experience, specific allowances for known troubled accounts, other currently available information including customer financial condition, and both current and forecasted economic conditions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <imab:ShortTermInvestmentsPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.9 Short-term investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term investments represent the investments issued by commercial banks or other financial institutions with a variable interest rate indexed to the performance of underlying assets within one year. These investments are stated at fair value. Changes in the fair value are reflected in the consolidated statements of comprehensive income (loss). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</imab:ShortTermInvestmentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.10 Property, equipment and software&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the following estimated useful lives, taking into account of any estimated residual value: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 51%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 46%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;3 to 10 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;1 to 5 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Office furniture and equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;5 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;Lesser of useful life or lease term&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group recognizes the gain or loss on the disposal of property, equipment and software in the consolidated statements of comprehensive income (loss). &lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <imab:ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the following estimated useful lives, taking into account of any estimated residual value: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 51%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 46%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;3 to 10 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;1 to 5 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Office furniture and equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;5 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;Lesser of useful life or lease term&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </imab:ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2020To12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2020To12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_SoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_SoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2020To12_31_2020_OfficeFurnitureAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2020To12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Lesser of useful life or lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="P01_01_2020To12_31_2020">&lt;div style="text-align: left;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.11 Intangible assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets acquired in a business combination that are used in research and development activities, or in-process research and development (IPR&amp;amp;D) intangible assets, are considered indefinite lived until the completion or abandonment of the associated research and development efforts. During the period that those assets are considered indefinite lived, they are not amortized but are tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. If after assessing the totality of events and circumstances and their potential effect on significant inputs to the fair value determination the Group determines that it is not more likely than not that the indefinite-lived intangible is impaired, then the entity shall calculate the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value of the asset with its carrying amount. If the carrying amount exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. For IPR&amp;amp;D assets, the impairment loss is recognized in research and development expenses in the consolidated statements of comprehensive income (loss).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets with finite useful lives are amortized over their useful lives. The useful life of an intangible asset is the period over which the asset is expected to contribute directly or indirectly to the future cash flows of the Group. The Group uses the straight-line amortization method when the economic benefits of the intangible assets are consumed or otherwise used up cannot be reliably determined. In particular, the Group amortizes the IPR&amp;amp;D intangible assets with finite useful lives over 10 to 20 years on a straight-line basis. Intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. If circumstances require an intangible asset be tested for possible impairment, the Group first compares undiscounted cash flows expected to be generated by that asset to its carrying amount. If the carrying amount is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. For IPR&amp;amp;D assets, the impairment loss is recognized in research and development expenses in the consolidated statements of comprehensive income (loss).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-align: left;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.12 Impairment of long-lived assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-lived assets, such as property, plant, and software, and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. For the years ended December&#160;31, 2019 and 2020, there was no impairment of the value of the Group&#x2019;s long-lived assets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="P01_01_2020To12_31_2020">&lt;div style="text-align: left;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.13 Goodwill &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The Group allocates the cost of an acquired entity to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price for acquisitions over the fair value of the net assets acquired, including other intangible assets, is recorded as goodwill. Goodwill is not amortized, but impairment of goodwill is tested on at least an annual basis or whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Group&#x2019;s reporting unit is less than its carrying amount, including goodwill. The qualitative assessment includes the Group&#x2019;s evaluation of relevant events and circumstances affecting the Group&#x2019;s single reporting unit, including macroeconomic, industry, market conditions and the Group&#x2019;s overall financial performance. If qualitative factors indicate that it is more likely than not that the Group&#x2019;s reporting unit&#x2019;s fair value is less than its carrying amount, then the Group will perform the quantitative impairment test by comparing the reporting unit&#x2019;s carrying amount, including goodwill, to its fair value. If the carrying amount of the reporting unit exceeds its fair value, an impairment loss will be recognized in an amount equal to that excess. For the years ended December&#160;31, 2019 and 2020, the Group determined that there were no indicators of impairment of the goodwill. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <imab:LongTermInvestmentsPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-align: left;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.14 Long-term investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group&#x2019;s long-term investments include equity investments in an affiliate in which it does not have a controlling financial interest, but has the ability to exercise significant influence over the operating and financial policies of the investee. The investment is accounted for using the equity method of accounting in accordance with ASC topic 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Under the equity method, the Group initially records its investments at fair value. The Group subsequently adjusts the carrying amount of the investment to recognize the Group&#x2019;s proportionate share of the equity investee&#x2019;s net income or loss after the date of investment. When the liquidation rights and priorities as defined by an equity investment agreement diff&lt;div style="display:inline;"&gt;e&lt;/div&gt;r from what is reflected by the underlying percentage ownership interests, applying the percentage ownership interest to U.S. GAAP net income in order to determine earnings or losses does not accurately represent the income allocation and cash flow distributions that will ultimately be received by the investors. As such, for this type of investments, the Group uses the Hypothetical Liquidation at Book Value (&#x201c;HLBV&#x201d;) method for allocating earnings or losses of the equity method investee. The HLBV method is considered as a balance sheet approach. Specifically, a calculation is prepared at each balance sheet date to determine the amount that the Group would receive if an equity investment entity were to liquidate all of its assets (as valued in accordance with U.S. GAAP) and distribute that cash to the investors based on the contractually defined liquidation priorities. The difference between the calculated liquidation distribution amounts at the beginning and the end of the reporting period, after adjusting for capital contributions and distributions, is the Group&#x2019;s share of the earnings or losses from the equity investment for the period. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As it relates to the share-based compensation awarded by an equity method investee to its own employees, the Group recognizes its proportionate share of the compensation expense over the vesting period, included in the equity in loss of affiliate in the consolidated statements of comprehensive income (loss). As it relates to the share-based compensation awarded by the Group to the equity method investee employees that are based on the Group&#x2019;s stock, when the other investors do not provide proportionate value to the investee or the Group does not receive any consideration, the Group expenses the entire cost associated with the award in the same period the costs are recognized by the investee, to the extent that the Group&#x2019;s claim on the investee&#x2019;s book value has not been increased. The expenses recognized by the Group is included in the equity in loss of affiliate in the consolidated statements of comprehensive income (loss). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group evaluates the equity method investment for impairment under ASC 323. An impairment loss on the equity method investments is recognized in losses when the decline in value is determined to be other-than-temporary. No impairment charge was recognized for the year ended December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</imab:LongTermInvestmentsPolicyTextBlock>
    <imab:DeferredSubsidyIncomePolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.15 Deferred subsidy income&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred subsidy income consists of deferred income from government grants. Government grants mainly consist of cash subsidies received by the Group&#x2019;s subsidiaries in the PRC from local governments as support on expenses relating to certain projects. Grants received with government specified performance obligations are recognized as other income when all the obligations have been satisfied. If such obligations are not satisfied, the Group may be required to refund the subsidy. The Group recorded cash grants&lt;/div&gt; of RMB7,509 and RMB3,920 and in deferred subsidy income as of December&#160;31, 2020 and 2019 respectively. &lt;/div&gt;&lt;/div&gt;</imab:DeferredSubsidyIncomePolicyTextBlock>
    <us-gaap:GrantsReceivable
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">7509000</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">3920000</us-gaap:GrantsReceivable>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.16 Revenue recognition&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Group adopted Accounting Standard Codification (&#x201c;ASC&#x201d;) 606, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers&lt;/div&gt;&lt;/div&gt; (Topic 606) (&#x201c;ASC 606&#x201d;) for all periods presented. Consistent with the criteria of Topic 606, the Group recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. An the entity performs the following five steps to account for the arrangements that an entity determines are within the scope of ASC 606: (i) identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Once a contract is determined to be within the scope of ASC 606 at contract inception, the Group audits the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Collaboration revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;At contract inception, we analyze its collaboration arrangements to assess whether they are within the scope of ASC 808,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Collaborative Arrangements&lt;/div&gt;&lt;/div&gt;&#160;(&#x201c;ASC 808&#x201d;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, we first determine if the collaboration is deemed to be within the scope of ASC 808. For any units of account that are reflective of a vendor-customer relationship those units of account are accounted for within the scope of ASC 606. For any units of account that are not accounted for under ASC 606 and therefore accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group&#x2019;s collaborative arrangements may contain more than one unit of account, or performance obligation, such as grant of licenses of intellectual property rights, promises to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. When multiple units of account or performance obligations are identified within the arrangements, the Group must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&#160;In developing the stand-alone selling price for a performance obligation, the Group considers competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licenses of Intellectual Property:&lt;/div&gt;&lt;/div&gt; Upfront &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; payments for licensing the Group&#x2019;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For the license that is determined to be distinct, the Group recognizes revenues in the amount of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; fees allocated to the license at a point in time, upon which the license is transferred to the licensee and the licensee is able to use and benefit from the license. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Services: &lt;/div&gt;&lt;/div&gt;The portion of the transaction price allocated to research and development services performance obligations is deferred and recognized as revenue over time as delivery or performance of such services provided to the Group&#x2019;s customers occurs. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Milestone Payments&lt;/div&gt;&lt;/div&gt;: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any resulting adjustment is recorded on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis, which would affect the Group&#x2019;s reported revenues and earnings in the period of the adjustment. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Royalties&lt;/div&gt;&lt;/div&gt;: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the sales-based royalties or milestone payments relate, the Group recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contract assets and liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets primarily represent revenue earnings over time that are not yet billable based on the terms of the contracts. The Group does not have impairment losses associated with contracts with customers for the years ended December 31, 2019 and 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract liabilities consist of fees invoiced or paid by the Group&#x2019;s customers for which the associated performance obligations have not been satisfied and revenue has not been recognized based on the Group&#x2019;s revenue recognition criteria described above. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets and contract liabilities are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current in the consolidated balance sheet when the Group expects to complete the related performance obligations and invoice the customers within one year of the balance sheet date, and as long-term when the Group expects to complete the related performance obligations and invoice the customers more than one year out from the balance sheet date. Contract liabilities are classified as current in the consolidated balance sheet when the revenue recognition associated with the related customer payments and invoicing is expected to occur within one year of the balance sheet date and as long-term when the revenue recognition associated with the related customer payments and invoicing is expected to occur in more than one year from the balance sheet date. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CapitalizedContractCostImpairmentLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">0</us-gaap:CapitalizedContractCostImpairmentLoss>
    <us-gaap:CapitalizedContractCostImpairmentLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">0</us-gaap:CapitalizedContractCostImpairmentLoss>
    <imab:ValueAddedTaxesPolicyPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.17 Value-added-tax (&#x201c;VAT&#x201d;) recoverable and surcharges&#160;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Value added tax recoverable represent amounts paid by the Group for purchases. The surcharges (i.e., Urban construction and maintenance tax, educational surtax, local educational surtax), vary from 6% to 12% of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&#160;value-added-tax&#160;depending&lt;/div&gt; on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&#160;tax-payer&#x2019;s&#160;location.&lt;/div&gt; The deductible input VAT balance is included in the prepayments and other receivables in the consolidated balance sheets, and VAT payable balance is recorded in the accruals and other payables in the consolidated balance sheets. &lt;/div&gt;</imab:ValueAddedTaxesPolicyPolicyTextBlock>
    <imab:VATSurchargesPercent
      contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.06</imab:VATSurchargesPercent>
    <imab:VATSurchargesPercent
      contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.12</imab:VATSurchargesPercent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2.18 Research and development expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Elements of research and development expenses primarily include (1)&#160;payroll and other related expenses of personnel engaged in research and development activities, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2)&#160;in-licensed&lt;/div&gt; patent rights fee of exclusive development rights of drugs granted to the Group, (3)&#160;expenses related to preclinical testing of the Group&#x2019;s technologies under development and clinical trials such as payments to contract research organizations (&#x201c;CRO&#x201d;), investigators and clinical trial sites that conduct the clinical studies, (4)&#160;expenses to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, and (5)&#160;other research and development expenses. Research and development expenses are charged to expenses as incurred when these expenditures are used for the Group&#x2019;s research and development activities and have no alternative future uses. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Group has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-commercial&lt;/div&gt; milestone payments, are immediately expensed as acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development in the period in which they are incurred, provided that the new drug compound does not also include processes or activities that would constitute a &#x201c;business&#x201d; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. All development expenditures are recognized in profit or loss when incurred, as long as the conditions enabling capitalization of development expenses as an asset have not yet been met. &lt;/div&gt; </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2020To12_31_2020"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.19 Leases&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In accordance with ASC 842 adopted on January&#160;1, 2019, the Group determines if an arrangement is a lease at inception. Operating leases are included in operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets, operating lease liability, and operating lease liability, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; in the Group&#x2019;s consolidated balance sheets. The Group does not have any finance leases since the adoption date. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ROU assets represent the Group&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Group&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. When determining the lease term, the Group includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Group&#x2019;s leases do not provide an implicit rate, the Group uses its incremental borrowing rate, which it calculates based on the credit quality of the Group and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Group has elected to adopt the following lease policies in conjunction with the adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02:&lt;/div&gt; (i) elect for each lease not to separate &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components from lease components and instead to account for each separate lease component and the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components associated with that lease component as a single lease component; (ii)&#160;for leases that have lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Group elected not to apply ASC 842 recognition requirements; and (iii)&#160;the Group elected to apply the package of practical expedients for existing arrangements entered into prior to January&#160;1, 2019 to not reassess (a)&#160;whether an arrangement is or contains a lease, (b)&#160;the lease classification applied to existing leases, and (c)&#160;initial direct costs. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In connection with the adoption of ASC 842, on January&#160;1, 2019, the Group recorded an impact of RMB13,100 on its assets and RMB11,333 on its liabilities for the recognition of operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use-assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; and operating lease liabilities, respectively, which are primarily related to the lease of the Group&#x2019;s offices and warehouses. The adoption of ASC 842 did not have a material impact on the Group&#x2019;s results of operations or cash flows. &lt;/div&gt; </us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn01_01_2019"
      decimals="-3"
      unitRef="Unit_CNY">13100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn01_01_2019"
      decimals="-3"
      unitRef="Unit_CNY">11333000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.20 Comprehensive income (loss)&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Comprehensive income (loss) is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220,&#160;Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as components of comprehensive income (loss) be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Group&#x2019;s comprehensive income (loss) includes net income (loss) and foreign currency translation adjustments, which are presented in the consolidated statements of comprehensive income (loss). &lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.21 Share-based compensation&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group grants restricted shares and stock options to eligible employees and accounts for share-based compensation in accordance with ASC 718, Compensation&#x2014;Stock Compensation.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employees&#x2019; share-based compensation awards, if equity-classified, are measured at the grant date fair value of the awards and are recognized as expenses over the requisite period of the award, which is generally the vesting term of share-based payment awards.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation in relation to the restricted shares is measured based on the fair market value of the Group&#x2019;s ordinary shares at the grant date of the award. Prior to the listing, estimation of the fair value of the Group&#x2019;s ordinary shares involves significant assumptions that might not be observable in the market, and a number of complex and subjective variables, including discount rate, and subjective judgments regarding the Group&#x2019;s projected financial and operating results, its unique business risks, the liquidity of its ordinary shares and its operating history and prospects at the time the grants are made. Share-based compensation in relation to the share options is estimated using the Binominal Option Pricing Model. The determination of the fair value of share options is affected by the share price of the Group&#x2019;s ordinary shares as well as the assumptions regarding a number of complex and subjective variables, including the expected share price volatility, risk-free interest rate, exercise multiple and expected dividend yield. In addition, the forfeiture rate is estimated based on an analysis of the Group&#x2019;s actual forfeitures and the appropriateness of the forfeiture rate will continue to be evaluated based on the actual forfeiture experience, analysis of employee turnover and other factors. The fair value of these awards was determined with the assistance from an independent third-party valuation firm. &lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.22 Income taxes&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group accounts for income taxes under the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates that expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded if it is more likely than not that some portion or all of the deferred income tax assets will not be utilized in the foreseeable future.&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Group evaluates its uncertain tax positions using the provisions of ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;740-10,&#160;Income&lt;/div&gt; Taxes, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Group recognizes in the financial statements the benefit of a tax position which is &#x2018;&#x2018;more likely than not&#x2019;&#x2019; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Group&#x2019;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense. &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.23 Borrowings&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost. Any difference between the proceeds (net&#160;of transaction costs) and the redemption value is recognized as interest expense in the consolidated statements of comprehensive income (loss) over the period of the borrowings, using the effective interest method. &lt;/div&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.24 Business combination&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group accounts for its business combinations using the acquisition method of accounting in accordance with ASC topic 805,&#160;Business Combinations&#160;(&#x201c;ASC 805&#x201d;). The acquisition method of accounting requires all of the following steps: (i)&#160;identifying the acquirer, (ii)&#160;determining the acquisition date, (iii)&#160;recognizing and measuring the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree, and (iv)&#160;recognizing and measuring goodwill or a gain from a bargain purchase. The consideration transferred in a business combination is measured as the aggregate of the fair values at the date of exchange of the assets given, liabilities incurred, and equity instruments issued as well as the contingent considerations and all contractual contingencies as of the acquisition date. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed and intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets may include, but are not limited to, future expected cash flows from acquired assets, timing and probability of success of clinical events and regulatory approvals, and assumptions on useful lives of the patents and discount rates. Management&#x2019;s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Additional information, such as that related to income tax and other contingencies, existing as of the acquisition date but unknown to us may become known during the remainder of the measurement period, not to exceed one year from the acquisition date, which may result in changes to the amounts and allocations recorded. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisitions that do not meet the accounting definition of a business combination are accounted for as asset acquisitions. For transactions determined to be asset acquisitions, the Group allocates the total cost of the acquisition, including transaction costs, to the net assets acquired based on their relative fair values. &lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.25 Segment information&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance with ASC 280,&#160;Segment Reporting, the Group&#x2019;s chief operating decision maker, the Chief Executive Officer, reviews the consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for the purpose of internal reporting. As the Group&#x2019;s long-lived assets are substantially located in and derived from the PRC, no geographical segments are presented. &lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.26 Income (loss) per share&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic income (loss) per share is computed by dividing net income (loss) attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period using the two-class method. Under the two-class method, the net income (loss) is allocated between ordinary shares and other participating securities based on their participating rights. Net income (loss) is not allocated to other participating securities if based on their contractual terms they are not obligated to share in the income (loss). Diluted income (loss) per share is calculated by dividing net income (loss) attributable to ordinary shareholders by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of shares issuable upon the conversion of the preferred shares using the if-converted method, shares issuable upon the issuance of ordinary shares to be issued to Everest using the if-converted method, shares issuable upon the conversion of the convertible promissory notes using the if-converted method, shares issuable upon the exercise of share options using the treasury stock method, shares issuable upon the issuance of ordinary shares for restricted shares units using the treasury stock method, and shares issuable upon the exercise of warrants using the treasury stock method. Ordinary equivalent shares are not included in the denominator of the diluted income (loss) per share calculation when inclusion of such shares would be anti-dilutive.&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.27 Adopted accounting pronouncements&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13,&lt;/div&gt; Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&#x201d;).&lt;/div&gt; This guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability. In November 2018, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-19,&lt;/div&gt; Codification Improvements to Topic 326, Financial Instruments-Credit Losses (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-19&#x201d;),&lt;/div&gt; which clarifies certain topics included within ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13.&lt;/div&gt; ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; and ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-19&lt;/div&gt; are effective for the annual reporting period beginning after December&#160;15, 2019, including interim periods within that reporting period. The impact of this ASU to the consolidated financial statements is immaterial. The Group elected to adopt this ASU and applied this guidance retrospectively to all periods presented. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In January 2017, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017-04,&lt;/div&gt; Intangibles&#x2014;Goodwill and Other (Topic 350), which simplifies the subsequent measurement of goodwill by removing the second step of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-step&lt;/div&gt; impairment test. The amendment requires an entity to perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. A goodwill impairment will be the amount by which a reporting unit&#x2019;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The Group adopted this ASU on January&#160;1, 2020 and the adoption of this ASU does not have a material impact to its consolidated financial statements. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In August 2018 the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2018-13,&lt;/div&gt; Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January&#160;1, 2020. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;In November 2018 the FASB issued &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASU&#160;No.&#160;2018-18,&#160;Collaborative&lt;/div&gt; Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This standard makes targeted improvements for collaborative arrangements as follows: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, Revenue from Contracts with Customers, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adds&#160;unit-of-account&#160;guidance&lt;/div&gt;&lt;/div&gt; to ASC 808, Collaborative Arrangements, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;This standard became effective for the Group on January&#160;1, 2020. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings. Since the Group&#x2019;s all relevant units of accounts were accounted for under ASC 606, the adoption of this ASU does not have a material impact to the Group&#x2019;s consolidated financial statements, with no adjustment to its opening retained earnings. &lt;/div&gt;&lt;/div&gt; </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <imab:NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.28 &#160; &#160; Recent accounting pronouncements&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2019, the FASB issued ASU 2019-12-Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for the Company beginning on January 1, 2022. Early adoption of the amendments is permitted. The Company is currently evaluating the impact of ASU 2019-12 on its consolidated financial statements.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In January 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-01,&lt;/div&gt; Investments &#x2013; Equity Securities (Topic 321), Investments &#x2013; Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying Interactions between Topic 321, Topic 323, and Topic 815. ASU 2020-01addresses accounting for the transition into and out of the equity method and provides guidance on whether equity method accounting would be applied to certain purchased options and forward contracts upon settlement. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-01&lt;/div&gt; is effective for the Group&#x2019;s annual periods beginning after December&#160;15, 2021. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-01&lt;/div&gt; will be applied prospectively. Early adoption is permitted. The Group is currently evaluating the effect the adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-01&lt;/div&gt; will have on its consolidated financial statements. &lt;/div&gt;</imab:NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <imab:AccountsReceivableAndContractAssetsTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3. ACCOUNTS RECEIVABLE AND CONTRACT ASSETS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable and contract assets, net of allowance for credit losses, consisted of the following: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, gross&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;130,498&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allowance for credit losses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 72%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;130,498&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 72%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets, gross&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;227,391&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;34,849&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allowance for credit losses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 72%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets, net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;227,391&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;34,849&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 72%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No allowance for credit losses was recorded as of December&#160;31, 2019 and 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</imab:AccountsReceivableAndContractAssetsTextBlock>
    <imab:ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable and contract assets, net of allowance for credit losses, consisted of the following: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, gross&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;130,498&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allowance for credit losses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 72%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;130,498&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 72%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets, gross&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;227,391&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;34,849&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allowance for credit losses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 72%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets, net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;227,391&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;34,849&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 72%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </imab:ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">130498000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">20000000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2019"
      unitRef="Unit_CNY"
      xsi:nil="true"/>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">130498000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">20000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerAssetGrossCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">227391000</us-gaap:ContractWithCustomerAssetGrossCurrent>
    <us-gaap:ContractWithCustomerAssetGrossCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">34849000</us-gaap:ContractWithCustomerAssetGrossCurrent>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLossCurrent
      contextRef="PAsOn12_31_2019"
      unitRef="Unit_CNY"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">227391000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">34849000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <imab:PrepaidexpensesandotherreceivablestextblockTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4. PREPAYMENTS AND OTHER RECEIVABLES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;RMB&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepayments:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Prepayments to CRO vendors&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;78,740&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,140&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,742&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Prepayments for other services&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;880&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,550&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;391&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Receivables due from employees &lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,201&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Receivables due from an affiliate (Note 2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&#x2014;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;21,212&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;3,251&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Value-added tax recoverable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;12,517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;63,664&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;9,757 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rental deposits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;546&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,766&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;271 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest receivables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;764&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;236&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;26,388&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;22,899&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3,509&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); width: 68%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); width: 68%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;136,036&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;195,467 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;29,957&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); width: 68%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The balance mainly represents the receivables due from &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;certain&#160;&lt;/div&gt;employees, arose from the Group&#x2019;s obligation to pay the withholding individual income tax (&#x201c;IIT&#x201d;) for those employees&#x2019; stock option activities. The balance was collected by the Group in January 2020. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </imab:PrepaidexpensesandotherreceivablestextblockTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;RMB&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepayments:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Prepayments to CRO vendors&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;78,740&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,140&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,742&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Prepayments for other services&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;880&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,550&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;391&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Receivables due from employees &lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,201&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Receivables due from an affiliate (Note 2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&#x2014;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;21,212&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;3,251&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Value-added tax recoverable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;12,517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;63,664&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;9,757 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rental deposits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;546&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,766&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;271 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest receivables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;764&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;236&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;26,388&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;22,899&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3,509&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); width: 68%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); width: 68%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;136,036&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;195,467 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;29,957&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); width: 68%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The balance mainly represents the receivables due from &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;certain&#160;&lt;/div&gt;employees, arose from the Group&#x2019;s obligation to pay the withholding individual income tax (&#x201c;IIT&#x201d;) for those employees&#x2019; stock option activities. The balance was collected by the Group in January 2020. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:Supplies
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">78740000</us-gaap:Supplies>
    <us-gaap:Supplies
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">83140000</us-gaap:Supplies>
    <us-gaap:Supplies
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">12742000</us-gaap:Supplies>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">880000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">2550000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">391000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:DueFromEmployeesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">16201000</us-gaap:DueFromEmployeesCurrent>
    <us-gaap:DueFromAffiliateCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">21212000</us-gaap:DueFromAffiliateCurrent>
    <us-gaap:DueFromAffiliateCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3251000</us-gaap:DueFromAffiliateCurrent>
    <imab:ValueaddedTaxRecoverable
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">12517000</imab:ValueaddedTaxRecoverable>
    <imab:ValueaddedTaxRecoverable
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">63664000</imab:ValueaddedTaxRecoverable>
    <imab:ValueaddedTaxRecoverable
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">9757000</imab:ValueaddedTaxRecoverable>
    <us-gaap:SecurityDeposit
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">546000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">1766000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">271000</us-gaap:SecurityDeposit>
    <us-gaap:InterestReceivable
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">764000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">236000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">36000</us-gaap:InterestReceivable>
    <us-gaap:OtherAssets
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">26388000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">22899000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3509000</us-gaap:OtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">136036000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">195467000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">29957000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5. PROPERTY, EQUIPMENT AND SOFTWARE &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, equipment and software consist of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory equipmen&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;t&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;24,265&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;30,808&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,722&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvement&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,856&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,842&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,121&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,531 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Office furniture and equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,526&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,531&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total property, equipment and software&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;47,867&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;56,171 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,608 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: accumulated depreciation and amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(18,221&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,899&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(4,735&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net book value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;29,646&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;25,272 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,873&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Construction in &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;progress&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;423&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total net book value of property, equipment and software&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;30,069&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;25,272 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,873&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total amounts charged to the consolidated statements of comprehensive income/(loss) for depreciation and amortization expenses amounted to approximately RMB6.7&#160;million, RMB9.8&#160;million and RMB12.7&#160;million, for the years ended December&#160;31, 2018, 2019 and 2020, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, equipment and software consist of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory equipmen&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;t&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;24,265&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;30,808&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,722&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvement&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,856&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,842&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,121&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,531 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Office furniture and equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,526&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,531&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total property, equipment and software&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;47,867&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;56,171 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,608 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: accumulated depreciation and amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(18,221&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,899&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(4,735&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net book value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;29,646&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;25,272 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,873&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Construction in &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;progress&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;423&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total net book value of property, equipment and software&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;30,069&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;25,272 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,873&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2019_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">24265000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">30808000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">4722000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2019_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">11856000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">13842000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2121000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2019_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">10220000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">9990000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1531000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2019_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">1526000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">1531000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">234000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">47867000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">56171000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8608000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">18221000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">30899000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4735000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <imab:PropertyPlantAndequipmentnetExcludingConstructionInProcess
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">29646000</imab:PropertyPlantAndequipmentnetExcludingConstructionInProcess>
    <imab:PropertyPlantAndequipmentnetExcludingConstructionInProcess
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">25272000</imab:PropertyPlantAndequipmentnetExcludingConstructionInProcess>
    <imab:PropertyPlantAndequipmentnetExcludingConstructionInProcess
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3873000</imab:PropertyPlantAndequipmentnetExcludingConstructionInProcess>
    <us-gaap:ConstructionInProgressGross
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">423000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">0</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">30069000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">25272000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3873000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2018To12_31_2018"
      decimals="-5"
      unitRef="Unit_CNY">6700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_CNY">9800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_CNY">12700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;. LEASES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020, the Company has operating leases recorded on its balance sheet for certain office spaces and facilities that expire on various dates through 2023. The Group does not plan to cancel the existing lease agreements for its existing facilities prior to their respective expiration dates. When determining the lease term, the Group includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. All of the Group&#x2019;s leases qualify as operating leases. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Information related to operating leases as of December&#160;31, 2019 and 2020 is as follows (in thousands, except for percentages and years). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,435&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,997&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities, current&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,807&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,058&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,235&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Operating lease liabilities, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,492&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,542&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;849&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining lease term (years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Information related to operating lease activity during the years ended December&#160;31, 2019 and 2020 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease rental expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Amortization of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,158&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expense for short-term leases within 12 months&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest of lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;543&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;679&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;104&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,395&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,837&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,354&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; Maturities of lease liabilities were as follows:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,901&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;837&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;536&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;82&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total undiscounted lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,901&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,301&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,600&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,084&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <imab:OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Information related to operating leases as of December&#160;31, 2019 and 2020 is as follows (in thousands, except for percentages and years). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,435&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,997&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities, current&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,807&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,058&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,235&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Operating lease liabilities, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,492&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,542&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;849&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining lease term (years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </imab:OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">16435000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">14997000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2298000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">6807000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">8058000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1235000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">7492000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">5542000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">849000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2019">P2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2020">P1Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2020">P1Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2019"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <imab:ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease rental expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Amortization of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,158&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expense for short-term leases within 12 months&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest of lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;543&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;679&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;104&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,395&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,837&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,354&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </imab:ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock>
    <imab:OperatingLeaseRightOfUseAssetAmortization
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">5260000</imab:OperatingLeaseRightOfUseAssetAmortization>
    <imab:OperatingLeaseRightOfUseAssetAmortization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">8158000</imab:OperatingLeaseRightOfUseAssetAmortization>
    <imab:OperatingLeaseRightOfUseAssetAmortization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1250000</imab:OperatingLeaseRightOfUseAssetAmortization>
    <us-gaap:ShortTermLeaseCost
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">592000</us-gaap:ShortTermLeaseCost>
    <imab:OperatingLeaseInterestExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">543000</imab:OperatingLeaseInterestExpense>
    <imab:OperatingLeaseInterestExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">679000</imab:OperatingLeaseInterestExpense>
    <imab:OperatingLeaseInterestExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">104000</imab:OperatingLeaseInterestExpense>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">6395000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">8837000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1354000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2020To12_31_2020">Maturities of lease liabilities were as follows:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,901&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;837&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;536&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;82&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total undiscounted lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,901&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,301&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,600&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,084&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">8901000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1364000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">5464000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">837000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">536000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">82000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">14901000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2283000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">1301000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">199000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">13600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2084000</us-gaap:OperatingLeaseLiability>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;7&lt;/div&gt;. INTANGIBLE ASSETS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets as of December&#160;31, 2019 and 2020 are summarized as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 51%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;carrying&#160;amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;br/&gt; amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D TJ103&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,556&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,550&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D TJ101&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;110,330&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;110,330&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,909&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;122,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,556&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;120,444&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;18,459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 51%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;br/&gt; amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&#160;carrying&#160;amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D TJ103&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,788&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;IPR&amp;amp;D TJ102&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D TJ101&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;110,330&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;110,330&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,909&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 51%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;148,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;148,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;22,811&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 51%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The three IPR&amp;amp;D assets (TJ103, TJ101, and TJ102) were acquired from the business combination of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Tianjin and its subsidiaries including Chengdu Tasgen &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bio-Tech&lt;/div&gt; Co., Ltd. and Shanghai Tianyunjian &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bio-Tech&lt;/div&gt; Co., Ltd. (together the &#x201c;Tasgen Group&#x201d;) in 2017. The licensor of these IPR&amp;amp;D assets was Genexine, Inc. The gross carrying amounts represent the fair value assigned to the respective research and development assets. At the date of acquisition, all three assets had not reached technological feasibility. They were considered indefinite lived. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;IPR&amp;amp;D related to TJ103 was subsequently determined to have a finite useful life as a result of an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-licensing&lt;/div&gt; arrangement. Consequently, the Group uses the straight-line method to amortize the asset. The amortization for the years ended December&#160;31, 2018, 2019 and 2020 was nil, nil, and RMB1,556 respectively, recognized as research and development expenses in the consolidated statements of comprehensive income (loss). The estimated amortization expense for each of the five succeeding fiscal years is RMB778. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September 15, 2020, I-Mab Hong Kong and Genexine, Inc. entered into amendments to Intellectual Property License Agreement with I-Mab Hangzhou to assign and transfer all the rights and obligations related to TJ102 to I-Mab Biopharma (Hangzhou) Limited (&#x201c;I-Mab Hangzhou&#x201d;), pursuant to an equity transfer and investment agreement entered into between I-Mab Hong Kong and various parties (see Note &lt;div style="display:inline;"&gt;9&lt;/div&gt;).&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2019 and 2020, there was no impairment of the value of the Group&#x2019;s intangible assets. &lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets as of December&#160;31, 2019 and 2020 are summarized as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 51%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;carrying&#160;amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;br/&gt; amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D TJ103&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,556&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,550&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D TJ101&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;110,330&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;110,330&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,909&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;122,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,556&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;120,444&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;18,459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 51%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;br/&gt; amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&#160;carrying&#160;amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D TJ103&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,788&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;IPR&amp;amp;D TJ102&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D TJ101&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;110,330&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;110,330&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,909&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 51%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;148,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;148,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;22,811&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 51%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_CNY">11670000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_CNY">-1556000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_CNY">10114000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1550000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_IprAndDTj101MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_CNY">110330000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020_IprAndDTj101MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_CNY">110330000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020_IprAndDTj101MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">16909000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">122000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-1556000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">120444000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">18459000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2019_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_CNY">11670000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_CNY">11670000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1788000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2019_IprAndDTj102MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_CNY">26844000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019_IprAndDTj102MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_CNY">26844000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019_IprAndDTj102MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">4114000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2019_IprAndDTj101MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_CNY">110330000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019_IprAndDTj101MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_CNY">110330000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019_IprAndDTj101MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">16909000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">148844000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">148844000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">22811000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2018To12_31_2018_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2019To12_31_2019_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2020To12_31_2020_IprAndDTj103MemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1556000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">778000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:GoodwillDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;. GOODWILL &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On July&#160;15, 2017, the Group acquired 66.67% of the equity interests in the Tasgen Group by issuing convertible preferred shares, and controlled the board of directors and business of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Tianjin since then. Tasgen Group is principally engaged in the research and development of innovative medicines and the Group acquired Tasgen Group for its research team, technical experience, and IPR&amp;amp;D pipeline assets (see Note &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;). As of December&#160;31, 2019 and 2020, the goodwill of RMB162,574 (US$24,916) represented the goodwill generated from the aforementioned acquisition of Tasgen Group and the business of Tasgen Group was fully integrated into the Company after the acquisition. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2019 and 2020, the Group performed a qualitative assessment by evaluating relevant events and circumstances that would affect the Group&#x2019;s single reporting unit and did not note any indicator that it is more likely than not that the fair value of the Group&#x2019;s reporting unit is less than its carrying amount and therefore the Group&#x2019;s goodwill was not impaired. &lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="PAsOn07_15_2017_TasgenGroupMemberusgaapBusinessAcquisitionAxis"
      decimals="4"
      unitRef="Unit_pure">0.6667</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">162574000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">162574000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">24916000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="PAsOn12_31_2019"
      decimals="0"
      unitRef="Unit_CNY">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_CNY">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <imab:InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;. INVESTMENT ACCOUNTED FOR USING THE EQUITY METHOD AND PUT RIGHT LIABILITIES&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(a) Investment accounted for using the equity method &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou, incorporated on June&#160;16, 2019, was a wholly owned subsidiary of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hong Kong with registered capital of US$30&#160;million, which was paid up by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hong Kong on September&#160;14, 2020. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On September&#160;15, 2020 (the &#x201c;Closing Date&#x201d;), &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hong Kong entered into an equity transfer and investment agreement (the &#x201c;SPA&#x201d;) with (i)&#160;a limited partnership jointly established by the management of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou to hold restricted equity of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou issued to the management (&#x201c;Management Holdco&#x201d;), (ii) a limited partnership established to hold the shares of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou for future equity incentive plan (&#x201c;ESOP Holdco&#x201d;) and (iii)&#160;a group of domestic investors in China (&#x201c;Domestic Investors&#x201d;). &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance with the terms of the SPA, &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(i)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hong Kong agreed to assign all rights and obligations/ownership of certain drug candidates in different stages of development (&#x201c;Target Pipelines&#x201d;) to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou as of the Closing Date as well as to transfer employment of a team of designated management/workforce to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou. The Target Pipelines were evaluated by an independent valuer, with a total value of US$105&#160;million as of the Closing Date; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(ii)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Management Holdco would acquire 10% of the equity of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hong Kong with no consideration. The &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;% equity is represented by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou&#x2019;s registered capital of US$3&#160;million, and that after acquiring such equity, Management Holdco is committed to pay US$3&#160;million in cash to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou to fulfil its capital contribution obligations in a period of four years starting from the Closing Date; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(iii)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;ESOP Holdco would acquire 5% of the equity of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hong Kong with no consideration. The &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;% equity is represented by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou&#x2019;s registered capital of US$1.5&#160;million. All of such equity would be used for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou&#x2019;s future equity incentive plan. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(iv)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Domestic Investors would acquire a total of 40% of the equity of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hong Kong with no consideration. The &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;40&lt;/div&gt;% equity is represented by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou&#x2019;s registered capital of US$12&#160;million, and after acquiring such equity of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou, Domestic Investors would pay US$120&#160;million collectively in cash to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou to fulfil its capital contribution obligations. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(a) Investment accounted for using the equity method (continued) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon closing of the SPA, the registered capital of I-Mab Hangzhou remained to be&lt;/div&gt;&#160;US$30&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million. As of December 31, 2020, among the total&#160;&lt;/div&gt; 25,500,000 outstanding shares of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou, 13,500,000 shares were held by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; H&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ong Kong&lt;/div&gt;&#160;while the remaining 12,000,000 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;shares was held by Domestic Investors. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shares subscribed by Management Holdco and ESOP Holdco, in the total number of 4,500,000, have not yet been purchased by or issued to Management Holdco and ESOP Holdco as of December, 31, 2020. &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Once all the&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;se 4,500,000&lt;/div&gt;&#160;subscribed shares of I-Mab Hangzhou are purchased&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;by&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;or issued to Management Holdco and ESOP Holdco, the equity interest in I-Mab Hangzhou held by I-Mab Hong Kong, Domestic Investors, Management Holdco and ESOP Holdco would be&lt;/div&gt;&#160;45%, 40%, 10% and 5% respectively&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On the same day, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hong Kong also entered into a shareholders agreement with the aforementioned investors (the &#x201c;SHA&#x201d;). According to the SHA and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou&#x2019;s articles of association, the board of directors of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou shall be composed of seven directors. The directors shall be elected in the following ways: &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hong Kong is entitled to appoint three directors, including the chairman of the board of directors, as well as nominate one independent director; the Management Holdco is entitled to appoint one director; two &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-related&lt;/div&gt; entities of the Domestic Investors are entitled to appoint one director respectively (&#x201c;Investors Directors&#x201d;). Each director of the board of directors shall have one vote. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hong Kong, Management Holdco and ESOP Holdco agree to act in concert, as long as each of Management Holdco and ESOP Holdco respectively holds equity in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou, when exercising the rights as a shareholder. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;As a result of the above transactions, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou became an affiliate of the Group on the Closing Date in accordance with ASC 810 since &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou meets the definition of a business under ASC 805. In accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;810-10,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou is a variable interest entity, and no shareholder shall consolidate &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou under VIE model as neither party have the power to direct all the activities that most significantly impact the economic performance of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou. Therefore, the Group deconsolidated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou and retained significant influence in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou. The investment was accounted for using the equity method. The retained investment in the common stock of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou was initially measured at fair value in accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;810-10-40.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group determined the fair value of its retained equity interest with the assistance of an independent third-party valuation firm. The Group used equity allocation model to estimate the fair value of the investment. The fair value as of the Closing Date was US$112,039 (equivalent to approximately RMB764,352), which reflected the fact that the shares subscribed by Management Holdco and ESOP Holdco were not issued and outstanding as of the Closing Date. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A gain of RMB407,598&#160;million was recognized as a result of the deconsolidation. The gain represented the difference between: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;i)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;The fair value of the retained noncontrolling investment in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou at the Closing Date; and &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;ii)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate of all of the following: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;a)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the carrying amount of transferred intellectual property related to TJ102 at the Closing Date (see Note &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;); &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;b)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;the fair value of the put right liabilities written by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hong Kong to Domestic Investors; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;c)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;the carrying amount of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou&#x2019;s net assets at the Closing Date&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(a) Investment accounted for using the equity method (continued) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequently, pursuant to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou&#x2019;s articles of association, the Group applies the HLBV method to allocate earnings or losses of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou because the liquidation rights and priorities sufficiently differ from what is reflected by the underlying percentage ownership interests. For the period from September&#160;15, 2020 to December&#160;31, 2020, the Group recognized RMB67,425 in equity in loss of an affiliate in the consolidated statements of comprehensive income. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The purchase price of US$3 million committed by Management Holdco under SPA, representing 10% of the equity of I-Mab Hangzhou, is significantly lower than the fair value of the corresponding subscribed shares as of the Closing Date. The excess is considered as share-based compensation to the I-Mab Hangzhou&#x2019;s management for the services to be used or consumed in the I-Mab Hangzhou&#x2019;s own operations. The share-based compensation is considered granted upon the Closing Date and cliff vests after five years of service since the Closing Date. Consequently, the Group recognizes its proportionate share of the compensation expense recorded by I-Mab Hangzhou. For the period from September 15, 2020 to December 31, 2020, the amount included in the equity in loss of an affiliate in the Group&#x2019;s consolidated statements of comprehensive income is RMB8,456.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Along with the equity transfer transaction, the team of designated management/workforce transferred from the Group to I-Mab Hangzhou consists of several grantees under the Group&#x2019;s 2020 Share Incentive Plan (&#x201c;2020 Plan&#x201d;, see Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;(f)). These individuals continued to qualify the definition of the eligible participants under the 2020 Plan after the Closing Date. Meanwhile, there has been no change to any of the award terms. The equity transfer transaction did not trigger the modification accounting to the share-based compensation. Additionally, given that I-Mab Hangzhou became an affiliate to the Group upon deconsolidation, and that the other shareholders of I-Mab Hangzhou are not providing proportionate value to sponsor the 2020 Plan nor is the Group receiving any consideration for the awards granted to employees of I-Mab Hangzhou, the Group is required, under Topic 323, to expense the full costs of share-based compensation as incurred at the same period as the costs are recognized by I-Mab Hangzhou. For the year ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;December 31, 2020, such expenses of&#160;&lt;/div&gt;RMB32,707 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;and was recorded in the equity in loss of an affiliate in the consolidated statements of comprehensive income.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December 31, 2020, the carrying value of the Group&#x2019;s long-term investment measured under equity method was&#160;&lt;/div&gt; RMB664,832. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group presented the summarized financial information of the Group&#x2019;s long-term investment measured under equity method below in accordance with Rule 4-08 of Regulation S-X (RMB in thousands).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;period&#160;from&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;,&#160;2020&#160;to&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating data:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;271&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;271&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from operations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(85,945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net Loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(85,945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 80%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance sheet data:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 80%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;923,010&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 80%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;810,623&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 80%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;31,519&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 80%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,933&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 80%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling&lt;/div&gt; interests&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(b) Put right liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the SHA, if &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou fails to close a public offering of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou&#x2019;s shares on the China Stock Exchange&#x2019;s Science and Technology Innovation Board, Main Board, Small and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Medium-Sized&lt;/div&gt; Enterprise Board, Growth Enterprise Board, or Hong Kong Stock Exchange, U.S. Stock Exchange, or other stock exchanges approved by the shareholders of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou in accordance with provisions of the SHA within 4 years after September&#160;15, 2020, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hong Kong is obligated to repurchase the equity held by Domestic Investors in cash or in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&#x2019;s&lt;/div&gt; stock (subject to the approval procedures of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab)&lt;/div&gt; within 3 years from the expiration of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4-year&lt;/div&gt; period after the Closing Date of September&#160;15, 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The put right written by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hong Kong to Domestic Investors is a freestanding equity-linked instrument, which is classified as a put right liability and is initially measured at fair value. Subsequent changes in fair value are recorded in other income (loss) in the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;consolidated statements of comprehensive income (loss).&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group determined the fair value of the put right with the assistance of an independent third-party valuation firm. The Group used the option pricing model (finnerty model) to estimate the fair value of the put right using the following assumptions: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;September&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15,&#160;and&#160;September&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected terms (Year)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;55.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;55.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Spot price&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;US$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;143,401&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;US$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;143,804&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Probability of triggering event for redemption option&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The model requires the input of highly subjective assumptions including the expected terms, estimated volatility, spot price and probability of triggering event for redemption option. Expected terms is estimated based on the timing of a hypothetical redemption event which is assumed to be the earlier of expected redemption date or expected public offering date. Expected volatility is estimated based on daily stock prices of the comparable company for a period with length commensurate to the expected terms of redemption event. The spot price was determined with assistance from an independent third-party valuation firm. The Group&#x2019;s management is ultimately responsible for the determination of the spot price and probability of triggering event for redemption option. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant decreases in interval between valuation date and maturity date, estimated volatility, spot price and probability of triggering event for redemption option would result in a significantly lower fair value measurement. &lt;/div&gt;&lt;/div&gt; </imab:InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock>
    <imab:RegisteredCapitalOfSubsidiary
      contextRef="PAsOn06_16_2019_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-6"
      unitRef="Unit_USD">30000000</imab:RegisteredCapitalOfSubsidiary>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized
      contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-6"
      unitRef="Unit_USD">105000000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis_ManagementHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <imab:RegisteredCapitalOfSubsidiary
      contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis_ManagementHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000</imab:RegisteredCapitalOfSubsidiary>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="P01_01_2020To12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis_ManagementHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2020_EsopHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="P01_01_2020To12_31_2020_EsopHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-5"
      unitRef="Unit_USD">1500000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2020_DomesticInvestorsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="2"
      unitRef="Unit_pure">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <imab:RegisteredCapitalOfSubsidiary
      contextRef="PAsOn12_31_2020_DomesticInvestorsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-6"
      unitRef="Unit_USD">12000000</imab:RegisteredCapitalOfSubsidiary>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="P01_01_2020To12_31_2020_DomesticInvestorsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-6"
      unitRef="Unit_USD">120000000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="P01_01_2020To12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-6"
      unitRef="Unit_USD">30000000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020_ManagementHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="INF"
      unitRef="Unit_shares">25500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="INF"
      unitRef="Unit_shares">13500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020_DomesticInvestorsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="INF"
      unitRef="Unit_shares">12000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="INF"
      unitRef="Unit_shares">4500000</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="PAsOn12_31_2020_ManagementHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="INF"
      unitRef="Unit_shares">4500000</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="2"
      unitRef="Unit_pure">0.45</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2020_ImabHongKongMembersrtConsolidatedEntitiesAxis"
      decimals="2"
      unitRef="Unit_pure">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2020_DomesticInvestorsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2020_EsopHoldcoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">112039000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_CNY">764352000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">407598000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:OciEquityMethodInvestmentAfterTax
      contextRef="P09_15_2020To12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_CNY">67425000</us-gaap:OciEquityMethodInvestmentAfterTax>
    <us-gaap:BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments
      contextRef="PAsOn12_31_2020_HoldcoMembersrtOwnershipAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000</us-gaap:BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2020_HoldcoMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P09_15_2020To12_31_2020_HoldcoMembersrtOwnershipAxis"
      decimals="-3"
      unitRef="Unit_CNY">8456000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_CNY">32707000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="P01_01_2020To12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_CNY">664832000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group presented the summarized financial information of the Group&#x2019;s long-term investment measured under equity method below in accordance with Rule 4-08 of Regulation S-X (RMB in thousands).&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;period&#160;from&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;,&#160;2020&#160;to&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating data:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;271&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;271&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from operations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(85,945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net Loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(85,945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 80%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance sheet data:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 80%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;923,010&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 80%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;810,623&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 80%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;31,519&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 80%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,933&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 80%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling&lt;/div&gt; interests&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_RevenueMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_CNY">271000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="PAsOn12_31_2020_GrossProfitMemberusgaapIncomeStatementLocationAxis_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">271000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_LossFromOperationMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_CNY">-85945000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_NetIncomeLossMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_CNY">-85945000</us-gaap:EquityMethodInvestments>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">923010000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">810623000</us-gaap:AssetsNoncurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">31519000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">10933000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group determined the fair value of the put right with the assistance of an independent third-party valuation firm. The Group used the option pricing model (finnerty model) to estimate the fair value of the put right using the following assumptions: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;September&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15,&#160;and&#160;September&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected terms (Year)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;55.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;55.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Spot price&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;US$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;143,401&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;US$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;143,804&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Probability of triggering event for redemption option&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2020To09_30_2020">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2020To12_31_2020">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2020To09_30_2020"
      decimals="3"
      unitRef="Unit_pure">0.552</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">143401000</imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice>
    <imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">143804000</imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice>
    <imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate
      contextRef="P01_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_pure">0.65</imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate>
    <imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_pure">0.65</imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate>
    <us-gaap:ShortTermDebtTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;. SHORT-TERM BORROWINGS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In July 2018, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bio-tech&lt;/div&gt; (Tianjin) Co., Ltd. borrowed a loan of RMB80,000 from China Merchant Bank Co., Ltd. for a term of one year and at the interest rate of 4.20% per annum. To facilitate this borrowing, another subsidiary of the Company in Hong Kong placed cash deposits of US$13,500 (equivalent to approximately RMB92,653) with the bank. The use of such cash deposits and the interest earned thereon are restricted by the bank during the period of the borrowing. The deposits have a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt; term and bear interest at 3.26% per annum. The borrowing was fully repaid during the year ended December&#160;31, 2019. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In June 2019, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bio-tech&lt;/div&gt; (Tianjin) Co., Ltd. borrowed a loan of RMB50,000 from China Merchant Bank Co., Ltd. for a term of one year and at the interest rate of 4.15% per annum. To facilitate this borrowing, another subsidiary of the Company in Hong Kong placed cash deposits of US$8,000 (equivalent to approximately RMB55,810) with the bank. The use of such cash deposits and the interest earned thereon are restricted by the bank during the period of the borrowing. The deposits have a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt; term and bear interest at 2.63% per annum. The borrowing was fully repaid in June 2020. &lt;/div&gt;</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:ShortTermBorrowings
      contextRef="PAsOn07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_CNY">80000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtLender contextRef="P07_31_2018To07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis">China Merchant Bank Co., Ltd</us-gaap:ShortTermDebtLender>
    <us-gaap:DebtInstrumentTerm contextRef="P07_31_2018To07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0420</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCollateralAmount
      contextRef="PAsOn07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">13500000</us-gaap:DebtInstrumentCollateralAmount>
    <us-gaap:DebtInstrumentCollateralAmount
      contextRef="PAsOn07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_CNY">92653000</us-gaap:DebtInstrumentCollateralAmount>
    <us-gaap:PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits
      contextRef="PAsOn07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0326</us-gaap:PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits>
    <us-gaap:ShortTermBorrowings
      contextRef="PAsOn06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_CNY">50000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtLender contextRef="P06_30_2019To06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis">China Merchant Bank Co., Ltd</us-gaap:ShortTermDebtLender>
    <us-gaap:DebtInstrumentTerm contextRef="P06_30_2019To06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0415</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCollateralAmount
      contextRef="PAsOn06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">8000000</us-gaap:DebtInstrumentCollateralAmount>
    <us-gaap:DebtInstrumentCollateralAmount
      contextRef="PAsOn06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_CNY">55810000</us-gaap:DebtInstrumentCollateralAmount>
    <us-gaap:PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits
      contextRef="PAsOn06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0263</us-gaap:PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="P06_30_2019To06_30_2019_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanTwoMemberusgaapDebtInstrumentAxis">The borrowing was fully repaid in June 2020.</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-align: left;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;. ACCRUALS AND OTHER PAYABLES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Staff salaries and welfare payables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;30,166&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;94,133&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,427&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued external research and development activities related expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;144,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;218,583 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;33,499&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued initial public offering costs payable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,504&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued private placement offering costs payable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;128,786 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19,737&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Withholding IIT payable related to stock options&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,201&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-refundable&lt;/div&gt; incentive payment from depositary bank &lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(2)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,424&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;371&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued traveling expenses, office expenses and others&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;65,682&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;116,632&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;273,553&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;560,558 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;85,909&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-refundable&lt;/div&gt; incentive payment from depositary bank &lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(2)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,145&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Advance payment received from an employee for exercise of stock options&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,501 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;230&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"&gt;8,975&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"&gt;1,375 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt; &lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;569,533&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;87,284&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;The Group received a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; incentive payment&#160;of US$1,857&#160;(equivalent to approximately RMB12,982) from depositary bank in April 2020.&#160;The amount was recorded ratably as other gains over a five-year arrangement period. For the year ended December&#160;31, 2020, the Group has recorded RMB2,348 as other income in the consolidated statements of comprehensive income. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Staff salaries and welfare payables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;30,166&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;94,133&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,427&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued external research and development activities related expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;144,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;218,583 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;33,499&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued initial public offering costs payable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,504&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued private placement offering costs payable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;128,786 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19,737&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Withholding IIT payable related to stock options&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,201&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-refundable&lt;/div&gt; incentive payment from depositary bank &lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(2)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,424&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;371&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued traveling expenses, office expenses and others&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;65,682&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;116,632&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;273,553&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;560,558 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;85,909&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-refundable&lt;/div&gt; incentive payment from depositary bank &lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(2)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,145&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Advance payment received from an employee for exercise of stock options&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,501 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;230&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"&gt;8,975&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"&gt;1,375 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt; &lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;569,533&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;87,284&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;The Group received a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; incentive payment&#160;of US$1,857&#160;(equivalent to approximately RMB12,982) from depositary bank in April 2020.&#160;The amount was recorded ratably as other gains over a five-year arrangement period. For the year ended December&#160;31, 2020, the Group has recorded RMB2,348 as other income in the consolidated statements of comprehensive income. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">30166000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">94133000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">14427000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <imab:AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">144000000</imab:AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent>
    <imab:AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">218583000</imab:AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent>
    <imab:AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">33499000</imab:AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent>
    <imab:AccruedInitialPublicOfferingCostsPayable
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">17504000</imab:AccruedInitialPublicOfferingCostsPayable>
    <imab:AccruedInitialPublicOfferingCostsPayable
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">0</imab:AccruedInitialPublicOfferingCostsPayable>
    <imab:AccruedInitialPublicOfferingCostsPayable
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</imab:AccruedInitialPublicOfferingCostsPayable>
    <imab:PrivatePlacementOfferingCostsPayable
      contextRef="PAsOn12_25_2019"
      decimals="-3"
      unitRef="Unit_CNY">0</imab:PrivatePlacementOfferingCostsPayable>
    <imab:PrivatePlacementOfferingCostsPayable
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">128786000</imab:PrivatePlacementOfferingCostsPayable>
    <imab:PrivatePlacementOfferingCostsPayable
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">19737000</imab:PrivatePlacementOfferingCostsPayable>
    <imab:WithholdingIitPayable
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">16201000</imab:WithholdingIitPayable>
    <imab:WithholdingIitPayable
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">0</imab:WithholdingIitPayable>
    <imab:WithholdingIitPayable
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</imab:WithholdingIitPayable>
    <imab:NonRefundableIncentivePaymentFromDepositaryBankCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">0</imab:NonRefundableIncentivePaymentFromDepositaryBankCurrent>
    <imab:NonRefundableIncentivePaymentFromDepositaryBankCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">2424000</imab:NonRefundableIncentivePaymentFromDepositaryBankCurrent>
    <imab:NonRefundableIncentivePaymentFromDepositaryBankCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">371000</imab:NonRefundableIncentivePaymentFromDepositaryBankCurrent>
    <imab:AccruedTravellingExpensesOfficeExpensesAndOthers
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">65682000</imab:AccruedTravellingExpensesOfficeExpensesAndOthers>
    <imab:AccruedTravellingExpensesOfficeExpensesAndOthers
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">116632000</imab:AccruedTravellingExpensesOfficeExpensesAndOthers>
    <imab:AccruedTravellingExpensesOfficeExpensesAndOthers
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">17875000</imab:AccruedTravellingExpensesOfficeExpensesAndOthers>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">273553000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">560558000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">85909000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <imab:NonRefundableIncentivePaymentFromDepositaryBankNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">0</imab:NonRefundableIncentivePaymentFromDepositaryBankNoncurrent>
    <imab:NonRefundableIncentivePaymentFromDepositaryBankNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">7474000</imab:NonRefundableIncentivePaymentFromDepositaryBankNoncurrent>
    <imab:NonRefundableIncentivePaymentFromDepositaryBankNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1145000</imab:NonRefundableIncentivePaymentFromDepositaryBankNoncurrent>
    <imab:AdvanceReceivedFromEmployeeForExerciseOfStockOptions
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">0</imab:AdvanceReceivedFromEmployeeForExerciseOfStockOptions>
    <imab:AdvanceReceivedFromEmployeeForExerciseOfStockOptions
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">1501000</imab:AdvanceReceivedFromEmployeeForExerciseOfStockOptions>
    <imab:AdvanceReceivedFromEmployeeForExerciseOfStockOptions
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">230000</imab:AdvanceReceivedFromEmployeeForExerciseOfStockOptions>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">8975000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1375000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">569533000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">87284000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <imab:ProceedsFromNonRefundableIncentive
      contextRef="P04_01_2020To04_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1857000</imab:ProceedsFromNonRefundableIncentive>
    <imab:ProceedsFromNonRefundableIncentive
      contextRef="P04_01_2020To04_30_2020"
      decimals="-3"
      unitRef="Unit_CNY">12982000</imab:ProceedsFromNonRefundableIncentive>
    <us-gaap:OtherIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">2348000</us-gaap:OtherIncome>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;. INCOME TAXES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cayman Islands &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&#160;is&lt;/div&gt; incorporated in the Cayman Islands. Under the current laws of the Cayman &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Islands,&#160;I-Mab&#160;is&lt;/div&gt; not subject to tax on income or capital gain. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; did business registration in Hong Kong and has a Hong Kong tax file number. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Hong Kong &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&#160;Biopharma&lt;/div&gt; Hong Kong Limited is incorporated in Hong Kong. Companies registered in Hong Kong are subject to Hong Kong profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Hong Kong tax laws. The applicable tax rate in Hong Kong is 16.5%. For the years ended December&#160;31, 2018, 2019 and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020,&#160;I-Mab&#160;Biopharma&lt;/div&gt; Hong Kong Limited did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earnings in Hong Kong for any of the periods presented. Under the Hong Kong tax &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;law,&#160;I-Mab&#160;Biopharma&lt;/div&gt; Hong Kong Limited is exempted from income tax on its foreign-derived income and there are no withholding taxes in Hong Kong on remittance of dividends. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Australia &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;I-Mab&#160;Biopharma Australia Pty Ltd is incorporated in Australia. Companies registered in Australia are subject to Australia profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Australia tax laws. The applicable tax rate in Australia is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30%.&#160;I-Mab&#160;Biopharma&lt;/div&gt; Australia Pty Ltd has no taxable income for all periods presented, therefore, no provision for income taxes is required. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;United States &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&#160;Biopharma&lt;/div&gt; US Ltd. is incorporated in U.S. and is subject to U.S. federal corporate income tax at a rate of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;21%.&#160;I-Mab&#160;Biopharma&lt;/div&gt; US Ltd. is also subject to state income tax in Maryland of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8.25%.&#160;I-Mab&#160;Biopharma&lt;/div&gt; US Ltd. has no taxable income for all periods presented, therefore, no provision for income taxes is required. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;China &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;16, 2007, the National People&#x2019;s Congress of PRC enacted a new Enterprise Income Tax Law (&#x201c;new EIT law&#x201d;), under which Foreign Investment Enterprises (&#x201c;FIEs&#x201d;) and domestic companies would be subject to corporate income tax at a uniform rate of 25%. The new EIT law became effective on January&#160;1, 2008. Under the new EIT law, preferential tax treatments will continue to be granted to entities which conduct businesses in certain encouraged sectors and to entities otherwise classified as &#x201c;High and New Technology Enterprises&#x201d;.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&#160;Shanghai&lt;/div&gt; has been qualified as &#x201c;High and New Technology Enterprise&#x201d; and enjoys a preferential income tax rate of 15% from 2018 to 2020. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s other PRC subsidiaries are subject to the statutory income tax rate of 25%. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No provision for corporate income taxes for corresponding tax residents has been made because the Group are in cumulative loss positions for all the periods presented. During the year ended December 31, 2020, the Group recorded withholding taxes with the amount of RMB12,231 &lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in relation to research and development service and other supporting service charges made by its non-PRC tax resident subsidiaries to its PRC tax resident subsidiaries. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reconciliations of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;t&lt;/div&gt;he differences between &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;t&lt;/div&gt;he PRC statutory income tax rate and the Group&#x2019;s effective income tax rate for the years ended December&#160;31, 2018, 2019 and 2020 are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income (loss) before income ta&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;x&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(401,111&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,451,950&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;483,146&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;74,044&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax computed at respective applicable tax rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(56,093&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(148,871&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;66,044&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,122&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-deductible&lt;/div&gt; expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;87,021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;72,256&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,073&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses plus deduction&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,254&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(60,776&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(9,314&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in valuation allowance&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;62,029&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;71,104&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(65,293&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(10,007&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,722&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,231&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,874&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of tax holidays entitled by the PRC subsidiaries on basic income (loss) per share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.55&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.34&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.05&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The principal components of the deferred tax assets and liabilities are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Net operating loss carryforwar&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;92,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;136,443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;107,344&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;16,451&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciat&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;i&lt;/div&gt;on and amortization of property, equipment, software and intangible asset, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,405&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;30,417&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,662&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrual expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,132&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,867&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,568&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,620&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: valuation allowance&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(94,511&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(165,497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(100,204&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(15,358&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax asset&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37,211&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37,211&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;48,125&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,375&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired intangible assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37,211&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37,211&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;18,067&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,768&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:top;"&gt; &lt;div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;30,058&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;4,607&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;37,211&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;37,211&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;48,125&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,375&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014; &#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014; &#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Movement of the valuation allowance is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of January&#160;1&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(49,541&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(94,511&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(165,497&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(25,364&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Addition&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;(62,029&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;(71,104&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(36,061&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5,527&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Utilization and reversal of valuation allowances&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;89,154&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;13,663&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decrease due to the change of tax rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;17,059&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,200&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,870&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(94,511&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(165,497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(100,204&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(15,358&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020, the Group had a majority of net operating losses of approximately RMB556,649&#160;which arose from the subsidiaries established in the PRC. The tax losses carried forward various in the PRC will expire during the period beginning from 2021 to 2030 based on entity&#x2019;s preferential tax status. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered as more likely than not that some portion or all of the deferred tax assets will not be realized in the foreseeable future.&#160;In making such determination, the Group evaluates a variety of positive and negative factors including the Group&#x2019;s operating history, accumulated deficit, the existence of taxable temporary differences and reversal periods. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group has incurred net accumulated operating losses for income tax purposes since its inception. The Group believes that it is more likely than not that these net accumulated operating losses together with other deferred tax assets will not be utilized in the foreseeable future. Therefore, the Group has provided full valuation allowances for the deferred tax assets as of December&#160;31, 2019 and 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of December&#160;31, 2019 and 2020, the Group did not have any significant unrecognized uncertain tax positions.&lt;/div&gt;&lt;/div&gt; </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2018To12_31_2018_HKsrtStatementGeographicalAxis"
      decimals="INF"
      unitRef="Unit_pure">0.165</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2019To12_31_2019_HKsrtStatementGeographicalAxis"
      decimals="INF"
      unitRef="Unit_pure">0.165</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020_HKsrtStatementGeographicalAxis"
      decimals="INF"
      unitRef="Unit_pure">0.165</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020_AUsrtStatementGeographicalAxis"
      decimals="INF"
      unitRef="Unit_pure">0.30</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_pure">0.0825</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020_CNMemberusgaapIncomeTaxAuthorityAxis"
      decimals="INF"
      unitRef="Unit_pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <imab:EffectivePreferentialIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020_CNMemberusgaapIncomeTaxAuthorityAxis"
      decimals="INF"
      unitRef="Unit_pure">0.15</imab:EffectivePreferentialIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020_IMobOtherSubsidiariesMembersrtConsolidatedEntitiesAxis"
      decimals="INF"
      unitRef="Unit_pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <imab:WithholdingTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">12231000</imab:WithholdingTax>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reconciliations of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;t&lt;/div&gt;he differences between &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;t&lt;/div&gt;he PRC statutory income tax rate and the Group&#x2019;s effective income tax rate for the years ended December&#160;31, 2018, 2019 and 2020 are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income (loss) before income ta&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;x&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(401,111&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,451,950&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;483,146&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;74,044&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax computed at respective applicable tax rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(56,093&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(148,871&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;66,044&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,122&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-deductible&lt;/div&gt; expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;87,021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;72,256&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,073&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses plus deduction&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,254&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(60,776&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(9,314&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in valuation allowance&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;62,029&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;71,104&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(65,293&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(10,007&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,722&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,231&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,874&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of tax holidays entitled by the PRC subsidiaries on basic income (loss) per share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.55&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.34&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.05&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-401111000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-1451950000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">483146000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">74044000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-56093000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-148871000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">66044000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">10122000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">2548000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">87021000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">72256000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">11073000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <imab:EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">6762000</imab:EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount>
    <imab:EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">9254000</imab:EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount>
    <imab:EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">60776000</imab:EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount>
    <imab:EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">9314000</imab:EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">62029000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">71104000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-65293000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-10007000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">1722000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">12231000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1874000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_CNY_per_Share">3.07</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_CNY_per_Share">9.55</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_CNY_per_Share">0.34</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.05</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2020To12_31_2020">The principal components of the deferred tax assets and liabilities are as follows:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Net operating loss carryforwar&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;92,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;136,443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;107,344&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;16,451&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciat&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;i&lt;/div&gt;on and amortization of property, equipment, software and intangible asset, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,405&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;30,417&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,662&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrual expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,132&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,867&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,568&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,620&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: valuation allowance&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(94,511&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(165,497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(100,204&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(15,358&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax asset&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37,211&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37,211&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;48,125&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,375&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired intangible assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37,211&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37,211&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;18,067&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,768&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:top;"&gt; &lt;div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;30,058&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;4,607&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt; &lt;div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;37,211&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;37,211&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;48,125&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,375&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014; &#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014; &#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">92185000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">136443000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">107344000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">16451000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">18405000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">44398000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">30417000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4662000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">21132000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">21867000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">10568000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1620000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">94511000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">165497000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">100204000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">15358000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">37211000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">37211000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">48125000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7375000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">37211000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">37211000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">18067000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2768000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <imab:DeferredTaxAssetsContractAssets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-30058000</imab:DeferredTaxAssetsContractAssets>
    <imab:DeferredTaxAssetsContractAssets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-4607000</imab:DeferredTaxAssetsContractAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">37211000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">37211000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">48125000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7375000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Movement of the valuation allowance is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of January&#160;1&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(49,541&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(94,511&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(165,497&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(25,364&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Addition&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;(62,029&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;(71,104&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(36,061&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5,527&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Utilization and reversal of valuation allowances&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;89,154&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;13,663&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decrease due to the change of tax rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;17,059&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,200&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,870&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(94,511&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(165,497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(100,204&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(15,358&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2017"
      decimals="-3"
      unitRef="Unit_CNY">49541000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">94511000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">165497000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">25364000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <imab:DeferredTaxesAdditionsValuationAllowance
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-62029000</imab:DeferredTaxesAdditionsValuationAllowance>
    <imab:DeferredTaxesAdditionsValuationAllowance
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-71104000</imab:DeferredTaxesAdditionsValuationAllowance>
    <imab:DeferredTaxesAdditionsValuationAllowance
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-36061000</imab:DeferredTaxesAdditionsValuationAllowance>
    <imab:DeferredTaxesAdditionsValuationAllowance
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-5527000</imab:DeferredTaxesAdditionsValuationAllowance>
    <imab:DeferredTaxAssetsValuationAllowanceUtilizationAndReversal
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">89154000</imab:DeferredTaxAssetsValuationAllowanceUtilizationAndReversal>
    <imab:DeferredTaxAssetsValuationAllowanceUtilizationAndReversal
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">13663000</imab:DeferredTaxAssetsValuationAllowanceUtilizationAndReversal>
    <imab:DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">17059000</imab:DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance>
    <imab:DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">118000</imab:DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance>
    <imab:DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">12200000</imab:DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance>
    <imab:DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1870000</imab:DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">94511000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">165497000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">100204000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">15358000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2020_PRCMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      unitRef="Unit_CNY">556649000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;. ORDINARY SHARES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2018 and 2019, 500,000,000 ordinary shares had been authorized by the Company. Each ordinary share is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors of the Company. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;29, 2019, the Company&#x2019;s shareholders and board of directors approved that immediately prior to the completion of initial public offering, the&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company&#x2019;s authorized share capital will be changed into US$&lt;/div&gt;80,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; divided into &lt;/div&gt;800,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; ordinary shares of a par value of US$&lt;/div&gt;0.0001&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; each.&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;17, 2020, the Company completed its IPO and became listed on the Nasdaq Global Market by issuing 7,407,400 American Depositary Shares (&#x201c;ADSs&#x201d;) at the price of US$14.00 per ADS for total gross proceeds of US$103.7&#160;million. On February&#160;10, 2020, the underwriters of the IPO have exercised their over-allotment option to purchase an additional 768,350 ADSs of the Company at the IPO price of US$14.00 per ADS. After giving effect to the exercise of the over-allotment option, the Company has issued and sold a total of 8,175,750 ADSs in the IPO, for total net proceeds of US$101.3&#160;million (equivalent to RMB697,788), netting of issuance cost from total gross proceeds of US$114.5&#160;million. Each ten ADSs represent &lt;span style="-sec-ix-hidden:hidden20395666"&gt;twenty&lt;/span&gt;-three ordinary shares of the Company. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;17, 2020, the Company also issued 6,078,571 ordinary shares to Everest (see Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;&#160;for details). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Upon the completion of the IPO, the Company&#x2019;s then outstanding 30,227,056 Series A Preferred Shares, 23,288,783 Series B Preferred Shares, 3,714,580 Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; Preferred Shares, 3,301,849 Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; Preferred Shares, 31,046,360 Series C Preferred Shares and 3,857,143 Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; Preferred Shares were converted into 30,227,056, 23,288,783, 3,714,580, 3,571,427, 34,420,469 and 4,537,814 ordinary shares, respectively. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July&#160;15, 2020, the Company&#x2019;s Board of Directors approved a share repurchase program to repurchase in the open market up to US$20&#160;million worth of outstanding ADSs of the Group. The Company made a total prepayment of US$5,000 (equivalent to RMB34,051) for the share repurchase. The prepayment was&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;collected subsequently in October 2020. No repurchase activity was taken place for the year ended December, 31, 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On September&#160;3, 2020, the Company entered into definitive subscription agreements with a consortium of institutional investors (the &#x201c;Investors&#x201d;) to raise approximately US$418&#160;million through a private placement. The consortium is led by Hillhouse Capital Group (&#x201c;Hillhouse&#x201d;), with significant participation by GIC Private Limited, and also includes certain other leading Asian and U.S. biotech investment funds, Hillhouse is entitled to nominate one representative to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&#x2019;s&lt;/div&gt; Board of Directors. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The private placement comprises (1)&#160;the sale to the Investors of the Group&#x2019;s 29,133,502 ordinary shares (equivalent to 12,666,740 ADSs) at a purchase price equivalent to US$33 per ADS amounting to approximately US$418&#160;million; and (2)&#160;warrants (the &#x201c;Investor Warrants&#x201d;, see Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;(b)) to subscribe for an aggregate of 5,341,267 ordinary shares (equivalent to 2,322,290 ADSs) at an exercise price equivalent to US$45 per ADS, which may further increase the proceeds of approximately US$104.5&#160;million if the Investor Warrants are fully exercised. The Investor Warrants will remain exercisable at the election of the Investors within 12 months after the closing of the private placement. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The subscription agreement with the Hillhouse entities contemplates two closings. The first closing occurred on September&#160;11, 2020, and the second closing is conditioned upon an existing director of the Company having resigned to enable the Hillhouse entities to appoint a director to replace such director and the lemzoparlimab &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-licensing&lt;/div&gt; agreement with AbbVie (see Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;) being or remaining effective. Upon the first closing, 20,421,378 ordinary shares and 3,744,032 Investor Warrants were issued to the Investors for total gross proceeds of approximately US$293.0&#160;million. On December&#160;17, 2020, the Group entered into a written amendment made to the subscription agreement with the Hillhouse entities, which removed one of the two conditions for the second closing that an existing director of the Company having resigned to enable the Hillhouse entities to appoint a director to replace such director. The second closing occurred as the other condition was satisfied and 8,712,124 ordinary shares as well as 1,597,235 Investor Warrants were issued to the Hillhouse entities for total gross proceeds of approximately US$125.0&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million. The total net proceeds, netting of issuance cost, from the private placement was US$397.2 million (equivalent to RMB2,653,669). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020, 1,841,373 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;stock options were exercised, and 7,000 restricted share units were issued as ordinary shares.&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2018"
      decimals="INF"
      unitRef="Unit_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockVotingRights contextRef="P01_01_2020To12_31_2020">Each ordinary share is entitled to one vote.</us-gaap:CommonStockVotingRights>
    <imab:CommonStockValueAuthorized
      contextRef="PAsOn10_29_2019_DirectorMembersrtTitleOfIndividualAxis"
      decimals="-3"
      unitRef="Unit_USD">80000000</imab:CommonStockValueAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn10_29_2019_DirectorMembersrtTitleOfIndividualAxis"
      decimals="INF"
      unitRef="Unit_shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn10_29_2019_DirectorMembersrtTitleOfIndividualAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_31_2020To01_31_2020_AdrMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">7407400</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn01_17_2020_AdrMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">14.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_31_2020To01_31_2020_AdrMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">103700000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <imab:CommonStockSharesIssuable
      contextRef="PAsOn02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">768350</imab:CommonStockSharesIssuable>
    <us-gaap:SharePrice
      contextRef="PAsOn02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">14.00</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P02_10_2020To02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">8175750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="P02_10_2020To02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">101300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="P02_10_2020To02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">697788000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P02_10_2020To02_10_2020_AdrMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">114500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="PAsOn01_17_2020_CollaborationAgreementWithEverestMemberusgaapTypeOfArrangementAxis_EverestsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">6078571</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn01_17_2020_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">30227056</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn01_17_2020_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">23288783</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn01_17_2020_ConvertiblePreferredStockSeriesBOneUponConversionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">3714580</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn01_17_2020_ConvertiblePreferredStockSeriesB2MemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">3301849</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn01_17_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">31046360</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn01_17_2020_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">3857143</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="P01_17_2020To01_17_2020_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">30227056</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="P01_17_2020To01_17_2020_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">23288783</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="P01_17_2020To01_17_2020_ConvertiblePreferredStockSeriesBOneUponConversionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">3714580</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="P01_17_2020To01_17_2020_ConvertiblePreferredStockSeriesB2MemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">3571427</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="P01_17_2020To01_17_2020_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">34420469</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="P01_17_2020To01_17_2020_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">4537814</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="PAsOn07_15_2020_AdrMemberusgaapStatementClassOfStockAxis_BoardOfDirectorsMembersrtTitleOfIndividualAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <imab:PrepaidExpenseStockRepurchaseProgram
      contextRef="PAsOn07_15_2020_AdrMemberusgaapStatementClassOfStockAxis_BoardOfDirectorsMembersrtTitleOfIndividualAxis"
      decimals="0"
      unitRef="Unit_USD">5000</imab:PrepaidExpenseStockRepurchaseProgram>
    <imab:PrepaidExpenseStockRepurchaseProgram
      contextRef="PAsOn07_15_2020_AdrMemberusgaapStatementClassOfStockAxis_BoardOfDirectorsMembersrtTitleOfIndividualAxis"
      decimals="0"
      unitRef="Unit_CNY">34051</imab:PrepaidExpenseStockRepurchaseProgram>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2020To12_31_2020_CollaborationAgreementWithInvestorsMemberusgaapTypeOfArrangementAxis"
      decimals="-6"
      unitRef="Unit_USD">418000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">29133502</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">33</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-6"
      unitRef="Unit_USD">418000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_InvestorWarrantsMemberusgaapInvestmentTypeAxis"
      decimals="0"
      unitRef="Unit_shares">5341267</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_InvestorWarrantsMemberusgaapInvestmentTypeAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">45</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P01_01_2020To12_31_2020_AdrMemberusgaapStatementClassOfStockAxis_InvestorWarrantsMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">104500000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2020_FirstClosingPeriodMemberIMABPeriodTypeAxis_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      unitRef="Unit_shares">20421378</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2020_FirstClosingPeriodMemberIMABPeriodTypeAxis_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      unitRef="Unit_shares">3744032</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <imab:GrossProceedsOfSharesAndWarrants
      contextRef="P01_01_2020To12_31_2020_FirstClosingPeriodMemberIMABPeriodTypeAxis_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">293000000.0</imab:GrossProceedsOfSharesAndWarrants>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2020_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis_SecondClosingPeriodMemberIMABPeriodTypeAxis"
      decimals="0"
      unitRef="Unit_shares">8712124</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2020_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis_SecondClosingPeriodMemberIMABPeriodTypeAxis"
      decimals="0"
      unitRef="Unit_shares">1597235</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <imab:GrossProceedsOfSharesAndWarrants
      contextRef="P01_01_2020To12_31_2020_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis_SecondClosingPeriodMemberIMABPeriodTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">125000000.0</imab:GrossProceedsOfSharesAndWarrants>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2020To12_31_2020_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis_SecondClosingPeriodMemberIMABPeriodTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">397200000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2020To12_31_2020_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis_SecondClosingPeriodMemberIMABPeriodTypeAxis"
      decimals="-6"
      unitRef="Unit_CNY">2653669000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SharesHeldInEmployeeStockOptionPlanAllocated
      contextRef="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"
      decimals="0"
      unitRef="Unit_shares">1841373</us-gaap:SharesHeldInEmployeeStockOptionPlanAllocated>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">7000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <imab:TemporaryEquityTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;. CONVERTIBLE PREFERRED SHARES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On October&#160;18, 2016, the Company issued 5,141,587 shares of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-1&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-2&lt;/div&gt; Preferred Shares with a consideration of US$11,282 (equivalent to approximately RMB74,742). In connection with the Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-1&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-2&lt;/div&gt; Preferred Shares issuance, the Company also issued 2,246,744 warrant to purchase its Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-3&lt;/div&gt; Preferred Shares (&#x201c;Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-3&lt;/div&gt; Warrants&#x201d;). &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On September&#160;6, 2017, in connection with the Group&#x2019;s acquisition of Tasgen Group, the Company issued 16,723,646 shares of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-3&lt;/div&gt; Preferred Shares at a price of US$2.55 per share with a total consideration of US$42,645 (equivalent to approximately RMB289,024). &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-1&lt;/div&gt; Preferred Shares, Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-2&lt;/div&gt; Preferred Shares and Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-3&lt;/div&gt; Preferred Shares are also referred to as Series A Preferred Shares. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On September&#160;22, 2017, the Company issued 15,894,594 shares of Series B Preferred Shares with a consideration of US$52,546 (equivalent to approximately RMB346,515). In connection with the Series B Preferred Shares issuance, the Company also issued convertible promissory notes that are convertible into Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; Preferred Shares (&#x201c;2017 Notes&#x201d; and see Note 14) and 5,633,780 warrants to purchase its Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; Preferred Shares (&#x201c;Series B Warrant&#x201d; and see Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;). &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Concurrently with the Company&#x2019;s issuance of Series B Preferred Shares, the Company also completed a round of onshore financing with respect to the Group&#x2019;s subsidiary &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-MAB&lt;/div&gt; Tianjin (&#x201c;Series B Onshore Financing&#x201d;). Series B Onshore Financing comprised 1) capital injection to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Tianjin by a number of investors (&#x201c;Series B Onshore Investors&#x201d;) (see Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;), 2) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Tianjin&#x2019;s issuance of convertible loans (&#x201c;Onshore Convertible Loans&#x201d; and see Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;), and 3) the Company&#x2019;s issuance of 2,620,842 warrants to purchase its Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; Preferred Shares (&#x201c;Series B Warrants&#x201d; and see Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;). &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On June&#160;29, 2018, the Company issued total 8,361,823 shares of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-3&lt;/div&gt; Preferred Shares upon exercise of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-3&lt;/div&gt; Option held by its holder. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On June&#160;29, 2018, the Company issued 2,535,201 shares of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; Preferred Shares upon conversion of 2017 Notes and issued 2,253,512 shares of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; Preferred Shares upon exercise of Series B Warrant by Series B preferred shareholders. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On June&#160;29, 2018, the Company issued 5,938,640 shares of Series B Preferred Shares upon exercise of the Series B Option held by a Series B Onshore Investor and issued 947,218 shares of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;), respectively. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On July&#160;6, 2018, the Company issued 1,455,549 shares of Series B Preferred Shares upon exercise of the Series B Option held by a Series B Onshore Investor, issued 232,161 shares of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;) and issued 1,048,337 shares of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; Preferred Shares upon exercise of Series B Warrant by Series B Onshore Investors, respectively. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Series B Preferred Shares, Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; Preferred Shares and Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; Preferred Shares are also referred to as Series B Preferred Shares. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July 6, 2018, the Company issued 31,046,360 shares of Series C Preferred Shares at a price of US$6.4419 per share with a total consideration of US$200,000 (equivalent to approximately RMB1,323,363). In connection with the offering of the Series C Preferred Shares, the Company incurred issuance costs of RMB16,730. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On July&#160;25, 2019, the Group entered into a share purchase agreement with certain third party investors, under which these investors will subscribe for an aggregate of 3,857,143 Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; convertible preferred shares of the Company for an aggregate purchase price of US$27.0&#160;million. Out of the aforementioned subscription of 3,857,143 Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; convertible preferred shares by certain third party investors, 1,428,571 Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; convertible preferred shares were issued to an investor on October&#160;17, 2019, and the Group also received the cash consideration of US$10,000 (equivalent to approximately RMB70,036). On November&#160;6, 2019, the Group received cash consideration of US$17,000 (equivalent to approximately RMB119,387) for the remaining 2,428,572 Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; convertible preferred shares from the investors and the issuance of such 2,428,572 Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; convertible preferred shares was consummated on that day. In connection with the offering of the Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; convertible preferred shares, the Company incurred issuance costs of approximately US$840 (equivalent to approximately RMB5,887). &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Series A Preferred Shares, Series B Preferred Shares, Series C Preferred Shares and Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; Preferred Shares are collectively referred to as Preferred Shares. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Key terms of the Preferred Shares are summarized as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dividends &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The holders of Preferred Shares are entitled to receive dividends, out of any assets legally available therefore, prior and in preference to any declaration or payment of any dividend on the ordinary shares or any other class or series of shares of the Group at the rate of eight percent (8%) of the original issue price per share per annum on each Preferred Share, payable in US$ and annually when, as and if declared by the Board of Directors. Such distributions shall not be cumulative. No dividend, whether in cash, in property or in shares of the capital of the Group, shall be paid on or declared and set aside for any ordinary shares or any other class or series of shares of the Group unless and until all dividends have been paid in full on the Preferred Shares (on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis). &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Conversion &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Each Preferred Share may be converted at any time into ordinary shares at the option of the preferred shares holders at the then applicable conversion price. The initial conversion ratio is 1:1, subject to adjustment in the event of (i)&#160;share splits, share combinations, share dividends or distribution, other dividends, recapitalizations and similar events, or (ii)&#160;issuance of ordinary shares (excluding certain events such as issuance of ordinary shares pursuant to a public offering) at a price per share less than the conversion price in effect on the date of or immediately prior to such issuance. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Preferred Shares shall be automatically converted into ordinary shares immediately upon the closing of a public offering of the Company&#x2019;s shares with an offering price (exclusive of underwriting commissions and expenses) that reflects a market capitalization (immediately prior to the public offering) of not less than US$1,000,000,000 or otherwise approved by all directors and certain preferred shareholders as specified in the Company&#x2019;s memorandum and articles of association (the &#x201c;Qualified Public Offering&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group determined that there were no beneficial conversion features (&#x201c;BCF&#x201d;) identified for any of the Preferred Shares during any of the periods. In making this determination, the Company compared the fair value of the ordinary shares into which the Preferred Shares are convertible with the respective effective conversion price at the issuance date. In all instances, the effective conversion price was greater than the fair value of the ordinary shares. To the extent a conversion price adjustment occurs, as described above, the Group will reevaluate whether or not a beneficial conversion feature should be recognized. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In the event of any liquidation (unless waived by the preferred shareholders) including deemed liquidation, dissolution or winding up of the Company, holders of the Preferred Shares shall be entitled to receive a per share amount equal to one hundred percent (100%) of the original issue price on each Preferred Share, plus an amount representing an internal rate of return of twelve percent (12%) per annum on the original issue price as adjusted for share dividends, share splits, combinations, recapitalizations or similar events, plus all accrued and declared but unpaid dividends thereon, in the sequence of Series C Preferred Shares, Series B Preferred Shares and Series A Preferred Shares. After such liquidation amounts have been paid in full, any remaining funds or assets of the Company legally available for distribution to shareholders shall be distributed on a pro rata basis among the holders of the Preferred Shares, on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis, together with the holders of the ordinary shares. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounting of preferred shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Preferred Shares are redeemable by the holders upon a liquidation event, including a deemed liquidation event (e.g., change in control), and as such are presented as mezzanine equity on the consolidated balance sheets. In accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;480-10-S99,&lt;/div&gt;&lt;/div&gt; each issuance of the convertible preferred shares should be recognized at the date of issuance after deducting fair value allocated to the detachable warrants and issuance costs. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Modification of preferred shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company assesses whether an amendment to the terms of its convertible preferred shares is an extinguishment or a modification using the fair value model.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;When convertible redeemable preferred shares are extinguished, the difference between the fair value of the consideration transferred to the convertible redeemable Preferred Shareholders and the carrying amount of such preferred shares (net of issuance costs) is treated as a deemed dividend to the Preferred Shareholders. When convertible redeemable preferred shares are modified and such modification results in value transfer between Preferred Shareholders and ordinary shareholders, the change in fair value resulted from the amendment is treated as a deemed dividend to or from the Preferred Shareholders. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;On December&#160;25, 2019, the Company&#x2019;s shareholders and board of directors approved that, where the final offering price of a Qualified Public Offering is no less than US$4.176 per ordinary share, the agreed provisions related to the number of shares to be converted into the Company&#x2019;s ordinary shares shall apply with respect to the Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; Preferred Shares, Series C Preferred Shares, Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; Preferred Shares and Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; Preferred Shares, which will generally give rise to a one to multiple conversion of the such rounds of Preferred Shares, provided that unanimous consent of the directors on the final offering price needs to be obtained in the event that the final offering price per ordinary share of such IPO is fixed at a price equal to or higher than US$4.176 per ordinary share but lower than US$5.22 per ordinary share. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company evaluated the aforementioned modifications and concluded that they represented modifications, rather than extinguishment, to Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; and C Preferred Shares, which resulted in a transfer of value from ordinary shareholders to preferred shareholders. The combined change in fair value of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; and C Preferred Shares immediately before and after the modification was US$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4.0&#160;&lt;/div&gt;million (equivalent to approximately RMB&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;27.8&lt;/div&gt; million) on December&#160;25, 2019. This decrease in fair value of the ordinary shares of US$4.0&#160;million (equivalent to approximately RMB27.8 million) on December&#160;25, 2019 was, in substance, a transfer of wealth mostly from ordinary shareholders to preferred shareholders, and therefore was recorded as a deemed dividend to the preferred shareholders&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company evaluated the aforementioned modifications and concluded that they represented extinguishment to Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; Preferred Shares. The difference between the fair value of the modified Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; Preferred Shares and the carrying value of the original Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; Preferred Shares was amounting US$0.8&#160;million on December&#160;25, 2019 and represented the fair value of the consideration transferred, and therefore was recognized as a deemed dividend to the preferred shareholders and adjustment to the carrying amount of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; Preferred Shares&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s convertible preferred shares activities for the years ended December&#160;31, 2019 and 2020 are summarized below: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Series&#160;A&#160;Preferred&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Series&#160;B&#160;Preferred&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Series&#160;C&#160;Preferred&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&#160;Preferred&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of January&#160;1, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,227,056&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;102,852&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;687,482&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,305,212&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,407&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;921,243&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,046,360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,478&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,306,633&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Issuance of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; Preferred Shares, net of issuance costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,857,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,160&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;183,536&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Adjustment at extinguishment of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; Preferred Shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;754&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,227,056&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;102,852&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;687,482&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,305,212&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,407&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;921,243&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,046,360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,478&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,306,633&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,857,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,914&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;188,819&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Conversion to ordinary shares upon IPO&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,227,056&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(102,852&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(687,482&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,305,212&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(139,407&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(921,243&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(31,046,360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(197,478&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,306,633&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,857,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(26,914&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(188,819&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </imab:TemporaryEquityTextBlock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn10_18_2016_SeriesA1AndA2PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5141587</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P10_18_2016To10_18_2016_SeriesA1AndA2PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">11282000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P10_18_2016To10_18_2016_SeriesA1AndA2PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">74742000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <imab:IssueOfWarrants
      contextRef="PAsOn10_18_2016_ConvertiblePreferredStockSeriesA3MemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">2246744</imab:IssueOfWarrants>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn09_06_2017_SeriesA3PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">16723646</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn09_06_2017_SeriesA3PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.55</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="P09_06_2017To09_06_2017_SeriesA3PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">42645000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="P09_06_2017To09_06_2017_SeriesA3PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">289024000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn09_22_2017_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">15894594</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="P09_22_2017To09_22_2017_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">52546000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="P09_22_2017To09_22_2017_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">346515000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <imab:IssueOfWarrants
      contextRef="PAsOn09_22_2017_ConvertiblePreferredStockSeriesBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">5633780</imab:IssueOfWarrants>
    <imab:IssueOfWarrants
      contextRef="PAsOn09_22_2017_ConvertiblePreferredStockSeriesB2MemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">2620842</imab:IssueOfWarrants>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn06_29_2018_ConvertiblePreferredStockSeriesAThreeUponExerciseMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">8361823</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn06_29_2018_ConvertiblePreferredStockSeriesBOneUponConversionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">2535201</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn06_29_2018_ConvertiblePreferredStockSeriesBTwoUponExerciseMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">2253512</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn06_29_2018_ConvertiblePreferredStockSeriesBUponExerciseMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">5938640</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn06_29_2018_ConvertiblePreferredStockSeriesBOneUponExerciseMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">947218</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn07_06_2018_ConvertiblePreferredStockSeriesBUponExerciseMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">1455549</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn07_06_2018_ConvertiblePreferredStockSeriesBOneUponExerciseMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">232161</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn07_06_2018_ConvertiblePreferredStockSeriesBTwoUponExerciseMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">1048337</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn07_06_2018_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">31046360</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn07_06_2018_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">6.4419</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="P07_06_2018To07_06_2018_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">200000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="P07_06_2018To07_06_2018_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">1323363000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P07_06_2018To07_06_2018_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">16730000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PreferredStockShareSubscriptions
      contextRef="PAsOn07_25_2019_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">3857143</us-gaap:PreferredStockShareSubscriptions>
    <us-gaap:PreferredStockSharesSubscribedButUnissuedValue
      contextRef="PAsOn07_25_2019_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">27000000.0</us-gaap:PreferredStockSharesSubscribedButUnissuedValue>
    <us-gaap:PreferredStockShareSubscriptions
      contextRef="PAsOn07_25_2019_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">3857143</us-gaap:PreferredStockShareSubscriptions>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn10_17_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1428571</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="P10_17_2019To10_17_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">10000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="P10_17_2019To10_17_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">70036000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="P11_06_2019To11_06_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">17000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="P11_06_2019To11_06_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">119387000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn11_06_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">2428572</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn11_06_2019_SeriesCOneConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">2428572</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P11_06_2019To11_06_2019_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">840000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P11_06_2019To11_06_2019_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">5887000</us-gaap:PaymentsOfStockIssuanceCosts>
    <imab:OfferingPriceOfConvertedShares
      contextRef="P12_25_2019To12_25_2019"
      decimals="0"
      unitRef="Unit_USD">1000000000</imab:OfferingPriceOfConvertedShares>
    <imab:PreferredStockLiquidationPreferencePercentage
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_pure">-1</imab:PreferredStockLiquidationPreferencePercentage>
    <imab:PreferredStockLiquidationPreferenceRateOfReturn
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_pure">-0.12</imab:PreferredStockLiquidationPreferenceRateOfReturn>
    <imab:QualifiedPublicOfferingPrice
      contextRef="PAsOn12_25_2019_MinimumMembersrtRangeAxis"
      decimals="3"
      unitRef="Unit_USD_per_Share">4.176</imab:QualifiedPublicOfferingPrice>
    <imab:QualifiedPublicOfferingPrice
      contextRef="PAsOn12_25_2019_MinimumMembersrtRangeAxis"
      decimals="3"
      unitRef="Unit_USD_per_Share">4.176</imab:QualifiedPublicOfferingPrice>
    <imab:QualifiedPublicOfferingPrice
      contextRef="PAsOn12_25_2019_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.22</imab:QualifiedPublicOfferingPrice>
    <us-gaap:EquityFairValueAdjustment
      contextRef="P01_25_2019To12_25_2019_PreferredStockMemberusgaapStatementEquityComponentsAxis_TemporaryEquityMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">4000000.0</us-gaap:EquityFairValueAdjustment>
    <us-gaap:EquityFairValueAdjustment
      contextRef="P01_25_2019To12_25_2019_PreferredStockMemberusgaapStatementEquityComponentsAxis_TemporaryEquityMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_CNY">27800000</us-gaap:EquityFairValueAdjustment>
    <imab:AdjustmentsAtExtinguishmentOfPreferredShares
      contextRef="P01_25_2019To12_25_2019_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">800000</imab:AdjustmentsAtExtinguishmentOfPreferredShares>
    <us-gaap:TemporaryEquityTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s convertible preferred shares activities for the years ended December&#160;31, 2019 and 2020 are summarized below: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Series&#160;A&#160;Preferred&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Series&#160;B&#160;Preferred&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Series&#160;C&#160;Preferred&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&#160;Preferred&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of January&#160;1, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,227,056&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;102,852&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;687,482&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,305,212&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,407&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;921,243&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,046,360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,478&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,306,633&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Issuance of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; Preferred Shares, net of issuance costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,857,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,160&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;183,536&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Adjustment at extinguishment of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; Preferred Shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;754&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,227,056&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;102,852&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;687,482&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,305,212&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,407&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;921,243&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,046,360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,478&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,306,633&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,857,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,914&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;188,819&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Conversion to ordinary shares upon IPO&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,227,056&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(102,852&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(687,482&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,305,212&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(139,407&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(921,243&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(31,046,360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(197,478&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,306,633&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,857,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(26,914&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(188,819&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">30227056</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">102852000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">687482000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2018_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">30305212</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2018_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">139407000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2018_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">921243000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2018_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">31046360</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2018_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">197478000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2018_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">1306633000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis"
      decimals="INF"
      unitRef="Unit_shares">3857143</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">26160000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_CNY">183536000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <imab:AdjustmentsAtExtinguishmentOfPreferredShares
      contextRef="P01_01_2019To12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">754000</imab:AdjustmentsAtExtinguishmentOfPreferredShares>
    <imab:AdjustmentsAtExtinguishmentOfPreferredShares
      contextRef="P01_01_2019To12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_CNY">5283000</imab:AdjustmentsAtExtinguishmentOfPreferredShares>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2019_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">30227056</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2019_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">102852000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2019_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">687482000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2019_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">30305212</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2019_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">139407000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2019_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">921243000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2019_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">31046360</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2019_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">197478000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2019_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">1306633000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">3857143</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">26914000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2019_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">188819000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2020To12_31_2020_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">-30227056</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2020To12_31_2020_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">-102852000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2020To12_31_2020_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">-687482000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2020To12_31_2020_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">-30305212</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2020To12_31_2020_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">-139407000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2020To12_31_2020_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">-921243000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2020To12_31_2020_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">-31046360</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2020To12_31_2020_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">-197478000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2020To12_31_2020_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">-1306633000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2020To12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">-3857143</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2020To12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">-26914000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2020To12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">-188819000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2020_SeriesC1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriescOneMemberusgaapFinancialInstrumentAxis"
      unitRef="Unit_CNY"
      xsi:nil="true"/>
    <imab:ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;div style="display:inline;"&gt;5&lt;/div&gt;. CONVERTIBLE PROMISSORY NOTES AND ONSHORE CONVERTIBLE LOANS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017 Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On September&#160;25, 2017, the Company issued US$11,520 convertible promissory notes (&#x201c;2017 Notes&#x201d;) to investors of Series B Preferred Shares (see Note 1&lt;div style="display:inline;"&gt;4&lt;/div&gt;) at a compound interest rate of 8% per annum, maturing on 36 months after the issuance date. Under the agreement, the holder of the 2017 Notes may convert the outstanding principal amount into Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; Preferred Shares at the conversion price of US$5.38 per share or a lower price as may be agreed by the investors and the Company at any time from six months prior to the maturity date and prior to the repayment in full of the 2017 Note. No interest shall be accrued if the 2017 Notes have been converted into Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; Preferred Shares. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As the fair value of the Company&#x2019;s ordinary shares on September&#160;25, 2017 was lower than the effective conversion price of US$5.38, the Company did not record a BCF. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On June&#160;29, 2018, the Company&#x2019;s 2017 Notes were converted into the Company&#x2019;s 2,535,201 Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; Preferred Shares at the nominal conversion price of US$5.38 per share. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On February&#160;3, 2018, the Company issued US$9,000 (equivalent to approximately RMB59,704) convertible promissory notes (&#x201c;2018 Notes&#x201d;) to Genexine, Inc. of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-3&lt;/div&gt; Preferred Shares at an annual interest rate of 0%, maturing on 36 months after the issuance date. Under the agreement, the holder of the 2018 Notes may convert the 2018 Notes outstanding principal amount into Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; Preferred Shares at the conversion price being lower of US$10 per share and fair market value at any time prior to the maturity date. Alternatively, the 2018 Notes shall be automatically converted into the Company&#x2019;s Series B Preferred Shares upon the maturity. As the fair value of the Company&#x2019;s ordinary shares on February&#160;3, 2018 of US$3.96 was equal to the effective conversion price (being lower of US$10 per share and fair market value), the Company did not record a BCF. On December&#160;17, 2020, the Group issued 900,000 ordinary shares to Genexine, Inc. upon the full conversion of the 2018 Notes with the conversion price of US$10 per share. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Onshore Convertible Loans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On September&#160;25, 2017, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Tianjin issued a US$5,359 convertible loan to Series B Onshore Investors at a compound interest rate of 8% per annum, maturing on 36 months after the issuance date. Under the agreement, the holder of the Onshore Convertible Loans may convert the outstanding principal amount into &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Tianjin&#x2019;s equity interest a stipulated conversion price at any time from six months prior to the maturity date and prior to the repayment in full of the Onshore Convertible Loans. No interest shall be accrued if the Onshore Convertible Loans have been converted into &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Tianjin&#x2019;s equity interest. As the fair value of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Tianjin&#x2019;s ordinary shares on September&#160;25, 2017 was lower than the effective conversion price of US$4.31, the Company did not record a BCF. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In June and July 2018, the Company reached agreements with holders of Onshore Convertible Loans and the principal amount of Onshore Convertible Loans were then effectively converted into 1,179,379 Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; Preferred Shares of the Company and the accrued interests were waived, resulting in an extinguishment loss of RMB8,548. &lt;/div&gt;</imab:ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn09_25_2017_ConvertiblePromissoryNotes2017MemberusgaapDebtInstrumentAxis_SeriesBPreferredStockHolderMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">11520000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn09_25_2017_ConvertiblePromissoryNotes2017MemberusgaapDebtInstrumentAxis_SeriesBPreferredStockHolderMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm contextRef="P09_25_2017To09_25_2017_ConvertiblePromissoryNotes2017MemberusgaapDebtInstrumentAxis_SeriesBPreferredStockHolderMemberusgaapStatementClassOfStockAxis">P36M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn09_25_2017_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn09_25_2017_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P06_29_2018To06_29_2018_ConvertiblePromissoryNotes2017MemberusgaapDebtInstrumentAxis_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">2535201</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn06_29_2018_ConvertiblePromissoryNotes2017MemberusgaapDebtInstrumentAxis_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn02_03_2018_ConvertiblePromissoryNotes2018MemberusgaapDebtInstrumentAxis_SeriesA3PreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">9000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:NotesIssued1
      contextRef="P02_03_2018To02_03_2018_SeriesA3PreferredSharesMemberusgaapStatementClassOfStockAxis_TwoZeroOneEightNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_CNY">59704000</us-gaap:NotesIssued1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn02_03_2018_ConvertiblePromissoryNotes2018MemberusgaapDebtInstrumentAxis_SeriesA3PreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm contextRef="P02_03_2018To02_03_2018_ConvertiblePromissoryNotes2018MemberusgaapDebtInstrumentAxis_SeriesA3PreferredSharesMemberusgaapStatementClassOfStockAxis">P36M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn02_03_2018_ConvertiblePromissoryNotes2018MemberusgaapDebtInstrumentAxis_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">10</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:SharePrice
      contextRef="PAsOn02_03_2018_ConvertiblePromissoryNotes2018MemberusgaapDebtInstrumentAxis_SeriesA3PreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.96</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn02_03_2018_ConvertiblePromissoryNotes2018MemberusgaapDebtInstrumentAxis_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">10</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_17_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TwoZeroOneEightNotesMemberusgaapDebtInstrumentAxis"
      decimals="0"
      unitRef="Unit_shares">900000</us-gaap:SharesIssued>
    <us-gaap:SharePrice
      contextRef="PAsOn12_17_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TwoZeroOneEightNotesMemberusgaapDebtInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn09_25_2017_OnshoreConvertibleLoanMemberusgaapDebtInstrumentAxis_SeriesBOnshoreInvestorsMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">5359000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn09_25_2017"
      decimals="2"
      unitRef="Unit_pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm contextRef="P09_25_2017To09_25_2017_OnshoreConvertibleLoanMemberusgaapDebtInstrumentAxis_SeriesBOnshoreInvestorsMemberusgaapStatementClassOfStockAxis">P36M</us-gaap:DebtInstrumentTerm>
    <us-gaap:SharePrice
      contextRef="PAsOn09_25_2017_OnshoreConvertibleLoanMemberusgaapDebtInstrumentAxis_SeriesBOnshoreInvestorsMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.31</us-gaap:SharePrice>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P09_25_2017To09_25_2017_OnshoreConvertibleLoanMemberusgaapDebtInstrumentAxis_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">1179379</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P09_25_2017To09_25_2017_OnshoreConvertibleLoanMemberusgaapDebtInstrumentAxis_SeriesBOnshoreInvestorsMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_CNY">8548000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <imab:WarrantsDisclosure contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;div style="display:inline;"&gt;6&lt;/div&gt;. WARRANTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(a) Warrants to purchase preferred shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In connection with the issuance of the Series B Preferred Shares on September&#160;22, 2017, 5,633,780 Series B Warrants were issued to Series B preferred shareholders, which provided the holders the right to purchase Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; Preferred Shares. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In connection with the Company&#x2019;s Series B Onshore Financing that took place on September&#160;25, 2017, 2,620,842 Series B Warrants were issued to Series B Onshore Investors, which provided the holders the right to purchase Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; Preferred Shares. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;During the period from June&#160;29, 2018 to July&#160;6, 2018, 3,301,849 Series B Warrants (representing Tranche I of Series B Warrants) were exercised to purchase 3,301,849 Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; Preferred Shares with proceeds of US$20,000 (equivalent to approximately RMB132,332). &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On July&#160;6, 2018, the Series B Warrants holders agreed that the Series B Warrants shall be divided into two tranches and exercisable in accordance with different time schedules, such that: (i)&#160;the holders have exercised part of the Series B Warrants in the total consideration of US$20,000 (&#x201c;Tranche I of Series B Warrants&#x201d;) and 3,301,849 Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; Preferred Shares of the Company in aggregate have been newly issued to such holders on a pro rata basis; (ii)&#160;only when the Company fails to submit a Qualified Public Offering application at an internationally recognized securities exchange by March&#160;31, 2019, the Warrant Holders may exercise the remaining part of Series B Warrants, in the total consideration of US$30,000 (&#x201c;Tranche II of Series B Warrants&#x201d;) and 4,952,773 Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; Preferred Shares of the Company in aggregate will be issued to such holders on a pro rata basis; (iii)&#160;provided that the Company successfully submits a Qualified Public Offering application at an internationally recognized securities exchange by March&#160;31, 2019, the holders shall unconditionally and irrevocably waive and cancel Tranche II of Series B Warrants; and (iv)&#160;the Tranche II of Series B Warrants may only be concurrently exercised by all the Warrant Holders in one lump. This is considered to be a modification to Series B Warrants. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;According to the confirmations issued by the Company&#x2019;s Series B Warrants holders in July 2019, the holders of Series B Warrants has unconditionally and irrevocably waived and cancelled the Tranche II of Series B Warrants. The fair value gain of warrants for the years ended December&#160;31, 2019 and 2020 was amounting to RMB5,644 and nil, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting of warrants for purchase preferred shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The warrant is a freestanding instrument and is recorded as liability in accordance with ASC 480, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Distinguishing Liabilities from Equity&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As the Company&#x2019;s issuance of warrants were bundled with other instruments (such as convertible preferred shares, convertible promissory notes, etc.), out of total considerations, the warrants are initially recognized at fair value and the remaining were allocated to other instruments on a relative fair value basis (if applicable). The fair value changes of the warrants (including the fair value changes arising from modification of warrants) up to the time of exercise or termination were recognized in earnings. Upon exercise, the total carrying value of the associated warrant liabilities was reclassified into the carrying value of the Preferred Shares into which it was converted. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company determined the fair value of the warrants with the assistance of an independent third-party valuation firm. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(b) Warrants to purchase ordinary shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As mentioned in Note 1&lt;div style="display:inline;"&gt;3&lt;/div&gt;, on September&#160;3, 2020, the Group entered into definitive subscription agreements with the Investors to raise approximately US$418&#160;million through a private placement, which comprises the Investor Warrants to subscribe for an aggregate of 5,341,267 ordinary shares (equivalent to 2,322,290 ADSs) at an exercise price equivalent to US$45 per ADS. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Subscription Agreement with the Hillhouse entities contemplates two closings. In the first closing occurred on September&#160;11, 2020 and second closing occurred on December&#160;17, 2020, the Investor Warrants were issued with fixed exercise prices of US$45.00 per ADS (equivalent to US$19.57 per share) and lives of one year. The number of common share purchasable upon exercise of the Investor Warrants shall be proportionally adjusted to reflect any share dividend, share split, combination of shares or reverse share split, or other similar event affecting the number of outstanding common shares. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting for warrants to purchase ordinary shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Investor Warrants are regarded as indexed to the Company&#x2019;s own stock and were classified as equity and initially measured at fair value and subsequent changes in fair value are not recognized as long as the Investor Warrants continue to be classified as equity. The estimated fair value of the Investor Warrants was shown below, which were used to determine the allocation of the total proceeds for the sale of ordinary shares between the Investor Warrants and ordinary shares. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Terms&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price&#160;per&lt;br/&gt; share&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;value&#160;at&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;the&#160;closing&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;date&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrants to purchase ordinary shares (first closing on September 11, 2020)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12 months&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,744,032&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;71,874&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrants to purchase ordinary shares (second closing on &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;17, 2020)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12 months&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,597,235&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;37,869&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group determined the fair value of the warrants with the assistance of an independent third-party valuation firm. The Group used the binomial model to estimate the fair value of the warrant on September&#160;11, 2020 and December&#160;17, 2020 when the Investor Warrants were issued using the following assumptions: &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-align:left;"&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 92%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of September&#160;11,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;17,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 92%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 92%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate of return&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 92%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturity date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;September 11, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 17, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 92%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated volatility rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;60.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;59.56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 92%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The model requires the input of assumptions including the risk-free rate of return, maturity date and estimated volatility rate. The risk-free rate for periods within the contractual life is based on the US treasury strip bond with maturity similar to the maturity of the warrants as of valuation dates plus a China country risk premium. For expected volatilities, the Group has made reference to the historical daily stock prices volatilities of ordinary shares of several comparable companies in the same industry as the Group. &lt;/div&gt;&lt;/div&gt; </imab:WarrantsDisclosure>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P09_22_2017To09_22_2017_SeriesBPreferredShareholdersMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5633780</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P09_25_2017To09_25_2017_SeriesBOnshoreInvestorsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">2620842</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn07_06_2018_TrancheIOfSeriesBWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">3301849</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn06_29_2018_SeriesB2PreferredSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">3301849</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="P06_29_2018To07_06_2018_SeriesB2PreferredSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20000000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="P06_29_2018To07_06_2018_SeriesB2PreferredSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">132332000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="P01_01_2020To12_31_2020_TrancheIOfSeriesBWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20000000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2020To12_31_2020_SeriesB2PreferredSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">3301849</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="P01_01_2020To12_31_2020_TrancheIiOfSeriesBWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">30000000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn07_06_2018_SeriesBWarrantsSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">4952773</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2020To12_31_2020_SeriesBWarrantsSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_CNY">5644000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2020To12_31_2020_CollaborationAgreementWithInvestorsMemberusgaapTypeOfArrangementAxis"
      decimals="-6"
      unitRef="Unit_USD">418000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2020To12_31_2020_AmericanDepositarySharesMemberusgaapStatementEquityComponentsAxis_InvestorWarrantsMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">5341267</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2020_AmericanDepositarySharesMemberusgaapStatementEquityComponentsAxis_InvestorWarrantsMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">45</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P01_01_2020To12_31_2020_HillhouseEntitiesMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_USD">45.00</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="P01_01_2020To12_31_2020">The estimated fair value of the Investor Warrants was shown below, which were used to determine the allocation of the total proceeds for the sale of ordinary shares between the Investor Warrants and ordinary shares.
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Terms&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price&#160;per&lt;br/&gt; share&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;value&#160;at&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;the&#160;closing&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;date&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&#x2019;000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrants to purchase ordinary shares (first closing on September 11, 2020)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12 months&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,744,032&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;71,874&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrants to purchase ordinary shares (second closing on &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;17, 2020)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12 months&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,597,235&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;37,869&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <imab:Classofwarrantorrightsexercisableterm contextRef="P09_11_2020To09_11_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis">P12M</imab:Classofwarrantorrightsexercisableterm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_11_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">19.57</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn09_11_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">3744032</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="PAsOn09_11_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-3"
      unitRef="Unit_CNY">71874000</us-gaap:WarrantsAndRightsOutstanding>
    <imab:Classofwarrantorrightsexercisableterm contextRef="P12_17_2020To12_17_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis">P12M</imab:Classofwarrantorrightsexercisableterm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_17_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">19.57</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_17_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">1597235</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="PAsOn12_17_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-3"
      unitRef="Unit_CNY">37869000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2020To12_31_2020">The Group used the binomial model to estimate the fair value of the warrant on September&#160;11, 2020 and December&#160;17, 2020 when the Investor Warrants were issued using the following assumptions: &lt;div style="text-align:left;"&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 92%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of September&#160;11,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;17,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 92%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 92%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate of return&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 92%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturity date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;September 11, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;December 17, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 92%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated volatility rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;60.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;59.56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 92%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;/div&gt; </us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_11_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.12</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_17_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.08</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="PAsOn09_11_2020_MeasurementInputMaturityMemberusgaapMeasurementInputTypeAxis">2021-09-11</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="PAsOn12_17_2020_MeasurementInputMaturityMemberusgaapMeasurementInputTypeAxis">2021-12-17</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_11_2020_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_pure">60.72</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_17_2020_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_pure">59.56</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_11_2020_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_pure">19.57</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_17_2020_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_pure">19.57</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;div style="display:inline;"&gt;7&lt;/div&gt;. SHARE-BASED COMPENSATION &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;(a) Restricted shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2016, the Company issued 4,019,554 ordinary shares to Mr.&#160;Zang Jingwu Zhang, Ms.&#160;Qian Lili, Mr.&#160;Wang Zhengyi and Mr.&#160;Fang Lei (collectively the &#x201c;Founders&#x201d;), including the 369,301 shares which represented the equity interests of Third Venture held by the Founders, and the Company recorded share-based compensation expense of RMB18.7&#160;million for issuance and grant of 3,650,253 ordinary shares to the Founders in June 2016. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2016, the Founders entered into an arrangement with other investors of the Company, and the 87,441 ordinary shares issued to the Founders in June 2016 were canceled and out of the remaining 3,932,113 ordinary shares held by the Founders, 70% became restricted and subject to service vesting conditions, that should vest 20%, 20% and 30% over the next three years, respectively. There shall be no acceleration of the vesting schedule except that, in case of a change of control of the Company or a Qualified Public Offering, or the termination of the Founder&#x2019;s employment with the Group without cause. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred share-based compensation was measured for the restricted shares using the estimated fair value of the Company&#x2019;s ordinary shares of US$0.77 at the date of imposition of the restriction in October 2016, and was amortized to the consolidated statements of comprehensive loss by using graded vesting method over the vesting term of 3 years. As of December&#160;31, 2019, all the restricted shares were fully vested. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amounts of shared-based compensation expense in relation to the restricted shares recognized in the years ended December&#160;31, 2018, 2019 and 2020 were RMB3,520, RMB1,566 and nil, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expenses related to restricted shares were included in: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,056&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;470&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2,464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,096&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3,520&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;(b) 2017 Employee Stock Option Plan (&#x201c;2017 Plan&#x201d;) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2017, the Company adopted the 2017 Plan. Under the 2017 Plan, a maximum aggregate number of 13,376,865 shares that may be issued pursuant to all awards granted was approved. Stock options granted to an employee under the 2017 Plan will be exercisable upon the Company completes a listing and the employee renders service to the Company in accordance with a stipulated service schedule starting from the employee&#x2019;s date of employment. Employees are generally subject to a three-year service schedule, under which an employee earns an entitlement to vest in 50% of the option grants on the second anniversary of the grant date, a vesting of the remaining 50% on the third anniversary of the applicable grant date. The stock option under 2017 Plan, to the extent then vested, shall become exercisable only upon the earlier of (i)&#160;a listing, and (ii)&#160;occurrence of a change in control. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;On December&#160;25, 2019, the Second Amended and Restated 2017 Plan was approved by the shareholders and board of directors of the Company, pursuant to which, in connection with the Company&#x2019;s IPO, the maximum aggregate number of shares that may be granted pursuant to all awards under 2017 Plan shall be adjusted in accordance with a formula &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-approved&lt;/div&gt; by the shareholders. In connection with above amendments to 2017 Plan, each of the Company&#x2019;s founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, is willing to irrevocably surrender by him or her, for no consideration, a portion of the unvested options granted to him or her, which, if vested, would entitle him or her to acquire up to 130,000 ordinary shares of the Company, par val&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;u&lt;/div&gt;e US$0.0001 per share, at an exercise price of US$1.0, respectively, under the Second Amended and Restated 2017 Plan (in respect of each individual, the &#x201c;Founder&#x2019;s Surrendered Options&#x201d;). On December&#160;25, 2019, the board of directors of the Company approved that the Company accepts all Founder&#x2019;s Surrendered Options from each of the founders, Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, for no consideration, with effect immediately prior to the completion of the IPO and such surrendered options be cancelled with effect immediately prior to the completion of the IPO. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior to the Company completes a listing, all stock options granted to an employee shall be forfeited at the time the employee terminates his employment with the Group. After the Company completes a listing, vested options not exercised by an employee shall be exercised until later of: (i) 90 days after the date when the options become exercisable, or (ii) 30 days after the date of cessation of employment or directorship, or such longer period as the Board of Directors may otherwise determine. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the years ended December 31, 2018 and 2019, the Group granted 1,470,000 and 640,000 stock options respectively, to its employees (all with an exercise price of US$1).&#160;&lt;/div&gt;The Group did not grant any stock options to employees for the year ended December&#160;31,&#160;2020. No options were exercisable as of December&#160;31, 2019 and 6,790,924 stock options were exercisable as of December&#160;31, 2020. No options were exercised as of December&#160;31, 2019 and 1,439,373 stock options were exercised as of December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the stock options activities of 2017 Plan for the periods presented: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Number&#160;of&lt;br/&gt; shares&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;br/&gt; US$&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&lt;br/&gt; term&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Aggregate&lt;br/&gt; intrinsic&lt;br/&gt; value&lt;br/&gt; US$&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;11,761,596&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;0.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;9.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;24,890&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,470,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(226,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;13,005,596&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;0.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;8.61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;70,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;640,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(397,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Repurchased (Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;(d))&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(3,435,215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31 ,2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;9,812,881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;0.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;7.76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;47,671&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(338,876&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(1,439,373&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;0.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Surrendered&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;(Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;(h))&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(332,566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31 ,2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;7,702,066&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;0.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;6.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;150,415&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;6,790,924&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;0.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;6.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;132,650&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;A summa&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;r&lt;/div&gt;y of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; stock option activities for the year ended December&#160;31, 2020 is presented below: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Grant&#160;date&#160;fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2019&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;9,812,881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(6,790,924&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,439,373&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.37&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(338,876&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Surrendered&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(332,566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;911,142&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;4.96&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Since the exercisability &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;wa&lt;/div&gt;s dependent upon the listing, and it &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;wa&lt;/div&gt;s not probable that this performance condition c&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ould&lt;/div&gt;&#160;be achieved until a listing, no share-based compensation expense relating to the 2017 Plan was recorded for the year ended December&#160;31, 2018 and 2019. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On January&#160;17, 2020, the Group completed its IPO. After achieving this performance condition, the options continue to vest based only on service period completed according to the graded vesting schedule. The Group has begun recognizing share-based compensation expense for the options granted using the graded vesting method with a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; for the service period completed to date during the year ended December&#160;31, 2020 and recognized RMB52,802&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;RMB69,213 and&#160;&lt;/div&gt;RMB4,277 share-based compensation expenses in administrative expenses&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt;&#160;research and development &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;expenses and equity in loss of an affiliate, respectively&#160;&lt;/div&gt;relating to options vested cumulatively. According to the amendments to 2017 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2017 Plan was changed to 9,609,084. Each of the Group&#x2019;s founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang surrendered 83,142 unvested stock options that were granted to him or her under 2017 Plan before, totally 332,566 unvested options, for no consideration, and these stock options were cancelled immediately. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;(c) 2018 Employee Stock Option Plan (&#x201c;2018 Plan&#x201d;) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February&#160;22, 2019, the Group adopted the 2018 Plan, which was subsequently amended on July&#160;22, 2019.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Under the amended and restated 2018 Plan, the maximum aggregate number of ordinary shares which may be issued pursuant to all awards is 14,005,745, and if the Group successfully lists on an internationally recognized securities exchange for a Qualified Public Offering by December&#160;31, 2019, the maximum aggregate number of ordinary shares which may be issued shall be 15,452,620. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On December&#160;25, 2019, the Second Amended and Restated 2018 Plan were approved by the shareholders and board of directors of the Company, pursuant to which, in connection with the Company&#x2019;s IPO, the maximum aggregate number of shares that may be granted pursuant to all awards under 2018 Plan shall be adjusted in accordance with a formula &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-approved&lt;/div&gt; by the shareholders. In connection with above amendments to 2018 Plan, the director of the Company, Dr.&#160;Jingwu Zhang Zang is willing to irrevocably surrender by him, for no consideration, of the right to acquire a certain amount of ordinary shares of the Company, par value US$0.0001 per share, at an exercise price of US$1.0 pursuant to the options granted to him under the Second Amended and Restated 2018 Plan (the &#x201c;Dr.&#160;Zang&#x2019;s Surrendered Options&#x201d;). On December&#160;25, 2019, the board of directors of the Company approved that the Company accepts the irrevocable surrender of Dr.&#160;Zang&#x2019;s Surrendered Options for no consideration, with effect immediately prior to the completion of the IPO and such surrendered options be cancelled with effect immediately prior to the completion of the IPO. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Stock options granted to an employee under the 2018 Plan will be generally exercisable when the Company completes a listing and the employee renders service to the Company in accordance with a stipulated service schedule starting from the employee&#x2019;s date of employment. The vesting schedule shall generally be a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-year&lt;/div&gt; vesting schedule consisting of a cliff vesting 50% on the first anniversary of the applicable vesting commencement date, and a vesting of the remaining 50% on the second anniversary of the applicable vesting commencement date. If a listing occurs at anytime prior to any option granted under the 2018 Plan becoming full vested, and to the extent such option has been granted and outstanding, any such option shall vest in full with immediate effect upon the listing. Except as otherwise approved by the board of directors, vested portion of option shall become exercisable upon the earlier of six months after a listing or the occurrence of a change in control; provided, however that in each case, no option of an employee shall become exercisable until the third anniversary of such employee&#x2019;s employment commencement date. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the Board of Director&#x2019;s approval of 2018 Plan on February&#160;22, 2019, the 10,893,028 stock options granted to a director of the Group under 2018 Plan were fully vested and exercisable upon the adoption of 2018 Plan. Out of aforementioned total 10,893,028 stock options, 454,940 stock options were repurchased by the Group (see Note 1&lt;div style="display:inline;"&gt;7&lt;/div&gt;&#160;(d) for further details). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amounts of shared-based compensation expense in relation to the aforementioned grant of stock options to a director of the Group (except for those repurchased by the Group as described in Note 1&lt;div style="display:inline;"&gt;7 &lt;/div&gt;(d)) recognized in the year ended December&#160;31, 2019 was RMB365,329&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;included in administrative expenses.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the stock options activities of 2018 Plan for the years ended December&#160;31, 2019 and 2020: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Number&#160;of&lt;br/&gt; shares&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;br/&gt; US$&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&lt;br/&gt; term&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Aggregate&lt;br/&gt; intrinsic&lt;br/&gt; value&lt;br/&gt; US$&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of January&#160;1, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,991,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Repurchased (Note 1&lt;div style="display:inline;"&gt;7&lt;/div&gt;&#160;(d))&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(454,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,536,588&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;64,840&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(402,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#x2014; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Surrendered (Note 1&lt;div style="display:inline;"&gt;7&lt;/div&gt;&#160;(h))&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;"&gt;(2,544,917&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#x2014; &#160;&lt;/div&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;10,589,671&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;8.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;206,499&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;9,764,670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;8.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;190,411 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options granted to certain directors and employees of the Group were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;54.64%-56.31&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate (per annum)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.15%-2.75&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise multiple&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contractual term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of the Group&#x2019;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the Group&#x2019;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;A summa&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;r&lt;/div&gt;y of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; stock option activities for the year ended December&#160;31, 2020 is presented below: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant-date&#160;fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2019&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3,098,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;5.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(1,871,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;5.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(402,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.57&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;825,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;5.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left;"&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options granted to the employees were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0.75%;"/&gt;
&lt;td style="width: 0.75%;"/&gt;
&lt;td style="width: 1.5%;"/&gt;
&lt;td style="vertical-align: bottom;"/&gt;
&lt;td style="vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0.75%;;text-align:center;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0.75%; text-align: right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;61.32%-62.13&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;54.64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate (per annum)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0.75%;;text-align:center;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0.75%; text-align: right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.81%-3.06&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right;"&gt;2.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise multiple&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0.75%; padding: 0pt 0.5pt;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0.75%; padding: 0pt 0.5pt; text-align: right;"&gt;2.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1.5%; padding: 0pt 0.5pt;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right;"&gt;2.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0.75%;;text-align:center;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0.75%; text-align: right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1.5%;;text-align:center;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&#x2014;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contractual term (in years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; width: 0.75%;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0.75%; text-align: right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; width: 1.5%;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of the Group&#x2019;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the Group&#x2019;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Except for the aforementioned grant of stock options to a director of the Group under 2018 Plan, since the exercisability is dependent upon the listing, and it is not probable that this performance condition can be achieved until a listing, no share-based compensation expense related to the 2018 Plan was recorded for the year ended December&#160;31, 2019. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On January&#160;17, 2020, the Group completed its IPO. After achieving this performance condition, the options continue to vest based only on service period completed according to the graded vesting schedule. The Group has begun recognizing share-based compensation expense for the options granted using the graded vesting method with a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; for the service period completed to date during the year ended December&#160;31, 2020 and recognized RMB48,055&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, RMB65,656 and&#160;&lt;/div&gt;&lt;/div&gt;RMB226 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;share-based compensation expense in administrative expenses and research, development expenses and equity in loss of an affiliate, respectively relating to options vested cumulatively. According to the amendments to 2018 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2018 Plan was changed to&lt;/div&gt; 11,005,888. The director of the Company, Dr.&#160;Jingwu Zhang Zang surrendered 2,544,917 unvested options that were granted to him under 2018 Plan, for no consideration, and these stock options were cancelled immediately. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;(d) Repurchase of share awards held by a director &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February&#160;22, 2019, the amendment and restated 2017 equity incentive plan was approved by the Board of Directors of the Group, pursuant to which only the 3,435,215 stock options held by the director (see Note 1&lt;div style="display:inline;"&gt;7&lt;/div&gt;(c)) under the 2017 equity incentive plan became fully vested and exercisable on February&#160;22, 2019. As a result of the performance condition being waived, the stock options held by the director of the Group were accounted for as a Type III modification where a condition that the Group expects will not be satisfied is changed to a condition that the Group expects will be satisfied. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additionally, on the same day, the Group repurchased such 3,435,215 stock options under the amendment and restated 2017 equity incentive plan that was held by the director of the Group along with 454,940 of his stock options under the 2018 equity incentive plan for which the share awards also became fully vested and exercisable, at a total consideration of US$21,902 (equivalent to approximately RMB148,308) at an average share price of US$5.63 per share. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the year ended December&#160;31, 2019, the Group recorded the total payment of US$21,902 (equivalent to approximately RMB148,308) as share-based compensation costs (included in administrative expenses) in the consolidated statement of comprehensive loss. There was no impact to the overall stockholder&#x2019;s equity balance as the amended shares vested immediately and were repurchased. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;(e) 2019 Share Incentive Plan (&#x201c;2019 Plan&#x201d;) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;29, 2019, the Group adopted 2019 Share Incentive Plan (the &#x201c;2019 Plan&#x201d;), which will become effective immediately prior to the completion of the Company&#x2019;s initial public offering. Under the 2019 Plan, the maximum aggregate number of ordinary shares available for issuance shall initially be 100,000. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left;"&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The options shall vest when the Group completes a listing and the employee renders service to the Group in accordance with a stipulated service schedule starting from the employee&#x2019;s date of employment. Stock options granted to 3 independence directors under the 2019 Plan will be generally exercisable under the following terms:(a) a cliff vesting of 1/3 of the option on the first anniversary of the vesting commencement date (January 17, 2020); (b) a cliff vesting of 1/3 of the option on the second anniversary of the vesting commencement date (January 17, 2020); (c) a vesting of the remaining 1/3 of the option on the third anniversary of the vesting commencement date. In the last year of the grantee&#x2019;s service, the options shall vest on a prorated basis to reflect the portion of the year during which the grantee provided services to the Group.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the year ended December&#160;31, 2020, the Group granted 72,000 stock options to 3 independent directors (all with an exercise price of US$6.09) and recognized RMB1,171 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;share-based compensation expenses in administrative expenses according to the options&#x2019; vesting schedule.&#160;&lt;/div&gt;No options were exercisable as of December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the stock options activities of 2019 Plan for the year ended December&#160;31, 2020 presented: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;remaining&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;contractual&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;intrinsic&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;72,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6.09&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;72,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6.09&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9.33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,038&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;A summary of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; stock options activity for the year ended December&#160;31, 2020 is presented below: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant-date&#160;fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2019&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;72,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;72,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-align: left;"&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options granted to the 3 independent directors were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 22%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 22%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;54.88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate (per annum)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 22%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.79&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise multiple&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 22%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contractual term (in years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 22%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="text-align: center;"&gt; &lt;div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-align: center;"&gt; &lt;div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;/div&gt; &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of the Group&#x2019;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the Group&#x2019;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;(f) 2020&#160;Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July&#160;15, 2020, the Group adopted 2020 Share Incentive Plan (&#x201c;2020 Plan&#x201d;). Under the 2020 Plan, the maximum aggregate number of shares authorized to be issued is 10,760,513 ordinary shares, provided that the maximum number of shares to be issued in the form of restricted share units shall not exceed 7,686,081 ordinary shares. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options granted to employees under the 2020 Plan are graded vesting in four years with 25% vesting each year. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the year ended December&#160;31, 2020, the Group granted 1,068,733 stock options to its employees and recognized RMB4,357 RMB10,435 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and RMB1,619&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;share-based compensation expenses in administrative expenses, research and development expenses and equity in loss of an affiliate, respectively, in the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;consolidated&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;statement of&lt;/div&gt; comprehensive&#160;income&lt;/div&gt;.&lt;/div&gt;&#160;No option became exercisable as of December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; The following table sets forth the stock options activities of 2020 Plan for the year ended December&#160;31, 2020: &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;price&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;intrinsic&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;value&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;1,068,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.91&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;(24,365&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;5.91&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;1,044,368&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;5.91&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;9.62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;15,237&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;A summary of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; stock option activities for the year ended December&#160;31, 2020 is presented below: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant-date&#160;fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2019&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,068,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(24,365&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,044,368&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 65in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-align: left;"&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options granted to the employees were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 18%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;56.51&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate (per annum)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;0.86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise multiple&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.20-2.80&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Contractual term (in years)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="text-align: center;"&gt; &lt;div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"&gt; &lt;/div&gt; &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of the Group&#x2019;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the Group&#x2019;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted share units granted to employees under the 2020 Plan will be exercisable under the following items: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(a) 1/3 of the awarded restricted share units shall vest based on the following time attribution:(i) a vesting of 25% of the time attribution based restricted share units on the first anniversary of the applicable adoption date;(ii) a vesting of 25% of the time attribution based restricted share units on the second anniversary of the applicable adoption date;(iii) a vesting of 25% of the time attribution based restricted share units on the third anniversary of the applicable adoption date;(iv) a vesting of 25% of the time attribution based restricted share units on the fourth anniversary of the applicable adoption date. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(b) 1/3 of the awarded restricted share units shall vest based on the Group&#x2019;s weighted average market value during the last 30 days prior to the initial vesting date, the terms and conditions of which are set forth in the executed award agreements. In the event that dilution of additional share issuance occurs, the market value targets herein shall be adjusted accordingly with the proportion of additional share issuance. In the event that the average market value of Standard&#160;&amp;amp; Poor&#x2019;s 500 index falls by more than 20% from the date of grant, it shall be deemed as a decline of the market, and the board of the Group or a committee that board delegated its powers or authority to shall adjust the vesting schedule as appropriate. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(c) 1/3 of the awarded restricted share units shall vest based on certain performance conditions:(i) a vesting of 20% of the performance conditions based restricted share units if one of the performance conditions has been met at the initial vesting date;(ii) a vesting of 40% of the performance conditions based restricted share units if two of the performance conditions have been met at the initial vesting date;(iii) a vesting of 60% of the performance conditions based restricted share units if three of the performance conditions have been met at the initial vesting date;(iv) a vesting of 80% of the performance conditions based restricted share units if four of the performance conditions have been met at the initial vesting date; (v)&#160;a vesting of all of the performance conditions based restricted share units if five of the performance conditions or more have been met at the initial vesting date. As of December&#160;31, 2020, it is probable that the 1/3 of the awarded restricted share units are fully vested because it is probable that at least five of the performance conditions will be met at the initial vesting date. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notwithstanding the foregoing, if the Group&#x2019;s weighted average market value during the last 30 days prior to the initial vesting date reaches US$2&#160;billion or above, and to the extent such restricted share units have been granted and outstanding, any such restricted share unit (except for those are based on time attribution) shall vest in full with immediate effect, inure to the benefit of the related grantees. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the year ended December&#160;31, 2020, the Group granted 4,093,079 restricted share units to employees and recognized RMB76,663&#160;RMB71,945 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;and RMB7,500 share-based compensation expenses in administrative expenses, research and development expenses and equity in loss of an affiliate, respectively, in the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;consolidated statement of comprehensive income&lt;/div&gt;. No restricted share units became exercisable as of December 31, 2020.&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the restricted share units of 2020 Plan for the year ended December&#160;31, 2020: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;restricted&lt;br/&gt; share units&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;remaining&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;contractual&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;intrinsic&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;4,093,079 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(13,461&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;4,079,618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;9.70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;83,632&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;A summary of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; restricted share units activities for the year ended December&#160;31, 2020 is presented below: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;restricted&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;units&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant-date&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;fair value&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2019&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;4,093,079&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;13.99&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(13,461&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;11.73&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 56%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;4,079,618 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;14.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 56%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Apart from the aforementioned restricted share units, up to 1,446,875 shares can be issued in the form of restricted share unit to eligible grantees that the board of the Group or a committee that board delegated its powers or authority determined appropriate with immediate effect of being fully vested, which are defined as special awards and are subject to terms and conditions under 2018 Plan. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the year ended December&#160;31, 2020, the Group granted 1,328,120 such restricted share units to employees and recognized&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;RMB25,985&#160;RMB67,182 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;and RMB19,085 share-based compensation expenses in administrative expenses, research and development expenses and equity in loss of an affiliate, respectively, in the consolidated statement of comprehensive incomes of December 31, 2020, 565,200 restricted share units were vested,&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;among&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;which&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &#160;558,200&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;restricted share units were vested but not issued as ordinary shares as the employees will not be entitled to the rights of ordinary shares from the Group until they have the consideration for the transaction settled.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the restricted share units subject to terms and conditions under 2018 Plan for the year ended December&#160;31, 2020: &lt;/div&gt;&lt;/div&gt; &lt;br/&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;restricted&lt;br/&gt; share units&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;remaining&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;contractual&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;intrinsic&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,328,120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;/div&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(565,200&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;762,920&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;9.65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;14,877&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;A summary of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; restricted share units activities for the year ended December&#160;31, 2020 is presented below: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;restricted&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;units&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant-date&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;fair value&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2019&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,328,120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13.34&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(565,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 56%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;762,920&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12.89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 56%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;(g) Establishment of Biomaster Trust &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Biomaster Trust was established under the trust deed dated October&#160;23, 2019, between the Company and TMF Trust (HK) Limited, or TMF Trust, as the trustee of the Biomaster Trust. Through the Biomaster Trust, the Company&#x2019;s ordinary shares and other rights and interests under awards granted pursuant to 2017 Plan and 2018 Plan may be provided to certain recipients of equity awards. Upon satisfaction of vesting conditions, TMF Trust will exercise the equity awards and transfer the relevant ordinary shares and other rights and interests under the equity awards to the relevant grant recipients with the consent of the advisory committee of Biomaster Trust. TMF Trust shall not exercise the voting rights attached to such ordinary shares unless otherwise directed by the advisory committee, whose members shall be appointed by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab.&lt;/div&gt; The Company has the power to direct the relevant activities of Biomaster Trust and it has the ability to use its power over the Biomaster Trust to affect its exposure to returns. Therefore, the assets and liabilities of the Biomaster Trust are included in the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Group&#x2019;s consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;(h) Surrender of stock options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;17, 2020, the Group completed its IPO. According to the amendments to 2017 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2017 Plan was changed to 9,609,084. Each of the Company&#x2019;s founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang surrendered 83,142 unvested stock options that were granted to him or her under 2017 Plan before, totally 332,566 unvested options, for no consideration, and these stock options were cancelled immediately. According to the amendments to 2018 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2018 Plan was changed to 11,005,888. The director of the Company, Dr.&#160;Jingwu Zhang Zang surrendered 2,544,917 unvested options that were granted to him under 2018 Plan, for no consideration, and these stock options were cancelled immediately. Upon the completion of the Company&#x2019;s IPO in January 2020, the Group has recorded RMB91,051 share-based compensation expense related to these surrendered options. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The stock options surrendered by the founders should be accounted for as capital contribution. As the founders did not get the title of the stock options to be surrendered and the number of stock options would not be determined until listing, the capital contribution was not accounted for during the year ended December&#160;31, 2019. For the year ended December&#160;31, 2020, the Group has reclassified RMB91,051 from additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital &#x2013; share-based compensation to additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital &#x2013; capital contribution relating to the stock options surrendered in the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;consolidated statement of comprehensive income. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-Based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left;"&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The allocation of share-based compensation expense was as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,056&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;470&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;284,431&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;43,591 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;514,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;209,033&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32,036 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; width: 67%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity in loss of an affiliate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: center; margin-left: 0.1in; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: center; margin-left: 0.15in; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;32,707&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;5,013&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 67%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 67%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,520&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;515,203&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;526,171&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;80,640 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 67%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P01_01_2016To12_31_2016_FoundersMembersrtTitleOfIndividualAxis"
      decimals="0"
      unitRef="Unit_shares">4019554</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P01_01_2016To12_31_2016_ThirdVentureMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis"
      decimals="0"
      unitRef="Unit_shares">369301</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P06_01_2016To06_30_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_CNY">18700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P06_01_2016To06_30_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">3650253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="P10_01_2016To10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">87441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="PAsOn10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">3932113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <imab:ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted
      contextRef="P10_01_2016To10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.70</imab:ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P10_01_2016To10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis"
      decimals="INF"
      unitRef="Unit_pure">0.20</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P10_01_2016To10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis"
      decimals="INF"
      unitRef="Unit_pure">0.20</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P10_01_2016To10_31_2016_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis"
      decimals="INF"
      unitRef="Unit_pure">0.30</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharePrice
      contextRef="PAsOn10_31_2016"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.77</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P10_31_2019To10_31_2019_FoundersMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">3520000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">1566000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expenses related to restricted shares were included in: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,056&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;470&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2,464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,096&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3,520&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">1056000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">470000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">2464000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">1096000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">3520000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">1566000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_CNY">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn10_31_2017_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">13376865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P10_01_2017To10_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P10_01_2017To10_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P10_01_2017To10_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2017To12_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_LeiFangMembersrtTitleOfIndividualAxis"
      decimals="0"
      unitRef="Unit_shares">130000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2017"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2017To12_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="1"
      unitRef="Unit_USD_per_Share">1.0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2018To12_31_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2019To12_31_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">640000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2019To12_31_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">1</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2018To12_31_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">1</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">6790924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2019To12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1439373</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"> &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the stock options activities of 2017 Plan for the periods presented: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Number&#160;of&lt;br/&gt; shares&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;br/&gt; US$&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&lt;br/&gt; term&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Aggregate&lt;br/&gt; intrinsic&lt;br/&gt; value&lt;br/&gt; US$&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;11,761,596&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;0.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;9.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;24,890&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,470,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(226,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;13,005,596&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;0.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;8.61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;70,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;640,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(397,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Repurchased (Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;(d))&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(3,435,215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31 ,2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;9,812,881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;0.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;7.76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;47,671&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(338,876&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(1,439,373&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;0.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Surrendered&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;(Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;(h))&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(332,566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31 ,2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;7,702,066&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;0.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;6.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;150,415&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;6,790,924&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;0.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;6.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;"&gt;132,650&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="PAsOn12_31_2016_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">11761596</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2016_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">P9Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2017_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">24890000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2018To12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2018To12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="P01_01_2018To12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">226000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2018To12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="PAsOn12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">13005596</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2018To12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">P8Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2018_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">70129000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2019To12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">640000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2019To12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="P01_01_2019To12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">397500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2019To12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased
      contextRef="P01_01_2019To12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">3435215</imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased>
    <imab:SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2019To12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.00</imab:SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="PAsOn12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">9812881</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2019To12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">P7Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">47671000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">338876</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1439373</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod
      contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">-332566</imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod>
    <imab:Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice
      contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_shares">1.00</imab:Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">7702066</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">P6Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">150415000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">6790924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">P6Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">132650000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">&lt;div style="text-align: left;"&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options granted to the employees were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0.75%;"/&gt;
&lt;td style="width: 0.75%;"/&gt;
&lt;td style="width: 1.5%;"/&gt;
&lt;td style="vertical-align: bottom;"/&gt;
&lt;td style="vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0.75%;;text-align:center;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0.75%; text-align: right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;61.32%-62.13&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;54.64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate (per annum)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0.75%;;text-align:center;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0.75%; text-align: right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.81%-3.06&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right;"&gt;2.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise multiple&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0.75%; padding: 0pt 0.5pt;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0.75%; padding: 0pt 0.5pt; text-align: right;"&gt;2.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1.5%; padding: 0pt 0.5pt;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right;"&gt;2.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0.75%;;text-align:center;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0.75%; text-align: right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1.5%;;text-align:center;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&#x2014;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contractual term (in years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; width: 0.75%;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0.75%; text-align: right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; width: 1.5%;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right;"&gt; &lt;div style="line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="P01_01_2018To12_31_2018_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.6132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="P01_01_2018To12_31_2018_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.6213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.5464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="P01_01_2018To12_31_2018_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0281</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="P01_01_2018To12_31_2018_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0306</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <imab:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple
      contextRef="PAsOn12_31_2018_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">2.80</imab:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple>
    <imab:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple
      contextRef="PAsOn12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">2.80</imab:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2019To12_31_2019_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      unitRef="Unit_pure"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2018To12_31_2018_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="P01_01_2020To12_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;A summa&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;r&lt;/div&gt;y of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; stock option activities for the year ended December&#160;31, 2020 is presented below: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Grant&#160;date&#160;fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2019&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;9,812,881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(6,790,924&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,439,373&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.37&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(338,876&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Surrendered&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(332,566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;911,142&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;4.96&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="PAsOn12_31_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">9812881</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">6790924</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">-1439373</imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares>
    <imab:Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_shares">1.37</imab:Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">338876</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.29</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <imab:Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">332566</imab:Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares>
    <imab:Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_shares">1.47</imab:Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">911142</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.96</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">52802000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">69213000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">4277000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_17_2020To01_17_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">9609084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="P01_17_2020To01_17_2020_SeniorManagementEmployeesMembersrtTitleOfIndividualAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">83142</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="P01_17_2020To01_31_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">332566</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn02_22_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">14005745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">15452620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2018"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P02_22_2019To02_22_2019_DrzangMembersrtTitleOfIndividualAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="1"
      unitRef="Unit_USD_per_Share">1.0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P02_22_2019To02_22_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P02_22_2019To02_22_2019_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P02_22_2019To02_22_2019_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="PAsOn02_22_2019_DirectorMembersrtTitleOfIndividualAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">10893028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased
      contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">454940</imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">365329000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the stock options activities of 2018 Plan for the years ended December&#160;31, 2019 and 2020: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Number&#160;of&lt;br/&gt; shares&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;br/&gt; US$&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&lt;br/&gt; term&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Aggregate&lt;br/&gt; intrinsic&lt;br/&gt; value&lt;br/&gt; US$&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of January&#160;1, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,991,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Repurchased (Note 1&lt;div style="display:inline;"&gt;7&lt;/div&gt;&#160;(d))&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(454,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,536,588&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;64,840&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(402,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#x2014; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Surrendered (Note 1&lt;div style="display:inline;"&gt;7&lt;/div&gt;&#160;(h))&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;"&gt;(2,544,917&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#x2014; &#160;&lt;/div&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;10,589,671&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;8.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;206,499&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;9,764,670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;8.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;190,411 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">13991528</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased
      contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">454940</imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased>
    <imab:SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.00</imab:SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="PAsOn12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">13536588</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">P8Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">64840000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">402000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod
      contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">-2544917</imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod>
    <imab:Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice
      contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_shares">1.00</imab:Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="PAsOn12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">10589671</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">P8Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">206499000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">9764670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">P8Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">190411000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options granted to certain directors and employees of the Group were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;54.64%-56.31&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate (per annum)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.15%-2.75&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise multiple&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contractual term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.5464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.5631</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <imab:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple
      contextRef="PAsOn12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">2.80</imab:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;A summa&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;r&lt;/div&gt;y of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; stock option activities for the year ended December&#160;31, 2020 is presented below: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant-date&#160;fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2019&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3,098,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;5.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(1,871,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;5.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(402,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.57&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;825,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;5.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 64%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="PAsOn12_31_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">3098500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.57</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1871500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.57</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">-402000</imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares>
    <imab:Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_shares">5.57</imab:Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">825000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.57</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">48055000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">65656000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">226000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_17_2020To01_17_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">11005888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="P01_17_2020To01_17_2020_SeniorManagementEmployeesMembersrtTitleOfIndividualAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">2544917</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="PAsOn02_22_2019_AmendedTwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis_DirectorMembersrtTitleOfIndividualAxis"
      decimals="0"
      unitRef="Unit_shares">3435215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased
      contextRef="P02_22_2019To02_22_2019_AmendedTwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis_DirectorMembersrtTitleOfIndividualAxis"
      decimals="0"
      unitRef="Unit_shares">3435215</imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased>
    <imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased
      contextRef="P01_01_2020To12_31_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">454940</imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased>
    <imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration
      contextRef="P02_22_2019To02_22_2019_DirectorMembersrtTitleOfIndividualAxis"
      decimals="-3"
      unitRef="Unit_USD">21902000</imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration>
    <imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration
      contextRef="P02_22_2019To02_22_2019_DirectorMembersrtTitleOfIndividualAxis"
      decimals="-3"
      unitRef="Unit_CNY">148308000</imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration>
    <imab:SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice
      contextRef="P02_22_2019To02_22_2019_DirectorMembersrtTitleOfIndividualAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.63</imab:SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_DirectorMembersrtTitleOfIndividualAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">21902000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_DirectorMembersrtTitleOfIndividualAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_CNY">148308000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn12_31_2020_TwentyNineteenShareIncentivePlanMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2020To12_31_2020_TwentyNineteenShareIncentivePlanMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">72000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2020To12_31_2020_TwentyNineteenShareIncentivePlanMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">72000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="P01_01_2020To12_31_2020_TwentyNineteenShareIncentivePlanMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.09</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_TwentyNineteenShareIncentivePlanMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1171000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the stock options activities of 2019 Plan for the year ended December&#160;31, 2020 presented: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;remaining&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;contractual&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;intrinsic&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;72,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6.09&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;72,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6.09&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9.33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,038&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">72000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="PAsOn12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">72000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">P9Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">1038000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;A summary of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; stock options activity for the year ended December&#160;31, 2020 is presented below: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant-date&#160;fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2019&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;72,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;72,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">72000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="PAsOn12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">72000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">&lt;div style="text-align: left;"&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options granted to the 3 independent directors were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 22%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 22%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;54.88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate (per annum)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 22%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.79&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise multiple&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 22%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contractual term (in years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 22%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="text-align: center;"&gt; &lt;div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-align: center;"&gt; &lt;div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.5488</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <imab:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple
      contextRef="PAsOn12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">2.80</imab:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2020To12_31_2020_TwentyNineteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn07_15_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">10760513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn07_15_2020_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">7686081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2020To12_31_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2020To12_31_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1068733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">4357000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">10435000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">1619000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="P01_01_2020To12_31_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">The following table sets forth the stock options activities of 2020 Plan for the year ended December&#160;31, 2020: &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;price&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;intrinsic&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;value&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;1,068,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.91&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;(24,365&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;5.91&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;1,044,368&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;5.91&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;9.62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;15,237&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1068733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">24365</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="PAsOn12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1044368</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis">P9Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">15237000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="P01_01_2020To12_31_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;A summary of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; stock option activities for the year ended December&#160;31, 2020 is presented below: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant-date&#160;fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2019&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,068,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(24,365&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,044,368&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 65in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1068733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">8.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">24365</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">8.65</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="PAsOn12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1044368</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">8.71</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2020To12_31_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">&lt;div style="text-align: left;"&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options granted to the employees were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 18%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;56.51&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate (per annum)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;0.86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise multiple&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.20-2.80&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73in;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Contractual term (in years)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18in;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0in;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0in;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="text-align: center;"&gt; &lt;div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.5651</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum
      contextRef="PAsOn12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">2.20</imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum>
    <imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum
      contextRef="PAsOn12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">2.80</imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2020To12_31_2020_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationTrancheFourMemberusgaapVestingAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <imab:NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">P30D</imab:NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares>
    <imab:MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_SecondOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</imab:MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2020To12_31_2020_OnePerformanceConditionMemberusgaapVestingAxis_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_TwoPerformanceConditionsMemberusgaapVestingAxis"
      decimals="2"
      unitRef="Unit_pure">0.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_ThreePerformanceConditionsMemberusgaapVestingAxis"
      decimals="2"
      unitRef="Unit_pure">0.60</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2020To12_31_2020_FourPerformanceConditionsMemberusgaapVestingAxis_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis"
      decimals="2"
      unitRef="Unit_pure">0.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <imab:NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_SecondOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">P30D</imab:NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ThirdOneThirdPortionMemberIMABPortionOfRestrictedShareUnitsAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-9"
      unitRef="Unit_USD">2000000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlan2020MemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">4093079</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">76663000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">71945000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">7500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the restricted share units of 2020 Plan for the year ended December&#160;31, 2020: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;restricted&lt;br/&gt; share units&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;remaining&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;contractual&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;intrinsic&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;4,093,079 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(13,461&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;4,079,618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;9.70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;83,632&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">4093079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">13461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">4079618</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis">P9Y8M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">83632000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;A summary of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; restricted share units activities for the year ended December&#160;31, 2020 is presented below: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;restricted&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;units&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant-date&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;fair value&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2019&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;4,093,079&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;13.99&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;(13,461&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;11.73&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 56%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;4,079,618 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;14.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 56%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">4093079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">13461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">4079618</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">14.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="P01_01_2020To12_31_2020_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1446875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1328120</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">25985000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">67182000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">19085000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">565200</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">558200</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the restricted share units subject to terms and conditions under 2018 Plan for the year ended December&#160;31, 2020: &lt;/div&gt;&lt;/div&gt; &lt;br/&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;restricted&lt;br/&gt; share units&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;remaining&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;contractual&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;intrinsic&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,328,120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;/div&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(565,200&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;762,920&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;9.65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;14,877&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1328120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">565200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">762920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis">P9Y7M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">14877000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyTwentyEmployeeStockOptionPlanMemberusgaapPlanNameAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;A summary of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; restricted share units activities for the year ended December&#160;31, 2020 is presented below: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;restricted&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;units&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant-date&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;fair value&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2019&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,328,120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13.34&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(565,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 56%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 56%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; at December&#160;31, 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;762,920&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12.89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 56%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1328120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">565200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">762920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn01_17_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">9609084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="P01_17_2020To01_17_2020_SeniorManagementEmployeesMembersrtTitleOfIndividualAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">83142</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="P01_17_2020To01_17_2020_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">332566</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_17_2020To01_17_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">11005888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="P01_17_2020To01_17_2020_SeniorManagementEmployeesMembersrtTitleOfIndividualAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">2544917</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_17_2020To01_17_2020_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_CNY">91051000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">91051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-align: left;"&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The allocation of share-based compensation expense was as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,056&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;470&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;284,431&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;43,591 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;514,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;209,033&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32,036 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; width: 67%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity in loss of an affiliate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: center; margin-left: 0.1in; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: center; margin-left: 0.15in; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;32,707&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;5,013&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 67%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 67%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,520&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;515,203&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;526,171&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;80,640 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 67%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_CNY">1056000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_CNY">470000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_CNY">284431000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">43591000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_CNY">2464000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_CNY">514733000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_CNY">209033000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">32036000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_CNY">32707000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_EquityInLossOfAnAffiliateMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">5013000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">3520000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">515203000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">526171000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">80640000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;div style="display:inline;"&gt;8&lt;/div&gt;. LICENSING AND COLLABORATION ARRANGEMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following is a description of the Group&#x2019;s significant licensing and collaboration agreements entered into from January&#160;1, 2017 to December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In-Licensing&lt;/div&gt; Arrangements &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licensing Agreement with MorphoSys AG (&#x201c;MorphoSys&#x201d;) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In November 2017, the Group entered into a license and collaboration agreement with MorphoSys, with respect to the development and commercialization of MOR202/TJ202, MorphoSys&#xb4;s proprietary investigational antibody against CD38 (the &#x201c;CD38 product&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under this agreement, MorphoSys granted to the Group an exclusive, royalty-bearing, sublicensable license to exploit MOR202/TJ202 for any human therapeutic or diagnostic purpose in the licensed territory, namely mainland China, Hong Kong, Macau and Taiwan (collectively &#x201c;Greater China&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to this agreement, the Group granted to MorphoSys an exclusive license to its rights in any inventions that the Group make while exploiting the CD38 product under this agreement, solely to exploit the CD38 product outside of Greater China. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to this agreement, the Group paid to MorphoSys an upfront license fee of US$20.0&#160;million (equivalent to approximately RMB132.7 million). The Group also agreed to make milestone payments to MorphoSys, conditioned upon the achievement of certain development, regulatory and commercial milestones, in the aggregate amount of US$98.5&#160;million (equivalent to approximately RMB653.5 million). Such milestones include first patient dosed in human clinical trials, marketing approval, and first annual net sales of CD38 products covered by the agreement in excess of a certain amount. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In addition, the Group is required to pay tiered &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-double-digit&lt;/div&gt; royalties to MorphoSys on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;country-by-country&lt;/div&gt;&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;product-by-product&lt;/div&gt;&lt;/div&gt; basis during the term, commencing with the first commercial sale of a relevant licensed product in Greater China. Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the expiration of the Group&#x2019;s last payment obligation under the agreement. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2017, the Group paid US$20.0&#160;million (equivalent to approximately RMB132.7 million) upfront fee to MorphoSys, which was recorded as research and development expense. No additional payments were made in 2018. Due to the uncertainty involved in meeting these developments and commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&#160;31, 2018. In March and April 2019, the project achieved the first and second milestone and the Group paid US$8.0&#160;million (equivalent to approximately RMB55.7 million) of milestone fees to MorphoSys, which was recorded as research and development expense in the consolidated statement of comprehensive loss for the year ended December&#160;31, 2019. No additional payments were made for the year ended December&#160;31, 2020 as no milestone has been achieved. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Summarized financial information related to the above agreement is presented below: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 41%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Year ended December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;As&#160;of&#160;December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Research and Development Expense&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Upfront&#160;Fees&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Milestones&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Extension/Termination&lt;br/&gt; of agreements&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Amortization&#160;of&#160;prepaid&lt;br/&gt; research and&lt;br/&gt; development&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Intangible&#160;asset&#160;balance&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 41%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; width: 41%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;US$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 41%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 41%; padding-bottom: 0.45pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 41%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In December 2017, the Group entered into an intellectual property agreement with Genexine with respect to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GX-I7/TJ107,&lt;/div&gt; a long-acting &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IL-7&lt;/div&gt; cytokine. Under this agreement, the Group obtained an exclusive, sublicensable and transferable license to use and otherwise exploit certain intellectual property in connection with the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; and clinical development, manufacturing, sale and distribution of GX-I7 to treat cancer in Greater China. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the terms of the agreement, the Group made an upfront payment of US$12.0&#160;million (equivalent to approximately RMB79.6 million) to Genexine which was recorded as a research and development expense in January 2018. The Group also agreed to make milestone payments in the aggregate amount of US$23.0&#160;million (equivalent to approximately RMB152.6 million), conditioned upon the achievement of certain development milestones, including completion of Phase 2 and Phase 3 clinical studies and new drug application (&#x201c;NDA&#x201d;) or biologic license application (&#x201c;BLA&#x201d;) approval in Greater China. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, the Group agreed to make milestone payments in the aggregate amount of US$525.0&#160;million (equivalent to approximately RMB3,482.7 million), conditioned upon the achievement of certain cumulative net sales of GX&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;-I7 &lt;/div&gt;&lt;/div&gt;up to US$2,000&#160;million. The Group also is required to pay Genexine a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-single-digit&lt;/div&gt; percentage royalty in respect of the total annual net sales of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GX-I7.&lt;/div&gt; The aforesaid milestones and royalties (other than the upfront payment) will be reduced by 50% following the entry of a generic version of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GX-I7&lt;/div&gt; in China, Hong Kong, Macau and Taiwan without the consent or authorization of the Group or any of the Group&#x2019;s sublicensees. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the later of (i)&#160;the expiry of the last to expire patent of the licensed intellectual property that includes a valid claim for Greater China and that covers the composition of GX-I7; and (ii) 15 years from the date of the first commercial sale of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GX-I7.&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No additional payments to Genexine were made in the year ended December&#160;31, 2019 and 2020. Due to the uncertainty involved in meeting these development and commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&#160;31, 2019 and 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Summarized financial information related to the above agreement is presented below: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 45%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Year ended December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;As&#160;of&#160;December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Research and Development Expense&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Upfront&#160;Fees&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Milestones&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Extension/Termination&lt;br/&gt; of agreements&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Amortization&#160;of&#160;prepaid&lt;br/&gt; research and&lt;br/&gt; development&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Intangible&#160;asset&#160;balance&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 45%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;US$&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;12,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 45%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In May 2020, the Group and Genexine entered into an amendment to this agreement whereby both parties desire to establish collaboration on TJ107 GBM Study in Greater China Under the terms of the expanded collaboration, the Group will be mainly responsible for using commercially reasonable efforts to conduct the Phase 2 GBM clinical trial in Greater China, and Genexine will share the development strategies, data and costs for success of this clinical trial. The Group shall undertake to bear &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-thirds&lt;/div&gt; (2/3) proportion of the clinical development costs and Genexine shall undertake to bear &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; (1/3) proportion of these costs. As of December&#160;31, 2020, the costs incurred for the development of this new indication was RMB4.3&#160;million and thus RMB2.9&#160;million expense was recorded in the consolidated statement of comprehensive income for the year ended December&#160;31, 2020. &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licensing Agreement with MorphoSys &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In November 2018, the Group entered into a license and collaboration agreement with MorphoSys for MorphoSys&#x2019;s proprietary antibody (MOR210/TJ210) directed against C5aR (the &#x201c;C5aR Agreement&#x201d;). Under this agreement, the Group obtained an exclusive, royalty-bearing license to explore, develop and commercialize certain anti-C5aR antibodies in Greater China and South Korea.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group will perform and fund all global development activities related to the development of MOR210/TJ210 in Greater China and South Korea, including all relevant clinical trials (including in the U.S. and China) and all development activities required for IND filing in the US as well as CMC development of manufacturing processes. MorphoSys retains rights in respect of development and commercialization of MOR210/TJ210 in the rest of the world. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Under the terms of the agreement, the Group also agreed to make milestone payments conditional upon the achievement of certain development milestones and certain annual net sales of anti-C5aR antibodies. The Group is also required to pay to MorphoSys tiered &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-single-digit&lt;/div&gt; royalties on annual net sales of anti-C5aR antibody products within the licensed territory. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2018, the Group paid US$3.5&#160;million (equivalent to approximately RMB23.2 million) upfront fee to MorphoSys, which was recorded as research and development expense in the consolidated statement of comprehensive loss for the year ended December&#160;31, 2018. No additional payments were made in the year ended December&#160;31, 2019. In August 2020, the project achieved the first milestone and the Group paid US$1.0&#160;million (equivalent to approximately RMB6.9 million) of milestone fees to Morphosys, which was recorded as research and development expenses in the consolidated statement of comprehensive income for the year ended December&#160;31, 2020. Due to the uncertainty involved in meeting these development and commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&#160;31, 2019 and 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Summarized financial information related to the above agreement is presented below: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 42%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Years Ended December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;As&#160;of&#160;December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Research and Development Expense&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Upfront&#160;Fees&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Milestones&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Extension/Termination&lt;br/&gt; of agreements&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Amortization&#160;of&#160;prepaid&lt;br/&gt; research and&lt;br/&gt; development&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Intangible&#160;asset&#160;balance&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 42%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;US$&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 42%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 42%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;US$&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;3,500&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 42%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licensing Agreement with MacroGenics &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In July 2019, the Group entered into a license and collaboration agreement with MacroGenics, Inc. for development and commercialization of an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fc-optimized&lt;/div&gt; antibody known as enoblituzumab that targets &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B7-H3,&lt;/div&gt; including in combination with other agents, such as the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;anti-PD-1&lt;/div&gt;&lt;/div&gt; antibody known as MGA012, in the People&#x2019;s Republic of China, Hong Kong, Macau and Taiwan&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;(&#x201c;Greater China&#x201d;). Under this agreement, the Group obtained an exclusive, sublicenseable, royalty-bearing license to MacroGenics&#x2019; patents and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; to develop and commercialize the enoblituzumab product, and a combination regimen of enoblituzumab and MGA012, in Greater China during the term of the agreement. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In exchange for these rights, in addition to certain financial consideration, the Group will grant to MacroGenics a royalty-free, sublicenseable, license outside of Greater China, to the patents and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; that are related to the enoblituzumab product or useful or necessary for MacroGenics to develop or commercialize the enoblituzumab product or a product containing MGA012, and combinations thereof. The license is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(i)&#160;non-exclusive&lt;/div&gt; with respect to the enoblituzumab product, and (ii)&#160;exclusive with regard to MGA012. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Pursuant to the agreement, the Group paid an upfront fee of US$15.0&#160;million (equivalent to approximately RMB104.4 million) to MacroGenics, which was recorded as research and development expense in the consolidated statement of comprehensive loss for the year ended December&#160;31, 2019. No additional payments were made in the year ended December&#160;31, 2020. Under the terms of the agreement, the Group also agreed to pay MacroGenics development milestone fees of up to US$75.0&#160;million and regulatory milestones fees of up to US$60.0&#160;million, respectively, and tiered double-digit royalties (ranging from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-teens&lt;/div&gt; to twenty percent) based on annual net sales in the territories. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group is responsible for all development costs in Greater China. MacroGenics is responsible for all development costs in the rest of the world, except that the Group is responsible for 20% of the costs incurred in (i) activities supporting global clinical trials in which the Group participates, (ii) certain CMC activities for material intended to be used in clinical trials in Greater China, and (iii) companion diagnostic development and validation for indications being studied in Greater China.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Due to the uncertainty involved in meeting these development and commercialization based targets, the Group evaluated and concluded that no milestones are probable as of December&#160;31, 2019 and 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 40%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Year ended December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;As&#160;of&#160;December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Research and Development Expense&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Upfront Fees&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Milestones&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Extension/Termination&lt;br/&gt; of agreements&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Amortization&#160;of&#160;prepaid&lt;br/&gt; research and&lt;br/&gt; development&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Intangible&#160;asset&#160;balance&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 40%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; width: 40%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 0%;"&gt;US$&lt;/td&gt;
&lt;td style="vertical-align: top; width: 0%;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 40%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other In-Licensing Arrangements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"&gt;In addition to the above arrangements, the Group has entered into other &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;various&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensing&lt;/div&gt; and collaboration agreements with third party licensors to develop and commercialize drug candidates. Based on the terms of these agreements the Group is contingently obligated to make additional material payments upon the achievement of certain contractually defined milestones. The Group recorded US$0.6&#160;million (equivalent to approximately RMB4.0 million) upfront fee and US$0.3&#160;million (equivalent to approximately RMB2.0 million) milestone payment under these agreements for the year ended December&#160;31, 2018. The Group recorded US$1.2&#160;million (equivalent to approximately RMB8.4 million) milestone payment during the year ended December&#160;31, 2019. The Group additionally recorded US$3.1&#160;million (equivalent to approximately RMB21.3 million) milestone payment during the year ended December&#160;31, 2020. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December 31, 2020, &lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;under the terms &lt;/div&gt;&lt;/div&gt; of the agreements, the licensors are eligible to receive from the Group up to an aggregate of approximately US$107.4&#160;million (equivalent to approximately RMB740.4 million) in milestone payments upon the achievement of contractually specified development milestones and sales milestones, such as regulatory approval for the drug candidates, which may be before the Group has commercialized the drug or received any revenue from sales of such drug candidate, which may never occur. &lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;B. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Out-Licensing&lt;/div&gt; and collaboration Arrangements &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licensing Agreement among HDYM, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; and Hangzhou HealSun Biopharm Co., Ltd. (&#x201c;HealSun&#x201d;) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In April 2017, one of the Company&#x2019;s subsidiaries, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Shanghai, entered into a technology transfer agreement with HDYM and HealSun with respect to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;anti-PD-L1&lt;/div&gt;&lt;/div&gt; humanized monoclonal antibodies. Under the agreement, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Shanghai agreed to grant to HDYM exclusive, worldwide and sublicensable rights to develop, manufacture, have manufactured, use, sell, have sold, import, or otherwise exploit certain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PD-L1&lt;/div&gt; related patents, patent applications, know-hows, data and information of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Shanghai, relevant cell lines as well as any &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;anti-PD-L1&lt;/div&gt;&lt;/div&gt; monoclonal antibody arising from such cell lines for the treatment of diseases. Further, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Shanghai and its cooperative party, HealSun agreed to provide subsequent research and development services on such intellectual property to HDYM, including the selection and examination of innovative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;anti-PD-L1&lt;/div&gt;&lt;/div&gt; humanized monoclonal antibodies, cultivation and selection of stable cell lines, establishment of cell bank, research and development of manufacturing processes and preparation of samples, toxicological and pharmacological testing, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; pharmaceutical experiment report drafting, and application for and registration of clinical trials. HDYM agreed to make milestone payments conditioned upon achieving certain contractually defined milestones. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group determined that this collaboration is reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, due to the early stage nature of the development, in which the underlying intellectual property is significantly modified by the development activities being performed, the Group determined the license to the intellectual property and research and development services are not distinct and thus were accounted for as a single performance obligation that is satisfied over time. The Group would receive RMB51.0&#160;million (inclusive of VAT) milestone payments under this agreement, and considered that the achievements of milestone II, III, IV are constrained such that the transaction price shall initially only include the milestones payment which have been achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone payment shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Group used a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; input method to measure progress as that method best depicts its performance under the agreement. For the year ended December&#160;31, 2017, the Group achieved milestones I and II and received milestone payments totaling of RMB29.0&#160;million (inclusive of VAT). The cumulative percentage complete in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; input method related to this agreement as of December&#160;31, 2017 is estimated to approximate 42%, the Group recognized RMB11.6&#160;million (exclusive of VAT of RMB0.7 million) of revenue in the consolidated statement of comprehensive loss, and RMB15.8&#160;million (exclusive of VAT of RMB0.9 million) were deferred as contract liability related to this arrangement. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;During the year ended December&#160;31, 2018, the Group achieved milestones III and IV and received milestone III payment of RMB11.0&#160;million (inclusive of VAT), milestone IV payment of RMB 11.0&#160;million (inclusive of VAT) was recognized as contract assets as of December&#160;31, 2018. As of December&#160;31, 2018, the cumulative percentage complete in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to&lt;/div&gt; cost input method related to this arrangement is estimated to approximate 100%. The Group recognized RMB36.5&#160;million (exclusive of VAT of RMB1.3 million) of revenue in the consolidated statement of comprehensive loss for the year ended December&#160;31, 2018. All of the milestone payments were received by the Group as of December&#160;31, 2019. &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Collaboration Agreement with Everest (&#x201c;Everest&#x201d;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"&gt;In January 2018, the Group entered into a collaboration agreement with Everest, which is controlled by the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ultimate &lt;/div&gt;controlling party of a principal shareholder of the Group. Under the agreement, both parties agreed to collaborate on programs to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-develop&lt;/div&gt; MorphoSys&#x2019; proprietary anti-CD38 antibody for all indications in hematologic oncology and commercialize of MOR202/TJ202 in Greater China. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A joint steering committee with equal representation from each party was established to coordinate and oversee the development and commercialization of the CD38 product. All decisions of the joint steering committee shall be made by unanimous vote. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the agreement, the Group is primarily responsible for carrying out the development, manufacture and supply of the CD38 product, as well as seeking regulatory approval of the CD38 product. Everest is primarily responsible for sharing the development costs of the CD38 product, including payments due to MorphoSys under the Licensing Agreement, dated November 30, 2017, in the proportion of 75% by Everest and 25% by the Group.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The joint steering committee will decide which party shall be responsible for conducting the commercialization of the CD38 product pursuant to the commercialization plan approved by the committee. If Everest is selected to be responsible for commercialization, the Group shall grant an exclusive royalty-free license to Everest to commercialize the CD38 product for all indications in hematologic oncology in Greater China. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Group and Everest will share the profit and loss and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-licensing&lt;/div&gt; revenue derived from the CD 38 product in proportion to the costs that each party incur in developing the product. The parties will also split &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-license&lt;/div&gt; revenue according to the proportion of development costs incurred, with the Group getting an additional five percent (5%) share and Everest receiving five percent (5%) less. Everest cannot share in any profit from the commercialization of CD38 product until it has fulfilled its payment obligations under this agreement. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Upon any termination of this arrangement, the terminating party has the right to continue the development and commercialization of CD38 product. If Everest is the rightful terminating party, the Group shall reasonably cooperate with Everest to facilitate the following: (i)&#160;assign the MorphoSys license to Everest (subject to the terms and conditions of such license); (ii) grant to Everest an exclusive license to all intellectual property rights that the Group owns or controls to further develop, manufacture, and commercialize the CD38 product; (iii)&#160;transfer the development, manufacture and commercialization of the CD38 product to Everest. The terminating party shall be solely responsible for the cost and expense of such development and commercialization after termination. In the event that such continuing party successfully develops and commercializes the CD38 product, it shall pay to the other party a percentage of the product profit and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-license&lt;/div&gt; revenue generated therefrom in accordance with the terms of this agreement. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2018, the US$26.0&#160;million in aggregate proceeds from Everest under the agreement represented the funding available under the agreement, and was recorded as a research and development funding received liability (equivalent to approximately RMB178.7 million) on the consolidated balance sheet as of December&#160;31, 2018, in accordance with ASC 730, Research and Development. Because there is a significant related party relationship between the Group and Everest, the Group is treating its obligation to make payments under the commercialization stage as an implicit obligation to repay the funds advanced by Everest (see Note 2&lt;div style="display:inline;"&gt;3&lt;/div&gt;). During the year ended December&#160;31, 2019, an additional US$7.6million (equivalent to approximately RMB53.1 million) of funding was received and recorded as a research and development funding received liability. No additional milestone has been achieved in the year ended December&#160;31, 2019. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman;font-size: 10pt;margin-top: 6pt;margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On November&#160;4, 2019, the Group and Everest have terminated the collaboration agreement with respect to the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-development&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and commercialization of TJ202 in Greater China. Upon the termination, Everest will not retain any rights or entitlements to develop or commercialize TJ202 or any economic interest in its commercialization. All intellectual property rights in respect of TJ202 arising from its development under the collaboration agreement are vested and owned by &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab,&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and the Group holds all intellectual property rights and have maximum flexibility to further develop, manufacture and commercialize TJ202 in Greater China. In consideration of the above arrangements, the board of directors of the Group has approved the issuance of a total value of US$&lt;/div&gt;37.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of ordinary shares (the &#x201c;CPP Shares&#x201d;) to Everest, representing Everest&#x2019;s historical contribution to the collaboration and the associated time cost. The CPP Shares will be issued concurrently with, and subject to, the completion of the Company&#x2019;s initial public offering within 180 days from termination of the collaboration agreement. The total value of US$&lt;/div&gt;37.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million was calculated based on the sum of (1)&#160;US$&lt;/div&gt;33.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, which equals cumulative &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; contributions historically made by Everest under the collaboration agreement; and (2)&#160;a negotiated US$&lt;/div&gt;3.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million time cost of the foregoing historical contribution in light of &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&#x2019;s&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; exclusive rights over the commercialization of TJ202 after this termination. The issuance of the CPP Shares was approved by &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&#x2019;s&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; existing shareholders on December&#160;25, 2019. In the event that the initial public offering has not been completed within 180 days from the termination of the collaboration agreement, the Company will issue &lt;/div&gt;4,762,751&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; ordinary shares (the &#x201c;Subject Shares&#x201d;) to Everest on the 181st day. As a result of the aforementioned termination of the collaboration agreement with Everest, the Group derecognized the research and development funding received from Everest and recognized a liability that represented the ordinary shares to be issued to Everest, which was measured at fair value in accordance with ASC 480, and the difference of US$&lt;/div&gt;3.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million (equivalent to approximately RMB&lt;/div&gt;23.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; million) between the initial fair value of the liability and the carrying amount of research and development funding received was recognized as other expenses in the consolidated statements of comprehensive loss for the year ended December&#160;31, 2019. Upon the completion of the IPO in January 2020, the Group issued &lt;/div&gt;6,078,571&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; ordinary shares to Everest.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licensing Agreement with ABL Bio &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2018, the Group entered into a license and collaboration agreement with ABL Bio, under which the Group granted to ABL Bio exclusive, worldwide (excluding Greater China), royalty-bearing rights to develop and commercialize a bispecific antibody (&#x201c;BsAb&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group agreed to share costs fifty-fifty (50:50) with ABL Bio through the completion of in vivo studies, with ABL Bio responsible for all costs and activities following that time. For the year ended December&#160;31, 2019, US$0.2&#160;million (equivalent to approximately RMB1.4 million) expenses were incurred by ABL Bio. Accordingly, the Group recorded US$0.1&#160;million (equivalent to approximately RMB0.7 million) &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&lt;/div&gt;50% cost sharing) of expenses in the Group&#x2019;s consolidated statement of comprehensive loss for the year ended December&#160;31, 2019. For the year ended December&#160;31, 2020, US$0.04&#160;million (equivalent to approximately RMB0.28 million) expenses were incurred by ABL Bio. Accordingly, the Group recorded US$0.02&#160;million (equivalent to approximately RMB0.14 million) &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&lt;/div&gt;50% cost sharing) of expenses in the Group&#x2019;s consolidated statement of comprehensive income for the year ended December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Pursuant to the license and collaboration agreement that signed in July 2018 and memorandum of understanding that subsequently entered into with ABL Bio in January 2020, ABL Bio agreed to pay the Group an upfront fee of US$2.5&#160;million (equivalent to approximately RMB17.2 million), and milestone payments in the aggregate amount of US$97.5&#160;million (equivalent to approximately RMB690.3 million) conditioned upon achieving certain research, clinical development and sales milestones. These include clinical milestones of up to US$32.5&#160;million (equivalent to approximately RMB230.1 million) and sales milestones of up to US$65&#160;million (equivalent to approximately RMB460.2 million). Further, ABL Bio agreed to pay the Group royalties at &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-single-digit&lt;/div&gt; percentages in respect of the total annual net sales of the licensed BsAb product. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, ABL Bio granted to the Group an exclusive, royalty-free, sublicensable license to use the BsAb technology solely to exploit the licensed BsAb product for all indications in Greater China. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group determined that this collaboration is reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, the only one performance obligation was to grant the BsAb license to ABL Bio. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Achievement of milestones that are not within the control of the Group or the licensee, such as regulatory approvals, are not considered probable until the approvals are achieved. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group recognized revenue of US$2.5&#160;million (equivalent to RMB17.2 million) of revenue in the consolidated statements of comprehensive loss for the year ended December&#160;31, 2018, which was the upfront fee related to the grant of the rights of BsAb to ABL Bio as mentioned above. As of December&#160;31, 2019 and 2020, no other milestone has been achieved. No revenue was recognized for the year ended December&#160;31, 2019 and 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December 4, 2020, I-Mab Hong Kong, ABL Bio and I-Mab Hangzhou entered into an amendment, which is made effective as of September 15, 2020, that I-Mab Hong Kong, as the subject of the aforementioned licensing agreement, shall be replaced and substituted by I-Mab Hangzhou&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Collaboration Agreement with ABL Bio &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In July 2018, the Group and ABL Bio entered into a collaboration agreement (the &#x201c;ABL Bio Collaboration&#x201d;) whereby both parties agreed to collaborate to develop three &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PD-L1&lt;/div&gt; based bispecific antibodies by using ABL Bio&#x2019;s proprietary BsAb technology and commercialize them in their respective territories, which, collectively, include Greater China and South Korea, and other territories throughout the rest of the world if both parties agree to do so in such other territories during the performance of the agreement. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;At contract inception, as both &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; and ABL Bio participate actively in the research and development activity. Also, the parties share the risk of failure of the BsAb products and share the income of licensing, so this contract meet the criteria of the definition of a collaborative arrangement, the Group categorized this agreement within the scope ASC 808. Prior to commercialization, the Group recorded the share of the expenses incurred by the collaboration for the development of three &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PD-L1&lt;/div&gt; based bispecific antibodies products in research and development expense in the consolidated &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;statements of comprehensive income (loss).&lt;/div&gt; As of December&#160;31, 2018, RMB1.0&#160;million expenses were incurred by the Group and ABL Bio did not incur any expense. According to the terms set out in the agreement, the Group recorded RMB0.5&#160;million &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&lt;/div&gt;50% cost sharing) of expense in the Group&#x2019;s consolidated statement of comprehensive loss for the year ended December&#160;31, 2018. For the year ended December&#160;31, 2019, RMB11.2&#160;million expenses were incurred by the Group and RMB8.0&#160;million expenses were incurred by ABL Bio. Accordingly, the Group recorded RMB9.6&#160;million (50% cost sharing) of expenses in the Group&#x2019;s consolidated statement of comprehensive loss for the year ended December&#160;31, 2019. For the year ended December&#160;31, 20&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt;, RMB43.6&#160;million expenses were incurred by the Group and RMB44.0&#160;million expenses were incurred by ABL Bio. Accordingly, the Group recorded RMB43.8&#160;million (50% cost sharing) of expenses in the Group&#x2019;s consolidated statement of comprehensive income for the year ended December&#160;31, 2020. &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Collaboration Agreements with Tracon Pharmaceuticals, Inc. (&#x201c;Tracon&#x201d;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In November 2018, the Group entered into collaboration agreements with Tracon, under which both parties agreed to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-develop&lt;/div&gt; the Group&#x2019;s proprietary CD73 antibody, TJD5 (the &#x201c;TJD5 Agreement&#x201d;) and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-develop&lt;/div&gt; up to five BsAbs (the &#x201c;BsAbs Agreement&#x201d;). Both agreements may be terminated by either party for the other party&#x2019;s uncured material breach, bankruptcy or insolvency or for safety reasons. In addition, the agreement in respect of TJD5 may be terminated by the Group: (i)&#160;for convenience within a certain period upon completing different clinical stages subject to certain payments and royalties, based on the clinical stage, that would be owed to Tracon upon the exercise of such termination for convenience; (ii)&#160;in the event that Tracon causes the Phase 1 study timeline to be delayed beyond the agreed extension periods; or (iii)&#160;if the Group decides to end the development of the collaborative product prior to its first commercial sale. Further, prior to the first commercial sale, Tracon may deem this agreement to be terminated by the Group if it reasonably believes that the Group has discontinued all meaningful development of the collaborative product for at least 12 months and certain other conditions are met. Additionally, in March 2019, the Group agreed with Tracon and F. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hoffmann-La&lt;/div&gt; Roche Ltd (&#x201c;Roche&#x201d;) on a clinical supply agreement for Roche to supply atezolizumab for use in clinical studies under the collaboration agreement with Tracon. As of December&#160;31, 2019, no payments or royalties are due under this agreement. As of December&#160;31, 2019, the Group has recorded US$4.0&#160;million (equivalent to approximately RMB27.8 million) of research and development costs in the consolidated statement of comprehensive loss for the year ended December&#160;31, 2019. As of December&#160;31, 2020, the Group has recorded US$0.03&#160;million (equivalent to approximately RMB0.17 million) of research and development costs in the consolidated statement of comprehensive &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;income for the year ended December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left;"&gt;&lt;div style="text-align: left;"&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In April 2020, Tracon issued a notice of disputes with respect to the TJD5 Agreement and the BsAbs Agreement. As of the date of this report, these disputes have not been resolved.&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licensing Agreement with CSPC Pharmaceutical Group Limited (&#x201c;CSPC&#x201d;) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In December 2018, the Group entered into a product development agreement with CSPC. The Group granted to CSPC exclusive, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-transferable,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-irrevocable&lt;/div&gt; and sublicensable rights in the PRC (excluding Hong Kong, Macau and Taiwan) to develop and commercialize TJ103 for treating type 2 diabetes. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CSPC is responsible for developing, obtaining market approval and commercializing the licensed products. The Group is responsible for transferring the manufacturing technology of the licensed products to CSPC and assisting CSPC in the continued optimization of such manufacturing technology thereafter. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In consideration of the license, CSPC agreed to pay the Group an upfront fee of RMB15.0&#160;million and milestone payments in an aggregate amount of RMB135.0&#160;million conditioned upon achieving certain clinical development and regulatory approval milestones. In addition, the Group is also entitled to royalties of up to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-double-digit&lt;/div&gt; percentages in respect of the total annual net sales of the products after its commercialization in the PRC. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group determined that this collaboration is more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, the only one performance obligation was to grant TJ103 license to CSPC. Considering that the achievements of milestones are constrained such that the transaction price shall initially only include upfront payment and subsequently, once another milestone was achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone payment shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. As of December&#160;31, 2018, the amount received of RMB14.2&#160;million (net of VAT) was recorded as advance from customers in the consolidated balance sheet. In February 2019, an additional amount of RMB0.8&#160;million (net of VAT) was received, and the license was also approved by China intellectual property office in May 2019. The first milestone was achieved in September 2019 and the amount of RMB15.0&#160;million (net of VAT) was received according to the terms of the agreement. Accordingly, RMB30.0&#160;million was recognized as revenue in the consolidated statements of comprehensive loss for the year ended December&#160;31, 2019. No additional revenue was recognized in the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;year&lt;/div&gt;&#160;ended December&#160;31, 2020 as no further milestone has been achieved. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 6pt;"&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In &lt;/div&gt;March 2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Group entered into a strategic partnership with Kalbe Genexine Biologics (&#x201c;KG Bio&#x201d;) to grant a right of first negotiation for an exclusive license for the development and commercialization of &lt;/div&gt;two&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab-discovered&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; product candidates: uliledlimab, a highly differentiated anti-CD&lt;/div&gt;73&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; antibody in Phase &lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; development for advanced solid tumors (&#x201c;First Program&#x201d;), and an &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; product candidate (&#x201c;Second Program&#x201d;) to be agreed upon by both parties in certain regions. Through this agreement, both parties intend to negotiate the terms that will be reflected in definitive agreements for each prospective program covered under this agreement.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;If and when the Group and KG Bio enter into the definitive licensing agreement, the Group will be eligible to receive from KG Bio an aggregate amount of up to approximately US$340&#160;million, including an upfront payment and subsequent payments conditional upon achieving certain development and commercial milestones. KG Bio will pay the Group tiered royalties in the low to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-teen&lt;/div&gt; percentages on net sales from certain regions. As the right of first negotiation has not been exercised and the definitive agreement has not been entered into as of December&#160;31, 2020, no revenue was recognized during the year ended December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Global Strategic Partnership with AbbVie &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On September&#160;3, 2020, the Group, through &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Biopharma (Shanghai) Co., Ltd. and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Biopharma US Limited, each a wholly-owned subsidiary of the Group, entered into a broad global strategic partnership with AbbVie Ireland Unlimited Group (&#x201c;AbbVie&#x201d;). &lt;/div&gt; &lt;div style="text-align: left;"&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to this collaboration, the Group will grant AbbVie a global license, excluding Mainland China, Macau, and Hong Kong, to develop and commercialize lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; for the treatment of multiple cancers. The Group will retain all rights to develop and commercialize lemzoparlimab (as well as certain other compounds directed against CD47) in Mainland China, Macau, and Hong Kong. The Group is also responsible for performing the development activities at its sole cost and expense as outlined in the initial development plan. Such initial development activities consist of two studies, Study I and Study II. Study I is conducted in the United States evaluating lemzoparlimab in combination with pembrolizumab or rituximab in patients with relapsed or refractory solid tumors and lymphoma. Study II is conducted in Mainland China evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of lemzoparlimab in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). AbbVie will conduct further global clinical trials (which the Group may elect to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-fund)&lt;/div&gt; to evaluate lemzoparlimab in multiple cancers. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Potential collaboration on future CD47-related therapeutic agents is also allowed for under this arrangement, including CD47-based bispecific antibodies and combination therapies with lemzoparlimab and AbbVie&#x2019;s venetoclax (Venclexta&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt;). Each party will have the opportunity, subject to rights of first negotiation to further licenses, to explore certain of each other&#x2019;s related CD47-antibody programs in their respective territories.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A joint governance committee was established as set forth in the agreement, functioning as an oversight and governance mechanism. Both parties will participate in the joint governance committee to facilitate decision-making during the terms of the collaborative endeavor. Furthermore, the Group and AbbVie will share manufacturing responsibilities, with AbbVie having the opportunity to manufacture supply outside of Mainland China, Hong Kong and Macau and the Group being the primary manufacturer for supply for Mainland China, Hong &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kong and Macau. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center;"&gt;&lt;div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;F-7&lt;div style="display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon the satisfaction of all the pre-effect date covenants, the collaborative agreement took effect on December 10, 2020, on which date the Group was entitled to a non-refundable upfront payment of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;US$180&#160;million. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition,&lt;/div&gt;&#160;the Group &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;is&lt;/div&gt;&#160;eligible to receive up to US$1.76&#160;billion in further success-based development, regulatory and sales milestone payments for lemzoparlimab, of which US$840&#160;million are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestones. Upon commercialization of lemzoparlimab, AbbVie will also pay tiered royalties&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;from low-to-mid teen double-digit percentages on global net sales outside of Mainland China, Macau, and Hong Kong.&#160;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group identified three performance obligations: (1)&#160;grant of lemzoparlimab license upon the effective date, (2)&#160;delivering the Study I initial development services, and (3)&#160;delivering the Study II initial development services. The total transaction price under the agreement for the year ended December&#160;31, 2020 is US$250&#160;million consisting of (i)&#160;the upfront payment of US$180&#160;million upon the effective date, (ii)&#160;the first milestone payment of US$20&#160;million upon the achievement of the first milestone event in late December 2020, and (iii)&#160;the second milestone payment of US$50&#160;million as of December&#160;31, 2020 as the Group deemed that the achievement of the second milestone event is probable as of December&#160;31, 2020 that a significant reversal of revenue would not occur. The achievements of the remaining development and regulatory based milestone events are constrained as of December&#160;31, 2020, and will be included in the transaction price when uncertainty associated with the variable consideration is subsequently resolved. Sales-based milestones and royalties will be recognized when the subsequent sales occur. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The non-constrained consideration of US$250&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million is then allocated to the three performance obligations based on the relative stand-alone selling price. For the grant of lemzoparlimab license, the Group adopted an income approach based on key assumptions and several factors including, but not limited to estimated market demand, stand-alone selling price by making reference to market comparable, development timeline, regulatory risks, future revenue potential and discount rate.&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The allocated price is US$228.8 million. The entire US$228.8&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million (equivalent to approximately RMB1,502.9 million) was recognized&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;as revenue at&lt;/div&gt; the point of the license transfer at the effective date. For the Study I and Study II initial development services, a cost-plus margin approach is utilized. The allocated price to Study I and Study II is&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;US$&lt;/div&gt;11.0 &lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and US$10.2 million respectively. These two performance obligations are determined to be satisfied over time. The Group uses a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; input method to measure progress as that method best depicts the transfer of the two performance obligations under the agreement. As of December&#160;31, 2020, the cumulative percentages complete in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; input method for Study I and Study II&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;wer&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;e&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;estimated to approximate 17 % and 41 % respectively. As a result, US$1.8&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million (equivalent to approximately RMB12.0 million)&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;and US$&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;4.2&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million (equivalent to approximately RMB27.8 million)&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;were&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; recognized as revenue for the year ended December&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;31&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; in the consolidated statement of comprehensive income for Study I and Study II respectively, resulting in a contract asset of &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;34.8&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;for this agreement as of December&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;31&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; in the consolidated balance sheets. As of December&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;31&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the upfront payment of US$&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;180&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million was received by the Group. The &lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;st milestone payment of US$&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million was subsequently &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;collected by the Group in March 2021. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <imab:UpfrontLicenseFee
      contextRef="P11_17_2017To11_17_2017_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000.0</imab:UpfrontLicenseFee>
    <imab:UpfrontLicenseFee
      contextRef="P11_17_2017To11_17_2017_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis"
      decimals="-5"
      unitRef="Unit_CNY">132700000</imab:UpfrontLicenseFee>
    <imab:MilestonePayments
      contextRef="P11_17_2017To11_17_2017_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis"
      decimals="-5"
      unitRef="Unit_USD">98500000</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P11_17_2017To11_17_2017_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis"
      decimals="-5"
      unitRef="Unit_CNY">653500000</imab:MilestonePayments>
    <imab:UpfrontLicenseFee
      contextRef="P01_01_2017To12_31_2017_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000.0</imab:UpfrontLicenseFee>
    <imab:UpfrontLicenseFee
      contextRef="P01_01_2017To12_31_2017_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_CNY">132700000</imab:UpfrontLicenseFee>
    <imab:UpfrontLicenseFee
      contextRef="P01_01_2018To12_31_2018_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">0</imab:UpfrontLicenseFee>
    <imab:MilestonePayments
      contextRef="P01_01_2019To12_31_2019_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">8000000.0</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P01_01_2019To12_31_2019_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_CNY">55700000</imab:MilestonePayments>
    <imab:UpfrontLicenseFee
      contextRef="P01_01_2020To12_31_2020_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphoSysAGMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">0</imab:UpfrontLicenseFee>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="P01_01_2020To12_31_2020_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Summarized financial information related to the above agreement is presented below: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 41%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Year ended December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;As&#160;of&#160;December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Research and Development Expense&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Upfront&#160;Fees&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Milestones&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Extension/Termination&lt;br/&gt; of agreements&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Amortization&#160;of&#160;prepaid&lt;br/&gt; research and&lt;br/&gt; development&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Intangible&#160;asset&#160;balance&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 41%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; width: 41%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;US$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 41%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 41%; padding-bottom: 0.45pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 41%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <imab:MilestonePayments
      contextRef="P01_01_2019To12_31_2019_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">8000000</imab:MilestonePayments>
    <imab:UpfrontLicenseFee
      contextRef="P01_01_2020To12_31_2020_GenexineIncMembersrtCounterpartyNameAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">12000000.0</imab:UpfrontLicenseFee>
    <imab:UpfrontLicenseFee
      contextRef="P01_01_2020To12_31_2020_GenexineIncMembersrtCounterpartyNameAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_CNY">79600000</imab:UpfrontLicenseFee>
    <imab:MilestonePayments
      contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">23000000.0</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_CNY">152600000</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">525000000.0</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">3482700000</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Gxi7MembersrtProductOrServiceAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000000</imab:MilestonePayments>
    <imab:PercentageOfReductionInMilestonePayments
      contextRef="P01_01_2018To01_01_2018_GenexineIncMembersrtCounterpartyNameAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</imab:PercentageOfReductionInMilestonePayments>
    <us-gaap:LongtermPurchaseCommitmentPeriod contextRef="P01_01_2018To01_31_2018_GenexineIncMembersrtCounterpartyNameAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis">P15Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="P01_01_2020To12_31_2020_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Summarized financial information related to the above agreement is presented below: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 45%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Year ended December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;As&#160;of&#160;December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Research and Development Expense&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Upfront&#160;Fees&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Milestones&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Extension/Termination&lt;br/&gt; of agreements&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Amortization&#160;of&#160;prepaid&lt;br/&gt; research and&lt;br/&gt; development&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Intangible&#160;asset&#160;balance&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 45%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;US$&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;;text-align:right;"&gt;12,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 45%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <imab:LicensingAgreementUpfrontFees
      contextRef="P01_01_2018To12_31_2018_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">12000000</imab:LicensingAgreementUpfrontFees>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020_GenexineIncMembersrtCounterpartyNameAxis"
      decimals="-5"
      unitRef="Unit_CNY">4300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020_GenexineIncMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_CNY">2900000</us-gaap:ResearchAndDevelopmentExpense>
    <imab:UpfrontLicenseFee
      contextRef="P01_01_2018To12_31_2018_LicensingAgreementsWithMorphosysMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">3500000</imab:UpfrontLicenseFee>
    <imab:UpfrontLicenseFee
      contextRef="P01_01_2018To12_31_2018_LicensingAgreementsWithMorphosysMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_CNY">23200000</imab:UpfrontLicenseFee>
    <imab:UpfrontLicenseFee
      contextRef="P01_01_2019To12_31_2019_LicensingAgreementsWithMorphosysMemberusgaapTypeOfArrangementAxis_MorphosysMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">0</imab:UpfrontLicenseFee>
    <imab:MilestonePayments
      contextRef="P08_01_2020To08_31_2020_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphoSysAGMembersrtCounterpartyNameAxis"
      decimals="-5"
      unitRef="Unit_USD">1000000.0</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P08_01_2020To08_31_2020_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_MorphoSysAGMembersrtCounterpartyNameAxis"
      decimals="-5"
      unitRef="Unit_CNY">6900000</imab:MilestonePayments>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="P01_01_2020To12_31_2020_LicensingAgreementWithMorphosysMemberusgaapTypeOfArrangementAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Summarized financial information related to the above agreement is presented below: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 42%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Years Ended December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;As&#160;of&#160;December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Research and Development Expense&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Upfront&#160;Fees&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Milestones&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Extension/Termination&lt;br/&gt; of agreements&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Amortization&#160;of&#160;prepaid&lt;br/&gt; research and&lt;br/&gt; development&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Intangible&#160;asset&#160;balance&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 42%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;US$&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 42%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 42%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;US$&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:right;"&gt;3,500&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 42%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <imab:MilestonePayments
      contextRef="P01_01_2020To12_31_2020_LicensingAgreementWithMorphosysMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000</imab:MilestonePayments>
    <imab:LicensingAgreementUpfrontFees
      contextRef="P01_01_2018To12_31_2018_LicensingAgreementWithMorphosysMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">3500000</imab:LicensingAgreementUpfrontFees>
    <imab:UpfrontLicenseFee
      contextRef="P01_01_2019To12_31_2019_LicensingAgreementWithMacrogenicsMemberusgaapTypeOfArrangementAxis_MacroGenicsMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000.0</imab:UpfrontLicenseFee>
    <imab:UpfrontLicenseFee
      contextRef="P01_01_2019To12_31_2019_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MacroGenicsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_CNY">104400000</imab:UpfrontLicenseFee>
    <imab:MilestonePayments
      contextRef="P01_01_2020To12_31_2020_DevelopmentMilestoneMemberIMABMilestoneTypeAxis_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_MacroGenicsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">75000000.0</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P01_01_2020To12_31_2020_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MacroGenicsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MinimumMembersrtRangeAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">60000000.0</imab:MilestonePayments>
    <us-gaap:CollaborativeArrangementRightsAndObligations contextRef="P01_01_2020To12_31_2020_LicensingAgreementWithMacrogenicsMemberusgaapTypeOfArrangementAxis_MacroGenicsMembersrtCounterpartyNameAxis">The Group is responsible for all development costs in Greater China. MacroGenics is responsible for all development costs in the rest of the world, except that the Group is responsible for 20% of the costs incurred in (i) activities supporting global clinical trials in which the Group participates, (ii) certain CMC activities for material intended to be used in clinical trials in Greater China, and (iii) companion diagnostic development and validation for indications being studied in Greater China.</us-gaap:CollaborativeArrangementRightsAndObligations>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="P01_01_2020To12_31_2020_LicensingAgreementWithMacrogenicsMemberusgaapTypeOfArrangementAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Due to the uncertainty involved in meeting these development and commercialization based targets, the Group evaluated and concluded that no milestones are probable as of December&#160;31, 2019 and 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 40%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;
&lt;td style="width: 0%;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Year ended December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;As&#160;of&#160;December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Research and Development Expense&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Upfront Fees&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Milestones&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Extension/Termination&lt;br/&gt; of agreements&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Amortization&#160;of&#160;prepaid&lt;br/&gt; research and&lt;br/&gt; development&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;Intangible&#160;asset&#160;balance&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 40%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; width: 40%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 0%;"&gt;US$&lt;/td&gt;
&lt;td style="vertical-align: top; width: 0%;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 40%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 0%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 0%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <imab:LicensingAgreementUpfrontFees
      contextRef="P01_01_2019To12_31_2019_LicensingAgreementWithMacrogenicsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">15000000</imab:LicensingAgreementUpfrontFees>
    <imab:UpfrontLicenseFee
      contextRef="P01_01_2018To12_31_2018_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">600000</imab:UpfrontLicenseFee>
    <imab:UpfrontLicenseFee
      contextRef="P01_01_2018To12_31_2018_OtherInLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-5"
      unitRef="Unit_CNY">4000000.0</imab:UpfrontLicenseFee>
    <imab:MilestonePayments
      contextRef="P01_01_2018To12_31_2018_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">300000</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P01_01_2018To12_31_2018_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">2000000.0</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P01_01_2019To12_31_2019_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">1200000</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P01_01_2019To12_31_2019_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">8400000</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P01_01_2020To12_31_2020_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">3100000</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P01_01_2020To12_31_2020_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">21300000</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P12_31_2020To12_31_2020_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">107400000</imab:MilestonePayments>
    <imab:MilestonePaymentsOutstanding
      contextRef="P01_01_2020To12_31_2020_OtherinlicensingarrangementsMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">740400000</imab:MilestonePaymentsOutstanding>
    <imab:MilestonePaymentsIncome
      contextRef="P01_01_2020To12_31_2020_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis"
      decimals="-8"
      unitRef="Unit_CNY">51000000000.0</imab:MilestonePaymentsIncome>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="P01_01_2017To12_31_2017_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">29000000.0</us-gaap:ProceedsFromLicenseFeesReceived>
    <imab:ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent
      contextRef="P01_01_2017To12_31_2017_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.42</imab:ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="P01_01_2017To12_31_2017_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">11600000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:ExciseAndSalesTaxes
      contextRef="P01_01_2017To12_31_2017_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_CNY">700000</us-gaap:ExciseAndSalesTaxes>
    <imab:DeferredRevenueFromCollaborativeArrangementExcludingVat
      contextRef="PAsOn12_31_2017_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">15800000</imab:DeferredRevenueFromCollaborativeArrangementExcludingVat>
    <us-gaap:ExciseAndSalesTaxes
      contextRef="P01_01_2017To12_31_2017_DeferredRevenueMemberusgaapBalanceSheetLocationAxis_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">900000</us-gaap:ExciseAndSalesTaxes>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="P01_01_2018To12_31_2018_HealSunMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis_MilestoneIiiMemberIMABMilestoneTypeAxis"
      decimals="-5"
      unitRef="Unit_CNY">11000000.0</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="P01_01_2018To12_31_2018_HealSunMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis_MilestoneIvMemberIMABMilestoneTypeAxis"
      decimals="-5"
      unitRef="Unit_CNY">11000000.0</us-gaap:ProceedsFromLicenseFeesReceived>
    <imab:ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent
      contextRef="P01_01_2018To12_31_2018_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">1</imab:ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="P01_01_2018To12_31_2018_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">36500000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:ExciseAndSalesTaxes
      contextRef="P01_01_2018To12_31_2018_HealSunMembersrtCounterpartyNameAxis_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">1300000</us-gaap:ExciseAndSalesTaxes>
    <us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms contextRef="P01_01_2020To12_31_2020_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">Under the agreement, the Group is primarily responsible for carrying out the development, manufacture and supply of the CD38 product, as well as seeking regulatory approval of the CD38 product. Everest is primarily responsible for sharing the development costs of the CD38 product, including payments due to MorphoSys under the Licensing Agreement, dated November 30, 2017, in the proportion of 75% by Everest and 25% by the Group.</us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="PAsOn12_31_2020_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="2"
      unitRef="Unit_pure">-0.05</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2018To12_31_2018_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-5"
      unitRef="Unit_USD">26000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2018To12_31_2018_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-5"
      unitRef="Unit_CNY">178700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019_CollaborationAgreementWithEverestMemberusgaapTypeOfArrangementAxis_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">7600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019_CollaborationAgreementWithEverestMemberusgaapTypeOfArrangementAxis_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_CNY">53100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CommonStockValue
      contextRef="PAsOn11_04_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-5"
      unitRef="Unit_USD">37000000.0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn11_04_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-5"
      unitRef="Unit_USD">37000000.0</us-gaap:CommonStockValue>
    <imab:CumulativePaidInContributions
      contextRef="PAsOn11_04_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-5"
      unitRef="Unit_USD">33700000</imab:CumulativePaidInContributions>
    <imab:TimeCostOfForegoingHistoricalContribution
      contextRef="PAsOn11_04_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-5"
      unitRef="Unit_USD">3300000</imab:TimeCostOfForegoingHistoricalContribution>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn11_04_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="INF"
      unitRef="Unit_shares">4762751</us-gaap:CommonStockSharesIssued>
    <imab:TimeCostOfForegoingHistoricalContribution
      contextRef="PAsOn11_04_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-5"
      unitRef="Unit_USD">3300000</imab:TimeCostOfForegoingHistoricalContribution>
    <imab:TimeCostOfForegoingHistoricalContribution
      contextRef="PAsOn11_04_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_OutLicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-5"
      unitRef="Unit_CNY">23000000.0</imab:TimeCostOfForegoingHistoricalContribution>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="PAsOn01_31_2020_CollaborationAgreementWithEverestMemberusgaapTypeOfArrangementAxis_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">6078571</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019_ABLBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019_ABLBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_CNY">1400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_CNY">700000</us-gaap:ResearchAndDevelopmentExpense>
    <imab:CostSharingRatio
      contextRef="P01_01_2019To12_31_2019_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</imab:CostSharingRatio>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020_ABLBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-4"
      unitRef="Unit_USD">40000.00</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020_ABLBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-4"
      unitRef="Unit_CNY">280000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-4"
      unitRef="Unit_USD">20000.00</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-4"
      unitRef="Unit_CNY">140000</us-gaap:ResearchAndDevelopmentExpense>
    <imab:CostSharingRatio
      contextRef="P01_01_2020To12_31_2020_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</imab:CostSharingRatio>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2018To07_31_2018_ABLBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2018To07_31_2018_ABLBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">17200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <imab:MilestonePayments
      contextRef="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">97500000</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">690300000</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_ClinicalMilestonesMemberIMABMilestoneTypeAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">32500000</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_ClinicalMilestonesMemberIMABMilestoneTypeAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">230100000</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_SalesMilestonesMemberIMABMilestoneTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">65000000</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P07_31_2018To07_31_2018_ABLBioMembersrtCounterpartyNameAxis_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_SalesMilestonesMemberIMABMilestoneTypeAxis"
      decimals="-5"
      unitRef="Unit_CNY">460200000</imab:MilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">17200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <imab:MilestonePayments
      contextRef="P01_01_2020To12_31_2020_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      unitRef="Unit_USD">0</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P01_01_2019To12_31_2019_LicensingAgreementWithABLBioMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      unitRef="Unit_USD">0</imab:MilestonePayments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2018To12_31_2018_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">1000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2018To12_31_2018_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:ResearchAndDevelopmentExpense>
    <imab:CostSharingRatio
      contextRef="P01_01_2018To12_31_2018_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</imab:CostSharingRatio>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">11200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019_ABLBioMembersrtCounterpartyNameAxis_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">8000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_CNY">9600000</us-gaap:ResearchAndDevelopmentExpense>
    <imab:CostSharingRatio
      contextRef="P01_01_2019To12_31_2019_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</imab:CostSharingRatio>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2010To12_31_2010"
      decimals="-5"
      unitRef="Unit_CNY">43600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2010To12_31_2010_ABLBioMembersrtCounterpartyNameAxis"
      decimals="-5"
      unitRef="Unit_CNY">44000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020_OperatingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_CNY">43800000</us-gaap:ResearchAndDevelopmentExpense>
    <imab:CostSharingRatio
      contextRef="P01_01_2020To12_31_2020_CollaborationAgreementWithABLBioMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</imab:CostSharingRatio>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019_CollaborationAgreementsWithTraconPharmaceuticalsIncMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">4000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019_CollaborationAgreementsWithTraconPharmaceuticalsIncMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_CNY">27800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020_CollaborationAgreementsWithTraconPharmaceuticalsIncMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-4"
      unitRef="Unit_USD">30000.00</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020_CollaborationAgreementsWithTraconPharmaceuticalsIncMemberusgaapTypeOfArrangementAxis_OperatingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-4"
      unitRef="Unit_CNY">170000</us-gaap:ResearchAndDevelopmentExpense>
    <imab:UpfrontLicenseFee
      contextRef="P01_01_2018To12_31_2018_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">15000000.0</imab:UpfrontLicenseFee>
    <imab:MilestonePayments
      contextRef="P01_01_2018To12_31_2018_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">135000000.0</imab:MilestonePayments>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2018_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">14200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="P02_28_2019To02_28_2019_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">800000</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="P09_30_2019To09_30_2019_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">15000000.0</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_CspcMembersrtCounterpartyNameAxis_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_CNY">30000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <imab:UpfrontLicenseFee
      contextRef="P09_03_2020To09_03_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-6"
      unitRef="Unit_USD">180000000</imab:UpfrontLicenseFee>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="P09_03_2020To09_03_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-7"
      unitRef="Unit_USD">1760000000</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="P09_03_2020To09_03_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ClinicalMilestonesMemberIMABMilestoneTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">840000000</us-gaap:ProceedsFromLicenseFeesReceived>
    <imab:UpfrontAndMilestonePayments
      contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LemzoparlimabLicenseMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">250000000</imab:UpfrontAndMilestonePayments>
    <imab:UpfrontLicenseFee
      contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LemzoparlimabLicenseMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">180000000</imab:UpfrontLicenseFee>
    <imab:MilestonePayments
      contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_FirstMilestoneMemberIMABMilestoneTypeAxis_LemzoparlimabLicenseMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</imab:MilestonePayments>
    <imab:MilestonePayments
      contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_LemzoparlimabLicenseMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SecondMilestoneMemberIMABMilestoneTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">50000000</imab:MilestonePayments>
    <imab:UpfrontAndMilestonePayments
      contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis"
      decimals="-6"
      unitRef="Unit_USD">250000000</imab:UpfrontAndMilestonePayments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">228800000</us-gaap:ResearchAndDevelopmentExpense>
    <imab:RevenueFromContractWithCustomerTimeOfTransferOfLicense
      contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">228800000</imab:RevenueFromContractWithCustomerTimeOfTransferOfLicense>
    <imab:RevenueFromContractWithCustomerTimeOfTransferOfLicense
      contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_CNY">1502900000</imab:RevenueFromContractWithCustomerTimeOfTransferOfLicense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study1MemberIMABTypeOfLicensesAxis"
      decimals="-5"
      unitRef="Unit_USD">11000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study2MemberIMABTypeOfLicensesAxis"
      decimals="-5"
      unitRef="Unit_USD">10200000</us-gaap:ResearchAndDevelopmentExpense>
    <imab:ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent
      contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study1MemberIMABTypeOfLicensesAxis"
      decimals="2"
      unitRef="Unit_pure">0.17</imab:ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent>
    <imab:ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent
      contextRef="P01_01_2020To12_31_2020_GenexineIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMemberusgaapTypeOfArrangementAxis_Study2MemberIMABTypeOfLicensesAxis"
      decimals="2"
      unitRef="Unit_pure">0.41</imab:ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Study1MemberIMABTypeOfLicensesAxis"
      decimals="-5"
      unitRef="Unit_USD">1800000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Study1MemberIMABTypeOfLicensesAxis"
      decimals="-5"
      unitRef="Unit_CNY">12000000.0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Study2MemberIMABTypeOfLicensesAxis"
      decimals="-5"
      unitRef="Unit_USD">4200000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_Study2MemberIMABTypeOfLicensesAxis"
      decimals="-5"
      unitRef="Unit_CNY">27800000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="PAsOn12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">34800000</us-gaap:ContractWithCustomerAssetNet>
    <imab:UpfrontPaymentReceived
      contextRef="P01_01_2020To12_31_2020_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-6"
      unitRef="Unit_USD">180000000</imab:UpfrontPaymentReceived>
    <imab:MilestonePaymentReceivable
      contextRef="PAsOn03_31_2021_AbbVieMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</imab:MilestonePaymentReceivable>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;. OTHER INCOME (EXPENSES), NET &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes other income (expenses), net recognized for the years ended December&#160;31, 2018, 2019 and 2020: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from conversion of 2017 Notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(18,375&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from conversion of Onshore Convertible Loan&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from issuance of 2018 Notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,081&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss on termination agreement with Everest&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23,039&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income of incentive payment from depository bank&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,348&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value change of short-term investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,288&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,730&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value change of put right liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,024&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;463&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from other financial assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,622&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net foreign exchange gains (losses)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;742&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(22,126&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,391&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsidy income&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt; (3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;750&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;568&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,633&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,783&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gains on deconsolidation of a subsidiary&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;407,598&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;62,467&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value change of other financial assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;42&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(873&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16,780&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(20,205&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;412,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;63,278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(3)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the year ended December&#160;31, 2020, subsidy income consists primarily of the government grant of RMB10&#160;million. The government grant was granted by the project management office of Shanghai Zhangjiang Science City to support the research and development activities in the local region. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes other income (expenses), net recognized for the years ended December&#160;31, 2018, 2019 and 2020: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from conversion of 2017 Notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(18,375&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from conversion of Onshore Convertible Loan&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from issuance of 2018 Notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,081&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss on termination agreement with Everest&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(23,039&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income of incentive payment from depository bank&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,348&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value change of short-term investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,288&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,730&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value change of put right liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,024&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;463&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from other financial assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,622&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net foreign exchange gains (losses)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;742&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(22,126&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,391&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsidy income&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt; (3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;750&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;568&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,633&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,783&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gains on deconsolidation of a subsidiary&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;407,598&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;62,467&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value change of other financial assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;42&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(873&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16,780&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(20,205&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;412,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;63,278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-18375000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <imab:LossFromConversionOfOnshoreConvertibleLoans
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">8548000</imab:LossFromConversionOfOnshoreConvertibleLoans>
    <imab:LossFromIssuanceOfNotes
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">5081000</imab:LossFromIssuanceOfNotes>
    <us-gaap:GainLossOnContractTermination
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-23039000</us-gaap:GainLossOnContractTermination>
    <imab:IncentiveIncomeFromDepositoryBank
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">2348000</imab:IncentiveIncomeFromDepositoryBank>
    <imab:IncentiveIncomeFromDepositoryBank
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">360000</imab:IncentiveIncomeFromDepositoryBank>
    <imab:FairValueChangeOfShortTermInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-703000</imab:FairValueChangeOfShortTermInvestments>
    <imab:FairValueChangeOfShortTermInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-11288000</imab:FairValueChangeOfShortTermInvestments>
    <imab:FairValueChangeOfShortTermInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-1730000</imab:FairValueChangeOfShortTermInvestments>
    <imab:FairValueAdjustmentsOfPutRightLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-3024000</imab:FairValueAdjustmentsOfPutRightLiabilities>
    <imab:FairValueAdjustmentsOfPutRightLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-463000</imab:FairValueAdjustmentsOfPutRightLiabilities>
    <imab:IncomeFromOtherFinancialAssets
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">13622000</imab:IncomeFromOtherFinancialAssets>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">742000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">1619000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-22126000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-3391000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:CharityCareReimbursementsReceived
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">750000</us-gaap:CharityCareReimbursementsReceived>
    <us-gaap:CharityCareReimbursementsReceived
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">568000</us-gaap:CharityCareReimbursementsReceived>
    <us-gaap:CharityCareReimbursementsReceived
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">11633000</us-gaap:CharityCareReimbursementsReceived>
    <us-gaap:CharityCareReimbursementsReceived
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1783000</us-gaap:CharityCareReimbursementsReceived>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">407598000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">62467000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <imab:FairValueAdjustmentsOfOtherFinancialAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">42000</imab:FairValueAdjustmentsOfOtherFinancialAssets>
    <imab:OtherIncomeexpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">110000</imab:OtherIncomeexpense>
    <imab:OtherIncomeexpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-98000</imab:OtherIncomeexpense>
    <imab:OtherIncomeexpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">-873000</imab:OtherIncomeexpense>
    <imab:OtherIncomeexpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-134000</imab:OtherIncomeexpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-16780000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-20205000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">412892000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">63278000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:Revenues
      contextRef="P01_01_2020To12_31_2020_GrantMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_CNY">10000000</us-gaap:Revenues>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt;. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;NET INCOME (LOSS) PER SHARE&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left;"&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net income (loss) per share for eac&lt;div style="display:inline;"&gt;h&lt;/div&gt;&#160;of the periods presented are calculated as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$ (Note 2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;;text-align:center;"&gt;(in thousands, except for share and per share data)&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(402,833&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,451,950&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;470,915&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;72,170&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Deemed dividend to Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; preferred shareholders at extinguishment of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; Preferred Shares&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(5,283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Deemed dividend to Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; and C preferred shareholders at modification of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; and C Preferred Shares&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(27,768&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) attributable to ordinary shareholders&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(402,833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,485,001&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;470,915 &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;72,170 &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 6.5pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: 6.5pt;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 2%;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 1%;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 1%;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 2%;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%; white-space: nowrap;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Denominator for basic calculation-weighted average number of common shares &lt;br/&gt; outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,529,092&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,381,230&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;134,158,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;134,158,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive effect of convertible preferred shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,373,047&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,373,047&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive effect of ordinary shares to be issued to Everes&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;t&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;266,458&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;266,458&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive effect of convertible promissory notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;865,479&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;865,479 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive effect of restricted shares&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;units&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255);"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255);"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;778,130&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;778,130&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive effect of stock options&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(255, 255, 255);"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(255, 255, 255);"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;16,789,714&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;16,789,714&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for diluted income (loss) per share calculation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;6,529,092&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;7,381,230&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;157,231,652&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;157,231,652&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) per share - basic&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;(61.70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;(201.19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.51&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.54&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) per share - diluted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(61.70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(201.19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.00 &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.46&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The effects of all outstanding convertible preferred shares, restricted shares and certain stock options have been excluded from the computation of diluted loss per share for the years ended December&#160;31, 2018 and 2019 as their effects would be anti-dilutive. For the years ended December&#160;31, 2018 and 2019, the Company also has certain dilutive potential stock options. These stock options which cannot be exercised until the Company completed its listing are not included in the computation of diluted earnings per shares as such contingent event had not taken place.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;The potentially dilutive securities that have not been included in the calculation of diluted net loss per share as their inclusion would be anti-dilutive are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible preferred shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;64,389,968&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;92,238,119&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,134,058&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;not&#160;applicable&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,388,776&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-align: left;"&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net income (loss) per share for eac&lt;div style="display:inline;"&gt;h&lt;/div&gt;&#160;of the periods presented are calculated as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$ (Note 2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;;text-align:center;"&gt;(in thousands, except for share and per share data)&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(402,833&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,451,950&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;470,915&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;72,170&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Deemed dividend to Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; preferred shareholders at extinguishment of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;C-1&lt;/div&gt; Preferred Shares&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(5,283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Deemed dividend to Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; and C preferred shareholders at modification of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; and C Preferred Shares&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(27,768&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) attributable to ordinary shareholders&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(402,833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,485,001&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;470,915 &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;72,170 &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 6.5pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: 6.5pt;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 2%;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 1%;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 1%;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 2%;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%; white-space: nowrap;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Denominator for basic calculation-weighted average number of common shares &lt;br/&gt; outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,529,092&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,381,230&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;134,158,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;134,158,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive effect of convertible preferred shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,373,047&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,373,047&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive effect of ordinary shares to be issued to Everes&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;t&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;266,458&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;266,458&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive effect of convertible promissory notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;865,479&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;865,479 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive effect of restricted shares&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;units&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255);"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255);"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;778,130&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;778,130&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive effect of stock options&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(255, 255, 255);"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(255, 255, 255);"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;16,789,714&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;16,789,714&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for diluted income (loss) per share calculation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;6,529,092&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;7,381,230&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;157,231,652&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;157,231,652&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) per share - basic&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;(61.70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"&gt;(201.19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.51&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.54&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) per share - diluted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(61.70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(201.19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.00 &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.46&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-402833000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-1451950000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">470915000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">72170000</us-gaap:NetIncomeLoss>
    <imab:PreferredStockDividendsAtExtinguishmentOfPreferredShares
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">5283000</imab:PreferredStockDividendsAtExtinguishmentOfPreferredShares>
    <imab:PreferredStockDividendsAtModificationOfPreferredShares
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">27768000</imab:PreferredStockDividendsAtModificationOfPreferredShares>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">-402833000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">-1485001000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">470915000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">72170000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2018To12_31_2018"
      decimals="0"
      unitRef="Unit_shares">6529092</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_shares">7381230</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">134158824</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">134158824</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">4373047</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">4373047</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
    <us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">266458</us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements>
    <us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">266458</us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">865479</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">865479</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <imab:IncrementalCommonSharesAttributableToRestrictedShareUnits
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">778130</imab:IncrementalCommonSharesAttributableToRestrictedShareUnits>
    <imab:IncrementalCommonSharesAttributableToRestrictedShareUnits
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">778130</imab:IncrementalCommonSharesAttributableToRestrictedShareUnits>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">16789714</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">16789714</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2018To12_31_2018"
      decimals="0"
      unitRef="Unit_shares">6529092</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_shares">7381230</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">157231652</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">157231652</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_CNY_per_Share">-61.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_CNY_per_Share">-201.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_CNY_per_Share">3.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_CNY_per_Share">-61.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_CNY_per_Share">-201.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_CNY_per_Share">3.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2020To12_31_2020">The potentially dilutive securities that have not been included in the calculation of diluted net loss per share as their inclusion would be anti-dilutive are as follows:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible preferred shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;64,389,968&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;92,238,119&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,134,058&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;not&#160;applicable&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,388,776&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2018To12_31_2018_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">64389968</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2019To12_31_2019_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">92238119</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2018To12_31_2018_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">1134058</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2019To12_31_2019_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">11388776</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;. EMPLOYEE BENEFITS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Full time employees of the Group in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical care, employee housing fund and other welfare benefits are provided to the employees. Chinese labor regulations require that the PRC subsidiaries of the Group make contributions to the government for these benefits based on certain percentage of the employees&#x2019; salaries, up to a maximum amount specified by the government. The Group has no legal obligation for the benefits beyond the contribution made. The total amounts charged to the consolidated statements of comprehensive income (loss) for such employee benefits amounted to approximately RMB9,294, RMB14,152 and RMB10,049 for the years ended December&#160;31, 2018, 2019 and 2020, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_CNY">9294000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_CNY">14152000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_CNY">10049000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;. COMMITMENTS AND CONTINGENCIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group is a party to or an assignee of license and collaboration agreements that may require it to make future payments relating to milestone fees and royalties on future sales of licensed products (see Note&#160;18). In April 2020, Tracon issued a notice of disputes with respect to the TJD5 Agreement and the BsAbs Agreement. As of the date of this report, these disputes have not been resolved (see Note&#160;18). As of December 31, 2020, the Group did not record any liabilities for these disputes. Information available prior to issuance of the financial statements did not indicate that it is probable that a liability had been incurred at the date of the financial statements and the Company is also unable to reasonably estimate the range of any liability or&#160; possible loss, if any. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group did not have significant capital and other commitments, long-term obligations, or guarantees as of December&#160;31, 2019 and 2020. &lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;. RELATED PARTY BALANCES AND TRANSACTIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The table below sets forth the major related parties and their relationships with the Group as of December&#160;31, 2019 and 2020: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 51%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 48%;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Name of related parties&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Relationship with the Group&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;Everest&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Controlled by the ultimate controlling party of a principal shareholder of the Group&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;CMAB Biopharma (Suzhou) Inc.&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Controlled by the ultimate controlling party of a principal shareholder of the Group&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;Tasly Pharmaceutical Group Co., Ltd.&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Controlled by the ultimate controlling party of a principal shareholder of the Group&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;Jiangsu Taslydiyi Pharmaceutical Co., Ltd.&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Controlled by the ultimate controlling party of a principal shareholder of the Group&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"&gt; &lt;div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Biopharma (Hangzhou) Co., Limited&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Subsidiary of the Group before September&#160;15, 2020; Affiliate of the Group after September&#160;15, 2020&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-align: left;"&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of related party balances as of December&#160;31, 2019 and 2020 are as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Ordinary Shares to be issued to Everest &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Everest (Note 1&lt;div style="display:inline;"&gt;8&lt;/div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;258,119&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other receivables&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; padding-bottom: 2.2pt; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 2.2pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 2.2pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 2.2pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,212&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 2.2pt; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 2.2pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,251&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-align: left;"&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accruals and other payables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Jiangsu Taslydiyi Pharmaceutical Co., Ltd.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,395&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;367&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of related party transactions for the years ended December&#160;31, 2018, 2019 and 2020 are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 10pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Receipt of CRO services&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;/div&gt;recognized in research and development expenses&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CMAB Biopharma (Suzhou) Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,786&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;681&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;104&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Jiangsu Taslydiyi Pharmaceutical Co., Ltd.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,395&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;367&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tasly Pharmaceutical Group Co., Ltd.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,590&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 10pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Receipt of research and development funding &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Everest (Note 1&lt;div style="display:inline;"&gt;8&lt;/div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;178,715&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;53,148&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;br/&gt;  &lt;div style="text-indent: -2%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 2%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Collection of loan to an affiliate&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: -2%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 2%; line-height: 12pt;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou &lt;div style="font-size:85%; vertical-align:top;display:inline;;font-size:9.4px"&gt;(4)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;52,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,969&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table style="border-spacing: 0px; margin-bottom: 0pt; margin-top: 12pt; width: 100%; table-layout: fixed;"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding: 0pt; width: 0%;"/&gt;
&lt;td style="width: 4%; padding-left: 0px; padding-right: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-left: 0px; padding-right: 0px; width: 96%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; line-height: normal;"&gt;In July 2019 and July 2020, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Shanghai provided an interest free loan to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou of RMB2,000 and RMB50,000 respectively to finance &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou&#x2019;s operation. These loans were repaid in November 2020. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expenses paid on behalf of an affiliate &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,212&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,251&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <imab:ScheduleOfRelatedPartyBalancesTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-align: left;"&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of related party balances as of December&#160;31, 2019 and 2020 are as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Ordinary Shares to be issued to Everest &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Everest (Note 1&lt;div style="display:inline;"&gt;8&lt;/div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;258,119&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other receivables&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; padding-bottom: 2.2pt; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 2.2pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 2.2pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 2.2pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,212&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 2.2pt; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 2.2pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,251&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-align: left;"&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accruals and other payables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Jiangsu Taslydiyi Pharmaceutical Co., Ltd.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,395&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;367&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</imab:ScheduleOfRelatedPartyBalancesTextBlock>
    <imab:CommonStockSharesIssuableForServicesAvailedCurrent
      contextRef="PAsOn12_31_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_CNY">258119000</imab:CommonStockSharesIssuableForServicesAvailedCurrent>
    <us-gaap:OtherReceivables
      contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_CNY">21212000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">3251000</us-gaap:OtherReceivables>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2020_JiangsuTaslydiyiPharmaceuticalCoLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_CNY">2395000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2020_JiangsuTaslydiyiPharmaceuticalCoLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">367000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 10pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Receipt of CRO services&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;/div&gt;recognized in research and development expenses&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CMAB Biopharma (Suzhou) Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,786&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;681&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;104&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Jiangsu Taslydiyi Pharmaceutical Co., Ltd.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,395&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;367&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tasly Pharmaceutical Group Co., Ltd.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,590&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 10pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Receipt of research and development funding &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Everest (Note 1&lt;div style="display:inline;"&gt;8&lt;/div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;178,715&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;53,148&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;br/&gt;  &lt;div style="text-indent: -2%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 2%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Collection of loan to an affiliate&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: -2%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 2%; line-height: 12pt;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou &lt;div style="font-size:85%; vertical-align:top;display:inline;;font-size:9.4px"&gt;(4)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;52,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,969&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expenses paid on behalf of an affiliate &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RMB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&#160;(Note&#160;2.5)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;I-Mab&lt;/div&gt; Hangzhou&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;21,212&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,251&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2018To12_31_2018_CmabBiopharmaSuzhouIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis"
      decimals="-3"
      unitRef="Unit_CNY">2786000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2020To12_31_2020_CmabBiopharmaSuzhouIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis"
      decimals="-3"
      unitRef="Unit_CNY">681000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2020To12_31_2020_CmabBiopharmaSuzhouIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis"
      decimals="-3"
      unitRef="Unit_USD">104000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2020To12_31_2020_JiangsuTaslydiyiPharmaceuticalCoLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis"
      decimals="-3"
      unitRef="Unit_CNY">2395000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2020To12_31_2020_JiangsuTaslydiyiPharmaceuticalCoLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis"
      decimals="-3"
      unitRef="Unit_USD">367000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2019To12_31_2019_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis_TaslyPharmaceuticalGroupCoLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_CNY">5590000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="P01_01_2018To12_31_2018_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_CNY">178715000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="P01_01_2019To12_31_2019_EverestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_CNY">53148000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:DueFromAffiliateCurrent
      contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_CNY">52000000</us-gaap:DueFromAffiliateCurrent>
    <us-gaap:DueFromAffiliateCurrent
      contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">7969000</us-gaap:DueFromAffiliateCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn07_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_CNY">2000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn07_31_2019_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_CNY">50000000</us-gaap:DebtInstrumentFaceAmount>
    <imab:ExpensesPaidOnBehalfOfAnAffiliate
      contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_CNY">21212000</imab:ExpensesPaidOnBehalfOfAnAffiliate>
    <imab:ExpensesPaidOnBehalfOfAnAffiliate
      contextRef="PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">3251000</imab:ExpensesPaidOnBehalfOfAnAffiliate>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;. CONCENTRATION OF CREDIT RISK&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that are potentially subject to significant con&lt;div style="display:inline;"&gt;c&lt;/div&gt;entration of credit risk consist of cash and cash equivalents, restricted cash, short-term investments, other financial assets, accounts receivable, contract assets, and other receivables. The carrying amounts of cash and cash equivalents, restricted cash, short-term investments, contract assets, and other financial assets represent the maximum amount of loss due to credit risk. As of December&#160;31, 2019 and 2020, all of the Group&#x2019;s cash and cash equivalents, restricted cash and short-term investments were held by major financial institutions located in the PRC and international financial institutions outside of the PRC which management believes are of high credit quality and continually monitors the credit worthiness of these financial institutions. With respect to the accounts receivable, contract assets, other receivables and other financial assets, the Group performs &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on-going&lt;/div&gt; credit evaluations of the financial condition of its customers and counterparties.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-align: center; top: 0px;;display:inline;"&gt;F-7&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-align: center; top: 0px;;display:inline;"&gt;8&lt;/div&gt;&lt;/div&gt; </us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;. SUBSEQUENT EVENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2021, the Group sent Tracon a notice to terminate the TJD5 Agreement, which would result in a prespecified termination fee of US$9.0 million owing to Tracon. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2021, the Group entered into two collaboration agreements with Complix, an EU-based biotech company (the &#x201c;Complix Agreement&#x201d;), and Affinity, a Shanghai-based biotech company (the &#x201c;Affinity Agreement&#x201d;), respectively, allowing the Group to access cutting edge technology platforms to create next generation of novel and highly differentiated drug candidates, including Cell Penetrating Alphabodies (&#x201c;CPAB&#x201d;) for otherwise intractable intracellular drug targets and masked antibodies for targeted tumor-site activation. Under the Complix Agreement, both parties will collaborate to discover, develop and commercialize novel therapeutics for mutually agreed targets based on the Complix&#x2019;s proprietary technology. Under the Affinity Agreement, both parties will collaborate to develop lead compounds for mutually agreed targets based on Affinity&#x2019;s Tumor MicroEnvironment Activated body (&#x201c;TMEAbody&#x201d;) platform technology. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2021, the Group entered into a license and collaboration agreement with Genbase, a Shanghai-based biotech company to develop bi-specific antibodies or/and multi-specific antibodies using antibody sequences from both companies. Under this agreement, Genbase granted to the Group a non-transferable, sublicensable, and royalty-bearing license under Genbase parental antibody technology and Genbase parental antibody improvements owned and controlled by Genbase to make, develop and commercialize the licensed compounds and licensed products in all uses and indications worldwide. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <imab:TerminationFeePayable
      contextRef="PAsOn02_28_2021_CollaborationAgreementsWithTraconPharmaceuticalsIncMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">9000000.0</imab:TerminationFeePayable>
    <us-gaap:RestrictedAssetsDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="margin-top: 18pt; line-height: 12pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;. RESTRICTED NET ASSETS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 100%;"/&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group&#x2019;s ability to pay dividends may depend on the Group receiving distributions of funds from its PRC subsidiary. Relevant PRC statutory laws and regulations permit payments of dividends by the Group&#x2019;s PRC subsidiary only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with U.S. GAAP differ from those reflected in the statutory financial statements of the Group&#x2019;s PRC subsidiary. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In accordance with the Company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;after-tax&lt;/div&gt; profit until such reserve has reached 50% of its respective registered capital based on the enterprise&#x2019;s PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise&#x2019;s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Group&#x2019;s PRC subsidiary was established as domestic invested enterprise and therefore is subject to the above mentioned restrictions on distributable profits. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the years ended December&#160;31, 2018, 2019 and 2020, no appropriation to statutory reserves was made because the PRC subsidiary had substantial losses during such periods. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As a result of these PRC laws and regulations subject to the limit discussed above that require annual appropriations of 10% of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;after-tax&lt;/div&gt; income to be set aside, prior to payment of dividends, as general reserve fund, the Group&#x2019;s PRC subsidiary is restricted in their ability to transfer a portion of their net assets to the Group. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign exchange and other regulations in the PRC further restrict the Company&#x2019;s PRC subsidiaries from transferring funds to the Company in the form of dividends, loans and advances. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020, the net asset base for purposes of calculating the proportionate share of restricted net assets of consolidated subsidiaries should be zero, while the Group has a consolidated shareholders&#x2019; equity. Therefore, as the restricted net assets of consolidated subsidiaries do not exceed 25% of consolidated net assets as of the most recent fiscal year end, the Group is not required to provide parent company financial information. &lt;/div&gt;&lt;/div&gt;</us-gaap:RestrictedAssetsDisclosureTextBlock>
    <imab:StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_pure">0.10</imab:StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit>
    <imab:ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_pure">0.50</imab:ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation>
    <imab:AppropriationtoStatutoryReserve
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">0</imab:AppropriationtoStatutoryReserve>
    <imab:AppropriationtoStatutoryReserve
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">0</imab:AppropriationtoStatutoryReserve>
    <imab:AppropriationtoStatutoryReserve
      contextRef="P01_01_2018To12_31_2018"
      decimals="0"
      unitRef="Unit_USD">0</imab:AppropriationtoStatutoryReserve>
    <imab:StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_pure">0.10</imab:StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit>
    <us-gaap:AssetsNet
      contextRef="PAsOn12_31_2020_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AssetsNet>
    <imab:PercentageOfNetAssetToNetAssetsOfGroup
      contextRef="PAsOn12_31_2020_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      decimals="INF"
      unitRef="Unit_pure">0.25</imab:PercentageOfNetAssetToNetAssetsOfGroup>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707711419304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">I-MAB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001778016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Shanghai<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">201210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">164,888,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary&#160;Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, par value US$0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Shanghai<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">201210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">6057-8000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Jielun Zhu<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">jielun.zhu@i-mabbiopharma.com<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">American Depositary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMAB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American depositary shares, each ten (10) American depositary shares representing twenty-three (23) ordinary shares<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number Section<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707807485720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">&#165; 4,758,778<span></span>
</td>
<td class="nump">$ 729,315<span></span>
</td>
<td class="nump">&#165; 1,137,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">130,498<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">227,391<span></span>
</td>
<td class="nump">34,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">31,530<span></span>
</td>
<td class="nump">4,832<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepayments and other receivables</a></td>
<td class="nump">195,467<span></span>
</td>
<td class="nump">29,957<span></span>
</td>
<td class="nump">136,036<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,343,664<span></span>
</td>
<td class="nump">818,953<span></span>
</td>
<td class="nump">1,361,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software</a></td>
<td class="nump">25,272<span></span>
</td>
<td class="nump">3,873<span></span>
</td>
<td class="nump">30,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">14,997<span></span>
</td>
<td class="nump">2,298<span></span>
</td>
<td class="nump">16,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">120,444<span></span>
</td>
<td class="nump">18,459<span></span>
</td>
<td class="nump">148,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">162,574<span></span>
</td>
<td class="nump">24,916<span></span>
</td>
<td class="nump">162,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment accounted for using the equity method</a></td>
<td class="nump">664,832<span></span>
</td>
<td class="nump">101,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">2,010<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">18,331<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">6,333,793<span></span>
</td>
<td class="nump">970,697<span></span>
</td>
<td class="nump">1,737,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accruals and other payables</a></td>
<td class="nump">560,558<span></span>
</td>
<td class="nump">85,909<span></span>
</td>
<td class="nump">273,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">8,058<span></span>
</td>
<td class="nump">1,235<span></span>
</td>
<td class="nump">6,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_CommonStockSharesIssuableForServicesAvailedCurrent', window );">Ordinary shares to be issued to Everest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred subsidy income</a></td>
<td class="nump">7,509<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">576,125<span></span>
</td>
<td class="nump">88,295<span></span>
</td>
<td class="nump">588,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PutRightLiabilities', window );">Put right liabilities</a></td>
<td class="nump">116,006<span></span>
</td>
<td class="nump">17,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">5,542<span></span>
</td>
<td class="nump">849<span></span>
</td>
<td class="nump">7,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Deferred subsidy income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other&#160;non-current&#160;liabilities</a></td>
<td class="nump">8,975<span></span>
</td>
<td class="nump">1,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">706,648<span></span>
</td>
<td class="nump">108,298<span></span>
</td>
<td class="nump">668,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total mezzanine equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,104,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares (US$0.0001 par value, 500,000,000 and 800,000,000 shares authorized as of December 31, 2019 and December 31, 2020, respectively; 8,363,719 and 164,888,519 shares issued and outstanding as of December 31, 2019 and December 31, 2020, respectively)</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">7,701,116<span></span>
</td>
<td class="nump">1,180,249<span></span>
</td>
<td class="nump">389,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(50,793)<span></span>
</td>
<td class="num">(7,784)<span></span>
</td>
<td class="nump">70,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,023,292)<span></span>
</td>
<td class="num">(310,083)<span></span>
</td>
<td class="num">(2,494,207)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity (deficit)</a></td>
<td class="nump">5,627,145<span></span>
</td>
<td class="nump">862,399<span></span>
</td>
<td class="num">(2,034,695)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity and shareholders' equity (deficit)</a></td>
<td class="nump">&#165; 6,333,793<span></span>
</td>
<td class="nump">$ 970,697<span></span>
</td>
<td class="nump">1,737,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesAConvertiblePreferredSharesMember', window );">Series A Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total mezzanine equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">687,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesBConvertiblePreferredSharesMember', window );">Series B Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total mezzanine equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">921,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesCConvertiblePreferredSharesMember', window );">Series C Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total mezzanine equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,306,633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesC1ConvertiblePreferredStockMember', window );">Series C-1 Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total mezzanine equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 188,819<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_CommonStockSharesIssuableForServicesAvailedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares issuable for services availed current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_CommonStockSharesIssuableForServicesAvailedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PutRightLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Put right liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PutRightLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesAConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesAConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesBConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesBConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesCConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesCConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesC1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesC1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707715312888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary Shares Par Value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary Shares Authorized</a></td>
<td class="nump">800,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary Shares Issued</a></td>
<td class="nump">164,888,519<span></span>
</td>
<td class="nump">8,363,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary Shares Outstanding</a></td>
<td class="nump">164,888,519<span></span>
</td>
<td class="nump">8,363,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesAConvertiblePreferredSharesMember', window );">Series A Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary Stock Par Value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary Shares Authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,227,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,227,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,227,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesBConvertiblePreferredSharesMember', window );">Series B Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary Stock Par Value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary Shares Authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,305,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,305,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,305,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesCConvertiblePreferredSharesMember', window );">Series C Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary Stock Par Value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary Shares Authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,046,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,046,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,046,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesC1ConvertiblePreferredStockMember', window );">Series C-1 Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary Stock Par Value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary Shares Authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,857,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,857,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,857,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesAConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesAConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesBConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesBConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesCConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesCConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesC1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesC1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707711261464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;) </div>
<div>&#165; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;) </div>
<div>&#165; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CNY (&#165;) </div>
<div>&#165; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Licensing and collaboration revenue</a></td>
<td class="nump">&#165; 1,542,668<span></span>
</td>
<td class="nump">$ 236,424<span></span>
</td>
<td class="nump">&#165; 30,000<span></span>
</td>
<td class="nump">&#165; 53,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(984,689)<span></span>
</td>
<td class="num">(150,910)<span></span>
</td>
<td class="num">(840,415)<span></span>
</td>
<td class="num">(426,028)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="num">(402,409)<span></span>
</td>
<td class="num">(61,672)<span></span>
</td>
<td class="num">(654,553)<span></span>
</td>
<td class="num">(66,391)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Income (loss) from operations</a></td>
<td class="nump">155,570<span></span>
</td>
<td class="nump">23,842<span></span>
</td>
<td class="num">(1,464,968)<span></span>
</td>
<td class="num">(438,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">24,228<span></span>
</td>
<td class="nump">3,713<span></span>
</td>
<td class="nump">30,570<span></span>
</td>
<td class="nump">4,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(957)<span></span>
</td>
<td class="num">(147)<span></span>
</td>
<td class="num">(2,991)<span></span>
</td>
<td class="num">(11,695)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expenses), net</a></td>
<td class="nump">412,892<span></span>
</td>
<td class="nump">63,278<span></span>
</td>
<td class="num">(20,205)<span></span>
</td>
<td class="num">(16,780)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of an affiliate</a></td>
<td class="num">(108,587)<span></span>
</td>
<td class="num">(16,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value change of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,644<span></span>
</td>
<td class="nump">61,405<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income tax expense</a></td>
<td class="nump">483,146<span></span>
</td>
<td class="nump">74,044<span></span>
</td>
<td class="num">(1,451,950)<span></span>
</td>
<td class="num">(401,111)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(12,231)<span></span>
</td>
<td class="num">(1,874)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,722)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to I-MAB</a></td>
<td class="nump">470,915<span></span>
</td>
<td class="nump">72,170<span></span>
</td>
<td class="num">(1,451,950)<span></span>
</td>
<td class="num">(402,833)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares', window );">Deemed dividend to Series C-1 preferred shareholders at extinguishment of Series C-1 Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,283)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PreferredStockDividendsAtModificationOfPreferredShares', window );">Deemed dividend to Series B-1, B-2 and C preferred shareholders at modification of Series B-1, B-2 and C Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to ordinary shareholders</a></td>
<td class="nump">470,915<span></span>
</td>
<td class="nump">72,170<span></span>
</td>
<td class="num">(1,485,001)<span></span>
</td>
<td class="num">(402,833)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to I-MAB</a></td>
<td class="nump">470,915<span></span>
</td>
<td class="nump">72,170<span></span>
</td>
<td class="num">(1,451,950)<span></span>
</td>
<td class="num">(402,833)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments, net of nil tax</a></td>
<td class="num">(120,920)<span></span>
</td>
<td class="num">(18,531)<span></span>
</td>
<td class="nump">10,747<span></span>
</td>
<td class="nump">53,689<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income (loss) attributable to I-MAB</a></td>
<td class="nump">349,995<span></span>
</td>
<td class="nump">53,639<span></span>
</td>
<td class="num">(1,441,203)<span></span>
</td>
<td class="num">(349,144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to ordinary shareholders</a></td>
<td class="nump">&#165; 470,915<span></span>
</td>
<td class="nump">$ 72,170<span></span>
</td>
<td class="num">&#165; (1,485,001)<span></span>
</td>
<td class="num">&#165; (402,833)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of ordinary shares used in calculating net income (loss) per share - basic | shares</a></td>
<td class="nump">134,158,824<span></span>
</td>
<td class="nump">134,158,824<span></span>
</td>
<td class="nump">7,381,230<span></span>
</td>
<td class="nump">6,529,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of ordinary shares used in calculating net income (loss) per share - diluted | shares</a></td>
<td class="nump">157,231,652<span></span>
</td>
<td class="nump">157,231,652<span></span>
</td>
<td class="nump">7,381,230<span></span>
</td>
<td class="nump">6,529,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share attributable to ordinary shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">&#8212;Basic | (per share)</a></td>
<td class="nump">&#165; 3.51<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="num">&#165; (201.19)<span></span>
</td>
<td class="num">&#165; (61.70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">&#8212;Diluted | (per share)</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="nump">0.46<span></span>
</td>
<td class="num">(201.19)<span></span>
</td>
<td class="num">(61.70)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share attributable to ordinary shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">&#8212;Basic | (per share)</a></td>
<td class="nump">8.07<span></span>
</td>
<td class="nump">1.24<span></span>
</td>
<td class="num">(462.74)<span></span>
</td>
<td class="num">(141.91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">&#8212;Diluted | (per share)</a></td>
<td class="nump">&#165; 6.90<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="num">&#165; (462.74)<span></span>
</td>
<td class="num">&#165; (141.91)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock dividends at extinguishment of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PreferredStockDividendsAtModificationOfPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock dividends at modification of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PreferredStockDividendsAtModificationOfPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712942520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders' Equity (Deficit)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Ordinary&#160;share </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Treasury stock </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Additional paid-in capital </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Accumulated other comprehensive income (loss) </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Accumulated deficit </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="num">&#165; (299,795)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 6<span></span>
</td>
<td class="num">&#165; (1)<span></span>
</td>
<td class="nump">&#165; 52,369<span></span>
</td>
<td class="nump">&#165; 5,691<span></span>
</td>
<td class="num">&#165; (357,860)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2017 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,363,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">53,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(402,833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(402,833)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">3,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock', window );">Transaction with redeemable non- controlling interests</a></td>
<td class="num">(309,685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(253,796)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="num">(955,104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 6<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,380<span></span>
</td>
<td class="num">(1,014,489)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2018 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,363,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">10,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(1,451,950)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,451,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">366,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 1<span></span>
</td>
<td class="nump">366,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares', window );">Deemed dividend to Series C-1 preferred shareholders at extinguishment of Series C-1 Preferred Shares</a></td>
<td class="num">(5,283)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,283)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PreferredStockDividendsAtModificationOfPreferredShares', window );">Deemed dividend to Series B-1, B-2 and C preferred shareholders at modification of Series B-1, B-2 and C Preferred Shares</a></td>
<td class="nump">27,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,768)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="num">(2,034,695)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389,379<span></span>
</td>
<td class="nump">70,127<span></span>
</td>
<td class="num">(2,494,207)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2019 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,363,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(120,920)<span></span>
</td>
<td class="num">$ (18,531)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">470,915<span></span>
</td>
<td class="nump">$ 72,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">402,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">7,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,841,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of ordinary shares for restricted share units (Note 17 (f))</a></td>
<td class="nump">&#165; 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of ordinary shares for restricted share units, Shares (Note 17 (f)) | shares</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion from convertible promissory notes (Note 15)</a></td>
<td class="nump">&#165; 58,826<span></span>
</td>
<td class="nump">$ 9,015<span></span>
</td>
<td class="nump">&#165; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion from convertible promissory notes, Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate', window );">Proportionate share of share-based compensation expenses recorded in an equity method affiliate (Note 9(a))</a></td>
<td class="nump">41,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender', window );">Capital contribution from stock option surrender (Note 17 (h))</a></td>
<td class="nump">91,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred shares to ordinary shares upon the completion of initial public offering ("IPO")</a></td>
<td class="nump">3,104,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,104,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred shares to ordinary shares upon the completion of initial public offering ("IPO"), shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,760,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of ordinary shares to Everest</a></td>
<td class="nump">254,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of ordinary shares to Everest, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,078,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares upon IPO and over-allotment, net of issuance cost</a></td>
<td class="nump">697,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">697,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares upon IPO and over-allotment, net of issuance cost, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,804,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of ordinary shares upon private placement, net of issuance cost</a></td>
<td class="nump">2,543,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,543,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of ordinary shares upon private placement, net of issuance cost, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,133,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants</a></td>
<td class="nump">109,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">&#165; 5,627,145<span></span>
</td>
<td class="nump">$ 862,399<span></span>
</td>
<td class="nump">&#165; 114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 7,701,116<span></span>
</td>
<td class="num">&#165; (50,793)<span></span>
</td>
<td class="num">&#165; (2,023,292)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,888,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital, stock option surrender.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock dividends at extinguishment of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PreferredStockDividendsAtModificationOfPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock dividends at modification of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PreferredStockDividendsAtModificationOfPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proportionate share of share based compensation expenses recorded in an equity method affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 3.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177168-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707711768104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">&#165; 470,915<span></span>
</td>
<td class="nump">$ 72,170<span></span>
</td>
<td class="num">&#165; (1,451,950)<span></span>
</td>
<td class="num">&#165; (402,833)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property, equipment and software</a></td>
<td class="nump">12,743<span></span>
</td>
<td class="nump">1,953<span></span>
</td>
<td class="nump">9,831<span></span>
</td>
<td class="nump">6,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">1,556<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property, equipment and software</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expenses of convertible promissory notes and onshore convertible loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value change of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,644)<span></span>
</td>
<td class="num">(61,405)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_FairValueAdjustmentsOfPutRightLiabilities', window );">Fair value change of put right liabilities</a></td>
<td class="num">(3,024)<span></span>
</td>
<td class="num">(463)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Fair value change of other financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_IncomeFromOtherFinancialAssets', window );">Income from other financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,622)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of an affiliate</a></td>
<td class="nump">108,587<span></span>
</td>
<td class="nump">16,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">493,464<span></span>
</td>
<td class="nump">75,627<span></span>
</td>
<td class="nump">366,895<span></span>
</td>
<td class="nump">3,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_LossFromConversionOfNotes', window );">Loss from conversion of 2017 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_LossFromConversionOfOnshoreConvertibleLoans', window );">Loss from conversion of onshore convertible loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_LossFromIssuanceOfNotes', window );">Loss from issuance of 2018 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Loss on termination agreement with Everest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities', window );">Amortization of right-of use assets and interest of lease liabilities</a></td>
<td class="nump">8,837<span></span>
</td>
<td class="nump">1,354<span></span>
</td>
<td class="nump">5,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gains on deconsolidation of a subsidiary</a></td>
<td class="num">(407,598)<span></span>
</td>
<td class="num">(62,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_FairValueChangeOfShortTermInvestments', window );">Fair value change of short-term investments</a></td>
<td class="num">(11,288)<span></span>
</td>
<td class="num">(1,730)<span></span>
</td>
<td class="num">(703)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(130,498)<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Contract assets</a></td>
<td class="num">(227,391)<span></span>
</td>
<td class="num">(34,849)<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepayments and other receivables</a></td>
<td class="num">(58,692)<span></span>
</td>
<td class="num">(8,995)<span></span>
</td>
<td class="num">(48,831)<span></span>
</td>
<td class="num">(76,276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accruals and other payables</a></td>
<td class="nump">173,713<span></span>
</td>
<td class="nump">26,624<span></span>
</td>
<td class="nump">188,375<span></span>
</td>
<td class="nump">55,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,803)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_IncreaseDecreaseAdvanceFromCustomers', window );">Advance from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,151)<span></span>
</td>
<td class="nump">14,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Research and development funding received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,148<span></span>
</td>
<td class="nump">178,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">7,474<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred subsidy income</a></td>
<td class="nump">3,589<span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="nump">1,420<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent', window );">Lease liabilities</a></td>
<td class="num">(8,837)<span></span>
</td>
<td class="num">(1,354)<span></span>
</td>
<td class="num">(6,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash generated from (used in) operating activities</a></td>
<td class="nump">433,558<span></span>
</td>
<td class="nump">66,446<span></span>
</td>
<td class="num">(867,982)<span></span>
</td>
<td class="num">(280,705)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, equipment and software</a></td>
<td class="num">(8,008)<span></span>
</td>
<td class="num">(1,227)<span></span>
</td>
<td class="num">(12,241)<span></span>
</td>
<td class="num">(14,409)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from disposal of short-term investments</a></td>
<td class="nump">2,503,749<span></span>
</td>
<td class="nump">383,716<span></span>
</td>
<td class="nump">102,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
<td class="num">(2,491,991)<span></span>
</td>
<td class="num">(381,914)<span></span>
</td>
<td class="num">(134,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Cash paid for investments in other financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Cash disposed of resulting from deconsolidation of a subsidiary</a></td>
<td class="num">(257,651)<span></span>
</td>
<td class="num">(39,487)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Cash received from disposal of other financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_CashReceivedOnIncomeFromOtherFinancialAssets', window );">Cash received on income from other financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties', window );">Cash received from repayment of loans due from an affiliate</a></td>
<td class="nump">52,000<span></span>
</td>
<td class="nump">7,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash generated from (used in) investing activities</a></td>
<td class="num">(201,901)<span></span>
</td>
<td class="num">(30,943)<span></span>
</td>
<td class="nump">212,462<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred shares, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,536<span></span>
</td>
<td class="nump">1,306,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering and over-allotment, net of underwriting discounts and commissions</a></td>
<td class="nump">726,300<span></span>
</td>
<td class="nump">111,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance cost for initial public offering and over-allotment</a></td>
<td class="num">(27,595)<span></span>
</td>
<td class="num">(4,229)<span></span>
</td>
<td class="num">(827)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement, net of payment of issuance cost</a></td>
<td class="nump">2,782,455<span></span>
</td>
<td class="nump">426,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">9,275<span></span>
</td>
<td class="nump">1,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits', window );">Proceeds from issuance of ordinary shares for restricted share units</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromBankDebt', window );">Proceeds from bank borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Repayment of bank borrowings</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="num">(7,663)<span></span>
</td>
<td class="num">(80,000)<span></span>
</td>
<td class="num">(99,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfEquity', window );">Prepayment for stock repurchase program</a></td>
<td class="num">(34,859)<span></span>
</td>
<td class="num">(5,342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram', window );">Cash received from collection of prepayment for stock repurchase program</a></td>
<td class="nump">34,859<span></span>
</td>
<td class="nump">5,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash generated from financing activities</a></td>
<td class="nump">3,440,481<span></span>
</td>
<td class="nump">527,277<span></span>
</td>
<td class="nump">152,709<span></span>
</td>
<td class="nump">1,479,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents and restricted cash</a></td>
<td class="num">(106,643)<span></span>
</td>
<td class="num">(16,344)<span></span>
</td>
<td class="nump">15,163<span></span>
</td>
<td class="nump">59,754<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="nump">3,565,495<span></span>
</td>
<td class="nump">546,436<span></span>
</td>
<td class="num">(487,648)<span></span>
</td>
<td class="nump">1,268,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of year</a></td>
<td class="nump">1,193,283<span></span>
</td>
<td class="nump">182,879<span></span>
</td>
<td class="nump">1,680,931<span></span>
</td>
<td class="nump">412,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of the year</a></td>
<td class="nump">4,758,778<span></span>
</td>
<td class="nump">729,315<span></span>
</td>
<td class="nump">1,193,283<span></span>
</td>
<td class="nump">1,680,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Additional ASC 842 supplemental disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for fixed operating lease costs included in the measurement of lease obligations in operating activities</a></td>
<td class="nump">8,837<span></span>
</td>
<td class="nump">1,354<span></span>
</td>
<td class="nump">6,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">7,459<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
<td class="nump">8,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_OtherSupplementalCashFlowDisclosuresAbstract', window );"><strong>Other supplemental cash flow disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">957<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">2,991<span></span>
</td>
<td class="nump">4,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash&#160;activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PayablesForInLicensedPatentRights', window );">Payables for in-licensed patent rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_AccuredInitialPublicOfferingCostPayable', window );">Accrued initial public offering costs payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares', window );">Deemed dividend to Series C-1 preferred shareholders at extinguishment of Series C-1 Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PreferredStockDividendsAtModificationOfPreferredShares', window );">Deemed dividend to Series&#160;B-1,&#160;B-2&#160;and C preferred shareholders at modification of Series&#160;B-1,&#160;B-2&#160;and C Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 27,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_AccruedPrivatePlacementOfferingCostsPayable', window );">Accrued private placement offering costs payable</a></td>
<td class="nump">128,786<span></span>
</td>
<td class="nump">19,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Ordinary shares issued to Everest</a></td>
<td class="nump">254,848<span></span>
</td>
<td class="nump">39,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred shares to ordinary shares</a></td>
<td class="nump">3,104,177<span></span>
</td>
<td class="nump">475,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible promissory notes to ordinary shares</a></td>
<td class="nump">&#165; 58,826<span></span>
</td>
<td class="nump">$ 9,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_AccruedPrivatePlacementOfferingCostsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued private placement offering costs payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_AccruedPrivatePlacementOfferingCostsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_AccuredInitialPublicOfferingCostPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued initial public offering cost payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_AccuredInitialPublicOfferingCostPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of right of use assets and interest of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_CashReceivedOnIncomeFromOtherFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on income from other financial assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_CashReceivedOnIncomeFromOtherFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_FairValueAdjustmentsOfPutRightLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustments of put right liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_FairValueAdjustmentsOfPutRightLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_FairValueChangeOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Change Of Short Term Investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_FairValueChangeOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_IncomeFromOtherFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income from other financial assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_IncomeFromOtherFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_IncreaseDecreaseAdvanceFromCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease advance from customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_IncreaseDecreaseAdvanceFromCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_LossFromConversionOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss From Conversion of Notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_LossFromConversionOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_LossFromConversionOfOnshoreConvertibleLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss from conversion of onshore convertible loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_LossFromConversionOfOnshoreConvertibleLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_LossFromIssuanceOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss From Issuance of Notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_LossFromIssuanceOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_OtherSupplementalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other supplemental cash flow disclosures [abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_OtherSupplementalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PayablesForInLicensedPatentRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payables for in licensed patent rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PayablesForInLicensedPatentRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock dividends at extinguishment of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PreferredStockDividendsAtModificationOfPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock dividends at modification of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PreferredStockDividendsAtModificationOfPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from cash received from collection of prepayment for stock repurchase program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with collection, whether partial or full, of long-term loans to a related party. Alternate caption: Proceeds from Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common limited partners units during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle a bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707803479752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Activities and Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Principal Activities and Organization</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. PRINCIPAL ACTIVITIES AND ORGANIZATION </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> (the &#8220;Company&#8221;) was incorporated in the Cayman Islands on June&#160;30, 2016 as an exempted company with limited liability under the Companies <div style="letter-spacing: 0px; top: 0px;;display:inline;">Act</div>&#160;of the Cayman Islands. The Company and its subsidiaries (together the &#8220;Group&#8221;) are principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People&#8217;s Republic of China (the &#8220;PRC&#8221;) and other countries and regions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Prior to the incorporation of the Company, the Group carried out its operation in the PRC since November 2014 mainly through Third Venture Biopharma (Nanjing) Co., Ltd. (&#8220;Third Venture&#8221;), which was incorporated on November&#160;17, 2014 in the PRC. For the purpose of introduction of overseas investors and in preparation for a listing of the Company&#8217;s shares on the overseas capital markets, the Group underwent a reorganization (the &#8220;Reorganization&#8221;) in 2016. The Reorganization was approved by the Board of Directors and a restructuring framework agreement was entered into by Third Venture, the Company, and the shareholders of the Company based on Reorganization framework agreement, pursuant to which on July&#160;7, 2016, Third Venture transferred all of its assets and operations to the Company&#8217;s wholly owned subsidiary, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma Co., Ltd. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;I-Mab</div> Shanghai&#8221;), which was a transaction in which shareholders had identical ownership interests before and after the transaction and was accounted for in a manner similar to a common control transaction. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Reorganization, as described above has been accounted for at historical cost. That Reorganization was reverse merger of Third Venture and Third Venture is the predecessor of the Company. As such, the assets and liabilities of Third Venture are consolidated in the Company&#8217;s financial statements at historical cost. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;17, 2020, the Company consummated its IPO on the Nasdaq Global Market, where 7,407,400 American Depositary Shares (&#8220;ADSs&#8221;) were issued at the price of US$14.00 per ADS for total gross proceeds of US$103.7&#160;million. On February&#160;10, 2020, the underwriters of the IPO have exercised their over-allotment option to purchase an additional 768,350 ADSs of the Company at the IPO price of US$14.00 per ADS. After giving effect to the exercise of the over-allotment option, the Company has issued and sold a total of 8,175,750 ADSs in the IPO, for total gross proceeds of US$114.5&#160;million. Each ten ADSs represents twenty-three ordinary shares of the Company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>December&#160;31, 2020, the Company&#8217;s principal subsidiaries are as follows: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 46%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subsidiaries</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Place of<br/> incorporation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date of<br/> incorporation or<br/> acquisition</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percentage<br/> of direct<br/> or indirect<br/> ownership<br/> by the<br/> Company</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Principal&#160;activities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma Hong Kong Limited <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;I-Mab</div> Hong Kong&#8221;)</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">Hong Kong</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">July 8, 2016</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">100</td>
<td style="vertical-align: top; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">Investment holding</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">PRC</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">August 24, 2016</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">100</td>
<td style="vertical-align: top; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: top;">&#160;<br/> &#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">Research and<br/> development of<br/> innovative medicines</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;<br/> &#160;<br/> &#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-tech</div> (Tianjin) Co., Ltd.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(&#8220;I-Mab</div> Tianjin&#8221;)</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">PRC</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">July 15, 2017</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">100</td>
<td style="vertical-align: top; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: top;">&#160;<br/> &#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">Research and<br/> development of<br/> innovative medicines</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;<br/> &#160;<br/> &#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma US Ltd.</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">U.S.</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">February 28, 2018</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">100</td>
<td style="vertical-align: top; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: top;">&#160;<br/> &#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">Research and<br/> development of<br/> innovative medicines</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;<br/> &#160;<br/> &#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712193752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Principal Accounting Policies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. PRINCIPAL ACCOUNTING POLICIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.1 Basis of presentation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant accounting policies followed by the Group in the preparation of the accompanying consolidated financial statements are summarized below. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.2 Basis of consolidation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All inter-company balances and transactions have been eliminated in consolidation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group consolidates entities in which it has a controlling financial interest based on either the variable interest entity (VIE) or voting interest model. The Group is required to first apply the VIE model to determine whether it holds a variable interest in an entity, and if so, whether the entity is a VIE. If the Group determines it does not hold a variable interest in a VIE, it then applies the voting interest model. Under the voting interest model, the Group consolidates an entity when it holds a majority voting interest in an entity. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for investments in which it has significant influence but not a controlling financial interest using the equity method of accounting (see Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">VIE Model </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An entity is considered to be a VIE if any of the following conditions exist: (a)&#160;the total equity investment at risk is not sufficient to permit the entity to finance its activities without additional subordinated financial support, (b)&#160;the holders of the equity investment at risk, as a group, lack either the direct or indirect ability through voting rights or similar rights to make decisions that have a significant effect on the success of the entity or the obligation to absorb the entity&#8217;s expected losses or right to receive the entity&#8217;s expected residual returns, or (c)&#160;the voting rights of some equity investors are disproportionate to their obligation to absorb losses of the entity, their rights to receive returns from an entity, or both and substantially all of the entity&#8217;s activities either involve or are conducted on behalf of an investor with disproportionately few voting rights. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the VIE model, limited partnerships are considered VIE unless the limited partners hold substantive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">kick-out</div> or participating rights over the general partner. The Group consolidates entities that are VIEs when the Group determines it is the primary beneficiary. Generally, the primary beneficiary of a VIE is a reporting entity that has (a)&#160;the power to direct the activities that most significantly affect the VIE&#8217;s economic performance, and (b)&#160;the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the Group determined that the one entity subject to the consolidation guidance is a VIE for which the Group is not the primary beneficiary. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: left;"><div style="margin-block: 0em; line-height: 8pt;">&#160;</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.3 Use of estimates </div></div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally, estimates are used in determining items such as fair value measurements of wealth management products, warrants and put right liabilities, impairment of accounts receivables, contract assets, other receivables, long-lived assets, intangible assets and goodwill, useful lives of property, equipment and software, recognition of right-of-use assets and lease liabilities, variable consideration in collaboration revenue arrangements, determination of the standalone selling price of each performance obligation in the Company&#8217;s revenue arrangements, valuation of share-based compensation arrangements and deferred tax assets valuation allowances. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.4 Fair value measurements </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial assets and liabilities of the Group primarily comprise of cash and cash equivalents, restricted cash, short-term investments, other financial assets, accounts receivable, contract assets, other receivables, short-term borrowings, accruals and other payables, warrant liabilities and put right liabilities. As of December 31, 2019 and 2020, except for short-term investments, other financial assets and put right liabilities, the carrying values of these financial assets and liabilities approximated their fair values because of their generally short maturities. The Group reports short-term investments, other financial assets and put right liabilities at fair value at each balance sheet date and changes in fair value are reflected in the consolidated statements of comprehensive income (loss).&#160;</div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group measures its financial assets and liabilities using inputs from the following three levels of the fair value hierarchy. The three levels are as follows: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 inputs are unadjusted quoted prices in active markets for identical assets that the management has the ability to access at the measurement date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 inputs include quoted prices for similar assets in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 includes unobservable inputs that reflect the management&#8217;s assumptions about the assumptions that market participants would use in pricing the asset. The management develops these inputs based on the best information available, including the own data.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Assets and liabilities measured at fair value on a recurring basis </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Group measures its short-term investments, other financial assets, warrant liabilities, and put right liabilities at fair value on a recurring basis. As the Group&#8217;s short-term investments, other financial assets, warrant liabilities and put right liabilities are not traded in an active market with readily observable prices, the Group uses significant unobservable inputs to measure the fair value of short-term investments, other financial assets, warrant liabilities and put right liabilities. These instruments are categorized in the Level 3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement.</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Group&#8217;s financial assets and liabilities measured and recorded at fair value on a recurring basis as of December&#160;31, 2019 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Active&#160;market</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Observable&#160;input</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">observable&#160;input</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Active&#160;market<br/> (Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Observable&#160;input<br/> (Level 2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">observable&#160;input<br/> (Level 3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31,530</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31,530</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Put right liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">116,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">116,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The roll forward of major Level&#160;3 financial assets <div style="letter-spacing: 0px; top: 0px;;display:inline;">a</div>nd financial liabilities are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Short-term<br/> investments</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Other&#160;financial<br/> assets</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Warrant<br/> liabilities</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Put right<br/> liabilities</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair&#160;value&#160;of&#160;Level&#160;3&#160;financial&#160;asset&#160;and&#160;liabilities&#160;as&#160;of&#160;December&#160;31,&#160;2018</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">255,958</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5,618</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">134,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposal of short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(102,703</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposal of other financial assets due to Termination Agreement</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(256,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value changes</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">703</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,644</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(26</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair&#160;value&#160;of&#160;Level&#160;3&#160;financial&#160;assets&#160;and&#160;liabilities&#160;as&#160;of&#160;December&#160;31,&#160;2019</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">32,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,491,991</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposal of short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,503,749</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant of put right liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">124,321</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value changes</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3,024</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5,291</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Level&#160;3 financial assets and liabilities as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31,530</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">116,006</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>&#160;for additional information about Level&#160;3 put right liabilities measured at fair value on a recurring basis for the year ended December&#160;31, 2020. </div></div>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.5 Foreign currency translation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group uses Chinese Renminbi (&#8220;RMB&#8221;) as its reporting currency. The United States Dollar (&#8220;US$&#8221;) is the functional currency of the Group&#8217;s entities incorporated in the Cayman Islands, the United States of America (&#8220;U.S.&#8221;) and Hong Kong, the Australia Dollar (&#8220;AUD&#8221;) is the functional currency of the Group&#8217;s entity incorporated in Australia and the RMB is the functional currency of the Company&#8217;s PRC subsidiaries. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transactions denominated in other than the functional currencies are translated into the functional currency of the entity at the exchange rates prevailing on the transaction dates. Assets and liabilities denominated in other than the functional currencies are translated at the balance sheet date exchange rate. The resulting exchange differences are recorded in the consolidated statements of comprehensive income (loss). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements of the Group are translated from the functional currency to the reporting currency, RMB. Assets and liabilities of the subsidiaries are translated into RMB using the exchange rate in effect at each balance sheet date. Income and expenses are translated at the average exchange rates prevailing for the year. Foreign currency translation adjustments arising from these are reflected in the accumulated other comprehensive <div style="letter-spacing: 0px; top: 0px;;display:inline;">income (loss). The exchange rates&#160;</div>used for translation on December&#160;31, 2019 and 2020 were US$1.00 = RMB6.9762 and RMB6.5249 respectively, representing the index rates stipulated by the People&#8217;s Bank of China. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translations of balances in the consolidated balance sheets, consolidated statements of comprehensive income (loss), consolidated statements of changes in shareholders&#8217; equity (deficit) and consolidated statements of cash flows from RMB into US$ as of and for the year ended December&#160;31, 2020 are solely for the convenience of the readers and were calculated at the rate of US$1.00=RMB6.5250, representing the noon buying rate in The City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New York on December&#160;31, 2020. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on December&#160;31, 2020, or at any other rate. The US$ convenience translation is not required under U.S. GAAP and all US$ convenience translation amounts in the accompanying consolidated financial statements are unaudited. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.6 Cash and cash equivalents </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Group considers all highly liquid investments with an original maturity date of three months or less at the date of purchase to be cash equivalents. </div></div> <div style="text-align: left;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.7 Restricted cash </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash consists of the guarantee deposits held in a designated bank account as security deposits under bank borrowing agreements. Such restricted cash will be released when the Group repays the related bank borrowings. The Group has presented restricted cash separately from cash and cash equivalents in the consolidated balance sheets. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash as reporte<div style="display:inline;">d</div>&#160;in the consolidated statement of cash flows are presented separately on the consolidated balance sheet as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December 31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,137,473</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,758,778</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">55,810</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,193,283</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,758,778</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td> </tr> </table>  <div style="clear: both; max-height: 0px; background: none;"/> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.8 Accounts receivable </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable are stated at amortized cost less allowance for credit losses. The allowance for credit losses reflects the best estimate of future losses over the contractual life of outstanding accounts receivable and is determined on the basis of historical experience, specific allowances for known troubled accounts, other currently available information including customer financial condition, and both current and forecasted economic conditions. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.9 Short-term investments </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments represent the investments issued by commercial banks or other financial institutions with a variable interest rate indexed to the performance of underlying assets within one year. These investments are stated at fair value. Changes in the fair value are reflected in the consolidated statements of comprehensive income (loss). </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.10 Property, equipment and software&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the following estimated useful lives, taking into account of any estimated residual value: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 46%; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">3 to 10 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">1 to 5 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Office furniture and equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">5 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Lesser of useful life or lease term</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group recognizes the gain or loss on the disposal of property, equipment and software in the consolidated statements of comprehensive income (loss). </div></div><div style="text-align: left;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.11 Intangible assets </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets acquired in a business combination that are used in research and development activities, or in-process research and development (IPR&amp;D) intangible assets, are considered indefinite lived until the completion or abandonment of the associated research and development efforts. During the period that those assets are considered indefinite lived, they are not amortized but are tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. If after assessing the totality of events and circumstances and their potential effect on significant inputs to the fair value determination the Group determines that it is not more likely than not that the indefinite-lived intangible is impaired, then the entity shall calculate the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value of the asset with its carrying amount. If the carrying amount exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. For IPR&amp;D assets, the impairment loss is recognized in research and development expenses in the consolidated statements of comprehensive income (loss).</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets with finite useful lives are amortized over their useful lives. The useful life of an intangible asset is the period over which the asset is expected to contribute directly or indirectly to the future cash flows of the Group. The Group uses the straight-line amortization method when the economic benefits of the intangible assets are consumed or otherwise used up cannot be reliably determined. In particular, the Group amortizes the IPR&amp;D intangible assets with finite useful lives over 10 to 20 years on a straight-line basis. Intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. If circumstances require an intangible asset be tested for possible impairment, the Group first compares undiscounted cash flows expected to be generated by that asset to its carrying amount. If the carrying amount is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. For IPR&amp;D assets, the impairment loss is recognized in research and development expenses in the consolidated statements of comprehensive income (loss).</div></div></div></div> </div><div style="text-align: left;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.12 Impairment of long-lived assets </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets, such as property, plant, and software, and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. For the years ended December&#160;31, 2019 and 2020, there was no impairment of the value of the Group&#8217;s long-lived assets. </div></div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: left;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.13 Goodwill </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The Group allocates the cost of an acquired entity to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price for acquisitions over the fair value of the net assets acquired, including other intangible assets, is recorded as goodwill. Goodwill is not amortized, but impairment of goodwill is tested on at least an annual basis or whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Group&#8217;s reporting unit is less than its carrying amount, including goodwill. The qualitative assessment includes the Group&#8217;s evaluation of relevant events and circumstances affecting the Group&#8217;s single reporting unit, including macroeconomic, industry, market conditions and the Group&#8217;s overall financial performance. If qualitative factors indicate that it is more likely than not that the Group&#8217;s reporting unit&#8217;s fair value is less than its carrying amount, then the Group will perform the quantitative impairment test by comparing the reporting unit&#8217;s carrying amount, including goodwill, to its fair value. If the carrying amount of the reporting unit exceeds its fair value, an impairment loss will be recognized in an amount equal to that excess. For the years ended December&#160;31, 2019 and 2020, the Group determined that there were no indicators of impairment of the goodwill. </div></div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="text-align: left;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.14 Long-term investments </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s long-term investments include equity investments in an affiliate in which it does not have a controlling financial interest, but has the ability to exercise significant influence over the operating and financial policies of the investee. The investment is accounted for using the equity method of accounting in accordance with ASC topic 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Under the equity method, the Group initially records its investments at fair value. The Group subsequently adjusts the carrying amount of the investment to recognize the Group&#8217;s proportionate share of the equity investee&#8217;s net income or loss after the date of investment. When the liquidation rights and priorities as defined by an equity investment agreement diff<div style="display:inline;">e</div>r from what is reflected by the underlying percentage ownership interests, applying the percentage ownership interest to U.S. GAAP net income in order to determine earnings or losses does not accurately represent the income allocation and cash flow distributions that will ultimately be received by the investors. As such, for this type of investments, the Group uses the Hypothetical Liquidation at Book Value (&#8220;HLBV&#8221;) method for allocating earnings or losses of the equity method investee. The HLBV method is considered as a balance sheet approach. Specifically, a calculation is prepared at each balance sheet date to determine the amount that the Group would receive if an equity investment entity were to liquidate all of its assets (as valued in accordance with U.S. GAAP) and distribute that cash to the investors based on the contractually defined liquidation priorities. The difference between the calculated liquidation distribution amounts at the beginning and the end of the reporting period, after adjusting for capital contributions and distributions, is the Group&#8217;s share of the earnings or losses from the equity investment for the period. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As it relates to the share-based compensation awarded by an equity method investee to its own employees, the Group recognizes its proportionate share of the compensation expense over the vesting period, included in the equity in loss of affiliate in the consolidated statements of comprehensive income (loss). As it relates to the share-based compensation awarded by the Group to the equity method investee employees that are based on the Group&#8217;s stock, when the other investors do not provide proportionate value to the investee or the Group does not receive any consideration, the Group expenses the entire cost associated with the award in the same period the costs are recognized by the investee, to the extent that the Group&#8217;s claim on the investee&#8217;s book value has not been increased. The expenses recognized by the Group is included in the equity in loss of affiliate in the consolidated statements of comprehensive income (loss). </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group evaluates the equity method investment for impairment under ASC 323. An impairment loss on the equity method investments is recognized in losses when the decline in value is determined to be other-than-temporary. No impairment charge was recognized for the year ended December&#160;31, 2020. </div></div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.15 Deferred subsidy income&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred subsidy income consists of deferred income from government grants. Government grants mainly consist of cash subsidies received by the Group&#8217;s subsidiaries in the PRC from local governments as support on expenses relating to certain projects. Grants received with government specified performance obligations are recognized as other income when all the obligations have been satisfied. If such obligations are not satisfied, the Group may be required to refund the subsidy. The Group recorded cash grants</div> of RMB7,509 and RMB3,920 and in deferred subsidy income as of December&#160;31, 2020 and 2019 respectively. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.16 Revenue recognition&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Group adopted Accounting Standard Codification (&#8220;ASC&#8221;) 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div> (Topic 606) (&#8220;ASC 606&#8221;) for all periods presented. Consistent with the criteria of Topic 606, the Group recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. An the entity performs the following five steps to account for the arrangements that an entity determines are within the scope of ASC 606: (i) identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once a contract is determined to be within the scope of ASC 606 at contract inception, the Group audits the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration revenue </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">At contract inception, we analyze its collaboration arrangements to assess whether they are within the scope of ASC 808,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Collaborative Arrangements</div></div>&#160;(&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, we first determine if the collaboration is deemed to be within the scope of ASC 808. For any units of account that are reflective of a vendor-customer relationship those units of account are accounted for within the scope of ASC 606. For any units of account that are not accounted for under ASC 606 and therefore accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s collaborative arrangements may contain more than one unit of account, or performance obligation, such as grant of licenses of intellectual property rights, promises to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. When multiple units of account or performance obligations are identified within the arrangements, the Group must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&#160;In developing the stand-alone selling price for a performance obligation, the Group considers competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. </div></div>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>   <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licenses of Intellectual Property:</div></div> Upfront <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> payments for licensing the Group&#8217;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For the license that is determined to be distinct, the Group recognizes revenues in the amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> fees allocated to the license at a point in time, upon which the license is transferred to the licensee and the licensee is able to use and benefit from the license. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Services: </div></div>The portion of the transaction price allocated to research and development services performance obligations is deferred and recognized as revenue over time as delivery or performance of such services provided to the Group&#8217;s customers occurs. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Milestone Payments</div></div>: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any resulting adjustment is recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect the Group&#8217;s reported revenues and earnings in the period of the adjustment. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties</div></div>: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the sales-based royalties or milestone payments relate, the Group recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</div>  <div style="text-align:left;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract assets and liabilities </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets primarily represent revenue earnings over time that are not yet billable based on the terms of the contracts. The Group does not have impairment losses associated with contracts with customers for the years ended December 31, 2019 and 2020. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities consist of fees invoiced or paid by the Group&#8217;s customers for which the associated performance obligations have not been satisfied and revenue has not been recognized based on the Group&#8217;s revenue recognition criteria described above. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets and contract liabilities are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current in the consolidated balance sheet when the Group expects to complete the related performance obligations and invoice the customers within one year of the balance sheet date, and as long-term when the Group expects to complete the related performance obligations and invoice the customers more than one year out from the balance sheet date. Contract liabilities are classified as current in the consolidated balance sheet when the revenue recognition associated with the related customer payments and invoicing is expected to occur within one year of the balance sheet date and as long-term when the revenue recognition associated with the related customer payments and invoicing is expected to occur in more than one year from the balance sheet date. </div></div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.17 Value-added-tax (&#8220;VAT&#8221;) recoverable and surcharges&#160;</div></div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Value added tax recoverable represent amounts paid by the Group for purchases. The surcharges (i.e., Urban construction and maintenance tax, educational surtax, local educational surtax), vary from 6% to 12% of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;value-added-tax&#160;depending</div> on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;tax-payer&#8217;s&#160;location.</div> The deductible input VAT balance is included in the prepayments and other receivables in the consolidated balance sheets, and VAT payable balance is recorded in the accruals and other payables in the consolidated balance sheets. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> 2.18 Research and development expensesElements of research and development expenses primarily include (1)&#160;payroll and other related expenses of personnel engaged in research and development activities, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(2)&#160;in-licensed</div> patent rights fee of exclusive development rights of drugs granted to the Group, (3)&#160;expenses related to preclinical testing of the Group&#8217;s technologies under development and clinical trials such as payments to contract research organizations (&#8220;CRO&#8221;), investigators and clinical trial sites that conduct the clinical studies, (4)&#160;expenses to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, and (5)&#160;other research and development expenses. Research and development expenses are charged to expenses as incurred when these expenditures are used for the Group&#8217;s research and development activities and have no alternative future uses.The Group has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-commercial</div> milestone payments, are immediately expensed as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development in the period in which they are incurred, provided that the new drug compound does not also include processes or activities that would constitute a &#8220;business&#8221; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. All development expenditures are recognized in profit or loss when incurred, as long as the conditions enabling capitalization of development expenses as an asset have not yet been met. <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.19 Leases&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In accordance with ASC 842 adopted on January&#160;1, 2019, the Group determines if an arrangement is a lease at inception. Operating leases are included in operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets, operating lease liability, and operating lease liability, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> in the Group&#8217;s consolidated balance sheets. The Group does not have any finance leases since the adoption date. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROU assets represent the Group&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Group&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. When determining the lease term, the Group includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Group&#8217;s leases do not provide an implicit rate, the Group uses its incremental borrowing rate, which it calculates based on the credit quality of the Group and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group has elected to adopt the following lease policies in conjunction with the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02:</div> (i) elect for each lease not to separate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components from lease components and instead to account for each separate lease component and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components associated with that lease component as a single lease component; (ii)&#160;for leases that have lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Group elected not to apply ASC 842 recognition requirements; and (iii)&#160;the Group elected to apply the package of practical expedients for existing arrangements entered into prior to January&#160;1, 2019 to not reassess (a)&#160;whether an arrangement is or contains a lease, (b)&#160;the lease classification applied to existing leases, and (c)&#160;initial direct costs. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the adoption of ASC 842, on January&#160;1, 2019, the Group recorded an impact of RMB13,100 on its assets and RMB11,333 on its liabilities for the recognition of operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use-assets</div></div></div> and operating lease liabilities, respectively, which are primarily related to the lease of the Group&#8217;s offices and warehouses. The adoption of ASC 842 did not have a material impact on the Group&#8217;s results of operations or cash flows. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.20 Comprehensive income (loss)</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive income (loss) is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220,&#160;Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as components of comprehensive income (loss) be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Group&#8217;s comprehensive income (loss) includes net income (loss) and foreign currency translation adjustments, which are presented in the consolidated statements of comprehensive income (loss). </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.21 Share-based compensation&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group grants restricted shares and stock options to eligible employees and accounts for share-based compensation in accordance with ASC 718, Compensation&#8212;Stock Compensation.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employees&#8217; share-based compensation awards, if equity-classified, are measured at the grant date fair value of the awards and are recognized as expenses over the requisite period of the award, which is generally the vesting term of share-based payment awards.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation in relation to the restricted shares is measured based on the fair market value of the Group&#8217;s ordinary shares at the grant date of the award. Prior to the listing, estimation of the fair value of the Group&#8217;s ordinary shares involves significant assumptions that might not be observable in the market, and a number of complex and subjective variables, including discount rate, and subjective judgments regarding the Group&#8217;s projected financial and operating results, its unique business risks, the liquidity of its ordinary shares and its operating history and prospects at the time the grants are made. Share-based compensation in relation to the share options is estimated using the Binominal Option Pricing Model. The determination of the fair value of share options is affected by the share price of the Group&#8217;s ordinary shares as well as the assumptions regarding a number of complex and subjective variables, including the expected share price volatility, risk-free interest rate, exercise multiple and expected dividend yield. In addition, the forfeiture rate is estimated based on an analysis of the Group&#8217;s actual forfeitures and the appropriateness of the forfeiture rate will continue to be evaluated based on the actual forfeiture experience, analysis of employee turnover and other factors. The fair value of these awards was determined with the assistance from an independent third-party valuation firm. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.22 Income taxes&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Group accounts for income taxes under the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates that expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded if it is more likely than not that some portion or all of the deferred income tax assets will not be utilized in the foreseeable future.&#160;</div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group evaluates its uncertain tax positions using the provisions of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-10,&#160;Income</div> Taxes, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Group recognizes in the financial statements the benefit of a tax position which is &#8216;&#8216;more likely than not&#8217;&#8217; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Group&#8217;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.23 Borrowings&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost. Any difference between the proceeds (net&#160;of transaction costs) and the redemption value is recognized as interest expense in the consolidated statements of comprehensive income (loss) over the period of the borrowings, using the effective interest method. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.24 Business combination&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group accounts for its business combinations using the acquisition method of accounting in accordance with ASC topic 805,&#160;Business Combinations&#160;(&#8220;ASC 805&#8221;). The acquisition method of accounting requires all of the following steps: (i)&#160;identifying the acquirer, (ii)&#160;determining the acquisition date, (iii)&#160;recognizing and measuring the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree, and (iv)&#160;recognizing and measuring goodwill or a gain from a bargain purchase. The consideration transferred in a business combination is measured as the aggregate of the fair values at the date of exchange of the assets given, liabilities incurred, and equity instruments issued as well as the contingent considerations and all contractual contingencies as of the acquisition date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed and intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets may include, but are not limited to, future expected cash flows from acquired assets, timing and probability of success of clinical events and regulatory approvals, and assumptions on useful lives of the patents and discount rates. Management&#8217;s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Additional information, such as that related to income tax and other contingencies, existing as of the acquisition date but unknown to us may become known during the remainder of the measurement period, not to exceed one year from the acquisition date, which may result in changes to the amounts and allocations recorded. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions that do not meet the accounting definition of a business combination are accounted for as asset acquisitions. For transactions determined to be asset acquisitions, the Group allocates the total cost of the acquisition, including transaction costs, to the net assets acquired based on their relative fair values. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.25 Segment information&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with ASC 280,&#160;Segment Reporting, the Group&#8217;s chief operating decision maker, the Chief Executive Officer, reviews the consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for the purpose of internal reporting. As the Group&#8217;s long-lived assets are substantially located in and derived from the PRC, no geographical segments are presented. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.26 Income (loss) per share&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Basic income (loss) per share is computed by dividing net income (loss) attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period using the two-class method. Under the two-class method, the net income (loss) is allocated between ordinary shares and other participating securities based on their participating rights. Net income (loss) is not allocated to other participating securities if based on their contractual terms they are not obligated to share in the income (loss). Diluted income (loss) per share is calculated by dividing net income (loss) attributable to ordinary shareholders by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of shares issuable upon the conversion of the preferred shares using the if-converted method, shares issuable upon the issuance of ordinary shares to be issued to Everest using the if-converted method, shares issuable upon the conversion of the convertible promissory notes using the if-converted method, shares issuable upon the exercise of share options using the treasury stock method, shares issuable upon the issuance of ordinary shares for restricted shares units using the treasury stock method, and shares issuable upon the exercise of warrants using the treasury stock method. Ordinary equivalent shares are not included in the denominator of the diluted income (loss) per share calculation when inclusion of such shares would be anti-dilutive.</div> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.27 Adopted accounting pronouncements&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13&#8221;).</div> This guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability. In November 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-19,</div> Codification Improvements to Topic 326, Financial Instruments-Credit Losses (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-19&#8221;),</div> which clarifies certain topics included within ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13.</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> and ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-19</div> are effective for the annual reporting period beginning after December&#160;15, 2019, including interim periods within that reporting period. The impact of this ASU to the consolidated financial statements is immaterial. The Group elected to adopt this ASU and applied this guidance retrospectively to all periods presented. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In January 2017, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2017-04,</div> Intangibles&#8212;Goodwill and Other (Topic 350), which simplifies the subsequent measurement of goodwill by removing the second step of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-step</div> impairment test. The amendment requires an entity to perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. A goodwill impairment will be the amount by which a reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The Group adopted this ASU on January&#160;1, 2020 and the adoption of this ASU does not have a material impact to its consolidated financial statements. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In August 2018 the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2018-13,</div> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January&#160;1, 2020. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.27 Adopted accounting pronouncements (continued)&#160;</div> </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In November 2018 the FASB issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASU&#160;No.&#160;2018-18,&#160;Collaborative</div> Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This standard makes targeted improvements for collaborative arrangements as follows: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, Revenue from Contracts with Customers, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Adds&#160;unit-of-account&#160;guidance</div></div> to ASC 808, Collaborative Arrangements, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and </div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This standard became effective for the Group on January&#160;1, 2020. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings. Since the Group&#8217;s all relevant units of accounts were accounted for under ASC 606, the adoption of this ASU does not have a material impact to the Group&#8217;s consolidated financial statements, with no adjustment to its opening retained earnings. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.28 &#160; &#160; Recent accounting pronouncements&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, the FASB issued ASU 2019-12-Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for the Company beginning on January 1, 2022. Early adoption of the amendments is permitted. The Company is currently evaluating the impact of ASU 2019-12 on its consolidated financial statements.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In January 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-01,</div> Investments &#8211; Equity Securities (Topic 321), Investments &#8211; Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying Interactions between Topic 321, Topic 323, and Topic 815. ASU 2020-01addresses accounting for the transition into and out of the equity method and provides guidance on whether equity method accounting would be applied to certain purchased options and forward contracts upon settlement. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-01</div> is effective for the Group&#8217;s annual periods beginning after December&#160;15, 2021. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-01</div> will be applied prospectively. Early adoption is permitted. The Group is currently evaluating the effect the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-01</div> will have on its consolidated financial statements. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712736584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable And Contract  Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_AccountsReceivableAndContractAssetsAbstract', window );"><strong>Accounts Receivable And Contract Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_AccountsReceivableAndContractAssetsTextBlock', window );">Accounts Receivable And Contract Assets</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. ACCOUNTS RECEIVABLE AND CONTRACT ASSETS </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable and contract assets, net of allowance for credit losses, consisted of the following: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December 31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, gross</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">130,498</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for credit losses</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">130,498</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December 31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets, gross</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">227,391</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">34,849</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for credit losses</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets, net</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">227,391</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">34,849</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No allowance for credit losses was recorded as of December&#160;31, 2019 and 2020. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_AccountsReceivableAndContractAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable And Contract Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_AccountsReceivableAndContractAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_AccountsReceivableAndContractAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable And Contract Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_AccountsReceivableAndContractAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712549064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayments And Other Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PrepaidexpensesandotherreceivablestextblockTextBlock', window );">Prepaid Expenses And Other Receivables</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. PREPAYMENTS AND OTHER RECEIVABLES </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;RMB&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepayments:</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Prepayments to CRO vendors</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">78,740</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,140</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,742</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Prepayments for other services</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">880</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">391</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receivables due from employees <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,201</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Receivables due from an affiliate (Note 2<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>)</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#8212;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">21,212</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">3,251</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Value-added tax recoverable</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">12,517</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">63,664</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">9,757 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rental deposits</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">546</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">1,766</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">271 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest receivables</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">764</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">236</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">36</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Others</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">26,388</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">22,899</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,509</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 68%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 68%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">136,036</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">195,467 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">29,957</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 68%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The balance mainly represents the receivables due from <div style="letter-spacing: 0px; top: 0px;;display:inline;">certain&#160;</div>employees, arose from the Group&#8217;s obligation to pay the withholding individual income tax (&#8220;IIT&#8221;) for those employees&#8217; stock option activities. The balance was collected by the Group in January 2020. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PrepaidexpensesandotherreceivablestextblockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other receivables [Text Block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PrepaidexpensesandotherreceivablestextblockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712392680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment And Software<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Equipment and Software</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. PROPERTY, EQUIPMENT AND SOFTWARE </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, equipment and software consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipmen<div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">24,265</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">30,808</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvement</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,856</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,842</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,121</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,531 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Office furniture and equipment</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,526</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,531</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">234</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property, equipment and software</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">47,867</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">56,171 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,608 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(18,221</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,899</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(4,735</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net book value</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">29,646</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25,272 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,873</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in <div style="letter-spacing: 0px; top: 0px;;display:inline;">progress</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">423</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total net book value of property, equipment and software</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">30,069</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25,272 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,873</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total amounts charged to the consolidated statements of comprehensive income/(loss) for depreciation and amortization expenses amounted to approximately RMB6.7&#160;million, RMB9.8&#160;million and RMB12.7&#160;million, for the years ended December&#160;31, 2018, 2019 and 2020, respectively. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707713966840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div>. LEASES </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the Company has operating leases recorded on its balance sheet for certain office spaces and facilities that expire on various dates through 2023. The Group does not plan to cancel the existing lease agreements for its existing facilities prior to their respective expiration dates. When determining the lease term, the Group includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. All of the Group&#8217;s leases qualify as operating leases. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information related to operating leases as of December&#160;31, 2019 and 2020 is as follows (in thousands, except for percentages and years). </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,435</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,997</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,298</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, current</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,807</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,058</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease liabilities, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,492</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,542</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">849</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term (years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information related to operating lease activity during the years ended December&#160;31, 2019 and 2020 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Year Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease rental expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Amortization of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,260</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,158</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expense for short-term leases within 12 months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">592</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest of lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">543</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">679</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">104</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,395</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,837</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,354</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> Maturities of lease liabilities were as follows:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,901</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">837</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">536</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">82</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total undiscounted lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,901</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,283</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,301</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(199</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,600</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,084</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707713128072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assests<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">7</div>. INTANGIBLE ASSETS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets as of December&#160;31, 2019 and 2020 are summarized as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;carrying&#160;amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net carrying amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D TJ103</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,556</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D TJ101</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">110,330</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">110,330</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,909</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">122,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,556</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">120,444</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,459</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross carrying amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;carrying&#160;amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 51%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 51%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D TJ103</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,788</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 51%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">IPR&amp;D TJ102</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 51%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D TJ101</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">110,330</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">110,330</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,909</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 51%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 51%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">148,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">148,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">22,811</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 51%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The three IPR&amp;D assets (TJ103, TJ101, and TJ102) were acquired from the business combination of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin and its subsidiaries including Chengdu Tasgen <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-Tech</div> Co., Ltd. and Shanghai Tianyunjian <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-Tech</div> Co., Ltd. (together the &#8220;Tasgen Group&#8221;) in 2017. The licensor of these IPR&amp;D assets was Genexine, Inc. The gross carrying amounts represent the fair value assigned to the respective research and development assets. At the date of acquisition, all three assets had not reached technological feasibility. They were considered indefinite lived. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">IPR&amp;D related to TJ103 was subsequently determined to have a finite useful life as a result of an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> arrangement. Consequently, the Group uses the straight-line method to amortize the asset. The amortization for the years ended December&#160;31, 2018, 2019 and 2020 was nil, nil, and RMB1,556 respectively, recognized as research and development expenses in the consolidated statements of comprehensive income (loss). The estimated amortization expense for each of the five succeeding fiscal years is RMB778. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On September 15, 2020, I-Mab Hong Kong and Genexine, Inc. entered into amendments to Intellectual Property License Agreement with I-Mab Hangzhou to assign and transfer all the rights and obligations related to TJ102 to I-Mab Biopharma (Hangzhou) Limited (&#8220;I-Mab Hangzhou&#8221;), pursuant to an equity transfer and investment agreement entered into between I-Mab Hong Kong and various parties (see Note <div style="display:inline;">9</div>).</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2019 and 2020, there was no impairment of the value of the Group&#8217;s intangible assets. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707715434312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div>. GOODWILL </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;15, 2017, the Group acquired 66.67% of the equity interests in the Tasgen Group by issuing convertible preferred shares, and controlled the board of directors and business of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin since then. Tasgen Group is principally engaged in the research and development of innovative medicines and the Group acquired Tasgen Group for its research team, technical experience, and IPR&amp;D pipeline assets (see Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>). As of December&#160;31, 2019 and 2020, the goodwill of RMB162,574 (US$24,916) represented the goodwill generated from the aforementioned acquisition of Tasgen Group and the business of Tasgen Group was fully integrated into the Company after the acquisition. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2019 and 2020, the Group performed a qualitative assessment by evaluating relevant events and circumstances that would affect the Group&#8217;s single reporting unit and did not note any indicator that it is more likely than not that the fair value of the Group&#8217;s reporting unit is less than its carrying amount and therefore the Group&#8217;s goodwill was not impaired. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2144439<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707713128072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment Accounted for Using the Equity Method and Put Right Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract', window );"><strong>Investment Accounted For Using The Equity Method And Put Right Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock', window );">Investment Accounted for Using the Equity Method and Put Right Liabilities</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>. INVESTMENT ACCOUNTED FOR USING THE EQUITY METHOD AND PUT RIGHT LIABILITIES</div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Investment accounted for using the equity method </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou, incorporated on June&#160;16, 2019, was a wholly owned subsidiary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong with registered capital of US$30&#160;million, which was paid up by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong on September&#160;14, 2020. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On September&#160;15, 2020 (the &#8220;Closing Date&#8221;), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong entered into an equity transfer and investment agreement (the &#8220;SPA&#8221;) with (i)&#160;a limited partnership jointly established by the management of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou to hold restricted equity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou issued to the management (&#8220;Management Holdco&#8221;), (ii) a limited partnership established to hold the shares of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou for future equity incentive plan (&#8220;ESOP Holdco&#8221;) and (iii)&#160;a group of domestic investors in China (&#8220;Domestic Investors&#8221;). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the terms of the SPA, </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(i)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong agreed to assign all rights and obligations/ownership of certain drug candidates in different stages of development (&#8220;Target Pipelines&#8221;) to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou as of the Closing Date as well as to transfer employment of a team of designated management/workforce to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou. The Target Pipelines were evaluated by an independent valuer, with a total value of US$105&#160;million as of the Closing Date; </div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(ii)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Management Holdco would acquire 10% of the equity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong with no consideration. The <div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div>% equity is represented by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou&#8217;s registered capital of US$3&#160;million, and that after acquiring such equity, Management Holdco is committed to pay US$3&#160;million in cash to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou to fulfil its capital contribution obligations in a period of four years starting from the Closing Date; </div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(iii)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">ESOP Holdco would acquire 5% of the equity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong with no consideration. The <div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>% equity is represented by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou&#8217;s registered capital of US$1.5&#160;million. All of such equity would be used for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou&#8217;s future equity incentive plan. </div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(iv)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Domestic Investors would acquire a total of 40% of the equity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong with no consideration. The <div style="letter-spacing: 0px; top: 0px;;display:inline;">40</div>% equity is represented by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou&#8217;s registered capital of US$12&#160;million, and after acquiring such equity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou, Domestic Investors would pay US$120&#160;million collectively in cash to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou to fulfil its capital contribution obligations. </div></td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Investment accounted for using the equity method (continued) </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Upon closing of the SPA, the registered capital of I-Mab Hangzhou remained to be</div>&#160;US$30&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million. As of December 31, 2020, among the total&#160;</div> 25,500,000 outstanding shares of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou, 13,500,000 shares were held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> H<div style="letter-spacing: 0px; top: 0px;;display:inline;">ong Kong</div>&#160;while the remaining 12,000,000 <div style="letter-spacing: 0px; top: 0px;;display:inline;">shares was held by Domestic Investors. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares subscribed by Management Holdco and ESOP Holdco, in the total number of 4,500,000, have not yet been purchased by or issued to Management Holdco and ESOP Holdco as of December, 31, 2020. </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">Once all the<div style="letter-spacing: 0px; top: 0px;;display:inline;">se 4,500,000</div>&#160;subscribed shares of I-Mab Hangzhou are purchased<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">by<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>or issued to Management Holdco and ESOP Holdco, the equity interest in I-Mab Hangzhou held by I-Mab Hong Kong, Domestic Investors, Management Holdco and ESOP Holdco would be</div>&#160;45%, 40%, 10% and 5% respectively<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On the same day, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong also entered into a shareholders agreement with the aforementioned investors (the &#8220;SHA&#8221;). According to the SHA and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou&#8217;s articles of association, the board of directors of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou shall be composed of seven directors. The directors shall be elected in the following ways: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong is entitled to appoint three directors, including the chairman of the board of directors, as well as nominate one independent director; the Management Holdco is entitled to appoint one director; two <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-related</div> entities of the Domestic Investors are entitled to appoint one director respectively (&#8220;Investors Directors&#8221;). Each director of the board of directors shall have one vote. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong, Management Holdco and ESOP Holdco agree to act in concert, as long as each of Management Holdco and ESOP Holdco respectively holds equity in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou, when exercising the rights as a shareholder. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As a result of the above transactions, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou became an affiliate of the Group on the Closing Date in accordance with ASC 810 since <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou meets the definition of a business under ASC 805. In accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">810-10,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou is a variable interest entity, and no shareholder shall consolidate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou under VIE model as neither party have the power to direct all the activities that most significantly impact the economic performance of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou. Therefore, the Group deconsolidated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou and retained significant influence in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou. The investment was accounted for using the equity method. The retained investment in the common stock of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou was initially measured at fair value in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">810-10-40.</div></div></div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group determined the fair value of its retained equity interest with the assistance of an independent third-party valuation firm. The Group used equity allocation model to estimate the fair value of the investment. The fair value as of the Closing Date was US$112,039 (equivalent to approximately RMB764,352), which reflected the fact that the shares subscribed by Management Holdco and ESOP Holdco were not issued and outstanding as of the Closing Date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A gain of RMB407,598&#160;million was recognized as a result of the deconsolidation. The gain represented the difference between: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">i)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The fair value of the retained noncontrolling investment in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou at the Closing Date; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">ii)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate of all of the following: </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the carrying amount of transferred intellectual property related to TJ102 at the Closing Date (see Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>); </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the fair value of the put right liabilities written by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong to Domestic Investors; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the carrying amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou&#8217;s net assets at the Closing Date<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> </td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Investment accounted for using the equity method (continued) </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Subsequently, pursuant to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou&#8217;s articles of association, the Group applies the HLBV method to allocate earnings or losses of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou because the liquidation rights and priorities sufficiently differ from what is reflected by the underlying percentage ownership interests. For the period from September&#160;15, 2020 to December&#160;31, 2020, the Group recognized RMB67,425 in equity in loss of an affiliate in the consolidated statements of comprehensive income. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The purchase price of US$3 million committed by Management Holdco under SPA, representing 10% of the equity of I-Mab Hangzhou, is significantly lower than the fair value of the corresponding subscribed shares as of the Closing Date. The excess is considered as share-based compensation to the I-Mab Hangzhou&#8217;s management for the services to be used or consumed in the I-Mab Hangzhou&#8217;s own operations. The share-based compensation is considered granted upon the Closing Date and cliff vests after five years of service since the Closing Date. Consequently, the Group recognizes its proportionate share of the compensation expense recorded by I-Mab Hangzhou. For the period from September 15, 2020 to December 31, 2020, the amount included in the equity in loss of an affiliate in the Group&#8217;s consolidated statements of comprehensive income is RMB8,456.</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Along with the equity transfer transaction, the team of designated management/workforce transferred from the Group to I-Mab Hangzhou consists of several grantees under the Group&#8217;s 2020 Share Incentive Plan (&#8220;2020 Plan&#8221;, see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>(f)). These individuals continued to qualify the definition of the eligible participants under the 2020 Plan after the Closing Date. Meanwhile, there has been no change to any of the award terms. The equity transfer transaction did not trigger the modification accounting to the share-based compensation. Additionally, given that I-Mab Hangzhou became an affiliate to the Group upon deconsolidation, and that the other shareholders of I-Mab Hangzhou are not providing proportionate value to sponsor the 2020 Plan nor is the Group receiving any consideration for the awards granted to employees of I-Mab Hangzhou, the Group is required, under Topic 323, to expense the full costs of share-based compensation as incurred at the same period as the costs are recognized by I-Mab Hangzhou. For the year ended</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">December 31, 2020, such expenses of&#160;</div>RMB32,707 <div style="letter-spacing: 0px; top: 0px;;display:inline;">and was recorded in the equity in loss of an affiliate in the consolidated statements of comprehensive income.</div></div></div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2020, the carrying value of the Group&#8217;s long-term investment measured under equity method was&#160;</div> RMB664,832. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Group presented the summarized financial information of the Group&#8217;s long-term investment measured under equity method below in accordance with Rule 4-08 of Regulation S-X (RMB in thousands).</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;period&#160;from</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">15</div>,&#160;2020&#160;to</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating data:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">271</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">271</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(85,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(85,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 80%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance sheet data:</div></div></div> </td>
<td style="vertical-align: bottom; width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 80%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets</div></div></div> </td>
<td style="vertical-align: bottom; width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">923,010</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 80%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div></div> </td>
<td style="vertical-align: bottom; width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">810,623</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 80%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities</div></div></div> </td>
<td style="vertical-align: bottom; width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">31,519</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 80%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,933</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 80%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interests</div></div> </td>
<td style="vertical-align: bottom; width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) Put right liabilities </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the SHA, if <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou fails to close a public offering of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou&#8217;s shares on the China Stock Exchange&#8217;s Science and Technology Innovation Board, Main Board, Small and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Medium-Sized</div> Enterprise Board, Growth Enterprise Board, or Hong Kong Stock Exchange, U.S. Stock Exchange, or other stock exchanges approved by the shareholders of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou in accordance with provisions of the SHA within 4 years after September&#160;15, 2020, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong is obligated to repurchase the equity held by Domestic Investors in cash or in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab&#8217;s</div> stock (subject to the approval procedures of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab)</div> within 3 years from the expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-year</div> period after the Closing Date of September&#160;15, 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The put right written by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hong Kong to Domestic Investors is a freestanding equity-linked instrument, which is classified as a put right liability and is initially measured at fair value. Subsequent changes in fair value are recorded in other income (loss) in the <div style="letter-spacing: 0px; top: 0px;;display:inline;">consolidated statements of comprehensive income (loss).</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group determined the fair value of the put right with the assistance of an independent third-party valuation firm. The Group used the option pricing model (finnerty model) to estimate the fair value of the put right using the following assumptions: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;September</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,&#160;and&#160;September<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected terms (Year)</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated volatility</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">55.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">55.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Spot price</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">US$</td>
<td style="vertical-align: bottom;;text-align:right;">143,401</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align: bottom;">US$</td>
<td style="vertical-align: bottom;;text-align:right;">143,804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Probability of triggering event for redemption option</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The model requires the input of highly subjective assumptions including the expected terms, estimated volatility, spot price and probability of triggering event for redemption option. Expected terms is estimated based on the timing of a hypothetical redemption event which is assumed to be the earlier of expected redemption date or expected public offering date. Expected volatility is estimated based on daily stock prices of the comparable company for a period with length commensurate to the expected terms of redemption event. The spot price was determined with assistance from an independent third-party valuation firm. The Group&#8217;s management is ultimately responsible for the determination of the spot price and probability of triggering event for redemption option. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant decreases in interval between valuation date and maturity date, estimated volatility, spot price and probability of triggering event for redemption option would result in a significantly lower fair value measurement. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment Accounted for Using the Equity Method and Put Right Liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712454856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">Short-Term Borrowings</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div>. SHORT-TERM BORROWINGS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2018, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-tech</div> (Tianjin) Co., Ltd. borrowed a loan of RMB80,000 from China Merchant Bank Co., Ltd. for a term of one year and at the interest rate of 4.20% per annum. To facilitate this borrowing, another subsidiary of the Company in Hong Kong placed cash deposits of US$13,500 (equivalent to approximately RMB92,653) with the bank. The use of such cash deposits and the interest earned thereon are restricted by the bank during the period of the borrowing. The deposits have a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> term and bear interest at 3.26% per annum. The borrowing was fully repaid during the year ended December&#160;31, 2019. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2019, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-tech</div> (Tianjin) Co., Ltd. borrowed a loan of RMB50,000 from China Merchant Bank Co., Ltd. for a term of one year and at the interest rate of 4.15% per annum. To facilitate this borrowing, another subsidiary of the Company in Hong Kong placed cash deposits of US$8,000 (equivalent to approximately RMB55,810) with the bank. The use of such cash deposits and the interest earned thereon are restricted by the bank during the period of the borrowing. The deposits have a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> term and bear interest at 2.63% per annum. The borrowing was fully repaid in June 2020. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707715497688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accruals And Other Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accruals and other Payables</a></td>
<td class="text"><div style="text-align: left;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div>. ACCRUALS AND OTHER PAYABLES </div></div></div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Staff salaries and welfare payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">30,166</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">94,133</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,427</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued external research and development activities related expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">144,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">218,583 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">33,499</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued initial public offering costs payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,504</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued private placement offering costs payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">128,786 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,737</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Withholding IIT payable related to stock options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,201</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-refundable</div> incentive payment from depositary bank <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,424</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">371</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued traveling expenses, office expenses and others</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">65,682</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">116,632</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">273,553</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">560,558 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">85,909</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-refundable</div> incentive payment from depositary bank <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,474</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advance payment received from an employee for exercise of stock options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,501 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;">8,975</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;">1,375 </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> <div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">569,533</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">87,284</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The Group received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> incentive payment&#160;of US$1,857&#160;(equivalent to approximately RMB12,982) from depositary bank in April 2020.&#160;The amount was recorded ratably as other gains over a five-year arrangement period. For the year ended December&#160;31, 2020, the Group has recorded RMB2,348 as other income in the consolidated statements of comprehensive income. </div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712595832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>. INCOME TAXES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cayman Islands </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab&#160;is</div> incorporated in the Cayman Islands. Under the current laws of the Cayman <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Islands,&#160;I-Mab&#160;is</div> not subject to tax on income or capital gain. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> did business registration in Hong Kong and has a Hong Kong tax file number. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Hong Kong </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab&#160;Biopharma</div> Hong Kong Limited is incorporated in Hong Kong. Companies registered in Hong Kong are subject to Hong Kong profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Hong Kong tax laws. The applicable tax rate in Hong Kong is 16.5%. For the years ended December&#160;31, 2018, 2019 and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020,&#160;I-Mab&#160;Biopharma</div> Hong Kong Limited did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earnings in Hong Kong for any of the periods presented. Under the Hong Kong tax <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">law,&#160;I-Mab&#160;Biopharma</div> Hong Kong Limited is exempted from income tax on its foreign-derived income and there are no withholding taxes in Hong Kong on remittance of dividends. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Australia </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">I-Mab&#160;Biopharma Australia Pty Ltd is incorporated in Australia. Companies registered in Australia are subject to Australia profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Australia tax laws. The applicable tax rate in Australia is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30%.&#160;I-Mab&#160;Biopharma</div> Australia Pty Ltd has no taxable income for all periods presented, therefore, no provision for income taxes is required. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">United States </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab&#160;Biopharma</div> US Ltd. is incorporated in U.S. and is subject to U.S. federal corporate income tax at a rate of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">21%.&#160;I-Mab&#160;Biopharma</div> US Ltd. is also subject to state income tax in Maryland of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8.25%.&#160;I-Mab&#160;Biopharma</div> US Ltd. has no taxable income for all periods presented, therefore, no provision for income taxes is required. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">China </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;16, 2007, the National People&#8217;s Congress of PRC enacted a new Enterprise Income Tax Law (&#8220;new EIT law&#8221;), under which Foreign Investment Enterprises (&#8220;FIEs&#8221;) and domestic companies would be subject to corporate income tax at a uniform rate of 25%. The new EIT law became effective on January&#160;1, 2008. Under the new EIT law, preferential tax treatments will continue to be granted to entities which conduct businesses in certain encouraged sectors and to entities otherwise classified as &#8220;High and New Technology Enterprises&#8221;.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab&#160;Shanghai</div> has been qualified as &#8220;High and New Technology Enterprise&#8221; and enjoys a preferential income tax rate of 15% from 2018 to 2020. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s other PRC subsidiaries are subject to the statutory income tax rate of 25%. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No provision for corporate income taxes for corresponding tax residents has been made because the Group are in cumulative loss positions for all the periods presented. During the year ended December 31, 2020, the Group recorded withholding taxes with the amount of RMB12,231 </div></div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in relation to research and development service and other supporting service charges made by its non-PRC tax resident subsidiaries to its PRC tax resident subsidiaries. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reconciliations of <div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div>he differences between <div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div>he PRC statutory income tax rate and the Group&#8217;s effective income tax rate for the years ended December&#160;31, 2018, 2019 and 2020 are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Note&#160;2.5)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before income ta<div style="letter-spacing: 0px; top: 0px;;display:inline;">x</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(401,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,451,950</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">483,146</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">74,044</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax computed at respective applicable tax rate</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(56,093</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(148,871</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">66,044</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,122</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-deductible</div> expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87,021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">72,256</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11,073</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses plus deduction</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,762</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,254</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(60,776</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(9,314</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in valuation allowance</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71,104</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(65,293</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(10,007</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12,231</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,874</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of tax holidays entitled by the PRC subsidiaries on basic income (loss) per share</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.34</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.05</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The principal components of the deferred tax assets and liabilities are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">RMB</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Note&#160;2.5)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets:</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Net operating loss carryforwar<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">d</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136,443</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">107,344</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16,451</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciat<div style="letter-spacing: 0px; top: 0px;;display:inline;">i</div>on and amortization of property, equipment, software and intangible asset, net</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,405</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,398</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">30,417</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,662</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrual expense</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,867</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,568</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,620</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: valuation allowance</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(94,511</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(165,497</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(100,204</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(15,358</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax asset<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,211</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,211</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">48,125</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,375</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities:</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired intangible assets</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,211</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,211</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">18,067</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,768</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr>
<td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:top;"> <div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets</div></div> </td>
<td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;&#160;&#160;</div></div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;&#160;&#160;</div></div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">30,058</div></div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">4,607</div></div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif;">&#160;</div> </td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 65%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">37,211</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">37,211</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">48,125</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,375</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets, net</div></div> </td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212; &#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212; &#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Movement of the valuation allowance is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Note&#160;2.5)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January&#160;1</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(49,541</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(94,511</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(165,497</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(25,364</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Addition<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(62,029</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(71,104</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(36,061</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5,527</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Utilization and reversal of valuation allowances</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">89,154</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">13,663</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease due to the change of tax rate</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">17,059</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">118</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12,200</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,870</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 65%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(94,511</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(165,497</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(100,204</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(15,358</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 65%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the Group had a majority of net operating losses of approximately RMB556,649&#160;which arose from the subsidiaries established in the PRC. The tax losses carried forward various in the PRC will expire during the period beginning from 2021 to 2030 based on entity&#8217;s preferential tax status. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered as more likely than not that some portion or all of the deferred tax assets will not be realized in the foreseeable future.&#160;In making such determination, the Group evaluates a variety of positive and negative factors including the Group&#8217;s operating history, accumulated deficit, the existence of taxable temporary differences and reversal periods. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group has incurred net accumulated operating losses for income tax purposes since its inception. The Group believes that it is more likely than not that these net accumulated operating losses together with other deferred tax assets will not be utilized in the foreseeable future. Therefore, the Group has provided full valuation allowances for the deferred tax assets as of December&#160;31, 2019 and 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of December&#160;31, 2019 and 2020, the Group did not have any significant unrecognized uncertain tax positions.</div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712595832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Ordinary shares</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>. ORDINARY SHARES </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2018 and 2019, 500,000,000 ordinary shares had been authorized by the Company. Each ordinary share is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors of the Company. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;29, 2019, the Company&#8217;s shareholders and board of directors approved that immediately prior to the completion of initial public offering, the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company&#8217;s authorized share capital will be changed into US$</div>80,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> divided into </div>800,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> ordinary shares of a par value of US$</div>0.0001<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> each.</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;17, 2020, the Company completed its IPO and became listed on the Nasdaq Global Market by issuing 7,407,400 American Depositary Shares (&#8220;ADSs&#8221;) at the price of US$14.00 per ADS for total gross proceeds of US$103.7&#160;million. On February&#160;10, 2020, the underwriters of the IPO have exercised their over-allotment option to purchase an additional 768,350 ADSs of the Company at the IPO price of US$14.00 per ADS. After giving effect to the exercise of the over-allotment option, the Company has issued and sold a total of 8,175,750 ADSs in the IPO, for total net proceeds of US$101.3&#160;million (equivalent to RMB697,788), netting of issuance cost from total gross proceeds of US$114.5&#160;million. Each ten ADSs represent <span style="-sec-ix-hidden:hidden20395666">twenty</span>-three ordinary shares of the Company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;17, 2020, the Company also issued 6,078,571 ordinary shares to Everest (see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div>&#160;for details). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon the completion of the IPO, the Company&#8217;s then outstanding 30,227,056 Series A Preferred Shares, 23,288,783 Series B Preferred Shares, 3,714,580 Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares, 3,301,849 Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares, 31,046,360 Series C Preferred Shares and 3,857,143 Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares were converted into 30,227,056, 23,288,783, 3,714,580, 3,571,427, 34,420,469 and 4,537,814 ordinary shares, respectively. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;15, 2020, the Company&#8217;s Board of Directors approved a share repurchase program to repurchase in the open market up to US$20&#160;million worth of outstanding ADSs of the Group. The Company made a total prepayment of US$5,000 (equivalent to RMB34,051) for the share repurchase. The prepayment was</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>collected subsequently in October 2020. No repurchase activity was taken place for the year ended December, 31, 2020. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On September&#160;3, 2020, the Company entered into definitive subscription agreements with a consortium of institutional investors (the &#8220;Investors&#8221;) to raise approximately US$418&#160;million through a private placement. The consortium is led by Hillhouse Capital Group (&#8220;Hillhouse&#8221;), with significant participation by GIC Private Limited, and also includes certain other leading Asian and U.S. biotech investment funds, Hillhouse is entitled to nominate one representative to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab&#8217;s</div> Board of Directors. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The private placement comprises (1)&#160;the sale to the Investors of the Group&#8217;s 29,133,502 ordinary shares (equivalent to 12,666,740 ADSs) at a purchase price equivalent to US$33 per ADS amounting to approximately US$418&#160;million; and (2)&#160;warrants (the &#8220;Investor Warrants&#8221;, see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div>(b)) to subscribe for an aggregate of 5,341,267 ordinary shares (equivalent to 2,322,290 ADSs) at an exercise price equivalent to US$45 per ADS, which may further increase the proceeds of approximately US$104.5&#160;million if the Investor Warrants are fully exercised. The Investor Warrants will remain exercisable at the election of the Investors within 12 months after the closing of the private placement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The subscription agreement with the Hillhouse entities contemplates two closings. The first closing occurred on September&#160;11, 2020, and the second closing is conditioned upon an existing director of the Company having resigned to enable the Hillhouse entities to appoint a director to replace such director and the lemzoparlimab <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> agreement with AbbVie (see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div>) being or remaining effective. Upon the first closing, 20,421,378 ordinary shares and 3,744,032 Investor Warrants were issued to the Investors for total gross proceeds of approximately US$293.0&#160;million. On December&#160;17, 2020, the Group entered into a written amendment made to the subscription agreement with the Hillhouse entities, which removed one of the two conditions for the second closing that an existing director of the Company having resigned to enable the Hillhouse entities to appoint a director to replace such director. The second closing occurred as the other condition was satisfied and 8,712,124 ordinary shares as well as 1,597,235 Investor Warrants were issued to the Hillhouse entities for total gross proceeds of approximately US$125.0&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million. The total net proceeds, netting of issuance cost, from the private placement was US$397.2 million (equivalent to RMB2,653,669). </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, 1,841,373 <div style="letter-spacing: 0px; top: 0px;;display:inline;">stock options were exercised, and 7,000 restricted share units were issued as ordinary shares.</div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712187320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_TemporaryEquityTextBlock', window );">Convertible Preferred Shares</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div>. CONVERTIBLE PREFERRED SHARES </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On October&#160;18, 2016, the Company issued 5,141,587 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> Preferred Shares with a consideration of US$11,282 (equivalent to approximately RMB74,742). In connection with the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> Preferred Shares issuance, the Company also issued 2,246,744 warrant to purchase its Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-3</div> Preferred Shares (&#8220;Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-3</div> Warrants&#8221;). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On September&#160;6, 2017, in connection with the Group&#8217;s acquisition of Tasgen Group, the Company issued 16,723,646 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-3</div> Preferred Shares at a price of US$2.55 per share with a total consideration of US$42,645 (equivalent to approximately RMB289,024). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> Preferred Shares, Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-2</div> Preferred Shares and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-3</div> Preferred Shares are also referred to as Series A Preferred Shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On September&#160;22, 2017, the Company issued 15,894,594 shares of Series B Preferred Shares with a consideration of US$52,546 (equivalent to approximately RMB346,515). In connection with the Series B Preferred Shares issuance, the Company also issued convertible promissory notes that are convertible into Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares (&#8220;2017 Notes&#8221; and see Note 14) and 5,633,780 warrants to purchase its Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares (&#8220;Series B Warrant&#8221; and see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div>). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Concurrently with the Company&#8217;s issuance of Series B Preferred Shares, the Company also completed a round of onshore financing with respect to the Group&#8217;s subsidiary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-MAB</div> Tianjin (&#8220;Series B Onshore Financing&#8221;). Series B Onshore Financing comprised 1) capital injection to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin by a number of investors (&#8220;Series B Onshore Investors&#8221;) (see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>), 2) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin&#8217;s issuance of convertible loans (&#8220;Onshore Convertible Loans&#8221; and see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>), and 3) the Company&#8217;s issuance of 2,620,842 warrants to purchase its Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares (&#8220;Series B Warrants&#8221; and see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div>). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On June&#160;29, 2018, the Company issued total 8,361,823 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-3</div> Preferred Shares upon exercise of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-3</div> Option held by its holder. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On June&#160;29, 2018, the Company issued 2,535,201 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares upon conversion of 2017 Notes and issued 2,253,512 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares upon exercise of Series B Warrant by Series B preferred shareholders. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On June&#160;29, 2018, the Company issued 5,938,640 shares of Series B Preferred Shares upon exercise of the Series B Option held by a Series B Onshore Investor and issued 947,218 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>), respectively. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On July&#160;6, 2018, the Company issued 1,455,549 shares of Series B Preferred Shares upon exercise of the Series B Option held by a Series B Onshore Investor, issued 232,161 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>) and issued 1,048,337 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares upon exercise of Series B Warrant by Series B Onshore Investors, respectively. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series B Preferred Shares, Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares are also referred to as Series B Preferred Shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 6, 2018, the Company issued 31,046,360 shares of Series C Preferred Shares at a price of US$6.4419 per share with a total consideration of US$200,000 (equivalent to approximately RMB1,323,363). In connection with the offering of the Series C Preferred Shares, the Company incurred issuance costs of RMB16,730. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On July&#160;25, 2019, the Group entered into a share purchase agreement with certain third party investors, under which these investors will subscribe for an aggregate of 3,857,143 Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> convertible preferred shares of the Company for an aggregate purchase price of US$27.0&#160;million. Out of the aforementioned subscription of 3,857,143 Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> convertible preferred shares by certain third party investors, 1,428,571 Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> convertible preferred shares were issued to an investor on October&#160;17, 2019, and the Group also received the cash consideration of US$10,000 (equivalent to approximately RMB70,036). On November&#160;6, 2019, the Group received cash consideration of US$17,000 (equivalent to approximately RMB119,387) for the remaining 2,428,572 Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> convertible preferred shares from the investors and the issuance of such 2,428,572 Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> convertible preferred shares was consummated on that day. In connection with the offering of the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> convertible preferred shares, the Company incurred issuance costs of approximately US$840 (equivalent to approximately RMB5,887). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Series A Preferred Shares, Series B Preferred Shares, Series C Preferred Shares and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares are collectively referred to as Preferred Shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key terms of the Preferred Shares are summarized as follows: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The holders of Preferred Shares are entitled to receive dividends, out of any assets legally available therefore, prior and in preference to any declaration or payment of any dividend on the ordinary shares or any other class or series of shares of the Group at the rate of eight percent (8%) of the original issue price per share per annum on each Preferred Share, payable in US$ and annually when, as and if declared by the Board of Directors. Such distributions shall not be cumulative. No dividend, whether in cash, in property or in shares of the capital of the Group, shall be paid on or declared and set aside for any ordinary shares or any other class or series of shares of the Group unless and until all dividends have been paid in full on the Preferred Shares (on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each Preferred Share may be converted at any time into ordinary shares at the option of the preferred shares holders at the then applicable conversion price. The initial conversion ratio is 1:1, subject to adjustment in the event of (i)&#160;share splits, share combinations, share dividends or distribution, other dividends, recapitalizations and similar events, or (ii)&#160;issuance of ordinary shares (excluding certain events such as issuance of ordinary shares pursuant to a public offering) at a price per share less than the conversion price in effect on the date of or immediately prior to such issuance. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Preferred Shares shall be automatically converted into ordinary shares immediately upon the closing of a public offering of the Company&#8217;s shares with an offering price (exclusive of underwriting commissions and expenses) that reflects a market capitalization (immediately prior to the public offering) of not less than US$1,000,000,000 or otherwise approved by all directors and certain preferred shareholders as specified in the Company&#8217;s memorandum and articles of association (the &#8220;Qualified Public Offering&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group determined that there were no beneficial conversion features (&#8220;BCF&#8221;) identified for any of the Preferred Shares during any of the periods. In making this determination, the Company compared the fair value of the ordinary shares into which the Preferred Shares are convertible with the respective effective conversion price at the issuance date. In all instances, the effective conversion price was greater than the fair value of the ordinary shares. To the extent a conversion price adjustment occurs, as described above, the Group will reevaluate whether or not a beneficial conversion feature should be recognized. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the event of any liquidation (unless waived by the preferred shareholders) including deemed liquidation, dissolution or winding up of the Company, holders of the Preferred Shares shall be entitled to receive a per share amount equal to one hundred percent (100%) of the original issue price on each Preferred Share, plus an amount representing an internal rate of return of twelve percent (12%) per annum on the original issue price as adjusted for share dividends, share splits, combinations, recapitalizations or similar events, plus all accrued and declared but unpaid dividends thereon, in the sequence of Series C Preferred Shares, Series B Preferred Shares and Series A Preferred Shares. After such liquidation amounts have been paid in full, any remaining funds or assets of the Company legally available for distribution to shareholders shall be distributed on a pro rata basis among the holders of the Preferred Shares, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, together with the holders of the ordinary shares. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting of preferred shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Preferred Shares are redeemable by the holders upon a liquidation event, including a deemed liquidation event (e.g., change in control), and as such are presented as mezzanine equity on the consolidated balance sheets. In accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> each issuance of the convertible preferred shares should be recognized at the date of issuance after deducting fair value allocated to the detachable warrants and issuance costs. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Modification of preferred shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company assesses whether an amendment to the terms of its convertible preferred shares is an extinguishment or a modification using the fair value model.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When convertible redeemable preferred shares are extinguished, the difference between the fair value of the consideration transferred to the convertible redeemable Preferred Shareholders and the carrying amount of such preferred shares (net of issuance costs) is treated as a deemed dividend to the Preferred Shareholders. When convertible redeemable preferred shares are modified and such modification results in value transfer between Preferred Shareholders and ordinary shareholders, the change in fair value resulted from the amendment is treated as a deemed dividend to or from the Preferred Shareholders. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">On December&#160;25, 2019, the Company&#8217;s shareholders and board of directors approved that, where the final offering price of a Qualified Public Offering is no less than US$4.176 per ordinary share, the agreed provisions related to the number of shares to be converted into the Company&#8217;s ordinary shares shall apply with respect to the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares, Series C Preferred Shares, Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares, which will generally give rise to a one to multiple conversion of the such rounds of Preferred Shares, provided that unanimous consent of the directors on the final offering price needs to be obtained in the event that the final offering price per ordinary share of such IPO is fixed at a price equal to or higher than US$4.176 per ordinary share but lower than US$5.22 per ordinary share. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company evaluated the aforementioned modifications and concluded that they represented modifications, rather than extinguishment, to Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> and C Preferred Shares, which resulted in a transfer of value from ordinary shareholders to preferred shareholders. The combined change in fair value of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> and C Preferred Shares immediately before and after the modification was US$<div style="letter-spacing: 0px; top: 0px;;display:inline;">4.0&#160;</div>million (equivalent to approximately RMB<div style="letter-spacing: 0px; top: 0px;;display:inline;">27.8</div> million) on December&#160;25, 2019. This decrease in fair value of the ordinary shares of US$4.0&#160;million (equivalent to approximately RMB27.8 million) on December&#160;25, 2019 was, in substance, a transfer of wealth mostly from ordinary shareholders to preferred shareholders, and therefore was recorded as a deemed dividend to the preferred shareholders<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company evaluated the aforementioned modifications and concluded that they represented extinguishment to Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares. The difference between the fair value of the modified Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares and the carrying value of the original Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares was amounting US$0.8&#160;million on December&#160;25, 2019 and represented the fair value of the consideration transferred, and therefore was recognized as a deemed dividend to the preferred shareholders and adjustment to the carrying amount of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s convertible preferred shares activities for the years ended December&#160;31, 2019 and 2020 are summarized below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;A&#160;Preferred&#160;Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;B&#160;Preferred&#160;Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;C&#160;Preferred&#160;Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1&#160;Preferred&#160;Shares</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January&#160;1, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,227,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102,852</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">687,482</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,305,212</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,407</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">921,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,046,360</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,478</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,306,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Issuance of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares, net of issuance costs</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,857,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,160</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">183,536</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Adjustment at extinguishment of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,283</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,227,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102,852</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">687,482</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,305,212</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,407</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">921,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,046,360</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,478</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,306,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,857,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,914</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">188,819</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion to ordinary shares upon IPO</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,227,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(102,852</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(687,482</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,305,212</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(139,407</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(921,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(31,046,360</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(197,478</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,306,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,857,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26,914</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(188,819</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_TemporaryEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_TemporaryEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712187320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes And Onshore Convertible Loans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract', window );"><strong>Convertible Promissory Notes And Onshore Convertible Loan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans', window );">Convertible promissory notes and onshore convertible loans</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">5</div>. CONVERTIBLE PROMISSORY NOTES AND ONSHORE CONVERTIBLE LOANS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 Notes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;25, 2017, the Company issued US$11,520 convertible promissory notes (&#8220;2017 Notes&#8221;) to investors of Series B Preferred Shares (see Note 1<div style="display:inline;">4</div>) at a compound interest rate of 8% per annum, maturing on 36 months after the issuance date. Under the agreement, the holder of the 2017 Notes may convert the outstanding principal amount into Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares at the conversion price of US$5.38 per share or a lower price as may be agreed by the investors and the Company at any time from six months prior to the maturity date and prior to the repayment in full of the 2017 Note. No interest shall be accrued if the 2017 Notes have been converted into Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the fair value of the Company&#8217;s ordinary shares on September&#160;25, 2017 was lower than the effective conversion price of US$5.38, the Company did not record a BCF. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On June&#160;29, 2018, the Company&#8217;s 2017 Notes were converted into the Company&#8217;s 2,535,201 Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares at the nominal conversion price of US$5.38 per share. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 Notes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On February&#160;3, 2018, the Company issued US$9,000 (equivalent to approximately RMB59,704) convertible promissory notes (&#8220;2018 Notes&#8221;) to Genexine, Inc. of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-3</div> Preferred Shares at an annual interest rate of 0%, maturing on 36 months after the issuance date. Under the agreement, the holder of the 2018 Notes may convert the 2018 Notes outstanding principal amount into Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares at the conversion price being lower of US$10 per share and fair market value at any time prior to the maturity date. Alternatively, the 2018 Notes shall be automatically converted into the Company&#8217;s Series B Preferred Shares upon the maturity. As the fair value of the Company&#8217;s ordinary shares on February&#160;3, 2018 of US$3.96 was equal to the effective conversion price (being lower of US$10 per share and fair market value), the Company did not record a BCF. On December&#160;17, 2020, the Group issued 900,000 ordinary shares to Genexine, Inc. upon the full conversion of the 2018 Notes with the conversion price of US$10 per share. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Onshore Convertible Loans </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;25, 2017, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin issued a US$5,359 convertible loan to Series B Onshore Investors at a compound interest rate of 8% per annum, maturing on 36 months after the issuance date. Under the agreement, the holder of the Onshore Convertible Loans may convert the outstanding principal amount into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin&#8217;s equity interest a stipulated conversion price at any time from six months prior to the maturity date and prior to the repayment in full of the Onshore Convertible Loans. No interest shall be accrued if the Onshore Convertible Loans have been converted into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin&#8217;s equity interest. As the fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Tianjin&#8217;s ordinary shares on September&#160;25, 2017 was lower than the effective conversion price of US$4.31, the Company did not record a BCF. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June and July 2018, the Company reached agreements with holders of Onshore Convertible Loans and the principal amount of Onshore Convertible Loans were then effectively converted into 1,179,379 Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Shares of the Company and the accrued interests were waived, resulting in an extinguishment loss of RMB8,548. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory notes and onshore convertible loan abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Convertible promissory notes and onshore convertible loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707715708776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_WarrantsDisclosureAbstract', window );"><strong>Warrants Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_WarrantsDisclosure', window );">Warrants</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">6</div>. WARRANTS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Warrants to purchase preferred shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In connection with the issuance of the Series B Preferred Shares on September&#160;22, 2017, 5,633,780 Series B Warrants were issued to Series B preferred shareholders, which provided the holders the right to purchase Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the Company&#8217;s Series B Onshore Financing that took place on September&#160;25, 2017, 2,620,842 Series B Warrants were issued to Series B Onshore Investors, which provided the holders the right to purchase Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the period from June&#160;29, 2018 to July&#160;6, 2018, 3,301,849 Series B Warrants (representing Tranche I of Series B Warrants) were exercised to purchase 3,301,849 Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares with proceeds of US$20,000 (equivalent to approximately RMB132,332). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On July&#160;6, 2018, the Series B Warrants holders agreed that the Series B Warrants shall be divided into two tranches and exercisable in accordance with different time schedules, such that: (i)&#160;the holders have exercised part of the Series B Warrants in the total consideration of US$20,000 (&#8220;Tranche I of Series B Warrants&#8221;) and 3,301,849 Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares of the Company in aggregate have been newly issued to such holders on a pro rata basis; (ii)&#160;only when the Company fails to submit a Qualified Public Offering application at an internationally recognized securities exchange by March&#160;31, 2019, the Warrant Holders may exercise the remaining part of Series B Warrants, in the total consideration of US$30,000 (&#8220;Tranche II of Series B Warrants&#8221;) and 4,952,773 Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Shares of the Company in aggregate will be issued to such holders on a pro rata basis; (iii)&#160;provided that the Company successfully submits a Qualified Public Offering application at an internationally recognized securities exchange by March&#160;31, 2019, the holders shall unconditionally and irrevocably waive and cancel Tranche II of Series B Warrants; and (iv)&#160;the Tranche II of Series B Warrants may only be concurrently exercised by all the Warrant Holders in one lump. This is considered to be a modification to Series B Warrants. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">According to the confirmations issued by the Company&#8217;s Series B Warrants holders in July 2019, the holders of Series B Warrants has unconditionally and irrevocably waived and cancelled the Tranche II of Series B Warrants. The fair value gain of warrants for the years ended December&#160;31, 2019 and 2020 was amounting to RMB5,644 and nil, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting of warrants for purchase preferred shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The warrant is a freestanding instrument and is recorded as liability in accordance with ASC 480, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity</div></div>. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the Company&#8217;s issuance of warrants were bundled with other instruments (such as convertible preferred shares, convertible promissory notes, etc.), out of total considerations, the warrants are initially recognized at fair value and the remaining were allocated to other instruments on a relative fair value basis (if applicable). The fair value changes of the warrants (including the fair value changes arising from modification of warrants) up to the time of exercise or termination were recognized in earnings. Upon exercise, the total carrying value of the associated warrant liabilities was reclassified into the carrying value of the Preferred Shares into which it was converted. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company determined the fair value of the warrants with the assistance of an independent third-party valuation firm. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) Warrants to purchase ordinary shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As mentioned in Note 1<div style="display:inline;">3</div>, on September&#160;3, 2020, the Group entered into definitive subscription agreements with the Investors to raise approximately US$418&#160;million through a private placement, which comprises the Investor Warrants to subscribe for an aggregate of 5,341,267 ordinary shares (equivalent to 2,322,290 ADSs) at an exercise price equivalent to US$45 per ADS. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Subscription Agreement with the Hillhouse entities contemplates two closings. In the first closing occurred on September&#160;11, 2020 and second closing occurred on December&#160;17, 2020, the Investor Warrants were issued with fixed exercise prices of US$45.00 per ADS (equivalent to US$19.57 per share) and lives of one year. The number of common share purchasable upon exercise of the Investor Warrants shall be proportionally adjusted to reflect any share dividend, share split, combination of shares or reverse share split, or other similar event affecting the number of outstanding common shares. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for warrants to purchase ordinary shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Investor Warrants are regarded as indexed to the Company&#8217;s own stock and were classified as equity and initially measured at fair value and subsequent changes in fair value are not recognized as long as the Investor Warrants continue to be classified as equity. The estimated fair value of the Investor Warrants was shown below, which were used to determine the allocation of the total proceeds for the sale of ordinary shares between the Investor Warrants and ordinary shares. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Terms</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price&#160;per<br/> share</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;value&#160;at</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">the&#160;closing</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">date</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB&#8217;000</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrants to purchase ordinary shares (first closing on September 11, 2020)</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12 months</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,744,032</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">71,874</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrants to purchase ordinary shares (second closing on </div></div><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;17, 2020)</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12 months</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,597,235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">37,869</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group determined the fair value of the warrants with the assistance of an independent third-party valuation firm. The Group used the binomial model to estimate the fair value of the warrant on September&#160;11, 2020 and December&#160;17, 2020 when the Investor Warrants were issued using the following assumptions: </div></div>  <div style="text-align:left;"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 92%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of September&#160;11,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;17,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 92%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 92%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate of return</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 92%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturity date</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">September 11, 2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 17, 2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 92%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated volatility rate</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">60.72</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">59.56</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 92%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom; width: 1%;"/>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">US$</div></td>
<td style="vertical-align: bottom;;text-align:right;">19.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;"/>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">US$</div></td>
<td style="vertical-align: bottom;;text-align:right;">19.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear: both; max-height: 0px; background: none;"/></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The model requires the input of assumptions including the risk-free rate of return, maturity date and estimated volatility rate. The risk-free rate for periods within the contractual life is based on the US treasury strip bond with maturity similar to the maturity of the warrants as of valuation dates plus a China country risk premium. For expected volatilities, the Group has made reference to the historical daily stock prices volatilities of ordinary shares of several comparable companies in the same industry as the Group. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_WarrantsDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_WarrantsDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_WarrantsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Warrants [Abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_WarrantsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707715689448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">7</div>. SHARE-BASED COMPENSATION </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(a) Restricted shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2016, the Company issued 4,019,554 ordinary shares to Mr.&#160;Zang Jingwu Zhang, Ms.&#160;Qian Lili, Mr.&#160;Wang Zhengyi and Mr.&#160;Fang Lei (collectively the &#8220;Founders&#8221;), including the 369,301 shares which represented the equity interests of Third Venture held by the Founders, and the Company recorded share-based compensation expense of RMB18.7&#160;million for issuance and grant of 3,650,253 ordinary shares to the Founders in June 2016. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2016, the Founders entered into an arrangement with other investors of the Company, and the 87,441 ordinary shares issued to the Founders in June 2016 were canceled and out of the remaining 3,932,113 ordinary shares held by the Founders, 70% became restricted and subject to service vesting conditions, that should vest 20%, 20% and 30% over the next three years, respectively. There shall be no acceleration of the vesting schedule except that, in case of a change of control of the Company or a Qualified Public Offering, or the termination of the Founder&#8217;s employment with the Group without cause. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred share-based compensation was measured for the restricted shares using the estimated fair value of the Company&#8217;s ordinary shares of US$0.77 at the date of imposition of the restriction in October 2016, and was amortized to the consolidated statements of comprehensive loss by using graded vesting method over the vesting term of 3 years. As of December&#160;31, 2019, all the restricted shares were fully vested. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amounts of shared-based compensation expense in relation to the restricted shares recognized in the years ended December&#160;31, 2018, 2019 and 2020 were RMB3,520, RMB1,566 and nil, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses related to restricted shares were included in: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">1,056</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">470</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative expenses</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">2,464</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,096</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,520</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">1,566</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(b) 2017 Employee Stock Option Plan (&#8220;2017 Plan&#8221;) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2017, the Company adopted the 2017 Plan. Under the 2017 Plan, a maximum aggregate number of 13,376,865 shares that may be issued pursuant to all awards granted was approved. Stock options granted to an employee under the 2017 Plan will be exercisable upon the Company completes a listing and the employee renders service to the Company in accordance with a stipulated service schedule starting from the employee&#8217;s date of employment. Employees are generally subject to a three-year service schedule, under which an employee earns an entitlement to vest in 50% of the option grants on the second anniversary of the grant date, a vesting of the remaining 50% on the third anniversary of the applicable grant date. The stock option under 2017 Plan, to the extent then vested, shall become exercisable only upon the earlier of (i)&#160;a listing, and (ii)&#160;occurrence of a change in control. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">On December&#160;25, 2019, the Second Amended and Restated 2017 Plan was approved by the shareholders and board of directors of the Company, pursuant to which, in connection with the Company&#8217;s IPO, the maximum aggregate number of shares that may be granted pursuant to all awards under 2017 Plan shall be adjusted in accordance with a formula <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approved</div> by the shareholders. In connection with above amendments to 2017 Plan, each of the Company&#8217;s founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, is willing to irrevocably surrender by him or her, for no consideration, a portion of the unvested options granted to him or her, which, if vested, would entitle him or her to acquire up to 130,000 ordinary shares of the Company, par val<div style="letter-spacing: 0px; top: 0px;;display:inline;">u</div>e US$0.0001 per share, at an exercise price of US$1.0, respectively, under the Second Amended and Restated 2017 Plan (in respect of each individual, the &#8220;Founder&#8217;s Surrendered Options&#8221;). On December&#160;25, 2019, the board of directors of the Company approved that the Company accepts all Founder&#8217;s Surrendered Options from each of the founders, Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, for no consideration, with effect immediately prior to the completion of the IPO and such surrendered options be cancelled with effect immediately prior to the completion of the IPO. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the Company completes a listing, all stock options granted to an employee shall be forfeited at the time the employee terminates his employment with the Group. After the Company completes a listing, vested options not exercised by an employee shall be exercised until later of: (i) 90 days after the date when the options become exercisable, or (ii) 30 days after the date of cessation of employment or directorship, or such longer period as the Board of Directors may otherwise determine. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For the years ended December 31, 2018 and 2019, the Group granted 1,470,000 and 640,000 stock options respectively, to its employees (all with an exercise price of US$1).&#160;</div>The Group did not grant any stock options to employees for the year ended December&#160;31,&#160;2020. No options were exercisable as of December&#160;31, 2019 and 6,790,924 stock options were exercisable as of December&#160;31, 2020. No options were exercised as of December&#160;31, 2019 and 1,439,373 stock options were exercised as of December&#160;31, 2020. </div></div>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the stock options activities of 2017 Plan for the periods presented: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Number&#160;of<br/> shares</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Weighted<br/> average<br/> exercise<br/> price<br/> US$</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Weighted<br/> average<br/> remaining<br/> contractual<br/> term</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Aggregate<br/> intrinsic<br/> value<br/> US$</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2017</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">11,761,596</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">0.94</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">9.50</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">24,890</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,470,000</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">(226,000</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2018</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">13,005,596</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">0.95</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">8.61</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">70,129</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">640,000</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">(397,500</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased (Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>(d))</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">(3,435,215</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31 ,2019</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">9,812,881</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">0.93</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">7.76</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">47,671</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">(338,876</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">(1,439,373</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">0.72</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Surrendered<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;(Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>(h))</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">(332,566</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31 ,2020</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">7,702,066</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">0.97</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">6.75</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">150,415</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">6,790,924</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">0.97</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">6.75</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">132,650</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">A summa<div style="letter-spacing: 0px; top: 0px;;display:inline;">r</div>y of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock option activities for the year ended December&#160;31, 2020 is presented below: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Grant&#160;date&#160;fair&#160;value</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2019</div> </td>
<td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">9,812,881</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">2.10</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(6,790,924</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">1.90</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1,439,373</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1.37</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(338,876</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">2.29</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Surrendered</div></div> </td>
<td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(332,566</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">1.47</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2020</div> </td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">911,142</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">4.96</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 64%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since the exercisability <div style="letter-spacing: 0px; top: 0px;;display:inline;">wa</div>s dependent upon the listing, and it <div style="letter-spacing: 0px; top: 0px;;display:inline;">wa</div>s not probable that this performance condition c<div style="letter-spacing: 0px; top: 0px;;display:inline;">ould</div>&#160;be achieved until a listing, no share-based compensation expense relating to the 2017 Plan was recorded for the year ended December&#160;31, 2018 and 2019. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;17, 2020, the Group completed its IPO. After achieving this performance condition, the options continue to vest based only on service period completed according to the graded vesting schedule. The Group has begun recognizing share-based compensation expense for the options granted using the graded vesting method with a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> for the service period completed to date during the year ended December&#160;31, 2020 and recognized RMB52,802<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;">RMB69,213 and&#160;</div>RMB4,277 share-based compensation expenses in administrative expenses<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div>&#160;research and development <div style="letter-spacing: 0px; top: 0px;;display:inline;">expenses and equity in loss of an affiliate, respectively&#160;</div>relating to options vested cumulatively. According to the amendments to 2017 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2017 Plan was changed to 9,609,084. Each of the Group&#8217;s founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang surrendered 83,142 unvested stock options that were granted to him or her under 2017 Plan before, totally 332,566 unvested options, for no consideration, and these stock options were cancelled immediately. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(c) 2018 Employee Stock Option Plan (&#8220;2018 Plan&#8221;) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;22, 2019, the Group adopted the 2018 Plan, which was subsequently amended on July&#160;22, 2019.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Under the amended and restated 2018 Plan, the maximum aggregate number of ordinary shares which may be issued pursuant to all awards is 14,005,745, and if the Group successfully lists on an internationally recognized securities exchange for a Qualified Public Offering by December&#160;31, 2019, the maximum aggregate number of ordinary shares which may be issued shall be 15,452,620. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On December&#160;25, 2019, the Second Amended and Restated 2018 Plan were approved by the shareholders and board of directors of the Company, pursuant to which, in connection with the Company&#8217;s IPO, the maximum aggregate number of shares that may be granted pursuant to all awards under 2018 Plan shall be adjusted in accordance with a formula <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approved</div> by the shareholders. In connection with above amendments to 2018 Plan, the director of the Company, Dr.&#160;Jingwu Zhang Zang is willing to irrevocably surrender by him, for no consideration, of the right to acquire a certain amount of ordinary shares of the Company, par value US$0.0001 per share, at an exercise price of US$1.0 pursuant to the options granted to him under the Second Amended and Restated 2018 Plan (the &#8220;Dr.&#160;Zang&#8217;s Surrendered Options&#8221;). On December&#160;25, 2019, the board of directors of the Company approved that the Company accepts the irrevocable surrender of Dr.&#160;Zang&#8217;s Surrendered Options for no consideration, with effect immediately prior to the completion of the IPO and such surrendered options be cancelled with effect immediately prior to the completion of the IPO. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Stock options granted to an employee under the 2018 Plan will be generally exercisable when the Company completes a listing and the employee renders service to the Company in accordance with a stipulated service schedule starting from the employee&#8217;s date of employment. The vesting schedule shall generally be a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> vesting schedule consisting of a cliff vesting 50% on the first anniversary of the applicable vesting commencement date, and a vesting of the remaining 50% on the second anniversary of the applicable vesting commencement date. If a listing occurs at anytime prior to any option granted under the 2018 Plan becoming full vested, and to the extent such option has been granted and outstanding, any such option shall vest in full with immediate effect upon the listing. Except as otherwise approved by the board of directors, vested portion of option shall become exercisable upon the earlier of six months after a listing or the occurrence of a change in control; provided, however that in each case, no option of an employee shall become exercisable until the third anniversary of such employee&#8217;s employment commencement date. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Board of Director&#8217;s approval of 2018 Plan on February&#160;22, 2019, the 10,893,028 stock options granted to a director of the Group under 2018 Plan were fully vested and exercisable upon the adoption of 2018 Plan. Out of aforementioned total 10,893,028 stock options, 454,940 stock options were repurchased by the Group (see Note 1<div style="display:inline;">7</div>&#160;(d) for further details). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amounts of shared-based compensation expense in relation to the aforementioned grant of stock options to a director of the Group (except for those repurchased by the Group as described in Note 1<div style="display:inline;">7 </div>(d)) recognized in the year ended December&#160;31, 2019 was RMB365,329<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;included in administrative expenses.</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the stock options activities of 2018 Plan for the years ended December&#160;31, 2019 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Number&#160;of<br/> shares</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Weighted<br/> average<br/> exercise<br/> price<br/> US$</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Weighted<br/> average<br/> remaining<br/> contractual<br/> term</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Aggregate<br/> intrinsic<br/> value<br/> US$</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of January&#160;1, 2019</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,991,528</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased (Note 1<div style="display:inline;">7</div>&#160;(d))</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(454,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,536,588</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">64,840</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(402,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1.00</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#8212; &#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Surrendered (Note 1<div style="display:inline;">7</div>&#160;(h))</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;">(2,544,917</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#8212; &#160;</div>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">10,589,671</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">8.15</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">206,499</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">9,764,670</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">8.15</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">190,411 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to certain directors and employees of the Group were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">54.64%-56.31</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate (per annum)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2.15%-2.75</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise multiple</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of the Group&#8217;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the Group&#8217;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A summa<div style="letter-spacing: 0px; top: 0px;;display:inline;">r</div>y of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock option activities for the year ended December&#160;31, 2020 is presented below: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2019</div></td>
<td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,098,500</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">5.57</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(1,871,500</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">5.57</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Exercise<div style="letter-spacing: 0px; top: 0px;;display:inline;">d</div></div></div></td>
<td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(402,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"/></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5.57</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2020</div></td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">825,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">5.57</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 64%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: left;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to the employees were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="width: 0.75%;"/>
<td style="width: 0.75%;"/>
<td style="width: 1.5%;"/>
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0.75%;;text-align:center;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0.75%; text-align: right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">61.32%-62.13</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;;text-align:center;">54.64</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate (per annum)</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0.75%;;text-align:center;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0.75%; text-align: right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2.81%-3.06</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; text-align: right;">2.15</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise multiple</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0.75%; padding: 0pt 0.5pt;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0.75%; padding: 0pt 0.5pt; text-align: right;">2.80</td>
<td style="vertical-align: bottom; width: 1.5%; padding: 0pt 0.5pt;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; text-align: right;">2.80</td>
<td style="vertical-align: bottom; text-align: right;"> <div style="line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.75%;;text-align:center;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.75%; text-align: right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1.5%;;text-align:center;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual term (in years)</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 0.75%;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0.75%; text-align: right;">10</td>
<td style="vertical-align: bottom; text-align: right; width: 1.5%;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; text-align: right;">10</td>
<td style="vertical-align: bottom; text-align: right;"> <div style="line-height: normal;">&#160;</div> </td> </tr> </table> </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of the Group&#8217;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the Group&#8217;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except for the aforementioned grant of stock options to a director of the Group under 2018 Plan, since the exercisability is dependent upon the listing, and it is not probable that this performance condition can be achieved until a listing, no share-based compensation expense related to the 2018 Plan was recorded for the year ended December&#160;31, 2019. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;17, 2020, the Group completed its IPO. After achieving this performance condition, the options continue to vest based only on service period completed according to the graded vesting schedule. The Group has begun recognizing share-based compensation expense for the options granted using the graded vesting method with a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> for the service period completed to date during the year ended December&#160;31, 2020 and recognized RMB48,055<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">, RMB65,656 and&#160;</div></div>RMB226 <div style="letter-spacing: 0px; top: 0px;;display:inline;">share-based compensation expense in administrative expenses and research, development expenses and equity in loss of an affiliate, respectively relating to options vested cumulatively. According to the amendments to 2018 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2018 Plan was changed to</div> 11,005,888. The director of the Company, Dr.&#160;Jingwu Zhang Zang surrendered 2,544,917 unvested options that were granted to him under 2018 Plan, for no consideration, and these stock options were cancelled immediately. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(d) Repurchase of share awards held by a director </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;22, 2019, the amendment and restated 2017 equity incentive plan was approved by the Board of Directors of the Group, pursuant to which only the 3,435,215 stock options held by the director (see Note 1<div style="display:inline;">7</div>(c)) under the 2017 equity incentive plan became fully vested and exercisable on February&#160;22, 2019. As a result of the performance condition being waived, the stock options held by the director of the Group were accounted for as a Type III modification where a condition that the Group expects will not be satisfied is changed to a condition that the Group expects will be satisfied. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, on the same day, the Group repurchased such 3,435,215 stock options under the amendment and restated 2017 equity incentive plan that was held by the director of the Group along with 454,940 of his stock options under the 2018 equity incentive plan for which the share awards also became fully vested and exercisable, at a total consideration of US$21,902 (equivalent to approximately RMB148,308) at an average share price of US$5.63 per share. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2019, the Group recorded the total payment of US$21,902 (equivalent to approximately RMB148,308) as share-based compensation costs (included in administrative expenses) in the consolidated statement of comprehensive loss. There was no impact to the overall stockholder&#8217;s equity balance as the amended shares vested immediately and were repurchased. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(e) 2019 Share Incentive Plan (&#8220;2019 Plan&#8221;) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;29, 2019, the Group adopted 2019 Share Incentive Plan (the &#8220;2019 Plan&#8221;), which will become effective immediately prior to the completion of the Company&#8217;s initial public offering. Under the 2019 Plan, the maximum aggregate number of ordinary shares available for issuance shall initially be 100,000. </div></div> <div style="text-align: left;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The options shall vest when the Group completes a listing and the employee renders service to the Group in accordance with a stipulated service schedule starting from the employee&#8217;s date of employment. Stock options granted to 3 independence directors under the 2019 Plan will be generally exercisable under the following terms:(a) a cliff vesting of 1/3 of the option on the first anniversary of the vesting commencement date (January 17, 2020); (b) a cliff vesting of 1/3 of the option on the second anniversary of the vesting commencement date (January 17, 2020); (c) a vesting of the remaining 1/3 of the option on the third anniversary of the vesting commencement date. In the last year of the grantee&#8217;s service, the options shall vest on a prorated basis to reflect the portion of the year during which the grantee provided services to the Group.</div></div></div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2020, the Group granted 72,000 stock options to 3 independent directors (all with an exercise price of US$6.09) and recognized RMB1,171 <div style="letter-spacing: 0px; top: 0px;;display:inline;">share-based compensation expenses in administrative expenses according to the options&#8217; vesting schedule.&#160;</div>No options were exercisable as of December&#160;31, 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the stock options activities of 2019 Plan for the year ended December&#160;31, 2020 presented: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number&#160;of</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">shares</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">exercise</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">price</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">remaining</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">contractual</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">term</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregate</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">intrinsic</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">value</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">72,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">72,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9.33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,038</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;">A summary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock options activity for the year ended December&#160;31, 2020 is presented below: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2019</div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">72,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2020</div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">72,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr> </table> <div style="text-align: left;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to the 3 independent directors were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 22%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom; width: 22%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">54.88</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate (per annum)</div></div> </td>
<td style="vertical-align: bottom; width: 22%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.79</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise multiple</div></div> </td>
<td style="vertical-align: bottom; width: 22%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual term (in years)</div></div> </td>
<td style="vertical-align: bottom; width: 22%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="clear: both; max-height: 0px; background: none;"/> </div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"/> <div style="clear: both; max-height: 0px; background: none;"/> </div> </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of the Group&#8217;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the Group&#8217;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(f) 2020&#160;Plan</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;15, 2020, the Group adopted 2020 Share Incentive Plan (&#8220;2020 Plan&#8221;). Under the 2020 Plan, the maximum aggregate number of shares authorized to be issued is 10,760,513 ordinary shares, provided that the maximum number of shares to be issued in the form of restricted share units shall not exceed 7,686,081 ordinary shares. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to employees under the 2020 Plan are graded vesting in four years with 25% vesting each year. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2020, the Group granted 1,068,733 stock options to its employees and recognized RMB4,357 RMB10,435 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;and RMB1,619<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>share-based compensation expenses in administrative expenses, research and development expenses and equity in loss of an affiliate, respectively, in the <div style="letter-spacing: 0px; top: 0px;;display:inline;">consolidated<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;statement of</div> comprehensive&#160;income</div>.</div>&#160;No option became exercisable as of December&#160;31, 2020. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> The following table sets forth the stock options activities of 2020 Plan for the year ended December&#160;31, 2020: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">exercise</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">price</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">remaining</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">contractual</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">intrinsic</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">value</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">1,068,733</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5.91</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">(24,365</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">)&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">5.91</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0in;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">1,044,368</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">5.91</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">9.62</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">15,237</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0in;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0in;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A summary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock option activities for the year ended December&#160;31, 2020 is presented below: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2019</div> </td>
<td style="vertical-align: bottom; width: 11in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 11in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,068,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.71</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 11in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(24,365</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 10in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65in;">&#160;</td>
<td style="vertical-align: bottom; width: 11in;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 10in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2020</div> </td>
<td style="vertical-align: bottom; width: 11in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,044,368</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.71</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 65in;">&#160;</td>
<td style="vertical-align: bottom; width: 11in;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 10in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr> </table> <div style="text-align: left;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to the employees were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 18%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom; width: 18in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">56.51</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate (per annum)</div></div> </td>
<td style="vertical-align: bottom; width: 18in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">0.86</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise multiple</div></div> </td>
<td style="vertical-align: bottom; width: 18in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2.20-2.80</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom; width: 18in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contractual term (in years)</div> </td>
<td style="vertical-align: bottom; width: 18in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr> </table> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> </div> </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of the Group&#8217;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the Group&#8217;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted share units granted to employees under the 2020 Plan will be exercisable under the following items: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) 1/3 of the awarded restricted share units shall vest based on the following time attribution:(i) a vesting of 25% of the time attribution based restricted share units on the first anniversary of the applicable adoption date;(ii) a vesting of 25% of the time attribution based restricted share units on the second anniversary of the applicable adoption date;(iii) a vesting of 25% of the time attribution based restricted share units on the third anniversary of the applicable adoption date;(iv) a vesting of 25% of the time attribution based restricted share units on the fourth anniversary of the applicable adoption date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) 1/3 of the awarded restricted share units shall vest based on the Group&#8217;s weighted average market value during the last 30 days prior to the initial vesting date, the terms and conditions of which are set forth in the executed award agreements. In the event that dilution of additional share issuance occurs, the market value targets herein shall be adjusted accordingly with the proportion of additional share issuance. In the event that the average market value of Standard&#160;&amp; Poor&#8217;s 500 index falls by more than 20% from the date of grant, it shall be deemed as a decline of the market, and the board of the Group or a committee that board delegated its powers or authority to shall adjust the vesting schedule as appropriate. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) 1/3 of the awarded restricted share units shall vest based on certain performance conditions:(i) a vesting of 20% of the performance conditions based restricted share units if one of the performance conditions has been met at the initial vesting date;(ii) a vesting of 40% of the performance conditions based restricted share units if two of the performance conditions have been met at the initial vesting date;(iii) a vesting of 60% of the performance conditions based restricted share units if three of the performance conditions have been met at the initial vesting date;(iv) a vesting of 80% of the performance conditions based restricted share units if four of the performance conditions have been met at the initial vesting date; (v)&#160;a vesting of all of the performance conditions based restricted share units if five of the performance conditions or more have been met at the initial vesting date. As of December&#160;31, 2020, it is probable that the 1/3 of the awarded restricted share units are fully vested because it is probable that at least five of the performance conditions will be met at the initial vesting date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the foregoing, if the Group&#8217;s weighted average market value during the last 30 days prior to the initial vesting date reaches US$2&#160;billion or above, and to the extent such restricted share units have been granted and outstanding, any such restricted share unit (except for those are based on time attribution) shall vest in full with immediate effect, inure to the benefit of the related grantees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2020, the Group granted 4,093,079 restricted share units to employees and recognized RMB76,663&#160;RMB71,945 <div style="letter-spacing: 0px; top: 0px;;display:inline;">and RMB7,500 share-based compensation expenses in administrative expenses, research and development expenses and equity in loss of an affiliate, respectively, in the <div style="letter-spacing: 0px; top: 0px;;display:inline;">consolidated statement of comprehensive income</div>. No restricted share units became exercisable as of December 31, 2020.</div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the restricted share units of 2020 Plan for the year ended December&#160;31, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number&#160;of</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">restricted<br/> share units</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">exercise</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">price</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">remaining</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">contractual</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">term</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregate</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">intrinsic</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">value</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">4,093,079 </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(13,461</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">4,079,618</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">9.70</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">83,632</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td></tr></table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">A summary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> restricted share units activities for the year ended December&#160;31, 2020 is presented below: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>restricted<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>share </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">units</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>fair value</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2019</div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">4,093,079</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">13.99</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(13,461</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">11.73</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2020</div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">4,079,618 </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">14.00</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Apart from the aforementioned restricted share units, up to 1,446,875 shares can be issued in the form of restricted share unit to eligible grantees that the board of the Group or a committee that board delegated its powers or authority determined appropriate with immediate effect of being fully vested, which are defined as special awards and are subject to terms and conditions under 2018 Plan. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2020, the Group granted 1,328,120 such restricted share units to employees and recognized<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>RMB25,985&#160;RMB67,182 <div style="letter-spacing: 0px; top: 0px;;display:inline;">and RMB19,085 share-based compensation expenses in administrative expenses, research and development expenses and equity in loss of an affiliate, respectively, in the consolidated statement of comprehensive incomes of December 31, 2020, 565,200 restricted share units were vested,<div style="display:inline;">&#160;</div></div></div>among<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>which<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> &#160;558,200</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;">restricted share units were vested but not issued as ordinary shares as the employees will not be entitled to the rights of ordinary shares from the Group until they have the consideration for the transaction settled.</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the restricted share units subject to terms and conditions under 2018 Plan for the year ended December&#160;31, 2020: </div></div> <br/>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number&#160;of</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">restricted<br/> share units</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">exercise</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">price</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">remaining</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">contractual</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">term</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregate</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">intrinsic</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">value</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,328,120</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; </div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(565,200</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">1.00</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; </div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; </div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">762,920</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">9.65</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">14,877</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A summary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> restricted share units activities for the year ended December&#160;31, 2020 is presented below: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>restricted<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>share </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">units</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>fair value</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2019</div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,328,120</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13.34</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(565,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2020</div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">762,920</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12.89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(g) Establishment of Biomaster Trust </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Biomaster Trust was established under the trust deed dated October&#160;23, 2019, between the Company and TMF Trust (HK) Limited, or TMF Trust, as the trustee of the Biomaster Trust. Through the Biomaster Trust, the Company&#8217;s ordinary shares and other rights and interests under awards granted pursuant to 2017 Plan and 2018 Plan may be provided to certain recipients of equity awards. Upon satisfaction of vesting conditions, TMF Trust will exercise the equity awards and transfer the relevant ordinary shares and other rights and interests under the equity awards to the relevant grant recipients with the consent of the advisory committee of Biomaster Trust. TMF Trust shall not exercise the voting rights attached to such ordinary shares unless otherwise directed by the advisory committee, whose members shall be appointed by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab.</div> The Company has the power to direct the relevant activities of Biomaster Trust and it has the ability to use its power over the Biomaster Trust to affect its exposure to returns. Therefore, the assets and liabilities of the Biomaster Trust are included in the <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Group&#8217;s consolidated balance sheets. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(h) Surrender of stock options </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;17, 2020, the Group completed its IPO. According to the amendments to 2017 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2017 Plan was changed to 9,609,084. Each of the Company&#8217;s founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang surrendered 83,142 unvested stock options that were granted to him or her under 2017 Plan before, totally 332,566 unvested options, for no consideration, and these stock options were cancelled immediately. According to the amendments to 2018 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2018 Plan was changed to 11,005,888. The director of the Company, Dr.&#160;Jingwu Zhang Zang surrendered 2,544,917 unvested options that were granted to him under 2018 Plan, for no consideration, and these stock options were cancelled immediately. Upon the completion of the Company&#8217;s IPO in January 2020, the Group has recorded RMB91,051 share-based compensation expense related to these surrendered options. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The stock options surrendered by the founders should be accounted for as capital contribution. As the founders did not get the title of the stock options to be surrendered and the number of stock options would not be determined until listing, the capital contribution was not accounted for during the year ended December&#160;31, 2019. For the year ended December&#160;31, 2020, the Group has reclassified RMB91,051 from additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital &#8211; share-based compensation to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital &#8211; capital contribution relating to the stock options surrendered in the <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consolidated statement of comprehensive income. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-Based Compensation Expense </div></div></div> <div style="text-align: left;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The allocation of share-based compensation expense was as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr></table></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">US$</div></div><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">470</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">284,431</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">43,591 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative expenses</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">514,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">209,033</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,036 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 67%; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in loss of an affiliate</div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px; text-align: center; margin-left: 0.1in; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#8212;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px; text-align: center; margin-left: 0.15in; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#8212;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">32,707</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">5,013</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 67%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,520</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">515,203</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">526,171</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">80,640 </div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707817247608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing And Collaboration Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Licensing And Collaboration Arrangements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">8</div>. LICENSING AND COLLABORATION ARRANGEMENTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a description of the Group&#8217;s significant licensing and collaboration agreements entered into from January&#160;1, 2017 to December&#160;31, 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">A. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Licensing</div> Arrangements </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement with MorphoSys AG (&#8220;MorphoSys&#8221;) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2017, the Group entered into a license and collaboration agreement with MorphoSys, with respect to the development and commercialization of MOR202/TJ202, MorphoSys&#180;s proprietary investigational antibody against CD38 (the &#8220;CD38 product&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under this agreement, MorphoSys granted to the Group an exclusive, royalty-bearing, sublicensable license to exploit MOR202/TJ202 for any human therapeutic or diagnostic purpose in the licensed territory, namely mainland China, Hong Kong, Macau and Taiwan (collectively &#8220;Greater China&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to this agreement, the Group granted to MorphoSys an exclusive license to its rights in any inventions that the Group make while exploiting the CD38 product under this agreement, solely to exploit the CD38 product outside of Greater China. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to this agreement, the Group paid to MorphoSys an upfront license fee of US$20.0&#160;million (equivalent to approximately RMB132.7 million). The Group also agreed to make milestone payments to MorphoSys, conditioned upon the achievement of certain development, regulatory and commercial milestones, in the aggregate amount of US$98.5&#160;million (equivalent to approximately RMB653.5 million). Such milestones include first patient dosed in human clinical trials, marketing approval, and first annual net sales of CD38 products covered by the agreement in excess of a certain amount. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, the Group is required to pay tiered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-double-digit</div> royalties to MorphoSys on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product</div></div> basis during the term, commencing with the first commercial sale of a relevant licensed product in Greater China. Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the expiration of the Group&#8217;s last payment obligation under the agreement. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2017, the Group paid US$20.0&#160;million (equivalent to approximately RMB132.7 million) upfront fee to MorphoSys, which was recorded as research and development expense. No additional payments were made in 2018. Due to the uncertainty involved in meeting these developments and commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&#160;31, 2018. In March and April 2019, the project achieved the first and second milestone and the Group paid US$8.0&#160;million (equivalent to approximately RMB55.7 million) of milestone fees to MorphoSys, which was recorded as research and development expense in the consolidated statement of comprehensive loss for the year ended December&#160;31, 2019. No additional payments were made for the year ended December&#160;31, 2020 as no milestone has been achieved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summarized financial information related to the above agreement is presented below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 41%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Year ended December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">As&#160;of&#160;December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Research and Development Expense</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Upfront&#160;Fees</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Milestones</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Extension/Termination<br/> of agreements</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Amortization&#160;of&#160;prepaid<br/> research and<br/> development</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Intangible&#160;asset&#160;balance</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 41%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 41%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">US$</td>
<td style="vertical-align: bottom;;text-align:right;">8,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 41%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 41%; padding-bottom: 0.45pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 41%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2017, the Group entered into an intellectual property agreement with Genexine with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-I7/TJ107,</div> a long-acting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-7</div> cytokine. Under this agreement, the Group obtained an exclusive, sublicensable and transferable license to use and otherwise exploit certain intellectual property in connection with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical development, manufacturing, sale and distribution of GX-I7 to treat cancer in Greater China. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of the agreement, the Group made an upfront payment of US$12.0&#160;million (equivalent to approximately RMB79.6 million) to Genexine which was recorded as a research and development expense in January 2018. The Group also agreed to make milestone payments in the aggregate amount of US$23.0&#160;million (equivalent to approximately RMB152.6 million), conditioned upon the achievement of certain development milestones, including completion of Phase 2 and Phase 3 clinical studies and new drug application (&#8220;NDA&#8221;) or biologic license application (&#8220;BLA&#8221;) approval in Greater China. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, the Group agreed to make milestone payments in the aggregate amount of US$525.0&#160;million (equivalent to approximately RMB3,482.7 million), conditioned upon the achievement of certain cumulative net sales of GX<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">-I7 </div></div>up to US$2,000&#160;million. The Group also is required to pay Genexine a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-single-digit</div> percentage royalty in respect of the total annual net sales of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-I7.</div> The aforesaid milestones and royalties (other than the upfront payment) will be reduced by 50% following the entry of a generic version of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-I7</div> in China, Hong Kong, Macau and Taiwan without the consent or authorization of the Group or any of the Group&#8217;s sublicensees. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the later of (i)&#160;the expiry of the last to expire patent of the licensed intellectual property that includes a valid claim for Greater China and that covers the composition of GX-I7; and (ii) 15 years from the date of the first commercial sale of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GX-I7.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No additional payments to Genexine were made in the year ended December&#160;31, 2019 and 2020. Due to the uncertainty involved in meeting these development and commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&#160;31, 2019 and 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summarized financial information related to the above agreement is presented below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Year ended December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">As&#160;of&#160;December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Research and Development Expense</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Upfront&#160;Fees</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Milestones</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Extension/Termination<br/> of agreements</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Amortization&#160;of&#160;prepaid<br/> research and<br/> development</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Intangible&#160;asset&#160;balance</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 45%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">US$</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">12,000</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 45%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In May 2020, the Group and Genexine entered into an amendment to this agreement whereby both parties desire to establish collaboration on TJ107 GBM Study in Greater China Under the terms of the expanded collaboration, the Group will be mainly responsible for using commercially reasonable efforts to conduct the Phase 2 GBM clinical trial in Greater China, and Genexine will share the development strategies, data and costs for success of this clinical trial. The Group shall undertake to bear <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> (2/3) proportion of the clinical development costs and Genexine shall undertake to bear <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> (1/3) proportion of these costs. As of December&#160;31, 2020, the costs incurred for the development of this new indication was RMB4.3&#160;million and thus RMB2.9&#160;million expense was recorded in the consolidated statement of comprehensive income for the year ended December&#160;31, 2020. </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement with MorphoSys </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In November 2018, the Group entered into a license and collaboration agreement with MorphoSys for MorphoSys&#8217;s proprietary antibody (MOR210/TJ210) directed against C5aR (the &#8220;C5aR Agreement&#8221;). Under this agreement, the Group obtained an exclusive, royalty-bearing license to explore, develop and commercialize certain anti-C5aR antibodies in Greater China and South Korea.</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group will perform and fund all global development activities related to the development of MOR210/TJ210 in Greater China and South Korea, including all relevant clinical trials (including in the U.S. and China) and all development activities required for IND filing in the US as well as CMC development of manufacturing processes. MorphoSys retains rights in respect of development and commercialization of MOR210/TJ210 in the rest of the world. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the terms of the agreement, the Group also agreed to make milestone payments conditional upon the achievement of certain development milestones and certain annual net sales of anti-C5aR antibodies. The Group is also required to pay to MorphoSys tiered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single-digit</div> royalties on annual net sales of anti-C5aR antibody products within the licensed territory. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2018, the Group paid US$3.5&#160;million (equivalent to approximately RMB23.2 million) upfront fee to MorphoSys, which was recorded as research and development expense in the consolidated statement of comprehensive loss for the year ended December&#160;31, 2018. No additional payments were made in the year ended December&#160;31, 2019. In August 2020, the project achieved the first milestone and the Group paid US$1.0&#160;million (equivalent to approximately RMB6.9 million) of milestone fees to Morphosys, which was recorded as research and development expenses in the consolidated statement of comprehensive income for the year ended December&#160;31, 2020. Due to the uncertainty involved in meeting these development and commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&#160;31, 2019 and 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summarized financial information related to the above agreement is presented below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 42%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Years Ended December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">As&#160;of&#160;December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Research and Development Expense</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Upfront&#160;Fees</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Milestones</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Extension/Termination<br/> of agreements</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Amortization&#160;of&#160;prepaid<br/> research and<br/> development</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Intangible&#160;asset&#160;balance</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 42%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: top;">US$</td>
<td style="vertical-align: top;;text-align:right;">1,000</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 42%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 42%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: top;">US$</td>
<td style="vertical-align: top;;text-align:right;">3,500</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 42%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement with MacroGenics </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2019, the Group entered into a license and collaboration agreement with MacroGenics, Inc. for development and commercialization of an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Fc-optimized</div> antibody known as enoblituzumab that targets <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B7-H3,</div> including in combination with other agents, such as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD-1</div></div> antibody known as MGA012, in the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(&#8220;Greater China&#8221;). Under this agreement, the Group obtained an exclusive, sublicenseable, royalty-bearing license to MacroGenics&#8217; patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> to develop and commercialize the enoblituzumab product, and a combination regimen of enoblituzumab and MGA012, in Greater China during the term of the agreement. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In exchange for these rights, in addition to certain financial consideration, the Group will grant to MacroGenics a royalty-free, sublicenseable, license outside of Greater China, to the patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> that are related to the enoblituzumab product or useful or necessary for MacroGenics to develop or commercialize the enoblituzumab product or a product containing MGA012, and combinations thereof. The license is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i)&#160;non-exclusive</div> with respect to the enoblituzumab product, and (ii)&#160;exclusive with regard to MGA012. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the agreement, the Group paid an upfront fee of US$15.0&#160;million (equivalent to approximately RMB104.4 million) to MacroGenics, which was recorded as research and development expense in the consolidated statement of comprehensive loss for the year ended December&#160;31, 2019. No additional payments were made in the year ended December&#160;31, 2020. Under the terms of the agreement, the Group also agreed to pay MacroGenics development milestone fees of up to US$75.0&#160;million and regulatory milestones fees of up to US$60.0&#160;million, respectively, and tiered double-digit royalties (ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-teens</div> to twenty percent) based on annual net sales in the territories. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group is responsible for all development costs in Greater China. MacroGenics is responsible for all development costs in the rest of the world, except that the Group is responsible for 20% of the costs incurred in (i) activities supporting global clinical trials in which the Group participates, (ii) certain CMC activities for material intended to be used in clinical trials in Greater China, and (iii) companion diagnostic development and validation for indications being studied in Greater China.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to the uncertainty involved in meeting these development and commercialization based targets, the Group evaluated and concluded that no milestones are probable as of December&#160;31, 2019 and 2020. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 40%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Year ended December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">As&#160;of&#160;December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Research and Development Expense</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Upfront Fees</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Milestones</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Extension/Termination<br/> of agreements</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Amortization&#160;of&#160;prepaid<br/> research and<br/> development</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Intangible&#160;asset&#160;balance</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 40%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: top; width: 0%;">US$</td>
<td style="vertical-align: top; width: 0%;;text-align:right;">15,000</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 40%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other In-Licensing Arrangements</div></div></div></div></div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;">In addition to the above arrangements, the Group has entered into other <div style="letter-spacing: 0px; top: 0px;;display:inline;">various</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> and collaboration agreements with third party licensors to develop and commercialize drug candidates. Based on the terms of these agreements the Group is contingently obligated to make additional material payments upon the achievement of certain contractually defined milestones. The Group recorded US$0.6&#160;million (equivalent to approximately RMB4.0 million) upfront fee and US$0.3&#160;million (equivalent to approximately RMB2.0 million) milestone payment under these agreements for the year ended December&#160;31, 2018. The Group recorded US$1.2&#160;million (equivalent to approximately RMB8.4 million) milestone payment during the year ended December&#160;31, 2019. The Group additionally recorded US$3.1&#160;million (equivalent to approximately RMB21.3 million) milestone payment during the year ended December&#160;31, 2020. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2020, </div></div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">under the terms </div></div> of the agreements, the licensors are eligible to receive from the Group up to an aggregate of approximately US$107.4&#160;million (equivalent to approximately RMB740.4 million) in milestone payments upon the achievement of contractually specified development milestones and sales milestones, such as regulatory approval for the drug candidates, which may be before the Group has commercialized the drug or received any revenue from sales of such drug candidate, which may never occur. </div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">B. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Out-Licensing</div> and collaboration Arrangements </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement among HDYM, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> and Hangzhou HealSun Biopharm Co., Ltd. (&#8220;HealSun&#8221;) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In April 2017, one of the Company&#8217;s subsidiaries, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai, entered into a technology transfer agreement with HDYM and HealSun with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD-L1</div></div> humanized monoclonal antibodies. Under the agreement, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai agreed to grant to HDYM exclusive, worldwide and sublicensable rights to develop, manufacture, have manufactured, use, sell, have sold, import, or otherwise exploit certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> related patents, patent applications, know-hows, data and information of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai, relevant cell lines as well as any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD-L1</div></div> monoclonal antibody arising from such cell lines for the treatment of diseases. Further, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai and its cooperative party, HealSun agreed to provide subsequent research and development services on such intellectual property to HDYM, including the selection and examination of innovative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD-L1</div></div> humanized monoclonal antibodies, cultivation and selection of stable cell lines, establishment of cell bank, research and development of manufacturing processes and preparation of samples, toxicological and pharmacological testing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> pharmaceutical experiment report drafting, and application for and registration of clinical trials. HDYM agreed to make milestone payments conditioned upon achieving certain contractually defined milestones. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group determined that this collaboration is reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, due to the early stage nature of the development, in which the underlying intellectual property is significantly modified by the development activities being performed, the Group determined the license to the intellectual property and research and development services are not distinct and thus were accounted for as a single performance obligation that is satisfied over time. The Group would receive RMB51.0&#160;million (inclusive of VAT) milestone payments under this agreement, and considered that the achievements of milestone II, III, IV are constrained such that the transaction price shall initially only include the milestones payment which have been achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone payment shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group used a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> input method to measure progress as that method best depicts its performance under the agreement. For the year ended December&#160;31, 2017, the Group achieved milestones I and II and received milestone payments totaling of RMB29.0&#160;million (inclusive of VAT). The cumulative percentage complete in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> input method related to this agreement as of December&#160;31, 2017 is estimated to approximate 42%, the Group recognized RMB11.6&#160;million (exclusive of VAT of RMB0.7 million) of revenue in the consolidated statement of comprehensive loss, and RMB15.8&#160;million (exclusive of VAT of RMB0.9 million) were deferred as contract liability related to this arrangement. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the year ended December&#160;31, 2018, the Group achieved milestones III and IV and received milestone III payment of RMB11.0&#160;million (inclusive of VAT), milestone IV payment of RMB 11.0&#160;million (inclusive of VAT) was recognized as contract assets as of December&#160;31, 2018. As of December&#160;31, 2018, the cumulative percentage complete in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to</div> cost input method related to this arrangement is estimated to approximate 100%. The Group recognized RMB36.5&#160;million (exclusive of VAT of RMB1.3 million) of revenue in the consolidated statement of comprehensive loss for the year ended December&#160;31, 2018. All of the milestone payments were received by the Group as of December&#160;31, 2019. </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration Agreement with Everest (&#8220;Everest&#8221;)</div></div></div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;">In January 2018, the Group entered into a collaboration agreement with Everest, which is controlled by the <div style="letter-spacing: 0px; top: 0px;;display:inline;">ultimate </div>controlling party of a principal shareholder of the Group. Under the agreement, both parties agreed to collaborate on programs to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-develop</div> MorphoSys&#8217; proprietary anti-CD38 antibody for all indications in hematologic oncology and commercialize of MOR202/TJ202 in Greater China. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A joint steering committee with equal representation from each party was established to coordinate and oversee the development and commercialization of the CD38 product. All decisions of the joint steering committee shall be made by unanimous vote. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the agreement, the Group is primarily responsible for carrying out the development, manufacture and supply of the CD38 product, as well as seeking regulatory approval of the CD38 product. Everest is primarily responsible for sharing the development costs of the CD38 product, including payments due to MorphoSys under the Licensing Agreement, dated November 30, 2017, in the proportion of 75% by Everest and 25% by the Group.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The joint steering committee will decide which party shall be responsible for conducting the commercialization of the CD38 product pursuant to the commercialization plan approved by the committee. If Everest is selected to be responsible for commercialization, the Group shall grant an exclusive royalty-free license to Everest to commercialize the CD38 product for all indications in hematologic oncology in Greater China. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group and Everest will share the profit and loss and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> revenue derived from the CD 38 product in proportion to the costs that each party incur in developing the product. The parties will also split <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-license</div> revenue according to the proportion of development costs incurred, with the Group getting an additional five percent (5%) share and Everest receiving five percent (5%) less. Everest cannot share in any profit from the commercialization of CD38 product until it has fulfilled its payment obligations under this agreement. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon any termination of this arrangement, the terminating party has the right to continue the development and commercialization of CD38 product. If Everest is the rightful terminating party, the Group shall reasonably cooperate with Everest to facilitate the following: (i)&#160;assign the MorphoSys license to Everest (subject to the terms and conditions of such license); (ii) grant to Everest an exclusive license to all intellectual property rights that the Group owns or controls to further develop, manufacture, and commercialize the CD38 product; (iii)&#160;transfer the development, manufacture and commercialization of the CD38 product to Everest. The terminating party shall be solely responsible for the cost and expense of such development and commercialization after termination. In the event that such continuing party successfully develops and commercializes the CD38 product, it shall pay to the other party a percentage of the product profit and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-license</div> revenue generated therefrom in accordance with the terms of this agreement. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2018, the US$26.0&#160;million in aggregate proceeds from Everest under the agreement represented the funding available under the agreement, and was recorded as a research and development funding received liability (equivalent to approximately RMB178.7 million) on the consolidated balance sheet as of December&#160;31, 2018, in accordance with ASC 730, Research and Development. Because there is a significant related party relationship between the Group and Everest, the Group is treating its obligation to make payments under the commercialization stage as an implicit obligation to repay the funds advanced by Everest (see Note 2<div style="display:inline;">3</div>). During the year ended December&#160;31, 2019, an additional US$7.6million (equivalent to approximately RMB53.1 million) of funding was received and recorded as a research and development funding received liability. No additional milestone has been achieved in the year ended December&#160;31, 2019. </div></div>  <div style="font-family: Times New Roman;font-size: 10pt;margin-top: 6pt;margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;4, 2019, the Group and Everest have terminated the collaboration agreement with respect to the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-development</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and commercialization of TJ202 in Greater China. Upon the termination, Everest will not retain any rights or entitlements to develop or commercialize TJ202 or any economic interest in its commercialization. All intellectual property rights in respect of TJ202 arising from its development under the collaboration agreement are vested and owned by </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab,</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and the Group holds all intellectual property rights and have maximum flexibility to further develop, manufacture and commercialize TJ202 in Greater China. In consideration of the above arrangements, the board of directors of the Group has approved the issuance of a total value of US$</div>37.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of ordinary shares (the &#8220;CPP Shares&#8221;) to Everest, representing Everest&#8217;s historical contribution to the collaboration and the associated time cost. The CPP Shares will be issued concurrently with, and subject to, the completion of the Company&#8217;s initial public offering within 180 days from termination of the collaboration agreement. The total value of US$</div>37.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was calculated based on the sum of (1)&#160;US$</div>33.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which equals cumulative </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> contributions historically made by Everest under the collaboration agreement; and (2)&#160;a negotiated US$</div>3.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million time cost of the foregoing historical contribution in light of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab&#8217;s</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> exclusive rights over the commercialization of TJ202 after this termination. The issuance of the CPP Shares was approved by </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab&#8217;s</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> existing shareholders on December&#160;25, 2019. In the event that the initial public offering has not been completed within 180 days from the termination of the collaboration agreement, the Company will issue </div>4,762,751<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> ordinary shares (the &#8220;Subject Shares&#8221;) to Everest on the 181st day. As a result of the aforementioned termination of the collaboration agreement with Everest, the Group derecognized the research and development funding received from Everest and recognized a liability that represented the ordinary shares to be issued to Everest, which was measured at fair value in accordance with ASC 480, and the difference of US$</div>3.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (equivalent to approximately RMB</div>23.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> million) between the initial fair value of the liability and the carrying amount of research and development funding received was recognized as other expenses in the consolidated statements of comprehensive loss for the year ended December&#160;31, 2019. Upon the completion of the IPO in January 2020, the Group issued </div>6,078,571<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> ordinary shares to Everest.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement with ABL Bio </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2018, the Group entered into a license and collaboration agreement with ABL Bio, under which the Group granted to ABL Bio exclusive, worldwide (excluding Greater China), royalty-bearing rights to develop and commercialize a bispecific antibody (&#8220;BsAb&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group agreed to share costs fifty-fifty (50:50) with ABL Bio through the completion of in vivo studies, with ABL Bio responsible for all costs and activities following that time. For the year ended December&#160;31, 2019, US$0.2&#160;million (equivalent to approximately RMB1.4 million) expenses were incurred by ABL Bio. Accordingly, the Group recorded US$0.1&#160;million (equivalent to approximately RMB0.7 million) <div style="letter-spacing: 0px; top: 0px;;display:inline;">(</div>50% cost sharing) of expenses in the Group&#8217;s consolidated statement of comprehensive loss for the year ended December&#160;31, 2019. For the year ended December&#160;31, 2020, US$0.04&#160;million (equivalent to approximately RMB0.28 million) expenses were incurred by ABL Bio. Accordingly, the Group recorded US$0.02&#160;million (equivalent to approximately RMB0.14 million) <div style="letter-spacing: 0px; top: 0px;;display:inline;">(</div>50% cost sharing) of expenses in the Group&#8217;s consolidated statement of comprehensive income for the year ended December&#160;31, 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the license and collaboration agreement that signed in July 2018 and memorandum of understanding that subsequently entered into with ABL Bio in January 2020, ABL Bio agreed to pay the Group an upfront fee of US$2.5&#160;million (equivalent to approximately RMB17.2 million), and milestone payments in the aggregate amount of US$97.5&#160;million (equivalent to approximately RMB690.3 million) conditioned upon achieving certain research, clinical development and sales milestones. These include clinical milestones of up to US$32.5&#160;million (equivalent to approximately RMB230.1 million) and sales milestones of up to US$65&#160;million (equivalent to approximately RMB460.2 million). Further, ABL Bio agreed to pay the Group royalties at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single-digit</div> percentages in respect of the total annual net sales of the licensed BsAb product. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, ABL Bio granted to the Group an exclusive, royalty-free, sublicensable license to use the BsAb technology solely to exploit the licensed BsAb product for all indications in Greater China. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group determined that this collaboration is reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, the only one performance obligation was to grant the BsAb license to ABL Bio. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Achievement of milestones that are not within the control of the Group or the licensee, such as regulatory approvals, are not considered probable until the approvals are achieved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group recognized revenue of US$2.5&#160;million (equivalent to RMB17.2 million) of revenue in the consolidated statements of comprehensive loss for the year ended December&#160;31, 2018, which was the upfront fee related to the grant of the rights of BsAb to ABL Bio as mentioned above. As of December&#160;31, 2019 and 2020, no other milestone has been achieved. No revenue was recognized for the year ended December&#160;31, 2019 and 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December 4, 2020, I-Mab Hong Kong, ABL Bio and I-Mab Hangzhou entered into an amendment, which is made effective as of September 15, 2020, that I-Mab Hong Kong, as the subject of the aforementioned licensing agreement, shall be replaced and substituted by I-Mab Hangzhou<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration Agreement with ABL Bio </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2018, the Group and ABL Bio entered into a collaboration agreement (the &#8220;ABL Bio Collaboration&#8221;) whereby both parties agreed to collaborate to develop three <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> based bispecific antibodies by using ABL Bio&#8217;s proprietary BsAb technology and commercialize them in their respective territories, which, collectively, include Greater China and South Korea, and other territories throughout the rest of the world if both parties agree to do so in such other territories during the performance of the agreement. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At contract inception, as both <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> and ABL Bio participate actively in the research and development activity. Also, the parties share the risk of failure of the BsAb products and share the income of licensing, so this contract meet the criteria of the definition of a collaborative arrangement, the Group categorized this agreement within the scope ASC 808. Prior to commercialization, the Group recorded the share of the expenses incurred by the collaboration for the development of three <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> based bispecific antibodies products in research and development expense in the consolidated <div style="letter-spacing: 0px; top: 0px;;display:inline;">statements of comprehensive income (loss).</div> As of December&#160;31, 2018, RMB1.0&#160;million expenses were incurred by the Group and ABL Bio did not incur any expense. According to the terms set out in the agreement, the Group recorded RMB0.5&#160;million <div style="letter-spacing: 0px; top: 0px;;display:inline;">(</div>50% cost sharing) of expense in the Group&#8217;s consolidated statement of comprehensive loss for the year ended December&#160;31, 2018. For the year ended December&#160;31, 2019, RMB11.2&#160;million expenses were incurred by the Group and RMB8.0&#160;million expenses were incurred by ABL Bio. Accordingly, the Group recorded RMB9.6&#160;million (50% cost sharing) of expenses in the Group&#8217;s consolidated statement of comprehensive loss for the year ended December&#160;31, 2019. For the year ended December&#160;31, 20<div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div>, RMB43.6&#160;million expenses were incurred by the Group and RMB44.0&#160;million expenses were incurred by ABL Bio. Accordingly, the Group recorded RMB43.8&#160;million (50% cost sharing) of expenses in the Group&#8217;s consolidated statement of comprehensive income for the year ended December&#160;31, 2020. </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration Agreements with Tracon Pharmaceuticals, Inc. (&#8220;Tracon&#8221;)</div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2018, the Group entered into collaboration agreements with Tracon, under which both parties agreed to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-develop</div> the Group&#8217;s proprietary CD73 antibody, TJD5 (the &#8220;TJD5 Agreement&#8221;) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-develop</div> up to five BsAbs (the &#8220;BsAbs Agreement&#8221;). Both agreements may be terminated by either party for the other party&#8217;s uncured material breach, bankruptcy or insolvency or for safety reasons. In addition, the agreement in respect of TJD5 may be terminated by the Group: (i)&#160;for convenience within a certain period upon completing different clinical stages subject to certain payments and royalties, based on the clinical stage, that would be owed to Tracon upon the exercise of such termination for convenience; (ii)&#160;in the event that Tracon causes the Phase 1 study timeline to be delayed beyond the agreed extension periods; or (iii)&#160;if the Group decides to end the development of the collaborative product prior to its first commercial sale. Further, prior to the first commercial sale, Tracon may deem this agreement to be terminated by the Group if it reasonably believes that the Group has discontinued all meaningful development of the collaborative product for at least 12 months and certain other conditions are met. Additionally, in March 2019, the Group agreed with Tracon and F. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Hoffmann-La</div> Roche Ltd (&#8220;Roche&#8221;) on a clinical supply agreement for Roche to supply atezolizumab for use in clinical studies under the collaboration agreement with Tracon. As of December&#160;31, 2019, no payments or royalties are due under this agreement. As of December&#160;31, 2019, the Group has recorded US$4.0&#160;million (equivalent to approximately RMB27.8 million) of research and development costs in the consolidated statement of comprehensive loss for the year ended December&#160;31, 2019. As of December&#160;31, 2020, the Group has recorded US$0.03&#160;million (equivalent to approximately RMB0.17 million) of research and development costs in the consolidated statement of comprehensive <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">income for the year ended December&#160;31, 2020. </div></div></div> <div style="text-align: left;"><div style="text-align: left;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2020, Tracon issued a notice of disputes with respect to the TJD5 Agreement and the BsAbs Agreement. As of the date of this report, these disputes have not been resolved.&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing Agreement with CSPC Pharmaceutical Group Limited (&#8220;CSPC&#8221;) </div></div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2018, the Group entered into a product development agreement with CSPC. The Group granted to CSPC exclusive, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-transferable,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-irrevocable</div> and sublicensable rights in the PRC (excluding Hong Kong, Macau and Taiwan) to develop and commercialize TJ103 for treating type 2 diabetes. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CSPC is responsible for developing, obtaining market approval and commercializing the licensed products. The Group is responsible for transferring the manufacturing technology of the licensed products to CSPC and assisting CSPC in the continued optimization of such manufacturing technology thereafter. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In consideration of the license, CSPC agreed to pay the Group an upfront fee of RMB15.0&#160;million and milestone payments in an aggregate amount of RMB135.0&#160;million conditioned upon achieving certain clinical development and regulatory approval milestones. In addition, the Group is also entitled to royalties of up to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-double-digit</div> percentages in respect of the total annual net sales of the products after its commercialization in the PRC. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group determined that this collaboration is more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, the only one performance obligation was to grant TJ103 license to CSPC. Considering that the achievements of milestones are constrained such that the transaction price shall initially only include upfront payment and subsequently, once another milestone was achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone payment shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. As of December&#160;31, 2018, the amount received of RMB14.2&#160;million (net of VAT) was recorded as advance from customers in the consolidated balance sheet. In February 2019, an additional amount of RMB0.8&#160;million (net of VAT) was received, and the license was also approved by China intellectual property office in May 2019. The first milestone was achieved in September 2019 and the amount of RMB15.0&#160;million (net of VAT) was received according to the terms of the agreement. Accordingly, RMB30.0&#160;million was recognized as revenue in the consolidated statements of comprehensive loss for the year ended December&#160;31, 2019. No additional revenue was recognized in the <div style="letter-spacing: 0px; top: 0px;;display:inline;">year</div>&#160;ended December&#160;31, 2020 as no further milestone has been achieved. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 6pt;"><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In </div>March 2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Group entered into a strategic partnership with Kalbe Genexine Biologics (&#8220;KG Bio&#8221;) to grant a right of first negotiation for an exclusive license for the development and commercialization of </div>two<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">I-Mab-discovered</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> product candidates: uliledlimab, a highly differentiated anti-CD</div>73<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> antibody in Phase </div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> development for advanced solid tumors (&#8220;First Program&#8221;), and an </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> product candidate (&#8220;Second Program&#8221;) to be agreed upon by both parties in certain regions. Through this agreement, both parties intend to negotiate the terms that will be reflected in definitive agreements for each prospective program covered under this agreement.</div><br/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">If and when the Group and KG Bio enter into the definitive licensing agreement, the Group will be eligible to receive from KG Bio an aggregate amount of up to approximately US$340&#160;million, including an upfront payment and subsequent payments conditional upon achieving certain development and commercial milestones. KG Bio will pay the Group tiered royalties in the low to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-teen</div> percentages on net sales from certain regions. As the right of first negotiation has not been exercised and the definitive agreement has not been entered into as of December&#160;31, 2020, no revenue was recognized during the year ended December&#160;31, 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Global Strategic Partnership with AbbVie </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;3, 2020, the Group, through <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma (Shanghai) Co., Ltd. and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma US Limited, each a wholly-owned subsidiary of the Group, entered into a broad global strategic partnership with AbbVie Ireland Unlimited Group (&#8220;AbbVie&#8221;). </div> <div style="text-align: left;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to this collaboration, the Group will grant AbbVie a global license, excluding Mainland China, Macau, and Hong Kong, to develop and commercialize lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> for the treatment of multiple cancers. The Group will retain all rights to develop and commercialize lemzoparlimab (as well as certain other compounds directed against CD47) in Mainland China, Macau, and Hong Kong. The Group is also responsible for performing the development activities at its sole cost and expense as outlined in the initial development plan. Such initial development activities consist of two studies, Study I and Study II. Study I is conducted in the United States evaluating lemzoparlimab in combination with pembrolizumab or rituximab in patients with relapsed or refractory solid tumors and lymphoma. Study II is conducted in Mainland China evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of lemzoparlimab in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). AbbVie will conduct further global clinical trials (which the Group may elect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-fund)</div> to evaluate lemzoparlimab in multiple cancers. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Potential collaboration on future CD47-related therapeutic agents is also allowed for under this arrangement, including CD47-based bispecific antibodies and combination therapies with lemzoparlimab and AbbVie&#8217;s venetoclax (Venclexta<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>). Each party will have the opportunity, subject to rights of first negotiation to further licenses, to explore certain of each other&#8217;s related CD47-antibody programs in their respective territories.</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A joint governance committee was established as set forth in the agreement, functioning as an oversight and governance mechanism. Both parties will participate in the joint governance committee to facilitate decision-making during the terms of the collaborative endeavor. Furthermore, the Group and AbbVie will share manufacturing responsibilities, with AbbVie having the opportunity to manufacture supply outside of Mainland China, Hong Kong and Macau and the Group being the primary manufacturer for supply for Mainland China, Hong </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kong and Macau. </div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-7<div style="display:inline;">2</div></div></div></div></div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Upon the satisfaction of all the pre-effect date covenants, the collaborative agreement took effect on December 10, 2020, on which date the Group was entitled to a non-refundable upfront payment of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>US$180&#160;million. <div style="letter-spacing: 0px; top: 0px;;display:inline;">In addition,</div>&#160;the Group <div style="letter-spacing: 0px; top: 0px;;display:inline;">is</div>&#160;eligible to receive up to US$1.76&#160;billion in further success-based development, regulatory and sales milestone payments for lemzoparlimab, of which US$840&#160;million are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestones. Upon commercialization of lemzoparlimab, AbbVie will also pay tiered royalties<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">from low-to-mid teen double-digit percentages on global net sales outside of Mainland China, Macau, and Hong Kong.&#160;<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group identified three performance obligations: (1)&#160;grant of lemzoparlimab license upon the effective date, (2)&#160;delivering the Study I initial development services, and (3)&#160;delivering the Study II initial development services. The total transaction price under the agreement for the year ended December&#160;31, 2020 is US$250&#160;million consisting of (i)&#160;the upfront payment of US$180&#160;million upon the effective date, (ii)&#160;the first milestone payment of US$20&#160;million upon the achievement of the first milestone event in late December 2020, and (iii)&#160;the second milestone payment of US$50&#160;million as of December&#160;31, 2020 as the Group deemed that the achievement of the second milestone event is probable as of December&#160;31, 2020 that a significant reversal of revenue would not occur. The achievements of the remaining development and regulatory based milestone events are constrained as of December&#160;31, 2020, and will be included in the transaction price when uncertainty associated with the variable consideration is subsequently resolved. Sales-based milestones and royalties will be recognized when the subsequent sales occur. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The non-constrained consideration of US$250<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">million is then allocated to the three performance obligations based on the relative stand-alone selling price. For the grant of lemzoparlimab license, the Group adopted an income approach based on key assumptions and several factors including, but not limited to estimated market demand, stand-alone selling price by making reference to market comparable, development timeline, regulatory risks, future revenue potential and discount rate.</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">The allocated price is US$228.8 million. The entire US$228.8</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">million (equivalent to approximately RMB1,502.9 million) was recognized</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;as revenue at</div> the point of the license transfer at the effective date. For the Study I and Study II initial development services, a cost-plus margin approach is utilized. The allocated price to Study I and Study II is</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;US$</div>11.0 <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;and US$10.2 million respectively. These two performance obligations are determined to be satisfied over time. The Group uses a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> input method to measure progress as that method best depicts the transfer of the two performance obligations under the agreement. As of December&#160;31, 2020, the cumulative percentages complete in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> input method for Study I and Study II<div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">wer</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">e</div></div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;estimated to approximate 17 % and 41 % respectively. As a result, US$1.8&#160;</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">million (equivalent to approximately RMB12.0 million)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">and US$</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">4.2</div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">million (equivalent to approximately RMB27.8 million)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">were</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> recognized as revenue for the year ended December&#160;</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">31</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">, </div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">2020</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> in the consolidated statement of comprehensive income for Study I and Study II respectively, resulting in a contract asset of </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">34.8</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">million</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">for this agreement as of December&#160;</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">31</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">, </div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">2020</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> in the consolidated balance sheets. As of December&#160;</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">31</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">, </div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">2020</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">, the upfront payment of US$</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">180</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was received by the Group. The </div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">1</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">st milestone payment of US$</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">20</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was subsequently </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">collected by the Group in March 2021. </div></div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712768696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Expenses), Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other Income (Expenses), Net</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>. OTHER INCOME (EXPENSES), NET </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes other income (expenses), net recognized for the years ended December&#160;31, 2018, 2019 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from conversion of 2017 Notes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,375</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from conversion of Onshore Convertible Loan<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,548</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from issuance of 2018 Notes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,081</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on termination agreement with Everest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23,039</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income of incentive payment from depository bank</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,348</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">360</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value change of short-term investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">703</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,730</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value change of put right liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,024</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">463</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from other financial assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,622</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net foreign exchange gains (losses)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">742</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22,126</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,391</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsidy income<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> (3)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">750</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">568</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,783</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gains on deconsolidation of a subsidiary</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">407,598</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,467</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value change of other financial assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Others</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(98</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(873</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(134</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,780</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20,205</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">412,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2020, subsidy income consists primarily of the government grant of RMB10&#160;million. The government grant was granted by the project management office of Shanghai Zhangjiang Science City to support the research and development activities in the local region. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707816265384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) per Share</a></td>
<td class="text"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div>. <div style="letter-spacing: 0px; top: 0px;;display:inline;">NET INCOME (LOSS) PER SHARE&#160;</div> </div></div></div> <div style="text-align: left;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per share for eac<div style="display:inline;">h</div>&#160;of the periods presented are calculated as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$ (Note 2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;">(in thousands, except for share and per share data)</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(402,833</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1,451,950</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">470,915</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">72,170</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Deemed dividend to Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> preferred shareholders at extinguishment of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5,283</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Deemed dividend to Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> and C preferred shareholders at modification of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> and C Preferred Shares</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(27,768</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to ordinary shareholders</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(402,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,485,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">470,915 </div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">72,170 </div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 6.5pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: 6.5pt;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 2%;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 1%;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 1%;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 2%;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Denominator for basic calculation-weighted average number of common shares <br/> outstanding</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,529,092</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,381,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">134,158,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">134,158,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive effect of convertible preferred shares</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,373,047</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,373,047</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Dilutive effect of ordinary shares to be issued to Everes<div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">266,458</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">266,458</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Dilutive effect of convertible promissory notes</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">865,479</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">865,479 </div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive effect of restricted shares<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;units</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">778,130</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">778,130</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive effect of stock options</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(255, 255, 255);">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(255, 255, 255);">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16,789,714</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16,789,714</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 57%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for diluted income (loss) per share calculation</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">6,529,092</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">7,381,230</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;157,231,652</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;157,231,652</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per share - basic</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(61.70</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(201.19</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3.51</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.54</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per share - diluted</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(61.70</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(201.19</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3.00 </div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.46</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr> </table> </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The effects of all outstanding convertible preferred shares, restricted shares and certain stock options have been excluded from the computation of diluted loss per share for the years ended December&#160;31, 2018 and 2019 as their effects would be anti-dilutive. For the years ended December&#160;31, 2018 and 2019, the Company also has certain dilutive potential stock options. These stock options which cannot be exercised until the Company completed its listing are not included in the computation of diluted earnings per shares as such contingent event had not taken place.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>The potentially dilutive securities that have not been included in the calculation of diluted net loss per share as their inclusion would be anti-dilutive are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible preferred shares</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">64,389,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">92,238,119</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted shares</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,134,058</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">not&#160;applicable</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,388,776</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707711441928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefits</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div>. EMPLOYEE BENEFITS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Full time employees of the Group in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical care, employee housing fund and other welfare benefits are provided to the employees. Chinese labor regulations require that the PRC subsidiaries of the Group make contributions to the government for these benefits based on certain percentage of the employees&#8217; salaries, up to a maximum amount specified by the government. The Group has no legal obligation for the benefits beyond the contribution made. The total amounts charged to the consolidated statements of comprehensive income (loss) for such employee benefits amounted to approximately RMB9,294, RMB14,152 and RMB10,049 for the years ended December&#160;31, 2018, 2019 and 2020, respectively. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707713113928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>. COMMITMENTS AND CONTINGENCIES </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingencies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group is a party to or an assignee of license and collaboration agreements that may require it to make future payments relating to milestone fees and royalties on future sales of licensed products (see Note&#160;18). In April 2020, Tracon issued a notice of disputes with respect to the TJD5 Agreement and the BsAbs Agreement. As of the date of this report, these disputes have not been resolved (see Note&#160;18). As of December 31, 2020, the Group did not record any liabilities for these disputes. Information available prior to issuance of the financial statements did not indicate that it is probable that a liability had been incurred at the date of the financial statements and the Company is also unable to reasonably estimate the range of any liability or&#160; possible loss, if any. </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group did not have significant capital and other commitments, long-term obligations, or guarantees as of December&#160;31, 2019 and 2020. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707711556648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Balances and Transactions</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>. RELATED PARTY BALANCES AND TRANSACTIONS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below sets forth the major related parties and their relationships with the Group as of December&#160;31, 2019 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 48%;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Name of related parties</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Relationship with the Group</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Everest</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Controlled by the ultimate controlling party of a principal shareholder of the Group</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">CMAB Biopharma (Suzhou) Inc.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Controlled by the ultimate controlling party of a principal shareholder of the Group</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Tasly Pharmaceutical Group Co., Ltd.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Controlled by the ultimate controlling party of a principal shareholder of the Group</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Jiangsu Taslydiyi Pharmaceutical Co., Ltd.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Controlled by the ultimate controlling party of a principal shareholder of the Group</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma (Hangzhou) Co., Limited</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Subsidiary of the Group before September&#160;15, 2020; Affiliate of the Group after September&#160;15, 2020</td> </tr> </table>  <div style="text-align: left;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Details of related party balances as of December&#160;31, 2019 and 2020 are as follows: </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares to be issued to Everest </div></div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Everest (Note 1<div style="display:inline;">8</div>)</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">258,119</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other receivables</div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; padding-bottom: 2.2pt; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 2.2pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 2.2pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 2.2pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">21,212</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 2.2pt; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2.2pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,251</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <div style="text-align: left;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accruals and other payables </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jiangsu Taslydiyi Pharmaceutical Co., Ltd.</div></div></div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,395</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">367</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Details of related party transactions for the years ended December&#160;31, 2018, 2019 and 2020 are as follows: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 10pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Receipt of CRO services<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div>recognized in research and development expenses</div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CMAB Biopharma (Suzhou) Inc.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,786</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">681</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">104</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jiangsu Taslydiyi Pharmaceutical Co., Ltd.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,395</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">367</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tasly Pharmaceutical Group Co., Ltd.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,590</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 10pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Receipt of research and development funding </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Everest (Note 1<div style="display:inline;">8</div>)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">178,715</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">53,148</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td></tr></table> <br/>  <div style="text-indent: -2%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collection of loan to an affiliate</div> </div></div> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 2%; line-height: 12pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou <div style="font-size:85%; vertical-align:top;display:inline;;font-size:9.4px">(4)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">52,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,969</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>
<table style="border-spacing: 0px; margin-bottom: 0pt; margin-top: 12pt; width: 100%; table-layout: fixed;">
<tr style="vertical-align: top;">
<td style="padding: 0pt; width: 0%;"/>
<td style="width: 4%; padding-left: 0px; padding-right: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(4)</div></div></td>
<td style="padding-left: 0px; padding-right: 0px; width: 96%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: normal;">In July 2019 and July 2020, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai provided an interest free loan to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou of RMB2,000 and RMB50,000 respectively to finance <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou&#8217;s operation. These loans were repaid in November 2020. </div></td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expenses paid on behalf of an affiliate </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the year ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou</div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">21,212</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,251</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712744728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration of Credit Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div>. CONCENTRATION OF CREDIT RISK</div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that are potentially subject to significant con<div style="display:inline;">c</div>entration of credit risk consist of cash and cash equivalents, restricted cash, short-term investments, other financial assets, accounts receivable, contract assets, and other receivables. The carrying amounts of cash and cash equivalents, restricted cash, short-term investments, contract assets, and other financial assets represent the maximum amount of loss due to credit risk. As of December&#160;31, 2019 and 2020, all of the Group&#8217;s cash and cash equivalents, restricted cash and short-term investments were held by major financial institutions located in the PRC and international financial institutions outside of the PRC which management believes are of high credit quality and continually monitors the credit worthiness of these financial institutions. With respect to the accounts receivable, contract assets, other receivables and other financial assets, the Group performs <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> credit evaluations of the financial condition of its customers and counterparties.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: center;"><div style="font-size: 10pt; letter-spacing: 0px; text-align: center; top: 0px;;display:inline;">F-7</div><div style="font-size: 10pt; letter-spacing: 0px; text-align: center; top: 0px;;display:inline;">8</div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707816952008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>. SUBSEQUENT EVENTS </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2021, the Group sent Tracon a notice to terminate the TJD5 Agreement, which would result in a prespecified termination fee of US$9.0 million owing to Tracon. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2021, the Group entered into two collaboration agreements with Complix, an EU-based biotech company (the &#8220;Complix Agreement&#8221;), and Affinity, a Shanghai-based biotech company (the &#8220;Affinity Agreement&#8221;), respectively, allowing the Group to access cutting edge technology platforms to create next generation of novel and highly differentiated drug candidates, including Cell Penetrating Alphabodies (&#8220;CPAB&#8221;) for otherwise intractable intracellular drug targets and masked antibodies for targeted tumor-site activation. Under the Complix Agreement, both parties will collaborate to discover, develop and commercialize novel therapeutics for mutually agreed targets based on the Complix&#8217;s proprietary technology. Under the Affinity Agreement, both parties will collaborate to develop lead compounds for mutually agreed targets based on Affinity&#8217;s Tumor MicroEnvironment Activated body (&#8220;TMEAbody&#8221;) platform technology. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2021, the Group entered into a license and collaboration agreement with Genbase, a Shanghai-based biotech company to develop bi-specific antibodies or/and multi-specific antibodies using antibody sequences from both companies. Under this agreement, Genbase granted to the Group a non-transferable, sublicensable, and royalty-bearing license under Genbase parental antibody technology and Genbase parental antibody improvements owned and controlled by Genbase to make, develop and commercialize the licensed compounds and licensed products in all uses and indications worldwide. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707715527480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Net Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_RestrictedNetAssetsDisclosureAbstract', window );"><strong>Restricted Net Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedAssetsDisclosureTextBlock', window );">Restricted Net Assets</a></td>
<td class="text"><div style="margin-top: 18pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div>. RESTRICTED NET ASSETS </div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 100%;"/> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s ability to pay dividends may depend on the Group receiving distributions of funds from its PRC subsidiary. Relevant PRC statutory laws and regulations permit payments of dividends by the Group&#8217;s PRC subsidiary only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with U.S. GAAP differ from those reflected in the statutory financial statements of the Group&#8217;s PRC subsidiary. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In accordance with the Company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> profit until such reserve has reached 50% of its respective registered capital based on the enterprise&#8217;s PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise&#8217;s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Group&#8217;s PRC subsidiary was established as domestic invested enterprise and therefore is subject to the above mentioned restrictions on distributable profits. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended December&#160;31, 2018, 2019 and 2020, no appropriation to statutory reserves was made because the PRC subsidiary had substantial losses during such periods. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result of these PRC laws and regulations subject to the limit discussed above that require annual appropriations of 10% of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> income to be set aside, prior to payment of dividends, as general reserve fund, the Group&#8217;s PRC subsidiary is restricted in their ability to transfer a portion of their net assets to the Group. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign exchange and other regulations in the PRC further restrict the Company&#8217;s PRC subsidiaries from transferring funds to the Company in the form of dividends, loans and advances. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the net asset base for purposes of calculating the proportionate share of restricted net assets of consolidated subsidiaries should be zero, while the Group has a consolidated shareholders&#8217; equity. Therefore, as the restricted net assets of consolidated subsidiaries do not exceed 25% of consolidated net assets as of the most recent fiscal year end, the Group is not required to provide parent company financial information. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_RestrictedNetAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Net Assets Disclosure [Abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_RestrictedNetAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707703205400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.1 Basis of presentation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant accounting policies followed by the Group in the preparation of the accompanying consolidated financial statements are summarized below. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of consolidation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.2 Basis of consolidation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All inter-company balances and transactions have been eliminated in consolidation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group consolidates entities in which it has a controlling financial interest based on either the variable interest entity (VIE) or voting interest model. The Group is required to first apply the VIE model to determine whether it holds a variable interest in an entity, and if so, whether the entity is a VIE. If the Group determines it does not hold a variable interest in a VIE, it then applies the voting interest model. Under the voting interest model, the Group consolidates an entity when it holds a majority voting interest in an entity. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for investments in which it has significant influence but not a controlling financial interest using the equity method of accounting (see Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">VIE Model </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An entity is considered to be a VIE if any of the following conditions exist: (a)&#160;the total equity investment at risk is not sufficient to permit the entity to finance its activities without additional subordinated financial support, (b)&#160;the holders of the equity investment at risk, as a group, lack either the direct or indirect ability through voting rights or similar rights to make decisions that have a significant effect on the success of the entity or the obligation to absorb the entity&#8217;s expected losses or right to receive the entity&#8217;s expected residual returns, or (c)&#160;the voting rights of some equity investors are disproportionate to their obligation to absorb losses of the entity, their rights to receive returns from an entity, or both and substantially all of the entity&#8217;s activities either involve or are conducted on behalf of an investor with disproportionately few voting rights. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the VIE model, limited partnerships are considered VIE unless the limited partners hold substantive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">kick-out</div> or participating rights over the general partner. The Group consolidates entities that are VIEs when the Group determines it is the primary beneficiary. Generally, the primary beneficiary of a VIE is a reporting entity that has (a)&#160;the power to direct the activities that most significantly affect the VIE&#8217;s economic performance, and (b)&#160;the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the Group determined that the one entity subject to the consolidation guidance is a VIE for which the Group is not the primary beneficiary. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="text-align: left;"><div style="margin-block: 0em; line-height: 8pt;">&#160;</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.3 Use of estimates </div></div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally, estimates are used in determining items such as fair value measurements of wealth management products, warrants and put right liabilities, impairment of accounts receivables, contract assets, other receivables, long-lived assets, intangible assets and goodwill, useful lives of property, equipment and software, recognition of right-of-use assets and lease liabilities, variable consideration in collaboration revenue arrangements, determination of the standalone selling price of each performance obligation in the Company&#8217;s revenue arrangements, valuation of share-based compensation arrangements and deferred tax assets valuation allowances. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.4 Fair value measurements </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial assets and liabilities of the Group primarily comprise of cash and cash equivalents, restricted cash, short-term investments, other financial assets, accounts receivable, contract assets, other receivables, short-term borrowings, accruals and other payables, warrant liabilities and put right liabilities. As of December 31, 2019 and 2020, except for short-term investments, other financial assets and put right liabilities, the carrying values of these financial assets and liabilities approximated their fair values because of their generally short maturities. The Group reports short-term investments, other financial assets and put right liabilities at fair value at each balance sheet date and changes in fair value are reflected in the consolidated statements of comprehensive income (loss).&#160;</div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group measures its financial assets and liabilities using inputs from the following three levels of the fair value hierarchy. The three levels are as follows: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 inputs are unadjusted quoted prices in active markets for identical assets that the management has the ability to access at the measurement date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 inputs include quoted prices for similar assets in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 includes unobservable inputs that reflect the management&#8217;s assumptions about the assumptions that market participants would use in pricing the asset. The management develops these inputs based on the best information available, including the own data.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Assets and liabilities measured at fair value on a recurring basis </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Group measures its short-term investments, other financial assets, warrant liabilities, and put right liabilities at fair value on a recurring basis. As the Group&#8217;s short-term investments, other financial assets, warrant liabilities and put right liabilities are not traded in an active market with readily observable prices, the Group uses significant unobservable inputs to measure the fair value of short-term investments, other financial assets, warrant liabilities and put right liabilities. These instruments are categorized in the Level 3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement.</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Group&#8217;s financial assets and liabilities measured and recorded at fair value on a recurring basis as of December&#160;31, 2019 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Active&#160;market</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Observable&#160;input</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">observable&#160;input</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Active&#160;market<br/> (Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Observable&#160;input<br/> (Level 2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">observable&#160;input<br/> (Level 3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31,530</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31,530</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Put right liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">116,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">116,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The roll forward of major Level&#160;3 financial assets <div style="letter-spacing: 0px; top: 0px;;display:inline;">a</div>nd financial liabilities are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Short-term<br/> investments</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Other&#160;financial<br/> assets</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Warrant<br/> liabilities</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Put right<br/> liabilities</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair&#160;value&#160;of&#160;Level&#160;3&#160;financial&#160;asset&#160;and&#160;liabilities&#160;as&#160;of&#160;December&#160;31,&#160;2018</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">255,958</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5,618</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">134,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposal of short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(102,703</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposal of other financial assets due to Termination Agreement</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(256,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value changes</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">703</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,644</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(26</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair&#160;value&#160;of&#160;Level&#160;3&#160;financial&#160;assets&#160;and&#160;liabilities&#160;as&#160;of&#160;December&#160;31,&#160;2019</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">32,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,491,991</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposal of short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,503,749</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant of put right liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">124,321</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value changes</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3,024</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5,291</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Level&#160;3 financial assets and liabilities as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31,530</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">116,006</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>&#160;for additional information about Level&#160;3 put right liabilities measured at fair value on a recurring basis for the year ended December&#160;31, 2020. </div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.5 Foreign currency translation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group uses Chinese Renminbi (&#8220;RMB&#8221;) as its reporting currency. The United States Dollar (&#8220;US$&#8221;) is the functional currency of the Group&#8217;s entities incorporated in the Cayman Islands, the United States of America (&#8220;U.S.&#8221;) and Hong Kong, the Australia Dollar (&#8220;AUD&#8221;) is the functional currency of the Group&#8217;s entity incorporated in Australia and the RMB is the functional currency of the Company&#8217;s PRC subsidiaries. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transactions denominated in other than the functional currencies are translated into the functional currency of the entity at the exchange rates prevailing on the transaction dates. Assets and liabilities denominated in other than the functional currencies are translated at the balance sheet date exchange rate. The resulting exchange differences are recorded in the consolidated statements of comprehensive income (loss). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements of the Group are translated from the functional currency to the reporting currency, RMB. Assets and liabilities of the subsidiaries are translated into RMB using the exchange rate in effect at each balance sheet date. Income and expenses are translated at the average exchange rates prevailing for the year. Foreign currency translation adjustments arising from these are reflected in the accumulated other comprehensive <div style="letter-spacing: 0px; top: 0px;;display:inline;">income (loss). The exchange rates&#160;</div>used for translation on December&#160;31, 2019 and 2020 were US$1.00 = RMB6.9762 and RMB6.5249 respectively, representing the index rates stipulated by the People&#8217;s Bank of China. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translations of balances in the consolidated balance sheets, consolidated statements of comprehensive income (loss), consolidated statements of changes in shareholders&#8217; equity (deficit) and consolidated statements of cash flows from RMB into US$ as of and for the year ended December&#160;31, 2020 are solely for the convenience of the readers and were calculated at the rate of US$1.00=RMB6.5250, representing the noon buying rate in The City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New York on December&#160;31, 2020. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on December&#160;31, 2020, or at any other rate. The US$ convenience translation is not required under U.S. GAAP and all US$ convenience translation amounts in the accompanying consolidated financial statements are unaudited. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.6 Cash and cash equivalents </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Group considers all highly liquid investments with an original maturity date of three months or less at the date of purchase to be cash equivalents. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.7 Restricted cash </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash consists of the guarantee deposits held in a designated bank account as security deposits under bank borrowing agreements. Such restricted cash will be released when the Group repays the related bank borrowings. The Group has presented restricted cash separately from cash and cash equivalents in the consolidated balance sheets. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash as reporte<div style="display:inline;">d</div>&#160;in the consolidated statement of cash flows are presented separately on the consolidated balance sheet as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December 31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,137,473</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,758,778</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">55,810</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,193,283</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,758,778</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td> </tr> </table>  <div style="clear: both; max-height: 0px; background: none;"/> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.8 Accounts receivable </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable are stated at amortized cost less allowance for credit losses. The allowance for credit losses reflects the best estimate of future losses over the contractual life of outstanding accounts receivable and is determined on the basis of historical experience, specific allowances for known troubled accounts, other currently available information including customer financial condition, and both current and forecasted economic conditions. </div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ShortTermInvestmentsPolicyTextBlock', window );">Short-term investments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.9 Short-term investments </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments represent the investments issued by commercial banks or other financial institutions with a variable interest rate indexed to the performance of underlying assets within one year. These investments are stated at fair value. Changes in the fair value are reflected in the consolidated statements of comprehensive income (loss). </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, equipment and software</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.10 Property, equipment and software&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the following estimated useful lives, taking into account of any estimated residual value: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 46%; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">3 to 10 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">1 to 5 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Office furniture and equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">5 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Lesser of useful life or lease term</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group recognizes the gain or loss on the disposal of property, equipment and software in the consolidated statements of comprehensive income (loss). </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible assets</a></td>
<td class="text"><div style="text-align: left;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.11 Intangible assets </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets acquired in a business combination that are used in research and development activities, or in-process research and development (IPR&amp;D) intangible assets, are considered indefinite lived until the completion or abandonment of the associated research and development efforts. During the period that those assets are considered indefinite lived, they are not amortized but are tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. If after assessing the totality of events and circumstances and their potential effect on significant inputs to the fair value determination the Group determines that it is not more likely than not that the indefinite-lived intangible is impaired, then the entity shall calculate the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value of the asset with its carrying amount. If the carrying amount exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. For IPR&amp;D assets, the impairment loss is recognized in research and development expenses in the consolidated statements of comprehensive income (loss).</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets with finite useful lives are amortized over their useful lives. The useful life of an intangible asset is the period over which the asset is expected to contribute directly or indirectly to the future cash flows of the Group. The Group uses the straight-line amortization method when the economic benefits of the intangible assets are consumed or otherwise used up cannot be reliably determined. In particular, the Group amortizes the IPR&amp;D intangible assets with finite useful lives over 10 to 20 years on a straight-line basis. Intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. If circumstances require an intangible asset be tested for possible impairment, the Group first compares undiscounted cash flows expected to be generated by that asset to its carrying amount. If the carrying amount is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. For IPR&amp;D assets, the impairment loss is recognized in research and development expenses in the consolidated statements of comprehensive income (loss).</div></div></div></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><div style="text-align: left;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.12 Impairment of long-lived assets </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets, such as property, plant, and software, and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. For the years ended December&#160;31, 2019 and 2020, there was no impairment of the value of the Group&#8217;s long-lived assets. </div></div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="text-align: left;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.13 Goodwill </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The Group allocates the cost of an acquired entity to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price for acquisitions over the fair value of the net assets acquired, including other intangible assets, is recorded as goodwill. Goodwill is not amortized, but impairment of goodwill is tested on at least an annual basis or whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Group&#8217;s reporting unit is less than its carrying amount, including goodwill. The qualitative assessment includes the Group&#8217;s evaluation of relevant events and circumstances affecting the Group&#8217;s single reporting unit, including macroeconomic, industry, market conditions and the Group&#8217;s overall financial performance. If qualitative factors indicate that it is more likely than not that the Group&#8217;s reporting unit&#8217;s fair value is less than its carrying amount, then the Group will perform the quantitative impairment test by comparing the reporting unit&#8217;s carrying amount, including goodwill, to its fair value. If the carrying amount of the reporting unit exceeds its fair value, an impairment loss will be recognized in an amount equal to that excess. For the years ended December&#160;31, 2019 and 2020, the Group determined that there were no indicators of impairment of the goodwill. </div></div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_LongTermInvestmentsPolicyTextBlock', window );">Long Term Investments</a></td>
<td class="text"><div style="text-align: left;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.14 Long-term investments </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s long-term investments include equity investments in an affiliate in which it does not have a controlling financial interest, but has the ability to exercise significant influence over the operating and financial policies of the investee. The investment is accounted for using the equity method of accounting in accordance with ASC topic 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Under the equity method, the Group initially records its investments at fair value. The Group subsequently adjusts the carrying amount of the investment to recognize the Group&#8217;s proportionate share of the equity investee&#8217;s net income or loss after the date of investment. When the liquidation rights and priorities as defined by an equity investment agreement diff<div style="display:inline;">e</div>r from what is reflected by the underlying percentage ownership interests, applying the percentage ownership interest to U.S. GAAP net income in order to determine earnings or losses does not accurately represent the income allocation and cash flow distributions that will ultimately be received by the investors. As such, for this type of investments, the Group uses the Hypothetical Liquidation at Book Value (&#8220;HLBV&#8221;) method for allocating earnings or losses of the equity method investee. The HLBV method is considered as a balance sheet approach. Specifically, a calculation is prepared at each balance sheet date to determine the amount that the Group would receive if an equity investment entity were to liquidate all of its assets (as valued in accordance with U.S. GAAP) and distribute that cash to the investors based on the contractually defined liquidation priorities. The difference between the calculated liquidation distribution amounts at the beginning and the end of the reporting period, after adjusting for capital contributions and distributions, is the Group&#8217;s share of the earnings or losses from the equity investment for the period. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As it relates to the share-based compensation awarded by an equity method investee to its own employees, the Group recognizes its proportionate share of the compensation expense over the vesting period, included in the equity in loss of affiliate in the consolidated statements of comprehensive income (loss). As it relates to the share-based compensation awarded by the Group to the equity method investee employees that are based on the Group&#8217;s stock, when the other investors do not provide proportionate value to the investee or the Group does not receive any consideration, the Group expenses the entire cost associated with the award in the same period the costs are recognized by the investee, to the extent that the Group&#8217;s claim on the investee&#8217;s book value has not been increased. The expenses recognized by the Group is included in the equity in loss of affiliate in the consolidated statements of comprehensive income (loss). </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group evaluates the equity method investment for impairment under ASC 323. An impairment loss on the equity method investments is recognized in losses when the decline in value is determined to be other-than-temporary. No impairment charge was recognized for the year ended December&#160;31, 2020. </div></div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_DeferredSubsidyIncomePolicyTextBlock', window );">Deferred subsidy income</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.15 Deferred subsidy income&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred subsidy income consists of deferred income from government grants. Government grants mainly consist of cash subsidies received by the Group&#8217;s subsidiaries in the PRC from local governments as support on expenses relating to certain projects. Grants received with government specified performance obligations are recognized as other income when all the obligations have been satisfied. If such obligations are not satisfied, the Group may be required to refund the subsidy. The Group recorded cash grants</div> of RMB7,509 and RMB3,920 and in deferred subsidy income as of December&#160;31, 2020 and 2019 respectively. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.16 Revenue recognition&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Group adopted Accounting Standard Codification (&#8220;ASC&#8221;) 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div> (Topic 606) (&#8220;ASC 606&#8221;) for all periods presented. Consistent with the criteria of Topic 606, the Group recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. An the entity performs the following five steps to account for the arrangements that an entity determines are within the scope of ASC 606: (i) identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once a contract is determined to be within the scope of ASC 606 at contract inception, the Group audits the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration revenue </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">At contract inception, we analyze its collaboration arrangements to assess whether they are within the scope of ASC 808,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Collaborative Arrangements</div></div>&#160;(&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, we first determine if the collaboration is deemed to be within the scope of ASC 808. For any units of account that are reflective of a vendor-customer relationship those units of account are accounted for within the scope of ASC 606. For any units of account that are not accounted for under ASC 606 and therefore accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group&#8217;s collaborative arrangements may contain more than one unit of account, or performance obligation, such as grant of licenses of intellectual property rights, promises to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. When multiple units of account or performance obligations are identified within the arrangements, the Group must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&#160;In developing the stand-alone selling price for a performance obligation, the Group considers competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licenses of Intellectual Property:</div></div> Upfront <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> payments for licensing the Group&#8217;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For the license that is determined to be distinct, the Group recognizes revenues in the amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> fees allocated to the license at a point in time, upon which the license is transferred to the licensee and the licensee is able to use and benefit from the license. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Services: </div></div>The portion of the transaction price allocated to research and development services performance obligations is deferred and recognized as revenue over time as delivery or performance of such services provided to the Group&#8217;s customers occurs. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Milestone Payments</div></div>: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any resulting adjustment is recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect the Group&#8217;s reported revenues and earnings in the period of the adjustment. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties</div></div>: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the sales-based royalties or milestone payments relate, the Group recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract assets and liabilities </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets primarily represent revenue earnings over time that are not yet billable based on the terms of the contracts. The Group does not have impairment losses associated with contracts with customers for the years ended December 31, 2019 and 2020. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities consist of fees invoiced or paid by the Group&#8217;s customers for which the associated performance obligations have not been satisfied and revenue has not been recognized based on the Group&#8217;s revenue recognition criteria described above. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets and contract liabilities are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current in the consolidated balance sheet when the Group expects to complete the related performance obligations and invoice the customers within one year of the balance sheet date, and as long-term when the Group expects to complete the related performance obligations and invoice the customers more than one year out from the balance sheet date. Contract liabilities are classified as current in the consolidated balance sheet when the revenue recognition associated with the related customer payments and invoicing is expected to occur within one year of the balance sheet date and as long-term when the revenue recognition associated with the related customer payments and invoicing is expected to occur in more than one year from the balance sheet date. </div></div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ValueAddedTaxesPolicyPolicyTextBlock', window );">Value-added-tax&#160;("VAT") recoverable and surcharges</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.17 Value-added-tax (&#8220;VAT&#8221;) recoverable and surcharges&#160;</div></div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Value added tax recoverable represent amounts paid by the Group for purchases. The surcharges (i.e., Urban construction and maintenance tax, educational surtax, local educational surtax), vary from 6% to 12% of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;value-added-tax&#160;depending</div> on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;tax-payer&#8217;s&#160;location.</div> The deductible input VAT balance is included in the prepayments and other receivables in the consolidated balance sheets, and VAT payable balance is recorded in the accruals and other payables in the consolidated balance sheets. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.18 Research and development expenses </div></div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Elements of research and development expenses primarily include (1)&#160;payroll and other related expenses of personnel engaged in research and development activities, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(2)&#160;in-licensed</div> patent rights fee of exclusive development rights of drugs granted to the Group, (3)&#160;expenses related to preclinical testing of the Group&#8217;s technologies under development and clinical trials such as payments to contract research organizations (&#8220;CRO&#8221;), investigators and clinical trial sites that conduct the clinical studies, (4)&#160;expenses to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, and (5)&#160;other research and development expenses. Research and development expenses are charged to expenses as incurred when these expenditures are used for the Group&#8217;s research and development activities and have no alternative future uses. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-commercial</div> milestone payments, are immediately expensed as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development in the period in which they are incurred, provided that the new drug compound does not also include processes or activities that would constitute a &#8220;business&#8221; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. All development expenditures are recognized in profit or loss when incurred, as long as the conditions enabling capitalization of development expenses as an asset have not yet been met. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.19 Leases&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In accordance with ASC 842 adopted on January&#160;1, 2019, the Group determines if an arrangement is a lease at inception. Operating leases are included in operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets, operating lease liability, and operating lease liability, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> in the Group&#8217;s consolidated balance sheets. The Group does not have any finance leases since the adoption date. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROU assets represent the Group&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Group&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. When determining the lease term, the Group includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Group&#8217;s leases do not provide an implicit rate, the Group uses its incremental borrowing rate, which it calculates based on the credit quality of the Group and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group has elected to adopt the following lease policies in conjunction with the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02:</div> (i) elect for each lease not to separate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components from lease components and instead to account for each separate lease component and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components associated with that lease component as a single lease component; (ii)&#160;for leases that have lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Group elected not to apply ASC 842 recognition requirements; and (iii)&#160;the Group elected to apply the package of practical expedients for existing arrangements entered into prior to January&#160;1, 2019 to not reassess (a)&#160;whether an arrangement is or contains a lease, (b)&#160;the lease classification applied to existing leases, and (c)&#160;initial direct costs. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the adoption of ASC 842, on January&#160;1, 2019, the Group recorded an impact of RMB13,100 on its assets and RMB11,333 on its liabilities for the recognition of operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use-assets</div></div></div> and operating lease liabilities, respectively, which are primarily related to the lease of the Group&#8217;s offices and warehouses. The adoption of ASC 842 did not have a material impact on the Group&#8217;s results of operations or cash flows. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive loss</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.20 Comprehensive income (loss)</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive income (loss) is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220,&#160;Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as components of comprehensive income (loss) be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Group&#8217;s comprehensive income (loss) includes net income (loss) and foreign currency translation adjustments, which are presented in the consolidated statements of comprehensive income (loss). </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock', window );">Share-based compensation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.21 Share-based compensation&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group grants restricted shares and stock options to eligible employees and accounts for share-based compensation in accordance with ASC 718, Compensation&#8212;Stock Compensation.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employees&#8217; share-based compensation awards, if equity-classified, are measured at the grant date fair value of the awards and are recognized as expenses over the requisite period of the award, which is generally the vesting term of share-based payment awards.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation in relation to the restricted shares is measured based on the fair market value of the Group&#8217;s ordinary shares at the grant date of the award. Prior to the listing, estimation of the fair value of the Group&#8217;s ordinary shares involves significant assumptions that might not be observable in the market, and a number of complex and subjective variables, including discount rate, and subjective judgments regarding the Group&#8217;s projected financial and operating results, its unique business risks, the liquidity of its ordinary shares and its operating history and prospects at the time the grants are made. Share-based compensation in relation to the share options is estimated using the Binominal Option Pricing Model. The determination of the fair value of share options is affected by the share price of the Group&#8217;s ordinary shares as well as the assumptions regarding a number of complex and subjective variables, including the expected share price volatility, risk-free interest rate, exercise multiple and expected dividend yield. In addition, the forfeiture rate is estimated based on an analysis of the Group&#8217;s actual forfeitures and the appropriateness of the forfeiture rate will continue to be evaluated based on the actual forfeiture experience, analysis of employee turnover and other factors. The fair value of these awards was determined with the assistance from an independent third-party valuation firm. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.22 Income taxes&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Group accounts for income taxes under the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates that expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded if it is more likely than not that some portion or all of the deferred income tax assets will not be utilized in the foreseeable future.&#160;</div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Group evaluates its uncertain tax positions using the provisions of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-10,&#160;Income</div> Taxes, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Group recognizes in the financial statements the benefit of a tax position which is &#8216;&#8216;more likely than not&#8217;&#8217; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Group&#8217;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Borrowings</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.23 Borrowings&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost. Any difference between the proceeds (net&#160;of transaction costs) and the redemption value is recognized as interest expense in the consolidated statements of comprehensive income (loss) over the period of the borrowings, using the effective interest method. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business combination</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.24 Business combination&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group accounts for its business combinations using the acquisition method of accounting in accordance with ASC topic 805,&#160;Business Combinations&#160;(&#8220;ASC 805&#8221;). The acquisition method of accounting requires all of the following steps: (i)&#160;identifying the acquirer, (ii)&#160;determining the acquisition date, (iii)&#160;recognizing and measuring the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree, and (iv)&#160;recognizing and measuring goodwill or a gain from a bargain purchase. The consideration transferred in a business combination is measured as the aggregate of the fair values at the date of exchange of the assets given, liabilities incurred, and equity instruments issued as well as the contingent considerations and all contractual contingencies as of the acquisition date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed and intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets may include, but are not limited to, future expected cash flows from acquired assets, timing and probability of success of clinical events and regulatory approvals, and assumptions on useful lives of the patents and discount rates. Management&#8217;s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Additional information, such as that related to income tax and other contingencies, existing as of the acquisition date but unknown to us may become known during the remainder of the measurement period, not to exceed one year from the acquisition date, which may result in changes to the amounts and allocations recorded. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions that do not meet the accounting definition of a business combination are accounted for as asset acquisitions. For transactions determined to be asset acquisitions, the Group allocates the total cost of the acquisition, including transaction costs, to the net assets acquired based on their relative fair values. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.25 Segment information&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with ASC 280,&#160;Segment Reporting, the Group&#8217;s chief operating decision maker, the Chief Executive Officer, reviews the consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for the purpose of internal reporting. As the Group&#8217;s long-lived assets are substantially located in and derived from the PRC, no geographical segments are presented. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Income (loss) per share</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.26 Income (loss) per share&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Basic income (loss) per share is computed by dividing net income (loss) attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period using the two-class method. Under the two-class method, the net income (loss) is allocated between ordinary shares and other participating securities based on their participating rights. Net income (loss) is not allocated to other participating securities if based on their contractual terms they are not obligated to share in the income (loss). Diluted income (loss) per share is calculated by dividing net income (loss) attributable to ordinary shareholders by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of shares issuable upon the conversion of the preferred shares using the if-converted method, shares issuable upon the issuance of ordinary shares to be issued to Everest using the if-converted method, shares issuable upon the conversion of the convertible promissory notes using the if-converted method, shares issuable upon the exercise of share options using the treasury stock method, shares issuable upon the issuance of ordinary shares for restricted shares units using the treasury stock method, and shares issuable upon the exercise of warrants using the treasury stock method. Ordinary equivalent shares are not included in the denominator of the diluted income (loss) per share calculation when inclusion of such shares would be anti-dilutive.</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adopted accounting pronouncements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.27 Adopted accounting pronouncements&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13&#8221;).</div> This guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability. In November 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-19,</div> Codification Improvements to Topic 326, Financial Instruments-Credit Losses (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-19&#8221;),</div> which clarifies certain topics included within ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13.</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> and ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-19</div> are effective for the annual reporting period beginning after December&#160;15, 2019, including interim periods within that reporting period. The impact of this ASU to the consolidated financial statements is immaterial. The Group elected to adopt this ASU and applied this guidance retrospectively to all periods presented. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In January 2017, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2017-04,</div> Intangibles&#8212;Goodwill and Other (Topic 350), which simplifies the subsequent measurement of goodwill by removing the second step of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-step</div> impairment test. The amendment requires an entity to perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. A goodwill impairment will be the amount by which a reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The Group adopted this ASU on January&#160;1, 2020 and the adoption of this ASU does not have a material impact to its consolidated financial statements. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In August 2018 the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2018-13,</div> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January&#160;1, 2020. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In November 2018 the FASB issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASU&#160;No.&#160;2018-18,&#160;Collaborative</div> Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This standard makes targeted improvements for collaborative arrangements as follows: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, Revenue from Contracts with Customers, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Adds&#160;unit-of-account&#160;guidance</div></div> to ASC 808, Collaborative Arrangements, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and </div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This standard became effective for the Group on January&#160;1, 2020. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings. Since the Group&#8217;s all relevant units of accounts were accounted for under ASC 606, the adoption of this ASU does not have a material impact to the Group&#8217;s consolidated financial statements, with no adjustment to its opening retained earnings. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.28 &#160; &#160; Recent accounting pronouncements&#160;</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, the FASB issued ASU 2019-12-Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for the Company beginning on January 1, 2022. Early adoption of the amendments is permitted. The Company is currently evaluating the impact of ASU 2019-12 on its consolidated financial statements.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In January 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-01,</div> Investments &#8211; Equity Securities (Topic 321), Investments &#8211; Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying Interactions between Topic 321, Topic 323, and Topic 815. ASU 2020-01addresses accounting for the transition into and out of the equity method and provides guidance on whether equity method accounting would be applied to certain purchased options and forward contracts upon settlement. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-01</div> is effective for the Group&#8217;s annual periods beginning after December&#160;15, 2021. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-01</div> will be applied prospectively. Early adoption is permitted. The Group is currently evaluating the effect the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-01</div> will have on its consolidated financial statements. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_DeferredSubsidyIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Subsidy Income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_DeferredSubsidyIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_LongTermInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_LongTermInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recent accounting pronouncements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ShortTermInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ShortTermInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ValueAddedTaxesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value Added Taxes Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ValueAddedTaxesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1D<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=SL116886442-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4549-113899<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (m)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707806732680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Activities and Organization (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ScheduleOfPrincipalSubsidiariesTableTextBlock', window );">Schedule of Principal Subsidiaries</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>December&#160;31, 2020, the Company&#8217;s principal subsidiaries are as follows: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 46%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subsidiaries</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Place of<br/> incorporation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date of<br/> incorporation or<br/> acquisition</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percentage<br/> of direct<br/> or indirect<br/> ownership<br/> by the<br/> Company</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Principal&#160;activities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma Hong Kong Limited <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;I-Mab</div> Hong Kong&#8221;)</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">Hong Kong</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">July 8, 2016</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">100</td>
<td style="vertical-align: top; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">Investment holding</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Shanghai</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">PRC</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">August 24, 2016</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">100</td>
<td style="vertical-align: top; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: top;">&#160;<br/> &#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">Research and<br/> development of<br/> innovative medicines</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;<br/> &#160;<br/> &#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bio-tech</div> (Tianjin) Co., Ltd.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(&#8220;I-Mab</div> Tianjin&#8221;)</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">PRC</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">July 15, 2017</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">100</td>
<td style="vertical-align: top; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: top;">&#160;<br/> &#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">Research and<br/> development of<br/> innovative medicines</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;<br/> &#160;<br/> &#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 46%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Biopharma US Ltd.</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">U.S.</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">February 28, 2018</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">100</td>
<td style="vertical-align: top; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: top;">&#160;<br/> &#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">Research and<br/> development of<br/> innovative medicines</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;<br/> &#160;<br/> &#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ScheduleOfPrincipalSubsidiariesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Principal Subsidiaries Table Text Block</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ScheduleOfPrincipalSubsidiariesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707706323144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Group&#8217;s financial assets and liabilities measured and recorded at fair value on a recurring basis as of December&#160;31, 2019 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Active&#160;market</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Observable&#160;input</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">observable&#160;input</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Active&#160;market<br/> (Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Observable&#160;input<br/> (Level 2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">observable&#160;input<br/> (Level 3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31,530</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31,530</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Put right liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">116,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">116,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Summary of Roll Forward of Major Level 3 Financial Assets and Financial Liability</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The roll forward of major Level&#160;3 financial assets <div style="letter-spacing: 0px; top: 0px;;display:inline;">a</div>nd financial liabilities are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Short-term<br/> investments</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Other&#160;financial<br/> assets</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Warrant<br/> liabilities</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Put right<br/> liabilities</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair&#160;value&#160;of&#160;Level&#160;3&#160;financial&#160;asset&#160;and&#160;liabilities&#160;as&#160;of&#160;December&#160;31,&#160;2018</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">255,958</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5,618</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">134,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposal of short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(102,703</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposal of other financial assets due to Termination Agreement</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(256,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value changes</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">703</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,644</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(26</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair&#160;value&#160;of&#160;Level&#160;3&#160;financial&#160;assets&#160;and&#160;liabilities&#160;as&#160;of&#160;December&#160;31,&#160;2019</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">32,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,491,991</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposal of short-term investments</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,503,749</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant of put right liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">124,321</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value changes</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3,024</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation differences</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5,291</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Level&#160;3 financial assets and liabilities as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31,530</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">116,006</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">summary of Cash, cash equivalents and restricted cash as reported in the consolidated statement of cash flows</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash as reporte<div style="display:inline;">d</div>&#160;in the consolidated statement of cash flows are presented separately on the consolidated balance sheet as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December 31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,137,473</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,758,778</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">55,810</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,193,283</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,758,778</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock', window );">Summary of Estimated Useful Lives</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the following estimated useful lives, taking into account of any estimated residual value: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 46%; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">3 to 10 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">1 to 5 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Office furniture and equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">5 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Lesser of useful life or lease term</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of useful life of property plant equipment [Table Text Block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707706295208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable And Contract Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_AccountsReceivableAndContractAssetsAbstract', window );"><strong>Accounts Receivable And Contract Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock', window );">summary of Accounts receivable and contract assets, net of allowance for credit losses</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable and contract assets, net of allowance for credit losses, consisted of the following: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December 31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, gross</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">130,498</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for credit losses</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">130,498</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December 31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets, gross</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">227,391</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">34,849</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for credit losses</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets, net</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">227,391</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">34,849</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_AccountsReceivableAndContractAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable And Contract Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_AccountsReceivableAndContractAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Accounts Receivable and Contract Assets Net of Allowance for Credit Losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707803479752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayments And Other Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of Prepayments And Other Receivables</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;RMB&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepayments:</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Prepayments to CRO vendors</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">78,740</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,140</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,742</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">- Prepayments for other services</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">880</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">391</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receivables due from employees <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,201</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Receivables due from an affiliate (Note 2<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>)</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#8212;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">21,212</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;">3,251</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Value-added tax recoverable</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">12,517</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">63,664</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">9,757 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rental deposits</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">546</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">1,766</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">271 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest receivables</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">764</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">236</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">36</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Others</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">26,388</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">22,899</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,509</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 68%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 68%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">136,036</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">195,467 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">29,957</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 68%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The balance mainly represents the receivables due from <div style="letter-spacing: 0px; top: 0px;;display:inline;">certain&#160;</div>employees, arose from the Group&#8217;s obligation to pay the withholding individual income tax (&#8220;IIT&#8221;) for those employees&#8217; stock option activities. The balance was collected by the Group in January 2020. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712932568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment And Software (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, equipment and software, net</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, equipment and software consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipmen<div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">24,265</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">30,808</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvement</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,856</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,842</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,121</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,531 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Office furniture and equipment</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,526</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,531</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">234</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property, equipment and software</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">47,867</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">56,171 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,608 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(18,221</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,899</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(4,735</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net book value</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">29,646</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25,272 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,873</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in <div style="letter-spacing: 0px; top: 0px;;display:inline;">progress</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">423</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total net book value of property, equipment and software</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">30,069</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25,272 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,873</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707715414120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock', window );">Operating Lease Related Assets And Liabilities And Other Related Information</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information related to operating leases as of December&#160;31, 2019 and 2020 is as follows (in thousands, except for percentages and years). </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,435</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,997</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,298</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, current</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,807</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,058</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease liabilities, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,492</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,542</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">849</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term (years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock', window );">Schedule of Components of Operating Lease Expense</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Year Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease rental expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Amortization of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,260</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,158</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expense for short-term leases within 12 months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">592</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest of lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">543</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">679</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">104</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,395</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,837</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,354</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease, Maturity</a></td>
<td class="text">Maturities of lease liabilities were as follows:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,901</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">837</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">536</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">82</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total undiscounted lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,901</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,283</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,301</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(199</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,600</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,084</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Related Assets And Liabilities And Other Related Information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of components of operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707711670952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Intangible assets</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets as of December&#160;31, 2019 and 2020 are summarized as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;carrying&#160;amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net carrying amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D TJ103</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,556</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D TJ101</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">110,330</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">110,330</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,909</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">122,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,556</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">120,444</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,459</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross carrying amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;carrying&#160;amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 51%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 51%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D TJ103</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,788</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 51%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">IPR&amp;D TJ102</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 51%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D TJ101</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">110,330</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">110,330</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,909</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 51%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 51%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">148,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">148,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">22,811</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 51%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707709333000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment Accounted for Using the Equity Method and Put Right Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract', window );"><strong>Investment Accounted For Using The Equity Method And Put Right Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Summary of Group Long term Investment Measured Under Equity method</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Group presented the summarized financial information of the Group&#8217;s long-term investment measured under equity method below in accordance with Rule 4-08 of Regulation S-X (RMB in thousands).</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;period&#160;from</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">15</div>,&#160;2020&#160;to</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating data:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">271</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">271</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(85,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(85,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 80%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance sheet data:</div></div></div> </td>
<td style="vertical-align: bottom; width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 80%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets</div></div></div> </td>
<td style="vertical-align: bottom; width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">923,010</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 80%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div></div> </td>
<td style="vertical-align: bottom; width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">810,623</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 80%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities</div></div></div> </td>
<td style="vertical-align: bottom; width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">31,519</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 80%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,933</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 80%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interests</div></div> </td>
<td style="vertical-align: bottom; width: 11%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Estimate the Fair Value of the Put Right Using the Following Assumptions</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group determined the fair value of the put right with the assistance of an independent third-party valuation firm. The Group used the option pricing model (finnerty model) to estimate the fair value of the put right using the following assumptions: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;September</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,&#160;and&#160;September<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected terms (Year)</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated volatility</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">55.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">55.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Spot price</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">US$</td>
<td style="vertical-align: bottom;;text-align:right;">143,401</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align: bottom;">US$</td>
<td style="vertical-align: bottom;;text-align:right;">143,804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Probability of triggering event for redemption option</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707715304856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accruals And Other Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Summary of accruals and other payables</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Staff salaries and welfare payables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">30,166</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">94,133</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,427</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued external research and development activities related expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">144,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">218,583 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">33,499</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued initial public offering costs payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,504</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued private placement offering costs payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">128,786 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,737</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Withholding IIT payable related to stock options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,201</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-refundable</div> incentive payment from depositary bank <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,424</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">371</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued traveling expenses, office expenses and others</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">65,682</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">116,632</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">273,553</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">560,558 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">85,909</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-refundable</div> incentive payment from depositary bank <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,474</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advance payment received from an employee for exercise of stock options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,501 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;">8,975</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;">1,375 </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> <div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">569,533</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">87,284</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The Group received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> incentive payment&#160;of US$1,857&#160;(equivalent to approximately RMB12,982) from depositary bank in April 2020.&#160;The amount was recorded ratably as other gains over a five-year arrangement period. For the year ended December&#160;31, 2020, the Group has recorded RMB2,348 as other income in the consolidated statements of comprehensive income. </div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707706461000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliations of the Differences Between the PRC Statutory Income Tax Rate and the Group's Effective Income Tax Rate</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reconciliations of <div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div>he differences between <div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div>he PRC statutory income tax rate and the Group&#8217;s effective income tax rate for the years ended December&#160;31, 2018, 2019 and 2020 are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Note&#160;2.5)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before income ta<div style="letter-spacing: 0px; top: 0px;;display:inline;">x</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(401,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,451,950</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">483,146</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">74,044</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax computed at respective applicable tax rate</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(56,093</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(148,871</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">66,044</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,122</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-deductible</div> expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87,021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">72,256</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11,073</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses plus deduction</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,762</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,254</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(60,776</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(9,314</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in valuation allowance</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71,104</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(65,293</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(10,007</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12,231</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,874</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of tax holidays entitled by the PRC subsidiaries on basic income (loss) per share</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.34</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.05</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the Deferred Tax Assets and Liabilities</a></td>
<td class="text">The principal components of the deferred tax assets and liabilities are as follows:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">RMB</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Note&#160;2.5)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets:</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Net operating loss carryforwar<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">d</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136,443</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">107,344</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16,451</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciat<div style="letter-spacing: 0px; top: 0px;;display:inline;">i</div>on and amortization of property, equipment, software and intangible asset, net</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,405</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,398</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">30,417</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,662</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrual expense</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,867</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,568</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,620</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: valuation allowance</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(94,511</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(165,497</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(100,204</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(15,358</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax asset<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,211</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,211</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">48,125</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,375</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities:</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired intangible assets</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,211</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,211</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">18,067</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,768</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr>
<td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:top;"> <div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets</div></div> </td>
<td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;&#160;&#160;</div></div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;&#160;&#160;</div></div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">30,058</div></div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;">&#160;</div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">4,607</div></div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0px 0in; line-height: normal; font-family: Calibri, sans-serif;">&#160;</div> </td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 65%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">37,211</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">37,211</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">48,125</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,375</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets, net</div></div> </td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212; &#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212; &#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Movement of the Valuation Allowance</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Movement of the valuation allowance is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Note&#160;2.5)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January&#160;1</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(49,541</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(94,511</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(165,497</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(25,364</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Addition<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(62,029</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(71,104</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(36,061</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5,527</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Utilization and reversal of valuation allowances</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding: 0pt 4pt 0pt 0pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">89,154</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">13,663</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease due to the change of tax rate</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">17,059</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">118</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12,200</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,870</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 65%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(94,511</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(165,497</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(100,204</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(15,358</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 65%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712392680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Shares (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Convertible Preferred Shares Activities</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s convertible preferred shares activities for the years ended December&#160;31, 2019 and 2020 are summarized below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;A&#160;Preferred&#160;Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;B&#160;Preferred&#160;Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;C&#160;Preferred&#160;Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1&#160;Preferred&#160;Shares</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January&#160;1, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,227,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102,852</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">687,482</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,305,212</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,407</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">921,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,046,360</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,478</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,306,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Issuance of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares, net of issuance costs</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,857,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,160</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">183,536</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Adjustment at extinguishment of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,283</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,227,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102,852</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">687,482</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,305,212</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,407</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">921,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,046,360</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,478</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,306,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,857,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,914</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">188,819</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion to ordinary shares upon IPO</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,227,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(102,852</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(687,482</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,305,212</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(139,407</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(921,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(31,046,360</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(197,478</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,306,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,857,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26,914</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(188,819</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707711200904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_WarrantsDisclosureAbstract', window );"><strong>Warrants Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of fair value of warrant liabilities</a></td>
<td class="text">The Group used the binomial model to estimate the fair value of the warrant on September&#160;11, 2020 and December&#160;17, 2020 when the Investor Warrants were issued using the following assumptions: <div style="text-align:left;"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 92%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of September&#160;11,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;17,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 92%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 92%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate of return</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 92%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturity date</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">September 11, 2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 17, 2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 92%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated volatility rate</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">60.72</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">59.56</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 92%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom; width: 1%;"/>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">US$</div></td>
<td style="vertical-align: bottom;;text-align:right;">19.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;"/>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">US$</div></td>
<td style="vertical-align: bottom;;text-align:right;">19.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear: both; max-height: 0px; background: none;"/></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text">The estimated fair value of the Investor Warrants was shown below, which were used to determine the allocation of the total proceeds for the sale of ordinary shares between the Investor Warrants and ordinary shares.
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Terms</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price&#160;per<br/> share</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;value&#160;at</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">the&#160;closing</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">date</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB&#8217;000</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrants to purchase ordinary shares (first closing on September 11, 2020)</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12 months</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,744,032</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">71,874</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrants to purchase ordinary shares (second closing on </div></div><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;17, 2020)</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12 months</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,597,235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">37,869</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_WarrantsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Warrants [Abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_WarrantsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712940504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Share-Based Compensation Expenses Related to Restricted Shares</a></td>
<td class="text"><div style="text-align: left;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The allocation of share-based compensation expense was as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr></table></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">US$</div></div><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">470</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">284,431</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">43,591 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative expenses</div></div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">514,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">209,033</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,036 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 67%; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in loss of an affiliate</div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px; text-align: center; margin-left: 0.1in; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#8212;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px; text-align: center; margin-left: 0.15in; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#8212;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">32,707</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">5,013</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 67%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,520</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">515,203</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">526,171</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">80,640 </div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Valuation Assumptions Used</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group determined the fair value of the put right with the assistance of an independent third-party valuation firm. The Group used the option pricing model (finnerty model) to estimate the fair value of the put right using the following assumptions: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;September</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,&#160;and&#160;September<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected terms (Year)</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated volatility</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">55.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">55.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Spot price</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">US$</td>
<td style="vertical-align: bottom;;text-align:right;">143,401</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align: bottom;">US$</td>
<td style="vertical-align: bottom;;text-align:right;">143,804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Probability of triggering event for redemption option</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Share-Based Compensation Expenses Related to Restricted Shares</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expenses related to restricted shares were included in: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">1,056</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">470</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative expenses</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">2,464</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,096</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,520</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">1,566</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Non vested Share Activity</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A summa<div style="letter-spacing: 0px; top: 0px;;display:inline;">r</div>y of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock option activities for the year ended December&#160;31, 2020 is presented below: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2019</div></td>
<td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,098,500</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">5.57</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(1,871,500</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">5.57</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Exercise<div style="letter-spacing: 0px; top: 0px;;display:inline;">d</div></div></div></td>
<td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(402,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"/></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5.57</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2020</div></td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">825,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">5.57</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 64%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Summary of Stock Options Activities</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the stock options activities of 2018 Plan for the years ended December&#160;31, 2019 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Number&#160;of<br/> shares</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Weighted<br/> average<br/> exercise<br/> price<br/> US$</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Weighted<br/> average<br/> remaining<br/> contractual<br/> term</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Aggregate<br/> intrinsic<br/> value<br/> US$</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of January&#160;1, 2019</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,991,528</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased (Note 1<div style="display:inline;">7</div>&#160;(d))</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(454,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,536,588</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">64,840</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(402,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1.00</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#8212; &#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Surrendered (Note 1<div style="display:inline;">7</div>&#160;(h))</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;">(2,544,917</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#8212; &#160;</div>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.75pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">10,589,671</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">8.15</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">206,499</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">9,764,670</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">8.15</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">190,411 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Valuation Assumptions Used</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to certain directors and employees of the Group were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">54.64%-56.31</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate (per annum)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2.15%-2.75</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise multiple</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember', window );">2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Non vested Share Activity</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">A summa<div style="letter-spacing: 0px; top: 0px;;display:inline;">r</div>y of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock option activities for the year ended December&#160;31, 2020 is presented below: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Grant&#160;date&#160;fair&#160;value</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2019</div> </td>
<td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">9,812,881</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">2.10</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(6,790,924</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">1.90</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1,439,373</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1.37</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(338,876</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">2.29</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Surrendered</div></div> </td>
<td style="vertical-align: bottom; width: 11%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(332,566</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">1.47</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2020</div> </td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">911,142</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">4.96</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 64%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 11%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 10%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Summary of Stock Options Activities</a></td>
<td class="text"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the stock options activities of 2017 Plan for the periods presented: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Number&#160;of<br/> shares</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Weighted<br/> average<br/> exercise<br/> price<br/> US$</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Weighted<br/> average<br/> remaining<br/> contractual<br/> term</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Aggregate<br/> intrinsic<br/> value<br/> US$</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2017</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">11,761,596</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">0.94</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">9.50</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">24,890</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,470,000</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">(226,000</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2018</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">13,005,596</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">0.95</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">8.61</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">70,129</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">640,000</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">(397,500</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased (Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>(d))</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">(3,435,215</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31 ,2019</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">9,812,881</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">0.93</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">7.76</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">47,671</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">(338,876</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">(1,439,373</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">0.72</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Surrendered<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;(Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>(h))</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">(332,566</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31 ,2020</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">7,702,066</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">0.97</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">6.75</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);;text-align:right;">150,415</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">6,790,924</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">0.97</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">6.75</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgb(204, 238, 255);;text-align:right;">132,650</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Valuation Assumptions Used</a></td>
<td class="text"><div style="text-align: left;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to the employees were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="width: 0.75%;"/>
<td style="width: 0.75%;"/>
<td style="width: 1.5%;"/>
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0.75%;;text-align:center;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0.75%; text-align: right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">61.32%-62.13</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;;text-align:center;">54.64</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate (per annum)</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0.75%;;text-align:center;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0.75%; text-align: right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2.81%-3.06</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; text-align: right;">2.15</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise multiple</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0.75%; padding: 0pt 0.5pt;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0.75%; padding: 0pt 0.5pt; text-align: right;">2.80</td>
<td style="vertical-align: bottom; width: 1.5%; padding: 0pt 0.5pt;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; text-align: right;">2.80</td>
<td style="vertical-align: bottom; text-align: right;"> <div style="line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.75%;;text-align:center;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.75%; text-align: right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1.5%;;text-align:center;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual term (in years)</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 0.75%;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0.75%; text-align: right;">10</td>
<td style="vertical-align: bottom; text-align: right; width: 1.5%;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; text-align: right;">10</td>
<td style="vertical-align: bottom; text-align: right;"> <div style="line-height: normal;">&#160;</div> </td> </tr> </table> </div> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyNineteenEmployeeStockOptionPlanMember', window );">2019 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Non vested Share Activity</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;">A summary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock options activity for the year ended December&#160;31, 2020 is presented below: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2019</div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">72,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2020</div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">72,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Summary of Stock Options Activities</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the stock options activities of 2019 Plan for the year ended December&#160;31, 2020 presented: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number&#160;of</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">shares</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">exercise</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">price</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">remaining</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">contractual</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">term</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregate</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">intrinsic</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">value</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">72,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">72,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9.33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,038</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Valuation Assumptions Used</a></td>
<td class="text"><div style="text-align: left;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to the 3 independent directors were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 22%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom; width: 22%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">54.88</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate (per annum)</div></div> </td>
<td style="vertical-align: bottom; width: 22%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.79</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise multiple</div></div> </td>
<td style="vertical-align: bottom; width: 22%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual term (in years)</div></div> </td>
<td style="vertical-align: bottom; width: 22%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="clear: both; max-height: 0px; background: none;"/> </div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"/> <div style="clear: both; max-height: 0px; background: none;"/> </div> </div> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember', window );">2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Non vested Share Activity</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A summary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock option activities for the year ended December&#160;31, 2020 is presented below: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2019</div> </td>
<td style="vertical-align: bottom; width: 11in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 11in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,068,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.71</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 11in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(24,365</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 10in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65in;">&#160;</td>
<td style="vertical-align: bottom; width: 11in;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 10in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2020</div> </td>
<td style="vertical-align: bottom; width: 11in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,044,368</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.71</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 65in;">&#160;</td>
<td style="vertical-align: bottom; width: 11in;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 10in;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Summary of Stock Options Activities</a></td>
<td class="text">The following table sets forth the stock options activities of 2020 Plan for the year ended December&#160;31, 2020: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">exercise</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">price</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">remaining</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">contractual</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">intrinsic</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">value</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">1,068,733</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5.91</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">(24,365</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">)&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">5.91</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0in;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">1,044,368</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">5.91</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">9.62</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">15,237</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0in;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0in;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 3in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 4in;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0in;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Valuation Assumptions Used</a></td>
<td class="text"><div style="text-align: left;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted to the employees were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 18%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom; width: 18in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">56.51</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate (per annum)</div></div> </td>
<td style="vertical-align: bottom; width: 18in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">0.86</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise multiple</div></div> </td>
<td style="vertical-align: bottom; width: 18in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2.20-2.80</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73in;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom; width: 18in;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contractual term (in years)</div> </td>
<td style="vertical-align: bottom; width: 18in;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0in;">&#160;</td>
<td style="vertical-align: bottom; width: 0in;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0in;">&#160;</td> </tr> </table> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> </div> </div> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember', window );">2020 Plan [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Summary of Stock Options Activities</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the restricted share units of 2020 Plan for the year ended December&#160;31, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/>
<td style="font-family: &quot;Times New Roman&quot;; width: 0%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number&#160;of</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">restricted<br/> share units</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">exercise</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">price</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">remaining</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">contractual</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">term</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregate</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">intrinsic</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">value</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">4,093,079 </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(13,461</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">4,079,618</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">9.70</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">83,632</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">A summary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> restricted share units activities for the year ended December&#160;31, 2020 is presented below: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>restricted<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>share </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">units</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>fair value</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2019</div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">4,093,079</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">13.99</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">(13,461</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">11.73</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2020</div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">4,079,618 </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">14.00</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember', window );">2020 Plan [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Summary of Stock Options Activities</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the restricted share units subject to terms and conditions under 2018 Plan for the year ended December&#160;31, 2020: </div></div> <br/>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number&#160;of</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">restricted<br/> share units</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">exercise</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">price</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">average</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">remaining</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">contractual</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">term</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregate</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">intrinsic</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">value</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">US$</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,328,120</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; </div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(565,200</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">1.00</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; </div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; </div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">762,920</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">9.65</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">14,877</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 3%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A summary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> restricted share units activities for the year ended December&#160;31, 2020 is presented below: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>restricted<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>share </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">units</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>fair value</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2019</div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,328,120</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13.34</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(565,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> at December&#160;31, 2020</div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">762,920</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12.89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 56%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 14%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_TwentyNineteenEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_TwentyNineteenEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712208056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMorphosysAgMember', window );">Licensing Agreement with MorphoSys AG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Licensing And Collaboration Arrangements Summarized Financial Information Disclosure</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summarized financial information related to the above agreement is presented below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 41%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Year ended December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">As&#160;of&#160;December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Research and Development Expense</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Upfront&#160;Fees</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Milestones</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Extension/Termination<br/> of agreements</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Amortization&#160;of&#160;prepaid<br/> research and<br/> development</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Intangible&#160;asset&#160;balance</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 41%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 41%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">US$</td>
<td style="vertical-align: bottom;;text-align:right;">8,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 41%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 41%; padding-bottom: 0.45pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; width: 9%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 41%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithGenexineIncMember', window );">Licensing Agreement with Genexine Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Licensing And Collaboration Arrangements Summarized Financial Information Disclosure</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summarized financial information related to the above agreement is presented below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Year ended December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">As&#160;of&#160;December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Research and Development Expense</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Upfront&#160;Fees</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Milestones</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Extension/Termination<br/> of agreements</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Amortization&#160;of&#160;prepaid<br/> research and<br/> development</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Intangible&#160;asset&#160;balance</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 45%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">US$</td>
<td style="vertical-align: bottom; width: 0%;;text-align:right;">12,000</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 45%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMorphosysMember', window );">Licensing Agreement with MorphoSys [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Licensing And Collaboration Arrangements Summarized Financial Information Disclosure</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summarized financial information related to the above agreement is presented below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 42%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Years Ended December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">As&#160;of&#160;December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Research and Development Expense</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Upfront&#160;Fees</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Milestones</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Extension/Termination<br/> of agreements</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Amortization&#160;of&#160;prepaid<br/> research and<br/> development</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Intangible&#160;asset&#160;balance</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 42%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: top;">US$</td>
<td style="vertical-align: top;;text-align:right;">1,000</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 42%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 42%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: top;">US$</td>
<td style="vertical-align: top;;text-align:right;">3,500</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 42%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMacrogenicsMember', window );">Licensing Agreement with MacroGenics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Licensing And Collaboration Arrangements Summarized Financial Information Disclosure</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to the uncertainty involved in meeting these development and commercialization based targets, the Group evaluated and concluded that no milestones are probable as of December&#160;31, 2019 and 2020. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 40%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/>
<td style="width: 0%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Year ended December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">As&#160;of&#160;December&#160;31,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Research and Development Expense</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Upfront Fees</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Milestones</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Extension/Termination<br/> of agreements</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Amortization&#160;of&#160;prepaid<br/> research and<br/> development</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;">Intangible&#160;asset&#160;balance</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 40%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: top; width: 0%;">US$</td>
<td style="vertical-align: top; width: 0%;;text-align:right;">15,000</td>
<td style="vertical-align: top; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 40%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 0%;">&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMorphosysAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMorphosysAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithGenexineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithGenexineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMorphosysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMorphosysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMacrogenicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMacrogenicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712377176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Expenses), Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Summary of Other Income (Expenses), Net</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes other income (expenses), net recognized for the years ended December&#160;31, 2018, 2019 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from conversion of 2017 Notes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,375</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from conversion of Onshore Convertible Loan<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,548</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from issuance of 2018 Notes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,081</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on termination agreement with Everest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23,039</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income of incentive payment from depository bank</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,348</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">360</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value change of short-term investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">703</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,730</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value change of put right liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,024</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">463</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from other financial assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,622</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net foreign exchange gains (losses)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">742</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22,126</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,391</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsidy income<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> (3)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">750</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">568</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,783</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gains on deconsolidation of a subsidiary</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">407,598</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,467</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value change of other financial assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Others</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(98</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(873</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(134</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,780</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20,205</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">412,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707708162760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Net Loss per Share</a></td>
<td class="text"><div style="text-align: left;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per share for eac<div style="display:inline;">h</div>&#160;of the periods presented are calculated as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$ (Note 2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;">(in thousands, except for share and per share data)</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(402,833</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1,451,950</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">470,915</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">72,170</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Deemed dividend to Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> preferred shareholders at extinguishment of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div> Preferred Shares</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5,283</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Deemed dividend to Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> and C preferred shareholders at modification of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> and C Preferred Shares</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(27,768</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to ordinary shareholders</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(402,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,485,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">470,915 </div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">72,170 </div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 6.5pt; font-size: 6.5pt; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 6.5pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: 6.5pt;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 2%;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 1%;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 1%;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 6.5pt; font-size: 6.5pt; width: 2%;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 6.5pt; font-size: 6.5pt;"> <div style="font-size: 6.5pt; line-height: 6.5pt; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Denominator for basic calculation-weighted average number of common shares <br/> outstanding</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,529,092</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,381,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">134,158,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">134,158,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive effect of convertible preferred shares</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,373,047</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,373,047</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Dilutive effect of ordinary shares to be issued to Everes<div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">266,458</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">266,458</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Dilutive effect of convertible promissory notes</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">865,479</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">865,479 </div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive effect of restricted shares<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;units</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">778,130</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">778,130</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive effect of stock options</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(255, 255, 255);">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(255, 255, 255);">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16,789,714</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16,789,714</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 57%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for diluted income (loss) per share calculation</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">6,529,092</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">7,381,230</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;157,231,652</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;157,231,652</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per share - basic</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(61.70</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(201.19</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3.51</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.54</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per share - diluted</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(61.70</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(201.19</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3.00 </div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.46</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr> </table> </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">The potentially dilutive securities that have not been included in the calculation of diluted net loss per share as their inclusion would be anti-dilutive are as follows:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible preferred shares</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">64,389,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">92,238,119</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted shares</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,134,058</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">not&#160;applicable</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,388,776</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707706962104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ScheduleOfRelatedPartyBalancesTextBlock', window );">Summary of Related Party Balances</a></td>
<td class="text"><div style="text-align: left;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Details of related party balances as of December&#160;31, 2019 and 2020 are as follows: </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares to be issued to Everest </div></div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Everest (Note 1<div style="display:inline;">8</div>)</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">258,119</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other receivables</div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; padding-bottom: 2.2pt; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 2.2pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 2.2pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 2.2pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">21,212</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 2.2pt; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2.2pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,251</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <div style="text-align: left;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accruals and other payables </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jiangsu Taslydiyi Pharmaceutical Co., Ltd.</div></div></div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,395</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">367</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Summary of Related Party Transactions</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 10pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Receipt of CRO services<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div>recognized in research and development expenses</div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CMAB Biopharma (Suzhou) Inc.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,786</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">681</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">104</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jiangsu Taslydiyi Pharmaceutical Co., Ltd.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,395</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">367</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tasly Pharmaceutical Group Co., Ltd.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,590</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 10pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Receipt of research and development funding </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Everest (Note 1<div style="display:inline;">8</div>)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">178,715</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">53,148</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: 0pt;">&#160;</div></td>
<td>&#160;</td></tr></table> <br/>  <div style="text-indent: -2%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collection of loan to an affiliate</div> </div></div> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 2%; line-height: 12pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou <div style="font-size:85%; vertical-align:top;display:inline;;font-size:9.4px">(4)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">52,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,969</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expenses paid on behalf of an affiliate </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the year ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RMB</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$&#160;(Note&#160;2.5)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I-Mab</div> Hangzhou</div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">21,212</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,251</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ScheduleOfRelatedPartyBalancesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of related party balances [Table Text Block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ScheduleOfRelatedPartyBalancesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707715078744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Activities and Organization - Schedule of Principal Subsidiaries (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=imab_IMabBiopharmaHongKongLimitedMember', window );">I-Mab Biopharma Hong Kong Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_EntityIncorporationCountryStateName', window );">Place of incorporation</a></td>
<td class="text">Hong Kong<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">Jul.  08,  2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of direct or indirect ownership by the company</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities', window );">Principal activities</a></td>
<td class="text">Investment holding<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=imab_IMabShanghaiMember', window );">I-Mab Shanghai [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_EntityIncorporationCountryStateName', window );">Place of incorporation</a></td>
<td class="text">PRC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">Aug. 24,  2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of direct or indirect ownership by the company</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities', window );">Principal activities</a></td>
<td class="text">Research and development of innovative medicines<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=imab_IMabtianjinMember', window );">I-MabTianjin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_EntityIncorporationCountryStateName', window );">Place of incorporation</a></td>
<td class="text">PRC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">Jul. 15,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of direct or indirect ownership by the company</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities', window );">Principal activities</a></td>
<td class="text">Research and development of innovative medicines<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=imab_ImabbiopharmaUsLtdMember', window );">I-MabBiopharma US Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_EntityIncorporationCountryStateName', window );">Place of incorporation</a></td>
<td class="text">U.S.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">Feb. 28,  2018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of direct or indirect ownership by the company</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities', window );">Principal activities</a></td>
<td class="text">Research and development of innovative medicines<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_EntityIncorporationCountryStateName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity incorporation country state name.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_EntityIncorporationCountryStateName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the principal activities of an investee accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=imab_IMabBiopharmaHongKongLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=imab_IMabBiopharmaHongKongLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=imab_IMabShanghaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=imab_IMabShanghaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=imab_IMabtianjinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=imab_IMabtianjinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=imab_ImabbiopharmaUsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=imab_ImabbiopharmaUsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712103352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Activities and Organization - Additional Information (Detail)<br> $ / shares in Units, &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 10, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 17, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 726,300<span></span>
</td>
<td class="nump">$ 111,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | American Depositary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued, ADS | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,407,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Number of share issued, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | American Depositary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued, ADS | shares</a></td>
<td class="nump">8,175,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering | $</a></td>
<td class="nump">$ 114,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_CommonStockSharesIssuable', window );">Common stock shares issuable | shares</a></td>
<td class="nump">768,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_CommonStockSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares issuable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_CommonStockSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707715931816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Principal Accounting Policies - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investments</a></td>
<td class="nump">&#165; 31,530<span></span>
</td>
<td class="nump">$ 4,832<span></span>
</td>
<td class="nump">&#165; 32,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PutRightLiabilities', window );">Put right liabilities</a></td>
<td class="nump">116,006<span></span>
</td>
<td class="nump">$ 17,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investments</a></td>
<td class="nump">31,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PutRightLiabilities', window );">Put right liabilities</a></td>
<td class="nump">116,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investments</a></td>
<td class="nump">31,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 32,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PutRightLiabilities', window );">Put right liabilities</a></td>
<td class="nump">&#165; 116,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PutRightLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Put right liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PutRightLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707711885096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Accounting Policies - Summary of Roll Forward of Major Level 3 Financial Assets and Financial Liability (Detail) - CNY (&#165;)<br> &#165; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments', window );">Disposal of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#165; (102,703)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Fair value change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Fair value of Level 3 financial asset and liability</a></td>
<td class="nump">&#165; 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements', window );">Purchase of short-term investments</a></td>
<td class="nump">2,491,991<span></span>
</td>
<td class="nump">134,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments', window );">Disposal of short-term investments</a></td>
<td class="num">(2,503,749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Fair value change</a></td>
<td class="nump">11,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Fair value of Level 3 financial asset and liability</a></td>
<td class="nump">31,530<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=imab_OtherFinancialAssetsMember', window );">Other financial assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Fair value of Level 3 financial asset and liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">255,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales', window );">Disposal of other financial assets due to Termination Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(256,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Fair value change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Fair value of Level 3 financial asset and liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=imab_WarrantLiabilitiesMember', window );">Warrant liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Fair value of Level 3 financial asset and liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,618)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Fair value change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences', window );">Currency translation differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Fair value of Level 3 financial asset and liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=imab_PutRightLiabilitiesMember', window );">Put Right Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues', window );">Grant of put right liabilities</a></td>
<td class="nump">124,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Fair value change</a></td>
<td class="num">(3,024)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences', window );">Currency translation differences</a></td>
<td class="num">(5,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Fair value of Level 3 financial asset and liability</a></td>
<td class="nump">&#165; 116,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis short term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation currency translation differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=imab_OtherFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=imab_OtherFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=imab_WarrantLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=imab_WarrantLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=imab_PutRightLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=imab_PutRightLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707715313720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Principal Accounting Policies - summary of Cash, cash equivalents and restricted cash as reported in the consolidated statement of cash flows (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">&#165; 4,758,778<span></span>
</td>
<td class="nump">$ 729,315<span></span>
</td>
<td class="nump">&#165; 1,137,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total</a></td>
<td class="nump">&#165; 4,758,778<span></span>
</td>
<td class="nump">$ 729,315<span></span>
</td>
<td class="nump">&#165; 1,193,283<span></span>
</td>
<td class="nump">$ 182,879<span></span>
</td>
<td class="nump">&#165; 1,680,931<span></span>
</td>
<td class="nump">&#165; 412,713<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707806723448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Accounting Policies - Additional Information (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Deferred subsidy income</a></td>
<td class="nump">&#165; 7,509<span></span>
</td>
<td class="nump">&#165; 3,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">14,997<span></span>
</td>
<td class="nump">16,435<span></span>
</td>
<td class="nump">$ 2,298<span></span>
</td>
<td class="nump">&#165; 13,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,084<span></span>
</td>
<td class="nump">&#165; 11,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostImpairmentLoss', window );">Impairment loss, contract assets with customer</a></td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_VATSurchargesPercent', window );">VAT surcharges percent</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_VATSurchargesPercent', window );">VAT surcharges percent</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_BankBranchAxis=imab_PeoplesBankOfChinaMember', window );">Peoples Bank of China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Translation exchange rates</a></td>
<td class="nump">6.5249<span></span>
</td>
<td class="nump">6.9762<span></span>
</td>
<td class="nump">6.5249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_BankBranchAxis=imab_FederalReserveBankOfNewYorkMember', window );">Federal Reserve Bank of New York [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Translation exchange rates</a></td>
<td class="nump">6.5250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_VATSurchargesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>VAT surcharges percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_VATSurchargesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68051541&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32618-110901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_BankBranchAxis=imab_PeoplesBankOfChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_BankBranchAxis=imab_PeoplesBankOfChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_BankBranchAxis=imab_FederalReserveBankOfNewYorkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_BankBranchAxis=imab_FederalReserveBankOfNewYorkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707711203512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Accounting Policies - Summary of Estimated Useful Lives (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imab_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imab_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imab_SoftwareMember', window );">Software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imab_SoftwareMember', window );">Software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imab_OfficeFurnitureAndEquipmentMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">Lesser of useful life or lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imab_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=imab_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imab_SoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=imab_SoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imab_OfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=imab_OfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707715452008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable And Contract Assets - summary of Accounts receivable and contract assets, net of allowance for credit losses (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrentAbstract', window );"><strong>Accounts Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable, gross</a></td>
<td class="nump">&#165; 130,498<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">130,498<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrentAbstract', window );"><strong>Contract with Customer, Asset, after Allowance for Credit Loss, Current [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGrossCurrent', window );">Contract assets, gross</a></td>
<td class="nump">227,391<span></span>
</td>
<td class="nump">34,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossCurrent', window );">Allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets, net</a></td>
<td class="nump">&#165; 227,391<span></span>
</td>
<td class="nump">$ 34,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707711178008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepayments And Other Receivables - Summary of Prepayments And Other Receivables (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAbstract', window );"><strong>Prepaid Expense, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">-Prepayments to CRO vendors</a></td>
<td class="nump">&#165; 83,140<span></span>
</td>
<td class="nump">$ 12,742<span></span>
</td>
<td class="nump">&#165; 78,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">-Prepayments for other services</a></td>
<td class="nump">2,550<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="nump">880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromEmployeesCurrent', window );">Receivables due from employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromAffiliateCurrent', window );">Receivables due from an affiliate (Note 23)</a></td>
<td class="nump">21,212<span></span>
</td>
<td class="nump">3,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ValueaddedTaxRecoverable', window );">Value-added tax recoverable</a></td>
<td class="nump">63,664<span></span>
</td>
<td class="nump">9,757<span></span>
</td>
<td class="nump">12,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Rental deposits</a></td>
<td class="nump">1,766<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest Receivable</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Others</a></td>
<td class="nump">22,899<span></span>
</td>
<td class="nump">3,509<span></span>
</td>
<td class="nump">26,388<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">&#165; 195,467<span></span>
</td>
<td class="nump">$ 29,957<span></span>
</td>
<td class="nump">&#165; 136,036<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ValueaddedTaxRecoverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value-added tax recoverable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ValueaddedTaxRecoverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120604989&amp;loc=d3e56071-112765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromEmployeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from an Entity employee, not to include stockholders or officers, which are usually due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromEmployeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707704876408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment And Software - Additional Information (Detail) - CNY (&#165;)<br> &#165; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, Depletion and Amortization</a></td>
<td class="nump">&#165; 12.7<span></span>
</td>
<td class="nump">&#165; 9.8<span></span>
</td>
<td class="nump">&#165; 6.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712655272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Equipment And Software - Schedule of property, equipment and software, net (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property, Plant and Equipment, Net, by Type [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">&#165; 56,171<span></span>
</td>
<td class="nump">$ 8,608<span></span>
</td>
<td class="nump">&#165; 47,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(30,899)<span></span>
</td>
<td class="num">(4,735)<span></span>
</td>
<td class="num">(18,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PropertyPlantAndequipmentnetExcludingConstructionInProcess', window );">Net book value</a></td>
<td class="nump">25,272<span></span>
</td>
<td class="nump">3,873<span></span>
</td>
<td class="nump">29,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total net book value of property, equipment and software</a></td>
<td class="nump">25,272<span></span>
</td>
<td class="nump">3,873<span></span>
</td>
<td class="nump">30,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imab_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property, Plant and Equipment, Net, by Type [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">30,808<span></span>
</td>
<td class="nump">4,722<span></span>
</td>
<td class="nump">24,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property, Plant and Equipment, Net, by Type [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">13,842<span></span>
</td>
<td class="nump">2,121<span></span>
</td>
<td class="nump">11,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property, Plant and Equipment, Net, by Type [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">9,990<span></span>
</td>
<td class="nump">1,531<span></span>
</td>
<td class="nump">10,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property, Plant and Equipment, Net, by Type [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">&#165; 1,531<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
<td class="nump">&#165; 1,526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PropertyPlantAndequipmentnetExcludingConstructionInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment net excluding construction in process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PropertyPlantAndequipmentnetExcludingConstructionInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imab_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=imab_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712321944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Operating Lease Related Assets And Liabilities And Other Related Information (Detail))<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">&#165; 14,997<span></span>
</td>
<td class="nump">$ 2,298<span></span>
</td>
<td class="nump">&#165; 16,435<span></span>
</td>
<td class="nump">&#165; 13,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">8,058<span></span>
</td>
<td class="nump">1,235<span></span>
</td>
<td class="nump">6,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">&#165; 5,542<span></span>
</td>
<td class="nump">$ 849<span></span>
</td>
<td class="nump">&#165; 7,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707713507528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Operating Lease Expense (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems', window );"><strong>Schedule of Components of Operating Lease Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_OperatingLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">&#165; 8,158<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">&#165; 5,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Expense for short-term leases within 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_OperatingLeaseInterestExpense', window );">Interest of lease liabilities</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">543<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating lease rental expense</a></td>
<td class="nump">&#165; 8,837<span></span>
</td>
<td class="nump">$ 1,354<span></span>
</td>
<td class="nump">&#165; 6,395<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_OperatingLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Interest Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_OperatingLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_OperatingLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Right Of Use Asset Amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_OperatingLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Components of Operating Lease Expense [line items].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707791183880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Operating Lease, Maturity (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ScheduleOfOperatingLeaseMaturityLineItems', window );"><strong>Schedule of Operating Lease Maturity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">&#165; 8,901<span></span>
</td>
<td class="nump">$ 1,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">5,464<span></span>
</td>
<td class="nump">837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">14,901<span></span>
</td>
<td class="nump">2,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1,301)<span></span>
</td>
<td class="num">(199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">&#165; 13,600<span></span>
</td>
<td class="nump">$ 2,084<span></span>
</td>
<td class="nump">&#165; 11,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ScheduleOfOperatingLeaseMaturityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Operating Lease Maturity [line items].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ScheduleOfOperatingLeaseMaturityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712060424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Summary Of Intangible Assets (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">&#165; 122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 148,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">120,444<span></span>
</td>
<td class="nump">$ 18,459<span></span>
</td>
<td class="nump">148,844<span></span>
</td>
<td class="nump">$ 22,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_IprAndDTj103Member', window );">IPR And D TJ103 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">11,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">10,114<span></span>
</td>
<td class="nump">1,550<span></span>
</td>
<td class="nump">11,670<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_IprAndDTj102Member', window );">IPR And D TJ102 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,844<span></span>
</td>
<td class="nump">4,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_IprAndDTj101Member', window );">IPR And D TJ101 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">110,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">&#165; 110,330<span></span>
</td>
<td class="nump">$ 16,909<span></span>
</td>
<td class="nump">&#165; 110,330<span></span>
</td>
<td class="nump">$ 16,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_IprAndDTj103Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_IprAndDTj103Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_IprAndDTj102Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_IprAndDTj102Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_IprAndDTj101Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_IprAndDTj101Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707715630712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Additional Information (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets | &#165;</a></td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">&#165; 1,556<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Estimated amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_IprAndDTj103Member', window );">IPR And D TJ103 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_IprAndDTj103Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_IprAndDTj103Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712313016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th"><div>Jul. 15, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">&#165; 162,574,000<span></span>
</td>
<td class="nump">$ 24,916<span></span>
</td>
<td class="nump">&#165; 162,574,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, accumulated impairment loss</a></td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=imab_TasgenGroupMember', window );">Tasgen Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting Interests Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.67%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=imab_TasgenGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=imab_TasgenGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707711220296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investment Accounted for Using the Equity Method and Put Right Liabilities - Summary of Group Long term Investment Measured Under Equity method (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_OperatingDataAbstract', window );"><strong>Operating Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in subsidiaries</a></td>
<td class="nump">&#165; 664,832<span></span>
</td>
<td class="nump">$ 101,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_BalanceSheetDataAbstract', window );"><strong>Balance Sheet Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">5,343,664<span></span>
</td>
<td class="nump">818,953<span></span>
</td>
<td class="nump">&#165; 1,361,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">576,125<span></span>
</td>
<td class="nump">$ 88,295<span></span>
</td>
<td class="nump">&#165; 588,479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=imab_LongTermInvestmentUnderEquityMethodMember', window );">Long Term Investment under Equity Method [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_BalanceSheetDataAbstract', window );"><strong>Balance Sheet Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">923,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non-current&#160;assets</a></td>
<td class="nump">810,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">31,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Non-current&#160;liabilities</a></td>
<td class="nump">10,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Non-controlling&#160;interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=imab_RevenueMember', window );">Revenue [Member] | Long Term Investment under Equity Method [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_OperatingDataAbstract', window );"><strong>Operating Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in subsidiaries</a></td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=imab_GrossProfitMember', window );">Gross Profit [Member] | Long Term Investment under Equity Method [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_OperatingDataAbstract', window );"><strong>Operating Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in subsidiaries</a></td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=imab_LossFromOperationMember', window );">Loss from Operation [Member] | Long Term Investment under Equity Method [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_OperatingDataAbstract', window );"><strong>Operating Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in subsidiaries</a></td>
<td class="num">(85,945)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=imab_NetIncomeLossMember', window );">Net Income Loss [Member] | Long Term Investment under Equity Method [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_OperatingDataAbstract', window );"><strong>Operating Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in subsidiaries</a></td>
<td class="num">&#165; (85,945)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_BalanceSheetDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance Sheet Data [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_BalanceSheetDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_OperatingDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_OperatingDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=imab_LongTermInvestmentUnderEquityMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=imab_LongTermInvestmentUnderEquityMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=imab_RevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=imab_RevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=imab_GrossProfitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=imab_GrossProfitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=imab_LossFromOperationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=imab_LossFromOperationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=imab_NetIncomeLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=imab_NetIncomeLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707706402680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment Accounted for Using the Equity Method and Put Right Liabilities - Summary of Estimate the Fair Value of the Put Right Using the Following Assumptions (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract', window );"><strong>Investment Accounted For Using The Equity Method And Put Right Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected terms (Year)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Estimated volatility</a></td>
<td class="nump">55.20%<span></span>
</td>
<td class="nump">55.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice', window );">Spot price</a></td>
<td class="nump">$ 143,401<span></span>
</td>
<td class="nump">$ 143,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate', window );">Probability of triggering event for redemption option</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Striggering Event For Redemption Rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Spot Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707803486104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment Accounted for Using the Equity Method and Put Right Liabilities - Additional Information (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 16, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Disposal of an equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 407,598<span></span>
</td>
<td class="nump">$ 62,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding | shares</a></td>
<td class="nump">164,888,519<span></span>
</td>
<td class="nump">164,888,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,888,519<span></span>
</td>
<td class="nump">8,363,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#165; (108,587)<span></span>
</td>
<td class="num">(16,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=imab_HoldcoMember', window );">HoldCo [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, Ownership percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments', window );">Purchase price committed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of affiliate | &#165;</a></td>
<td class="nump">&#165; 8,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=imab_ImabHangzhouMember', window );">I-Mab Hangzhou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Equity method investment fair value</a></td>
<td class="nump">&#165; 764,352<span></span>
</td>
<td class="nump">&#165; 764,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Equity method investment, Amount sold | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 664,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_RegisteredCapitalOfSubsidiary', window );">Registered capital of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized', window );">Assets recognized value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, Ownership percentage</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Proceeds from contributions from affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding | shares</a></td>
<td class="nump">13,500,000<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciEquityMethodInvestmentAfterTax', window );">OCI, equity method Investment, after tax | &#165;</a></td>
<td class="nump">&#165; 67,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Employee benefit and share based compensation recognized in comprehensive income of entity | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 32,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Shares subscribed,not yet been purchased or issued | shares</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=imab_ImabHongKongMember', window );">Imab Hong Kong [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, Ownership percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=imab_ManagementHoldcoMember', window );">Management Holdco [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding | shares</a></td>
<td class="nump">25,500,000<span></span>
</td>
<td class="nump">25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Shares subscribed,not yet been purchased or issued | shares</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=imab_ManagementHoldcoMember', window );">Management Holdco [Member] | I-Mab Hangzhou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_RegisteredCapitalOfSubsidiary', window );">Registered capital of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, Ownership percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Proceeds from contributions from affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=imab_EsopHoldcoMember', window );">Esop Holdco [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, Ownership percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=imab_EsopHoldcoMember', window );">Esop Holdco [Member] | I-Mab Hangzhou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, Ownership percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Proceeds from contributions from affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=imab_DomesticInvestorsMember', window );">Domestic Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, Ownership percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding | shares</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=imab_DomesticInvestorsMember', window );">Domestic Investors [Member] | I-Mab Hangzhou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_RegisteredCapitalOfSubsidiary', window );">Registered capital of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, Ownership percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Proceeds from contributions from affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_RegisteredCapitalOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Registered capital of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_RegisteredCapitalOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total remaining unamortized or unaccreted amounts of premiums, discounts, and intangible assets, in years subsequent to the year of acquisition, when the total amounts of remaining discounts, premiums, and intangible assets exceed 30 percent of stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The assets recognized for each amount of assets recorded in a transaction with the acquiree that is recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117311354&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciEquityMethodInvestmentAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of other comprehensive income (loss) (OCI) for proportionate share of equity method investee's OCI.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=121548190&amp;loc=d3e32472-111569<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciEquityMethodInvestmentAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=imab_HoldcoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=imab_HoldcoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=imab_ImabHangzhouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=imab_ImabHangzhouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=imab_ImabHongKongMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=imab_ImabHongKongMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=imab_ManagementHoldcoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=imab_ManagementHoldcoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=imab_EsopHoldcoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=imab_EsopHoldcoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=imab_DomesticInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=imab_DomesticInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707711068136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Borrowings - Additional Information (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 25, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loan Borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=imab_LoanOneMember', window );">Loan One [Member] | China Merchant Bank Co., Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLender', window );">Lender name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">China Merchant Bank Co., Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loan Borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateralAmount', window );">Collateral Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 92,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits', window );">Percentage of interest bearing on deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=imab_LoanTwoMember', window );">Loan Two [Member] | China Merchant Bank Co., Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLender', window );">Lender name</a></td>
<td class="text">China Merchant Bank Co., Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan Term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loan Borrowed</a></td>
<td class="nump">&#165; 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateralAmount', window );">Collateral Value</a></td>
<td class="nump">&#165; 55,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits', window );">Percentage of interest bearing on deposit</a></td>
<td class="nump">2.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt instrument, maturity</a></td>
<td class="text">The borrowing was fully repaid in June 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCollateralAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets pledged to secure a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCollateralAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of interest-bearing domestic time deposit liabilities to total deposit liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLender">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender or type of lender, such as bank, insurance entity, pension fund.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLender</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=imab_LoanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=imab_LoanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=imab_ChinaMerchantBankCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=imab_ChinaMerchantBankCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=imab_LoanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=imab_LoanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712009288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accruals And Other Payables - Summary of accruals and other payables (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 25, 2019 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Staff salaries and welfare payables</a></td>
<td class="nump">&#165; 94,133<span></span>
</td>
<td class="nump">$ 14,427<span></span>
</td>
<td class="nump">&#165; 30,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent', window );">Accrued external research and development activities related expenses</a></td>
<td class="nump">218,583<span></span>
</td>
<td class="nump">33,499<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_AccruedInitialPublicOfferingCostsPayable', window );">Accrued initial public offering costs payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PrivatePlacementOfferingCostsPayable', window );">Accrued private placement offering costs payable</a></td>
<td class="nump">128,786<span></span>
</td>
<td class="nump">19,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_WithholdingIitPayable', window );">Withholding IIT payable related to stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_NonRefundableIncentivePaymentFromDepositaryBankCurrent', window );">Non-refundable incentive payment from depositary bank</a></td>
<td class="nump">2,424<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_AccruedTravellingExpensesOfficeExpensesAndOthers', window );">Accrued traveling expenses, office expenses and others</a></td>
<td class="nump">116,632<span></span>
</td>
<td class="nump">17,875<span></span>
</td>
<td class="nump">65,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts Payable and Accrued Liabilities, Current</a></td>
<td class="nump">560,558<span></span>
</td>
<td class="nump">85,909<span></span>
</td>
<td class="nump">273,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract', window );"><strong>Non-current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_NonRefundableIncentivePaymentFromDepositaryBankNoncurrent', window );">Non-refundable incentive payment from depositary bank</a></td>
<td class="nump">7,474<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_AdvanceReceivedFromEmployeeForExerciseOfStockOptions', window );">Advance payment received from an employee for exercise of stock options</a></td>
<td class="nump">1,501<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent', window );">Accounts Payable and Accrued Liabilities, Non-current</a></td>
<td class="nump">8,975<span></span>
</td>
<td class="nump">1,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">&#165; 569,533<span></span>
</td>
<td class="nump">$ 87,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued external research and development activities related expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_AccruedInitialPublicOfferingCostsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued initial public offering costs payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_AccruedInitialPublicOfferingCostsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_AccruedTravellingExpensesOfficeExpensesAndOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Travelling Expenses Office Expenses And Others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_AccruedTravellingExpensesOfficeExpensesAndOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_AdvanceReceivedFromEmployeeForExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advanced received from employee for exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_AdvanceReceivedFromEmployeeForExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_NonRefundableIncentivePaymentFromDepositaryBankCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non refundable incentive payment from depositary bank current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_NonRefundableIncentivePaymentFromDepositaryBankCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_NonRefundableIncentivePaymentFromDepositaryBankNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non refundable incentive payment from depositary bank, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_NonRefundableIncentivePaymentFromDepositaryBankNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PrivatePlacementOfferingCostsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Private Placement offering costs payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PrivatePlacementOfferingCostsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_WithholdingIitPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Withholding IIT payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_WithholdingIitPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707704953576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accruals And Other Payables - Additional Information (Details)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ProceedsFromNonRefundableIncentive', window );">Proceeds from non-refundable incentive</a></td>
<td class="nump">$ 1,857<span></span>
</td>
<td class="nump">&#165; 12,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 2,348<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ProceedsFromNonRefundableIncentive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from non-refundable incentive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ProceedsFromNonRefundableIncentive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707715147368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - CNY (&#165;)<br> &#165; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Applicable tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Applicable state tax rate</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_WithholdingTax', window );">Withholding Tax</a></td>
<td class="nump">&#165; 12,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=imab_IMobOtherSubsidiariesMember', window );">I MOB other subsidiaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Applicable tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">HONG KONG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Applicable tax rate</a></td>
<td class="nump">16.50%<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">AUSTRALIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Applicable tax rate</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=imab_PRCMember', window );">PRC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss</a></td>
<td class="nump">&#165; 556,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=imab_CNMember', window );">CN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Applicable tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_EffectivePreferentialIncomeTaxRate', window );">Preferential income tax rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_EffectivePreferentialIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective preferential income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_EffectivePreferentialIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_WithholdingTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Withholding Tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_WithholdingTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=imab_IMobOtherSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=imab_IMobOtherSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=imab_PRCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=imab_PRCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=imab_CNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=imab_CNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707715706808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliations of the Differences Between the PRC Statutory Income Tax Rate and the Group's Effective Income Tax Rate (Detail)<br> &#165; / shares in Units, $ / shares in Units, &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;) </div>
<div>&#165; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;) </div>
<div>&#165; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CNY (&#165;) </div>
<div>&#165; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="nump">&#165; 483,146<span></span>
</td>
<td class="nump">$ 74,044<span></span>
</td>
<td class="num">&#165; (1,451,950)<span></span>
</td>
<td class="num">&#165; (401,111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax computed at respective applicable tax rate</a></td>
<td class="nump">66,044<span></span>
</td>
<td class="nump">10,122<span></span>
</td>
<td class="num">(148,871)<span></span>
</td>
<td class="num">(56,093)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="nump">72,256<span></span>
</td>
<td class="nump">11,073<span></span>
</td>
<td class="nump">87,021<span></span>
</td>
<td class="nump">2,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount', window );">Research and development expenses plus deduction</a></td>
<td class="num">(60,776)<span></span>
</td>
<td class="num">(9,314)<span></span>
</td>
<td class="num">(9,254)<span></span>
</td>
<td class="num">(6,762)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="num">(65,293)<span></span>
</td>
<td class="num">(10,007)<span></span>
</td>
<td class="nump">71,104<span></span>
</td>
<td class="nump">62,029<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense</a></td>
<td class="nump">&#165; 12,231<span></span>
</td>
<td class="nump">$ 1,874<span></span>
</td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="nump">&#165; 1,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare', window );">Effect of tax holidays entitled by the PRC subsidiaries on basic income (loss) per share | (per share)</a></td>
<td class="nump">&#165; 0.34<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">&#165; 9.55<span></span>
</td>
<td class="nump">&#165; 3.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation, deductible expense, research and development, amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707703353416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of the Deferred Tax Assets and Liabilities (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">&#165; 107,344<span></span>
</td>
<td class="nump">$ 16,451<span></span>
</td>
<td class="nump">&#165; 136,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 92,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization of property, equipment, software and intangible asset, net</a></td>
<td class="nump">30,417<span></span>
</td>
<td class="nump">4,662<span></span>
</td>
<td class="nump">44,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accrual expense</a></td>
<td class="nump">10,568<span></span>
</td>
<td class="nump">1,620<span></span>
</td>
<td class="nump">21,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(100,204)<span></span>
</td>
<td class="num">(15,358)<span></span>
</td>
<td class="num">(165,497)<span></span>
</td>
<td class="num">$ (25,364)<span></span>
</td>
<td class="num">(94,511)<span></span>
</td>
<td class="num">&#165; (49,541)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">48,125<span></span>
</td>
<td class="nump">7,375<span></span>
</td>
<td class="nump">37,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred Tax Liabilities, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Acquired intangible assets</a></td>
<td class="nump">18,067<span></span>
</td>
<td class="nump">2,768<span></span>
</td>
<td class="nump">37,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_DeferredTaxAssetsContractAssets', window );">Contract assets</a></td>
<td class="nump">30,058<span></span>
</td>
<td class="nump">4,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">48,125<span></span>
</td>
<td class="nump">7,375<span></span>
</td>
<td class="nump">&#165; 37,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 37,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_DeferredTaxAssetsContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets contract assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_DeferredTaxAssetsContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707938687048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Movement of the Valuation Allowance (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance as of January&#160;1</a></td>
<td class="num">&#165; (165,497)<span></span>
</td>
<td class="num">$ (25,364)<span></span>
</td>
<td class="num">&#165; (94,511)<span></span>
</td>
<td class="num">&#165; (49,541)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_DeferredTaxesAdditionsValuationAllowance', window );">Additions</a></td>
<td class="num">(36,061)<span></span>
</td>
<td class="num">(5,527)<span></span>
</td>
<td class="num">(71,104)<span></span>
</td>
<td class="num">(62,029)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_DeferredTaxAssetsValuationAllowanceUtilizationAndReversal', window );">Utilization and reversal of valuation allowances</a></td>
<td class="nump">89,154<span></span>
</td>
<td class="nump">13,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance', window );">Decrease due to the change of tax rate</a></td>
<td class="nump">12,200<span></span>
</td>
<td class="nump">1,870<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">17,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance as of December&#160;31</a></td>
<td class="num">&#165; (100,204)<span></span>
</td>
<td class="num">$ (15,358)<span></span>
</td>
<td class="num">&#165; (165,497)<span></span>
</td>
<td class="num">&#165; (94,511)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_DeferredTaxAssetsValuationAllowanceUtilizationAndReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets valuation allowance utilization and reversal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_DeferredTaxAssetsValuationAllowanceUtilizationAndReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_DeferredTaxesAdditionsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Taxes Additions Valuation Allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_DeferredTaxesAdditionsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Taxes Decrease Due to Change of Tax Rate Valuation Allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707707141848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 10, 2020 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 10, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 17, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jul. 15, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jul. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 29, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each ordinary share is entitled to one vote.<span></span>
</td>
<td class="text">Each ordinary share is entitled to one vote.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 726,300,000<span></span>
</td>
<td class="nump">$ 111,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_AmericanDepositorySharesCommonShareEquivalent', window );">American depository shares, common share equivalent</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Issuance of Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 2,782,455,000<span></span>
</td>
<td class="nump">$ 426,430,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of ordinary shares for restricted share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember', window );">2017 Employee Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated', window );">Shares Held in Employee Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,841,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementWithEverestMember', window );">Collaboration Agreement with Everest [Member] | Everests [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares Issued Upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,078,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_HillhouseEntitiesMember', window );">Hillhouse Entities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_HillhouseEntitiesMember', window );">Hillhouse Entities [Member] | First Closing Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,421,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,744,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_GrossProceedsOfSharesAndWarrants', window );">Gross proceeds of shares and warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 293,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_HillhouseEntitiesMember', window );">Hillhouse Entities [Member] | Second Closing Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Issuance of Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 2,653,669,000,000<span></span>
</td>
<td class="nump">$ 397,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,712,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,597,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_GrossProceedsOfSharesAndWarrants', window );">Gross proceeds of shares and warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementWithInvestorsMember', window );">Collaboration agreement with investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Issuance of Private Placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 418,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_CommonStockValueAuthorized', window );">Common stock value authorized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,227,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,227,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,227,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of preferred shares converted to common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,227,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBMember', window );">Convertible Preferred Stock Series B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,288,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of preferred shares converted to common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,288,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBOneUponConversionMember', window );">Convertible Preferred Stock Series B-1 Upon Conversion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,714,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of preferred shares converted to common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,714,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesB2Member', window );">Convertible Preferred Stock Series B2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,301,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of preferred shares converted to common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,571,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,046,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of preferred shares converted to common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,420,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesCOneConvertiblePreferredStockMember', window );">Series C-1 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,857,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of preferred shares converted to common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,537,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">American Depositary Shares [Member] | Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued, ADS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,341,267<span></span>
</td>
<td class="nump">5,341,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">American Depositary Shares [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued, ADS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,407,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Number of share issued, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">American Depositary Shares [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued, ADS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,133,502<span></span>
</td>
<td class="nump">29,133,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Issuance of Private Placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 418,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">American Depositary Shares [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued, ADS</a></td>
<td class="nump">8,175,750<span></span>
</td>
<td class="nump">8,175,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_CommonStockSharesIssuable', window );">Common Stock Shares Issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">768,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from initial public offering, net</a></td>
<td class="nump">&#165; 697,788,000<span></span>
</td>
<td class="nump">$ 101,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">American Depositary Shares [Member] | Board Of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Amount of stock repurchase | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PrepaidExpenseStockRepurchaseProgram', window );">Prepaid Expensestock repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 34,051<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_AmericanDepositorySharesCommonShareEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>American depository shares common share equivalent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_AmericanDepositorySharesCommonShareEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_CommonStockSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares issuable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_CommonStockSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_CommonStockValueAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock value authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_CommonStockValueAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_GrossProceedsOfSharesAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds of shares and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_GrossProceedsOfSharesAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PrepaidExpenseStockRepurchaseProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expense stock repurchase program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PrepaidExpenseStockRepurchaseProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of allocated shares held by the Employee Stock Option Plan at balance sheet date. Allocated shares are shares that have been assigned to individual participant accounts based on a known formula.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementWithEverestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementWithEverestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_EverestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_EverestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_HillhouseEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_HillhouseEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PeriodTypeAxis=imab_FirstClosingPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PeriodTypeAxis=imab_FirstClosingPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PeriodTypeAxis=imab_SecondClosingPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PeriodTypeAxis=imab_SecondClosingPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementWithInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementWithInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBOneUponConversionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBOneUponConversionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesB2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesB2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesCOneConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesCOneConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=imab_InvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=imab_InvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=imab_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=imab_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707707325080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Shares - Additional Information (Detail)<br> $ / shares in Units, &#165; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">11 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 25, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 06, 2019 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 06, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 17, 2019 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 17, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 06, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jul. 06, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 22, 2017 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 22, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 06, 2017 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 06, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 18, 2016 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 18, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 25, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 25, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jul. 25, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 29, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Consideration in issuance Preference Shares | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 183,536<span></span>
</td>
<td class="nump">&#165; 1,306,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 27,595<span></span>
</td>
<td class="nump">$ 4,229,000<span></span>
</td>
<td class="nump">&#165; 827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_OfferingPriceOfConvertedShares', window );">Offering Price of converted shares | $</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PreferredStockLiquidationPreferencePercentage', window );">Preferred Stock Liquidation Preference Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100.00%)<span></span>
</td>
<td class="num">(100.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PreferredStockLiquidationPreferenceRateOfReturn', window );">Internal Rate of Return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.00%)<span></span>
</td>
<td class="num">(12.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_QualifiedPublicOfferingPrice', window );">Final Offering Price | $ / shares</a></td>
<td class="nump">$ 5.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_QualifiedPublicOfferingPrice', window );">Final Offering Price | $ / shares</a></td>
<td class="nump">$ 4.176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesA1AndA2PreferredStockMember', window );">Series A1 And A2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Consideration in issuance Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 74,742<span></span>
</td>
<td class="nump">$ 11,282,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Issuance of Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,141,587<span></span>
</td>
<td class="nump">5,141,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesA3Member', window );">Convertible Preferred Stock Series A3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_IssueOfWarrants', window );">Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,246,744<span></span>
</td>
<td class="nump">2,246,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesA3PreferredStockMember', window );">Series A3 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Consideration in issuance Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 289,024<span></span>
</td>
<td class="nump">$ 42,645,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Issuance of Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,723,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBMember', window );">Convertible Preferred Stock Series B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_IssueOfWarrants', window );">Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,633,780<span></span>
</td>
<td class="nump">5,633,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Consideration in issuance Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 346,515<span></span>
</td>
<td class="nump">$ 52,546,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Issuance of Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,894,594<span></span>
</td>
<td class="nump">15,894,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesB2Member', window );">Convertible Preferred Stock Series B-2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_IssueOfWarrants', window );">Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,620,842<span></span>
</td>
<td class="nump">2,620,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesAThreeUponExerciseMember', window );">Convertible Preferred Stock Series A Three Upon Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Issuance of Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,361,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBOneUponConversionMember', window );">Convertible Preferred Stock Series B-1 Upon Conversion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Issuance of Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,535,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBTwoUponExerciseMember', window );">Convertible Preferred Stock Series B Two Upon Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Issuance of Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,048,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,253,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBUponExerciseMember', window );">Convertible Preferred Stock Series B Upon Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Issuance of Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,455,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,938,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBOneUponExerciseMember', window );">Convertible Preferred Stock Series B One Upon Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Issuance of Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">947,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.4419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Consideration in issuance Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 1,323,363<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Issuance of Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,046,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock Issuance Costs | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 16,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesCOnePreferredStockMember', window );">Series C One Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5,887<span></span>
</td>
<td class="nump">$ 840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockShareSubscriptions', window );">Subscription of Preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,857,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesSubscribedButUnissuedValue', window );">Aggregate Purchase Price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_AdjustmentsAtExtinguishmentOfPreferredShares', window );">Adjustments At Extinguishment Of Preferred Shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesCOneConvertiblePreferredStockMember', window );">Series C-1 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Consideration in issuance Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 119,387<span></span>
</td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="nump">&#165; 70,036<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Issuance of Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,572<span></span>
</td>
<td class="nump">2,428,572<span></span>
</td>
<td class="nump">1,428,571<span></span>
</td>
<td class="nump">1,428,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_TemporaryEquityMember', window );">Temporary Equity [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Increase in the fair value of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 27,800<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_AdjustmentsAtExtinguishmentOfPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments at extinguishment of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_AdjustmentsAtExtinguishmentOfPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_IssueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_IssueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_OfferingPriceOfConvertedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering Price of converted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_OfferingPriceOfConvertedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PreferredStockLiquidationPreferencePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock liquidation preference percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PreferredStockLiquidationPreferencePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PreferredStockLiquidationPreferenceRateOfReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Internal rate of return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PreferredStockLiquidationPreferenceRateOfReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_QualifiedPublicOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Qualified public offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_QualifiedPublicOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockShareSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of nonredeemable preferred stock (shares) (or preferred stock redeemable solely at the option of the issuer) allocated to investors to buy shares of a new issue of preferred stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockShareSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesSubscribedButUnissuedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription received from investors who have been allocated nonredeemable preferred stock or preferred stock redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesSubscribedButUnissuedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesA1AndA2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesA1AndA2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesA3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesA3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesA3PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesA3PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesB2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesB2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesAThreeUponExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesAThreeUponExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBOneUponConversionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBOneUponConversionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBTwoUponExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBTwoUponExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBUponExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBUponExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBOneUponExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_ConvertiblePreferredStockSeriesBOneUponExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesCOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesCOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesCOneConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesCOneConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_TemporaryEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_TemporaryEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712372696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Shares - Schedule of Convertible Preferred Shares Activities (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Issuance of Series C-1 Preferred Shares, net of issuance costs, Value | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 3,104,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion to ordinary shares upon IPO, value | &#165;</a></td>
<td class="nump">&#165; 3,104,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Opening Balance</a></td>
<td class="nump">&#165; 687,482<span></span>
</td>
<td class="nump">$ 102,852<span></span>
</td>
<td class="nump">&#165; 687,482<span></span>
</td>
<td class="nump">$ 102,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Opening Balance, Shares</a></td>
<td class="nump">30,227,056<span></span>
</td>
<td class="nump">30,227,056<span></span>
</td>
<td class="nump">30,227,056<span></span>
</td>
<td class="nump">30,227,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion to ordinary shares upon IPO, value</a></td>
<td class="num">&#165; (687,482)<span></span>
</td>
<td class="num">$ (102,852)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion to ordinary shares upon IPO, shares</a></td>
<td class="num">(30,227,056)<span></span>
</td>
<td class="num">(30,227,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Closing Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 687,482<span></span>
</td>
<td class="nump">$ 102,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Closing Balance, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,227,056<span></span>
</td>
<td class="nump">30,227,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Opening Balance</a></td>
<td class="nump">&#165; 921,243<span></span>
</td>
<td class="nump">$ 139,407<span></span>
</td>
<td class="nump">&#165; 921,243<span></span>
</td>
<td class="nump">$ 139,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Opening Balance, Shares</a></td>
<td class="nump">30,305,212<span></span>
</td>
<td class="nump">30,305,212<span></span>
</td>
<td class="nump">30,305,212<span></span>
</td>
<td class="nump">30,305,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion to ordinary shares upon IPO, value</a></td>
<td class="num">&#165; (921,243)<span></span>
</td>
<td class="num">$ (139,407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion to ordinary shares upon IPO, shares</a></td>
<td class="num">(30,305,212)<span></span>
</td>
<td class="num">(30,305,212)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Closing Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 921,243<span></span>
</td>
<td class="nump">$ 139,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Closing Balance, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,305,212<span></span>
</td>
<td class="nump">30,305,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Opening Balance</a></td>
<td class="nump">&#165; 1,306,633<span></span>
</td>
<td class="nump">$ 197,478<span></span>
</td>
<td class="nump">&#165; 1,306,633<span></span>
</td>
<td class="nump">$ 197,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Opening Balance, Shares</a></td>
<td class="nump">31,046,360<span></span>
</td>
<td class="nump">31,046,360<span></span>
</td>
<td class="nump">31,046,360<span></span>
</td>
<td class="nump">31,046,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion to ordinary shares upon IPO, value</a></td>
<td class="num">&#165; (1,306,633)<span></span>
</td>
<td class="num">$ (197,478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion to ordinary shares upon IPO, shares</a></td>
<td class="num">(31,046,360)<span></span>
</td>
<td class="num">(31,046,360)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Closing Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 1,306,633<span></span>
</td>
<td class="nump">$ 197,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Closing Balance, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,046,360<span></span>
</td>
<td class="nump">31,046,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesC1ConvertiblePreferredStockMember', window );">Series C-1 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Opening Balance</a></td>
<td class="nump">&#165; 188,819<span></span>
</td>
<td class="nump">$ 26,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Opening Balance, Shares</a></td>
<td class="nump">3,857,143<span></span>
</td>
<td class="nump">3,857,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Issuance of Series C-1 Preferred Shares, net of issuance costs, Shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,857,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,857,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Issuance of Series C-1 Preferred Shares, net of issuance costs, Value | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 188,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion to ordinary shares upon IPO, value</a></td>
<td class="num">&#165; (188,819)<span></span>
</td>
<td class="num">$ (26,914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion to ordinary shares upon IPO, shares</a></td>
<td class="num">(3,857,143)<span></span>
</td>
<td class="num">(3,857,143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Closing Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 188,819<span></span>
</td>
<td class="nump">$ 26,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Closing Balance, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,857,143<span></span>
</td>
<td class="nump">3,857,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesC1ConvertiblePreferredStockMember', window );">Series C-1 Convertible Preferred Stock [Member] | Series C -1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Issuance of Series C-1 Preferred Shares, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,857,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,857,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Issuance of Series C-1 Preferred Shares, net of issuance costs, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 183,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_AdjustmentsAtExtinguishmentOfPreferredShares', window );">Adjustment at extinguishment of Series&#160;C-1&#160;Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5,283<span></span>
</td>
<td class="nump">$ 754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Closing Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_AdjustmentsAtExtinguishmentOfPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments at extinguishment of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_AdjustmentsAtExtinguishmentOfPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesC1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesC1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=imab_SeriescOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=imab_SeriescOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712201800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Promissory Notes And Onshore Convertible Loans- Additional Information (Detail)<br> $ / shares in Units, &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 29, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 03, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 25, 2017 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 17, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 03, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 25, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imab_SeriesB1PreferredSharesMember', window );">Series B-1 Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=imab_TwoZeroOneEightNotesMember', window );">2018 Notes [Member] | Genexine Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=imab_TwoZeroOneEightNotesMember', window );">2018 Notes [Member] | Series A-3 Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Convertible promissory notes&#160; issued to Investors | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 59,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=imab_OnshoreConvertibleLoanMember', window );">Onshore Convertible Loan [Member] | Series B-1 Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion number of share issue | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,179,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=imab_OnshoreConvertibleLoanMember', window );">Onshore Convertible Loan [Member] | Series B Onshore Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on Extinguishment of Debt | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 8,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity period of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes&#160;issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=imab_ConvertiblePromissoryNotes2017Member', window );">Convertible Promissory Notes 2017 [Member] | Series B-1 Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price of debt instrument</a></td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion number of share issue | shares</a></td>
<td class="nump">2,535,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=imab_ConvertiblePromissoryNotes2017Member', window );">Convertible Promissory Notes 2017 [Member] | Series B Preferred Stock Holder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity period of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes&#160;issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=imab_ConvertiblePromissoryNotes2018Member', window );">Convertible Promissory Notes 2018 [Member] | Series B-1 Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=imab_ConvertiblePromissoryNotes2018Member', window );">Convertible Promissory Notes 2018 [Member] | Series A-3 Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity period of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes&#160;issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesB1PreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesB1PreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=imab_TwoZeroOneEightNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=imab_TwoZeroOneEightNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_GenexineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_GenexineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesA3PreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesA3PreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=imab_OnshoreConvertibleLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=imab_OnshoreConvertibleLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesBOnshoreInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesBOnshoreInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=imab_ConvertiblePromissoryNotes2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=imab_ConvertiblePromissoryNotes2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imab_SeriesBPreferredStockHolderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imab_SeriesBPreferredStockHolderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=imab_ConvertiblePromissoryNotes2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=imab_ConvertiblePromissoryNotes2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707715083304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Additional Information (Detail)<br> $ / shares in Units, &#165; in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 06, 2018 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 06, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 25, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 22, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 29, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Value of outstanding securities | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 132,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value gain of warrants for the year | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#165; (5,644)<span></span>
</td>
<td class="num">(61,405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 2,782,455<span></span>
</td>
<td class="nump">$ 426,430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementWithInvestorsMember', window );">Collaboration agreement with investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_HillhouseEntitiesMember', window );">Hillhouse Entities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=imab_SeriesBPreferredShareholdersMember', window );">Series B Preferred Shareholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued, ADS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,633,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=imab_SeriesBOnshoreInvestorsMember', window );">Series B Onshore Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued, ADS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,620,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=imab_TrancheIOfSeriesBWarrantsMember', window );">Tranche I Of Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Value of outstanding securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued and exercised</a></td>
<td class="nump">3,301,849<span></span>
</td>
<td class="nump">3,301,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=imab_SeriesB2PreferredSharesMember', window );">Series B2 Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued, ADS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,301,849<span></span>
</td>
<td class="nump">3,301,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Value of outstanding securities</a></td>
<td class="nump">&#165; 132,332<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued and exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,301,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=imab_TrancheIiOfSeriesBWarrantsMember', window );">Tranche II of Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Value of outstanding securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=imab_SeriesBWarrantsSharesMember', window );">Series B Warrants Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued and exercised</a></td>
<td class="nump">4,952,773<span></span>
</td>
<td class="nump">4,952,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value gain of warrants for the year | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=imab_AmericanDepositarySharesMember', window );">American Depositary Shares [Member] | Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued, ADS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,341,267<span></span>
</td>
<td class="nump">5,341,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementWithInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementWithInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_HillhouseEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_HillhouseEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=imab_SeriesBPreferredShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=imab_SeriesBPreferredShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=imab_SeriesBOnshoreInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=imab_SeriesBOnshoreInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=imab_TrancheIOfSeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=imab_TrancheIOfSeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=imab_SeriesB2PreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=imab_SeriesB2PreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=imab_TrancheIiOfSeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=imab_TrancheIiOfSeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=imab_SeriesBWarrantsSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=imab_SeriesBWarrantsSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=imab_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=imab_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=imab_InvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=imab_InvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707803349704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - Details of accounting for warrants to purchase ordinary shares (Detail) - Warrants to purchase ordinary shares [Member]<br> &#165; in Thousands</strong></div></th>
<th class="th">
<div>Dec. 17, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 11, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 17, 2020 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 11, 2020 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_Classofwarrantorrightsexercisableterm', window );">Class Of Warrant or Rights Exercisable Term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 19.57<span></span>
</td>
<td class="nump">$ 19.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,597,235<span></span>
</td>
<td class="nump">3,744,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 37,869<span></span>
</td>
<td class="nump">&#165; 71,874<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_Classofwarrantorrightsexercisableterm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ClassOfWarrantOrRightsExercisableTerm</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_Classofwarrantorrightsexercisableterm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=imab_WarrantsToPurchaseOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=imab_WarrantsToPurchaseOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707713437256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - Summary of fair value of warrant liabilities (Detail)<br></strong></div></th>
<th class="th"><div>Dec. 17, 2020</div></th>
<th class="th"><div>Sep. 11, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free rate of return [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">0.08<span></span>
</td>
<td class="nump">0.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputMaturityMember', window );">Maturity date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">Dec. 17,  2021<span></span>
</td>
<td class="text">Sep. 11,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Estimated volatility rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">59.56<span></span>
</td>
<td class="nump">60.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Exercise price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">19.57<span></span>
</td>
<td class="nump">19.57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputMaturityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputMaturityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707622190568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Detail)<br> $ / shares in Units, &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="8">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 17, 2020 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th">
<div>Feb. 22, 2019 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 22, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 15, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 29, 2019 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 526,171<span></span>
</td>
<td class="nump">$ 80,640<span></span>
</td>
<td class="nump">&#165; 515,203<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">&#165; 3,520<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Estimated fair value of Company's ordinary shares | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,051<span></span>
</td>
<td class="nump">91,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=imab_ThirdVentureMember', window );">Third Venture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 209,033<span></span>
</td>
<td class="nump">$ 32,036<span></span>
</td>
<td class="nump">514,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,431<span></span>
</td>
<td class="nump">43,591<span></span>
</td>
<td class="nump">470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=imab_EquityInLossOfAnAffiliateMember', window );">Equity in Loss of an Affiliate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,707<span></span>
</td>
<td class="nump">5,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=imab_FoundersMember', window );">Founders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,019,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice', window );">Stock options, repurchased during the period, average price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration', window );">Stock options, repurchased during the period, total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 148,308<span></span>
</td>
<td class="nump">$ 21,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share based payment award, maximum shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,686,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Share based compensation by share based payment arrangement restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">558,200<span></span>
</td>
<td class="nump">558,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 1,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member] | Tranche One [Member] | Third One Third Portion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based payment award, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member] | Tranche Two [Member] | Third One Third Portion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based payment award, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member] | Tranche Three [Member] | Third One Third Portion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based payment award, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member] | Tranche Four [Member] | Third One Third Portion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based payment award, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member] | One Performance Condition [Member] | Third One Third Portion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based payment award, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member] | Two Performance Conditions [Member] | Third One Third Portion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based payment award, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member] | Three Performance Conditions [Member] | Third One Third Portion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based payment award, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member] | Four Performance Conditions [Member] | Third One Third Portion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based payment award, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member] | Founders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 18,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,650,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of shares cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,932,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted', window );">Ordinary shares held, restriction percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based payment award, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member] | Founders [Member] | Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based payment award, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member] | Founders [Member] | Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based payment award, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member] | Founders [Member] | Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based payment award, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Share based payment award, stock options surrendered, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Director[Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 148,308<span></span>
</td>
<td class="nump">$ 21,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Lei Fang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share based payment award, stock options surrendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=imab_TwentyNineteenShareIncentivePlanMember', window );">2019 Share Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share based payment award, maximum shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share based payment award, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Stock Option, Exercise Price, Increase | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Share based compensation arrangement, shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565,200<span></span>
</td>
<td class="nump">565,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember', window );">2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,609,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share based payment award, maximum shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,609,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,376,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Share based payment award, stock options surrendered, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share based payment award, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
<td class="nump">1,470,000<span></span>
</td>
<td class="nump">1,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share based payment award, stock options granted exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased', window );">Stock options, repurchased during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,435,215<span></span>
</td>
<td class="nump">3,435,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice', window );">Stock options, repurchased during the period, average price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,790,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,439,373<span></span>
</td>
<td class="nump">1,439,373<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of shares unvested</a></td>
<td class="nump">332,566<span></span>
</td>
<td class="nump">332,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,876<span></span>
</td>
<td class="nump">338,876<span></span>
</td>
<td class="nump">397,500<span></span>
</td>
<td class="nump">397,500<span></span>
</td>
<td class="nump">226,000<span></span>
</td>
<td class="nump">226,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember', window );">2017 Plan [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 52,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember', window );">2017 Plan [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember', window );">2017 Plan [Member] | Equity in Loss of an Affiliate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 4,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember', window );">2017 Plan [Member] | Senior Management Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of shares unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember', window );">2017 Plan [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based payment award, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share based payment award, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
<td class="nump">1,470,000<span></span>
</td>
<td class="nump">1,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share based payment award, stock options granted exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of shares unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,876<span></span>
</td>
<td class="nump">338,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Share based compensation arrangement, shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,790,924<span></span>
</td>
<td class="nump">6,790,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember', window );">2017 Plan [Member] | Employee Stock Option [Member] | Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based payment award, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember', window );">2017 Plan [Member] | Employee Stock Option [Member] | Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based payment award, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 91,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,005,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share based payment award, maximum shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,005,745<span></span>
</td>
<td class="nump">14,005,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,452,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share based payment award, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,991,528<span></span>
</td>
<td class="nump">13,991,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share based payment award, stock options granted exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased', window );">Stock options, repurchased during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,940<span></span>
</td>
<td class="nump">454,940<span></span>
</td>
<td class="nump">454,940<span></span>
</td>
<td class="nump">454,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice', window );">Stock options, repurchased during the period, average price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,764,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,000<span></span>
</td>
<td class="nump">402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 48,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 365,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member] | Equity in Loss of an Affiliate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member] | Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based payment award, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member] | Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based payment award, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member] | Dr. Zang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share based payment award, stock options granted exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member] | Director[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share Options, Vested And Exercisable Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,893,028<span></span>
</td>
<td class="nump">10,893,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member] | Senior Management Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of shares unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,544,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member] | Restricted Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">762,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share based payment award, stock options granted exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Share based compensation arrangement, shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,871,500<span></span>
</td>
<td class="nump">1,871,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member] | Employee Stock Option [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 25,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member] | Employee Stock Option [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member] | Employee Stock Option [Member] | Equity in Loss of an Affiliate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 19,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_AmendedTwentySeventeenEmployeeStockOptionPlanMember', window );">Amended 2017 Plan [Member] | Director[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased', window );">Stock options, repurchased during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,435,215<span></span>
</td>
<td class="nump">3,435,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share Options, Vested And Exercisable Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,435,215<span></span>
</td>
<td class="nump">3,435,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember', window );">2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based payment award, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share based payment award, maximum shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,760,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share based payment award, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,068,733<span></span>
</td>
<td class="nump">1,068,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,446,875<span></span>
</td>
<td class="nump">1,446,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember', window );">2020 Plan [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 4,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember', window );">2020 Plan [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember', window );">2020 Plan [Member] | Equity in Loss of an Affiliate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 1,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember', window );">2020 Plan [Member] | Restricted Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,093,079<span></span>
</td>
<td class="nump">4,093,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember', window );">2020 Plan [Member] | Restricted Shares [Member] | Third One Third Portion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares', window );">Number of days for calculating the weighted average market value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Share based comensation equity instruments other than options aggregate fair value vested in period | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember', window );">2020 Plan [Member] | Restricted Shares [Member] | Second One Third Portion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares', window );">Number of days for calculating the weighted average market value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares', window );">Maximum Percentage Reduction In The Weighted Average Market Value Of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember', window );">2020 Plan [Member] | Restricted Shares [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 76,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember', window );">2020 Plan [Member] | Restricted Shares [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember', window );">2020 Plan [Member] | Restricted Shares [Member] | Equity in Loss of an Affiliate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember', window );">2020 Plan [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based payment award, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Share based compensation by share based payment arrangement restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,328,120<span></span>
</td>
<td class="nump">1,328,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_ShareIncentivePlan2020Member', window );">2020 Plan [Member] | Restricted Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Share based compensation by share based payment arrangement restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,093,079<span></span>
</td>
<td class="nump">4,093,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Percentage Reduction In The Weighted Average Market Value Of Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days for calculating the weighted average market value of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Non vested Options Repurchased Total Consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options nonvested options repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation by share based payments award percentage of shares restricted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangements by Share-based Payment Award, Options, Repurchased in Period, Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=imab_ThirdVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=imab_ThirdVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=imab_EquityInLossOfAnAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=imab_EquityInLossOfAnAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=imab_FoundersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=imab_FoundersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PortionOfRestrictedShareUnitsAxis=imab_ThirdOneThirdPortionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PortionOfRestrictedShareUnitsAxis=imab_ThirdOneThirdPortionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=imab_ShareBasedCompensationTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=imab_ShareBasedCompensationTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=imab_OnePerformanceConditionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=imab_OnePerformanceConditionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=imab_TwoPerformanceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=imab_TwoPerformanceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=imab_ThreePerformanceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=imab_ThreePerformanceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=imab_FourPerformanceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=imab_FourPerformanceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=imab_LeiFangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=imab_LeiFangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=imab_TwentyNineteenShareIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=imab_TwentyNineteenShareIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=imab_SeniorManagementEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=imab_SeniorManagementEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=imab_DrzangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=imab_DrzangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_AmendedTwentySeventeenEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_AmendedTwentySeventeenEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PortionOfRestrictedShareUnitsAxis=imab_SecondOneThirdPortionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PortionOfRestrictedShareUnitsAxis=imab_SecondOneThirdPortionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_ShareIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_ShareIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707711282536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share-Based Compensation Expenses Related to Restricted Shares (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses related to restricted shares</a></td>
<td class="nump">&#165; 526,171<span></span>
</td>
<td class="nump">$ 80,640<span></span>
</td>
<td class="nump">&#165; 515,203<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">&#165; 3,520<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses related to restricted shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses related to restricted shares</a></td>
<td class="nump">284,431<span></span>
</td>
<td class="nump">43,591<span></span>
</td>
<td class="nump">470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Restricted Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses related to restricted shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses related to restricted shares</a></td>
<td class="nump">209,033<span></span>
</td>
<td class="nump">32,036<span></span>
</td>
<td class="nump">514,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Restricted Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses related to restricted shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">&#165; 1,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 2,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=imab_EquityInLossOfAnAffiliateMember', window );">Equity in Loss of an Affiliate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses related to restricted shares</a></td>
<td class="nump">&#165; 32,707<span></span>
</td>
<td class="nump">$ 5,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=imab_EquityInLossOfAnAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=imab_EquityInLossOfAnAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707711498088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Stock Option Activities (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Jan. 17, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember', window );">2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Numbers of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,812,881<span></span>
</td>
<td class="nump">13,005,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,761,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
<td class="nump">1,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited</a></td>
<td class="num">(332,566)<span></span>
</td>
<td class="num">(332,566)<span></span>
</td>
<td class="num">(338,876)<span></span>
</td>
<td class="num">(397,500)<span></span>
</td>
<td class="num">(226,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased', window );">Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,435,215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,439,373)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod', window );">Surrendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(332,566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,702,066<span></span>
</td>
<td class="nump">9,812,881<span></span>
</td>
<td class="nump">13,005,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable as of December&#160;31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,790,924<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.93<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice', window );">Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice', window );">Surrendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="nump">$ 0.93<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable as of December&#160;31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months<span></span>
</td>
<td class="text">7 years 9 months 3 days<span></span>
</td>
<td class="text">8 years 7 months 9 days<span></span>
</td>
<td class="text">9 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,415<span></span>
</td>
<td class="nump">$ 47,671<span></span>
</td>
<td class="nump">$ 70,129<span></span>
</td>
<td class="nump">$ 24,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Numbers of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,536,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,991,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased', window );">Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(454,940)<span></span>
</td>
<td class="num">(454,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(402,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod', window );">Surrendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,544,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,589,671<span></span>
</td>
<td class="nump">13,536,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable as of December&#160;31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,764,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice', window );">Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice', window );">Surrendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable as of December&#160;31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 24 days<span></span>
</td>
<td class="text">8 years 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206,499<span></span>
</td>
<td class="nump">$ 64,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyNineteenEmployeeStockOptionPlanMember', window );">2019 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Numbers of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_ShareIncentivePlanTwoThousandTwentyMember', window );">2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Numbers of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,068,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,365)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,044,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 7 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options nonvested options repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangements by Share-based Payment Award, Options, Repurchased in Period, Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsSurrendersInPeriodWeightedAverageExercisePrice</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_TwentyNineteenEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_TwentyNineteenEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_ShareIncentivePlanTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_ShareIncentivePlanTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707710978632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Valuation Assumptions Used (Detail)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">55.20%<span></span>
</td>
<td class="nump">55.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual term (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.31%<span></span>
</td>
<td class="nump">62.13%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.64%<span></span>
</td>
<td class="nump">61.32%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (per annum)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="nump">3.06%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.15%<span></span>
</td>
<td class="nump">2.81%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple', window );">Exercise multiple</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80<span></span>
</td>
<td class="nump">2.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyNineteenEmployeeStockOptionPlanMember', window );">2019 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (per annum)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.79%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple', window );">Exercise multiple</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_ShareIncentivePlanTwoThousandTwentyMember', window );">2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.51%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (per annum)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.86%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum', window );">Exercise multiple, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum', window );">Exercise multiple, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions exercise multiple maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions exercise multiple minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, fair value assumptions, exercise multiple.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_TwentyNineteenEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_TwentyNineteenEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_ShareIncentivePlanTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_ShareIncentivePlanTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707803487304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of non-vested stock option activities (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Jan. 17, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember', window );">2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Numbers of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,812,881<span></span>
</td>
<td class="nump">13,005,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
<td class="nump">1,470,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited</a></td>
<td class="num">(332,566)<span></span>
</td>
<td class="num">(332,566)<span></span>
</td>
<td class="num">(338,876)<span></span>
</td>
<td class="num">(397,500)<span></span>
</td>
<td class="num">(226,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,702,066<span></span>
</td>
<td class="nump">9,812,881<span></span>
</td>
<td class="nump">13,005,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember', window );">2017 Plan [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Numbers of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,812,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
<td class="nump">1,470,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,790,924)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,439,373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(338,876)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares', window );">Surrendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(332,566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">911,142<span></span>
</td>
<td class="nump">9,812,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted average Grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue', window );">Surrendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.96<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Numbers of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,536,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,991,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,589,671<span></span>
</td>
<td class="nump">13,536,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Numbers of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,098,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,871,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(402,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="nump">3,098,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted average Grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.57<span></span>
</td>
<td class="nump">$ 5.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyNineteenEmployeeStockOptionPlanMember', window );">2019 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Numbers of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted average Grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_ShareIncentivePlanTwoThousandTwentyMember', window );">2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Numbers of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,068,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,365)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,044,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted average Grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based payment award options non vested options exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsSurrendedNumberOfShares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationByShareBasedPaymentArrangementNonVestedOptionsExercisesInPeriodWeightedAverageGrantDateFairValue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_TwentySeventeenEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_TwentyNineteenEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_TwentyNineteenEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_ShareIncentivePlanTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_ShareIncentivePlanTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707806764984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation -Schedule of Nonvested Restricted Stock Units Activity (Detail) - Restricted Stock [Member] - 2020 Plan [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems', window );"><strong>Schedule Of Nonvested Restricted Stock Units Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">1,328,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(565,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Numbers of shares, Outstanding | shares</a></td>
<td class="nump">762,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">$ 13.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares</a></td>
<td class="nump">13.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Outstanding | $ / shares</a></td>
<td class="nump">$ 12.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">4,093,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(13,461)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Numbers of shares, Outstanding | shares</a></td>
<td class="nump">4,079,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">$ 13.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited | $ / shares</a></td>
<td class="nump">11.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Outstanding | $ / shares</a></td>
<td class="nump">$ 14.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_ShareIncentivePlanTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_ShareIncentivePlanTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_TwentyTwentyEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707703692872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Schedule of Share-based Payment Arrangement Restricted Stock Unit Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember', window );">2018 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imab_ShareIncentivePlanTwoThousandTwentyMember', window );">2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">5.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding</a></td>
<td class="nump">$ 5.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member] | 2018 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Numbers of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted</a></td>
<td class="nump">1,328,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(565,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Numbers of shares, Outstanding</a></td>
<td class="nump">762,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested</a></td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term, Outstanding</a></td>
<td class="text">9 years 7 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">$ 14,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member] | 2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Numbers of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted</a></td>
<td class="nump">4,093,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Forfeited</a></td>
<td class="num">(13,461)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(565,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Numbers of shares, Outstanding</a></td>
<td class="nump">4,079,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested</a></td>
<td class="nump">$ 13.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term, Outstanding</a></td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">$ 83,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_TwentyEighteenEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imab_ShareIncentivePlanTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imab_ShareIncentivePlanTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707616836936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing And Collaboration Agreements - Additional Information (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="9">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th">
<div>Nov. 17, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 17, 2017 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2010 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 04, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 04, 2019 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,910<span></span>
</td>
<td class="nump">&#165; 984,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 840,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 426,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 43,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Issue of shares, Value</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issue of shares | shares</a></td>
<td class="nump">164,888,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,888,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,363,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,888,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Milestone revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 236,424<span></span>
</td>
<td class="nump">1,542,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=imab_ABLBioMember', window );">ABL Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=imab_GenexineIncMember', window );">Genexine Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember', window );">Licensing Agreement With CSPC Pharmaceutical Group Limited [Member] | CSPC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_UpfrontLicenseFee', window );">Upfront License Fee | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestone payments | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Advance from customers | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from milestone achievement | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 15,000<span></span>
</td>
<td class="nump">&#165; 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Milestone revenue recognized | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithABLBioMember', window );">Licensing Agreement With ABL Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Milestone revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">17,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithABLBioMember', window );">Licensing Agreement With ABL Bio [Member] | ABL Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestone payments | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 690,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithABLBioMember', window );">Licensing Agreement With ABL Bio [Member] | ABL Bio [Member] | Clinical Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="nump">230,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithABLBioMember', window );">Licensing Agreement With ABL Bio [Member] | ABL Bio [Member] | Sales Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">&#165; 460,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementWithABLBioMember', window );">Collaboration Agreement With ABL Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_CostSharingRatio', window );">Cost sharing ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementWithABLBioMember', window );">Collaboration Agreement With ABL Bio [Member] | ABL Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMorphosysAgMember', window );">Licensing Agreement with MorphoSys AG [Member] | MorphoSysAG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">&#165; 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMorphosysAgMember', window );">Licensing Agreement with MorphoSys AG [Member] | MorphoSys [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_UpfrontLicenseFee', window );">Upfront License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">&#165; 132,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,500<span></span>
</td>
<td class="nump">&#165; 653,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithGenexineIncMember', window );">Licensing Agreement with Genexine Inc [Member] | Genexine Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PercentageOfReductionInMilestonePayments', window );">Reduction in milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Long-term Purchase Commitment, Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMacrogenicsMember', window );">Licensing Agreement with MacroGenics [Member] | MacroGenics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementRightsAndObligations', window );">Licensing&#160;Arrangements, Description of terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Group is responsible for all development costs in Greater China. MacroGenics is responsible for all development costs in the rest of the world, except that the Group is responsible for 20% of the costs incurred in (i) activities supporting global clinical trials in which the Group participates, (ii) certain CMC activities for material intended to be used in clinical trials in Greater China, and (iii) companion diagnostic development and validation for indications being studied in Greater China.<span></span>
</td>
<td class="text">The Group is responsible for all development costs in Greater China. MacroGenics is responsible for all development costs in the rest of the world, except that the Group is responsible for 20% of the costs incurred in (i) activities supporting global clinical trials in which the Group participates, (ii) certain CMC activities for material intended to be used in clinical trials in Greater China, and (iii) companion diagnostic development and validation for indications being studied in Greater China.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_OtherinlicensingarrangementsMember', window );">Other&#160;In-Licensing&#160;Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_UpfrontLicenseFee', window );">Upfront License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestone payments</a></td>
<td class="nump">$ 107,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">&#165; 21,300<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">&#165; 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePaymentsOutstanding', window );">Milestone payments due | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember', window );">Licensing Agreement among HDYM, I-Mab and Hangzhou HealSun Biopharm Co., Ltd [Member] | HealSun [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative arrangement, excluding assessed tax | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 36,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from milestone achievement | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePaymentsIncome', window );">Milestone payments income | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_DeferredRevenueFromCollaborativeArrangementExcludingVat', window );">Deferred revenue from collaborative arrangement excluding VAT | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 15,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent', window );">Cost-to-cost&#160;input method percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember', window );">Licensing Agreement among HDYM, I-Mab and Hangzhou HealSun Biopharm Co., Ltd [Member] | HealSun [Member] | Deferred Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExciseAndSalesTaxes', window );">Excise and Sales Taxes | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Genexine Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Licensing Agreement with MorphoSys AG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Licensing Agreement with MorphoSys AG [Member] | MorphoSys [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_UpfrontLicenseFee', window );">Upfront License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">132,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">55,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Licensing Agreement with Genexine Inc [Member] | Genexine Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_UpfrontLicenseFee', window );">Upfront License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">79,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Licensing Agreements With Morphosys [Member] | MorphoSys [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_UpfrontLicenseFee', window );">Upfront License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">&#165; 23,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Licensing Agreement with MacroGenics [Member] | MacroGenics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_UpfrontLicenseFee', window );">Upfront License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating Expense [Member] | Licensing Agreement With ABL Bio [Member] | ABL Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">&#165; 140<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">&#165; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_CostSharingRatio', window );">Cost sharing ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating Expense [Member] | Collaboration Agreement With ABL Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 9,600<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating Expense [Member] | Collaboration Agreements with Tracon Pharmaceuticals Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">&#165; 170<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">27,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating Expense [Member] | Licensing Agreement among HDYM, I-Mab and Hangzhou HealSun Biopharm Co., Ltd [Member] | HealSun [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExciseAndSalesTaxes', window );">Excise and Sales Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_OtherInLicensingAgreementsMember', window );">Other In Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_UpfrontLicenseFee', window );">Upfront License Fee | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_MorphoSysAGMember', window );">MorphoSysAG [Member] | Research and Development Expense [Member] | Licensing Agreement with MorphoSys AG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_UpfrontLicenseFee', window );">Upfront License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_GenexineIncMember', window );">Genexine Inc [Member] | Licensing Agreement with Genexine Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,000<span></span>
</td>
<td class="nump">&#165; 3,482,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_GenexineIncMember', window );">Genexine Inc [Member] | Licensing Agreement with Genexine Inc [Member] | GXI7 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_GenexineIncMember', window );">Genexine Inc [Member] | Strategic Alliance Agreement with PT Kalbe Genexine Biologics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_UpfrontAndMilestonePayments', window );">Potential value of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_GenexineIncMember', window );">Genexine Inc [Member] | Strategic Alliance Agreement with PT Kalbe Genexine Biologics [Member] | Study 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent', window );">Cost-to-cost&#160;input method percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax', window );">Deferred Liability from Collabarative Arrangement excluding Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_GenexineIncMember', window );">Genexine Inc [Member] | Strategic Alliance Agreement with PT Kalbe Genexine Biologics [Member] | Study 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent', window );">Cost-to-cost&#160;input method percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax', window );">Deferred Liability from Collabarative Arrangement excluding Tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_GenexineIncMember', window );">Genexine Inc [Member] | Research and Development Expense [Member] | Licensing Agreement with Genexine Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">&#165; 152,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_MacroGenicsMember', window );">MacroGenics [Member] | Licensing Agreement with Genexine Inc [Member] | Development Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_MacroGenicsMember', window );">MacroGenics [Member] | Licensing Agreements [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_UpfrontLicenseFee', window );">Upfront License Fee | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_MacroGenicsMember', window );">MacroGenics [Member] | Licensing Agreements [Member] | Research and Development Expense [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_HealSunMember', window );">HealSun [Member] | Licensing Agreement among HDYM, I-Mab and Hangzhou HealSun Biopharm Co., Ltd [Member] | Milestone III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from milestone achievement | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_HealSunMember', window );">HealSun [Member] | Licensing Agreement among HDYM, I-Mab and Hangzhou HealSun Biopharm Co., Ltd [Member] | Milestone Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from milestone achievement | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_EverestMember', window );">Everest [Member] | Collaboration Agreement with Everest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
<td class="nump">53,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,078,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_EverestMember', window );">Everest [Member] | Out Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms', window );">Description of Payment Terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under the agreement, the Group is primarily responsible for carrying out the development, manufacture and supply of the CD38 product, as well as seeking regulatory approval of the CD38 product. Everest is primarily responsible for sharing the development costs of the CD38 product, including payments due to MorphoSys under the Licensing Agreement, dated November 30, 2017, in the proportion of 75% by Everest and 25% by the Group.<span></span>
</td>
<td class="text">Under the agreement, the Group is primarily responsible for carrying out the development, manufacture and supply of the CD38 product, as well as seeking regulatory approval of the CD38 product. Everest is primarily responsible for sharing the development costs of the CD38 product, including payments due to MorphoSys under the Licensing Agreement, dated November 30, 2017, in the proportion of 75% by Everest and 25% by the Group.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Sharing the profit and loss</a></td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">&#165; 178,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Issue of shares, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issue of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,762,751<span></span>
</td>
<td class="nump">4,762,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_CumulativePaidInContributions', window );">Cumulative Paid In Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_TimeCostOfForegoingHistoricalContribution', window );">Time cost of foregoing historical contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">&#165; 23,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_ABLBioMember', window );">ABL Bio [Member] | Licensing Agreement With ABL Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Milestone revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">&#165; 17,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_ABLBioMember', window );">ABL Bio [Member] | Research and Development Expense [Member] | Licensing Agreement With ABL Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">&#165; 280<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">&#165; 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_AbbVieMember', window );">AbbVie [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_UpfrontLicenseFee', window );">Upfront License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_RevenueFromContractWithCustomerTimeOfTransferOfLicense', window );">Revenue from contract with customer at time of transfer of license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,800<span></span>
</td>
<td class="nump">1,502,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract asset with customer</a></td>
<td class="nump">$ 34,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_AbbVieMember', window );">AbbVie [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePaymentReceivable', window );">Milestone Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_AbbVieMember', window );">AbbVie [Member] | Study 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative arrangement, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_AbbVieMember', window );">AbbVie [Member] | Study 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative arrangement, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">&#165; 27,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_AbbVieMember', window );">AbbVie [Member] | Clinical Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_AbbVieMember', window );">AbbVie [Member] | Lemzoparlimab License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_UpfrontLicenseFee', window );">Upfront License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_UpfrontAndMilestonePayments', window );">Potential value of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_AbbVieMember', window );">AbbVie [Member] | Lemzoparlimab License [Member] | First Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_AbbVieMember', window );">AbbVie [Member] | Lemzoparlimab License [Member] | Second Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability cumulative cost to cost input method percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_CostSharingRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost sharing ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_CostSharingRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_CumulativePaidInContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative paid in contributions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_CumulativePaidInContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred liability from collaborative arrangement excluding tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_DeferredRevenueFromCollaborativeArrangementExcludingVat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue From Collaborative Arrangement Excluding VAT.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_DeferredRevenueFromCollaborativeArrangementExcludingVat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_MilestonePaymentsIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_MilestonePaymentsIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_MilestonePaymentsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_MilestonePaymentsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PercentageOfReductionInMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Reduction In Milestone Payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PercentageOfReductionInMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_RevenueFromContractWithCustomerTimeOfTransferOfLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from contract with customer at time of transfer of license</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_RevenueFromContractWithCustomerTimeOfTransferOfLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_TimeCostOfForegoingHistoricalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Time cost of foregoing historical contribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_TimeCostOfForegoingHistoricalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_UpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_UpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_UpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_UpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementRightsAndObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of rights and obligations under the collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementRightsAndObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExciseAndSalesTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of excise and sales taxes included in sales and revenues, which are then deducted as a cost of sales. Includes excise taxes, which are applied to specific types of transactions or items (such as gasoline or alcohol); and sales, use and value added taxes, which are applied to a broad class of revenue-producing transactions involving a wide range of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExciseAndSalesTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118644919&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=imab_ABLBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=imab_ABLBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=imab_GenexineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=imab_GenexineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=imab_CspcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=imab_CspcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithABLBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithABLBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_MilestoneTypeAxis=imab_ClinicalMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_MilestoneTypeAxis=imab_ClinicalMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_MilestoneTypeAxis=imab_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_MilestoneTypeAxis=imab_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementWithABLBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementWithABLBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMorphosysAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMorphosysAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=imab_MorphoSysAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=imab_MorphoSysAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=imab_MorphosysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=imab_MorphosysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithGenexineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithGenexineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMacrogenicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMacrogenicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=imab_MacroGenicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=imab_MacroGenicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_OtherinlicensingarrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_OtherinlicensingarrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=imab_HealSunMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=imab_HealSunMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=imab_DeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=imab_DeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementsWithMorphosysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementsWithMorphosysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_OtherInLicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_OtherInLicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_MorphoSysAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_MorphoSysAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_GenexineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_GenexineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=imab_Gxi7Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=imab_Gxi7Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_TypeOfLicensesAxis=imab_Study1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_TypeOfLicensesAxis=imab_Study1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_TypeOfLicensesAxis=imab_Study2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_TypeOfLicensesAxis=imab_Study2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_MacroGenicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_MacroGenicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_MilestoneTypeAxis=imab_DevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_MilestoneTypeAxis=imab_DevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_HealSunMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_HealSunMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_MilestoneTypeAxis=imab_MilestoneIiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_MilestoneTypeAxis=imab_MilestoneIiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_MilestoneTypeAxis=imab_MilestoneIvMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_MilestoneTypeAxis=imab_MilestoneIvMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_EverestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_EverestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementWithEverestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementWithEverestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_OutLicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_OutLicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_ABLBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_ABLBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_LemzoparlimabLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=imab_LemzoparlimabLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_MilestoneTypeAxis=imab_FirstMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_MilestoneTypeAxis=imab_FirstMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_MilestoneTypeAxis=imab_SecondMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_MilestoneTypeAxis=imab_SecondMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707711942344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing And Collaboration Arrangements - Summary of Financial Information (Detail) - Research and Development Expense [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Licensing Agreement with MorphoSys AG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Licensing Agreement with Genexine Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_LicensingAgreementUpfrontFees', window );">Upfront&#160;Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Licensing Agreement with MorphoSys [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_LicensingAgreementUpfrontFees', window );">Upfront&#160;Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_MilestonePayments', window );">Milestones</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Licensing Agreement with MacroGenics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_LicensingAgreementUpfrontFees', window );">Upfront&#160;Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_LicensingAgreementUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing agreement upfront fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_LicensingAgreementUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMorphosysAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMorphosysAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithGenexineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithGenexineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMorphosysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMorphosysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMacrogenicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_LicensingAgreementWithMacrogenicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707712483176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Expenses), Net - Summary of Other Income (Expenses), Net (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Loss from conversion of 2017 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#165; (18,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_LossFromConversionOfOnshoreConvertibleLoans', window );">Loss from conversion of Onshore Convertible Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,548)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_LossFromIssuanceOfNotes', window );">Loss from issuance of 2018 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,081)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Loss on termination agreement with Everest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#165; (23,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_IncentiveIncomeFromDepositoryBank', window );">Income of incentive payment from depository bank</a></td>
<td class="nump">&#165; 2,348<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_FairValueChangeOfShortTermInvestments', window );">Fair value change of short-term investments</a></td>
<td class="nump">11,288<span></span>
</td>
<td class="nump">1,730<span></span>
</td>
<td class="nump">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_FairValueAdjustmentsOfPutRightLiabilities', window );">Fair value change of put right liabilities</a></td>
<td class="nump">3,024<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_IncomeFromOtherFinancialAssets', window );">Income from other financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Net foreign exchange gains (losses)</a></td>
<td class="num">(22,126)<span></span>
</td>
<td class="num">(3,391)<span></span>
</td>
<td class="nump">1,619<span></span>
</td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CharityCareReimbursementsReceived', window );">Subsidy income</a></td>
<td class="nump">11,633<span></span>
</td>
<td class="nump">1,783<span></span>
</td>
<td class="nump">568<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Gains on deconsolidation of a subsidiary</a></td>
<td class="nump">407,598<span></span>
</td>
<td class="nump">62,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_FairValueAdjustmentsOfOtherFinancialAssets', window );">Fair value change of other financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_OtherIncomeexpense', window );">Others</a></td>
<td class="num">(873)<span></span>
</td>
<td class="num">(134)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other Income (Expenses), Net</a></td>
<td class="nump">&#165; 412,892<span></span>
</td>
<td class="nump">$ 63,278<span></span>
</td>
<td class="num">&#165; (20,205)<span></span>
</td>
<td class="num">&#165; (16,780)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_FairValueAdjustmentsOfOtherFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Adjustments Of Other Financial Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_FairValueAdjustmentsOfOtherFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_FairValueAdjustmentsOfPutRightLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustments of put right liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_FairValueAdjustmentsOfPutRightLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_FairValueChangeOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Change Of Short Term Investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_FairValueChangeOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_IncentiveIncomeFromDepositoryBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incentive income from depository bank.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_IncentiveIncomeFromDepositoryBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_IncomeFromOtherFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income from other financial assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_IncomeFromOtherFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_LossFromConversionOfOnshoreConvertibleLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss from conversion of onshore convertible loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_LossFromConversionOfOnshoreConvertibleLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_LossFromIssuanceOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss From Issuance of Notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_LossFromIssuanceOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_OtherIncomeexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Income (Expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_OtherIncomeexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CharityCareReimbursementsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of subsidies received by the entity for providing charity care, for example, from an uncompensated care fund.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68052803&amp;loc=d3e8255-115641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CharityCareReimbursementsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15743-112638<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707709343864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Expenses), Net - Summary of Other Income (Expenses), Net (Parenthetical) (Detail)<br> &#165; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">&#165; 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707714907800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) per Share - Summary of Basic and Diluted Net Loss per Share (Detail)<br> &#165; / shares in Units, $ / shares in Units, &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;) </div>
<div>&#165; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;) </div>
<div>&#165; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CNY (&#165;) </div>
<div>&#165; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to I-Mab</a></td>
<td class="nump">&#165; 470,915<span></span>
</td>
<td class="nump">$ 72,170<span></span>
</td>
<td class="num">&#165; (1,451,950)<span></span>
</td>
<td class="num">&#165; (402,833)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares', window );">Deemed dividend to Series&#160;C-1&#160;preferred shareholders at extinguishment of Series&#160;C-1&#160;Preferred Shares | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,283)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PreferredStockDividendsAtModificationOfPreferredShares', window );">Deemed dividend to Series&#160;B-1,&#160;B-2&#160;and C preferred shareholders at modification of Series&#160;B-1,&#160;B-2&#160;and C Preferred Shares | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to ordinary shareholders</a></td>
<td class="nump">&#165; 470,915<span></span>
</td>
<td class="nump">$ 72,170<span></span>
</td>
<td class="num">&#165; (1,485,001)<span></span>
</td>
<td class="num">&#165; (402,833)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Denominator for basic calculation-weighted average number of common shares outstanding</a></td>
<td class="nump">134,158,824<span></span>
</td>
<td class="nump">134,158,824<span></span>
</td>
<td class="nump">7,381,230<span></span>
</td>
<td class="nump">6,529,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock', window );">Dilutive effect of convertible preferred shares</a></td>
<td class="nump">4,373,047<span></span>
</td>
<td class="nump">4,373,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements', window );">Dilutive effect of ordinary shares to be issued to Everest</a></td>
<td class="nump">266,458<span></span>
</td>
<td class="nump">266,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Dilutive effect of convertible promissory notes</a></td>
<td class="nump">865,479<span></span>
</td>
<td class="nump">865,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_IncrementalCommonSharesAttributableToRestrictedShareUnits', window );">Dilutive effect of restricted shares units</a></td>
<td class="nump">778,130<span></span>
</td>
<td class="nump">778,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of stock options</a></td>
<td class="nump">16,789,714<span></span>
</td>
<td class="nump">16,789,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Denominator for diluted income (loss) per share calculation</a></td>
<td class="nump">157,231,652<span></span>
</td>
<td class="nump">157,231,652<span></span>
</td>
<td class="nump">7,381,230<span></span>
</td>
<td class="nump">6,529,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share - basic | (per share)</a></td>
<td class="nump">&#165; 3.51<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="num">&#165; (201.19)<span></span>
</td>
<td class="num">&#165; (61.70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share - diluted | (per share)</a></td>
<td class="nump">&#165; 3.00<span></span>
</td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="num">&#165; (201.19)<span></span>
</td>
<td class="num">&#165; (61.70)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_IncrementalCommonSharesAttributableToRestrictedShareUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted shares units</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_IncrementalCommonSharesAttributableToRestrictedShareUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock dividends at extinguishment of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PreferredStockDividendsAtModificationOfPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock dividends at modification of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PreferredStockDividendsAtModificationOfPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2029-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2029-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity unit purchase agreements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707706180328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) per Share - Summary of Antidilutive Securities Excluded from Computation of Earnings per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities that have not been included in calculation of diluted net loss per share</a></td>
<td class="nump">92,238,119<span></span>
</td>
<td class="nump">64,389,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities that have not been included in calculation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,134,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities that have not been included in calculation of diluted net loss per share</a></td>
<td class="nump">11,388,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707704980344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Additional Information (Detail) - CNY (&#165;)<br> &#165; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employee benefit expenses</a></td>
<td class="nump">&#165; 10,049<span></span>
</td>
<td class="nump">&#165; 14,152<span></span>
</td>
<td class="nump">&#165; 9,294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707814929144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Balances and Transactions - Summary of Related Party Balances (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_CommonStockSharesIssuableForServicesAvailedCurrent', window );">Ordinary shares to be issued to Everest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 258,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromAffiliateCurrent', window );">Collection of loan to an affiliate</a></td>
<td class="nump">&#165; 21,212<span></span>
</td>
<td class="nump">$ 3,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=imab_ImabHangzhouMember', window );">I-Mab Hangzhou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">21,212<span></span>
</td>
<td class="nump">3,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromAffiliateCurrent', window );">Collection of loan to an affiliate</a></td>
<td class="nump">52,000<span></span>
</td>
<td class="nump">7,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ExpensesPaidOnBehalfOfAnAffiliate', window );">Expenses paid on behalf of an affiliate</a></td>
<td class="nump">21,212<span></span>
</td>
<td class="nump">3,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_EverestMember', window );">Everest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_CommonStockSharesIssuableForServicesAvailedCurrent', window );">Ordinary shares to be issued to Everest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 258,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember', window );">Jiangsu Taslydiyi Pharmaceutical Co Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Accruals and other payables</a></td>
<td class="nump">&#165; 2,395<span></span>
</td>
<td class="nump">$ 367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_CommonStockSharesIssuableForServicesAvailedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares issuable for services availed current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_CommonStockSharesIssuableForServicesAvailedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ExpensesPaidOnBehalfOfAnAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses paid on behalf of an affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ExpensesPaidOnBehalfOfAnAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120604989&amp;loc=d3e56071-112765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=imab_ImabHangzhouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=imab_ImabHangzhouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_EverestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_EverestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707703287976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Balances and Transactions - Summary of Related Party Balances (Parenthetical) (Detail) - CNY (&#165;)<br> &#165; in Thousands</strong></div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=imab_ImabHangzhouMember', window );">I-Mab Hangzhou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">&#165; 2,000<span></span>
</td>
<td class="nump">&#165; 50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=imab_ImabHangzhouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=imab_ImabHangzhouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707711703576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions - Summary of Related Party Transactions (Detail)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_CmabBiopharmaSuzhouIncMember', window );">CMAB Bipharma Suzhou Inc [Member] | Receipt of Contract Research Organizations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Research and development expenses recognized</a></td>
<td class="nump">&#165; 681<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 2,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember', window );">Jiangsu Taslydiyi Pharmaceutical Co Ltd [Member] | Receipt of Contract Research Organizations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Research and development expenses recognized</a></td>
<td class="nump">&#165; 2,395<span></span>
</td>
<td class="nump">$ 367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_TaslyPharmaceuticalGroupCoLtdMember', window );">Tasly Pharmaceutical Group Co Ltd [Member] | Receipt of Contract Research Organizations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Research and development expenses recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_EverestMember', window );">Everest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Receipt of research and development funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 53,148<span></span>
</td>
<td class="nump">&#165; 178,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_CmabBiopharmaSuzhouIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_CmabBiopharmaSuzhouIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=imab_ReceiptOfContractResearchOrganizationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=imab_ReceiptOfContractResearchOrganizationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_TaslyPharmaceuticalGroupCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_TaslyPharmaceuticalGroupCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_EverestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imab_EverestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707706973368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional information (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember', window );">Collaboration Agreements With Tracon Pharmaceuticals Inc [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_TerminationFeePayable', window );">Termination fee payable</a></td>
<td class="nump">$ 9.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_TerminationFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Termination Fee Payable .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_TerminationFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139707715434120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Net Assets - Additional information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_RestrictedNetAssetsDisclosureLineItems', window );"><strong>Restricted Net Assets Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit', window );">Statutory reserve, annual appropriation percentage from after tax profit</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation', window );">Statutory reserve, threshold limit for annual appropriation</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_AppropriationtoStatutoryReserve', window );">Appropriation to statutory reserve</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Prc Subsidiaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_RestrictedNetAssetsDisclosureLineItems', window );"><strong>Restricted Net Assets Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNet', window );">Net assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imab_PercentageOfNetAssetToNetAssetsOfGroup', window );">Percentage of net asset to consolidated net assets</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_AppropriationtoStatutoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Appropriation to statutory reserve.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_AppropriationtoStatutoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_PercentageOfNetAssetToNetAssetsOfGroup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net asset to net assets of group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_PercentageOfNetAssetToNetAssetsOfGroup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_RestrictedNetAssetsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Net Assets Disclosure .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_RestrictedNetAssetsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Statutory reserve annual appropriation percentage from after tax profit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imab_ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold Percentage Of General Reserve To Registered Capital For Reserve Appropriation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imab_ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net assets (liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77885760&amp;loc=SL35686385-199418<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 205<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118262037&amp;loc=d3e9915-115836<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874367-224272<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604008-122996<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874367-224272<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>171
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M*MBO6FSE8U(9;^#!Y<D&^"2<Y-728$:C<(K,9 4*RP9LQ,+8">P7@)7(K'Q
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M3N"@"+;LD*K/_/@/E 45@"%/9?&.CB>M/W-0>)"*9V6P)LB2_/3)?I47HA%
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M, 86@3 "?7[+N7H>F%V*:E=J^3]02P,$%     @ VCV<4M<<$.B<!P   2$
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MDJ<6ZTS(YEBJ_- VAAX<DJQYC[ZT0IPTX/Y( ]8V8.<VX&T#?FX#MVW@GMM
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MXB'%S8@D/"2YM4DB0N-T2/5AA"I.#5%W(ZO1B"5QL*<;.)'NG4C?YL1SM-L
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MYATA&Q F$34;^@D"AV;V2 ;[H<QI3<6&"B$+4AR9YB26.8Q@9G6>H^*&QO3
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M=Z/DIGU?Y5$J)=?MY8IG@$$U ?R^E(!$NQO]"LS^/:^K_P!02P,$%     @
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M(F<] N0?8Z_*)X;529C5IY/_"O\ CL<T0YDC<"$D25&&G!0#R09"O=J5&-U
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M,AU_H/'Y[>3SY';R=D;CJPNZOGDWOIK\/KZ=7%_19.^CF@L@$**-)6_()TQ
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MHV)T: S]%E%2UG&#I52KN4[+P?8T$EY1,X:#-G82N6@&L7L8Q+M2OD9155:
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MAZULP.\+8WS]( &:_U"G_P!02P,$%     @ VCV<4@7B_7(-)@  QX8  !@
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M6(J-P@/JD)/HIPDV_,F)R@E!$@016$7EH,+Q#L%J)(I)DX9M"_H+,@!LQ#2
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MW6%!)&D(=(!!B@'WL?^&IMU6V=5X.U(% RQ5ZUH'>P\,O2>N(0R3UTDH!\,
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M,%4*,#W\/G9<Q[\$T($!2>#NO)K%;/XT^@TC7X=)!M+M$.=[VOC ;^<?77Q
MU^'PQ.J:0UX-OQ[1ZS0>5#_JY;[MLAQ(/*Y@DB(%$>-J=9GE]JF^3DI1EUWJ
M6D/HQQ8,3V>'O<&^ *,B<</8:_J, U'#;PYHC*OTUCWY"S5N+/X2%+DHK'#)
MC2LW3[X<PMV86N7Q4O$E]Q?8,G H%CB:.N90=2"I[@- _[.(VCRP!6(TIW5V
MLG"1'3CTWY*R0YA%]XQF+QOVO[6%R_.NN4$D48X2.+XNA5<P'-SDX:/$5?A
M."07#1#+MQ]^_63E:]B3U5,C=L([#=DM!^U23NFJ=I;1(;P[=PD'M].X;%[
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M=I-.[-G CLMR+@&_-LB'I(48.73W;NU6[27PL7.%TN*6"Y<M+84JT98932&
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MP_1+ )1;LK_=%XL_52\-C^3@02_Z:IQXH,Z3I-C*])TAQF3 CU_-]R/0+WW
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M#A.+&4ISH+7 \SOV5&N3ZR&8W_WT[?NQT A!H_6A=D1;'1:2R.#=FW;@!Y_
M#[UZL],FE+KG>;7HM+HJY: ]SF+<GN+X=R/QX6:^-!$$%_6PXT/8K+>;G5>9
M^(MAW\ !_EB<.T78,+L50M+U);A#LV#-FD_$&&[ L<OA[E6F N7"UE\%=I_+
M(E7-5B4^*BO;<WCY/EPSN<BX@ASGE.HU+EH.R++FE@,M5K;.S82FJFF[2WJF
M4)H 6I\+.H;MP!!4#]_@#U!+ P04    " #:/9Q2265^/U(#  "W!@  &0
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M</6C+1M*MX%YG<.=7)LM5S@)#$6QMD&V1SSO$-E/$",&U[(VA8:K.L?\-4!
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MS0*T/U>4E?6$#6R?HF?_ E!+ P04    " #:/9Q24*[Q+5L$    "@  &0
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MF&597=:"6=+RF=K&B_/.[?4<-K\O=S_"P6=E$9+CP6'G.[<[5S>W'UA9G5_
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MH78,=)XK@J4EG('MHV_Z#U!+ P04    " #:/9Q2$3M+02L#  "H!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6R=5=MNXT8,_15"1?N46K:<Q&EJ
M&T@V[6X*! UV>WDH^C"2*'F0T8Q"CNS-WY<<V5YOVTV!/MC6\'+.(3FBE[M
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MC0:'PH:/M^'&FYH_F$Z-]V;)EPN%8Y:E!7@_,\A3>T,*-E_0S_X#4$L#!!0
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M 6D2FB9@?*50#=T#;3#\GG+Y?U!+ P04    " #:/9Q2?CO:ZZ0,  #X)0
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M/P+6D"WOE3\2KHS.+P)7.)M.SG#RH!!QDVNAOGR1\(6B&*6#=MUV9,@5Q(,
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M-/M;BPLUKF*8;0 58^"2SPU?6O:N$HA!RMOT7'K8^ACS8@B"(==<$.*4X .
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MKISAII4"/3+OV4W9#]W%8G2"ON_.0[NSCFI_YGK>R<4NK9H.N Y. 8R+F\-
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M.&!P6AJ)M[C5JZ'HS\INIBR:UBG]?A(ZR;W"Z]BX/&^-JYKNA#HT:')=IA#
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M970R-"YX;6SM7>MOVT:V_]Z_@LC>+FQ 4B39CIVD#6 G3>HV:8PZZ=W%Q?U
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M S^!1QK'&NR)&L?)"J0VPH$*,#;;L?G1K@J_LJ(,\[3M.DGG[Q,[)\PHQ+Y
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M</O:E\-L=J47:&W)'.[(6W82E04\8SC:L<"J26W =L:T,K.QA+(R/:[L5M=
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M]:9*,I*?J_/Q]R<C]@4WK\:SX%.N[\=K?8^+!HBTQB8#JW&P-O:E5-BR]HU
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MA!PB0#8] ITPML^U<F8BI/-6288MMB!D_F"82=LZ1L.3\1U2(Y;@X@A1Z$^
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MZZMHKC!/3,,S/ NH\@SJ!PP6,<SAYQ)AK2JJ+"$+L'Q585=>XF^2I#P+T;'
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MF<YG[VFRNV'V#T*P79RWA0TTO>.RI><2'2O0>6UM. OL8'J M_\!4$L#!!0
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M*YK3%%7]HV'4!54-R=7"R,(-IBMI<,QUCQG^KZ#*"N!^*M&9>F$)FG\JD_\
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MSE4+_GUX^W56*IV6J(DHNF(J!)CJUJ=2:?-2:MDXC>J8(X"^/'JQ0H=WM 6
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M JB<G-CG+H!HP6R_Y>BJ:!9L[QJ*O';W<+!\ZH'T7B<X8)N,, <AL3&XW>,
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M'G4/^?0T/EM86_,1><SPQ>?'8#1[+T[AK5<;LYC$NO-^,'H0=R='&6-"9]'
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M7#YM8]:71?9':[30 *<97#[58KN: LG-E$(85K&S*CU"27I+^NT>HZL%=>
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MS0*83X30VP]CH+G%G_\+4$L#!!0    ( -H]G%+CJD4VDP(  *P&   9
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M(,>&."ZT&&P3V@I-+<U.:_J&H#0&=%X)NJ'3PCB8ODK+?P!02P,$%     @
MVCV<4BU\=HHZ P  S@8  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
MC55=;]LV%'W7K[C0BB$!A$BB/BRGM@$[[; !36?$[?90](&6*(LH1;HD%3?[
M];N4%"7!FF0/MDCJWG//N22/%B>EOYF&,0L_6B'-TF^L/5Z&H2D;UE)SH8Y,
MXIM:Z99:G.I#:(Z:T:I/:D5(HB@/6\JEOUKT:UN]6JC."B[95H/IVI;JNPT3
MZK3T8_]^X88?&NL6PM7B2 ]LQ^SGXU;C+)Q0*MXR:;B2H%F]]-?QY29U\7W
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MM O ][7"(S=.7('I$[;Z%U!+ P04    " #:/9Q2<\2OT1 $  #*"0  &0
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M2Y*@\J\$/S&R<C?S4AJZY]UP30\K5-: ON=2FOW$)FB>:I-_ %!+ P04
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M7^BZ#*\[5I6^]!TK2X6T;^;(,M1.@.8G2ME5QSEH_@P9_ %02P,$%     @
MVCV<4E.2$G+P P  Q @  !D   !X;"]W;W)K<VAE971S+W-H965T-#@N>&UL
MC59M;]LV$/[N7W'0AL$!M$BB9%G.' -)FVX%FC9(V@W#L ^T=+:(2*1'TG&R
M7[\C):O>$F?]8(ND[IY[[HVG^4[I>U,C6GAL&VG.@]K:S5D4F;+&EIM3M4%)
M;U9*M]S25J\CL]'(*Z_4-A&+XSQJN9#!8N[/;O1BKK:V$1)O-)AMVW+]=(F-
MVIT'2; _N!7KVKJ#:#'?\#7>H?VRN=&TBP:42K0HC5 2-*[.@XOD[#)S\E[@
M5X$[<[ &Y\E2J7NW>5^=![$CA V6UB%P>CS@&VP:!T0T_NHQ@\&D4SQ<[]'?
M>=_)ER4W^$8UOXG*UN=!$4"%*[YM[*W:_8*]/Q.'5ZK&^'_8=;)9'$"Y-5:U
MO3(Q:(7LGORQC\.!0G%,@?4*S//N#'F6;[GEB[E6.]!.FM#<PKOJM8F<D"XI
M=U;36T%Z=O')UJCAO2Q5BS"^>J1D&S0G(7RD@AA_YLN&=O/(DBFG$)4][&4'
MRX[ )@RNE;2U@2M98?5O@(@X#D39GN@E>Q7Q+9:GD"8AL)C%K^"E@^.IQTN_
MQ7$N*]C[#G]<+(W55"Y_OF(F&\QDWDQVQ,Q=5^R@5O!:J%^*\.O GVN$E6JH
MJ81<@W6)ZCM+_$U.*&],],;PJS%)>=58JK4DN8H@-) H/"'7!M E"RC4V"Y)
MO0MW4OC_F8^2B_[9Z'>2[C)[*#QRLIVH$QM]5):8W%Y?#K\O=]^/QNX8V.GD
M9/1!&0,KK5HHE7Q [3N=(D404^BT$YC F!BDTPF<P _?%2QA/_WW>13HDS2U
MT@AO_*D5+D@?%)?0 Q?A)"N^"5<8L^6RQ)Y><4AO$L9%\G\H1,BBI@[FW6VT
MUHATN5GJ=UO#%=%#8PFO&-3'+ WC=/8<>-37$%&A!!,&W6NPX4\>SK.M<*.,
ML(H*;\GE/<$FS]BQ,"7?TSP>O>-"PP-OM@AES>7:([O V1\=93+R0-P<NAFT
MIW$*21*RHH DG*9'0#9;*C9W+T(C^%(TP@HTSYB0FRR#+$_WCGD?N@I>4<!D
M*7@#W!@D DD:YHP=C;6[MJBFZ3*6@(\]DS4-)P/CAO) /0#3C!'IG,ITS%B8
ML)Q"/$[#=$9)'-UMET943T/KI"0_B6&2%\[?/$V=OT4Z^MEC4B8K:B9I5".J
M+K/D-J=.="C"=?[L&=<LGH:360$Y"[-\^G+DCG@_0#R+P,A?+Q2?)(;QS!7U
MN)BF[I&D&?DU3G+B';L#%H<L=NV4)2PL9@SR-&33XJ7;+CJ8+"WJM9^?AKIL
M*VTW9(;3841?=)/IJW@WWZ^Y7KN0-;@BU?AT.@FZVMAOK-KX.;54EJ:>7];T
MF8':"=#[E:*6ZS?.P/#ALO@'4$L#!!0    ( -H]G%*0X'1@N@0  *@+   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;(U6;6_J-A3^SJ^PV#2!%"#.
M"PE=BU3:3JNT5E6Y=],T[8-)#L1J$F>V4WK__8Z=$.B%TOL!_!+[.<]Y];G<
M"OFB,@!-WHJ\5%?]3.OJ8C)1208%4V-108E?UD(63.-2;B:JDL!2>ZG()Y[K
M3B<%XV5_?FGWGN3\4M0ZYR4\2:+JHF#RVP)RL;WJT_YNXYEO,FTV)O/+BFU@
M"?IK]21Q->E04EY J;@HB83U5?^:7BQ"<]X>^)/#5AW,B=%D)<2+6=RG5WW7
M$((<$FT0& ZO< -Y;H"0QG\M9K\3:2X>SG?HOUG=49<54W C\K]XJK.K?MPG
M*:Q9G>MGL?T=6GTLP43DROZ3;7O6[9.D5EH4[65D4/"R&=E;:X<?N>"U%SS+
MNQ%D6=XRS>:74FR)-*<1S4RLJO8VDN.E<<I22_S*\9Z>/Z+?[\M$%$ &?PBE
MAJ0"2989D[CQA:UR4,/+B49)YOPD:5$7#:KW 2KUR(,H=:;(79E"^AY@@A0[
MGMZ.Y\([BW@+R9CXU"&>Z[EG\/Q.;]_B^1_@W3%9\G*CR%.G[C_7*Z4EALF_
M9_"##C^P^,$'^,LFR(E8DP53/"&L3,DMSVL-*3%&-\;>V_J4B<\*,,EZH2J6
MP%4?LU&!?(7^_$!6VLHJ419O'9QW#E968\QI BPA6>]O8++Q%4%+0['",S[M
M>2Z-T>)T9LW>>WY8D-WOZ_)G,G@4&H@W#H>] 2^)SD2M4+9R"+PE4&DKH!%E
M*.T%IQBJP]YC78!D6LB+WN,12Z:UY*M:FQ D6I#[T0-;D4'@>D[L^V1(!M0)
M0NK,0A<70>0Z,QJ2R'-HY/9N 0HP-GCE*:!DO+\$R4&1FQ&UOU]^BCWJ_4H&
MH>/%!FZWT8YG(!8C#,/%R-M/.C O<J)I? +M<_V$3'EI(L9:*!-Y"E)]KV\<
M.JY+3^E;"BP.C2T/%M8!*QL3"<N3.F>F%(ZVME:A=NP5'; !4M;6XQBL2+'
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ML;.STPQ;:9#F 'Y?"_1SNS "NN9\_C]02P,$%     @ VCV<4MP/"CBD P
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M3?&Y1:79@.N)P,/4 ^.@><!-_P%02P,$%     @ VCV<4@KV<EB- P  @ \
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M&E]:653[=F\_,;+V+=9&&MNP^6%I6V10;H%]OY72'"?.0=MT+_X#4$L#!!0
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M$#P'^!V L *$KP5$%2 JDV6B6Z9F3A09#P4_(*&M@4T/ROR6:,@(RW4IKI2
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M;"]W;W)K<VAE971S+W-H965T-3,N>&ULK59K3]LP%/TK5QF:F 0D3OJ"M96
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M5,[ ?A]+:5XV;M8IA^'N7U!+ P04    " #:/9Q2IM HP-,$  #L%   &0
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MN72?&JC] 7<_4\H^+SQ!_?$R^@U02P,$%     @ VCV<4HA'Z)_O @  / D
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MSM@R4[=\_1&K>#J:+^:9-$]85[:.!?%2*IY78/(@3XORS1XK';8 GGL X%4
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M"FU ZS/.U6:B#\3ZPA3^ U!+ P04    " #:/9Q2=78O7G\#  !."P  &0
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MK+]"4\^IY<LDU^Z?U(UO%)!LHXTL&S!F4#+AO_2QN8<.(!X> "0-('D-&!P
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M =<)ZOF$,?D2Z+.^NCP._P)02P,$%     @ VCV<4NVI7F8$ P  0P@  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C,N>&ULE59K;]HP%/TK5E9-K52:%TF@
M Z06.JU2NU5EW31-^V#(A5A-;&:;TNW7[]H)*6^Q+\1V[CT^Y_C&E\Y"R&>5
M 6CR6N1<=9U,Z]FEZZIQ!@55%V(&'-],A"RHQJF<NFHF@:8VJ<C=P/-BMZ",
M.[V.77N0O8Z8ZYQQ>)!$S8N"RC_7D(M%U_&=Y<(CFV;:++B]SHQ.80CZ:?8@
M<>;6*"DK@"LF.)$PZ3I7_N4@,?$VX!N#A5H9$Z-D),2SF=RF7<<SA""'L38(
M%!\OT(<\-T!(XW>%Z=1;FL35\1+]H]6.6D9405_DWUFJLZ[3<D@*$SK/]:-8
M?()*3V3PQB)7]I<LJEC/(>.YTJ*HDI%!P7CYI*^5#RL)@;\G(:@2@F,3PBHA
M/#:A624TK3.E%.O#@&K:ZTBQ(-)$(YH96#-M-LIGW!S[4$M\RS!/]^X 35.D
M0?JBF D.7"LB)N3+#"35C$^)#2 WKUAG^#P=@*8L/R/OW_EQ]($P3KYF8JXH
M3]4Y.5F;=UR-!,TV[K@B<UV2"?:0\0-R+[C.%+GA*:3K "XJJ^4%2WG7P4'$
M 8PO2.B?D\ +O/[G'^2T)'ZV@US_/Z">A@-R>K(+97 TBM_>3VA-;%B?96BQ
MPSW80[P3TGD.Y@"/.\Z?=PA!;C44ZM<! LV:0-,2:.XA<%4(J=E?:K]HW%::
MCZXA)HTY[D65 KVS*$K0V(*::^JEU_*C5L=]63V<,BA9"?*#R%L/&FPC14'\
M%K0F*JI%10=%+;W"*Y:H# 4V-,B"Y.6'LV ZPZ+'RBULY>ZJB!(_6F75#G:3
MBFM2\4%2MQQ)@-+&9<N$Y(R.6,XT@YT>QUL<XJ2]8?%VC.\U-QS>CHF:X6XM
M2:TE.:CEK3A+)1*KEN8$2M]WB4FV"Z85)AMJDNV"":--.=M(<=B.-O2X*]=K
M 7)JVY0B8S'GNKR*ZM6Z$U[9!K"Q?HT=LFQH;S!E>[VG<LJX0@<F".E=).BP
M+%M6.=%B9B_QD=#8$NPPPRX/T@3@^XD0>CDQ&]3_&WK_ %!+ P04    " #:
M/9Q2I0=M,=H"  !,"   &0   'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6R5
MEFUOFS 4A?^*Q:JIE=KP3DB71%H33>O4;E73;IJF?7#"36+58&:;I/WWLPUE
M-)"T^Q(PW'/NXP/&&6X9?Q!K (D>4YJ)D;66,C^W;;%80XI%C^60J3M+QE,L
MU9"O;)%SP(D1I=3V'">R4TPR:SPTUV[X>,@*24D&-QR)(DTQ?[H RK8CR[6>
M+]R2U5KJ"_9XF.,5S$#>YS=<C>S:)2$I9(*P#'%8CJR/[ODTUO6FX#N!K6B<
M(SV3.6,/>G"9C"Q' P&%A=0.6!TV, %*M9'"^%-Y6G5++6R>/[M_,G-7<YEC
M 1-&?Y!$KD=6;*$$EKB@\I9M/T,UGU#[+1@5YA=MR]I^:*%%(21+*[$B2$E6
M'O%CE4-#X+E[!%XE\-XJ\"N!_U9!4 D"DTPY%9/#%$L\'G*V15Q7*S=]8L(T
M:C5]DNG'/I-<W25*)\=7H$(3Z Q]RX%C2;(5,I=.T366!2?R"1U/06)"3]#[
M=VX4?D D0W=K5@B<)>(4';T8#VVIH+2UO:@ +DH ;P_ %!8]Y+NGR',\9_+U
M)SHNVYQT6$W^P^I^-D7'1UTNT\,N7W#60XYQ<0?[@6P5=)VV5Z?M&6]_C_=,
MK=JDH(#8<C?P?WG_NE(J="DA%;\/]/3KGK[I&>SIJ<)PNQY+J8J,2G\<-N-X
MX*C*33/PLJC?*'+]**B+7@ %-5#P&I#7!52JPD:O,&CT*H':1;'?[^8):Y[P
M-1Z_BR=L\_C1#DZ[)O:Z::*:)CI(<\<DIJC($B(6K,@D)(B:]R/'3^IS*SN7
M6-3"<(/VPVQ7>5[L=^/V:]S^0=PK$.(<D30O-"E1O!R$[&+LM[J?N7Z+L:MJ
M,.AFC&O&^ V1EBE2@N>$$DF@,\BXM2C4^^XX.Y!Q:U5X3KSSIDX[K%S?WXW;
M;GRZ]3Y[C?F*9$+1+I7.Z>F=B9=[5SF0+#=?\SF3:F\PIVNUW0/7!>K^DC'Y
M/- ;1/T'8OP74$L#!!0    ( -H]G%)B8O$+?P,  %8.   9    >&PO=V]R
M:W-H965T<R]S:&5E=#8U+GAM;+U7:T_;,!3]*U:&)I" Q'DU96TE:&%C H9X
M;)K0/KBIVUHD=F>[%/;K9R<A39JT!*GB2QLG]YY[[B/'3F?!^*.88BS!<QQ1
MT36F4LZ.3%.$4QPC<<AFF*HG8\9C)-623TPQXQB-$J<X,FW+\LT8$6KT.LF]
M:][KL+F,",77'(AY'"/^<H(CMN@:T'B]<4,F4ZEOF+W.#$WP+9;WLVNN5F:.
M,B(QIH(P"C@>=XUC>'0* ^V06/PD>"$*UT"G,F3L42_.1UW#THQPA$.I(9#Z
M>\)]'$4:2?'XFX$:>4SM6+Q^13]+DE?)#)' ?1;](B,Y[1J! 49XC.:1O&&+
M;SA+R--X(8M$\@L6F:UE@' N)(LS9\4@)C3]1\]9(0H.-ESC8&<.=E,')W-P
MFCJXF8/;U,'+')+4S33WI' #)%&OP]D"<&VMT/1%4OW$6]6+4#THMY*KIT3Y
MR=XYE8A.R##"X%@(+ 4X +?IT( ?8U!]O#O $I%H#WS^!'WO"R 4W$W97" Z
M$OM@I[3NF%)1U(',,*-SDM*QU] 9X/ 0.' ?V)9M]:]^@]TTS%X-5/\=4/>W
M ["[4X<R:(P"VV\0.GT'5"TA4S4O[Z"==]!.8)TUL&>$$HD/+M3[-JKIU\.%
ML@?G$L?BSX9H3A[-2:*Y:Z)]Y4P($"+.7PB= !2S.95U?4YA_ 1&J]53#]I*
MO:R.^52L?HV9&P2NFYN56+HY2W<CR^,PG,?S"$E5$D612_(/:5VJ(YHB>04&
M!]#S_'H"7D[ VTC@2DE\@R)YE=C0MMQ"]NF@IV:MHEG@>NV54M: E4N9#FD5
MS+8#".OS]?-\_8WYGE_?@&,Z @-P]QU:#GBXQ/$0\TT3U\JA6Q\PWT$>+=C.
M? ?5:D._M3K>;UF5.+9SCNVM37?[/=,-K>6N86UCOC.44OX6A*OS76?F>:NU
MK+.JEORTSJP5!&LR+NR3\!T3;C>9<+B4</@1&@Z7(@ZWH^*##*=83-M?*\]P
MJ<]PLT WFY\!K(IS.7S6\JJ96YRR,LFEAL/-(EYN.6S4\J5@0O\C6KY44=C:
MCK!E..77S'*<RNOXIEV9Z5*!X68);JHM0?7H4,.SG]F5=D^_;:WNG@WA3M^$
M2[,V"T=R_<5UB?B$4 $B/%9^UF%+U8VG'S'I0K)9<DH?,JG._,GE5'WX8:X-
MU/,Q8_)UH0_^^:=D[S]02P,$%     @ VCV<4C!I,4WL @  ^P@  !D   !X
M;"]W;W)K<VAE971S+W-H965T-C8N>&ULK59K;],P%/TK5IC0)HWET289HXW4
MU[0A#55[@!#B@YO<-M82.]AN.Q _'CM.0\K2T@F^M+9SS_&YUR>^Z:T9?Q0I
M@$1/>49%WTJE+"YL6\0IY%B<L0*H>C)G/,=23?G"%@4'G)2@/+,]QPGL'!-J
M1;UR;<JC'EO*C%"8<B26>8[Y]R%D;-VW7&NS<$L6J=0+=M0K\ +N0#X44ZYF
M=LV2D!RH((PB#O.^-7 O+D,=7P9\)+ 6C3'2F<P8>]23ZZ1O.5H09!!+S8#5
MWPI&D&6:2,GX5G%:]98:V!QOV"_+W%4N,RQ@Q+)/))%IWSJW4 )SO,SD+5M?
M096/K_EBEHGR%ZVK6,="\5)(EE=@I2 GU/SCIZH.#8#G[@!X%< [%-"I )U#
M =T*T#T4X%< _U! 4 &"LO:F6&6EQUCBJ,?9&G$=K=CTH#RN$JT*3*@VUIWD
MZBE1.!E=4XGI@LPR0 ,A0 KT!@V2A.ACQQFZIL:[V@3'8Y"89"?H]2LW\-\A
M0M%]RI8"TT2<HJ.M><^62IS>PHXK(4,CQ-LAQ/70#:,R%6A"$TBV"6R559V:
MMTEMZ.UE'$-\ACKN*?(<SQE]^(R.C?"3%G&C%U ]W(W1\5$;R_A@%O?M7P1-
M7D"U6]#EX2SGK2Q;A>_4GNJ4M-U=GLH+3+BZ?21B<V6+VF'8..QGY: VDQCF
MH&36E^(J<GKVJEGC?1%;<KNUW.Y>N8.<<4E^&).W"6[3V7VFPO7]8%OJR 2%
MC2"O<]XNUJ_%^GO%3H0DZGV$!.&F;'A2G49 F[,-G]\0$88[1 2UB&#_ 4]O
MT8 F:(SNW[M.!WVY@7P&_.L>[X0U=?C?#V,4/JOS\\.8[-U7]^\+4> 8^I9J
MT +X"JP(M;U2_\YC"F,W+NT<^*)LKP+%;$FEN>3JU;J##\K&]<?Z4'5VTXA_
MTYC/@AO,%X0*E,%<43IGH7(!-ZW63"0KRM8P8U(UFG*8JJ\3X#I /9\S)C<3
MO4']O1/] E!+ P04    " #:/9Q2M'XA.K4"  "F!P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970V-RYX;6R]56U/VS 0_BM6QB:0H'EI7@9K*Y66L4YC0KQ-
M$]H'-[FV%HX=;(>R?S_;"5'+VM!]V9?$=NYY[IZ[R[FWY.)!+@ 4>LXIDWUG
MH51QXKHR74".98<7P/27&1<Y5GHKYJXL!.#,@G+J!IX7NSDFS!GT[-FE&/1X
MJ2AA<"F0+/,<B]^G0/FR[_C.R\$5F2^4.7 'O0+/X1K4;7$I],YM6#*2 Y.$
M,R1@UG>&_LE98NRMP1V!I5Q9(Z-DROF#V4RRON.9@(!"J@P#UJ\G& &EADB'
M\5AS.HU+ UQ=O[!_MMJUEBF6,.+T!\G4HN]\=% &,UQ2=<677Z#6$QF^E%-I
MGVA9V4;:."VEXGD-UA'DA%5O_%SG8040^%L 00T(=@5T:T!W5T!8 \)7 #_<
M HAJ@)7N5MIMXL98X4%/\"42QEJSF87-OD7K?!%F^N1:"?V5:)P:G'.>+0FE
MZ @-LXR8XF&*)JSJ0%/*_3$H3.@!VD.$H9L%+R5FF>RY2KLW)&Y:NSJM7 5;
M7(TA[:"N?X@"+_!&WW^B_0_O_#CZ=+"!:O0/5+?78[2_MXEEO#.+?_Q&0&?M
M5%]+VD%^9*F2=;BK*]*4)6C*$EB^[A:^"=/-3AA1<$3UCY3IBBC,YF1* 0VE
M!"71_3>-01,%N?S5XK';>.Q:C^$;C;"IKA4RMD@S>)X&?AQ$2>AY7L]]6BU;
M99FL6 ;AL1^O6XUWX5L3$38BPIU$'.H!E)9Y2;'2N2-Y@8G0PTTARN7&S@W_
MBNB5LG&;Q5JL41-KU!KK#99S8.A<\+) ]Q>03T&T%3)N>./_U#I)XS%I57+'
M%6%SXP<$2,T_3!]+(B#;]!^U4\5Q)T[>;XK)79EQY@:[P&).F$049IK)ZR0Z
MVZ*Z%:J-XH4=>U.N]!"URX6^2$$8 _U]QKEZV9A)VES-@S]02P,$%     @
MVCV<4I+SF^0=!   GQ   !D   !X;"]W;W)K<VAE971S+W-H965T-C@N>&UL
MM5AK;]LV%/TKA%8,*=!$(O6PU-H&$GN/ $EGQ,V&H=@'6J9MHA+IDI3= OOQ
M(R5%4B)+L;OD2RQ*O(?W'%X>DAGNN?@B-X0H\"U-F!Q9&Z6V[VU;QAN28GG!
MMX3I+RLN4JQT4ZQMN14$+_.@-+&1XP1VBBFSQL/\W4R,ASQ3"65D)H#,TA2+
M[U<DX?N1!:V'%W=TO5'FA3T>;O&:S(FZW\Z$;MD5RI*FA$G*&1!D-;(NX?LI
M\DU WN-/2O:R\0P,E07G7TSC>CFR'),124BL# 36/SLR(4EBD'0>7TM0JQK3
M!#:?']!_S<EK,@LLR80G?]&EVHRLT )+LL)9HN[X_G=2$LH3C'DB\[]@7_9U
M+!!G4O&T#-89I)05O_A;*40C ,&. %0&H&,#W#+ /3; *P.\7)F"2J[#%"L\
M'@J^!\+TUFCF(1<SC];T*3/S/E="?Z4Z3HVOV8Y(I2=2@<LXYAE39 ET.8%[
M2=D:J T!OWS-J/H.;HG:\"7 ; EFF0)YA8 ;BA<TH8H2"<[!O"@>P%?@-\&S
M+;CA!H.(%#3&N2589D(/<\^61#S IP7\V90H3).WX.>?8.!_ )2!3QN>23VL
M? ?>/&H/;:45,#SLN&1[5;!%'6RG)+X +GP'D(.<R<>_P5DQS-L#4),3H.[G
M4W#VYA#*]&@4&'4G9.M9K:8655.+<FRW _N/+1%8F5DTE0$^7RZD$GJ=_=.#
M[5;8;H[M/5LVTDR)S!:2+BD6N@X.S4H!%N1@QHEVXR#P0A<-[5U3\:+;H-$-
M.C",G*K;HUR]*E>O5X<KG& 6$S#/??1X+?P*W^_58I()8>H:2TG40?I%O-_@
MY;N>JR5XPK_=+]3T??=QMZG?4A.Z 71A=%BGH.(1',4CJ=?T(3)!F\P@@,A_
MPB5HS648HNA)KVG0HN*'H3?H8#*HF QZF>2V\^F)[61-MRG-[/,M21=$]%5!
M6(T9ODJ5115^]#^K+&I-3(1<!W:L'NC4.X33._)'SL[C8G1C3LZ'[A1*I,<5
M[ 3([<BAL4O!EZC-$J4YO@O]KH4!:R>%Z#0)GLL#M?* 3N1VR5"[+NRWW3P/
MSI3@B?ZT+G*A>L\6NLH/9^*V,NDJB-I/H=>;Q1W9$9:1:O6 ?\%+KCA8&R_T
M7WR'@[4=PGX_/'&/@VUC1 /8H77M9+#?RO0Y2DHP$WQ%U:L)7GL<[#>Y'Q*\
M=CC8;W&G"MXVO$[!4>UVJ-_M;HS>*\%34)+5EY-7TAW5]H?@B^N.&N?$?G<[
M47?4-K?ST(\\OT/ZVMW0,^ZF-\YK%O.4@'P67DOVVNA0_\GQAV2OW0OUGQM/
ME;U][#LHN]VX#)JK^RT6:\HD2,A*!SH7 XTCBMMPT5!\F]\/%USIVV;^N"%8
M2VLZZ.\KSM5#PUPYJ_])C/\#4$L#!!0    ( -H]G%)O*]<!!@,  &@(   9
M    >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;)U6;6_3,!#^*Z<(I$V")DW?
M8&HK==TFD)A4409"B ]N<FVL)7&P+^WV[SD[6=9!%C2^-'Y['C^/[^SK]*#T
MK4D0">ZR-#<S+R$JSGS?1 EFPO14@3G/;)7.!'%7[WQ3:!2Q V6I'P;!V,^$
MS+WYU(VM]'RJ2DIECBL-ILPRH>_/,56'F=?W'@8^RUU"=L"?3PNQPS723;'2
MW/,;EEAFF!NI<M"XG7F+_MER8M>[!5\E'LQ1&ZR3C5*WMO,QGGF!%80I1F09
M!'_VN,0TM40LXU?-Z35;6N!Q^X']RGEG+QMA<*G2;S*F9.:]\R#&K2A3^JP.
M'[#V,[)\D4J-^X5#O3;P("H-J:P&LX),YM57W-7G< 1@GG9 6 /"/P'C9P"#
M&C!P1BMESM:%(#&?:G4 ;5<SFVVXLW%H=B-S&\4U:9Z5C*/YQWR/AC@L!(LH
M4F5.& ,G!]P8F>^ $H3+7Z6D>[A&2E0,(H]A51*X>,,G*38RE231P%M85ZD
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M$TX+7=6UJD.J<*5AHX@+C6LF_%< M5W \UNEZ*%C-VC^7,Q_ U!+ P04
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M#EQMD-^O&!//"S4AU5/]Y#M02P,$%     @ VCV<4A!&2HYT!   L0\  !D
M  !X;"]W;W)K<VAE971S+W-H965T-S(N>&ULO9=M;]LV$,>_"N$50PJDD:AG
M9XZ!U,ZP &L;-.F*O:2E<TR$$C62MI-O/Y*29462'_9F;Q))_M_I?KKC\3C9
M<O$B5P *O>:LD#>CE5+EM>/(= 4YD5>\A$+_LN0B)TK?BF='E@)(9HURYGBN
M&SDYH<5H.K'/'L1TPM>*T0(>!)+K/"?B[3,POKT9X='NP7?ZO%+F@3.=E.09
M'D']*!^$OG,:+QG-H9"4%TC \F9TBZ_O<&@,K.(O"EO9ND8&9<'YB[FYSVY&
MKHD(&*3*N"#ZWP9FP)CQI./XIW8Z:MYI#-O7.^^_6W@-LR 29IS]I)E:W8R2
M$<I@2=9,?>?;/Z &L@&FG$G[%VUKK3M"Z5HJGM?&.H*<%M5_\EI_B):!AP\8
M>+6!=ZZ!7QOXYQH$M4%PKD%8&UATIV*W'VY.%)E.!-\B8=3:F[FP7]]:Z^]%
M"U,HCTKH7ZFV4]/;-!5KPB2Z+3+T3:U H ?R1A8,)/J$'JOR07RI,UH+B19R
M*RQWPHLY*$+91_3K+S@*?T.T0$\KOI9:*B_1AW?W$T?IL,W+G;0.\7,5HG<@
MQ#FD5\C'E\AS/7?V]6]T4;WFXX"KV7]P]>-QCBX^#'F9G^T%CT\$='>&*R\\
MY<K166U2ZS6I]:QO_X#OV5H(*-3U$5=^X\JWKH(#KAX562Z1)(P("E4);($M
MB8"F"(;R6CF-K%/3L3;3<8!]?^)LVBFK5'%+A8/ B]^KYGU?OHNCJ%&]XPH:
MKN HEZU^R!"\*A %8;KU22 B75G$##:ZD9:Z+:JJH5%EZ 4PHJR1[M9RF+QZ
M;=B*UL-)F'31^S+?#\;C#GI?I3^0Z[K#[&'#'I[%3@N-I='+]8+15"_U)0A:
M/*.42R5WZ1UB#'MAN1V\DXIY7X'CT V&R:*&+#J+K!1THS.%2D92L%D\'R[J
M!^8E<1)U" =DX]COU.Y=U*O= [F+&\+X*.%/JE8KSC*#<G__M -I2E-QI'>.
M] 7QTFS'@R4:GTS?2<6\K\"1[F3#<$D#EQR%^\J+3WI:6!>99:)%JE.GIPE#
M:;.X%#S7B[/DDBJS.RU(\3)$F/078> %'<B^R(]Q![.O.9"_<8,X/JM"E2"Z
MQ9@L[IK)I:E1FD+S8+_?#F9QW,^ [HJ^UZ$<D,5)''8X^ZHHC!)OF!6[^Q'#
M/47+UX5>;_5D89%VG^!/2A:4V<YZB>HM:W!&<'O!A9$;ADF'=$"7A&.WVU,'
M9%[LAZ%_ +8U3^&CNZZIWO3TSHOWNSCV_I_E4+^GC1P'<7<]#*@P#KJ5,J Z
ML"3P?L; QX>,VVQ#-%S#)2 %S9E5@*1 D)>,OP$@?3[2ZP-$2B68V?1DKZO?
M_ XJ='$7O:_R_&[+P_U!Y!#Y?@K!)\>0,Q=(J[H&.?NC0C+N+O/9@ K[+=5[
MBOT\@8\/%$]<$3885=C[9&$T#GN#8*UK3X))["7=:<!IG7;,8?8+$<^TD(C!
M4MNY5[%V(ZKS876C>&D/0 NN]''*7J[TF1J$$>C?EYRKW8TY4S6G].F_4$L#
M!!0    ( -H]G%*&39P9F0(  (X&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#<S+GAM;)55;4_;,!#^*Z<,32 !>6NA8VFDM-DT/K!5,#9-TSZXR;6)<.S,
M=BC\^]E.FA76%O8E\3GW//?<G7V)5ES<R0)1P4-%F1P[A5+UA>O*K,"*R%->
M(]-?%EQ41&E3+%U9"R2Y!574#3SOS*U(R9PXLGLS$4>\4;1D.!,@FZHBXG&"
ME*_&CN^L-Z[+9:',AAM'-5GB#:K;>B:TY?8L>5DADR5G(' Q=A+_(AT:?^OP
MK<25W%B#R63.^9TQ+O.QXQE!2#%3AH'HUSU.D5)#I&7\[CB=/J0!;J[7[!]M
M[CJ7.9$XY?1[F:MB[(P<R'%!&JJN^>H3=OE8@1FGTCYAU?EZ#F2-5+SJP%I!
M5;+V31ZZ.FP  G\'(.@ P6L!80<(7PL8=("!K4R;BJU#2A2)(\%7((RW9C,+
M6TR+UNF7S+3]1@G]M=0X%2=9)AI")20LAR^J0 $S\DCF%"6<0)+GI6D/H7#)
MVC-FFG68HB(EE4?P]HU_-GP/)8.O!6\D8;D\AH,G=N0JK=-$<[-.TZ35%.S0
MY,,59ZJ0\('EF&_!IR_@@ST$KBY07Z5@7:5)L)<QJ<4IA-XQ!%[@W=ZD<'AP
MM$77]#]8II]_P&%;OFU4Z7ZJ%#--Y;]$]239L#\2H>4.=W#W_=?=@_Y\_$SF
M4@E]37_M"3'H0PQLB,&N$()GB+F$A> 5,,Y.]&UO6&[BZL.3(3/38-O):7G/
M+:\9:?>Q/QJ>1^[]9AM:I[--I^#=*.B]GF@>]IJ'>S6WET.+X]4V9>GPGZ!!
M.!@]B^ENW-0*Q=)./ D9;YAJCV._VP_5Q,Z29_L3_V+:SL:_-.VDOB)B63()
M%!>:TCL]U\)$._U:0_':SH,Y5WJZV&6A?Q@HC(/^ON!<K0T3H/\%Q7\ 4$L#
M!!0    ( -H]G%+*2I34-P,  (\+   9    >&PO=V]R:W-H965T<R]S:&5E
M=#<T+GAM;*U6:V_3,!3]*U80:$C0Q&F3M:.MU >P"K95>S AQ <WN6VL.7:P
MW77\>^RD2[O1>07M2V([/L?GV+XWM[L2\D9E !K=Y8RKGI=I71SYODHRR(EJ
MB *X^3(7,B?:=.7"5X4$DI:@G/EA$,1^3BCW^MUR;"K[7;'4C'*82J26>4[D
M[R$PL>IYV+L?.*>+3-L!O]\MR (N0%\54VEZ?LV2TARXHH(C"?.>-\!'8QQ;
M0#GC&X65VFHC:V4FQ(WM3-*>%UA%P"#1EH*8URV,@#'+9'3\6I-Z]9H6N-V^
M9_]4FC=F9D3!2+!KFNJLY[4]E,*<+)D^%ZMC6!N*+%\BF"J?:%7-/0P]E"R5
M%OD:;!3DE%=O<K?>B"V ,;H;$*X!X6- ZPE <PUH[@MHK0&M<F<J*^4^C(DF
M_:X4*R3M;,-F&^5FEFACGW)[[A=:FJ_4X'1_PA.1 [HD=Z#0>S1(4VK/@S T
MX=6MLJ=S, 9-*'MK9HQ.OZ.#-Z]P''UXBZHWHAQ=9F*I"$]5U]=&EB7WD[6$
M824A?$("#M&)X#I3Z"-/(7U(X!L_M:GPWM0P=#*.(6F@)GZ'PB ,=@@:[0W'
MG1WP\?[PML--LSZB9LG7>H)O4!2,)F3& &ERAR31L&N3W20A;@3!:X>:5JVF
MM:\:I8T4IR8W5;L11BY)42TI<O)<4YUE@J64+^Q%WB6D(HA+ IL*;\VM"YNX
MZ]_N6#>NUXV=ZT[0R=D0"9V!3:0S15-*)#5Q].,$\AG(GPYOA_4:AR]Q^&Z2
M,'KF\-NUFK:3Z/CL]#/Z8AX.KD[-U7D)9VX2'#>BQ\ZJ$/]/W/C?<0_<XV"3
M> .W_ZN+R_/!U\G Q;:5QO%+[.8S+,W@F8N"PXV@T$DU/1_M$P=XDP6Q.X.=
M%6!<V1AG0NW^S33_BO(HBN-69W>8XTW*P^Y$-3K=R\HF7V%WPMKWL-PLST8U
MWB0R[,YD4U-L@02NJ?GQTZHD<"IST^$GE?E;E4H.<E%6? HE8LEU]7^O1^NJ
M<E#64H_&A[;:+"N@#4U5JIX0N:!<(09S0QDT#LTNRJKZJSI:%&4]-!/:5%=E
M,S,5,T@[P7R?"Z'O.W:!N@;O_P%02P,$%     @ VCV<4NDQZJA!!   *0T
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M3@/,8E$WYO5 \4)WGCNNL(_5MPE^RX"H /A\S[EZ&U0+M%]'B_\!4$L#!!0
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MOE#OI/99\XVF?61]Q'Q;48$(;!2E=S]26\+;ATO;D6QG;N8UD^J>-\U2O?6
M:X#ZOF%,'CMZ@O[U./L?4$L#!!0    ( -H]G%)(?OHY6@D  *TQ   9
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MNUW%M\'K.9<3HHG>/%A%Z?_@5=I: S#?1G&PEH.%!VO/S_ZZWV4@2@,P[!B
MY !4&X#LC@%8#L"F X@<0$P'4#F F@Y@<@"K#^B:M"T'V/4H=1W!D0,<4Y?&
M<L#8= "T\LQ9IK. 1;(;V>X\2IYN:)QOF"<<&F<<YBF'C9QWSB5/.JQGO;-R
M89YV:)QWF"<>UC/?/21//6SDOG-(GGS8R'[G*LRSCQK9[PHRRK./ZME'77!
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M/HOI,X@S::XM.\BG*Q_- ^Q'66;=L9C?]?DX-K^BT1.)F7\?$'#+)Y7$,=F
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M;+69;6_;-A#'OPKA94,#M)9(2I;=.@:2.$XR)&W0+!N&8B]DFXZ%2J1'TGD
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MJE2C;R=NP3&9=0&,M"#R6TQU\H:IWER/P;N]?:M:HW?ZAOFVT3MSZWV9R2[
M,-?K-0EYJNC+RD=EY:-<&3<&<BI-5><@_G:A;@#GDF3B'X<\+N5Q+A\TR)]3
M292C$GR-):F+H]N\W_7]7QUN!*4;@5/G6H=+K>QD5N?$66$,_=Q:][F[D=^-
MHJ%W5S-F6(X9NL<D/%%K_N@#5 .3!>&<S,%U 8)OER2;$NZ*<*\<IK>+!$:E
M?.2<145YI<,'V$(U135D0H7D:]6_95U:H]<1#;NX7Q_1?NE+W^F+7IR&R4\!
M!#_ *:'D(9\SG;4)[* <;;"+P$+?]AS_?Q3EB;&.*B&$?GT 8:7/P<UCJD8D
MQ%I5XX]F()T8H; R_,#7?PTN6.! M$46S6HY_("W6BW0 @GBG:35H@:Z65/=
M(JSL7H+J&>NNYW]Z"K]DJF;O%!T9%RH$14NL[=/%B+WJ:AI$?M"0"DLHZ$94
MTZZF)C';8@Q:CL&=@ Q:DD$WRO(!9G8 NM;.:Z#EJZ#(BFM-C,T U34!833
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M+"F,%8,D2O-?^KW8B)H!\3L,2&% ^AK8A8%]:&!U&#B%@=/7P"T,W+Z4O,+
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MWW.NS_%U3%0+^:@V $B><EZHF;-!+*]<5R4;R*D:B!(*/9,)F5/4H5R[JI1
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M2#L3P5\T4*"D\22YZX,UP@@ =R;%HH#@ D!1T#_LP=KEY%@YMAV *)\ P0&
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M!,8%3L_[*5N"2OH)F4M4A>K[B:*^?S=Q$DZZ  2V**I"U?^$3.W;)@BY$!
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ML9)E+:!_7Q>%^GI1/Z;M_E-@_A]02P,$%     @ VCV<4B!/N*5% P  TPH
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MOX]];^"N*J@[)76GD?HV=[B)N;/'?-CI=G2-J6;NELS=1N:+S#PR:=YRSGV
M+C,E%6$Q9?-&1=T]1;VN']:%HE<*ZKWS%K;OK(H]1\'>BZMH!>UJ]G[)WG_?
M1323YR 8OR0/.]7D84D>-I+?V4JIZ<D*A*[\:&YB@6*B ,T(%6A%D@Q>7U"S
MTK B3'ZK'U8KQ=ZV.GK_G"P%Q.X+:7MAX/7JV'=J,VYDU_\[,Z!O\N/]G,%!
MNXMKZ/TMO?]125,@OXQ)+^SB?HVH;0G%P7])G +F=>:$=9>R+9^XN7[N7LH;
M$MH5^8-;O:!&PK:,XN8Z^A$95%#V=K6^KC+N3I^1@IC;;DJBB&=,Y2U'N5IV
M;,=YG[(]GK=[YT3,*9,H@9DV]5H]32_R#BJ?*+ZT7<N4*]T#V>%"=YT@S &]
M/^-<;2:&H.QC1W\ 4$L#!!0    ( -H]G%(U-XE>300  /01   9    >&PO
M=V]R:W-H965T<R]S:&5E=#DQ+GAM;+V86T_C.!2 _XI5S<.,!"1VVB9!I1*4
MO<P#NX@N,P^K>3#):1N1Q%W;I2#MC]_C)(T+)6Z9&?:%)H[/_?C#]F@MY+U:
M &CR6.2E.NLMM%Z>>IY*%E!P=2*64.*7F9 %U_@JYYY:2N!I)53D'O/]H5?P
MK.R-1]78M1R/Q$KG60G7DJA547#Y= &Y6)_U:&\S<)/-%]H,>./1DL]A"OIV
M>2WQS6NUI%D!I<I$223,SGKG]'025 +5C"\9K-76,S&AW EQ;UX^IV<]WW@$
M.23:J.#X\P 3R'.C"?WXIU'::VT:P>WGC?9?J^ QF#NN8"+RKUFJ%V>]J$=2
MF/%5KF_$^G=H AH8?8G(5?67K)NY?H\D*Z5%T0BC!T56UK_\L4G$E@ ;= BP
M1H"]$*#]#H&@$0BJ0&O/JK NN>;CD11K(LULU&8>JMQ4TAA-5IHR3K7$KQG*
MZ?%TP24<FT2D9"(*[ [%J_P>DRFV3+K*@8@9V9YVS9^PCIJ<2\G+.53/-Z"T
MS!*-GZ=:)/?DMLQPAJE1II_(QTO0/,L_H=;;Z27Y^.$3^4 \HHQ61;*RFJZ.
M<!"?_UJ(E>)EJD:>Q@B-GU[21'-11\,ZHJ&,7(E2+Q3YI4PA?:[ P]2T^6&;
M_%PPI\9+2$Y(0(\(\YG_BD.3@\5I[' G:,L55/KZ'?I0342N<UZ2OZ^@N /Y
MS:&TWRKM5TJ##J5?JU['TO$'D+AV"3R"3#(%9(DU!8>%06MAX'3[-^P4_;(>
M=?YJP; 2-,QY&-.1]_"*K6%K:^BT]>=**XWMDY7SUQIHZ+!7>^2:\<RCL/4H
MW%,TYA]<M*A5&KU3T>+60OR=1;NH!2G=RM'@).Y($_4MB_P?*5TC;7X.,;N%
M0.HTNPVOFDB;.I%_R9M6'&76)G.6[X^5T:4,6VL*NK1:.E W'APE:R0'VVT=
ML(@:JKV:/DL/VG<:_8+IZ[#9W[%Y/!@.<(O18=/RA+J!LI.^([*O>08[OH1#
M%G>&;W%#A^^T$*D%"'43Q%77\%!<48L6&GUO1:/=+NJP9C%#W9S95[CXT "9
M!0US@V:G9A+,EA<]( GN'R1N+E<\)QIDL;>Q]IB*R1-P[-20%/7.A/5)RI]<
MZYU9<C$WN<[G<PESK@'W38@PW%PGY('G*]CO-=W-:C\*PX[,6JXQ]B,L?<,_
M0F:IQX*?QE)FL<;<6'.L.;;+M;X?!WX8=Z3/<HVYN89'DQED769W$79,@_ZP
M:SE8A#'WEJE[O3>"!Q.<6:0Q-]+>3O!&X?.LA_&01AV^6-ZQ]]I+,4LYYJ:<
M(\?Q[K:&!B?QX/6P DNYX/^CW!Y3&\I%&\KA26P/Y0)+N>"]*!?L4BX*A@%[
MD5EOZ_Q<@)Q7UPH*D[0J=7U4;$?;JXOSZL#^8OR"GD[J"PBKIKX/N>)RCIZ3
M'&:HTC\)L8UE?<50OVBQK$[I=T+CF;]Z7 !/09H)^'TFA-Z\& /M1<_X/U!+
M P04    " #:/9Q2R4SQ "<4  !$DP  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Y,BYX;6SM76MSVSBR_2LHWYU;F2K'9O/-W215CCU)/!,GBN4D,[.U'V@)
MMEBA1"U)V?'4_?$7? D@\2 HR[.LK?EB6S+0!-! GT:C<?CB/DF_90N,<_1]
M&:^REP>+/%___?@XFRWP,LR.DC5>D?_<).DRS,G']/8X6Z<XG)>5EO&Q:1CN
M\3*,5@>O7I3?3=)7+Y)-'D<K/$E1MEDNP_3A-8Z3^Y<'<-!\<1G=+O+BB^-7
M+];A+9[B_/-ZDI)/QULI\VB)5UF4K%"*;UX>G,#?3TXA<(LJ99DO$;[/F+]1
MT9GK)/E6?#B?OSPPBC;A&,_R0DA(?MWA4QS'A2S2DG_78@^V3RTJLG\WTM^4
MW2?=N0XS?)K$7Z-YOGAYX!^@.;X)-W%^F=R_PW67G$+>+(FS\B>ZK\L:!VBV
MR?)D65<F+5A&J^IW^+T>"J:"Z4DJF'4%LUL!)!6LNH*E6\&N*]BZ%9RZ@J-;
MP:TKN+H5O+J"UZD MJ2"7U?P=9\0U!4"W0I@-)HSM*MLE<UI6UJE43=HZQL:
MA8.VQJ%1.71U+AU@:)0.7:W+IWJC=NCJ75ZE43QT-2_O2Z-ZX'0O6U+0*!^T
MM6\VVC>UM6\VVC>UM6]N%[NV]LU&^Z:V]LU&^Z;VBC<;[9O<FI?:K4;[)K?J
M9=HW&^V;G/:E3VFT;VIKWVRT;Y;:/ZYL=VGXS\(\?/4B3>Y16I0G\HH_2O0H
MZQ-['ZT*J)OF*?EO1.KEK]Y'LP*W5K?H9#5'!"[B\#I)PQ*$3FY3C FLY1EZ
MCD[F\ZCX-HS1^:J"V*+,LS.<AU'\(_K?_P'7^0>*5NAJD6RR<#7/#M'?6I]?
M'.>DQ<5SCV=UZUY7K3,EK3O#LR-DP2$R#=/X/#U#S_[V8[8(4RR2=:J6-<7K
M(V18+5D"*6<:4BRCD +!Z8??T+.JXR)1/ZE%O<'71\CTM42]48OZ>1,WXP2^
MO&]O!TCI:="['E'AB@QV+4I0_5Q=_4-R=X3 *ZM[\O[\/$!*3W]^48LZV=QR
M$U$@Y?T *3T-NMB+QC_L3^,?-31NR34^V>-*_S1 5D^O+K5%02 ?YND *6R#
MI#V\TA>HT/[G 5)ZQNF+OBC%@OTZ0$I/@W[5%]4W!WY3B[H(T^UT GG??M]Q
M4DKGP,F)]HHS#;F4'H@MC:1AMV:X7%@/QK:$]77RF+@J6W_%W/HK9OD$2_($
MQD.YP^@D3</5;>FC(.)AM#Y_S!<X1?DB7*%VI7^^)S+1>8Z7V;\4+;*V+;+*
M%MF2%EWB#(?I;%$V8([O<)RLRP;@[VOB6F&1+:PD>J7$(AAQ]PH<(P#CQ?$=
M:^:J8BY3+/!MUP_:Q:9\,=\V;'#:Q3[SQ6S3-4R_7>Q703'+-6C36H-D;P?)
M5@[2>99M,$IN4#41#M&7,-Z(AN:US0^-UV[AI+_(U.8ZX;9+_,Z7 +#%G72V
MG72&=!+]'Y(NI->5)(=]O&O[ON] 1[L3[9)3OJ1ON9;7+?>[CL36 +C; 7"5
M W 1Q9CL6<CJ2LDZ6&V*W[/D=A7]@>>B9>!RBC0MUS;MSC)P^?8Z9.JZG9D[
M=3F56H9A=!;59UZ:8WD^B'ON;7ON*7M^\OH]>ATEZ)\7>'F-4Y5=\;<B_9%8
MNF#;HN!1EHY,^,K<B^ ZX,V*;<C,"AAT^VHHV_06K_#WLI>KF<[H [,QAI&,
M/U#P _/)-/"IEMVV[%(-4/@#-?XQ$80F7H"^1OD"G4XGIVA"+. RG.%-'LW"
M&+U-D\T:O8^648[G6WV19I>%=?1'$0?LL>B/ @2H$>+S^B9-R!.K,</H#5:J
M[#,(3+4C7S743H.NH5Z'#U6$1]D,@06V%.V@5A-ZS.;\+ES-,"*CLJSC73CM
M:8O'M\4VI4VAUA9\95,F:3+#>)Y5;5EN!RB<+2*RT,J)HFC762W>E:JJ#@GQ
MQ7QIXZEA!K5E5@&OJM736JXCQ<RVDT[-LJDVRU*C,  H36JJS;&8:I/9IZA-
M-;_$1!Y0+81U@3HSYE)9I-TX:K--M<T>Z*A=F?R&Q70XSZHNU5J:GG1IFM22
MF^K-@_9D(E-]R/RB9MMTQC*_J DW]VG"WYJ\<^P&AA3^36K"3;4)?XQR"MPG
M\DK/8-N?3$MWU*Z;8W&C36JN35USK; -;VHA[**S^%7WUN1-N&D9(-.L16VX
MM2<;+M;L-"2='*A6BYI\:RPFWZ(FW]J#R7]3"V'UY?*.PEM+X*V[AM2:6DRX
M2FW[)6=\@^'9HO;;&HLG;E&3;JD]\<?LI*:U[';PR.3P4%1,ZEM9U/);:LM_
MFF1Y&5DJEF:I1F&(42W$,8X,XP?1-G'7BI>[5ISN6O%JUXJ?=ZC85A:%1TL-
MCX-6VS#_Q:(8:(T% RV*@=8^,-#B,3#P'&DTFF*;K<:V1RW_6G9G#R=K$X4T
M&P;C[7TQ32Z2=+U(I@\9.GG+SI7M]\S7"MW8%,CLL1RRV!2V;-TMBV*^_&(+
M3E8X;'UO\V<<Q!F6*9 YXQB^3]%3H);Z*+;98]FNV!2T;+5)%42^1&DAMN!(
M@(_A_VSSNQFP3$^J0FJN;;6YUIIEY[60EE7R.<_\Y[I8:YHYEMQZ47MNJV-5
MTHDFC(:3B38T2FY3,VX'(YEK#C7N3I]QGV^J-.IHQ43R:HV*DIEZ!/;Z PXU
M\DZ/D4]6M\]SG"[19$/P)R1+X319+J.\:-HAFN T2D0AF(\]<L%!#P315$?L
M#K7_CGHC(S=DX2Q-R&2*9EG+C@F^5C6$&GW'&LOLHE;>T;3RA8-@_(-I1':(
MSG V2Z-U.?F2&U0H6ACWZWG&U0+71R51AE*<K1/RQ.L8HYLD16$<MUR6&=D/
M9,54?YOBD#P1G2ZB57C4TLH0,60DB\)YV0'R]WV2QO-#XAG-\#HOAC@OOY:V
MSS1^:*HV,F>;-,7S0OBSZ,?J<D.41SA#V6:]3M*\F&JW<7(=QFC6!(3R- KC
MLD'WBXAX:O29ZY#4F$5KTEDRY,\B(G*&TSPD14\O3EGQ17.6Q9@04412CE=S
MTHP\0=<8;;*J18('M@;RL)QKY"G%8Y+E.EP5RIU'X>V*]"Z:M0:Q*'H7QM&\
M\O>+YT>K.1%??,S(8XN>9OEF'E4/;ZM,M!W[:Z;\-5/Z9DK;DC'I*NH82&DS
M*RMVOGJNL&M:1IVZ@HX[%J-._3Y'[??IN:=7#N_X25.C'.K..6IW3LOI?%T+
M:6]M/+OK=4X$Y2SHEOKD\.>0)EC=8I>BAW*!KFE=JI5YQ#7L2M0P+F8F:I=T
M;^U0-]49&FU \XTZ7<+AX^IDM&U96USJGKK#X^KADOB%Z-W9;Q>'Z/SY17A=
MKH5W9"7\L4@VZ!T.X^EF542&UD5"!5D.1X?H?=Y*H6@*:2Q6E_JK[ECB["YU
M3]V^+)CJS++*&F@]*Z0-*G$H)O:3#&R893@KK'@>?E=F%[A\U-URN9W=5T$Q
M *DE<*F_ZZJ#'(],0OCJ\B>P9B!=/B[U>5VUER%8/@2JDZ5Z!=5"6ZEV131&
MWB *7:X:NL[P#2X=A51K+C!3X<O)E7H(!4%[1YJBX3*ID?U1^^=Y\KQP="J$
MC5;K38Z6.%\D<[3&Z4R\.;WJ$4Q&5!;FWKGFEYZ:MBFI^'6'BNT!I9#M#C]X
M?@HS2K[:SK;&\NB86 K_[EBB\R[%2U>-ES]]GT7$#2H:4)WC7H7?L3+#X*O+
M9WA*8ZH>!4MO0*#^C/&??ZH#]8^(<GD4!;VQH*!'4=![PEQ0CS^$-N7:HOCE
M#;@+T:.M8=%RU9!1&//&<A#M423SU$BFY?Q?>H+<?BF,>A24/+4Y?CI]#3W=
M\)A,>V\L2J0FW%/OX#2WCQZ_ ^IXEE\$100'(%\]?L>E.@#QJ.'W]G L>^GQ
M>R.?:^144,IQI&WT*2;X^\.$)S\J\2F(^&,!$9^"B*\&$;V)._%YN "34_@G
M03$OD&Z+? HK_I/"2E9E6U3V*'O(=C92/D4:?RQ(XU.D\0=?/A"M;9^'FFXD
M1U#$XM.!?7XG95K2!#:?@I;_9X#67DZR?(I:_EA0RV<NF.T#M2Y] =;(+W_X
M%&I\-=1\)'O>L SH=Q6GNJM&42(P1C+B 86 0'U*^RB?O9;-ZL&VI)&)@&)
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M<1P7OS.,OY69;?AV$X=YDCZ@<$T*WH6QJ.[1UO0HF]KDRW5:63->"-L4K9I
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M$4@EVY0J5-6\X0H5Q(@%'!=; S*9LAOR'<WN$H^BX*BS/8KUNA44!,>0LWL
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M)NT]0-=)3K9>Y9\+',YQ6A0@_[])B!6H/QP3^?=)^JU\QJO_!U!+ P04
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M/%1R0Y1]C6AVX7+CK#$:)JR,<Z/PEJ&=&7_#2KD4N2R!'%U)K8])!8K,"ZJ
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MN89&3]?RY9)K]R4;;WM^'I!\I5%6#=A$4#'A5_K8Y&$'$/<. )(&D+P&I <
MG0;0>2L@;0 NU:&7XO(PI4BS@9(;HJRU8;,;ETR'-O*9L&6_1V7^,H/#[*JJ
MN7P"(&,0L&"HR4<R*@IFBT(YN1'^9=D2G4P!*>.GQF+RY2<Y>?\N[G4_G1*_
M$B;(UU*N-!6%'H1H8K,>PKR)8^SC2 [$$2?D5@HL-;D2!10O"4(CJE66;)6-
MDZ.,4\C/2"?^0)(HB?8$-'DS/.[O@4_?#K\XHJ;3UJGC^#H'^&92([A:F9[#
MYVK]&LTU*M,]OX\X25LGJ7.2_N\QS#T]@4<S7C3LK:>GZCDJ.US661Q%J4G5
M>C?)>ZS2N)N\M)K^:]5/^FEKY,6$.Z^\ K5TTT*37*X$^F?1WK8#:>3Z\-7]
MV PJ/U>>:?R4NZ5JR80F'!:&,CH[[P9$^<GA#RAKUTMSB:8SW;8TPQ:4-3#_
M%U+B]F =M.,[^PM02P,$%     @ VCV<4@(8TKA> P  A0L  !D   !X;"]W
M;W)K<VAE971S+W-H965T.3DN>&ULM59M;]LX#/XK@F\8.F"K+2?.RY8$6),=
MUL.Z!6UWPS#<!\6F8V&RE4ERTMRO/\IVG;2)O=R'P( MR>3#1R1%<;21ZJ=.
M  QY2$6FQTYBS.JMZ^HP@93I2[F"#/_$4J7,X%0M7;U2P*)"*16N[WD]-V4\
M<R:C8FVN)B.9&\$SF"NB\S1E:GL%0F[&#G4>%V[Y,C%VP9V,5FP)=V"^KN8*
M9VZ-$O$4,LUE1A3$8^<]?3NC@54H)/[FL-%[8V*WLI#RIYU<1V/'LXQ 0&@L
M!,//&J8@A$5"'K\J4*>V:17WQX_H?Q:;Q\TLF(:I%-]X9)*Q,W!(!#'+A;F5
MFX]0;:@@&$JABS?95+*>0\)<&YE6RL@@Y5GY90^5(_84?-J@X%<*_JD*G4JA
M<ZI"MU+H%IXIMU+X8<8,FXR4W!!EI1'-#@IG%MJX?9[9N-\9A7\YZIG)+0AF
M(")SILR67#'!LA T85E$[A7+-"O"H\D;<E=F!I$Q:5"ZF(%A7+PB+_^@O> =
MX1FY3V2N$4R_)B^>S$>N0?:6@QM63*]*IGX#TQF$EZ1#7Q/?\[WIY^_DHC3S
MZ@C4]'] ?;V;D8L7QU!F)Z/083,A%R-2A\6OP^(7V)V3PK(7"?+C$XJ2:P.I
M_J?%4*<VU"D,=1L,?5$1SVQ8=<(4QM!(L@#"M<[1.DX^K &7S3'OE,"] MB6
ME_7$#P:4#D?N^@BA;DVHVTH(#_!C3<!,$Y)EE@:^61QSP=$KQU*G>\B%XE-3
M*;.BE.KO277\@![G&]1\@U:^UV]NV()\9-GR7\QM\N,&T@6HMM#T:N3>>7.@
M7QOJM^> 24!A$0^!K]E"P-'#64($O_'PH52SAP<UO<$9,F)PP"3 N]![QO=0
MJC_L-63PL.8[;.7[X0$O98UG:<5X1)#U A(F8DO^=Z2')SGY4*K9R=3;701>
M.^WRI)^2P73O=J'GS6&ZJYC4/U<EJY!/+65T5UQI>W7]BV-=T#FY9UIL([[E
M9([D4A9";GC(!)E*\LE$)_E\5T!I]\P^W]4^VE[\WH>ARIDH^P59E)$5VS;6
MD KMB9\[P^!9>E=23\ITK_\L%.Y>RV,;U!NFEAS[% $Q:GF7?0119<]73HQ<
M%5W00AKLJ8IA@GTR*"N _V,IS>/$-E9UYSWY#U!+ P04    " #:/9Q2=(#$
MU2T"  "X!   &@   'AL+W=O<FMS:&5E=',O<VAE970Q,# N>&ULC51A3]LP
M$/TKITR:0 *2II1MK(TTBB9 8JJ ;9JF?;@FER;"L3O[0F&_?F<GK3J-(K[$
M=_:]EW<OOHQ7QMZ[BHCAL5':3:**>7D:QRZOJ$%W9):DY:0TMD&6U"YBM[2$
M10 U*DZ3Y"1NL-91-@Y[,YN-3<NJUC2SX-JF0?MT1LJL)M$@6F_<U(N*_4:<
MC9>XH%OBK\N9E2S>L!1U0]K51H.E<A)]&IQ.A[X^%'RK:>6V8O"=S(VY]\EE
M,8D2+X@4Y>P94)8'FI)2GDAD_.XYH\TK/7 [7K-_#KU++W-T-#7J>UUP-8G>
M1U!0B:WB&[.ZH+Z?D>?+C7+A":N^-HD@;QV;I@>+@J;6W8J/O0];@,'Q#D#:
M ]+7 H8](#@7=\I"6^?(F(VM68'UU<+F@^!-0$LWM?9?\9:MG-:"X^R&%#(5
M,$/+3W"&"G5.#E 7<&=1.PQN.SB$V^X[@REA!VA/<M)<$=<YJGW8.R?&6H)#
MF'[Y 7MOWPQ.1A_WH5NAUG!7F=;)N]PX9FG&2XKS7OA9)SS=(?RJ54<P'!Q
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M/1]NJ5HQH0F'U% &ESVSPU1U(U<=E(6[HY82S8WGFIEYQ8"R$\SW5$K<=:Q
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M!ASZF_%7FK)%GC1774,AZJLVXR^07A@WVWX=BXF4+FDZKJ=R-C%#3P]TU/H
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #:/9Q2<56++"D'  "U0P  #P
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M5[T]0&]?/>P&Z.U5;P_0VZO>'J"W5[T]0&^O>GN WE[U]@"]@^H= 'H'U3L
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M2P$"% ,4    " #:/9Q2P/"NCN\    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #:/9Q2F5R<(Q &  "<)P
M$P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( -H]G%(X5T=GYP8  (L@   8              " @0X(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #:/9Q2HTWPM6P(  !_)0
M&               @($K#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ VCV<4K?&OAVJ P  H1(  !@              ("!S1<  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( -H]G%+7'!#HG <
M  $A   8              " @:T;  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " #:/9Q2_'->KF (  #S)0  &               @(%_
M(P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ VCV<4HV
M2P'?#0  #D   !@              ("!%2P  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( -H]G%(MX6IHV@4  $\-   8
M  " @2HZ  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #:
M/9Q2!>+]<@TF  #'A@  &               @($Z0   >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ VCV<4M/IF%K5 @  ! <  !@
M         ("!?68  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( -H]G%))97X_4@,  +<&   9              " @8AI  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ VCV<4ENZ0$O8 P   P@
M !D              ("!$6T  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " #:/9Q2!JZ3%*P$  "6"@  &0              @($@<0
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( -H]G%)0KO$M
M6P0    *   9              " @0-V  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ VCV<4A$[2T$K P  J 8  !D
M ("!E7H  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #:
M/9Q2*H$F!*8)  !>&P  &0              @('W?0  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( -H]G%+:7'NI#@(  )H$   9
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M970R,"YX;6Q02P$"% ,4    " #:/9Q2,SS^3WT#  !F"   &0
M    @(&*K   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M -H]G%(QYC6)_ @  +07   9              " @3ZP  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ VCV<4KC^!9Z@&0  1F\  !D
M             ("!<;D  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " #:/9Q2F?ED4L8>  !@=   &0              @(%(TP  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( -H]G%(Q*B$X@P0
M .X)   9              " @47R  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ VCV<4NFF.^<F!0  7 P  !D              ("!
M__8  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #:/9Q2
MZ_=BIH0#  ",!P  &0              @(%<_   >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( -H]G%)MEDAFLP,  "X(   9
M      " @1<  0!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ VCV<4BE=?Z)5!   M0P  !D              ("! 00! 'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #:/9Q2AD7Y]B<"  "V!
M&0              @(&-" $ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( -H]G%*A$[^*OP0  "8+   9              " @>L* 0!X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ VCV<4CKOA:VQ
M!   _@H  !D              ("!X0\! 'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " #:/9Q2>]2(1)DN  ![K@  &0
M@(')% $ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( -H]
MG%)XJBL1LP(  ,\%   9              " @9E# 0!X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ VCV<4LS&LS^/!0  T0\  !D
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M=#,Y+GAM;%!+ 0(4 Q0    ( -H]G%( ]X?/W (   $'   9
M  " @3Q: 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
MVCV<4@Z^4,I+!   M@D  !D              ("!3UT! 'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " #:/9Q2T+8DO: #  "6!P  &0
M            @('180$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( -H]G%)3FT@B;04  *\,   9              " @:AE 0!X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ VCV<4L--/=)\ P
M3PD  !D              ("!3&L! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    " #:/9Q2+PGMG> #  #L"   &0              @('_
M;@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( -H]G%*T
M8SYXC H  (LR   9              " @19S 0!X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ VCV<4BQ0:[;J P  &!$  !D
M     ("!V7T! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -H]G%(AU>I@C@,  . +   9              "
M@;&2 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ VCV<
M4B"M^54B P  & L  !D              ("!=I8! 'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6Q02P$"% ,4    " #:/9Q2IM HP-,$  #L%   &0
M        @('/F0$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0
M   ( -H]G%+P *]CYP(  ,P(   9              " @=F> 0!X;"]W;W)K
M<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ VCV<4B)QY[W- P  B0P
M !D              ("!]Z$! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q0
M2P$"% ,4    " #:/9Q2?@-[ZQD#  #(#   &0              @('[I0$
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( -H]G%*(1^B?
M[P(  #P)   9              " @4NI 0!X;"]W;W)K<VAE971S+W-H965T
M-3@N>&UL4$L! A0#%     @ VCV<4G5V+UY_ P  3@L  !D
M ("!<:P! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " #:
M/9Q2E1@'KG<"  #Z!0  &0              @($GL $ >&PO=V]R:W-H965T
M<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( -H]G%+7;L4'[P,  *T/   9
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M970V-2YX;6Q02P$"% ,4    " #:/9Q2,&DQ3>P"  #["   &0
M    @(%7Q $ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    (
M -H]G%*T?B$ZM0(  *8'   9              " @7K' 0!X;"]W;W)K<VAE
M971S+W-H965T-C<N>&UL4$L! A0#%     @ VCV<4I+SF^0=!   GQ   !D
M             ("!9LH! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"
M% ,4    " #:/9Q2;RO7 08#  !H"   &0              @(&ZS@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( -H]G%)*PV<?(P<
M &(G   9              " @??1 0!X;"]W;W)K<VAE971S+W-H965T-S N
M>&UL4$L! A0#%     @ VCV<4MB'=[_U P  X0\  !D              ("!
M4=D! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " #:/9Q2
M$$9*CG0$  "Q#P  &0              @(%]W0$ >&PO=V]R:W-H965T<R]S
M:&5E=#<R+GAM;%!+ 0(4 Q0    ( -H]G%*&39P9F0(  (X&   9
M      " @2CB 0!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%
M  @ VCV<4LI*E-0W P  CPL  !D              ("!^.0! 'AL+W=O<FMS
M:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " #:/9Q2Z3'JJ$$$   I#0
M&0              @(%FZ $ >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+
M 0(4 Q0    ( -H]G%(I3(?:) 0  /8.   9              " @=[L 0!X
M;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ VCV<4KAP:<EL
M P  20H  !D              ("!.?$! 'AL+W=O<FMS:&5E=',O<VAE970W
M-RYX;6Q02P$"% ,4    " #:/9Q22'[Z.5H)  "M,0  &0
M@('<] $ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( -H]
MG%*#3UJ3I@@  +0Q   9              " @6W^ 0!X;"]W;W)K<VAE971S
M+W-H965T-SDN>&UL4$L! A0#%     @ VCV<4E0JB DY!@  X",  !D
M         ("!2@<" 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"% ,4
M    " #:/9Q2\!3E8E\%  "'&@  &0              @(&Z#0( >&PO=V]R
M:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( -H]G%+%^\[75 4  +86
M   9              " @5 3 @!X;"]W;W)K<VAE971S+W-H965T.#(N>&UL
M4$L! A0#%     @ VCV<4H?_NR3: @  ?@@  !D              ("!VQ@"
M 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q02P$"% ,4    " #:/9Q2PZIQ
MG:P"   C"   &0              @('L&P( >&PO=V]R:W-H965T<R]S:&5E
M=#@T+GAM;%!+ 0(4 Q0    ( -H]G%((R."K;A,  (Z@   9
M  " @<\> @!X;"]W;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @
MVCV<4K";E-10!   O10  !D              ("!=#(" 'AL+W=O<FMS:&5E
M=',O<VAE970X-BYX;6Q02P$"% ,4    " #:/9Q2;N_7F$@'  #5*0  &0
M            @('[-@( >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4
M Q0    ( -H]G%).TH(D=00  -(5   9              " @7H^ @!X;"]W
M;W)K<VAE971S+W-H965T.#@N>&UL4$L! A0#%     @ VCV<4M?B=3VW!0
M-2   !D              ("!)D," 'AL+W=O<FMS:&5E=',O<VAE970X.2YX
M;6Q02P$"% ,4    " #:/9Q2($^XI44#  #3"@  &0              @($4
M20( >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+ 0(4 Q0    ( -H]G%(U
M-XE>300  /01   9              " @9!, @!X;"]W;W)K<VAE971S+W-H
M965T.3$N>&UL4$L! A0#%     @ VCV<4LE,\0 G%   1),  !D
M     ("!%%$" 'AL+W=O<FMS:&5E=',O<VAE970Y,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -H]G%*$Q@H" P,  .$)   9              "
M@5%U @!X;"]W;W)K<VAE971S+W-H965T.3<N>&UL4$L! A0#%     @ VCV<
M4JUBZ"=B @  R@4  !D              ("!BW@" 'AL+W=O<FMS:&5E=',O
M<VAE970Y."YX;6Q02P$"% ,4    " #:/9Q2 AC2N%X#  "%"P  &0
M        @($D>P( >&PO=V]R:W-H965T<R]S:&5E=#DY+GAM;%!+ 0(4 Q0
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M965T,3 S+GAM;%!+ 0(4 Q0    ( -H]G%+(+"P*7 ,  !86   -
M      "  6F* @!X;"]S='EL97,N>&UL4$L! A0#%     @ VCV<4I>*NQS
M    $P(   L              ( !\(T" %]R96QS+RYR96QS4$L! A0#%
M  @ VCV<4G%5BRPI!P  M4,   \              ( !V8X" 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( -H]G%(*2%)NZP(  (8\   :
M  "  2^6 @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M -H]G%*$=9N'8P(  &$Z   3              "  5*9 @!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !O &\ A!X  .:; @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>473</ContextCount>
  <ElementCount>587</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>187</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - Principal Activities and Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PrincipalActivitiesAndOrganization</Role>
      <ShortName>Principal Activities and Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Principal Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PrincipalAccountingPolicies</Role>
      <ShortName>Principal Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Accounts Receivable And Contract  Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/AccountsReceivableAndContractAssets</Role>
      <ShortName>Accounts Receivable And Contract  Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Prepayments And Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PrepaymentsAndOtherReceivables</Role>
      <ShortName>Prepayments And Other Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Property, Equipment And Software</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PropertyEquipmentAndSoftware</Role>
      <ShortName>Property, Equipment And Software</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Intangible Assests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/IntangibleAssests</Role>
      <ShortName>Intangible Assests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Investment Accounted for Using the Equity Method and Put Right Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilities</Role>
      <ShortName>Investment Accounted for Using the Equity Method and Put Right Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Short-Term Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ShortTermBorrowings</Role>
      <ShortName>Short-Term Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Accruals And Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/AccrualsAndOtherPayables</Role>
      <ShortName>Accruals And Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Ordinary Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/OrdinaryShares</Role>
      <ShortName>Ordinary Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Convertible Preferred Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ConvertiblePreferredShares</Role>
      <ShortName>Convertible Preferred Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Convertible Promissory Notes And Onshore Convertible Loans</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoans</Role>
      <ShortName>Convertible Promissory Notes And Onshore Convertible Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Licensing And Collaboration Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/LicensingAndCollaborationArrangements</Role>
      <ShortName>Licensing And Collaboration Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Other Income (Expenses), Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/OtherIncomeExpensesNet</Role>
      <ShortName>Other Income (Expenses), Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Net Income (Loss) per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/NetIncomeLossPerShare</Role>
      <ShortName>Net Income (Loss) per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/EmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Related Party Balances and Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/RelatedPartyBalancesAndTransactions</Role>
      <ShortName>Related Party Balances and Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Concentration of Credit Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ConcentrationOfCreditRisk</Role>
      <ShortName>Concentration of Credit Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Restricted Net Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/RestrictedNetAssets</Role>
      <ShortName>Restricted Net Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Principal Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PrincipalAccountingPoliciesPolicies</Role>
      <ShortName>Principal Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://IMab.com/role/PrincipalAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Principal Activities and Organization (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PrincipalActivitiesAndOrganizationTables</Role>
      <ShortName>Principal Activities and Organization (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://IMab.com/role/PrincipalActivitiesAndOrganization</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Principal Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PrincipalAccountingPoliciesTables</Role>
      <ShortName>Principal Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://IMab.com/role/PrincipalAccountingPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Accounts Receivable And Contract Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/AccountsReceivableAndContractAssetsTables</Role>
      <ShortName>Accounts Receivable And Contract Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://IMab.com/role/AccountsReceivableAndContractAssets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Prepayments And Other Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PrepaymentsAndOtherReceivablesTables</Role>
      <ShortName>Prepayments And Other Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://IMab.com/role/PrepaymentsAndOtherReceivables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Property, Equipment And Software (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PropertyEquipmentAndSoftwareTables</Role>
      <ShortName>Property, Equipment And Software (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://IMab.com/role/PropertyEquipmentAndSoftware</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://IMab.com/role/Leases</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://IMab.com/role/IntangibleAssests</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Investment Accounted for Using the Equity Method and Put Right Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTables</Role>
      <ShortName>Investment Accounted for Using the Equity Method and Put Right Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilities</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Accruals And Other Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/AccrualsAndOtherPayablesTables</Role>
      <ShortName>Accruals And Other Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://IMab.com/role/AccrualsAndOtherPayables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://IMab.com/role/IncomeTaxes</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Convertible Preferred Shares (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ConvertiblePreferredSharesTables</Role>
      <ShortName>Convertible Preferred Shares (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://IMab.com/role/ConvertiblePreferredShares</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://IMab.com/role/Warrants</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://IMab.com/role/ShareBasedCompensation</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Licensing and Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/LicensingAndCollaborationAgreementsTables</Role>
      <ShortName>Licensing and Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Other Income (Expenses), Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/OtherIncomeExpensesNetTables</Role>
      <ShortName>Other Income (Expenses), Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://IMab.com/role/OtherIncomeExpensesNet</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Net Income (Loss) per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/NetIncomeLossPerShareTables</Role>
      <ShortName>Net Income (Loss) per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://IMab.com/role/NetIncomeLossPerShare</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Related Party Balances and Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/RelatedPartyBalancesAndTransactionsTables</Role>
      <ShortName>Related Party Balances and Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://IMab.com/role/RelatedPartyBalancesAndTransactions</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Principal Activities and Organization - Schedule of Principal Subsidiaries (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail</Role>
      <ShortName>Principal Activities and Organization - Schedule of Principal Subsidiaries (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Principal Activities and Organization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail</Role>
      <ShortName>Principal Activities and Organization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Principal Accounting Policies - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail</Role>
      <ShortName>Principal Accounting Policies - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Principal Accounting Policies - Summary of Roll Forward of Major Level 3 Financial Assets and Financial Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail</Role>
      <ShortName>Principal Accounting Policies - Summary of Roll Forward of Major Level 3 Financial Assets and Financial Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Principal Accounting Policies - summary of Cash, cash equivalents and restricted cash as reported in the consolidated statement of cash flows (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfCashCashEquivalentsAndRestrictedCashAsReportedInTheConsolidatedStatementOfCashFlowsDetail</Role>
      <ShortName>Principal Accounting Policies - summary of Cash, cash equivalents and restricted cash as reported in the consolidated statement of cash flows (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Principal Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Principal Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Principal Accounting Policies - Summary of Estimated Useful Lives (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail</Role>
      <ShortName>Principal Accounting Policies - Summary of Estimated Useful Lives (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Accounts Receivable And Contract Assets - summary of Accounts receivable and contract assets, net of allowance for credit losses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/AccountsReceivableAndContractAssetsSummaryOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesDetail</Role>
      <ShortName>Accounts Receivable And Contract Assets - summary of Accounts receivable and contract assets, net of allowance for credit losses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Prepayments And Other Receivables - Summary of Prepayments And Other Receivables (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail</Role>
      <ShortName>Prepayments And Other Receivables - Summary of Prepayments And Other Receivables (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Property, Equipment And Software - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PropertyEquipmentAndSoftwareAdditionalInformationDetail</Role>
      <ShortName>Property, Equipment And Software - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Property, Equipment And Software - Schedule of property, equipment and software, net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail</Role>
      <ShortName>Property, Equipment And Software - Schedule of property, equipment and software, net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Leases - Operating Lease Related Assets And Liabilities And Other Related Information (Detail))</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail</Role>
      <ShortName>Leases - Operating Lease Related Assets And Liabilities And Other Related Information (Detail))</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Leases - Components of Operating Lease Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail</Role>
      <ShortName>Leases - Components of Operating Lease Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Leases - Operating Lease, Maturity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/LeasesOperatingLeaseMaturityDetail</Role>
      <ShortName>Leases - Operating Lease, Maturity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Intangible Assets - Summary Of Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail</Role>
      <ShortName>Intangible Assets - Summary Of Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Intangible Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/IntangibleAssetsAdditionalInformationDetail</Role>
      <ShortName>Intangible Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Goodwill - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/GoodwillAdditionalInformationDetail</Role>
      <ShortName>Goodwill - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Investment Accounted for Using the Equity Method and Put Right Liabilities - Summary of Group Long term Investment Measured Under Equity method (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail</Role>
      <ShortName>Investment Accounted for Using the Equity Method and Put Right Liabilities - Summary of Group Long term Investment Measured Under Equity method (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Investment Accounted for Using the Equity Method and Put Right Liabilities - Summary of Estimate the Fair Value of the Put Right Using the Following Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetail</Role>
      <ShortName>Investment Accounted for Using the Equity Method and Put Right Liabilities - Summary of Estimate the Fair Value of the Put Right Using the Following Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Investment Accounted for Using the Equity Method and Put Right Liabilities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail</Role>
      <ShortName>Investment Accounted for Using the Equity Method and Put Right Liabilities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Short-Term Borrowings - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail</Role>
      <ShortName>Short-Term Borrowings - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Accruals And Other Payables - Summary of accruals and other payables (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail</Role>
      <ShortName>Accruals And Other Payables - Summary of accruals and other payables (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Accruals And Other Payables - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/AccrualsAndOtherPayablesAdditionalInformationDetails</Role>
      <ShortName>Accruals And Other Payables - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure - Income Taxes - Reconciliations of the Differences Between the PRC Statutory Income Tax Rate and the Group's Effective Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Reconciliations of the Differences Between the PRC Statutory Income Tax Rate and the Group's Effective Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure - Income Taxes - Components of the Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Components of the Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure - Income Taxes - Summary of Movement of the Valuation Allowance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/IncomeTaxesSummaryOfMovementOfTheValuationAllowanceDetail</Role>
      <ShortName>Income Taxes - Summary of Movement of the Valuation Allowance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure - Ordinary Shares - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/OrdinarySharesAdditionalInformationDetail</Role>
      <ShortName>Ordinary Shares - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1079 - Disclosure - Convertible Preferred Shares - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail</Role>
      <ShortName>Convertible Preferred Shares - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1080 - Disclosure - Convertible Preferred Shares - Schedule of Convertible Preferred Shares Activities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail</Role>
      <ShortName>Convertible Preferred Shares - Schedule of Convertible Preferred Shares Activities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>1081 - Disclosure - Convertible Promissory Notes And Onshore Convertible Loans- Additional Information (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail</Role>
      <ShortName>Convertible Promissory Notes And Onshore Convertible Loans- Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>1082 - Disclosure - Warrants - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/WarrantsAdditionalInformationDetail</Role>
      <ShortName>Warrants - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>1083 - Disclosure - Warrants - Details of accounting for warrants to purchase ordinary shares (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail</Role>
      <ShortName>Warrants - Details of accounting for warrants to purchase ordinary shares (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>1084 - Disclosure - Warrants - Summary of fair value of warrant liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail</Role>
      <ShortName>Warrants - Summary of fair value of warrant liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>1085 - Disclosure - Share-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Share-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>1086 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Expenses Related to Restricted Shares (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail</Role>
      <ShortName>Share-Based Compensation - Schedule of Share-Based Compensation Expenses Related to Restricted Shares (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>1087 - Disclosure - Share-Based Compensation - Schedule of Stock Option Activities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail</Role>
      <ShortName>Share-Based Compensation - Schedule of Stock Option Activities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>1088 - Disclosure - Share-Based Compensation - Summary of Valuation Assumptions Used (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Valuation Assumptions Used (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>1089 - Disclosure - Share-Based Compensation - Summary of non-vested stock option activities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail</Role>
      <ShortName>Share-Based Compensation - Summary of non-vested stock option activities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>1090 - Disclosure - Share-Based Compensation -Schedule of Nonvested Restricted Stock Units Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail</Role>
      <ShortName>Share-Based Compensation -Schedule of Nonvested Restricted Stock Units Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>1091 - Disclosure - Share-based Compensation - Schedule of Share-based Payment Arrangement Restricted Stock Unit Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail</Role>
      <ShortName>Share-based Compensation - Schedule of Share-based Payment Arrangement Restricted Stock Unit Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>1092 - Disclosure - Licensing And Collaboration Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail</Role>
      <ShortName>Licensing And Collaboration Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>1093 - Disclosure - Licensing And Collaboration Arrangements - Summary of Financial Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail</Role>
      <ShortName>Licensing And Collaboration Arrangements - Summary of Financial Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>1094 - Disclosure - Other Income (Expenses), Net - Summary of Other Income (Expenses), Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail</Role>
      <ShortName>Other Income (Expenses), Net - Summary of Other Income (Expenses), Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://IMab.com/role/OtherIncomeExpensesNetTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>1095 - Disclosure - Other Income (Expenses), Net - Summary of Other Income (Expenses), Net (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetParentheticalDetail</Role>
      <ShortName>Other Income (Expenses), Net - Summary of Other Income (Expenses), Net (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://IMab.com/role/OtherIncomeExpensesNetTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>1096 - Disclosure - Net Income (Loss) per Share - Summary of Basic and Diluted Net Loss per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail</Role>
      <ShortName>Net Income (Loss) per Share - Summary of Basic and Diluted Net Loss per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://IMab.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>1097 - Disclosure - Net Income (Loss) per Share - Summary of Antidilutive Securities Excluded from Computation of Earnings per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail</Role>
      <ShortName>Net Income (Loss) per Share - Summary of Antidilutive Securities Excluded from Computation of Earnings per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://IMab.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>1098 - Disclosure - Employee Benefits - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/EmployeeBenefitsAdditionalInformationDetail</Role>
      <ShortName>Employee Benefits - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>1099 - Disclosure - Related Party Balances and Transactions - Summary of Related Party Balances (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail</Role>
      <ShortName>Related Party Balances and Transactions - Summary of Related Party Balances (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>1100 - Disclosure - Related Party Balances and Transactions - Summary of Related Party Balances (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesParentheticalDetail</Role>
      <ShortName>Related Party Balances and Transactions - Summary of Related Party Balances (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>1101 - Disclosure - Related Party Balances and Transactions - Summary of Related Party Transactions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail</Role>
      <ShortName>Related Party Balances and Transactions - Summary of Related Party Transactions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>1102 - Disclosure - Subsequent Events - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/SubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="d10811d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>1103 - Disclosure - Restricted Net Assets - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://IMab.com/role/RestrictedNetAssetsAdditionalInformationDetail</Role>
      <ShortName>Restricted Net Assets - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" original="d10811d20f.htm">d10811d20f.htm</File>
    <File>d10811dex121.htm</File>
    <File>d10811dex122.htm</File>
    <File>d10811dex131.htm</File>
    <File>d10811dex132.htm</File>
    <File>d10811dex151.htm</File>
    <File>d10811dex152.htm</File>
    <File>d10811dex81.htm</File>
    <File>imab-20201231.xsd</File>
    <File>imab-20201231_cal.xml</File>
    <File>imab-20201231_def.xml</File>
    <File>imab-20201231_lab.xml</File>
    <File>imab-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g10811g01sp38.jpg</File>
    <File>g10811g01sp38b.jpg</File>
    <File>g10811g0421055924793.jpg</File>
    <File>g10811g0421055926650.jpg</File>
    <File>g10811g0421055926915.jpg</File>
    <File>g10811g0421055927227.jpg</File>
    <File>g10811g0421055927492.jpg</File>
    <File>g10811g0421055927757.jpg</File>
    <File>g10811g0421055928116.jpg</File>
    <File>g10811g0421055928818.jpg</File>
    <File>g10811g0421055929083.jpg</File>
    <File>g10811g0421055929349.jpg</File>
    <File>g10811g0421055929630.jpg</File>
    <File>g10811g0421055929880.jpg</File>
    <File>g10811g0421055930161.jpg</File>
    <File>g10811g0421055930457.jpg</File>
    <File>g10811g0421055930753.jpg</File>
    <File>g10811g0421055931065.jpg</File>
    <File>g10811g0421055931346.jpg</File>
    <File>g10811g0421055931627.jpg</File>
    <File>g10811g0421055931987.jpg</File>
    <File>g10811g0421055932314.jpg</File>
    <File>g10811g0421055932611.jpg</File>
    <File>g10811g0421180830740.jpg</File>
    <File>g10811g0421180831083.jpg</File>
    <File>g10811g0421180831411.jpg</File>
    <File>g10811g0421180832592.jpg</File>
    <File>g10811g0421180832985.jpg</File>
    <File>g10811g0421180834233.jpg</File>
    <File>g10811g0421180834623.jpg</File>
    <File>g10811g0421180835046.jpg</File>
    <File>g10811g0421180835597.jpg</File>
    <File>g10811g0421180836199.jpg</File>
    <File>g10811g0421180836738.jpg</File>
    <File>g10811g16s85.jpg</File>
    <File>g10811g17x63.jpg</File>
    <File>g10811g19n02.jpg</File>
    <File>g10811g20j63.jpg</File>
    <File>g10811g22m32.jpg</File>
    <File>g10811g2sp71.jpg</File>
    <File>g10811g2sp73.jpg</File>
    <File>g10811sp039.jpg</File>
    <File>g10811sp042.jpg</File>
    <File>g10811sp181.jpg</File>
    <File>g10811sp19.jpg</File>
    <File>g10811sp37.jpg</File>
    <File>g10811sp48.jpg</File>
    <File>g10811sp68.jpg</File>
    <File>g10811sp70a.jpg</File>
    <File>g10811sp70b.jpg</File>
    <File>g10811sp71.jpg</File>
    <File>g10811sp73.jpg</File>
    <File>g10811sp74.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>177
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d10811d20f.htm": {
   "axisCustom": 5,
   "axisStandard": 37,
   "contextCount": 473,
   "dts": {
    "calculationLink": {
     "local": [
      "imab-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "imab-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "d10811d20f.htm"
     ]
    },
    "labelLink": {
     "local": [
      "imab-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "imab-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "imab-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 917,
   "entityCount": 1,
   "hidden": {
    "http://IMab.com/20201231": 3,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 7
   },
   "keyCustom": 118,
   "keyStandard": 469,
   "memberCustom": 137,
   "memberStandard": 41,
   "nsprefix": "imab",
   "nsuri": "http://IMab.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "role": "http://IMab.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:PrepaidexpensesandotherreceivablestextblockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Prepayments And Other Receivables",
     "role": "http://IMab.com/role/PrepaymentsAndOtherReceivables",
     "shortName": "Prepayments And Other Receivables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:PrepaidexpensesandotherreceivablestextblockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn07_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1100 - Disclosure - Related Party Balances and Transactions - Summary of Related Party Balances (Parenthetical) (Detail)",
     "role": "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesParentheticalDetail",
     "shortName": "Related Party Balances and Transactions - Summary of Related Party Balances (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn07_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020_CmabBiopharmaSuzhouIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1101 - Disclosure - Related Party Balances and Transactions - Summary of Related Party Transactions (Detail)",
     "role": "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail",
     "shortName": "Related Party Balances and Transactions - Summary of Related Party Transactions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020_CmabBiopharmaSuzhouIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ReceiptOfContractResearchOrganizationsMemberusgaapRelatedPartyTransactionAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn02_28_2021_CollaborationAgreementsWithTraconPharmaceuticalsIncMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "imab:TerminationFeePayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1102 - Disclosure - Subsequent Events - Additional information (Detail)",
     "role": "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail",
     "shortName": "Subsequent Events - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn02_28_2021_CollaborationAgreementsWithTraconPharmaceuticalsIncMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "imab:TerminationFeePayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RestrictedAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "imab:StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1103 - Disclosure - Restricted Net Assets - Additional information (Detail)",
     "role": "http://IMab.com/role/RestrictedNetAssetsAdditionalInformationDetail",
     "shortName": "Restricted Net Assets - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RestrictedAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "imab:StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Property, Equipment And Software",
     "role": "http://IMab.com/role/PropertyEquipmentAndSoftware",
     "shortName": "Property, Equipment And Software",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Leases",
     "role": "http://IMab.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Intangible Assests",
     "role": "http://IMab.com/role/IntangibleAssests",
     "shortName": "Intangible Assests",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Goodwill",
     "role": "http://IMab.com/role/Goodwill",
     "shortName": "Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Investment Accounted for Using the Equity Method and Put Right Liabilities",
     "role": "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilities",
     "shortName": "Investment Accounted for Using the Equity Method and Put Right Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Short-Term Borrowings",
     "role": "http://IMab.com/role/ShortTermBorrowings",
     "shortName": "Short-Term Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Accruals And Other Payables",
     "role": "http://IMab.com/role/AccrualsAndOtherPayables",
     "shortName": "Accruals And Other Payables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Income Taxes",
     "role": "http://IMab.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Ordinary Shares",
     "role": "http://IMab.com/role/OrdinaryShares",
     "shortName": "Ordinary Shares",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Consolidated Balance Sheets",
     "role": "http://IMab.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:TemporaryEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Convertible Preferred Shares",
     "role": "http://IMab.com/role/ConvertiblePreferredShares",
     "shortName": "Convertible Preferred Shares",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:TemporaryEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Convertible Promissory Notes And Onshore Convertible Loans",
     "role": "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoans",
     "shortName": "Convertible Promissory Notes And Onshore Convertible Loans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:WarrantsDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Warrants",
     "role": "http://IMab.com/role/Warrants",
     "shortName": "Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:WarrantsDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Share-Based Compensation",
     "role": "http://IMab.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Licensing And Collaboration Arrangements",
     "role": "http://IMab.com/role/LicensingAndCollaborationArrangements",
     "shortName": "Licensing And Collaboration Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Other Income (Expenses), Net",
     "role": "http://IMab.com/role/OtherIncomeExpensesNet",
     "shortName": "Other Income (Expenses), Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Net Income (Loss) per Share",
     "role": "http://IMab.com/role/NetIncomeLossPerShare",
     "shortName": "Net Income (Loss) per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Employee Benefits",
     "role": "http://IMab.com/role/EmployeeBenefits",
     "shortName": "Employee Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Commitments and Contingencies",
     "role": "http://IMab.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Related Party Balances and Transactions",
     "role": "http://IMab.com/role/RelatedPartyBalancesAndTransactions",
     "shortName": "Related Party Balances and Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020_SeriesAConvertiblePreferredSharesMemberusgaapStatementClassOfStockAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Concentration of Credit Risk",
     "role": "http://IMab.com/role/ConcentrationOfCreditRisk",
     "shortName": "Concentration of Credit Risk",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Subsequent Events",
     "role": "http://IMab.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Restricted Net Assets",
     "role": "http://IMab.com/role/RestrictedNetAssets",
     "shortName": "Restricted Net Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Principal Accounting Policies (Policies)",
     "role": "http://IMab.com/role/PrincipalAccountingPoliciesPolicies",
     "shortName": "Principal Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:ScheduleOfPrincipalSubsidiariesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Principal Activities and Organization (Tables)",
     "role": "http://IMab.com/role/PrincipalActivitiesAndOrganizationTables",
     "shortName": "Principal Activities and Organization (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:ScheduleOfPrincipalSubsidiariesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Principal Accounting Policies (Tables)",
     "role": "http://IMab.com/role/PrincipalAccountingPoliciesTables",
     "shortName": "Principal Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "imab:AccountsReceivableAndContractAssetsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Accounts Receivable And Contract Assets (Tables)",
     "role": "http://IMab.com/role/AccountsReceivableAndContractAssetsTables",
     "shortName": "Accounts Receivable And Contract Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "imab:AccountsReceivableAndContractAssetsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Prepayments And Other Receivables (Tables)",
     "role": "http://IMab.com/role/PrepaymentsAndOtherReceivablesTables",
     "shortName": "Prepayments And Other Receivables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Property, Equipment And Software (Tables)",
     "role": "http://IMab.com/role/PropertyEquipmentAndSoftwareTables",
     "shortName": "Property, Equipment And Software (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Leases (Tables)",
     "role": "http://IMab.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Intangible Assets (Tables)",
     "role": "http://IMab.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Investment Accounted for Using the Equity Method and Put Right Liabilities (Tables)",
     "role": "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTables",
     "shortName": "Investment Accounted for Using the Equity Method and Put Right Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Accruals And Other Payables (Tables)",
     "role": "http://IMab.com/role/AccrualsAndOtherPayablesTables",
     "shortName": "Accruals And Other Payables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Income Taxes (Tables)",
     "role": "http://IMab.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Convertible Preferred Shares (Tables)",
     "role": "http://IMab.com/role/ConvertiblePreferredSharesTables",
     "shortName": "Convertible Preferred Shares (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Warrants (Tables)",
     "role": "http://IMab.com/role/WarrantsTables",
     "shortName": "Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://IMab.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Licensing and Collaboration Agreements (Tables)",
     "role": "http://IMab.com/role/LicensingAndCollaborationAgreementsTables",
     "shortName": "Licensing and Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Other Income (Expenses), Net (Tables)",
     "role": "http://IMab.com/role/OtherIncomeExpensesNetTables",
     "shortName": "Other Income (Expenses), Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Net Income (Loss) per Share (Tables)",
     "role": "http://IMab.com/role/NetIncomeLossPerShareTables",
     "shortName": "Net Income (Loss) per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2017",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Deficit)",
     "role": "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
     "shortName": "Consolidated Statements of Changes in Shareholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2017",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:ScheduleOfRelatedPartyBalancesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Related Party Balances and Transactions (Tables)",
     "role": "http://IMab.com/role/RelatedPartyBalancesAndTransactionsTables",
     "shortName": "Related Party Balances and Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:ScheduleOfRelatedPartyBalancesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imab:ScheduleOfPrincipalSubsidiariesTableTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020_IMabBiopharmaHongKongLimitedMembersrtConsolidatedEntitiesAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:EntityIncorporationCountryStateName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - Principal Activities and Organization - Schedule of Principal Subsidiaries (Detail)",
     "role": "http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail",
     "shortName": "Principal Activities and Organization - Schedule of Principal Subsidiaries (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imab:ScheduleOfPrincipalSubsidiariesTableTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020_IMabBiopharmaHongKongLimitedMembersrtConsolidatedEntitiesAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:EntityIncorporationCountryStateName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - Principal Activities and Organization - Additional Information (Detail)",
     "role": "http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail",
     "shortName": "Principal Activities and Organization - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - Principal Accounting Policies - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)",
     "role": "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
     "shortName": "Principal Accounting Policies - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imab:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - Principal Accounting Policies - Summary of Roll Forward of Major Level 3 Financial Assets and Financial Liability (Detail)",
     "role": "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail",
     "shortName": "Principal Accounting Policies - Summary of Roll Forward of Major Level 3 Financial Assets and Financial Liability (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imab:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Principal Accounting Policies - summary of Cash, cash equivalents and restricted cash as reported in the consolidated statement of cash flows (Detail)",
     "role": "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfCashCashEquivalentsAndRestrictedCashAsReportedInTheConsolidatedStatementOfCashFlowsDetail",
     "shortName": "Principal Accounting Policies - summary of Cash, cash equivalents and restricted cash as reported in the consolidated statement of cash flows (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "imab:DeferredSubsidyIncomePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GrantsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - Principal Accounting Policies - Additional Information (Detail)",
     "role": "http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Principal Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "imab:DeferredSubsidyIncomePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GrantsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imab:ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Principal Accounting Policies - Summary of Estimated Useful Lives (Detail)",
     "role": "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail",
     "shortName": "Principal Accounting Policies - Summary of Estimated Useful Lives (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imab:ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "imab:ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock",
       "imab:AccountsReceivableAndContractAssetsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - Accounts Receivable And Contract Assets - summary of Accounts receivable and contract assets, net of allowance for credit losses (Detail)",
     "role": "http://IMab.com/role/AccountsReceivableAndContractAssetsSummaryOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesDetail",
     "shortName": "Accounts Receivable And Contract Assets - summary of Accounts receivable and contract assets, net of allowance for credit losses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "imab:ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock",
       "imab:AccountsReceivableAndContractAssetsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Supplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure - Prepayments And Other Receivables - Summary of Prepayments And Other Receivables (Detail)",
     "role": "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail",
     "shortName": "Prepayments And Other Receivables - Summary of Prepayments And Other Receivables (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Supplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure - Property, Equipment And Software - Additional Information (Detail)",
     "role": "http://IMab.com/role/PropertyEquipmentAndSoftwareAdditionalInformationDetail",
     "shortName": "Property, Equipment And Software - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure - Property, Equipment And Software - Schedule of property, equipment and software, net (Detail)",
     "role": "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail",
     "shortName": "Property, Equipment And Software - Schedule of property, equipment and software, net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imab:OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure - Leases - Operating Lease Related Assets And Liabilities And Other Related Information (Detail))",
     "role": "http://IMab.com/role/LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail",
     "shortName": "Leases - Operating Lease Related Assets And Liabilities And Other Related Information (Detail))",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imab:OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imab:ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imab:OperatingLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure - Leases - Components of Operating Lease Expense (Detail)",
     "role": "http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail",
     "shortName": "Leases - Components of Operating Lease Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imab:ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imab:OperatingLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure - Leases - Operating Lease, Maturity (Detail)",
     "role": "http://IMab.com/role/LeasesOperatingLeaseMaturityDetail",
     "shortName": "Leases - Operating Lease, Maturity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1065 - Disclosure - Intangible Assets - Summary Of Intangible Assets (Detail)",
     "role": "http://IMab.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail",
     "shortName": "Intangible Assets - Summary Of Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1066 - Disclosure - Intangible Assets - Additional Information (Detail)",
     "role": "http://IMab.com/role/IntangibleAssetsAdditionalInformationDetail",
     "shortName": "Intangible Assets - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:Goodwill",
       "div",
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1067 - Disclosure - Goodwill - Additional Information (Detail)",
     "role": "http://IMab.com/role/GoodwillAdditionalInformationDetail",
     "shortName": "Goodwill - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
       "div",
       "div",
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1068 - Disclosure - Investment Accounted for Using the Equity Method and Put Right Liabilities - Summary of Group Long term Investment Measured Under Equity method (Detail)",
     "role": "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail",
     "shortName": "Investment Accounted for Using the Equity Method and Put Right Liabilities - Summary of Group Long term Investment Measured Under Equity method (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020_LongTermInvestmentUnderEquityMethodMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1069 - Disclosure - Investment Accounted for Using the Equity Method and Put Right Liabilities - Summary of Estimate the Fair Value of the Put Right Using the Following Assumptions (Detail)",
     "role": "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetail",
     "shortName": "Investment Accounted for Using the Equity Method and Put Right Liabilities - Summary of Estimate the Fair Value of the Put Right Using the Following Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": "-3",
      "lang": null,
      "name": "imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1007 - Disclosure - Principal Activities and Organization",
     "role": "http://IMab.com/role/PrincipalActivitiesAndOrganization",
     "shortName": "Principal Activities and Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1070 - Disclosure - Investment Accounted for Using the Equity Method and Put Right Liabilities - Additional Information (Detail)",
     "role": "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail",
     "shortName": "Investment Accounted for Using the Equity Method and Put Right Liabilities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020_HoldcoMembersrtOwnershipAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1071 - Disclosure - Short-Term Borrowings - Additional Information (Detail)",
     "role": "http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail",
     "shortName": "Short-Term Borrowings - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:ShortTermDebtTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P07_31_2018To07_31_2018_ChinaMerchantBankCoLtdMemberusgaapLineOfCreditFacilityAxis_LoanOneMemberusgaapDebtInstrumentAxis",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtLender",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1072 - Disclosure - Accruals And Other Payables - Summary of accruals and other payables (Detail)",
     "role": "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail",
     "shortName": "Accruals And Other Payables - Summary of accruals and other payables (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P04_01_2020To04_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imab:ProceedsFromNonRefundableIncentive",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1073 - Disclosure - Accruals And Other Payables - Additional Information (Details)",
     "role": "http://IMab.com/role/AccrualsAndOtherPayablesAdditionalInformationDetails",
     "shortName": "Accruals And Other Payables - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P04_01_2020To04_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imab:ProceedsFromNonRefundableIncentive",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1074 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1075 - Disclosure - Income Taxes - Reconciliations of the Differences Between the PRC Statutory Income Tax Rate and the Group's Effective Income Tax Rate (Detail)",
     "role": "http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail",
     "shortName": "Income Taxes - Reconciliations of the Differences Between the PRC Statutory Income Tax Rate and the Group's Effective Income Tax Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1076 - Disclosure - Income Taxes - Components of the Deferred Tax Assets and Liabilities (Detail)",
     "role": "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail",
     "shortName": "Income Taxes - Components of the Deferred Tax Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1077 - Disclosure - Income Taxes - Summary of Movement of the Valuation Allowance (Detail)",
     "role": "http://IMab.com/role/IncomeTaxesSummaryOfMovementOfTheValuationAllowanceDetail",
     "shortName": "Income Taxes - Summary of Movement of the Valuation Allowance (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "lang": null,
      "name": "imab:DeferredTaxesAdditionsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1078 - Disclosure - Ordinary Shares - Additional Information (Detail)",
     "role": "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
     "shortName": "Ordinary Shares - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1079 - Disclosure - Convertible Preferred Shares - Additional Information (Detail)",
     "role": "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail",
     "shortName": "Convertible Preferred Shares - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P12_25_2019To12_25_2019",
      "decimals": "0",
      "lang": null,
      "name": "imab:OfferingPriceOfConvertedShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Principal Accounting Policies",
     "role": "http://IMab.com/role/PrincipalAccountingPolicies",
     "shortName": "Principal Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1080 - Disclosure - Convertible Preferred Shares - Schedule of Convertible Preferred Shares Activities (Detail)",
     "role": "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail",
     "shortName": "Convertible Preferred Shares - Schedule of Convertible Preferred Shares Activities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PreferredStockValueOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "imab:ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn09_25_2017",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1081 - Disclosure - Convertible Promissory Notes And Onshore Convertible Loans- Additional Information (Detail)",
     "role": "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail",
     "shortName": "Convertible Promissory Notes And Onshore Convertible Loans- Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "imab:ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn09_25_2017_SeriesB1PreferredSharesMemberusgaapStatementClassOfStockAxis",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2018To12_31_2018",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1082 - Disclosure - Warrants - Additional Information (Detail)",
     "role": "http://IMab.com/role/WarrantsAdditionalInformationDetail",
     "shortName": "Warrants - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "imab:WarrantsDisclosure",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P09_22_2017To09_22_2017_SeriesBPreferredShareholdersMemberusgaapStatementEquityComponentsAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P12_17_2020To12_17_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:Classofwarrantorrightsexercisableterm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1083 - Disclosure - Warrants - Details of accounting for warrants to purchase ordinary shares (Detail)",
     "role": "http://IMab.com/role/WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail",
     "shortName": "Warrants - Details of accounting for warrants to purchase ordinary shares (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P12_17_2020To12_17_2020_WarrantsToPurchaseOrdinarySharesMemberusgaapClassOfWarrantOrRightAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:Classofwarrantorrightsexercisableterm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_17_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1084 - Disclosure - Warrants - Summary of fair value of warrant liabilities (Detail)",
     "role": "http://IMab.com/role/WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail",
     "shortName": "Warrants - Summary of fair value of warrant liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_17_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1085 - Disclosure - Share-Based Compensation - Additional Information (Detail)",
     "role": "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
     "shortName": "Share-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2016To12_31_2016_ThirdVentureMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1086 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Expenses Related to Restricted Shares (Detail)",
     "role": "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail",
     "shortName": "Share-Based Compensation - Schedule of Share-Based Compensation Expenses Related to Restricted Shares (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1087 - Disclosure - Share-Based Compensation - Schedule of Stock Option Activities (Detail)",
     "role": "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail",
     "shortName": "Share-Based Compensation - Schedule of Stock Option Activities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2016_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1088 - Disclosure - Share-Based Compensation - Summary of Valuation Assumptions Used (Detail)",
     "role": "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail",
     "shortName": "Share-Based Compensation - Summary of Valuation Assumptions Used (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2019_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1089 - Disclosure - Share-Based Compensation - Summary of non-vested stock option activities (Detail)",
     "role": "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail",
     "shortName": "Share-Based Compensation - Summary of non-vested stock option activities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentySeventeenEmployeeStockOptionPlanMemberusgaapPlanNameAxis",
      "decimals": "0",
      "lang": null,
      "name": "imab:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:AccountsReceivableAndContractAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Accounts Receivable And Contract  Assets",
     "role": "http://IMab.com/role/AccountsReceivableAndContractAssets",
     "shortName": "Accounts Receivable And Contract  Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imab:AccountsReceivableAndContractAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1090 - Disclosure - Share-Based Compensation -Schedule of Nonvested Restricted Stock Units Activity (Detail)",
     "role": "http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail",
     "shortName": "Share-Based Compensation -Schedule of Nonvested Restricted Stock Units Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_ShareIncentivePlanTwoThousandTwentyMemberusgaapPlanNameAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2019To12_31_2019_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1091 - Disclosure - Share-based Compensation - Schedule of Share-based Payment Arrangement Restricted Stock Unit Activity (Detail)",
     "role": "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail",
     "shortName": "Share-based Compensation - Schedule of Share-based Payment Arrangement Restricted Stock Unit Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis_TwentyEighteenEmployeeStockOptionPlanMemberusgaapPlanNameAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1092 - Disclosure - Licensing And Collaboration Agreements - Additional Information (Detail)",
     "role": "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
     "shortName": "Licensing And Collaboration Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2010To12_31_2010",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2019To12_31_2019_LicensingAgreementWithMorphosysAgMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imab:MilestonePayments",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1093 - Disclosure - Licensing And Collaboration Arrangements - Summary of Financial Information (Detail)",
     "role": "http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail",
     "shortName": "Licensing And Collaboration Arrangements - Summary of Financial Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2018To12_31_2018_LicensingAgreementWithGenexineIncMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis",
      "decimals": "-3",
      "lang": null,
      "name": "imab:LicensingAgreementUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2018To12_31_2018",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainsLossesOnRestructuringOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1094 - Disclosure - Other Income (Expenses), Net - Summary of Other Income (Expenses), Net (Detail)",
     "role": "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail",
     "shortName": "Other Income (Expenses), Net - Summary of Other Income (Expenses), Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2018To12_31_2018",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainsLossesOnRestructuringOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020_GrantMembersrtProductOrServiceAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1095 - Disclosure - Other Income (Expenses), Net - Summary of Other Income (Expenses), Net (Parenthetical) (Detail)",
     "role": "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetParentheticalDetail",
     "shortName": "Other Income (Expenses), Net - Summary of Other Income (Expenses), Net (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020_GrantMembersrtProductOrServiceAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1096 - Disclosure - Net Income (Loss) per Share - Summary of Basic and Diluted Net Loss per Share (Detail)",
     "role": "http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail",
     "shortName": "Net Income (Loss) per Share - Summary of Basic and Diluted Net Loss per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2019To12_31_2019_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1097 - Disclosure - Net Income (Loss) per Share - Summary of Antidilutive Securities Excluded from Computation of Earnings per Share (Detail)",
     "role": "http://IMab.com/role/NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail",
     "shortName": "Net Income (Loss) per Share - Summary of Antidilutive Securities Excluded from Computation of Earnings per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2019To12_31_2019_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1098 - Disclosure - Employee Benefits - Additional Information (Detail)",
     "role": "http://IMab.com/role/EmployeeBenefitsAdditionalInformationDetail",
     "shortName": "Employee Benefits - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imab:CommonStockSharesIssuableForServicesAvailedCurrent",
      "reportCount": 1,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1099 - Disclosure - Related Party Balances and Transactions - Summary of Related Party Balances (Detail)",
     "role": "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail",
     "shortName": "Related Party Balances and Transactions - Summary of Related Party Balances (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "imab:ScheduleOfRelatedPartyBalancesTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d10811d20f.htm",
      "contextRef": "PAsOn12_31_2020_ImabHangzhouMembersrtConsolidatedEntitiesAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_CNY",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 187,
   "tag": {
    "country_AU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA"
       }
      }
     },
     "localname": "AU",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_HK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "HONG KONG"
       }
      }
     },
     "localname": "HK",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AdrMember": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depository Receipt (or American Depository Share, ADS).",
        "label": "ADR [Member]",
        "terseLabel": "American Depositary Shares [Member]",
        "verboseLabel": "ADS [Member]"
       }
      }
     },
     "localname": "AdrMember",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/CoverPage",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address",
        "terseLabel": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name",
        "terseLabel": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard",
        "terseLabel": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r652",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement",
        "terseLabel": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report",
        "terseLabel": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when an entity was incorporated",
        "label": "Entity Incorporation, Date of Incorporation",
        "terseLabel": "Date of incorporation"
       }
      }
     },
     "localname": "EntityIncorporationDateOfIncorporation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r652",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag",
        "terseLabel": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "imab_ABLBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ABL Bio [Member]",
        "terseLabel": "ABL Bio [Member]"
       }
      }
     },
     "localname": "ABLBioMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_AbbVieMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Abb Vie [Member]",
        "terseLabel": "AbbVie [Member]"
       }
      }
     },
     "localname": "AbbVieMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_AccountsReceivableAndContractAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable And Contract Assets.",
        "label": "Accounts Receivable And Contract Assets [Abstract]"
       }
      }
     },
     "localname": "AccountsReceivableAndContractAssetsAbstract",
     "nsuri": "http://IMab.com/20201231",
     "xbrltype": "stringItemType"
    },
    "imab_AccountsReceivableAndContractAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable And Contract Assets.",
        "label": "Accounts Receivable And Contract Assets [Text Block]",
        "terseLabel": "Accounts Receivable And Contract Assets"
       }
      }
     },
     "localname": "AccountsReceivableAndContractAssetsTextBlock",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/AccountsReceivableAndContractAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imab_AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued external research and development activities related expenses.",
        "label": "Accrued External Research And Development Activities Related Expenses Current",
        "terseLabel": "Accrued external research and development activities related expenses"
       }
      }
     },
     "localname": "AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_AccruedInitialPublicOfferingCostsPayable": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued initial public offering costs payable.",
        "label": "Accrued Initial Public Offering Costs Payable",
        "terseLabel": "Accrued initial public offering costs payable"
       }
      }
     },
     "localname": "AccruedInitialPublicOfferingCostsPayable",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_AccruedPrivatePlacementOfferingCostsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued private placement offering costs payable.",
        "label": "Accrued Private Placement Offering Costs Payable",
        "terseLabel": "Accrued private placement offering costs payable"
       }
      }
     },
     "localname": "AccruedPrivatePlacementOfferingCostsPayable",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_AccruedTravellingExpensesOfficeExpensesAndOthers": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Travelling Expenses Office Expenses And Others.",
        "label": "Accrued Travelling Expenses Office Expenses And Others",
        "terseLabel": "Accrued traveling expenses, office expenses and others"
       }
      }
     },
     "localname": "AccruedTravellingExpensesOfficeExpensesAndOthers",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_AccuredInitialPublicOfferingCostPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued initial public offering cost payable.",
        "label": "Accured Initial Public Offering Cost Payable",
        "terseLabel": "Accrued initial public offering costs payable"
       }
      }
     },
     "localname": "AccuredInitialPublicOfferingCostPayable",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_AdjustmentsAtExtinguishmentOfPreferredShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments at extinguishment of preferred shares.",
        "label": "Adjustments At Extinguishment Of Preferred Shares",
        "verboseLabel": "Adjustment at extinguishment of Series\u00a0C-1\u00a0Preferred Shares"
       }
      }
     },
     "localname": "AdjustmentsAtExtinguishmentOfPreferredShares",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail",
      "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital, stock option surrender.",
        "label": "Adjustments To Additional Paid In Capital Stock Option Surrender",
        "terseLabel": "Capital contribution from stock option surrender (Note 17 (h))"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockOptionSurrender",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_AdvanceReceivedFromEmployeeForExerciseOfStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail": {
       "order": 11.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advanced received from employee for exercise of stock options.",
        "label": "Advance Received From Employee For Exercise Of Stock Options",
        "terseLabel": "Advance payment received from an employee for exercise of stock options"
       }
      }
     },
     "localname": "AdvanceReceivedFromEmployeeForExerciseOfStockOptions",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_AmendedTwentySeventeenEmployeeStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended Twenty Seventeen Employee Stock Option Plan [Member]",
        "terseLabel": "Amended 2017 Plan [Member]"
       }
      }
     },
     "localname": "AmendedTwentySeventeenEmployeeStockOptionPlanMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_AmericanDepositarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American depositary shares.",
        "label": "American Depositary Shares [Member]"
       }
      }
     },
     "localname": "AmericanDepositarySharesMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_AmericanDepositorySharesCommonShareEquivalent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American depository shares common share equivalent.",
        "label": "American Depository Shares Common Share Equivalent",
        "terseLabel": "American depository shares, common share equivalent"
       }
      }
     },
     "localname": "AmericanDepositorySharesCommonShareEquivalent",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "imab_AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of right of use assets and interest of lease liabilities.",
        "label": "Amortization Of Right Of Use Assets And Interest Of Lease Liabilities",
        "terseLabel": "Amortization of right-of use assets and interest of lease liabilities"
       }
      }
     },
     "localname": "AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_AppropriationtoStatutoryReserve": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Appropriation to statutory reserve.",
        "label": "AppropriationTo Statutory Reserve",
        "terseLabel": "Appropriation to statutory reserve"
       }
      }
     },
     "localname": "AppropriationtoStatutoryReserve",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/RestrictedNetAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_BalanceSheetDataAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance Sheet Data [Abstract]",
        "label": "Balance Sheet Data [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetDataAbstract",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_BankBranchAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank Branch",
        "label": "Bank Branch [Axis]"
       }
      }
     },
     "localname": "BankBranchAxis",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_BankBranchDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank Branch",
        "label": "Bank Branch [Domain]"
       }
      }
     },
     "localname": "BankBranchDomain",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_BoardOfDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board Of Directors [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_CNMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CN Member",
        "label": "C N [Member]",
        "terseLabel": "CN [Member]"
       }
      }
     },
     "localname": "CNMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_CashReceivedOnIncomeFromOtherFinancialAssets": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 37.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on income from other financial assets.",
        "label": "Cash Received On Income From Other Financial Assets",
        "verboseLabel": "Cash received on income from other financial assets"
       }
      }
     },
     "localname": "CashReceivedOnIncomeFromOtherFinancialAssets",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_ChinaMerchantBankCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "China Merchant Bank Co., Ltd [Member].",
        "label": "China Merchant Bank Co Ltd [Member]",
        "terseLabel": "China Merchant Bank Co., Ltd [Member]"
       }
      }
     },
     "localname": "ChinaMerchantBankCoLtdMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_Classofwarrantorrightsexercisableterm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ClassOfWarrantOrRightsExercisableTerm",
        "label": "Class Of Warrant or Rights Exercisable Term"
       }
      }
     },
     "localname": "Classofwarrantorrightsexercisableterm",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "imab_ClinicalMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Milestones [Member]",
        "terseLabel": "Clinical Milestones [Member]"
       }
      }
     },
     "localname": "ClinicalMilestonesMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_CmabBiopharmaSuzhouIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CMAB Biopharma (Suzhou) Inc.",
        "label": "CMAB Biopharma Suzhou Inc [Member]",
        "terseLabel": "CMAB Bipharma Suzhou Inc [Member]"
       }
      }
     },
     "localname": "CmabBiopharmaSuzhouIncMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_CollaborationAgreementWithABLBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement with ABL Bio.",
        "label": "Collaboration Agreement With ABL Bio [Member]",
        "terseLabel": "Collaboration Agreement With ABL Bio [Member]"
       }
      }
     },
     "localname": "CollaborationAgreementWithABLBioMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_CollaborationAgreementWithEverestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement with Everest.",
        "label": "Collaboration Agreement with Everest [Member]"
       }
      }
     },
     "localname": "CollaborationAgreementWithEverestMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_CollaborationAgreementWithInvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement with investors.",
        "label": "Collaboration agreement with investors [Member]"
       }
      }
     },
     "localname": "CollaborationAgreementWithInvestorsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_CollaborationAgreementsWithTraconPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration Agreements With Tracon Pharmaceuticals Inc [Member]",
        "terseLabel": "Collaboration Agreements with Tracon Pharmaceuticals Inc [Member]"
       }
      }
     },
     "localname": "CollaborationAgreementsWithTraconPharmaceuticalsIncMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_CommonStockSharesIssuable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock shares issuable.",
        "label": "Common Stock Shares Issuable",
        "terseLabel": "Common stock shares issuable"
       }
      }
     },
     "localname": "CommonStockSharesIssuable",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imab_CommonStockSharesIssuableForServicesAvailedCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock shares issuable for services availed current.",
        "label": "Common Stock Shares Issuable For Services Availed Current",
        "terseLabel": "Ordinary shares to be issued to Everest"
       }
      }
     },
     "localname": "CommonStockSharesIssuableForServicesAvailedCurrent",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_CommonStockValueAuthorized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock value authorized.",
        "label": "Common Stock Value Authorized",
        "verboseLabel": "Common stock value authorized"
       }
      }
     },
     "localname": "CommonStockValueAuthorized",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability cumulative cost to cost input method percent.",
        "label": "Contract With Customer Liability Cumulative Cost to cost Input Method Percent",
        "terseLabel": "Cost-to-cost\u00a0input method percent"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCostToCostInputMethodPercent",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imab_ConvertiblePreferredStockSeriesA3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Series A3 [Member]",
        "terseLabel": "Convertible Preferred Stock Series A3 [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSeriesA3Member",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ConvertiblePreferredStockSeriesAThreeUponExerciseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Series A Three Upon Exercise [Member]",
        "terseLabel": "Convertible Preferred Stock Series A Three Upon Exercise [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSeriesAThreeUponExerciseMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ConvertiblePreferredStockSeriesB2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Series B2 [Member]",
        "terseLabel": "Convertible Preferred Stock Series B-2 [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSeriesB2Member",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ConvertiblePreferredStockSeriesBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Series B [Member]",
        "terseLabel": "Convertible Preferred Stock Series B [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSeriesBMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ConvertiblePreferredStockSeriesBOneUponConversionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Series B One Upon Conversion [Member]",
        "terseLabel": "Convertible Preferred Stock Series B-1 Upon Conversion [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSeriesBOneUponConversionMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ConvertiblePreferredStockSeriesBOneUponExerciseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Series B One Upon Exercise [Member]",
        "terseLabel": "Convertible Preferred Stock Series B One Upon Exercise [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSeriesBOneUponExerciseMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ConvertiblePreferredStockSeriesBTwoUponExerciseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Series B Two Upon Exercise [Member]",
        "terseLabel": "Convertible Preferred Stock Series B Two Upon Exercise [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSeriesBTwoUponExerciseMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ConvertiblePreferredStockSeriesBUponExerciseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Series B Upon Exercise [Member]",
        "terseLabel": "Convertible Preferred Stock Series B Upon Exercise [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSeriesBUponExerciseMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ConvertiblePromissoryNotes2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Notes 2017 [Member]"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotes2017Member",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ConvertiblePromissoryNotes2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Notes 2018 [Member]"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotes2018Member",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible promissory notes and onshore convertible loan abstract.",
        "label": "Convertible Promissory Notes And Onshore Convertible Loan [Abstract]"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotesAndOnshoreConvertibleLoanAbstract",
     "nsuri": "http://IMab.com/20201231",
     "xbrltype": "stringItemType"
    },
    "imab_CostSharingRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost sharing ratio.",
        "label": "Cost Sharing Ratio",
        "terseLabel": "Cost sharing ratio"
       }
      }
     },
     "localname": "CostSharingRatio",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imab_CspcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CSPC [Member]",
        "terseLabel": "CSPC [Member]"
       }
      }
     },
     "localname": "CspcMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_CumulativePaidInContributions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative paid in contributions.",
        "label": "Cumulative Paid In Contributions"
       }
      }
     },
     "localname": "CumulativePaidInContributions",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_DeferredLiabilityFromCollaborativeArrangementExcludingTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred liability from collaborative arrangement excluding tax.",
        "label": "Deferred Liability From Collaborative Arrangement Excluding Tax",
        "terseLabel": "Deferred Liability from Collabarative Arrangement excluding Tax"
       }
      }
     },
     "localname": "DeferredLiabilityFromCollaborativeArrangementExcludingTax",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_DeferredRevenueFromCollaborativeArrangementExcludingVat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Revenue From Collaborative Arrangement Excluding VAT.",
        "label": "Deferred revenue from collaborative arrangement excluding VAT",
        "terseLabel": "Deferred revenue from collaborative arrangement excluding VAT"
       }
      }
     },
     "localname": "DeferredRevenueFromCollaborativeArrangementExcludingVat",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_DeferredRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Revenue [Member].",
        "label": "Deferred Revenue [Member]",
        "terseLabel": "Deferred Revenue [Member]"
       }
      }
     },
     "localname": "DeferredRevenueMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_DeferredSubsidyIncomePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Subsidy Income.",
        "label": "Deferred Subsidy Income [Policy Text Block]",
        "terseLabel": "Deferred subsidy income"
       }
      }
     },
     "localname": "DeferredSubsidyIncomePolicyTextBlock",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imab_DeferredTaxAssetsContractAssets": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets contract assets.",
        "label": "Deferred Tax Assets Contract Assets",
        "negatedLabel": "Contract assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsContractAssets",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_DeferredTaxAssetsValuationAllowanceUtilizationAndReversal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets valuation allowance utilization and reversal.",
        "label": "Deferred Tax Assets Valuation Allowance Utilization and Reversal",
        "terseLabel": "Utilization and reversal of valuation allowances"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowanceUtilizationAndReversal",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesSummaryOfMovementOfTheValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_DeferredTaxesAdditionsValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Taxes Additions Valuation Allowance.",
        "label": "Deferred Taxes Additions Valuation Allowance",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "DeferredTaxesAdditionsValuationAllowance",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesSummaryOfMovementOfTheValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Taxes Decrease Due to Change of Tax Rate Valuation Allowance.",
        "label": "Deferred Taxes Decrease Due to Change of Tax Rate Valuation Allowance",
        "terseLabel": "Decrease due to the change of tax rate"
       }
      }
     },
     "localname": "DeferredTaxesDecreaseDueToChangeOfTaxRateValuationAllowance",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesSummaryOfMovementOfTheValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_DevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Milestone [Member]",
        "label": "Development Milestone [Member]"
       }
      }
     },
     "localname": "DevelopmentMilestoneMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_DomesticInvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Investors [Member]"
       }
      }
     },
     "localname": "DomesticInvestorsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_DrzangMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DrZang [Member]",
        "terseLabel": "Dr. Zang [Member]"
       }
      }
     },
     "localname": "DrzangMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation, deductible expense, research and development, amount.",
        "label": "Effective Income Tax Rate Reconciliation deductible Expense Research and Development Amount",
        "negatedLabel": "Research and development expenses plus deduction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_EffectivePreferentialIncomeTaxRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective preferential income tax rate.",
        "label": "Effective Preferential Income Tax Rate",
        "terseLabel": "Preferential income tax rate"
       }
      }
     },
     "localname": "EffectivePreferentialIncomeTaxRate",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imab_EntityIncorporationCountryStateName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity incorporation country state name.",
        "label": "Entity Incorporation Country State Name",
        "terseLabel": "Place of incorporation"
       }
      }
     },
     "localname": "EntityIncorporationCountryStateName",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_EquityInLossOfAnAffiliateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity in loss of an affiliate.",
        "label": "Equity in Loss of an Affiliate [Member]",
        "terseLabel": "Equity in Loss of an Affiliate [Member]"
       }
      }
     },
     "localname": "EquityInLossOfAnAffiliateMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_EquityMethodInvestmentSummarizedFinancialInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment Summarized Financial Information",
        "label": "Equity Method Investment Summarized Financial Information [Line Items]"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationLineItems",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_EquityMethodInvestmentSummarizedFinancialInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment Summarized Financial Information",
        "label": "Equity Method Investment Summarized Financial Information [Table]"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationTable",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_EsopHoldcoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Esop Holdco [Member]"
       }
      }
     },
     "localname": "EsopHoldcoMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_EverestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Everest.",
        "label": "Everest [Member]"
       }
      }
     },
     "localname": "EverestMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_EverestsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Everests [Member]"
       }
      }
     },
     "localname": "EverestsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of warrants.",
        "label": "Exercise Of Warrants",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "ExerciseOfWarrants",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_ExpensesPaidOnBehalfOfAnAffiliate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses paid on behalf of an affiliate.",
        "label": "Expenses Paid on Behalf of an Affiliate",
        "terseLabel": "Expenses paid on behalf of an affiliate"
       }
      }
     },
     "localname": "ExpensesPaidOnBehalfOfAnAffiliate",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_FairValueAdjustmentsOfOtherFinancialAssets": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Adjustments Of Other Financial Assets.",
        "label": "Fair Value Adjustments Of Other Financial Assets",
        "terseLabel": "Fair value change of other financial assets"
       }
      }
     },
     "localname": "FairValueAdjustmentsOfOtherFinancialAssets",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_FairValueAdjustmentsOfPutRightLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail": {
       "order": 12.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value adjustments of put right liabilities.",
        "label": "Fair Value Adjustments Of Put Right Liabilities",
        "negatedLabel": "Fair value change of put right liabilities",
        "terseLabel": "Fair value change of put right liabilities"
       }
      }
     },
     "localname": "FairValueAdjustmentsOfPutRightLiabilities",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_FairValueChangeOfShortTermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Change Of Short Term Investments.",
        "label": "Fair Value Change Of Short Term Investments",
        "negatedLabel": "Fair value change of short-term investments",
        "terseLabel": "Fair value change of short-term investments"
       }
      }
     },
     "localname": "FairValueChangeOfShortTermInvestments",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis short term investments.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Short Term Investments",
        "terseLabel": "Disposal of short-term investments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisShortTermInvestments",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation currency translation differences.",
        "label": "Fair Value Net Derivative Asset Liability Measured on Recurring Basis Unobservable Inputs Reconciliation Currency Translation Differences",
        "terseLabel": "Currency translation differences"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationCurrencyTranslationDifferences",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_FederalReserveBankOfNewYorkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Reserve Bank of New York",
        "label": "Federal Reserve Bank of New York [Member]"
       }
      }
     },
     "localname": "FederalReserveBankOfNewYorkMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_FirstClosingPeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Closing Period [Member]"
       }
      }
     },
     "localname": "FirstClosingPeriodMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_FirstMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First milestone.",
        "label": "First Milestone [Member]",
        "terseLabel": "First Milestone [Member]"
       }
      }
     },
     "localname": "FirstMilestoneMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_FoundersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Founders [Member]",
        "terseLabel": "Founders [Member]"
       }
      }
     },
     "localname": "FoundersMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_FourPerformanceConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Performance Conditions.",
        "label": "Four Performance Conditions [Member]"
       }
      }
     },
     "localname": "FourPerformanceConditionsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_GenexineIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genexine,Inc.",
        "label": "Genexine Inc [Member]",
        "terseLabel": "Genexine Inc [Member]"
       }
      }
     },
     "localname": "GenexineIncMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_GrossProceedsOfSharesAndWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds of shares and warrants.",
        "label": "Gross Proceeds Of Shares And Warrants",
        "terseLabel": "Gross proceeds of shares and warrants"
       }
      }
     },
     "localname": "GrossProceedsOfSharesAndWarrants",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_GrossProfitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Profit [member]",
        "label": "Gross Profit [Member]",
        "terseLabel": "Gross Profit [Member]"
       }
      }
     },
     "localname": "GrossProfitMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_Gxi7Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GX-I7.",
        "label": "GXI7 [Member]"
       }
      }
     },
     "localname": "Gxi7Member",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_HealSunMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Heal Sun.",
        "label": "Heal Sun [Member]",
        "terseLabel": "HealSun [Member]"
       }
      }
     },
     "localname": "HealSunMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_HillhouseEntitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hillhouse Entities [Member]"
       }
      }
     },
     "localname": "HillhouseEntitiesMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_HoldcoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "HoldCo [Member]"
       }
      }
     },
     "localname": "HoldcoMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_IMabBiopharmaHongKongLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab\u00a0Biopharma Hong Kong Limited.",
        "label": "I Mab Biopharma Hong Kong Limited [Member]",
        "terseLabel": "I-Mab Biopharma Hong Kong Limited [Member]"
       }
      }
     },
     "localname": "IMabBiopharmaHongKongLimitedMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_IMabShanghaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab\u00a0Shanghai.",
        "label": "I Mab Shanghai [Member]",
        "terseLabel": "I-Mab Shanghai [Member]"
       }
      }
     },
     "localname": "IMabShanghaiMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_IMabtianjinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab\u00a0Tianjin.",
        "label": "I MabTianjin [Member]",
        "terseLabel": "I-MabTianjin [Member]"
       }
      }
     },
     "localname": "IMabtianjinMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_IMobOtherSubsidiariesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I MOB Other Subsidiaries.",
        "label": "I MOB Other Subsidiaries [Member]",
        "terseLabel": "I MOB other subsidiaries [Member]"
       }
      }
     },
     "localname": "IMobOtherSubsidiariesMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ImabHangzhouMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Imab Hangzhou [Member]",
        "terseLabel": "I-Mab Hangzhou [Member]"
       }
      }
     },
     "localname": "ImabHangzhouMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesParentheticalDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ImabHongKongMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Imab Hong Kong [Member]",
        "terseLabel": "Imab Hong Kong [member]"
       }
      }
     },
     "localname": "ImabHongKongMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ImabbiopharmaUsLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab\u00a0Biopharma US Ltd.",
        "label": "IMabBiopharma US Ltd [Member]",
        "terseLabel": "I-MabBiopharma US Ltd. [Member]"
       }
      }
     },
     "localname": "ImabbiopharmaUsLtdMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_IncentiveIncomeFromDepositoryBank": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail": {
       "order": 13.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive income from depository bank.",
        "label": "Incentive Income From Depository Bank",
        "terseLabel": "Income of incentive payment from depository bank"
       }
      }
     },
     "localname": "IncentiveIncomeFromDepositoryBank",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_IncomeFromOtherFinancialAssets": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income from other financial assets.",
        "label": "Income From Other Financial Assets",
        "negatedLabel": "Income from other financial assets",
        "verboseLabel": "Income from other financial assets"
       }
      }
     },
     "localname": "IncomeFromOtherFinancialAssets",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_IncreaseDecreaseAdvanceFromCustomers": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease advance from customers.",
        "label": "Increase Decrease Advance from customers",
        "verboseLabel": "Advance from customers"
       }
      }
     },
     "localname": "IncreaseDecreaseAdvanceFromCustomers",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities current.",
        "label": "Increase Decrease In Operating Lease Liabilities Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_IncrementalCommonSharesAttributableToRestrictedShareUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted shares units",
        "label": "Incremental Common Shares Attributable To Restricted Share Units",
        "terseLabel": "Dilutive effect of restricted shares units"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToRestrictedShareUnits",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Accounted For Using The Equity Method And Put Right Liabilities [Abstract]"
       }
      }
     },
     "localname": "InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract",
     "nsuri": "http://IMab.com/20201231",
     "xbrltype": "stringItemType"
    },
    "imab_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Accounted for Using the Equity Method and Put Right Liabilities.",
        "label": "Investment Accounted For Using The Equity Method And Put Right Liabilities [Text Block]",
        "terseLabel": "Investment Accounted for Using the Equity Method and Put Right Liabilities"
       }
      }
     },
     "localname": "InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTextBlock",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imab_InvestorWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Warrants [Member]",
        "terseLabel": "Investor Warrants [Member]"
       }
      }
     },
     "localname": "InvestorWarrantsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_IprAndDTj101Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPR And D TJ101 [Member]",
        "terseLabel": "IPR And D TJ101 [Member]"
       }
      }
     },
     "localname": "IprAndDTj101Member",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_IprAndDTj102Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPR And D TJ102 [Member]",
        "terseLabel": "IPR And D TJ102 [Member]"
       }
      }
     },
     "localname": "IprAndDTj102Member",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_IprAndDTj103Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPR And D TJ103 [Member]",
        "terseLabel": "IPR And D TJ103 [Member]"
       }
      }
     },
     "localname": "IprAndDTj103Member",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://IMab.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_IssueOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue of warrants.",
        "label": "Issue Of Warrants",
        "terseLabel": "Issuance of Warrants"
       }
      }
     },
     "localname": "IssueOfWarrants",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imab_JiangsuTaslydiyiPharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jiangsu taslydiyi pharmaceutical co ltd.",
        "label": "Jiangsu Taslydiyi Pharmaceutical Co Ltd [Member]",
        "terseLabel": "Jiangsu Taslydiyi Pharmaceutical Co Ltd [Member]"
       }
      }
     },
     "localname": "JiangsuTaslydiyiPharmaceuticalCoLtdMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail",
      "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_LeiFangMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lei Fang [Member]",
        "terseLabel": "Lei Fang [Member]"
       }
      }
     },
     "localname": "LeiFangMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_LemzoparlimabLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lemzoparlimab license.",
        "label": "Lemzoparlimab License [Member]",
        "terseLabel": "Lemzoparlimab License [Member]"
       }
      }
     },
     "localname": "LemzoparlimabLicenseMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreement among HDYM, I-Mab and Hangzhou HealSun Biopharm Co., Ltd [Member]",
        "label": "Licensing Agreement among HDYM IMab and Hangzhou HealSun Biopharm Co Ltd [Member]",
        "terseLabel": "Licensing Agreement among HDYM, I-Mab and Hangzhou HealSun Biopharm Co., Ltd [Member]"
       }
      }
     },
     "localname": "LicensingAgreementAmongHdymImabAndHangzhouHealsunBiopharmCoLtdMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_LicensingAgreementUpfrontFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing agreement upfront fees.",
        "label": "Licensing Agreement Upfront Fees",
        "terseLabel": "Upfront\u00a0Fees"
       }
      }
     },
     "localname": "LicensingAgreementUpfrontFees",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_LicensingAgreementWithABLBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreement With ABL Bio.",
        "label": "Licensing Agreement With ABL Bio [Member]",
        "terseLabel": "Licensing Agreement With ABL Bio [Member]"
       }
      }
     },
     "localname": "LicensingAgreementWithABLBioMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreement With CSPC Pharmaceutical Group Limited.",
        "label": "Licensing Agreement With CSPC Pharmaceutical Group Limited [Member]",
        "terseLabel": "Licensing Agreement With CSPC Pharmaceutical Group Limited [Member]"
       }
      }
     },
     "localname": "LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_LicensingAgreementWithGenexineIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreement with Genexine, Inc.",
        "label": "Licensing Agreement with Genexine Inc [Member]"
       }
      }
     },
     "localname": "LicensingAgreementWithGenexineIncMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsTables",
      "http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_LicensingAgreementWithMacrogenicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreement with MacroGenics.",
        "label": "Licensing Agreement with MacroGenics [Member]",
        "terseLabel": "Licensing Agreement with MacroGenics [Member]"
       }
      }
     },
     "localname": "LicensingAgreementWithMacrogenicsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsTables",
      "http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_LicensingAgreementWithMorphosysAgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreement with MorphoSys AG.",
        "label": "Licensing Agreement with MorphoSys AG [Member]",
        "terseLabel": "Licensing Agreement with MorphoSys AG [Member]"
       }
      }
     },
     "localname": "LicensingAgreementWithMorphosysAgMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsTables",
      "http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_LicensingAgreementWithMorphosysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreement with MorphoSys.",
        "label": "Licensing Agreement with MorphoSys [Member]"
       }
      }
     },
     "localname": "LicensingAgreementWithMorphosysMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsTables",
      "http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_LicensingAgreementsWithMorphosysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreements With Morphosys.",
        "label": "Licensing Agreements With Morphosys [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsWithMorphosysMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_LoanOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan One [Member].",
        "label": "Loan One [Member]",
        "terseLabel": "Loan One [Member]"
       }
      }
     },
     "localname": "LoanOneMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_LoanTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Two [Member].",
        "label": "Loan Two [Member]",
        "terseLabel": "Loan Two [Member]"
       }
      }
     },
     "localname": "LoanTwoMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_LongTermInvestmentUnderEquityMethodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Investment under Equity Method [Member]",
        "label": "Long Term Investment under Equity Method [Member]",
        "terseLabel": "Long Term Investment under Equity Method [Member]"
       }
      }
     },
     "localname": "LongTermInvestmentUnderEquityMethodMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_LongTermInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Investments.",
        "label": "Long Term Investments [Policy Text Block]",
        "terseLabel": "Long Term Investments"
       }
      }
     },
     "localname": "LongTermInvestmentsPolicyTextBlock",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imab_LossFromConversionOfNotes": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss From Conversion of Notes.",
        "label": "Loss From Conversion of Notes",
        "terseLabel": "Loss from conversion of 2017 Notes"
       }
      }
     },
     "localname": "LossFromConversionOfNotes",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_LossFromConversionOfOnshoreConvertibleLoans": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss from conversion of onshore convertible loans.",
        "label": "Loss From Conversion Of Onshore Convertible Loans",
        "negatedLabel": "Loss from conversion of Onshore Convertible Loans",
        "terseLabel": "Loss from conversion of onshore convertible loans"
       }
      }
     },
     "localname": "LossFromConversionOfOnshoreConvertibleLoans",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_LossFromIssuanceOfNotes": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss From Issuance of Notes.",
        "label": "Loss From Issuance of Notes",
        "negatedLabel": "Loss from issuance of 2018 Notes",
        "terseLabel": "Loss from issuance of 2018 Notes"
       }
      }
     },
     "localname": "LossFromIssuanceOfNotes",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_LossFromOperationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss from Operation [Member]",
        "label": "Loss from Operation [Member]",
        "terseLabel": "Loss from Operation [Member]"
       }
      }
     },
     "localname": "LossFromOperationMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_MacroGenicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Macro Genics.",
        "label": "Macro Genics [Member]",
        "terseLabel": "MacroGenics [Member]"
       }
      }
     },
     "localname": "MacroGenicsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ManagementHoldcoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management Holdco [Member]"
       }
      }
     },
     "localname": "ManagementHoldcoMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Percentage Reduction In The Weighted Average Market Value Of Shares.",
        "label": "Maximum Percentage Reduction In The Weighted Average Market Value Of Shares",
        "verboseLabel": "Maximum Percentage Reduction In The Weighted Average Market Value Of Shares"
       }
      }
     },
     "localname": "MaximumPercentageReductionInTheWeightedAverageMarketValueOfShares",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imab_MilestoneIiiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone III [Member].",
        "label": "Milestone III [Member]"
       }
      }
     },
     "localname": "MilestoneIiiMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_MilestoneIvMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone IV [Member].",
        "label": "Milestone IV [Member]",
        "terseLabel": "Milestone Four [Member]"
       }
      }
     },
     "localname": "MilestoneIvMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_MilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Receivable.",
        "label": "Milestone Payment Receivable",
        "terseLabel": "Milestone Payment Receivable"
       }
      }
     },
     "localname": "MilestonePaymentReceivable",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_MilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Milestones",
        "verboseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_MilestonePaymentsIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments income.",
        "label": "Milestone Payments Income",
        "terseLabel": "Milestone payments income"
       }
      }
     },
     "localname": "MilestonePaymentsIncome",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_MilestonePaymentsOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments outstanding.",
        "label": "Milestone Payments Outstanding",
        "terseLabel": "Milestone payments due"
       }
      }
     },
     "localname": "MilestonePaymentsOutstanding",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_MilestoneTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Type [Axis]"
       }
      }
     },
     "localname": "MilestoneTypeAxis",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_MilestoneTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Type [Domain]",
        "terseLabel": "Milestone Type [Domain]"
       }
      }
     },
     "localname": "MilestoneTypeDomain",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_MorphoSysAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MorphoSysAG.",
        "label": "MorphoSysAG [Member]"
       }
      }
     },
     "localname": "MorphoSysAGMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_MorphosysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MorphoSys Member.",
        "label": "MorphoSys [Member]"
       }
      }
     },
     "localname": "MorphosysMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_NetIncomeLossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income Loss [Member]",
        "label": "Net Income Loss [Member]",
        "terseLabel": "Net Income Loss [Member]"
       }
      }
     },
     "localname": "NetIncomeLossMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recent accounting pronouncements.",
        "label": "New Accounting Pronouncements Not Yet Adopted [Policy Text Block]",
        "terseLabel": "Recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imab_NonRefundableIncentivePaymentFromDepositaryBankCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non refundable incentive payment from depositary bank current.",
        "label": "Non Refundable Incentive Payment From Depositary Bank Current",
        "terseLabel": "Non-refundable incentive payment from depositary bank"
       }
      }
     },
     "localname": "NonRefundableIncentivePaymentFromDepositaryBankCurrent",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_NonRefundableIncentivePaymentFromDepositaryBankNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail": {
       "order": 10.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non refundable incentive payment from depositary bank, noncurrent.",
        "label": "Non Refundable Incentive Payment From Depositary Bank Noncurrent",
        "terseLabel": "Non-refundable incentive payment from depositary bank"
       }
      }
     },
     "localname": "NonRefundableIncentivePaymentFromDepositaryBankNoncurrent",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days for calculating the weighted average market value of shares.",
        "label": "Number Of Days For Calculating The Weighted Average Market Value Of Shares",
        "verboseLabel": "Number of days for calculating the weighted average market value of shares"
       }
      }
     },
     "localname": "NumberOfDaysForCalculatingTheWeightedAverageMarketValueOfShares",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "imab_OfferingPriceOfConvertedShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering Price of converted shares.",
        "label": "Offering Price Of Converted Shares",
        "terseLabel": "Offering Price of converted shares"
       }
      }
     },
     "localname": "OfferingPriceOfConvertedShares",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_OfficeFurnitureAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office furniture and equipment",
        "label": "Office furniture and equipment [Member]"
       }
      }
     },
     "localname": "OfficeFurnitureAndEquipmentMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_OnePerformanceConditionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One performance condition.",
        "label": "One Performance Condition [Member]"
       }
      }
     },
     "localname": "OnePerformanceConditionMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_OnshoreConvertibleLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Onshore Convertible Loan.",
        "label": "Onshore Convertible Loan [Member]",
        "terseLabel": "Onshore Convertible Loan [Member]"
       }
      }
     },
     "localname": "OnshoreConvertibleLoanMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_OperatingDataAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Data [Abstract]"
       }
      }
     },
     "localname": "OperatingDataAbstract",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_OperatingLeaseInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesRentExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Interest Expense.",
        "label": "Operating Lease Interest Expense",
        "terseLabel": "Interest of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseInterestExpense",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Related Assets And Liabilities And Other Related Information [line items].",
        "label": "Operating Lease Related Assets And Liabilities And Other Related Information [Line Items]"
       }
      }
     },
     "localname": "OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationLineItems",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Related Assets And Liabilities And Other Related Information.",
        "label": "Operating Lease Related Assets And Liabilities And Other Related Information [Table]"
       }
      }
     },
     "localname": "OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTable",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Related Assets And Liabilities And Other Related Information.",
        "label": "Operating Lease Related Assets And Liabilities And Other Related Information [Table Text Block]",
        "terseLabel": "Operating Lease Related Assets And Liabilities And Other Related Information"
       }
      }
     },
     "localname": "OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imab_OperatingLeaseRightOfUseAssetAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesRentExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Right Of Use Asset Amortization.",
        "label": "Operating Lease Right Of Use Asset Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortization",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_OtherFinancialAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other\u00a0financial assets [Member]",
        "label": "Other financial assets [Member]"
       }
      }
     },
     "localname": "OtherFinancialAssetsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_OtherInLicensingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other In Licensing Agreements.",
        "label": "Other In Licensing Agreements [Member]"
       }
      }
     },
     "localname": "OtherInLicensingAgreementsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_OtherIncomeexpense": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income (Expense).",
        "label": "Other Income Expense",
        "verboseLabel": "Others"
       }
      }
     },
     "localname": "OtherIncomeexpense",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_OtherSupplementalCashFlowDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other supplemental cash flow disclosures [abstract].",
        "label": "Other Supplemental Cash Flow Disclosures [Abstract]",
        "verboseLabel": "Other supplemental cash flow disclosures"
       }
      }
     },
     "localname": "OtherSupplementalCashFlowDisclosuresAbstract",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_OtherinlicensingarrangementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other\u00a0In-Licensing\u00a0Arrangements[Member].",
        "label": "OtherInLicensingArrangements [Member]",
        "terseLabel": "Other\u00a0In-Licensing\u00a0Arrangements [Member]"
       }
      }
     },
     "localname": "OtherinlicensingarrangementsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_OutLicensingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Out licensing agreements.",
        "label": "Out Licensing Agreements [Member]"
       }
      }
     },
     "localname": "OutLicensingAgreementsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_PRCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PRC.",
        "label": "PRC [Member]",
        "terseLabel": "PRC [Member]"
       }
      }
     },
     "localname": "PRCMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_PayablesForInLicensedPatentRights": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payables for in licensed patent rights.",
        "label": "Payables For In Licensed Patent Rights",
        "terseLabel": "Payables for in-licensed patent rights"
       }
      }
     },
     "localname": "PayablesForInLicensedPatentRights",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_PeoplesBankOfChinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "People's Bank of China",
        "label": "Peoples Bank of China [Member]"
       }
      }
     },
     "localname": "PeoplesBankOfChinaMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_PercentageOfNetAssetToNetAssetsOfGroup": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net asset to net assets of group.",
        "label": "Percentage Of Net Asset To Net Assets Of Group",
        "terseLabel": "Percentage of net asset to consolidated net assets"
       }
      }
     },
     "localname": "PercentageOfNetAssetToNetAssetsOfGroup",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/RestrictedNetAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imab_PercentageOfReductionInMilestonePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Reduction In Milestone Payments.",
        "label": "Percentage Of Reduction In Milestone Payments",
        "terseLabel": "Reduction in milestone payment"
       }
      }
     },
     "localname": "PercentageOfReductionInMilestonePayments",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imab_PeriodTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period Type [Axis]"
       }
      }
     },
     "localname": "PeriodTypeAxis",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_PeriodTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period Type [Domain]"
       }
      }
     },
     "localname": "PeriodTypeDomain",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_PortionOfRestrictedShareUnitsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portion Of Restricted Share Units [Axis]"
       }
      }
     },
     "localname": "PortionOfRestrictedShareUnitsAxis",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_PortionOfRestrictedShareUnitsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of restricted share units.",
        "label": "Portion Of Restricted Share Units [Domain]"
       }
      }
     },
     "localname": "PortionOfRestrictedShareUnitsDomain",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_PreferredStockDividendsAtExtinguishmentOfPreferredShares": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 13.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock dividends at extinguishment of preferred shares.",
        "label": "Preferred Stock Dividends At Extinguishment Of Preferred Shares",
        "negatedLabel": "Deemed dividend to Series C-1 preferred shareholders at extinguishment of Series C-1 Preferred Shares",
        "negatedNetLabel": "Deemed dividend to Series C-1 preferred shareholders at extinguishment of Series C-1 Preferred Shares",
        "negatedTerseLabel": "Deemed dividend to Series\u00a0C-1\u00a0preferred shareholders at extinguishment of Series\u00a0C-1\u00a0Preferred Shares",
        "verboseLabel": "Deemed dividend to Series C-1 preferred shareholders at extinguishment of Series C-1 Preferred Shares"
       }
      }
     },
     "localname": "PreferredStockDividendsAtExtinguishmentOfPreferredShares",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_PreferredStockDividendsAtModificationOfPreferredShares": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 14.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock dividends at modification of preferred shares.",
        "label": "Preferred Stock Dividends At Modification Of Preferred Shares",
        "negatedNetLabel": "Deemed dividend to Series B-1, B-2 and C preferred shareholders at modification of Series B-1, B-2 and C Preferred Shares",
        "negatedTerseLabel": "Deemed dividend to Series\u00a0B-1,\u00a0B-2\u00a0and C preferred shareholders at modification of Series\u00a0B-1,\u00a0B-2\u00a0and C Preferred Shares",
        "terseLabel": "Deemed dividend to Series\u00a0B-1,\u00a0B-2\u00a0and C preferred shareholders at modification of Series\u00a0B-1,\u00a0B-2\u00a0and C Preferred Shares",
        "verboseLabel": "Deemed dividend to Series B-1, B-2 and C preferred shareholders at modification of Series B-1, B-2 and C Preferred Shares"
       }
      }
     },
     "localname": "PreferredStockDividendsAtModificationOfPreferredShares",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_PreferredStockLiquidationPreferencePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock liquidation preference percentage.",
        "label": "Preferred Stock Liquidation Preference Percentage",
        "terseLabel": "Preferred Stock Liquidation Preference Percentage"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferencePercentage",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imab_PreferredStockLiquidationPreferenceRateOfReturn": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internal rate of return.",
        "label": "Preferred Stock Liquidation Preference Rate Of Return",
        "terseLabel": "Internal Rate of Return"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceRateOfReturn",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imab_PrepaidExpenseStockRepurchaseProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expense stock repurchase program.",
        "label": "Prepaid Expense Stock Repurchase Program",
        "terseLabel": "Prepaid Expensestock repurchase program"
       }
      }
     },
     "localname": "PrepaidExpenseStockRepurchaseProgram",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_PrepaidexpensesandotherreceivablestextblockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other receivables [Text Block].",
        "label": "PrepaidExpensesAndOtherReceivablesTextBlock [Text Block]",
        "terseLabel": "Prepaid Expenses And Other Receivables"
       }
      }
     },
     "localname": "PrepaidexpensesandotherreceivablestextblockTextBlock",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrepaymentsAndOtherReceivables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imab_PrivatePlacementOfferingCostsPayable": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Placement offering costs payable.",
        "label": "Private Placement Offering Costs Payable",
        "terseLabel": "Accrued private placement offering costs payable"
       }
      }
     },
     "localname": "PrivatePlacementOfferingCostsPayable",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 52.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from cash received from collection of prepayment for stock repurchase program.",
        "label": "Proceeds from Cash Received from Collection of Prepayment for Stock Repurchase Program",
        "verboseLabel": "Cash received from collection of prepayment for stock repurchase program"
       }
      }
     },
     "localname": "ProceedsFromCashReceivedFromCollectionOfPrepaymentForStockRepurchaseProgram",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_ProceedsFromNonRefundableIncentive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from non-refundable incentive.",
        "label": "Proceeds From Non Refundable Incentive",
        "terseLabel": "Proceeds from non-refundable incentive"
       }
      }
     },
     "localname": "ProceedsFromNonRefundableIncentive",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/AccrualsAndOtherPayablesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_PropertyPlantAndequipmentnetExcludingConstructionInProcess": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property plant and equipment net excluding construction in process.",
        "label": "Property Plant And Equipment Net Excluding Construction In Process",
        "terseLabel": "Net book value"
       }
      }
     },
     "localname": "PropertyPlantAndequipmentnetExcludingConstructionInProcess",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proportionate share of share based compensation expenses recorded in an equity method affiliate.",
        "label": "Proportionate Share Of Share Based Compensation Expenses Recorded In An Equity Method Affiliate",
        "terseLabel": "Proportionate share of share-based compensation expenses recorded in an equity method affiliate (Note 9(a))"
       }
      }
     },
     "localname": "ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_PutRightLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Put right liabilities.",
        "label": "Put Right Liabilities",
        "terseLabel": "Put right liabilities"
       }
      }
     },
     "localname": "PutRightLiabilities",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_PutRightLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Put Right Liabilities [Member]"
       }
      }
     },
     "localname": "PutRightLiabilitiesMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_QualifiedPublicOfferingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qualified public offering price.",
        "label": "Qualified Public Offering Price",
        "terseLabel": "Final Offering Price"
       }
      }
     },
     "localname": "QualifiedPublicOfferingPrice",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "imab_ReceiptOfContractResearchOrganizationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receipt Of Contract Research Organizations [Member]",
        "terseLabel": "Receipt of Contract Research Organizations [Member]"
       }
      }
     },
     "localname": "ReceiptOfContractResearchOrganizationsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_RegisteredCapitalOfSubsidiary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered capital of subsidiary.",
        "label": "Registered Capital Of Subsidiary",
        "terseLabel": "Registered capital of subsidiary"
       }
      }
     },
     "localname": "RegisteredCapitalOfSubsidiary",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_RestrictedNetAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Net Assets Disclosure [Abstract].",
        "label": "Restricted Net Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "RestrictedNetAssetsDisclosureAbstract",
     "nsuri": "http://IMab.com/20201231",
     "xbrltype": "stringItemType"
    },
    "imab_RestrictedNetAssetsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Net Assets Disclosure .",
        "label": "Restricted Net Assets Disclosure [Line Items]"
       }
      }
     },
     "localname": "RestrictedNetAssetsDisclosureLineItems",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/RestrictedNetAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_RevenueFromContractWithCustomerTimeOfTransferOfLicense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from contract with customer at time of transfer of license",
        "label": "Revenue from Contract with customer Time of Transfer of License",
        "terseLabel": "Revenue from contract with customer at time of transfer of license"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTimeOfTransferOfLicense",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_RevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue [member]",
        "label": "Revenue [Member]",
        "terseLabel": "Revenue [Member]"
       }
      }
     },
     "localname": "RevenueMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Milestones [Member]",
        "terseLabel": "Sales Milestones [Member]"
       }
      }
     },
     "localname": "SalesMilestonesMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Accounts Receivable and Contract Assets Net of Allowance for Credit Losses.",
        "label": "Schedule Of Accounts Receivable and Contract Assets Net of Allowance for Credit Losses [Table Text Block]",
        "terseLabel": "summary of Accounts receivable and contract assets, net of allowance for credit losses"
       }
      }
     },
     "localname": "ScheduleOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesTableTextBlock",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/AccountsReceivableAndContractAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imab_ScheduleOfComponentsOfOperatingLeaseExpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Components of Operating Lease Expense.",
        "label": "Schedule of Components of Operating Lease Expense [Table]"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfOperatingLeaseExpenseTable",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of components of operating lease expense.",
        "label": "Schedule Of Components Of Operating Lease Expense [Table Text Block]",
        "terseLabel": "Schedule of Components of Operating Lease Expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imab_ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Convertible promissory notes and onshore convertible loans.",
        "label": "Schedule of Convertible promissory notes and onshore convertible loans",
        "terseLabel": "Convertible promissory notes and onshore convertible loans"
       }
      }
     },
     "localname": "ScheduleOfConvertiblePromissoryNotesAndOnshoreConvertibleLoans",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imab_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Nonvested Restricted Stock Units Activity [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_ScheduleOfNonvestedRestrictedStockUnitsActivityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Nonvested Restricted Stock Units Activity [Table]"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTable",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_ScheduleOfOperatingLeaseMaturityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Operating Lease Maturity [line items].",
        "label": "Schedule of Operating Lease Maturity [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeaseMaturityLineItems",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LeasesOperatingLeaseMaturityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_ScheduleOfOperatingLeaseMaturityTableTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Operating Lease Maturity Table",
        "label": "Schedule of Operating Lease Maturity Table [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeaseMaturityTableTable",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LeasesOperatingLeaseMaturityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_ScheduleOfPrincipalSubsidiariesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Principal Subsidiaries Table",
        "label": "Schedule Of Principal Subsidiaries [Table]"
       }
      }
     },
     "localname": "ScheduleOfPrincipalSubsidiariesTable",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_ScheduleOfPrincipalSubsidiariesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Principal Subsidiaries Table Text Block",
        "label": "Schedule Of Principal Subsidiaries [Table Text Block]",
        "terseLabel": "Schedule of Principal Subsidiaries"
       }
      }
     },
     "localname": "ScheduleOfPrincipalSubsidiariesTableTextBlock",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imab_ScheduleOfRelatedPartyBalancesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of related party balances [Table Text Block].",
        "label": "Schedule Of Related Party Balances [Text Block]",
        "terseLabel": "Summary of Related Party Balances"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyBalancesTextBlock",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityLineItems",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTable",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of useful life of property plant equipment [Table Text Block].",
        "label": "Schedule Of Useful Life Of Property Plant Equipment [Table Text Block]",
        "terseLabel": "Summary of Estimated Useful Lives"
       }
      }
     },
     "localname": "ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imab_ScheduleofComponentsofOperatingLeaseExpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Components of Operating Lease Expense [line items].",
        "label": "Schedule of Components of Operating Lease Expense [Line Items]"
       }
      }
     },
     "localname": "ScheduleofComponentsofOperatingLeaseExpenseLineItems",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_SecondClosingPeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Closing Period [Member]",
        "terseLabel": "Second Closing Period [Member]"
       }
      }
     },
     "localname": "SecondClosingPeriodMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SecondMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second milestone.",
        "label": "Second Milestone [Member]",
        "terseLabel": "Second Milestone [Member]"
       }
      }
     },
     "localname": "SecondMilestoneMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SecondOneThirdPortionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second One Third Portion.",
        "label": "Second One Third Portion [Member]"
       }
      }
     },
     "localname": "SecondOneThirdPortionMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeniorManagementEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Management Employees [Member]",
        "label": "Senior Management Employees [Member]",
        "terseLabel": "Senior Management Employees [Member]"
       }
      }
     },
     "localname": "SeniorManagementEmployeesMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriesA1AndA2PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A1 And A2 Preferred Stock [Member]",
        "terseLabel": "Series A1 And A2 Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesA1AndA2PreferredStockMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriesA3PreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A 3 preferred shares",
        "label": "Series A 3 Preferred Shares [Member]",
        "terseLabel": "Series A-3 Preferred Shares [Member]"
       }
      }
     },
     "localname": "SeriesA3PreferredSharesMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriesA3PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A3 Preferred Stock [Member]",
        "terseLabel": "Series A3 Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesA3PreferredStockMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriesAConvertiblePreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Shares [Member]",
        "terseLabel": "Series A Convertible Preferred Shares [Member]"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredSharesMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriesB1PreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B1 preferred shares",
        "label": "Series B1 Preferred Shares [Member]",
        "terseLabel": "Series B-1 Preferred Shares [Member]"
       }
      }
     },
     "localname": "SeriesB1PreferredSharesMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriesB2PreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B2 Preferred Shares [Member]",
        "terseLabel": "Series B2 Preferred Shares [Member]"
       }
      }
     },
     "localname": "SeriesB2PreferredSharesMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriesBConvertiblePreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Convertible Preferred Shares [Member]",
        "terseLabel": "Series B Convertible Preferred Shares [Member]"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredSharesMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriesBOnshoreInvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Onshore Investors [Member]",
        "terseLabel": "Series B Onshore Investors [Member]"
       }
      }
     },
     "localname": "SeriesBOnshoreInvestorsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriesBPreferredShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Shareholders [Member]",
        "terseLabel": "Series B Preferred Shareholders [Member]"
       }
      }
     },
     "localname": "SeriesBPreferredShareholdersMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriesBPreferredStockHolderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock Holder [Member]"
       }
      }
     },
     "localname": "SeriesBPreferredStockHolderMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriesBWarrantsSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants Shares [Member]",
        "terseLabel": "Series B Warrants Shares [Member]"
       }
      }
     },
     "localname": "SeriesBWarrantsSharesMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriesC1ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C 1 convertible preferred stock [Member]",
        "label": "Series C 1 Convertible Preferred Stock [Member]",
        "terseLabel": "Series C-1 Convertible Preferred Shares [Member]",
        "verboseLabel": "Series C-1 Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesC1ConvertiblePreferredStockMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriesCConvertiblePreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Convertible Preferred Shares [Member]",
        "terseLabel": "Series C Convertible Preferred Shares [Member]"
       }
      }
     },
     "localname": "SeriesCConvertiblePreferredSharesMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriesCConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCConvertiblePreferredStockMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriesCOneConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C One Convertible Preferred Stock [Member]",
        "terseLabel": "Series C-1 Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCOneConvertiblePreferredStockMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriesCOnePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C One Preferred Stock [Member]",
        "terseLabel": "Series C One Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCOnePreferredStockMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SeriescOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SeriesC One [Member]",
        "terseLabel": "Series C -1 [Member]"
       }
      }
     },
     "localname": "SeriescOneMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Striggering Event For Redemption Rate.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Striggering Event For Redemption Rate",
        "terseLabel": "Probability of triggering event for redemption option"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionStriggeringEventForRedemptionRate",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions exercise multiple maximum.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Multiple Maximum",
        "terseLabel": "Exercise multiple, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions exercise multiple minimum.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Multiple Minimum",
        "terseLabel": "Exercise multiple, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Spot Price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Spot Price",
        "terseLabel": "Spot price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSpotPrice",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based payment award options non vested options exercised.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Non Vested Options Exercised Number Of Shares",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsExercisedNumberOfShares",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Non vested Options Repurchased Total Consideration.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Options Repurchased Total Consideration",
        "verboseLabel": "Stock options, repurchased during the period, total consideration"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOptionsRepurchasedTotalConsideration",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options nonvested options repurchased.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Options Repurchased",
        "negatedLabel": "Repurchased",
        "verboseLabel": "Stock options, repurchased during the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsRepurchased",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Surrenders In Period",
        "terseLabel": "Surrendered"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSurrendersInPeriod",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imab_ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation by share based payments award percentage of shares restricted.",
        "label": "Share Based Compensation by Share based Payments Award Percentage of Shares Restricted",
        "terseLabel": "Ordinary shares held, restriction percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationByShareBasedPaymentsAwardPercentageOfSharesRestricted",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imab_ShareBasedCompensationTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation tranche four.",
        "label": "Share Based Compensation Tranche Four [Member]",
        "verboseLabel": "Tranche Four [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationTrancheFourMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ShareIncentivePlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ShareIncentivePlan2020Member [Member].",
        "label": "Share Incentive Plan 2020 [Member]",
        "terseLabel": "2020 Plan [Member]"
       }
      }
     },
     "localname": "ShareIncentivePlan2020Member",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ShareIncentivePlanTwoThousandTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ShareIncentivePlanTwoThousandTwentyMember",
        "label": "Share Incentive Plan Two Thousand Twenty [Member]",
        "terseLabel": "2020 Plan [Member]"
       }
      }
     },
     "localname": "ShareIncentivePlanTwoThousandTwentyMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, fair value assumptions, exercise multiple.",
        "label": "Sharebased Compensation Arrangement by Sharebased Payment Award Fair Value Assumptions Exercise Multiple",
        "terseLabel": "Exercise multiple"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExerciseMultiple",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "imab_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Repurchased in Period, Weighted Average Exercise Price.",
        "label": "Sharebased Compensation Arrangements by Sharebased Payment Award Options Repurchased in Period Weighted Average Exercise Price",
        "terseLabel": "Repurchased",
        "verboseLabel": "Stock options, repurchased during the period, average price"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsSurrendedNumberOfShares.",
        "label": "Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares",
        "negatedLabel": "Surrendered"
       }
      }
     },
     "localname": "Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendednumberofshares",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imab_Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue",
        "label": "Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue",
        "terseLabel": "Surrendered"
       }
      }
     },
     "localname": "Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionssurrendedweightedaveragegrantdatefairvalue",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imab_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsSurrendersInPeriodWeightedAverageExercisePrice",
        "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsSurrendersInPeriodWeightedAverageExercisePrice",
        "terseLabel": "Surrendered"
       }
      }
     },
     "localname": "Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionssurrendersinperiodweightedaverageexerciseprice",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imab_Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ShareBasedCompensationByShareBasedPaymentArrangementNonVestedOptionsExercisesInPeriodWeightedAverageGrantDateFairValue",
        "label": "ShareBasedCompensationByShareBasedPaymentArrangementNonVestedOptionsExercisesInPeriodWeightedAverageGrantDateFairValue",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "Sharebasedcompensationbysharebasedpaymentarrangementnonvestedoptionsexercisesinperiodweightedaveragegrantdatefairvalue",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imab_ShortTermInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term investments.",
        "label": "Short Term Investments [Policy Text Block]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsPolicyTextBlock",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imab_SoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Software [Member]",
        "label": "Software [Member]"
       }
      }
     },
     "localname": "SoftwareMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statutory reserve annual appropriation percentage from after tax profit.",
        "label": "Statutory Reserve Annual Appropriation Percentage from After Tax Profit",
        "terseLabel": "Statutory reserve, annual appropriation percentage from after tax profit"
       }
      }
     },
     "localname": "StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/RestrictedNetAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imab_StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Strategic Alliance Agreement with PT Kalbe Genexine Biologics [Member]"
       }
      }
     },
     "localname": "StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_Study1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Study 1 [Member]"
       }
      }
     },
     "localname": "Study1Member",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_Study2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Study 2 [Member]"
       }
      }
     },
     "localname": "Study2Member",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_TasgenGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tasgen group [Member].",
        "label": "Tasgen Group [Member]",
        "terseLabel": "Tasgen Group [Member]"
       }
      }
     },
     "localname": "TasgenGroupMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_TaslyPharmaceuticalGroupCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tasly Pharmaceutical Group Co., Ltd.Member.",
        "label": "Tasly Pharmaceutical Group Co Ltd [Member]",
        "terseLabel": "Tasly Pharmaceutical Group Co Ltd [Member]"
       }
      }
     },
     "localname": "TaslyPharmaceuticalGroupCoLtdMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_TemporaryEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity [Member].",
        "label": "Temporary Equity [Member]"
       }
      }
     },
     "localname": "TemporaryEquityMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_TemporaryEquityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity.",
        "label": "Temporary Equity [Text Block]",
        "terseLabel": "Convertible Preferred Shares"
       }
      }
     },
     "localname": "TemporaryEquityTextBlock",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredShares"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imab_TerminationFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination Fee Payable .",
        "label": "Termination Fee Payable",
        "terseLabel": "Termination fee payable"
       }
      }
     },
     "localname": "TerminationFeePayable",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_ThirdOneThirdPortionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third One Third Portion [Member]"
       }
      }
     },
     "localname": "ThirdOneThirdPortionMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ThirdVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third Venture",
        "label": "Third Venture [Member]",
        "terseLabel": "Third Venture [Member]"
       }
      }
     },
     "localname": "ThirdVentureMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ThreePerformanceConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three Performance Conditions [Member]"
       }
      }
     },
     "localname": "ThreePerformanceConditionsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold Percentage Of General Reserve To Registered Capital For Reserve Appropriation.",
        "label": "Threshold Percentage Of General Reserve To Registered Capital For Reserve Appropriation",
        "terseLabel": "Statutory reserve, threshold limit for annual appropriation"
       }
      }
     },
     "localname": "ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/RestrictedNetAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imab_TimeCostOfForegoingHistoricalContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time cost of foregoing historical contribution.",
        "label": "Time cost of foregoing historical contribution",
        "terseLabel": "Time cost of foregoing historical contribution"
       }
      }
     },
     "localname": "TimeCostOfForegoingHistoricalContribution",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_TrancheIOfSeriesBWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche I Of Series B Warrants [Member]",
        "terseLabel": "Tranche I Of Series B Warrants [Member]"
       }
      }
     },
     "localname": "TrancheIOfSeriesBWarrantsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_TrancheIiOfSeriesBWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche II of Series B Warrants [Member]",
        "terseLabel": "Tranche II of Series B Warrants [Member]"
       }
      }
     },
     "localname": "TrancheIiOfSeriesBWarrantsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_TwentyEighteenEmployeeStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 plan",
        "label": "Twenty Eighteen Employee Stock Option Plan [Member]",
        "terseLabel": "2018 Plan [Member]"
       }
      }
     },
     "localname": "TwentyEighteenEmployeeStockOptionPlanMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail",
      "http://IMab.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_TwentyNineteenEmployeeStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Nineteen Employee Stock Option Plan [Member]",
        "label": "Twenty Nineteen Employee Stock Option Plan [Member]",
        "terseLabel": "2019 Plan [Member]",
        "verboseLabel": "2019 Plan [Member]"
       }
      }
     },
     "localname": "TwentyNineteenEmployeeStockOptionPlanMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail",
      "http://IMab.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_TwentyNineteenShareIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Share Incentive Plan [Member].",
        "label": "Twenty Nineteen Share Incentive Plan [Member]",
        "terseLabel": "2019 Share Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwentyNineteenShareIncentivePlanMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_TwentySeventeenEmployeeStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 plan",
        "label": "Twenty Seventeen Employee Stock Option Plan [Member]",
        "terseLabel": "2017 Plan [Member]",
        "verboseLabel": "2017 Employee Stock Option Plan [Member]"
       }
      }
     },
     "localname": "TwentySeventeenEmployeeStockOptionPlanMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_TwentyTwentyEmployeeStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twenty Twenty Employee Stock Option Plan [Member]",
        "terseLabel": "2020 Plan [Member]",
        "verboseLabel": "2020 Plan [Member]"
       }
      }
     },
     "localname": "TwentyTwentyEmployeeStockOptionPlanMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_TwoPerformanceConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Performance Conditions [Member]"
       }
      }
     },
     "localname": "TwoPerformanceConditionsMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_TwoZeroOneEightNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Notes.",
        "label": "Two Zero One Eight Notes [Member]",
        "terseLabel": "2018 Notes [Member]"
       }
      }
     },
     "localname": "TwoZeroOneEightNotesMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_TypeOfLicensesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Licenses [Axis]"
       }
      }
     },
     "localname": "TypeOfLicensesAxis",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_TypeOfLicensesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Licenses [Domain]"
       }
      }
     },
     "localname": "TypeOfLicensesDomain",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_UnderwriterAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriter [Axis]"
       }
      }
     },
     "localname": "UnderwriterAxis",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "imab_UnderwriterDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriter [Domain]"
       }
      }
     },
     "localname": "UnderwriterDomain",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_UpfrontAndMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments.",
        "label": "Upfront And Milestone Payments",
        "terseLabel": "Potential value of license agreement"
       }
      }
     },
     "localname": "UpfrontAndMilestonePayments",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_UpfrontLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Upfront License Fee",
        "documentation": "Upfront license fee.",
        "label": "Upfront License Fee"
       }
      }
     },
     "localname": "UpfrontLicenseFee",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_UpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment received.",
        "label": "Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "UpfrontPaymentReceived",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_VATSurchargesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VAT surcharges percent.",
        "label": "V A T Surcharges Percent",
        "terseLabel": "VAT surcharges percent"
       }
      }
     },
     "localname": "VATSurchargesPercent",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imab_ValueAddedTaxesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value Added Taxes Policy.",
        "label": "Value Added Taxes Policy [Policy Text Block]",
        "terseLabel": "Value-added-tax\u00a0(\"VAT\") recoverable and surcharges"
       }
      }
     },
     "localname": "ValueAddedTaxesPolicyPolicyTextBlock",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imab_ValueaddedTaxRecoverable": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value-added tax recoverable",
        "label": "Valueadded tax recoverable",
        "verboseLabel": "Value-added tax recoverable"
       }
      }
     },
     "localname": "ValueaddedTaxRecoverable",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_WarrantLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant liabilities [Member]",
        "label": "Warrant liabilities [Member]"
       }
      }
     },
     "localname": "WarrantLiabilitiesMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_WarrantsDisclosure": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants disclosure.",
        "label": "Warrants Disclosure",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsDisclosure",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imab_WarrantsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Warrants [Abstract].",
        "label": "Warrants Disclosure [Abstract]"
       }
      }
     },
     "localname": "WarrantsDisclosureAbstract",
     "nsuri": "http://IMab.com/20201231",
     "xbrltype": "stringItemType"
    },
    "imab_WarrantsToPurchaseOrdinarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants To Purchase Ordinary Shares.",
        "label": "Warrants To Purchase Ordinary Shares [Member]",
        "terseLabel": "Warrants to purchase ordinary shares [Member]"
       }
      }
     },
     "localname": "WarrantsToPurchaseOrdinarySharesMember",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imab_WithholdingIitPayable": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Withholding IIT payable.",
        "label": "Withholding IIT payable",
        "terseLabel": "Withholding IIT payable related to stock options"
       }
      }
     },
     "localname": "WithholdingIitPayable",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imab_WithholdingTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Withholding Tax.",
        "label": "Withholding Tax",
        "terseLabel": "Withholding Tax"
       }
      }
     },
     "localname": "WithholdingTax",
     "nsuri": "http://IMab.com/20201231",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r435",
      "r436",
      "r440",
      "r441",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesParentheticalDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail",
      "http://IMab.com/role/RestrictedNetAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r435",
      "r436",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesParentheticalDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail",
      "http://IMab.com/role/RestrictedNetAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r68",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director[Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail",
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r209",
      "r317",
      "r321",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r338",
      "r341",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r542",
      "r602",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r338",
      "r341",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r542",
      "r602",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r209",
      "r317",
      "r321",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r206",
      "r317",
      "r319",
      "r543",
      "r601",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetParentheticalDetail",
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r206",
      "r317",
      "r319",
      "r543",
      "r601",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetParentheticalDetail",
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r326",
      "r338",
      "r341",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r542",
      "r602",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail",
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r326",
      "r338",
      "r341",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r542",
      "r602",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail",
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail",
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r207",
      "r208",
      "r317",
      "r320",
      "r604",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r207",
      "r208",
      "r317",
      "r320",
      "r604",
      "r632",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r279",
      "r339",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SubsidiariesMember": {
     "auth_ref": [
      "r334",
      "r500",
      "r501",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [Member]",
        "terseLabel": "Prc Subsidiaries [Member]"
       }
      }
     },
     "localname": "SubsidiariesMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/RestrictedNetAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r210",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      },
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accruals and other payables",
        "totalLabel": "Accounts Payable and Accrued Liabilities, Current"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail",
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r569",
      "r592"
     ],
     "calculation": {
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.",
        "label": "Accounts Payable and Accrued Liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accruals and other Payables"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/AccrualsAndOtherPayables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.",
        "label": "Accounts Payable and Accrued Liabilities, Noncurrent",
        "totalLabel": "Accounts Payable and Accrued Liabilities, Non-current"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Noncurrent [Abstract]",
        "verboseLabel": "Non-current:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, gross"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/AccountsReceivableAndContractAssetsSummaryOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r34",
      "r211",
      "r212"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 31.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/AccountsReceivableAndContractAssetsSummaryOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesDetail",
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/AccountsReceivableAndContractAssetsSummaryOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r48",
      "r269"
     ],
     "calculation": {
      "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r37",
      "r71",
      "r72",
      "r73",
      "r587",
      "r611",
      "r612"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r70",
      "r73",
      "r74",
      "r133",
      "r134",
      "r135",
      "r438",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r378",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock": {
     "auth_ref": [
      "r292",
      "r293",
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.",
        "label": "Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock",
        "terseLabel": "Transaction with redeemable non- controlling interests"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r344",
      "r347",
      "r384",
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r283",
      "r293",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r347",
      "r374",
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense",
        "verboseLabel": "Share-based compensation expenses related to restricted shares"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r41",
      "r217",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/AccountsReceivableAndContractAssetsSummaryOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r113",
      "r252",
      "r259"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities that have not been included in calculation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Type of arrangement [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsTables",
      "http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r126",
      "r188",
      "r198",
      "r204",
      "r228",
      "r435",
      "r440",
      "r465",
      "r562",
      "r585"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail",
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r67",
      "r126",
      "r228",
      "r435",
      "r440",
      "r465"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 25.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "terseLabel": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.",
        "label": "Assets, Fair Value Adjustment",
        "terseLabel": "Fair value change of other financial assets"
       }
      }
     },
     "localname": "AssetsFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNet": {
     "auth_ref": [
      "r1",
      "r613",
      "r614",
      "r615",
      "r616"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net assets (liabilities).",
        "label": "Net Assets",
        "terseLabel": "Net assets"
       }
      }
     },
     "localname": "AssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/RestrictedNetAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r126",
      "r228",
      "r435",
      "r440",
      "r465"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "terseLabel": "Non-current\u00a0assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r348",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r444",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r337",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r337",
      "r340",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Voting Interests Acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total remaining unamortized or unaccreted amounts of premiums, discounts, and intangible assets, in years subsequent to the year of acquisition, when the total amounts of remaining discounts, premiums, and intangible assets exceed 30 percent of stockholders' equity.",
        "label": "Business Acquisitions, Purchase Price Allocation, Subsequent Years, Remaining Adjustments",
        "terseLabel": "Purchase price committed"
       }
      }
     },
     "localname": "BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized": {
     "auth_ref": [
      "r421"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The assets recognized for each amount of assets recorded in a transaction with the acquiree that is recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.",
        "label": "Business Combination, Separately Recognized Transactions, Assets Recognized",
        "terseLabel": "Assets recognized value"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r122",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business combination"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedContractCostImpairmentLoss": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Impairment Loss",
        "terseLabel": "Impairment loss, contract assets with customer"
       }
      }
     },
     "localname": "CapitalizedContractCostImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r44",
      "r115"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 26.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfCashCashEquivalentsAndRestrictedCashAsReportedInTheConsolidatedStatementOfCashFlowsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfCashCashEquivalentsAndRestrictedCashAsReportedInTheConsolidatedStatementOfCashFlowsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r116",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r13",
      "r116",
      "r122",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r108",
      "r115",
      "r121"
     ],
     "calculation": {
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfCashCashEquivalentsAndRestrictedCashAsReportedInTheConsolidatedStatementOfCashFlowsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of the year",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of year",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfCashCashEquivalentsAndRestrictedCashAsReportedInTheConsolidatedStatementOfCashFlowsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r108",
      "r470"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CharityCareReimbursementsReceived": {
     "auth_ref": [
      "r633"
     ],
     "calculation": {
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of subsidies received by the entity for providing charity care, for example, from an uncompensated care fund.",
        "label": "Charity Care, Reimbursements Received",
        "terseLabel": "Subsidy income"
       }
      }
     },
     "localname": "CharityCareReimbursementsReceived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r124",
      "r126",
      "r150",
      "r154",
      "r157",
      "r160",
      "r162",
      "r170",
      "r171",
      "r172",
      "r228",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail",
      "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail",
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail",
      "http://IMab.com/role/CoverPage",
      "http://IMab.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail",
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r301",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants issued and exercised",
        "verboseLabel": "Number of warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r301",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r427",
      "r428",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Licensing And Collaboration Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementRightsAndObligations": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of rights and obligations under the collaborative arrangements.",
        "label": "Collaborative Arrangement, Rights and Obligations",
        "terseLabel": "Licensing\u00a0Arrangements, Description of terms"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsTables",
      "http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralAxis": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral [Axis]"
       }
      }
     },
     "localname": "CollateralAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral [Domain]"
       }
      }
     },
     "localname": "CollateralDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r60",
      "r278",
      "r571",
      "r591"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r133",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary\u00a0share",
        "verboseLabel": "Ordinary\u00a0Share [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://IMab.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Common shares, par value",
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Ordinary shares, par value",
        "verboseLabel": "Ordinary Shares Par Value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary Shares Authorized",
        "verboseLabel": "Ordinary shares, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary Shares Issued",
        "verboseLabel": "Issue of shares"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r33",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Ordinary Shares Outstanding",
        "verboseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Shares Subscribed but Unissued",
        "terseLabel": "Shares subscribed,not yet been purchased or issued"
       }
      }
     },
     "localname": "CommonStockSharesSubscribedButUnissued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "presentationGuidance": "Issue of shares, Value",
        "terseLabel": "Ordinary shares (US$0.0001 par value, 500,000,000 and 800,000,000 shares authorized as of December 31, 2019 and December 31, 2020, respectively; 8,363,719 and 164,888,519 shares issued and outstanding as of December 31, 2019 and December 31, 2020, respectively)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r324",
      "r325",
      "r342",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefits"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/EmployeeBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r76",
      "r78",
      "r79",
      "r86",
      "r575",
      "r596"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income (loss) attributable to I-MAB"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConcentrationOfCreditRisk"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossCurrent": {
     "auth_ref": [
      "r231",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAccumulatedAllowanceForCreditLossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/AccountsReceivableAndContractAssetsSummaryOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetGrossCurrent": {
     "auth_ref": [
      "r303",
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, before Allowance for Credit Loss, Current",
        "verboseLabel": "Contract assets, gross"
       }
      }
     },
     "localname": "ContractWithCustomerAssetGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/AccountsReceivableAndContractAssetsSummaryOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r303",
      "r305",
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract asset with customer"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r303",
      "r305",
      "r318"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, Net, Current",
        "terseLabel": "Contract assets",
        "verboseLabel": "Contract assets, net"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/AccountsReceivableAndContractAssetsSummaryOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesDetail",
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]",
        "terseLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Current [abstract]"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/AccountsReceivableAndContractAssetsSummaryOfAccountsReceivableAndContractAssetsNetOfAllowanceForCreditLossesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r303",
      "r304",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Advance from customers"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r118",
      "r119",
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "verboseLabel": "Conversion of preferred shares to ordinary shares"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r118",
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Number of preferred shares converted to common shares"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible promissory notes"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Shares [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r31",
      "r32",
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Shares Issued Upon Conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r118",
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion from convertible promissory notes (Note 15)",
        "verboseLabel": "Conversion of convertible promissory notes to ordinary shares"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r118",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Debt conversion number of share issue",
        "verboseLabel": "Conversion from convertible promissory notes, Shares"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Conversion [Line Items]",
        "terseLabel": "Debt Conversion [Line Items]"
       }
      }
     },
     "localname": "DebtConversionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r23",
      "r25",
      "r26",
      "r563",
      "r565",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail",
      "http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCollateralAmount": {
     "auth_ref": [
      "r579"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets pledged to secure a debt instrument.",
        "label": "Debt Instrument, Collateral Amount",
        "terseLabel": "Collateral Value"
       }
      }
     },
     "localname": "DebtInstrumentCollateralAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price of debt instrument"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r482",
      "r484"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Convertible notes\u00a0issued",
        "verboseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest Rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail",
      "http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.",
        "label": "Debt Instrument, Maturity Date, Description",
        "terseLabel": "Debt instrument, maturity"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDateDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail",
      "http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r58",
      "r130",
      "r294",
      "r296",
      "r297",
      "r298",
      "r481",
      "r482",
      "r484",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Loan Term",
        "verboseLabel": "Maturity period of debt instrument"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail",
      "http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Summary of Prepayments And Other Receivables"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeCurrent": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Income, Current",
        "terseLabel": "Deferred subsidy income"
       }
      }
     },
     "localname": "DeferredIncomeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeNoncurrent": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Income, Noncurrent",
        "terseLabel": "Deferred subsidy income"
       }
      }
     },
     "localname": "DeferredIncomeNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r28",
      "r29",
      "r400",
      "r564",
      "r581"
     ],
     "calculation": {
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r406",
      "r407"
     ],
     "calculation": {
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciation and amortization of property, equipment, software and intangible asset, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r406",
      "r407"
     ],
     "calculation": {
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accrual expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "negatedPeriodEndLabel": "Balance as of December\u00a031",
        "negatedPeriodStartLabel": "Balance as of January\u00a01"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail",
      "http://IMab.com/role/IncomeTaxesSummaryOfMovementOfTheValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r406",
      "r407"
     ],
     "calculation": {
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "terseLabel": "Acquired intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesComponentsOfTheDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Employee benefit expenses"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/EmployeeBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r113",
      "r267"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation of property, equipment and software"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r113",
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PropertyEquipmentAndSoftwareAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r445",
      "r446",
      "r448",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block [Abstract]",
        "terseLabel": "Disclosure Text Block [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueFromAffiliateCurrent": {
     "auth_ref": [
      "r64",
      "r131",
      "r501",
      "r503",
      "r507"
     ],
     "calculation": {
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).",
        "label": "Due from Affiliate, Current",
        "terseLabel": "Collection of loan to an affiliate",
        "verboseLabel": "Receivables due from an affiliate (Note 23)"
       }
      }
     },
     "localname": "DueFromAffiliateCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromEmployeesCurrent": {
     "auth_ref": [
      "r64",
      "r131",
      "r501",
      "r503"
     ],
     "calculation": {
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from an Entity employee, not to include stockholders or officers, which are usually due within 1 year (or 1 business cycle).",
        "label": "Due from Employees, Current",
        "terseLabel": "Receivables due from employees"
       }
      }
     },
     "localname": "DueFromEmployeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r131",
      "r501",
      "r570",
      "r593"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Accruals and other payables"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income (loss) per share attributable to ordinary shareholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r87",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r147",
      "r150",
      "r160",
      "r161",
      "r162",
      "r166",
      "r167",
      "r576",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "\u2014Basic",
        "verboseLabel": "Net income (loss) per share - basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r87",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r150",
      "r160",
      "r161",
      "r162",
      "r166",
      "r167",
      "r576",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "\u2014Diluted",
        "verboseLabel": "Net income (loss) per share - diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r163",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Income (loss) per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net Income (Loss) per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/NetIncomeLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r470"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r395",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Applicable tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r395",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "Applicable state tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee Benefits and Share-based Compensation",
        "terseLabel": "Employee benefit and share based compensation recognized in comprehensive income of entity"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Staff salaries and welfare payables"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/AccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options [Member]",
        "verboseLabel": "Employee Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail",
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of employee stock ownership plan.",
        "label": "Employee Stock Ownership Plan (ESOP) Name [Axis]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entities identify multiple employee stock ownership plans by unique name.",
        "label": "Employee Stock Ownership Plan (ESOP), Plan [Domain]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r137",
      "r143",
      "r145",
      "r169",
      "r230",
      "r293",
      "r299",
      "r378",
      "r379",
      "r380",
      "r409",
      "r410",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r607",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail",
      "http://IMab.com/role/CoverPage",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.",
        "label": "Equity, Fair Value Adjustment",
        "terseLabel": "Increase in the fair value of ordinary shares"
       }
      }
     },
     "localname": "EquityFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination.",
        "label": "Equity Interest Type [Axis]",
        "terseLabel": "Equity Interest Type [Axis]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.",
        "label": "Equity Interest Issued or Issuable, Type [Domain]",
        "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the principal activities of an investee accounted for under the equity method.",
        "label": "Equity Method Investment, Description of Principal Activities",
        "terseLabel": "Principal activities"
       }
      }
     },
     "localname": "EquityMethodInvestmentDescriptionOfPrincipalActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Percentage of direct or indirect ownership by the company",
        "verboseLabel": "Equity method investment, Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "auth_ref": [
      "r89",
      "r90",
      "r113"
     ],
     "calculation": {
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail": {
       "order": 11.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.",
        "label": "Equity Method Investment, Realized Gain (Loss) on Disposal",
        "terseLabel": "Disposal of an equity method investment",
        "verboseLabel": "Gains on deconsolidation of a subsidiary"
       }
      }
     },
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail",
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSoldCarryingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the entity's equity method investment which has been sold.",
        "label": "Equity Method Investment, Amount Sold",
        "terseLabel": "Equity method investment, Amount sold"
       }
      }
     },
     "localname": "EquityMethodInvestmentSoldCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Summarized Financial Information [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r45",
      "r189",
      "r225"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 24.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment accounted for using the equity method",
        "verboseLabel": "Investments in subsidiaries"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments accounted under the equity method.",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "terseLabel": "Equity method investment fair value"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Summary of Group Long term Investment Measured Under Equity method"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ExciseAndSalesTaxes": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of excise and sales taxes included in sales and revenues, which are then deducted as a cost of sales. Includes excise taxes, which are applied to specific types of transactions or items (such as gasoline or alcohol); and sales, use and value added taxes, which are applied to a broad class of revenue-producing transactions involving a wide range of goods and services.",
        "label": "Excise and Sales Taxes",
        "terseLabel": "Excise and Sales Taxes"
       }
      }
     },
     "localname": "ExciseAndSalesTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r113",
      "r290"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Fair value change of warrants",
        "terseLabel": "Fair value change of warrants",
        "verboseLabel": "Fair value gain of warrants for the year"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r451",
      "r452",
      "r453",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r451",
      "r452",
      "r453",
      "r461",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": {
     "auth_ref": [
      "r459"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.",
        "label": "Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)",
        "terseLabel": "Fair value change"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r457",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r457",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of fair value of warrant liabilities"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r452",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r451",
      "r452",
      "r455",
      "r456",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r452",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements": {
     "auth_ref": [
      "r458"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)",
        "terseLabel": "Purchase of short-term investments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales": {
     "auth_ref": [
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales",
        "negatedLabel": "Disposal of other financial assets due to Termination Agreement"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r460",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r457",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "auth_ref": [
      "r457",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Roll Forward of Major Level 3 Financial Assets and Financial Liability"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues": {
     "auth_ref": [
      "r458",
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues",
        "terseLabel": "Grant of put right liabilities"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": {
     "auth_ref": [
      "r451",
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs",
        "periodEndLabel": "Fair value of Level 3 financial asset and liability",
        "periodStartLabel": "Fair value of Level 3 financial asset and liability"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r221",
      "r222",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Estimated amortization expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r253",
      "r254",
      "r258",
      "r261",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://IMab.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsTables",
      "http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r258",
      "r545"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Gross carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r253",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://IMab.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsTables",
      "http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r258",
      "r544"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Net carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "auth_ref": [
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.",
        "label": "Foreign Currency Exchange Rate, Translation",
        "terseLabel": "Translation exchange rates"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r466",
      "r467",
      "r468",
      "r469"
     ],
     "calculation": {
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Net foreign exchange gains (losses)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnContractTermination": {
     "auth_ref": [
      "r114",
      "r274"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail": {
       "order": 10.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.",
        "label": "Gain (Loss) on Contract Termination",
        "negatedLabel": "Loss on termination agreement with Everest",
        "terseLabel": "Loss on termination agreement with Everest"
       }
      }
     },
     "localname": "GainLossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r113",
      "r439"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "negatedLabel": "Gains on deconsolidation of a subsidiary"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of property, equipment and software"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r113",
      "r286",
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Loss on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnRestructuringOfDebt": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.",
        "label": "Gains (Losses) on Restructuring of Debt",
        "terseLabel": "Loss from conversion of 2017 Notes"
       }
      }
     },
     "localname": "GainsLossesOnRestructuringOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "negatedLabel": "Administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r245",
      "r246",
      "r560"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r122",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r122",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillDisclosureTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill.",
        "label": "Goodwill Disclosure [Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/Goodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Goodwill, accumulated impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Deferred subsidy income"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r113",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r265",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r91",
      "r114",
      "r138",
      "r139",
      "r140",
      "r141",
      "r158",
      "r162",
      "r434"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r83",
      "r188",
      "r197",
      "r200",
      "r203",
      "r205",
      "r558",
      "r573",
      "r578",
      "r598"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income tax",
        "totalLabel": "Income (loss) before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r84",
      "r113",
      "r186",
      "r225",
      "r572",
      "r594"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in loss of an affiliate",
        "presentationGuidance": "Equity in loss of affiliate",
        "verboseLabel": "Equity in loss of an affiliate"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r396",
      "r398",
      "r404",
      "r411",
      "r414",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r144",
      "r145",
      "r187",
      "r394",
      "r412",
      "r415",
      "r599"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 12.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "totalLabel": "Income Tax Expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions.",
        "label": "Income Tax Holiday, Income Tax Benefits Per Share",
        "terseLabel": "Effect of tax holidays entitled by the PRC subsidiaries on basic income (loss) per share"
       }
      }
     },
     "localname": "IncomeTaxHolidayIncomeTaxBenefitsPerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r80",
      "r122",
      "r392",
      "r393",
      "r398",
      "r399",
      "r403",
      "r408",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Changes in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax computed at respective applicable tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Non-deductible expenses"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accruals and other payables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedLabel": "Contract assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredLiabilities": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.",
        "label": "Increase (Decrease) in Deferred Liabilities",
        "terseLabel": "Deferred subsidy income"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Research and development funding received"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepayments and other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r155",
      "r156",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Dilutive effect of convertible promissory notes"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": {
     "auth_ref": [
      "r155",
      "r156",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock",
        "terseLabel": "Dilutive effect of convertible preferred shares"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements": {
     "auth_ref": [
      "r151",
      "r152",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity unit purchase agreements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements",
        "terseLabel": "Dilutive effect of ordinary shares to be issued to Everest"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Dilutive effect of stock options"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IntangibleAssests"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r251",
      "r256"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r81",
      "r184",
      "r480",
      "r483",
      "r577"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r94",
      "r285"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expenses of convertible promissory notes and onshore convertible loans"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r107",
      "r110",
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r93",
      "r183"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "verboseLabel": "Leasehold improvement [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail",
      "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases of Lessee Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://IMab.com/role/LeasesOperatingLeaseMaturityDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LeasesOperatingLeaseMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://IMab.com/role/LeasesOperatingLeaseMaturityDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LeasesOperatingLeaseMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://IMab.com/role/LeasesOperatingLeaseMaturityDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LeasesOperatingLeaseMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://IMab.com/role/LeasesOperatingLeaseMaturityDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LeasesOperatingLeaseMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LeasesOperatingLeaseMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r53",
      "r126",
      "r199",
      "r228",
      "r436",
      "r440",
      "r441",
      "r465"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "verboseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail",
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r40",
      "r126",
      "r228",
      "r465",
      "r566",
      "r589"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, mezzanine equity and shareholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, mezzanine equity and shareholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r55",
      "r126",
      "r228",
      "r436",
      "r440",
      "r441",
      "r465"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r26",
      "r27",
      "r126",
      "r228",
      "r436",
      "r440",
      "r441",
      "r465"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "terseLabel": "Non-current\u00a0liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r51",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Long-term Purchase Commitment, Period"
       }
      }
     },
     "localname": "LongtermPurchaseCommitmentPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset.",
        "label": "Measurement Input, Exercise Price [Member]",
        "terseLabel": "Exercise price [Member]"
       }
      }
     },
     "localname": "MeasurementInputExercisePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputMaturityMember": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using due date of last payment of principal and interest for financial instrument. Excludes expected term.",
        "label": "Measurement Input, Maturity [Member]",
        "terseLabel": "Maturity date [Member]"
       }
      }
     },
     "localname": "MeasurementInputMaturityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Estimated volatility rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free rate of return [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 40.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash generated from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 31.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash generated from (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r108",
      "r111",
      "r114"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash generated from (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r75",
      "r77",
      "r85",
      "r114",
      "r126",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141",
      "r144",
      "r145",
      "r158",
      "r188",
      "r197",
      "r200",
      "r203",
      "r205",
      "r228",
      "r465",
      "r574",
      "r595"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 16.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "disclosureGuidance": "Net income (loss) attributable to I-MAB",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to I-Mab",
        "totalLabel": "Net income (loss) attributable to I-MAB",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r141",
      "r147",
      "r148",
      "r159",
      "r162",
      "r188",
      "r197",
      "r200",
      "r203",
      "r205"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net income (loss) attributable to ordinary shareholders",
        "totalLabel": "Net income (loss) attributable to ordinary shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Adopted accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash\u00a0activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesIssued1": {
     "auth_ref": [
      "r118",
      "r119",
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of notes issued in noncash investing and financing activities.",
        "label": "Notes Issued",
        "terseLabel": "Convertible promissory notes\u00a0 issued to Investors"
       }
      }
     },
     "localname": "NotesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OciEquityMethodInvestmentAfterTax": {
     "auth_ref": [
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of other comprehensive income (loss) (OCI) for proportionate share of equity method investee's OCI.",
        "label": "OCI, Equity Method Investment, after Tax",
        "terseLabel": "OCI, equity method Investment, after tax"
       }
      }
     },
     "localname": "OciEquityMethodInvestmentAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office furniture and equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating Expense [Member]"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease, liability",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LeasesOperatingLeaseMaturityDetail",
      "http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r488"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r488"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r489",
      "r492"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for fixed operating lease costs included in the measurement of lease obligations in operating activities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r487"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail",
      "http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r495",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r494",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "totalLabel": "Operating lease rental expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r132",
      "r146",
      "r180",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Principal Activities and Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalActivitiesAndOrganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r21",
      "r561",
      "r584"
     ],
     "calculation": {
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 15.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments, net of nil tax",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r600"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/AccrualsAndOtherPayablesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r323",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other Income (Expenses), Net"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OtherIncomeExpensesNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other\u00a0non-current\u00a0liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expenses), net",
        "totalLabel": "Other Income (Expenses), Net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r7",
      "r243"
     ],
     "calculation": {
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "-Prepayments for other services"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivables": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Other receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other.",
        "label": "Other Receivables"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfEquity": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 50.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common and preferred stock.",
        "label": "Payments for Repurchase of Equity",
        "negatedLabel": "Prepayment for stock repurchase program"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 47.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payment of issuance cost for initial public offering and over-allotment",
        "terseLabel": "Stock Issuance Costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 39.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "negatedLabel": "Cash disposed of resulting from deconsolidation of a subsidiary"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 35.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedLabel": "Cash paid for investments in other financial assets"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 32.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property, equipment and software"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 34.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchase of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of interest-bearing domestic time deposit liabilities to total deposit liabilities.",
        "label": "Percentage of Interest-bearing Domestic Deposits to Deposits, Time Deposits",
        "terseLabel": "Percentage of interest bearing on deposit"
       }
      }
     },
     "localname": "PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r348",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail",
      "http://IMab.com/role/ShareBasedCompensationTables",
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail",
      "http://IMab.com/role/ShareBasedCompensationTables",
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Postemployment Benefits [Abstract]"
       }
      }
     },
     "localname": "PostemploymentBenefitsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred Stock Price"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockShareSubscriptions": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of nonredeemable preferred stock (shares) (or preferred stock redeemable solely at the option of the issuer) allocated to investors to buy shares of a new issue of preferred stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Preferred Stock, Shares Subscribed but Unissued",
        "terseLabel": "Subscription of Preferred shares"
       }
      }
     },
     "localname": "PreferredStockShareSubscriptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Issuance of Preference Shares"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Closing Balance, Shares",
        "periodStartLabel": "Opening Balance, Shares",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesSubscribedButUnissuedValue": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of subscription received from investors who have been allocated nonredeemable preferred stock or preferred stock redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Value, Subscriptions",
        "terseLabel": "Aggregate Purchase Price"
       }
      }
     },
     "localname": "PreferredStockSharesSubscribedButUnissuedValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "periodEndLabel": "Closing Balance",
        "periodStartLabel": "Opening Balance"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r42",
      "r43"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 29.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepayments and other receivables",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromBankDebt": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 44.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from bank borrowing during the year.",
        "label": "Proceeds from Bank Debt",
        "terseLabel": "Proceeds from bank borrowings"
       }
      }
     },
     "localname": "ProceedsFromBankDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties": {
     "auth_ref": [
      "r96",
      "r500"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 38.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with collection, whether partial or full, of long-term loans to a related party. Alternate caption: Proceeds from Advances to Affiliates.",
        "label": "Proceeds from Collection of Long-term Loans to Related Parties",
        "terseLabel": "Cash received from repayment of loans due from an affiliate"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfLongtermLoansToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromContributionsFromAffiliates": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.",
        "label": "Proceeds from Contributions from Affiliates",
        "terseLabel": "Proceeds from contributions from affiliates"
       }
      }
     },
     "localname": "ProceedsFromContributionsFromAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 42.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible promissory notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 46.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering",
        "verboseLabel": "Proceeds from initial public offering and over-allotment, net of underwriting discounts and commissions"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 51.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common limited partners units during the period.",
        "label": "Proceeds from Issuance of Common Limited Partners Units",
        "terseLabel": "Proceeds from issuance of ordinary shares for restricted share units"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonLimitedPartnersUnits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 41.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of convertible preferred shares, net of issuance cost",
        "verboseLabel": "Consideration in issuance Preference Shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Consideration in issuance Preference Shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 48.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from Issuance of Private Placement",
        "verboseLabel": "Proceeds from private placement, net of payment of issuance cost"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from issuance of warrants",
        "verboseLabel": "Proceeds from Issuance of Warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from initial public offering, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds from License Fees Received",
        "terseLabel": "Proceeds from milestone achievement"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 36.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "verboseLabel": "Cash received from disposal of other financial assets"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 33.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "verboseLabel": "Proceeds from disposal of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r101",
      "r377"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 49.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 43.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants",
        "verboseLabel": "Value of outstanding securities"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r48",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail",
      "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r273",
      "r635",
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property, Equipment and Software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PropertyEquipmentAndSoftware"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r122",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r47",
      "r268"
     ],
     "calculation": {
      "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property, equipment and software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail",
      "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r270",
      "r590"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total net book value of property, equipment and software",
        "verboseLabel": "Property, equipment and software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net, by Type [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetByTypeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r46",
      "r122",
      "r270",
      "r635",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, equipment and software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property, equipment and software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PropertyEquipmentAndSoftwareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail",
      "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, Plant and Equipment, Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r334",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsTables",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r334",
      "r500",
      "r501",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Research and development expenses recognized"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.",
        "label": "Related Party Transaction, Other Revenues from Transactions with Related Party",
        "terseLabel": "Receipt of research and development funding"
       }
      }
     },
     "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r334",
      "r500",
      "r504",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsTables",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r498",
      "r499",
      "r501",
      "r505",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Balances and Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/RelatedPartyBalancesAndTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfBankDebt": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 45.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to settle a bank borrowing during the year.",
        "label": "Repayments of Bank Debt",
        "negatedLabel": "Repayment of bank borrowings"
       }
      }
     },
     "localname": "RepaymentsOfBankDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r391",
      "r648"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development expenses",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]",
        "verboseLabel": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r122",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction.",
        "label": "Restricted Assets Disclosure [Text Block]",
        "terseLabel": "Restricted Net Assets"
       }
      }
     },
     "localname": "RestrictedAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/RestrictedNetAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r2",
      "r13",
      "r121"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 27.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfCashCashEquivalentsAndRestrictedCashAsReportedInTheConsolidatedStatementOfCashFlowsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfCashCashEquivalentsAndRestrictedCashAsReportedInTheConsolidatedStatementOfCashFlowsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Shares [Member]",
        "verboseLabel": "Restricted Shares [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail",
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r36",
      "r299",
      "r381",
      "r588",
      "r610",
      "r612"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r137",
      "r143",
      "r145",
      "r230",
      "r378",
      "r379",
      "r380",
      "r409",
      "r410",
      "r607",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [
      "r426",
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "terseLabel": "Revenue from collaborative arrangement, excluding assessed tax"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r181",
      "r182",
      "r196",
      "r201",
      "r202",
      "r206",
      "r207",
      "r209",
      "r316",
      "r317",
      "r543"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Milestone revenue recognized",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Licensing and collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r123",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.",
        "label": "Revenue, Performance Obligation, Description of Payment Terms",
        "terseLabel": "Description of Payment Terms"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "terseLabel": "Sharing the profit and loss"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r82",
      "r126",
      "r181",
      "r182",
      "r196",
      "r201",
      "r202",
      "r206",
      "r207",
      "r209",
      "r228",
      "r465",
      "r578"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r493",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail",
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of accruals and other payables"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/AccrualsAndOtherPayablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/NetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "summary of Cash, cash equivalents and restricted cash as reported in the consolidated statement of cash flows"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Milestone payments due"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsTables",
      "http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Licensing And Collaboration Arrangements Summarized Financial Information Disclosure"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of the Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/NetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliations of the Differences Between the PRC Statutory Income Tax Rate and the Group's Effective Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r347",
      "r373",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r347",
      "r373",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Share-Based Compensation Expenses Related to Restricted Shares"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r0",
      "r126",
      "r227",
      "r228",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r253",
      "r257",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r253",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of Intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r260",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "verboseLabel": "Schedule of Nonvested Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "verboseLabel": "Schedule of Non vested Share Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Summary of Other Income (Expenses), Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OtherIncomeExpensesNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r48",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfEstimatedUsefulLivesDetail",
      "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r128",
      "r502",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyTransactionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Summary of Related Party Transactions"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r348",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail",
      "http://IMab.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Valuation Assumptions Used",
        "verboseLabel": "Summary of Estimate the Fair Value of the Put Right Using the Following Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesTables",
      "http://IMab.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "terseLabel": "Summary of Stock Options Activities"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r301",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.",
        "label": "Schedule of Subsidiary or Equity Method Investee [Table]"
       }
      }
     },
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/RestrictedNetAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Rental deposits"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense, Total",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Share based payment award, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of shares granted",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Numbers of shares, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average grant date fair value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted average remaining contractual term, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "verboseLabel": "Share based comensation equity instruments other than options aggregate fair value vested in period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "verboseLabel": "Estimated volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (per annum)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail",
      "http://IMab.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "negatedLabel": "Forfeited",
        "terseLabel": "Number of shares cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Numbers of shares, Outstanding",
        "terseLabel": "Number of shares outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Share based payment award, maximum shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable as of December\u00a031, 2020",
        "verboseLabel": "Stock options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable as of December\u00a031, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Share based payment award, stock options surrendered"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted",
        "verboseLabel": "Share based payment award, stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Numbers of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding",
        "periodStartLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Share Options, Vested And Exercisable Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r346",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpensesRelatedToRestrictedSharesDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Share based payment award, stock options surrendered, exercise price",
        "verboseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Share based payment award, stock options granted exercise price",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Tranche Three [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock": {
     "auth_ref": [
      "r343",
      "r345",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.",
        "label": "Share-based Payment Arrangement, Forfeiture [Policy Text Block]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationForfeituresPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Estimated fair value of Company's ordinary shares",
        "verboseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Share based payment award, vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate intrinsic value, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfShareBasedPaymentArrangementRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r368",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Contractual term (in years)",
        "verboseLabel": "Expected terms (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfValuationAssumptionsUsedDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Number of shares Outstanding",
        "periodStartLabel": "Number of shares Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Numbers of shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedLabel": "Forfeited",
        "terseLabel": "Number of shares unvested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average grant date fair value Outstanding",
        "periodStartLabel": "Weighted average grant date fair value Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average Grant date fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Vested",
        "terseLabel": "Share based compensation arrangement, shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationSummaryOfNonVestedStockOptionActivitiesDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of allocated shares held by the Employee Stock Option Plan at balance sheet date. Allocated shares are shares that have been assigned to individual participant accounts based on a known formula.",
        "label": "Shares Held in Employee Stock Option Plan, Allocated",
        "verboseLabel": "Shares Held in Employee Stock Option Plan"
       }
      }
     },
     "localname": "SharesHeldInEmployeeStockOptionPlanAllocated",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares, Issued",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Number of share issued, price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r22",
      "r563",
      "r586"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt",
        "terseLabel": "Short-term borrowings",
        "verboseLabel": "Loan Borrowed"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtLender": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender or type of lender, such as bank, insurance entity, pension fund.",
        "label": "Short-term Debt, Lender",
        "terseLabel": "Lender name"
       }
      }
     },
     "localname": "ShortTermDebtLender",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for short-term debt.",
        "label": "Short-term Debt [Text Block]",
        "terseLabel": "Short-Term Borrowings"
       }
      }
     },
     "localname": "ShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShortTermBorrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r24",
      "r567",
      "r568",
      "r583"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 28.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r628",
      "r629",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r491",
      "r497"
     ],
     "calculation": {
      "http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesRentExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Expense for short-term leases within 12 months"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LeasesComponentsOfOperatingLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Principal Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PropertyEquipmentAndSoftwareScheduleOfPropertyEquipmentAndSoftwareNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r124",
      "r126",
      "r150",
      "r154",
      "r157",
      "r160",
      "r162",
      "r170",
      "r171",
      "r172",
      "r228",
      "r293",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail",
      "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail",
      "http://IMab.com/role/ConvertiblePromissoryNotesAndOnshoreConvertibleLoansAdditionalInformationDetail",
      "http://IMab.com/role/CoverPage",
      "http://IMab.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail",
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r63",
      "r133",
      "r134",
      "r135",
      "r137",
      "r143",
      "r145",
      "r169",
      "r230",
      "r293",
      "r299",
      "r378",
      "r379",
      "r380",
      "r409",
      "r410",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r607",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail",
      "http://IMab.com/role/CoverPage",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail",
      "http://IMab.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetParentheticalDetail",
      "http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesParentheticalDetail",
      "http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail",
      "http://IMab.com/role/WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r169",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://IMab.com/role/IncomeTaxesReconciliationsOfTheDifferencesBetweenThePrcStatutoryIncomeTaxRateAndTheGroupSEffectiveIncomeTaxRateDetail",
      "http://IMab.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/OtherIncomeExpensesNetSummaryOfOtherIncomeExpensesNetParentheticalDetail",
      "http://IMab.com/role/PrincipalAccountingPoliciesAdditionalInformationDetail",
      "http://IMab.com/role/RelatedPartyBalancesAndTransactionsSummaryOfRelatedPartyBalancesParentheticalDetail",
      "http://IMab.com/role/ShortTermBorrowingsAdditionalInformationDetail",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r118",
      "r119",
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Ordinary shares issued to Everest"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r62",
      "r293",
      "r294",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred shares to ordinary shares upon the completion of initial public offering (\"IPO\"), shares",
        "verboseLabel": "Conversion to ordinary shares upon IPO, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Ordinary shares issued",
        "verboseLabel": "Issuance of ordinary shares upon private placement, net of issuance cost, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r32",
      "r33",
      "r293",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "presentationGuidance": "Number of share issued, ADS",
        "verboseLabel": "Issuance of ordinary shares upon IPO and over-allotment, net of issuance cost, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Issuance of ordinary shares to Everest, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r293",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "verboseLabel": "Share based compensation by share based payment arrangement restricted stock units granted"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r32",
      "r33",
      "r293",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of ordinary shares for restricted share units, Shares (Note 17 (f))",
        "verboseLabel": "Issuance of ordinary shares for restricted share units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r32",
      "r33",
      "r293",
      "r299",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "terseLabel": "Exercise of stock options, share",
        "verboseLabel": "Exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://IMab.com/role/ShareBasedCompensationScheduleOfStockOptionActivitiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r63",
      "r293",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred shares to ordinary shares upon the completion of initial public offering (\"IPO\")",
        "verboseLabel": "Conversion to ordinary shares upon IPO, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "verboseLabel": "Issuance of ordinary shares upon private placement, net of issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r32",
      "r33",
      "r293",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of ordinary shares upon IPO and over-allotment, net of issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Issuance of ordinary shares to Everest"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r293",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of ordinary shares for restricted share units (Note 17 (f))"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r63",
      "r293",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.",
        "label": "Stock Option, Exercise Price, Increase"
       }
      }
     },
     "localname": "StockOptionExercisePriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Amount of stock repurchase"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r33",
      "r38",
      "r39",
      "r126",
      "r219",
      "r228",
      "r465"
     ],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r126",
      "r133",
      "r134",
      "r135",
      "r137",
      "r143",
      "r228",
      "r230",
      "r299",
      "r378",
      "r379",
      "r380",
      "r409",
      "r410",
      "r432",
      "r433",
      "r442",
      "r465",
      "r471",
      "r472",
      "r476",
      "r608",
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling\u00a0interests"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesSummaryOfGroupLongTermInvestmentMeasuredUnderEquityMethodDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r125",
      "r299",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinaryShares"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r477",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r477",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r477",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r477",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r508",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/PrincipalActivitiesAndOrganizationAdditionalInformationDetail",
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Summary of Movement of the Valuation Allowance"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Additional ASC 842 supplemental disclosures"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Supplies": {
     "auth_ref": [
      "r5",
      "r7",
      "r242",
      "r243"
     ],
     "calculation": {
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Supplies",
        "terseLabel": "-Prepayments to CRO vendors"
       }
      }
     },
     "localname": "Supplies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Abstract]",
        "terseLabel": "Mezzanine equity"
       }
      }
     },
     "localname": "TemporaryEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r9",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail",
      "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [],
     "calculation": {
      "http://IMab.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "terseLabel": "Issuance of Series C-1 Preferred Shares, net of issuance costs, Value",
        "verboseLabel": "Total mezzanine equity"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheets",
      "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesAdditionalInformationDetail",
      "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r9",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Temporary Stock Par Value",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "verboseLabel": "Temporary Shares Authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "verboseLabel": "Temporary Shares Issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Issuance of Series C-1 Preferred Shares, net of issuance costs, Shares",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "verboseLabel": "Temporary Shares Outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r9",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Schedule of Convertible Preferred Shares Activities"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r221",
      "r222",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConvertiblePreferredSharesScheduleOfConvertiblePreferredSharesActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r61",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of arrangement [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/LicensingAndCollaborationAgreementsAdditionalInformationDetail",
      "http://IMab.com/role/LicensingAndCollaborationAgreementsTables",
      "http://IMab.com/role/LicensingAndCollaborationArrangementsSummaryOfFinancialInformationDetail",
      "http://IMab.com/role/OrdinarySharesAdditionalInformationDetail",
      "http://IMab.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://IMab.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/PrincipalAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/WarrantsDetailsOfAccountingForWarrantsToPurchaseOrdinarySharesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.",
        "label": "Warrants and Rights Outstanding, Maturity Date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants and Rights Outstanding, Measurement Input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/WarrantsSummaryOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r149",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Weighted-average number of ordinary shares used in calculating net income (loss) per share - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Denominator for diluted income (loss) per share calculation"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r147",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Denominator for basic calculation-weighted average number of common shares outstanding",
        "verboseLabel": "Weighted-average number of ordinary shares used in calculating net income (loss) per share - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://IMab.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://IMab.com/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=77885760&loc=SL35686385-199418"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1930-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2029-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=117311354&loc=d3e32014-111567"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=121548190&loc=d3e32472-111569"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/subtopic&trid=2144439"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 3.C)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177168-122764"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=SL116886442-113899"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4549-113899"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(m)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118644919&loc=SL5834089-161433"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(7)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=120604989&loc=d3e56071-112765"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(1),(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262037&loc=d3e9915-115836"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604008-122996"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874367-224272"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874367-224272"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=68052803&loc=d3e8255-115641"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r649": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r651": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-3"
  },
  "r652": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r653": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r654": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r655": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r656": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r657": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r658": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r659": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>178
<FILENAME>0001193125-21-135440-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-135440-xbrl.zip
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M)4%.$RUB1\530@0=8;T*ZV_OM#Z/_3T:NF++5L\8$.,5J)T'X"=D;CFO_+&
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M(LYAM($-1P56L1XKL&I/Y2(#5O-08"T='I0I8,5Q\D["@=6\+-8NR\7XYDU
M5=,!U@TUB&SIQGSN'%*+)2IW-86^4L66U,3"@TTFZWK+K@6'=E3VB,7+4C,6
M]@!K8!Z!1FO@D\P_>^5_Q):FM$HY+=RP8?3'=%C$&F.OV(CBL"S?>[C#LH#
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MD98Y@$0RY'$+8 F$5?4I3_=Y9[-?P##H:K(^(?.$H#M==B;'I *).6MA(_;
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M/LFD?7(:\*S?-!.R5SX\N]>],>"C[Q0B2R[8]MQO%/=F^+VWXY]DG?=8T!S
MH\1LM74-!F.Q_?^/AGL*%1?$2$HOT?#:U&LGY3H2"=+)WK6#<@9]G0/V1B-!
M-MG;T\B/J:XYMYG+_FL^^;V&)MD$0 D9[M$@G0QVQM#.TZ0\OV?]T%/-2U!
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ML?#<Q/-3=@&"Y[P8Y)D8)F,^@Y(]96<C>XN)[A+[HDI>:]'.P .4<*W#']8
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M!?_N-LR_NUT8Z89"#/X"0;8-H+7%=3T85/[)X !$.V^XA%95:6K"S]ZG^:7
M>"^6G,;(7J#;W^H_-_E^[DUE&%*82^8W9+GZ8DTU2J7:AK;$-6WMX(&N>?5:
M3>QHUF,[@]M=OQ/J.<Z&XI?63=_D'\4OCFZ 9[@2:4V( 235! 7T@DG!;IC!
M#3*A4\N$&R1+(*\ 'M D@FX;0NMF8'X10IR[TYGXJ#-09Z#..(G.&*SJ#*X$
M0G2&.9:XX4$D>0S6K"9\$(L?W1IDT XS.^ Z(%ZPWN#?V:4%/@81/I3*[ET
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M9<048BJFGC?KQ4*-[1O*%*)P;2+1SG9.AHE1)D0$(@(1@8A 1" B$!%)7YO
M58<SK3JH5!I1E5J4X-)#<EWE<K%9$*MBQEQE#+Z<#U$5L5JH-2J(*$147"'B
M6J-09!M5$%&(J/^?O3=MCMO(TH7_"L(S?4.*@-A<1(D:W;D1LF2[-;=E*23Y
M==R/*""K"A8**",!4N5?_YXM-P!%4B;%I9@1,VZ*K )R.?GD69]S+2-_OO\L
M??8TAD:C1%U;:'3_A,F[=DJB8L[80[7>5NJOO[(:?B.E]-&$N[O0D^Z#ROWB
MY,6.@4^\SFXS>^P%R-31\:Y=:%&F;M'5E![ Y7[P?-?R,FZT1/Q^3/?2A>DW
M.9V)$O@HA[L]W2B'NV4T1G/PQLW!3\NL54L8D6HUR>[SETFAYF5>=K=B$WZ?
MY,7[]-2_@>'W:'9QS>[*4^.:Q36[ZE.C WD7"%??MT599^TFT:@,Z.31;Y_^
M<W]O?W__ +:G34ZSJE=I<KR_G^[S_YL/9GVW;%IX<Y%D.FGFR1N5J]5,M7Q*
MC@Y@E_8/7E!KPI._^?7#_32!#Z]5WI6GJMJ\3$[2HV='Z7-XKCRGU+K'9\!;
MFK[3'?R 1+$7#ND &2%/3M+C*SQJ.+S'-^Y#OPZ>K8?3=3'.=/=F>G#P<%C3
M#ZZW758TYN_VU?P9%E;W>#5W3?[E7MXMCZY.SOGXOIS.^S'72$\;5RFN4FPA
M<@/7YJNB*+NRJ;/J^LG0UUE9P+3E.LRS==EEU3V['(\/P9B]#UW1=^V<WV4M
MXNCD17KT_#Y(Q?7,]WGZ?/\@/;CF9E!W><8PVY/]]/!I;+?XD(RY5WG>K_HJ
MPWY6#34(R9O5NE5+!6M]JI*RAG^KY%'5:'T__8C'Z;,7#Z<7PS' ],G#:<;P
M?#\].'PXW=H?'>\S;]G=-^BO:<)P#Y]<W9/Z^(:NI(=H3MV!BVLB.>C>7$^/
MCHZ?IR?/K@[9]^=,8_7(T_3IR=4US?LSY\/TZ8NGZ>'^U>^J^S3G_<.C]/#%
MU?L;WI\Y'QWLI_LGUWQ#;[NQ(@WCG> 5>B#3C(1:42*B1$2)B!(1)2)*1)2(
M2,,8*[<FB3ST1/T64WK\\Y&X:H)00B3WN(1E>7,C?W3XXD7Z_,5][0SU^"HK
M'XD8OI-,O3@^1BZ&*%-1IJX/I]+]HZ?ILXA44:JN;^3'Z;/#Y^E!;(P89>K:
M1G[R[# ]>K%K9&DQ*G&GS>P',LWH7XH2$24B2D24B"@142*B1-SUJ,3.IHCN
M1NS":R&5CAC)B8,E1C?NM2U^D.X?'J='T;\39>H:J<N/GA^G+XXB=7F4J>O#
MJ>='S]/CYX=1IJ),75=7L_3HZ(@+R*),19FZEI&_>+Z?/GNQ:PT68FQCTE@_
M F.]:/I9I7;;*7%GYGD/_%1W9JT>RCRC3$29B#(192+*1)2):XARP'\S&%@X
MP[Q264O37^+LOMHQTNM=" ,'S6JWO&JH?;/"?'+9D,*$_NX]X3K68A@QD8W.
M50V/'JCK%X=Y_N:<;B:B<9P,Q."<_]DBW134&<X)?^?%MV9JWK08WZK.LHWV
M9&%I;:>SLNB6.(W]?[Q,C"@=X?"]$-C!\5&:F/\\?OG#/[>*T\'1WN$)?CL8
MZMZSYQ.CE5^[WU=-_N6)[K*V&W^'_J90K,W7?!,R(1L2YI<ERU;-__N'_^B:
M_(?_\QF/#W+QOX;/@ACI__W/[(+S<+<FL&6\$\=C@(.RK2=[QR4<#O_S&!*T
MHVKYY5G?-8.8(?UJ*HYY2Z\UX=.G_]@M)/B\5/"0JFK.L',$X7VR;I5&:4V:
M'LZIJE2.5#IY4U,TGGAU0,@ZM>(/S9,\T\MD#L](X*\9/*]-.GCN!FX*G8#,
MP1<F&UL\I_^>>$TNL$7%?R5;<=F?[N&5;PY^Q#5<'7B!TLKEJJK668%=./[[
MA_T?Z-_R8/IW@*/T A%"5@GX-WG?MK"RA'\ODP @KR 8HG3 4ZMLK>'7YB?[
MIV %?MCNX_+^7 P.WO')/Z:]5686,(?M/E5/&;G$S_'1-_+HJR2\G%RI"M?X
M2>5 N6MOW?T-@^3<QXP?!J<#SD/]WS\<G/QPT9/E_/ __=0=I\V''S$[Y)U+
M^0N]Z;\X[2EPW]O[[N8\X#\W@M: Y?S#_P- YY]^0E#G'T?(_C<=_A=O\T,7
MQ<.'*HFH*GPWJ;K6Q\2]0H4N[M6]V:N_6WIV6WOU[.'NU>%^O%EO[6:]87F/
M$'=-Q^;CNQ_O&<+%K8I;%;<J;M4U;=5OG_YS=]6&OT_F?"6/SRUOZ:.R-HZ9
MIM=97>C'?V^+;ZPA3RQMNZ.E;9\DNL-R\-H+\?!O/MDX#_^[F<LG,[WDGWZN
MFC-Q!&9=]E^W4M_V?5)I[]-3_\85>H]F%]?LKCPUKEE<LZL^]3OJ&3NN0=R,
M3O"KZCBCXU&O59&4]>-DH6K54N+'O&U62;/&?V'"2)9WY2G5Q-]X2?NW?F.Z
M$<WQ87IP_*!:[YSLI\_WCQ_0C$^>/4]?G#R@5D-/CX[2X^.3*T_XOLSWV;/T
MZ=/K;<<;;>&'<9.5]:G2.W&3P2V6/GOV@'#]17J\_W#:V1X>'*9/GUW]$KLO
M\P4\/$A?[%^]/?.]D>='1_OIBZ<WU!\PVEIW[(8:W$OSLL[J? ?NI>?')^GQ
MR=6OI?MRB@_2I\]?P$5\]0ZV]V;&8$(_WW\X\ST"8V,_?7IR]:OIOLSX^/!Y
M>OC\ZDZ2:&#MVO7UTWRN\@Y+P-37?)G5"Y7@)9;PSSII:K[=L+2+?D ZS-.L
MHL(Q_&4+UE=;<GT9_/U>7G&/#HX>D'/I^$7Z_/CI@\&^@^/TX-G5E?+[,MU'
M!_O/TF?7;87<[1D_2X^>7EV@8UOV^\/H_4"F>0]H7N[*4CV0:4:)B!(1)2)*
M1)2(*!%WKP%*=,E<4T2AK'-87JV21X7BGQ[#[\C#DNZN'^;HZ4GZ[.CAN&4/
MTL-G)^GAP<-)]'GT].1Y^NSIU2=\;[P31^GQL^/TZ8N'$T [?OHL?7H4L[GB
MS3:\V5Y?^OI*DYF"F=08/V_FEHON7MYJSYZF^]>0O'I?CO_3@\/T^<'#<;@?
MI,].]M,7#TIM.7AQE!Z>/* ]/CE,3YY?;X9$C##<:9/Y@4PS^HJB1$2)B!(1
M)2)*1)2(*!$QPA#],($?1L$O[[L')KHD=G_&#\TE\33%PISGSQ].[.CYX8OT
MZ.!ZXRC1"7.W>YH]E'G> X7ZSJS50YEGE(DH$U$FHDQ$F8@R<4]ZP1Y<O1GL
MP75U@\5U^):6?G>^@=^E?6(RWJ<3[>/0/>;;5M14\R:9KW_<^T:BZRTCWMI6
ME-N$?F\'WSTFC'Z=K<L.%NNOK"N;FIQ^;^M"S3I5U$KK)-P?#UB^!XQL;51\
M'<!TG6U?GUT>QVXH2[SIDFR]KN"LP';L7:[C:H3G",_G8M+K",^W#,\?5::;
M6ML6S._G<]422O^FJ1/YA[;)E2IN&*@CK$98C;#Z=V'U3835VX;54G])?L[R
MKFEO#SFO:7^^ 33OZE;HY*.JB"RQ:Y+W?9O\S'2)695\:'1I+9-?%?(IPE7X
M"I ,?PL?$ -F<A?OT6+3S_88??,J;GD>F7;Y^.._JV29G:HD@T.\*G'A70N
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M/%?K3'>T$;!5/I#C+L/6KU D\3J#\S&'UQA!YB^SO-\IS>J60/PM-0(1.&,
M#R%[K-G9>QU080DR!(<2$0C!#8$=#F2)N :K7Q%LP&&N.SQC_1IN\KHS:A@=
M?= <<"OX3/G PB>M6V:PRP,U@_9[#H\G7=&I.HG"(YGE!+#_! #3V5RQUK-
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MZJ#5]-V\:L[D)%F>#J\@R:OS)V8)DBDE-<1,5>.YV23FQWZX>5\7HY)69G5
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MJ?DW]@-* ,2$UXEH6%"G<^1PED_8E"TC$#T1(2NV$B5:MBMF.";7?JFIE1G
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MG4%$9N9$6&A>\CUOVV# T8*SK*J4+Q2#%X[Q"%U."_8Z8%\ %&IJ5N-D<V(
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MAR;G-K)*H;YFJS52*)E1@S@QK1CI8^AKJ!0OEM'-O/8*K#/A10K2JH@QE71
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M*;"^6EYE@.?+L;MTE&[R^V1NEO5;P&TI6BV[OJFME4TEK%5WUK1?I$-8K>8
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M?LM&Y^>E2D:=V#G%>"JN3PY7GO"8:@ 7$GVIG.E-QI)SD9UB.TK,D(?S1W<
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M\!ZR70FV =$WHE?>)_9YA>D,!8'^:]SW5Q0)A_U8*5+IQ+;[%[L$Z2/XM9]
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M>V*+91L/;5[2YR*T1&B)T++CT"(IST]>4WV**I+W?8>]*73RT33C>RO]53E
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M>X<OD^S'9BKB$5*GV#YY;#?I+[P\Y!'PGV6Z+,/]01<JO#"C#?A=F<0O"C:
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MG-5HKNL[Z1O>-$_\I7E=3V=@D:5HKGTDK7&9*,6PGAN3YZ\C;#,'ZMF$%C.
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M?OC7 ,Q51/?BG\T[?N_Y\TB0CS1_9GM.+;#(5IZ4]PZ7>.&L@TMB&WX% HV
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MSE%0P@_[V5=/GT[EJ@_-%=6F>T@3?W1#_=$ON"W;KO>O^PEDGZ-SM3MU($L
M;QC9Z_T3_Y$6+>EO^OT)\M#\,01TL-%#DF^X+OD\#/) 4XJ3=\5]9=?^N(!_
M]I5,F=/$QF7' @#P2UH-;$8"([^DFCDIV&*2/HMO3TGUJ<Q*.7_S5\,Z^$S
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M-X0/7-%+N\)KJOT0WLCI4:H^0?*T!=!U0,,+LL,.G6C84QH!-F8&J(.]43"
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MJL91^=+FY'W8U+2A.GTVBBD["]2>G 9+6=<YZ==_P(?>4DZ;:)H5.X2L&J>
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M(\7C7<2S\J(YRLNWZX==$0B%#^B_@"(][]":%9?MYT.#+!LKJ#2B>N);=#Q
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M).%F<QCC'$H]*0P?9VNH2W!;J848/JB''!3<RGY@9&IT L2GF#KB]DW[E]N
MRV"06;CH_)^P?@Q:7"6:[Q*P.SGM*:J5@RGH\W[H*(5Z1$EJGJ*397R0JB6I
MG;1DW"C+8X8W,OC_CO[XI_49WR6H+Y4&0VL,NQ#75'XD:U<&T]RT.[^.R5I&
MN\TL7#55W""/[TK2];NVN>[W#\IMO#\@9:@PF^FS>XIF2PK/P73C*:E'!!G1
M&BH1>1U(!F+U."N<%A)=E=+KY[ ",&064V*.RRRRW]MM7K8Q$LM^V!_P#6]0
M.C*]G0)/&4L_%*G0<Q' 9NB0<L%[$M3H$TY2N('_R1\6SM@DB,>S\#B V 9(
MME9XN DH@SF5:-_[,+*0>;+T=F)6&$,8UR."KV2LS OZ(FG,TCD4[@[R@$.[
MF0<A6IP;3Q(')[GF;N/W!0?5AX_R[0T7A:$)+:==<H"@Z=3)*.#XZ-,38>[-
MAZ>_6 $VW\^*E<W#A^4E39Y;X:K\Q,^/OE 8JE[?[QJ: [^#VN'8CU8SC.;#
M0/PWG10+I.(>(15_6B 5CQ)2<<?=:_]F+MI;JFWE= B:'E=ID-CE& ]SX#:;
MN^+27$AI>YN\V0R8[R916)3-[5TJ&,KQ;L!0^+AUZ-GQF\!32'0QAE0\*&?O
MG</^!0=)T'RW\VY-#L_.TT2'B3^HJM._9N9?8YB/G@X[MNZ).%\\/UT_%(@G
MCA,Q1@PY>=< #NV2B)!_:X+,>@<G,0HBKSOP&>%-VH>DQ06W"F ;9*LJ..C4
M:AE"B@]EIU5CK<M?K/[&&0B<1W8S]PZ I9N<6B,IV4!XU1TA3W%%>\L!@3JL
M3N^_= 2$QS#8#Y"+.%O(8-KU"Y>'<AM04*!+1+K?>'=^Y]280UWG=*LS8Z([
MF/JF]@+1O41(M(7X?Z"$$]Z,-I*_POL:IZXZ47M1^#%?=UQK\W/7P["X(BT.
MC,96- B_5A"ISE,)4 9.Q+0M5,&N@5+LT-381<69NGPHREY>G)D/++#YRTC!
M$"6\_!N$?))BKGWL!XXZO *_Z[%S"7=%5TK6CM]K-BHQ0'LEH]OMXISIEYT#
MSTR N (JBTR-F"/"Z _>TVOO,^<[WEW<G>"MK28D)])@G>K\GC3/<XM,):.7
M!!1'$)4H9(.+:0&6O6_,:@YKP([@4H+R)RRL&K[BC0!L;PB3!,C-=E'RH?#-
M+H#[Z*LD]<;RZ]IF %^3I<B*13#N8U-!SX^\0X647ZS^T?20=01[5"AEZ-S'
M,VHL*P_9Q[?#_D]/X)^\E #\T#J(].I<VBCT$$AQW'(Z \P%Q('QVP.ULU'Z
MDK-D^+^P<*%A EY,1XDM'R9C1Q3>9NW\K%JD.^YKK/0%T 5L<YIE/Q]JFO$-
M%'[E\9A2X2F-E.C^NO'A9*]X9RMKSP9EXS6MZL-*Z(.$NU>EW?K:"9C!_5HT
M<&%Y^?/6U9N3C*?>5$,APZ.D8.-/ 6]S_(@ M+'+S(*#['T%P2B)V?-+@VU
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MAF)WX/Q$YQ^3RW&(%Y1<A_A"L*E9\)L#AJ;BS"):ETQD9\(C:EB*P W  +N
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MKE"]%!X-F^G8T&!O,ZQ6W H\[3S8F=DW#\^;597+_XT'OG DWRZ >&DI=N%
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M*"X%$E:'LF81AXV_6Q4LG\V3P2(JNP:W7S;U+6PCSK1"3E <9(>A[D82 NS
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M[!ZDPH'\7A6(R8[[4Z=Q1<3W">H:$"!D26=HK;0!O'"$Q27:;)B4#<#SP#0
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M;Y3EY)=WUE>/(=G<(R Z1H [AV0"\#DVU,&&JB0;)W?7K1*&$1$28JN:561
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M(X.:;^/#D;K;5#C=/J11K[,E2A]5M\C-%RZ,#RTAU=K'.]N2:?Z),U6__*"
M,/>HIG3K9:?KXH?OGE_2+S"LJW,",=0AH@..7HKHWIK/"W4B+]\WWSZ'D,VU
M!V3RC-SE+<9QN(K9Z>LH5\)L&S<GN_!R4.@GE]W5-LL9EH$@BVB944( <!!
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MKF\>T&C:!S06'\P_H-$\I)EI#C[8VSVD+?603/)#6C4/:5X>DCL!29+79?>
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M(2V8W")![*F3YOO@WR=_HNYIWGVZ=P=X5H*]-F0Q?*X+/*4GA%/[9D-)U1?
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M5^3BL=XP!:YD#64+6Q"<I0.0^<OYZE5^2?_TZQ_O%(HYKJ>7,E\<<++<7KA
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M#I51?1.^O/6N?I>KW[+/[' 8\BF&([92GL*,^!9/=UU(C8S;4%$+OM0!"Z[
M+Y)F6?DG!]R^8%]#U'_6!;G#V?9OYVS[9YEM?Y>^QYU;U<S$VPT<$)S'B&]X
M T5:6-9TBUG6BT7>=DS(NW:K? V[+!_ ,Y805N@K1!\RSHU?NOJRR7=7K*C
M'L.V)N039S!;J4B5&XFT:/)\&7H-^HC@/4!TK@+9 6!VPW.%4BJ]*O4>=%M>
M))7$X=&<]* X1\CBHN;9C"+??@/F?*C9& N.>V%">-MK5$"-WRKKB<-TX!Z$
M4WB5[W"9E SU=@)#V.6ODT#&@8A>__FF/6_SQZ[R=69W3I:L7Z57T$5F_?>
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M1 _5!'A 6XB(C Y$#K@],$B_^XWHKY7^RJ\Q=%)#I'2&=ROTM+"CK8:UX."
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M0P;RA&=9> )&:DC?MJ4ZDT%*L!MS0&D%]0EN<P!V/MD<;$J0- ZP(RY9/S:
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M.87@-1P%F#L 5LN\:FW1YI3Z.7W)5&UX?RSUS>Z4O?QX3C^C/M=^/@3>\P)
MR/7B$03F117EN:.JN37($!XN?O);J-X[ '_\57WQC&9R\:N?E,47!K% G\5O
M)7_S97;*X[]]@\=_._%X_^OO%D3W!%B;+)BI+W^7?#D$]*A"Z(3O^T^E+U?_
M5!)(5 .#I4XE[8?6HBQU,/)*K]MLP"^'G*!?W#F,,M7,<:- 4,@Q2F^9B>5)
MPY(4K9"_1>^!;P5]PW>V2'*HNV$ALMEX75T2OGUM]4QCU>0$\2'!EO_RZ-&O
M=%WP/?_9+9L^;_8<[[O_+6@T[E_P#&F?$2B]RM?L9*D^AJ06PA!D@5\OBT,T
M&A<^\+><# <,49.\G"IPZXBU4+O#+%TKJKU$6/OR$C@3#N0_S"XN'F3?/7@P
MSKY\EWWW];?9@XO[XS\]O$^'W#"C@+;YL_"!_^O]T0--*7;8+F$=?YO^R LV
M7:C\@5B !BBY>QW2(]I7CDDW=!7>..;866'Z ,O)&(_/$,2UJ&*D3E!#X@5^
M=!1@H*-I*%_82/=5T8EWL7+%]7AL'V07][[)+KZ^.#H4H6NQ,X=>=7O?$#*_
MK6/,ER2[^PFD4+XY7_P85^$+1D@8YA8,A)HJ)4_ZX7SQV&YOW]\?D\W\4RA>
M?";+6KXY97':D/G^V *)OR&.4A;^]L^ >;5KJ <Y9-H*,@0V/L+5'TP.4@]5
M'_*.1!YD*],EX97;&S0.$8-&(REI<G*91^[%X5992ZLI%-86&D0ZT+Q@&X=$
M4@<?3ZH6XH)D(SV;0Z45!P(\$EM[Y\ZR;[KJ@\B2HHN&4&.UJRNW9JCW.W\S
MA?;[G58\TY4B"[8'(*J5R8AC_CG"ETJ&AB5H?<1("1\Y[2;]1N&FPB4&SRK@
MVG/YPNJJKEFZ:UTOVCI<&XV410++9AE[.3</+@G_L>;R6$)NOC^$O$ )H:ZH
M :$5S@L6]+152B&\;X/[IVRK<'Z2=B#^-DBLSM<")M#P1M6H(_E+/,OM*)$1
M[[=5D0K/DB.XKLLR)_8)HQ?!4PAXM"+*4@J#'_+J%>7OHB@EW@E4WT:6!<YP
M(6,.M7+\+N+JZF@PTN R0]2B"J!(0X>YQRL./--6RH>^"@U7D$<V>L?4\(@'
M#15W=&Z-2^89]+D??$U'-ZQ\+6++1/A:KLI7$&JB$T)4\XAWR[&\!SPB="R&
MDW90S2Q8TG&Q=N&G821>!N;0B S.2\9\I,2W(MX'\#H7_'/V)<#N_7^&-8["
M"R*"4+E*_]F]'U 9-%^R@8^T;!:KN+,(B/LS N*S1$!\TC0"!.$R-YU@<(4$
M.)A<<YJ>2C9'Q>X]L6OF314$^F)H1E&CV<BUR0(><HSAU&)LPH^IR).<W ,R
M<BW$>-U9@!OXQ(64WK>Z2QZ OVL @+P&=!C' U(0,9T.;=R0*$_'[/C1?!M3
M32?>@S\S^XI:&V27J$U!&CXZ.;BY5S+\V4#V:VKZ#C5MG. V<#[[022B_$0)
MRQ%=-V5^]>*(0ZUOJD,I8JD:8B9:G<HC9]^G32KYWP[%4Z*;[&^PES8 1L4
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MAKUB/N#F ^Y3/.#2*W>^K/ON\#$7*1_ DE94U!4&'>557N[;CESK5:?0:TI
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MG8/?R@_"M;WO&(<Y/=*4FK4A]^F<):5^&8<.W>=L:H8(8LI.J>C+8FW5Z_U
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M_/\]S<EX?9M%U/\'GA)IS*3[]('NDMZ*_^R638^[ 0_&1[@ T&0T^Y*P$PF
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MXP&(K(0?1$[[VRY\C3EYUR$TG%*.%LSUJ[QUM7XQOZY4#U<.[T;A97Q\D5@
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M%/(8&8PWY0+'-EG9L^@Y(<\-3((:L%X)*,4U]YQ/X/ *@4+'^$\>@HS%ZY%
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M8:GO,+=V@XFI*^BP(Y,(ZK"4(QK'YKV4?Z+]]=AO=]P,>J&9 =5RBX?L<_E
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M&I^K\G+*(HBN]R">F?9!_]H-I 7Z[Z8ONJ B]J?QW.QSO?D[;\'NA\K6Z L
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M#LK+U4J,(]98O!9GO 9[.?QZ"2XNK:NQJ<-+OW%%E;*.J#/N!#19D-O=MP2
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MV0=&)^(B  \QN"WFSL2 :PFY@2SP0'&X_.]0FH9QD4"MR<J=R\-G^VV\4ZD
M3@J&W7"7I!,<T4;G@CB1,58:M$%,]DU.QR0A7\8<"R[*)(FOX(MC3'#VW<K>
M,.(;Q&7EE'K=UL%!=5NX69FG).L>\8;4'CYL]9[KP[L[+=<75ZHZ82!S,]\P
M37$AL(,D5_F\S*4X/GIKK6P6K9V#)P^I?GZN=!PE-0D@UP$9&*5X'PHE:)9U
M&)]51>)IL!6=+B8D3FHL[WX1 E?;--2U1"JC=(*MA_9K<Z;_"R&F1U1<WT37
MP3G3OC_+[:]@J6X2,1XD$:.[*=M\3&D9#^F@OHG,?]I23I$!:C6INOO9ER!;
MO9WN7AN2]?7VK>*OC[N&X<_7@-Q5=H:Y[='PVQ>WL@ZEF'6?-U6A[#][YE>A
M])[M:A7*#Q\\?GQQ)"AUSF;+9A+Y\UH+:!34J6;0@=$ 0$*AHA 6+X*M[K90
M^<44.I_IF<*U9#!ED?^=:Y]Z.RA_Z!H_#[.2.+;TN9SG< K,Q6?IYB-M X#Z
MT@G.\FQ.VK<DR4[B?BPFL'14F69#*2KET:KQV";?>PPME(%(N$Q;L=H\!WO5
MM[XBUYP85>@;)&PY7$5YX<&5N('&93SD&CN.[A-/>]X*?HN204AF_58?7NT_
MLFG<WVZ1:G>5Q--X&&SY0:9MK<S\$DXC,MD+^"&V?CL_,9NW+:7GZBFP;MZ/
M)EYT'L73?ID7@F[,KJH/=++VK%_R^%L]/=G&H'8G. E)^R^G)6?<<,K!/[-)
M2I/QE53]TS8V.8IQ]C"E8YV('^$3>]F/S;D-HXG]LX1U15ME?3N6-K+4MT"\
MXMR)I2!I+D3&!A"1;)P3D)7>(@: (@7:C,!K%O&78$)V0*%AD7 XC5-<@%QQ
M^*0,/>14 #]XJD'3BE'G14[YT&NQSU;-C#1N55PIZX+EHO:8#7PN+JZ]L!-<
M+*8S8BV%]1&- #D-,!JRUN@=*28<MM \/1U,,F(6Q;053!8S>C']>;@H9BD^
MI[]$.5=;(Y26A/DB':.A>#2,-!^*[/"I0 3PW^C597]0SL,TD@T&O.CR#C/N
MT8#,7<!YY@Q]XWUW&%W%@XC3+M)L'BS@.:USH1O\0X]4WF\27'66O4.7X'I;
M$$&7C;KRL=[>_0[[9\;JWF]J+YT>G5?ZC[\=_&W5K 6=\1Z!#"MIEF<&H^O(
MW.\L5R9[5+_QJ[)E5U%@EV]U]1R,QBF7^M87I7JF=E=[?_M)Q_TKM'MX%UGI
M0:-S69FJ<S#,EFK!_A1OO+63K%H+SA.02O!:,;FY%0$+!.YT>.LJSO6:ZW_*
MFZ>W>)6#<']5T5]MH)?NH8/._NR+D:)<FMN<-1_<GB^OH Y546^+3FL&^_.(
M 4MP ^HW%L0 OY:QV<2],Z?1K:BZ^PWUQ8^0,H^ER\Z&<#:$\VV$\Y9QA=2?
MP= X&QK:T- WTI!D]:KK1*#/;D%/#UCS)\: Y\[Y%K/G&XE9WK7:4;3V5QL#
M8^TOVOU@W1>/Y(3OS]SS2Z+N4#]\WMF#?L@8$<N:X9K/\V$*8N\ZO?0'W;*/
M3X]^T)41&X&7G'-[)1';)B+YQ1?+12&2PINE;2ZVN;T;Y=[8T?N"Y T\WOW[
MV\W@7JGD(DRS4?SCB#1)#]]])/1SYVSR\]$O[9V#Y_=$')_#RV@8WM.9=9_V
MUOXFYL'W &>P07[\_E/AODODQPV.VP98\=YOBGK9D9PPC(>:;HURE!P5&K$$
MSFPV@7#['G^*('HU!03E#"#@#?#A([PP/QSPX0-=F$:\E&I5*;LP^5*@?L-'
M4)'6]F@Z83#H@W"<1Y(HY>&H5-OTHN;A]-,Y66(FP^4:0XVD2A79<LO@1*TE
M!  TNS4X#9_#^!H5*^\R^N673/N?GH:#,-NN0)94,Z&X]8* *P <H681-N M
MF'2VI]^&F^I0**HH GZ1:2.B@ \G( 4V2\ !WQLBUN/+[3RBG48% (B6L6M:
M*W!I;'$2CB:E2X/.(8-)F,;%E+//)#$KG&;:<M=DTU7ZY"7H)6'*$ROM7EA0
MS4VAH:D:\PK,7/.+H:2@<M9^XURK:7UI."]S9*29;C5X,*+QHVDLW5(<4A&#
MHXRE7Z.I'W-IK8R40-L'Q ^.V7/#'OG2B#-7(U.EI7F<W!=0RILDY="T\Q,4
M%K<0>Y&6\TY-WS=4I''7!;.+/!W;7N7+S& U>)7X[1%R:8LROT)+;)MA>/;F
MPE:-<1,5G>;2%S]=^-5EM K71>[8<)*6.YJLG'-K'LY^?9K[#Z#'=C )ARZY
MTRY96J.;[N%70HF%::Q=I@4-44CUZL+4.19S+)YS HG06'$PY8YF&[0)C.PO
MK5B <2]T7.8PW">I3*?17-K@T!+0O+FS@JZ B^1!Z:#V,D4S)29M4E.(8*3)
MD68VAXP)$6D;T0C9N:ETZ</X_VT*<;ENV.^(:/?3($I4R^$JA;6H2Z8K1Y/Q
MEBC8.E)_R)6BM"^<)FL/V&OF(0@)]?SN)5:[JN)H4RKVT*5BO0UF[Z8X[(%:
M"=[-W7E\(!T7!H_F ^/1O*[BT5Q\>+W]/<%V7'PCNHYB/4SRC.102R1U6X &
MI*3""MV&=GZLR:$^PH=(0F,^M@$BZ33-O6Z#41@GZ'+((#.0?$.20I-.<+:$
M),/@/B'9:7DH[7.SMHKG6)JL,1(<:Z)W[NLOLO8 P'&FB[&L5SM!?XD,'D.<
M"R*#L>N&$8,MF8H: ><IO&H0TFJ*DO:-3)YQQ)AN0(LH3&$&+44P=*0^8Q:B
MBD,ZEQ77&<TG#?Z-YNA%BU08P!L)RJ>MXP"ZU8S;$T]"FEN2%?3-*:EHDZ!,
M!A'*H,PXW&R:]F<(2":B2-@#=#CS>%Q&+44&H?^'Q02ZZ&Q&5A6T& _DPI76
MD*(6F;Z =BU7*/^X1B730DT$"X;I-$2\9Y24@WF):I@R)8.#=#*8=0O64!E^
M4$C"T)J'0-J!T1X!:"0C*U(44S$I!.X0K0?-8]S7#CV2S:M!KL9>SU$]I:>B
M:\<?E%8?$EW!X8VP?DLZ\)354. ZA8GIZ0FBN5Y'N[W]G3;)>5V^8&/XV"#T
M<\'P5^K6H"E,@>Z%DB=!X4F%-ZSCCG9WVKO[.K7JI#*8&'0'7Y=Y1H2;\I%^
M)!J9!$=3XD8X>L9AR:7OI5^:9[H; C".)GX6,:S8KVG,Y7KS1? &M7_!NZR8
M09 $6Q^"TS* /$@Z+1$=+3B6#K<%#\P[*!]KA73X?UN\$ 8:(2VEVQ6]EF@H
M42L4Q<P/27]5MDR##WE5<"!G(^+UP9CMZ#L_W)0,6=329?'0:[I)(HDX8A).
MI](7E M%C7W-?3,+L,+(W7*M)7/&CJZ$3IQ,N$Q?P8SH*1EF4B1J0)E"MGIM
MS8DZ"]Z<',G)= 4K4?\L1VM@+VT]8BMX%1&K)/83;,'QP1ETVZUU "2_:C-3
MSP:+>601$N.IU+L&6Z\^+"ZV:;1HP!U[;6VLUY24EO+VXI>6 3:ZSO)D:#NS
M<M&K[<_JBN\,<!0(@XL73[D[*)QWJ%"=1F\CW,"4+AP8,O,#H,'.:3?FM#2T
MK%G+?GP^.G[??C/0K=!RR!FJ@R&?0[;BT?88B*S8'(%R#\[./=BO]GM 2^)K
M'^(QE[T>G9V__[#=8L\ 0P^.H9_4*E?%\\/^85._NDPFQG_D&>*C942]#O&:
M:Q'PXBMSS@S/+=#@TJ#9+3)UC#14;B^7=[M:;MOMN;"PLDP+=!D*U(%J:UY%
MM+X-PJ0;$8HE]L5ID4ZK EM1 3[(<@MC50&@%''7,AV E8S9$0DUB:$;N=MS
M5(7+-9B8-Z)@JFN2B1K[1.H+NZ4!\"2.&59EZWMG!""\5.7, 8_>!Y:L@*!Z
M@*=%1HI+7@T#3+1PW8/!S&A?$((0.$ZC)[6GI%Z/%BP,:XODN^U!Z,(Q5@SR
MN,^DE@#E[D:@::O6TD4AF1$;Y:54!UX(E&F:T/OS<U):PTL!I#;;/PJOLCIT
M-(.8@VSA#FO#6^;\:-+WRMPJUJH=>/M/#$5Y;#;HJ').E93<QV"_WHB['U8,
MS1NP]AL;*<"(!\$9%&0/PV\U0+\@6R<A";&)%VTX,C'UT&14+J'),I+<510F
M%:9KO,0^)CH\MQG0^_H%G.(2EI=@G')"Q\=%PM1["GC"(KPBZT4O#(-, W.Z
MUOH!N[ ZV=X@W*I]SP*IB.F8PWP]G$VD%PLC@^TWJN)8M$0)G"WRR")8\E\F
M,6E84T056I7]5_UO&+"]&C:AV^,ENSNDVZ8ETB>V $U<T@G\IQ3N(E\MMAFX
M0R$?\"4!QDWL-T@G\)WPNYU]_/.,_I%GC+C_VAD:"2CZEAE=;-W,Z '@DFQO
MT?\ SD__'#RI!U6K$]H[?'+K.4@8;34K#XLB&\@]8[*P&PHH;8!AS(GH^J7!
M0R0Z3\+!I0\23>\[Y@CB%8PJ%MT36H<'8HXXB6%6?1+^HWA>!0F<9PG=SWZ<
MF!&:!(OK18\;GL$C9@?S,"MA"O 89*J-)9@W,28>4=:B)OQ*(MO+Z%9;6:5'
MQP"&621(%L/L.FT;C4J>C;[,+*ZVXBF7.;PL#'3K =F:&+QH,+0YM)MY!O$9
MIV@! QD*\-98][D"8EM]F.W06<1GVCCC@K6_6L<7 =X!1"RI2B T')L3QVZY
M57G<" Q^[4+#K)38T_<Y.]O%A2--4L<>TCY^H #0&X#A-.WAJ*;TP?EAMDH\
M:A+\$RVX[:P@%W@V^.S')PQO:CRNK/&1/F8,2!:]\OP2YOS=%_5 QNLIKU3@
MX_0J2U1L-FR.N@EJR](E!"'[*@.RY<9\RUYQC!J[QH/[75)$2/MO$]U-O<1D
M::8#L:C$E3@6"WSA/F@%Q!OY\DM4N+*,&:?T<4*"VU4WX:]AW/SP&NRIGX-R
M)#DHCT)E?2A>X%WY/BV263F+$=QW%26L =4EB9*^NTZ7L>"91U-8K[%Q?=@V
M"&131[R++O<!'8KGV9=X /%BXDI')\?'E6R3FT:83<(Q?%:,)>Z-<.80L1B.
MKC)9;>NP I%=M&XQ*I'N-6-%LNZW>!@NQ;JTW/&H^8;7^)?U*SG6S&ZA3;+&
M=Y*LL;M)UM@D:RAA5R31[I,? M!UO+/7ZW8/=PYW=P[V=IJ@77=W>A5HU]W;
M0;O^3*5</WTQQ.'MBR$>6 %]$X]+8KO?6"O\7==FW/,&>QJMJ*0<9NIK#HJ?
M0^NKJ= Z)89'RF.GT2:XC^J!G\,*,ZV=(7V-G^:<HWM?;7W]0UMC?G,ZOS.A
M[9[VM!<&VEH1OAG:L%K,=S6&-#UPA*XJL81HWT9TTNGBX9LB/30I\FZ><!--
M?RO$;LS(X&PG83]*-*M15+%6,,R*J!T51+CB591#N9:X)@TEOFN_1YC8S^$H
MFG,2_@CN)+;O<DWT!^"QR=]?#@3Q87_MD!%2VOWO79Y=X,U.>X1B>H YY_Z&
M!3A87$S4%/Z"Y!+UBH/D> C;2^OSB6NDZ$.:\[<8,#SCHAM4A=%'RQY_OSH+
MSMKH,N'6TW<>"NK';1F]I20M/:QS_A<MJFK0YKK"D]?_XU8H*:N5TAHIM\BF
M%B?=U<9\.JUX*V@DO,['5+??_?#ZX])WZ1S289@/S=YICS;:<O4 ?G6W"X%D
M%Y!;8AJC.)^:LER4\^B?9"&##$$L#H&$<Z39%G-&(T>B6<DZ9%'V_\W11226
M53,!> +<3*VP5;]"^>SZ'$J(<*>STPVFXZ>7G!/7?=;9D=]:59ASEKX..=VB
MF?_FLHIM^.H1L:?[ZZ%@0QBZQ2H@0QO0Y:CL@(S'$:#0YU&+^-B JU/%1MCM
MMK1,E9NTLM#E;H6NR<*&_S-'KG)^G^2O31#0L<:EUJ4K^/%2L>N6U+AMM[0+
M.*T'0H 345;Q'&(1+<.^ N(U3RM_((:"/SB646_W'$J84+O1<2 2E+/_S"V!
M[ZQP"G9W%EIR)[$Y-QW#;5I(6B.FMHO@4)1#TESQ0-;]^KJP5Y@Y$P**R<(D
MMGOM#4';4B5 VZ9M<_O<BC#2)GBTGJM02@"T1R<T=ZR76(^&L UH58OXGV3*
M<^1?1AA60IXFB.)';Z5.59S:YJ2\R*^4!LZ\5L7B'D_MQ+C)I@9\[-WDD6)I
MYB"9E?%0(^HF('J:N0RYZJ;4-E;8.['8(C:D@H2VG*-H$AOUH1<>I(]TC>BJ
M#2V*=61HSJ^S-I(C=-'O?W.)!&C1S0D05F)6DS8&69D@[PR^K'(@"A$R-SB_
M@W[P,CK0"M8E=&"\PJH269_;(QNMCN3L(,HAP(^X9 $5LBIN6W8";3"+.:?<
MA2:>YT4'Z9HN!J0-H&<&$E6^J+K.;3.\8#RQ@ %[;IAK= ]!1\^[[E)O=9]W
M#I^(EB%WD(@-U((D;%KM-!LR-[,<P;_I1D>@!9D\ .8Z(7PL"TX900;)UE[
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MFB][$+P [4,F4!P-!LP>QF9'WN3(7OQ[."5*O"B3)$;1TSE7M;?$*[G?.>
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M@J$Q.AK#J)LZ5E3(*V*@(@2-\N@_I>!I^BT4YM?Q(&J3$)U/."?0AQ78;C4
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M[Q[=[_0.].^C"F?<UH'%G!)?&-N2VI&Q+2^J^%M^7L5'*B>BE(O?.L$;OV.
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M\I?+-+FG'0^]./@!FW_\@P"R<)R1CERJ)3 1(&(_O:,?V+MT_#\EM]7Q/E3
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MZ=+4QN&0/E2:$:R&:?I.CP:>$KG$9'$92,=\JUH CE+N (_'9AN2DZ.E]#G
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MC"E!Q6FA3!7-\0@CG1'"$'7"3:"&T(;%)L_-XGFPY1A3U9876O!"Z(OQ^+O
MOPGB["$V)-(PY+-&J+>5M2>'BOJ0;AF.KXK$I8'LA,^.BD,,!9<-.#"(*0XS
M4AO$A!E&;514+K% 0DF^0HQ*QQ-''\--*XJ&D8:J%;#R;_TPHA0VGL5B[,J
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M'FHP7E++U3ORI@'_R/1CX5)PAD9%G(W3A?\'"FG11AF^S;@),,6T/]"Y((H
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M0^4ARY6GJ6:.>X5PIDC/0=L9$J&2$#J="6LK8F0<1_Z<]#L\<;A,P\B*$$[
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M>_V]@[U>TZYH<(PL,V%@6ZR#UMHI"MG-RBRS @COQIVE(.CA6*VZ$B7K(>4
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M_'.G0QJ6E.M%;F!S' /;/+78QZR'"Q&9G/P'GV"Q\'U[%'^;)>]H(*0XC<=
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M.4Q<-G0,2M5919[IXS5E 6K($8*G:EUOPVA&:C;+$;(K0N_A2HF$E/&8[/.
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M+]1ZH=8++U,OC$DMT+KOL XP=,R*CS3+6=4ZH=8)M:OP"ER%SVZ21D)=++1
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MD<&9(:&KL#1P</X+C6*I)R>8'H.$$FW&V1&=,FL-Z@3(MEK6;P]++>M^/Y\
MZ7;%LEY=KWICMW)C>_WN;NG&[G5S+M-AC?-:NTRURU2[3,_69;K(C)?2&FX4
M@AK[![V<7'H2A1/NY3(0/MI,DD^0_02;IF#1R-]R=LUEN' 6;N#-6K;1HZQ@
M.FI<+B?&<XX40=!/#/\EJCR!P4JN0^PT7!K>;<:/*6E$VDBN3.LL.O079H5
M 75RBV?#I_.NP08*4-?XVOKR5Z#Q[G1V]F"DC\FQZNZ1W\;;ZK 2:6&XZ0)N
M%\F2+K571N&2W204%KL*T.+C::MHZVL?HN-<J"\QXHM\3XQ%92BVLL;$56/R
MB@2&?E-%^=9I8_#W]\V?_E_^J?EW_.=]LRW_^E_RK_^OHY3KP$S=1S4D/&'V
M*?X+_\Z=XW6!_HO_.7O_Y=,/W7 ';]^M>?AF3U6WT]W3S;-2B3K/EL._<OY+
MI.IP3YV<#"E1MG;FR<>T?Q ;?!_SI>[3>==ULNJIDU6]G3I9];3)JJV=P!8F
MURINEGSB HUM[8.KM/4M#!@*\.7UOSUG'[[LVLL=P/Z;EQ:GV>]V2^,TG,NV
MB#;?UA7(=1"D#H+409#2!<[G\1X?K6?/;:MZ277XCHZ[W6&^,TD**<^=^8!1
MSR7S>SM%;309#^%8\KH=YWWD>U= )9L"1M$/: /&ZA- ,_*#43K, B6QQR [
M8W^6RHUI\M\9VE%+@QT$6?6HX"Z. 1%'ICP^W-W;X6PS/JNAE,S+.LX'DP,>
M>?QEDSFFB7$.?1!%&/^9-_;I'5?VY]'A14>63*7&V8?3IFZ*G/ \R#@*4C*?
MED#OXM!1H/ZADMN/OU_8G?;7$[59Z+X,R'*ZS>7P)"]I5<IRN$JES55G&(T^
M92/N(XUC^M4=.U\CA )N?)='3BXV7NFB7]R@,F1@#R\\>V[:=W-0'#FH8S_@
M_T(@LT8WVG9,3X153&+3'CYWV<K>"&B!=,R[;$)SW _FM$\[PAAWE4AFKH%^
MM6F^5=(RK[!>F2&%%UP:Y'L[.XZTP6=89U6,. C;NE6_K5KUVU+UT 91B5[,
MQN<O@Y-/33G20&>1Z4"'A6FRKD<_<R@8R$"=I:^_&A@#!(]SR 'D-[FSJS::
M#J5@AZP6AUX![$-F"8O9'U&?398+!A=D;);23O*7XRB\ +\@7NP?EGH#O;PW
MT.O7WD#M#=3>0.T-E/.-K=ZA;-2YX[D/3!&&YW =&'9T8$[_E>43,^N:KK N
M'?">Y&H.]N2N)>M])F [0-U0CX5<*]B2Q"J!0\(RGH6) A+.E;7R'TT3EYB8
M;@8Z[IQ=' /2=AJ.ZR31*TX2=>LD4=W1]+)R/=O7&+V>G?(U]RZ7,)O O?RM
M<]%A]A+#Y@$*0?" 9/F92HE-RJE+W""@ZVRDZ$O&8:PZ1>XA,^%D&.-K*QPM
M&]%+?\.&QE*5.EY@<*$EBF3C=#)>ESL7U&P/K(Z>H&[IH)M9";L:72,H&@.$
M/=@U?#\/H6!A\A5-2/D %A8=0U0KPZ-GQC2)[ZG/Q$Y,8QJG,\3/7@AMB^:(
M8[E -"C1@4F7+DLNH%L!47WU))*/7Z3V2_OH>/?]/TP5&LC_9B17W#]S;/K
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M;^7?9)8G0L&UEM9^Q:5:H7S,V-'S_@)48)P.YWZB1,NB:Z2'#!:1/S/O-3[
M7>]5K/=/:Q-OGZ6UU3R&'W/<;T[CXU&S ).MD6!';AJ+:RJ?;6MP_#&=TVF,
M S ;PPSH /Y9'776X;BEX)7KBQ\''3^&;2\6_FJ2'V.Q-#Z>_-*D+WETB6N^
M.:!MPX6.<]XRAC*E<ZP8^5K**!#_7_6C"SK\K6;F,W_H.#^'MW0O18KS0POS
MT N\*[J*C#,)O8:+47+)@?/E_-R) %),2\+GM_\&!Z3;?<-!@(ACJHJJ6?.9
M3#PG#>;D49*MP&\)/,54]O$HTXN6)6?>[F/[R2H0B J7OGC+WY'N*S>Z]B+Z
MFAX\XUJH/#HK-+8*#G;>X#M&*^!PQ[ZP0)^D$5<11Y:ILPCI\J*[0((:9<:4
M;4LQHK&I\#"JV89]U"#'@@:L[ESUMVM_-I.[59"7!\='1_S!H^,CNFED(W),
M!V:KZ/ZB_X[(MI.@!6 6)(RC @ D(U+H!%7'H!I9$44)0 (HP,9N-,X)%5;+
M<R.42>?T75& S&!8K2:(F\Q\TJU>?EW*S4C2S4RLSO*TNN#,J:$N:28D"]$H
MIT^5Q"IR6V)J06CPHJ[[6B*QTS&&38\OFHG+]I#1X;.;FH2?EI()#H<>(Z<8
MF]6$F*80(/3DL26/[^NU,"3TV5,$.CYK.6R/HQ0DE<$?*<K$X@JH[8X&Y^U+
MS0=2"3#ZT7%?5DZ]9.@;6[[ ^]F2O:/5DBWBW6!A4<8C"89E;[FP.XR8D1XB
MQXQUF"^6S\A?"+X,DXFJ56\I5N%L%]G><$FJI=*^2&]H@XFH:BC.4T8!)-F;
MSXVJX\TR!F)H&%'5;SI5;QZ,.-8DPLYBC#,+M-\<.C^.4UI/4N>)!48^ R$
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MPS6:NJAGOG$:\>C#31-9C, 86-5 #)3PS;.]#)TUANG(U64(8Q5J5\P$ ")
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MA2M2G%O'@J6)35P!"?.F'IVH&XL3(<=K"#8]8.)_\T8IY\PL[CS#IR4*\K>
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M&E\?05TZ2QY2DYH'5T6&<[E?Y7C[55 ?V9&$;]7&$387@.'>,%WY7F H)@7
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M](/[9$'.."TSV%,P\#3P_YUB>54$< 2\&V@..8%\<H"/R_DB)8/*VJ4OT2$
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MC'Q/!_YFA$2*-!)XKV;'K14'T$:@ZH]3+CKWOHUF*1*W+2<*E^XL69(YY )
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M%>=-_\R&8#XF\+<0ASLVHV5M!9ZCSZ0>6 M7-!T<$RH()NC3)X%4AT5B'RJ
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M_.S];J>7#_LW.*&][ZA_-U4@(^5/]SJ'99_>S3Z-QT8>PCV"EP'3UTW'7 *
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MK$9Q%3F_4LA-I;@P>)0GBV+A;4@!V0N$K.*4@<\4"4^SH#ZB/;4"B]B2O^'
MPHN']WM@.6-;.8.4@KP;(,I#S-CO/7VZ :)L@"@_&A"E6_&3AK3VH-;[W4P<
M]S^F4_!136^Z\)P;72/;9QQA1Q$B/-8%<0Q8OFH6:)Y1[KU+]YID]U5JU#VX
M%SZ.XQIU'A]:(#X.R*6D,1!"3C!#\QMF>>IZ6T=5)[S*O:N8+Q+",TZRY#R'
M26;CEG%.(!I6*E-*?$]<]?(H)2>*S)I)QY[==]+X>P!LALQV\_ 3-0+3VAXM
MM^6?4<;F#L+#M_Y CNSA'/A?P11&V/9W>"V'&CAHLREL^-;>?GV!U;]YAOQE
MB8=#]>+A,)G39WUQ+$&P<!R2H,A8!Z+-)4+_-5)\B+N#N[;-N+M@R:U4%CS>
MROX.&M9EV,08Y&G8)NGIBY:0ZEXUW%H&IR4NZI2QVXW<.XK0NN%N[0Q.,Q0(
M-7=RKDS,)R\Z7E86M= <RWM74"XZXKRO!^Z-9TF#Z!^O?"0%\+TP;%4R36MU
M<"C@$# Y15 V!<3W(L5LV3/7!N27<)8HQ(SQ]GS)$5YF4C)]P1;I.)NBSJ$_
MR]H3[#297))(QSXVXSB1&EH1-^1]&R-Y2(HY/\3;25;M>@ZO>%YQ<FL-Y)E<
M+#\ (JVR.[$6WBS*J7T+YLP\M:GBQ.5ZT#,?;<:/.,S1>@O:D1QO=3SK6*.O
MP^G=;-V"_.$-%XW#ICW[$68 OF))XJ5M/2)>+Y*1G9!#'*S_;H$4)2M1O0$8
M6H1_K0QK>E0TD]W]S4<,/OM()_;V.Q3DVXYC0];VH,1PN5"5/!2XVG5-F6X
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M';EUI=3/XW2%X0*<%QF&L5J!;@<H\9%L6',*.?X H)*A+?%$6Z9+!;30)AT
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M[1QT(BV9X#!+VB;^4HO(FMH(<&R&2_5]LG@K;#803^Z)(#Y#$FHZA;PL_VS
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MC22?ZPG\68Y3*LT]$0'AV3"?4B;J<#5X$/SHCA7N]#.FLGY/'&+5>W 84>,
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MI(.C4.%](H5WC?B_F97 2K)3L4ZY32KR6I39-%.8.8.X<=1I#B*[I.(#(5%
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MB[O>]A-T3P%/,T.\!7ZF=(%LXEJ"_VC+1;J"%<XZ&3L!H(O.UXY.%<MD9"T
MF;!HM+^(X'Q8J0D_3!47N<,326@+6:;.COC%F65",BODWDH&BT\G>087#2P
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M]('@<E$LXG%SB>#IVJ(CR!F3E0'2F]*FYD'OP75"64UGN4-2L/B1:/B:;XU
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M/T3EPGZ#0*^+I;ANY$C^^!ZC$$Z&@: Q!TYY,)3[,.G_2E.Q;T>'399M]N,
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M9?KU$MR%0TY'R'GUT(--64H M0_^7<L.YC";;CVG;/Y"T$/%+)]7W0#_TT'
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MYF-9EW*X,W(YJW/'A.#9JC90*P(!@KK/R_6*H(][#_'$&>48%?!V7DDOPIT
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M/<8]^587R&!F.-3Y&#YZ<K/A3@5'IPMF%@3V7*]7NN0/;D4UO]6(51Q=T,+
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M<Z]4YI$>^N-G+W\V!(9=N'B+\LWLO ZC(';=Q(Y.@50BYJ@/<$J=$@GO12X
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M;$4UKM>9<N1T8Z+$8H<TR5<J\$35"505%$2I1@)-\-CS%>91'<XQM1WKN3;
M>$DHT*)2"0W'52#S@#P13WV,4S\ML(Y60*-!RAEC/EP8AI52M2\I*0BKA!-
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MW>UG57OWR8WC#5N=E[K/^ZC7;O7X.![:Z!UL]KHV[V!RM<:EC^_1Z]UU5DD
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M!W])4Q'HU20^R*Y(>@1IZSI.O@.=%(;."3*8=WP@L,4_QRG%;B\BYV(^#\(
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MPG^U@A\!X< ?*/BH68%K]'3&SO&O;\RM'W/Z;;W^2MO!ILS)4NI;U:QO(]-
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MN_>@^KKZW_O/YK#K1EMEITM^PHMNK_ .KO"_R4%PE'?T;'>7]-6^;NGVY/8
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MRXNO:JMA:UAITA!0+>>6NXT+7+^LQ06GJV3L MX#L4)X/;@B6TR"19RB.<+
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M0$$SMW?(WJ$CNT-?5#CF@'/ 'J@)6!>Y'QYP%M]$LK07^)@N\(6*!AV0:CX
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M],VLZ87H.FF O8*-V^5/F$4&R%)6@K9WK2^RQ/3)\"FDB%423^B8J9/P9@Q
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M&XK@)Q *!6+C6%WF:U%%P!Y+_)]?34$P?B!*M7_E!R%['('!(& SW0#&JY+
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M#[K&F[D?,=5I#J\AS:'&F]FXH'2]2S5%U7OU%&D.VUFMLWG( "\9;T9%0UZ
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M3]DN^FWCGAV9%\QX(54QE:Q)RUH( ; BU.?*FA>M8(2U1J2A_L:54?3#^QO
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M!I@J6$2A8V[FL7\#CC:?XDL#4?K%M:^JA(XP2#S,+BD=SWZKP. DO7EEJN!
M09E8Q/I3"XR/W)B>EAB+IE9%,Z5)"6G1/G);G8Y[T&R7DKIV]"$1GD#;[7:[
M[N%^DS+6=M$O[B$VP7#BR6(+QWX$WMOI4 XA/(%L!.M*?'8Q>4Z[<?0WO%Q3
MW&FQI+6G G>:>R-O+O2<FSC,002P"H<.-_3SCL7<WQ00#E5&"V'Q##BYE!.N
M(P/" ?;QP.WLM]QV]_"N+6R[G7;;;1^9.Q@5ZE7*6[A_L' +]^'N;=(>N@:
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M)K&??D/0]/:UI_QFNPUP:Z?>7W%"VA7OO*T):B](63HWG#]@G]#Q$##,'K)
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MDG&SJBUUV&UT*CC"LFD!R428 XCO1T,W8%Y.C_@86@-JB#AY[<X\.^F\5D1
MGNT,#'S, ](QZEL_O$8/L9Q$D6\9=*(IQ D#CI1)8J]B8/X/S'?@Q#G<5YE
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M-).9?Z73UU<#0Z]E6"W#EC/NTUJ&/;8,6[OGZ>+Z>F_@A:C1BKO5GZ GX]@
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M7%@F79>T/WM)^T%=TOX\)>VOSC"XSX5]6KN@E$RVQ#"88(FZI8!+E0[&'<;
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MY?M3L4E?@.*E=G=D[Q28M.^MR37I?*TG2E,2VU@UCV]S'_12N25P;1!*@HR
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MM=V;964-IJ_<"&M?P*?SJSU8A)A_8=:&@M@N>'(/7):,MOKD:@%9U )A%2?
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MH4>DF\\80WK$[S_[[>(__D&,Y+FCW6VBW5=@Z_.^Q&/^7VJDY YQ6P_Q$9G
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MG,,A<C\SQ2YCU4T)6U^PA:;&P_8X-;.B9$W@Q^TWF$1P="0K^A2U:PI@^:,
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MQ--887+J[F^(*BHQ76?(O\=^=%)?F6$\G8GHMN/]9L,KFA'OV2=.7(L@)$&
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MBRP>?BUB6GCVY>T=YZC3\#&PZQ2]5S#L%,92CVK?Q*I7C&;R3-$$.GR\+$_
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M$]J^'/NVH;+H-VBMCH,DS5#ZYRF6&"X][#&,]V!@70^I)S+#:<_(>:#C\JH
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MY_$4_<2&TY=I_?4W':/Z!'KB4";Z33Z-=P:#X3/B(#A:7O#L/I&^;+?'8UW
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MO*I$2R&.UK^.;DSJ%6':*]@0_ZK+&"/_%T#('(7+Q%>)F2)7DKOW<*\'T[Q
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M8_J -6+))J@F3]0;Q]D2EK0QW3G/9%/I7:8B-YI)!P3_ @J>;I'L&^ >RGN
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M.V[-]<.)9R%K^Y1WH<54Y0P>,_GELJ:=C&+XA\J,)O6AG "+'761CN@><Y]
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M B2*(MP@0&.11/_Z6YE952B ($5*7$"J')X9200+M61FY?HD"P80IL QR?7
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M1C[*.PLKP"]4Y737FK([/O,WR%?PZ8>!:Q.!2 (4<QX)&AU)&HWSC@"OZ"O
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M8AA&1S\^:-P3V1S"?X@!6-]YEJD[(D<!X3U'$9-1<I'& \-2Y "[:M(*(*>
M?BYF!-JRF;%P&41,;^<K+@OK ;XG=T4AKKB,#T, Y7R,4<C-.K3EBBO7(Q"+
M;$&6$X7^T^*P9'?@W@M'#C2,"+F4P6=QQ_B@F7F2_;6?J\&,\QFEQ<)+VSH?
M\&E1D@7_]$> >?P=>.>L+@<FYY%RS//0H5*.?>CTQ8=)2%6AG/AC/MB3AQP&
M!,LP,8?O S11XFR+)"WA9I%V-2$QBL*^EU"_5"Z#; OA#M!A.>*20K6')4*.
ML*L$O2;G%@Z<1/@1O8 _YB&* 7(/),L0K[EI0J"N$<'E!C+^0'/VO9],H<,J
M^4D1(ER?*GEY!.SP0#IK2[!FA>,*O4^),QS!JV%_2&").);F2L)UQ$F4BE#0
M"SC8,1:$CHTNO^C APER2ZPW5X]=.@F!WIN?&*($@X\DP84Z7#"F4OXET+IZ
MG(]#J=B7$"!_YZ3BAD/8]6:]44<\7MS#9W"\"MB[;/A@//$"F9F:G0&39IQ$
M0(\T@R"4B-2]<3X#M+3>?+X:(Y.9LYG,G$.3F6,R<]:7F;,>LKZC5D QM5"@
MKH$B2]49@7L<))5L+BY [17*E^;)SA38XM56%.$!A&A1,H/;&G14$4S)PJK"
M)Y-K4R0GAR)53$W(:%F]V=>J-VTP)FEDNI'Y$]X39)]BYW4*WW']V?$+J\HO
MIC!Y86CD]0%8<04S^==#/S=AIB( "AP<&K)SGFPPZQHAXF3;IABT$;U3B"",
M\M%@EZ&2JR_R++(277T(4?SAYOZ8H5422N58=6F .?J8NO^6R]B8&6"+5\NV
M^*$,3YC;)9GKH-I=$^/RV5K?G&>JUX D^J'(@!#1N]1G&&$E+9*^"MIWUX>&
M$:YJT4#6*6J7PK4,)4>05F9IW6ZZH:M*UX7N2U_T8M7S1K1OP)G=R^X3VL1!
M!X>U:!/2O!TJ=Y$*4"3RJC_699C#[7$/"Z2:1[],&0@;IH6$\/P<1K[[#,ND
M!T@3+]LJ+E3[E%]"V67S;H9P+\"?*+E$YC[$5C_E$ANCUVD7L-P25;D:TM_!
M=J'D?34TMD+" 87/'CKTA-!D ZL^1>.[@/DVYL6I #FU?4D\Y2G*]@9B!%:;
M_^AS0Z%^1@D?Z'ZPVN[0"[*(+_^FX@%1#73N13UN 436:5-5E9!DBE5E&$A&
MK^_UK!YF*WH.GK1,V<%;<<"$BX3-NZ]X42X]!X:3WX$X 9^Y,@\F(R/9_237
MDR7L]Z&H 8TJF;THZ;]FM?UD #8A><=Z<K^P]0_:E91LJ0;)WA9;V53@!LGS
M!AI<!78!-^L(]8%$!-0G1R@8^WT*W3!(M\#:$'E&L:K]DU4C<NH$'=+WD>?F
MH!51=J98ULJ0$0-^4STO<NP@6Z&$1&2GT0;B=NOT)-UQJL<->!52(GWT1T[N
M-3\HS",5CL0<73N!=L;ZR6M;G]]HIW@RF+57=EJ:1OCH1*Z4D?!H;@5\T"<O
M2DBK&#B8$ <2;,Y]R^2QW *"DE1.:4B ]<A>Q\Z<C-]=>UD6*.;!HG\6*5QS
M92R=!Y<^H.N,^65ZP/^3N[)!(#JB%%[;->1NVJQ\AF%/=&8K9KQG)ZH(/6NA
M";)WD(*JQ4^2JVH]]%=ASK9J@"HR_O1K; 1"E'\=],;HT0F\_V1.%B7B)X3-
MYWSF;NG4Y#$Z,6?P6-T2L)ZNZB$KVHG:2K&,&1<7E(]%7>@*?5!Q=50[#(_Q
MU<BY85,\JCW+S912NY[$9%69PU']%R LT0>8WB5;+X"+CK*(R.O&;1PH$^AZ
MHMZ+>$43O9NS4&Y3DLTBN<VV_I8&7YGU[=N=C5UFB77"$1=7:  ZB9VE<WNR
M:A:4 C<K9% -WV#D;S)BH\7D[>4SX_7!=Z<K]E&(76$&%[4ZF)225FQ2JRM3
MY;JLYT#*\TJGK8PBP.C7A1]6HFB"K[;:>4RH#5D/M"P"Y"72-?OZA5)VG6#&
M)N84@X^Z!YYV%WI70H16EW*/*7\U3!+8!4L;,(%/0H"13R+TO=X8%0%^3R'O
MRT01(3LY:0I6#,D$!II G"I1TH 9"C"RZV&I"^BX8O2LR%FJO.BN '-VP!SW
MWZD34>L5;% MU63/]9R(!L\JDT!863\9&U$)E*:1<?W^9W9C\74&JS]D1TG-
MTN,6%AO7-^!1Z1<27[&1^7\R*9]1E,*?PF=0T0;>2.N[Z)&HT+?%5N9>80PA
MCK//A8CG,EAMI( .D')<MLLJ:3LJ8Y4E3^OUQ[+)MQ3_=MZHU%+#9REL.0L5
M \7JGI0ZGR,;=4MS&,82S5,3V=DP#81!@G^)&,R+[%KIO!$7>C[T+:7%/$:?
MRGLJR7E_Y 0-R:W,&H<I&1)E,U6>Q@2*+9R,<2Q(S-KDG7;=G[J]A?*+U7/8
MK,MFMON VK 6[?X, T&CKJDNA,\",66LN9&E]XY_;R65&7*UDS:I5I(E?(%#
MJ&H17L.(TA]$(!/C>G1CB^7D?,6DH<9Y#XZ*YX*I:.>]+0VNKNGN;=CI/82L
M_T69C0[5-*UC5S+;UE(B* U\0O;2H[@:88A8JO):J!@I^D4< 9=E*T<\N=CY
MEWS.0G@WK_F\<^T+-?$-A\_/6EOY2 07R/VOFA$LF4IDFE(YC320$M1N5X,X
M<EL8%K?M'02#VAN_:%#=DEZME2R.[[I2R_7%Y*,$JHQ/RJ:>[W@4$^JR@/6]
M));UAGK87W4+II)5M!!%PEIV20NM3-X)XD2I6[JLPH/[7Z.FJ8(;H*;RJ<NM
MFO5WKL),8M1=U*Q[+_YI75%EL\Q,YG^*%1X>7^A%"#RA,INE-!./7_?E[/B&
MQ#%!C+S5C!&)9'*DG@33AJWG0Z4^1E_20+5\GTPVRXJ;X?362C YZB\D;INT
MC"K%'YNM(Y.6L8&TC&Q[*Y&CL>(T]2T)R.;29*TKD1VMQ3[/A7]*.$XK$;/-
MYX%#"6N*Q:IDU&AYX;-2OK5%%5W1F9= E-H6U;YIV>#H8<*7?B5_[IXC(YXN
M83_NTYWN]#!O)9XY&CJ]^3BO/*6"%U*U)G^%O(+V5(37EN'+,4%74 ]>F>:]
MK^5@XQ*N@17!JW\/RD@*!4_D9FN<G1[;>,T/$>?.EE@J\(!(0\\?BI;]REX\
MPO3(G8U(^E;8B7GWA"<!=8K9])!5@YF4MDQL'TM71!*%#OG%R$,F4S![7"'M
M8A8FWZ8THJ19"0\_L>0.%'+UF%KA]7W'IB 4H!XG$VX& DSFAR,I9G([E!^5
MVT01Z%1JP^5F4/*N;3UZ_<2VOC.7ZT)@#A"P"\X0%P91NF$Z+*%HFB,$'&@D
MS+>G 5:B%,'TA30HF\QT_H( ]MSL-;&7-F(<A.@ARNH=Z&/T4#OHD(IGB *1
MCJ6#[0RAXD( '$)BKT<1S!RBC8\("PJ,1K.)M+H)C/0.J;T<KB>'BZ,1.$;V
M!1?$$(8AZA9U%;^]HD6:)B^5*?LS35YVLLE+UPE^ZJ#V65P::A@XPR*_FM9O
M1@P8,;##8H"?O5 8R2_H,</SAN<-S^\RSRM<,]\Q-[SA=L/M.\WMO5!D9#V9
MJ]TPNV'VG69V472/Z=29S\YH]H;]#?M_"/97H19= "11&B>&^PWW&^[?9>[O
M1N%/_CR H['(L+MA=\/N:V%WZ)_!*(9>;';#?!$.AU*V%12E+WU : \$%;'4
M)BC'1T.6#*B[7U88FF6#&O%BQ(L1+SND34B(#DBREVBG/2[:_L,H2<T/@\<#
MK'R3.?%&Y3 RP<B$M<N$I=S["><^]L*&(ZVJC/08K8Q,]KOK U-20M^^T0 ,
MMQMNWTD-(,OK?1Z$ N<WT4L!S(5O1( 1 1]'!(3/@;5'4!]0>0,5 O0S0<$&
MA"OC/3%_O(_5W8#P%!*@.V++)F'OI[4'>&5A@C@U3XZ?LGTC1HP8,6+DPX@1
M42@HZHRFU0".TBA.1<D2E'UQV\0/QTR 7%CAB*JK(JUS 78!'D)Z(QHG1JP8
ML6+$RH<0*P0J H6K"&\^6[(X,=9 $DXPH-*ZKL]L:\!<*+KE>@QTJB9@'TVG
M$6V"A;S!LMU'@F]#2':'FKA _?&T"FT)"H)]OHUH,J+)B*:/(IH0=M.Q^FG0
M$[#"JA]2H0,<"@\72"[:A/ZR)L! U?HO',H:]7SO%(&LCYM'6 E6S&D),92P
M5YEH8 ) YJ(Z7L)1U*Q+IS?(058 \E;T2.A/(-,1=RF)":S0??+B,!(@VQ+L
M4I?AMJ5##JP%<4#<&EEY;@G"1UE;QYE( P:X:9$UK0NXZ=@ -WW(?EHKO@[?
MC=6$/ZN+]%V92=IX .;C]28?_UWT?YC$8MH8(M.&),(5X/A+%'39.5?'AW$D
M-I)VPZE>#@ 61?"-B.6 J#2O(3R)SB7V7,:+G;5^</3VH.C9(8AK2A*Q\$X5
M:(D"*#F'S&5K+12<7">Q/65E811ZG,>)U)^<9\;[5D]\733B%&T3 +U)H4/Y
MSC.?I#TYRQSJD&IU+*"3+CSJ94E2QD^'7<^Q]4X+@%"MOJGZIO4S2"@17!>M
MPKA^%BM@U7G6)K061"65*-L(P8H+U9HH4 V M=?66D X$VU9RI"J] 8?<3H"
M\*A8/"YPP0@V"G05^OX VC\'3'G_\2%J34$.0-2&<08"*'HL%#-J;\1U0[WM
M4=9>0\)MXU)@?5_4:E#'U@!7(;+@N5Q/Q Q,TORZ!<!1;5X:)1#@UP?M8W?=
M%XUE)9C5;%;4GYR/%=\BH#(,>'QYU@Q1O%[BR^JSH9:'J@^8RT;0-%'!'F<8
M\MH7%68M@JQYLB-6V1/:JVK67?9+K%#[7P/!(Q>5' >CZQ,F"CVC&2FQ9J6\
M1??_</1\-=>-1ITU,FIA+R,A-!#7,&=*<H+ 39:]F31^R*"3\Z0-?T?YXH_A
MX 011&S$_P/ZINI(#0-3FSEJ0:#:>>;1]@#D;RCO[8G9*3)8W0Q5.RR( G/6
M J@[)#O *70CYQD;B/4GZ+X?ZE/+]GNR>^J4,]OF9I3KU:?O '":W[)7U,/-
MNLY$Q;D  '\5!75CFG=[Y?X538>T)2:ACHYN*^XI@H"/Q,:*YGB3==9C4+U0
M_;J[NCZ?3ZG&AP32.EJM8P")]_H6\_#NY2JW=7*4RZ< CIM0%W$E^%WT%<4$
M$RDSN9/QB&XT83^(I61]X&177]#+J=U6]C[@?LS6D"\7'63V]$M6M/I0K8N[
M3DPMK1Q+-.V!SH;0NO*1[5MNB@"HV:1!.4BX0MU-$PE*+]Z"HHZZ6:JF: KO
ME314V>D27B</27;NO,*GO%AN.+1LB <$/DHOX#+2Y30LHC^)4,CA+L8'H2$@
M.!6A4\XCUUC_4R0''$:I!X(2LNZ&8>@B064.O32 GFIHE'!%]Q%>2%H H*X&
M]&Y19P,:AKX>37*2^8#-?88A:!W"F<SWE?_-E2U(;-4:"(!+ VCN%H5CQT]4
M7R!J75'H"NT5]Y,V"QM)E=PN_#I!Q00A><,('=V)BM>+QEJB[Q!_)3_QUY_/
M3"9@#UJ>;@!"GQXT.IX1@M6V])2D+$')QHXMDIPQ PDSCU2W;,A,VF0'';ZC
M;B@N0M]C3TSU27@&A%\'A8FB]IR80+QBZX+UL!<>&42M!E]QO5G7>HP^3[SA
MO8/;><1A@4+\R EELGD2R%9\B]"\Y<MDW[K<2X4P[*?0HRSW$6E'^=Y.:+=2
M.PW1N$&V/.\R\J+3FZG]!LE"6_67(]W/P:9-!\ E@> TR%$96]2%,<"6'T$
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MI<1&39KU20N>>B5'_!=OA"IM(?#0984 /*PIIW!G46X188$W"UI4SXA6JF
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M8TQ:%KD:I8IF"U=4!L.;;P8EJPZ3S/$D_+:%!_NAI-^"#V'S(8 )@XQSU>P
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MUIN2$>[ I$ ?LZVL\EFDVG/[*>U)IR!\/_]=V8(37DD6.B8(A2"Y1B"MP-O
MOX5@(F1R]U!?ZJ8>(3\J"2B&*DQ#X$/YTN0?,M?C.\@LW^F"R1]"1IE8[X^
MJB 3DI!9)JF1DD9*&BGY$:1DLUD[F922CRQ@$6 R"#\A@ZRM41CGL1Z>P^BG
MD(?H50S ZMI?:[9I+H#;K)L [M0 [E'-.K^]>;B__48!68S$7ORX?STSP,1B
MX;673XZ?*K"""R\&5WP:,4Q+BD*?O'88^G'3J!2J:0-AJEM20+CPI\Q*E1X^
M IPX3/745)7>P&-]<,'W4G33"/^5R&^&S_I<8PEZ(I(!G]G6P-&[@4.GB-Q.
MH5XE'3\!B^/,4Z:VL*=OX2C;PCWT'O%W4LCC/O57X/YNM)R#QM$>D\&IK)^T
M%@^YE)4Y;<HN;9RU#FTMA+8//\O50O5A7_?)]4)$3B.WUV1.J!/+DAY\9*7+
M[$XN4U];S?KB@,=-Q&.<1#M-6ZJSJZ8F3@["GPPSL,763G,2SDE+Z,G-/)"0
MQ!S$I),K;V@^4"M.A.KOQ1OHA%)E,= 1QC3$,^,K@EQ%KG6EW:&73-ED:"M
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M3H#(922:GT6)EY/R.X5PF/EGV@"R'\Q$EU<)]0>5U= T^J(3"P1#J/I09@F
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M)YU2,6':"V*<U0CAAA/H9,>]$%8!3ZO;$;Q9P7LZL2Q)8RDN3S)MR9\Y"P_
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M(;,W6)F$M04- 2*2!Y('D@>2!Y('5B957IET0_QE%RA>)J3YOFL^+GSMT2(
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M@-*DF4O5_6]@ IRLP9]+:="Y^NEY#\3\X.55^K\2_#;^G:K4!W;_'>3,);5
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M2N 'S<,N<A*[/QO4)DJ:+P$T82V@\1EE#^J6E;^;94\[B5\@1F<-U1N"[0C
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M>=CIMG;P?/UD4KO$*9$FRS'Y:5OGKCSL51:X:2Q5'D="H!K/H#8VR>H4=$?
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M1E6%+H.XHG9NPW U.%Y<J9WV2NO#22>7#*;7,VK&Y_=OG[*A,SNH$$@(I%J
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MR.I8(D?LW0-HP&N[>:,SD >]C.T_EJR04]!A8QODD?)X9&>8/16/#.1N+\F
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M_TQT\OQ(7&YU=!6PN3K*B/T<LUH3&FU$D&<%^>G$LB3M&:Q.(&G3!O ["P_
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M0_+).@'W,)0?<*9J,/[E//K@C;>5M2'R@=44^R?R_1AU4[MQ_:CTM8@)_4A
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M-/O@CT^:9WJL[-JC<T382PL/'N)YGXFGN^:<OC2QC0E8EP!@V-T=?%DWB?<
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M@OW$9 S].UB8:]=H30A[0) A?P0R)BY_15^X+A XJ^7X( 7Y]K'Z>ZX<+G\
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M4+@U%E9%B6X#U6CNA"!*P4MWWR]1#U9EV*3'RUY#9K)X6GB^I/;0EJG6ECD
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M,"*A+5 #P<AEA!>7NG/GE; .^X$LXG[5DEC9EYX=,"DB8H52>M!6E:-\Q>4
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MU_T2!D_H ?%,8W-YD!IK=:[3ZFRQ[)"1M/IPN%+SW#$;=)V^SN(F.B!+.M2
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M$I4D( \HND7*@0P"8-W*TD0.)_KXM[U<\0\=Q*&CQ/"UV+2*HR0E@\#<\FQ
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M67@5\QYGKGY!8N5?. 9,EX(<F)T'MV;BP4<KTO-W$)XP!YK@@@E2J$FCT)N
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M4H[W#O'Q"B5,+5W*MO7R\^,5=[)^=^>T&K/F]&S%B;[VG)9CR#2.=ZXS_/:
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MDYYZ%9SJ?WIA2K* % AZ)TB+(.["U(3P!PT"A4=,WX6/8 S0P<=%*=JB6=#
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M#T !C9+R,_0=QR+5ZC&SE!:C6EH+ENER62]"5OA?2=CY\,L#U94&WG2)?#1
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MSL+7T;G =_)U^-VN,UNLXQ)6T%GEDW9&L>'S-1DXCZ= !>01^%-E4TP8X5_
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M0R2ACB8&[Y)2%U0! #VKC$,A.#R#@0,  -2X #+3<;>X2]R OY)8!G(Q-'7
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M3((WN\$G2\"6_+@2#VWP4Q <%?;RX%TS%8-3Q>L)P!.C[4@H]\=]C>&[<&/
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M,IZ/B<U>VF[)= TRO8P1^BSZ]I5(\ T=VJ$'8&[-4P!OA0 OH^5@NY-1*1Y
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MLB(F:005V-YBNU=6\K(L'W5F%4U--[Y!!J7R,TMO82)P?%HXWM.5M-7B#NJ
MS+G2"OO.1YR/I8U*^ ^Q+4UU9L&)2#D?I7@=X;$3CCA-XC25-M#A:$Z3\.8?
MMS>_#2:H9GG8Q[!,=_ZQ[J=N^1:"H(Y\/X*@!$$)@CHE!)S:?O;R&,._*BP$
M/X"^BIJQ;GHJSSU)?B.E7*%,3QSD];FN+-L>[.(AS6ISDW0I<QQ/"*C\=D)+
MW>P3WW%/U3B(OURT]S&B^IG3;F/_64'DU%>>A 1^%PDAC E81QA",%[5I8-
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M4U4[WKS2*-J$X,*-Q@,U 8]UX^Y5Q$KZ//A7:U;2DCO=KMS-&J=3)2N1#XN
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MMIGZI_'+J:K;T@OF.(=._@2C0>X39,ZOBOV%T?D@22!L5\+]//@IY07B;KO
M]X1.(+H;/ *Z"48I?,M#_&L>@UD,SV#MPZY#E]/&S36D$>,XP W0I:=FK"_T
M_EF3B8>YMRJ"EV>*2^H8SFPT.XZ6$]B$X'O1H>5'&@"UR,/4]20""[,\; B%
M\)M8SR8&!TLZ9+7UFG_5__)TC7&C0[C-;Q-N7CPU1F1-9]P$>57UES ^E<V9
MSS$AA?M=-:Q8T:*/DM$)[%B&YX?[7G637@J$%)?7<C1*F7D0 STB*URI1LPH
M9GM)Y"]@[GB-91)I!J(=GQ6$_=:(UWC&1@198;[A WN,^IPLG5@UR3@N;1?>
MJKEA%_@13&/XM"%'."UN-P0R5P<M00&B!2<,;C8!3#L(9,J*D4$2&Q_F!U!M
M B>9!2Q>B?%"B@+J(SS_?OI(GWXHL*;SUP"JL<#O2OAB9)<R4R[H$A$1/T3B
M!U'BX9-T, 2?D(B%,$2A=V$RL3T>@0W#R)X+\* 1T3 ,0Z4WGD.N,SEP*DA\
M%D160>'JGG^1#)RLB5+#*4HH&LF(<A3?'9(=N94I!PK37*<>CR#Q=(-$?50Z
M^V":B#;1:$I4?0QX1W 5RP3$H(Z%A*VRT"TNE*H89!,[DJ6*H\H@@ZUG)FH#
M%22QQI3TWR10]O 6;2%<Z^@M&DXF2)'<;DP%70^5J9.I?<*?(%@IH7-1[..=
M&L9J[*117B%'A+*:(9:YZ#\CC><&<"+0)Y\)'Z[JVI;!AUJH?NC4IL(?10)+
MY)J3__Q'A9-*4,;JF% 2A$!!UN,[D!VI!E5XG1F!,\Q47@"ZK=%O*0D/GZZ+
M/S^%/[ S:%ZTFA=/EY=RC""H,(W&E,,H\(I4Y"S=US<0_.!P\$"5<E*-:-Z$
MDFE$V0=>9DTHD+E# :PA6 RED&#FAM\E,TP1%OQ@-9*_61J8J).@R*<6'.&
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MU6A70X>"?ZKJMO2"2:0^_CBAT S,_B<GU=W46JD72:] CHPZW9EJTJ>1Z90
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M,_R2OE<QQS&9L/;"<<^J]G\>&GG9+D T3CU#C6$O,WUE5QI<V_3"![0P!C+
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M=S5<9VN/Z/H><W@&MW>Y5F.LL]P*K+KY7+5TDFN@2=IO38%0PPRW7J?UM^)
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MN0U.\U2R?4U3,'&:ISJI>'ZK,7&:IY+TU11,G.:I9/L:&1W(*&U5GPR:$QT
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MYZ*_VOHRL>R@GF5KVFT%R[*>>_MU]9YL:>I=J%6@H._0BF17+-(5L/0JJ;6
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MQ[4*N/.?'CZ T]JK0G0WB=178M,%X-QDP6K8H8KQ5VJ\7JCS.5TS@,Q5C:Z
M!($R@(7,EX(DV5,[)$=)(KI#_J2VY<.3GV,)?YD40(LP,50,LP,UK%4XGFJ^
MDKGJ+(-U'"0VW74(+R126.0^ A(+X(LP44U@5OH:*1;7"+8A>JTR,N&A=SP
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MLE.P\7L#Y*B$3!YDQGE][3<'&1*BP8U(AC-D&EQ4F;X *.*K"[ 1VLDQMQI
MQJ9JT8J1RD!;VN,VZG2G61;T$8O/J@3.?HX%I3?N';86QME8#).L1Q%T+N1C
MNO@RFOQS:\5SUJ-*C\KR,[)9>%*)CS7E2EX*\6"P8<+KX=R#(@42@V$('X<I
M5!\P:7<?,M@Y-D8!U6NT.&R/;A"8;1?)CW&-E:'5H:Z#].TN,](=D)J?P:BE
M#/>A>ERP-+K?!69)'8Q*:S]O<3.)<_634-PY XXO44$*'#:Q8R#"L@TQ=IIQ
M2/Q;+,RE4S35FSU 9+[SOH7\G3FK_G%9,G[0'G#:?U\J]U@T1H1%#77MP-O^
MJ^"C& #>\4-E=>*,?!PT[O-;;@YWV>0[WF<Q<R5<J'3_\<P'M/?7$C02-!(T
MY7[->H)FL+8B<GNR93 P*=3+5(B'4$)UQD,FI"*=2RM9*;T>L'Q@\B;7XK=T
M7.4R(;ZTZ*;[9*CS?\>:=6=7@%56/5,XU[WHQ.(-I0K\NK#:N J4K[UR[+GC
MGJ//6ARJ1*D0D'LG V3N/,ATMI6_@'O#(M6$^K@;R=N.9"2MH'$_7ZM1+.1T
MP"OR\B1T:X&N[T25X*T%O,PUW2C8GHYN@=Y^J5A(Q>)DF8=4+*1BT5KH!DDG
M$KZUP!>#<!C<]%2C41 ^'?T"$\BD@B$5C-/E(3,_P;I1'.1TX*L#B\;PQ5S"
MMQ;X/N/(T$;!]G2D7WW6=31B5B90R#,N<B.%1<>B;SY-;%+Y\'VFY&G^ /)#
MEBIYKN.J)DMXR\]0ZTWW):LPT)X?@=VV1,84@3T"PUG+9,U69HE^_5^.O%D)
M-@DV";:C@:U&0==R$39HG C[C=>\'$]"[4[G623=BL*4HW5-RBU.:1^O; 2Y
M.#O1RRX];@Y 1O44XK21EDY-[DJP5:JN"+&:49M0.NLYKJ(<A8WFCH3H1B8@
MA)K,C\![S<N+UC^$WQK]#%V%X'_G>;I-U'6^@W;1C$T>Y8KMD(7^9M:68)5@
M;<3:TI'[-AVY_>X;,).KF/RV<=+;QNY0TD1N$:F4\*A$+MP.YG&=I"/-XEKH
M)Z<-0TE.DT\^]WXJWL<P9^R1VJO^03PMR6'QFF=CEX)WOTX[@Z!=L ")I(WZ
M><N-GY3R.V9/'):;[-G0I3M(]XF5[@[I[I#NCM,Q("58)5C;L[8,Y[?'D7%=
ML&>:S$AKF>(MP2;!)L$F;9ZVF1.MV*34(ANRM@2K!&LCUN8" _Y%31I?Q%VW
M+1BA_E-BD/R.E6*U35H_4/__B^'&&="C#3,1TG5UL<;*:/,ECTI7,2/WB2XL
M&XU<XT5]=1 *8LUEH'Z(*\G*WH@OJ 9XJDC8OS<<*,3_Y_R7=S]M16)"GHJG
M3#I#'5"8&FGCG\/FC^=]@V,6+GNKK@KDG>@H$T>;VSD/.OU)1(G@Z.N,QAD8
M%&^'[V/W[PLV!2;]&_89-;7P9]$:1\**'$N.\E')TL9@PG^YUOS=KX]\Q/B"
M8% +\X__^I.:K@)]P\2Q0[GIT5C2S<67V8=M@]QJ!-\N'>&;"+_;N\?K!_)X
M1Q[_?DT^WMT^W'V^N9H]7E^13S>WL]N/-[//Y.$1WOAR??OX4!K0+1> 9S/#
M(.K*\H!;\.F0EN>HIN8HA/Z8T[7+VNB+:=>F%DZNQ8%'JD(\TZ".0RQW2>T7
M'#QB6B[5XH,(\\<'O5TJ[95A^V,.UPYY^/OL_OKBP^P!J/OCW9>OU[</L\>;
MNUMR!H3_>'/[[?JJ(3,AV>O&C\\\^\@UX20%;U8@&J3-)Y1YHFM_>X=32AXH
MS@W#](@U3A#ZH]\=3(?C2?>/7I=G.[!#S]QMW^YM2]@)YJ8$27X,!3,^H^.U
MN6-3:H@!Q9Q+C&&]^W5&'&^U$L/D8EI6AG-R9Y( O%QPJ N"R)R4\KK#:!3=
M":>CD"=J6"\_;U.GW]9TE/&HDNDH%8U V32'H=?/'\00^UV1US6M72:&7-N0
MA%2'E@H62B^W0W^P3%Z1:!K6"SJ&Q3S>F8W#*ITFNU';2@P8*/'<Z&W/ZJA?
M$9Z:@?!6X-;/L.4GS>HD^F0G/%/U;JAR\<H&?U[@I%=^QH6J"UK.Z;IUZ!.G
M&E15>@MD/=-!TH J(=7;I":HNAN;3NV1W(,R7R8.2+C)%D"R!=!AJ+\-526R
M!U!SN&7[Z"51I<8^O )]\Q-HFEFU2:UH!'39&=9,4*W-VRM'W4W(B6O%)H^C
MJS4P7ZFE]1_2/#R2>>A7@)RJHB>[6$@E[Y"TLJM^U^A.%FW2ZZ2VUIY-MH2-
ME/W%EMSQ@GD6V<9EA"4XR%<XOW(<;\7?:U0>1BJE]%UE&4H%T\1*1V4.XX%[
MB&5S?.?^./@!R^48$-1=,5\'T$0TW:9SU[(=\D)M2E94=3P;O@QZ'D:M" M8
M$<MD/\6(%BL"9DL2S\'^9OC!!]VT5KIJ$(Y@@LV6\+,OED8-N'7NDGUM81F&
M]<*;H@4D]O,.&53[YHR43R.K--_D<%DGHTE3LD[&@\U9)_V3SPRI*HNA@FAM
M^:WD;:A=R0KU1MG_255A)%]CZAQ_F;*>,[(!FH#@Z%;DG9)WJB%W*MELI$'H
MJ^K&'-S'R45S&WV<!^V$LP9%&33C9\L *\G0W=>2$>Y^&YQ9^T0L R=5Q)#T
MP?=[ +U[,":.$*5<>W$GUF7@Q+KH;_1B#2\[DQI:*;YO8)J+9 @%&,*][OS[
M8F%3"O8T_) Z+K&!I,D9EKZI)E#/N600Q1D$@O,30/-& +-M[ 'TB!K:-1^*
M.TBEXICM]2A9>8:KKPUZHAP#KLC3_L&Q;'V"0^Z+ -P!XV%)%E$T#-;O3 X?
M!DO?>';A2?SJ;> <2-A;[CT0^,: 4.&[F<<@HE>L^.W,ONF!'@_;!7"8&GG5
MJ:$5OG+\"%LO6119 E<;%RJQQ/[YV/MM4HJA4Q-#D=D&< ?M%3G335;SZYR,
M"EOQW(A-)BZ.A^@==SQ$KUOK<(A41+I(.Y1#= N:&W!\=I(E?OM'<,-X!D+
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MA'@96\10=T%,QKX3^*@P^*S%K8.%3^ G7OR$;QK);N"FX?+O,).]1K$QD+#
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MD2"J-C:T@;/:(ME+)Z!7JI-.Z<C'O_W/R>W@Q^>_=3N#5@#9K)FV]7*"2:C
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M0*<4+/:@UP07,;<=GGWMLNA)4_V517WGX9%XR!VW<V-QJKYN _24ZZ?'ZT2
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M[NW^Y(OMNAIU\!K9%O96$'#X<$P<:"G'5=N3K[[5W=U9>4YWV3I%R\*IDRE
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MFV/FN'"2U8!0,)9ON%-1 K^#V3R&LZ%B%7<#<--0VE47JO7)UMV<;.L_=%V
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M7> Q.,4T#?1?--W%GQA.N,8WVS?'V.]+MSSC9"S*H=O:Y_4';]$/KF'NNK4
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MHM'8(EQ<F-U9%[1(N;0EDKNH!$'>=B3VBP.1\6<#N45P0.'XED14ZE%2>7F
M@RN03 NR4 ^H?,$!T]''!9N*"^<H=E+UN?'6 K:UGD_@G=.$!P9?@RP_!Q28
MWV>RY"ZA2%(FYMRX+#<GRV-63ZC2\2@RV$5 VUJ>-'6K,B:7EL9=?3Q7%F?5
M%N?'R.)\ZG\1 >U'[6GX;W*M?='N>WUI? Z?M/N!UAO>/=PWQ/:L3W!EN=^(
MF?8K\9@O=ENP(G#7F=(_1#Q(2(6,=[%X%^/A+R@@$^Z$QL=\3U])6O^Y=^64
M-11(RDQN(RHDSSOE%9*=%<L8,[=]ZLX?N_,*M#KK@^YAOT&QR,C4>B5#ZT.5
MZIOP4T)%9#3$XJ1WC 9_]W,?O@:[>XM+(-\CHGO@A,YCTX$96OMZ^!-ZEM*=
M1:L?'1L+<PVFS"-.@-A@0R6#[PLD7 5UF8(U7K3/D88)HLIOBD$;X1UY3\D[
MEBM[=M?Z)X?MV[B;2NR=2UP/81O7W': JZ>4O!\$?T_LX .X]WI;B6%3V5F)
MX8&)X9!ZYHP\"B'462"N".WXGMUND2^^H<2QL6RMQ/' Q/$W3JUG+R!"+ T^
MXUG15$+9!#Y10GE,0IE"P^<UUET#LTQ'X1P3)O"O(/O2")92SJ=<=!3?LJ /
M(E37+(WIDA4(9, </Q')ZYS++-YGHHW'W.2)U%<8_AL#+8KN*JZ;6:]*)O\8
MZ"P;'1% ><.:E@M5T[)V3<MN:C1RUZ@\J'XH!3<KUM#\O)0WML$:N^>,?4CP
M%57OJ.*=>HIWCFEKK*-V9QLY_#WGT50.?_,D_7N)%_W:O_FPA)^;6#JU:D]>
M!(24H$8TQX%]-K[T6^== < %_/51HC]T$N=R34W$R558C+6P69;PW#9TR9Y
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MIW12Q12BK]QY?[#J0 -+7=8W8X>6>8ZKS3#.EE]4"9'(G>V=17X+S!G![("
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M7HZ"OR'+6<@<)@\X]':KGGKSO"WT3/2DDX.B-]9GM=7BX<&A?P-02P,$%
M  @ VCV<4C55--"Z @  (@H   \   !D,3 X,3%D97@X,2YH=&W-5EUOFS 4
M?:_4_V!1M=JD$<+43A$A2!!8@T831$B[/AIP$F]@(W!7=;]^-A]-0].ETE*M
M>2#X^MH^Y_A<8WT27GF&/G%,VS@^TD,W]!S#^2X/>JJNU"T>5II^H%LS^Q98
ME^.9-PM&TLW$#1W) ,='/&F,"$.%H=ON-9B'MYXSDNYQPM;:H'>!B01@BE=D
M)*5HR:1J+K]-RV"QPD1F--?Z.1N"IAU1QFA6AY:4,+G$OY&F;MI+F.'T00MQ
MADHP1?<@H!GD*YF>>SD=205>K?E2NF7H"\YIXEIN""IB"P/H"@\KOF"W"X?Z
M^8! XDJ9"HF'2P;H$O@%)C'.80KF=U&)$PP+S,?R'OWK;!H^"KC&#,EE#F.D
M$7I?P%PR7/G*M'1%I.VF\02B8-%1]QDGR3@C49D/Q31 >,"T/ >,'<^;^^;8
MG5Z.I+Y4M7W3MMOVC6N'DY&D]ONG$K!F@>T$5;S!4$=D[A//].>.UK[\5;"N
MNL\$%#ZK( 9&\V*W0"[44RZP$MJ;GNMF=$UU [E-W)[@?-#&^2.H.X.63@Y7
M2(X*!'_*F/#M0AK\17$"7DUG('1^ ==T=A.87/O-#H+M/0,[G1C1(D%%&U)[
M?9%9TI3#.NE7OR%(<)FG\$%C,$J1'*,T[8#:0Z#R[%.'MGY[*F"'3V.GUE0O
MYG4VM^6^GY9DO/KL4+=+=A_A717KI[SX:C)T6?^[)*9%3@O(,"5;BE36V;CT
M8/:IJJ&K(^?,$;[BN(!1>UQ8F.9K6&003"A9@6_BX>&,CTK^94<%DJYTCPN\
M64T=7I3%''@LZ1U:B@41 H,Y@TQ4T#N78V\VUTMF*%ZW SZ$&)(?F'P$8]K[
M]"8*^HCF*3H[4<^_#$L0H/PN2G$L/I?C-2;PW6NZL=C_ETC<YZIO?#6KPJ]K
M/-Y<WNJ#2Q&W/!ZL[H9_ %!+ P04    " #:/9Q2I3S;)>1Q  "V?   $0
M &<Q,#@Q,6<P,7-P,S@N:G!GW+ME5%Q-MRV\&W>"NT,@! ]NC00/@> 6"!""
M!7=M0G!W@KL%"^X2(+B[>R"X.W3??IYS[QGC&^>\[SGON??7M_M'C>J]NWK5
MJEISS5E5&S8/6P>>*<HJR (@^.<#_ / H #-&QG)U[0:9J86MG:?[<PMS9QH
M%6Q-.6BUN#FXN '8$A  H*&@H*(@HZ&BHF*@HV%@$^-@8V%A4Q 0/B.FI:2G
MHZ&DH69@>?62X3G7<VH:-C%V+CY^(6$A^I=@:7%!Z5>"0@(@= P,;$QL<AP<
M<@%&&D:!?_F"]8!R 0"$#/K[ O[W!4) 1$)&045#Q\ $ 8B@_W/]AYO/  00
M(B("$B(R,A(2_(X/_!Z A(>,3\<MB4+PSAB5WH&0YTML#AJ#5-5/(K6)4\97
M)H[^Z!C$)*1DY$S/F5E>L/+R\0L("@E+OY:1E9-74%37T-32UM'5,_UH]LG<
MPM+*R=G%U<W=P_-K0&!0<$AH6%Q\0F)2\K>4U-R\_(+"HN*2[]4UM77U#8U-
MS5W=/;]Z^_H'!B>GIF=FY^87%C<VM[9_[^S^V=L_.[^XO+J^N;V[QX.;C("$
MA(B$^I?)( 2WO_J#AX1,QXV"+_D.U=B!@)[G"QJA5&Q.U4]TAE=JIT0FCA,8
MQ(R\&TQG?UG]M]'_/9O]_T=&_[O-_VXRK!/ 0P-5@:P007#K\4"(>"#8(H"%
M"()7$/$ ,'!S#[  V0A^&'\5* /T,A0*#$BOD5.^K0/"\1*4O8%GF-VK=#,D
M;ZLS73(U.5&S;,_8NZ+*R8POL)PNLW'BC[AL7"^VELBZ,[HQ?' + $PG1'QB
M]U&0:1 EX) UZ4=PY+H,R9<9Y;Z(<IJZR$;-KQIH&8HULEQ<>FOO@PTXS,$
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MF\ B!I>>,.!Y7XG!;>HF0?@8]OZIZ6T<8SID6\#T7O-)CW.C!"X#1NB,^I/
MQ'_&H-6;^D;W#_5):S0WBV') 67UVI>64.5@'O:?E18W[/5K6M4)]TQ= N=\
MZ<6:46?6VWW.1DA<R/(,TUHB6'K_'QG[TL#R6EOW02:? #(GWPT13B9MF^#
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M8'X__UMR^]!6K!B!Z4PVA<O8AC&N(>%CQ-W;$F96K@I9]*'B3C&5JFR,>JC
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MJ@OW#+O*(WKP9=[-JE%(A\/N+6:+&N*3<@D,J"\#7^MQZE<_K-TA%[M!'&$
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MMG76)=X/N(DD,&"KUC#+_"]4Q.RN^0O_T$SG@I7*Q3J.5OJ@HQ9MXF-_G=V
M_QX&&-$50?'QQO?*;^7!O=$K'L''C[TIHO+"^I;PI&.S3?- 5V3U?FT#:EHG
M?FC<>"9U.<5;" ?U.U3H1)&5V-IRQS"[4@L\<85>G^!7KHZ7J3RDAH)'Z>38
M:78@;H]XYU-PS(;\Q#UB]_8YP:6# 8YW*A?OY)@X=QX1D[(N?$%/E>6<JZ?#
MNT]#Q2H7QG(U18\PX"N./$1@?=B.V#U8N^&T(K>[:RZ/JYK8TMA,U9U-2L@6
M-*9R5EZL]K6X[>HO("P@MW<A:>T@R#X=V;Z!DD]55-B03^K2J8TW:![=7SU:
M9]9J6/%F#%O]DK5A=M*J?O4?#X=&U13*E?U)OC>HYG58E3A]5:2)E?_1UQD4
MO@%![MXH'3C^M;;(G$D;]1K]&;,3-[/%;E(G%2& #+C\)?N(L_#EML1LDF;H
M>/3U:H2_I$29442)K"/OIK,<A0$K__*!2,Z>>#G<H#K^Q!E0?:PD,QF3/.(9
M7SGABOQ24P&31REQ[8!IFE)='#-.$%/WBWY1C1&^YRD\6O%OZE3E_Q$;(TU2
M$+[MT^$9KHBTMC)135/D,"-E!G,OD^Y&99M&Q& W_RL&_O,"BX;8VLE"SYG@
M)WOM<P4RK ;:;^-H^;X2#"42;9#P#D4@L%7:C6DL.+),J]P:\B+H, 7=/6O
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MFZRY/LP)CTFT![LVD=4A2]-$/" ,4'J)*<8SP<[&;EQ7_^8HC!"M-#[>3_!
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M('@"I4\IQJ%]\S9G#M!&#Z6'L9M&>/>0;81_S=?H=O;T;<>9HKYX6LUR6RH
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MG$.\]1'!#.\2<A<4FVS4?787XH.3R2!W'?)W-7#>Q&(]_!?^/PP>L@BE*#)
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M*^5T%O7TS'P0Y(Z6BG@ZY@[W.#J[CMPE_O36F@(E"TP-@6[-[^M:0I'P=!(
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M@\JP,R%LZD;,_XNT^D\8$&GROP%02P,$%     @ VCV<4GL82_J"H0  8KL
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M-/;$=\HB<-[_C(F_4OR+HE.3;E=MA%J6/.(E'%=N$5%8C:^"<D0]"/^CT>1
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M_E0T'I1EL6E6LQ"\F2^45:F*6PKBQ/M'^I3.9<F.'J?I\&$8X-'\G.%@N6Q
M\;R%QUA9A/]_R<%?3:5(^OIAC@RT_KFU:#&[AEH#07+10R]BF *ZI8R969&;
MS0W#S7+,V*N8KP4[1_<>"5\YV,\&YCJ]8]*]"#/\;\6B&"Q./E38(.;NC%ZX
MD/;@0E-21<.Z955PXT*34.=9]-V"W$RAX2)2,_K\7SCXB0!T_'NAY3?Q@Y<I
MF0SXEH?;2C5=S)LHQ\5,-9>C,8W(Q,=_"T:F. BB">W93_?TB#F/+_W? _.T
M1-*E\A?LT_;]-Y6WE#O?$!U*DOOT?S6R?W76)WC21I NRW*=2Z]3X+)J<LL<
M]JV;$J;_O<.*+;L<;) 64+8P?HBV,S/_?G?-Y@("E.VLWH<'UKURE#?A+<<5
MLYGX-MA%'FS=CBFAS2@Y9L=G4W0<D?P_Y'O=BS03 ;"HP+:V=Z;4=W]5((0Q
MPV^#%C'&5%M @9Z<4#C)N/Q-_FLI)ZO99P,%#)\X\JR;@.(T["E#;:J^_Q[E
M5CIN( 6G-_RI=EK!4?3L/]I*)0Z93_H,/,924K(K X0))Q]_&BZB7G;^3X5T
M1K;WESE:"@D-]6N:G%_T[%KOC[1J))]=^SJEGC$@ /T] A^@SKL9ZAXQ/D=\
M","?>GX.?WC^S4+C\8D9Q]J]>VEKFY*LD5FB?EP));?"_DL^9@S/ZV&3>N9G
M8X//BE'TXL(DUNUX8(W*0/P&O:Z?=850S3U\BGEOM[PQI0'HV/&$#6.UV])@
M#+$[J9-]+R&J&^PI6.Y*5TI8?^3=M]*P1;>B;V-L]G@L&IHBISBO/]=LA(S2
M]";, GVK16>'N+>OW9?TGRWK3FRJRG.A^]$]LL-0M)500G+J3Q9!A7,^O![F
MO5BL&QI8],QRIP4=]F32B2X\73[=23BZ5^>4U^VF]6DX#UCI^!\F03/7BW7,
M6<Q389AI>'=V82E:70# '^)Y;U_G--4O]1!C& '8JD-V9[Y [E!!E0;UT*_1
M9BPQ4:*9K:!#[LW4DS-.>""8OZ+A.0) SY&' !@Z(&\VS7VA;"(9(==.1J)D
M)[W+HS_<] 'XPG[X?"YO6YR@5)ZG1=@@W/$-0]-4LV9-]%LV.I6:5TFO70J;
M D<%A TJ%\&T^VW.UB@O(^T/63$6PJN?:R6DMLZX>$L8#ZYY"[?SO@CKM[:[
M$Z[2N#D,P;>2K,_=5#7'>#%LK8']4;P?\%:XRN6,ZFW-#$M#6=W<=2]4)7DD
M96Y9ZZ!M[2-D 8AOJ3/J[VW+D(_C G!_=X*YT>9@0'7 D;G07>TME([AG0NW
MDCCOLY6M+03[D#4,&?N_VH^T.'LE.>7K8&@K>A"V%+0Z4"5=%+)#NUC'K*J7
M5&88NVZDXH, \&IO&S >2$*!814WN#Y]I^37'YP/);>CHOH6= QHZP_8&W<.
M*L:N!7#SC:$-W]W3C-+/2IZ,>.G4Q09OGPP8#P3;DQV^BF<OGZ.&1Q= ED!W
M-S4=]6?.J4UJXW;=<1<ZQ1M9$S=W'*X:^:8<TS45$V>W5IV_$0DWI.)5'&7.
M;E3%JDQ_6_*HQ8MT4]Y*<(J: K6"\*9>64-'7X=)>#,VF"@EYZ F',G-$;+W
M!;(=FUM3H((=AK*:7RTQS*.$S=8619\'4&[J:.0Y0WGKHK^8"IEI^UUL^6%(
M"O+.W)VIM[5G&2C3G(395?%O+>6)*JYP3GS[J89C9S)3EL>?GCU^?M:JW-B6
MG)+W6,+,T24^5$&(9@0FT'HWS/\F_I0' 0 V67*N0N[O3'&%&YP(7+,)0D?Y
M9$IXI8N/9Z0L(GLU5Z3).JP@L@;-.>J#<Y\]S9V\;;3//]!D<B0:.>:.:W4^
M>9NC]O4SV2H"8%PL"-(YFMP4E5A<YY.GHP;*#=(-'J\O'^'(7G4+C-9Z;*63
MDFD74(UD05FSB91?6AH3Y9V-;3(SJ^Z5#"MA6O]IH#6M#T01@-8S!03@JY=A
M5TU(N$XWWC4#6/<\1$<O516F8%%+4V'L,9HMN?:![76]]S-/*+>4A>7A>X;Y
M:@F#3P4;H]4T9 VZTD49GZS3CZ()+61J6JAH)''= R,*J%G _BL7I=-/^^O,
MJ&B0M,,ML0RG_FGM_5#NB]:J"@:U9IJH2[''%RBS/H^;6HB1:6B!(<8,Y9:)
M;D>VRE72BT+9M.4DUTO-ETN4;M#2D<*%2ETMJP3*N&?MJBX'@1TEW"KXU0\G
M9_/MP*:*!/K3%K$Q8QQ#BDZ=WUS??/XHJ/<V*:^G4V0;/X^8I-!H0"9B2U*J
MR.:UQ32DH]8( =!'.L0))'&+L1" ]PZPU M;3GBW=CQ-)==XG@T[AP)7E&^_
M69"-5!$Y3>6+! K&U-.46B/CW1],R<JU.RD0V1-#W(EQ13":BTO5P*LQ5Q:U
MG)^G/X+* GL=N^#D)72E#9[85YX='X]H(XSUSFA7*TP.Q-/JXNI+:R.'7[)%
M3J717NCV:IE1K<U^+5)0'>#Q4*?'U38_UUC4HEBD[%!8E'TF8".Z+UXYC0"8
M0 -3H>9-)BA[1<B#[;YBU,]2KGE3']I28L?:,1[HL(;>V2EVI*MC^*F$=S78
M*UQ8MXU%5[*G59[VAZWJ2UG'R&GFX1"#=BY*&<S2-J+XLTSZT>HGO,=[%VA;
MH)-FT U%=**.CCUP0K@/=/CKU_B(+95J$['/%<9+Y(*7@\8> Q%;:M*+/9%3
MB>*UJXUT+2T)0H03?10P>YI4JX%I+B;"CE8_"4$8"]>& 3AB2U< SE#7X$<V
MD$"E*V4KCD5GR!;Y(5M2\+J I?1+84:/11=7O9GN8C+-[I5*E()<L @E6*78
M>N2>/RM=K(W8IIA 2^D&#5G="$>1^) W56DGMJA)II;_.^\P]_G38E*EIMH1
M6XI=N*.]W3Q&Q/=.P&N?:+Z8 D?CT#M]3!.,)CS/*#_<<\"LE"I+\ OM.HUP
ML&EO"LU)A!.06RG&Q%1EW:0\'K/,:.JY.-*;T1NI9!JI!!=< #22NZTQ=\-:
M]HGEZ$>KWKN_C?@RLSR1DP;I\.B#UVG8;_I4IB\<@JH++Q" F.@DZ<ZU1J"Y
M>(>J?UT(ZU<:WU >^E$D<S*DC).,4X0=!^MML<TGK4[K].I":""3NUGWY8#1
MQ)ZO3WKL+F@J2ZP7*1/EZ5@?WPW3,N-NXXZ([FC!P9\MSR.7T7GT93FJ7B04
M+!,Y)UW^=6BMPH^US6O:W<WB#1HQ6AB\\;Q0C$EZJ,CFT1#'JI^WPGS^),^S
M0<EO68=<>I6]F:[N%K9@1[O!'[:IC)1DKT[:Q&%:WX;H(D58,^_)= /RW4_(
MJ8#V2GGRDF/LP\'1VTZSK+4IU*2*?H([:4$K6#5:=-C?I'MYCHOY*YSE]3:5
M)IZ7&[M\OK#$-B[ME0,6F2Y[C'Y9ZJ;D$8Y<C6[;%:^$ED Z3&TSD()'5^[
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MVW?TV)<I,$8LFZ$G!P/SLK86AS2LKS^F<)=5LY4<2I4_7V+'3Y=$3AHN'&K
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M74_'6R* /LDUN=MPV@V/]_"7J?X-%RXQX\'D@M2*,\7\0-+Q-N9::]#/6H>
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M=_YC^/[UYFET7EO.=,<A4R)1*2\W2]7HY.R'TD*C3^V&NC?M7#!-6\T<Y&!
M/\0!?[C!S^,N8/! *^N[X!L@_;!70Y#] 3R.]\#'BS+X&5PKT<I3SL/,VF[L
M&W-UE%Q"<]?8]A:=9*!\%[G?FDA5+M5:-531;(D2K(OMB3$TL),FW7$!=Z3[
MMCBQX=_1+G)2)/;MT553/1RE>G33</$:25_%?Z+ \!\1]2!;]!M;\507LZG3
M5/KN#W;3;9UOZ@6_HY"%>:/;7PU=M1SE)GOI5"9"Z(666-NGRY#=%VE+L4%/
M$8!T#5 7"/ZHK@D5[%)WM:D9XT+716L4WD6VB;+V3@PBNX^[<;-P,5;J14&[
MH9."!6I2O,&H;-%H[77)\_2@%J12MZQT-ZNLIQZ-LD6UZ.C!,8[UBO2_6BWQ
MCIF#N[U$ENY>9M;T]P0'5D6RUWN?]2!>(W.54Y"^5L.S\1)9S7HQM\GFF[]O
M%>^V10!$D<WP&SK3Y$[3VB*2E<JG];87Y\'P*Z)*&K__TULM*;!/=2$7"Z0W
M^X^OV)NN]X/AYT2IX"H$(/5CTUZIU-\K<LTY)ZP1@+7WAF??,[>1UX^:.:_F
M5;R+I^ ^MYNW ?]>))F>UF12C0"DX$/F[H2732$ ?5A->[XR?S_T]R**P#].
MVEDQ<IS8\_;H51C@406YJ_GPPY,?>T%#D;M ]H;ZCZ[S.S_]R8M9IEJJ1_MP
MUM1+(S6. EK=[X'<4T)'2F%*K-(O>2_B":WYC%VP+HWS=RAUA-.ZHUF>W7@_
MYK8 $W3UF=+;UBT7X_6//?!BY!R_CMNSR@"9!''3QZ+,4#*).HG7@&1+@8&?
MS&ED"O=I--UFYP718U&!CZF] 06G]O"W0BOCFS8<Q^/660F"Z;6''3B?T4S)
MKRU-X7TN;D^KCOR,88>[J#31;9P!)G*/?#F<3M@MB)@(7I-H=HJ)L3CU[\:V
M/ICK=#0J8TYYMB&.S:R'4H%C[!'I*%4>+H,I6D^6@K8_&YR_,?G^;-*ZL;7
MFR70>1GGN+@ _B <!])/, 2_X O=GS57E1Y^+D<1!6&F3+I_,G&3/0?W>8@
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M'W:#P@[:2Q@>VRV:>M9PQ^W38=]!4.(./U(8#O!NKHE&9)/JRTRP'*U"#/_
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M,=AR]E1*[:,#';+Z1*_EN&#D9YUK"6Q-21P(P)?AOD"%>,]<7+%7) Z\#OA
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M,8;&.^4YM-8DPLHT\8V/5<;9:3-D^GF(S#(.)#=?MN>+]=[J1.- @)$OR^!
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M3D5?P>1YD@X9V>A.8YM?\)]2['LNHW+GJ.SNT%4)T2+3_X6/![.':_@,O 7
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M543L5!989+DTSSM##UCT0 NP9^!8QG2"0WFJ;!PU)%=<1EO1R@A@984R/KP
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M$VR*?3EPI/!80DL-O.CH3BR?B4I>+-3:Y''2#S:X-=,N.8SL,1:I9"("KPS
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M]TR=2^#Q.RBMVL%<'*B+?0('.@5&GX\#^O?>#+:*Q/I9;3^,K>KJ9H6V(1%
M5CT/K"^^ *OJT.,?$+?3VJI(\9A28X%]"2S^]JAPH"%5@D]_XXX1H(U[.;##
MBSC0TFV"3QQJ 2+13_#85  H[),F$GL6MG/-^]@'\BS%R#9[L9?AV<H2EI5+
M%-YMJ_^U5\5..7%9_*\'\[>IOD>Z,Y=J&KZ4$G[,\UY&="8INC'/SJX6RA.E
M_8[%CT=8+.PCJ;*P>(C(P4!\<!6SK"@")2A)8!'"3XWPQL8Q[;9>7;D*:_<;
M[>@2)OJFD/W5@ +* &[S<C_YWM8@P_8KN5=.,FL8' [3-_?NJ"UCO'_MA*U
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MOXU9+?2U_5[.+QLHUF6?"4*\8N[?H5&IT%:L[&^,MJ14+..8RB<;64\$C^;
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M\BOZYKZ6$B:NEG!#;J7"R*_0:(-C?E O5I>](5V6V63BHNW]V5F)TGYDJ17
M9.<"@2XU'=WG/_Y6M<P(;8# @#4#IAC/W ^-]RC >[&2P_B%"B/WX07 WE:J
M"C$NM$>8A,2<9 0T7HB_(KS3#B#[9=@/'?PVSK^J3_^C%5E>?-'I'[V110G
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M-;^_DS<V-0/6WCZ]V:L3F$#2M;LTRP_ !R1B1],#TY]X&>1QOC.Q]C&BIG:
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MM;4?PHDJ:?EX4@_? P^ERNX69*;%[M^,Y*D,PX3P[&+^V:.]P/T[:R#1Z^2
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MW3I47)N)$)_FG5&ZM436S9Z;$$2UZ^CJ(8X-AH8Q\/1?$VHAKTF$ ""KMW#
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M&5E3SQ6SD=.Y4_ 2*6KYH9TO_P=02P,$%     @ VCV<4BG S<Z?)@  B2D
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M[)D</FQ,&;K/Y;5$@Y?42WT$$M8YG%:4ZQU*6%TY7W[I2I4?CM?$I)H#QFL
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M+&"R+Q85=[T.WI"[)%0O^W3DMFM9NY['L_27R0$";)/B&T$=DX??&Z-^(&9
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M0!<R0&OL/U57_Y\ ?)S_'U!+ P04    " #:/9Q2E&%.*ZU,  !95   &
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M7-XN^W6:KE[P5@.MYO58D[ VW510RQ0TN:#6S3(3KH2"#Q54%GM]<(LG>Z2
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M%]8?+ZR8SU7Z1\W%OL\&4\V.\:Q#1]\Y/(P=2/;V6'=![ H$*NSJ)1IX1&R
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MQE[ KF I/O^Q*X!^91EAD@J1]PS]EUH#Z#]J#1XYA(..E9I 2 !%=K*+_#C
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MA:H2?'AK-9^HQ!U/4ZS31_(R#C$3$6V+;*Y?:.OWWL!X3(M6B$B<"V5[DGW
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M$<H$:AT&BA( C04%@P7UW@<@!P"@X*#^50#_6:"@86#AX!$0D9!1_E:HQP1
M0\' 0,/"P,'!POY]ZO7W.0 6"P[[(ZLH/(ZR(0*E'2Z;7VP.(I58=3>>RO0%
M-?MW>W\D9/P/!(1$-)]HZ>@9.#BYN'EX^<2_2$A*2<O(JJJI:VAJ:>L8&?\P
M,34SMW!P=')V<75S#_@5&!0<$AH6%Y^0F)2<DIJ6FY=?4%A47%):4UM7W]#8
MU-S2T]O7/S X-#PR,SOW9WYA<0FRN;6]L[NW?W!X='EU?7-[=__P^/0/+R@
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M-UG8(L(R0;\0$X94T%17PX&AL ?P]^(MIUWN[(%<:1IOZBT:ZLA\I8\#Z@X
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M:<'.5"N] *ANTUL5C/G,<N1:W7'!D=<45G/D[$<HE#,IAYN*)SQC?PZC)'5
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M2;]'I(W.BKMU;=QQ#K4[2"_T[F*W:-J2="5J?&4-HK#[KRE 9<90@8,(G?4
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M<;"HD1<,6'3]." 3$W6J#YNX:) 3D.G&.9.#>5"\QN!<J DD&T\E64RR,J]
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M5TN1T@1[(4%;9,?$I4)ENS.=@Y@P'759FI/.^/WX7=2 \LH@&>,)3]?.'?"
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M45*3E "X</Q_+(7]_QM^;XO_#U!+ P04    " #:/9Q20"NGO$8Z  "G/0
M&    &<Q,#@Q,6<P-#(Q,#4U.3(W-#DR+FIP9YVZ!5B=O=8F_%#<I;AKH46*
MP\:E>'%W*.[N3HL6*5[<BKO;QMW=W=W=A_?,]\UYSUQSYC_S9U_KNI*]\B2Y
M(RMWDO4Z][H&H$F*2H@"$! 0@-[;#WA=!(0!.!@86!AH.%A86'AX. 0D3&0D
M1$0D/(SWJ)A$^"3$1/B$A*24#-2DY'04A(0T'!_I&)E865E)J$&\G,P\#"RL
MS'\5 @$/#X^$B(2+C(S+3$9(QOS_'%[; '0X8!K"$Q*"''B'#@&)#O':!9
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MKXYFXG<KIA!56[[?(P[MN:F*LDBA-L?"G .H(&_]41FW/1\*+=,SMNU"UIO
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M/NCJRUHU,>8X=6,2A;$XC/'SEV+;T-P"I'E#,.+4D?IV;*CH*U)8-6EY!:^
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M;%3]2I"4]H/?H]DCS$NF@T)*9CQB6U*>ND/=DGV%)K9H$&=M8F$S1YL9V:W
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MDL=T%RP8[)47$OWK<]YL<&>EP7C)1XCQU\[_N)4;<MU/JC IW<</ANE5KFB
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MSFHE!.H89,5Q/FST( A.9" GZ@^[$*OONRT)YWM95:R,N)A.S/AEA/>K=/V
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M0"%0,T.E<2'D"HS+0J.5K/Q!I#YZ3,?]SC4('8.8A)2,_"4] R,3,P\O'[^
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M2=]5&"L<2#T6-/FGJ9W_<U63]P9$B^U9<<%+>8VOLDAJK)7BJ5MQM.J2AYZ
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M:9FM/G1_JJ*T4O7B M);'$%T67@H9XC70TKV6Z_]N(PWO*1.PL-^.X;6G.)
M/<:YJ^K<+"(,=;S6-YJ(]NG$7]CDG^&V) @'XD1O'Q#@0%:IPQRH)XT*-@2"
MOO->?WAS>W2%^A!:6V\+!RB=0=.\#UK5#Q@P4#RW2=?'2!C]8\@C$/\W^1F1
MI:O]E'7/!'8(!_I+=]M/,6O@0!D3',@$%ZZ97!-[<-Q<@C:USY>OD>= TX1P
M8$3:[C%3M()Z8^I/V=2DB>+,I E5$?X-4$768ZX)CMI7J&[(IQ;S[WQ^P '#
MZ6MM!HC8ADH;' @ [=@;>&:<;*/>NYEL&HBME.M<T_+>R>ZTJ]LQ9E?R_*GJ
M_@N8,2,#B0GQ&FXNBE@OE0>UWZ%XKQ/AIT2X!%N5$L7SDK%N1#OVVBRLR GY
MV\O8)I)>4KJ-^(Z2%;['#XZ KOUP7R)M(P:7;7&1R>VUGAQ!0!BUV9AQV7J1
MW5H9_4;].?D4.&6<;Q/M(YZA4\_'')ZHI?Y.Y3UCY^O#%8;N,7^E9Z:(]FCM
M*I ?2"8_UR#6G<-[96I.ZRPZJ6S?YWT*];E38J"#_I"N?W=/E'1Q6^ ZUD7.
M.5&XH?V)H,<%8X# 46;'5L9.N=<U&%(2#V8LIO[K8 4&MEM<X "-_^4=(AR0
MTI]_O)D8 ;'?*7" 67% @./ >&Z+DXXCNM]O9>-C]C<M-##X5=$K9)NMUI28
MU'MTM<M48C!C23\&$WHW]W"DYS(G]VY39.!++CUU0@Y:9+6%"2]^&C2L+')Q
M(0;ZQG3U$]YP+?,675K:P)A4,87^/"U$!?>%>VR3 Q>1/;JWQ(2"GB*W[VJ[
MG?$7]+SMY>MLY@R^1>W;RBW6MZTA&XVT:-ZT<#=+O,)KT'3.14=Y'7B@IU'(
MKL-0F"?';DE:_#R=C"B4\F;G $P?K7+2N*NS?WYB-S\X)K?AEM"SJ=_AFJ1(
MUH_!XGI J*:?G.SVZF'$= /G<+O]24;:1-(%S0&7@(ONL)M(@D,B$[\Y<M &
M?ZNKEB-^\\Q>[N?)Q-7R!B/FE:^C&_ZNG#H;5J<E7?E4S:IN>[)B!431SUNG
M6OW(A=6ES9^%03=(N?!Z546XAU>-I">+%CHK5BA,-<?4DWBFU8MJ*76Y:J7<
M8NB"$%"G"GK';0_J-%T)[TI09$28H4-#6R7+[RHA2F,?RCD-6>U\,]P@4/SB
ML;D+=IZCTO-#HS%KMU5[/KK5ZB!_P6[;HA#2)_F0#L::G?UU4KD1Y@>M&*8D
ME7?QB7@0M1B!BU)R]U7"&UJ>2?F^LI*1V#5ZT4F=3LB'106\AS*A*,;SWJWJ
M(][>*9'*8-;H#FG2 <'STFA$E<1.)3@@1[TPN&5;>;^U317"[/2UR&5'2[I/
MJ="#UR8;?" 05+A@U^2?M^"91%(A[<+.]^84&$H(#(050[=OVJ %H(ZI^LG$
M_BT#XJH@ CJUG )+:!]V<RQ@ZLJ(.,)83M"L0FQ;43 !JA5.35>>$WH#<5KR
M3\Y-?94 !T0XZQG&$6N-8U1.BN" :6%]&PY292/TV\(;F<UJBK1UFN>-(G
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MH:N?I?XIH5W0[+H5U X;&1M(2'1<GE;/VQ_'S,-^4N.XS=YPO[RZH''@Z.B
M&><<Q-F_ZA*XS!LF,%43.3;6-:UZ>)U ^MY/1X-"WW\,B4;+5M3PJ2Q/'KKQ
M-#-7='G_4#3QP]R!WA3,.JX"1T2DV*JEZ;;3S:8IUPM/_F7#<E?<*40$)\_#
MUS/?\PC/RAQEG_.G=UG#I-J'J TH">-9SK?'Q).YA2$595D9^%M1BQ<=PR!
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M^I2S=9]$X2^?_N(Q9.:H4Z0J)@<F_T,L/,F[_Z1S$?^#7F=0,F3Z"&'?/L.
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ME!W-!D $GZ"R0/)#U3(T5!_7XYRGBZD9[&PTQ;NG,VC0)6^^R9* K5G?,QO
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MV8)OW*#V9KG/LQX9DW]F$"M(V)G_;M&7/+"-PL[9M@FY-CB7TB'7,^7R1HJ
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M@@(J4P 854P&L'S-#<90HC"C>LW<SXVCZ"B(=*>I4]LFCDXL7U8^,;W-W8]
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M6)"2);I%<AVG^$#9D9RFY_C#7!\/U#TUG5-T:?N].7?7FHC_:IZQ127?/'_
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MVUZO'M^:A7#9INY/@\\U;0AL^->CS#(^')@30O2CTV*);&9/%!II-DO+T@H
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MB\4*\/)BV I0_Q44E[1%(;;4W5V%**QENS'B2$4@*=!'Z4N]$#[IN]LN0M_
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M[P#$[4244B;C-B3U7<L"P,?( 3A8R/A_/$;_&T9W^7K?.W5)&J>642K)$6&
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MUH;HL$5^7F;^*$.E=XKVL@B&8<@HL!=O0,M^V\[N/=^D /B<1BL5V:<PO_(
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M.1T]C8;FZ-"57?V7@QNR.#.U,8/?/W*Q5[O<G8NE;0;ULQH9P6*5.A0++R_
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M+5+9$%O;&^>7-RID7$RQZY\CD!)(+1^QR[&;J5E][$  _@<+X[C?ZD$J,"D
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MWP_5I:Y;E;!NT;SUKCU%:/#Q@$RQ+@#?C;32S)_@#U[)$;JLQ4N7+P_@
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MP6I^55]_HQG\/E2$1Z591*#)X#>O;I*Q1LQ#]GGT!Y\]SHZ0+U0R)RSIDF>
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M9\-'?<,^I>>:[!$.X$ %KG=J=3M*;GGV/UD6U+DN(!26NW3S/Y(.ZG33)P4
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M1]Q3)[%^!RN>Q<$R"*Z=X7]2(DQO]4(@@#BS\4M.-)=F1.2D_FC;L,"'/3W
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MS8C8?JSA=K%ZMSN]JSOON&+V:7VKSGH22B>QXX+OD/SZE/RZK+FW#@+$=JA
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M"9B%L0V:WXN+T7'/F\BAT>QZQ(G6P,'E+]HFS]3B#\JAR52@ 7 U\.4B_<%
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MGC#BR,Z=X-IY?U7=A%1%;<S]>+(AFU>>ISSG?LEI0[^3D<=R&PG6U'"\'A$
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M3W;E!XZPD1;9;7V:,B 8 SF")I9#(JQ:#T//CU-A3]=Y"CT^AZU=;+!\*O$
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M4U5C>T?UUN_VJ197\L0D[X&=<8W4Y4=[XGO]Y_!PW ,"IBM(VFO<.>AX[5G
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MYX$&ER ]H:3<+3UY&%ZZY3'3PQ73[@HG/ORT6WHLYK/FQ*<,%K;^9OTCQ.L
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MA2;D#EBN-]1%;VN3&<>+ F) \RV;ZC]?; )Q2S\E MU/_2]02P,$%     @
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M2[*%=D>FTFXTO12^OOJF7&:)CU74((A<-)/XW4;3"_L$&L0O!S^):P_<-D;
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MO=0#];66/YWO9/;L6SZB ,9G'Z5VFZ1NGCJD3[@/E!$Z/"W<SDL5O/9XE%X
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M3ZKY*ND/8>*@G8(#9%+Z]V$?)Q0 6T#*:[=+;$M:7]TMK;N5TH(H+O)RM9-
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M&AH:>CIZ" ,#1%J05U#Z/S;B!X"9&N@"YLA!YP$R9A Y,XC8!4 ! $0)^M.
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M$LO?G!E!/W$:<Q3CESK)<(N$W)8:;_DUX=C!TWOZ$[*@B6%=-L#D/P,HN[)
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MP-=4]MK3OG6LNVZC^>+=(DNN'L1N\6<1[$7)NO[E@8;4C LADSC?W-,PZ$/
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M'\WW+??I\WK-$=;-CE'%#V(YL2XUXJJ]RVFZ=B=\26^.TJ /S;?%-]S*;.R
M'H\P87]J=>>C%^S\7UF/:($->,4<U;KD[DT4*M IEOUTL/6=JRKA-D&N6).2
MS>0?<#Q,7+[R@DQ+' L^J%WP5,?E'X_7.[MOV[!C@W5\85H/JJ^VHW2%FM0S
M\L"NUU\7WMR,0["QPUO9HK3(ZMS3GCWESX8$QB1;U3#CRV")A>LC6^5UH(^#
MBS<?'0DFPYZN9M;*9$3W5G%AIGG0AV/^6ZG[YG6)]*\ZVOUV'DZ=M!.&=XB
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M_=C=7<R5F]IIQXM%>Q6N:!S2XT&F!NU*>B5]B]V1%U$+O*#>WVXHT6DZ3OA
M7KV.0*!M1CFXFUTG:,IFU49?HWF:*2%PKJ"'[1\IJ!:.EUY>2%W2N70I.RM3
M-5=:6X,RL<FSD)PZZ!P#$&AN*5=TH51NK[5[.&F4*\FQW?@.Q%R<<5N*IXUV
MW17X2SD ]-<BT[\+XM1_ 5!+ P04    " #:/9Q2A'-BTDP]   100  &
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MK?,)OT3QUP*Q&Y4$AL19+=S]VH?O>3[D0#(6?_&)TA77&)/0-P+15!MT<*%
MA\6NC^,WIRR)B,XC-L%M)FC).;<CO+UPU2N^$],I,&&^"&/"ZNHHEI,8*\4*
M[.17S5:%]PD(?'W# KJ3:Z?LB_,DJ/[>V8AQLQ)#]W76B?N1[H#^%X.)C];N
MP7N5)!T[%&^!$_SE89:D/ 7XT)RPE6KY)!#&!*9PC<%[U=]M^JUW29+2Q>L
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MZN58=9$C[0Y^9HCBL=\YL#)V<?6FJATV1[!K#(VD[>Y%2SYG4OV3[*K]##
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M)Y?[682>#+@*>(<")Z8C\]D/7SRQ<(0_[YMC"'B@Z^B@+I8=-&E.J])?5WC
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M^M"'UL'?%%E$:8F(=M+)R'^AE4_@A@RE_70%CBSE?UYT!%-4W<*X'49>+U/
M-J6C-D^'3QTR%.I,=..NSX?X:!"8\&B8:*N%[#)'"D8_YH31):ZC);-.=5[3
M/7C.(BO+B O#4>2C97Y,A _UE^UKRRA&!:EO%X,>19VM&[HR/VGY<ZR0Z>C4
MQT_]Z)FXGNN/$^*4,<D7O\X49'\1A]R_SA8>)N#17K?)OAYQ >!+WA$MT*_F
M,U'%*VHD7KYB'B="KR"NGM]M;>AEK^SPRDJ8XBTLZSD3;PU#J01U6_=Z(C =
MNMV-Q@ '5'?X1)H?!2IV=+ .KN*FG MYOA>L&B%9$I[AT E^*\T0Q!$_(&!^
M47:975\59GA?F6RR7,TU90I1_$13BG;0T,X3=[%;87*3F"4:L<W6"\K/OQW^
M=44AU3&\W\9:726(?%75)".0/Z-R\,:>!ZME.[P3%I52V,: (M#" "\@,NWB
MQGQI$2^;EHDDV'OQHAJ+O[/A9M>,%6U&SDQEN5S_FB?)X5S9A%T*KNWGVZ83
M?QXD/S\PZZFX%),M6-Q=9L-KW)# MC^YXESB=<YI 06^Q;:IIO8X&%S@57&]
M=?-Z62-#,N)]WJ32 -.26A,W221I<57G 1=_D'Q^L0\;'@="?= I-];@X=9;
M-L<2_1A1/9HEBG6%CT[1(4/O.!SC/WG%?-[]KBX1M6TXI$'X.%;,K12O[H,M
M*Y_\V<H\?+%;:%UMP)F53ZV@Q\C%<8DIOLTT=;A0%M"J4!:G213)HK'A;DEB
MC=*[]Y?1V1F!S&<JX/U^B-@?"?_,3,MVRUK$IYV0NP^RR'(G1?(VN02ZN+SQ
M@X0?56:_FNYH5;77E*)95!R('=SHW",^CEN8WX\:3480#>0ZF$A&#NN^L!A;
MN1,&\V@;J+1-)ZUY/TC7[QBZM:C'_=FXJ.C"]V>7[')5!F"<5V)E-7 W4N*<
MQ&%,GP^+90$K1G%%H?[):!G*1R^U$+!#L)F/D3*C4*L+%UE0?IFTWYS-[5+7
M=<-H#7PSNU"T#P]"?L+\-LH"[7[GO_=+BAXG-HZ+"TJ/1!1[R!&ZU\P%7?E^
M+XB^&QJGH)Z8.Q;RI.E+;BOY'23?4J%L19W_Y7^PNB_U7>IT8/3J[MVT#67C
M*V#(Y)J^&L.>YI;*<A=USZ /Q!LBYNYW2'O/WJ]M^Q+Z<,,GI><=_L?[#PF>
M?9\<4"1AQ^'O $:J5GTY'7P3!@HW>=[U:YI"<C& T_?1_@(397I6MF\K\T'O
M9L:1O*%SELEZ):&0O-YB50<)3SYYFW@FE<#LU^V645&M1+0EKI:%F<P)/*<Y
MIWJ26F'-TV$?.:^<&CS:63YXS\]52,LFK^$0][%^U(G'O#JZG!])$WXQ1Z,Q
M7-'_ RB&TU[+T/A C/.-YXC;V;HDGT,"(G)-)@Z&L)6)-6ECE!,5Z79>]<EN
MS7?FBJ/FFXB.B':>W ?\7V>QZ,7?A'5:7&%_2QK3>]V?_3"F^.'7"?_-KT10
M1,?MGI=0,-[UQZZ*=9S/"V6?(HR&!>KNO'VU]%K%MGSJ@_545VVL]2/>5+$A
MSP"N(6N'-UY,,]27J?>!WMA&& :XQI):BS?5[T;D+>M2[A5JH&<-&Y?@;"#J
MM'C(+=JSX9IH50-U]VU]K'#GADV,ILQY-[5K2B>]9-U"O-N'B7[CGN ",]/O
MGG(KMIW^J<+*[L:773IH)2\4*"Z$:3UC>6$0YYHR2?/*R[(LQ-N)*-<T6A+'
MWL--'Q\M,$2WW_'*(*?OLVV$>CL->9IXB+P$S&5=[UIS8G+"W9L-\4TH2\[*
M)[A1,<;';<5D8Y=&H$L'\*LFWWTPP!A\/%+ N(-IL/8I\9<[O=JM(B7E_VD$
MW>7BJJK]I.CNXN[=H.;R*K.QO4T%;9-[[%U\RI:."V5+Q\\4T)0BM.W&+@*)
M_-APMH;URP*T_S=A?IY=K&$1)]5AN3I=]5SQ6+^LP(2GU/ Q?UOPN00QBU(P
MRSI:L#*=XZ5F("&0 772BMU08G_R$JM!ZZX("_Y3>YX*:>S:V$*I^93I502,
M.9!]Z(?N#"B [4X#D&+!QY5<N_OI/#/U$Y8"\P"/2.[BL.)$C4#9@,:>I_SK
M4EABF<B63L(B-]B"K#_C0Z5'3KYA>+RCQ@\[6RAU69.EQ)$5\+\GON]7W6A\
MQ<AC0>IV/IX(_NE"J35613?MCX[D;#,"2?NQ6O $_K604E,*A!G_/U!+ P04
M    " #:/9Q2*O'#Y\ C   W+   &    &<Q,#@Q,6<P-#(Q,#4U.3,Q,#8U
M+FIP9\5Z!5C4W;;W?Q@Z!4$ZI"04I*090EJED48I$21'$% 81!&E&T5ZZ)1N
M1E $04$::20&&;IK9KZ!-X[G_<X]WSW?<^ZY?Y[-LW/MM=9>^[?6VH =Q<X
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M&>QA@.$R'ZCEK.)[']UW:)"?03J"V%S'!0)TJ6:2TV>UXN5^6>K_:7=>\*C
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M;QI[D8G 6#3W7H1U)]AW!7H:SE.J&F#:@G<AM=I>W)'$%S5TKU(J2C'*1>X
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MQH7#O8Z<E]0&7&SHMD=D1Y'7"QZD-WTBG2Z:U] &%)"=\>JSU&N5F5 .5HN
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M2/$E/!Z=KN%C*8Z5B,+A=H7>FYC?GOK4^Q6M6+5$8"N%5HNY9ZZ/O/=_EYU
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M9F27D!$7E.85$A;\ZR8@7%Q< GP":D)":L%'=(\$_]OMK@,@Q0'ZT%S00<P
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M0>\];V&.7=,5AS>S_I2YB#F$:4U.%ZPB_N+M'<" (+Z)A,J=6%3U_6N'_S]
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M]P@L28<V$_C7,&Y%^GI+3!P>JB3P3]BEX.//)\VDH- &XJU?VIBMN-!+T<W
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MDB\@?X:J<_]T3E':<8UI4@IY'4XKSER/QS,A\BH\,R[7_>U)61D('J1P!R1
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M(99VW>N<_>X)AMTL+-"& M1O[L3 7C_I$C'ZWLKC:_O![L'GL,Y-IPB1]3N
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M+BR$9&>TZX8_T_2M]>$<P&5_5FW'\&*_\SOO#"$-L@ITDIE)+L:J)WYX$W\
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M'^Z_Z^?.EQ.5^.6MU2X$^F$FB83Y7C^[ [)ER>^ ]EFY:TV=F8.J>2($;+C
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M;AUQ]MBP48E</ <D(Z/,[DS[8>0<\1-T_Y*7EK2;W^X9[.@O]V;+JN6%7"A
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MF!TK\$J6[C K(7+-)MS0Q9I[GJT1STS$=D%7#?W7J"-'+N[Z8<[[(K<C^_3
MKZ]78,V99![:VF:.]5DK>[+PEZU3CY.,?U;9&KY'A/-'?+;TL53AO[\S;PZA
MO0V-5J*U?I@!@^)*N"_I9--&E?$KA"&-)K1.)\TX*-L(<R' >JWLGEW-?[':
M]?>*U]W/_P%02P,$%     @ VCV<4@<,S 3'*0  A2P  !@   !G,3 X,3%G
M,#0R,3 U-3DS,3DX-RYJ<&>U>7547,^6[NDTP24D0+#@) 0"":Z-A. A$((W
M[N[N$@BN 8*[!(< '0CN[MHX'5P;;0@R_.;-G7MGULQ];]YZ;Y^U_SEUUEGU
M5=7>W[=WW<W>K0"/9"5E) $0" 3HW3_ W3P@#F"BHV.@/\3$P,# PL+$QB7"
MP\7!P25[_(2 Z!DY-=4S<DI*&@:V%S1TK^@I*9EX7[YZP\[%Q47]@A_"QR'$
MQLG%\==/0%A86+@XN*1X>*0<M)2T'/]CNVL%"#&!"9 B&$0'/" $@0E!=YT
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M=@U=787!UQJKB++P\"&=@_7"QC@^LC%_21QRW^I"2A_N!;>CS8XWL4NW(W>
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M&05_I'&G/[L#U-7C+*/(Y1/3?Z,J)0IWR+6>)LO]S&)UYQ71>I)I 9S2EN[
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M =NK&'=W*5MUKXO.4+N6/Z0GM#P,DR&K"D\KU^AH&W=OXN<+*J/)+EJ)JI!
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M4>L@Q&808KH#PWYUF\:Y74U;[VE=I59;XWBG-]5O+DIB.]QM-V%@ L<O,+7
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MD!L9"TYG"'L]_5C$J5SO6GS_C827%Y?(N-_,@OH,9L"I+3B2@JR[133LOCY
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M@$>>7"_G_V&?N;T87O%+Z:@>1(2^9\#%_:XL/1CK[O<M5D[>W,SBS#/F ]>
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M#_(> 5-1,C+\(9O)83U-["MKC7L+D56+1T L$8KN^@BT^PC(,B8QYL?$%"_
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MT4XAB$M[I4.R7*V+GO'K,X3]>X-DH7?R\+B_RO)VG+[%Z'F=X< ?1ADV:OQ
M)EQ78:UO%,=4HB^AQQ%TUHK*%)<S%#OR L"B;]$NJ#P%(OZ43TSJXUAI:#O-
MAC 6>:C)?10@SF*^#$*,8'8C7^3P-@SQ_DY:L7=;LO[G&;&A4JB_HT&&=6/#
M'US7C&<10;EP,LM[=Y/WT$M9Q7WT\G&=AD? 5X+X*;BLX@.'CE3E>8B>-VW)
MJL0(=]!%SC\"4W;].#L'&J%SW\Y$<4B42RGCSW0&GD*DR;J;_?H\ [-L7_!D
M7 MJ/=5C#N^>:+0\@?/X/P(AQ:XVK97<<I/C*_XJC5%T\5Z5<8Z"W02B"H)K
M^7?-# $ID:DUM\F+4GF8[R#"1T3=9/>_-.R&P8+AG*&K/@+&6;MU?)/6P[E/
M!'0G()Z]1Y6;9>)=$_8(=$T)IR[8Z5Y_DNO?DDF1SN3?9$SH:VE739.Y<1.:
MAHB2/E'9IQJ1C2-%R)W!FLCU!<7L[8S('M?F(^!3]]?.OJV6CE+L/^.*#U61
M4%G,M#KL>X^=@_-4&+Q?#Q,/-.25KDMQNF;B'2__"'0J;UB)GN7.IU_9/-V8
M,2O3A[^YH6TON^ 1<-Z!MD=<)_D/A;UY^K(J<E(:'0+TCUB7,A=3$[(EF$2O
MRO 08(A^IK;G*Y']'T3^7X@!IPE<Y)1:WGK)<[LQKP9>9$6?SHZ]U^TN]\P4
M5;0)BSH2):/M6ML@=5S+D:QLNU)Y5YKK.BF7O_NS,F(8Y;14G8][^^-0H,YT
M71)CF\KG/BKDAR'0'[OQZ>:/X9CRDC^Y?[@79J>;JGO\^M %@G)"!.MZ=H;I
MR/+!#6W4N,A2XLI=0IQ<F73J[&][ 3A!&]_;:\KZ@[?C2M&W'0>$+@<04I4>
MF46BSV>$1G74,0'#'WOV/H1TPY>UXPZIG(M8"H(B1!K9$GR8:Q_^\%]F8"6]
MH4RCCB.4H;)1B_3#'IEP/M71>U=+L,E/96N[RR=<%!A^I:0S3P^A:PQ@[JI-
M?Q7E(_GY2U'A!?-IN+MZ;> ^9)^F4@MS)E#.XL-HWZST@C0/(!+DMZP-+/,V
MN.N1\-37Z/CQ$LGE?W$:6FI^,U5[Z;([:.&$U%ZPWO7*5H2A??SC?I%3WN).
MK;S@L%"8?>2A%O[WY_,/SI%U>]T,26_S,+^.S.OH]YH$$JU8/.]@N%B,]'>@
M;S\'3CW0@/UW 41*3TMB=;_-%/;7+QA[+I?I[!++/]A%8NNVR,["FOF[/2:U
M'H'JL+Z'!,O?K0Z7S#>SM530U*.KRL848](1%"WFU*;!%S)H,2^"7X2'<OK?
M)J63;C7;&V':,';7^>G HK5*1Z08/],H$77!1#D(498*?TW,=8^(SK5+:K5,
MC1=5^<G[D[R+=-X2YAL25$*Q%.7K02$-P2LR*4!)(76?IIV:ZZFW&!R\JV+^
M_!P[EAK1]\V;\9_\9(VJZDG6JXM>40HYB%(?TV0630Q><I#%8&XK+*PU \YT
MEGXP -1[CM<51QB5I863*OI925)4&$OX&,JP=D@UQ7I430*I7(19<9<,F'Z2
M?-4B&NIGFT4EXE+^.X,EM^;;Z^\JX2/BEA7T*$-H&&D&NF?I]2D.X3] LP%
M-$"\YSOEE^&'BDB>A0_+*2UW0FJ"\.3A 7H<.+2SLF$M2I$7PTLPZ*>+\9T2
MP1WG,$?4.G.E/M3?V%5F$26 )GVQO>J+70F!_X.:_K\$0E,<3_1"R4#<+Z&=
ML(HJ@U^P#^351O__^@0_SOXO4$L#!!0    ( -H]G%)[=][J)2,  !TE   8
M    9S$P.#$Q9S T,C$Q.# X,S W-# N:G!GG7EU5-O-NG4H3BD4"<6A0'%W
MATK0 L4A6-$"*1J<4GB1EJ:X%B].D& )$MR+.Q0O%MR*^^U[OGL^6>NN>^[Y
MGM_:?\VL6;-_S\R>/?/<_[S_!7BLIJ2J!,#"P@*\_?,![N< +P$$>'CX>+@$
M^/CXA(0$1,24CX@?/B2F(:<@I62@96)DH*6G9V;CYV!FX66EI^>4X.(5%!(5
M%67BD)*3%);E%Q$5_GL0+$)"0N*'Q-2/'E$+/Z5_*OQOQWTK@(P L(7%CXW%
M GA AH5-AG7?"6 " +!PL?X1@/\,K ?8.+AX^ 2$1 __=$ ]!CS PL9^@(.-
MBXN#\Z<UX$\[ (<,E_RIT',\"FU+?!8W2N&_8K,)6%]4M@%U1@_91*S<@PF)
MJ)Y0T] ^8^?@Y.(6%1.7D)22?OD*I*2LHJJFJZ=O8&AD#+:VL;5[9^_@"/7P
M]/+V\?4+"0W[]#G\"RPN/B$Q*?E;2FI.;EY^06$1O+BJ&HFJJ:VK1[=W='9U
M]_SH[1L;GYB<FOXY,[N\LKJVCMG8W-H^^GU\<GIV?G%Y]3<O+  VUC_CO^1%
M]H?7 QP<;!S\OWEA/?#^NP,9#NY3(3SRY]KXEFX4+,)_$5"^B,VN;"-D%=$Y
M!%JYCQ)1L8DN/SOZF]H_F/W/B 7_?S'[W\3^#Z]9 #$VUI_D89,!% #G5YPY
M043_';A$U!5Q*;45<8$:IYPZ-[-."6@$QO6S5;37)K=%S>QMNM;9MP]QKFR+
MXO&GWPDWBWO>5.M[2;S!HNF(9[[4RC[)AUR++:&WL=:#+(1)$Q@WQH)XM?7Q
MX&_'9*U^/_@1K'390^3'E*_*L(Y$P!DZ-7<;$O7;V/QN.1_X_:N9_3\H7?#6
M-Z-323U-]N?L=+C%R.&*(G9#%Q('N2$_*N'OWA9+Q[F9OOLL:^CIYL$\:2PB
MP-TG^/@J@"OU#/UH.*D^9H.LL["\OD0O;]V:RT#5C(%OJ!K'^O''RULTT8^)
MQN=>J1X8P<HZ<QIE'M/L210UATQCT;= K-?C2_I>J,N:01&*)C>D58T>K1"T
MZ+2>_TL91-MQ)'O"MOX/P95TO-4)QIPF1IEOMI*JP.@"R)"H?X-DFK-L_5Q(
M2\O(-(ANGRYAE>%8VT!ZSRI;NXPDR?BF1D_O72R:\\[FK(BM*6X!V]2D@FWY
ME?)'+<O9.B8RR!,G>/A*0^H\[UO\R+/UDNS#Q6IHR>;>H^T2<];=^<*#J,$>
MM<%Q1]GNT:*\77##^.P^!N.%K#=,?4K]-'F]Y^9A:D;<-@3BLU$=<"1=+Q0*
M6!VA6JGQUWYC[QYC/RW>90-;&*CLK:=]+:ZDVH9[>VV5Q\B0R8F)HU)*-5S,
M]%JM9B,G6(APFP..CRI2*QQ&_X"UR^3UXUJCY24^\>V,9R:^4QMMJ7Z7:LWI
ME:BTRPZ08EN=2YW\=Q+Z!_ BA[.KC%P34[A0)7[(#]8FDZ(-JQB5CB(=$(&6
M=>C$B8:,5FP$^5"WH/%7P5_7;J99&6QQR 'C/ ZI?9Z*2;6FB"ZL^3<;<CNQ
ME1/@3M4:L8"=*'_#;*6;LE,I47?:8V24V<]JQKS4>L>:<B>>0?G>)_L(ORG?
ML.;>LW(A\:3N@9N)'?5<%X%O9$P1EI] [R>G0L!RJMW3=$8/2,L<^!:&$D/?
M470:LF)ZM7K&JG+GKU/T8J0DZ8E&J_V?X^1XLK\\=],6*\B;O:+RY(F44*_0
MT-(-.R!;TW</8<4<1#\'3S7+COPR,7K/R[;@]OZ<(!;GS8NSG8F_8DUO#/T\
M41&QC@,M-E$@FT5"0/H]X'3GG7K5X5,?9EC[,_2K2^]7RR.X?$%:S$X<L.7B
MU,1(>R_1^)XS"]M/#N_Y5X1WGY*T*]KRBH1$!>>@+A+SS$RVQGV?D'W=&B!L
M<"!2/B(G(3J.B#A^TW#!LV= GN8^)I<K2Z?S H<G-D[:[4<O)KOV<ZN$M-"D
MY7B<NDW,JZ]K4I[0"!S='QQ1B;$C7FC/$[_("&_M$FXIR4?3P<HG)?I]6W[E
MGY')]4BD29'XCP*]1)NG#,/8F"%2.5P/\>2I\V;OF.O&E-<Z;A&"W<H[BE3V
M.3  9T[J4%%^1G#1MFKK=Q**%0F8IP9A*=^)9PJ"+J#S3K\EXSJ//ECH=[ *
MS9[1;Y]IPT#*UZ([1YX4KW/X)'IU7O/AW0-$F)U_G0_)&'XW]0E1KK5B:PJM
M6"7R9AHK*8=YF.ZKTDEVO^*[ ^;D:F_G#&3XJ<[T!FR0D<+V\\9$OUAT;5)=
MZ3^9_OA*T:@R,JVO6[#>LA;3N](DW-N9)"A9=ZUH/_&E C^E9W$URN_(6'5%
M#D]C-&7E30\OHS"6_(U!6=,"J@^SZ)/'M"LHFJ_I=I'XF1:Y<=@KW$69DE\D
M^M\N;0B@3^^$E7*;$SNR(:A#I+,C^Z;+=?9'K"<^":QE85:0H/S-]&IMU-*>
MCEIEXJ]]!?^M U.^C=@2= =MHF5<E2"BCZ*ZOH=MF8=^+5;]85&2N(Z2HN6$
M_G7_YOX4&4-=^/<VUB9QR*,7ZJA/;X8NVBMEW_I/VFJ4HR[:VA"#SXIN'QH<
M]Y-+LR8:4EON&.P]>]Q;UUWE%B'&MC0S==P^2L'KTP]W;"C\"0J@1ZRHZ&7%
MUS).)N25>86>;#]W*3"&<,E*S($9^D.7(F+!AN+-].,85=;Z"=O&U\[V^?0W
M#:ZJU%O@FE1;N-'RM;3P"8UI:HCAH5E[M?RWMM&6]31ZX!7C2KW-,I<C97WI
M+/NX+%/V-E621(7IXH_8]B-0,^B9=C3/>>#5:3;D5P9[_\N['I2$X.R75Z.[
MR8\HHK;=NNPW:2$.M,]0\17O(C]Z,?3N@#V']@)(4/Z.4!T?#JTD"#P5<Z(.
MK>AECO6FTHS,: K4<AP;.S$Z@2-L8-O;%DB%;ULBP=D56*R M^D&&92?*'O9
MC$8:*O2UXU1;*>>^K-3\A4EI5PKA[4%!58'#,+OC=TMX"85K$:YVY_*3>5S'
M_L.OK W*>=9AC2FBL[=3V2(FFUYW7B2T&$U6B\(RWH\TD +R[?-QLQ8+/LT)
MIC"7YS@&(Z5OE"J[<['TWNJAG&OY$R9;A*F8TL"(>T#RPITMG1.3)@KPTI9H
MM;E5"^/X*Y+24EOQC'*;YPF7W$RC)?5FK+D)CW$;^=R+7Z?S05/ZPV&B,R8#
MM8;(Y.K63NO#LEGN7 .W"V.17,U <JD0]H:<#V.K.M4,QDILVK>0=YJ33F(J
M'_H=O*T/GBXG7,-"=Z[>3@Y]F^:N5<1&'A*>#)>C]"=.6,9O6UX'5EL(* @\
MY*@$EHMR.\@Q!1X+JGF<%EPF.[<(7+"? A-S(0_A2D=JF1IKLAJ$NP'**,<I
MX:]?JZ6?2@[)COY9VWD5.3!.P/]"\ J40!^TQ)/.LD%SE:4&R*PX96NYFSYV
MRCUF@?VL,/ &-)M08P?[>988BFP_?AE7P;!+*1T??MRM(@=2$:WKBSQ_\GIA
M;H]$^&/0KS>XXLVI<OA[3)#8//[L/'M!0UZL2[<Y^<2,6WA9\/?NZ_:[O0]1
M[*9,WXY^9^(SK9J4Y<W5=:A[=$AAUN\!W<G7_/2!B(9[0&N*0G>0T$J\[A-A
MOLYJ#;1DRN,N%+0!LT8R$6.^?<[Q-DZEEW6 ?>E6];(JES6V=2,3-<9)D.WN
M*DDC5530& QX754,()22PWW@Q#<DT1474/AB/'5]ENY,!O97!.G*CY/22%;-
MYJ3#\#VCOB<\]4%O2+U.KO1J*081VV-F>^S";5:Z,]#?T3T'M ?(.>I=WBDV
M*6?$[4Q#O!E9,INGI/[.A-<H_8<KSP$5@WU5_9:?6(;'"+L5'BW);^-K^$G.
M4/,F6:%AYR,U$3JN1R?E F,G4F(:.NH02 ZS@9T ]_Y3D2 \H4$'K<?M^01=
M^?,-#H6\ DPI[^@=-PCEEQ*RX%MFK_RH82+/NEKUM>.17E=3#3-=?-$S[(PV
M_N+IYPBK.\C:V+[H0:-3&NE3Y]<!S2CRHFV>,B(]?0F';9>MF)E&0NA[]1(/
MNS+:M1O&<^H4(?2<'/3<9,O,%MHT5.RU/L*9 P.%/=U2-Y9_V@)AX!H(W,F7
M-[6>GWS![ZYMII(^P;)V19-,UZA:2J=O?9MA/Y,0?6F_F#B>P\VLAZ6O!& H
M_O2U$)%6 ,(_BD6_W.XILY^<3'5)DA'8QG@PCVTD=]X#2O[846.ZL+\]*?2.
MYXC(WL_M]P\)Z(-*@<+Z,R <OBWHX$6^,"_^<Y7FG&/$,$XTV9QKFJV^KB_[
M^N?FEY]$=4I7U<E BYF>))E*#Q_2U-FN8UL6%\$G&_Y7T];+%E2.M(LE8LBS
M8LLV-Q:W=9+6*TS=H.8RZF&=1P,.'VW%*]"=^#V Z)24Q%[;'@PV01 /'K]>
MO4B[P37=<](T94E+1O]1R?*MW[GLY6^%?%WZL>X!?!1U8H4%2UUPHRY/LDM3
M=P6T/ZP6AD$>W4:O.)S<)4V'#(5Z/9K7C3YXVG=NXL>@8]Z7$S=K<G4N[<B9
M4R$=#./\_N!OE)B!GOH4A#O[?+DD[/[E=R=F!P,<[YEKN*A.@@^3(;[?G&.[
M)RPSR3X?UKY=X*D8\_1W B\-!"5Z2,:Q+\=<,1V55'70'XGJY#0Z"_9U,,.6
M/>4X[LANGSN7.:]%T5NJK.<.@Q067Q[\*!Y-'\/D7285'13G8[)=;!W'^UGV
MS(,854^ &[7R?(VHT*^HB#^YX.JH%6MM*U&'^+M/[5S74R<JL865.NJ]B8N&
MCG98;I@G%!N7>)O<#*5U-K.BXSO/GM1R?^QY,A]F]%=6H)_3=*0!QBH:P\9Q
MH>WC4N9>"]7Z<+W/Y"5-$J2OI&P*9.!Y(M56RQ"U_JG#BJL;Z!$W_N/DX=ZK
MF0L'_D1WL'NG0!_A)D]F2#<ZL;2$S;$DY(:_/4?#&7(KYP%W&K5F2XQ/W]_3
M%_5_"-DS,C$?>OOE.=]?_=85B-1$O6P: :V4#<M#]WRN=O^RC\KPGSZ+?";M
MYSH;MBN%R<@(FTP>Y39Q*SI"! '&<+9PQN?.<^,J"67MR'>R8T3%:>V&HG27
MZSU%G+^88JY"UM;&Q#[\4%EK5K@(5_#JH4=LP\5LSJ31G4TU%!#A5R2R.R_H
M#F4-%GV&(*Q:"N\G]P^4K_(>4 \CI+.&BNG$]<U,#5/"EB'EE=ON,_V_+].)
M[P$^AA#3Z"^BOJQIUTH3C/4Q F\"'#&1*T;.UD8N#-;IKM2WT_> G3&_[<<?
MFG>DN;FP<&R8NI/R)GC2)S[/->I:V@=.MA;8,?6AI3=.3H4O:G5B/U_53>(Z
M*6LZ>%D<DGQX@5F/]KX'X"Q1(K6-,K! E&^P-+SUE/[<DW+9XD=T2X9OO%=,
M\49WEW@#5Y<33I@6"H'>UM(H?<EC$8HNVK5%UDF#L8%X")V5H$+$G]E.&!XK
MYSKT6SHOM<38*3. I/NH3^2DRIV?2) 3L_CYZRU2C.0=X16?3P>A2C7JCT?G
MJFYY LA_RT9_++V9&?$A[<BR"7*L5;V^5-[7BZYK;M&]*:G+ V %">(K<D'P
M]O?]3N#%;NO/30]@(QTN#D6%2\@,$X7=S$<>^LDKU!_V'EP*92V0*Y! U/@G
M*3C(&!UUE.($/0S,(X2Y)M55H>S1=AOP,.BE_NR0VF"NBKQ] :4VB.7O3873
M(XK\(R/NYB)-X[]JKN4F^U[RQE(I;M"T(6KJ#AC!#K4U,2\]G:M,WPDUJW#*
MW'GDS1I^T0Z3:@8GU\:N+\VZ;Y/*93\4-:%)K%EUEJ8=^D3B QQ9?.Y4"$[S
M5PF6;13QE+R:]#?1Q <.TCJ?)VT4Z@))S,&.HW<H;K[:_K%O4XN3#6?FTGHN
MD#T3HU\;WH*O)3$9;"^V0L-79&*G.?XH1^M4>M*DCGJ@8S[$O=>,2"2=O?CY
MK#H\WHU^I!=M]%.BKJQ.5M4;2DQ%9E)TV29,KBET4XS86J73,7RXE<E-R.^,
M]MV7_PQ,S=446' 2V('/R;[? ?D;@7K?G]Z4^K]_X@TN2Q"OL5S]_-88\<UZ
MFT).J\G9Q$09XASSHD$;#X!XV&K.E[0/'#^(,B:92+[$-O]L1F)H8,*H4[!R
MP.'U%! %29SVX),7@X35J1O([CKK-X>4.4+\QAQ<G5Z+=40G:KE 31>BH@,0
M \Z(?-N(K-,(8:WKG+#Y%.3M!.+=G&/RE*S)@J3VS_3R-8B: )6C=7"E^CT
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MM@4F230>+W-14Z7S5^8;BF\/:ZE>U\W(T>3Y6(W4)MIR#5=A)DUC1.6:>SI
M]=XGUVF#@-]"N0G::/!1UN8^UAIH*'?GU+'G,;-304U1<<0ZOD\#F;1K*C)Q
MR'4SM9/;8 XLK'S;_ZU#EWGLM.'=$NF9FFK$$R/Q^$M##9##WOJD0#U-@ $#
MG84XM+NG,]Y&M7BNO?#.%Q1_-=(,#'Y'[BB1+%$JHW)A\</P)8AQ$>(D]S@
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M.<TK9BL! "3M23#N5Y3:(,"_0N#]S'\ 4$L#!!0    ( -H]G%*F5C,G@#,
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MU>3OJ7+^W@SGG;FI]Z\+K-'(.WKQ).(=]).NQ*8[Y(BTR" '%'PM:+KD;UD
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MC/.S.S'JGK$V=DO0J92/:RF1F)+OM70?]#;NU+72+UF+ESR&&3AP9R7:Z3R
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M1W\:-:3HHM1/JSU1R#8INVBB>.GN[XFZA+7Y8D#Z\  24J=_IWSW"'8!'Q^
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M],XZPNLG=$H8+/$'1) RB:VGO= $_4+2(PE]:G[Z.XDD$A%G!?8\QGL+ Z8
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MHUK[&W1JSP&W%O$)JXJWHYQV^<')SW]4U$Q:M&],2VY_&5D5L#Z+$WA$&JK
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MS=*XNE9I&5/-=R*\P1P8K;/AF]%:/JX10Z.IR#WNG95&82PFW8F\)ZS]N$2
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M,#@S,C4Y,BYJ<&>MEG=04VNWQG=((%3I2(]"E-Y#;[: B$@/)4COO9<#B(B
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M;6VHA0<]EW@H*<.=A.R*=C)N"9T]1DO/$7(F.&+QQOX?:'^2_3VP9_\4V7^
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MXHTPD*".*15&*7-]75-)0=Z?T-VUMH85$%,LHZ628%9-9%.#8F=-?BY"/X<
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M('SN0,G*[WN%2B;F0T4+$9N Y@[8[.T ,?4MP7GVW5_0?B/[[P'S^Q\A^[_
M_L0U 9#@@K#DX5( 4L#Q&5>V#W%'P^Z+"'/V#<?I>['?<Y1BS-[*2KKX^NY3
M^@\)51OGP^>"#\.^RT /5:)K_5B>[RURB5<J^Q%?M,5%NZ.I0/T&ZXG".RV\
MU</VG[)B^=($N&D)"3,2[.N\%&0K!H5,"9%XRONR;Y^=JQ3R(TK) -[PC(0I
M=9 <U?_<C(?10E6!ZXI)2F,<D1RW]]L*%+OXA@^^,LW1K=GVBJM>?K!;1!F]
MA]#/WI%]3378YLI*)+^( 7A&%)]EI26R#47R@WY6('KHNNHGOE#$1'(/ZZ6Y
M^8VU:ZZ[+UCOK&=/O*B^>;RE6:R6RDK?0HOOAN_H_QUPDN3  -'; <T;+!C@
MC$-YK:2OH'942V?G%2*B7>-#,D2_U(!/:4E2+5D_;C9J>"RK_[\N':Q[MJXB
MYBCH$FN\N9QX7_WAX6EPUE5M'0G1(Y7SYV(3*J_H$Z[SQRK NU6-LW!"N?YM
MV4(>;*Y'&I!3##"UE[F6D2ZQ?@A0:<C]1P,O>PL8*:+9?BCQI/JZ!DKLCAN5
M?0O0.7Y6>+IH7/@5\-^P'1'3R["Y+AFRH+8Q3:D[S%(?9Q%!BNH0JF$,!J#E
ME>8L.^\6AZH!=SQ-GHI;8>FE'P+GI%N.)+@/AJ<K7!==1)"/QSA+3Z9>QJ*4
MG%^$'5$%3\8]P)G/)?5Y<B_3Z;"/.0'0WQ6^"/+DQ0#/"3'  +^>JC'^;#"E
MP:@X0X_56S_K@"])+YZ?EDUMDO?'I&[_!+)#N8!BNQ+K(N'8B8#L;K+!0$O2
MS,=69<:E179SHA>WVF@E51@V:->Y<'7_<$I6$P:(NAIUMC3;75"X(BUX7:Z!
M?KC<BY\+A_0N6EJW^?";#L)OE+VF)G)*<IM79J7@W[Z\302WLUL)I=TRBS1P
M7,ZIP]\=PVT"-)GW!)G/#J3.KI4I=WO)*@236AY>=;AZ-Y9C/R@1^I/\\9).
M@Y=R]Q;T9@TBT)H-E&[^9E)Z+4T=O_C7_L&:@'-S=?Y[GJ.D%]/S\K!#F_./
MHHY:UF:+YY*<B'KAZZ)!,^H<_(0T5*G("]_7,%08['9B&UKZ:/;P*RPZZ^K?
M^%LU8:UY>>$%GG)QW1;T&V';VV#+X/9QF?+LE-\+Q8W;O^/6X<X+[:RUG3>Z
M2P&S^IJWOJ<JEALG9^O(WU(CWQ(3_T!3^-H5W**?T"QR!4:(^$MW]::Z1CJO
MY@E[/8N]4W.GL)_(NI*!;#DZ)%V '' [TD?7:RS8R8,=(2R:7BHS]'I"6%G*
MN6%KZ^ [8.'F1U-6#2-JP;-ET)CESV;YHLX2!Q"OVR;NX@T8K\]09A!1*UI\
M?J$@&_VEA>.*9,+P[ZC')Y75K1VRY\E*?\$+O9M J_A5?9QS10)!]_U]A[NV
MH2Q*C1291-4YOL);24!:%<Y'0\O85<:HIE [8E'E$<*I97LWG3F!6[J!YBO2
MA.@")>AF^EC%NFK U9MZJ3&RV<:S9G'?V^JT'S^,G'+<1K1DK;]TP5*S)452
M'CD#K,;R"QCIA.6=Z"D-P%5'XN_2;XP76Y@5BFWB[:8Y&FD#&G)40#A_.%]:
M9$K'&Q<3JE%>9E7+V@I2:P^>BZ<BI\Q9S'=-RURK22?!E>GQT:WW62*GU D)
MB]S8#(9?C'P3UG71F"WD)Z%]'/%3']_2]%7JEM,)>_40-JB<H68A&BD$(!;S
M4%6A"=7[/Z;#^,*O*RV-% -<V:$ A%Y_X,7P(>G]=4CRAW.J@*-&^IXE<]JN
M+V6I7+@A]3OLWT?]4A^E-LK<2B^@Y[V_9^1JU864N%*"IML)<W-!KS@/YV5P
M)S%I/,T1MXQZT,?PC*P)]1C6U0]#]6. GS+57+^W4:YY "?MES45Q8>6M^6E
M:5A]1%!WP>P;"$-Z(K,;V^(>*</!$[P_" G3-B5N!Y;MXDS*H0?/=>(V/SDI
M_N!0_22 X[(T!P&$KWE0H PK3US;1N_WB S:Z?#*=KTW8^;PWF4VC!UJ0Q!/
M=HV>J68KN/AT?U9L\Q.+R@-L.EB_$RN_ SN37)&(D(S19@U0Q_'U(;0Q_ W^
MMP.Z#WGUI=I%;GX>88E5@3Z+%*/A:-!B,IX+> @>]R/J?8C,<\^#]@5OK?HO
M@)O/G)HM)^TK6;\[,K@LU>-"0UP8+P"&HPU2P%W89JGZ[E4;5U?$\%%J0EGA
M\'PH99B9 =@QP]7Y6;L5@YZ1'/#&/2IHHZH)UBK0@9/7;>R5ECS=_ER7$,#C
M>?A3XA+56&[5/KO'N%-[^8X9 SSZ^E0(N_D47^+XVZ9J5N@.\_KC^I'XA^:?
MU:0ZORR@"X G5O#'K43FCJ6:P)"'R$NGUZOJ8V];Y2<S!+ZMI-=KH#(G)Y[
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M-L5PW">T'0U#-L*VHI9-[OQ3A251Q2JQ#?18+"W-QK!C.;$JANIUPD]V!S'
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MY=ELGP>6.YG!<%Y!@SOBC^SL>2@8Y.UTW[*/ZX2\?3M%:6@Z_AF" 3Y\EKH
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M7934%DLFW>R:\U(8K6]0"WDH?K_,6NCB V-^!M=%] =]^/34ESVR)]O8/HC
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MC2SN>K[,>'<G(9-5HYU&0R?7^_=K]%#@+X%<FSDRNO(B#Q9Q1T,N0 5*K];
M':U=\CK)?B R8ZO(%*D$K9UMWSM5[=51ZL.L&?2O^7(BN2KV^5]-Z1\^Z--
M,L6#:@G##XC*>+?H-?V8JZX5QSX@H?%QB1;;DQ*=@8LFS2.L$8&)9[KYB4<U
M@Y9F#>H8@._VDX$OMS9_>NQ!^A/UI],U1E+(:'!C"V8'?;AL$0D9*?F"M?T2
M[9K\[2R*[1$0OB_J!?ZQ'J.D8\$7=\USK1&^0VUMK/6UBF545<19IT',K01D
M#F>CZ.J<MK+Q,.L7J01*U/HK[WQV$6E^_%=0ZQ"RQ?FC= =+_!Q3T])[17+$
M:\?Z%*R922=[2ML9R5E7J0V10=5B)3VP"@7:H1%.JPR\*S?P($6K#'<]KXEI
M3IQ$M0PV[AFN&ZI((F-?1,2QNTVIP5\/IEC/D_)#(G02MZPM/OMO#!9:F-Z1
M? /HT+))02N]4)SZ.V3O[Z>S!V3D+)G<TZ!)04HU*)Z1,.E*YGQ6JP94"FT^
M4P[E#CE[V(G2=U#O)=^JEILD499^H?Z&L*_*PC'.*'&B.3 #/3$XBE(3UES.
MBI1H>/_RF2+RX_,#@HJ-"[Q;0^6\0F'5Z9:51NS4NZ=F#XZIGTDH=?LY]$X=
M%Q[ <8Q?HN\$:=4,@S=NOI.)_O8^5YOX"XM$1=USQ)QY1A5HZM?9V7\PT#(B
MRD?HAW-)2!E[K9' FX'V0!FI@7R[(5RD\0Z^_FO2DQ&[_ AGE;33B^"MUL H
M$E!45!RMB:C#Z9D.%6CEZEP41?7(A)I;F:W$>)W,I^<?1%[5 "V.T8XG>CIS
M\:.P"CHO%R75I<&*'QSR[0QW0&O1_%[?G:I^GP@0<B["R$QM=PPP@)6X-;^8
M')\+Y#R)QI/9F SROF+G=1B/=V^/M[GDBZ^2WR5'QY,I8A7;2',2X.K9/N*=
MID0GG4ZA2D(<'H5W&J?WC"V5CW]T:K%%V63*]'LJY;GY=0Y_YS%\%<'^?;!S
M.49?N+NA>:*/[3-DX&<63CW\NINU<YF:"H)Z]-MH[_)R#,@97Y&F:P-:GA@*
M[+/O(*,XE6*/]974(P;@[SOGWH 68Z+>HW0)?!<Y8H>\+K_9Q(FDYS3S6'SM
MKB.Y=X/A%5P.JU-53=N\.9I&RK?*JCWJLJTX:!:;+-0;)$WC2;S.BCW%%I6V
MEO>K#7)"ICV1H8=!R0WQ%V%1TW,X#U"I!X9<N#U1OA=R#F_IME847K@QEE-?
MMMU-_-X/\\#W?KZM0ACD:?3<PPJ=<C<%YA3B=>N.$47PF-.[Q<!N<XECO<)_
M26DF2PQPQ;Z9H, #:FEKCK=@6Y13;Q1H<.>1/W&X-DX6DV-&EED<^MHVY;17
MI,IYW\Q#66B/B+5YRWL\!HMH1K$C^)-L'VQ73'"GW%,(OQ,Q"+,VCA,<^ QS
MSL#Q<2<!'-95G?XBW)DQ/_X/4$L#!!0    ( -H]G%+9H1:>YRL  '0Q   8
M    9S$P.#$Q9S T,C$Q.# X,S0R,S,N:G!GS7H%4)S+L^_B#@$6=]>%X&XA
MN!,DL! 2(-CB3H @@9 L%CRXN\L" 0($2'!W=V?1X/;(D?\Y__O.?77OK7I5
M=[:ZZIOIGI[^=?<WTU/[W4_=+P$>*<LKR0,0$!  +Q]^@/M9@"P '145#14%
M'0T-#0,#'1,;B(.-A85-1D"(!Z0BIZ&F(J>DI&7D8J&EYV2@I&058N-\S,//
MST_#(B(AS"O.Q<?/^TL) @8&!C86-BD.#BDO'24=[W^[W;<"\-$1L!!$D1#H
M 8CX"$CX"/<= !H   $%X;<&^*,A("(AHZ"BH6-@8CT(P!X!$!&0D!"1D5!0
MD)$?N+X/?  R/@H!'8\,*J'6*S1Z)R!O0%0F.L.3RF]$VL.'C'RFSH$8F,0D
MI&3D3,PLK&SL_ *"0L(BHK)/Y>05%)64G^GHZND_-S T,W]M86EE;>/BZN;N
MX>GUYEU0\/N0#Q^AT3&Q<?$)GQ.3LK)S<O/R"PJ+JJIK8+5U]5\:VMH[OO_H
M[.KN&1D=&Y^8G)J>65Y975O?V-S:WCDZ/OEY>G9^<7GU"Q<"  GAS_:/N/ ?
M<"$B(R,AH_W"A8#H\4L 'QF%C@>50$8+[943(3UO #KP251FY3<,!C[M0R)3
MYV%,8D;^9::C7]!^0_9? Q;X/T+V+V!_X9H!8",A/ 0/"1\@!3B_8LWRQ_P;
M,:1YVKV,]OZHS6JF/<@81J2#FQ,SI&O,;3@JT&CQ9>0 ?D"G-S6('.#O(!MQ
M$SE0U>26.>\9V4:29!<5-B>F0-_)UJ92)><<YDO*)46^?B.7>Y%L0CQ:%Y*&
MY1KA.=-&I6;JP%_T(8\S")$$FR=:P<@] T\EJRG/!/$B>N.4N;FQ/DTG0566
MW^. U',8<?Y39@AHT#9M/*[(TZ.#32 M*+ZNSN%,365O*RE4OA))]#9U^MQG
M%H&&C7%UDC0##Y+5U."'[5FK 9PU?H393@H%U^\KDG"<:8<X<D_V;R)(4U+&
M)/4U'4Y^$.?):"Z*F?M8XKJ+557JQ;C@]E.U[34#XZ>=6<_5_%R -Y/%S@NZ
MX1KO#[1C,!45I7SAC\R).BW"2]33!YJ>&FI?1GRX7UE[\\>\0+_I360T[>A9
MJS[VMC=%JR *]LB%D'M$.IPF&].##">U88%S^ZD,$!/.6GF*(L&]HP$%90"\
MH)S>!.VBO7M,ARS[JS?'5EZ3T'KP3970/F:9GT>%1VNGNLV:),I$B=MI4W7T
MEAQNH26GV"F)(^UQ:T-/-66\[1KUUP*D,:MR@L/:CRO%I;@JUV"V.I5\#2RL
M^2=/N,WY<$+LE\QF D)T!Z0'>&UNZP)\U)P@.*5']6#%M3$J.O!QL)[BZC$0
M;M;JV$E&JXE6KO5"-\M:DBZR4]0BP<]#/#[*8';GO+//+!06VL6SOZ7[V>OS
MZ;,7Q=+ 4Y"^QG!)_T*^-TIN/9U/=PK[VD_*\[-".VY0.9R^L29-!+YN/-Q+
M@:I'G0'=\#')L=$7;0DY314=YAZ($R]GBNEA.$'ZH<,;?^G!MF8Y=F)T>A#B
M\\QO1;>%V,[&/'X$;,W0TF:]%89]]/D;0N_-/ *:!Z.IOX0H]%CD+?5N=>O
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MA9[!I!)OU[GW?(7N?!Y,.9C*OJ91>UB(PN_ZC(-*W".C<;>(2_&N0WOR=6Q
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MW&<VMEE3_[!G90/8PD)^P%L#O690Y7'97AZFGJ9_R)E8_AH(CK&W:^M+><2
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M;<DS T\]JUZ%FV;.)HV[;KBDYJ<5N-?:W.MQ5SAB;R-U^F.34@]7@)8<$&'
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MU7<H<L4$.7(TY&2<O!P@3$TN/?C[C,<K:!?)9-\UY#X;HP"U%%_) 341Y&1
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MJMW8A%[$G1-(NNJX54R*/F6+O3X^R#!3M_7G/\>_4=&YT,2$]]OAQY$>JO>
M-/;O%C8S,N/2SYR/\MK"_,TI'Q*%B,]9Z]P#6&Z'Q:!=#2FOQ@HZ"6"P\.K:
M526'!7S,(=':>X(@]2(]X+3H'C 5E8C%WR=3[]75>1YCP<[AAY?SJ.2%X\M(
M0@[T5D:Z+N3SD@/]2J%TT\FS\=#O'#).E&51-<FR9K1N&[F16K!H\W?]6GP%
M=%+82]0AT&SND-4HQ9,I2SA-^SU XLV=SMK0V<[C>8'1BJ#U1Q'IS'.^8D.I
MX)W $X%MP?#9"B&$L)%A,/%_O&3]$Q$9GK5-:M5=2ZQQ<!K@P+XJR.I996!/
M'MY%,M]>V57BV8.>>YFATCH34OO__%GTS)-/MKZ^UMK6U J4'<50RRI>851H
MR5!H5H-]CGPU<0M$"+5>MF.?U$U_)M@-VJNZ+.:$\E$_HM5=]2=RE,R?R*4F
M&]8;@,CDS89Z)1JO8!ROJ\L@U>(Q4''H00&! SV3&C 5L)@G'#XJ9O;Q24$W
MXQ*>LYK&OU5:_RDAW$__'U!+ P04    " #:/9Q2><+PR.8@   6(P  &
M &<Q,#@Q,6<P-#(Q,3@P.#,T-C(S+FIP9YUY=51<7]9E%11N@10.18)[@CLD
M$-S="1+<W4(@) 37($&"NULAA02"0X(4!044[FY!$V3X]7SS3:_NGNF9/F_M
MO^Y9]][]WEO[G'WO_<S],N"1DIRB'  (! +,'Q[ /0H@ \#&Q,3"Q,#&PL+"
MP<'&Q0<3X./AX5.2/"8"TU+106BI:&B>,'*S/*'G9*"A815BXWS.P\_/3\<B
M(B',*\[-Q\_[UR1 '!P<?#Q\"@(""MZG-$]Y_[_CO@M C W8 7*C ^D!:,1
M=&+@?2^ #@  8@#_%H#_"B :.@@#$PL;!Q?O(0'Z"( &1$=' Z%C8(! #Z-!
M#^, $#$&R5.>EYB/-2VPZ-W!O.\3\[ 9I.NZ2;4FCAGY+#U"<7#)R"DHJ9B8
M65C9V/D%!(6$141E7LG*R2LH*FGKZ.KI&Q@:6;VQMK&ULW?P]/+V\?7S#_CP
M,>Q3>$1D5-+GY)34M"_I&?D%A47%):5EY?4-C="FYI96V/>>WK[^@<&A8?@D
M8FH:.3,[M[*ZMKZQN;6]LWMR^NOL_.+RZOKW7[R  '3@_XI_R8OX@1<:"(0.
MPOJ+%Q#-]Z\$8A#&4QY,DI>:6!;NC^EYWV.#I1/SZKIQ&/BTCDDM/29PR1CY
M5YA._J+V-V;_;\1"_R-F_TWL?_.: ^"C Q\^'CHQ0 IP^9LU/P3W_XA*5Q*'
M9IA@PN6T#_UQ;]<(9/_1U\%S^L\^^NR//).B%C)%\EMFVGT)R\KMIT4)OJ$R
MO$E,ZL1D88$Y1X'ZEFQR2L;D>C$[_,65,XV:LIH)FK)@P'^$E\*4 I&8WR 5
MI3^MBN49)_HKZY>8Q4N7ZF-N?YTM:V!67O*\J#3MM);^0Y[ZQ+MKUY&J1V]:
M0 QA=^9I7_P+9CR XHA#65$.W&#?@?<(,$=D?IV+K&><_AGAXEK?\@J39WQF
M#?E>T;U616CQ2^5XT WD":A4= *(K/^:^T(B%+;>FC52Z@@KZEIJM8RSP+<:
MMP"PG C(]V4PVJ"7[LSQ+NZ!*MT51H-]4>Z4 Z2YG<_A&]+C_K]($PO>Q(G7
MHJ:^+5P>*;PU+8[$]?>59W%Z)>W.YXNS^ZZE<-*A3]JD7@NZ[ZZW"$+PTTHC
MT"7.B_:(FJC]57AEGEWVL-$]@_KJ47$=IKN-D34'>KO6OG?UA]ZY+$D*6?TJ
MW3C135:S<'1<:MQ?NG!E("$]G&')/2]=/<G^RLC&UMP9)ZAAF$WX*#&!D$@[
MCMV"4/:-<T3O&#&W_]%2RQ\I8A.F,Q^JT72!V!^Q36R/+VN5@K((B1J IAB>
M4L=9]L+1E[Z!192ZIVVVM)[QTZE<?%KP&OB:8M:\/9((YBA6(A(M820H'G^I
M:CCJU:A#UIR*K*/DLHU[H\=J2"W,4/H;<1;"FA\%^/>H/Q*7*390L\A>Q\'2
MU3"F,]%T?%^F<\ZEAE*&\LUWDN>7[@Z,Z[XZD8S92WS[8?8]UK4^P2JM_A]]
M'7L&2^>U:TO(XK=8$W,4@C![I'\:22[-$>W3'!M')CV+OK=C2MN'T)M.,AGL
MDHMNR7$X5;#@&V; CU+W%29E6%R UC8ZIE,MJ!.G#E9X39V1_N3((75H,$W/
M;^%Y(L7I@,ESM&=J\WY5X5S!D 5%^L.*DZ^'2-,LH(PN[6GB B/%3.:[<VL9
M=U_O,JQFW^:F)DNA]Y]2.CK [Z!J.!5/))0&M#M/" LVY^C[\@9:C12U-]LD
M)#4"GIP?&5],UQJB"LG&"Y_G?L_G!MQPC%7>6)3-Y1=<:Y<NNYK0_= ^O+$M
M,V$>U!,+UC-3WS/\(T*XE:M*HHZ?,,B;Q*8'R8VA^M%RO)CBB1VEK#M'3\P]
M&5I.Z"<1%SCEBNOP>=<H,#IMB5^UL=F#XUU>A1AP+![#3K-_HL?.7-\T?GU0
MWXT!2W@O^_S)<6I">7F=$JE(!$[FI?R4__+T!CAD+%JN/O+#1Q]WXNC 5DN=
MK&Q5/5<\>R?2MV72K.CF*:%97HRVI>=5&:SH.9($$W&GEE_:0FG;-T?0$1#_
MJIDU@WR%! MBZ=(SM!Q9@,6B(7/TQ<)KE5H^4R5@!NBS70)A)9;JS,V>VO??
MM'+]U(-X_EK5&_.%Q/OR588U4B=CT8<WM!5&ZB3*WACCQ/S<'V6)QXC:"3L1
ME^CCK.7U2S+.%A=MD:3TV+29S4H;KU<ELYG8F_2Y**2"G]@>YS$/V/@DZW-F
M2TU02?Q 8B\M\'@:B-;TBD4V0-(!8<%;E05<5X2A<7IDM@5:R.C@[[)5_HNN
M%U]';[:.3JZ]:M2/.RL$Z_+E/47?LUK&R,LQ=!!RH>L)EN9'2?\KA21N:%RK
M%JZARQ)N35;.X?-?RFX=$]@7"*^^\D%JARIJ\=#.@"JC>%I^TQFU*,KNXO\"
M>N.90G-=E]BQK+N7Z0*:&>$F%(A2)AWZ,+/&P55[&X-/Z'6HH3YYB3G[9L"0
M:!^]$ AR-S71V1O'D$4<KZF)D@W@4FE6^L+[J(I"S'W&<[&HN2W4;^,SGDC"
MVYJVPQRC$%,^$XGBH:;\\'GY0<6SRP(-NK=IL$QY&E_\>C(-I?@OI?ML&THD
ME=@6W9A)A_#9:N<-12.Y\"UY4/7T@ ##:"BB0J[M SGO5E: EID,^X 3?8:_
MGB+%L.<GI["UV@-EIV8\M.@R$D7_$?KE=SI&KP>89M"P_*9T>T17:""S%>X1
M12VN/+T\6=F8[@>J=50!<E6"H:NZQ#_!:UP4+G)2B34OX.?*07H(=9>@='5=
MR4_M5<P\?8P6&N&[??YT2M""H0!8C.:,T@YC#! U'N]N.$R.L*V84&B=X_5P
M'RJJQ 1KR@+ F@9&FVW<:9XT/(4 BA]A)1YY=3<<[R]+T7WRLRELPPI:8ADC
MPW_4L[*_RT6RN*XI7J)Z)"(2BY.?9J,"I4-"_87_]+249S.>2,QMN_=L<)*3
MRW:N/8[H[O='!TTJQG)\67QV D!4=W;;N5N[N)^>>4CE5EM&X0#>G%5IU>7K
MX:K$:YKH-:\:;J4?[!?R?"_!0%;0;7-D<V\T4](TEUEE^)".Z4EPS-QP.'&]
M%;()\1AJOU47.+U(6>6HH"1E22QN%B>U2NI<1L(7L:?-I]HE +'=?F"&P+C^
M_$!<=9FB_"@.7K0HUMQ_0NO88[_P/[Q2]:@0)"^WHL2C@%O'@AH.9+']^1[2
M"BY=L"U<44)=R^MM^%FMV1Y4QD=*K70/\+NH%E2$V%,I4C0T:SFZ]JH$3TPV
M,]=6=&;4\UEG4@_49XF>AH>_UC0-57862/:0-BQT2E)?&'!8*;]+*\UD\Q'Y
MP>E/MW"9[]99^E@T2+S58#0_SYC%+V1K)P8AE&@BS"O#C?*2_P4N]G4?D"B?
M].>=:0\T4;IETNL'QRV>8_,:VVL95<+YWQDNM*\W86DY$A;AE63ZW4@Y'$Z0
MNZ'5)EN_V$O47!BB07K(@"MHH^4 "4J@O+8UJ"VJN[B[Q+"CKU(DF=WEU/=-
MCAF'DC.'6I1EF:LS>UP,/06_4Y=ONDLNNXH@ /#L"=<Y<\<SQ7A9.">93FL3
MELT.LSTY2YS_60UO]O!W>^58T6GQ>%@BOMY6>'"=#'=.8/[LCWK:TGN K5:/
M1#PM.W/UIUCC;]'9)-#T N.R0Y[^;7.F8+ZH[)Y5_3!HQT7M+O.<K1;8)"^^
MN49]NGSQ+=UQT7S,29^G@\&6$]_;@FU"A^FTXX;O&2;YFI9(-4P@+/CY.U,I
MI?@%5*F#_V91C9V"Y+!W_9TVCQPT;-YE7YG&-GLM)P!Y'!YYENG/6579+EW'
MU[G7VQZ;H!0\PVC^3CQC^ZCST976J5Z2L(NS,LTJ3NU?B_3_M0C,9.]Y0V 9
M>1XLH84N7(FZQ"6OC/:HKP;'<'0";Z@:-XLLE&3D^D2M_JI@14)QF&M-EA54
M/O]*VQT]5X)/\_5;^N.B_2KVE^X./SQ>/;:0'Z=!P'R_Y^#NP'$DAYA^A)A3
M1^(!C^*2I6R=N:FR1C]7F_K!4/I)"T51%XNJ)Q5F_.Z<AF<@_*C-\YF:C9<>
M2!^XOQ76",S70XKJG MOY2(]#^7PG+%!I7D WV Y_QQ@69-#9#I$-+N)K#%#
MQ!8_3ZP@/9LG%QBS\?+LDR"B@09=U#6MSIJ5E)7/(7YBQGK3!RU_Q)U#G&W
MO96C*?H9PHX+4%";1>/H"A%S"48M*+R)*=M(5%/+Y"5354\W>XJ7\!.$]RN,
M0/+ND6NKEN:(NMFG?A$7NU)&)QMZOMA1AE^6@8L= RMJX4P=\YQ[?3#RA'M
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MFKWC(,54J18$P9;8R_AVS!T;R* 0R=20W:EL_DX^"DJ?'$^!.#-6U4#G34G
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M_7K40CJZ$S O6HDDEJ5^^G%M\R%E&B;+F1?CSA=&)XCI;ICA$^]8K"J>X++
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M$EWCF]%=/+[6MU@)@EQL7HAUP5^ZA(MU=P=;'!B.LB.="#/O2 [X_J3= ZZ
M0O> Q_(W3'.VE\_N <=HKG?,S7:57I2;[UBNVESS36]3)Y5:,E1L?[1B8MP
M*07"B :4W[/^D0LGCO^6YN;[CI)TGSP@Z.MOI_;&T!7YEYP6X7LZ5>W/<F>'
M-HVWIXD[/5N=D5+#54ID4WC:PV^MUPX@M^8^<&]F^]P-YN"G ,EP4$[7:AWG
MW=.=IJ+D*QO26*0]S_S7D7[>PCB"P-NIL*]GEF)M!BPO)ZQCGM-]U6@^;GKO
M^"P=,]:"^GR^:2]G0U6);$9 _&)M%1H?WNB(%T@ N;Z4:258.>VB,WF[%&8K
M>S*]KE#L3().%Y0&HD/HUYG,S)F]HH=!0_T&9%.?]YP*2!/A;I/!KVNWF[#O
M 8MD#W-*)W.5X_$LTB M3R#1F"4$[<>,K;?S(Z$\-P,=VB<Y$?*?VH4DCD$_
MW!*)+N*5M@&XN8 '^U.MWJ>GO*IG2F  _#KZQ[-Q^G%*:ACS9\3RC8Q_<)F?
M7(]N ZPC:=3UZEJ(_"UGR!JUWYK 0(^G<$O\VRNM+AK%MK,:U_!NLJ;?!-F9
M&),%1I]ZBT@_I/Z9U>[S3X6N['A]-5(62[]!2%,*]C]Z?I#AKK+(%]?+N/QX
MQ\RV?+$SKTR5CR[-70<2HE\L/!_364"ZX4LLT(&H;>EA2'#,HQR,BV(M5MP-
MQA&7Y_KZ&Z6PWM<BUY6SXI*36)-;L7$/"$]-&GD[&G)WJA/[KK6FE(/MD/E!
M-UZ$_OW!6ID#E6Y<88AI5TUS@1?'U=2<O,;VX *%^3A6\NY0R<#;H>+&>-QC
MPU&/H(Z*3-AX7OK(]T5MB$*_7H?E2#<LJ+**<:/:_UKW2D/RZUX<D@LRIM>B
MUWQ*SZUB3I3FZJ2OPN[X1EF>_!Z ?3L:/-T7;^:PT?0![ 3QY4V<>-%5Y8WQ
MA3WTQP" L' JND(LFKK!F=?2(@Z\5:,TA0C$'52LK.:RDDNECUCR:1V$SC*>
M<&981& G/Z+NE#^K;M!L^Y9H%7K*0#:10"GX^<C09T[+Q,'&T5&=]U06E4+)
MJ".[<T00YV5(G(C@K>W&RB-EMT\R-.@?<MXP#B:<"&$_Z \K1\EW&E/Z6"45
M^$BQ1SFK;3H^M=OP>885YW=>B-KFL_T^A^9 DCE2^!-&PYZS)GDWM8V;!V8/
M 2P#YQK.:((MYH@?Q?/$)^O%>@ZKUCWHEM9_:Y;F&(,L'JQZM4#,,V;:IVJ5
M5DPV&\ZQHV*S,_QT#1U=1'+*B(["KIF<&;NZV3EFT*1,%X!_+KPU%\(0^%/K
MG+) &_SB37UL+M'EES=WZ"?Y8JI*%/FM]<_;>#?J)6VPLGV];_KD_5>%;>I[
M#!?[\,O:?PR&Z4D=Y60*WP:53Z5%>J%Z0#YF3D.,56BBS/KL(D=95AWR#8=]
MEHN9@=X>HVEZG\C4;I;OL&Y4W;\15\Z8&)F%B2GPU%WN<HSO0F_#.HMLF:H0
M%JON@W<%B]6BX*_Q^-6!KX]W$-0'>H5X(9+6XECW@#UDR6XV ,%5:#,YZY*W
M7RG=<O>I[ML*)5+(^6ZD9>Q/ 6EY$O=.MA!S9A!><M*H6\\$SIVNI_KQP>U9
M-(PYE&[5'U/JJ=EDR16U05M"4!X9G'M_'^<&4/V]IPLFD*Z?*@1+\$UO&1MW
ME\D@B]CHI/'3=+ZIF(XH:D1_A$G3YNMP]MLA/S],%S?7'/ <0[3!9;W9+3^*
M#?L?+]G8DGK @UH&4XAS/4KP;U:T&"K)K\Y"7S&R>(9F0STD4R@G.%'ZHID5
M_%> -S<%Z)0#51Z^1J]CD#JM27/+T)JYC6Q2QQBW[A2=^,-G!/':!XJ0SZL?
MH<:!8XT+)O)$*:[N&#NR6"S<UR*6<HNY9P?3V1U=^P*J[$MZC<]'V^,T!W0%
M9'HZ(:(\Z1N)C.FCZ*S;T+%8\MYQOE>G\RHA\?6-0K*O5/L-+WD8O2G$VH[Y
MM%!V$-:FYG"JS'2JV=[!40/.<)?GR@_&8#Q NPT:<NB0TO^Y9*'%?W\E,=SC
M@T#_5[Z^=367V<U0?_$E9KS\&CH0"(LAQ$T-NTH=S\!1$.G[V!%'*/VIF*=(
M(M@'?>L>,!M,90R<8O^H40X F /G4J/8_O["&:ATJ3!YSGG;!&<[;9/R:UT3
M68/7'4JMD(^?DQKF?\(K>[1&W&"MCB4,(NJ'&95X%ADL*KQIA4;I<]0V<*LM
M*0'6]X_::27S:-M],M_\2B?-$OPNKY*5V'@Q1CK=76R 4K$)G69=9VS2=1_:
M#5:J%!<IJ#P>A7FW)#T".3VF?K%CE/RP"W??C-<1UJ*AJ.MH;S%>>1_DQU=U
M65;88G$!P'-^X)RFF3=WY)II;?T"SX\H%ET8 WN4G,8] #H/N4$T7 4:9U_X
M/S4>"?3$'/'+/L_*VQ*A?QE_$[BGUA6 03I 2V?T:7AN3D8"0:S^U&\5QM/&
M+2G3WN1&9*F^!L^%GP4%]%\?VOY1Z=OR&+F([;$ />.\$A:^(\TE7(T:&2>Y
MX()@"V"O&W]!.C:T!&VQ9(4&&R$*_[VA_\^ =3_[/P!02P,$%     @ VCV<
M4K/2E9HG,@  #S8  !@   !G,3 X,3%G,#0R,3$X,#@S-3 T-BYJ<&>=>P54
M',VV;F,AN 02-'CP$#2X)<A T 2W!'<8W =W"9X07(,,A.#N'MR"NT-P'V;>
M_.?*.^>L<]^ZY]6LW5.]JGM7[>K:^_MV"^(W8A4@5) %R0(H*"C 1^0/0"P
M;X#'CQYA/L)XC(F)B87U&!N7! \7!P>7G/@) 0DU!<US:@HJ*EK&E\RT]!P,
M5%0LKUDY7G'S\?'1, N)"?*(ON3EX_E+"0H6%A8N#BX9'AX9#QT5'<^_71#M
M -%C( +5'@V%'D E0D$C0D%T S0 @(*!\K<"_&=!045#QWB$^1@+&P=Y0 TA
M@(J"AH:*CH:!@8Z.;/5%M@/H1!C$=-Q2CYZH?<*D!Y/P!,3G/&:0KNP@51\_
M8>0U=@K$PG[ZC(R<@ND%,PLK&Q^_P&M!(>$W;V5DY>1!"N\_:&AJ:>OHFIB:
MF5M86ED[N[BZN7MX>@4%AX2&A4=$)B0F):>D?OF:EIN77U!8]+VXY&=5=4UM
M77U#8V=7=T]O7__ X,3DU/3,[.^Y^;7UC<VM[9W=O?W3L_.+RZOKF]N[O^Q"
M =!0_JO\2[N(D':AHJ.CH6/^91<*JOM?!Q"A8]!Q/R*64L/\!'Y"SQ/PF$0Z
M/J>R XN!5_V$U-AI'/LI(]\:T^E?IOW-LO^=88'_7Y;]MV'_UZYY !<-!7GQ
MT(@ ">#Z3G)0^SMM_)1% 6['ATI!P'3VZXW?AFI4SYC--87=+X'YPP3I<Y%
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M)Z'C=S/5-HI<6"M=]HSA),M'E,D6'T7B9\60!(;P7Q(8_B4&64]R#1*SK['
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M4XH9F53-0#U>#7Z<CNXO9KZ*;DJF=*066=52TM\)]OM3B0 ^L4(* !<7-1F
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M3B.5Y=47U><^[%BIF$M6!_(_/*ZN$$3;O-]Q4,Z\)/:X_Y YP9IW<I[C.T=
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M(%$+N<99OI?[API@FEWHDUQQ?SL' U9D(2<$_U"!>Q^>M>70>K9O"P,",6%
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M *8GXKFM# ,R_+5@ -(9Y 0$:7?/@XRT/!G&AYO6Z^1=,%\G6=OH6\-(1>B
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MI:QBFULG!L8CH%W]W_Q;PO\[08'-_0]02P,$%     @ VCV<4F[\+L[]/
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MQC"F20KKNKO)$PTZ%0>Q_GOZ0X9'J>=K2ZN]I71/NF -)0)X6@UKZ"7]6M)
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ML;_. ?F@*6V6!79:9/0OQ.Z%3!W/IL9<*)26;V$^OI<0$@D&P$X7.F/M'[I
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M]PTV/ODOFAEI6WI/+2GZ2QUY<9],I'_LU>!9)56+V#@[L$"'BU>>RW&3=[^
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MI2>?E,P*F^U#QI+=/7UZ>I:?3723OT4CRF) T!+ZJ_8,AW+8DDS8NDBAR4Y
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M^0JH]C9Y0-'9/W1 _2NG]Q\Y:@C7_V[OE=Y.5=%N,XBS0[-"+&(#.B;%+Y-
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MHS2YP#!]U2(K/P[.[WN)/ ^!(092M72FGB(O%;*$N0TN@<\QBC9AXHJ54!V
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M .;WD=P26,-V(%8EW)0+$;OHTB$D(S^,.8:4+V6,A24K @=7)1HPA)98<HT
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M(D<G[GJF#>XSWVV?-U_MRFI7/AJQYON;\W?E,[]H/0&G)IT-3(-DDC62  "
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MM]0S',/50T");R[$+K^W6F,7/,73KC6S0CY&K1T:?PN3:VIZ6_:V"OZD,H[
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M2@[E,UQCAPED/"K.=>KS?YCV+Y;]UPSS_[^R['\9]N]V00!4&*C7R8/!!$2
MVWNZ+%_D_Q1EE!OJJ3[%FN8WVEZ>*W+BL'Y@?Z$FLM-?_88-?7Q7&>@KH7\N
ME:JF-Z>N/#WK3_T";;',MW\<?/27V[2D!Y\8(BP;2U$T$L9_B92UQ=:ZBUM_
M'O358DZ6,I6-3MV^(:4284&Q!X\C_%;2I4DH.5P]2Y?.UT,)<=I1V8:K)?\
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M)?TY0HIY\STI_ELUZ S#+O")B1Y".!>S0_=^]-Z-AG(?]21QH?4FNCIK%V/
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MW9O[^11LENU %C9"T@<%VD.]FK0$(T.1":;U[_=9@(]P#>O/;1S([U::"+Q
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MU_R[=OJM9ED6ED0E4RB2('M*0%\F#M20F_Z01**-4_J=I%'0 X?IVYT(/M0
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MR9N:CM^**-C=#0J5^NR_!*T^*8L7;)8H7!YVHV3?=NWR(@(M_3$O0[IFW8B
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M<=N2]#:YO&#Y/GYGZ1IO+_N4)^]NK,-.H+FQ_E:I7W@D:<$N</R8AT?,6H9
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MGPO8$?LVM"&F_]$]<N1I<V_W%<+ 0+R;E! \OE%2"^(T.<T<*7/Y4$1Z=;,
M7Z.Q^]-GCMM)3BO%H)50"\5J=O9X[6#GS7:]V$X 8%_@"7XO+;P=\#5X;&QY
MYC))-LQNM(,?NJR*<Z;QP^<H0UYOLQCQEGGQB11RJIM,W7]$7@JY=@T2:Q0%
M%CAE.T9_FZU7F<)HZ?$M31'_=H.7\JX?XJ?;$4BL%,W4LF8MZNT2XN9YVPX6
M])'SE7F</)=>I9G&' GK$K9!^5#2ELXS8JI9.X3B BH ]>WX?.Z@Q1+7JV<2
MACG$5,WT1B9T3E.XX$>>H<TKEP;ZX>$S+[%X;"WE?/I[].Z[W9L#,3COX-
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M<$F<"*Q\D]L@ JH1^D0@_7OXB%R;"(!\JS&K4 AH*W+O33?>?35%43(X8XC
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M1Q;T&BT8#,OYG@U/:0*OA!M&WYCM$O;'V@8EY;_1[P#/S)Y/=V;-?)YXK87
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ME(<P,U?UZ1;2H($G1M*I')C\M2C?C-92@*J)_'U\?-#K6>]^>_XZ^Q!\O)N
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M].A**\MK2ZC>U2O:VLJU_VK-PX@NZ[V$ *0Q&SR*[@FQ2& GLT+A?;D\^PZ
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M.=>>W'&2CD2=G!RG.F7_6'?QHJIJ%ZKC6$2>7-Q-X/05 MG #,+D_I3:0#'
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M0I_X=P+<[S2WMJ"L16B_K58/09^$#T$='OMP7ZC_,*21B&H2(07ZF*/J,)/
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MG[7VWFN;7:)T;$\IL/@W=\<!UF3Q[7W$0]C&B++%9E8UK9PW)F/%,^0_]>,
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M_OLX0"O8GP9=!IDJ"L,FZ65=>)5 88@K/3VLXS .0+=7CI7% 4;P'CKK1LG
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M+[,/^PX[NZ!'JVF<1EQ>J(/3^%)K9N#."6OJ/[/9PA1O3'BB)]Q$=GFV3FS
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MQZHR/S\\+>=8/Z56TZ)Z,5='OL_2.G7QN?;=R(ROFY%]\!DX7.T(#"6O,QE
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MRJLMFX7R]NO^,BP7ZC8>WI#?TN-817METG$GRCC'?KG.WU@IXK>6\NUH![X
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MDX&D.@:@V(@.ZT@VHE/M&;0N58&:&H'\L,QS5!3M.AY'Q&@$T/$0898UM1Y
M:*45>D0\];/-'?$5.Z=HN#\IJWXE3%\[(J?I>OYG/\/1NR(Y%N%/BN@&OQPE
M A2F9,H4?_F^7S04:VD1G%]T=F3^'G 9W9U:]7K>;\_:AN;$U_88QP-Z^6GI
M]WR2_$NJ7A/C!(T$L]9UPGE^]A#[K)G]0Z6)Q&J&]1X#.XO[#+D]D2;99OV8
M/==NV%PHY.4UOO#TZX#%@@OO.^TO[[^I72F[TB*9=:CT!1E1US)V;I U1SM!
M/?4E\<,1->63+]9-[_+NCC$[$WNJ))-K>]?]@IL2E.F\&UC?&%OTH5=[<PPR
M2P6^/A?[\792@.?AKZ(:&3^KRT,.KXT<:PV<G&I:QCU(5YSU/@^5X67<+%=Y
MXY<Z;@8+7G%_?+F4=W?9?'AL>.KI&R\7WW?'CUPJQ_B5%9N8F)@.^ZOWGED2
MBIG@7#@ZP1-F?E3:2TB9\_OEX,/G!FZ::'W;SV=PM*CY1'.^T@K')>TQ@=LO
M,T(NGJW0OQVR(F&>NTHWG"P9'.M9<JV\6+34^C:=W\5J[J(6YH9GWWF9(^]&
M\;Z+*:GMOY25SXGS[MN6-+\;<^!!][O;Q9D_D372C6'-5:85G>:)\1/3\:FV
MZI7EUN\ES_::7&P_%C)_V$)'5$_O\#VS-RN*#.<_;;D2+[,<!8\+R?;GZ)H\
M*XCGZ/C,30]E(]K[B%BF\A":-3<PA/[G%PPU__]<*G/(NIQK:*2K5]=*A)C^
M*3\OMV5JI9<N.ZPJGZ^3+[O[R.GW]ZUV99OY*UZ[/F^!&7YQ_'M!+F/V5SBK
MRC'O9&SD/>&[>LH7<G^&F,VIAG=.M[C(Q;_*^KK _YKDM;?T+B<"<7_'<U$;
M!3&S9&$!Y91!?I130V36]W&#$!7BD>M_^@=ZFS[(!XCB>,.2A7*RL*J3-B[Z
M>S3V8(Y_>".S+TUQ">?$"/OX?FS,7K_""^;EO/..Q/5.\=I=B>_5-]?S)*4D
MK=[F%O?N$/NZ__">/_(_>1FR0WO_N:Q'Y\__M*P'VP/KN[$1R=O8" .?_N^X
M_'+J>&[&2-^NXJAG;:4]=OD:X4:3EQY=YEE2^9C!<.4.3Z^X$IB3V70BZVV4
M3F>?:G33X<7F.'ZIBR3^@ [K\N;/U)4SFI]?2,=L+[T'G,NT7N+M+O.[NJ>>
M(1:VE=4F\-M\,CGFSOD9/GT[O?Z6T:Y/WQ[M,T@2YILD&^T^_VJE2L3<9&^[
M3U_Y[631UJ<%/(4=[](BHP34=AP?=G#G<8O63T%=4T2>U?6:23 V8ZZR$5?L
M#4WCOW(59*B(NBV</G:EZ!+?$XKRP\OE[\]_4=(J)/--!4Y(';2]<T?U3V]R
MM[IJ_UO;[$\("=HD[\ZC8E\4+TX4E19I6SA#$L5&(^XG96OUHJ\J8(:NED;/
MF97@0G9''WUB_&LH6 CKK;38OOK0A:]"QO!R7%4<5O+AX(J5O>F,Q7RDUWXN
M#H&GRJ/38QH:M"<J)XJO-;BIK L[XX/GLIAA0GY_D5PD('*?X;43>4SAHU_L
MRM9BGNS>/.A-"QM;WLLH(DFQQ/%P7F._Y*HP,U=N@+F&W%A8VR?DW-1=K;2W
MEI(0/*@DF)5Q6N^7F&UM).]-22<'Q.8VDKQX.\^52!XMRS\^W+>Z+@EU?_FC
MFTIG5@\FCQ*^,Z'4>+,7C_:5SW[N_;'OP ,>,Y8#YQHM&NOV"#7 D0#-@YJ*
M3.)F5;(1D4WC;(1\ ZPH.\YL.O/:"4]<2]XM>E; 76M"-OYTUAL5P=ELF[1#
M&I'WSK]BW:?VOI7\(NA/(#O]_LA&M*8)Q.!<*S.%3O"_SLP\U;E\]L6QZ\2
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M,!-\L+C@=S9B)*3@48$K:AX/U#Q+U'JKP&ZUHBCEE&8F31DV+_>$/0G4FPR
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MW!G #S2OL?4"_[[@"-1B 2Q"\M\GF'@R&Z$9)P=NIC(OFM&C[TL8FX4-27I
MD<I!PVKN9. 6IHI 3G< [1>1_$:JUG@!-?=T8YJ->+JS![GA#S"05"%"NDL-
M@I-Q%=!:J>9FA;"R6<76EW*W)IHX8-E1XW\]O#D!^S\=WKPNXAO$1HC26'>5
MX2-]DKZS*"VL%@6YO+T&_K0 $=48FI[PQ @;\>O:UIXSD9 5&P%:SFFZ%Z@[
MRP89^)0MBC:&];>(@S_F8C=RD(R;Q#.FL#ZX+ UB/2::#R,W=BH#W5_*1JQG
M*5 \\*SF0-89H!#=P^>7A0=E8Y;@O+X^O^V@A;[  #00?$"7\ 1EQ07"VCQ0
M[VDQLZR'"XY4!JS?!\((;$YS=0[J'6X5Q<C8FFL#FM/91F&<KP:UMNX/(""M
M%+?2NR V@Z(;>>+H<YAEKI?(1US!U2A"6RILA0-<-R'?!)%5R*(!<UA*G2O$
M$@5_*PW_@OP?RU O@T=L_M]M!=>CZ/GLCT>][(/ZZ5]//.#SQT^_-DNV/ZT2
M^BG$Y(/!":^IW+S8$VZ1WA_/;/]:<I!3L8VF@+<?<D0^&Y.Y("&N]]PR02EL
MFX72SI%7.X,1>Z<2N#Y45E64O?WE+JN\^Y3=$QYKCO.!PBG^E1X##0ZC"AIG
M?:EH\]EEQFN3VN0[G-5RNIBR:W]&2J5[CV\FS>M?>3I_.09?PQ?2H-LE[=,Q
M'<J)^!*Y5J%S"UDI'W31(^@C-6-?>K73IZN];GDV&[VC.>;"VS.^A-8Z2NG4
MI%5MCV'=7;TJ&&#-,3O@ZVK#O( WS>"NO2B'SSL](F?R.+Y9OWFXLC7UEMK[
M3PG8[<7?\2^5X /!WVJZQ[N:0[ G=QPR3]+?*40[\NZ,YF%SCV$#V<*LFN=[
M/Z>&?!#1O_ZX4?.$N\%8N1NO8__@WO>L%&_G5<KJW'C?C(W(LQBYOQZ(77(;
MS"HYX[,]YDGVRQ/W\H]H'R,TZPAG/-2.L5=H#(LH$O@]:^U8-H+9I44]A"\=
M?O?ZP(G/_JJW4K>G9-_ZW.1CMMKT3N&7_<';?<<SMU>N9XX3NW:/$MI[)L-_
M#KLG=CRS8&A@#]V/%A+RY6]!&RK>\WJ<EO+YRPU+:>FWYRY?WGY5Z63X?3WA
M,;E%)$@Z.^_8S3:GX? )VI&LQT8'=VI5A]Y8"7^ONI=>I,\KY,9=.OLK@6KT
M^>6^/ >Q^#E$FIU&KH__%V[%#Y:P+20P7_'$H9J5-;K![/JM-8XD59.DBD(W
MZI1XN;@O]'5:S[XTL[(6?A<2>>50I)>HBDG\IR+%7[@_'ZA5Y8%US>Y>5)1&
MS][;' =?)"AU=V\_?NCX+YOP#V'8(,UPCZ$3(R/-DZ4^*M^M2P^WJ:YH[?F]
M^X^FLFYFC:<]S: ?Z[ETPF%)4A(KC7X9J= 0>CUAU30\/%8U2%57X5ZVE4E9
MYV;=/:8SZ0YU=B3<E*;V*.[##>-T.;N'*DY^>KO'A!ZK/;JR5[OQ "09[N$X
MT^-7:M\F_>[NR0R?>6D30][K'29 TUW&,*0(,82-]RMH!MD#75_'N '<6LY[
M:#8,M\ <?8)5A%IGVZ%5,ZBO<O.<X%3R2W_S LI624?1]P PE+.%R+[&Y&/U
MZQ EG8)EB0/\RN'(@H8@NA096FW" AB*@WFV 50[OM+&1AQ,WV0CQHB<))P[
MBJYW P?':D%]0<2 _XC5_R=BM6P4?H*CFN/$V8@5L0C6I$=<;3DU%$["@'MV
M<+.LXC+O)*.F76;0]'DV GLDQ9%T=TZB;PPZ16:(*4X!M^$!K'Z 03<M#.T#
MT;7HGG L&T$MD-(9*$%3BDG85?!<8]T,U"P-C)O,"AL!!N[>#.CZ"V1YP *.
MDK:*9DF<!2/-F:$P!T@P$ 0J669K"B_[(BW*_Z[""=P+ M4,>Q"W(N^(87UK
M9W#X?@9YU3;"O:F_=;:GQE]F28#(/,6ACB?0B^HA5_HT-,3Y%%JYN$:&U]_[
M-FC62+$4CJ'FT5LC5XW=VH<W1E:3OA (H_JQ@IM[^B^NX>/9B-![NG!?'X$1
M)E61!\+\!M53L*&LWL;ZB-UZN44PM'[Z]!LDE9>7^')WMG6#G\RWZ<?I24FG
M,N.0W6YESM^N-#*">0IV&X@M(%8ZZC56XZ1,5S%RJX:B#T=;=N;/5H\,RQ>]
MLCVKEACTZHN24_?<R>+72T((YWX+?%5$Y*EW>V.&H^&V9SZ]4MRK'7Z_WC2V
M^S0\$8D3N'-:.VED2L3')O[Y_:KM,!XURKDD772MC3PKPQM1>N1Q6>^K1LWV
MGES#T'BG_=K8M(AQ0<?YG@B& GX2]@]O!&,X X(=XDMC)H@-0TPI,SP@9'ZT
M!F0$$B3:B(VP=_=#MLV64I(:5J(FPY?;QB_Y!A2PD@6(;V!D4'9>;NKR!%78
MLI%7.?$TK#WS46$PX%U ,F!<5YA<PSF:ZDUMPVN8SN0U>.-QN=KF_DI36G>N
MU>3PTVS63.'DO\Z\"3BC*%EB2&KSH-4&D7)_O] DB7V^J3)>N316ISOPFSLZ
MJ:],T9J9,KPAWX\/W/=\J9KI)'DBZ?/;W*R0]]>HHQ]T?*K,U'2%(SW6*X3X
M Q2F<5(0&,=1ZQ'U(.M9DL.T(\7<9NP4GPSFZ(K[?LTK5TY?^AZ:?JX[=+ R
M4[@C]\[L@3%8T&'F0NI[/^GJ4QZ!86*S7>9LA#4W#C<+E:'6.'^P$0,=UDB*
M [EJ@'6)";+5%=^QR?EIEES7QMK$DCER@F"5)/)071;%L++0%"_\*J_)0O9:
MJ(3R41FGSO$9U5G"8/6U2-40 ^M8J8IW89RAJXO[2)RC1P8Q-6,]CW_5]SG(
MI>4SH&>.Y^WS6GU[;;8??YGK\CQS[$Q@KE52+;=.1JEIV.CL1:>B$=GHHX]"
M+AQ?X?%V\_KW4S/\DO]Y;$8$JWEKD2>!C9!OAA5]3M6O6&>R$9_C)N-8T7P/
MH'$:T%/5(QE51X:1FS[P*!O1W85:&$D2<"$P<^6$F6O<&T1W:\(_#_BU\__'
M ;]I_SG@]]\/^.T<.U(#A( SID6V]6$-.N9SHH6'XMG"\ZIFDQ:%WG<J1.S-
MQ247&VZ=U$],/11M$A>^UVLA*S+N'+4L,G@BPT:(9CY71'(*H8M4EW@O-8:-
M=92B7?2F7?1*74@)PT/EI(D13@']H@J'TM+,C:KS&VR$,L]@;\/-7V&C.YGK
M^\O10&*>, \>2NRQ6)(OE_*=4G)T-Y__.;52*.EZKA(7-/GT4Z..WI'HUF9>
MC;IOV)3\7]*7 P_L:4DP:KEO"*2IJM-HYLC548MZK.U^,BU=O2SJ"]YE*?L8
MQ3CAP9+; :7@GSJ=:E?WZ0O*UJ?(!D=?Q^S I"\])H_ZIAC7NF E978I'X_
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M@AL9IAD1O QIMELK91Z#9AA"ZX^K?R(!R$P_J +]>X-:^$/4P/KO(?)5VW0
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M FWZ'8$F6J$EF=P?$; >4+/S.J@E9!Y7(6K%H@$:S@$MKWS&6#@WP(AR!BG
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M$O.R6T\R$+2"UG"?,1+833P51U+'_>U<$A,9(G\[EWH):U;-2]!4GG"(M7*
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MM(UF7.+_1WDL DY6PK)$)7"3/>Z18[^AU@R Q>KP#B(:/0.,TU,&!=SRL"(
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MSN!)X:]-+\Y-XO@R7EX;4)((>"*R&L/*S=5SD?OJ9Z5Z!-YSM=,/,:]%"*I
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ME-BP'(GY<WMD&=77?M7US4S W_$\(N3W#S=SZ0%YV%+'771V^:HA644FFK#
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M*FLHX= J/X7;PNAI>?#!?U=I]*\J]8].#-?T+B$]B>NQ9'%7/7 G!H;K[J]
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MY&<@88&XU\*\WZ$<.PE^!5(P'^M?Y'5@ZV=Z*]ANJJQ2J*[)I[<<_:CN0(-
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MCWAV&@G^J?,.1ZZ PD([W?X+9%S;]B1E =WR#;+<4#1J*Y(/AW'_J'"P<+(
MO1JHJ[+<5DYH))>%@P/"%FJQU7S+DKFPZ#^!G%&P'Q;QBXW<@O]J-(R%\Q\C
MV?Z5Q/^MMNSTQ=O 4?^E:N\TVY($WL()KF -:L5/[_PO_M_)SSY0&U"H<'!1
M$/S7\_@?<>TW$_N7B&%P)UOGOT;[:TRN?QK@+V3PGP[X[R7R;VWP_[1$?E?]
M?]3V'WYHAXLJ6WS:]O__8UW;Z@O['WFUG;[H_Y5G^C7;WY;SGR!PC[#-@)^;
M$SFNO]/?Z>_T=_H[_9W^3O_WI3_"&W 4N%G"<\O+_78!Y=*O"RA4_WG:]4>B
M_I7^5$_U>\U_F'8NH-12Z5!3,?U^ 86?\I[J]=9=IEW4O]U&H]U+LV?W/FJZ
M753 ?A!,0_W']1.PM&<W->VNO53[@*T+*+NHJ'=345-O4;2+9A^.:A?U;J8]
MAVA.TA[F!O8*'U$0X6'>=^/R40M>T6/:CG>/6P:=4GR5_?VTF!,=2V6S^)EO
M.A+W9H)?*^EBE%4@JM"S>OH&K#GOO@S,PKRQ(??A<;E5+8/G+EK-X?@DI:ZH
M734T,K:VL;5SQKO<=GW@X_OPD5]H6'C$L\BH^(3$I.24U+S\@L*BXI+WU1]J
M:NOJ6]O:.SJ[NH>&1T;'QB?F%Q:7EE=6F;9(WKJPLF?W[MTT-'N0(,E,NT\>
MVB-, W ?5KA!*V)QQ''OY;L\0<S:KRR/BN[+YJUL5G3Z?NS;/;%3P3K'H4HS
MKW-.B[/H2BC#SM!AO$-4L%OTZL%Q^I#[#[8)GCO'&AJ?MW5S)6SGZLI950.K
MB[]NK_QQ>>:*H8W+PV?)1;6=8\N2:D:VMQ]%IA37=8VO\$E=-;9S]8M*+:GO
MGEC]\QV7_L'^DB6S)7)91]E:%F[:<[+7[0>@C6&]GA3S?KPBUB.LW#53HTZ]
MQ-;SB/O-[HL]#[3,G7TM%C;8S596IA7SUW9AB<^.O^[JDAT/F,BH%+B94R-4
M]_FZ(K/&)3$F(1!52T#-2M:LM>#3)D1O4TG.19E"<Q)YZ1.N;RUBH/ 63**F
M8<K\FC-MK?^C4I\H5M=K:*UI]DB_3@)$E)Y?KX;&ZL!8ZDM?'D6C0\UK65A.
M4E-TA<0Q&V1UKW1!+&/9J>7'M/6]!(.PY;O=1O2$?L/>FL^$45=GFG?$8)*S
MG=F;*4[_%QE/*@?CWH_:I<P6RS@KA&?Z)-JEJD&7S":Y5NKF,,B:H(\6=K#I
MQJJ GDB/LCOCS[4^")#R1=QFHYW=68FQ?-F14@+5^WFJ@B;E:N+K2,9\8C,U
MT8<IP('49];:[&:3O5?JW2=65!\VX1(\B:1T:UN<OCD:P=%4,TV']I6MRI[U
M\,\IC&W<\&^>SEN2$W6 ?JM';#3?&6\D!F?4::@]>>TR4I6H80M]=37?"T=^
MA?.MSPHYGHZN*7\UU=A$-/4V*L97P!'FP<QK:X/E$V_UE;,A* JPXE'(TS,?
MW6)+DJ([;K\Z@"KN?M9F?-S61GC^]O%3R5&$Y83]+6Y9..F\Q2:+Q3.S;9L&
M+N5Q?6MS4/<P(M,Z;BKF6:UNP,=W6A&DS)#EN9)"'9P7]DL^.X>FQJ/NV^=/
M1(LZ-I,MF,_G6(4ET.N=X-CH*%$1K WH_.#^A)RYGOH!/VKH+.CJ?G79UCS7
MM=\9I[_6=W#=(\0+;;:1\0%G-?JVI04EE]]))$>%A^PB3IZ-.WE:I$)85>N&
MVF1BD&Q'"?T:]7!L [FO:BJS^2/I/'FV#G?,RTM0H#JW'$(*2)@J?Y56MRAO
ML8Y\-170'\C3V57OZE??39]6.DOT97W6<_^&I65RO"]S<+)/IE*D1T?)L37&
MD:1ZY$:'1UEAB72!&T>@ S+05\\CK8,MXLQW@N<@A )XD$JGKUIB<I8**L/3
M$#H(5#Z)H81</%FPJ&HY<NYT9OS5TW=G HWT%+7[)GM/E&_4D8TV+[OS]KQX
M'-KGEOM-0$L5KZR_V7.Q]/10W'M8N2)LS-53,Z2GM[?@^Q'=8E;VC(A.$;36
M-P?=&XE2@4ZZE\.$:_36I;5*EI1HD^4NNZ]/>C3ZC=,38K)JE54)J=+F@TOJ
MBTW&9/8FXHM',V<\W ?[V75R)")@SA=,+A2_B#3)DX-<@NQA-U/0$7S\NN8S
M!3AVNQ[&#=K4Y[LM%1?E[%#/5M>DBR&R'"/+<\0B]NB-Q15(;KG,\-C0<FX7
M<VA9W:.4KM@>KPM>:TL%A7*#76PWU<-3?6P*UJ,?A;^VNI=S[RH:1XYK=@_?
MO-4;^[RR#>W152QU2".D/[9ATLJY7Q\749,>8TBJYYCK)!H(=S.SR*X1LDU>
MQPGGJFS6>228=UT>+_B6*F9D'!8<]1H-N@^M=^[$E9 BG20'25-B^&0J:<%W
MK"RLBY D.L/IUJ[:P9Z\C(YR"7S*^2YY(D6X,U*$S1Z'_50;Y<)_*J7ZAAS\
M$$MB4NV7'-#0NSJ\SI4K.K?/3&CTF^L%35S5J"3(,8^L$<[DR(F1ZPUZ\V0S
MUBO<&MQ0&O[=..DT%&PVDCZN8%,9.842@=Q-MA="&QSE*S?LC;-:,AM7;I,7
M\]0A9Q!R%LD=&H^_2'LCUX7&-WNJ<.35Y<J^(M#4W#VGQAJS@OJDD_9WLD'1
M5H%J61I+&7J:W>G$MN\P>Z'E"8<VE_I \?,DD/V%_>QAW;UIW_$#'$-]^>RY
M;6N^N9MFZ^CNLJJ"7':D;P/Y?(U9.[Y-A=%U:F/M3I=+;V->FFN#9+YPGVOI
MD+#V-\QQWH 2I?CX##O8DME8&1(=P0FQ7?32G5KGZ'@\N+G?@1P8X"$07C,D
M)X\J:].9"?0:=2O$S"].CU_#'<D18^O8YSUQ0E,>^P7E.IY4TYPAU::G6Q=8
MK\TK-]G+8"[!;R?,*5'B'),E6Q 7+G\WEOOL$@J:4S)76FBN.^P4[+Q48U%8
MOL3<6GS>C(VE8O9BE.R79:0X,XN+;?F"K06V/ M'OA?3LE(Y&Y(T6W%&W]?-
M+_--Y=>SD/[W&J0B3QE4[+?(%UFJQ-X;':9S[66O1A*K8..%A1\,YZX]DSR=
MG)C:+\9V[VIM7$;(/EU0^[5<IJ,J1"4"AKNE%3W:.JQ&:O ,7H@ZPKE-<=2$
M:2Z1DS67&)CO//)AY03?XCS+PVSI)$:3NU4UI@_B$3AZ&3.9)]_&176O@]X,
M:YX;"]F\M8A7FN[+[,]&V95<^#J&X.W*[.NJ8,63N;/2\!'8]6.UBS32B8=M
MRDZ9*L/<0DK&G SMSE>%I[]O>UEE("/)FNZ^"7JSHZXM([[U]('Y-A(#%A#4
MF?U?W.P'.XR=(09DP8"RW*B^-<%X",)#P.?U2G:AM,!,[#L"0PAUGJAT#$&^
MH-3HZH1=Z?4 0ZX(MI" I%ZWE$@ZOGK.8<6V(MD.\RZCY_<Y91?9V?4-26:M
M1.D6Z;SX3=LX@?"F@OW4@9M+E@4^T,3AM*QDW",'"M"; I.Y_C0&) F3N#(]
MF\9(X!_,2$OK9^-W0CW_('KN*9$"L$':6>->EC38K\_U40 .D;*W]^QNWH\>
M"7.UO';4+#,\$;+F4"5]0.1;XU7!DB7EI4%\'<?P<G]KV>U\#!O:_;I%]@N%
M#EW3H-XV3G:WPUCG:6UD7^6*]=SA_6%3S\LY3SZL&X(4?*RN\^\6WU\XD)@L
M;<!61!3@%8'"Z#E+EA1IZZ8CO(25!1T6\*9HCL\)C:08T*]4KU'#W;7[I,W%
M"]<8TYS,CQ3JD#?SWX]DNY$/?&HGH<JGZ$?U7V=F9@\GUI1)2,7P?82;Z()"
MS,Q:\9A-VQ,Y??Z8/JY<+AAA[>B>G3QYC<S_JE"#87^YFW5:(>1ZP)LQ]B$2
MG00$TNM&[01+TURX.S[NA%::T]8Z^$%?IP'<62 -/IE'BDUW[7M4?ZM07S\7
M@3_M9H^\2H[NE;7=Z$P=KXAD2TH:7[1JGY+IH\:2;F;=6O2]%F5<>H(0$"7#
M;*;M1U=Y_GBZ=ZL"N.'I7Y#S$BU9S<V J R^;!HH9!CJ9(/(OZ@FEQ$XFGJ/
M]WR"H@9S6*[2U^6]JH6_ZEY9E9KP#<@]$:;'KWP]:V_XI:BFDJ7+M!4X<MET
MKUN6&[B[Z ,ENO030/G\KS=;_TV 4I;KL%0#_6R24U5'F;E:N9S)L*? !47)
MH%@L;#%4?LR:LY/E&MJ4)//A:Z238:G>4;<<^SG1%C4-97&]\V)&+.]*?<[:
M@2LP=YGI^ML2XJ#@E4&I@=C!4^9:I&E_#WSW6D-^R9(]VA:?V-'Y0KRU@@>V
MO$XD)!0JFTGP];6\G9:9J;=^XZA7[1N[;,::&HZ[EU[)!DK5#N+[L;RO,[(I
M; V-G]>LZ\YQ]QA?E_=$>JQ%DY/8U6,FGP28O!%>>+;9W)MGBM,)F<A\5PUU
M)2/2H"=KK&V3:@S>?FZ35KX1U^L6K\FYXM]F3>#,6&1<.I-5\$#+WAVVG#4K
M#5,L==-,-.[90-?Y=Y4X(]C5%8*ZU@2Q2$D(!_$CTO$("[Q6[5%]0W B4Y[C
M/FMS'/E)4WWY)HDSD C=5^Y,JTP!$DE9JL42!9 W-C,>WO[=Q/984,$3B9VM
M8NS0 GNA2$/I_9X;Y!'FIP-V]D*?VY6OM#;K1:4^/ PR_I)GR\I"$$DFX4+W
MA&;F^]%"6BO2]%.VZ,$,E8G^Z7SG@K4J=^OI:_**SHE:[B/G"F*\3F:GI.1$
MKIXGBY]+SODRY-!&)5:E=R(HJV1)C8&P:95'G,.OZTY^#%0C7RB="@Q]85OH
MQHC ??K>XS(&8;C\8DEEBNB1MW$[_ B6:)Z=S<F934 %.HT.^60&EU38DD\X
MJW*J2A1S@=.,=N59>0F5-AD<L1XR\X(CW37WPW JT")I\ZS%@*4&<OG[2=G8
M?#=:#**Q+2(]OA;A7_BH]^*4LR#<RLEF7C0]</V"\:T'?<? #6B&U;WRQ_P*
MRJ$?VEHZ!G-T0]N65R?4M%V-N_EJM5^'9T:Y-*B*RRH=XH]+X:M7. %J^O@>
MHJER!_ODF]E>*%':.-!U2F;8;%>%0,&L. N='=]$65:1HUL6NDGL67T]:YEA
M1LW]^/2'^X##.J^XNK>,Y)#L_\X@M@&4YO_ P&A-.G)FV+@KCCU.J9S6J EN
MT-'O4%3,60PWQ[9J?_ZLIG&@+9+IR3VEETFN?GD!HCS4/#UGI8S!S2!O14N!
M]*9'Q&VOL81>\PV-+9/V2D+@U]<NS%* 9O62BM7HK<$H@&;G],JBZ3 %>!V!
M\UJ ;-G_YHOL_KDI0@,%4+XP00$FMG9*;AO2T(K1+GS$II]I&P5HW786J\XU
M7DTYTX(;1PAI%"!EF^IY4@ %B(7WF:^>PQM0 )TMS](_3F2G '(-I17SVN2L
MS41PBLT*)-FHZ-%BB+PCB174)-/8*<Z P4'GZ<:IF(QZ[>D3#/WOT3)]&UW1
MQ,S).:*]P]?LZ%RJL%[)*+6HS(!X6;FKDJ_V"7#-@H;,.B3'/V\V^=Y"^$5T
MH:?A(FR>2.?YO+?XP.B-P8(U9T'E"PN5SC1L"7A]B 5N\\N[Q!HB,039$F7P
M*C&^/O_\PF<-(SX#W4EP7W.EVT31 ;EO:0$IZ.A.!I>8Q:6$O@4]HYC 2=:F
M;V&<U0FI];>^/L&ZJ_(7SDICM;]:^'*U.4'!O99A<OP]I6 C<%^O2NH/W+C=
M0<@H/*:EN_YA?-UP[%/Z\JAR[J+YC6_FZ%LE52EXB85>HB=[X<; Y/,1'<:2
M-%%3_TB[)Z];9;*K=5A;3DDF/>KH=4LJ:VF1Q4NHV^AB%QCKO?P--;()2Q +
M6(&O^KQ$4Q+19/ -Q&XP)8<PZ=*,_I3>+V) [G:''PF=U_M<)I/GDVG;OL!Q
MSA+4]L//EUN:7=(91DQC56?7DL_%O5UDV(^$+WH9/8I.*1G,<U/Q+G6K@$^Y
M:C1FXV7WR/61_&=\_:XUIR?6ZC^!G0M\'1[^@@E4>6QZ;+Q4+,9JD>-[__'8
ML-ZP(N<'6M?)+AB3I.24KY*R"\U&&RTE4KYOA)=[B[,7^P1OC10T:BYD)28G
M$;&="$_H,>[/0[:IMNO9X%KXV>/!<E-@5_\QT=C#BV9S*X],.UC,7DPQ/(XS
M76M]5M+UQDVU4$0\!TWJT+O0U>EF<(J SV!@$S!7OVN4<--3=L);5KJS:,EL
MHK*@WX[D$5<H)&V 7H#@![^S0>G]B$77W#UN$-C/.AXW/BY<U"UFRV5K>BXY
M)8C*4FU_706HXS%-KH-WLR<OS*Q[2$5CA8;,)_*&MCR#;''Y#81_Q.- ",$9
MC4&N*W6]*"ZTK#7 <<R[\'Z:IJ]\TNUF<.1U()L>I-=Z2<XNX%[,V,%6W9=6
M>J=\2Y:N4O=U?JM9%9F^()^D@PK9G#V7[@':1,.&%+0Z<%5TFL' 8+W>_Y,+
M9RN=FP\%H&X"*2& )JA[M&)5E+SFZC42AC)9+8^)9<A:H !)HZ"%WM0""2T$
M47(NLFN47/E*G#CW<!VD=,+J,*& ;(Y!;J3HY1-$$4/X:RNL,O2:I,G&NCOO
M#8:$7?RF-C3%G1:P7M ];A;9.#VF&OZDL'-#=.K[.7%D'_/_V%N94[[T!FL]
MZS]Z,M(V8?K3FX"4G-Z*NW:JO8;#Z=Z0SRS/]?O(I1JF;%?X;&;9+:*:KK=8
M688QC<5G)#'01HF OHB_@+$VYB&)[^8#O)GSM#EJ]9J>]O4A.X?H.&8]9G98
MJ/AMI?@7U5?O)U^L9TG%>K[28GGJ3VT LN;!314H4Y%PWNUT!AWVZ*JA6\;/
M/4V83#6"/W2T%)^T.SN9/!P5GDK#U=7<I5%>#CHDQ[^:S&=^ N0\FW6^D+CX
M\8_E*E)E#Z+C%!_?"U8*2#1M*@@/C[*UMT^V-"Y]\HDGX8'1<$KH$?]M%L56
M?+D!>C*OKMC5_6<HP,TM279.!:,WUSEJ=2PO>10>@-<.I2O,VL%#-#Z%$6QW
M=[\- H=7S7G+EV2Q*(37QSXD=3M*QR,>\3ZBJK\==;%;^4 E(J&= B2;][JE
M8YS]Q<6L[!HC*I+/M;U62:FSL'%L3>.=4]72.JQG !\??]\F?BC>\212^\J$
MW_Z#C"5+IJK=H3IJ7Y.ZW3XE)L[2Q,>_?*^GK_KUJ8*V55S2)W6]O7')%D>&
MFY4.,YV(NCF^Q0J'Q2?,PJHWU'*DZ0JBX(<4#!3O)&3$)?L_:#>V*[F9WMK&
M='%51/3<.B?(+CS$NJ5%[)Q>+J271T^#79R[;4"XU:<@T[#/9BRY?%#T6%]'
MW@UI%^X.B5!,8GT[J(&"J[<JO4(8OW;-MN4H[Z%+)UC$GKQQO60\);N6$%IP
M.3%3\*;P._:1P/:[$;'@ !H40$UUTX,"6'F-G8_=V);57[!X>C[4:[1_T7KS
M7AT%Z.#<7GI.<:XL;412@)<Y7@LU.\O6/Z+ZHOB&<*3I#:15ON="?6!=+N3J
M)#*SX%BEP:;\P]F:,=JA&7 )3$(<@RMJ>!-;9Z=B*A\,O1_XFFC\?,\IWC#,
M$Q@FRMAP0F2L3?SU7M./PO9/>5'M?$]4P=WKX'!@S8;_; <&=WKR$UES>O)C
M[#5+:8M%.<7,B9GC,N$0-V>KSG<W2'*UW@(:Q996#;@$E9Z;(ZPQ%G(2)88?
MPYBT- ZG@(L+7Y/[C5["8[P%/J!_)7#.EYIQ"66:<LE!<B,_RK1:;?V8C3(S
M[K2Y0/A'2\SM=#,MZW8K:'A4E&$4PM\HS2\QYI02B(3H;O-N0 Z"C6D;7YXD
M2+^Q[&HA7_7;F"L]5S!UN^>3JC/J9OMZG8&UW3%'5EQZ2K2CNO;^B[/:W8YK
M9J] )AT;";34&5Z5ICW%\;D_3"RKGP(<MK.=3'; WN:C*_*M*T\(XP@H\!:4
M/7431R6F-$/@J1U[N9H);KXAZ*X]["%K=[LT$B)QISM55+Y<:4U:OE,2[>"5
M!)KJPS8OY:_"T>K,=U/Z7E3FTU 7\I!=9<?#JTE/.&8^H<[KDY)[B'"W8U@K
M"#M3?V=CL='SJ+N-VJK,&B=:L2US!Z1 ZU4=W&1'&N(+^OI8$!3@]D@<,4_<
MD,XCPRC_^[,>E!9C6&4'J8<"S,3Y?_IL;;_D.5BI7Z=G&F;\<")5Y.ZLLD#&
MUAIE(W4&K='\#%F7/VZULJ=\L<S9->)DKJ,T$0UU$F=WNYM ?':-E71 !<5R
MZZ.5(W?6X5-VZL%1J2D<*7&'CK== I< 14*A8Y-S18VQ.3EQH6J\G]AN7OKI
MEK[O"3%L#33P0)AE 9+YL'VI6OSDWG5_&7!(Z_]\]^=%::G@##/562_YWB\8
M,9BYWBG/C3]6Q[$VL5D]?7&FS*B4ZU5TH46=12/'A(V-"?[6[NB^"O:9&K;
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M_S"9-N5?;#3+QED&S>@SZO'D.=G)#M5XDW.[MR$_GE@TU./R1 L6&O 8]>@
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MK*U+EO0WNG/2$-PM!XT27!^J\W*.L]FRO+J95G=HQ):E32A73>NI4^I0J-H
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MX?0C4J^Q_81S/P'7:9@G3N$,]Z*-@HO38)47#T!8@#3NF^%E5%);SB;XCUS
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M-*[H5959(4%!X+[ \3VZ59DM%$2D5\!9XVEK;*)W;?-SC5_]B=X?N:/2[LJ
M&8[&S7:H!A4H#WN3,50[KYG >CLL?[)"20_&%7B&>'F&\[VG",Q5>?Z^+:H#
MIZK6(!=0+,#VZ)0)E8WC!04</HGB$G7;,]^E(\KSD\GO5#.RASP H5C3C[&
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M#?Q3A.G#1S@QBUM+\(- 7*["$^K:AYF\1R_]C7%>20P+V&,TS<4"/(!K2DO
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M/?LNBU^N>9ES[QVSX1.&G[3!,ZIN4EON _YLFS<50G+: CDV%_U%-W7^1,X
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M+GV]NQU#J5[Q4=OI"^]WB7%9 BZ='K8<)THY:E5*L6@_S))(Y"7%-=R;[ (
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M>JJ8:3[LOXTDED=4L&9C<GW7NG+W[KW7O?NO=>]^Z]U__]E02P,$%     @
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MVT=,]$N>"O$OV;2('_)N_Y!__,4/XY< 5,>ML5+2))1Q )KC$L#VCV,\!O
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M;8;L Q4C5KY*H0UL9XOAZ]'NW<1]MCQ;EK,]^Z8[&F-X -<W=EI_EOWP'3P
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M3D+9,:AUF#6U6L-(7PIOP9.=C!XD"C[GC=9_'*["'?(\SY8X@",@=A/=":=
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M.1]M5V]"";-8A1JWF\IJVQR+;JH:=Z3([<DP(GL/Y$7=,\JMUX@(,UQ&Q_D
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M>*(4;2T6$GAE0^Y!W.K;3C$BSK+)3Y;R>$#2G6S!6EQ/V65=;>P>W.;+!8-
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MVI$@BZ'I -($UMONHX=XHRN8]*;V9.Y\;\**\*I!$Z.YXHBF%>5N!V.XYS%
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M=&9%Z\C"+I>$BI&]9V!,5F7;Z.+>7^_=)J<G*[?-MK'50]7[^? 5GZ5QY#^
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M>E15T-MY4SLL[7:ND_10I<#1X5#E=BT<^YC._+6TMS::OBQ]O&B#]C!B7R*
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MQKOVZ6T>$B;MUXW/T@1 ')Q<7'8TMLPQ][;-O@[BS'IIXH=)5J^,(_.1_RU
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MP,5'W0!?JK(;RB>-."*O@^I5_9-?V&*>98I,#:9-I+[">Z[B2&KU+C26)<J
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MO7I.'^3TG?"9;4JI&. H9'TM6K6HQ]K1Q64]G,F.]N%*TB0&]B.&XKPWD)(
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M].NLD_83FI%%=[6"<</3M>*2<NG\@)2XW?1W2%?,<K.4,*>/4K5'_9\DF#B
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M="1$QCK5C6\9*C=6"X\ @X.%YGY\7>'LF7(03WN9<>,C&34]?7WWB\/MO;J
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M65Z!\FZ W0?BX5 BU.LA;Z'].!1_%#M(0UL^K?>B__H_VK=8V,_1;<;^])>
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MGG] ,%!Y=%+8MO7V"/BM36=MY4?=MTHVHW*90M=-D/\Y9UMWA_\*4$L#!!0
M   ( -H]G%(A9CJC]$8" +F4 @ 0    9S$P.#$Q9S(R;3,R+FIP9^RY95!<
M[[,N.F@@2(([P0/!W9- < WN.OC (#,X),&#!@;7! ^!P1D8+ FN@^O@,K@$
M#2' ^9U]:__WWE6WZI[SY=:^=4^O#ZNJN^NI7N_J[J>[WH?YAS7 4PT5=14
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MR+*FT,/X>(#EV=$2[]U1XGU[T;;\]1^Z[TH/@,$7Y3IWZX_VLF\4?!^MFCP
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MR$!MX*7UX7'VLQU!:!B*(P[0%]W4Z B11A<>S=U1=?PSW5TD__R[V0QYLOH
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MS43?9@F2.8HZZ]6UD&\:>JLRR#HO>*A409<UY$--F=>-SZ]7 PU^7[G?6M!
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M:$!#9=YLTUB(=G"LG^FFX&@6F.E9,1.O]03<\V)99W-6TB]SLI['PRZ.Y9;
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M;T&T;1@*=LBB3L#78(&FMMD<G=CR>M2&[(<]AW-:!A\,)E/V[S%OF?CZ*(0
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M7[)N373G4JMJU23/W<VAC=CC6L,].#"F% JYUJ12V,H:SKE5=EFN;-_)K(2
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M*9*$6?0N-+_7!:/.OXG3T^L!S^ =4,)M+_GK'5"H<ZF[^O>Q[)&/VCO@';#
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M8GZ7Q?BVR-S/=4B1P@G4'_UZ^Q7R9K+;J]QO=![QAT"B\P0G[X5A=_,"+-S
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M+\AHH'2N5<KLSM0SGMI5I]7AQA>0#_GPMBV&^S&%Z=N7Y5>\I])-+?##5[N
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MKX>([]>W1MX)?I,?S8QR_]LKI__#1%0B<$4/!52&#!Q0]2BXJT46)5.F+(A
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M,^&G7YI]VG+NZ\N//D :PUS I!8$U/WQ0P-JZ($'MRG1MS\+Q/TF@DL=7K:
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MT[.6P>)A=_)BUPT@"*'V:-H@)!@PRQE+X[N8^?>LY1K:6;X=U8:O;2:OIN?
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MW TKPSL^!_H)CT&.I*;FBHUGROI53I@*F*H1;8:)]D# T0F*IW0[E#,-F -
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M:HE\_%@AS!P6+*XX:SH1DG%8(LH@;2_CQ5R=3TC-Q6TN1)+R*32& C>95V8
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MT&'K%%=YZT'2C]68BA^@3!>=ZW!0A,A[HIR_;WS%8Z+96GKP"X\(3]C>OPF
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M*XH20I4=$,+EH14#R=5_&V."/;8TQKD=CRXAV4)14Y<MUL\[6FL&^I9CTU;
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M+];:+O1O!F2BZ;4C?<]?UJD"\J!O8MOM5M\(3WFJTP]40Z_"Y>U$XF/?^V'
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M(-AM_&M#NS7QGQI:4>6RH14B@0<J Z[O'W1]A4_?J;0$1+[M(/6BWQ.F/E@
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M& 11Q1&ME'0JCYC8S<.*HE-8KNA7(_T]L+?;SRN]]4JQW6.1I].-!0;F=]C
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M3?_00<HP<_H!BLA@!]>Q):$1.82B?J!+CO_"T=1*@MWT3->F\E33ZG Q5'H
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MJK-M*9Z,ZDQZH^?%YJ-1'('F[Y;1<'N6LE0T\1IA?W XWP-+2[LIF+][;_#
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M&$XBUEG[+RX!SI-=<A&;W3H0,M%!/BPW1-CH=G?%BO^62:';5K=0VI=Q^A?
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MZ!!%K\.<!)='X*F7(K5C+)R CU9B,-G38,"[H_:SH:)@X\=9X TI\Q>R(86
M^*__Y"S*Z)8RY&@TZ#2:/F)L"T/),Q2 2KI6;99_"I\6F3A!;@&F?2<6&SA:
M<$:O,'WEE4S8/TH'1;?X#_!C*K?.IGJU\3/#)W"C.]A4!'J2B.B/<9CN1D 5
MCI'_I/>?Q<8]DD?!6#75_2M$<Z_/NL)N(T$8MYF@ 06*^X$&5^"P<^W"MQHD
M;:1(%RHX@8?'.(E$PV%@U;T@3*+F=<GYBGH6Z?\($ZI-2"?^"7+#.'%HI&!F
M;,;0W:DD*(8Q\7#-Y,W4:P,-7FYY>\=)?R%R$QA,2192U[1_4KN3LHCF;+ (
M7+!DPEX"(E,]L5VX%\T4_9)TET1N>6P>DJQ<%)<.0J9/Q(#4'@F6LD/IGU"6
M?T"S2S\+@4;+3))[+0\'6BP'GJUEJ9\;H:#.**O1"A3\@ZBY80F8(<(XE,&&
M'K'2_O&O_:-;HOO]R95;\].]!(28;1.X4R5L)8(]ET1WVSA"#\-_%?11T0.B
MYS*I3<A1T]9-\?]QQB8S(@8$D1>(]#V(&P07:XW+%4<M!G,OBTJUT^=2?S+6
M.WLGUCIV[X;*3TS3)UM*7]&A8K Q;HU-3TG?EV)2I91DLRHXT2LS-@VNH'P"
M^E24'X^S)>F5.45;P.(M2B(HR\-!JONW@C?!*E[6) 7 'B '0G;'6LFKB:=!
M"$/4+*V5*HMQ-M)AF;^$B4]!F74D@_)7$@5.TS31RPF75V-14&\B$3)KD.!#
M(&*#"F57@AB^PHXA(M@:_4%B>$1_(S'L\E@IXA;B?A[+(GOMX@%'8??9W91T
M@*CY%#IC,K34%1.8[BX[%98)K+1L"60_-AR6$$<2*;)18@)B$T4;S6%_O;=[
M_NY1!B!4?AS];Q:"J?Z0[[C_8"LPT2436KK/,28J/^>>*+B=?JKVU.TH>77K
MVG?>8EO^W24V:A_9NKW9:Y /RREJ+L6SF8\-KH#[)UPE_@U<Q:N*7'5+^*$X
MZ7]OJ[?C+UFABH9F=]<T"1Z\[@D0:E?QJI?'%_*UJW>,RP B?BGMFOE'MN*B
M1=>'DI(I!AO 04079(_]"<O;?P/+0"JU<IT7/YS9^A\H!><OLO5(BR[X)K//
M9E[+/'0Z\^\=V[\X;;,NO'6+#ME%M.UL]?\ 'A[1WX '4AX+P]Z\V,>#7%AK
M7-Q@+QP\9YSLCLEO#@?O6 X5=<E$K#+70:>8#Y:#Z6U'K8-@V11))"2KI[I>
MX/#^,S_^NTH>M;*XPK<M:ITC4G_AWQ4_F7I%M.&AAS6$4% J!.E#@T3EIXW'
M@M,/BX5I)&VE/.BK\_#)V3E,^0F3&4.B2;"3N*3ZT*H6:=_Y8DXUU")F'WS(
M-"#/.>,83[T;NB[PT[Z?^6[=N.>PR3QTTRG<X@*_L[708YJ#PB=D(L^XD4,$
M*(O]N6X4_\VZ2:0\W4JKD >1C>9E2Z4-:](<0BHHHZNRD6_]^"TOKD8YDTI)
M3!YWG4I[F\0/]%;^C;4+_/X5W(BZ(")BL0!32*"(W(S1N%_:41&(7L)&TIFN
M*A>'BHO;0( XCB4XC!PCD5.R&[ETCN&;-WQ/735XZMF=5!WL@B>6X<RKL?T0
M)[7BW&/[U"F;5?JR@U'^#(^D]M_%/IJS[<1B^1<RT6\X$QA"ZS6&X;,+:4O-
MY=I^WN3$5"EF$VC(J&)/4A@>$OE(O)3>L#^1P"X[>1",#7[ZZ"4_X"TA57OH
MI3_XF.GLQ(<-WN)GX^G)++J].;[8%M7NP$8-_ ]JCM%&%=CT12Y)/4?!^&"<
MO+>2(]Y07".&T &[! ]EO#8\^ (\&;1/@WFS:E@8$8K.,#M!'J7^YSU/0EC?
M@Z_2HINR:-V1K]'20XZ;K^ WE%%/>Q<?-H6=7Q-G[;$#WHQT"/^#D-<]_ Z]
M",XK8^@BDA1'7@12?BP006C*'#)HF>PL1]D/1*E&ET< -UYP_(&%R$_<%>DH
MPB\[,3#[*/KMZ]*SG,*6 O9(RG.<VK++UC.DMQSA6=_2_9:8WPA=Z3D7W,_1
M3MX"M[,W.\'Q3MFPJC/.43&%18\TH:.<&_7[+C>IQQNOP;-VNYI?GG'Q>V@.
M76U_B8W.T7^+C="%['\F!(G_)B%(\$ILI9)'?6:)6$*7Y2Z,AB[*@" .29_'
M0*I4F..N@@R7K=7@YT9+DAGO-!8 )#Y2C&$$_W?959E'\&;A]W9(BGL.@MJ\
M2WQL4?D=;=@$UW;=F>=UVM7V4\2"\X[6_L,WPG[* R^GOR0T9UA_2VC0A.W_
MGL61D/R;+ [8_F#)&?=U L/=QTUBZ7=,%Y_<49=;QI/W0.6IYX_&CNYO2HOO
M;B$+;SV0=6H21G<>YJ*)==F\4%J' B4",E87AM)6 B2* @B,+FN>M1GC#+'=
MY'NXUYH&Y([LA2&AC;&BQN#1D0C_+V[82N96^][=D/TV8K_]!&A[RBWI^-@<
M\@K]W%CA0VGW"]<MO^>KY#/(X4M]25OLH3OBS7O'VT-5#;UN0/M+M47NI=%_
M5EO,^XC_4[6%A?;_K=K"6)6OF*3ED-?A'GT]COZ>KXJ'ZOR*^.Z&]W?2J5TH
MC]@"QOQ'ZWW/Y4SY'9V,I]4A]\;BMWQM8#=M1_5@U.9<0ED'YG$.Z%'G?,H2
M;)XB#/]]8%,,J4^HQ :,X[KJDV#Z(]3L+R9A&/4,HD0RH"B'I/B"KY2V 6K%
M^<@-[ZU?*%,<W<-(\;O*RO*VT"$?7)?3+ZZRWR'G<4(O18]8"\]V%3Y2MQ]*
M9Y^ N6TD$?/_;\5+1O\O7&J&[ 6MV2L=O%Q)N9@%E_)KK:2)V6 [0=RY#=1%
MMG!(C"P.VLQA4*G4R"\=&1-9<"O:VA&L=I9<.8'9##3!/^JKD)M&Y$HS$9^<
M*T,=Y]-X2(E2Y1EO,69 "G@*MN(K4U);ZD;C=_C0NHN+@B^F::DQC"TDW\4
M#L:)JF^8K?74WT$-QLRJ16NR%%2[B';T;5UX*B?=BG.RHS3;Y9@,%##'DIM&
M;)M-'DJ:J0..! (42>=8Q[3X!1NRH=T$%T7\WJ,^ 7<[;]I WZ%/P//-!RT2
MG^$GX.WI$X !F5?G]^'U"8@*EEOM^03P? *&^LDN]3X!N9^ _3TTPP!L1%1C
M/#OG>D$F+Z^M;GQE1%@WOQ>G_6B^=YU.X'-P&U_,A=JS>/;'\Q;'(?KKN]/2
M)R!2Q_LM*H4E;_M)KWKBV5:AAR'$1LNO@&]^^(\]=VQ/ED4<F]SMK\>!HD]
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M+T#RX)^<KU!,2 81Z:>IM[/GOPQ *=)<C)6)E4!A9V-OJ2 Q_ H& P42;*5
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M3J6K:S#U.N)P^(FU"?.(6.TGM='9-X7[=[*^1AXZH:,<MC113S^:.SJ.VT_
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MRS7GWXP>?.K?&.QI1G.XG%*W",TT$14(S?9J+XK&9C^=9)$.H5?@*V<V%$O
M]-JGUR\)FG8D(3'ZP@2$YV*_:)&ZQXG50OG;G.D>=FCH :'M"ZMGQ%'#$BL(
M%/<2V!4K9.?105#)^B3Z A%(PC&%OX35"DA$HT3O]M3\_\7FPO^T.?F_VBSW
M3S9WNKG_BSRB]92Z0@BVCJC W^(-"/OIG_%&[-_$FW^65^9->/@F-^^-(S1_
MSZNQX.%L5G:[PWB71_?3\QM"P5U<\QOM#$+%L^[T)V#%8<4V[90-MYFL&WV;
MY+VV*L[4<N / J-D_ ]BGAL1_9.8N?\K,8_HM.OE;SJNYO[6<D][[&]_IRG
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MF ;^$N\9*'NW4[/94JA#<TC/V&'8@@6WM@+'&O%QBU5B9WW]3"GJ&:.6@'T
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ML^'E<T,W:F6O8B<^RTP4'$"?ZY5]U*L,B'?>39HV\,Q)I4F3;JYMHVI)NV.
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MBO'<.Y=?O[^PB1@?_![<AXW8>6*M^+0D!.Y>T8X0.=X_//_$_U3W]?KW0.P
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M)$\6!-.[PSI$;Q]*YVWLP!J%GWS9WEC4ESG/?]R;"R*2C=*NCRMII!YA'U.
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M*K0BW9X*WF^Z?\'HW07NIQN* ([D+;]WK9RS_]1-&^#O5-QI'DJ<OT<6+HA
MC=XPYSHX/02D(C"]'?<7PG'PE.J%C'U]MZY"HR:+,TT-T]V[^^8[K*'%>&?7
M-E"ZB(YTZP#J\>GXRGPHIYC[X!M[1V:+65S83&HI=X/4$-/4:YCE(S1MU$;#
M38<#Q$5*5C.*K_P?7Z2)8]%1J0?H;$/TOLK1T4ON_O5?2"F_8/[M6#N6/]N@
M,2=<>\QMI)@.!@@H3=+9/(^? ./70&*N=4IM<LN$$PB%L54$!$5>< 9')9.Q
M[:LJYW*A%9L)&L>8LA+YDBT5^.S$?ZAM7</[OCMMEAF_7U#BW\R3ZE9*@F ]
MOG6?Q!A@J^+N[<0Z<^,O@B7 ?9B_P3D6NS[1VQR1H2C'I/:1FI=E_A@&\+3F
MAP5&5/^X;8X>C&/VC!5SB&%#%18@3U.H9GC,BV9&3(/6F$P<X0X=^W!P&T@<
M(8;TK1.Q=@TSG95[4+IX2A6ZC!=_EKJH!E2I^W:>F0<],2*7+@M4',M;?6"P
MXHHPEB!PEU2J"Y<V9EODU(V]GS=9/3A8*.]?&THIJ:^&>GHCE[Y6Z?GH8G'1
M)/2& E>P[UIG.H\9!;"P+'#<9J-<ZPP,$E=-DVKMD=VRE>&06_;R'YZSK]Z@
MVV3**'KC368[$"MY%R_ !9Q_OZI#=:6MI_TFR9>X:]L]L^8FEJ:U66,T9#T0
MVUZ'-#:[.[MJ^EN$%2-:$4J9 Q^VV1*/+,&!+QN>JA91WK[R_/8AP\)(Y\C$
M(NYF*]!,.RO0G<>ZF-+<?OTJR\NBAB&K1WUQ\;2&0HJ2Q4._J$45+SRZ^>NC
M&^Y8/7K-&1<; 2KU5S'I^W!O']R1 VPFL>QV;0!@D/N3!12DDW=^(GR+4</-
M7::=>*IC&^Z-ML@%MG(//0PG,%>T(+R-K\B\WLP;MQ:L[*_7*UJ4%K?X^EV5
M1+54):J'*CLDLF#B>3/8TW*4GJ$[>+'\ &0G?.88H8/1U5!YAB*?E]]XP+/<
MJ)J"DFTRKNB@&+,B;]1XF0Z_7\+4E]4Y=(CQ)82)&CO7I"E4]T>=P4E*6KOV
M-\)ID*[^_)=>+%#R),TL?'OS,.L"9_AY.Z3(!1)IEJ3+YBOTTZ"PB"W_1L$N
M'F(ZD).;VO09,YT76QHQ_]&P ^4Y)<D.N6-1/LS$16[Z:@"8-[EP[E<B1&O/
MMX.1ZP').+KCH%D73UM'=70M2P48R#GH@-I,Z1FH0NG5;#^!,4RX KO<@/YF
M!?O3^2ROUBZ;=Z^3]YVD*I4K:D0AM4#5<U@!3\DMVFQ 5!*33%Y=#(!OB..@
M2C#3IHR3-M^,T)+*:P]7]L<UO294OYX&AVLJ_=U*W4B-I&MVGCMQ2 NX8!])
M$,V84)/8B.:(>3A&/*YN#RM-W=:,C7.XK;4>YXB:3HPC!P5P_L+_W@]*B9/*
M$"=#$6TV!^6#C?0;XG#A<U/ZGC980RM5\F%MBW1=90P_5C6E*D:VV<1E"9LU
MS3N_5PX#5_JO&<:^QKBO>->%_K65OL46]B(&]B^8V7[GJM7F:!UH>ZM<K?UX
MZ5C\9S>3L_O8\NV9VZ]/LP^]L1+![XJ'/9LE,YPF7E&%QNB,_JP5E?F-WB0'
MR@4CO$65Z-'&+'JG%F_1!I^T?HAT&GMTBV3XZFNVA8L]5-?_B[VWC(IKV_J\
M"X)+<"N\H'!W]\)="W=WMT ([N[N[JX)[I#@%A+<(83@A.3-N>?:N/?T\SSG
M[:='=X_1GVJ/41_V7FO-^9]SS[7V_,'BR\87,Q<TX$-60F/,/_ASRZ2<.GC%
MZ;.ME,TV&1[C?QES(15U4A$?RV#R8AY8SXRS/ZHOHVU<ME-%.]A! >GL8'\"
M37*BL$%[U9F];'\T1$.ZXEKU_-DQ6RD:6_&&S3C1W9;92N6+<;1T-N+0(CJF
MX]S[2NOF;06\E5J'JBZDBISD.<TMT_5@FQM&Y"%Q C\!.J1!B_29JSQ67'.$
MT[9IB<OPCTL1J4FV9M&24+LILI^ RGZMH_GDSG7DU@[#M$F<&47*U8,;M[8P
M.OD=5U^]PAC;:E;+\39^IY/G'I)F1C"V'MGGU5,O7QK7%=@\!\:HT>=FBQ:X
M\3=4@1WYQ=Q/M0*@IGC>$VPJ)W5+6:IACYH-N0DY#2QOU-][V>G/->$\>]?5
M>'*[$1K1=I#>Z7R8.S9,7Z,*K&=L.3S)PV7,4317(XC\F*\G876 D\C#6>3A
MH'[QHP^6C8&1UFLO)J_MKC=*B2-,C1$Y5!]I:Q<M K97KHYK<3XQ>X8)URNC
M"Q4\%\7LV8UO:64IG=U5[^'+7U/RA>6 GS+1<H(!\MXR-X8ZR8(-P]^N:U+H
MG"M+2V-+#+R=K>QY.ZS\5,\MA3U:8VZI%H_ W3?AA6A]VGZ/ET(:_YF915DB
M-9IIN+4VCE$O+=Z'&7E/(\#UPFV,M^R6TSK'[NGE0+D]>1 VR@]:'<AJAD$\
MIG]Z6F5MA#7]&]9E=>!6@20_-'JQIQMF_P6.Q@O7R5A-5VITM5(H%4%/K6D*
M_DF.45X6-SND%!_[9-#I,\]2),321()B]MK<O(>>IZRE[:O=:M6B'/?58IM_
M]*&V3\X$0*@<$9$[U))NO/9E_B,NC)H7OP>OSEWP9X>,2?M,7&0\3BVM9:'B
MP8)5@4VD]27,<0OV\"\\!F>',!6T1]IOJR=!V4$F&(-X]M&LHUBX2QI/\:]>
M;=P+X^@N<58^J]N+O&]5JK57YYHB<O5O:WN&P.;-$\$DE#6G0;'FQ);U43Y,
M##%%<9M*G-$,J9V@@-6R0">B2)UK-J^)O&B?;IB?7[L<8CL;+^<IW(>-O1>V
M/5>Y2QL[WOM>W&@$Q4/YY[> ]AB#X\,UA5./;?6P:;51<+]ZG)UI',=AV43$
M*G4DVIA)\"<L<PI-[R6DD"1LLCD+7U8'#^LNO?"Z2DC#Y#'S]90O)_<,N#[M
M7!0OHG<K:0.I!E[.U4FMIUOJCK/]87^ZP[P:J;\S'N;2A>]Y>T@Y[5ME^MA_
M2[9CRR)DH?U<%6O./^N0-<H>:][!/VOY,O/758#!(?]AHO\9\F<E _2WK;_W
M@B7_:R_8;@",$J6 =C$I<VRG3&ZJS)X=<4H.;"LZ-GZ*)3:LUF,#M<QD%+M<
MKG3CCYVPZHF+HD&<\!<<V%US<0(781_T6Y7,EA7L,_05#[C6C7.3L@Y>?HN6
M8-[)>\B3F:*R)6"[XUXT>S^6O^:DV](3-3=N[OLBNP#A,,!WDC/'?D:9Q65G
MCQH(7]_]3P=@]?[QL9&VX-\*!01>9Z3N*SUVAAB-S'J@[!;:M.T@'AB>1GLD
MJ5E#!*ZV,G[ ^*MDZ=&];T1L+ZEAI#DB=SA#^G^EL(ZQUOEY]?%ZBVOG^SH\
MG^6<G2.7F[8DN2RS2WYE[*6[7.N6;$VZ]5HAE(J-V6;L;*CHIES=!]A6EP\'
M6OSC>W;:??EG(-4P2MPO+Q?K-.LWR'49GRU7QCFYBIK=IFAL(C3PABV;I=[;
MT$:7-J\;JW*,SE%[.S1AB^NB!%"*H=%_;+>@U,1Q21)!!=T.M;GKVK>7'P!_
M @QM,AF)^3+#/\R\K#R]G]* %G_YQF]@H30SW70M^R%:D*YICT763?5%:LSG
M7$V\C_QV2=F0B+P2 <5B@3%,415NB_M<4R>#$C7WMMLR#D$RUTGW>4M_8KH=
MD*.M?FIT'..(LIJ5CQ62<%_P+ <DD*S(SC:%*YT_^UW] =2&9EZ!&>W2H\R.
M/IN1S#+];.KP& P;N_]5:%TK/33+S1/FWJB'7NYK''GXRV."M_35CP-P#> ;
M7'(#.AM'%5-X%]JE4/7"!O.EO2V6*+8WTQSW&E*^)$[R!+B4 [3;=N:7KM +
MC%91C5"H^\NH8S3-FVJS1^?JIC86U16[_1')EWV:#H<-#<8+P+A;I-;E^V!W
M/$FC9#JV,D<K"UG-=':XP5"20R+03+%>7QTF@GJ)JI)W\;;:($YS&64P6%V,
MRJ&T+&[RJU!\.7U5MD@4LNVJ-<S0)(5)+SQCNT!S(QXY_2#5IP9[J?1^WW8+
MOR^0=^O)7$AZI3SZFW( ST;R[/7Y,HG5]6\<AN0BTD=ONE"PD2E2%F.;Y:D!
M"&R8B(0@_I/;5F&1XE0A^S[\<["3]N769Y![%07J9U76)&AGQQZJFB!#0G8?
M0\>&/6$J$QL"G%TI]!L5![B >9")&S_6EM,>A\FP1X7;$LZ*F^,^CC2^>&4R
MC1$'/BQ8O?QF@U$<"WMCO=Q0 *3P30*5V=LE$7'D#. :S"B5(-5F>"L1+KNF
MN*+*7<W"-W-JAM!5?YKI\@45 7OKF":\TU!Y)@DP?D@]Z@"9V*>_XBZE8W]N
M8Z_(=B65\(33]_\/.T R2?@;B]7)ANP'6 ^"\(50E#-;U66E;KEFV")EU5)+
MP\JH7\7)JO&U"-+0FZG'(=LAL\%P-<80?D$D&L %]<BU3LSB:SGM5SX.;QLF
M)O-\DD+V1-9B#$L.)CGE"XPL9F!ZI3K*,0\Q9CIF6)Z_E :$&81-[[B\(*C&
M*M7,]?"7_X0[C=]S@E#?S=28M5'2<N/T*PG0J-?@2VCEYQ!J;5+$T,#F6N,4
MU!^V;-/SJ''SA:-W5K2!Q4I4#8(DUR^1&G@TY#'H"#L4YMI5#$@CW.G65]BW
M>7[K+T("KA<%>X33Q6>1N.!"ZN*PK7IS,WW%\HC@D[:#BB^QJ4LT/9U<2:X]
M%O3IZ%_)@%S)S.:CO7H2902_H%#);X[LQ<^-..8=0EQ&W34/!\^%1E/-R/WI
M9<>1>I6[7U<YMSW<"'ZJ/ZT9@58]1*N7MWJ6ULB@/$OELV)9-^QR<&Y7[]+*
M* 7&]^_6G47B(_-H4MM(Y!%)PKHI,%'K5'HUG3KZFO!OL*'[EVPMERR8*C;P
M6 A4O)%V0+1RPZ844U#(G4A[@QOG;TJGCX.-C:[.$:SN]B;H3N$E&X3/)48&
MW%T 2IHLG<<&QU9%!28*"R7G+BJ$V\(+\-,;Z-(@$5T@#08%OLC=/;'F>\S]
MD#TF!4ROJ-FT4_LDMFQ@,$4'7U^)+3P+^ YJ943NV=2/B:ER(F8$),L(I/)9
M42]<UOH?.=(\=[$'NKC\>NE,_U3:IJ+<L2>L\53@OINU3G_-DQ+X,?,=']_K
MW3%UO8H*_2NR_,./]P=>T0'HI9\[:%AG7Y+??UU,KSI>_AY1T74GPI]77"!I
MRWL^$?,M).*'D">XVL_S'>7Q1<#[>&N;B@_K2D]N9M^WMG\"$DCE[/+SG,?]
M_/__WZEA+D^8FW,>CR.+@Q9?ZL!GBG@#AU&QS OF1BR#08E,P R=W#J2XC;K
MXWF_&Y;U"_0QA2/=.6,9ECJ/"0>@W0%[O7V!4MRT"BX9-GLY;.BB2OLF[%KV
M:95D(2(F#-QWO"W2?+(Q2Z<3:CGB9!JQ-^Q(<U04I1/8-'1P%<JYB2;-4=3%
MEYCXNB8O?X58TLPQWEY,24=4Q_/U9;'1\+8Z7/07   A '8&.BH]0&*" ".&
MT$]0D:(I]Q\ZZ'\13 L>RPW_W,89>T@TDL(WRQE[:TTT7+3PZRJA)G97Z HC
M((KXN":I8_GW$H?YWTH<MU#6*P-UZ5%4F]K4]U0W#+C+.,;#.?@04]YF?D;%
MLWTF0W)WH(]91&Y)H#)8N-H@O7"@&%D"Q2R&(O[-)R493>)PC_*A,D$?QU8K
MGBM1X=[LKTG",TEW&&%[^D0<DX,_ ;,J3+J1IECL36-Y=C@?'Q,W$/1R[L\!
M:;W7[U.Y$@]EH;9$GB2,H_XY!B]5@:NT_]SRW?XG8'_W/$+F)\#["6^RR8E\
M>4KE6Z 59#VG^'*ASD=]E#2RXZ8X3H>+I.Z5/8'4C[K:Q2DTOO"#A\%E(672
M+/0 HJK<9,P3L]<$(*8KL1+A$ 3.X_6C_=1&I9M!2?(,I9VK1\@5HRXK%<Z:
M_XOO6+.B1EV#(/3FT-4,T0Y&X6Z:MY2PB52NK'7<_''GJ'*B9$#W('8LJ:_/
M([??H=NPT1"O F4M@;72-KJ:7;6GMZG"@X.40C,/=;'W.)P>N?*6H4FFW *T
MLC0[BW"L]&GX1BZE+;_D/"^NS8_1F"YMK*XO:7%<HM/@#8FRRYBY =>UK92R
M!B_UP^XK.^TUFB00=[@XJW*__03=,J",!2 %-H7)I*6!BU;S2;7_QE$N)DNM
MN:N^ENOE:SK:?WF.(E&M@^-H;:UF/4L$VR8N_79,?Y5L8_3[@4QT9JD]SKYN
M)M/\%8BN_SEU+GSHI+[\Q^+!C8Y*A2$]!MEBQ3RYPW:;JCD6+[!F.(!IXE"L
M39EX(][FI)=*<0#N$); G5IW<,H9:KH$N+A#Y0F/4;69LN&:\K68[3.OQ$Y5
MG&*.17@9Z)X,U85/,Q6P%!#:-V(C2!,A>NV0M9;,NA1@9@\^CZ"JKEK"<D/$
M&J5=<;<_YGYMNHM%-'06MLQQM6?AZOZ6G21CHOAB4I6.5Y@S^';?"I<*7=E+
M#)+9:%6234S%P7IY /5PTF*(50@?.,[8A5H=ELAF.Y(E1?54$QM4[J'(,B^!
M&M"A46R-^2^/0F*3+$PBI.392A1B9%"Y4M;QL$V(B &F\N83H5%OQ"51#)!:
M5N<2P%1DG&]H&/F1?9'<_\K>O-Z2_8V]21^ $9Y%+ \W,; ?+T^F[Q^:G L?
M,?4)+[LV?OI5<HJTC3\"4PRU)M[_0\O^'X.6-<)3/8J>H\->;76%IB7::9EI
MCJ\6RJ?0>>$\'"]:+)9,#),\"M41PJ]C,<XJSW)8^7\$O23%XAI2XF F85M(
M\-9T#;%P( JO2BQ'H;U!B)5SH\)X)8V&V^@[*U5::T)C(3YFC13T9VV*V;RN
M_8M&G;W<9&I=:6>20B:)<;&X9G19L^JR,NMBS1L:.<K&J:Q!A/"L[ F&,4C?
MOA)3PE1Z2UZ(%$@>2WH/3B.T-]OH;6S5Z_PTJ 3E>/\<B?8=*PL],+:,19Q1
M+"LL3"%E%HL[$;%KJ%I]K@SS:QA+M3RR*78(3&R2E@NZ3[K9#(8.*MO=L8+'
MNF+:"+<^A4=T4"-\4K41/5YH,%,].O!U,JV?LJZ-H4$ROR@MO;0&=F6I7;,X
M+FK3AFFE@+8%O><=G77MXNSW#T=-,]RIRR:=CIZ[[I+$>UF+W+4,ZO7TJ&_:
ME%2+]>Z/0Q7/I022Q:OE48)"+?2-$&@D8NB*U[)CZ)*!V,E0XGE <XI,:I0]
MK%L0M@OVN#E4*#N6<!0V\^,>9 OTWAFISB@LU..9MJ2X[R_ THIL@;\#2TO^
M%5B*5!/_9Q>NIB16.F<11@_I&Q /<BT"3'6DPZ%#3.>IM'*\()%W(21GM=:V
MDQ#DO)*+(Q(_ S23).G\/[3Q_VZTL1XYQZI6+?9*Y0/>OE\9EX"4/2?E9-8,
MUC%2!'\W*#Z[H+,4OI2[L@W1DC<8TU1$A7.PGXW=Z]M%V_Q%1[D]@9^']G)]
M]*<#Z+H*OSKA'1>.S!MU!"[<ZH'ZN_*K3Q?Z7F-8]M3NXOPUTLGL8UO0U_-,
MAJ)RE]G5QW[D3,=]_/E_&_W7?QO]E+.AWT] L>Y/P(F/7<ZGIR]X!+O>6JYG
MQ2V_,44?A_^J[:'_!-BL^"/ IM&[H_37C_E _\\!.\7?G4[NP.L1B^+*N%K/
M@8GT&/3J8F4.T%QZS0I;5!@4G*VRP@':Y&$T$&!HE:)T%'G4Q4BPUW.EX1%<
M\*,B//_NLT_E.^+N2E3K/,0/=Z=^6T8Z^R*ZGZQ565FNR!K&'\F6?(^%<AI$
M2R^?^D1CK2,VO\2T_=L#7#Z#1A:N"Y"KZW^WX:R_T47)R?^-+OJO=ZY)L,3[
MS:9UEFG^&A1H8O]NTV#^?[?I^.Z;GP"IEI^ Q<N%O\ZA]I#:BH6V2V7G;J\7
M/UXRK29\+74[",QIMDUCC8JEZ_B5C0I;"&3*6H+DPG*9N N?48 &8A)\X?HH
MW_')=C:GJETP0#-[%*@LAVC:%46YVT=]0-AA"OM4XHS*3?#0U^_@+4J30R((
MVTO5--3?KJ@6^>&1[+MO[.\S92OVMYE:?/C7F>JP8TKS"4!%.GY4D8'\SME5
MX?+X&V=7YE\YNU@Z) (@V_!L"ST^TPJRB\I=A/%53G0-2D5<E1-TPN0]:;+[
M6$)ZDV^Y47+0?L7QD/A9+/_D)H[?^,%6=G]EZ7:4*N-6:[2&!84A7ZI1_/O*
M@RZ#_VQF4.F'C[5PG1\?_3L[-M_F[^S8A']=75#]GTY4NA_,G=66'OS(:NJ_
MB524JBSZ9J0_\&;Z?"*/6O$57<]G=8Y:>)7A['[J [&#$P"IA0$-]/C^"L$=
M7_T'!%?]#R"X6*K73%05Q\*D>+\[I]#<PH-SEN_[C'MA\H@/#V,;@036$8O?
M&ZQ?GW9"#%R.HLJ!MDDVV[]CC8FI3/Z!-5;X ZPQQ/-J]%-)S=6UL([A08"*
M;$'E-U;F*V>VK[VB./57K]N$C#[CE#^P?#I<OHQ>1/*0*D'AZFQU:9$3+E*C
M@4EJ1, M%\J4S<3%92OKCQ&.([Q29]_EPS9K2<Q(C!#.!14=0654YOT$&/]"
M*?;S+?D[I5CT7RG%+M&=?QJL?KH?UR>CLW_D5]\S_9B?)*IV8*2_]\ETUR>0
MUG#O)\#.I^\MK=*58=_[NFV\RC^=A4E^:(PO*+WVT"D[>M52?OU-1F7_K>6A
MB/'6=2"YY"&YX[UA/KG&55_>3T#]-I[KG\T*";HT<$ ?*E&6K<I,M7VKT\(T
M_" PFF62LID8JB4(R4(DOM.2DY2QAL78BGNYA^##GD%6I#]+T8V9KHI*BDLS
M5:R=48(W9?#H9*[KH_+U492_8917":*F+MP*3N>GYZ(XNPA=0D E_(*F.X&/
M^#]U9,#DM'&!P*<G]M4M(='+]PY(9@VW*'Q=<F>T1R< "NKV"M[O#%@(^'[:
MK7OYMK8QJH7%C3AH^!PL&YN'<@*;%RDL.>"W^1L3YUG.W+LFL%=0*"&<<PXW
M$G-<G'\(\*ZMD'^TO"WY"_K><GV'APNR,:'Y/EIIO4D%WFP=.SH@$89"-;DT
M /E'.K?*=\_O&XJ^*3\!_^C.-?;WXP*#%WCP[*LT0/1ZPGV@@YJVXZ?6S\U8
M$\L"(+"%0$ZSOA6'U[(I-Z<PNE2:OQD[?E#*8!Y]Q2$,MSC@G$Q8T)"DJX+S
MMF.M1B_Z#B%RO!VONB'Y N_)VE#1(Q=LH3VR0HLI-&AKTPO./\R<YIYD#*S'
M;M.\Y+@PL!S)ZBVU;Q9;$(!K::R-@5_%<#R?64.E^93$IPUDEY/QLC:P40KL
MP.^_J-&VI0SJUA2$$6[=9*G^6ODL6JLZ<\8]Q\_H1Z/8U<F1.=W7FA2GUZR1
MCH5E]VICU=EM3#A?7H3=WO$BV5=04C13@"'%(3_K?>V$Y(U@QP?^O7Q+CMJT
M,XU3^:^3/%KL![R%FN8&85%8<0BIR^MH('5(&S%\R88EE7=)VRS'[>#6 \MM
MEM=\E=5D7:@\MN97@O33U[HX9^P5A0W & &&<R?U*M+I&"Y@/5_6G(:,O/IU
M%O60+&CE6*79Z8*_MZ,I>&89$>JA+F,)KJ%F[PIX4FQ=:J*_W= 0C)SO 2Y*
MV7T*6S^[.;OBIG6V:MA?(.![ $<E#;'HZH7V@D&;8)'/3YZ4M]6^'WRQT?WL
M"Z0.%C?:/)EC';AGH_F%XOO;WY(VSK-/6C(+'./GS6-#F-@7<G+BS4#*KHRQ
MS&):M!>[E*!E/O(VG:XE6_TN<3-_3J!UF)7)$(U%"65.6GN;.ZJ]V83RM8(E
M^^(3/%KU@#UOC5/@*L/#B/L$NI&I!5-$7A:B,D4%USQ+F+_>_$J9V+=N<F(=
M>:.,/H-6=V3W*$7? Q;!?'<-6Z,VS16E[\.KE[DA)%3M(W68;D(1JGN!-ESA
MQ$FH+;!8!'J=?[QE]>W0ZHEB#:>R]2+/^E,6,4+;N+A=A4GQ)F..W \.?\.:
MQK@GPJ[P%2O']=4\8U$ELI3JUT[._N91DE9;]H']BJ^)9NHJ:$"1:^]J2M^@
M,1W9UP\O-L/&%&U[S-/2SD@:,AEUGCS>AFVZ@MT@Z=+3[S=1@[C 42C\F<.6
MFIJHZZE;3JCI54S2V1!:V><W1;/GV(KLFXWW#O4VAZU?.+WO#[I*I#<$>$UO
M S-7.Z_5;4:UVM77\/2-.1?N0^L2LG>#1$?S\=+UPM_>#YKBCG4$?E#)42-=
MHBGO>7Q;N'ARYG*P.L7-7\_R-3H;S,)A#I]:WFH#3&LQV2 Z\6T1?,4VJDF1
M6%/ 26/GJ8U&@37TM1.R+,"#P5I;5=W>60!%U/M&AX; B)ZD6YTHVMZIDENB
M.$$4ER%8EJ;D8$MC3#Z8@*)#TG4S)Q\63F@;$2OYWA3W=P;D <+UA6&.N%Y;
MG9IA0WW-M8I'W'GCMPVGA?*+@#=.<B]+R1B.3BHA 4H?FGW28KBS^)A;HSP]
MU=/4MN)&]?'YLZ-T(5G!D85ZGS^Y]:+%:=*LADQ\-EB8MN?ZHDU*12[FJ&2H
MD]&7.J PS[$6[TB_)[#VFL'1AE4[@S!A))=$K9@:A828>"A_ ,OTQOCMC*(2
MJO:,%T-Y0;\C(D..YJ&7N1X161.$BC&D)6THM9M?N%R7-L< .?<1X78?.^"(
MRK'3IVF>2NIE4P(L(8(M_@+Y!? 09>5D<KY "]N7\;S!TZAUP7W)*1@TIZU3
M4_.4/UQ;F.!5&[W<7A25F5,J5WPDA^*AL-(KT@ODJD,_J.+G$$J2Q&3U?9P!
M*\C+LV9[S=;1:GRCI[LNJIOX"= U'6_^XB:QY>:%"ML=I<B3@H\>HC<^Q $L
M97;=:Z9?</>3?#671M_)B)ADH=!W9.O5U<N!VZ'M721M)4NM 3,)2LV5GHD9
M/,[\N#;9K=&(SW^C5,/O%Z(I7XYU9U%6:11:X19C*RR??H6='7DCI8]:LE'^
MT(6A([@R1 1O;#"64VD+D=[D!X&T(G\"$+JJK9[HV[7HIQ$^M)I!RE_+'LB7
M#_>KAHV J((U@M6U0OOA8@I?@78MB[Y;KA9\6>RX>1[*E>M[K>?)ND- +G13
MT2;Z28>\(N4J>L#71)/^;Z&+(337S3Q:-7<!254\+%=\+Q,43[T3]B;55CJ$
MDL@*GVV7$I\S=I?O? QD_AEG."EY#2@.!\24I@AFAR,11Z'I;(W@2MRR0]HR
M%%S1-SP9,X%&B[U1_;C;J9Q[C(E\T=$3U'\X.% R"@O["17@FA)$XBU-LC7M
M[;_YT=-8.N=S0.^Z^]:BN6]/>R&G1A382_,,&^9K4'^T(,J<0]^G):M%$Z9.
MVT/SPO>*I#\!=U[^]N9=+=I2_RFK[+^/<5H2:(ZRWOX3\,_%9J>"?ZHU3]UA
MG%I6/+SC!!UK/W=/H[@MWY\,W1H6&%KP,)5N1B6>*!K=)WV$E1B!]W2IHRQG
M7::)F#K!@<E0NH(1$AJ=E*_L+52.W:_"KA.E^<O)NKX.J[[^XXUR4Z,ES8 5
MCNH\%DZ2'9->SY\ %Y:QC&H[@$5]G)M3W*?W[8Q,?IG'1>NCF]12_++[&-\>
M\'(55B2#TQB-*J/C1GK?[M[FN12C:]KO9T#Y=;]: S?SW^N7/$6F*Q(C.]K6
M,S43^.R*-W=JI+]E2S,U7$#4ELM=4Z/3([8WGV!F/+DQF8#39ZW/<+KKU,=3
M0+[.SG3JF6)&]*KJXFE]8669 ;2:&*8R9:7&$=?C">LM:VZ.%H<2U8Q7I^\[
MQ,OA*1H; .>PAW'+"F4A5?H$#F?Z&[.7I-"D"[JC&=951]N(@25AM9X-V'"I
M4UD\7\8FVM%EQU1#.<P>+!U\M.TZ#WCS&8_,*IA92GNC^VL$3UN2Q21%MXG0
M95.EHY<]]/9WX'#CZ!2-D5D>="%)W_%X38PS9Y?2]A3P#7.5/DJX(0?B?IP]
MX7JZTM4=_+&R@-C!F1V)Q8H$\[E&([%TX(9N6ZA7B-%Y0Z* GSA'C,KR8)E:
M18[==AP/FV\: 6[&I(6#YRFEG:82$+]#P2!87_#M+Z&.+8FU\G23@E0\&@M_
M/FC3E[-WJ)-T'RU1MW>=689&SV77O\K6<.D<H8<[<YB/<RHT>3*9<6TJ:EX<
MQZ2ASD P?4?I[. ^_MDPHZM,&C(KQ<@;Z'G-'-\^T3<YH3VXMRV:$VVM[=SG
M3Y=?T^Y]OQ)EX37:LDY2PV '5Q^V3 ?3+QT>0)X(26?K,<5!14IPE[63^!5R
M^:C69:P5=L96(PSS-(.]$8L*]-;:L1)L:DI53]45CSV56 26V;4=N9:-SN0?
MJZB3.<;;U=!52!OVX#&S!!54T1RTVVP)W.[_K;?R6)J<T%W/W*9 D-$,IC^Y
MF8/"?GH3. #G-:]S_/Y[^S2M)6N;=ZO8MBD"%LS:(QC6QLTMJUD?QB;DW\*-
M5R%)=XVPZNRF0OIT[P!W=LIOY>M.5=;7*%7<'J+YAKYY%9^_VA&77YDS'$F8
MV\Y^;Z*V@=0E/2S0-><<H938-#P1V]E=XL1N)Y89:3;HQ@KWS4]X>]7^@"A6
M)+2"7'W*2WFU=L,"^YG@#C?AT2RKEGB9/D(/QT^[SO,MCW#K>1QF/XTD.\$+
M!TV;YJSQI? &)IO(XN&GA2\*UFOU6%JI;HY^#52"NH 8O_V"C5\>Y>">-H_=
MP1P;(4#=F/79HFF?,]7U1K4S9BCGV>HH"YEN#TES>Q_9T$T5RY&UX\?"E^'L
M[BPV@U:X?$2:VK:P=$--]10EG\W76AN<<QK<BTO*QAWZIH[^L'2243S#23L4
M?!Y!"H>_U2;9N7U2DFVD(+4<!>[.W@<91P *OV1(';%W"8'\(=3PO.F"5&$<
MR)+FV3;'P(!./-SL2V^N ZP[4%U=0.VZ.-$CF,032:;[RH"DZA>>3)_5\:IO
MC3@_&5*1W3JXZD8P<82:+W7=XU2>I*\TAZY4IPUOKM32V*CW\B6N:PJ19153
M;&U;Z>Q+U?2V)G/IJC[^J&4:9'QVG2^O>U,_81!Z)YT^8^"^%FA<JP&95,Z
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M/QIEF!>OCE78SD6>4^$"7&[E!!6BAE.B&&TV]"5M?]MR)\:1>8XZ2QG4>LJ
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MF5FC9-[&8M&4GGAN!CA,P?XD%"J7.38_$<7+'CY)5*JO@.2I$AW9^.7T<-B
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M;Q9@G[H'=G^_+PL:<:D/Y/^F,Y;*!(R5#/0VKF$((GG0^<W!Y&1%V"%K]/(
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MC\J8)Q_?+]0UB=A,GW"8.%Q$E'7S\CH365>1,MDDC^JGD1>-^B,?$=BCJ1'
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M\1CK%FZP/GG.C=78N1<VV;QG_%)^\GURPE<X:7%3RV#9SU]NX]3;L550.._
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M&2A'4%>BJ]*D>J0SZ/6J-S?@?7MZEX# ;N=3ISC:?&5+*]4HBS=[SPW9WMH
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MC9NBTJ=6-Z34" Y<@W^6:P@YTQ9"71:W%;DPCO4N@]FB)N )[^'\E]@6O?Y
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MWVICM%1,AO(^T?J5OZ <5%V?!==B*CVP6VU%[OZ]6V56I9_^!_4*%2V)7TK
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MQCZU)1?76G]5GW>/^D:HJHN@(_9B^T)[*]PD.5"@>F)75[TEPS^'UB?K<>\
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M"-3PN01(6O> +BAELK8G2,1F5=@,8.<HE2_\#CCBK?W3\WE[*K43847%]8'
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M?<.7J5$\_IXAE(?;F LJE&R\C=@&$]WKN4.IL]R>_V6,#! W!!R9U7PU)_(
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M^3,6XG/)CN+?4_^"]I#QD.<V\IXN%6EO 7AS*)%X"Y#;/&M.AR'4D!AVXQ9
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M9.4>IB5\U!G.=M6WQ^C&R<5]$-7-^14RH&#HP$8^IJRX\AM\]YH/9M^;9:<
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M&X=^L0H)3?C*;HP;VFY&[79PY[Z]QG(.(5;?V15LU97H=^/J;R#3FM$+QU^
M2GSO&UD=L=:(/[M+,<RAQB1TX,0_+M^VJ=A9WZW"CHZ87FKZ2-71FL0Z:&%#
MLBY?(L<]'&I=WYP<_,>0+I+?5:5-=$C*3XBM^F$']:S3D*6Q^QU(]AB9<T=S
M$\M,G[Z\P4T/%5G1#SZ":;2;.3XLCO%Y<#J"8HU"M[D7/3<8'?2\X/+ZW%[4
M[&7SDELS_MO5Q^TS6*!VKT/JQ)8VAWLXFV893HHB^/RLS"WQMYV!72U*LUL
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MJ,AS-BDY26$Y/F$1(1 Z!@8V)C8Y#@ZY$)@&+/3_W!Z[0%\! (0,^GL#_M%
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M,'YZ/9G&,$$R&/XM?LCW$]'<@<9+YSV1FUA ;U(<6^(@J?_*PB8P640%'%1
MPL;*9<J=,Q-ZYP]#JVC&+C/=O?3YO19%"M&@W">L[=LA(\4?P0IX=O8,?DD(
M*O-<U6^<=+K _-CN[>OHSM;+_QUFM^:7*9[/B@I\%Q%AHDSN!LR-_!!U:FMJ
M435?";3.3KF[,X/EDXJZLOUESM[NK)@_ GZC*)/45"U5X^<4-+QLN5;@.$6_
M1\#W3'[5H/RM.2_AE=A3JF"(QH==<,@IA TZ6,SI-C34>U+\Y'NN3.C2QU&S
M"&'Z4PU*+[[6AU1/OHX8-%Z:U_ Q933L@S!PX8LPM(M@,DD'9)M*DV@=4U<X
MS$!3LW(X.N%.D9=:!%_U 5=S7Z[!7K>-^QF7B!"N76JB20$-!&/[@+RZ *LZ
MH:3AR*K??KF\!)'J&A3N/7YK(8+BJJL#F0[+:F%+:\P/ _P>U1,L_I)*>NN5
MPTN>RXXX.IJH/(]/F^3*;SO]SA?V1YPYX:E3#$$3[YP*-5W,4:RT[Y5,OX8\
MUP YW!Y%1C@V>!D^3-J$^Y*DS0JIMM'%\9()HX:TQ$MC^&81GD@<U7DZI4VT
MX\#QEOS7+4GLFJM*FK,7PSUX01VW6=(2'O]*)C3=V:=,CMD7JU(/'QV @?\S
M19 #OWRF9248MS^;[-&/'XQ.F]MQ5,^P;4ZZ:-WYO+G$>/UNC4JJ^_L<9'<$
MB4<0N?EC6CUJS(;M<;?_E+L O38\N%URA*OO6/>[2]ZVSVW%CWOOAEWB@-BA
M0;?J1MVI!C=,5);3(+?9\FMXR]BIKITL=N&D^E+C XI4'&<-A(U*4(U-RU$(
M^H!IC]&19&V5J)G]B=)2I Q']OT#>R/Y0YFMQ>F2S&OSXD-*1!X3EP2"FQX4
M(G4)-/IWTMA5)S&-M1]@B_8!L9D#S=.C>Q"4;;V@!DU4S#O#D9=N8B$XOKHG
MEPT49C<_J%CHIL(;7:/P2A47^F"?%7DA9+<G<R&B4<WZ1;)0-&(U_ID X_2J
MGL2$<>424OSP/4E[C\"05B,@TJ]7]UW;G%XINV5#2WW4DG5*-8:@_"D/HKWX
M0=MMG!U"RTB7ZCY;)%WS>!E,T@5N4@ZQOU\KIQ>3M,'X\XG2_1;0JKX.+Y,1
M> 3F2XDJ[>HT>[9M.OHJ-C=8P.$6!A<@'- V0(4:T6SH7;97>PQ'DB4[M$GF
M;O#2BU[I3NA"D(O!3Y#<A>'\_,_EG8@4H7T6W33YZ?#L2OQ+XKV3<,XJ-6;V
M%\3ZVB4=03).HPCV2]3'U5403*\?'[7KYNGOPW9*4(QMQ2#L#>M;PX&C*.E1
M%[O-(ODMM_9EOE@O1OC0D^C(0[-*_9E@@$<0,R*"1C3Y&UQW_CGGA8 W%.N.
M[^I\H0G^!U_XLANR@A0E=D#6U[$;L-!SE9X\K)C+KU8WELI)>D'WD@<?>RNH
MST%2'^_,5G^]X2HV&BF=;?=V+U >:V?OK^+V&UY.R7B2L%]6X^^2N7 >@1FH
M)JJA-#(@QY%9/8-OK(KDRB]RNIA"_/*6>C+CE:]-8HEP=P='WI4)O.AS^+\1
M#GXS'IQ=N]EA7%Y%D3ZUK[UW59I $Y5CS6#+Y)5:ACUYT"Q?GB9<?+ \QF.6
ME@4)H8'Z;A15CJ%JZ1=%X/7S!.5/:5+-[Z\0Z1.?(FG"J7H#W=:9DI99(\4S
M1&7C:O/3_9/@UP$^" L+2Q0BM/P8_,V<.%HL.4JD?"!QOZ]2F%<J#W%>^&&8
M]G<LR, _#5SQM7OOHE1@P;HTM?/Q-+@J#1._V-"D6;#[Q9QI7E$[97%D2O@C
M$$KIM14BQA'<<>L;13Y4,;=K-#284-,RT*$;V>.1Y[F[FRS]1/*KH.-],S5?
MCKQD\;&45.O,6<I/=[4>>>O^,F&_X#"T+ZLS'\S4(8(1.^&)>6>Q&S_=%T+)
M7GZI(V+-\=DF10CA]"OOGWC N[>ZA[+GOV]7;T] LB6%89AA!6]\]O-]:!X/
M$>W_#]+S69?4OI?9'S2E1P#6 CB/_GU:H!<=?@6!K:P*0<FI3M0?$&I+R!04
M]W-219@"?3FG&7/^=06>#)$W17UIJ17T-=U+9TEC#A:R]:-")IIPP/]WJ&=.
M2UG,;;5^92])0I33C#:>!\^G82W4%>")-G93_JXD'M@?@42Q)_56@?X(G$,T
M4<PZ:6X83:F>_N"'X53]AU0XKO@HJA];$T]A&-PA%2QFT'.B1-XME%)[A?0,
MW@?O%2&CI0RP0ISS^N3J7!TH+$"1VO@SCLAP2W<.["9I@UBK!A@_#<.V],+R
M?9X_G\II#ZKQ[3VJT7B&R]&EO-JLH8NUG1&EJ&[W8*+QRXW:'AQ%BIP1]6;H
M7K>%M1&/&GU6.+)*[>=Z]2GP-N*H3;UZ5SFOR+BVK,MZN4[\MHI8*K/PD<K+
MD'_%J\B.ETKFY(;>8X<8?_RM82U60\O.NXSF0*N8)^'3"R0GQBF]!;E3*S*:
M!=28M1!^\==KAG=L7S,5J3A5-[7%AZI*'4G!6)7B%Q* 5#A@M2\I]45VTIO_
MYUA^=,<89:?;9N]<=(<5G:1:RR>/Y0Z-&D!.JDMLP#\VV:Z22D&^BM_BX,:"
M/Y01+#FX30"*;9'9)@26R>[DCENR/UQ@"Y[I0 +_E(E A<F%P#>)F<VA<9[[
MTN3!_TW(#$\>;>M'=W15S+N .H64$[P3XJ[!@%B2F%4(UJ)Z/X<H-LHTP4%1
M(1W[-ON!+MPB,$F%:5^:BNHI5&;!RA;V8//"7'!6!U1=O4\MK[S_N(1@QJ/W
M3X\Q*TYQB_N%Q"-P.Y4'-5T+P"=\8!0<VCBSP75F?[WPG:.."C6G0(N-32P:
M>W&1A.V9-J99$].]E^NV=JR#2PN^A%8BX0P/)*:_6ZE\7,'X-8L3,74<6'H@
M@T8K.JWT +'HGQD;1YMPWI%U?2A-K7M<699VRQP[55I7XK!D'EX&%ND;&:&,
MI<?UH;P2@>%J3/+_4=/K467;(0ZT=_\IN./F(:7)C)#R0#K&Z<K0E*T686B-
M1>.W4-;@4SGG!]>6$1X6AJ%!VI>H';6<YHP5N3=OF'Q>A$L)>H;!6,AZ "ID
M@"OZ:^P;BC(0>4CM,U#HJ+]-"-]/TD< SGO\^]X_'_!.^9>TPA^A[\;W"MUZ
M?8>F\^P1",*3,@(&XKOPX=_*UF:-*Z ^D)YYU9=WQX+)<1_ *P#Z#C9@,%Z]
M;DTQY$Z;=>O9Z%\Y,Z;TM=P-=<T?G(#4.N9\0;:6YE\N$]4)B]/.,4  M?V&
MPS!/"M+)OVTYP[ JX4_C%WD31JP1U/'1)EZF:O/$YMT&ZHTF;?JJ:ISQ)OD:
MQ1DO#**HA#V;C/^Y?HN[?9Y_S"5T37>G 2?>IY=^B@[:FC]5P3.*#UZ)^6HS
M7YF^V;R:DEIO;UW6N,?2FY24:CTE7V@PB/PKGA"RB@0.B'%N@Z F"VY(&MR1
M^ M'M.>WFJC(*U%#CT!TEKU5A$I9V1*W97/H,2;G6X-5M4Y6$3AB0< _#D.P
M@HF#^S++@V?>/T4-1R$BU[_GE[^*%&CPC<P)]E7X&Z+@4OO:(D]?E+;(E52*
M3YS*E!FVPC <KI7L2&\N8B/3)8?I%]\ZG8A_?$U]*;CE!GI@/X2?MQWVH9:-
M(ECAK(40AXA4X/F%L5$I#H]*<L]_2_3G"4/;W8<+[+YVJRI2?_6G>9A2D4[6
M/7YYPTNS&,Q<>=^6ZR+!-ISLW)19!"[]@(=&&_-N+N&2S:B;7$7$8$HY(40:
M,08C)4FPB$6 <%E6 N*Y.R&#+_FF6$^ 2N41D-C56*WBPK:;>I4VX$G2:>1\
MGW]>M1!&_^O5[W=G5L'AEB\(/C9)4';B*^8+D+KN>!.-^WTCB:KQJVXR&+=C
MM$Z-H +FT&A7SF:(%L,Z&\==..QT=(<"5>-KYA3<-\5E%1:(3A+$;(G@VI1)
M[BT'3#D"TF'_ENE8%?@F0Y:YJN[(/=F(+!1?-#T24D=HO^\H[_C?D@.K#]3&
M]A..S^?&>U_9'7 843B^HX/V, ^PL!"&ZU2N^M,>M]@AEI_$M7JN9N,.%<T;
ME"VGZ+O9"R(CAUPQ53@ V]X:4=KVOM ODFE)!@8C$N5ZP4O-B9#/\/DZD#*%
M9\8V2@A!<*11:G-$=W637"%SFN+SU>9L#MHXRXCYS"YE%)XX=!AZ\^OU(%9<
M[#U![>XW3 T3F>G6&>7OWMB2>6OG5HB?2)/3_&=%3+9=T2 $U5.:B,M;%8(9
M+*@BE"2;YWXW0D\=G=OPM-Y/V:WGR^%^7Q1$!MWDY3A,##$@7)]<S9YJ\D#U
MD 8?WY$(0E_JU0END41:BJ5$P)EBR($I& 9YDMS/J3R=+7-T<PEL5X7^<=7*
M6/GJ5O?5K%W9^6S6Y1PWD=</(["KNQ9[0SE#AT>@[!'H*VEX(Q8,06<.0^>@
MUXXFENL)_N5 /\3 M'F;(VE0W5KVV<N2TJM435&-=;X=/)*96&09+Z/2Q):*
MU@!7<!D,Q'99NO0WKUZ8$",Q60>P<-2LR:/5^WY7O,MD+M*9)1_M>#[P[*?B
MGV$EICO4&H?4.#*-+PK?Y_]1-%5PONV/X4*MZJ+R$A)R1ZVRS<6@XSP>/HHV
M>B7VEP.,2:=2*:).D1GA-Q^8)A\!KN'&0HW9X=&@BQO"S%I!QYB$OR@!C8OC
M:T.=51K:]OQ9<5].Q&J?L.0YJ/]:J'OF=KTL(K^@G>@<WV9+-? 7@_3*^GLE
M&ZK;6TM^T.2R@=&>C[;A4EORO$KL27V?L A-(2%(X8XG1Z5XJ%@RV>YJ@BY.
M!4IK.!F;1V,<)YFAB>RYDHU%Q>,UD3/[12!E\#D/%BH]TH-QD/!3*.@A7/-!
M '-,]&/4>T]^4/IQ[X-*^H?@_2%FQ-*_D.+(K2%/7IGB354O4BD,%YXX&TSS
MT,HEO'6Z*W:?$#_O!MQH$,2ERG>O&LNV&BR<CT-IS]807J8Q?'=/:,:M((7A
M.B::)$0NT <D0AW@>TR!=MJ5+?HUAC:-40/WH^^HT"D]/"$Z!?9&;):LGLTN
MLU+9_.\CS5G%Q%N9[QH? =8X@XJH^^XSH2IN[T,:S9_UU9:%M H)R&9L(7=G
M,_,YY7><SU.%X1X/$CBBYPYJ%8''H@:=D0G*,LF([EHA&C7^Y3.C1_JU>:Z.
MKO1I26B?X[7[T8M?)>F]5,</J'X!   WJC0K!JOQUJD(A\6?. PXDS45&O4C
M,'!>]/8R<BG[")I1!^':SY%3&2USX@)G,:4T$H3PD/:@UMAB.'#N['6ML^J%
MO4\Z<NHK'./M!\E*FB_R0 KZC^(ES'*^6%Y2Z$+E\=G\8W)MP3'' "4TGV7R
MRM73H3*I9D8>$D&2.!T8WRRB_$>I=R_H*5H"4I*,*Q^!#X] B(52<0([*0'J
M</8M7H'<^I]'@!:2+H/D_K]I )04\MJMW] G(W1R%#7YCJ>EJFGZ<"WL,(M"
MC(6NJA9ZM)A?&]F85)H8>W.C8]UH.;D5(N'R/^]T_U;XW0,*NEW1[!X81+&W
MO@[X%#A6R0]'+B^"?1\!QA A^8"X$G*R@=W:KB,>Q97!];%/;EFK'L%SA*!<
M>WM72Z?:R^^EFN5NQ=PB(DQ[&B(P]$)$(2V?IIJL.;+F]_26"Y9TZF[25".N
M#KM?4\#Y#,'T&/%03I;YP8)59PFO?19Z2"CGUF(\E[V9Z]O4<L&*&JA/W> (
MIL9L=\G"4OFSTA)/1X;.7,RP4%)ND,SV'73ZF9::P;"F1V":#AZ,!XZ8O&_X
M0UZK*0Y>_IHWCV'@;CYD6#"K-=^6@6+/:SQ5EV0@$'(AGP/=</[( O0.XV#B
M7@:AMF[N:P1%VO^]Q'"9G3*!Z#XBHI/CP@!=AC$RP?DFUEF3^2'V7<*^ ^,,
MQ"QNUI:,7)^Q?+7<'<E+>3O37R2\_>^18U8C_(8#@QQVOT&SY6UBS#!W2?0T
M/ 4N!C1H$_+\/=H ?_$KJ?$F]YI5+47^J?2+&R+&K%X54WLD/J/Y!3R;,!&T
M%1)I]YNI'H_XC@.22K![+P92%!&>ERXI0GX=D\\_E1B(<EWP% %THX&Z*TUM
M>;RCZES!$*/W(LU]3G FXFC/8+V3&3/*4I,O.2;8:Q2U2!,UP]$,SYN#1'?Z
MS7R@?F7U,X[BWIHEVSA<_I*J@4^WU)7GB!F)TO@:)ZB&H;%9_#V-9J)R'D1W
M297S2I*C356D-Y^&CSYF^,"P*XBN8Y7>US!_49TT+)@PJ>MU&B%WB3DV<._Q
MAZ'_>S6&+'8OPZY%2 ?=TM8CQ0L9%^3K"0 M9"$#_K'+G8\ DLEU_3[YP<%<
MB>J6L5%7Z7?^#)_YY(N1H<F+;F\E5".M;:V)#7TV"8<&%=JFANAQE"3#]?>@
MS)&)T]_Z:"]<X,91< 63)K( O6_>.XNYZ58\M92LJ98C5,,@HBG3^"FHVI,C
MRWL(B_]XYX[.R1N,/F?6I03$]"F<FW[DL]F%YW'#,(32!YQYF>;,90T0*B9Q
M36L(4ALS^0L;NG_JW[^)FMX3!!27/,V?;9Y*M;WU.FHD:_2 [.YY0.L^7& N
M:AT!X?('"&';,5QO)4J@7ODLQI?']7O\1<R.!>F?I^=Z1N?DGEEZT+Z*UV0K
M8F.C)E)A48-[6YB\^#ZO?'!2@81(=^/YB[Q>":I7R>8)/;[8RBW2\"$?9F,>
MBVZ.SN9VX<T5V+&PTX1]73MZ!.0,X?/ZGM^4O]8JLA9,Q;/WWD+/%C*ROH&)
M>1$83))8>/FPQZJ.->K+6$L,;^BJ-BUH_W7;T7[BDE[D<"LO>*L[,^M"?(3^
M\DOT*K$TI, 4M')LAW 8FY;C*A)89GBT/A\;@:0>Y($,V(TB:QR4B1U6F=Z'
MS1]J<_9^Z3<Y^!E>F<2,P'5 17/@:'N?;'VI&\PM=^GUB^+/O'O,GU'D8*(G
M9O[R7VI*:N>U[%A3BN.Z2,8QFXB]M3T<!KM1M+'(/J3DK'4P8OS;I])CZ!25
M==V7[GM&N\SCI$#P"+AK6%_N!4"G^;],FQV_7?%Y<;!YP5:X=2)K4NVPI(4!
M0?:GHJ#R>TB=Q?(FUS$A7KR7>I5O7IF\F<K?0"[VSI*MMTI-=B7^TJ=B/^:A
M!GYHD3FIO^8A7-?$['"II?!U$251WIH;8CLT,^FI4RDY_"*_EC\_(M:>56^A
M\]C*T6E&N#'6VIRO19T;=U+O4TP'Z;?4TO3L.\2OWPR^0]M=[_VA/\'UEE\'
ML^V4%G1LA']99C55*7B(GN3_5C";L32FIAHNUI 3ZR!8Z.%,(VU^T*GTYU8R
MMDCJ"O0NKFEZVY@I$D%-N&!RU3#^I2D%&$%_'_R#+/WBU3WKE(BJ36L%A-KR
MTM&QM?-NF*WK5+&QW2;][3D27NN'&\+6'_NZ5ZDU/A(9Q+R$NQ[\YV(2O,H<
M7DT&5E"P5ZP<=IMGG%TL6;?'KU.VD;FIE!D]\_TL^I:JJ=6ZF@BRL4CNE)N/
M!#QQN,;9FZ;A6%@.$]LI9<X=V:P?&\;E9WXPGQ%Q]* $1T7]/I R6G/(\)GL
ME=EUI%3(:T]SR<G8N$<M6%49:A&4\1 3R&3X,ABJ93*P(1D(NF<M%JXNO40Q
M+I7_]R<]?QE4FA.^KL;@B#?X08PPJ^X#5WN\6 _51D&Q\Y51;?T]3RFLYJ!\
M^ H'GT9-V%Y@":D>NF);8:G4'!/IK=6?5R\V>V*^55"IASE[7-[U)PL,:M;U
M5QK*,2J56_5HW*%:Z]?_9+H*-LLI[ABZ_'/@=ML;7DUQ&"2 F<F#/"GO3$ G
M^VNW!5TL_L\LTT]'Z-LI>*.[SV[!'>)4OAP*K"57'_)GX&Y$LQ8N;Y_3XCO'
M4TL;G3L6)(4Q-96L-WE&A:9H#._=^OT((!X+M^B_^E%SDA=@:2^:6]H92 0T
M@"]TV_OC/(>#.=_L#K-6<'R^('62,%PQ\=8F#UH6&KN40!$[9)7)/.X)8M!@
M?W@)*M]DIN%@%8X\=YTPZ_->3,V_?Y](&T,?__/3>L9% 7,1V[,7-2\$"#//
MF:\#U7_4GKDX'8UOTK T@+%0<-7%)K7?ZQ4M[/;JEXC)YOD[EQ?W#(ZAYS*W
MF=\62N64&35L=ZAS[D0/CXLI]_>&X;K!@EFUHB$D>B6%1P,"BHHV^?E?;E8]
M-RQ(<)K6P4EBSQ)[:YS5W<)\(8^ 22R]MI;>R]%80<5BV3 4G+'0:PSX#=YB
M'R?[X)D"2SH*X\([<V%A^MOIA*)^:.UJ(+$2@. 1Y$B'^9^Y^R^O/UO_3>!@
M1%C+/6O<;DTY:CPXP]?;H-H3DF><P-N5'9RR%L+SP*A!_6,UZL";!FVO+K';
M^;*Z_H-Y'-F;'W"&SC<-(FNA!99,JQ&E;\16 DG/GZC#T?,^'VG"6/8Y"U]B
M;*?GNSA4!ST*7Q6J]#LFT?1[M"RZ1^#GT[V> G\>3+JDPN\IU7GHG?=1C+(;
MQ);X[MV6^XL!CY1-TOJ"W(6R@C>:0;KETYWM<^=;PSYU&:QR?QI(BK.7O GA
M'-GD9F1ZKU:P_?I@A:Z<6"$!,3=9':EIFY[\#:ZPW]?J NR6#W@:>,'+>(_
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MK)%%@^S>\60?":Z)T,SD>XY5:#L7R5_^8"]!CWC/\*+*N;SES51%P86GU?6
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M+[+06)<FV?GK5<JGR6;,;PX^;^63%[O6]ASSH60(C9]]T0DI+>VQE-0SSX8
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MY XZSR?Q2JF^\'^^2]]BWON;L@R#<GG3,"C2K)S0Q]5+1O8/1&<,!J=>WVS
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M\Q_&Z\SCJ"080/BKG3QLWCT,MPX0 K<9%@>A7>#<$;_-R)>T.- K?S=  "(
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M&1,?O/3Z0D*U/MVHVVEOF'N21@6\M5_XDQ1YBR]EYUA]'2OCJ=0R1[]=WT5
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M?$7$>1^=5=F!1,6I>HIK[#2.C$?-M?[N["_4?P/]W\,<\'\%^E\Q_RODEW8
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M&FW?-C9_F31I<)4168&E,>ZBLE,6<CN T$$E\X9='CEK-4S:FC3H'(TOA_^
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MZG);RI"H>0'TDX7\/2,2*= ]J"X(GS-*26$*WP1D92\U:*Q7ML])B8Y6YN\
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M4NK)CY/X2ZW[A?AY/5JE_FV]CE)6[V_PO/3I^ V/=*I!'6 WZN29VT$\C:0
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MBUJ?#$V$(1A]O(Y9/<:PC,4;IR#?EFZ)3],TUB2!Q(L./4[UGVDXQF@_M?(
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MRG=AX1YR8:<V073H9#RPL56)!YK%"C SD(1#"]')[Y/A6WTI%1!(P^?##G%
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M'+ []ETQKQUSKQ[.&V$4@;BP%8Z>/HMKN<Z,=']MY=1T3;.#[8J]@*+M$FO
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MDL46.Y.0I;T&.!SV5PLM593?_E>PP/J[&JQGC%<TO#([LXQ((@- $ U<(J?
M.VO@TQ>N6'[_*SGZO])PR*,!%MP-I#>FS563Q<M& XQ-E4B?2E18M#_OZ+\P
MFJCE* ='<NNHKUVXM:7TH97GZ0FW'M;@SAF"S&XI?MQ*TZM1:]2.$4(D@)V4
M5(\26U'9N),_%OBX)PP)S5*+ _I+S/LX9 G:);]KQRI-9R:F;Z?/#%S?U#$+
M[S<+MMV L^&YO @VJCM"5=4/];,6Y<72?4@). 8903SZ#"T/L.@#;>R/K.MN
MINM]H>7XK7MMV1'UF3TB4:XXU=[Y'B))T;=S:E-Z57 #*/;FY+24F2R C.7/
M><VH\M8;GP[OX8'KMO#YLUW"%8;'%]\]^\T%[I<7K.LM%(:P_&Z()%FUHA'K
MYFPTWIO>\YV^@9S"=#P38'5H0.88#?C;&MBZ0R!W.AS&!=K=VS8S9:7]8[%V
M8+F]>SIU>ESVQ%_^ZP0IN#@Q%)9!!(1_Y3W;]P5HA?CC/QEERW7SJ+.Z.'_,
M?OVY<P+D;!W'_?7S'@6VYPG-(?FPL$]YM+_#Q<-:)Z?X3Y FTW#3F?5G\?'K
M(=]F3%W :QL579-'?J'K $\!J6 ($VF+?RD>+.3*3S,]H)E62N!EVWPETG/S
M%/ZL"6QB&E)J'+K7 LJ9'[JK-:_>IJN@-9W ^T39:$T1BRDRBY]O)MS&U'%'
M#65P%:Z9K(<$.8Z<[JM9+6>*[ZV$F<@_B6$B9F@I_\Y5O3;<L79<?&!F>9NP
MV\:N<@W\ X-^I@_3;&##\)FK77G\"+N#BMK3B<^S3(V-(!N&SI]CWT-["71-
M4VZ+'SZ5H_VF;;_S&]I8Z,C]\]S>%;(RY<&Y;?)X2G"@51NN"$E^,7&K94+)
MR^?@2<7R#P$:?&PQ.E3JUZ"V:Y#C &+TRC#YB9L[= .ED'S4%L0P8%@[8V)>
MPTYU)_')5Z.O9BGLUKW L?C[K+XV>'[-38J"B_W:Y2P\9<O'/D=>D$)JKC&+
MCY-_MK^O-M<IB;A.8U2#$/]6NKI*SS>DS-+,0EB$CC:HO/P$=GVV:_=[OLO7
M-OFIX_&<I6=<K?UE*:"TS&$[/'A'T]Q+_L]:(>!E;0P?UJL)8&\@OFE8T.36
MOZDGPV\C'T^ RHK-BW0E*W8;SCMJA/3/O__X\(;UV+@EGJ7Z*<%#71G7./^/
MJROW-/JXSFJNA,"=E9I\#75LS>!V-,#OLN)+:J+%UO!QG&:=4@'T)'Q[-9CH
MM<9*QZ++S.B2E,B!(V;"W9HBRJ'E>Q=P-6K75DM;CXL//?<]*93N?A^LICK1
M46"E)*#S8C2!JU;H)K1MU5V\0164%(T;)]S 3'-+=;3^-0"%*Z7TLFX\5Z5B
M]GE8!MMI\-QCJ5]?)90:VQ_4<AO$?/!B9Q]]-USSUNHK;.MD6&=]99\C*O1\
M "MXF(Q?\8-3&E5%+V-3Q3GO*"X!>-4,H]<JK<&GCZV!"8QJNWB-.4U$ V-\
MH[C7_P(2";@-T8/2/M:(S B;J<9?)2V)O--_RBC^O5M62D+[FTU%D$9?Q36M
M^F+Z&^Z6DCJN+1.URCHCY04M4,CO&I);N-B.C!PO#]+NJ[-.APE=H &3@,&)
MUK.)0P_34/BEW)-9@N4$'6BR7?C@O@7W0\[JLA?NOJ.T36\;=](>'?B8@+UU
MH>7--JLO]-@[UXY5YGE;1J8E"9^DB=96-8!^&^@/1H%9P8+6!0]=B$N(,Z)Z
M-7TVTCP<5* B)^XSAUN.PZOF>9G-AFLPU(/U^$O1UEG3@7+3\DN*9>5/G+?S
M$D4?F!"8]8CA5]*LD)T[+("CH'V>6XV2)85^V85[5W6PWHGJT9RJ:9XSP32]
MK*W7EKC:KU8:9W.J-OE_+I*0Z!BP)7NC =.9$DW=],TR6QV:/Z/&KQ]O;?+X
ME:1#X1O-9^3:JMHZNA;J7?/T1X=># ]65%"SDZ@N5I,7RB8"J^QY\:D.H@/[
M+/6<&>DVD/(#L+HO3KS!HV)'8YF*8)Q+^R)D$]U.Q$UI<T.Q &&%67U<&"L?
M]M,E3]I^?\^="2+I@\ZB[ V47V;'=AD:**=$Q+-&M%,\'XM;)GV5@BBS-#Q9
MZQWG ;LAUP67K^P=LM<&KHA J8((-$"5B3HUG$ P4J5_G!&^[LYCC85F$$90
MAKC[,"9$"E3A?O!<S7KL&ZV1!%D"7</6BKJ$8=!,C.R3$CP[>3C10FI3I&DO
M>#_QR-I!8<#A&.J%,DU._F&YYA47J"GV30=TA'!#G-V9,L2$&0T$;*IY+VZ>
M$>_\=G"+4BAW5$7F];U0N_.5AD@YQD_*S\%[LG/^9!J#XEO,]0=N14FHMO,[
ME\+3*\/S7TU*53S/Z]X==X2U0)]\0V1[6-&OWJPG3$M6#OE>0WNT(M;L>\JA
MQ(;'_/8^%+XVRP2/HO<,NA>F['5L?))3NJEM=(I(3F;68LE?2Z[#UIV=;TQG
MSJ #!84#--V,5IAI&-! 6>GE;3VU]C(R\&V)/E+*+/P1:;D!<! !NP"@8]_Z
M8]H^>8ODSSK GJ#M(B&SEV0@LG'ZG6FJ9?.VV;O7(2Q4[6Y4LSL?C0[9^6+)
M30^,M+4EL54OU6C&V;'R[)HDN?V<\IE9]/$QS7V.W(^QW:^G^7O623Z++;0'
M=8S(>A:,VXXX7E(ARB\(A;-%3-" ! J<ZOW\<-7@;K6@R,S+4KF[6&S'AQ'W
MEYSJY$8D5[-_E _U7VP?7, 0H5J1]O9/RB\AU^E"N/\JI6-^F:#>,F5G45-+
MY-]+6R3">T<A*+:=0]I*YL=/[(70+5%(-0K*V,[X8WPG5^>D<\;@<QC3)&NL
M(2Q'4\PBW2-[K=?@Z:MBFF%GND8:R?L??,JAVWMO4(S@6,V%\)BS,50V;U8F
M-]/?K5S^S1M:\>%JU]33U=\. QX?OINKQ=&MH@$GY<ZX/A86?Z>L+TIOG*]1
MP&E$'.Y,6%Y0EVX3Y3.U?OX3Z3,%4=:'WW7*5GG<XUM<1E29#T36D'[4DQAC
MA8',G:IF69(T.1)*5<5GC^U\<04KR.594)0<X(T@E'GE[QII5\;#.,S8)1E/
M[GH+TV].UF48&[+V%\J3A>262E!ECAG\A=R4)Y5!R;B97E^9(N\P *9_HN[@
M=%W!&'?PSR0]O=N1M>6W'E,P;>_%BSX(8A^EOT]5K7UPO8?T7:F/BE-:EK!Q
MLQ$\K6]XTISXZ$?HFAM6ZMW]X47R#_@F'T75].NAI1)^7N!VMNTML$$IRB .
M$FYG/KHG]":O(8S'F$5?-8CI_8<44=8/FNRBWQ:TPW<<>[3+"VY,#Z%75&>9
M1M;3[]?**BKBY*RHM@ORR,J<E;!'+;/:)^&&_%\,?U4RAMFS3LO4Q!,')519
MS>8))UBEKD6[-%M)\1UD<9;M(BI/:FH0K@]WE."';3-G*(@"5\S]WS ;X9EC
M?1,4LO E 44J"T4\*_?)GNCL1QV575)"$U6N;YH'=5!!H6]^&G I<-^^ZS=Y
MCK>CD2=J;]G=G*QI_BFT6(NN0^2R3[D1>KB3%"WW?5=4'5!]@HS-Y Y7++S)
M'2;B)7;G0T+EY3.(2L<=1*#)WL'$V2Q\9G7@?G)HV6DIGYOXBS&Z /S>G),,
M ;<E/9R$7=\2)=U\^#7"%?(-?[\(KGD,/=L<\OH;0LPMV?[\XD:"CBX]="W1
MPNKS6PI+?^);[7$)"*9L6TQH\ L,N0PNTS7:CABF/UNCW*;R]ALXMT)C:'2(
M'5@WON)XQ5K'M%(_JB;T+F=OYAA9B9+&<C88/PSMTU=^A094'\K14B#F,P,1
M,*^-8D%N"[!F8]'!!=O-%=GL;T\47:7I3KZPX+P!7!<2[BV[1Q);D-O;CA4B
M*WW)M++P3=O)7OI3D4G)7\S272'?%UM4BCN[(B).)5==;3]ZH0N=3WO/::7]
M1^OBC7OLZ3C1P _-8I&PF<XQL60MBJOJO&KRQTX=9LKL,KM!D9&+]YV,9D#%
M9TC7.Q<ZCB4F!]W"5'K4-D*MH^&_I-F("A^YTEJ:IDN$>/N+GW24:*;:')],
MP[.R#V^I*V& 'QLC8[>NDD];WY,:$+R#A+^F9';7P^:+==^SHQ2(];+\X+GU
MV@%F<[ES18GA%L9.>=4XN7^YH*^CXX7$RB-G7 I;>!C*1]GZ]&_WZR=R=P"(
M N_UX/P&J3(Y-$!P2EK:];7/P_G@ <W/+A_(!Z+26&HQK-#%@&W"6Z$WT)D^
MY#D:8/+":!$/M564+R;*@3<H21[P3@*8TVF><-?);=SL+M:,C<PQ<= F.+7"
MT\&>(:3S+U%-1^N_N>* I]OXML3V=M>]X+/R:OQYSCF#VA]ROYP>6F1Y;VP]
M&U=I#<I74 .32MX?:[TQ%R1D&2%A>Z!C95S6!7$67S1SD\QZRNO.S3/$JWAP
MA;H%2BU"9 ]Q^9DTI4(>W#*6EZW]/BGTV&#_=P@/MPG(E6O],U-W]6(67[R&
M>/27%>M^;E?(4L[$926&26/.JHJ_?O1:RTF2XM(Z)OV9OH^+!C(_1HM=O7Y1
M^MVEUX3\A8Z>NKOI]%)19>49TLC2A/KC61?4>^HCE6,=@4\DHV37&M5\\_X>
MBMY-ROLU>W^:B8W//,KKF@@>5;EAWRJSR"NQ/G?)KMTT9K]K.5V.Z"U.,U_N
MW4.N4)%\L^QOHE2M7XF15Y%0Y:U6VX>L)V8AO6,TO8?@*.S]MOW/EN':]]2H
MF"S82W*W?R8F?M:A^<M N^@N4&4^JFMLF+R](/?AN*8#*^J1XGNSR,+T?&&Y
MD1,QJB0(R(\*>H;2=?:9T01M7=I<4MBB2.UMF4%N?G[=295WG7K6?RZ ?#?<
M5?2\LO<I+L=!'@P/DH[53K8NR/AK] X\-E"&-6 U2%/M!'?Y@4/\]CHKT0FK
MXM-5CUF5G@T]X4*N0@L.A6Y.[J1MM;]:@M.\;<U=2:=<X*T-(@G4I32D_O)4
M4M"QP=.J4D+39%)I/BW9<6??5TM-7_0"U8;J\G8D4;,IET*(5-GI)NZM@'R^
MV.@+IJ=[#/*+TM",^''$-)4?7V$H'YR]* ;AW?FF:\J#!E(&-/'>R$OG2_7+
M.3L@NFZWO#!3<)]32AKL9/4WI,&)7+0<JQ7SE2%MV]DD7?#IP ]:J3^2RJJZ
MMT"U ._C\S058$R_#%C2V$WL>6V2TJ63V(@1_8N^-S;;-[$K;HR\.]?'*J[B
MMO%_L6S4?<06BF*:" [P5H"X(S<;Z@3HW3D\@&CQ$.:J+15>3Y&)@YL>;]YM
MN."K!_<L9T)R&;8)=%XZQTE*9*BO>;[A;4Z$(42'P1%U!@DJB/&K9FC/:#K7
MHRVPA/T6TC.Z_C"S8=JACFOB7J=F X&NL'[;.Z+!WN'V*FQ:X,,'N9V7EGG+
MT')'-$"^41%0:G,.@8/ G7YV_A]Y:,[L'UX3ARY1 >N"$&RQW109IFZ\IWY:
M^+8VLPXFNHB+FX/M9+/X%KMF-)!\98!,WW<3#/GOK(D,[GA$,$8(BC(WFDK6
MT)JIK;^1K"8@7?6=,3JS".3K,6 ^DIY&5<+.WDHQ@X70 /[,1-VO7V<T#CZ>
M1+\6E)R(WR3P=_A9_M(@HOJ<J*6D1)]Q_3+PLA()3C@^LTB#\&)<0#:\ ID9
MG1<;/OMIQ-'B256&>#29U'9>Q2[;;K3WC<,-RHL7><QE\OS=<.<_G'&LR@T/
MQP\K)@W3TJ^E8@E%C*65?VK#5"]Q]O4JO#]T/^#O1Z)_-UV%I7XFH7^F?+IA
M0[7^BB<U^,=3!ED?>_8V@0R7<"H(1-;+ *G86?IKSC;!INJ%^B17XV1WN_LP
M320E/S^6:.\P/X=!A26YDOD9P/)4.XF)_*4LR4D>&L@J00.^1.YO/_S3R9,?
MJ]FJLCI3T%5JF5$PWVN&OJ0>%F,\9EF&)(RB9-H!7Z_+)+H,N'S<%?]'\-:>
MQ_ZUO%/0SH%=,0Y>I<8?10,"1L=SLQ*DGU&*Q"/7YY_1P+.D@IR_M;^@ Y)?
MMM3QQNI.)04QD:%":BE:9A:?5&Y%9WYN!?30P"<1-4R$RZTPF>&1C7#W)[^4
M=X5>74^##ST\T4"/-3:9MS'1^/X^<>'1DUL$:99Q9]ZM-=]BB]^S#3NWO_4?
MEJ.E'ZW3,U%=:/9% Y\-L2=\ZV8F]"YQA-.>5+ZE4UC6S]I>VGMC:M@XU!)>
M6-_&+B4KRM7P4O5 8^8F,\75L0Y*!TZ[Z=E*$J<J*36V.<RF8/;_3ME6XU:M
M7EY7%19&XR!M)C!IZ:(JWI-^/7V.R-ZFO'B'R89RZ!!I<^UH&2\[I,F4\F?<
MS_&"'KWFW\+CV#@_?P_KNV&+K0@FE:J?3DS]]F.QG6V%<O->\6Y%47FIU(8L
M&GS,)G4Z]YRX<5AQJUDES_#-S\K?=]AYE3BKAM$A$Z/IFP@HYCN21];E/9$!
M5N<G:Y=IEK712N0/ZES"6JIQ @1$UUR&=ZTRK.YQO79#ND*+SR;'Y!HYT(!>
MW?A597)J?H&UE]_7^%3[%A6SL5AAHQT(3D9D((D'B<PME[U74Y$);=W)".8F
M4P02)',I@8&QE=KPOYUXX)_'1L"Q-@I;<[+,]<K!;;VAY?TKPK(%A@9%.\C!
MQ]Z7T:LH06Y'A_ _$"-Z6N^DZD%BP5;3EXL/0Z!E>ZF]P!K?4J-L$CK1[H&0
M'HW/^'&*X9)#:,! 9M(4E$BS57*I"-*L-S3Z&+@^.D?GEL;@O!1D]B[]@9^L
MEE@OSCE>QLN$\ .4C1]WX=6OU#[Y-*3,8K-O7]M\NGBH)'?!G&<PCU!KZ!HV
M@\,):70#\N#%T:7.EG/3K]XDF'S,0)SYD61]U--/\VR5'FL5AM8.5C@5^_Q8
M6UDIK-'EF,&J'=#I:@Z<PO?OQUKK]/@<*2WKW0C:\Y/OE<:=?]&1%_3,^$#0
M,P2!F).JQ6MM;!7/G8,]1M8)37PB1@X,*Z&KXOJ2,O?6ZMI\%)<MP])>3U?4
MRZ_3*]();#Q1%,4A6]6-YE;IJ9LI5=WSG>_5T> T/CLU_CGVY'3>UHGQW".\
M+/^A>O4<J.;>(SH0R:.!!VWY]&X%B5-(1OAW6 TD,ZRR3%!*0(MJ)OLPK@M+
M]^'N#K6?"F<P)C\JYC-S,O9Z:(8_EAB*P(ZVKA+[82INHY6K-HR_$TR(>>_=
M<612643--IP\Q,$C4YI]*H=#_Y@]PT+LGOL4S[67],@U J=.S[AR&UIQ3KQY
M2L?5'.&;]2BCG0#^H,[YWBKA.DWW5L]0S?H&=KU+E[Q[1+)CGX3(,?B01[!B
MW!A,O <V/6ZM"!R&JS2$O6NJ/E+_]&+LJ^=9XZ^WJ"UIXTXS*^RL5-J5M#9#
M:;VVTG5HN<Q2)9&>T0#(= T)-I# .+F0+?#)61F&0_=/T$#TY)>__<LH%D9P
M.B2C 1F#$139@<SE'O#/+L'EPM#;EKC/M/)>92_D)8%\3_F\.;]<A]T@F6@/
M@%'B,95+7Z58AK8NFTG4J>42C'V9>>HFG&.O!L'UE<)8L7S9(I4LX2P';#-J
M?B)H@%FD?_P _ .^_K*E;G378C+MW1$3B)8EPFQZ7R6ESS]=!ARM@KT..^AB
MW:]<GYFKO )A:N-9?$NC3^45&HCS5A\]E3)8>+S'XS8=HJRCM6'0 N#1 JB+
M"@+1B](O1H::N8^3H4NDXVA@8^<-&NB8WT ##"4TX!]TA6A@9+H&#00UCZ D
M9/'_ICJ!?X,KL.1U1UVC'LYRA=&9IHEDB6HFEL_[I/_BL&AZVZT\S.^YI<[5
MI]2PE^^;V%\TTFG5A=U99;*CLWU+1OB5L=>FIUHT(9Z9!O@W/BUMNV!>8P+H
M'1)LC,OK/K/]Z"PDJFC.1,F-.DQ' N3R@>W^U #KMZ<$1IJQSK)7@1L9KG]
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MQ,H]>EMTWJC&H0]+=G&#T;3P=4*X9O$FU^_ZIDS&(,$;>TYF"QN:: +SV6\
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M1#W!/$9+WW=O=T3)]*3$DC+*ZY'CZJ77;V2S>N@DS'CON6RU%N;1LR$(+42
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M:U>7KCBVDK4H79_O_Y[O^<'A[R[5!=? V[2C[2US;VSV$5^+ZL/6("0:\4N
M4NI*!WK[/U?#1?1TV.C$,8<COMYJQ,LWQK%_VQ8Q]]1\GHZ4W9P+0?"=6O]=
M./6(23_(CP<F.3V>2O]U,NSY\804=FNT+/F4[6&W*]^P:O@=T; N^6ZZDD:#
M0!Q-4OR.DO\BE')+EW?J@C;3BWN=4J9$@EY".FY+#>_PT@M#C7;\.P$  .AN
MPFY,#Q':1@CS,KA3C10TY^OXH5//(S;=MGO3O4P4]WEXQ(^M&AL"OPV%';/R
MU7Y5&L/W*\TXS]N^_=,2[G888ZFQA?;_[5F%SB;_Z'=*9]DP[#FS]%E6!^C
MR.LK(:7 9'W2^<297,G:H9/:53%.,8+)_D;)BU9M28#470A\M^,ZP/VZX$_B
M^-60OID<]8L;^UCC1JI\EP"2OHOLB0/?(V#%LA_JBI0DS!-P6B$L(RV2,U!_
MR6W[*&-5_-QW/?IXS %STT#_@\E'\W:<F["!)&VFL M7:C)0T<):^O'3F*9
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M_W]I1-I746#TAHON:60(U[^@FWOSPBP['YT>*/H'U4>%CO0^X'74JJ"F<*S
M6FR[8Y[^G]3IR?FW7ZD!RK\=1:=28F[1CG9*Y\J;>;^653*Q>$;8*P>HK3L2
M 4?+=D1 ,(0(Z-H ',&@YP<U1$ K_-I->0)\44C\V0P1L ""'C0 I+'FA  G
M(F"?#WF& 3![5UZ'=%'H&>T\WOD3I90!$9#-*(<G=R&(R9-D7KOVH:ALPFT$
M$<#X\^;@!!&PWC5$!-Q $P%1P__\E^Q_R?Z7[/\/LN3BSD1 +3]_15Z8G."+
M9;WPUT2 9SU;?-[E? $ 2ISY;U!+ P04    " #:/9Q2..P<!M!4  "$8
M#@   &<Q,#@Q,7-P,S<N:G!G['ME7!Q?DV[C$"P0W#4X!'<+P8,'MP2WP9W
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MXJ%G94ZI7OY.MZ(!+Q5=7T\:_JWAV%!K=[9GD"Y(="IMDR:;WA-W2\W](7.
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MT^_YS.5E<F5W""3,+(2['@\5\9L42WYN>>2V\+OX]"4H0Z'4?X$%_^,#L5I
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M_Y4!)'<9&*X8O@UQ#Z%97;M_DZ^@^LJM(_(]S!W!'(9'20SSWX(#G27@FU)
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M[.E]+\-S'@Q29+S8?FFT3&P962:S_%19Z*+-6641NZUYE@@_5T1DY4H:N^*
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MH%&7*1Q1DV0%W9$F89K9+EDK$57+FCLEK$##'];_V7PQU]+YJ6**)C ]"6N
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MPV7N,?7CO&<[45;I0\5=2/8U%4N(.O';J2.SH^XKA7FWQVE22O$=C9[Z\M2
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M'Q9W#@3TFU]!=;/1[3>5>.OO."Z?B%ZIW963FJ/16& <=/,G91Q?7Q E O[
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MUAM"T8@I83(K24J.A9T["M#>_'$ZDJ3=C8=%#1:7LW^#BGUIG [MR?[JN?$
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M_&2HN:@ZVIH*1EI.]3/>3\*.>!GQF7$(#V5%57@N^WQ[F&B=%AO/:;0P'Q
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M&ZD"]UGK3-![+!EM'XJ5]R[;-)H.--LHVH/\!/Q$>LR!@$GFGH"4SSWCE$]
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M?J\,&T@AH!&;&"FU313F# @JF,0H0L_%"$AA9B[\6-&%FX<+[5!7'!J"F+=
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ME))PSSIH94]=P25W3IE]L%(L>H=@\RL-A/E//!TT>"_1VC!^#RI9GAT>->B
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MV0H_N!\6$Y#_]X?L_OG).\%,L$%ZST )2RZ6S?JP@KL8^N_P67%@2VX1:5C
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MT.*[9$"\C_JRDUE-]4!!NBQE;7O;$SOB)RJSZ\ST-QDIC)Y/0D80_']!1+[
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MIPIH_^U<:K@N%+/-($/-@XE:.JH<0-P"SX+@QURW$HAT-J3K")!45#A+8V5
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MF1](P(B&NJ=R]M?=;Z<-KNC1U)V*?$Y74/^0F&?5VP!1B,KV%$)B52DJ4IS
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MK6$V7N>V-IQ8]2>#8CV1D_AC87#TY,[7+BNR*H/KSWA*V:JJ]9ZQS_@-46^
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MG6EC!.].6_P<O%GA"48OW;@G=]GLUAL.8 9JS06=C$KG,W:Z7AK? JVT(;=
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M>^:H*LN=+C#C0;72:WG$ +ZI^[5M<?D&HD,1+B]_HU&+Y^(WV@_Z[:0#M;<
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MG[B!R=".$R$ ,]J]M#X$2*>" &W]]_(OY6C;^B_1H%U!"(!4 KK:A@!W\Q
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MTW*C.D5;,>8=OYP*5-VQEQ&[JJO.LDD1UA:-PY_ATTH<CS$<>;$U>''"WQ"
M S !.:C_VN"#?WKQV-W)NINDZ?EH(\AY%P_T[;RNZDRF[95^[R]BNG74P-^;
MMPV$']IZ?4FZ;*]FXFO']-!=Y/2! -_1*E;_K'FQ_2]/K& 3 W#\)=H)/@C<
M&3AO"][[NSRHF@DT_(!P&T;4OMY]S-%^M6,/ 7Q&B!82TG>>OS^)H:V=Z]_B
MK3U<-D" =I/PX]^REZ^"+]F!9_>,3V_/GA^TP&O58K<F5 ]@XM>)[KMG'.^
MIU>O,M#91/83R_OG]@BPV<;3*PI_M^>?U525Z.YXXB4QZ%6W]_^F1F9-;RKY
MQ@A2]2&TXK)QVHU855MMI#ACP<^NBBT3K)6Y:C^EX"/#]LAFVWZA"7%Z6*3(
M0K>:JR8GLQ8[0M.8AI%B!7T2AU(RNK1/05V]89# S%K-X?]:+_4:?2D*WHFZ
M6_?#N<-_4KIL]-*U5Y7W.3!7EA<J@%+2@UHLI3/[:?-86?4ERA^U$;DSL)*
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ME,3P6_5G)J['/X[$+2@Q>^'*\JU74Y"RW619FC=H'=NX&=E%*, =U)2?AXA
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MWS53!ABFKCNQEB4I?JCB6UQD#^%YM%A<BR-QAT)W\D26YI_0XA*#K_S?=D
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M5U!UBC^617O8M7-=O-Y%$2),)22Q[I7_\!KKE*08%$<B,1F?_<D[R5WYU^H
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MU]-D%U.6[NC?^<!/G-UH%C_U))DV&!L$"!7EBD+AV7EX1 M%2W84C:A3U4*
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M(RRZX#:&UA*!YB\!S%IM+F<>A#J3^7XX/-S%[LR2PREEO?6>F8G$W'L5.LH
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MG)L4&/:/.D>V+(NB&^8<?)H??-MWP!45Z1U #(?<,/O_Y<X.S145S=4HZ [
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M]*U6&L-OQUZ '8^6Q;=1QD:$]N!0]KFPZ/A 50&2 #H/KG"__8_JF<V< A<
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M-4M =^0]2/R9 5"SK,^W$3=0#3590B9]1L%_\B6XY-WL_P)02P,$%     @
MVCV<4BBY;MK%:@  <W<   X   !G,3 X,3%S<#<Q+FIP9]R\=5Q<R[8N.G&"
M!K=@P36X$RQXT. :(%APMT 3$MP]D.#NP1V"NVMP)[A[TWT[:^V]S]I[GW/N
MN_?=^_YXL_GU;'K4K!ICU)!O5,W9T'GH&O!4049>!H"#O=["7@ 4 E"^EI9X
M1:5A;F9E[V#K8&EM[D(E;V_&3J7%R<[!"4 7@<\ *C(R"C(2*@H*"MH35#1,
M0BQ,# Q,,CS\IX14SYY34SZCI*!AY&:AH>>@IZ!D%67CX.43%!)\SB(F]5)
MBEM D!_N"1H:)CHF*186*3\M)2W___(![8;+!@ X)+@_#N!O!QP\ B(2,@KJ
M$S1T.  ![N_'OQ&? O!P" CPB A(2(B(,(HOC 8@XB#A4G-*(..IF: \=\+G
M^AB;A4HC6=E!H#YQ2LMMZASP!(V0B)B$E(Z>@9&)F8>7CU] 4$CJE;2,K)R\
MPAL-32UM'5T]LW?F%I96UN]=7-W</3R]O#]]#@P*#@D-BXM/2$Q*_I*2FIV3
MFY=?4%A47%5=4UM7W]#8U-G5W=/;US\P.#DU/3,[-_]S87UC<VM[9_?7WO[9
M^<7EU?7-[=T]#HQE>$1$!$24WRS#P7O\E@<'$8F:$QE70@W%Q GO.=='5'S)
MV*S*CB<TW.JG!*;.$VB$M#SK=&>_N?Z#Z?]G/ ?\;S']#Y[_P3+T!X"#"H<'
M3X$ !^,>!PX!!PZZ & @P,'^0< !Q(";>X 1R(3W1_LO3O#H0PVV=K2-:75]
MQ .\:N'Q:J^4G0J(F&RC!:8_.!0M#:^^<[+#\E/%Q_7+G:M605!F69W)X-?G
M*6/R.WFE!@4^5QA @<Q/4&"5!4)0,<,(!9B"KX,8[MJI_IF&[ZL>??XGY;E<
MB^(&23UJ!9UOF&Y=+Q:PKT+.),*&>AP6)4S$EG?[XASU=X.M\_66)-D.82T.
M%<I ;'1)YB-$I_E&81GMNQ?G]$J6/>IZC_F"[.D8>#NL5.4H1D[JOTS>;+NW
M%]D01#GM*BU.08"RTMLB-NDA>5<J*OXO)F2./KOXS,1:=Z[MA2+*@K)I]?;7
M4,!?XU]D &GD@/.-%X@S=L#! QL.3Z6KAUL2^<NWE\*X1&7)F5C94*K(^DQS
M6MJ1(%)BZRQS8K]@DMX,0H% L6(UB!K(RA3T]9R2,O3J[IW.9FOL<A1\,1/#
M9=:Z%9U[4.5\D3"3'SHX0 7/,X"MS7RKJ%6*?4LMQILB[8^.4:)Z9+U@]"!0
MIW8Y:%P""IPD0@&TWRQE0\:[H0#_U@LPG??N(R(EY,[X-&<_ 90@5L,I-G*'
ME^;3?2 L.;7T1)LLIIN+2_R969OL[INK#[P5Y@YO5,HV\;:;VPO </9N[?@_
MF6NGZY\BK[^.11K;89()(@6AJ>S@]9A9@^TJDL'PQ&"5BJ'G?02'48>.Q86Y
M\7>:+6R(Y1/HY&'Q5<EK[?U)NX9GHK%J;KS=9&TG*4\-(*;Y A]X(/@9PXT;
M9S40OKDA")PQ!+?5!1* #04^5-QJ_I[Z%"CPAV:P;Q6NQNY1Q1[/V]=E?YL+
MXY\:8[>&\,_86;QQH6H,%^.J\@?!LPA](74V.HY8B++6PUZ=H8@W]R"X^J:M
MRF<6Z\S2DV! NW%/J:CL5$0@<#BPK_B'16.H/#W8R_F!RT&QW3=8D'G#VQ/1
M4\KCNGQHJ5[P7*#^3*::9LN(8,Q<#4*PUM*%N]IS2Y.\,-;(-"LB4T5KH>A_
M,E@4GG2/H?EH0YRJ[7$)LXZ7W@'D#MV*')]'!!+.GW9S@3#4KEI,/]3_0:28
MS.]6VE"R)BXQ:C#I0)*ES)/J,]6*,@X@JLUP$ENGGP7MWOUM"HV-_Y@]BEG?
MOHH0MSX,K6,M-"XY<4=1;TU6>Z:C%QV@&!_Y&Q(H\(2O&@J(C?VA.(U'$!YX
M-<9']^99^O/9K;=%'C2XCH"XLZ_0&YW#-Q.*IQ)'#$M2&X;6\LA7'<^>:CC=
MJUV!%1Z,?U^!!\&ULX2 ,G[;2=X56.7"3^+(<LG9,]P@)B;9F6]<YTC<$>7-
M9&J?:?HDF.@.I2;#\27U'*$*Z_(@I<#B=\OS'DK#'@9[.]\_:?'=>EO*ZHJ-
M.'V:[X#HR>"H'NF?0Z?&6Q23-H6KM_*U&7<0T,,VJ#-Y[@QFC2BU&8XPM_JJ
M"P4R=J% FS:8\1[R.R9<5Q\+>(;K<Z8@+7V%Z[#[!-R[%EP=:E:,%&1C6[_<
M!/U7.BL(<1N 8_)@>8OKZ+^&59"GWKOQ=[:=,D[C;<0NP']S0I6_,^ D&UH;
M ]J\:_^CKY?MH1"'?M'2AS3*X ]:<_%L>1#$LAM:!+C62.\&5I_BQS2ED;V9
MG8DT.^^==7$X 1(1-& 8A&-UUC\!,]P?QRU<O8N#C^Z[!'ZCAJ&[T4[MIW'6
M8A<W4"!F$<QX[4PD(@7!56* ^$&!<S)0(,6HQ-A3F +BY6$*: <'K:[+5L>X
M=(NMTTZ"=D^@ '7]K=KAUK,S[%MYGHR[!RC0;P?!]Q%$^;_92[(,RN[T\Q#O
MH03*E!\Y/X>^N_0UYN%7CN$.8(33VO6_$T0Y*ZP-IQ1' O#AQFXG!6E/IS<X
ME$GD^S)YIP+C(JWJG,RRF-:WLKTT?9^<P\&:N0IA7F?8%:Q(B$Q*LTXTF-(@
M<BP& KOE\IOM!'U&!'2T&Q4V%%&X98R2:O'5UI?G)#G[A'5Z8:BT<61>STT$
MDU'8:BL#4!!HG91K!95)]T^R!+S'"]2<F^EKVW->[/'/JB[HD.1]Q'#LCZ:.
M;>D>$I-^1H&Z+SRK:<+/I"LZ5R"5@ZWUS0S+HD:E=;8BOS/\ .?MVA \T?>G
M)]IF3&\S[19OO"- >H(,(]4K$/W'34UK1E'M+OOZ11M;RUMO?=3-% =$H)J=
M0KQT4' ,(Q?GDFJV(9!OC@X*5!R,[W8JQ"EIU%_MMZ^E$D[H&4IV#@K0-43-
M4C=FKF0>V_TD%MDD2/B6_?BP<%*QY"K)D?JXH)3;9%S2/FQ[L9=THV2WK8?$
MO53:&&*N?<OAU"?*^<I,76VG>4'L5%I0[7.C;7WBY4,H3</DV[ YW$42ZJ3G
MM*_0W(^$FS"NKAA.<S<UZW-FN!)^2<MJNLZ!*?>J4-DO&[(CP_1: LC,[S8Q
M/\7ON)$[S1:K%JX:KH(1!*9S\-.3:[Q]MP-K:WV>F-<&(-@B35AX.BLCV#+/
MK\%%;>2-*LC+-S^T^EU(*V-A=K#X+(O:63C?R')GT>.=O[B/_3C5WE[1ZB'E
M<"%2_+6LR=9M3F@VS<U'9(2+=6($ER8J3H96:VSZ+81@5R92KH>VIOI.6&SX
MFB$T3["1O]AFISQCS<1X92_9NW2$K3H7;NFD/B:>FB' XQW6(^=LTUYG+E7I
MU13H%@5)K\92LZYFSK)]1;<^_G4 %%!J^)@M7O7*8D#0 "Y.<._;3G5<$>/@
MB]'>[ZYF @I\R\;WX%X;#\(XZX-G+U#CCS >J-T=)2@]DWYY/D/0E.12;SZ:
MUDGIF*JQ\[EL!H_Z-8T)P)( MN:IJ9"G_9( #6ULQNNYT8U4M]R):V+BAO6-
ME'%MP7E\0!5.G,)I$X=J3J=!6 &S]J*Q5*\X;[*/SNW$8&1B-VA1NS9U,R3V
M7)D[6NJ6PN83)F-GC;EH1.9DG.W<]W1%GWZEE;)GX6V21,-+R*J1B\WOOIDV
M,XYTVJ1G^UR=>R]-LH]I*5IZ/2-4Q!Q9<EGZG(PPNHEB3P2R_WQU=**M4!PA
M:,G2ZGUO[52DJUO]<OVH_(/J.<\$#\8=&]7@XTJ:C-<F[PC_DXVO=OJGCZCN
M+B\4'U-BKO?>69I'.P_^H"*Q6\;BOO'V(YAX8=8BZ)#_X-:^=T]XYZT365Z&
ME>Y?VV96XZKY9J9E%!E;5'!W>KHIX3%U4:Z];:.IOM\,9$XVCT@A'IE8X,#Q
M#EX6YPHA /M-E+68R6BCG9TQ&"O@QB'+K=QU6VXCM"Q)K%:*QE_\QP(_SNV]
MS^RQJ[I:9)DK%,!4;'&79FJO5BK-1'>AC!M^QG_R8;D/88Y<M-+@_%JDPD;W
M?F7KI3[2P=XA:,*T!IM\=AHE\-WB3..615AY_"WNI'%@TZ?M7ZH3.U$D#ACE
MA:2SF@;IN17PC:>3,.=_8/TB;%#K1IE2AE[H4+8I8]Z=;C5X"B=05BQSU;A)
M6S>[S7MBR"4J\ZIAUBZ&P%.5]KU',)T$Y+GPM-9[M^PFJ_KV%28;6J-&4E?<
M]A3,S#@F>M009[1 80^7.7?1@VR_7K9EEGS(@34H127Q*?)4>H^\HKEV:*JZ
M0*SYP ^UO:E%DM(3Z:[\T<>3[:T7[CUG["G!]696=;UKQ)WUFN=+\*NAY#8%
MJ4&5[K67E]6U0RWN3*^2./6[B0X=W*E)<#F8TG8%!7N=PG;#\HA+]%.7W5?!
M(09%7O&^^<-[0S@^)MM]SIDT.!>4S1'G$F6">P\O#7G484!"<Z9L'\[5H4:2
M6!\5L?+N'65*O,-8^UF?'EOPCK[>_DJ:/<7VL*^DHM?;6D^S,$&.CMF70OPD
M8):PZL\Y1/CQ<V9,>H/=A'"+JO4XNZ O#7VS$:P&)3VR#1)&"GT5].[LWAMM
M/R[1%@+!0G9?#48:_"6+J8:$*> +C^6+(PS28KY6-:91Q/+EO[I?Q\)F,2W[
M8@8%?!YVYT2\L:X,!H5D3QB2H !.);Y:%VD?O@WI"SB-M]B=U4NMP>._\\ ?
M_O2W$QP)L2@CPG-?9/S8<M=Z4M]5]8D7QUM0P%>(?^[3+QMI_IK:5P)7>GA[
MWO%&3]XVADCXVHNG/MO"N#07G;X64YLF39%9* LF\B7)4E=51: /90C-CI60
M(:8:1\$LO$5:</<AF5']=N0TV5RT^5Y"=]\KL6J0EVZX!@8C.Q&*H,"858G*
MT1,0K )Y)982#*82R@!?AT7#OF$$O9.Z^P+Z6Z-"R'CR^?_1-E'1/YIJE)J$
M$V2NU*6Q*1E:5&??$._G]_Z#KW8]L1HZ&(CO#[[@@"5CE#=0('U"[3'KQ3;V
M80B(&_M6W$WL[HB <@$7HOJ[$>?FCX6F7C/]7%3O0@;DY+EMG_,L*/"NA\6E
M,N/4?Q]TL< ,@K55^[\LU[^U27%1.44,,+?Y.9TIYH:B-YHOE#N3%#1=U<2S
M/<*FO(^JOH(8Q+L0P@&4XTW3_EEA(E :C>?,LOU >;=W0UI9)D.P/L!E3D!G
MX52Q]FA"'!C&3Y%U9B0UR#L)"@;C89OL\$-PV"PAOIM0H#WC\;WQ3VP8'L2^
M?7Y-80(%4)-@Z/CE&:Q2&X/44OZ-1'THTO5/UXA545Y *$^EYKV"P<_UQL /
M?5  )'8_#7HGM@L66PO^?H%]^PH&66^B(1#052&D'S1V"^J #4UY&@J#DB>4
MCS T>:#V& /#7:=0(("B:UAL'1>&3%?$'F CSN8\4,,P^CH40!0-ABF-KA2F
MM!;0S044*).]EH* NB"H/MB_IUGQ-P#VA,%9& C6BSX,AG4;#'[ZOR5)F A#
M&1.BN'_49Q@:G"UXC)M;_%,4Y-/TNF'=3,GNK7@&/0KUE7*8&G$>L#G_B>.\
M?\CRXO\[*4VC40]H-_LC0#^@P/TT%/B'+# ,#F9[S&!L;'Y[@=V4DSV7$]C1
MA5$S<\,7R(M06-XE1<PX+:)\".[*IT)M;=DE8=A_&@%JLU$)HLAU>"%EF6>A
M2_DMO>:0)1CVKL-.X>P]\;;!:^! .F!]EZ&,$#U\IP#V'ISZ!_']'\2BW\1_
M^WI-@H2<":-O-OG0@]"[Q0P3,8"I$JPFB.9R2:=_^K(VEU>95E&1VZ*:];]=
M0?E_<^*J<;B]G\5V\7:! GZ;!"X_O?'(?Y:HJF6XDR(OO5Q_9-'9EQHON8[V
M+E>WI[2ZR4E@=TINZJUJ@N10+CB8G-^@ZWN6(731&BE[I'!V>:60^\#5?YNL
MU&9:]LS>N%"<3!555*]-T*M?H$"GM[#NS)]AGO@6D?1+C%0+GHSRJ6<'6-;.
MP0LQU$&T6R(D?"LDG&.2A?(XA?CM;O'W$4(/]&SN\MLJX=;G3 R-,;6'$Z.F
MM9W]V5N,F]8_SF_,6%M<DGH9J]%S3(V?ON?V[#"=8J=/Q::JK&_XW(-.WLZ(
M_;WN<"O.LQ?Y28&=M NHZV8A]YX\-W4:IZ,0G^(]S3%)W_C;!Y?H-TI4C7DP
M 06EG2NNJS UYKD27;!3(].)+1']GOFY&:0:&"S,MR/PG-L9=]]KB.(HOM'
M %#>=X\/G@E @; WVJ*SDUH4W=0T5P2N$)Y7$,+WTX1_S4C/*J+66AHF#]51
MC[<KB4+<4 _#O<:0R:C=P=WVBS$MFSQP'RV]'@,K]K35K-.I(/V0L<90G".+
MAECBX4 I@"1Y&S-RZ6,/H!HTNP/"8YO-*#A0W1\K?6+D998N@)DBQF$WK]*<
MCB+8 S!\KEDEZ"NRNK?/O3G3SX]F4GPL8#0_EXN\@4<,D?K8X-K7"DA[F6S
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M5L\N2F!UQAX4F+#6%DW.XMR'628^X)J)5FV4^X%J!:2P41(>P1-5NL"COU1
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M PZ=L%"%IW9<7G$LV&2WYFM>.;-E[T+A6"?:UCBXO+7:?W[IGC;D^]*XN11
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M?>W3D)ODQ5ZJ<!<GZ]\LQ8X*]W7G]U.]_L)DBNC"B$R6UIA-:QC2Q!(?I_*
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MVQF9G0/[X;RY!FG!&U2KG.'QRP'XB1QAANG;'-=&::#0R07'KL*-ST0)?(E
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M[]F^R&:7G<N6EM2(P#0+)S7)6IJ"KJAT '.E:5>6A5'44FU4$?:>PW91*T>
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MT3GNG?^Y\]?OJB%@0Z7UVA[$4.B^4NM*-OQ\9;6]BUW'5'"BPBVHV<'%Z0%
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M1!^K:^\P+;XIE2#/?*UF]PS;,,5U*Z]G+5FY*^;6?T-_OJXKS=SA:?; +L+
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M8>I LW4-)FK\";O_)XOVQ$:((+?#%N.CU7>OC4+B:WXJN(*_5D7P8"KP$0)
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M:"7,@X,3/;K;C"DR4[O03&BZ,;!AV JFW>"$=O>/! CQ>+XG1 #8QRL^?-O
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MZZ<A]QPZL"5V]FOW\PSB+R/H9&&C909T(>J.5IUO:U#]I'WV8WGFT)*P&)I
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M:96J<2]<,L@AGW@]6-!F8_]#J)[8S<-X\[7050:JA=G&"8^3_4QH3KI=G'W
M[^\Q1EB)GP[!9-*U$D/ 2P)];/DVGG,=T/;.]G>>8-[<H= GH&"N=>L@9J(9
ML+U1F==.;%*U*RZNJA#Y.< 6_#8THK)C]$5:8O9\>%&!8ZR)NZWSO$E8?+)I
MS30.C?K!*!V74_ZAKF6UY5!_82.C_MX ]V8T\TST#-LM)C*2/>'>R061K:6
MR,_8@KJ<X^7A+<)+.9FE.%8X/@Y<_ ;$-@,H]7U6,:_>Z\9+ <-O^:0;"Z=U
M9UF25@RRM;_  N682(/X 0#6VMUDPVCU_:%$9SUMO=<C0T?NV-%/C[ACF >.
M'XFQ,?W(HX"HP*=E5@D!EWWQU]Q_?-_!;GQ8=BPFE%C]>6 @M"\:5U=*@BZ%
M[XV8P](XQC8=:A^XPXIY.BVNTZ ^FXV"/.S1"HKD873Y7>JY57$#@E_D5XI-
MG*NL1_2^=K82%!<O+!+.I7'?1^4;_;J^>XS;4=]T#Q*\%-QSNG^)1J2D]SU5
M35NA\,^.4L:GZ@74IB%&T;;-.!%=VV_^M9P$__*[SP0<>1- K&,>U3Z6SCBD
M)328A]HO1KB(W*,W"51XI)^6K&D^>J KY^%T1B,.@,*R+".=PA=?0(GT<.R7
M(16,-!44Z/@Y  \8&_2+&L8^\^P]&V>X&L'TC9/,JVQ'%^!>Q*&YA?02K"TH
M=FMPU=L!Q*FB7S)"/\D<3Q]3/4]]J:&HWM(_;M.TIHK!MRU20EO#3\#QU4'O
MPRZ84:):>R""H$TGST<5WF_B#QEJ?[&H%:;V['C*GY3Z(KN]:;3<#]^<'5=)
M-D-"A<F-R+07"Z9TM2X^=-F(=Z_O;PQJO,<!/FZDSHVLC6(-5Y1*N= 1TI4[
M%W3C6!3W=RC6<PKB_+I@CX<05T[@)Y05#B[LIZ];'65$U\I]@A^?7^JSPRWR
M>B7)0#S4/>$W0FHE_1Q(V(1F\74UNYWC6A%_2?^C8]OXT#[H^1#DNOZ3JT!:
M43#NB-K$[&-WJA5SHP[7U_SMEM6,'1+0WI$N7B8]SXHJ0Z6*C"M+)9-!)0^P
M&3-?NRW%P/2K:N+9\'/ON6G2["(1]]QH)* +IDJ_;W5)/2_M0X /^UIDL^9B
MGH6L9H! @]7?N"&%8Y'M*%!I%5<IJ-.:UM%[[D8ZZ&9#ENY78JWKH6(5NX(F
MQ6TW:-7=E:4:_J.1X@1O6+V85D:=XK]"+7Y?L@;IM4FSD-= P[<_9G;)><0)
M-*Z$&>C)1T8*-3<>-OC%AR:+3.J;?64>(6VK91_QPIMJ-Z"DK)]-TW8Z:E06
M&YJ&L\NUFL8F-[;A=T* MLD6X@7]Y?V75@6Z/<P'MH+^;.(2^3U >KPXHDPW
M4@X@^;*#CWDS*F/*3'?_#!C+[V32J?!QHO9>D05D'E]^4*0PFSSF":@T?T_>
M@%GR0J0QTGLE![!PIQUF%K'#G6\W9N\IB&PQ#J/V[6FBB_\H\V .+LJ [P(@
MUQE@LDG :!Y&R'BKS+DA*,;-D<!@[:#ARDXY*5K3ZV=DOJ[:H+348WCS!,A>
M;.@?R'=9&%4XBQ3%)C</C69" 8!Q5$9:LKS+ZUNHJFR;)'<59QQ'>[C&SRTD
M?(Y DS/*?%E1M%=@,+XN4R SVW\H3/)9[L"/0HAQ(DJ,91>.J\8B3QF%/WMX
MQBCBQSF)G^XH=/[#VA8)UA62A+'L-OV0-1F:58=+4GJP4WNMC==:HV!\9*\.
M+TVYJ'LH[N+F<]C9!9A:/@H%2-4UU28K?M^$13!1EYYH6)7S'_D1GUV2U0&Y
MY)T+,LMO:B=82#(\I'2E#%76TDMUNE=857M6@;E'^KWK80)M-%C]!1I<-K);
M@4>JY['#^=4!].4#1IZV985[]/6PQ*NFAGSZ+MD=;'$!;.0]**G-OSR"I -#
MA^UYZY)RC-9D=*BVB12+B@R^\RPI!4<_D&347+XPJL[GZ5V^75.J*GN^[5UH
MK%^2A?U?XO1/PG="NFQ9PW.M8C$QA&Y];V*>]FI_X!<'-M+ MA'I&92 Z;B4
M58C<8&)6OD#& 8)[ZR05&-XC".-ON_\)XQ)BM7 P6KMA/BZ>7GYO@16++(C7
MVR4E1O&0[90$T)VV!#G/T/HPS*LZK\M\D\)*[,@4_?XP4@RP/[Q:VV91B+"X
M[_/>[C0PN=VY$OV>@>3;SIQQ^\/N\)L^Y_"]U 9D)-&S=L;O5@E!'\TAWSWK
ML;WUW@X!<([]1_<IUV/  D_ [XN%N<V'H>8O]XQ/P$R7D[KWD$3+S\OFSDUS
M/S]=QC<&_Y0 Q&W8(MYV,J[;I MET#^&D,0W@F8"(5#]+H6CH;^(VB2JO9!
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M/4%P#M+!62HGJ[<O &'^42L93A^'C0X@,FA;7VSQR^J,J,O5PMA#6!25<[
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MSN&DK[M7U>X<C<97*S(C_8S2XW0B65+4G:RPNT?>ODQ.YV2>Y' U5. ;I,B
M>%(_LG>G$:#?J>%*T""?.AE3.I^F6-E]1@EZ\3'%WEXMZB3M<OQ%XU+RT)HH
M9M"S'<3\WB-ZMD=^HZKQP1G#$T)D&K:F?_/VQ/KCZ57AGTR$<851\3,^D%)@
M#P6FH,L0F;F=4\83$*C8D>F["?KY!*S2^*Y)KJA8._5(GZ:V?J/V%\6:5YC)
MWZSZADX+26(["FN6,,H'-^P0XJ'O^JZ].%TC/P<FI/\T2#_B(64&)K$&4IY9
M+DAGSLMS7]+@UHQ5L4.">_<Z2!\B#%,<H,0KI\$W3H\P(K-'N.<_@(8L&LP"
M6;PM\F=SO]A,V_NYR=C@!#4UV<X*^ M-(5&81<@">W^]9.</P#7R !_Q0 \F
M&NCXA.^+9QF9^Z7X8>LS@2_/$+SF@%\9_C4_=?BS9EF3H[K;^PZV_O3]JR=0
MDC^?@]>"A4SRYYZ =F821P_ZA>WJK^W]N810?IUXH4A>&[[G^ QTFOL%&+E&
M3'Y6C:@G( @P-<>V\/0-N4J6(R73%=&B#AX9(.IB*-E"#\FE3MD1_BLJ_@\3
M@(R4EX&^RR4O,*/J([X\1EUO?#[  NTA?9FQRP'M:[O,P, %0:A#@.%O$A/,
M5Y1YVGO79[J'[-^-0AGQ^5:C'G<S,. XV$. D9K1RP-A*;E[KS?AZV]FM1P1
M^7:;$>W_:F-$#$I$B@ X:12N?1/%\6E8VPA0K:J]@!0V'(4EP\<A6?11YPDW
MYX%UKZR0F\)FHA#JT(T,5A@1".F$^?! *OL[8A7G5_S&M1*X55_/4J+)_:'Z
MS2F>9+$@YI&O5=^T;-83E(*-ZV+%0XCI/.!7-W(E9DCIX2*^' OQ%NSS>K9\
MJ]'^'NM1">^RS*%!;0^<!^**-H[( KN[< C5P:QZA[2T400\UFGO92@^6?L*
M (FA9U#"^"3$=*-"7<OXL[>U"?H'*8.'Q!-;=.!<0RB1V;,%_&#NZ1*?XY2G
M/4_CIB%Z8$RX,Q,>P$?8HW<)ROEON<[_(([S7V#.85*/^X]:+/''!U0R\/7$
MLGY5KQ$<SO/W4OR&@->G+(GSW@2F7OYE<C3]*W0L1W71C:X;PN411E (;RN&
MF4!@C.8^#@V\!TP>F\GDMD)&B:V55[(-LK<,8UY\8!BUT^"0]\ +K"3X+*E:
MGR0U['J%J/[K&@]4N_8$8-+ZN3G&'_KW=D?]@MSW@GMW1$,#L0RAI/\7;O\B
MD?0@#F%SH/<J TP]J02*VJ<'.0J;/]^3!$B\GJ^/H(C2>7_7P6UZCL(9/_^>
M*2CJX/E^\?_(V/6['TBUS#!=%EJA!1_ER%W&+DI,4^"<]DR:V4HW _;7GF2%
MKP(YW-,[?M>>5M7:7<MI/ $:@O+U^B>L [449"MA@'.#_)>O1R["6FM5X8Q>
MP8:LUWW?-V>91WFZ"=%_^1$**W*!ON?<F'4R8L7E+RW*?A'35.I,DWNS&K!%
M +]YYN^^P04*LE@KQ9<^_0VMDN/O+D:/":LH1T2R -/D^*W",#F[(7^0D>1]
MUQ2KEVY^G.Y-+/0Q2%M':Q6@F(GC;T<BK@73V8DNMF6@6%O;.9]\B9]VL_^3
MQIXG542(2\NSO>FXWTK_RG.#Q!1&,V;-<ND+.7AY8.C%7;V0SKX9(KPVKT,?
M&DH084='LP%N>7:Q:[H\^S,ZT]OR/,?]_>LT[3I]]:%M+>N8VTN1:L=WF+,
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M%8F'[$KZA$3-:Y/VF#8IOBI5:0,]F18O3Z\SL&3^S_;B'Z3W'Q3$)N  140
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M]>DK[9<U85&HWUJE14@3BJU<&0U#/'4&R</.90:RT:E>.M:7JB,BE.-,7>Z
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M[UL\SC3D)T((39)&@(5\'.R'$H/$2[I%4%RDFY_3Y^/1.N[=D7W&PY6A^R<
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M(T;V<Z2B2$M?1VO)0!QC>("*,#^:648Z^UCL!07V;H#0SN-T[;RA@[/WUL/
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MH@G.>FD7YX]MXD/&C62,L6_<7! B\ALT.+\K2Q0LS:TRD,EF8[':H8FOM^'
MW/.ZB<FZ<S(DZQKUJ?W?6)MW$!G)& FAHP*7#NUPT+]4WQM9?P6$8!CF:,U#
M$3T_K.W>LDFVU$",5;"TMW\5CQK>2_5,S%QG5ULO-S"@E_9#R"N5\,"W\ S
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M^=T=/@&]R5@&@>1(DJ8&6)U@=';,^_"=F805,<[+)^#+,HX!EI7!O"]9V/-
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M$(]G>5DX,B4!04R4_H)C1,*N1RK=B&E,VG!+LLN)BQCY,ZYP7%[4*3.&Y!#
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M$Y3^$M[CYR(YM6BWD?@SG?%ST7;_3:@SH"NXA'<<J8WA]=>$>M$'[IJ1('N
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MT%D46[[<9/4"[;;1U1"K&X+G$*$1H!C/1+M<0[L\GFL?7K)7U)^\8CNXD<[
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M(,FAAIOMHDZ9L>=B6W Y$Q^<,C&*8U0(- &(G18OP0)E(&D(K^'&IG(@;-E
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MPV-&E#(K.''LSR&P6-RRM,MYW/\;DBIZW:VI0L3,I/%F6$U6>3\:G=3LZGO
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M,(TA=2=NKFLA82M'G5OF2<>HM'3@]$DQ^1@^=P,0$:;G4?ROO#"OC:=_ 80
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M_1S5U]Z%.:4#Q"">Q/QCF&<5^5Y=I?PMYF\_E^1U(FQ*\]_3O"3Q;S]7Q92
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MG%.EG0/=)3#RGWZ%(4(]$RE&Q"8OM7"YB#Z,G,&((4&U,M1AR!R7BXC"R$G
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MR9!MM;)7.F]>Y"GM 'DA-/1:$#'EXKAMK0GS3M97 "HH5?00^'DM'F%Y:^#
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M7ILM(U2;;!BEA<6&"V^@>MLMJM$"G" \09,K0'7U#-00V/!2Y*@5+A]I.BC
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MV1@$FA-(40V0;L>D#J?'[,,ZT9Z^Y<Y&J+PQ@1+5UNB6335*%QF,:W+ICD@
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MG'<,ZRY9S&LGRH:$)>).WBGB^S0:DKFG 32\S!H0R%'WF(V\U0R0=??9 D>
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M%@)#"83NNQE3-]2%P%;U0+>WNE/[3S:_W>1SN'%+@NG6N 0 G3O$6SC=LK8
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M@/JA]H^U"0^VQ \GA%DS(H*-M6_)B#;UE(O7 @C!]H]1SQA YY<8(NO@<A&
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M3(BPHG +'$ BPDL3GR2&<K[PRZ;N]' 8VIL3DQQNNMH".VK,,[.1)N?5!B'
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MTGPDPSR+#?4L+2RD[,Y"J,0 :!KA)IFA&8S6CF@:;RUI>6%5\L--F =4,W4
M-",\,-C50"0'K?4DL&Q)Z,+37LK8BTM-DYS:ND !TA$B\V&3CGU";Y]]W3G^
MV,4Y?M=5FV46,PDIH*\IEC34X.]UQYUD$;; "V1Z<F$$D$MQ\7A_<3^.BDDT
M)-.*&2@^%_GT[3:9)!6)Z_!HTJ+0%FKD'N_\6ND!X-W)JP:I=,N;A_YK'9)W
MJK,P.\>'J)$LO#,*@P;H<V'8D.<5-YUJS6H+7T44 X@'\BPQ ]RYL)D .>&9
M*!02/9EMS@^E-H!B[08%6M1'F=X9ME$#0+H+4XY\[C".D6E8G4\])Q][!85!
M _2Y,!$!4S^+B/AJ$ _2L/HS#ZB(^ES!_W()@@;H<^'>P-]K)UFZD&@-D\F[
M=F5-)O\I;KYHAZ19X 7X<N'HL-MU^I,\>_T]GDUNZ.\4X^]4JK_'^91%=2RG
M&5W W]CL?I'?5M;G$_NVN0YP([1Y':@-- +T"A>>&? 6SBC4IF%U?K'S84ZA
MMJ !^ER8AAXK*@5Y38;]-$U8[MD-<>ZK?T;I"UFL[K2+I?FK=F%MTB:+5'C:
M0WU@YI!H)YH $D/[,325&Z=GVTE;5EML)3X*HY:8 >Y:>EUR7^0L;^V@>"3%
M.Q5<\;I$5I3YN)Z>^+$UA'E)I]4$P&=+KTOFHC&P<^%*Y1L$L+S XVE[;/1Z
M1*EED!0%$H"9EEZ+N&8&^R+, T6ZFZY3%Q:=S]^3$_6BM2HAY$*YN3+KTI+E
M1R(]H$V$R!'G4<KV.(]C0DQ#^4!5V )Z=O0CA7LVU@C -X(GD$Q4;? 7N))
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MW!^FDVG*I_C[*(EOLHL\JXKD9<JG=]#I055)/,%&O2]UL++=,F? BDSF65<
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M<M6?PBDM&A2&="E%H.LW_OH?44%^_Q]02P,$%     @ VCV<4C:GZ6='TP
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M';(?HGP7Q/])@^P#^\V8PZ:T!H:MRJT6!K(IX6V):(P'W26YAH:O!A]# -:
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M!:X&#FM[R7*1^$R/:59$R<-M$13:0PHS":S/K.-;YXB6BWE-0"0%F@>]$O_
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MPM#3XR$@K)^4*0N2/.+.KQ58U>;0R9I4?O6ID>JVZ,!=E&WP]$X:C RF>M(
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ML_XDOFY-JN:(UP=+LPY^E:#%R^"%@A8LJP'[<K?/MJ<P8KUMBX+FA7!V#/M
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M>BA'E1:Z ;FNIT>:%2\W;*P+9G3X0="1KP:,*>.";B(#7<F-_*NKG6R^(8)
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MQ*F"H/+/Y!?>  4BHP-;X6%T5%>>_/*+7Q*>(R+:1S2\2 ]!I&Q+*IGT[:%
M8.!8#P39! \*8\/<@</8&$.^#XAYRIPLB#5&0=<0-/J_QZ,:V%,U0#0(YA%5
M8^"'AA-CWK760-\49>ZU-J ]^XA68&QD]0C TOU>^N&;(+O.Q$H5BMPV-S03
MOHH!&M8]X.49-T@UGEV<$1,>V"K(998BPCJ0+NKB/C>_<4DBRS1+2X@I3W>Y
MD.@)F!RQ.)))>PR(:#HFG?]MG5[,7K=42CR=&I!B7)?*;5U#Y4E.?B=A1H5
MU!D=MD9T10<L9!V1J09=]:.BPM:-FGMKO5@IM>(<G; 0PL@\NBYT,62E!UT
M(>O =9,2TE41.J38VM"5PUHE6F1>Z86M. !BS'$9;8296ZM%_MD[PS"@6%;6
M84"K4)(+3]BJ65'CI"!VV+MTLQ+#;L\L3<8TP>JWAJ71T&[*UKW964B(*J]O
MG749U_#-PMJH+$AYBEVWR X& ,6F.6R-C50X-LQB%]FU7>MOAUT5W4*$OI7"
MW\Q/Y+]2:B7?NR?*;;N7M] $1&4>W<-K*3"56+OM'5)@;VHBC/#>UUS<XP9[
MOGNE KQ23_/QP@BV$=72[EC!3(:IH.8MZ["6KKD)GZ:J9BGZ^NK!6<BT><CE
M/)0+;:H7 U65+0X$;/0!L@Q(&5%TO9<O946E=J5\F%6Q5L>>0 N(N$JI5A<I
M>^!KR&#Y/.QR +@RPA;)F(19M8+&),"N&V9WDZ7A:5=<5]F(#"&6PTV!@NLT
M?"H9)F0S\3RT;(D<:VD:X'9LG6ET02 @7IR6B:2,D9:&]K!@&.38"A'(09>C
M(SX #/UP0Y;5?*+)B6W6QU=GM2EHR4R%3[5 IFR"OHPZ\(I;[W)XZM7JEL/S
M#@[2#TR$\S013/P<%8_G)^;1'VCV_NLN/G'?=YOGE/U?:*[4/*DW>*@[2JM!
M&.'S3JI^R#/KB%0];4C=%ZDZ6Z5FL^6N;AG!KY@Y9;X7+UW)UH<=#VV]3S/Q
M_)ED\@NX5T#+B/DQBBDC2&@E%/OO+GU(L$^.9^BJQO!,452$A.WOOQX9[JQ6
M4@,-1H+V <[UB<RKQNBKK O[51,O\JSK@*+-KZY#">0"G%,F[B-S6"^84L;I
MD6]Z2[Z,2ZV1#G11-4N@+I^R?5GGN*:H\+\<YO\@!4CH [\$'U\C9\@1MN2@
M&I6 <I&7%0-WQ;-0#G5ML] ,. 7_B2;B 5@2;L,#<V6XH>%%O,=5?)024,G'
MI>CCJJ20U0H[--B*[BY+CW^=@D.JAB6L^LIAB2DX]9#'N%=IGE?.:)2<V,I<
M+M%I8GJN:D,,J"16LBAWW_+P_A4G^[[94TI*TI!NR"<9?<M\\8U7I=-GB1TW
M8J=U>TS%L@=D7[?LT0BI7D]L+\L70,G=95*(<A9&I=*1@*J2EF\52573.H=S
MU1K' W/B7?[)@_S-8TA1T6Z&B4]+R#NZ3[/RQI"93YJ__\K6O;2,OK@LZ$$D
MW^4G(6G,^'NP4I,5O^K5HC5G]*:N=N1>?+2ZVA:?E3FKF\^LJ.;++'MK#)Q<
M+\O1D5:#%,%7W6X-RN)!#@7_CCH"?OL,LRV0N[,QV_Q 6W#&9+D-><=V*?MH
MW/H.4(!;SB&N-<K+FE9[7_*J;*UDWH;:!3MSOZJ5L3>XT\8;WSIHT3VLV5IH
MPVDEVV\V5L:@B[UV@!K8Y["/ [YC[GH</NV;;;B/.LM^T./^\NSC]MWR5ZY1
MOF/?.V74XLK55R$L+\:=V<=QL!89Y> >TPH.6I.^[1LT):"/*/H!IHRCZ[TY
MZL5(!?N$PL#]0.2^&D(LK:2_1XUN(LK2*+N.H!-L$?";A3$$#CQ9&(,?DL\@
M:K7RH;U+6^\JRAHM[X(\VMEZ%38]8?D=5E):>"95-QR'[>=-94\;(OKR8/V9
M++!9]]+.L]VR.P\\,TQQT19H>]4U+N'V>@MGHCX$4282(FS#OYSD"?;U_N<@
MRX*D,&US1N@ S<^8!'TP\O9EXI2&@J_O%0W6&<0D041Z#K)[9'\0;X:?%Q?"
MQ3+Z+8+E+FB&$ ]!E+1%$"76BT=*7FB089HS*S7O&R\K'9]3L+I3^NDB>HI"
MFH3YMGC_E8<CGJ+\47ZS5TA@P"S-[ ^L]/5TB=7'2=V"975G;(M"NMV1Z[V2
MOFPM(\<6/)U^+3T"%Y0>F#QAV0=W(UKYVEJ5P5HN!7,\".T.CCG-&_1B\+_Y
M(#F4 /S?=Y"Z2+H;+V$/,%*R^C"36_[@/F:]#L9&#ZPDSMQ%JE,CQXL5RJI2
MXRHKE:S1&-8KU2 <>M#)?[M0+4>M1!_3,-I'.S$<\WV-D=[0/8TQ:9W\C'9G
MWX27X2J]?F5X=_9FP_[GK0CI/C<L$H?V&#5+1(_>[R7U?]]A&R\*M_Z@R161
M2U[]]%;^,&T,1[K[!OR6?]"1Q?=IK)9".X\&;AV<Y\],7P\'O)D^+&;[,@N]
M'2X>:?8I3=+JI:<\DQY_=#5&"/F*>$P&Y2DQ)R!MBOJ.J21""E^8*$EU@5*]
MM_I>9*#'N1*:*$)O_,N[==3'TE::H;R8ME(++R(U++($6%'[$;EA>'H_,X(#
M/<W -*FE7@T%=7@:MS&6C, !C,#KYP!G(N \S6CTD)R?V#*?[%[NLB#)&9/,
M =@FH?A7+-R!Y@[%(HAJK0]"K]=KC-FP"AC5O_P>J3Y(6E\4&\G6-UN7PFV[
M@>@J0 QB-4*[:H2*UH@$=0]-U9LDBH?>F4#=T7HW,.A.S&KF:=#Y6<TV03ZS
MD0]\QG=!2DO09S5]+K6O9I$323APZD$R%<WLJ\]/!J<>#J4_,WUZ9*._988Q
M>*"?3H=[FEWOE73<8P&DCOT (MQ5PCZJ*GI2=D!D#^)43DDDOU;<J.6RM92L
M9T$I:U++VHV@S,F))UF,V,(5Q+M3+,\_$B4.DVU@)0$Y(_=X$;5SQ^6")NF!
MB<^44(1<"5$:T=/D[+E"B3IRNW;1*U_2]4_2^[[UFJ3TZ+;M(HI/174":U>X
MP[DG?/MFD'*FA2M[QDT^NIS4J]BZ<*4QFK<..(Q.W^*5 FE%;ME"#\W:F,I;
M&K8Q?<?*PB+KJ7ZDQ6,:-IEB['-Y:>G1,J/H);+(<2*)B:0F+7(L=9PJ6RD(
MLSQ<W;AE"A(2[/=1'+$=$VXN W^E*>?FR(BJ6UN+!65!J70BX25)&3$0YG0G
M(]8!SNB]#[*$6=N\JJUJ<?>D)P$T;0:^%32539N:R^@71P[<J^_P&@?!^Q=Y
M8^CJ*\D8M/#T8NRL1M,>42-T^VY5'5 ?YMJR_>M?_?[MF[=_0CT*LN75I+.:
M,QM,K32>1QB!C:>/Y;;!02-K"D2=;+BVT<JU#@4FZ:6>]5(SU^)VHF[J^35K
MI^:4 5,_>U@?T] >T%&*?;9?R4M?UZW$IXD>I["G42)CJ<LVY6^JC32V!XHA
M&5(1SW$L&DIWC@,14+\<3M=QS\]M3D,A2EXSPQZE(9O.3/OVR(7E=_0A2KBM
M93Y<S,\^-IIZ[PLQ_CX9/3BR8?N]^,,8SZ#::7MH[,&Q<!/WDM^EVS 4MRE!
M?!-$X65R'ARC(H@%F\ROIZ+"+TUR<4+VF3*#D4<%+0MYWHA)_2Q+L?$&(E&#
M08G7_S2@30 81Z7JR<WE^49ZTV>B5W(3O(C%:\L38CQ0&3%XF>PRROXL+F7.
MT[P@K;XW1"1APUFE$<:L/5J[5H>8Y@)*!?O6!TK__#)FE3KP7V39"R^B>$A/
MW!GZ3$-*#_RTL?LT:Z8)F_)!SPS7I#%3BS35'^*GN<VG"/\6OPXIO]8R6>*7
M\HM$?I([YLU'VP\8^6?]M6.+#&$[2%S4L\V:D4C2Y(RTJR]$9: @JBNTKD9.
ML6C3U1'.CEW0^^(\39X8^)@ \J>",AG8WDP\+)6.XV6>GVCXQF"?7#L"M#O.
M,JKQ)O<%:7K8D+H/TG2RJ>*19#]8QW>SA6V(9<#"3G81<<T_LE]$>9YF+\P(
M%'S3B9%Y8-EYW37R-D%6\A SXI28-FV:=O9MU335],@&2;,YR_K47?AD=QJY
M)EH<V8&GVJ>7SL7$D%>?V'_(FW]>_L'Z4A;52E 1:VT04XDZ0'6F7%72V>3T
M]'%6:JOTF&;"_6*[1#YR99#WN_Y>LGIYSW>/6<BYV2;M^*%M%1LU8&C6^Q1<
M4JPUQDG-$-+Z2ADD=%V&:A/Q)=+^5%/IOOH8LV]DF_3")+>K!>+9I#B"'S?I
M?E1^R, A4EUXF.W+RG&+^&M>0N6X'>2XU=%^I17]PZO@>\6. F;>64U3>VEY
M_%93RYP]V+ C\V&'E/)'[*6E.WMQRMB^6YX:BJ-"\;?KHZB+]_XKS791;HQ^
MF= 7Z+VZNZ3J331/Y20[(;(7(KO9R%3QFS+[8=D7J3O#NG&?+W/U-P%V(5QZ
M1*\W/1FVZK7[1,RBJZC<B2ZDH\;.\)74+*OI.JGC0;5NX,C]R_ EW7.0,64N
MO[*I%3CGUELRXY4JNXV,5I?+"WJL?2.(<&@%.Q:5#C5*<+HILK2[%G9HQO[7
MZFZU^?:M2$\2TFS GL[L#VHG.T-BTTWAG7I3>%G?%'9<(%)WB; ?75#Z2C9Q
ME\??O]0G<FU30_*JB^HL[E_(JT?$?>1<Q'<VBU[ W6I'N!+LBY0$#>R/Y07Y
MKKH@'T:"AQN[YKCQ>G_>G+3>TAUK642#V>P7ZA??E[0>@0F;O^XA=JMCTO3L
ME?LX>3"ZDO;S%P\<T9/3D;7E-:[X*4E,J]3'(E4$UZ;3?1SMV&]81WQD7WUW
M>7/]'=I-QHKCI1L;)N]&U@?ST,5SLQLNNVQKHX%N.Z5SNH+QM.X8WWK:CX&+
M^:SB\K\Y^SE].* ,Z&K/!9;8VJ]I2?%OAI<Q(TX[YV_'F K;+W*$3G0V2UI\
MD]B19(+3*$B]LFI&B7AS_J9G*,$64\CW3R*^U4.]4Q'GXJ9TX(:N/>4;I6GJ
MTR'&UY^N+%/<!O\TR"R3G0IYOX1-T:4![*$KD]#O3_19_&7JV4>+'E^E%(DF
M+$N,7#;PS74<%<ZD7I5_*-+YIXR1LR".TS*-?YFS/JKH=ZF_"YF"5Y?%3 $K
MN@Y*NS!#"94.\+50E6G*XN:M'HZ+MZ@BKO?NW2W!X.31^#3T9()-]/;BUD,C
MHU%(IV7>/S,CK)_\]8<T*Q_*3EWR!_K!-SI:"2>X .4?^1/UJB//;)"UM*.F
MZ)A%3SRP\Q@'._KMN0-:3+NX!5I H^MM^]G5+,75=H2ON7H9I[@-_NNNO;Q+
M*>]J+L3\HP*;8;CNB1X-OI[UP"*-:*N3#^&!3;*))ODYX+&EA>368)8F].59
MVHF^I#,R2I1=K?4,?+$T$6,BM^W3LVSK?7Z'0<!.2=TPB%9/'(;/-"^R:%>4
M.2-$<+>H),?LR9Y&Q2F;[D/8]>V+6V$Y$E,\C:;K,O*SC*$OBV*V/N#ANCMQ
M7$P>"7>YLF9,Y&;_E$1%G0.B%1RZ5X-#O7#+0,?%6Q?&Q7XX>34NQ@/=EHJ]
MX3JFU*%K?$OJ,@X33EN^43LZ9U2FF0NS^?3 >#@KC,LAC9^FXXZG[SIE+X*G
MCY2?=!NLP6!K0 4?YE9-["9;E>KXBVR(E#S;D67Q%@%3-0R Z*/=@ ;(3?[@
M[F84RB-TH)MWLP3J1KVS,S]K=N;(4)\AR+$4I'R3@[L)MP"4NN&V0!.@4NQV
MIP,O!TE#73GW<06Q[P-261PD4_!V?7Y)MKTZ6#?,/4D*;,V9(U5#2U).+.+,
M:^IN^1)4Q7(%I:)DKHB$4[C/M BBA(95?951[=(1 *J2EN<^PJJ&I"X\A*LM
MUHRW58-7-]Y%J/? 9I#TT6Y&"$JEGO,@?_P0I\^Y6X&> 3*<NCQ#_!N+UG "
M(BA\*L*SCAA(%7>TF#(4VM$""DXKV,Z=<W&3I4]12,-W+U]RGI;L^D@S49]\
MNRNB)_%RQT)7IG0&J$&39!VJI"9P6'7#,_F\^B(KNW]/ZLY(TQNZSBTBN!!Z
M+Y1/Y)U(:TF#FAQ3%Z<CN:^ATV$,6KA=)*R_H%7B^IJ]<L]FH:\NG<"6<+>7
M;:".NZP2\:HB_Y[?^3=Z69\Q("OE+"G/'WDB,9$4K*6'>4Z+7 0TQU%P'\7H
M.NF.TH$2XHX0Q=3!<YZ=A_'R<U0\GI_R@NWDLBV?%2<E-/2"JH4FZ2S5L.I"
M%BJI.MD0T0U6?K1YDM8B2?7S2]U& 3FN;Z-HQ%2XFXSR(]>+,GM!F5]WF\B#
M%<&FZ59X:H>H:F@ILZ5&EKU5V;W%ZB$ZDCJ)EK1P,;D%V8N,!Q1O?81P&=W1
MZ(D?GGJFL2Z('E=>%SACZO%VM^-%!O*;X(7/"6.0_28[,9@TCHR3'MMUB*K'
MEC);ZG'5&RF[$U@O.R17>G<0R]F=*+UH%,1M53[*'CS38Q=$C^NQ"YQ]<X K
M%E]F.\&MGKQSA-M2SG2&ZZY\T557>6O!O-V&6N%TFF^L@'1&PN#^%[?A$P]7
M^\ DK#XWM"PZT$(E K:41*LY%1TI"<MJ5!4I= SS')GL) !+T>N"L4XZ7G"
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M W(CA[J)M9=':Q>N]Z1[)EY1,S7'4O"YLC4J.RP:VOVK(_XZ]Z\8X+.Z?UT
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M"9CQ'DD4):O+-<J+6G.N*!,%U(LD(]=*7)>H,[>O2U(&\AX?/>G2^-!WWO8
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MOK'&X1M$'+ZQG-<WGN!P/K\8.'QCA\,W:^#PK34.WR+B\*WEO+[U!(?S^<7
MX5L['+[%2DI[>3@&4<;/R*_W?5=!>A$Q]R(,3JQU#Y!E<JVE4K!44_)3Z0&?
MMO1Y!3W.MF\IX:)&.+R'FA-QJ%0.=@.A%[O#]E%.^>IENV<($%%5C&#B >=H
MKW[L*2VD=]IN;L3+H5W_N'-# MYK&5S(*+T[JIDP$._S@BT@_6-0'S(2+ !W
MEW-12ZQCW/5>)B'=+W'?:]<1RIVOI8RF>]^FBV_C[M=E6O7WORYS"N@+FKEZ
M]_(Q^$N:G<?,6U!N&8<<PTG=07J)T^157Q37$(X]OS>>,\.*RS5C>N$P_5.:
MAL]1'$L'D8:MJ[3&9[PR'],[] &(7A?)E(/NDG9#*NKNA7%KHW"%5K!N&0';
M92.C1JQX0"Q(373&95_]G$$)IW/O3CE3^#S?[OYVBO)(%**464F#![;X_3GE
M<7K5@W_9*C,>,4SM$% ;)\O<1V[5$6GU5"?HY:EMF=,D>ZMS)I1M,ZP#B<5D
MMY8+4E/GH;FOMO.@C*K#VZ^1:9744N!J8<FUC9J17WAC5 =M9-@MT-0><URX
M2.S2BY0GCW<$3H\6&4)]2>QL=D5&?I&$W@%K<()L(#8X.S/NSNZ"_($F/V7I
MZ6B^.AMH"'5S-L2C\D!1M"&B$>:MV6*\@MV8:1'0N3!;=_JMLHXX#.U#9VB1
M,HCP:H#%RT=:/*9LB_[$G HNXNWI< BRZ.\T_! E0;*+@KA5FF=[GQ=9L#/%
M<\[K%M"<SY1?.7D7W1'9'VDZW)"F2U+WV:UW5'6+N@XL@8?^$K$$&&:L'E,^
M;\SX-J-#J-5HCLRVF+: -')ZN-DSWUE=_)AVJU7(B^G'6= NDUUZH+=L?*@\
MX=H%%IM3(Q7HE8.)>_5F@;<F=7-2M=?L5&&.>]:5 ?8Z9!1+ZJW'*)#0=6%T
MQSU"AZ\/VIVV 4V:33:J3BPHAP=Z83XHL +5##?O$RWD)_BEAOF88+ IE&LV
MS.?04ZP2!+P=YFG!L@R#.7\&/'3<NK7!8.6P+3?&,S2(]_F!#6*9*R--S%JD
M;0ZE27I^E>0M?+0X/DC=%E.CUF$<3+-&<-+1+@B06&G8\F,^0]/$([N;+-U'
MA5G'!AI":=<0C\,/(F4C3(5:C%<P'=(BH*,]ZTZ_E=ZX#^UA457Y3)]H<J)F
M->DU@E*1/F_]<2G_CJD9<UD$4XC!>>XHPWJ3;*4(UB.Y+/ZG'.5=C55;F-FI
MSZ?85X9(W!DGV5<>E&I8! JSC[37P<%JQ]JKX&$AW7X7,'9V]/:1TN(B* +#
MQ>I(>RB--'"L!+W(ID2T);PQ\A6GU9!WU -DO*V0O\:XPYU#E]EWV/2<,EX=
MUW#TK#8%/&T>X%/),58E=:H;X1PH6[#*_GA6_O77OWKSN]=_PG_%JP-"_ZQ8
MAP+ M,A-T3\KW&K:0Z8XUG"L'&\T[?!A;,NT@F7DHHQ6,%$R$9LP O@&M4AW
M?WU,XY!-D/2 +I-=? JCY.&&OY=-DVU19-']J1 EYE+.:YH4;%CB5NRY01>6
M^@#DF]6EQD1YR]KJ^#=$=KTA=>>D[)VTNR=%2KH?J)\\(!4$7FMTA%HW+:5J
M5Y4 <(L&+ZHDRDO?135DB>+$-ML/36/P8L0C#G"3H=^738=QE(>K]@X-\>0E
M(L^*UO+ _M5?&MBO6J_/A[?9ZF\I_10<J":R:GZ7 +A:0&XU<J.)^>7-$,.8
MEIK5"J%+3>FZ.-9QH(UZLB$"PN(H[^-H0PP/LA_]-J+LAGY66$/R<$>S0S-6
M7Q*V\+:_.Q;H8-T!7.B#O4SJ_39;&CEQ^\3SQ,E)]T 4-4("43[ 0 I'9/9"
M*S!@:1EL@31]@+OHQR"C]T%.P_/TP%-+R3C?+&.RB #'=R]-D[+,T/8YR,(/
M093].8A// _*Z7#D5'F5FHR+_<:TLU[QHY"[[37'3MF!\Y[.1%>D_3G2^AZY
M?R'M=N4WB?CHAO#/$O%=TOIP*Z,<_S96'G/0P:PE9B;\D)-7/)/:]TB'$I!R
MG_/=-]N*G8)8B$Y>10EY8<+GBO2@IQ2K&R'EY&)U"P1LPM^-R_+.198_IS'K
MAM>6^QP4Q@Q^$%^'-NJKCR:&=6^8()P+5$,//L!-+M&GNBFBP8>7OT*!7GQP
MBP]CLP9-/XS!FK';7Y3+VV-:W&31;LB.K_HUJ'.$U49KT$Z3=V8[_:ZTTV6[
MCIW6F&G"/TK$5Q&.*>"&CTMY')(2[+!B7<7JG&Q\ UIE=0SRCZ1=SOEI .SS
M;9%%#P\TBY*']T^LW8<T^TQ#*O^H<;\QF/@6K;G-V +!D+1X(8(9PK@A#3OK
MN.6PYG_*>-]DZ7U9R)RG_6R-$A6CM&>CE#6CE![[L<O?[ )BK?FKK2NP:@^^
MW'QSZH^4/VWL/MRAD(.Y Y0"#B,RF0HWZ-Y6>%:OP6;6]'4:;*9L3LTX]C__
MS@;X[X_I::1FW$!+L)IQ0URJI:6">U*U0JT89\7MV4<;=N$*QFF!T"T8IT7!
M7!"FR<-_L/^W &&O)2@(^UP.@Y#?+_-FZ"AT97?@82D\"@>1H*)P$ 8S4/@Q
M2 +I0?Q[&H>[U(Q$76LH-&JY[4]QTY#(EOBVQCS2G9DV#_.<1\]Y>K299[4=
MV--DE4/UYB0]>C.KNA'M/@?6#.>,F;Q(#\PKBG;2.TJSD<Q<VN90\ZKGMS^]
M54M2-\6?Y9'1[DSVR%![M(6ZLB@FYM*)3UNI*\/S=,OMU)4?M</<I]%Y7Z7,
M(7:>]+P^.;F(\EV<YJ?,M-=WZ00]![I&-ML<"GDGL*+I B=V8 D1#U+$J(E*
MW7,!GSB]?RG;3="T2]!NPB6VXGVF0<S3<_P41 G/UW:=,!Z/:1XH(!@=*%-7
MZ$IHE-.^^$#5#>']D%>\I^])FI"J,Y^4TDGDZD]\B0P20C6:BA6RM8"$O%'.
MYRJDS![D:1R%\E"=2TSRTWT>A5&0H08E3=51.SLTKJ#8UNB6[9G.@RQ[B9*'
M[2$]&3-%V'>!;GT&Y;*W.I*$\%Y\,C N4BF6I)8J'Y *7^?T2+0LRJ*%X:P4
MC@]1SI^LLZZ/41'$U_O;VF[I3@)&B.!2/)IY5[, 5NU)24"N]^16:Z8!SIIG
MB+ K16!K#>Y*8X^C7LI(*!!9II!<=B;^__*^MC=R'$GSKQ!88-$-9,UM]0 [
M,[O  6F[JMJWKDJ?[:Z^V\9A(:>8MK8SI1Q)Z2K/KS^2>I?X*E$12O>7F2XG
M@XH(/A$D@\$@TIEW]>3?97)XC&(A\3T]!FF0T_WK'5NF/,5\OGY(@S@+MB*1
MK"CHU/RFF1^]]([P(.0T;2B?C&QUNR)-QZ2A)NVN5]63\LWON(_^^E5+*5S:
M"(^^_?9H#:JW-3V8 IQWN$V3+:6A*+8NKLWQ,C:<-?Z']6X7[2/&ORZ6:]T#
MH)7;2R5)TA.414GY#FWQIX8:QU)]B;8=BA8H18.T4$=$]JW0$8ZHCRIGMPPB
MST%&1<[V>K\O7]GARPSZ]Q-;H/ ;N\P_\-H:?(T?_O>IC/993,F^/H3[7/,T
M'=F\[<QFX>H;1?(\:;ZR(LUWB/@0#\^5GR*M;^%.V[/IJU:,N,W"G,;A$.7Y
M<)6",87[-22+E[(]6!%@[.MPW">OE%[0F.ZB/%O'H3SC6!?\LN\#,OKE(-D@
M4%32DHJ8!''8N6[<[@ I#N9#OL>"6(B7B0SN0KQM.].[M3"/8O%32I_9K]$+
M97\0+U>Q'2S#+_(U6F<L#\)GKD"&L]/--I(']]8[AI:'X+O&/BUH >W21I)!
M]<?+ZY4R6V+%5J2,DC!2'$L<+5'W9&LH43Z4"-*>K#'7MR-KP,'9#[/> [\
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M[*YH#(L&66.T!;9BH=!;32L6"Q@+YTD,XRV1=>L:-2"P$*Q](=A,@H9F[>O
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M'$-_'8NAOWK#T"<:T^\\;2K>Z@$C:0B%#AF/@VR.L@W;IF\QIW)OO((A5(F
M#ASG'7ZK&=M%M2O6R-=4/=@,\\#@L]@,VP7PM)1HT0V9%#;AC1;= N)Y,/+@
MA6N46-/':Y1 F[(Y3(-X^TRO-[OR<[\&*?M3;MHAFLC MHE&_@=[Q8*"7//W
M<&KL5&2H.T8H6>"VDG;HZNXG[: UW??_-.)H54D$[/&5O*N<XT\+/%F=50IH
M[ZY'D\RQZZ'DP:='(YVZF@[:JVLD4+K"Z^8-L(7Y=0!IP#V["6-2UVX"V'3?
M7O7KX-GE),!^7<&W<LE; V(Q/GTN":#]N0Y!,F^N@\^4IRX/K/MM$%_18Y)%
M>9"^VD#:1 7VG*6)^\'[?R4!:2@6 PR[H>B^U0@W#G:O,XX>C[ 9CY$/+_K)
M_*_,;!V'=_R()^/1TZLHV^Z3[)32]6.6I\%6=W7'N@? K'][J?H#5+O/( Y)
M02M"Y:2A)K]5]*B7@!U'KI\<[SAL<(B\W =9MMF5_&U2P9VI'H2."!!W6MZ'
M)40"?AMQ5TW9)$D+Q"VAC()Y%/J ,@\!,H8,!64U--@(4A25U0 (O;*L<02L
MX(-375;*BK%8K)8*&T'*4JX:#"V@G*O%2%CAR%NQU6K6?$ANV;@]!QG=I&$4
M6VXC;*FAMA/6TBA720\)J4A)1;N O?-TP?*$'"O!DDJP;"$[)S<4=G90"!"T
MVDG-"D6DO974%=U85'@R$6+/)C>:FDF:">5F&=63[(;%:EX9C,F41#7^@63W
MK?A DJ9B5T:+IW#X,IJ77%/-+);$8*EJEK+(P;,9@B>KGD/BQ.2!4>,EJ[F,
M4S=;#7R0K%SOI,'J6T36&J?^,"%[WNI5*7'GO_XQJQC7U;88V1^VG[:0V-I]
MKYH'R6ZK8A'UW%N;*5;UF(6*CSZMV6+>:K:S!3RRG=N5@3:38ENOJ0"Q$JF:
M:M#H@+2H3&P[,HB')'80TY-A'H?HH24[ UD(IFQ&PGC2@8JECT&4BFK;ZRRC
M/%$CX,<MX2:^H]L36WO%3Q=!%F6_Q,EC1M,7OHZZCH^GG/W,5!3M([&6,YV'
M>/T*Y(MJ7K4S>+>*]5Z5S"\^0*HO\*J0]3>(^,B*M#]#Q'=(]T-+.*F9 5"#
M=]_\HVD9SOMSD)_2*'^]"G*=-=EWL1"GWI/+T<&O2$5/> =+]?>RP7/Q_;*1
M6P@L"P/C.W=A1V.A.>AF*? <RN<.T::/PC7CU%]$%W,QUJC K)-%*@ +9Y5]
M#A[8!PUY VH20&O3\-V'W !1A#=>0,J 2?=]))D4CXL:8[Z C@@9.<IL 15V
M%I J8!X#&_RX)PK,@Z!.J$V95.!$C8@IN31&< UBKK@/PH^3JA;AJ!4!TU0T
M8#/9C 9I>,8CF/F:[-FN<\_6]\[FHZ!'-""51!8F5%A.0[LP([*5[$.61P>V
M40O)2R-*ROZP2(O2(M!D4UKXX5G5793]_C&E]#IF TVS_(XIW]FT=)T@VI=6
M-@LCX_2$=T"J'LB=#ILXMN8D)6_\;L=%$E:6[$A*\U.*6\UP/#9-1F<&)I[E
M58$J9VOK$R):V$ &"ZNJHY#+,B.S*!7?X5+G)SFB3#8BA].$E+>K]!\!C_KH
M<J:[;: 2V'J<#5Z&2?^3_1,SP]G(X)^(ED6P=#G9&'>RXF0#/ %3-S3Z: 15
MKQ$4JOJ\#9ZGHQ'YB RLR3R"(4LZTAUH28=Y K8^)J?87-"LWPH*70/N!L??
M90-,>$UG$@Q?\M'N $P^U)/*;<11DGX.XN!)S+L?#L=]\DK-)3<,9'!E-TS\
M#PM7< K2D)":!K?Z!H0@@$4XK'#5*\0!!RK+%VOF'A.X/=Y7ML>,XB?#V6*G
M%>#NK<M=7ZOEKXHC0YA-V10.(7=>DG'N;[,D@PR.0^-I9:\=/!:59Y+U6"L.
M(4'Q.)I+!$SJ3T>E PZ'2W%Q\R+(:'B9'(XTSL3,L/X6I&%9]6P3F\//3KT
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M<T[S? _21\VDL1GL4'2-Y:?.74V@OFI.*QRXK#E-$,YS^6'^)HKI-?/"NH0
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M4?RT?DJIB,P:@D]F.J@)W4*"/@R*LY#KF-1$I*'"GUEMQZ0SVX(.B-4VQO?
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MP!9!UBCK+'Y@(6:UZ)EQ<) 6.U<GD5M?3XX1S8H*Y_DZ#K^PL2W^H0N:V?8
M&3:SEFH0.#N)_.WV0@CM(MMX*=;;;7H*]IFH!U+41SX&K^@3G2/8!E$S-Z1-
MF!8OV?]<1$FQ*[D__>,Y.5W'6WT 04\#-1D:.!\<37Q>7Y"Z/2D(>)DFS,#
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M;D5% ;I?A@(3+I58)#3NT2Q4D<8;P@(*Q0])2+[_B\R5/&Z5!?"(9ME:1,K
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M!--6 ZT9- GG_EN,%FM+/\V+(/Y?T51+M:@"B*'E&V Q(@FQ/EN2V$Z^FY%
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M,* &#'9%X>)%C3&36^6Y,"Z0W$LT_*C(E,%P%5JX3H1O!R?6(!^S!,3T/RP
M^D<0$Q;,OK@)LFP>)2.60EUE"#:JSV6&Y9U@QJ;D3&N%#C]T<7U]6.=D9*#E
M;PF5Y4$BR'G&JO"M1H,?T-C!5 X7OODS&1"JSW1C\D0*/<VJ:F^7%YU3K/<N
M==@V H4?]=C!))\F7!Z_1P55ZKQ()R3C C/BWJ V+*1>K.V6$[P%-OQ(R0[.
M5>,T*UY)-GF@1\F\8%M;Y<E*4!SD@6S7K,*U$@Q^_.3ZY/8S,@VB\.[[E"0Y
MH?N67C%>J'.N'^8&M4%:R%;/*M3;8,./O^SXP&9Z4 ,9(IL]*ZWC0A3.@BZG
M11"CC>AT2K)BWH\#]@HI9(>0*9NXZ/*D',KR:B ?+W9KAL=P(S2N C#CGL9[
M%&C O#$?29"3YV@T+GK#;W3&8O)2$*ZL!S+RXO1MR+@9'/Q(S?4)?Z!,)"-F
MT0<!496^^SZ(9^Q)Q)<T#3^C6!0NUJ8ZR,N+P[@A_5:H\ ,ZU]<" Z8W<%]Z
M<=(R9'.GY_CAF^LS!LDBOY)BG(9F1RE)C;?+X\LKK-1?E?C4 <&/]>Q@'5X?
M#Y[29*#=1PO+@\(CO0VIMNXJ8>#'@'9U,-*>B "S%S8.J[NJ5;^=Q71&//P\
M1L%[%$<%<TE+P-%AG,842 Y3D,%%I&D3(#=?'"]-+YNMT>&'A7:J%>87TO)*
M(!ODIRO61&KU0882/Z*T0QOV=9IEZ2<]%!B9L->E01K()A #LC1F; $@_ #3
M[FXH^\&<7<G1 4%_D\UHSW<D9G!A:= *EQY6;L_:ZE %*'X :]>FLB78N5XS
MU!5!1L@[@<K*8(@--]2UQ/UW)ZX+2[''5/H^S5Y(]A$-Z.KX$40Q">4D5VR)
MN\YB9<FJS'I=L/@AL>M/ [>+CK*HPA.B'_W"\MQV<85\4J\\Z-60\(-G-['G
MM]KKP[R';&.K3*\"C[,@V8BG_-*CAL<T&;&-[5-:D.5^1NV7I*K)W[I@I2>M
MS;HI.-QPVI*EO#\K^*5=";ULK184A:FK;?MQ+1K\2-J-;;K-;.2ZNJ#3![;U
M%L##C\OM>MMEQ+^L"LBE;7MO8U2N0GFC7X>51&1^)R:L!%,BLD="]8&NQX4?
MX=OIGMMLLPT:C_RPUKTE?07+6;QOU,WV9!+!?3U[UI3RR'\D&:A)5M0"Z?AS
MM*I#N@E,_ CA]97@E4Q8^J5L;GR-*JG!I8(51]HQ^3J(^!'$G1._?,38G; +
MA&Y19-'[K&"GR]>T'VA6=^NV0)+(NWL=RT:Z88'551AR7*_D2JX7ZI%XAI43
MUO&T88#251ASY'?BZVL&[9/PK:(@">3MO@%1\EV!$ U^7','=^UA& & ?A#1
M,^Q-,(WH[K2$677%KJW,976,'J"P(O,6^/"#H#OQNYA-9C&+K\R/N"R32D;&
M),FC#P+FC<<T9\[XO>%K\%WM>V'3$D@1W?FNJI94!(L?7MU%L(@BB!(2W@59
MPOR02K*X)<-H$*DC1^@J@ZR0+8.5%<,"7V,1V5$WB5:;0Y %>KBGBEPK\$BX
M;=4S5-UFN88'-LC)'UNP(ZNA&JLD'FY]4R).!@8X](Y)$0THG$-,QW!\?+7R
M%\; 9IN.@?47?2ZU$*QL5A6B\BH=0X6#=,SV %D0:\*^;Q9DJ8&/.NA[(2$A
MLH.SL/]>96.HP9X^O/M649  LME+0HJ.P2T$7N5@V&-"E-,VC#\]!*]R+" D
M1#E%NJ36,R-@4HL$*[F"XRV.FX0H=$1<H=L;+19)/11'.1:PULNZ"5&8%-!-
M@SJ.),NG'(ZCW K6I"(G1&'H/8R\OR!ED\5*R!RE57#+:_.Y4!AZY"?457@U
M1^8HHX);7IM/@\+08Q]8*O!JC@PMM0)^"I0V3L3FR%PE7&AU#A0F3E^L@%:;
MX5T,KI(M(&V#MSS(^D'6RSC:D/N4]$G&IR=S?SM9"R P=%\;*8]BXFW!N4JT
M$))AE'"+])=9%+(+#735@&6J.RO&:1;]N;Z7T:O$=DUNK3M"?D975Q6DH%SE
M8L#UJA.B90_X[8F'6B ?Y)?L;DC? N0J#X.'A/=F15X$"0MO:LMZJ2I(RA?C
M5RWJ1:A<95_PQHVVPB; H#;(RY=["E,ML 'F*E.#-XI@L>0K:H%\D ]U=8B7
M CJ$A S"*#UV5)?70V1C6WV:M\ XR]7@$\5FR[JJ&L@'V0)7GVP1(E?Y&G88
MWYL+W$HN>6\H<?I&](6#3O!WK#M=LW.+,VGI[;QS=71\A&@CL_:0N^Q@/UNN
M*F.-\6P3H%?.<D:^'OTL#6>#HK>,7J?PU!$5Y<B/?9DS-\G8=>]0(O#*5<Z&
M.^[^O(@]J/33D98'&2 -4"TQ4AX50+SRF4-WTZ'CP1<CM6J(FD/QRJ<.P4WG
MLM/QQ=0LY4BR797#P72MRY>LYF3P\RC]^"4D$1!*_['-(_W56S?,I+?#&W]_
MN[PZ13]5**2^29.XZXZ\XK#C*M2]X*4"\\76;S6-[F+ \HAS]1#V@R0SDAN<
MK+:+@@1\--@",6(FI2@<><#AOFKFV.ZIE$3IH5>IZ%C*'?I_H?HQ?(76X*2'
M[/4J95BI$)5@.O*N\R1UYR+)L,E<(*T#IP9?_)Y-)P4]'%?^=KC30TZH(,?T
MJ'=+E3Y.>2[:!63E1*"H!V,!^?9&SY]L[)L@J^V2=P7<)V3$S*](['\A"7\]
MEX3=<!(E$1-0$7T0/?^:FB GY(N=JAI@BJVV&Y\7.K V\"^7NRB94:$MI)<F
MJGV\OC)("_E\5E43+."Y\N+#C(RQ3H *P!\2NC31WR@50%P%Y()\)U&==@TH
M5_YZR,FZ.2C]7+]5$J2 ;/"L3JT82VV'/"_F<AZSZRE-TJ5T0'_U%*LK<BF=
M(%M$JS)N",V51Q[ND"XO5_99O8WJOUT>7QUAA[YULZ#K$!Z&<]Y]$&7<^; ;
M_GL&$'O#WX,L"]3:H*P'XP;9/[>J%I@AJ^VIY\62H-_"7I-AFBW<,UZ#[R2_
M^TZ%2.%&29#-N:F$985@=K TCOD$:K M;.RKP$]+C0O[D(LS]T/4D\@"_T*^
MU_1(/E0&X)34 *FTU!"APU3;[="+&>J)%"4G0SG#&^6X#$Y;NB45(Y&P:?_*
MM]*XE26_VWB7?!M]1"%)PKQ+#U ,^"S*Q[!\;CU-%_!8JSWV%OKTK&7CV UB
MB5Y4-3-2Y6M<.;ZF832,!IR?^JJA; W$U#)KA N\$K4P-SC65XL&YG^>W!FR
MCY0\[Q>!9Z^#/!J8KA#ZEK@HSY%=3IRL(198)6K3JBR[U78,5T<7EVT]-XB1
M2+BT=ND+HWP0I_DL(WB1 P1O!999!@Q\#PQJOYU?'G5.6VJQL,$GT8I663)5
MR2?NZ?DX&B60YW(P?\V")*?X&9%)R'^*@=:5<<<@RT<S'X2]/79L(@O=49C0
MFQ..1&%;E3Q$(>1JTQ9(IZ7WYB:X)*S;.U?ZLA'9[]:52O'L$,P?%E@E&M.J
M=]6_T\ER3(];W0\JNQ%YFK&' +WASM-BG;Y8M0,76BW5EFI()0_4K'TS<:_N
M)-AOHWA6+ T"9@_S+5L".;;T:%P5JT1GK VP/@1B6^;I6@:<,3A#R:J M'T,
MTJ%RW]:BD;#=JAS(VR!UJX:P/%]?SY%WFEJZS%C>!"2AV-XGTR.*%[.8!<F+
M&EPJ%\A^.XYHWH8D(;J^/R9._)5QD(Q(_I!PK!M)UY:)*/%"L51,GVU0G[%Y
M>MS9_Q"K'':%]=>7V!Q&DA6/+@DLKX*M5"=UD>8^G4S3A(TOTS@/HGI<-B>>
M/5)>T*7A5@G'46P6U'5R$Y\V[H.P/ C$EZBC2LHD"Z42E:.H+9[$I9/&AY"6
MY8(X13[)J"F2VE,E2!Q%:L&D]#4C03[+YF:D"DJ#\)!O6:K0JL+B*%H+)K'=
M,(R@__T@"A^2FV :%4&LI5A9#P34PC%LALI1*!A4VM>IX647AWH5,&T#!(=M
MO*BB#M8('065P8TV4%#)D'!YGM?J@;@"B 3Y<6D5TC5P#B#<C./0>NQLXTM@
M4ZOCEA0*5O(U3T+K,2GX$BM1RI%D$RZ'@Y9YS9/0;6S^\B5@HM4PW<7@*M<:
M&I7;1D EE=N%N1C.?#& [+(CHU.*PU6JM2G)HI19Z3,L-WF;VWY!I'HF#P]#
M<*EYE<)P%6T%G]8#\G0]/?,P\*-2P1J6Q6&D=:O\/A/]O9ZU/H@A'$:RMK6>
MYJ^IQ!C%)]SW("<\=0,=$9RQ9T+7U#PJR"(8?)]/FL]DD([ S8G'4E :])K]
M-##ERSG15-GV)I5#"&W#MWB09^EVEM&M &#F0/G?>AQ??O>=9(,H5SK(6+?%
M/01]#&"JWQ57@NDJ[HV'"@-;2D<:HV@,9-FV_5 -G(>0UTXU8IY)7F31H%@\
MU^Y^!EG(-WQTGS@D43$3OVQWU?3;Y47G\LS#A(B5IR KU(>04D\YN)I1+_.V
M0=('-5]9P6XL@]\>%>R6O!<W:4*/&3F% ?^BZ!\2*H<9$VMWDLZ2HJ/0(],F
MX,V$+X9\4W6Q1N<L)$\EK6A#2)Y+7YPA=3K@!JKC6#R^3A3EM+:UIHN-AF!8
MM>V87A%C[? \-8U&OH=LNFR+;= %4%=!=_RW(#XD ^;42-@OLFS.<N3P-;4W
M?"8A(1-V.;LIS)IV0_L/LK=&Q]COW1JQ%M:0A:M00HYW.NDTS7B?"L*'U.+=
M]_6V173Y0IC90&G7J4BZ23FZ<W<XC.*(MB*?R9Q_"DPCOKA%&$YSS4D!-RR1
M1,.,;/!KN]<+OPP,A2Z+M=H#*;7%O.,&ZB&$_5$9N-:;QMYPL6V,Z 3\0@:T
M9!%5-A=JVP4)MV5_Y1:RLZA"_BD5["D;T"K#AD'&;=LW.<)\"+&'5".,>\)4
MG)!X79!4VP[WYK!<!13R4 $6;G;5-*!4&635-J.P!2Y7 8(\U &N\4_DD_^E
MZLYD59]+S!N/<!>3P2XT5_&#L+.V*[2_ACYL-0!2:Z5?N3DV5^&&O-0(/@K@
MU_=IMG \JSI1[+0#,CPD#RLY1%?!BKQ4D_)E2"T]D30$4CPH/P4Y1HFF'*#C
M\2+Y&HBBYHW 1EL@R[88UNK#E*A,^WQ]:[YA.V_E252,0\*IM:$4'CO=)5AN
M!S5?L!U?'I^V;N*7PI"0:FVH%)**$[8PR,?W<?J9(T8G7/7!+BCA3C5&Z_D1
M0BS")U*PSO2SE+D8A-?S;SF[7%N%0NX.BNB#FR8-$-HW!KA]N3I0$2,>;S40
M.PIWB+EP5GZI=XZ=2;$&;U)%$$!T%.?0H_TTNW]/!E%,-@"_INXFD28^!X3X
MLBNWGV8:E8FC*(VX2GI+:&\'$>=4Z4"Z+@8"0-ZW-\JL6)F$,CB N([="7,E
M^G/A&OE N4Q&[':UF^=$F7A>71&.NG\]-3&4R@'$C?P21 F38"]Y"6+"O&I3
M*K5BWH\#"(H[98)7*)!9 US>V#F4$!3)4CIU(U)Z\>*!#A=""2X6;HO,IU^A
M/X+2( [D"PH$95&)X@ "4MX'4<:O:]:B[0T7EE75$J6L!P)"-E4AZ(J94%"#
M7$K<@ 4]S^G$."N>62:IQRAXCV*9<YU= WR=/D5^-+='W:@H'4=1,E&WOWQ?
M)H"NVOG*ZG#I7B'[3V!L>K4"<15ZT^E\ @*YIQ+D#F3W41)0606Q].AC4 L0
M_W7./38BJ1VTTY--ZBKV' 5<?DWSD'R0A=B5VU:#^C#%_O5F$COAU X;ZH5"
MB9]NZ6Y==RHPR5X<_77V+(;2<!6#U.G*LU3P\LN&I[20[URE%3C.SE_G%&,H
M#5<Q/1MGO9?DXS0CI6<MCVF06.F!I F0!;*?OP^:H9./J\"AC>@*<QQCN8D-
MYX>MXASC\5]G33"2Q2$$VEQ;AZE:<XF\DFQ"]]V:K8.RWMOY1>?L[*^C+79"
MJ1UNL^9F4_8V?N/"B9MJ>D,J$3A[=9-P:1ON#1]9U D#,UF-)F&0(;\^W?>$
MXT)>AQ"8<_O*ZGJ61PE1^CC)JL 1#]GUQ(-;OQUYU ZQV<PLM++]059L%H^$
MC@DVC:J-(N:5^4C!3NJ+9I(WDLPA1,=<!D>Z)<L@22O1+5Y4&#C#F3<"LO/%
M7]W>Q:T"4MQHF4UI27<P8#&T6*0C$GUH,L2;5&<Q9T\OD'<R%>@UU1,%XL,(
MG[D+>;F[_STJQC=T'J<S=L;W:%:J(FT%*$ VN#2H,7K@M:-I>JHX_8Q,@RB\
M76!8>-G0C3V_[M)Z2E9KD$L5^PJH076RDD'MT)R>:M9R%NX'<S8%4_3T-]F,
M]E!Y3*_7($@5>=.SAZ7-2 :X(37WN=0MT:O>Z5JV!%)$?HBVYR5O%[R7,3.W
MP73##V8,YY<C"R0J%Q=M74#?]MV./5Q7\3!Q'_X(!,=6W97TJBX_TE:X_+#O
M%AJ<*?3 #R'FI03W4YH,>.!8C1-NE6;@5(KL4->TXJB1'T)4RUW@RXU_5941
MU(>QAOS\HT%=44'&C7QIN DIR6+[)@PR^(I,,15;8FD=SL_;?LJI"_X0@F&:
MAQU03"#FC3 F+KW)(]ID=(T54E=1,HN4:K1?6@(798YBLB@:>SNG8N@<G-:8
M(#Z,B)K]8+X,Y3;XSRS*R,:+VVX2FKQI-F^$2P\[]6P-TL5:5 %_[4";7IAV
M*<X!(2%W/ 37#4,/"+L&0&K(?C'NM<8.^V$$W-P9*K8*8U(?9(9\>FY^EE%"
MKQULTX\)9ALS-QQ45)7MNEQ6V(&=FU<3*>S:L3O]5)&EW^E#\C)[SZ,P"C(F
MO62=]\M*:PR: S]%9*^9YA7)1A*U0XCZH5M;2S3%^C4H6/Z=>6]H,Q79M /C
M\^"TJ9(()&ID;01VG*F6B09<R$C82ZJ]J+=I@\L#.S*',Y6H#E\2><[:W(N\
M!RX-A9LTCLD WE \ILF(SK 3_E"/>5K';.KK!YG&R%>I/7[/<GEP)_%:HI"H
MUR&8C04B=6((A*&)[*_G7(TJX)?HSB$8DQ>SL1MCLJ(QD*4O21R=&9--$$NT
M9T_Q&MPO:^M7R*4'Z,:YU2U; BGZ:>XQ(5^_E-D(0:)*K0K/N[F,KQ!K0F,J
M:G'I8,=3;51%9( EZM J3U_14'A(J*2"N#][CZ-!;TB1J).V&+?!31AG?NYH
MW,XF:O@2Q;'V[_7COJ$W7.4Y8]!OTMS(=BRJ!A+RTVQ<0T%,$$MTHJK%^-6S
M.87%FXX^:,_Z<3 @NDMOHP9 ='Y>7;K>FTBQ2]3&V@G8'[/-(G+PW7>2#:+<
MV#JS70U6Z4/6#BEBB4ZTRKUWPZ;-9LT>QY,OT:JR16KKPNCQ\QK C6ZH84N2
M1;0JKH/L##>9L#1WDVAA@TQH%[_1S9CI-&+2%#=J7OEIWW5_*-9*0:)-K3+M
MEL%?!\D?%L?A97&8?@]Y4ME!*F'>WC"+R/PSF:ZVYP;,BXJ#/)!?+CIG7HE4
MPGS+ C,L#V;W:4;1SK+!.,CIG*=-/JRLQU?9\X.SAQE!EJC%WEQO)3X%&\:\
MTN7X]E4FCR#!<;*T[&P+M<9*VQAEP43F<N#P$W1A/4'/=>],@1J3CD376N:T
M:RYG)_>!G*2+0YN<*N"7:(]]B 7$.^6[X9 .'#H)?Q_P:'[/=,[L)4P2[']L
M:OX(8L)#<E$Q1@,ZH[(_=)-P\Q>ED@HE:^!KC(W.$?+&J<:M=),BD2AHJ]*L
MU9)$GV>XWWVI.HAG(1W399D##PK=W6]'.(<M?KF')"V)QMO'LT"<DIN:?.O/
M*=@I/;#T<05>HE[65O$I5W *)RO^5K)M.;<WM[L;\)*LN=:6=5"RNP0MA=1L
M.HVY)(-X*<F'9)AF$Z!4[Z-HV )(KKU;0%N8$@5IE;%\,U;(TC*DT 5Q!2Z3
M8V1O(%O^Q%J@ 2@AO5UV\LTL%+WW(H@2=LI>[NCNTTP<1$9E2:W1*D@7>\%Q
MHCXNI"#1,=RT=/S%D4A&MU$^B--\EBG]W:W;X-*XQ#YYU=*)ZI@E&F#MG8P=
M2!)>PO:#*'S21%+?* DC <E5O3IKXAE!ADW"<:M<CEEL0BJ8]8N?)%Q9:A_H
M/LSH!8QI&R!GI+.O:ZVP1RW1%]Q(PDN'I-YPX<(F?<B[6Y(C.\%VZ[/F03#'
M*[!)6-N3[5=VB0K!S]D-\$/R& U8</VP3P].2<'W+U(2M14Y;NR@WTXX-8<J
MH7A/P7MEJ?\& SH;A<+'"\Q;?0%/1K1A=2X#=$<I%W3; I:0OB?'7*ES1/FM
MVVW$KE"3,.\6=]^98&91/@;3R+H@2Y M'^X5VX.\F-B/@YS, G4E(-:3B[W%
M8K#5E*]I& VC0;!RXJBE)\K60$;8+X0:U1(S_!(=V9,A4;Z L+0HVZ]5RG-B
MKE]$3)L M[-#V M6 2U1@%89%5?OX4C8$2B$J!C@;_EF40E,0FRK A; D^F<
MSV <9'?",B@M7E*KV=;6!4FU? -ICU:B%RVS[S$W\C7F%<R'A$IKQB8]P*]2
M$-,F0'+8P2L<Z8DU:(FZN/"/_:4LRT?:VVWYLM]M")A\IV?@</UJ;T/$#U^#
M]Y\'Z02^1Q=!*IQI$)?<0).PEXV"9)$2_<=]WW>6ODT%GZ=Q%((:)73)7J/N
M#5?!U58WRB;&3"?M4_7IG!U?(=P&RWI_'>11SC>P*P3+[..W)!]DT72!<9%>
MCPZ(/JT\H(2_4GVYCM61;!K]+I?F";*?M%N]D-Q<[T6*DB3SM7<T^YJ(MA'N
M>P;:[8'!M"*OQ'BYND28*UZB4<+/MG2YJC3HS1K@^*Z0-X@&XI<<"NPPMG)L
M[28+IS/),CGF(KBK V.$[ALZWP.+)MZNCB[.5]Y,#?=;-52LVX">8UZ15A&S
MV(IB#[J5PV?]3BY?YK=>@][[ZM2'Q-O"A-N+]&$&RY5%*VSNNUB]D*QITF8?
M)?#1/$C"E'TU6PNSH+2\,XW1CKDJ;0$29!-F%<F+#=K5\;=T&$(NHE4.(BJ[
MEW18?%*Q[W\02O(B&0T]35V^V3CJ['_#*.W9VGG&9-MHTPQ@1;Z'-&=$O(>L
M!-C1&-RWP8@[Q.Y]T8.O&@RNS8)4V,>GEY?['TG0C=[PD1[@";$;/MJZ@ KY
M%8=$T.(!8@ZIE2O3 VTC&;&(M6P9SVU.4V[4[4N:AI]1'-.Y9[,O1;X6ML'H
ML6J'<7:^RCJU7Z=E2==,AI=!;4"&_(2S&A?B\6>#N94C<"FLO\[ .[<ZD+E%
M:S?@%+4 "?*!K)KLQ0/-!&LK!]@ZI]7"[D/"^S3[ED?)Z'5,(##55U*,TY!=
ME\S  ;>4V+RV?;%N!W3&1U?MLQOAXR.K5;$AQ%H3BK,/ &:D&X!FV!-87-R+
MJY4SP2I9ZW6:9>DG1;_W[:Y@=C588Q6U^-Q\>8YP1;<4)G,X,;J2$U: _B.?
M"$WD*[F#4X-JY3#A3J9!O+HQ6#Y6V;NE<O%=\!V +AG8*.6U&"T7'81CW_+"
M:=&W9=<H^^LYUFYG6K%%D #R\="$(?%HJXNZE<,1\G*^!M_W/P(;6:TN3A%6
MJY40;2TN\FJ !=EYQ$36,L.* 31' R;>UUCI96&4!-E\\:((XY7".(VID'+8
M5#^EA8D-15V1L7'90;@*$'?+;@09MP$HT0,\&1$AV0M:0VWE>B1,?X@RWE[)
M9)IF=+B#M*W,EMJZE*2SDX[55;;$&K+U*:UQ0U:>]PA[P3&7F\ .H476_@&1
M3J(\3S,^]/D)*LGI$9&4RO#\U[6-BA4^JK,CUFB2$GAQ=.3"J?%E,";A+-Y.
MLVHJ5@FT>JT".DPCH0MJ!./1D5A:.6I7(67J:NRR(:/E1U.#BO3TXO+(P3C:
M_89Y;Z 7'41]-Y"00)T52%JIHGQ7=1WD)+Q))\Q9$N55VUJ:/,O7JA_/)&:Y
M5_B;<][3]X 'L9F;/F>KUS"EELX_"&]3C+M]7>ZVR5FI9LM<(I?(;]$<D2H^
M8;D24"MG P@3!2^#62Z<X#W-%NQF+/8G!-?UY5&G9T]>+X[/$*R.)9H^2(DF
M.Q.*12MOYY='G1/D(Z);SL0S0169M'+4\QLXL-4NWEWD+-KIOH?YNA?,27S1
M$9/QJZS(#&'')QAOT3>ZQ7]:],UN:%JUP]&>8K\5-R-$/.JJP6WEN*.##( ^
MICG+5<.W%?L>=G=!EC OE>7W#0:<K ICHV-GSFP&@\FPDM8!%,A1W;0B%@\>
M/:B6OJNYFTSC=$[(-4G(,-K_'K1/M_V$]X'M ):],'$5459DM!Q=(5R[E4\V
M;([>%"][J65TFK1IAJO@$?+29$B';$-8 6TK5R:6:3TJEF^ZV;-U.JN0!"/<
MB*(K5I=Q5NUP1;@\0QF7^EX:CDR+A@ O<B##:@Q)AVH5^*T<K O+5#_(BOEU
M0&>A ;]1>:4'UCS@R8SW/FC+72KWPV"<ZJKR%\(G"$-3UC&[<6G1"B!%-K08
MTR$>AU7@MG(0TBEF0%AT%[ ZW=!>1L5SE/^Q]Z%'O\F&_S?:GXSE;M(\[S&J
MQ[G!< _;$"OKHNTJJ*_.L1TCW43:25^VUEF ;.7@>IF]Y^0_,]K4W0?&#<3V
M]XU23HJK,"(N3ZQNWYO!8.18*:L#*)#'C%;$XN&B!]7*,;+.!_M$7$6M$[1I
M[H%B5)G'7%KE7]GK;F[9NRI1$@QJ<V3G2.:."@3(]F_F0%LY;!2!50\GP"H+
MYKW_(;:(VKO5LSG\?Y-19M8 X$-VZC<0OWB 66)L:HSM=TN_OJXW5P95-2Z>
M8V33<F45,$(F)KY5"5:^L?R"=WE!%Z="F(I)7!!$@+S7K$RN!(N8SE:E5;D/
MHNRW()Z1KR1@&P)F;+6=X8W; ,$A7\I65@)[F&+]L$ZO@JH?:4:B40)!6P>;
MQL.%=3KF#.86^E*U31"LSU'8E?I3&[98GUJ5JIFE*F9W.?0_[&G71Q"ST[O%
M!L*D/@@,.4U/]9V$%41)!M#VZ\3ZT*H2B+6JF#7+Q8N=K<6Q!EDBEV1[:I-B
MT3DU7$<?WXGEK]4@H_IOEQ>=,RP346U5L8,HU@G<%-.KP$KKV&4&ZXEI51@.
MR+&[K=FU1B<F=D]II!L.[&Z^N3!M L2&'!RI\I"W1BDQ5UDGC\;4#D4 U.V?
MM<N"=5L@263'K,KZ4AVN1'%:9>A\F$SIN9_G3LYNHWR:YD'<&SZFR>@Q^EA>
MJ)A/,56: WFV]=A;"[%$@UIE,56,G^6?ZDPYFVV Y-IZ]+6'*5&0/=E@)5M2
MIMS5=J3ZFBRP;@<KQ$B]#:D%. FM>S*=2FB]7<:PFKWG43B'5U^&Q)K4!:5N
MVQVH/3P)N:VR8SZ3#Y+,R#V5WS(?X.]1,;Z9Y05%GIEO".P:XC(\;>LU6D6L
M$GW9DXU3,AGPFZ!N&)*0!UPUO3,SK@OHVW;&M(<G(;=5=L9G2@X5++.IWE(5
MCU-^G%X\>-;N[0QJ@[20<XC4&/;F "7JL"<3HQMU@ Q@D _,?"%0U +IM-5^
M8 ),0GNK#)#L86E&QBSTS@<I[X!LW*/,F@"YM?649XU2XC;5*@.D.$3;?9H-
M253,,IN9PK8I+L>SMMY0548KT9IV61^7L=<M+(R2*B"7MMUD&:.2L-TJ2R%+
M#6-.M* T2*.M#G8J0!)Z6^5K>3W+HX1NAN@\]AXE95<OE?N\M!+(IFTG1 M<
M$LY;Y3_Y0D;LL/-,IFE6Y?6$47V06%N/AW80)4K1*N/A=H G<W70U 0IM?6@
M: I.H@*M\GE\(I\E.65I0O\Y(*4[$7.=L&T*Y-C6PV-EM!*MV9.A46)%5J!Y
M2HO_(D4WI%TFH:%AN6)S(*-67CS512S1BOKVQGV]=RVB#\CNFH3E<+JO*(D8
MVQ+DN7-V8O5:79N"9$4(7(!&0<:2X3(.]$ZH-HU WY'G;K<L" 9U-9$<VLMU
MG"'<Q+OU*X1,JJO7>N ^1%6SE/IS\8(O["7/9##+,HB5_Y0FV?)'_J);.X";
M^QC(S>_#_94T_6J#\CB M_,KZ3R1XI9DT0?$IF>B6HII+A 2E\JW)'W/2<8?
M9SPDTQD]-@]2.H/$T7K9M]+8IOL Q/E])#50Y+V)Z0!"!)22A0D?FADKJ5U#
M;U='%V=7?I]BY)I6$2MJ" +MMOA;3H:S^#$:\JU<Z=G)ZLV)[1[9MD60>MN4
MPA7HI@(0-+HEWGV%N C^RP0&&PK;K;%$40V^I(N/9M$$&[/GQU8Y3+0#S.#S
M=.6BY>(X_60QA>_3#**:LFP5]D=4M]_C$L%Z95V9/N50;4A +3W;DNDR;=OB
MA?%:+$C'6]ZG:)G.9O7PF1,#D3D*DWP0YJWPP'H8F8N6+OD\U]U-,(V*(([^
M).&B[YN=M@N<6+=I+A/L_$95.)3Y+3@21TM'.6Q(5GL1BO<E'1:?+',-TAB7
M/' V&MF:NCP&\Q%"Y'IISVJ];-^,+7V$?$XWE[YX)%K ;.58 R=JG%$%WS88
M0IL%V5GD],I%PO<>I39@ARC^@45. I&!<;W9X$4>DF&:3<S,8\U\"&2 ;,R5
MT"+8S3:'']5XJSU,,?_B-&';U=YP4P:+38+M:<FR028F],L]<S6IC_, ;)WP
MN&43]-HR'!2SC/[7V.!9H34NS OD==M(:5R ;,K<V>BJO1W* &?]5L16L$K!
M9M4.(^[\!"&A]GIRNH^2J" \UHB0"+N+"./6 #ERG(9J7.DN*.QET,K-]CI,
MQ<*H1\+[-/N6TSGK=4S8T8+=_17CE)WP^[/B.1J-B]+NR)&1NFXW=!9L5^VS
MV!W'&!D*RETLA18Q<J?65'V[/#DZPPJVT@P[XL%M+(@#<+]83V3KIX5]L%-W
M/X,L?"DHX!Z'F+.[?^ [SV<3^%V%5</%ASB#6!'T]ZF+#8G-T6%CWSFSJ:BS
M61"OSMI4$IC7)XNOT]ZL.F9@5)778EN$"XQ58_?*;M'+92=)N+V6VXUY^V9!
M%LB^"B9<Z<9M#>@MW2DN'B=C#<M5!ZQ.<HI:G(]3A%O+M1+=#8>$O6X@JVX^
M!P6IZ.Y8IUDN"^SP"29<Z89E#>@'M>U;WM=2 8BLVA64RJI%$"IR( 87^E0-
M]0$8?5]FDTF0S7O#]?9SZ<YCEI!57QW$A1S)H8:2V$!LI5'W)J6GH:Q@IJ_^
MLIO\O(*T!7@EDVF:49G#.<QJ(Z"M2ZDZ.^F<[G^D;?7,>&I6U@,TR.$2S&4N
M'F%F"%NYG?X]R+(@<>;ENVS./.FQO 83;.<4X3YCZT55U3<G]F_9ZGX))(9T
MJ6W*IGB(-26)@]I,<VO<.(TIAARFHJ>T($N9]S)N!#3+4U^US;?+X[/32TPK
M?645JX_9T78ZWM?D+@[GA[-G6M,%/BS+WBS\F;@_+^_O>\D&;6+PK-<PU9GS
MDR/42W,Q2UVFC"-XQW\]%UOG.9.6ER*5OD&E='%\@GQ"<D2T^45(/5$Y6GEB
MG$6'>?4^!1/2_1ZI$D^7BP%RY*V^>Q[%^B($WL#Z@$#Y;3H)HL2 ="@(Z+&=
MV45TJ)G;ZKTCPX@U=Y*#U.LG13V_8QL10I*[R31.YX24KF,9C*]D\DXRV<G*
MH@DNA5-D,ZF$F$T6*R-#S0^N)/F%9>JHR;)9&TP8)V?(?G*V-%M"0\W;K>3Y
M*4I(39J-FF#^0T>7V"_^+%FV0^8H$;? OZ0^S8O)J3K)!@UP05PA[\=M*;;!
MY2@A=E6"'87WXIM)^A7-)GJC'!-!!]N7>5^[:#%R1YFOD;;1U26VED82&F_&
MF_@<,($=M5:H&Y+3>Y-"<)2O&TD=GTE>9-&@(.#+*5V E.6Y++"#"#1*LEBO
MU,)PE:L;23,$*[%6.Z1UJ%!*3X__.AJB%XBKQ-RX>QFM:&62?:0;^X>"3%0;
MH/J-\^/?.7*NSGWMFAR*RU7.;ZR]UMK?<CD.2?81#8A$1#'O2\3");.+XU'"
M0\>0+$KA^L#2O=7M-_D-!=:CDP9T2W?1TI3X<-.4NU;LIY2_!%HXO"UBT)L[
M9]DUQ,_?V.DJ]JB"5C)QE2<=>2'?]()8O.UZ3N/X/LU6*U %'Q)=2W !B_SB
M9H^Z92>40\C3WM;'GIQ1WX\N#A73I<QP\\4WMMAN'?R_)5&1NUA[S=L%*\-?
M1ROKB,A57OM]OS=^I-O>)(><##=TB0C>TPPD/,H(G!/_SBVDRFIS<7R&^FZR
M1-H'*1_O(<G&0/+G5_JOG")8S:M&DXBKCW&YG2/?,+G5 -WDXEQT[7;N6WA,
M]H.,3JDEC-?S\E\TMY;FC8#4L$^5S2F#[.[ 6C[M]A\LP])>6^X6!BD@GP\K
MD*9G?PL?EJ>AH\=1\H!DU_.OP;_3["8.\EPS>5BTPN5V@;T1WO?L445 CEP<
M_5.L-5XCEPC+ED!^R,Y45?BVUAPE>D>.DTC:P^YN>\/2@--,0,+R5!:7I]C1
M(O8^U:A%X<C5$DDM=J46B 6E]7RP; GDAQR&7,VLQ"6O(DY''INNWD^L32M+
M4\KO43'^FF;3<9K/\^Y([8EK6!W0(S]YJLK8)O^58&-Y:EJ1_H4DY#NS1R:#
M*J3O5 ?TV-Z139,NAXWE#UEMI-<:YV7DV'D-]S;*MT"C>3G:\1U088Y($@VJ
M,;Y=G</'MD8TS[D4MBNO1:1]GX.M\Z.!XZ++S\!!S)N''WLZ?#0BP8/Q:G1%
M@F4":-=?Y<1@OTAL1-/V=?&T*\K&O!P;O?'F8;4AU.$B71%+T8ITR;WN"TM?
MM^B.R>VULB(+M7A\BI"T<*UUO(-4O=)EWI\-B5>8$6P:!/S8U\MF%.F&;R7<
MK8P#2$<A8&.ID?LDXVX]../R+L@2*NI5+PQ&I*P*XZ3301V+VUUC8>P&5"=O
MHWA6D"K>ME8M@@20H[-HZ=&-PVJ0#RKV7S<IHI#!I3N%%Q83D<=]OOL^B&=T
MA-]3F3,7O=G2:V9;8I;Y%!Q]#*A -I75UC[GTF@J+'>C*T39H^$ZB%EX:;:+
MW=FJ[GV]D/EL&*P;NJH\@_&Y52QF;>93D1PM\IPJJ_/^8D7GM!:JP$QEB_.@
MIGB9X"KL$<R:XF*\0CZ75U27VIA;.0GWLR@91-,@7GC$+Q)#EYQIU_)8E7V9
MO>=T 0LR6OJ6%$$4_^U/+O8F[IR==IQ.]D(.9"[?QG5Y3\^1QZU;F2O7 @-)
M>.60G6=%:6S0G[;'!?W5VUIF)+RC.TP^EL5.2ZKB( $DGR5[GC9Y-@+FE5=T
M96JE7HOJ"B %I/.[$3UFC&ZA\2S:*EMDKZ-T2H]KD^#7-!G]B_[O,9I$%('Z
M.EE?DV/&\E\VI$,P^UH \S&T*NL^/7TGHW$0Z1G<+ G D!R"ZS$F >)C4%36
MW2(*DG]'FJB8.P4!%I+773U^Q#@<^=BZI8?^O_?E^/^6/Q:ZB5!2'D!ZMH 9
MD*6#X\C?%=7RL-R./YK$Z-HI#*) <I&JN_,T@.69<RO7W3F[I,NFBV?B-RSS
M;S;G&-B+#MG8-*CZ=GYRU$%_HRDG0S!$;5 Y\EFM/EKSY7#-R>#G4?KQ2T@B
M&*GT']L#E/Y*A.Z6HNH--WXE8-R\,A?N)7;"#E/.*^!RY;J*.4E#?JJOI!BG
MX0,/D<&$U?M,:)_&T;1/L@%C;:2*(6#<!I<<MD'86".JPW/EW>J?8MR2?)!%
M4S"\":S%UEJB:Q!DBAVUT(W*&&-UY6#JV^5!-PPC /60#%.Z\^4S[-]7!BKS
M]7GGJ"57!N<=Y/>(;F5>X\J 2^(O?65PCI63V9XGNRN#<WDJYK_0E<$YELN?
M$3VV5P;G<F^^MH1-6:GW_"5810?5Q"B0UGF[/+XZNL3,\UQC )NC:W<\DQ(J
M9HKH#4L^*?JL+MK*("7L<+I:#B7<F\-K=UB2AWY/&UEB589C1C]]FU,CYG87
M#NKUAJ/3R ?)6"AZL"R8Y4J1U@'!8!^9Z_*LAW=(5R0\:I+ALBVK X)I@ZN.
M:MG6HFMW^K8R+.TRO5L8I( <3$S/D9A;!1S,)&C6=R?=,)/.SAM_!WC(5A&%
MU'=O0':[?@B7' YNHL^QGADYGUAW8;4\& ?7[(<\GY'P=D;%,X+T/?QQ5/Y$
M/OF?U(R;-  C CN AIQ%&>U6V%S=/)3%\V46A>Q]#5)6N1S0TX$S(,LW<RIE
MD-4!&7GIPJ#B7POG$/)9];-T0$B8L\>2#"M3MX<D*J(@[L_>XVC0&U(D5/L5
MQ!NW 9+#-HW8*H(]/%<)J9SZ#=ZDDTF:\%EMK=JJVRMI!8:S<X1M#C&ET1#+
M0>1Y8M#X7*6;IGDAP(YM[J@T+V_VWU6NHWVGF2G=^P^8@QS;9*1T0J$;TY?9
M9!)D\]*%*T2*[B;A8Q2\1S&_B?E*@GQ&T76+^R#*6'8HTDNZS^PI/)N06#0&
MI(>%NX@,KO[EE=@+_<N3\_T/J95<5>+O)2N10_BH;(,!72899]_@4CI%MG$8
MD"@>V.[%X)4C0775NYXOT+-I\CXC_YF19*#+ F-0F\64[&"] &B.=8UV&<C#
M*R^%ZGHCPJG/T:"O#7)"/L_;\*G1" .D[?9Q$"'-5R-*>U]F4ATDA7RTLV'4
M7">D4%&?5SI?8U;__#4B&97[>/Y(/DALOLPH&N!S\QGRB1%AI3$12;O]*(0#
M9A=VI65'V@[(#CD=C"7-%O.-%G:[4[^LX#TDTUF1<U&=F"]"N[5 +LC/I:HQ
MJ=$*!5:LM"[^'*M-KB2=?@=DCWR/L?=5S*GDVNV"LA"%@2%KHR"@]V5O[)1/
ML>Y(X&.ZJK@PKJ=9\4JRR?I9FO)J7%"<2^(<.RN5F!R9L5V! BT!C1M"2_IO
M,*0%I4$0R/<G^QS7*AF@N<)(KCO[L^(Y&HV+4I]E%YV"HOQJ"3L^LDK<@CM.
M%8S6OXN5WH\]IW%\GV:?01;VACR/*FR7=^_-5K]9"FA^.%=CJS!F&'OX)U+<
MDBSZ@&0I3-PK"0LF(#[C?$O2]YQD'VPCR@\Y],\I)2>.N-(8WY@U]&F0*?9"
MK:=<LW5O6CKMOE];B^8AH7*=L<W-<Y3K7A&HJH%D?+D9:9I^L?89R:?=-VQK
MB#=IPD<D2^BKM7&JJH%DD,^(1M3I6%=@:_<MFN@LI#5;RBMQJ5PBW[X;T69^
M--Q"AO5.6'(DX$FCMO:%ZMB)\AJ $7FFK\">*2RL6RD)=;_S_*K%QM%619RL
M/,>'_<*S*FU:4%CW0N9'<#5KT@K\''N,_!RL*FUZ5 =RE^-^OVEUQ=/@YV&$
M(>L?\KY^KW)N]SU1'5&Q[-\[XFI*_\4? Q9\\0O=A[JYUWB-9!U=A4WA26(1
M9 6V UG)[4&,?9.#36EQF?9GV6 <Y"1G$3#RY4NK_(4414QTUVU[[0>C\>KX
M<,T\U@-DKT+'?5<OV>NZ$87A'7/#7Z22OKK"#DF)J-[[$N\A!#MV. 7PD;^?
M*9Y_BD\H1[ZXY1S$++XIU]J7SE>@WPD9L?"3V!KN@J$M$6H#;#3_<3!"_+V7
MV:.D#R%NQ);;D4PR-RSM%97)MR0C01S]2<(O090\IKF%TZY]V^R%SO$)\CM8
MGW2ZMB"]C&C1Y)"]H679JS$>?#&&</L1B_-!V+%$NR??>X]@T?WK3N.^B/\0
MPH@<@/GRKWQ\W8-D705< ?OE7;*QMT=W*;T)\C'['\M%\T%/- EW'WVFY_<L
M&M"#"/M;ETX/4WJV)^%#\CHFY3#YJX@VT-)]G'XB!6'A'4W";2QZ;U-UQ3<Z
MTYT?6>5C;Q1/<1-DV9PRR;7='M9F?4"'_+C4D #QP+>#Z<B)$W/!VAR:L%*K
MU%M8'@2"?&BHQ;L:EB.72TR>!1/SUJR\/4V72FKFA<KM@H"Q0Q77G2_JPW?D
MW%FD11#[L!WP*.5: R]&KLX0@JFM=D:Z]QV;!:&_R(^Q#,0I\9,58\%Z.R&Q
MI5P'R1_7]&@[&$N>/PA*<2SGR#.?1+P"ZX"D\UA/$;1$2-\3",L!'LS<<1+Y
M*IG8ZCO6 P&9 RM)IS')67?I66X<)8'&?U52'O A.52I)2[R5]6A\,RM_Y[0
M[P<QW:&0[(- MY_(YW^EV1]JNK05 3&24=6:-W,X7H6<,LK"^,QN*!09-5=_
MYQ@OVK FB;OM56@G<VJD VVK!.!$6J7$$I>PLM5?KUSTC7CY&B719#91,K-1
M!K BS78RN>^R(^ZS5P[C9OP$W_7\E,L 5L3TL8;\"/O<\M@_M=,@T877ET#[
MJD7) $/+H_[<IQF)1JOKW+OO ^[]\$SQEJYV.PI^#5L @?F8[ 1XE%P:6H([
M!!_6+^Q5);ON)]&'QC"U713F-^3+(FN2I2@:"Q-4YWSW6_?UA;\.R$8D[Y-L
M(+[<D98%=+YD?M1QI(=Q".Z#O2D]JC)CZB,)<L*?Q_:&WW+P3E",/V6]M_.+
MSMD9\KLUZ\%H!@G7 :\)TE<^*,9TKVJ 5'Q,*&A.]"Z80W =NPFF40$^I,M'
M\C=I7CQ,ID&4<6&I77^-ZK]=7IUVSMLRH5>#YLK#RK^ ?7=Y0=>X@H1TCAO.
MXL?H@QQ.CJJK$X1 ?.4<MRF=9(IY/Z8;O&X2LGOZJ=&%JV$3@-'KP'B< LFI
MUA9ENP/<24%>SUGD$DV<.X/:("?L#9<MJ6+=L(';[NAU<C&9!+$SJ UR0MZ>
MV?!IJ1$"I)Y=7-./I1DK/5]U6GT5*JT ")&M6#9,"$[3>G">W6B_I,/BDTI&
MS=EF*8[E%#G%4DVB)(@\BT77&PZC ;F?94E4S#)2AJF))JBK"(B1K8DU.30'
MZ=55M_4JR@_QXS0.Z0$N2S^(63A012V0"_*IMCKY-@C;=YENYW]RBNU_4F]+
M+ ;4OAMV>\^44V\\4TZ-/%-.I6=4I)OU!CU33I$<P&5R%W@^"/OLUWUY@ZXI
MIQZYID@($O89+7--P\?Y1P-?%7UE$!.V&T/#-IY=M*YNPGU3BJ71?:BR!AO4
MYI%!SI#W.19\6BJ$ .@A7+M+\8HN9:HHB*@=<#7SU3)16U64D%U=VY>GD49O
M\!9W*R7G(/:L='%?"6&$5C=Y!F6?2$'+Q7'ZR<)YWJ?9#44<\:M.^UL_B3W&
MH!N*>SW;)OA[U]4-V/YO*TM]I,)=//(VO[=45@=LF.^4JA A'J]6> \@!L(N
MWB\9'67Z8 CJBB BY+L<*RY-U4&(\@""))1GV]MT]E[016D7O8%>V+0# O3C
MB78M-:D$VE7H Z^FC[7L*JXJ7#RGR*\>&IDZ!!@=W2!^D.P]Q?/>6RRT+/K7
MS2POT@G)^*)KM=.P: 7$A_EHW=V&HPIL1S>;J!Z?,MB&VP^C^B P9$>C*@1;
MJHH0LZ-[4D^G%CH 9Y-9S [0XG-B#14R;1M$C;S)W8-Z6<O#T46ME_.3T?[&
MH#8("WGKNP?E$2!V="4LF)D:]E(GTV#.'1/H8L^38:Z7_[5Y2UT,QV6=]RD*
M[[Y/29(3\SV9LM[;^7'G8N5VM$_']=ET&D=*2_.R"/01W3O&1(KB<;4#Y !L
M3GQ,"(6B8%1>"42#?J=4G6,#: =@8+J=D7LJMKO)-$[GA!ALT"0UX.4;\LI9
MAV\=K@.P"RT@=H=#'G[<8'Q+:KQ=4J%<(EN#') MQ85L 9(]GF>QGH.0;HQ>
M@^\LCCQM7_(63%D>A(/\\*L*?6:H'!EB<,_8+RR$?U3,;\DTS2/5&-TJ"6)
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M=6'=G-JHC%7.O\'EB'5Z:$8CFM&Z78FU^TY<&\),7!#0(VT$F^-2<A@50S^
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MD,XN+DZL0G)H3TABL?!=HN'92-<"]!K;-BT6I/)49 S,T_.0#('Q(4C; $C
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M^S@OANK:9FHR5->E01K8OM*5AZH B*O7=+C^(YMZNXR#S@+Z<6&%1JZ*YHV
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M,U:GFG)PYL'C^;YGN8%,0F=:)6H2@J CNW6BZ9=2(LY\AK8U#>467_&6/C^
MJWOF>7'IQ *^#EPGWB')[=^ZFKR7V.&L3:0HM'(;HSN *W4^<B#@DT(A2Z4
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MU6:+"D /(4GLUFZ)9!-SYSE:&&31RCV" HRKQ*^XCNJ; .^# 8$W9<8$KZN
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M9Q7K!>4>,<\)<ZP*6+?"7O+,[E.9D\9UD$?YMR1]STGVP?8;#\ET5M _I\F
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MS3LA&.FK;1D13T##K?U\GA_C--@)X$;1E$5(LP".EYC]:#,IL#R1YD+#++O
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M)$YD_VS " 089 /&VFQ]::4;@I.NFL4:7E[:90 8%9TJR_BQ#&B#_H3&=<^
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M #O6)K.VV?E*CS2K?*7DYZ"-D!C)" ^A?\R1O,\ 2]9VK=99XJ?+/,WH"I)
M'A5Y0R[[-?+!N=6I4X$!P#]FR6\C_IE-83P[$ P\$RG;"R001Z^"G&,F]6(
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M5;N"9&V%8)CG40786FI*,@#DH,6</&?Y]/U4%P^_;R,$P;P-70FOS#H@ZSU
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M])S%D[^^!\M<I2'EI@*'CW/. ^4'],#:S%R$L(JAV;E&/"\H!^E]FN9$91
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M%74$DA=1*&*BKVJC+ZK' ",2?5<4LB89YC>=N?@0S\/P<U=99E0^X!N"PZM
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M$3UFC):D\2IDV(C3G9I384"'L[PAEQJKR+HA(<<L*N3PL4B9<BE2'3 LGN8
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M     &0Q,#@Q,60R,&8N:'1M4$L! A0#%     @ VCV<4BS"R<W7!P  TBD
M !               ( !P$<( &0Q,#@Q,61E>#$R,2YH=&U02P$"% ,4
M" #:/9Q2<)P<:]<'   **@  $               @ '%3P@ 9#$P.#$Q9&5X
M,3(R+FAT;5!+ 0(4 Q0    ( -H]G%)>/&0U8@0  )H/   0
M  "  <I7" !D,3 X,3%D97@Q,S$N:'1M4$L! A0#%     @ VCV<4J"5.TU7
M!   @@\  !               ( !6EP( &0Q,#@Q,61E>#$S,BYH=&U02P$"
M% ,4    " #:/9Q2M#;9*@($  !@#   $               @ '?8 @ 9#$P
M.#$Q9&5X,34Q+FAT;5!+ 0(4 Q0    ( -H]G%) BF+N3 (  *@%   0
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M9S T,C$P-34Y,C0W.3,N:G!G4$L! A0#%     @ VCV<4BG S<Z?)@  B2D
M !@              ( !5:8) &<Q,#@Q,6<P-#(Q,#4U.3(V-C4P+FIP9U!+
M 0(4 Q0    ( -H]G%*484XKK4P  %E4   8              "  2K-"0!G
M,3 X,3%G,#0R,3 U-3DR-CDQ-2YJ<&=02P$"% ,4    " #:/9Q2/6@^;K9\
M   &@0  &               @ $-&@H 9S$P.#$Q9S T,C$P-34Y,C<R,C<N
M:G!G4$L! A0#%     @ VCV<4D KI[Q&.@  IST  !@              ( !
M^98* &<Q,#@Q,6<P-#(Q,#4U.3(W-#DR+FIP9U!+ 0(4 Q0    ( -H]G%(.
M3=:%HB8  )XI   8              "  771"@!G,3 X,3%G,#0R,3 U-3DR
M-S<U-RYJ<&=02P$"% ,4    " #:/9Q29]=5IK@F   W*@  &
M    @ %-^ H 9S$P.#$Q9S T,C$P-34Y,C@Q,38N:G!G4$L! A0#%     @
MVCV<4A8T$;<@4@  SU@  !@              ( !.Q\+ &<Q,#@Q,6<P-#(Q
M,#4U.3(X.#$X+FIP9U!+ 0(4 Q0    ( -H]G%)U?-BM#3P  *M!   8
M          "  9%Q"P!G,3 X,3%G,#0R,3 U-3DR.3 X,RYJ<&=02P$"% ,4
M    " #:/9Q21<&?> H=  "/(   &               @ '4K0L 9S$P.#$Q
M9S T,C$P-34Y,CDS-#DN:G!G4$L! A0#%     @ VCV<4NE$N5)Q)P  \2H
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M,#<U,RYJ<&=02P$"% ,4    " #:/9Q2*O'#Y\ C   W+   &
M    @ %6F P 9S$P.#$Q9S T,C$P-34Y,S$P-C4N:G!G4$L! A0#%     @
MVCV<4H4]Y<!P(P  @"4  !@              ( !3+P, &<Q,#@Q,6<P-#(Q
M,#4U.3,Q,S0V+FIP9U!+ 0(4 Q0    ( -H]G%+Z?R511S,  #XX   8
M          "  ?+?# !G,3 X,3%G,#0R,3 U-3DS,38R-RYJ<&=02P$"% ,4
M    " #:/9Q2!PS,!,<I  "%+   &               @ %O$PT 9S$P.#$Q
M9S T,C$P-34Y,S$Y.#<N:G!G4$L! A0#%     @ VCV<4KB%/IXX(@  ]"D
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M,30Q,2YJ<&=02P$"% ,4    " #:/9Q2^W,/S;L2   O%0  &
M    @ &B0@X 9S$P.#$Q9S T,C$Q.# X,S(U.3(N:G!G4$L! A0#%     @
MVCV<4M><1^A['@   2,  !@              ( !DU4. &<Q,#@Q,6<P-#(Q
M,3@P.#,R.3@U+FIP9U!+ 0(4 Q0    ( -H]G%+9H1:>YRL  '0Q   8
M          "  41T#@!G,3 X,3%G,#0R,3$X,#@S-#(S,RYJ<&=02P$"% ,4
M    " #:/9Q2><+PR.8@   6(P  &               @ %AH X 9S$P.#$Q
M9S T,C$Q.# X,S0V,C,N:G!G4$L! A0#%     @ VCV<4K/2E9HG,@  #S8
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M &<Q,#@Q,6<Q-W@V,RYJ<&=02P$"% ,4    " #:/9Q2M66U4K]L   (F
M$               @ %_=!$ 9S$P.#$Q9S$Y;C R+FIP9U!+ 0(4 Q0    (
M -H]G%(("E/'E]0  /\! 0 0              "  6SA$0!G,3 X,3%G,C!J
M-C,N:G!G4$L! A0#%     @ VCV<4B%F.J/T1@( N90" !
M ( !,;82 &<Q,#@Q,6<R,FTS,BYJ<&=02P$"% ,4    " #:/9Q2D^K='Y52
M  #A5@  $               @ %3_10 9S$P.#$Q9S)S<#<Q+FIP9U!+ 0(4
M Q0    ( -H]G%+%W!QQSRP  ,LO   0              "  190%0!G,3 X
M,3%G,G-P-S,N:G!G4$L! A0#%     @ VCV<4E E^7?V-0  ;ST   \
M         ( !$WT5 &<Q,#@Q,7-P,#,Y+FIP9U!+ 0(4 Q0    ( -H]G%($
MET\L-S8  &\\   /              "  3:S%0!G,3 X,3%S<# T,BYJ<&=0
M2P$"% ,4    " #:/9Q2%^^9>FTV  "N3P  #P              @ &:Z14
M9S$P.#$Q<W Q.#$N:G!G4$L! A0#%     @ VCV<4H]"A.Y5<@  .XL   X
M             ( !-" 6 &<Q,#@Q,7-P,3DN:G!G4$L! A0#%     @ VCV<
M4CCL' ;05   A&    X              ( !M9(6 &<Q,#@Q,7-P,S<N:G!G
M4$L! A0#%     @ VCV<4D[9Q5^F7@  FVD   X              ( !L><6
M &<Q,#@Q,7-P-#@N:G!G4$L! A0#%     @ VCV<4KX%YC7)+0  FC,   X
M             ( !@T87 &<Q,#@Q,7-P-C@N:G!G4$L! A0#%     @ VCV<
M4J8S>5E8/0  !D$   \              ( !>'07 &<Q,#@Q,7-P-S!A+FIP
M9U!+ 0(4 Q0    ( -H]G%+E=;6# BT  -TQ   /              "  ?VQ
M%P!G,3 X,3%S<#<P8BYJ<&=02P$"% ,4    " #:/9Q2*+ENVL5J  !S=P
M#@              @ $LWQ< 9S$P.#$Q<W W,2YJ<&=02P$"% ,4    " #:
M/9Q2BO$9[W%%  #!2   #@              @ $=2A@ 9S$P.#$Q<W W,RYJ
M<&=02P$"% ,4    " #:/9Q21-G;(]8N  "+,0  #@              @ &Z
MCQ@ 9S$P.#$Q<W W-"YJ<&=02P$"% ,4    " #:/9Q2CA/.G9@F  "KRP$
M$0              @ &\OA@ :6UA8BTR,#(P,3(S,2YX<V102P$"% ,4
M" #:/9Q2]_Z&E:P5   2-@$ %0              @ &#Y1@ :6UA8BTR,#(P
M,3(S,5]C86PN>&UL4$L! A0#%     @ VCV<4FE02%N-A0  BXP( !4
M         ( !8OL8 &EM86(M,C R,#$R,S%?9&5F+GAM;%!+ 0(4 Q0    (
M -H]G%(VI^EG1],  &>4#  5              "  2*!&0!I;6%B+3(P,C Q
M,C,Q7VQA8BYX;6Q02P$"% ,4    " #:/9Q2%^4'/52L   Z90L %0
M        @ &<5!H :6UA8BTR,#(P,3(S,5]P<F4N>&UL4$L%!@    !" $(
*_A   ",!&P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
